<SEC-DOCUMENT>0000950123-19-008748.txt : 20190920
<SEC-HEADER>0000950123-19-008748.hdr.sgml : 20190920
<ACCEPTANCE-DATETIME>20190830170420
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-19-008748
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		26
FILED AS OF DATE:		20190830
<PUBLIC-REL-DATE>20190920
DATE AS OF CHANGE:		20190830

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-02690
		FILM NUMBER:		191070174

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>This draft registration statement has not been publicly filed with the United States
Securities and Exchange Commission and all information herein remains strictly confidential. </B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the
United States Securities and Exchange Commission on August&nbsp;30, 2019 as Amendment No. 2 to the initial confidential submission. </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">F-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES ACT
OF&nbsp;1933</B><B><I> </I></B><B> </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Innate Pharma S.A. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>France</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(State or other jurisdiction of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">incorporation or organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Primary Standard Industrial</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Classification Code Number)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(I.R.S.&nbsp;Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Identification&nbsp;Number)</P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Innate Pharma S.A. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>117 Avenue de Luminy&#151;BP 30191 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>13009 Marseille, France </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>+
33 (0) 4 30 30 30 30 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive
offices) </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Corporation Service Company </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1180 Avenue of the Americas, Suite 210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10036-8401 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(800) <FONT STYLE="white-space:nowrap">927-9801</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service) </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies of all communications, including communications sent to agent for service, should be sent to: </I></B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Richard Segal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Yvan-Claude Pierre</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Divakar
Gupta</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Brandon Fenn</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>500 Boylston
Street, 14<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02116</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>+1 617 937 2300</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bertrand S&eacute;n&eacute;chal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Linklaters LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>25 rue de
Marignan</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>75008 Paris, France</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>+33 1 56 43 56 43</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Deanna L. Kirkpatrick</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Yasin Keshvargar</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Davis
Polk&nbsp;&amp; Wardwell LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>450 Lexington Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10017</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>+1 212
450 4000</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Arnaud Duhamel</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Th&eacute;ophile Strebelle</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Gide&nbsp;Loyrette&nbsp;Nouel&nbsp;A.A.R.P.I.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>15 rue de Laborde</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>75008
Paris, France</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>+33 1 40 75 60 00</B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public</B>: As soon as practicable after this Registration Statement becomes
effective. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act, check the following box:&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any new or revised financial accounting standards&#134; provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Registration Fee </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class&nbsp;of Securities to be Registered<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>Maximum<BR>Aggregate<BR>Offering&nbsp;Price<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration&nbsp;Fee<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Ordinary shares, &#128;0.05 nominal value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All ordinary shares in the U.S. offering will be in the form of American Depositary Shares, or ADSs, with each ADS representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary share. ADSs
issuable upon deposit of the ordinary shares registered hereby are being registered pursuant to a separate registration statement on Form <FONT STYLE="white-space:nowrap">F-6.</FONT> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes ordinary shares (which may be in the form of ADSs) that the underwriters have an option to purchase. See &#147;Underwriting.&#148; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes ordinary shares that are being offered in a private placement in Europe and other countries outside of the United States, but which may be resold from time to time in the United States in transactions requiring
registration under the Securities Act of 1933, as amended, or the Securities Act, or an exemption therefrom. The total number of ordinary shares (including shares in the form of ADSs) in the U.S. offering and the European private placement is
subject to reallocation between them to the extent permitted under applicable laws and regulations. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum offering price. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration
Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The term &#147;new or revised financial accounting standard&#148; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&nbsp;5, 2012.
</TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and may be changed. We may not
sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in
any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#de1a1e"><B>SUBJECT TO COMPLETION, DATED
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2019 </B></FONT></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>PRELIMINARY
PROSPECTUS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ORDINARY SHARES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><I>(Including Ordinary Shares in the Form of American Depositary Shares) </I></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g14p44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per American Depositary Share
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Ordinary Share </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">We are offering an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in a global offering. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">We are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in the form of American Depositary Shares, or ADSs, in the
United States, referred to herein as the U.S. offering. Each ADS represents the right to receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary share and the ADSs may be evidenced by American Depositary Receipts, or
ADRs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">We are concurrently offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in Europe and
countries outside of the United States in a private placement, referred to herein as the European private placement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">This is our initial
public offering of our ADSs in the United States. We intend to apply to list our ADSs on the Nasdaq Global Market under the symbol &#147;IPHA.&#148; Our ordinary shares are listed on Euronext Paris under the symbol &#147;IPH.&#148; The final
offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros will be determined through negotiations between us and the representatives of the underwriters for the U.S. offering, and by reference to the
prevailing market prices of our ordinary shares on Euronext Paris after taking into account market conditions and other factors. On
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, the last reported sale price of our ordinary shares on Euronext Paris was
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, equivalent to a price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, assuming an exchange rate of &#128;1.00 = $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
the exchange rate on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">The closings of the U.S. offering and the European private placement, which are together referred to as the global offering, will occur
substantially simultaneously. The number of ordinary shares (including ordinary shares in the form of ADSs) in the U.S. offering and the European private placement is subject to reallocation between these offerings to the extent permitted under
applicable laws and regulations. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:11pt; font-family:Times New Roman"><B>Investing in our ADSs and ordinary shares involves a high degree of risk. See &#147;<A HREF="#toc752656_4">Risk Factors</A>&#148; beginning
on page 13 of this prospectus. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD style="width:31pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:31pt"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD style="width:17pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:17pt"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD style="width:14pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:14pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PER&nbsp;ORDINARY</B><br><B>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PER&nbsp;ADS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Underwriting discounts<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; beginning on page 231 of this prospectus for additional information regarding underwriting compensation. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable within 30 days from the date of this prospectus, to purchase up to an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ordinary shares (which may be in the form of ADSs) at the offering price, less underwriting discounts. If the underwriters exercise this option in full, the total underwriting discounts
payable by us will be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) and the total proceeds to us, before expenses, will be
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">We are an &#147;emerging
growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission, or SEC, nor any U.S. state securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">The
underwriters expect to deliver the ADSs to the purchasers in the U.S. offering on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 through the book-entry facilities of The Depository
Trust Company. The underwriters expect to deliver the ordinary shares to purchasers in the European private placement on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 through the book-entry facilities of Euroclear France. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:20pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:20pt">
<TD VALIGN="top"><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>SVB Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore ISI</B></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019.
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_1">PROSPECTUS SUMMARY</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_2">THE GLOBAL OFFERING</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_3">SUMMARY CONSOLIDATED FINANCIAL DATA</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_4">RISK FACTORS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_5">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_6">USE OF PROCEEDS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_7">DIVIDEND POLICY</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_8">CAPITALIZATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_9">DILUTION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_10">SELECTED CONSOLIDATED FINANCIAL DATA</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_11">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_12">BUSINESS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_13">MANAGEMENT</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_15">PRINCIPAL SHAREHOLDERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_16">DESCRIPTION OF SHARE CAPITAL</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_17">LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY</A></B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_18">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_19">SHARES AND ADSS ELIGIBLE FOR FUTURE SALE</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_20">MATERIAL UNITED STATES FEDERAL INCOME AND FRENCH TAX
CONSIDERATIONS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_21">ENFORCEMENT OF CIVIL LIABILITIES</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_22">UNDERWRITING</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_23">EXPENSES RELATING TO THE GLOBAL OFFERING</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_24">LEGAL MATTERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_25">EXPERTS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_26">WHERE YOU CAN FIND MORE INFORMATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc752656_27">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>We are responsible for the information contained in this prospectus and any free-writing prospectus we prepare or authorize. We and the
underwriters have not authorized anyone to provide you with different information, and we and the underwriters take no responsibility for any other information others may give you. We are not, and the underwriters are not, making an offer to sell
these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than its date. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>For investors outside the United States: neither we nor any of the underwriters have done anything that would permit this offering or
possession or distribution of this prospectus or any free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this
prospectus or any free writing prospectus must inform themselves about, and observe any restrictions relating to, the global offering of the ADSs and ordinary shares and the distribution of this prospectus and any free writing prospectus outside the
United States. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated in France, and a majority of our outstanding securities are owned by <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> residents. Under the rules of the U.S. Securities and Exchange Commission, we are currently eligible for treatment as a &#147;foreign private issuer.&#148; As a foreign private issuer, we will not be
required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial statements included in this prospectus are presented in euro and, unless
otherwise specified, all monetary amounts are in euro. All references in this prospectus to &#147;$,&#148; &#147;U.S. dollars,&#148; and &#147;dollars&#148; means U.S. dollars and all references to &#147;&#128;&#148; and &#147;euro,&#148; mean euro,
unless otherwise noted. Throughout this prospectus, references to ADSs mean ADSs or ordinary shares represented by such ADSs, as the case may be. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market, Industry and Other Data </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless
otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including our general expectations and market position, market opportunity and market size estimates, is based on information
from independent industry analysts, third-party sources and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and third-party sources, as well as data from our
internal research, and are based on assumptions made by us based on such data and our knowledge of such industry and market, which we believe to be reasonable. In addition, while we believe the market opportunity information included in this
prospectus is reliable and is based on reasonable assumptions, such data involves risks and uncertainties and is subject to change based on various factors, including those discussed under the heading &#147;Risk Factors.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trademarks and Service Marks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Innate Pharma,&#148; the Innate Pharma logo, Lumoxiti and other trademarks or service marks of Innate Pharma S.A. appearing in this
prospectus are the property of Innate Pharma S.A. or its subsidiaries. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus are listed without the
<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the
fullest extent under applicable law, their right thereto. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. We do not intend to use or display other companies&#146;
trademarks and trade names to imply any relationship with, or endorsement or sponsorship of us by, any other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information you should consider
before investing in our ordinary shares (including ordinary shares in the form of ADSs). You should read the entire prospectus carefully, including &#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements&#148;,
&#147;Business,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes appearing elsewhere in this prospectus before making an investment
decision. Unless otherwise indicated or the context otherwise requires, &#147;Innate Pharma&#148; &#147;the company,&#148; &#147;our company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Innate Pharma S.A. and its consolidated
subsidiaries, taken as a whole. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company focused on discovering, developing and commercializing <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need. We have extensive experience in research and
development in immuno-oncology, having been pioneers in the understanding of natural killer cell, or NK cell, biology, and later expanding our expertise in the tumor microenvironment, tumor antigens and antibody engineering fields. We have built,
internally and through our business development strategy, a broad and diversified portfolio including an approved product, three clinical product candidates and a robust preclinical pipeline. We have entered into collaborations with leaders in the
biopharmaceutical industry, such as AstraZeneca and Sanofi, to leverage their development capabilities and expertise, and we have received upfront and milestone payments and equity investments from our collaborations of an aggregate of approximately
$550&nbsp;million over the last ten years. We may be eligible to receive an aggregate of approximately $5.5 billion in future contingent payments from existing collaboration agreements and any license agreements that become effective upon the
exercise by our collaborators of options to license future product candidates. We believe our product candidates and clinical development approach are differentiated from current immuno-oncology therapies and have the potential to significantly
improve the clinical outcome for patients with cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The immune system is the body&#146;s natural defense against invading organisms
and pathogens and is comprised of two arms: the innate immune system and adaptive immune system. Recent immunotherapy developments have focused on generating a tumor antigen-specific T cell response and have led to an unprecedented change in the
treatment paradigm of many solid tumor cancers. Despite these successes, the breadth and durability of the clinical benefit achieved has been limited to a subset of patients and tumor types. Our innovative approach to immuno-oncology aims to broaden
and amplify anti-tumoral immune responses by leveraging both the adaptive and the innate immune systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The innate immune system is
comprised of a variety of cells, including NK cells, which are involved in anti-cancer immunosurveillance through a variety of modalities. Activation of the innate immune system also helps trigger the adaptive immune system to elicit a response
directed against specific antigens and can provide durable immune memory. Our scientific expertise, strategic collaborations and discovery engine are focused on harnessing the potential of the innate immune system across three pillars. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g48k25.jpg" ALT="LOGO">
 </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a pipeline of innovative immunotherapies that we believe have the
potential to provide a significant clinical benefit to cancer patients. The following table summarizes our commercial, clinical and preclinical pipeline. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g41w75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">&#147;SCCHN&#148; denotes Squamous Cell Carcinoma of the Head and Neck; &#147;CRC&#148; denotes Colorectal Cancer;
&#147;MF&#148; denotes Mycosis Fungoides; &#147;PTCL&#148; denotes Peripheral T-cell Lymphomas; &#147;NSCLC&#148; denotes Non-Small Cell Lung Cancer; and &#147;HCC&#148; denotes Hepatocellular Carcinoma. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development efforts are guided by our three pillars. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Broad spectrum immune checkpoint inhibitors</B>. We are targeting checkpoints expressed on NK cells and
myeloid cells, rather than focusing solely on T cells, in order to increase the pool of anti-tumor effector cells and potentially mount a larger anti-tumor response. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Tumor antigen targeting</B>. We are developing antibodies that target tumor antigens in the form of
(i)&nbsp;antibody-drug conjugates, or ADCs, (ii)&nbsp;antibody-dependent cellular cytotoxicity, or ADCCs, inducing antibodies and (iii)&nbsp;antibody-based multi-specific NK cell engagers, or NKCEs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Suppressive factors of the TME</B>. We are developing product candidates that target suppressive pathways of
the TME in order to relieve the immunosuppression of the innate and adaptive immune responses. We are developing IPH5401, an anti-C5aR antibody that disrupts the complement pathway. In addition, we are developing product candidates that disrupt the
adenosine pathway, including IPH5201, an anti-CD39 antibody, and IPH5301, an anti-CD73 antibody. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Competitive Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our key competitive strengths are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our lead product candidate, monalizumab, which we are developing in collaboration with AstraZeneca for the
treatment of SCCHN, CRC and other solid tumors, is a novel, dual-targeting checkpoint</I></B> <B><I>inhibitor that has shown promising clinical data.</I></B> Monalizumab is a humanized antibody that is capable of acting on NK cells and CD8+ T cells
in order to activate both innate and adaptive immune responses. We believe these properties may allow monalizumab, in combination with other therapies, to address some of the limitations of current therapies that only target T cells and potentially
provide a chemotherapy free therapeutic alternative in earlier lines of treatment. Preliminary data from a Phase II expansion cohort of 40 patients with R/M SCCHN previously treated with chemotherapy alone or chemotherapy followed by <FONT
STYLE="white-space:nowrap">PD-1/L1</FONT> checkpoint inhibitors, </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
showed an overall response rate to monalizumab in combination with cetuximab of 27.5%, including one complete response (2.5%) and 10 partial responses (25%), and a disease control rate at 24
weeks of 35%. Median progression-free survival and overall survival were 5.0 months and 10.3 months, respectively. In addition, we observed that there were three (18%) responders among the 17 patients who had been previously treated with <FONT
STYLE="white-space:nowrap">PD-1/L1</FONT> checkpoint inhibitors. Following these preliminary results, in 2018, AstraZeneca expanded its agreement with us by exercising its option to gain exclusive rights to
<FONT STYLE="white-space:nowrap">co-develop</FONT> and commercialize monalizumab in oncology. Since then we initiated two additional expansion cohorts evaluating monalizumab in combination with cetuximab in immuno-oncology, or IO, pretreated
patients (Cohort&nbsp;2) and monalizumab in combination with cetuximab and an anti-PD-(L)1 in IO na&iuml;ve patients (Cohort&nbsp;3). We expect to present follow-up data from the first expansion cohort in the second half of 2019 and preliminary
efficacy data from the second expansion cohort in 2020. AstraZeneca is also evaluating monalizumab in a Phase&nbsp;I/II clinical trial in combination with durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in patients with advanced solid tumors,
including colorectal cancer, or CRC. Under our collaboration agreement with AstraZeneca, we are eligible to receive a $100&nbsp;million milestone payment at the start of the first Phase&nbsp;III clinical trial for monalizumab. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our proprietary product candidate, IPH4102, has shown single agent activity for the treatment of relapsed
or refractory S&eacute;zary syndrome</I></B>. In our Phase I clinical trial evaluating IPH4102 in CTCL, in the subgroup of 35 patients with S&eacute;zary syndrome, we observed an objective overall response rate of 42.9%, median duration of response
of 13.8 months, median progression-free survival of 11.7 months and that approximately 90% of patients experienced improved quality of life. IPH4102 has also been granted orphan drug designation in the European Union and in the United States for the
treatment of CTCL. In January 2019, the FDA granted Fast Track designation to IPH4102 for the treatment of adults with R/R S&eacute;zary syndrome who have received two prior systemic therapies. The results of the dedicated S&#233;zary syndrome
cohort may support a future Biologics License Application, or BLA, to the FDA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>We believe that by targeting C5a receptors, IPH5401 has potential as a novel target in cancer treatment and
as a scientifically validated pathway to reduce inflammation.</I></B> IPH5401 binds to and blocks C5a receptors expressed on subsets of myeloid derived suppressor cells, or MDSCs, and neutrophils, cells that impair anti-tumor T cell response and
chemotherapy efficacy. We are currently conducting a Phase I clinical trial of IPH5401 in combination with durvalumab, initially in patients with select advanced solid tumors, and plan to initiate a subsequent cohort expansion trial to evaluate
IPH5401 in combination with durvalumab in patients with NSCLC or HCC. We also plan to explore the potential of IPH5401 in inflammation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our commercial stage product, Lumoxiti, is the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
treatment for hairy cell leukemia in over 20 years</I></B>. Lumoxiti was approved by the FDA under priority review in September 2018 based on positive data in a Phase II clinical trial. In this trial, 75% of patients receiving Lumoxiti achieved an
overall response, 30% had a complete response and 34% achieved a complete durable response with a negative minimal residual disease. A negative minimal residual disease complete response has been shown to be a surrogate for long-term disease control
and potentially survival in several hematological malignancies. Following our <FONT STYLE="white-space:nowrap">in-licensing</FONT> of Lumoxiti in the United States and the European Union from AstraZeneca, we are leveraging AstraZeneca&#146;s
capabilities to advance commercialization efforts through a transition period while we build our commercial organization. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>We believe that our broad, early stage pipeline of innovative immunotherapies targeting innate immunity
pathways provides us with multiple opportunities for future value creation</I></B>. Our expertise and leadership in the field of innate immunity has allowed us to create a diversified and differentiated portfolio in immuno-oncology<B><I>. </I></B>We
have developed a large panel of molecular and cellular assays and <I>in</I> <I>vivo</I> models for assessing the pharmacodynamics, toxicology and the therapeutic activity of product candidates targeted towards the innate immune system. In many
cases, our product candidates are among a limited number of therapeutic antibodies in development for a given biological target. As a result, our differentiated approach has allowed us to forge collaborations with the leading academic institutions,
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
cancer centers and industry partners to evaluate and advance our product candidates either alone or in combination with other investigational or approved therapies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our diversified business model provides us with a strong financial base and strategic flexibility</I></B>.
In addition to our internally developed pipeline, we have a track record of acquiring the rights to product candidates at different stages of development, including monalizumab, Lumoxiti, IPH5401 and our IPH52 program assets. We have already derived
substantial value from these acquisitions and subsequent business development transactions relating to these assets. Our collaborations have also allowed us to leverage development capabilities and financial resources of leading biopharmaceutical
companies, while retaining optionality to <FONT STYLE="white-space:nowrap">co-develop</FONT> and potentially <FONT STYLE="white-space:nowrap">co-promote</FONT> certain assets. At the same time, we have retained or acquired exclusive development and
commercialization rights to other product candidates. We believe that our strategic collaborations, our current financial position and the proceeds from this offering will position us to continue to develop our proprietary portfolio of assets and
build our commercial infrastructure, while maintaining our leadership in the development of novel immunotherapies. As of June&nbsp;30, 2019, we had
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million in cash, cash equivalents, short term investments and <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets.<B><I> </I></B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Experienced management team with a track record in the development and commercialization of cancer
therapeutics. </I></B>Our management team and board of directors have substantial experience in the biopharmaceutical industry, including in drug discovery, clinical development and commercialization. Our Chief Executive Officer, Mondher Mahjoubi,
MD, has 28 years of oncology development, product strategy and commercial management experience.&nbsp;Previously, he was the Oncology Global Manager at AstraZeneca and had tenures at Genentech and Roche. Pierre Dodion, MD, MBA, Chief Medical
Officer, has 24 years of experience in clinical and regulatory development efforts and medical affairs. He previously held positions at ARIAD Pharmaceuticals, Pfizer, Novartis and Aventis.&nbsp;Our Chief Scientific Officer, Eric Vivier, DVM, PhD,
has over 25 years of immuno-oncology experience and a substantial track record of publications in key scientific journals.&nbsp;Jennifer Butler, Executive Vice President and General Manager of Innate Pharma U.S., Inc., has over 20 years of
experience in&nbsp;strategic marketing and commercial leadership expertise across several therapeutic areas. Ms.&nbsp;Butler has led and built multiple global and US commercial teams, including the product launch of durvalumab, while serving at
AstraZeneca.<B><I> </I></B><B><I></I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to harness the immune system for the treatment of conditions with serious unmet medical needs in oncology. By leveraging our
extensive experience in immuno-oncology research and development, we strive to continue to internally discover, externally identify and develop a broad and diversified portfolio of first and <FONT STYLE="white-space:nowrap">best-in</FONT> class
immunotherapies across various therapeutic modalities. The key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Deliver our clinical programs and improve patient outcomes in indications with high unmet medical need by
building on our scientific discoveries. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complete our ongoing clinical trial of monalizumab for the treatment of SCCHN, which, together with the data from
the CRC clinical trial, will inform further development and the potential path to market. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Execute the clinical development of our wholly owned product candidate, IPH4102, for the treatment of patients
with S&eacute;zary syndrome, MF and PTCL. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Progress the clinical development of our wholly owned product candidate, IPH5401, for the treatment of patients
with cancer and explore its potential to treat inflammation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance our pipeline of other proprietary product candidates, including IPH5301. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Build a commercial stage oncology-focused biotechnology company. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Build a commercial infrastructure for Lumoxiti in the United States and, if approved, in the European Union.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leverage our commercial infrastructure for future approved products in order to build a hemato-oncology focused
commercial franchise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Retain optionality to <FONT STYLE="white-space:nowrap">co-promote</FONT> product candidates in strategic regions
for select partnered assets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continue to invest in our proprietary and partnered portfolio by leveraging our strong financial position and
revenue from our existing collaborations. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximize the value of our partnered product candidates under existing collaborations and any license agreements
that become effective upon the exercise by our collaborators of options to license future product candidates, under which we may be eligible to receive up to an aggregate of approximately $5.5&nbsp;billion in future contingent payments, including
up-front option exercise fees and payments upon the achievement of specified development and sales milestones. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to explore opportunities to accelerate the development of our proprietary pipeline programs through
additional collaborations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combine our disciplined business development strategy with our immuno-oncology research and development
capabilities to further expand our product portfolio. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand our pipeline of proprietary product candidates that target novel pathways in immuno-oncology using our
internal development engine. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Associated with our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in our ordinary shares (including ordinary shares in the form of ADSs) involves a high degree of risk. Any of the factors set
forth under &#147;Risk Factors&#148; may limit our ability to successfully execute our business strategy. You should carefully consider all of the information set forth in this prospectus and, in particular, should evaluate the specific factors set
forth under &#147;Risk Factors&#148; in deciding whether to invest in our securities. Among these important risks are the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Biopharmaceutical development involves a high degree of uncertainty and most of our product candidates are in
early stages of development, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend upon our existing collaboration partners, AstraZeneca, Sanofi and other third parties, and may depend
upon future collaboration partners to commit to the research, development, manufacturing and marketing of our drugs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will become fully responsible for the commercialization of Lumoxiti by mid-2020, but we currently have no
sales, marketing or commercial product distribution organization and have no experience in marketing or managing the manufacturing of products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to establish sales, marketing and distribution capabilities for Lumoxiti on a timely basis, we
may not be successful in commercializing Lumoxiti. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The scientific evidence to support the feasibility of developing product candidates is both preliminary and
limited. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be successful in our efforts to develop additional products that receive regulatory approval and are
successfully commercialized. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred and may in the future incur significant operational losses related to our research and
development activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may need to raise additional funding to complete the development and any commercialization of our product
candidates, which may not be available on acceptable terms, or at all, and failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we do not achieve our product development or commercialization objectives in the timeframes we expect, we may
not receive product revenue, milestones or royalty payments and we may not be able to conduct our operations as planned. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is
expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory processes that will govern the approval of our product candidates are complex and changes in
regulatory requirements could result in delays or discontinuation of development or unexpected costs in obtaining regulatory approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We intend to develop monalizumab, IPH5401 and other product candidates in combination with other therapies, which
exposes us to additional risks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have no manufacturing capabilities and rely on third-party manufacturers for Lumoxiti and our product
candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may encounter difficulties in managing our growth, which could disrupt our operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There are material weaknesses and significant deficiencies in our internal controls over financial reporting and
if we are unable to maintain effective internal controls over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected, which could hurt our business, lessen investor confidence and depress the market
price of our securities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to compete may be adversely affected if we do not adequately obtain, maintain, protect and enforce
our intellectual property or proprietary rights, or if the scope of intellectual property protection we obtain is not sufficiently broad. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There has been no prior market for our ADSs and an active and liquid market for our securities may fail to
develop, which could harm the market price of the ADSs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The rights of shareholders in companies subject to French corporate law differ in material respects from the
rights of shareholders of corporations incorporated in the United States. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are
permitted to file less information with the SEC than a U.S. company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information about the risks we
face, please see the section of this prospectus titled &#147;Risk Factors.&#148; </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as
defined in the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to present only two years of audited financial statements in addition to any required interim
financial statements and correspondingly reduced disclosure in management&#146;s discussion and analysis of financial condition and results of operations in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemption from the auditor attestation requirement of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the
Sarbanes-Oxley Act, in the assessment of our internal controls over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that we no longer qualify as a foreign private issuer, (i)&nbsp;reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements and (ii)&nbsp;exemptions from the requirements of holding a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation, including golden
parachute compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until such time that we are no longer an emerging
growth company. We will cease to be an emerging growth company upon the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; (ii)&nbsp;the date we qualify as a &#147;large
accelerated filer&#148; with at least $700&nbsp;million of equity securities; (iii)&nbsp;the issuance, in any three year period, by our company of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities
held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> and (iv)&nbsp;the last day of the fiscal year ending after the fifth anniversary of our initial public offering of our ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to take advantage of some but not all of these reduced burdens. For example, we have presented only two years of audited
financial statements and only two years of related &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus, and intend to take advantage of the exemption from auditor
attestation on the effectiveness of our internal control over financial reporting. Accordingly, the information that we provide shareholders and holders of our ADSs may be different than you might obtain from other public companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;107 of the JOBS Act provides that an emerging growth company can use the extended transition period provided in
Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Given that we currently report and expect to continue to report under International Financial Reporting Standards, or IFRS, as issued by the
International Accounting Standards Board, or IASB, we have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of
such standards is required by the IASB. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Implications of Being a Foreign Private Issuer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also considered a &#147;foreign private issuer&#148; under U.S. securities laws. In our capacity as a foreign private issuer, we are
exempt from certain rules under the Exchange Act that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section&nbsp;14 of the Exchange Act. In addition, members of our Executive Board and Supervisory
Board and our principal shareholders are exempt from the reporting and &#147;short-swing&#148; profit recovery provisions of Section&nbsp;16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our
securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. In addition, we are not required to
comply with Regulation FD, which restricts the selective disclosure of material information. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until such time as we are no longer a foreign
private issuer. We will remain a foreign private issuer until such time that more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)&nbsp;the majority of our members of
the Executive Board or Supervisory Board are U.S. citizens or residents; (ii)&nbsp;more than 50% of our assets are located in the United States; or (iii)&nbsp;our business is administered principally in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have taken advantage of certain reduced reporting and other requirements in this prospectus. Accordingly, the information contained herein
may be different than the information you receive from other public companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated on September&nbsp;23, 1999 as a <I>soci&eacute;t&eacute; par actions simplifi&eacute;e</I> and converted into a
<I>soci&eacute;t&eacute; anonyme</I>, or S.A., on June&nbsp;13, 2005. Our principal executive offices are located at 117, Avenue de Luminy, 13009 Marseille, France. We are registered at the Marseille Business and Company Registry (<I>Registre du
commerce et des soci&eacute;t&eacute;s</I>) under the number SIREN 424 365 336 RCS Marseille. Our telephone number at our principal executive offices is +33 4 30 30 30 30. We have two wholly owned subsidiaries&#151;Innate Pharma, Inc., a Delaware
corporation created in 2008, and Innate Pharma France SAS, a French <I>soci&eacute;t&eacute; par actions simplifi&eacute;e</I> created in 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our agent for service of process in the United States is Corporation Service Company. Our website address is www.innate-pharma.com. The
reference to our website is an inactive textual reference only and information contained in, or that can be assessed through, our website is not part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to make our reports and other information filed with or furnished to the SEC pursuant to Section&nbsp;13(a) or 15(d) of the Exchange
Act available, free of charge, through our website, as soon as reasonably practicable after those reports and other information are electronically filed with or furnished to the SEC. Information on our website or any other website is not
incorporated by reference into this prospectus and does not constitute a part of this prospectus. The SEC maintains an internet site at http://www.sec.gov that contains reports and other information regarding issuers that file electronically with
the SEC. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_2"></A>THE GLOBAL OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </P></TD>
<TD>Innate Pharma S.A. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Global offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares offered by us, consisting of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in the form of
ADSs offered in the U.S. offering and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares offered in the European private placement. The closings of the U.S. offering and the European private placement will occur
substantially simultaneously. The total number of ordinary shares (including ordinary shares in the form of ADSs) in the U.S. offering and the European private placement is subject to reallocation between these offerings to the extent permitted
under applicable laws and regulations. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">U.S. offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs, each representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary share </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">European private placement </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Offering price </P></TD>
<TD>The offering price is expected to be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, or &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, the closing price of our ordinary shares on Euronext Paris
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. The final offering price per ADS in U.S. dollars and the corresponding offering price in euro will be determined by
reference to the prevailing market prices of our ordinary shares on Euronext Paris after taking into account market conditions and other factors. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ordinary shares (including ordinary shares <BR>in the form of ADSs) to be outstanding after <BR>the global
offering </P></TD>
<TD><BR><BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional ordinary shares (including ordinary shares in the form of ADSs) <BR>in the
global offering </P></TD>
<TD>We have agreed to issue, at the option of the underwriters, within 30&nbsp;days from the date of this prospectus, up to an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional
ordinary shares (which may be in the form of ADSs). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">American Depositary Shares </P></TD>
<TD>Each ADS represents&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary share, nominal value &#128;0.05 per share. You will have the rights of an ADS holder as provided in the deposit agreement
among us, the depositary and all holders and beneficial owners of ADSs issued thereunder. To better understand the terms of the ADSs, you should carefully read the section in this prospectus titled &#147;Description of American Depositary
Shares.&#148; We also encourage you to read the deposit agreement, which is filed as an exhibit to the Registration Statement that includes this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Depositary </P></TD>
<TD>Citibank, N.A. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We estimate that we will receive net proceeds from the global offering of approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), based on an assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, or &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, the closing
price of our ordinary shares on Euronext Paris on </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, after deducting estimated underwriting discounts and estimated offering expenses payable by
us. We intend to use the net proceeds from the global offering, together with our existing resources, to (i)&nbsp;advance the clinical development of our lead product candidate, monalizumab, in collaboration with AstraZeneca, (ii) advance the
clinical development of IPH4102 for the treatment of S&#233;zary syndrome, MF and PTCL, (iii) advance the clinical development of IPH5401 for the treatment of solid tumors, including NSCLC and HCC, (iv) build our commercial capabilities for
Lumoxiti; (v) expand and advance our preclinical programs pipeline and (vi) the remainder for working capital and other general corporate purposes. See &#147;Use of Proceeds&#148; for more information. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Dividend policy </P></TD>
<TD>We do not expect to pay any dividends on the ordinary shares or ADSs in the foreseeable future. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in the ordinary shares or ADSs. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market symbol for our ADSs </P></TD>
<TD>&#147;IPHA&#148;. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Euronext Paris trading symbol for our ordinary shares </P></TD>
<TD>&#147;IPH&#148;. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of ordinary shares (including ordinary shares in the form of ADSs) that will be outstanding
after the global offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding as of June&nbsp;30, 2019 and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of share warrants (BSA) outstanding as of June&nbsp;30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of redeemable share warrants (BSAAR) outstanding as of June&nbsp;30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2017) outstanding as of June&nbsp;30, 2019, assuming all related performance conditions are met; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
vesting of free shares (AGA) outstanding as of June&nbsp;30, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2016) as of June&nbsp;30, 2019, assuming all performance conditions are met; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares reserved for future
issuance under our share-based compensation plans and other delegations of authority from our shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as
otherwise noted, the information in this prospectus assumes no exercise by the underwriters of their option to purchase additional ordinary shares (which may be in the form of ADSs). </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our historical consolidated financial and other data. We derived the summary consolidated statement of income
(loss) data for the years ended December&nbsp;31, 2018 and 2017 from our audited consolidated financial statements included elsewhere in this prospectus. Our audited consolidated financial statements have been prepared in accordance with
International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, as of and for the years ended December&nbsp;31, 2018 and 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical results are not necessarily indicative of the results that may be expected in the future. The following summary financial data
for the periods and as of the dates indicated are qualified by reference to, and should be read in conjunction with, our consolidated financial statements and related notes beginning on <FONT STYLE="white-space:nowrap">page&nbsp;F-1</FONT> of this
prospectus, as well as the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Income (Loss) Data: &nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except per share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue and other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">93,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">44,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from distribution agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net financial loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares outstanding used for computing basic and diluted net income (loss) per
share<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,776,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,351,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 reflect the impacts of the adoption of IFRS 9 and IFRS 15 that became applicable on January&nbsp;1, 2018. The comparative
consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. The impact on the consolidated statement of income (loss) of the adoption of IFRS 9 is not material and the impact of the adoption of IFRS
15 and transition measures are presented in Note 2.a to our consolidated financial statements appearing elsewhere in this prospectus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the year ended December&nbsp;31, 2018, the dilutive effect of warrants granted but not yet exercised and unallocated free shares is not material. As we were in a net loss position for the year ended
December&nbsp;31, 2017, warrants granted but not yet exercised and unallocated free shares do not have a dilutive effect. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Financial Position Data: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, short-term investments and non-current financial assets<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">202,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">451,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial debt and defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As adjusted to give effect to the issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares (including ordinary shares in the form of ADSs) in
the global offering at the assumed initial offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported closing price of our ordinary shares
on Euronext Paris on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, after deducting estimated underwriting commissions and estimated offering expenses payable by us,
assuming no exercise of the underwriters&#146; option to purchase additional ordinary shares (which may be in the form of ADSs). The as adjusted information presented above is illustrative only and will adjust based on the actual offering price, the
actual number of ordinary shares (including ordinary shares in the form of ADSs) offered by us, and the other terms of the global offering determined at pricing. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Non-current assets account for &#128;35.2 million. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed initial offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), the last reported closing price of our ordinary shares on Euronext Paris on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, would increase or decrease each of as adjusted cash and cash equivalents, total assets and total shareholders&#146;
equity by approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), assuming that the number of ordinary shares (including ordinary shares in the form of ADSs) offered by
us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares (including
ordinary shares in the form of ADSs) we are offering. Each increase or decrease of 1,000,000 in the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us would increase or decrease each of as adjusted cash and cash
equivalents, total assets and total shareholders&#146; equity by approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming that the initial offering price
remains the same, and after deducting estimated underwriting discounts and estimated offering expenses payable by us. The as adjusted information discussed above is illustrative only and will adjust based on the actual initial offering price, the
actual number of ordinary shares (including ordinary shares in the form of ADSs) offered by us and other terms of the global offering determined at pricing. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our ordinary shares and ADSs involves a high degree of risk. You should carefully consider the risks and uncertainties
described below, together with all of the other information in this prospectus, including our consolidated financial statements and related notes, before deciding whether to purchase our ordinary shares or ADSs. If any of the following risks are
realized, our business, financial condition, operating results and prospects could be materially and adversely affected. In that event, the market price of our ordinary shares and ADSs could decline, and you could lose part or all of your
investment. Please also see &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Development and Commercialization
of Lumoxiti and Our Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Biopharmaceutical development involves a high degree of uncertainty and most of our
product candidates are in early stages of development, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company with one commercial product, Lumoxiti, which we recently acquired from AstraZeneca and which we have not yet
begun to commercialize on our own. The rest of our portfolio consists of product candidates, some of which we are <FONT STYLE="white-space:nowrap">co-developing,</FONT> in the early stages of clinical development and preclinical programs. Although
we have generated limited revenue from product sales from our only product approved by regulatory authorities, Lumoxiti, we do not expect to have any other significant product sales or related revenue unless our additional product candidates or any
future product candidates are approved for sale and successfully commercialized. Accordingly, our ability to predict our future operating results or business prospects is more limited than if we had a longer history of approved products on the
market or later-stage clinical product candidates. Although Lumoxiti has been approved by the U.S. Food and Drug Administration, or the FDA, it has only been marketed for a short period of time and, to date, AstraZeneca has been responsible for its
commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key element of our strategy is to mature and expand our portfolio of proprietary and partnered product candidates to
address unmet medical needs in immuno-oncology. Although our research and development efforts to date have resulted in a pipeline of product candidates, all of our product candidates require additional development, regulatory review and approvals,
substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before they can be commercialized and before we can generate any revenue from product sales or royalties. If we or our collaboration
partners are unable to successfully develop and market these product candidates, our business, prospects, financial condition and results of operations may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aside from our acquisition of Lumoxiti, our operations to date have been limited to developing our product candidates and undertaking
preclinical studies and clinical trials of our product candidates, including monalizumab, through our partnership with AstraZeneca, IPH4102 and IPH5401, our most advanced product candidates. The success in development of our current and future
product candidates by us or our collaborators will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining positive results in clinical trials including by demonstrating efficacy, safety and durability of
effect of such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completing preclinical studies and receiving regulatory approvals or clearance for conducting clinical trials for
our preclinical programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receiving and maintaining approvals for commercialization of such product candidates from regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing or overseeing the manufacturing of our product candidates in acceptable quantities and at an
acceptable cost; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter, and
performing our obligations pursuant to such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining, protecting, enforcing and expanding our portfolio of intellectual property rights, including
patents, trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">avoiding and defending against third-party interference, infringement or other intellectual property claims; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining and growing an organization of scientists, medical professionals, marketing, distribution and sales
personnel and executives who can develop our product candidates and commercialize any approved products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
if we are unable to reduce our dependence on Lumoxiti and our current clinical and preclinical product candidates, either by <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquiring new product candidates, developing our other product
candidates or discovering new product candidates, we may be similarly adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We will become fully responsible for the
commercialization of Lumoxiti by mid-2020 but we currently have no sales, marketing or commercial product distribution organization and have no experience in marketing or managing the manufacturing of products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company with one commercial product, Lumoxiti, which we recently acquired and have not yet begun to commercialize on
our own. AstraZeneca is currently responsible for all aspects of the commercialization and manufacturing of Lumoxiti in the United States, and we will begin transitioning these activities in the United States in the second half of 2019 and
thereafter be fully responsible for its commercialization and manufacturing by mid-2020. We currently have no sales, marketing or commercial product distribution capabilities and have no experience in managing the manufacturing of or marketing
products. We plan to develop <FONT STYLE="white-space:nowrap">in-house</FONT> marketing and sales capabilities and infrastructure, which will require significant expenses, management resources and time. If we are able to achieve this goal, we will
compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing, sales and distribution personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable or decide not to establish or expand internal sales, marketing and commercial distribution capabilities for Lumoxiti or any
of the products we may develop, we will likely pursue contractual arrangements for the sale, marketing and distribution of such products. However, there can be no assurance that we will be able to establish or maintain such arrangements, and if we
do, we may have little or no control over the sales, marketing and commercial distribution efforts of such third parties. Any revenue we receive will depend upon the efforts of these third parties, and their efforts may not be successful. Our
revenue from product sales may be lower than if we had commercialized Lumoxiti or any future product candidates we may develop, if approved, ourselves. We will also face competition in our search for third parties to assist us with the sales,
marketing and distribution efforts of Lumoxiti or any of our product candidates that receive regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no
assurance that we will be able to develop <FONT STYLE="white-space:nowrap">in-house</FONT> sales and commercial distribution capabilities or establish or maintain relationships with third-party partners to successfully commercialize any product in
the United States, Europe or elsewhere and, as a result, we may not be able to generate product revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to
establish sales, marketing and distribution capabilities for Lumoxiti on a timely basis, we may not be successful in commercializing Lumoxiti. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have a sales, marketing or distribution infrastructure and have no experience in the sale, marketing or distribution of
pharmaceutical products. To achieve commercial success for any approved product, including our approved product, Lumoxiti, we must either develop a sales and marketing organization or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outsource these functions to third parties. Lumoxiti has only been commercially available for a very short period of time and, to date, the responsibilities of commercialization have been handled
by AstraZeneca. We will begin transitioning activities in the United States in the second half of 2019 and thereafter be fully responsible for its commercialization by mid-2020. We plan to use a combination of
<FONT STYLE="white-space:nowrap">focused&nbsp;in-house&nbsp;sales</FONT> and marketing capabilities and third-party collaboration, licensing and distribution arrangements to sell any of our products that receive marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of sales, marketing and distribution capabilities will require substantial resources, will be time-consuming, could delay the
continued commercialization of Lumoxiti and could delay any other potential product launch. If the commercial launch of a product for which we recruit a sales force and establish marketing and distribution capabilities is delayed or does not occur
for any reason, we could have prematurely or unnecessarily incurred these commercialization costs. This may be costly, and our investment could be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we may not be
able to hire or retain a sales force that is sufficient in size or has adequate expertise in the medical markets that we plan to target. If we are unable to establish or retain a sales force and marketing and distribution capabilities, our operating
results may be adversely affected. If a potential partner has development or commercialization expertise that we believe is particularly relevant to one of our product candidates, we may seek to collaborate with that potential partner even if we
believe we could otherwise develop and commercialize the product independently. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The scientific evidence to support the feasibility
of developing product candidates is both preliminary and limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our innovative approach to immuno-oncology aims to activate both
the innate and adaptive immune systems against abnormal or cancerous cells and restore the body&#146;s ability to disrupt their proliferation, potentially leading to durable responses in patients. This approach is focused on developing checkpoint
inhibitors, tumor-targeting antibodies and antibodies that affect the tumor microenvironment, and several of our product candidates rely on novel mechanisms of action for which we have limited scientific evidence and preclinical and clinical data.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not ultimately be able to provide the FDA, European Medicines Agency, or EMA, or other regulatory authorities with substantial
clinical evidence to support a claim of efficacy and durability of response to enable the applicable regulators to approve our product candidates for any indication. This may occur because later clinical trials fail to reproduce favorable data
obtained in earlier clinical trials, because the applicable regulator disagrees with how we interpret the data from these clinical trials or because the applicable regulator does not accept these therapeutic effects as valid endpoints in pivotal
clinical trials that are sufficient to grant marketing approval. Additionally, because product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical
studies and earlier clinical trials our collaborators in earlier stages of clinical trials may eventually choose to discontinue later stage trials. For example, following initial promising results assessing the safety and efficacy of our product
candidate lirilumab for the treatment of various cancer indications, our collaborator decided not to continue development after receiving Phase II clinical trial data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the safety and efficacy traits of any product candidate, clinical trial failures may result from a multitude of factors
including flaws in trial design, dose selection, placebo effect and patient enrollment criteria. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse
safety profiles, notwithstanding promising results in earlier trials, and it is possible that we will as well. Based upon negative or inconclusive results, we or our collaborators may decide, or regulators may require us, to conduct additional
clinical trials or preclinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also need to demonstrate that our product candidates are safe and well tolerated. We do not have significant data on
possible harmful long-term effects of our product candidates and do not expect to have this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
data in the near future. As a result, our ability to generate clinical safety and efficacy data sufficient to support submission of a marketing application or commercialization of our product
candidates is uncertain and is subject to significant risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We intend to develop monalizumab, IPH5401 and other product candidates
in combination with other therapies, which exposes us to additional risks. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently developing monalizumab and IPH5401,
and may develop other product candidates, in combination with one or more currently approved cancer therapies. Specifically, with AstraZeneca, we are currently evaluating monalizumab in an ongoing open-label Phase Ib/II trial in combination with
cetuximab, an epidermal growth factor receptor, or EGFR, inhibitor. AstraZeneca is also currently evaluating monalizumab in ongoing Phase I and II trials in combination with durvalumab, an anti-PD-L1 immune checkpoint inhibitor. Additionally, we are
currently conducting a Phase I clinical trial of IPH5401 in combination with durvalumab, initially in patients with select advanced solid tumors. Patients may not be able to tolerate our product candidates in combination with other therapies. Even
if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA, EMA or other comparable foreign regulatory
authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the
treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other therapies or for indications other than cancer. This could result in our own products, if approved, being
removed from the market or being less successful commercially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also evaluate monalizumab, IPH5401 or any other future product
candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA, EMA or comparable foreign regulatory authorities. We will not be able to market and sell monalizumab, IPH5401 or any other
product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA, EMA or other comparable foreign regulatory authorities do not approve, revoke their approval of, or if safety, efficacy,
manufacturing or supply issues arise with, the products or product candidates we choose to evaluate in combination with monalizumab, IPH5401 or any other product candidate we develop, we may be unable to obtain approval of or market monalizumab,
IPH5401 or any other such product candidate we develop. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We and our collaborators rely on third parties to conduct some of our
preclinical studies and clinical trials and perform other clinical development tasks. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, it may not be
possible to obtain regulatory approval for, or commercialize, our product candidates and our business could be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied upon and plan to continue to rely upon third parties to conduct clinical trials of our product candidates or product candidates
that we have licensed to them. For example, under our license and collaboration agreements with AstraZeneca, AstraZeneca is responsible for a number of clinical trials relating to monalizumab and IPH5201, which are subject to such agreements. In
addition, we and our collaborators are responsible for and are supporting several clinical trials that are sponsored by academic or research institutions, known as investigator-sponsored trials. By definition, the financing, design and conduct of an
investigator-sponsored trial are the sole responsibility of the sponsor, and we or our collaborators, as applicable, have limited control over these aspects of these clinical trials, or the timing and reporting of the data from these trials. We and
our collaborators also depend on independent clinical investigators and Contract Research Organizations, or CROs, to conduct clinical trials. CROs may also assist in the collection and analysis of data. There are a limited number of CROs that have
the expertise to run clinical trials of our product candidates. Identifying, qualifying and managing performance of third-party service providers can be difficult and time consuming and can cause delays
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in our development programs. These investigators and CROs are not our employees and we are not able to control, other than by contract, the amount of resources, including the amount of time, that
they devote to our product candidates and clinical trials. If the investigators sponsoring trials of our product candidates, independent investigators participating in clinical trials that we or our collaborators are sponsoring or CROs fail to
devote sufficient resources to our clinical trials and development of our product candidates or product candidates we have licensed to others, or if their performance is substandard, it may delay or compromise the prospects for approval and
commercialization of any product candidates that we or our collaborators develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this
information will be misappropriated, and we may not be able to obtain adequate remedies for such disclosure or misappropriation. Further, the FDA, EMA and other regulatory authorities require that we comply with standards, commonly referred to as
current Good Clinical Practice, or cGCP, and other local legal requirements, including data privacy regulations, for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the
rights, integrity and confidentiality of clinical trial subjects are protected. If clinical investigators or CROs fail to meet their obligations to us or comply with cGCP procedures or other applicable legal requirements, the data generated in these
trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory
authority, such regulatory authority will determine that all of our clinical trials comply with cGCP regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our
clinical trials must be conducted with product produced under current Good Manufacturing Practice, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval
process. If clinical investigators or CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the
failure to adhere to our protocol or regulatory requirements, or for other reasons, our clinical trials or those of our collaborators may be extended, delayed or terminated, and we or our collaborators may not be able to obtain regulatory approval
for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are heavily dependent on the success of our current clinical-stage product candidates and we cannot be certain that we or our
collaborators will be able to obtain regulatory approval for, or successfully commercialize, these product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
business and future success depend on receiving regulatory approval for, and the commercial success of, our proprietary and partnered product candidates. We have agreements with AstraZeneca with respect to the advanced development, clinical trial
collaboration and potential future registration and marketing of several of our product candidates, including monalizumab and IPH5201, and with Sanofi for the research and development of IPH61. Our near-term prospects depend heavily on
AstraZeneca&#146;s successful clinical development and commercialization of monalizumab as well as the successful clinical development of our other product candidates. The clinical success of these product candidates will depend on a number of
factors, including the ability and willingness of AstraZeneca and our other collaborators to complete ongoing clinical trials for monalizumab, our ability to complete the clinical trials for which we are responsible, and the safety, tolerability and
efficacy of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to develop additional products that receive regulatory
approval and are successfully commercialized. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than our commercial product, Lumoxiti, our pipeline consists of various
product candidates at different phases of preclinical and clinical development. The development of a product candidate is a long, costly and uncertain process, aimed at demonstrating the therapeutic benefit of a product candidate that competes with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
existing products or those being developed. There is no guarantee that we or our collaborators will be able to demonstrate a sufficient degree of clinical efficacy or safety of one or more of our
proprietary or licensed product candidates in order to gain regulatory approval or to become commercially viable. The degree of uncertainty associated with clinical development and the risks associated with developing new product candidates may make
it difficult to evaluate our current business and our future prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to continue to develop our product candidates that are
currently in clinical trials, including monalizumab, IPH4102 and IPH5401. Monalizumab is currently being investigated in multiple Phase I and Phase II clinical trials under a <FONT STYLE="white-space:nowrap">co-development</FONT> agreement with
AstraZeneca. IPH4102 is currently being investigated in an open-label, multi-cohort Phase II clinical trial. IPH5401 is currently being evaluated in Phase I and Phase II clinical trials. While we believe that we will eventually have the <FONT
STYLE="white-space:nowrap">in-house</FONT> capabilities to complete the development of monalizumab, IPH4102 and IPH5401, we have not yet completed the clinical trials for these or other product candidates, and there can be no assurance that these or
other product candidates will gain regulatory approval or become commercially viable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays in the preclinical development of a product
candidate could lead to delays in initiating its clinical development. A failure in the preclinical development of a product candidate could lead to abandoning its development. Further delays or failures at the various clinical stages for a given
indication could result in delay or halt the development of the product candidate in such indication or in other indications. Moreover, disappointing results during the initial phases of development are often not a sufficient basis for deciding
whether or not to continue a project. At these early stages, sample sizes, the duration of studies and the parameters examined may not be sufficient to enable a definitive conclusion to be drawn, in which case further investigations are required.
Conversely, promising results during the initial phases, and even after advanced clinical trials have been conducted, do not guarantee that a product candidate or an approved drug, such as Lumoxiti, will be successfully commercialized and marketed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risks related to the failure of a product candidate&#146;s development are highly related to the stage of maturity of the product
candidate. Given the relatively early stage of the product candidates in our pipeline, there is a substantial risk that some or all of our product candidates will not obtain regulatory approval or be commercialized, which would have an adverse
impact on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to
identify, discover or develop additional product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are seeking to develop a broad and innovative pipeline of product
candidates in addition to monalizumab, IPH4102 and IPH5401. We may not be successful in identifying additional product candidates for clinical development for a number of reasons. For example, our research methodology may be unsuccessful in
identifying potential product candidates or the potential product candidates we identify may have harmful side effects, lack of efficacy or other characteristics that make them unmarketable or unlikely to receive regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research programs to pursue the development of our product candidates for additional indications and to identify new product candidates and
disease targets require substantial technical, financial and human resources. Our research programs may initially show promise in identifying potential indications or product candidates, yet fail to yield results for clinical development for a
number of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research methodology used may not be successful in identifying potential indications or product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates may, after further study, be shown to have harmful adverse effects or other
characteristics that indicate they are unlikely to be effective drugs; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may take greater human and financial resources to identify additional therapeutic opportunities for our
product candidates or to develop suitable potential product candidates through internal research programs than we will possess, thereby limiting our ability to diversify and expand our product portfolio. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, there can be no assurance that we will ever be able to identify additional
indications for our product candidates or to identify and develop new product candidates through internal research programs. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to
be unsuccessful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter substantial delays in our clinical trials, or may be unable to conduct our clinical trials on the
timelines we expect. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any
clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful
or timely completion of clinical development include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the
initiation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or failure in reaching a consensus with regulatory agencies on clinical trial design;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective CROs and investigational sites, the terms of
which can be subject to extensive negotiation and may vary significantly among different CROs and investigational sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a temporary or permanent clinical hold by regulatory agencies, including as a result of a new
safety finding that presents unreasonable risk to clinical trial participants, a negative finding from an inspection of our clinical trial operations or investigational sites, developments in trials conducted by competitors for related technology
that raise regulators&#146; concerns about risk to patients of the technology broadly or if a regulatory body finds that the investigational protocol or plan is clearly deficient to meet its stated objectives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in recruiting suitable patients to participate in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty collaborating with patient groups and investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us, our CROs or other third parties, including our collaborators, to adhere to clinical trial
requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in having patients complete participation in a clinical trial or return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients withdrawing from a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of adverse events associated with a product candidate that are viewed to outweigh its potential
benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical trial protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory feedback requiring us to amend the protocols of ongoing clinical trials in response to safety
considerations, as we have previously been required to; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the standard of care on which a clinical development plan was based, which may require new or
additional clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates being greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates producing negative or inconclusive results, which may result in our
deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfer of manufacturing processes to larger-scale facilities operated by either a contract manufacturing
organization, or CMO, or by us, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">batch recalls, recalls of manufactured product candidates or delays in manufacturing, testing, releasing,
validating, or importing or exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to
generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical
study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates
and may harm our business and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Lumoxiti or our product candidates in development may cause undesirable side
effects or have other properties that could halt or delay their clinical development, prevent their regulatory approval, limit their commercialization or result in other negative consequences. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Use of our approved product, Lumoxiti, or our product candidates in development could be associated with side effects or adverse events which
can vary in severity and in frequency. Undesirable side effects or unacceptable toxicities caused by our products or product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials. The FDA or European
regulatory authorities could delay or deny approval of our product candidates for any or all targeted indications and negative side effects could result in a more restrictive label for any drug that is approved. Side effects such as toxicity or
other safety issues associated with the use of our product candidates could also require us or our collaborators to perform additional studies or halt development of product candidates or sale of approved products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial, or could
result in potential product liability claims. In addition, these side effects may not be appropriately or timely recognized or managed by the treating medical staff, as toxicities resulting from immunotherapy are not normally encountered in the
general patient population and by medical personnel. Inadequate training in recognizing or managing the potential side effects of our product candidates or our approved product, Lumoxiti, could result in adverse effects to patients, including death.
Any of these occurrences may have an adverse impact on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We
face substantial competition from companies with significantly greater resources and experience. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and
pharmaceutical market, and notably the immuno-oncology field, is characterized by rapidly advancing technologies, products protected by intellectual property rights and intense competition and is subject to significant and rapid change as
researchers learn more about diseases and develop new technologies and treatments. We face potential competition from many different sources, including major pharmaceutical companies, specialty pharmaceutical and biotechnology companies, academic
institutions and governmental agencies and public and private research institutions. Any product candidates that we or our collaborators successfully develop will compete with existing therapies and new therapies that may become available in the
future. If competing products are marketed before ours, or at lower prices, or cover a wider therapeutic spectrum, or if they prove to be more effective or better tolerated, our business, prospects, financial condition and results of operations
could be affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors who are developing immuno-oncology and anti-cancer therapies have considerably greater
resources and experience in research, access to patients for clinical trials, drug development, finance, manufacturing, marketing, technology and personnel than we do. In particular, large pharmaceutical companies have substantially more experience
than we do in conducting clinical trials and obtaining regulatory authorizations. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of
our competitors. Smaller or early-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors are also likely to compete
with us to recruit and retain scientific and management personnel, acquire rights for promising product candidates and other complementary technologies, establish clinical trial sites and patient registration for clinical trials and acquire
technologies complementary to, or necessary for, our programs, as well as to enter into collaborations with partners who have access to innovative technologies. If we cannot successfully compete with new or existing products, our marketing and sales
will suffer and we may never be profitable. Should any of these risks materialize, our business, prospects, financial condition and results of operations may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that our product candidates or our approved product, Lumoxiti, will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain regulatory authorizations or become commercially available before those of our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">remain competitive in the face of other products developed by our competitors, which may prove to be safer, are
more effective, have fewer or less severe side effects, are more convenient, have a broader label, have more robust intellectual property protection or are less expensive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">remain competitive in the face of products of competitors that are more efficient in their manufacturing or more
effective in their marketing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not become obsolete or unprofitable due to technological progress or other therapies developed by our
competitors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while our approved product and any future product candidates that are approved may compete
with many existing drugs or other therapies, to the extent they are solely used in combination with these therapies, our product candidates will not be competitive with such therapies but any sales of such products could be limited to sales of the
combination therapy. In this case, we would be exposed to the same competitive risks as the product used in combination with our product, such as a product that is marketed before the combination therapy, has lower prices, covers a wider therapeutic
spectrum or proves to be more effective or better tolerated. For additional information regarding competition to our business see &#147;Business&#151;Competition.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We depend on enrollment of patients in our clinical trials for our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful and timely completion of clinical trials will require that we or our subcontractors enroll a sufficient number of suitable patients.
Clinical trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. Patient enrollment depends on many factors, including the size and nature of the patient population, eligibility
criteria for the trial, the proximity of patients to clinical sites, the design of the clinical protocol, the availability of competing clinical trials, the availability of new drugs approved for the indication the clinical trial is investigating,
and clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug being studied in relation to other available therapies. For example, we are developing IPH4102 for the treatment of cutaneous <FONT
STYLE="white-space:nowrap">T-cell</FONT> lymphoma, or CTCL. CTCL is an orphan disease, which means that the potential patient population is limited. In addition, there are several other product candidates potentially in development for the
indications for which we are developing product candidates, and we may compete for patients with the sponsors of trials for those drugs. These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely
and cost-effective manner. Delays in the completion of any clinical trial of any of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to
commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the inability to obtain regulatory approval of our product
candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and reimbursement may be limited or unavailable in certain market segments
for our approved product, Lumoxiti, and product candidates, if approved, which could make it difficult for us to sell our product or product candidates profitably. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful sales of Lumoxiti and our product candidates, if approved, will depend, in part, on the availability of adequate coverage and
reimbursement from government authorities and third-party payors, such as private health insurers and health maintenance organizations. Patients who are provided medical treatment for their conditions generally rely on third-party payors to
reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States or the Social Security in France, and commercial payors
are critical to new product acceptance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities and third-party payors, such as private health insurers and health
maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination
that use of a product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Policies for coverage and reimbursement for products vary among third-party payors. No uniform policy of coverage and reimbursement for
products exists among third-party payors, and third-party payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of approved drugs and medical services, in addition to questioning their
safety and efficacy. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us or our partners to provide to each payor
supporting scientific, clinical and cost-effectiveness data for the use of our products on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate
reimbursement will be obtained. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available.
Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find
unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> evaluations required following the use of our product candidates or approved
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because our product candidates and our approved product, Lumoxiti, represent new approaches to the treatment of cancer and
accordingly, may have a higher cost than conventional therapies and may require long-term follow-up evaluations, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be elevated. There are currently a
limited number of immunotherapy products that are designed to treat cancer on the market and, accordingly, there is less experience or precedent for the reimbursement of such treatments by governmental entities or third-party payors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Government restrictions on pricing and reimbursement and other healthcare cost-containment initiatives may negatively affect our ability
to generate revenues for Lumoxiti and other product candidates for which we obtain regulatory approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities and
other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, including by limiting coverage and the amount of reimbursement for particular </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medications. Increasingly, third-party payors are requiring that pharmaceutical and biotechnology companies provide them with predetermined discounts from list prices as a condition of coverage,
are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes and are challenging the prices charged for medical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the European Union and other foreign jurisdictions, there have been a number of legislative and regulatory changes to
the healthcare system that could affect our or our partners&#146; ability to sell our products profitably. By way of example, in the United States, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Reconciliation Act, which we collectively refer to as the ACA, was enacted in March 2010 and is having a significant impact on the provision of, and payment for, healthcare in the United States. The ACA was intended to broaden access to health
insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and
impose additional health policy reforms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the provisions of the ACA of importance to our product candidates are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and
biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to
23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#146;s
outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of a manufacturer&#146;s Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been judicial and Congressional
challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal and replace certain aspects of the ACA, and we expect such challenges to continue. Since January 2017, President Trump has signed two executive
orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and
replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision
that repealed, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year
that is commonly referred to as the &#147;individual mandate.&#148; Additionally, on January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
implementation of certain fees mandated by the ACA, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance
plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. Further, the Bipartisan Budget Act of 2018, or the
BBA, among other things, amended the ACA, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; In July and December 2018, CMS published final rules with respect to
permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under its risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses
to determine this risk adjustment. On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by the U.S. Congress as part of the Tax
Cuts and Jobs Act of 2017 Act. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision,
subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and
adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2027 unless additional Congressional action
is taken. Both the Budget Control Act of 2011 and the American Taxpayer Relief Act of 2012, or ATRA, further reduced Medicare payments to several providers and the ATRA increased the statute of limitations period for the government to recover
overpayments to providers from three to five years. Additional legislative proposals to reform healthcare and government insurance programs, along with the trend toward managed healthcare in the United States, could influence the purchase of
medicines and reduce demand and prices for our product candidates, if approved. This could harm our or our partners&#146; ability to market any drugs and generate revenues. Cost containment measures that healthcare payors and providers are
instituting and the effect of further healthcare reform could significantly reduce potential revenues from the sale of any of our product candidates approved in the future, and could cause an increase in our compliance, manufacturing, or other
operating expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United States, federal programs impose penalties on drug manufacturers in the form of mandatory
additional rebates and/or discounts if commercial prices increase at a rate greater than the U.S. Bureau of Labor Statistics consumer price index, and these rebates or discounts, which can be substantial, may affect our ability to raise commercial
prices. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there has been increasing legislative and enforcement interest in the United States with respect to drug pricing
practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between
pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration&#146;s budget proposals for fiscal years 2019 and
2020 contain further drug price control measures that could be enacted during the budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare
Part B, to allow some states to negotiate drug prices under Medicaid and to eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT> patients. The Trump administration also released a &#147;Blueprint&#148; to
lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list
price of their products and reduce the out of pocket costs of drug products paid by consumers. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1,
2020. This final rule codified CMS&#146;s policy change that was effective January 1, 2019. The U.S. Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control
drug costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts,
restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some countries, the proposed pricing for a biopharmaceutical product must be approved
before it may be lawfully marketed. In addition, in certain foreign markets, the pricing of biopharmaceutical product is subject to government control and reimbursement may in some cases be unavailable. The requirements governing drug pricing vary
widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of
medicinal products for human use. An EU member state may approve a specific price for the medicinal product, it may refuse to reimburse a product at the price set by the manufacturer or it may instead adopt a system of direct or indirect controls on
the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and
pricing arrangements for any of our products. Historically, biopharmaceutical products launched in the European Union do not follow price structures of the United States and generally tend to have significantly lower prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that pricing pressures will continue and may increase, which may make it difficult for us to sell Lumoxiti or any of our product
candidates that may be approved in the future at a price acceptable to us or any of our existing or future collaborators. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Lumoxiti
and any of our other product candidates, if approved and commercialized, may fail to achieve market acceptance by physicians, patients, third-party payors or the medical community to a degree that is necessary for commercial success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the medical community accepts a product as safe and efficacious for its indicated use, physicians may choose to restrict the use of the
product if we are unable to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our drug is preferable to any existing drugs or treatments. We cannot predict the degree of market acceptance of Lumoxiti or
any product candidate that receives marketing authorization, which will depend on a number of factors, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demonstration of the clinical efficacy and safety of the drug; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approved labeling for the drug and any required warnings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevalence and severity of adverse side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the advantages and disadvantages of the drug compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ease of the drug&#146;s use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to educate the medical community about the safety and effectiveness of the drug;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of any approval provided by the FDA or foreign regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicity about our product or about competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the coverage and reimbursement policies of government and commercial third-party payors pertaining to the drug;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market price of our drugs relative to competing treatments. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Poor market penetration could have an adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if some of our other product candidates receive marketing authorization, the terms of such approval, ongoing regulation and
potential post-marketing restrictions or withdrawal from the market may limit how the drug may be marketed and may subject us to penalties for failure to comply with regulatory requirements, which could impair our ability to generate revenues.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if any of our other product candidates receives marketing authorization, such approval may carry conditions that limit the
market for the drug or put the drug at a competitive disadvantage relative to alternative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapies. Regulators may limit the marketing of products to particular indications or patient populations. Regulators may require warning labels and drugs with warnings are subject to more
restrictive marketing regulations than drugs without such warnings. These restrictions could make it more difficult to market any drug effectively. Marketing restrictions may reduce the revenue that we are able to obtain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of our product candidates for which we obtain marketing authorization, and the manufacturing processes, post-approval studies and
measures, labeling, advertising and promotional activities for such products, among other things, will be subject to continual requirements of and review by the FDA, EMA and other regulatory authorities. These requirements include submissions of
safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding
the distribution of samples to physicians and recordkeeping. Even if marketing authorization of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the
conditions of approval, including the FDA requirement to implement a risk evaluation and mitigation strategy to ensure that the benefits of a drug or biological product outweigh its risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA, EMA and other national authorities may also impose requirements for costly post-marketing studies or clinical trials and surveillance
to monitor the safety or efficacy of a product, such as long-term observational studies on natural exposure. The FDA and other agencies, including the U.S. Department of Justice, closely regulate and monitor the post-approval marketing and promotion
of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. Later discovery of previously unknown problems with our product candidates
or with manufacturing processes, including adverse events of unanticipated severity or frequency, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of
post-market studies or clinical studies to assess new safety risks, or the imposition of distribution or other restrictions including suspension of production and/or distribution and withdrawal of regulatory approvals. Failure to comply with these
requirements may lead to financial penalties, compliance expenditures, total or partial suspension of production and/or distribution, product seizure or detention, refusal to permit the import or export of products, suspension of the applicable
regulator&#146;s review of a company&#146;s submissions, enforcement actions, product recalls, injunctions and even criminal prosecution, any of which could materially and adversely affect our business, financial condition and results of operations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are exposed to a number of regulatory and commercial risks relating to the United Kingdom&#146;s potential exit from the
European Union. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, a majority of the eligible members of the electorate in the U.K. voted to withdraw from the European
Union in a national referendum, commonly referred to as &#147;Brexit.&#148; Pursuant to Article 50 of the Treaty on European Union, the U.K. will cease to be an EU Member State either on the effective date of a withdrawal agreement (entry into such
a withdrawal agreement will require U.K. parliamentary approval) or, failing that, two years following the U.K.&#146;s notification of its intention to leave the EU (the &#147;Brexit Date&#148;), unless the European Council (together with the U.K.)
unanimously decides to extend the two year period. On March&nbsp;29, 2017, the U.K. formally notified the European Council of its intention to leave the EU. It is unclear how long it will take to negotiate a withdrawal agreement, but it appears
likely that Brexit will continue to involve a process of lengthy negotiations between the U.K. and EU Member States to determine the future terms of the U.K.&#146;s relationship with the EU.&nbsp;For example, in March 2018, the U.K. reached a
provisional agreement (the &#147;Withdrawal Agreement&#148;) with the EU on transitional arrangements following Brexit (which are intended to enable the U.K. to remain within the EU single market and customs union for a transitional period through
2020), but this Withdrawal Agreement needs to be formally agreed as part of the withdrawal arrangements currently under negotiation.&nbsp;Given that no formal withdrawal arrangements have been agreed, there have been several extensions to the Brexit
Date and the U.K. has yet to formally leave the EU. On April&nbsp;11, 2019, the EU granted the U.K. a further extension to the Brexit Date until October&nbsp;31, 2019. The purpose of this extension is to allow for the ratification of the Withdrawal
Agreement by the U.K. House of Commons.&nbsp;If the Withdrawal Agreement is ratified, the U.K. will leave the EU earlier than October&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2019, the U.K. Prime Minister, Theresa May, announced that she would
formally resign from the role of Prime Minister on June&nbsp;7, 2019.&nbsp;Following the resignation of Mrs.&nbsp;May, a leadership contest amongst Conservative party candidates will begin, and a new Prime Minister is set to be appointed by <FONT
STYLE="white-space:nowrap">mid-July.&nbsp;Any</FONT> new Prime Minister may choose to renegotiate the Withdrawal Agreement, or leave the EU on October&nbsp;31, 2019 with no formal withdrawal arrangements in place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical trials in the U.K. are subject to the UK Medicines and Healthcare Products Regulatory Agency, or MHRA and EMA regulations. If the
U.K. proceeds to leave the EU without any formal withdrawal arrangements, there could be considerable uncertainty as to the continued applicability of such regulations in the U.K. We are currently conducting clinical trials of IPH4102 in the U.K.
and we cannot be certain such trials will not be affected if the U.K. leaves the EU without any formal withdrawal arrangements. IPH4102 received an orphan drug designation in the EU, which provides for an exclusive
<FONT STYLE="white-space:nowrap">10-year</FONT> marketing period during which no similar product may apply for a marketing authorization in the EU for the same indication, as well as an exemption from regulatory fees and other advantages. We may
lose this designation and benefits for IPH4102 in the U.K. in the event that the U.K. exits the EU without any formal withdrawal arrangements. Furthermore, if we obtain an MA in the EU, such authorization may not permit us to engage in commercial
sales of our product candidates in the U.K. and we may not be able to obtain the required authorization from the U.K. regulator. If we are required to obtain additional authorizations in the U.K., we will incur additional costs to obtain such
authorizations, which may be significant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred and may in the future incur significant operational losses related to our research and development activities.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net losses in each year since our inception except for the years ended December&nbsp;31, 2016 and 2018. Our net
income (loss) was &#128;3.0&nbsp;million and &#128;(48.4)&nbsp;million for the years ended December&nbsp;31, 2018 and 2017, respectively. Substantially all of our net losses resulted from costs incurred in connection with our development programs
and from general and administrative expenses associated with our ongoing operations. We expect to incur significant expenses and operating losses for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently only have one product, Lumoxiti, that has received regulatory approval for sale or has generated revenues from commercial sales,
and none of our other product candidates have received regulatory approval. Unless this happens, the likelihood and amount of our future operational losses will depend, in part, on the commercialization of our approved product, Lumoxiti, the pace
and amount of our future expenditures and our ability to obtain funding through milestone or royalty payments under our license and collaboration agreements, equity or debt financings, strategic collaborations and government grants and tax credits.
We expect that our main source of income for the near- and medium-term will be: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">revenue from the commercialization of Lumoxiti; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments received under our license and collaboration agreements with third parties, including AstraZeneca and
Sanofi; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">government grants and research tax credits. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The interruption of one of those sources of income could have a material adverse effect on our business, prospects, financial condition and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to be profitable in the future will depend on our ability to generate revenue from sales relating to
our sole commercial product, Lumoxiti, and other product candidates, if approved, and our ability to obtain regulatory approval for marketing our product candidates. If our product candidates receive regulatory approval, our future revenues will
depend upon the size of any markets in which our product candidates have received approval, and market acceptance, reimbursement from third-party payors and market share. Any of these factors could have a material adverse effect on our business,
prospects, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may need to raise additional funding to complete the development and any
commercialization of our product candidates, which may not be available on acceptable terms, or at all, and failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently advancing our product candidates through preclinical and clinical development, and anticipate relying
on partners less as we develop into a commercial stage biopharmaceutical company with research, development and commercial capabilities. We currently retain the full development and marketing rights to IPH4102 and IPH5401 and may retain rights to
additional proprietary product candidates in the future. The development of immunotherapy product candidates is expensive, and we expect our research and development expenses to increase as we advance our product candidates through clinical trials
and regulatory approvals. If clinical trials are successful and obtain regulatory approval for product candidates that we develop, we expect to incur commercialization expenses before these product candidates are marketed and sold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our expenses will increase substantially if and as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our research, preclinical and clinical development of our product candidates if our current
collaboration partners cease their collaborations with us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand the scope of our current clinical trials for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate additional preclinical, clinical or other studies for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">further develop manufacturing processes for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change or add additional manufacturers or suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory and marketing authorizations for our product candidates that successfully complete clinical
studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize Lumoxiti and any other products for
which we may obtain marketing authorization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify and validate additional product candidates that may result in additional preclinical, clinical
or other product studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone or other payments under any <FONT STYLE="white-space:nowrap">in-license</FONT> agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, protect, defend and expand our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract and retain new and existing skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create additional infrastructure to support our operations as a public company in the United States following the
completion of this global offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience any delays or encounter issues with any of the above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, we had cash, cash equivalents, short-term investments and <FONT STYLE="white-space:nowrap">non-current</FONT>
financial assets of &#128;202.7&nbsp;million. We believe our cash, cash equivalents, short-term investments and <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets, together with the net proceeds of the global offering and our cash
flow from operations (including payments we expect to receive pursuant to our collaboration agreements) and government funding of research programs will be sufficient to fund our operations for at
least&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, in order to
complete the development process, obtain regulatory approval and, if approved, commercialize our product candidates that we are developing <FONT STYLE="white-space:nowrap">in-house,</FONT> including IPH4102 and IPH5401, develop our proprietary
technology and develop a pipeline of additional product candidates, we will require additional funding. Our existing resources and the net proceeds from the global offering may not be sufficient to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cover any additional financing needs, in which case new funding would be required. The conditions and arrangements for such new financing would depend, among other factors, on economic and market
conditions that are beyond our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will
be available in sufficient amounts or on terms acceptable to us, if at all. Under French law, our share capital may be increased only with shareholders&#146; approval at an extraordinary general shareholders&#146; meeting on the basis of a report
from the Executive Board. In addition, the French Commercial Code imposes certain limitations on our ability to price certain offerings of our share capital without preferential subscription rights (<I>droit pr&eacute;f&eacute;rentiel de
souscription</I>), which limitation may prevent us from successfully completing any such offering. See &#147;Description of Share Capital&#151;Key Provisions of Our Bylaws and French Law Affecting Our Ordinary Shares.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders and the issuance of additional
securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ordinary shares or the ADSs to decline. The sale of additional equity or convertible securities would dilute our shareholders. We may
seek funds through arrangements with collaborative partners or otherwise at an earlier stage of product development than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or
otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we need and are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more
of our research or development programs or the commercialization of any product or product candidate or we may be unable to expand our operations or otherwise capitalize on our business opportunities as desired, which could impair our growth
prospects. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The terms of our loan agreement with Soci&#233;t&#233; G&#233;n&#233;rale and certain other loan obligations place restrictions on our
operating and financial flexibility. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2017, we entered into a loan and security agreement with Soci&#233;t&#233;
G&#233;n&#233;rale (the &#147;Loan Agreement&#148;) in order to finance the construction of our future headquarters. The Loan Agreement is secured by collateral in the form of financial instruments valued at &#128;15.2 million held at
Soci&#233;t&#233; G&#233;n&#233;rale. The Loan Agreement subjects us to a covenant to maintain a minimum balance of our total cash, cash equivalents and current and non-current financial assets as of each fiscal year end at least equal to the amount
of outstanding principal under the Loan Agreement. Compliance with this covenant may limit our flexibility in operating our business and our ability to take actions that might be advantageous to us and our shareholders. For example, if we fail to
meet our minimum cash covenant and we are unable to raise additional funds or obtain a waiver or other amendment to the Loan Agreement, we may be required to delay, limit, reduce or terminate certain of our clinical development efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may be required to repay the entire amount of outstanding indebtedness under the Loan Agreement in cash if we fail to stay in
compliance with our covenant or suffer some other event of default under the Loan Agreement. Under the Loan Agreement, an event of default will occur if, among other things, we fail to make payments under the Loan Agreement or we breach our covenant
under the Loan Agreement. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In that case, we may be required to
delay, limit, reduce or terminate our clinical development efforts or grant to others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Soci&#233;t&#233; G&#233;n&#233;rale could also
exercise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its rights as collateral agent to take possession and dispose of the collateral securing the loan for its benefit. Our business, financial condition and results of operations could be
substantially harmed as a result of any of these events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to a &#128;1.5 million PTZI loan (Pr&#234;t &#224; Taux
Z&#233;ro Innovation&#151;interest-free loan for innovation) from Banque Publique d&#146;Investissement, or BPI France, entered into in 2013. In addition, in 2008 we entered into a finance lease agreement with Sogebail, a subsidiary of
Soci&#233;t&#233; G&#233;n&#233;rale. The present value of all minimum lease payments under this agreement is &#128;1.1 million at December 31, 2018. Our business, financial condition and results of operations could likewise be substantially harmed
if, among other things, we fail to make payments under these agreements, or we breach any of our covenants under these agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we do not achieve our product development or commercialization objectives in the timeframes we expect, we may not receive product
revenue, milestones or royalty payments and we may not be able to conduct our operations as planned. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received and
expect to continue to receive payments from our collaborators when we satisfy certain <FONT STYLE="white-space:nowrap">pre-specified</FONT> milestones in our licensing or collaboration agreements. We currently depend to a large degree on these
milestone payments from our existing collaborators in order to fund our operations and we may enter into new collaboration agreements that also provide for milestone payments. For example, we have granted options to license or acquire intellectual
property rights in certain of our programs to our collaborators which, if exercised, will result in up-front option exercise fees and, assuming we meet all specified development, clinical, regulatory and sales milestones, could result in substantial
milestone payments. These milestone payments are generally dependent on the accomplishment of various scientific, clinical, regulatory, sales and other product development objectives, and the successful or timely achievement of many of these
milestones is outside of our control, in part because some of these activities are being or will be conducted by our collaborators. If we or our collaborators fail to achieve the applicable milestones, we may not receive such milestone payments. A
failure to receive any such milestone payment may cause us to: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay, reduce or terminate certain research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce headcount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raise funds through additional equity or convertible debt financings that could be dilutive to our shareholders
and holders of our ADSs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain funds through collaboration agreements that may require us to assign rights to technologies or products
that we would have otherwise retained; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sign new collaboration or license agreements that may be less favorable than those we would have obtained under
different circumstances; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consider strategic transactions or engaging in a joint venture with a third party. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, although we may be eligible to receive an aggregate of approximately $5.5 billion in future contingent payments from existing
collaboration agreements and any license agreements that become effective upon the exercise by our collaborators of options to license future product candidates, there is no guarantee that we will receive any contingent payments or that our
collaborators will exercise any options to license or acquire additional intellectual property rights in any of our programs. If our collaborators decide not to exercise such options with respect to a program, we will not receive the up-front option
exercise fee and will not be eligible to receive any of the related commercial, development, royalty or other milestone payments. Even if our collaborators exercise such options with respect to a particular program, we may never achieve the related
milestones for any number of reasons. The failure to receive milestone or royalty payments and the occurrence of any of the events above may have a material adverse impact on our business, prospects, financial condition and results of operations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The revenues generated from our collaboration and license agreements have contributed
and are expected to contribute a large portion of our revenue for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into collaboration and
license agreements with pharmaceutical companies, including AstraZeneca. The cash payments received from our partners were &#128;40.3&nbsp;million and &#128;14.0&nbsp;million for the years ended December&nbsp;31, 2018 and 2017, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also enhance our research efforts by establishing collaborations with academic or <FONT STYLE="white-space:nowrap">non-profit</FONT>
research institutions and other biopharmaceutical companies. The participation in these collaborations may generate revenue and funding in the form of operating grants or the reimbursement of research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to renew or maintain our license agreements or collaborative research contracts or may be unable to sign new agreements
with new collaborators on reasonable terms or at all. The early termination of a contract, the <FONT STYLE="white-space:nowrap">non-renewal</FONT> of a contract or our inability to find new collaborators would adversely affect our business. Should
any of these risks materialize, this could have an adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We benefit from tax credits in France that could be reduced or eliminated. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a French biopharmaceutical company, we benefit from certain tax advantages, including the Research Tax Credit (<I>Cr&eacute;dit Imp&ocirc;t
Recherche</I>), which is a French tax credit aimed at stimulating research and development. The Research Tax Credit is calculated based on our claimed amount of eligible research and development expenditures in France and represented
&#128;13.5&nbsp;million and &#128;11.0&nbsp;million for the years ended December&nbsp;31, 2018 and 2017, respectively. The Research Tax Credit is a source of financing to us that could be reduced or eliminated by the French tax authorities or by
changes in French tax law or regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Research Tax Credit can be offset against French corporate income tax due by the company
with respect to the year during which the eligible research and development expenditures have been made. The portion of tax credit in excess which is not being offset, if any, represents a receivable against the French Treasury which can in
principle be offset against the French corporate income tax due by the company with respect to the three following years. The remaining portion of tax credit not being offset upon expiry of such a period may then be refunded to the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, since we currently qualify as a small- and <FONT STYLE="white-space:nowrap">medium-size</FONT> business, the French Treasury refunded
each of our 2016 and 2017 Research Tax Credit claims immediately (meaning that, in practice, we receive the refund during the year following the year in which the eligible research and development expenditures are made). We expect that in the future
we will no longer qualify as a small- and <FONT STYLE="white-space:nowrap">medium-size</FONT> business and therefore would no longer be entitled to the immediate reimbursement of the Research Tax Credit but instead would be reimbursed within the
expiry of the period of three years mentioned above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The French tax authorities, with the assistance of the Higher Education and Research
Ministry, may audit each research and development program in respect of which a Research Tax Credit benefit has been claimed and assess whether such program qualifies in their view for the Research Tax Credit benefit. The French tax authorities may
challenge our eligibility for, or our calculation of, certain tax reductions or deductions in respect of our research and development activities (and therefore the amount of Research Tax Credit claimed), or the accelerated reimbursement allowed for
small- and <FONT STYLE="white-space:nowrap">medium-size</FONT> businesses and our credits may be reduced, which would have a negative impact on our revenue and future cash flows. Furthermore, the French Parliament may decide to eliminate, or to
reduce the scope or the rate of, the Research Tax Credit benefit, either of which it could decide to do at any time. If we fail to receive future Research Tax Credit amounts or if our calculations are challenged, even if we comply with the current
requirements in terms of documentation and eligibility of its expenditure, our business, prospects, financial condition and results of operations could be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to carry forward existing tax losses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have accumulated tax loss carry forwards of &#128;220.1&nbsp;million as of December&nbsp;31, 2018. Applicable French law provides that, for
fiscal years ending after December&nbsp;31, 2012, the use of these tax losses is limited to &#128;1.0&nbsp;million, plus 50% of the portion of net earnings exceeding this amount. The unused balance of the tax losses in application of such rule can
be carried forward to future fiscal years, under the same conditions and without time restriction. There can be no assurance that future changes to applicable tax law and regulation will not eliminate or alter these or other provisions in a manner
unfavorable to us, which could have an adverse effect on our business, prospects, financial condition, cash flows or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Changes to U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws could materially adversely affect our company.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, the Tax Cuts and Jobs Act was signed into law and significantly revised the Internal Revenue Code of
1986, as amended, or the Code. The Tax Cuts and Jobs Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the
tax deduction for interest expense to 30% of adjusted taxable income (except for certain small businesses), implementation of a &#147;base erosion anti-abuse tax,&#148; which requires U.S. corporations to make an alternative determination of taxable
income without regard to tax deductions for certain payments to affiliates, taxation of certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporations&#146; earnings considered to be &#147;global intangible low taxed income,&#148; which is
also referred to as GILTI, repeal of the alternative minimum tax, or AMT, for corporations and changes to a taxpayer&#146;s ability to either utilize or refund the AMT credits previously generated, changes to the limitation on deductions for certain
executive compensation particularly with respect to the removal of the previously allowed performance based compensation exception, changes in the attribution rules relating to shareholders of certain &#147;controlled foreign corporations,&#148;
limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, <FONT STYLE="white-space:nowrap">one-time</FONT> taxation of offshore earnings at reduced rates regardless
of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or
repealing many business deductions and credits. Notwithstanding the reduction in the U.S. corporate income tax rate, the overall impact of the Tax Cuts and Jobs Act is uncertain and our business and financial condition could be adversely affected.
The impact of the Tax Cuts and Jobs Act on holders of our ordinary shares or ADSs is also uncertain and could be adverse. For example, recent changes in U.S. federal income tax law resulting in additional taxes owed by U.S. holders (as described
under &#147;Material United States Federal Income Tax and French Tax Considerations&#151;Material U.S. Federal Income Tax Considerations&#148;) under the new GILTI tax rules or related to &#147;controlled foreign corporations&#148; may discourage
U.S. investors from owning or acquiring 10% or greater of our outstanding ordinary shares or ADSs, which other shareholders may have viewed as beneficial or may otherwise negatively impact the trading price of our ordinary shares or ADSs. We are
unable to predict what federal tax law may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices, could
affect our effective tax rates in the future in countries where we have operations and have an adverse effect on our overall tax rate in the future, along with increasing the complexity, burden and cost of tax compliance. We urge our shareholders
and holders of our ADSs to consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our ordinary shares or ADSs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes
or <FONT STYLE="white-space:nowrap">non-realization</FONT> of expected benefits. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A tax authority may disagree with tax positions
that we have taken, which could result in increased tax liabilities. For example, the French tax authorities, the U.S. Internal Revenue Service or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts
paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject
to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#147;permanent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
establishment&#148; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. A tax authority may take the
position that material income tax liabilities, interest and penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing
the assessment, the result could increase our anticipated effective tax rate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval and Marketing of Our Product
Candidates and Legal Compliance Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we complete the necessary preclinical studies and clinical trials, the marketing
approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required
regulatory approvals, in particular in the United States or the European Union, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research and development of pharmaceutical products is governed by complex regulatory requirements. The regulatory agencies that oversee
these requirements have the authority to permit the commencement of clinical trials or to temporarily or permanently halt a study. They are entitled to request additional clinical data before authorizing the commencement or resumption of a study,
which could result in delays or changes to our product development plan. As we advance our product candidates, we will be required to consult with these regulatory agencies and comply with all applicable guidelines, rules and regulations. If we fail
to do so, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our
ability to generate sufficient product revenue to maintain our business. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical trials of our product candidates are, and the
manufacturing and marketing of our one approved product, Lumoxiti, and our other product candidates will be, subject to regulation by numerous government authorities in the United States, in the European Union and in other countries where we intend
to test and, if approved, market any product candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate, with substantial evidence gathered in well-controlled clinical trials, and, with
respect to approval in the United States, to the satisfaction of the FDA, with respect to approval in the European Union, to the satisfaction of the EMA or, with respect to approval in other countries, similar regulatory authorities in those
countries, that the product candidate is safe and effective for use in each target indication. When we acquired Lumoxiti, AstraZeneca had already obtained marketing approval from the FDA. We have never submitted a product candidate for marketing
approval in the United States or elsewhere. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, we expect that the requisite regulatory submission to seek
marketing authorization for our product candidates will be a Biologic License Application, or BLA, and the competent regulatory authority is the FDA. In the European Union, the requisite approval is a Marketing Authorization, or MA, which for
products developed by the means of antibody-based therapeutics, gene or cell therapy products as well as tissue engineered products, is issued through a centralized procedure involving the EMA (see &#147;Business&#151;Regulation&#148;). Satisfaction
of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. Failure to comply with the applicable requirements at any time during the product development process, approval process or after
approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include, for example, the FDA&#146;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters,
product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data from preclinical and clinical studies are likely to give rise to different interpretations, which could delay regulatory authorization,
restrict the scope of any such authorization or force us to repeat trials in order to meet the requirements of the various regulators. Regulatory requirements and processes vary widely among </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
countries, and we may be unable to obtain authorization within each relevant country in a timely manner. Regulatory authorities may prevent us from starting clinical trials or continuing clinical
development if the data were not produced according to applicable regulations or if they consider that the balance between the expected benefits of the product and its possible risks is not sufficient to justify the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite our efforts, our product candidates may not: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer improvement over existing, comparable products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be proven safe and effective in clinical trials; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meet applicable regulatory standards. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This process can take many years and may include post-marketing studies and surveillance, which will require the expenditure of substantial
resources beyond our existing cash on hand and the net proceeds we expect to raise in this offering. Of the large number of drugs in development globally, only a small percentage successfully complete the regulatory approval process and not all
approved drugs are successfully commercialized. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary for us or our partners to bring a potential product candidate to market could have a material adverse
effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory processes that will govern the
approval of our product candidates are complex and changes in regulatory requirements could result in delays or discontinuation of development or unexpected costs in obtaining regulatory approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates are based on new technologies that are constantly evolving and have not been extensively tested on humans. The
applicable regulatory requirements vary between jurisdictions and are also complex, potentially difficult to apply and subject to significant modifications. Modifications to regulations during the course of clinical development and regulatory review
may lead to delays or the refusal of authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Europe, the United States and other countries, regulations can potentially: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significantly delay or increase the cost of development, testing, manufacturing and marketing of our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the indications for which we will be authorized to market our products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impose new, more stringent, requirements, suspend marketing authorizations, or request the suspension of clinical
trials or the marketing of our products if unexpected results are obtained during trials performed by other researchers on products similar to our products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketing authorization in one jurisdiction does not ensure marketing authorization in another, but a failure or delay in obtaining marketing
authorization in one jurisdiction may have a negative effect on the regulatory process in others. Failure to obtain marketing authorization in other countries or any delay or setback in obtaining such approval would impair our ability to develop
additional markets for our product, Lumoxiti, or any additional product candidates that are approved. This would reduce our target market and limit the full commercial potential of our product or product candidates. Should any of these risks
materialize, this could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to obtain marketing approval in jurisdictions other than the United States
and Europe would prevent our product candidates from being marketed in these other jurisdictions, and any approval we are granted for our product candidates in the United States and Europe would not assure approval of product candidates in other
jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market and sell our other product candidates in jurisdictions other than the United States and Europe,
we must obtain separate marketing approvals and comply with numerous and varying regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements. The approval process varies among countries and can involve additional testing. The time required to obtain approval may differ from that required to obtain FDA approval or
approvals from regulatory authorities in the European Union. The regulatory approval process outside the United States and Europe generally includes all of the risks associated with obtaining FDA approval or approvals from regulatory authorities in
the European Union. In addition, some countries outside the United States and Europe require approval of the sales price of a product before it can be marketed. In many countries, separate procedures must be followed to obtain reimbursement and a
product may not be approved for sale in the country until it is also approved for reimbursement. We may not obtain marketing, pricing or reimbursement approvals outside the United States and Europe on a timely basis, if at all. Approval by the FDA
or regulatory authorities in the European Union does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States and Europe does not ensure approval by
regulatory authorities in other countries or jurisdictions or by the FDA or regulatory authorities in the European Union. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any
market. Marketing approvals in countries outside the United States and Europe do not ensure pricing approvals in those countries or in any other countries, and marketing approvals and pricing approvals do not ensure that reimbursement will be
obtained. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Side effects that appear following the launch of a drug on the market may result in the product being taken off the
market or additional warnings being added to the label despite having obtained all regulatory approvals. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A drug&#146;s launch in
the market may expose a large number of patients to potential risks associated with the treatment with a new pharmaceutical product. Certain side effects, which may not have been identified during clinical trials, can subsequently appear. For these
reasons, regulatory agencies require companies to implement post-approval monitoring. Depending on the occurrence of serious undesirable effects, the agencies may require that we or a collaboration partner of ours take a drug off the market
temporarily or permanently, even if it is effective and has obtained all the necessary marketing authorizations. Such an action would negatively impair our ability to generate revenue from such product and could more generally negatively affect our
ability to develop, obtain regulatory approval for, and commercialize our other product candidates and our reputation generally, each of which could have a material adverse effect on our business and results of operations. In addition, if the
product candidates we develop receive marketing authorization and we or others identify undesirable side effects caused by Lumoxiti or any other products after the approval, a number of potentially significant negative consequences could result,
including that regulatory authorities may require the addition of labeling statements, such as a &#147;boxed&#148; warning or a contraindication, we may be required to create a medication guide outlining the risks of such side effects for
distribution to patients and our reputation may suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Lumoxiti and any other product candidate for which we obtain marketing
approval will be subject to strict enforcement of post-marketing requirements and we could be subject to substantial penalties, including withdrawal of our product from the market, if we fail to comply with all regulatory requirements or if we
experience unanticipated problems with our product and product candidates, when and if any of them are approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lumoxiti and any
product candidate for which we obtain marketing approval, will be subject to continual requirements of and review by the FDA, EMA and other regulatory authorities, including requirements relating to manufacturing processes, post-approval clinical
data, labeling, advertising and promotional activities for such product. These requirements include, but are not limited to, restrictions governing promotion of an approved product, submissions of safety and other post-marketing information and
reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to
physicians and recordkeeping. In addition, even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed, restrictions for specified age groups,
warnings, precautions or contraindications or to the conditions of approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other federal and state agencies, including the U.S. Department of Justice, or
DOJ, closely regulate compliance with all requirements governing prescription products, including requirements pertaining to marketing and promotion of products in accordance with the provisions of the approved labeling and manufacturing of products
in accordance with cGMP requirements. The FDA and DOJ impose stringent restrictions on manufacturers&#146; communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use and if we do not market our products for their approved
indications, we may be subject to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing. Prescription products may be promoted only for the approved indications and in accordance with the provisions of the approved
label. However, companies may also share truthful and not misleading information that is otherwise consistent with the labeling. Violations of such requirements may lead to investigations alleging violations of the Food, Drug and Cosmetic Act and
other statutes, including the False Claims Act and other federal and state health care fraud and abuse laws as well as state consumer protection laws. Our failure to comply with all regulatory requirements, and later discovery of previously unknown
adverse events or other problems with our products, manufacturers or manufacturing processes, may yield various results, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">litigation involving patients taking our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on such products, manufacturers or manufacturing processes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the labeling or marketing of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning letters or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of the products from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall of products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">damage to relationships with any potential collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable press coverage and damage to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-compliance</FONT> by us or any future collaborator with the FDA, EMA or other regulatory requirements
regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with regulatory
requirements regarding the protection of personal information can also lead to significant penalties and sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our future
growth depends, in part, on our ability to penetrate multiple markets, in which we would be subject to additional regulatory burdens and other risks and uncertainties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future profitability will depend, in part, on our ability to commercialize Lumoxiti and our product candidates, if approved, in markets in
Europe, the United States and other countries where we maintain commercialization rights. If we commercialize Lumoxiti and any of our product candidates, if approved, in multiple markets, we would be subject to additional risks and uncertainties,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency exchange rate fluctuations and currency controls; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially adverse and/or unexpected tax consequences, including penalties due to the failure of tax planning or
due to the challenge by tax authorities on the basis of transfer pricing and liabilities imposed from inconsistent enforcement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the burden of complying with complex and changing regulatory, tax, accounting and legal requirements, many of
which vary between countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different medical practices and customs in multiple countries affecting acceptance of drugs in the marketplace;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing payor reimbursement regimes, governmental payors or patient
<FONT STYLE="white-space:nowrap">self-pay</FONT> systems and price controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tariffs, trade barriers, import or export licensing requirements or other restrictive actions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is common; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced or loss of protection of intellectual property rights in some foreign countries, and related prevalence
of generic alternatives to therapeutics; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">becoming subject to the different, complex and changing laws, regulations and court systems of multiple
jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other risks
associated with international operations may adversely affect our ability to attain or maintain profitable operations. Future sales of Lumoxiti or our product candidates, if they are approved, will be dependent on purchasing decisions of and
reimbursement from government health administration authorities, distributors and other organizations. As a result of adverse conditions affecting the global economy and credit and financial markets, including disruptions due to political
instability or otherwise, these organizations may defer purchases, may be unable to satisfy their purchasing or reimbursement obligations, or may affect milestone payments or royalties for Lumoxiti, monalizumab or any of our product candidates that
are approved for commercialization in the future. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if our product candidates obtain regulatory approval, they will be subject to continuous regulatory review. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If marketing authorization is obtained for any of our product candidates, the candidate will remain subject to continuous review and therefore
authorization could be subsequently withdrawn or restricted. We will be subject to ongoing obligations and oversight by regulatory authorities, including adverse event reporting requirements, marketing restrictions and, potentially, other
post-marketing obligations, all of which may result in significant expense and limit our ability to commercialize such products. For example, we will be responsible for the completion of an FDA required post-marketing trial of Lumoxiti. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture
of a product, or if we or one of our distributors, licensees or <FONT STYLE="white-space:nowrap">co-marketers</FONT> fails to comply with regulatory requirements, the regulators could take various actions. These include imposing fines on us,
imposing restrictions on the product or its manufacture and requiring us to recall or remove the product from the market. The regulators could also suspend or withdraw our marketing authorizations, requiring us to conduct additional clinical trials,
change our product labeling or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory
requirements, which could materially adversely affect our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if one of our product candidates has orphan drug designation, we may not be able
to obtain any benefit from such designation. Furthermore, if a product is granted orphan drug exclusivity in the same indication for which we are developing IPH4102 or our other product candidates that is granted orphan drug designation, we may not
be able to have our product candidate approved by the applicable regulatory authority for a significant period of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory
authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is
a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. In the European Union, the European Commission may designate a product candidate as an
orphan medicinal product if it is a medicine for the diagnosis, prevention or treatment of life-threatening or very serious conditions that affects not more than five in 10,000 persons in the European Union, or it is unlikely that marketing of the
medicine would generate sufficient returns to justify the investment needed for its development. Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such
designation, the product is entitled to a period of marketing exclusivity, which, subject to certain exceptions, precludes the FDA from approving the marketing application of another drug for the same indication for that time period or precludes the
EMA, and other national drug regulators in the European Union, from accepting the marketing application for another medicinal product for the same indication. The applicable period is seven years in the United States and ten years in the European
Union. The European Union period can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug
exclusivity may be lost in the United States if the FDA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare
disease or condition. The granting of a request for orphan drug designation does not alter the standard regulatory requirements and process for obtaining marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IPH4102 has been granted orphan drug designation for CTCL in Europe and in the United States and we may pursue orphan drug designation for
another product candidate that we may develop in the future in the United States and/or Europe. However, there is no assurance we will be able to receive orphan drug designation for other product candidates that we may develop in the United States
and/or Europe or for any other product candidate in any jurisdiction. Even if we are successful in obtaining orphan drug designation, orphan drug status may not ensure that we have market exclusivity in a particular market. Even if we obtain orphan
drug exclusivity for any of our product candidates, that exclusivity may not effectively protect the product from competition because exclusivity can be suspended under certain circumstances. In the United States, even after an orphan drug is
approved, the FDA can subsequently approve another drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the
European Union, orphan exclusivity will not prevent a marketing authorization being granted for a similar medicinal product in the same indication if the new product is safer, more effective or otherwise clinically superior to the first product or
if the marketing authorization holder of the first product is unable to supply sufficient quantities of the product. In addition, if another product is granted marketing approval and orphan drug exclusivity in the same indication for which we are
developing a product candidate with orphan drug designation, we may not be able to have our product candidate approved by the applicable regulatory authority for a significant period of time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>A fast track, breakthrough therapy or other designation by the FDA may not actually lead to a faster development. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek fast track, breakthrough&nbsp;therapy or similar designation for our product candidates. If a product is intended for the treatment
of a serious or life threatening condition and the product demonstrates the potential to address unmet medical need for this condition, the sponsor may apply for FDA fast track designation. We have received fast track designation for IPH4102 for the
treatment of adult patients with relapsed or refractory S&eacute;zary syndrome who have received at least two prior systemic therapies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may in the future seek a breakthrough therapy designation for some of our
product candidates that reach the regulatory review process. A breakthrough therapy is a drug candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and that, as
indicated by preliminary clinical evidence, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs
designated as breakthrough therapies by the FDA are eligible for accelerated approval and increased interaction and communication with the FDA designed to expedite the development and review process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, these designations do not ensure that we will experience a faster development process, review or approval compared to conventional
FDA procedures. In addition, the FDA may withdraw a designation if it believes that the designation is no longer supported by data from our clinical development program. A designation alone does not guarantee qualification for the FDA&#146;s
priority review procedures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Priority review designation by the FDA may not lead to a faster regulatory review or approval process
and, in any event, does not assure FDA approval of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA determines that a product candidate offers
major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six
months, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if
we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster regulatory review process or necessarily confer any
advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the <FONT STYLE="white-space:nowrap">six-month</FONT> review cycle or thereafter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our
operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to other laws and regulations governing our international operations, including regulations administered by the governments of
the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as the trade
control laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing
payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in
obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect
all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the
FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in
connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">French anti-corruption laws also prohibit acts of bribery and influence peddling: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles 433-1 1&deg; and 432-11 1&deg; of the French Criminal Code (bribery of domestic public officials);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles 433-1 2&deg; and 432-11 2&deg; of the French Criminal Code (influence peddling involving domestic public
officials ); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article 434-9 of the French Criminal Code (bribery of domestic judicial staff); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article 434-9-1 of the French Criminal Code (influence peddling involving domestic judicial staff);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles 445-1 and 445-2 of the French Criminal Code (bribery of private individuals); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article 433-2 of the French Criminal Code (influence peddling involving private individuals);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles 435-1 and 435-3 of the French Criminal Code (bribery of foreign or international public officials);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles 435-7 and 435-9 of the French Criminal Code (bribery of foreign or international judicial staff);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles 435-2, 435-4, 435-8 and 435-10 of the French Criminal Code (active and passive influence peddling
involving foreign or international public officials and foreign or international judicial staff); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">French Law of December 9<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2017 on Transparency, the Fight
Against Corruption and the Modernization of the Economy (Sapin 2 Law). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no assurance that we will be effective
in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the French anti-corruption laws or other legal requirements, including trade control laws. If we are not in compliance with the FCPA, the French anti-corruption
laws and other anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial
condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA, the French anti-corruption laws, other anti-corruption laws or trade control laws by U.S. or other authorities could also have an
adverse impact on our reputation, our business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to healthcare laws
and regulations which may require substantial compliance efforts and could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings, among other penalties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and others will play a primary role in the recommendation and prescription of our products, if approved. Our
arrangements with such persons and third-party payors and our operations will expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we research, market, sell and distribute our products, if we obtain marketing authorization. Restrictions under applicable U.S. federal, state and foreign healthcare laws and regulations include, but are not limited to, the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and
willfully soliciting, offering, receiving or providing remuneration, including any kickback, bribe or rebate, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the
purchase or lease, order or recommendation of, any item, good, facility or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False
Claims Act, which impose criminal and civil penalties, including those from civil whistle-blower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment that
are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal
criminal statutes that impose criminal and civil liability for, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or covering up a material
fact or making false statements relating to healthcare matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing
regulations, which impose certain requirements on covered entities and their business associates, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health
information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal transparency requirements under the Physician Payments Sunshine Act, enacted as part of the ACA,
that require applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, with specific exceptions, to track and annually
report to CMS payments and other transfers of value provided to physicians and teaching hospitals, and certain ownership and investment interests held by physicians or their immediate family members; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state or foreign laws and regulations, such as state anti-kickback and false claims laws, including the
French &#147;Bertrand Law&#148;, French Ordinance <FONT STYLE="white-space:nowrap">n&deg;2017-49</FONT> of 19&nbsp;January 2017, and the UK&#146;s Bribery Act 2010, which may apply to items or services reimbursed by any third-party payor, including
commercial insurers, state marketing and/or transparency laws applicable to manufacturers that may be broader in scope than the federal requirements, state laws that require biopharmaceutical companies to comply with the biopharmaceutical
industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, state laws that require the reporting of information relating to drug and biologic pricing; state and local laws that require
the registration of pharmaceutical sales representatives and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect as
HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that our business arrangements with third parties comply with
applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable
fraud and abuse or other healthcare laws and regulations. If our operations were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and
administrative penalties, damages, fines, disgorgement, imprisonment, possible exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate
integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our
operations, any of which could substantially disrupt our operations. If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil
or administrative sanctions, including exclusions from government funded healthcare programs. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>European data collection is governed by restrictive regulations governing the collection, use, processing and cross-border transfer
of personal information. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may collect, process, use or transfer personal information from individuals located in the European
Union in connection with our business, including in connection with conducting clinical trials in the European Union. Additionally, we intend to commercialize Lumoxiti, and any of our product candidates that receive marketing approval, in the
European Union. The collection and use of personal health data in the European Union is governed by the provisions of the General Data Protection Regulation ((EU) 2016/679), or the GDPR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
This legislation imposes requirements relating to having legal bases for processing personal information relating to identifiable individuals and transferring such information outside of the
European Economic Area, or EEA, including to the United States, providing details to those individuals regarding the processing of their personal information, keeping personal information secure, having data processing agreements with third parties
who process personal information, responding to individuals&#146; requests to exercise their rights in respect of their personal information, reporting security breaches involving personal data to the competent national data protection authority and
affected individuals, appointing data protection officers, conducting data protection impact assessments and record-keeping. The GDPR imposes additional responsibilities and liabilities in relation to personal data that we process and we may be
required to put in place additional mechanisms ensuring compliance with the new data protection rules. Failure to comply with the requirements of the GDPR and related national data protection laws of the member states of the European Union may
result in substantial fines, other administrative penalties and civil claims being brought against us, which could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Reliance on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We depend upon our existing collaboration partners, AstraZeneca, Sanofi and other third parties, and may depend upon future collaboration
partners to commit to the research, development, manufacturing and marketing of our drugs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have significant collaborations with
AstraZeneca for the commercialization of Lumoxiti and the development of monalizumab, IPH5201 and other product candidates. We also collaborate with Sanofi for the development of IPH61, and we may enter into additional collaborations for other of
our product candidates or technologies in development. We cannot control the timing or quantity of resources that our existing or future collaborators will dedicate to research, preclinical and clinical development, manufacturing or marketing of our
products. Our collaborators may not perform their obligations according to our expectations or standards of quality. Our collaborators could terminate our existing agreements for a number of reasons, including that they may have other, higher
priority products in development or because our partnered programs may no longer be a priority for them. If any of our collaboration agreements were to be terminated, we could encounter significant delays in developing our product candidates, lose
the opportunity to earn any revenues we expected to generate under such agreements, incur unforeseen costs, and suffer damage to the reputation of our product, product candidates and as a company generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to optimize the launch and market penetration of certain of our future product candidates, we may enter into distribution and
marketing agreements with pharmaceutical industry leaders. For these product candidates, we would not market our products alone once they have obtained marketing authorization. The risks inherent in entry into these contracts are as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the negotiation and execution of these agreements is a long process that may not result in an agreement being
signed or that can delay the development or commercialization of the product candidate concerned; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">these agreements are subject to cancellation or <FONT STYLE="white-space:nowrap">non-renewal</FONT> by our
collaborators, or may not be fully complied with by our collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of a license granted by us, we lose control of the development of the product candidate licensed; in
such cases we would have only limited control over the means and resources allocated by our partner for the commercialization of our product; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly obtain, maintain, enforce, or defend our intellectual property or proprietary
rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these risks materialize, or should we fail to find suitable collaborators, this could have a material adverse effect on our
business, prospects, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The late-stage development and marketing of our product candidates may partially
depend on our ability to establish collaborations with major biopharmaceutical companies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to develop and market some of
our product candidates, we rely on collaboration, research and license agreements with pharmaceutical companies to assist us in the development of product candidates and the financing of their development. For our most advanced clinical product
candidate, monalizumab, we entered into an agreement with AstraZeneca, in part because of their late-stage development and marketing capabilities. As we identify new product candidates, we will determine the appropriate strategy for development and
marketing, which may result in the need to establish collaborations with major biopharmaceutical companies. We may also enter into agreements with institutions and universities to participate in our other research programs and to share intellectual
property rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may fail to find collaboration partners and to sign new agreements for our other product candidates and programs. The
competition for partners is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for example, development
or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the collaborator terminates the collaboration. Any such collaboration, or other strategic transaction, may require us to incur <FONT
STYLE="white-space:nowrap">non-recurring</FONT> or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail
numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#146;s time and attention in order to manage a collaboration or develop acquired products, product
candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill
or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or
customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Accordingly, although there can be no assurance that we will undertake or successfully complete any
transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material and adverse effect on our business, financial condition, results of operations and prospects.
Conversely, any failure to enter any additional collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the
competitiveness of any product candidate that reaches market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to supply key materials used in our research
and development, to provide services to us and to assist with clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make considerable use of third-party suppliers
for the key materials used in our business. The failure of third-party suppliers to comply with regulatory standards could result in the imposition of sanctions on us. These sanctions could include fines, injunctions, civil penalties, refusal by
regulatory organizations to grant approval to conduct clinical trials or marketing authorization for our products, delays, suspension or withdrawal of approvals, license revocation, seizure or recalls of our products, operating restrictions and
legal proceedings. Furthermore, the presence of <FONT STYLE="white-space:nowrap">non-conformities,</FONT> as detected in regulatory toxicology studies, could result in delays in the development of one or more of our product candidates and would
require further tests to be financed. Although we are involved in establishing the protocols for the production of these materials, we do not control all the stages of production and cannot guarantee that the third parties will fulfil their
contractual and regulatory obligations. In particular, a partner&#146;s failure to comply with protocols or regulatory constraints, or repeated delays by a partner, could compromise the development of our products or limit its liability. Such events
could also inflate the product development costs incurred by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also use third parties to provide certain services such as
scientific, medical or strategic consultancy services. These service providers are generally selected for their specific expertise, as is the case with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
academic partners with whom we collaborate. To build and maintain such a network under acceptable terms, we face intense competition. Such external collaborators may terminate, at any time, their
involvement. We can exert only limited control over their activities. We may not be able to obtain the intellectual property rights to the product candidates or technologies developed under collaboration, research and license agreements under
acceptable terms or at all. Moreover, our scientific collaborators may assert intellectual property rights or other rights beyond the terms of their engagement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, we use third-party investigators to assist with conducting clinical trials. All clinical trials are subject to strict regulations and
quality standards. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We do not and will not have access to all information regarding our product candidates that are subject to collaboration and license
agreements. Consequently, our ability to inform our shareholders about the status of product candidates that are subject to these agreements, and our ability to make business and operational decisions, may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not and will not have access to all information regarding our product candidates that are subject to our license and collaboration
agreements with AstraZeneca, Sanofi and other third parties, including potentially material information about clinical trial design, execution and timing, safety and efficacy, clinical trial results, regulatory affairs, manufacturing, marketing and
other areas known by our collaborators. In addition, we have confidentiality obligations under our collaboration and license agreements. Therefore, our ability to keep our shareholders informed about the status of product candidates subject to such
agreements will be limited by the degree to which our collaborators keep us informed and allow us to disclose information to the public or provide such information to the public themselves. If our collaborators do not inform us about our product
candidates subject to agreements with them, we may make operational and investment decisions that we would not have made had we been fully informed, which may have an adverse impact on our business, prospects, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Manufacture of Lumoxiti and Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have no manufacturing capabilities and rely on third-party manufacturers for Lumoxiti and our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates that are tested during our preclinical and clinical trials are manufactured by third parties. We have no production
capabilities and rely on third parties to manufacture our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This strategy means that we do not directly control certain key
aspects of our product development, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the quality of the product manufactured; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the delivery times for drugs for a given clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical and commercial quantities that can be supplied; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with applicable laws and regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on third-party manufacturers creates risks that may not exist if we had our own manufacturing capabilities. These risks include:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of third-party manufacturers to comply with regulatory and quality-control standards;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production of insufficient quantities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">damage during transport and/or storage of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">breach of agreements by third-party manufacturers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the agreements for reasons beyond our
control. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should our third-party manufacturers breach their obligations or should we fail to renew
our contracts with them, we cannot guarantee that we will be able to find new suppliers within a timeframe and under conditions that would not be detrimental. We could also be faced with delays or interruptions in our supplies, which could result in
a delay in the clinical trials and, ultimately, a delay in the commercialization of the product candidates that we are developing or a loss of product sales. For example, manufacturing issues, leading to out-of-specification product, can occur
during a manufacturing campaign at the CMO in charge of the production of our product candidates. Reproducing a batch of product is a lengthy and costly process and sometimes can lead to drug shortage that can in turn lead to a delay in the
development of the candidate, or even an early stop of a clinical trial. This happened in the early clinical development of IPH4102 and led to the decision to limit the number of patients in order to ensure drug supply for treated patients. Should
any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are reliant upon third parties to manufacture and supply components of certain substances necessary to manufacture Lumoxiti and our
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently independently conduct manufacturing activities for Lumoxiti or our product candidates in
development, and we are reliant on several third-party CMOs for the manufacture and supply of components and substances for all of the product candidates we are developing. In addition, certain component materials are currently available from a
single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to manufacture
these materials for us. We cannot assure you that, if required, we will be able to identify alternate sources with the desired scale and capability and establish relationships with such sources. A loss of any CMO or component supplier and delay in
establishing a replacement could delay our clinical development and regulatory approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing facilities and
clinical trial sites are subject to significant government regulations and approvals and if our or our partners third-party manufacturers fail to comply with these regulations or maintain these approvals, our business could be materially harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our third-party manufacturers are subject to ongoing regulation and periodic inspection by national authorities, including the
EMA, FDA and other regulatory bodies to ensure compliance with cGMP, when producing batches of Lumoxiti and our product candidates for clinical trials. CROs and other third party research organizations must also comply with GLP when carrying out
regulatory toxicology studies. Any failure to follow and document our or their adherence to such GMP and GLP regulations or other regulatory requirements may lead to significant delays in the availability of products for commercial sale or clinical
trials, may result in the termination of or a hold on a clinical trial, or may delay or prevent filing or approval of marketing applications for our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with applicable regulations could also result in national authorities, the EMA, FDA or other applicable regulatory
authorities taking various actions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">levying fines and other civil penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposing consent decrees or injunctions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring us to suspend or put on hold one or more of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspending or withdrawing regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delaying or refusing to approve pending applications or supplements to approved applications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring us to suspend manufacturing activities or product sales, imports or exports; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring us to communicate with physicians and other customers about concerns related to actual or potential
safety, efficacy, and other issues involving our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandating product recalls or seizing products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposing operating restrictions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeking criminal prosecutions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the foregoing actions could be detrimental to our reputation, business, financial condition or operating results. Furthermore, our key
suppliers may not continue to be in compliance with all applicable regulatory requirements, which could result in our failure to produce our products on a timely basis and in the required quantities, if at all. In addition, before any additional
products would be considered for marketing authorization in Europe, the United States or elsewhere, our suppliers will have to pass an inspection by the applicable regulatory agencies. We are dependent on our suppliers&#146; cooperation and ability
to pass such inspections, and the inspections and any necessary remediation may be costly. Failure to pass such inspections by us or any of our suppliers would affect our ability to commercialize Lumoxiti or our product candidates in Europe, the
United States or elsewhere. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our production costs may be higher than we currently estimate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lumoxiti and our product candidates are manufactured according to manufacturing best practices applicable to drugs for clinical trials and to
specifications approved by the applicable regulatory authorities. If any of our products were found to be <FONT STYLE="white-space:nowrap">non-compliant,</FONT> we would be required to manufacture the product again, which would entail additional
costs and may prevent delivery of the product to patients on time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other risks inherent in the production process may have the same
effect, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contamination of the controlled atmosphere area; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unusable premises and equipment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new regulatory requirements requiring a partial and/or extended stop to the production unit to meet the
requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unavailable qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">power failure of extended duration; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">logistical error. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these risks materialize, this could have a material adverse effect our business, prospects, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may use hazardous chemicals and biological materials in our business and any claims relating to improper handling,
storage or disposal of these materials could be time-consuming and costly. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development processes involve the
controlled use of hazardous materials, including chemicals, biological and radioactive materials. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We also handle genetically
recombined material, genetically modified species and pathological biological samples. Consequently, in France and in the jurisdictions where we conduct clinical trials, we are subject to environment and safety laws and regulations governing the
use, storage, handling, discharge and disposal of hazardous materials, including chemical and biological products and radioactive materials. We impose preventive and protective measures for the protection of our workforce and waste control
management in accordance with applicable laws, including part four of the French Labor Code, relating to occupational health and safety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In France, we are required to comply with a number of national, regional and local legislative or regulatory provisions regarding radiation
and hazardous materials, including specific regulations regarding the use, handling and storage of radioactive materials and the potential exposure of employees to hazardous materials and radiation. We must also comply with French regulations
concerning the use and handling of genetically modified organisms, or GMOs, in confined spaces. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable regulations, we could be subject to fines and may have
to suspend all or part of our operations. Compliance with environmental, health and safety regulations involves additional costs, and we may have to incur significant costs to comply with future laws and regulations in relevant jurisdictions.
Compliance with environmental laws and regulations could require us to purchase equipment, modify facilities and undertake considerable expenses. We could be liable for any inadvertent contamination, injury or damage, which could negatively affect
its business, although we have subscribed to an insurance policy covering certain risks inherent to its business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Organization
and Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy involves continuing to grow our business internally. However, we may also grow externally through selective acquisitions of
complementary products and technologies, or of companies with such assets, although no such plan is currently contemplated. As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our
operations, particularly in the areas of research, drug development, regulatory affairs and sales, marketing and distribution for our approved product, Lumoxiti. To manage our anticipated future growth, we must continue to implement and improve our
managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company
with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. This risk is compounded by the fact that we are located in Marseille, France and compete with
other locations that potential recruits may find more attractive. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management may need to divert a disproportionate amount of its
attention away from its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and devote a substantial amount of time to managing internal or external growth. We may not be able to effectively manage
the expansion of our operations which may result in weaknesses in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could
require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and additional product candidates. If our management is unable to effectively manage our expected growth, our
expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we were to acquire assets or companies, the success of such an acquisition would depend on our capacity to carry out such acquisitions and
to integrate such assets or companies into our existing operations. The implementation of such a strategy could impose significant constraints, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">human resources: recruiting, integrating, training, managing, motivating and retaining a growing number of
employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial and management system resources: identification and management of appropriate financing and management
of our financial reporting systems; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">infrastructure: expansion or transfer of our laboratories or the development of our information technology
system. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to manage internal growth or have difficulty integrating any acquisitions, it could have a
material adverse effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We will need to hire new
employees and expand our use of service providers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2019, we had 208 employees. As our development and
commercialization plans and strategies develop, we must add a significant number of additional managerial, operational, sales, marketing, financial and other personnel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely, and for the foreseeable future will continue to rely, in part on certain
independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when
needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical
trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or
find other competent outside contractors and consultants on economically reasonable terms, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not able to effectively
expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize Lumoxiti and our product candidates and,
accordingly, may not achieve our research, development and commercialization goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We depend on qualified management personnel and
our business could be harmed if we lose key personnel and cannot attract new personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to retain key persons in our
organization and to recruit qualified personnel is crucial for our success. In particular, our success depends heavily on its ability to retain key people in our organization, including key scientific and medical personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should we be unable to retain the individuals who form our team of key managers and key scientific advisors, it could have a material adverse
effect on our business and development and could consequently affect our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will need to recruit qualified scientific and medical personnel to carry out our clinical trials and expand into new areas that require
specialized skills, such as regulatory matters, marketing and manufacturing. We compete with other companies, research organizations and academic institutions in recruiting and retaining highly qualified scientific, technical and management
personnel. Competition for such personnel is very intense in the biopharmaceutical field and there can be no assurance that we will be successful in attracting or retaining such personnel and the failure to do so could harm our operations and our
growth prospects. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our business may be exposed to foreign exchange risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incur some of our expenses, and derive certain of our revenues, in currencies other than the euro. In particular, as we expand our
operations and conduct additional clinical trials in the United States, we will incur additional expenses in U.S. dollars. As a result, we are exposed to foreign currency exchange risk as our results of operations and cash flows are subject to
fluctuations in foreign currency exchange rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not engage in hedging transactions to protect against uncertainty in
future exchange rates between particular foreign currencies and the euro. Therefore, an unfavorable change in the value of the euro against the U.S. dollar could have a negative impact on our revenue and earnings growth. We cannot predict the impact
of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our financial condition, results of operations and cash flows. The ADSs being offered in the U.S. offering will be quoted in U.S. dollars on
Nasdaq, while our ordinary shares trade in euro on Euronext Paris. Our financial statements are prepared in euro. Therefore, fluctuations in the exchange rate between the euro and the U.S. dollar will also affect, among other matters, the value of
our ordinary shares and ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our license and collaboration agreements with AstraZeneca, the payments we receive are in U.S.
dollars. In the future, we could generate part of our sales in the United States and part in Europe and could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therefore be subject to an unfavorable euro/dollar exchange rate. Therefore, for example, an increase in the value of the euro against the U.S. dollar could be expected to have a negative impact
on our revenue and earnings growth as U.S. dollar revenue and earnings, if any, would be translated into euro at a reduced value. We could also sign contracts denominated in other currencies, which would increase our exposure to currency risk. In
accordance with our business decisions, our exposure to this type of risk could change depending on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currencies in which we receive our revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currencies chosen when agreements are signed, such as licensing agreements, or
<FONT STYLE="white-space:nowrap">co-marketing</FONT> or <FONT STYLE="white-space:nowrap">co-</FONT> development agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the location of clinical trials on product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our policy for insurance cover. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, we have not put any specific hedging arrangements in place to address these risks. Should any of these risks materialize, this
could have a material adverse effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Product liability
and other lawsuits could divert our resources, result in substantial liabilities, reduce the commercial potential of Lumoxiti or our product candidates and damage our reputation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given that we develop therapeutic products intended to be tested on humans and used to treat humans, the risk that we may be sued on product
liability claims is inherent in our business. Side effects of, or manufacturing defects in, products that we develop could result in the deterioration of a patient&#146;s condition, injury or even death. For example, our liability could be sought
after by patients participating in the clinical trials in the context of the development of the therapeutic products tested and unexpected side effects resulting from the administration of these products. Once a product is approved for sale and
commercialized, the likelihood of product liability lawsuits increases. Criminal or civil proceedings might be filed against us by patients, regulatory authorities, biopharmaceutical companies and any other third party using or marketing our
products. These actions could include claims resulting from acts by our partners, licensees and subcontractors, over which we have little or no control. These lawsuits may divert our management from pursuing our business strategy and may be costly
to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities, may be forced to limit or forgo further commercialization of the affected products and may suffer damage to our reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after
regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians
and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use Lumoxiti or our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have obtained liability insurance coverage for each of our clinical trials in compliance with local legislation and rules. In the United
States, our aggregate insurance coverage for our ongoing clinical trials is &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million in the aggregate. Our insurance coverage may not be sufficient to cover any
expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due
to liability. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved in our favor, could be
substantial. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have obtained product liability insurance with a coverage amount of &#128;10&nbsp;million per year. Our product liability
insurance will need to be adjusted in connection with the commercial sales of Lumoxiti and our product candidates, and may be unavailable in meaningful amounts or at a reasonable cost. If we are the subject
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of a successful product liability claim that exceeds the limits of any insurance coverage we obtain, we would incur substantial charges that would adversely affect our earnings and require the
commitment of capital resources that might otherwise be available for the development and commercial launch of our product programs. Should any of these risks materialize, this could have a material adverse effect on our business, prospects,
financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>There are material weaknesses and significant deficiencies in our internal controls
over financial reporting and if we are unable to maintain effective internal controls over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected, which could hurt our business, lessen investor
confidence and depress the market price of our securities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must maintain effective internal control over financial reporting in
order to accurately and timely report our results of operations and financial condition. In addition, as a public company listed in the United States, the Sarbanes-Oxley Act will require, among other things, that we assess the effectiveness of our
internal control over financial reporting at the end of each fiscal year starting with the end of the first full fiscal year after the completion of the global offering. However, our independent registered public accounting firm will not be required
to attest to the effectiveness of our internal controls over financial reporting for so long as we are an &#147;emerging growth company,&#148; which may be up to five fiscal years following the date of this global offering. An independent assessment
of the effectiveness of our internal controls could detect problems that our management&#146;s assessment might not. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management has
not completed an assessment of the effectiveness of our internal control over financial reporting, and our independent registered public accounting firm has not conducted an audit of our internal control over financial reporting. In the course of
auditing the consolidated financial statements as of and for the year ended December&nbsp;31, 2018, a material weakness in our internal controls related to the recognition of the revenue from our collaboration and licensing agreement with
AstraZeneca on monalizumab was identified. The specific weakness in our internal controls involved insufficient review of the calculation of the transaction price and percentage of completion of costs incurred, leading to an incorrect amount of
revenue recognized for the year ended December&nbsp;31, 2018, which was corrected prior to the issuance of our audited financial statements. In the course of auditing the consolidated financial statements as of and for the year ended
December&nbsp;31, 2017, three material weaknesses in our internal controls were identified. The material weaknesses related to (i)&nbsp;the accounting for subcontracting clinical costs for which there was insufficient control on the input data from
clinical studies (termination date of the study and/or number of expected visits), (ii) stock-based compensation with insufficient control surrounding the valuation of AGAP by external valuators, and (iii)&nbsp;a risk of management override of
controls on manual journal entries due to insufficient supporting documentation for certain entries. Errors not detected in relation to topics (i)&nbsp;and (ii) have led to incorrect amounts of research and development expenses and personnel
expenses for the year ended December&nbsp;31, 2017, which were corrected prior to the issuance of our audited financial statements. A number of significant deficiencies in our internal controls have also been identified for the years ended December
31, 2018 and December 31, 2017. A number of significant deficiencies in our internal controls have also been identified for the years ended December&nbsp;31, 2018 and December&nbsp;31, 2017. Over the course of 2019, we continue to work to remediate
these material weaknesses and significant deficiencies and strengthen our controls in these areas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have taken and are taking steps to
remediate the foregoing weaknesses and deficiencies. However, if we do not successfully remediate these issues or if we fail to design and operate effective internal controls in the future, it could result in material misstatements in our financial
statements, result in the loss of investor confidence in the reliability of our financial statements and subject us to regulatory scrutiny and sanctions, which in turn could harm the market value of our ordinary shares and ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules governing the standards that will have to be met for our management to assess our internal control over financial reporting pursuant
to Section&nbsp;404 of the Sarbanes-Oxley Act are complex and require significant documentation, testing and possible remediation. These stringent standards require that our audit committee be advised and regularly updated on management&#146;s
review of internal control over financial reporting. We have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
begun the process of designing, implementing, and testing the internal control over financial reporting required to comply with this obligation. This process is time-consuming, costly, and
complicated. Our management may not be able to effectively and timely implement controls and procedures that adequately respond to the increased regulatory compliance and reporting requirements that will be applicable to us as a public company
listed in the United States. If we fail to staff our accounting and finance function adequately or maintain internal control over financial reporting adequate to meet the demands that will be placed upon us as a public company listed in the United
States, our business and reputation may be harmed and the price of our ordinary shares and ADSs may decline. In addition, undetected material weaknesses in our internal control over financial reporting could lead to restatements of financial
statements and require us to incur the expense of remediation. Any of these developments could result in investor perceptions of us being adversely affected, which could cause a decline in the market price of our securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those of our third-party contractors or consultants, may fail or suffer security breaches, which could
result in a material disruption of our product development programs. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have implemented a security policy intended to secure
our data against impermissible access and to preserve the integrity and confidentiality of the data. Despite the implementation of security measures, our internal computer systems and those of our third-party contractors and consultants are
vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures, and other sources. In addition, our research and development facility and headquarters in Luminy, France
is located in an area that may be more susceptible to wildfires. If our facility or computer systems are damaged by fire despite the fire prevention and data archiving measures we have put in place, we could suffer financial losses and delays in our
operations. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of
our programs. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. To the extent that any
disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could
incur liabilities, including penalties under data privacy laws such as the GDPR and other regulations, and the further development of our product candidates could be delayed. Should any of these risks materialize, this could have a material adverse
effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our employees may engage in misconduct or other
improper activities, including violating applicable regulatory standards and requirements, engaging in insider trading or violate the terms of their confidentiality agreements, which could significantly harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
legal requirements or the requirements of national authorities, the EMA, FDA and other government regulators, provide accurate information to applicable government authorities, comply with fraud and abuse and other healthcare laws and regulations in
the United States, Europe and elsewhere, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws
and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer
incentive programs and other business arrangements. Employee misconduct could also involve the improper use of, including trading on, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm
to our reputation. We have a Code of Ethics that applies to all employees and consultants, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may be ineffective in
controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to protect our proprietary technology and processes, we rely in part on
confidentiality agreements with our partners, employees, consultants, outside scientific collaborators and sponsored researchers, and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not
provide an adequate remedy in the event of unauthorized disclosure of confidential information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain
trade secret protection could adversely affect our competitive business position. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may acquire businesses or products in the future and we may not realize the benefits of such acquisitions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although our current strategy involves continuing to grow our business internally, we may grow externally through selective acquisitions of
complementary products and technologies, or of companies with such assets. If such acquisitions were to become necessary or attractive in the future, we may not be able to identify appropriate targets or make acquisitions under satisfactory
conditions, in particular, satisfactory price conditions. In addition, we may be unable to obtain the financing for these acquisitions under favorable conditions, and could be led to finance these acquisitions using cash that could be allocated to
other purposes in the context of existing operations. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from an acquisition that delay or prevent us from realizing their expected benefits or
enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction, which could have a material adverse effect on our business, financial conditions, earnings and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to compete may be adversely affected if we do not adequately obtain, maintain, protect and enforce our intellectual property
or proprietary rights, or if the scope of intellectual property protection we obtain is not sufficiently broad. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success
depends, in large part, on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to Lumoxiti and our product candidates. However, we may not be able to obtain,
maintain or enforce our patents and other intellectual property rights which could affect our ability to compete effectively. For example, we cannot guarantee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that we will file all necessary or desirable patent applications or that we will obtain the patents that we have
applied for and that are under review; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that we will be able to develop new patentable product candidates or technologies or obtain patents to protect
such new product candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that we or our licensing or collaboration partners were the first to make the product candidates or technologies
covered by the issued patents or pending patent applications that we license or own; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that we will be able to obtain sufficient rights to all necessary or desirable patents or other intellectual
property rights, whether at all or on reasonable terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the scope of any issued patents that we own or license will be broad enough to protect Lumoxiti or our
product candidates or effectively prevent others from commercializing competitive technologies and product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that there is no risk of our owned and licensed patents being challenged, invalidated or circumvented by a third
party. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file,
prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. For example, we do not intend to systematically file, maintain, prosecute and defend patents on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Lumoxiti and our product candidates in all countries. Consequently, we may not be able to prevent third parties from exploiting products that are the same as or similar to our products and
product candidates in countries in which we do not obtain patent protection, or from selling or importing such products in and into the countries in which we do have patent protection. It is also possible that we will fail to identify patentable
aspects of our research and development output in time to obtain patent protection. Although we enter into confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as
our employees, consultants, CROs, outside scientific collaborators, sponsored researchers, and other advisors, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our
ability to seek patent protection. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are
commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. In addition, in some circumstances, we may not have the right to
control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering technology that we license to or from third parties. For example, pursuant to our license agreement with AstraZeneca for
monalizumab, AstraZeneca retains control of such activities for certain patents that we license to it under the agreement and patents that arise under the collaboration. We cannot be certain that these patents and patent applications will be
prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interest of our business. If any third party that controls our patents and patent applications fails to maintain our patents or such third party
loses rights to our patents or patent applications, our rights to those patents and underlying technology may be reduced or eliminated and our right to develop and commercialize our product candidates that are subject to such rights could be
adversely affected. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, some of our patents and patent applications are, and may in the future be, <FONT
STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we are unable to obtain an exclusive license to any such third-party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents or patent applications, such <FONT
STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. We may also need the cooperation of any such <FONT
STYLE="white-space:nowrap">co-owners</FONT> of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted
after issuance. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will
provide us with any meaningful protection, prevent competitors or other third parties from circumventing our patents by developing similar or alternative technologies or products in a noninfringing manner, or otherwise provide us with any
competitive advantage. Challenges from competitors or other third parties could reduce the scope of our patents or render them invalid or unenforceable, which could limit our ability to stop others from using or commercializing similar or identical
technology and product candidates, or limit the duration of the patent protection for Lumoxiti and our product candidates. The legal proceedings that we may then have to enter into in order to enforce and defend our intellectual property could be
very costly and could distract our management and other personnel from their normal responsibilities, notably in the case of lawsuits in the United States. The probability of disputes arising over our intellectual property will increase
progressively as patents are granted and as the value and appeal of the inventions protected by these patents are confirmed. The occurrence of any of these events concerning any of our patents or intellectual property rights could have a material
adverse effect our business, prospects, financial condition and results of operations. These risks are even higher for us, because of our limited financial and human resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions,
and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in
patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates. Furthermore, our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may be subject to a reservation of rights by one or more third parties. For example, the
research resulting in certain of our owned and licensed patent rights and technology was funded in part by the U.S. government. As a result, the government may have certain rights, or <FONT STYLE="white-space:nowrap">march-in</FONT> rights, to such
patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license
authorizing the government to use the invention for <FONT STYLE="white-space:nowrap">non-commercial</FONT> purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise <FONT
STYLE="white-space:nowrap">march-in</FONT> rights to use or allow third parties to use our licensed technology. The government can exercise its <FONT STYLE="white-space:nowrap">march-in</FONT> rights if it determines that action is necessary because
we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our
rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of such rights could harm our competitive position, business, financial
condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may allege that we or our partners infringe, misappropriate or
otherwise violate such third parties&#146; intellectual property rights, which could prevent or delay our development efforts, stop us from commercializing Lumoxiti or our product candidates, or increase the costs of commercializing Lumoxiti or our
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends on our ability and the ability of our partners to develop, manufacture, market
and sell Lumoxiti and our product candidates, and use our proprietary technologies, without infringing, misappropriating or otherwise violating any intellectual property or proprietary rights of third parties. The field of biopharmaceuticals
involves significant patent and other intellectual property litigation, which can be highly uncertain and involve complex legal and factual questions. The interpretation and breadth of claims allowed in some patents covering biopharmaceutical
compositions also may be uncertain and difficult to determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be aware of all third-party intellectual property rights
potentially relating to our product candidates. In general, in the United States patent applications are not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot be sure that we were the first to make the
inventions claimed in any owned or licensed patents or pending patent applications, or that we were the first to file for patent protection for such inventions. If we were not the first to invent such inventions or first to file any patent or patent
application for such inventions, we may be unable to make use of such inventions in connection with our products. We may need to obtain licenses from third parties (which may not be available under commercially reasonable terms, or at all), delay
the launch of product candidates, or cease the production and sale of certain product candidates or develop alternative technologies that are the subject of such patents or patent applications, any of which could have a material adverse effect on
our business, prospects, financial condition and results of operations. For example, third parties may claim that IPH4102 and other product candidates may use technology protected by their patents. Although we believe that our current activities and
our planned development of IPH4102 does not and will not infringe on such patents, which expire in the near term, third parties may disagree. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may allege that we or our partners infringe, misappropriate or otherwise violate any such third party&#146;s patents or other
intellectual property rights and assert infringement claims against us, regardless of their merit. A court of competent jurisdiction could hold that these third party patents are valid, enforceable and infringed, which could materially and adversely
affect our ability to commercialize Lumoxiti and any product candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S.
patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court
of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intellectual property rights, and we are unsuccessful in demonstrating that such rights are invalid or unenforceable, we could be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">bear the potentially significant costs of proceedings brought against us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay damages, which may include treble damages and attorney&#146;s fees if we are found to have willfully
infringed a third party&#146;s patent rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cease developing, manufacturing and commercializing the infringing technology or product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire a license to such third-party intellectual property rights, which may not be available on commercially
reasonable terms, or at all, and may be <FONT STYLE="white-space:nowrap">non-exclusive</FONT> thereby giving our competitors and other third parties access to the same technologies licensed to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other intellectual property proceedings may cause us to incur significant expenses and could
distract our management and other personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors
perceive these results to be negative, it could have a material adverse effect on the price of our ordinary shares or ADSs. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Should one or more of the
foregoing risks materialize, this could have a material adverse effect on our reputation, business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our patents could be found invalid or unenforceable if challenged and we may not be able to protect our intellectual property.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our and our licensors&#146; patents and patent applications, if issued, may be challenged, invalidated or circumvented by third
parties. U.S. patents and patent applications may also be subject to interference proceedings, <FONT STYLE="white-space:nowrap">re-examination</FONT> proceedings, derivation proceedings, post-grant review or <I>inter partes</I> review in the United
States Patent and Trademark Office, or USPTO, challenging our or our licensors&#146; patent rights. Foreign patents may be subject also to opposition or comparable proceedings in the corresponding foreign patent office. For example, two of our
European patents with claims covering a class of anti-NKG2A antibodies defined by characteristics shared with monalizumab have been challenged in oppositions at the European Patent Office, or the EPO. Although the Opposition Division of the EPO
issued a decision that some claims covering such class of anti-NKG2A antibodies are valid, the Opposition Division&#146;s decisions for both patents are currently under appeal. We have also received notices that third parties filed oppositions
challenging our <FONT STYLE="white-space:nowrap">in-licensed</FONT> European patents covering certain of our CD39 technology, and these oppositions are currently pending. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may allege that third parties infringe our or our licensors&#146; patents and the defendant could counterclaim that such
patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several
statutory requirements, including lack of novelty, obviousness, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent
withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we
cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such patent litigation or proceeding could result in the loss of our or our licensors&#146; patents, denial of our or our licensors&#146;
patent applications or loss or reduction in the scope of one or more of the claims of such patents or patent applications. Accordingly, our or our licensors&#146; rights under any issued patents may not provide
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
us with sufficient protection against competitive product candidates or processes, we could become unable to manufacture or commercialize Lumoxiti or our product candidates without infringing
third-party patent rights, and the duration of the patent protection of Lumoxiti or our product candidates could be limited. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation,
there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Even if we are successful, such litigation or proceedings may be costly and may distract our management and other personnel
from their normal responsibilities. Any of the foregoing could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and
other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid
to the USPTO, and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and/or patent applications and any patent rights we may own in the future. In certain circumstances, we may rely on
our licensing partners to pay these fees. The USPTO and various foreign patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an
inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of
the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which
could have a material adverse effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Developments in
patent law could have a negative impact on our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws
could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, from time to time, the U.S. Congress, the USPTO or similar foreign authorities may change
the standards of patentability and any such changes could have a negative impact on our business. In addition, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into law in September 2011, includes a number of
significant changes to U.S. patent law. These changes include a transition from a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> system to a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, changes to the way issued patents are challenged and changes to the way patent applications are disputed during the examination process such as allowing third-party
submission of prior art to the USPTO during patent prosecution. These changes may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. Under a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> system, assuming that other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the
patent on an invention regardless of whether another inventor made the invention earlier. The USPTO has developed new regulations and procedures to govern the full implementation of the America Invents Act, and many of the substantive changes to
patent law associated with the America Invents Act, and, in particular, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> provisions, became effective in March 2013. Substantive changes to patent law
associated with the America Invents Act, or any subsequent U.S. legislation regarding patents, may affect our ability to obtain patents, and if obtained, to enforce or defend them. Accordingly, it is not clear what, if any, impact the America
Invents Act will have on the cost of prosecuting our U.S. patent applications, our ability to obtain U.S. patents based on our discoveries and our ability to enforce or defend any patents that may issue from our patent applications, all of which
could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changes to or different interpretations of patent laws in the United
States and other countries may permit others to use our or our partners&#146; discoveries or to develop and commercialize our technology and product candidates without providing any compensation to us, or may limit the number of patents or claims we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
can obtain. The patent positions of companies in the biotechnology and pharmaceutical market are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of U.S. patent
protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on
future actions by the U.S. Congress, the federal courts, and the USPTO, as well as similar bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our
existing patent portfolio and our ability to protect and enforce our intellectual property in the future, which could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain protection under the Hatch-Waxman Amendments and similar <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
legislation for extending the term of patents covering Lumoxiti and each of our product candidates, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and conditions of FDA marketing authorization of Lumoxiti and our product candidates, one or more of our
U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments
permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the
remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended.
However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents, fail to exercise due diligence during the testing phase or regulatory review process or otherwise fail
to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can
enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from Lumoxiti or an applicable product could be reduced, possibly materially, which
could have a material adverse effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We will not seek to
protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights in all jurisdictions where we seek intellectual property protection. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, maintaining, prosecuting and defending patents on Lumoxiti and our product candidates in all countries and jurisdictions throughout the
world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. Consequently, we may not be able to prevent third parties from using
our product candidates or technologies in all countries outside the United States, or from selling or importing products made using our product candidates or technologies in and into the United States or other jurisdictions. Competitors may use our
technologies in jurisdictions where we do not pursue and obtain patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, and enforcement is not as strong as
that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in
particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the federal and state laws
in the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not
favor the enforcement of patents and other intellectual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property protection, especially those relating to biopharmaceuticals or biotechnologies. This could make it difficult for us to stop the infringement of our patents, if obtained, or the
misappropriation or other violation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the
enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain
countries, and we will not have the benefit of patent protection in such countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proceedings to enforce our patent rights in foreign
jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not
issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal
decisions by courts in the United States and other countries may affect our ability to obtain adequate protection for our technology and the enforcement of our intellectual property. Accordingly, our efforts to enforce our intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Should any of these risks materialize, this could have a material adverse effect on our business,
prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may assert ownership or commercial rights to products,
product candidates or technologies that we develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties have made, and may in the future make, claims challenging the
inventorship or ownership of our intellectual property, which may result in the imposition of additional obligations on us, such as development, royalty and milestone payments. We have written agreements with partners or other third parties that
provide for the ownership of intellectual property arising from our collaborations and our other work with such third parties. These agreements provide that we must negotiate certain commercial rights with partners and other third parties with
respect to joint inventions or inventions made by our partners or such third parties that arise from the results of the collaboration or other work with such third parties. In some instances, there may not be adequate written provisions to address
clearly the resolution of intellectual property rights that may arise under our agreements. For example, Orega Biotech SAS, or Orega Biotech, has made claims of joint ownership of certain patents relating to IPH5201, and we and Orega Biotech have
agreed to resolve those claims in an arbitration proceeding. If we cannot successfully negotiate sufficient ownership and commercial rights to the inventions that result from our use of a third party&#146;s materials where required, or if disputes
otherwise arise with respect to the intellectual property developed with the use of a third party&#146;s samples, we may be limited in our ability to capitalize on the market potential of these inventions. In addition, we may face claims by third
parties that our agreements with employees, contractors, or consultants obligating them to assign intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in
ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such inventions. We also may be unsuccessful in executing assignment agreements with each party
who, in fact, conceives or develops intellectual property that we regard as our own, or such agreements might not be self-executing or might be breached. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual
property, may lose our exclusive rights in such intellectual property or may be required to acquire a license to such intellectual property, which may not be available on commercially reasonable terms or at all. Any of the foregoing could have a
material adverse impact on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations under license or technology agreements with
third parties, we could lose license rights that are critical to our business, and we may not be successful in obtaining necessary intellectual property rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We license intellectual property from third parties that is critical to our business through license agreements, including but not limited to
licenses related to the manufacture, composition, use and sale of our product candidates, and in the future we may enter into additional agreements that provide us with licenses to valuable intellectual property or technology. For example, we depend
on our license agreement with AstraZeneca for the commercialization of Lumoxiti and our license agreement with Novo Nordisk A/S for the development and commercialization of monalizumab. Our license agreements impose various obligations on us, which
may include development, royalty and milestone payments. If we fail to comply with any of these obligations, our licensors may have the right to terminate the agreements. If our license agreements with AstraZeneca or Novo Nordisk A/S or any other
current or future licensors terminate, we would lose valuable rights and may be required to cease our development, manufacture or commercialization of Lumoxiti or our product candidates, including monalizumab. In addition, our business would suffer
if our licensors fail to abide by the terms of the agreements, if our licensors fail to prevent infringement by third parties, or if the licensed patents or other rights are found to be invalid or unenforceable. Should any of these risks
materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, disputes may arise regarding intellectual property subject to a license agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our technology and processes infringe on intellectual property of the counterparty that is
not subject to the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship or ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our counterparties and us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreements under which we currently license intellectual property from third parties are complex, and certain provisions in such
agreements may be susceptible to multiple interpretations. The resolution of any contract dispute that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property, or modify in a manner adverse to us
what we believe to be our or our counterpart&#146;s financial or other obligations under the relevant agreement, any of which could have material adverse effect on our business, financial condition, results of operations and prospects. If disputes
over intellectual property that we have licensed prevent or impair our ability to maintain our current license agreement on acceptable terms, we may be unable to unsuccessfully develop and commercialize the affected product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the growth of our business may depend, in part, on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or
use proprietary rights held by third parties. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> intellectual property rights from third parties that we identify as necessary for our product candidates on reasonable
terms or at all. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may
consider attractive. These established companies may have a competitive advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a
competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our business, we collaborate with <FONT STYLE="white-space:nowrap">non-profit</FONT> and academic institutions to accelerate our
preclinical research or development under agreements with these institutions. Typically, these institutions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide us with an option to negotiate a license to any of the institution&#146;s or its employees&#146; rights in technology resulting from the collaboration. Regardless of such option, we may
be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to
pursue our applicable development or commercialization program. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon
the development and commercialization of the relevant program and our business, financial conditions, results of operations and prospects could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may assert that our employees, consultants or independent contractors have wrongfully used or disclosed confidential
information or misappropriated trade secrets of their current or former employers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ individuals who are currently, or
were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the
proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, and no such claims against us are currently pending, we may be subject to claims that we or our employees, consultants or independent
contractors have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s current or former employer or other third parties. Litigation may be necessary to defend against these
claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to our management and other employees. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be materially harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, because we operate in the highly technical field of biopharmaceutical drug development, we rely
in part on trade secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. We seek to protect our trade secrets, in part, by entering into confidentiality agreements with our
employees, consultants, CROs, outside scientific collaborators, sponsored researchers, and other advisors. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential information
developed by such party or made known to such party by us during the course of such party&#146;s relationship with us. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our
trade secrets and confidential information and these agreements may be breached, and we may not have adequate remedies for any breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by
an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a
competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and
time-consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. Moreover, trade secrets may be independently developed by others in a manner that could prevent legal
recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed to or misappropriated by a third party, or if any such information was independently developed by a third party, our competitive
position could be materially harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our trade and technical secrets include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain unpatented technical expertise that we believe provides us with an advantage in conducting research and
development work in our field; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain scientific knowledge generated by the work we carry out; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain information relating to the product candidates we are currently developing; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain information relating to the agreements signed between us and third parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unauthorized disclosure or misappropriation of certain of these secrets could allow third parties to offer products or services to compete
with ours or generally have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The structures put in place to protect our trade and technical
secrets do not constitute a guarantee that one or more of our trade and technical secrets will not be disclosed or misappropriated. The agreements or other arrangements to protect our trade secrets may fail to provide the protection sought, or are
breached, or that our trade secrets are disclosed to, or developed independently by, our competitors. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Unauthorized use of our trademarks may generate confusion and result in costs and delays to the detriment of our
marketing efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our trademarks are a key component of our identity and our products. Although the key components of our
trademarks have been registered, notably in France and the United States, other companies in the pharmaceutical sector might use or attempt to use similar trademarks or components of our trademarks, and thereby create confusion in the minds of third
parties. Our registered trademarks may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. In addition, there could be potential trademark infringement claims brought by owners of other
trademarks that incorporate variations of our registered or unregistered trademarks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we develop trademarks for products that
conflict with intellectual property rights of third parties, we would then have to redesign or rename our products in order to avoid encroaching on the intellectual property rights of third parties. This could prove to be impossible or costly in
terms of time and financial resources and could be detrimental to our marketing efforts. Should any of these risks materialize, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make products that are the same as or similar to Lumoxiti and our product candidates or
utilize similar technology but that are not covered by the claims of the patents that we license or may own in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our license partners or current or future collaborators, might not have been the first to make the
inventions covered by the issued patent or pending patent application that we license or may own in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our license partners or current or future collaborators, might not have been the first to file patent
applications covering certain of our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our owned or licensed intellectual property rights; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our owned or licensed pending patent applications will not lead to issued patents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal
challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent in order to maintain certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent covering such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Ownership of Our Ordinary Shares and the ADSs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>There has been no prior market for our ADSs and an active and liquid market for our securities may fail to develop, which could harm the
market price of the ADSs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this global offering, while our ordinary shares have been listed on Euronext Paris since 2006,
there has been no public market on a U.S. national securities exchange for our ordinary shares or ADSs. Although we anticipate that the ADSs will be approved for listing on Nasdaq, an active trading market for the ADSs may never develop or be
sustained following this global offering. The initial offering price of the ADSs will be determined through negotiations between us and the underwriters. This offering price may not be indicative of the market price of our ordinary shares or ADSs
after this global offering. In the absence of an active trading market for the ADSs, investors may not be able to sell their ADSs at or above the offering price or at the time that they would like to sell. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of our equity securities may be volatile, and purchasers of our ordinary shares or ADSs could incur substantial
losses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is likely that the price of our ordinary shares and ADSs will be significantly affected by events such as announcements
regarding scientific and clinical results concerning product candidates currently being developed by us, our collaboration partners or our main competitors, changes in market conditions related to our sector of activity, announcements of new
contracts, technological innovations and collaborations by us or our main competitors, developments concerning intellectual property rights, as well as the development, regulatory approval and commercialization of new products by us or our main
competitors and changes in our financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity markets are subject to considerable price fluctuations, and often, these
movements do not reflect the operational and financial performance of the listed companies concerned. In particular, biotechnology companies&#146; share prices have been highly volatile and may continue to be highly volatile in the future. As we
operate in a single industry, we are especially vulnerable to these factors to the extent that they affect our industry. Fluctuations in the stock market as well as the macro-economic environment could significantly affect the price of our ordinary
shares. As a result of this volatility, investors may not be able to sell their ordinary shares or ADSs at or above the price originally paid for the security. The market price for our ordinary shares and ADSs may be influenced by many factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated fluctuations in our financial condition and operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in our growth rate relative to our competitors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition from existing products or new products that may emerge; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures,
collaborations or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse results of delays in our or any of our competitors&#146; preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval for any of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the termination of a strategic alliance or the inability to establish additional strategic alliances;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed financial estimates and projections of the investment community or that we provide to
the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuance of new or updated research or reports by securities analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary share and ADS price and volume fluctuations attributable to inconsistent trading volume levels of our
ordinary shares and ADSs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">price and volume fluctuations in trading of our ordinary shares on Euronext Paris; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key management or scientific personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments related to proprietary rights, including patents, litigation matters and our
ability to obtain patent and other intellectual property protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to coverage policies or reimbursement levels by commercial third-party payors and government payors and
any announcements relating to coverage policies or reimbursement levels; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcement or expectation of additional debt or equity financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our ordinary shares or ADSs by us, our insiders or our other shareholders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and market conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other market and industry factors may cause the market price and demand for our ordinary shares and ADSs to fluctuate substantially,
regardless of our actual operating performance, which may limit or prevent investors from readily selling their ordinary shares or ADSs and may otherwise negatively affect the liquidity of the trading market for the ordinary shares and ADSs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the price
of the ordinary shares or ADSs and their trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for the ADSs and ordinary shares depends
in part on the research and reports that securities or industry analysts publish about us or our business. As a public company in France since 2006, our equity securities are currently subject to coverage by a number of analysts. If fewer securities
or industry analysts cover our company, the trading price for the ADSs and ordinary shares would be negatively impacted. If one or more of the analysts who covers us downgrades our equity securities or publishes incorrect or unfavorable research
about our business, the price of the ordinary shares and ADSs would likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, or downgrades our securities, demand for the ordinary
shares and ADSs could decrease, which could cause the price of the ordinary shares and ADSs or their trading volume to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We
do not currently intend to pay dividends on our securities and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of the ordinary shares and ADSs. In addition, French law may limit the amount
of dividends we are able to distribute. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our ordinary shares and do not
currently intend to do so for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Therefore, you are not likely to receive any dividends on your ADSs for the foreseeable future and the success of an investment in the ADSs will depend upon any future appreciation in its value.
Consequently, investors may need to sell all or part of their holdings of the ADSs after price appreciation, which may never occur, as the only way to realize any future gains on their investment. There is no guarantee that the ADSs will appreciate
in value or even maintain the price at which our shareholders have purchased them. Investors seeking cash dividends should not purchase the ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, under French law, the determination of whether we have been sufficiently profitable to pay dividends is made on the basis of our
statutory financial statements prepared and presented in accordance with accounting standards applicable in France. Moreover, pursuant to French law, we must allocate 5% of our unconsolidated net profit for each year to our legal reserve fund before
dividends, should we propose to declare any, may be paid for that year, until the amount in the legal reserve is equal to 10% of the aggregate nominal value of our issued and outstanding share capital. In addition, payment of dividends may subject
us to additional taxes under French law. Therefore, we may be more restricted in our ability to declare dividends than companies that are not incorporated in France. See &#147;Description of Share Capital&#151;Key Provisions of Our Bylaws and French
Law Affecting Our Ordinary Shares&#148; for further details on the limitations on our ability to declare and pay dividends and the taxes that may become payable by us if we elect to pay a dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, exchange rate fluctuations may affect the amount of euro that we are able to distribute, and the amount in U.S. dollars that our
shareholders receive upon the payment of cash dividends or other distributions we declare and pay in euro, if any. These factors could harm the value of the ADSs, and, in turn, the U.S. dollar proceeds that holders receive from the sale of the ADSs.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase ADS in this global offering, you will experience substantial and immediate dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you purchase ADS in this global offering, you will experience substantial and immediate dilution of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per ordinary share in the net tangible book value after giving effect to the global offering at an assumed offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (based on &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, the closing price of our ordinary shares on Euronext Paris on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019), because the price that you pay will be substantially greater than the net tangible book value per ordinary share that
you acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less than the initial offering price when they purchased their ordinary shares. You will experience additional dilution upon exercise of any
outstanding warrants to purchase ordinary shares or if we otherwise issue additional ordinary shares or ADSs below the offering price. For a further description of the dilution that you will experience immediately after this global offering, see
&#147;Dilution.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this global offering and may not use them
effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have broad discretion in the application of the net proceeds that we receive from this offering as well as of
our existing cash, cash equivalents short-term investments and non-current financial assets, and we may spend or invest these funds in a way with which our shareholders or holders of our ADSs disagree. Our failure to apply these funds effectively
could harm our business and financial condition. Pending their use, we may invest the net proceeds from the offering in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of ordinary shares or ADSs by existing shareholders could depress the market price of the ordinary shares or ADSs.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing shareholders sell, or indicate an intent to sell, substantial amounts of ordinary shares or ADSs in the public
market after the <FONT STYLE="white-space:nowrap">90-day</FONT> contractual <FONT STYLE="white-space:nowrap">lock-up</FONT> and other legal restrictions on resale discussed in this prospectus lapse, the trading price of the ADSs could decline
significantly and could decline below the offering price. Upon completion of the global offering, we will have outstanding &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares, including
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ordinary shares represented by ADSs, approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of which are subject to a contractual
restriction on selling for up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; days, subject to customary exceptions. As of the date of this prospectus, the exercise of all our instruments convertible into ordinary shares would enable the
subscription of new ordinary shares, representing approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the diluted share capital. The underwriters may permit our members of the Executive Board and of the Supervisory Board, employees and current shareholders
to sell ordinary shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. See &#147;Underwriting&#151;Lock-up Agreements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements pertaining to this offering expire, and based on the number of ordinary
shares outstanding upon completion of this global offering, including ordinary shares represented by ADSs, additional ordinary shares will be eligible for sale in the public market, all of which ordinary shares are held by members of the Executive
Board and of the Supervisory Board and other affiliates and will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended, or the Securities Act. In addition, the ordinary shares subject to subscription under our
instruments convertible under shares will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. Sales of a large number of the ordinary shares in the public market could have an adverse
effect on the market price of the ADSs. See &#147;Shares and ADSs Eligible for Future Sale&#148; for a more detailed description of sales that may occur in the future. If these additional ordinary shares are sold, or if it is perceived that they
will be sold, in the public market, the trading price of the ordinary shares and ADSs could decline substantially. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The dual listing
of our ordinary shares and the ADSs following this global offering may adversely affect the liquidity and value of the ADSs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following this global offering and after the ADSs begin trading on Nasdaq, our ordinary shares will continue to be listed on Euronext Paris.
Trading of the ADSs or ordinary shares in these markets will take place in different currencies (U.S. dollars on Nasdaq and euro on Euronext Paris), and at different times (resulting from different time zones, different trading days and different
public holidays in the United States and France). The trading prices of our ordinary shares on these two markets may differ due to these and other factors. Any decrease in the price of our ordinary shares on Euronext Paris could cause a decrease in
the trading price of the ADSs on Nasdaq. Investors could seek to sell or buy our ordinary shares to take advantage of any price differences between the markets through a practice referred to as arbitrage. Any arbitrage activity could create
unexpected volatility in both our share prices on one exchange, and the ordinary shares available for trading on the other exchange. In addition, holders of ADSs will not be immediately able to surrender their ADSs and withdraw the underlying
ordinary shares for trading on the other market without effecting necessary procedures with the depositary. This could result in time delays and additional cost for holders of ADSs. We cannot predict the effect of this dual listing on the value of
our ordinary shares and the ADSs. However, the dual listing of our ordinary shares and the ADSs may reduce the liquidity of these securities in one or both markets and may adversely affect the development of an active trading market for the ADSs in
the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The rights of shareholders in companies subject to French corporate law differ in material respects from the
rights of shareholders of corporations incorporated in the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a French company with limited liability. Our
corporate affairs are governed by our bylaws and by the laws governing companies incorporated in France. The rights of shareholders and the responsibilities of members of our Executive Board and of our Supervisory Board are in many ways different
from the rights and obligations of shareholders in companies governed by the laws of U.S. jurisdictions. For example, in the performance of its duties, our Executive Board is required by French law to consider the interests of our company, its
shareholders, its employees and other stakeholders, rather than solely our shareholders and/or creditors. It is possible that some of these parties will have interests that are different from, or in addition to, your interests as a shareholder or
holder of ADSs. See &#147;Management&#151;Corporate Governance Practices&#148; and &#147;Description of Share Capital.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. investors may have difficulty enforcing civil liabilities against our company and
members of the Executive Board and the Supervisory Board. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of the members of our Executive Board and Supervisory Board and the
experts named in this prospectus are <FONT STYLE="white-space:nowrap">non-residents</FONT> of the United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may
not be possible to serve process on such persons or us in the United States or to enforce judgments obtained in U.S. courts against them or us based on civil liability provisions of the securities laws of the United States. Additionally, it may be
difficult to assert U.S. securities law claims in actions originally instituted outside of the United States. Foreign courts may refuse to hear a U.S. securities law claim because foreign courts may not be the most appropriate forums in which to
bring such a claim. Even if a foreign court agrees to hear a claim, it may determine that the law of the jurisdiction in which the foreign court resides, and not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable,
the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still be governed by the law of the jurisdiction in which the foreign court resides. In particular,
there is some doubt as to whether French courts would recognize and enforce certain civil liabilities under U.S. securities laws in original actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of
punitive damages in actions brought in the United States or elsewhere may be unenforceable in France. An award for monetary damages under the U.S. securities laws would be considered punitive if it does not seek to compensate the claimant for loss
or damage suffered but is intended to punish the defendant. French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek indemnification from the directors of a corporation in the corporation&#146;s
interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and any legal fees relating to such action may be borne by the relevant shareholder or the group of shareholders. The
enforceability of any judgment in France will depend on the particular facts of the case as well as the laws and treaties in effect at the time. The United States and France do not currently have a treaty providing for recognition and enforcement of
judgments, other than arbitration awards, in civil and commercial matters. See &#147;Enforcement of Civil Liabilities.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our
bylaws and French corporate law contain provisions that may delay or discourage a takeover attempt. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions contained in our
bylaws and French corporate law could make it more difficult for a third party to acquire us, even if doing so might be beneficial to our shareholders. In addition, provisions of our bylaws impose various procedural and other requirements, which
could make it more difficult for shareholders to effect certain corporate actions. These provisions include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, the owner of 90% of the share capital or voting rights of a public company listed on a
regulated market in a Member State of the European Union or in a state party to the EEA Agreement, including from the main French stock exchange, has the right to force out minority shareholders following a tender offer made to all shareholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a non-resident of France as well as any French entity controlled by non-residents of France may
have to file a declaration for statistical purposes with the Bank of France (<I>Banque de France</I>) within 20 working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such
filings are required in connection with investments exceeding &#128;15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold. See &#147;Limitations Affecting Shareholders of a French
Company&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, certain investments in a French company relating to certain strategic industries by individuals
or entities not residents in a Member State of the EU are subject to prior authorization of the Ministry of Economy. See &#147;Limitations Affecting Shareholders of a French Company&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger (i.e., in a French law context, a share for share exchange following which our company would be
dissolved into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the European Union would require the approval of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
our Executive Board as well as a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present, represented by proxy or voting by mail at the relevant
meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger of our company into a company incorporated outside of the European Union would require 100% of our
shareholders to approve it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a cash merger is treated as a share purchase and would require the consent of each
participating shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders may in the future grant our Executive Board broad authorizations to increase our share capital
or to issue additional ordinary shares or other securities (for example, warrants) to our shareholders, the public or qualified investors, including as a possible defense following the launching of a tender offer for our ordinary shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders have preferential subscription rights on a <I>pro rata </I>basis on the issuance by us of any
additional securities for cash or a <FONT STYLE="white-space:nowrap">set-off</FONT> of cash debts, which rights may only be waived by the extraordinary general meeting (by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote) of our
shareholders or on an individual basis by each shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board appoints the members of the Executive Board and shall fill any vacancy within two months;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board has the right to appoint members of the Supervisory Board to fill a vacancy created by the
resignation or death of a member of the Supervisory Board for the remaining duration of such member&#146;s term of office, and subject to the approval by the shareholders of such appointment at the next shareholders&#146; meeting, which prevents
shareholders from having the sole right to fill vacancies on our Supervisory Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Executive Board can be convened by the chairman of the Executive Board or other members of the Executive
Board delegated for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board can be convened by the chairman or the vice-chairman of the Supervisory Board. A member of
the Executive Board or one-third of the members of the Supervisory Board may send a written request to the chairman to convene the Supervisory Board. If the chairman does not convene the Supervisory Board 15 days following the receipt of such
request, the authors of the request may themselves convene the Supervisory Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board meetings can only be regularly held if at least half of its members attend either
physically or by way of videoconference or teleconference enabling the members&#146; identification and ensuring their effective participation in the Supervisory Board&#146;s decisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval of at least a majority of the votes held by shareholders present, represented by a proxy, or voting by
mail at the relevant ordinary shareholders&#146; general meeting is required to remove members of the Executive Board and/or members of the Supervisory Board with or without cause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the crossing of certain ownership thresholds has to be disclosed and can impose certain obligations; see the
section of this prospectus titled &#147;Description of Share Capital&#151;Key Provisions of Our Bylaws and French Law Affecting Our Ordinary Shares&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice is required for nominations to the Supervisory Board or for proposing matters to be acted upon at
a shareholders&#146; meeting, except that a vote to remove and replace a member of the Supervisory Board can be proposed at any shareholders&#146; meeting without notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of shares shall comply with applicable insider trading rules and regulations, and in particular with
the Market Abuse Regulation 596/2014 of April&nbsp;16, 2014; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to French law, our bylaws, including the sections relating to the number of members of the Executive and
Supervisory Boards, and election and removal of members of the Executive and Supervisory Boards from office may only be modified by a resolution adopted by <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes of our shareholders present,
represented by a proxy or voting by mail at the meeting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Purchasers of ADSs in the U.S. offering will not be directly holding our ordinary
shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of ADSs will not be treated as one of our shareholders and will not have direct shareholder rights. French law
governs our shareholder rights. The depositary, through the custodian or the custodian&#146;s nominee, will be the holder of the ordinary shares underlying ADSs held by purchasers of ADSs in the U.S. offering. Purchasers of ADSs in the U.S. offering
will have ADS holder rights. The deposit agreement among us, the depositary and purchasers of ADSs in the U.S. offering, as an ADS holder, and all other persons directly and indirectly holding ADSs, sets out ADS holder rights, as well as the rights
and obligations of us and the depositary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Your right as a holder of ADSs to participate in any future preferential subscription
rights offering or to elect to receive dividends in shares may be limited, which may cause dilution to your holdings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to
French law, if we issue additional securities for cash, current shareholders will have<B><I> </I></B>preferential subscription rights for these securities on a pro rata basis unless they waive those rights at an<B><I> </I></B>extraordinary meeting
of our shareholders (by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote) or individually by each<B><I> </I></B>shareholder. However, our ADS holders in the United States will not be entitled to exercise or sell such<B><I>
</I></B>rights unless we register the rights and the securities to which the rights relate under the Securities Act or<B><I> </I></B>an exemption from the registration requirements is available. In addition, the deposit agreement provides<B><I>
</I></B>that the depositary will not make rights available to you unless the distribution to ADS holders of both the<B><I> </I></B>rights and any related securities are either registered under the Securities Act or exempted from registration<B><I>
</I></B>under the Securities Act. Further, if we offer holders of our ordinary shares the option to receive<B><I> </I></B>dividends in either cash or shares, under the deposit agreement the depositary may require satisfactory<B><I>
</I></B>assurances from us that extending the offer to holders of ADSs does not require registration of any<B><I> </I></B>securities under the Securities Act before making the option available to holders of ADSs. We are under<B><I> </I></B>no
obligation to file a registration statement with respect to any such rights or securities or to endeavor to<B><I> </I></B>cause such a registration statement to be declared effective. Moreover, we may not be able to establish an<B><I>
</I></B>exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to<B><I> </I></B>participate in our rights offerings or to elect to receive dividends in shares and may experience dilution in<B><I> </I></B>their
holdings. In addition, if the depositary is unable to sell rights that are not exercised or not distributed<B><I> </I></B>or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case you<B><I> </I></B>will
receive no value for these rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>You may not be able to exercise your right to vote the ordinary shares underlying your ADSs.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the
provisions of the deposit agreement. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to
give instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute to the holders as of the record date (i)&nbsp;the notice of the meeting or solicitation of consent or proxy
sent by us and (ii)&nbsp;a statement as to the manner in which instructions may be given by the holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may instruct the depositary
of your ADSs to vote the ordinary shares underlying your ADSs. Otherwise, you will not be able to exercise your right to vote, unless you withdraw the ordinary shares underlying the ADSs you hold. However, you may not know about the meeting far
enough in advance to withdraw those ordinary shares. If we ask for your instructions, the depositary, upon timely notice from us, will notify you of the upcoming vote and arrange to deliver our voting materials to you. We cannot guarantee you that
you will receive the voting materials in time to ensure that you can instruct the depositary to vote your ordinary shares or to withdraw your ordinary shares so that you can vote them yourself. If the depositary does not receive timely voting
instructions from you, it may give a proxy to a person designated by us to vote the ordinary shares underlying your ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner
of carrying out voting instructions. This means that you may not be able to exercise your right to vote, and there may be nothing you can do if the ordinary shares underlying your ADSs are not voted as you requested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>You may be subject to limitations on the transfer of your ADSs and the withdrawal of
the underlying ordinary shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your ADSs are transferable on the books of the depositary. However, the depositary may close its
books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of your ADSs generally when our books or the books of the
depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason subject to your
right to cancel your ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of your ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have
closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#146; meeting or we are paying a dividend on our ordinary shares. In addition, you may not be able to cancel your ADSs and withdraw the
underlying ordinary shares when you owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary
shares or other deposited securities. See the section of this prospectus titled &#147;Description of American Depositary Shares.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less
information with the SEC than a U.S. company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a foreign private issuer, as defined in the SEC&#146;s rules and regulations
and, consequently, we are not subject to all of the disclosure requirements applicable to public companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations
and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act, including the U.S. proxy rules under Section&nbsp;14 of the Exchange Act. In addition, our
Executive Board and Supervisory Board members are exempt from the reporting and &#147;short-swing&#148; profit recovery provisions of Section&nbsp;16 of the Exchange Act and related rules with respect to their purchases and sales of our securities.
Moreover, while we currently make annual and semi-annual filings with respect to our listing on Euronext Paris and expect to file financial reports on an annual and semi-annual basis, we will not be required to file periodic reports and financial
statements with the SEC as frequently or as promptly as U.S. public companies and will not be required to file quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or current reports on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> under the Exchange Act. In addition, foreign private issuers are not required to file their annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;20-F</FONT> until four months after the end of each
fiscal year. Accordingly, there will be less publicly available information concerning our company than there would be if we were not a foreign private issuer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that
differ significantly from Nasdaq corporate governance listing standards and these practices may afford less protection to shareholders than they would enjoy if we complied fully with Nasdaq corporate governance listing standards. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer listed on Nasdaq, we will be subject to their corporate governance listing standards. However, Nasdaq rules permit
foreign private issuers to follow the corporate governance practices of its home country. Some corporate governance practices in France may differ significantly from Nasdaq corporate governance listing standards. For example, neither the corporate
laws of France nor our bylaws require a majority of our Supervisory Board members to be independent and although the corporate governance code to which we currently refer (the AFEP/MEDEF code) recommends that, in a widely-held company like ours, a
majority of the Supervisory Board members be independent (as construed under such code), this code only applies on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;comply-or-explain&#148;</FONT></FONT> basis and we may in
the future either decide not to apply this recommendation or change the corporate code to which we refer.&nbsp;Furthermore, we could include <FONT STYLE="white-space:nowrap">non-independent</FONT> members of the Supervisory Board as members of our
compensation and nomination committee, and our independent Supervisory Board members would not necessarily hold regularly scheduled meetings at which only independent members of the Supervisory Board are present. Currently, we intend to follow home
country practice to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maximum extent possible. Therefore, our shareholders may be afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic
issuers. For an overview of our corporate governance practices, see &#147;Management&#151;Corporate Governance Practices.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We
are an &#147;emerging growth company&#148; under the JOBS Act and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our ordinary shares ADSs less attractive to investors.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act, and we intend to take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies,&#148; including not being required to comply with the auditor attestation requirements of Section&nbsp;404(b) of the
Sarbanes-Oxley Act, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In addition, Section&nbsp;107 of the JOBS Act
also provides that an emerging growth company can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. We will not take advantage of the
extended transition period provided under Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict if investors will find the ordinary shares or ADSs less attractive because we may rely on these exemptions. If some
investors find the ordinary shares or ADSs less attractive as a result, there may be a less active trading market for the ordinary shares or ADSs and the price of the ordinary shares or ADSs may be more volatile. We may take advantage of these
exemptions until such time that we are no longer an emerging growth company. We would cease to be an emerging growth company upon the earliest to occur of (1)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in
annual revenue; (2)&nbsp;the date we qualify as a &#147;large accelerated filer&#148; with at least $700&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> (3)&nbsp;the issuance, in any three year
period, by our company of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> and (4)&nbsp;the last day of the fiscal year ending
after the fifth anniversary of our initial public offering of the ADSs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may lose our foreign private issuer status in the
future, which could result in significant additional cost and expense. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we currently qualify as a foreign private issuer, the
determination of foreign private issuer status is made annually on the last business day of an issuer&#146;s most recently completed second fiscal quarter and, accordingly, our next determination will be made on June&nbsp;30, 2020. In the future, we
would lose our foreign private issuer status if we to fail to meet the requirements necessary to maintain our foreign private issuer status as of the relevant determination date. For example, if more than 50% of our securities are held by U.S.
residents and more than 50% of the members of our Executive Board or Supervisory Board are residents or citizens of the United States, we could lose our foreign private issuer status. Immediately following the closing of this global offering,
approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding ordinary shares (including ordinary shares in the form of ADSs) will likely be held by U.S. residents (assuming that all purchasers in the U.S. offering are residents of the United States).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more than costs we
incur as a foreign private issuer. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects
than the forms available to a foreign private issuer. We would be required under current SEC rules to prepare our financial statements in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, rather than IFRS, and modify
certain of our policies to comply with corporate governance practices required of U.S. domestic issuers. Such conversion of our financial statements to U.S. GAAP would involve significant time and cost. In addition, we may lose our ability to rely
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers such as the ones described above and exemptions from
procedural requirements related to the solicitation of proxies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we are a passive foreign investment company, there could be
adverse U.S. federal income tax consequences to U.S. holders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our analysis of our income, assets, activities and market
capitalization for our taxable year ending December&nbsp;31, 2018, we believe that we were not classified as a passive foreign investment company, or PFIC, for the taxable year ending December&nbsp;31, 2018. Based on the expected nature and
composition of our income, assets, activities and market capitalization for our taxable year ending December&nbsp;31, 2019, we believe that we will not be classified as a PFIC for the taxable year ending December&nbsp;31, 2019. However, there can be
no assurance that we will not be considered a PFIC in the current year or for any future taxable year. Under the Code, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company will be considered a PFIC for any taxable year in which (1) 75% or more
of its gross income consists of passive income or (2) 50% or more of the average quarterly value of its assets consists of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income includes
dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation that directly or
indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets and received directly its proportionate share of the income of such other corporation. If we are a PFIC for any
taxable year during which a U.S. holder (as defined below under &#147;Material United States Federal Income Tax and French Tax Considerations&#151;Material U.S. Federal Income Tax Considerations&#148;) holds our ordinary shares or ADSs, we will
continue to be treated as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns the ordinary shares or ADSs, regardless of whether we continue to meet the PFIC test described above, unless the U.S. holder
makes a specified election once we cease to be a PFIC. If we are classified as a PFIC for any taxable year during which a U.S. holder holds our ordinary shares or ADSs, the U.S. holder may be subject to adverse tax consequences regardless of whether
we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements. For further
discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, see the section of this prospectus titled &#147;Material United States Federal Income Tax and French Tax
Considerations&#151;Material U.S. Federal Income Tax Considerations.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If a United States person is treated as owning at least
10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. holder is
treated as owning, directly, indirectly or constructively, at least 10% of the value or voting power of our ordinary shares or ADSs, such U.S. holder may be treated as a &#147;United States shareholder&#148; with respect to each &#147;controlled
foreign corporation&#148; in our group, if any. Our group currently includes one U.S. subsidiary and, therefore, under current law our current <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiary and any future newly formed or acquired <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries will be treated as controlled foreign corporations, regardless of whether we are treated as a controlled foreign corporation. A United States shareholder of a controlled foreign corporation may
be required to annually report and include in its U.S. taxable income its pro rata share of &#147;Subpart F income,&#148; &#147;global intangible <FONT STYLE="white-space:nowrap">low-taxed</FONT> income&#148; and investments in U.S. property by
controlled foreign corporations, regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax
credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with controlled foreign corporation reporting obligations may subject a United States shareholder to significant monetary penalties. We cannot
provide any assurances that we will furnish to any United States shareholder information that may be necessary to comply with the reporting and tax paying obligations applicable under the controlled foreign corporation rules of the Code. U.S.
holders should consult their tax advisors regarding the potential application of these rules to their investment in our ordinary shares or ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, particularly the sections of this prospectus titled &#147;Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business,&#148; contains forward-looking statements. All statements other than present and historical facts and conditions contained in this prospectus,
including statements regarding our future results of operations and financial position, business strategy, plans and our objectives for future operations, are forward-looking statements. When used in this prospectus, the words
&#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;is designed to,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;potential,&#148;
&#147;predict,&#148; &#147;objective,&#148; &#147;should,&#148; or the negative of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prospects of attaining, maintaining and expanding marketing authorization for monalizumab, IPH4102 and our
other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our preclinical studies and clinical trials and those conducted
by third parties, including our collaborator AstraZeneca; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully develop and advance our pipeline of product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization of Lumoxiti, including the expected transitioning of commercialization activities in the
United States from AstraZeneca to us commencing in mid 2019, and any of our product candidates, if approved, for which we retain commercialization rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future agreements with third parties in connection with the commercialization of our product candidates and any
other approved product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop sales and marketing capabilities and transition into a commercial-stage company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of Lumoxiti and our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of increased competition as well as innovations by new and existing competitors in our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain, maintain, protect and enforce our intellectual property rights and propriety technologies
and to operate our business without infringing the intellectual property rights and proprietary technology of third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States, Europe and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of compliance and our failure to comply with new and existing governmental regulations including, but not
limited to, tax regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and stock
performance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected use of proceeds of the global offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed in the section of this prospectus titled &#147;Risk
Factors.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should refer to the section of this prospectus titled &#147;Risk Factors&#148; for a discussion of
important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus
will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any
other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law. The Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the Securities Act do not protect any forward-looking statements that we make in connection with the global offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the
Registration Statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. We qualify all of our
forward-looking statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds from the global offering of approximately
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming an offering price of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported closing price of our ordinary shares on Euronext Paris on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, after deducting estimated underwriting discounts and estimated offering expenses payable by us, and assuming no exercise
of the underwriters&#146; option to purchase additional ordinary shares (including ordinary shares in the form of ADSs). If the underwriters exercise their option in full, we estimate that we will receive net proceeds from the global offering of
approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million) after deducting estimated underwriting discounts and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal purposes of the global offering are to increase our financial flexibility in order to advance our proprietary and partnered
pipeline and build out our commercial capabilities. We currently expect to use the net proceeds from the offering, together with a portion of our cash, cash equivalents, short-term investments, and non-current financial assets (in aggregate ) as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to advance the clinical development of
our lead product candidate, monalizumab, in collaboration with AstraZeneca, which is currently being evaluated for the treatment of patients with R/M SCCHN and in patients with advanced solid tumors, including CRC; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to advance the clinical development of
IPH4102 for the treatment of patients with S&#233;zary syndrome, MF and PTCL, and approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to advance the clinical development of IPH5401 in patients with solid tumors, including NSCLC
and HCC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to build our commercial capabilities for
Lumoxiti in the U.S. and, if approved, in the European Union; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to expand and advance our preclinical
pipeline, including transitioning IPH5301 into clinical development. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to use the remainder of any net proceeds
from the global offering, together with a portion of our cash, cash equivalents, short-term investments and non-current financial assets, for general corporate purposes. We may also use a portion of the net proceeds to in-license, acquire or invest
in complementary technologies, products, businesses or assets, either alone or in collaboration with a partner. However, we have no current plans, commitments or obligations to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no specific plans as to how the net proceeds from the global offering will be allocated beyond the uses specified above and
therefore management will retain discretion with respect to the use of the net proceeds of the global offering. We may also use a portion of the net proceeds to acquire, license or invest in complementary technologies or businesses. However, we
currently have no agreements or commitments to complete any such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, we had cash, cash
equivalents, short-term investments and non-current financial assets of &#128;202.7&nbsp;million. We believe our cash, cash equivalents, short-term investments and non-current financial assets, together with the net proceeds of the global offering
and our cash flow from operations (including payments we expect to receive pursuant to our collaboration agreements) and government funding of research programs, will be sufficient to fund our operations for at least
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected use of the net proceeds from the global offering and time horizon
for the use of our funds represent our intentions based upon our current plans and business conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the
completion of the global offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures and the extent of clinical development may vary significantly depending on numerous factors,
including the progress of our development efforts, the status of and results from preclinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies and any ongoing clinical trials or clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties for our product candidates and
any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from the global offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from the global offering, we intend to invest the net proceeds in a variety of capital preservation
investments, including short-term, investment-grade, interest-bearing instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed initial offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
ADS) would increase or decrease our net proceeds from the global offering by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming the number of ordinary shares
(including ordinary shares in the form of ADSs), as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and estimated offering expenses payable by us. We may also increase or decrease
the number of ordinary shares (including ordinary shares in the form of ADSs) we are offering. An increase or decrease of 1,000,000 ordinary shares (including ordinary shares in the form of ADSs) offered by us would increase or decrease the net
proceeds to us by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming that the assumed initial offering price remains the same and after deducting estimated
underwriting discounts and estimated offering expenses payable by us. The actual net proceeds payable to us will adjust based on the actual number of ordinary shares (including ordinary shares in the form of ADSs) sold by us, the actual initial
offering price and other terms of the global offering determined at pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividends on our ordinary shares. We do not anticipate paying cash dividends on our equity securities in
the foreseeable future and intend to retain all available funds and any future earnings for use in the operation and expansion of our business, given our state of development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the requirements of French law and our bylaws, dividends may only be distributed from our distributable profits, plus any amounts
held in our available reserves which are reserves other than legal and statutory and revaluation surplus. Dividend distributions, if any in the future, will be made in euro and converted into U.S. dollars with respect to the ADSs, as provided in the
deposit agreement. See &#147;Description of Share Capital&#148; for more information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our current assets and capitalization as of December&nbsp;31, 2018 on an actual and on an as adjusted basis to
reflect the issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares (including ordinary shares in the form of ADSs) in the global offering at an assumed initial offering
price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported closing price of
our ordinary shares on Euronext Paris on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, after deducting estimated underwriting discounts and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our capitalization following the global offering will be adjusted based on the actual initial offering price and other terms of the global
offering determined at pricing, including the amount by which actual offering expenses are higher or lower than estimated. The table should be read in conjunction with the information contained in &#147;Use of Proceeds,&#148; &#147;Summary
Consolidated Financial Data,&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; as well as our consolidated financial statements and the related notes included elsewhere in this
prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash and cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary and preferred shares, &#128;0.05 nominal value: 63,932,655 ordinary shares and 6,931
preferred shares issued and outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; preferred shares issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">167,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">171,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed initial offering price of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported
closing price of our ordinary shares on Euronext Paris on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, would increase or decrease each of as adjusted cash and cash equivalents, total
shareholders&#146; equity and total capitalization by approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming that the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us, as set forth on the cover page of
this prospectus, remains the same and after deducting estimated underwriting discounts and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares (including ordinary shares in the form of ADSs) we
are offering. Each increase or decrease of 1,000,000 ordinary shares (including ordinary shares in the form of ADSs) offered by us would increase or decrease each of as adjusted cash and cash equivalents, total shareholders&#146; equity and total
capitalization by approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million),
assuming that the assumed offering price remains the same, and after deducting estimated underwriting discounts and estimated offering expenses payable by us. The as adjusted information discussed above is illustrative only and will adjust based on
the actual initial offering price, the actual number of ordinary shares (including ordinary shares in the form of ADSs) offered by us and other terms of the global offering determined at pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of ordinary shares (including ordinary shares in the form of ADSs) that will be
outstanding after the global offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding as of June 30, 2019 and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of share warrants (BSA) outstanding as of June&nbsp;30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of redeemable share warrants (BSAAR) outstanding as of June 30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2017) outstanding as of June 30, 2019 assuming all related performance conditions are met; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
vesting of free shares (AGA) outstanding as of June&nbsp;30, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2016) as of June&nbsp;30, 2019 assuming all performance conditions are met; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares reserved for future
issuance under our share-based compensation plans and other delegations of authority from our shareholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in the ordinary shares or ADSs in this global offering, your ownership interest will be diluted to the extent of the difference
between the offering price per ordinary share or ADS paid by you and the as adjusted net tangible book value per share after the global offering. Our net tangible book value as of December&nbsp;31, 2018 was &#128;82.7 million ($94.8 million), or
&#128;1.29 per ordinary share (equivalent to $1.48 per ADS), based on the exchange rate in effect as of December&nbsp;31, 2018. Net tangible book value per share is determined by dividing (i)&nbsp;our total assets less our intangible assets and our
total liabilities by (ii)&nbsp;the number of ordinary shares outstanding as of December&nbsp;31, 2018, or 63,932,655 ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to our sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary
shares (including ordinary shares in the form of ADSs) in the global offering, assuming an offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported closing price of our ordinary shares on Euronext Paris on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, and after deducting estimated underwriting discounts and estimated offering expenses payable by us, our as adjusted net tangible book value at
December&nbsp;31, 2018 would have been approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), or &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share (equivalent to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS). This amount represents an immediate increase in net tangible book value of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS) to our existing
shareholders and an immediate dilution in net tangible book value of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS) to new investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table illustrates this dilution on a per ordinary share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Ordinary<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per ordinary share or ADS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per ordinary share or ADS attributable to new investors
participating in the global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per ordinary share or ADS after the global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in as adjusted net tangible book value per ordinary share or ADS to new investors
participating in the global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed initial offering price of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported
closing price of our ordinary shares on Euronext Paris on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, would increase or decrease our as adjusted net tangible book value by approximately
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), or approximately
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), and the dilution to
new investors participating in this global offering would be approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), assuming that the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us, as set forth on the cover page of
this prospectus, remains the same, and after deducting estimated underwriting discounts and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares (including ordinary shares in the form of ADSs) we
are offering. An increase in the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us by 1,000,000 would increase the as adjusted net tangible book value by approximately
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), or
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), and the dilution to
new investors participating in this global offering would be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), assuming that the initial offering price remains the same, and after deducting estimated underwriting discounts and estimated offering
expenses payable by us. Similarly, a decrease in the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us by 1,000,000 would decrease the as adjusted net tangible book value by approximately
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), or
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), and the dilution to
new investors participating in this global offering would be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share ($&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; per ADS), assuming that the initial offering price remains the same, and after deducting estimated underwriting discounts and estimated
offering expenses payable by us. The as adjusted information discussed above is illustrative only and will be adjusted based on the actual offering price, the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us
and other terms of this global offering determined at pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise in full their option to purchase additional
ordinary shares (which may be in the form of ADSs), the as adjusted net tangible book value after the global offering would be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the increase in the as adjusted net tangible book value to existing shareholders would be
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), and the dilution to
new investors participating in this global offering would be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets
forth consideration paid to us in cash for ordinary shares purchased from us by our existing shareholders (translated into U.S. dollars at an exchange rate of $1.00 =
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ) and by new investors participating in this global offering based on an assumed offering price of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported
closing price of our ordinary shares on Euronext Paris on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, and before deducting estimated underwriting discounts and estimated offering expenses
payable by us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares or<BR>ADSs&nbsp;Purchased&nbsp;from&nbsp;Us</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Price<BR>per Ordinary<BR>Share/ADS</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Number&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Percent&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Amount&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Percent&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00 ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed
initial offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), the last reported closing price of our ordinary shares on Euronext Paris on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, would increase or decrease the total consideration paid by new investors participating in this global offering by
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming that the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us, as set forth on the
cover page of this prospectus, remains the same and before deducting estimated underwriting discounts. We may also increase or decrease the number of ordinary shares (including ordinary shares in the form of ADSs) we are offering. An increase or
decrease by 1,000,000 in the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us would increase or decrease the total consideration paid by new investors participating in this global offering by
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming that the initial offering price remains the same and before deducting estimated underwriting discounts. The
information discussed in the table above is illustrative only and will be adjusted based on the actual offering price, the number of ordinary shares (including ordinary shares in the form of ADSs) offered by us and the other terms of this global
offering determined at pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the underwriters exercise their option to purchase additional ordinary shares (which may
be in the form of ADSs) in full, the number of ordinary shares held by the existing shareholders after this global offering would be reduced to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of ordinary shares (including ordinary shares in the form of ADSs) outstanding
after the global offering, and the number of ordinary shares (including ordinary shares in the form of ADSs) held by new investors participating in this global offering would increase to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , or &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of ordinary shares (including ordinary shares in the form of ADSs) outstanding after the global
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of ordinary shares (including ordinary shares in the form of ADSs) that will be outstanding after the global
offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding as of June 30, 2019 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of share warrants (BSA) outstanding as of June&nbsp;30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of redeemable share warrants (BSAAR) outstanding as of June 30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2017) outstanding as of June 30, 2019 assuming all related performance conditions are met; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
vesting of free shares (AGA) outstanding as of June 30, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2016) as of June&nbsp;30, 2019 assuming all performance conditions are met; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares reserved for future
issuance under our share-based compensation plans and other delegations of authority from our shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as
otherwise noted, the information in this prospectus assumes no exercise by the underwriters of their option to purchase additional ordinary shares (including ordinary shares in the form of ADSs). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_10"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derived the selected consolidated statement of income (loss) data for the years ended December&nbsp;31, 2018 and 2017 and the selected
consolidated statement of financial position data as of December&nbsp;31, 2018 and 2017 from our audited consolidated financial statements included elsewhere in this prospectus. Our consolidated financial statements have been prepared in accordance
with IFRS as issued by the IASB. Our historical results are not necessarily indicative of the results that may be expected in the future. The following selected financial data for the periods and as of the dates indicated are qualified by reference
to and should be read in conjunction with our consolidated financial statements and related notes beginning on page <FONT STYLE="white-space:nowrap">F-1</FONT> of this prospectus and the section of this prospectus titled &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Income
(Loss) Data: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except per share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue and other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">93,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">44,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from distribution agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B>Operating income (loss)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net financial loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B>Net income (loss)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares outstanding used for computing basic and diluted net income (loss) per
share<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,776,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,351,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 reflect the impacts of the adoption of IFRS 9 and IFRS 15 that became applicable on January&nbsp;1, 2018. The comparative
consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. The impact on the consolidated statement of income (loss) of the adoption of IFRS 9 is not material and the impact of the adoption of IFRS
15 and transition measures are presented in Note 2.a to our consolidated financial statements appearing elsewhere in this prospectus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the year ended December&nbsp;31, 2018, the dilutive effect of warrants granted but not yet exercised and unallocated free shares is not material. As we were in a net loss position for the year ended
December&nbsp;31, 2017, warrants granted but not yet exercised and unallocated free shares do not have a dilutive effect. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated
Statement of Financial Position Data: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, short-term investments and non-current financial assets<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">202,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">451,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial debt and defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Non-current assets account for &#128;35.2&nbsp;million. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion of our financial condition and results of operations in conjunction with the &#147;Selected
Consolidated Financial Data&#148; and our audited consolidated financial statements and the related notes thereto included elsewhere in this prospectus. In addition to historical information, the following discussion and analysis contains
forward-looking statements that reflect our plans, estimates and beliefs. Our actual results and the timing of events could differ materially from those anticipated in the forward-looking statements. Factors that could cause or contribute to these
differences include those discussed below and elsewhere in this prospectus, particularly in sections titled &#147;Risk Factors&#148; and &#147;Special Note Regarding Forward-Looking Statements.&#148; Our consolidated financial statements have been
prepared in accordance with IFRS as issued by the IASB, which may differ in material respects from generally accepted accounting principles in other jurisdictions, including the United States. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company
focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need. We have extensive experience in
research and development in immuno-oncology, having been pioneers in the understanding of natural killer cell, or NK cell, biology, and later expanding our expertise in the tumor microenvironment, tumor antigens and antibody engineering fields. We
have built, internally and through our business development strategy, a broad and diversified portfolio including an approved product, three clinical product candidates and a robust preclinical pipeline. We have entered into collaborations with
leaders in the biopharmaceutical industry, such as AstraZeneca and Sanofi, to leverage their development capabilities and expertise. We believe our product candidates and clinical development approach are differentiated from current immuno-oncology
therapies and have the potential to significantly improve the clinical outcome for patients with cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have
devoted substantially all of our financial resources to research and development efforts, including conducting preclinical studies and clinical trials of our product candidates, providing general and administrative support for our operations and
protecting our intellectual property. Our marketed product, Lumoxiti, was approved by the U.S. Food and Drug Administration, or FDA, under priority review in September 2018 and was commercially launched by AstraZeneca AB, or AstraZeneca, in November
2018. We have not yet generated any material revenue from product sales. We have funded our operations to date primarily through private and public offerings of ordinary shares, payments from our collaborators and research tax credits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, we had &#128;202.7&nbsp;million in cash, cash equivalents, short-term investments and <FONT
STYLE="white-space:nowrap">non-current</FONT> financial assets. Since our inception, we have raised a total of &#128;240.4&nbsp;million through the sale of equity securities, including &#128;33.7&nbsp;million in the initial public offering of our
ordinary shares on Euronext Paris in 2006. We have also received $475.0&nbsp;million (&#128;415.9&nbsp;million) in payments from our collaborators, including AstraZeneca, since 2011, excluding payments received for purchases of our equity securities
by our collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have significant agreements with AstraZeneca pursuant to which we have the right to earn milestone and royalty
payments. We have other license agreements pursuant to which we have acquired intellectual property and under which we will be required to make payments to the counterparty upon the achievement of certain milestone events and commercial sales
related to our product candidates. See &#147;&#151;Our Strategic Collaborations and Licensing Agreements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net
losses in each year since our inception except for the years ended December&nbsp;31, 2018 and December&nbsp;31, 2016. Our net results were a &#128;3.0&nbsp;million net income and a &#128;48.4&nbsp;million net loss for the years
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ended December&nbsp;31, 2018 and 2017, respectively. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from
general and administrative expenses associated with our operations. As we continue our intensive research and development programs and invest in the commercialization of Lumoxiti, we expect to continue to incur significant expenses and may again
incur operating losses in future periods. We anticipate that such expenses will increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue the research and development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate clinical trials for, or additional preclinical development of, our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">further develop and refine the manufacturing processes for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change or add manufacturers or suppliers of biological materials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory and marketing authorizations for any of our product candidates that successfully complete
development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize Lumoxiti and any other products for
which we may obtain marketing authorization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify and validate additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or license other product candidates, technologies or biological materials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty or other payments under any current or future license agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, protect and enforce our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">secure manufacturing arrangements for commercial production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to attract and retain new and existing skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create additional infrastructure to support our operations as a U.S. public company and incur increased legal,
accounting, investor relations and other expenses; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience delays or encounter issues with any of the above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that we will need to raise additional funding, in addition to the net proceeds of the global offering, prior to completing
clinical development of any of our product candidates. Until such time that we can generate substantial revenues from sales of Lumoxiti our product candidates, if approved, we expect to finance our operating activities through a combination of
milestone payments received pursuant to our strategic alliances, equity offerings, debt financings, government or other third-party funding and collaborations, and licensing arrangements. However, we may not receive milestone payments when expected,
or at all, and we may be unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all, which would have a negative impact on our financial condition and could force us to delay, limit, reduce or
terminate our development programs or commercialization efforts or grant to others rights to develop or market product candidates that we would otherwise prefer to develop and market ourselves. Failure to receive additional funding could cause us to
cease operations, in part or in full. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation of Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audited consolidated financial statements included herein for the years ended December&nbsp;31, 2018 and 2017 have been prepared in
accordance with IFRS as issued by the IASB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the listing of our ordinary shares on Euronext Paris and in accordance with the
European Union&#146;s regulation No.&nbsp;1606/2002 of July&nbsp;19, 2002, we also prepare and publish our consolidated financial statements in accordance with IFRS as adopted by the European Union, or EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All the standards published by the IASB that are mandatorily applicable in the years ended December&nbsp;31, 2018 and 2017 are endorsed by the
EU and are mandatorily applicable in the EU. Therefore, our audited </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consolidated financial statements for the years ended December&nbsp;31, 2018 and 2017 are compliant with both IFRS as issued by the IASB and IFRS as adopted by the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in accordance with IFRS requires us to make significant judgments and estimates which are presented
below in &#147;&#151;Critical Accounting Policies and Significant Judgments and Estimates.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Principal Collaboration and Licensing Agreements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreements related to monalizumab with Novo Nordisk A/S and with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>2014 Novo Nordisk A/S monalizumab agreement</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;5, 2014, we in-licensed from Novo
Nordisk A/S full development and commercialization rights to monalizumab. Novo Nordisk A/S received &#128;2.0&nbsp;million in cash and 600,000 of our ordinary shares at a price of &#128;8.33 per share (&#128;5.0 million) and is eligible to receive
up to &#128;20.0&nbsp;million in potential regulatory milestones and tiered <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-to-high</FONT></FONT> single-digit percentage royalties on net sales. The agreement with Novo Nordisk
A/S included a right to additional consideration in the event of an <FONT STYLE="white-space:nowrap">out-licensing</FONT> agreement. Consequently, following the agreement signed with AstraZeneca in April 2015 as described below, we paid Novo Nordisk
A/S additional consideration of &#128;6.5&nbsp;million. In addition, as a result of AstraZeneca&#146;s exercise of its option under our agreement in October 2018, Novo Nordisk A/S became entitled to a second and final additional payment amounting to
$15.0&nbsp;million (&#128;13.1 million), which is recognized as a liability as of December&nbsp;31, 2018 and was paid in February 2019. These amounts of additional consideration were added to the net book value of the intangible asset and are
amortized according to the same amortization plan as the initial &#128;7.0&nbsp;million payment recognized in 2014. The net book value of the license amounted to &#128;12.7&nbsp;million as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>2015 AstraZeneca monalizumab agreements</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Under co-development and option agreements signed with
AstraZeneca in 2015, we granted to AstraZeneca an exclusive license, subject to certain exclusions, to certain of our patents and know-how to develop, manufacture and commercialize licensed products, including monalizumab, in the field of diagnosis,
prevention and treatment of oncology diseases and conditions. We further granted to AstraZeneca a worldwide, non-exclusive license to certain of our other patents to develop, manufacture and commercialize licensed products, including monalizumab, in
the field of diagnosis, prevention and treatment of oncology diseases and conditions. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We received an initial payment of $250 million under
these agreements on June 30, 2015, of which $100 million was paid to us as an initial payment for the co-development agreement and $150 million was paid to us as consideration for the option agreement. In connection with AstraZeneca&#146;s exercise
of its option under the option agreement, we received an upfront payment of $100 million in January 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the option exercise,
AstraZeneca is the lead party in developing the licensed products and must use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize each licensed product in certain major markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the initial payment and option exercise payment, AstraZeneca is obligated to pay us up to $925 million in the aggregate upon
the achievement of certain development and regulatory milestones ($500 million) and commercialization milestones ($425 million). We are eligible to receive tiered royalties ranging from a low double-digit to mid-teen percentage on net sales of
licensed products outside of Europe. We are required for a defined period of time to co-fund 30% of the Phase III clinical trials of licensed products, subject to an aggregate cap, in order to receive 50% of the profits and losses in Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we opt out of our <FONT STYLE="white-space:nowrap">co-funding</FONT> obligations, we would forfeit the option to co-promote licensed
products under the agreement, and our right to share in 50% of such profits would terminate and sales in Europe will instead be factored into net sales used to calculate royalty and milestone payments to us. Additionally, Phase III and regulatory
milestone payments that may be payable to us will be reduced and AstraZeneca will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
responsible for the promotion of licensed products worldwide, subject to our option to co-promote the licensed products in certain European countries. Should we elect not to co-promote, our share
of profits in Europe will be reduced by a specified amount of percentage points not to exceed the mid-single digits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreement
related to Lumoxiti with AstraZeneca </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we obtained an exclusive license from AstraZeneca under certain patents and
know-how of AstraZeneca to develop, manufacture and commercialize Lumoxiti for all uses in humans and animals in the United States, the European Union and Switzerland. Under this Agreement, AstraZeneca is obligated to provide support for the
continued development and commercialization of Lumoxiti in the European Union and Switzerland prior to regulatory submission and approval as well as support for the continued commercialization of Lumoxiti in the United States for a specified period.
We are scheduled to transition to full commercialization responsibilities by <FONT STYLE="white-space:nowrap">mid-2020.</FONT> Under the agreement, we were obligated to pay a $50.0&nbsp;million initial payment (&#128;43.8 million), which we paid in
January 2019, and are obligated to pay conditional payments up to $25.0&nbsp;million in the aggregate upon the achievement of certain commercial and regulatory milestones. We will reimburse AstraZeneca for the development, production and
commercialization costs it incurs during the transition period, subject to certain limitations for the year ending December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreement related to IPH5201 with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we signed a collaboration and option agreement with AstraZeneca for <FONT STYLE="white-space:nowrap">co-development</FONT> and
<FONT STYLE="white-space:nowrap">co-commercialization</FONT> of IPH5201. Under the agreement, AstraZeneca paid us a $50.0&nbsp;million upfront payment ($26.0 million paid in October 2018 and $24.0&nbsp;million paid in January 2019), and is obligated
to pay us up to an aggregate of $10.0&nbsp;million upon the achievement of certain development milestones. Upon exercise of its option under the agreement, AstraZeneca is committed to pay an option exercise fee of $25.0&nbsp;million and up to
$800.0&nbsp;million in the aggregate upon the achievement of certain development and regulatory milestones ($300 million) and commercialization milestones ($500 million). The arrangement also provides for a 50% profit share in Europe if we opt into
certain co-promoting and late stage co-funding obligations. We would be eligible to receive tiered royalties ranging from a high-single digit to mid-teen percentage on net sales of IPH5201, or from a mid-single digit to low-double digit percentage
on net sales of other types of licensed products, outside of Europe. The royalties payable to us under the agreement may be reduced under certain circumstances, including loss of exclusivity or lack of patent protection. We recognized
&#128;15.6&nbsp;million as revenue from proceeds related to this agreement for the year ended December&nbsp;31, 2018, and were also reimbursed by AstraZeneca for certain research and development expenses related to IPH5201. We have the option to <FONT
STYLE="white-space:nowrap">co-fund</FONT> 30% of the shared development expenses related to the Phase III clinical trials in order to acquire <FONT STYLE="white-space:nowrap">co-promotion</FONT> rights and to share in 50% of the profits and losses
of licensed products in Europe. If we do not opt into the co-funding obligations, among other things, our right to share in 50% of the profits and losses in Europe and right to co-promote in certain European countries will terminate and will be
replaced by rights to receive royalties on net sales at the rates applicable to outside of Europe. Additionally, certain milestone payments that may be payable to us would be reduced. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreement related to additional preclinical molecules with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we granted to AstraZeneca four exclusive options that are exercisable until IND approval to obtain a worldwide,
royalty-bearing, exclusive license to certain of our patents and know-how relating to certain specified pipeline candidates to develop and commercialize optioned products in all fields of use. Pursuant to the agreement, AstraZeneca paid us a
$20.0&nbsp;million upfront payment (&#128;17.5 million) in October 2018. We recognize this upfront payment in the consolidated statement of financial position as deferred revenue as of December&nbsp;31, 2018, until the exercise or the termination of
each option, at the earliest. Upon exercise of an option, we would be entitled to an option exercise payment of $35 million, as well as development and regulatory milestone payments ($320 million) and commercialization milestone payments ($500
million) and tiered, mid-single digit to mid-teen percentage royalties on net sales of the applicable product. The royalties payable to us </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be reduced under certain circumstances, including loss of exclusivity, lack of patent protection or the specific nature of the compound included within the applicable product. Additionally,
we would have rights to co-fund certain development costs in order to obtain profit and loss sharing in Europe. So long as we elect to co-fund such development costs, we also will have a right to co-promote optioned products in Europe. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreements related to IPH5401 with Novo Nordisk A/S and with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>2017 IPH5401 <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreement with Novo Nordisk
A/S</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>In July 2017, we signed an exclusive license agreement with Novo Nordisk A/S relating to IPH5401. Under the agreement, Novo Nordisk A/S granted us a worldwide, exclusive license to develop, manufacture and
commercialize pharmaceutical products that contain or comprise an anti-C5aR antibody, including IPH5401. We made an upfront payment of &#128;40.0&nbsp;million, &#128;37.2&nbsp;million of which was contributed in new shares and &#128;2.8&nbsp;million
of which in cash. We are obligated to pay up to an aggregate of &#128;370.0&nbsp;million upon the achievement of development, regulatory and sales milestones and tiered royalties ranging from a low double-digit to low-teen percentage of net sales.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 IPH5401 AstraZeneca agreement</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>On January&nbsp;1, 2018, we entered into a clinical trial
collaboration agreement with AstraZeneca to sponsor a Phase I/II clinical trial <FONT STYLE="white-space:nowrap">(STELLAR-001)</FONT> to evaluate the safety and efficacy of durvalumab, an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> immune checkpoint inhibitor, in combination with IPH5401, as a treatment for patients with select solid tumors. We are the sponsor of the trial and the costs are equally shared between us and
AstraZeneca. This collaboration agreement is a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> agreement and does not include any licensing rights on IPH5401 to AstraZeneca. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Bristol-Myers Squibb licensing agreement in relation to lirilumab </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our agreement with Bristol-Myers Squibb Company, or BMS, related to the licensing of lirilumab, a product candidate that we
discontinued developing in 2017, we received an upfront payment of $35.3&nbsp;million (&#128;24.9 million) in July 2011 and were eligible to receive additional payments of up to an aggregate of $430.0&nbsp;million depending on the achievement of <FONT
STYLE="white-space:nowrap">pre-specified</FONT> milestones during the development and commercialization period. We received a milestone payment of $5.0&nbsp;million (&#128;4.5 million) in October 2015, which was fully recognized as revenue in the
year ended December&nbsp;31, 2015, and another milestone payment of $15.0&nbsp;million (&#128;14.0 million) in January 2017, which was fully recognized as revenue in the year ended December&nbsp;31, 2016. We were also entitled to receive <FONT
STYLE="white-space:nowrap">pre-specified</FONT> tiered, low double-digit to <FONT STYLE="white-space:nowrap">mid-teen</FONT> percentage royalty payments on worldwide net sales. We do not expect to receive any additional proceeds from this agreement.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Orega License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our licensing agreement with Orega Biotech SAS, or Orega Biotech, we acquired an exclusive license to Orega Biotech&#146;s
intellectual property rights relating to its anti-CD39 checkpoint inhibitor program. As of December 31, 2018, we had paid a total amount of &#128;1.8&nbsp;million to Orega Biotech for the acquisition of these intellectual property rights, and in
June of 2019 we paid Orega Biotech &#128;7.0&nbsp;million as consideration relating to the collaboration and option agreement signed on October 22, 2018 with AstraZeneca for IPH5201. We may also be obligated to pay Orega Biotech up to an additional
&#128;51.5 million in the aggregate upon the achievement of development and regulatory milestones, and mid-single digit to low-teen percentage payments, depending on determinations relating to Orega Biotech&#146;s intellectual property rights for
certain patents, on sublicensing revenues we receive pursuant to our agreement with AstraZeneca relating to IPH5201. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal Components of Our
Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue and other income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue and other income mainly consists of revenues from collaboration and licensing agreements and government financing for research
expenditure in the form of the research tax credits, as well as other grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue from collaboration and licensing agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently derive substantially all our revenues from payments pursuant to our licensing and collaboration agreements with AstraZeneca
relating to monalizumab and IPH5201, consisting of (i)&nbsp;upfront payments, (ii)&nbsp;milestone payments based upon the achievement of <FONT STYLE="white-space:nowrap">pre-determined</FONT> development, regulatory and commercial events and
(iii)&nbsp;research and development fees related to charges for full time equivalents, or FTEs, at contracted rates and reimbursement of research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not generated any revenue from product sales since our inception, with the exception in 2018 of Lumoxiti sales, which are classified
in the net income (loss) from distribution agreements during the transition period with AstraZeneca. Our ability to generate significant product revenue and to become profitable will depend upon our ability to successfully commercialize Lumoxiti and
our ability to successfully develop, obtain regulatory approval for and commercialize any other product candidates. Because of the numerous risks and uncertainties associated with product development and regulatory approval, we are unable to predict
the amount, timing or whether we will be able to obtain product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2018, IFRS 15 <I>Revenue from contracts with
customers</I>, or IFRS 15, became mandatorily applicable. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IFRS 15 supersedes IAS 11 <I>Construction contracts</I>, IAS 18
<I>Revenue</I>, or IAS 18, and related interpretations, and changes the accounting treatment of the revenue relating to our agreement with AstraZeneca with respect to monalizumab. Under IFRS 15, our <FONT STYLE="white-space:nowrap">co-funding</FONT>
share of research and development expenses incurred by AstraZeneca is no longer recorded as research and development expense, but rather is deducted from the recognition of the upfront payment received by us upon execution of the agreement. The
amount of our <FONT STYLE="white-space:nowrap">co-funding</FONT> obligation is now recognized as a collaboration liability and is no longer recorded as deferred revenue in the consolidated statement of financial position. When the collaboration
liability is in a foreign currency, which is the case in the context of this agreement, it is translated at each reporting date using the closing exchange rate, which generates foreign exchange gains or losses in our consolidated statement of income
(loss). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have opted for the modified retrospective approach without any of the practical expedients allowed by IFRS 15.
Accordingly, the comparative information is not restated and the cumulative impact of the first application is presented as an adjustment of the opening equity as of January&nbsp;1, 2018. Consequently, the first application of IFRS 15&nbsp;may
affect the comparability of our revenue and research and development expenses for the years ended December&nbsp;31, 2018 and 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
January&nbsp;1, 2018, agreements are analyzed according to IFRS 15. For our agreements relating to monalizumab and IPH5201, we have concluded that the license is not distinct from the research and development services because those services increase
the utility of the license. As a result, the estimated transaction price is spread over the period when we are engaged to deliver services to AstraZeneca based on the percentage of completion of the costs to be incurred, and <FONT
STYLE="white-space:nowrap">non-refundable</FONT> initial payments received are deferred and recognized as revenue over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Variable
consideration can be included in the estimated transaction price only if it is highly probable that the related revenue will not reversed in the future. According to the level of uncertainty relating to the results of preclinical studies and
clinical trials and the decisions relating to regulatory approvals, related payments are excluded from the transaction price as long as the triggering event is not certain. If and when the triggering event occurs, the corresponding milestone is
added to the transaction price and revenue is recognized relative to the percentage of completion related to the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a
collaboration contract grants to the collaborator an option to acquire a license, we exercise judgment to determine the beginning date of transfer of the control of the license. Depending on the situation, the recognition of the revenue begins from
the date of the contract, with the payment relating to the exercise of the option being therefore considered as variable consideration, or the recognition is deferred until the exercise or expiration of the option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the agreements with AstraZeneca relating to IPH5201 and IPH5401, we are
reimbursed for some of our internal and external costs. We recognize these reimbursements as revenue in our consolidated statement of income (loss) when the related costs are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue recognition involves significant judgments and estimates by management. See &#147;&#151;Critical Accounting Policies and Significant
Judgments and Estimates.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to 2018, revenue was recognized in accordance with IAS 18, which resulted in a difference in revenue
recognition accounting policies used for the audited consolidated financial statements for the year ended December&nbsp;31, 2018 and 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Government financing for research expenditures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our government financing for research expenditures consists of research tax credits (<I>cr&eacute;dit d</I><I>&#146;</I><I>imp&ocirc;t
recherche</I>) and grants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research tax credit is granted to companies by the French tax authorities in order to encourage them to
conduct technical and scientific research. Companies demonstrating that they have expenses that meet the required criteria, including research expenses located in France or, since January&nbsp;1, 2005, within the EU or in another state that is a
party to the agreement in the European Economic Area that has concluded a tax treaty with France that contains an administrative assistance clause, receive a tax credit which can be used against the payment of the corporate tax due for the fiscal
year in which the expenses were incurred and during the next three fiscal years, or, as applicable, can be reimbursed for the excess portion. The expenditures taken into account for the calculation of the research tax credit involve only research
expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main characteristics of the research tax credit are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research tax credit results in a cash inflow to us from the tax authorities, i.e., it is used to offset the
payment of corporate tax or is paid directly to us for the portion that remains unused the year after the date of its record as a tax credit in the income statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our corporate income tax liability does not limit the amount of the research tax credit&#151;if we do not pay any
corporate income tax, we can request direct cash payment of the research tax credit the year following its record in the income statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research tax credit is not included in the determination of the corporate income tax. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When the research tax credit is not deductible from taxes payable by us, it is usually reimbursed by the French government during the fourth
fiscal year following the period for which it was booked in the consolidated statement of income (loss). Since 2010, companies classified as small- and medium-sized, according to the European Union criteria, have been eligible for early
reimbursement of the research tax credit. We qualified for early reimbursement of the research tax credit and received the amount corresponding to 2016 and 2017 in July 2017 and September 2018, respectively. Since 2008, repayable grants have been
deducted from the basis of calculation of the research tax credit. We also conduct studies outside of the EU, notably in the United States, and these research expenses are not eligible for the research tax credit calculation. We expect that our
status as a small or medium size company may be lost at the end of the fiscal year ending December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have concluded that
the research tax credit meets the definition of a government grant as defined in IAS 20 <I>Accounting for government grants and disclosure of government assistance</I>, or IAS 20, and that the classification as &#147;Revenue and other income&#148;
in our consolidated statement of income (loss) is appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also from time to time receive government grants, which are recognized
in our consolidated statement of income (loss) when we comply with the conditions attached to the grants and they are <FONT STYLE="white-space:nowrap">non-repayable</FONT> grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, our operating expenses have consisted primarily of research and development expenses and general and administration expenses.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We engage in substantial research and development efforts to develop innovative product candidates. Research and development expense consists
primarily of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel costs, including salaries, related benefits and share-based compensation, for our employees engaged in
scientific research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost of third-party contractors and academic institutions involved in preclinical studies or clinical trials that
we may conduct, or third-party contractors involved in field trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases of biological raw materials, real estate leasing costs as well as conferences and travel costs; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain other expenses, such as expenses for use of laboratories and facilities for our research and development
activities as well as depreciation and amortization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development efforts are focused on our existing
product candidates and preclinical programs, including the advancement of our lead product candidates, monalizumab, IPH4102 and IPH5401. Our direct research and development expenses consist principally of external costs associated with
subcontracting of preclinical and clinical operations to third parties, which we track on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis. We also use our employee and infrastructure
resources across multiple research and development programs, and do not track these indirect expenses on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Costs for certain activities are recognized based on an evaluation of the progress to
completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our preclinical studies or other services performed. Significant judgment and estimates are made in determining the accrued
expense balances at the end of any reporting period. <FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance payments for research and development goods or services to be received in the future from third parties are deferred and capitalized.
The capitalized amounts are expensed as the related goods are delivered or the services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development
activities are central to our business. As product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of
later-stage clinical trials, we expect that our research and development costs will increase in the foreseeable future. Such cost increases are expected to occur as we conduct existing clinical trials and initiate future clinical trials, manufacture
<FONT STYLE="white-space:nowrap">pre-commercial</FONT> clinical trial and preclinical study materials, expand our research and development efforts, seek regulatory approvals for our product candidates that successfully complete clinical trials,
access and develop additional technologies and hire additional personnel to support our research and development efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot
determine with certainty the duration and total costs of our future clinical trials of our product candidates or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our product candidates, or those of
our collaborators, that might obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will
depend on a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, rate of progress and expense of our ongoing clinical trials as well as any additional preclinical
studies, clinical trials conducted by our collaborators and other research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial and preclinical study results; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expense of filing, maintaining, prosecuting, defending and enforcing patent claims and other intellectual
property rights; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to market, commercialize and achieve market acceptance for any products that receive regulatory
approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of monalizumab, IPH4102 and
IPH5401 or any other product candidate or preclinical program that we are developing or could develop in the future could mean a significant change in the costs and timing associated with the development of such product candidates or preclinical
programs. For example, if the FDA, the European Medicines Agency, or EMA, or another regulatory authority were to require us to conduct preclinical studies and clinical trials beyond those that we currently anticipate will be required for the
completion of clinical development, or if we experience significant delays in enrollment in any clinical trials, we could be required to spend significant additional financial resources and time on the completion of clinical development. For a
discussion of the risks associated with completing the development projects on schedule, see &#147;Risk Factors&#151;Risks Related to the Development and Commercialization of Lumoxiti and Our Product Candidates.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of personnel costs and share-based compensation for personnel other than research and
development staff. General and administrative expenses also consist of fees for professional services, mainly related to audit, IT, accounting, recruitment and legal services, communication and travel costs, real-estate leasing costs, office
furniture and equipment costs, allowance for amortization and depreciation, director&#146;s attendance fees and insurance costs and overhead costs, such as postal and telecommunications expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expense will increase in the future as we grow our support functions for the expected
increase in our research and development activities and the commercialization of Lumoxiti. Our share of Lumoxiti operational expenses are included in net income (loss) from distribution agreements because AstraZeneca has been responsible for
commercialization activities to date. However, we expect that we will directly incur operational expenses related to Lumoxiti in the fiscal year ending December&nbsp;31, 2019 and future periods, which will be included in general and administrative
expenses. We also anticipate increased expenses associated with being a public company in the United States, including costs related to strengthening our support functions and hiring additional staff as well as our audit, legal, regulatory and <FONT
STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with Nasdaq listing and SEC requirements, director and officer insurance premiums and investor relations costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Net income (loss) from distribution agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When commercialization activities related to a product that we own or license are performed by a third-party under a collaboration or
transition agreement, we must determine if the collaborator acts as an agent or a principal. With respect to our agreement with AstraZeneca related to Lumoxiti, we concluded that AstraZeneca acted as principal during the periods presented because
AstraZeneca controls the commercialization activities and is the holder of the applicable regulatory marketing authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a
result, we recognize on a single line the net income (loss) from our Lumoxiti distribution agreement in an amount equal to the sales for the period (which were immaterial for each of the periods presented), net of the administrative and selling
expenses associated with the sales revenue allocated to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Net financial loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial loss primarily consists of (a)&nbsp;realized and unrealized foreign exchange gains and losses primarily related to the purchase
of services as well as deposit accounts denominated in U.S.&nbsp;dollars and (b)&nbsp;gains </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and losses and interest received in relation to cash and cash equivalents that have been deposited in cash accounts, short-term fixed deposits and short-term highly liquid investments with
original maturities of three months or less. Our cash and cash equivalents generate a modest amount of interest income. We expect to continue this investment philosophy in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Comparisons
for the years ended December&nbsp;31, 2018 and 2017 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our consolidated statements of
income (loss) for the periods presented. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">79,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">32,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government financing for research expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue and other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>93,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from distribution agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(39,983</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net financial loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,034</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss) before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,718</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,016</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 reflect the impacts of the adoption of IFRS 9 and IFRS 15 that became applicable on January&nbsp;1, 2018. The comparative
consolidated financial statements as of and for the year ended December&nbsp;31 2017 have not been restated. The impact on the consolidated statement of income (loss) of the adoption of IFRS 9 is not material and the impact of the adoption of IFRS
15 is presented in &#147;Principal Components of Our Results of Operations&#151;Revenue from Collaboration and Licensing Agreements.&#148; See Note 2.a to our consolidated financial statements appearing elsewhere in this prospectus for more details
on transition measures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below provides a reconciliation of our consolidated statement of income (loss) as
published for the year ended December&nbsp;31, 2018 and our consolidated statement of income (loss) without the application of IFRS&nbsp;15, which reflects the application of the same accounting principles as for the year ended December&nbsp;31,
2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Published</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15&nbsp;Impact</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Excluding&nbsp;IFRS&nbsp;15<BR>Impact</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">79,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">21,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">100,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government financing for research expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue and other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>93,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>114,985</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(15,542</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(103,293</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from distribution agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income/(loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,491</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,637</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net financial loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,858</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(569</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss) before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,718</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,349</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,067</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>7,349</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,397</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue and other income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue and other income resulted from collaboration and licensing agreements and government financing for research expenditure. Revenue and
other income increased by &#128;49.9&nbsp;million, or 113.4%, to &#128;94.0&nbsp;million for the year ended December&nbsp;31, 2018, as compared to revenue and other income of &#128;44.0&nbsp;million for the year ended December&nbsp;31, 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborations and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">79,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">32,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government financing for research expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue and other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>93,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>44,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenues from collaboration and licensing agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from collaboration and licensing agreements increased by &#128;47.3&nbsp;million, or 144.8%, to &#128;79.9&nbsp;million for the year
ended December&nbsp;31, 2018, as compared to revenues from collaboration and licensing agreements of &#128;32.6&nbsp;million for the year ended December&nbsp;31, 2017. These revenues were derived principally under our agreements with AstraZeneca and
are set forth in the table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from collaboration and licensing agreements:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Monalizumab agreement</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">61,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">32,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>IPH5201 agreement</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invoicing of research and development (IPH5201 and IPH5401 agreements)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange gains on collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue from collaboration and licensing agreements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>79,892</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>32,631</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Proceeds related to monalizumab.&nbsp;&nbsp;&nbsp;&nbsp;</I>Revenue related to monalizumab increased by
&#128;29.2&nbsp;million, or 90.3%, to &#128;61.5&nbsp;million for the year ended December&nbsp;31, 2018, as compared to &#128;32.3&nbsp;million for the year ended December&nbsp;31, 2017. This change is primarily due to (i)&nbsp;the exercise of the
option by AstraZeneca in October 2018, which resulted in revenue of &#128;32.0&nbsp;million in the year ended December&nbsp;31, 2018 and (ii)&nbsp;an increase of &#128;18.3&nbsp;million in revenue recognized in the period based on the percentage of
completion of development work, partially offset by (iii)&nbsp;the impact of the adoption of IFRS 15, which had a negative impact of &#128;21.0&nbsp;million on revenue for the year ended December&nbsp;31, 2018 . As of December&nbsp;31, 2018, the
deferred revenue related to monalizumab is &#128;104.9&nbsp;million (&#128;54.2&nbsp;million as &#147;Deferred revenue&#151;Current portion&#148; and &#128;50.7&nbsp;million as &#147;Deferred
<FONT STYLE="white-space:nowrap">revenue&#151;Non-current</FONT> portion&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Proceeds related to
IPH5201.&nbsp;&nbsp;&nbsp;&nbsp;</I>Revenue related to IPH5201 for the year ended December&nbsp;31, 2018 was &#128;15.6&nbsp;million compared to nil for the year ended December&nbsp;31, 2017. Revenue related to the partial recognition of the
$50.0&nbsp;million <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment received from AstraZeneca in 2018, which has been recognized as revenue based on the percentage of completion of the development work. As of December&nbsp;31,
2018, the amount not yet recognized in revenue amounted to &#128;27.9&nbsp;million, classified as &#147;Deferred revenue&#151;Current portion.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Invoicing of research and development costs.&nbsp;&nbsp;&nbsp;&nbsp;</I>Revenue from invoicing of research and development costs for the
year ended December&nbsp;31, 2018 was &#128;2.2&nbsp;million compared to nil for the year ended December&nbsp;31, 2017. Pursuant to<I> </I>our agreements with AstraZeneca, research and development costs related to IPH5401 are equally shared between
us and AstraZeneca and research and development costs related to IPH5201 are fully borne by AstraZeneca, resulting in periodic settlement invoices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Government financing for research expenditures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government financing for research expenditures increased by &#128;2.7&nbsp;million, or 23.3%, to &#128;14.1&nbsp;million for the year ended
December&nbsp;31, 2018, as compared to &#128;11.4&nbsp;million for the year ended December&nbsp;31, 2017. This change is primarily a result of an increase in the research tax credit of &#128;2.5&nbsp;million, which is mainly due to an increase in
eligible research and development personnel expenses and an increase in amortization of the monalizumab intangible asset following the additional consideration due to Novo Nordisk A/S in 2018. The table below details government funding for research
expenditures for the years ended December&nbsp;31, 2018 and 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">11,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Government financing for research expenditure</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>14,060</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>11,402</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research tax credit is calculated as 30% of the amount of research and development expenses, net of grants
received, eligible for the research tax credit for the years ended December&nbsp;31, 2018 and 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents our operating expenses for the years ended December&nbsp;31, 2018 and 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">69,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>87,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>84,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses in the periods presented primarily relate to activities for our monalizumab, IPH4102 and IPH5401
programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses are broken down as set forth in the table below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Monalizumab<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">15,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPH4102</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPH5401</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other preclinical programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lumoxiti<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discovery projects and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total direct research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>42,282</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses (including share-based payments)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Personnel and other expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,409</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,718</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>69,555</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>67,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As a result of the adoption of IFRS 15 as of January&nbsp;1, 2018, monalizumab expenses do not include our <FONT STYLE="white-space:nowrap">co-funding</FONT> share of research and development work performed by
AstraZeneca, which amounted to &#128;15.5&nbsp;million and is recorded as a reduction to the transaction price, which is to be recorded as a revenue based on the percentage of completion. See the table appearing on Page 93 of this Prospectus for
reconciliation to IFRS 15. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Lumoxiti research and development expenses mainly relate to the generation of additional data for regulatory purposes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development increased by &#128;2.6&nbsp;million, or 3.8%, to &#128;69.6&nbsp;million for the year ended December&nbsp;31, 2018,
as compared to research and development of &#128;67.0&nbsp;million for the year ended December&nbsp;31, 2017. The increase is mainly explained by: (i) an increase of &#128;9.6 million in expenses related to IPH5401 following our acquisition of the
related rights from Novo Nordisk in June 2017, (ii) an increase of &#128;8.3 million in expenses related to the progress of our monalizumab program (excluding the IFRS 15 impact), partially offset by (iii) a decrease of &#128;15.5 million related to
the impact of IFRS 15. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Personnel expenses including share-based compensation to our employees and consultants decreased by
&#128;0.5&nbsp;million, or 3.2%, to &#128;14.2&nbsp;million for the year ended December&nbsp;31, 2018, as compared to &#128;14.7&nbsp;million for the year ended December&nbsp;31, 2017. This decrease is the cumulative impact of (i)&nbsp;the decrease
of &#128;3.0&nbsp;million in share-based payments partially offset by (ii)&nbsp;the increase in wages and salaries of &#128;2.8&nbsp;million due to increases in employee headcount and bonuses paid. As of December&nbsp;31, 2018 and 2017, we had 154
and 147 employees engaged in research and development activities, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased by &#128;1.1&nbsp;million, or 6.6%, to &#128;18.1&nbsp;million for the year ended
December&nbsp;31, 2018, as compared to general and administrative expenses of &#128;17.0&nbsp;million for the year ended December&nbsp;31, 2017. General and administrative expenses represented a total of 20.7% and 20.3% of the total operating
expenses for the years ended December&nbsp;31, 2018 and 2017, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents our general and administrative expenses by nature for the years
ended December&nbsp;31, 2018 and 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses (including share-based payments)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non scientific advisory and consulting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total general and administrative</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>18,142</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>17,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Other expenses are related to intellectual property, maintenance costs for laboratory equipment and our headquarters, depreciation and amortization and other general and administrative expenses. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Personnel expenses includes the compensation paid to our employees and consultants, and decreased by &#128;2.9&nbsp;million, or 27.3%, to
&#128;7.6&nbsp;million for the year ended December&nbsp;31, 2018, as compared to personnel expenses of &#128;10.5&nbsp;million for the year ended December&nbsp;31, 2017. This decrease results from a decrease in share-based payments of
&#128;4.3&nbsp;million, partially offset by the increase in wages and salaries of &#128;1.4&nbsp;million. As of December&nbsp;31, 2018, we had 41 employees in general and administrative functions, which was stable compared to December&nbsp;31, 2017.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-scientific</FONT> advisory and consulting expenses mostly consist of auditing, accounting, taxation
and legal fees as well as consulting fees in relation to business strategy and operations and hiring services. <FONT STYLE="white-space:nowrap">Non-scientific</FONT> advisory and consulting expenses increased by &#128;1.5&nbsp;million, or 39.7%, to
&#128;5.3&nbsp;million for the year ended December&nbsp;31, 2018 as compared to &#128;3.8&nbsp;million for the year ended December&nbsp;31, 2017, primarily as a result of our agreement with AstraZeneca entered into in October 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Net income (loss) from distribution agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognized a net loss of &#128;1.1&nbsp;million from the Lumoxiti distribution agreement in the year ended December&nbsp;31, 2018, which
reflected immaterial revenue from sales of Lumoxiti in the period, less administrative and selling expenses associated with the sales revenue allocated to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Financial income (loss), net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net financial loss decreased by &#128;5.6&nbsp;million, or 69.8%, to &#128;2.4&nbsp;million for the year ended December&nbsp;31, 2018, as
compared to &#128;8.0&nbsp;million for the year ended December&nbsp;31, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents the components of our net financial loss for the years ended
December&nbsp;31, 2018 and 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange gains</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,002</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized losses on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,942</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,851</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,429</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,535</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net financial loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(2,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(8,034</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2018 and 2017, the foreign exchange gains and losses mainly result from
the variance of the exchange rate between the Euro and the U.S. dollar on U.S. dollar-denominated cash and cash equivalents and financial assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unrealized losses on financial assets relate to unquoted instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
liquidity and capital resources discussion that follows contains certain estimates as of the date of this prospectus of our estimated future sources and uses of liquidity (including estimated future capital resources and capital expenditures) and
future financial and operating results. These estimates reflect numerous assumptions made by us with respect to industry performance, general business, economic, regulatory, market and financial conditions and other future events, and matters
specific to our businesses, all of which are difficult or impossible to predict and many of which are beyond our control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Sources
and uses of liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have primarily financed our operations through our receipt of $475.0 million (&#128;415.9&nbsp;million)
in payments from our collaborators, including AstraZeneca, since 2011, excluding payments received for purchases of our equity securities by our collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also financed our operations since our inception through several rounds of public and private financings. Since our inception, we have
raised a total of &#128;240.4 million through the sale of equity securities, including &#128;33.7 million in the initial public offering of our ordinary shares on Euronext Paris in 2006. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have received an aggregate of &#128;67.1&nbsp;million in research tax credits received to date. As a French biopharmaceutical
company, we have benefited from certain tax advantages, including, for example, the research tax credit. The research tax credit can be offset against French corporate income tax due and the portion in excess, if any, may be refunded. The research
tax credit is calculated based on our claimed amount of eligible research and development expenditures in France. The research tax credit increased by &#128;2.5&nbsp;million, or 22.5%, to &#128;13.5&nbsp;million for the year ended December&nbsp;31,
2018, as compared to a research tax credit of &#128;11.0&nbsp;million for the year ended December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently qualify as
a small or medium size business. Therefore, the French Treasury refunded our 2016 research tax credit claims during the following year and we received reimbursement of the 2017 research tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
credit in compliance with the applicable regulatory rules in September 2018. We expect our status as a small or medium size business will be lost at the end of the fiscal year 2019 and,
therefore, we would no longer be entitled to the immediate reimbursement of the Research Tax Credit but instead would be reimbursed within the expiry of a three-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are potentially eligible to earn a significant amount of milestone payments and royalties under our agreements with AstraZeneca in the
event that we satisfy certain <FONT STYLE="white-space:nowrap">pre-specified</FONT> milestones. We may enter into new collaboration agreements that also provide milestone payments. These milestone payments are dependent on the accomplishment of
various development, regulatory and commercialization objectives, and the achievement of many of these milestones is outside of our control. However, our ability to earn these payments and their timing will, in part, be dependent upon the outcome of
our research activities which is uncertain at this time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;3, 2017, we borrowed from the bank Soci&eacute;t&eacute;
G&eacute;n&eacute;rale in order to finance the construction of our future headquarters. This loan, amounting to a maximum of &#128;15.2&nbsp;million, can be drawn down during the period of the construction in order to pay supplier payments as they
become due, but in any event no later than August&nbsp;30, 2019. We have decided to postpone this construction. Until this construction begins, the proceeds of the loan will be used to finance several projects, such as extension of our current
building, improvement of our information systems and development of our commercial infrastructure. Repayment of any amounts drawn down are payable over a <FONT STYLE="white-space:nowrap">12-year</FONT> term beginning on August&nbsp;30, 2019 and
ending on August&nbsp;30, 2031. As security for the loan, we pledged collateral in the form of financial instruments held at Soci&eacute;t&eacute; G&eacute;n&eacute;rale amounting to &#128;15.2&nbsp;million. The security interest on the pledged
financial instruments will be released in accordance with the following schedule: &#128;4.2&nbsp;million in July 2024, &#128;5.0&nbsp;million in July 2027 and &#128;6.0&nbsp;million in July 2031. As of December&nbsp;31, 2018, we had drawn down
&#128;1.3&nbsp;million under the loan. The loan bears a fixed interest rate of 2.01%. Under the loan, we are subject to a covenant that our total cash, cash equivalents and current and <FONT STYLE="white-space:nowrap">non-current</FONT> financial
assets as of each fiscal year end will be at least equal to the amount of outstanding principal under the loan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lease our headquarters
in Luminy, Marseille, France under a finance lease agreement. The present value of the minimum lease payments until 2021, which is the term of the lease, is recognized as a financial liability of &#128;1.1&nbsp;million at December&nbsp;31, 2018. In
addition, we obtained a &#128;1.5&nbsp;million PTZI loan (<I>Pr&ecirc;t &agrave; Taux Z&eacute;ro Innovation</I>&#151;interest-free loan for innovation) from <I>Banque Publique d&#146;Investissement</I>, or BPI France, in 2013. The loan is repayable
beginning in September 2016 over five years. Lastly, during the years ended December&nbsp;31, 2016 and 2017, we also used lease-financing and bank loans to finance the acquisition of laboratory equipment and to set up new laboratories. The debt
related to these loans amounts to &#128;1.4&nbsp;million at December&nbsp;31, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity position </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and short-term investments increased by &#128;51.4&nbsp;million, or 44.3%, to &#128;167.5&nbsp;million for the year
ended December&nbsp;31, 2018, as compared to cash, cash equivalents and short-term investments of &#128;116.1&nbsp;million for the year ended December&nbsp;31, 2017. The cash assets that we hold consist of current accounts and fixed term accounts.
Short-term investments primarily consist of shares of money market funds and mutual funds. Their purpose is to finance our activities, including our research and development costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Excluding share options, we have received a total of &#128;240.4&nbsp;million from capital
increases, before deducting the costs associated with capital increases, between 1999 and December&nbsp;31, 2018. The table below summarizes the main capital increases between 1999 and December&nbsp;31, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;Proceeds</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April 2000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 2002</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.0&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2004</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 2004</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2006</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2006</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.7&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 2009</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.3&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.3&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.0&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.6&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;<B></B><B></B><B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>240.4</B><B></B><B>&nbsp;million</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cash flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth cash flow data for the years ended December&nbsp;31, 2018 and 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from / (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from / (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from / (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of the exchange rate changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase / (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>52,947</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(76,539</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash flows from / (used in) operating activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net cash flow used in operations decreased by &#128;15.5&nbsp;million to &#128;32.5&nbsp;million for the year ended December&nbsp;31, 2018
as compared net cash flows used in operations of &#128;48.1&nbsp;million for the year ended December&nbsp;31, 2017. This improvement of our operating cash flows results from the collection of &#128;40.3&nbsp;million of proceeds relating to the
agreements signed with AstraZeneca in October 2018, partially offset by an increase of outflows in relation to our research and development activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash flows from / (used in) investing activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net cash flows from investing activities for the year ended December&nbsp;31, 2018 were &#128;24.3&nbsp;million and mainly consisted of
(i)&nbsp;disposal of net financial assets for &#128;24.2&nbsp;million, (ii)&nbsp;interest received on financial assets for &#128;1.4&nbsp;million, less (iii)&nbsp;acquisitions of property and equipment for &#128;0.8&nbsp;million and
(iv)&nbsp;acquisition of intangible assets for &#128;0.6&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net cash flows used in investing activities for the year ended
December&nbsp;31, 2017 were &#128;29.5&nbsp;million and mainly consisted of (i)&nbsp;acquisitions of net financial assets for &#128;25.7&nbsp;million, (ii)&nbsp;the IPH5401 acquired rights from Novo Nordisk A/S resulting in a cash out flows of
&#128;2.8&nbsp;million, as the remaining part of the upfront payment of &#128;40.0&nbsp;million was contributed in kind through a capital increase of &#128;37.2&nbsp;million, (iii)&nbsp;acquisitions of property and equipment for
&#128;3.0&nbsp;million (mainly related to the acquisition of the land attached to our headquarters and certain pieces of laboratory equipment), less (iv) interest received on financial assets for &#128;1.4&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The acquisitions of current financial assets consist of purchases of current marketable
securities that do not meet the conditions under IAS 7 <I>Statement of cash flows</I> to be considered as cash equivalents. See Note 4 to our consolidated financial statements for the year ended December&nbsp;31, 2018 appearing elsewhere in this
prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash flows from / (used in) financing activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net cash flows from financing activities for the year ended December&nbsp;31, 2018 increased by &#128;60.3&nbsp;million to
&#128;61.2&nbsp;million as compared to net cash flows from financing activities of &#128;0.9&nbsp;million for the year ended December&nbsp;31, 2017. On October&nbsp;22, 2018, AstraZeneca acquired 9.8% of our capital through the issuance of 6,260,500
new shares at &#128;10 per share, generating a &#128;62.6&nbsp;million cash inflow.<B><I> </I></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Funding requirements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the net proceeds of this global offering, together with our existing cash, cash equivalents, short-term
investments and non-current financial assets, will enable us to fund our operating expenses and capital expenditure requirements for at least&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months. We
have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we can generate a sufficient amount of revenue from sale of approved products, if ever, we expect to finance our operating activities
through our existing liquidity, the proceeds of this global offering and expected milestone payments from collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our present and
future funding requirements will depend on many factors, including, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size, progress, timing and completion of our clinical trials and preclinical studies for any current or
future product candidates, including our lead product candidates, monalizumab and IPH4102, IPH5401; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of potential new product candidates we identify and decide to develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with our payment obligations to third parties in connection with our development and potential
commercialization of certain of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with expanding our organization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against
claims of infringement raised by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the time and costs involved in obtaining regulatory approval for our product candidates and any delays we may
encounter as a result of evolving regulatory requirements or adverse results with respect to any of these product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selling and marketing activities undertaken in connection with the commercialization of Lumoxiti and any other
current or future product candidates, including monalizumab, IPH4102, IPH5401 and IPH5201 and other product candidates, together with the costs involved in the creation of a sales and marketing organization; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of revenues, if any, we may derive either directly, or in the form of milestone or royalty payments
from any future potential partnership agreements, from monalizumab, IPH5201, or relating to our other product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information as to the risks associated with our future funding needs, see &#147;Risk Factors&#151;We may need to raise additional
funding to complete the development and any commercialization of our product candidates, which may not be available on acceptable terms, or at all, and failure to obtain this necessary capital when needed may force us to delay, limit or terminate
our product development efforts or other operations.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Capital expenditures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations mainly require investment in intangible assets. We acquired the rights of IPH5401 from Novo Nordisk A/S in 2017. We paid an
upfront of &#128;40.0&nbsp;million, of which &#128;37.2&nbsp;million was contributed in new ordinary shares and &#128;2.8&nbsp;million in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2019, we paid to AstraZeneca an initial payment for the license related to Lumoxiti ($50.0&nbsp;million, or &#128;43.8 million,
using the foreign exchange rate of 1.1422 at the date of payment), and in February 2019, we paid to Novo Nordisk A/S additional consideration relating to monalizumab ($15.0&nbsp;million, or &#128;13.1&nbsp;million as of December&nbsp;31, 2018). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations generally require little investment in tangible assets because we outsource most of the manufacturing and research activities
to third parties. We lease some of our computer equipment under operating lease agreements. We account for our payments for these items as operating expenses in the consolidated statement of income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our capital expenditures in the year ended December&nbsp;31, 2018 and 2017 primarily related to laboratory equipment. Clinical research and
development costs are not capitalized until marketing authorizations are obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate office in Luminy, Marseille, France is
leased under a finance lease agreement signed in 2008 with Sogebail, a subsidiary of Soci&eacute;t&eacute; G&eacute;n&eacute;rale, for an aggregate of &#128;6.6&nbsp;million. The lease-financing agreement has a 12-year term. We have a purchase
option for all of the buildings and land for the lump sum of &#128;1 at the end of the term of the contract in June 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since July
2017, we also rent office space in Marseille, France under a commercial lease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations at December&nbsp;31, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 to 3<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3 to 5<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI France PTZI interest-free loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;real
estate<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Down payment&#151;real estate<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans&#151;Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease&#151;Building &#147;Le Virage&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease&#151;Vehicles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,688</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,862</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>678</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,061</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,289</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Lease finance obligations&#151;real estate relate primarily to real estate property in relation to our acquisition of our headquarters and main laboratories and are presented in the above table net of the cash
collateral paid to Sogebail, the lessor. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We paid a guarantee to Sogebail for our real estate lease in the form of a down payment. This down payment amounted to &#128;0.2&nbsp;million at December&nbsp;31, 2018. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all
significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. The table does not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include obligations under agreements that we can cancel without a significant penalty as well as obligations under our employment benefit plans, which amounted to &#128;3.7&nbsp;million as of
December&nbsp;31, 2018. Also, this table does not include the undrawn part of the building loan amounting to &#128;13.9&nbsp;million that we are committed to fully draw before August&nbsp;30, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2018, we have non-cancellable purchase commitments for a total of &#128;7.2 million with various CMOs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of a supply of scientific equipment, we were committed towards a supplier to minimum annual purchases of consumables. As of
December&nbsp;31, 2018, the overall commitment was amounting to &#128;0.3&nbsp;million for the period from January 2019 to June 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, we have certain obligations under the terms of research, collaboration and licensing agreements which usually require us to bear all expenses relating to the procurement, examination and extension procedures of patents, as well as to
uphold and defend the patents and will require, according to certain milestones, the payment of lump sums and royalties on sales to the licensor. The timing of the obligations depends on when related milestones are reached, which cannot be
anticipated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also signed option agreements which require us to (i)&nbsp;bear all expenses relating to the procurement, examination and
extension procedures of patents, as well as to uphold and defend the patents, (ii)&nbsp;pay a lump sum of money as option payment and (iii)&nbsp;if we decide to later <FONT STYLE="white-space:nowrap">opt-in,</FONT> to pay to the licensor of lump
sums (milestone payments) and royalties on sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lastly, we signed certain agreements with collaborators, which defined the rules of
joint-ownership and the granting of rights regarding certain aspects of intellectual property. Under these contracts, we usually bear all expenses relating to the procurement, examination and extension procedures of the patents and to any procedure
required to uphold and defend the patents. These agreements also usually require, in exchange for a license over the share of rights owned by the <FONT STYLE="white-space:nowrap">co-owner,</FONT> and according to certain milestones, the payment of
lump sums and royalties on sales to the <FONT STYLE="white-space:nowrap">co-owner.</FONT> For example, we may be obligated to pay Novo Nordisk A/S up to &#128;20.0&nbsp;million in potential regulatory milestones relating to monalizumab and tiered
mid-to-high single-digit percentage royalties on net sales of monalizumab products, and up to an aggregate of &#128;370.0 million upon the achievement of development, regulatory and sales milestones relating to IPH5401 and tiered royalties ranging
from a low double-digit to low-teen percentage of net sales of IPH5401. We may also be obligated to pay Orega Biotech up to an additional &#128;51.5&nbsp;million in the aggregate upon the achievement of development and regulatory milestones, and
mid-single digit to low-teen percentage payments, depending on determinations relating to Orega Biotech&#146;s intellectual property rights for certain patents, on sublicensing revenues we receive pursuant to our agreement with AstraZeneca relating
to IPH5201. Finally, we are obligated to pay up to $25.0&nbsp;million to AstraZeneca in the aggregate upon the achievement of certain regulatory and commercial milestones relating to Lumoxiti, and low single digit percentage royalties on our net
sales of Lumoxiti, and are obligated to pay Selexis&nbsp;SA, for each of IPH4102, IPH5201 and IPH5301, up to 1.6&nbsp;million Swiss francs in development and regulatory milestones and either up to 50.0&nbsp;million Swiss francs in commercial
milestones or low single digit percentage royalties on net sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the periods presented, we did not, and we do not currently, engage in <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
financing arrangements as defined under SEC rules, such as relationships with other entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating
financing transactions that are not required to be reflected on our consolidated statement of financial position. In addition, we do not engage in trading activities involving <FONT STYLE="white-space:nowrap">non-exchange</FONT> traded contracts. We
therefore believe that we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we did engage in these relationships. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management has not completed an assessment of the effectiveness of our internal control over financial reporting, and our independent
registered public accounting firm has not conducted an audit of our internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the audit of our
consolidated financial statements as of and for the years ended December 31, 2018 and 2017, we identified material weaknesses in our internal control over financial reporting. A company&#146;s internal control over financial reporting is a process
designed by, or under the supervision of, a company&#146;s principal executive and principal financial officers, or persons performing similar functions, and effected by a company&#146;s board of directors, management and other personnel to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. Under standards established by the Public Company Accounting Oversight
Board, a material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement in our annual or interim financial statements will not
be prevented or detected and corrected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the course of auditing the consolidated financial statements as of and for
the year ended December 31, 2018, a material weakness in our internal controls related to the recognition of the revenue from our collaboration and licensing agreement with AstraZeneca on monalizumab was identified. The specific weakness in our
internal controls involved insufficient review of the calculation of the transaction price and percentage of completion of costs incurred, leading to an incorrect amount of revenue recognized for the year ended December 31, 2018, which was corrected
prior to the issuance of our audited financial statements. In the course of auditing the consolidated financial statements as of and for the year ended December 31, 2017, three material weaknesses in our internal controls were identified. The
material weaknesses related to (i) the accounting for subcontracting clinical costs for which there was insufficient control on the input data from clinical studies (termination date of the study and/or number of expected visits), (ii) stock-based
compensation with insufficient control surrounding the valuation of AGAP by external valuators, and (iii) a risk of management override of controls on manual journal entries due to insufficient supporting documentation for certain entries. Errors
not detected in relation to topics (i) and (ii) have led to incorrect amounts of R&amp;D expenses and personnel expenses for the year ended December 31, 2017, which were subsequently corrected prior to the issuance of our audited financial
statements. A number of significant deficiencies in our internal controls have also been identified for the years ended December&nbsp;31, 2018 and December&nbsp;31, 2017. Over the course of 2019, we continue to work to remediate these material
weaknesses and strengthen our controls in these areas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were not required to perform an evaluation of our internal control over
financial reporting in accordance with the provisions of the Sarbanes-Oxley Act. Accordingly, we cannot assure you that we have identified all, or that we will not in the future have additional, material weaknesses. Material weaknesses may still
exist when we report on the effectiveness of our internal control over financial reporting as required by reporting requirements under Section 404 after the completion of this global offering. See &#147;Risk factors&#151;There are material
weaknesses and significant deficiencies in our internal controls over financial reporting and if we are unable to maintain effective controls over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected,
which could hurt our business, less investor confidence and depress the market price of our securities.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and
Significant Judgments and Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are prepared in accordance with IFRS. Some of the accounting
methods and policies used in preparing the financial statements under IFRS are based on complex and subjective assessments by our management or on estimates based on past experience and assumptions deemed realistic and reasonable based on the facts
and circumstances. The actual value of our assets, liabilities and shareholders&#146; equity as well as our income and expenses could differ from the value derived from these estimates if conditions </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
changed and these changes had an impact on the assumptions adopted. See Note 2 to our consolidated financial statements for the years ended December&nbsp;31, 2018 and 2017 appearing elsewhere in
this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the most significant management judgments and assumptions in the preparation of our consolidated
financial statements are described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Accounting for collaboration and licensing arrangements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, our revenue has been generated primarily from payments received in relation to research, collaboration and licensing agreements signed
with pharmaceutical companies. These contracts generally provide for components such as upfront payments, milestone payments upon reaching certain predetermined development objectives, research and development funding, as well as payment of
royalties on future sales of products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-refundable</FONT> upfront payments are deferred and
recognized as revenue over the period we are engaged to deliver services to the third party. Revenue is recognized based on completion of the underlying work. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Milestone payments represent amounts received from our collaborators, the receipt of which is dependent upon the achievement of certain
scientific, regulatory, or commercial milestones. We recognize milestone payments when the triggering event has occurred, there are no further contingencies or services to be provided with respect to that event, and the counterparty has no right to
refund of the payment. The triggering event may be scientific results achieved by us or another party to the arrangement, regulatory approvals, or the marketing of products developed under the arrangement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Measurement of the subcontracting costs relating to clinical trial costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our expense accruals for clinical trials are based on estimates of the fees associated with services provided by clinical trial investigational
sites and clinical research organizations. Payments under some of the contracts we have with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing
service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we
may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activity or fees associated with a study or service at a given point in time, adjustments to research and development
expenses may be necessary in future periods. Historically, our estimated accrued expenses have approximated actual expense incurred. However, due to the nature of such estimates, we cannot assure you that we will not make changes to our estimates in
the future as we become aware of additional information about the status or conduct of our clinical trials and other research activities. &nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Measurement of AstraZeneca invoices under the monalizumab and Lumoxiti agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The quarterly invoices submitted under these agreements are based on estimates made by AstraZeneca on the basis of its accounting work, which
requires AstraZeneca to make estimates regarding the advancement of clinical programs and associated costs. AstraZeneca provides us with an update on their budgets, which provides us with visibility into variations and allows us to identify
potential deviations. These invoices have a significant impact on our operating expenses and trade payables. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Measurement of the
fair value of share options, warrants and free shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2018, we have granted share-based compensation under
several plans to certain employees and members of our executive and supervisory boards in the form of free shares (<I>Attributions gratuites d&#146;actions</I>, or AGA), free preferred shares convertible into ordinary shares (<I>Attributions
gratuites d&#146;actions de pr&eacute;f&eacute;rence</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>convertibles en actions ordinaires</I>, or AGAP) and free performance shares (<I>Attributions gratuites d&#146;actions de performance</I>, or AGA Perf) as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Types</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>issued&nbsp;as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>warrants<BR>outstanding<BR>as of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>number of<BR>shares&nbsp;to&nbsp;be<BR>issued&nbsp;as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>price<BR>per<BR>share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>date<BR>share&nbsp;fair<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;3, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">AGAP <FONT STYLE="white-space:nowrap">2017-1</FONT> (Employees)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;3, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">AGAP Management&nbsp;2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;3, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">AGA Employees 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;3, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">AGA Bonus 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;20, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">AGA Perf Employees 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;20, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">AGA&nbsp;Perf&nbsp;Management&nbsp;2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for share-based compensation in accordance with the authoritative guidance on share-based
compensation, IFRS 2 <I>Share-based payment</I>, or IFRS 2. Pursuant to IFRS 2, the awards are measured at their fair value on the date of grant. The fair value is calculated with the most relevant formula regarding the conditions and the settlement
of each plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Determining the fair value of share-based awards at the grant date requires judgment. We use the Black-Scholes option and
Monte Carlo approach pricing models to determine the fair value of share-based compensation. Free preference shares plans includes performance conditions that are based on the market price of our ordinary shares. Holders of free preference shares
may also benefit from accelerated vesting triggered by the achievement of internal goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The determination of the grant date fair value
of warrants and free shares is affected by assumptions regarding a number of complex and subjective variables. These variables include the fair value of our ordinary shares on the date of grant, the expected term of the awards, our share price
volatility, the employee turnover weighted average probability, risk-free interest rates, expected dividends, and performance conditions when applicable. We estimate these items as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Fair value of our ordinary shares.</B> As our ordinary shares are publicly traded on Euronext Paris, for purposes of determining the fair
value of our ordinary shares we have established a policy of using the closing sales price per ordinary share as quoted on Euronext Paris on the date of the grant by the management board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Expected Volatility.</B> We use the historical volatility of our ordinary shares on Euronext Paris, made on the basis of a Capital Asset
Pricing model of the share price using a Monte Carlo approach. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Employee turnover weighted average probability</B>. This rate is based
on the historical data from our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Risk-Free Interest Rate</B>. The risk-free interest rate is based on the Euribor swap. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Dividend Yield.</B> We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable
future. Consequently, we have used an expected dividend yield of zero. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the assumptions used in the Black-Scholes and
Monte-Carlo models change significantly, share-based compensation for future awards may differ materially compared to the awards granted previously. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Measurement of employee-benefit obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of defined benefit obligation is measured according to actuarial valuations. Inherent in these valuations are key actuarial
assumptions such as the discount rate, mortality tables and rates of turnover in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employee personnel. These assumptions are provided in Note 10 to our consolidated financial statements appearing elsewhere in this prospectus. Any change in these actuarial assumptions could have
a significant impact on our consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Measurement of contingencies and loss provision </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our activities, we may be exposed to contractual commitment risk. Management exercises its judgment to estimate the probability and
amount of cash outflows, as well as the information to disclose regarding contingent liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Estimate of the recoverable
amount of the acquired and under progress licenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Impairment tests are performed on a yearly basis for the intangible assets
which are not amortized (such as intangible assets in progress). We test amortizable intangible assets for impairment when there is an indicator of impairment. Impairment tests involve comparing the recoverable amount of the licenses to their net
book value. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. If the carrying amount of any asset is below its recoverable amount, we recognize an impairment loss to reduce the carrying
amount to the recoverable amount. The main assumptions used for the impairment test include (a)&nbsp;the amount of cash flows that are set on the basis of the development and commercialization plans and budgets approved by Management,
(b)&nbsp;assumptions related to the achievement of the clinical trials and the launch of the commercialization, (c)&nbsp;the discount rate, (d)&nbsp;assumptions on risk related to the development and (e)&nbsp;for the commercialization, selling price
and volume of sales, and are provided in Note 6 to our consolidated financial statements which are included elsewhere in this prospectus. Any change in these assumptions could lead to the recognition of an impairment charge that could have a
significant impact on our consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of failure of the clinical trials in progress, we may have to fully
depreciate the intangible asset. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Estimate of the useful life of the acquired licenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets are amortized on a straight line basis over their anticipated useful life. The estimated useful life is the period over which
the asset provides future economic benefits. It is estimated by management and is regularly revised by taking into consideration the period of development over which it expects to receive economic benefits such as collaboration revenues, royalties
and product of sales. However, given the uncertainty surrounding the duration of the research and development activities for the programs in development and their likelihood to generate future economic benefits to the company, the estimated useful
life of the rights related to these programs is rarely longer than the actual development phase of the product candidate. When a program is in commercialization phases, the useful life takes into account the protection of the exclusivity rights and
the anticipated period of commercialization without taking into account any extension or additional patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures
about Market Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our activities are exposed to liquidity risk, foreign currency exchange risk, interest rate risk and credit risk.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not believe that we are exposed to short-term liquidity risk, considering our cash and cash equivalents of &#128;152.3&nbsp;million as of
December&nbsp;31, 2018, which consist primarily of cash and money market funds and term deposits that are convertible into cash immediately without penalty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign currency exchange rate risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to foreign exchange risk inherent in certain subcontracting activities related to our operations in the United States, which are
invoiced in U.S. dollars. We do not currently have material recurring </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revenues in euro, dollars or in any other currency. As we further increase our business, particularly in the United&nbsp;States, we expect to face greater exposure to exchange rate risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue denominated in U.S. dollars has represented approximately 100% of revenue in the years ended December&nbsp;31, 2018 and 2017,
respectively. Our payments in U.S. dollars represented approximately 31.9% and 15.1% of our payments in the years ended December&nbsp;31, 2018 and 2017, respectively. In order to cover this foreign currency exchange rate risk in part, we kept in
U.S. dollars a part of the consideration received from AstraZeneca in June 2015 and January 2019. We do not use hedging instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Interest rate risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited exposure to interest rate risk. Our exposure primarily relates to money market funds and time deposit accounts. Changes in
interest rates have a direct impact on the rate of return on these investments and the cash flows generated. We do not have any credit facilities bearing variable interest rates. The repayment of the advances from BPI France<B> </B>is not subject to
interest rate risk. The effect of an increase or decrease in interest rates would have an immaterial effect on profit or loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Credit risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
credit risk related to our cash equivalents, short-term investments and <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets is not significant in light of the quality of the issuers. We deemed that no instrument of its portfolio is
exposed to credit risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is
disclosed in Note 2 to our consolidated financial statements appearing elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Exemptions and Foreign Private Issuer
Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>JOBS Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with an annual revenue under $1.07&nbsp;billion, we qualify as an &#147;emerging growth company&#148; as defined in the JOBS Act.
As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to present only two years of audited financial statements in addition to any required interim
financial statements and correspondingly reduced disclosure in management&#146;s discussion and analysis of financial condition and results of operations in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemption from the auditor attestation requirement of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the
Sarbanes-Oxley Act, in the assessment of our internal controls over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that we no longer qualify as a foreign private issuer, (i)&nbsp;reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements and (ii)&nbsp;exemptions from the requirements of holding a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation, including golden
parachute compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions for up to five years or until such earlier time that
we are no longer an emerging growth company. We will cease to be an emerging growth company upon the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue, (ii)&nbsp;the date we
qualify as a &#147;large accelerated filer&#148; with at least $700&nbsp;million of equity securities; (iii)&nbsp;the issuance, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any three year period, by our company of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities held by
<FONT STYLE="white-space:nowrap">non-affiliates;</FONT> and (iv)&nbsp;the last day of the fiscal year ending after the fifth anniversary of our initial public offering of our ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to take advantage of some but not all of these reduced burdens. For example, we have presented only two years of audited
financial statements and only two years of related &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus, and intend to take advantage of the exemption from auditor
attestation on the effectiveness of our internal control over financial reporting. Accordingly, the information that we provide stockholders may be different than you might obtain from other public companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;107 of the JOBS Act provides that an emerging growth company can use the extended transition period provided in
Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Given that we currently report and expect to continue to report under IFRS as issued by the IASB, we have irrevocably elected not to avail
ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required by the IASB. Since IFRS makes no distinction between public and
private companies for purposes of compliance with new or revised accounting standards, the requirements for our compliance as a private company and as a public company are the same. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Private Issuer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon consummation of this global offering, we will report under the Exchange Act as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company
with foreign private issuer status. Even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are
applicable to U.S. domestic public companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of
a security registered under the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading
activities and liability for insiders who profit from trades made in a short period of time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> containing unaudited financial and other specified information, or current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> upon the occurrence of specified significant events; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulation FD, which regulates selective disclosures of material information by issuers. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company
focused on discovering, developing and commercializing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutic antibodies designed to harness the immune system for the treatment of oncology
indications with significant unmet medical need. We have extensive experience in research and development in immuno-oncology, having been pioneers in the understanding of natural killer cell, or NK cell, biology, and later expanding our expertise in
the tumor microenvironment, tumor antigens and antibody engineering fields. We have built, internally and through our business development strategy, a broad and diversified portfolio including an approved product, three clinical product candidates
and a robust preclinical pipeline. We have entered into collaborations with leaders in the biopharmaceutical industry, such as AstraZeneca and Sanofi, to leverage their development capabilities and expertise, and we have received upfront and
milestone payments and equity investments from our collaborations of an aggregate of approximately $550&nbsp;million over the last ten years. We believe our product candidates and clinical development approach are differentiated from current
immuno-oncology therapies and have the potential to significantly improve the clinical outcome for patients with cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The immune
system is the body&#146;s natural defense against invading organisms and pathogens and is comprised of two arms: the innate immune system and adaptive immune system. Recent immunotherapy developments have focused on generating a tumor
antigen-specific T cell response and have led to an unprecedented change in the treatment paradigm of many solid tumor cancers. Despite these successes, the breadth and durability of the clinical benefit achieved has been limited to a subset of
patients and tumor types. Our innovative approach to immuno-oncology aims to broaden and amplify anti-tumoral immune responses by leveraging both the adaptive and the innate immune systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The innate immune system is comprised of a variety of cells, including NK cells, which are involved in anti-cancer immunosurveillance through
a variety of modalities. Activation of the innate immune system also helps trigger the adaptive immune system to elicit a response directed against specific antigens and can provide durable immune memory. Our scientific expertise, strategic
collaborations and discovery engine are focused on harnessing the potential of the innate immune system across three pillars. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g48k25.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a pipeline of innovative immunotherapies that we believe have the
potential to provide a significant clinical benefit to cancer patients. The following table summarizes our commercial, clinical and preclinical pipeline. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g41w75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">&#147;SCCHN&#148; denotes Squamous Cell Carcinoma of the Head and Neck; &#147;CRC&#148; denotes Colorectal Cancer;
&#147;MF&#148; denotes Mycosis Fungoides; &#147;PTCL&#148; denotes Peripheral T-cell Lymphomas; &#147;NSCLC&#148; denotes Non-Small Cell Lung Cancer; and &#147;HCC&#148; denotes Hepatocellular Carcinoma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these product candidates, we have an active development pipeline with programs in the discovery and preclinical stages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development efforts are guided by our three pillars. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Broad spectrum immune checkpoint inhibitors</B>. We are targeting checkpoints expressed on NK cells and
myeloid cells, rather than focusing solely on T cells, in order to increase the pool of anti-tumor effector cells and potentially mount a larger anti-tumor response. Our most advanced checkpoint inhibitor product candidate, monalizumab, is a dual
checkpoint inhibitor designed to activate both tumor-infiltrating NK cells and CD8+ T cells, potentially resulting in increased effector functions and greater killing of tumor cells by the immune system. By activating NK cells, which are potent
producers of cytokines, monalizumab may also favor dendritic cell maturation, which may in turn increase the generation of a T cell response against the tumor. We believe monalizumab has the potential to be a first-in-class treatment for various
cancer indications, which we define as the ability to target a receptor that has not previously been targeted to treat cancer indications, given that no approved products or, to our knowledge, product candidates in clinical development by third
parties target the NKG2A receptor. </P></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">We and AstraZeneca AB, or AstraZeneca, are currently evaluating monalizumab in
an open-label Phase Ib/II clinical trial in combination with cetuximab, an epidermal growth factor receptor, or EGFR, inhibitor in patients&nbsp;with relapsed or metastatic squamous cell carcinoma of the head and neck, or R/M SCCHN. In addition to
unleashing tumor-infiltrating NK and CD8+ T cells, the combination of cetuximab and monalizumab may activate NK cells through the recognition of cetuximab-coated tumor cells via the CD16 activating receptor. In 2018, we presented data from a first
expansion cohort from this trial, including efficacy data and have since then expanded to two additional expansion cohorts evaluating monalizumab in combination with cetuximab in patients who had been previously treated with chemotherapy alone or in
patients who had been treated with chemotherapy followed by checkpoint inhibitors. We expect to present follow-up data from the first expansion cohort in the second half of 2019 and preliminary efficacy data from the second expansion cohort in 2020.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">AstraZeneca is also evaluating monalizumab in a Phase I/II clinical trial in combination
with durvalumab, an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> immune checkpoint inhibitor, in patients with advanced solid tumors, including colorectal cancer, or CRC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">We are also exploring the possibility of developing an antibody designed to reduce the effects of
<FONT STYLE="white-space:nowrap">Siglec-9</FONT> receptors, expressed on NK cells and myeloid cells, for the treatment of cancer. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Tumor antigen targeting</B>. We are developing antibodies that target tumor antigens in the form of
(i)&nbsp;antibody-drug conjugates, or ADCs, (ii)&nbsp;antibody-dependent cellular cytotoxicity, or ADCCs, inducing antibodies and (iii)&nbsp;antibody-based multi-specific NK cell engagers, or NKCEs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>ADCs</I></B>. One approach is to directly kill tumor cells using either an ADC, such as with our IPH43
program, or an immunotoxin, such as with our commercial-stage product Lumoxiti. Lumoxiti is a marketed, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> CD22-directed immunotoxin, which was approved by
the FDA under priority review in September 2018 for the treatment of adult patients with relapsed or refractory, or R/R, hairy cell leukemia, or HCL, who have received at least two prior systemic therapies, including treatment with a purine
nucleoside analog, or PNA. Lumoxiti is the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> treatment for HCL in over 20 years. IPH43 is as an ADC targeting MICA/B that we are developing for the treatment of oncology indications.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>ADCCs.</I></B> Another approach is to develop antibodies that activate cells of the innate immune system,
such as NK cells, in order to induce ADCC. Our most advanced product candidate utilizing this approach is IPH4102, an antibody targeting KIR3DL2, a receptor not expressed on healthy tissues except on a subset of NK cells and T cells. We believe that
IPH4102 has the potential to be a first-in-class treatment for various cancer indications, given that no approved products or, to our knowledge, product candidates in clinical development by third parties target KIR3DL2. We are developing IPH4102
for the treatment of various forms of T cell lymphomas, or TCL, including cutaneous T cell lymphoma, or CTCL, and peripheral T cell lymphoma, or PTCL. Mycosis fungoides, or MF, is the most common form of CTCL, and S&eacute;zary syndrome is an
aggressive form of CTCL. In January 2019, the FDA granted IPH4102 Fast Track designation for the treatment of adults with R/R, S&eacute;zary syndrome who have received at least two prior systemic therapies. IPH4102 has also been granted orphan drug
designation in the European Union and in the United States for the treatment of CTCL. In May 2019, we initiated a Phase II clinical trial evaluating IPH4102 in different subtypes of TCL. We expect to announce the outcome of the first stage of the MF
and PTCL cohorts in the second half of 2020 and report first efficacy data for the different cohorts beginning in 2021. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Antibody-based multi-specific NKCEs</I></B>. We are also developing a pipeline of multi-specific NKCEs that
engage an activating checkpoint, NKp46, on NK cells, in order to direct NK cells to the tumor. We believe this innovative approach may allow for immuno-oncology treatments with a more favorable safety profile than T cell engagers.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Suppressive factors of the TME</B>: We are developing product candidates that target suppressive pathways of
the TME in order to relieve the immunosuppression of the innate and adaptive immune responses. We are developing IPH5401, an anti-C5aR antibody that disrupts the complement pathway. In January 2018, we entered into a non-exclusive clinical trial
collaboration with AstraZeneca for IPH5401. As part of this collaboration, we are conducting a Phase I/II clinical trial to evaluate the safety and efficacy of IPH5401 in combination with durvalumab as a treatment for patients with solid tumors,
including NSCLC and HCC. We expect to report preliminary safety data from this dose-escalation clinical trial in the second half of 2019. In addition, we are developing product candidates that disrupt the adenosine pathway, including IPH5201, an
anti-CD39 antibody, and IPH5301, an anti-CD73 antibody. In October 2018, we entered into a collaboration and option agreement for IPH5201 with AstraZeneca. We expect to file INDs for IPH5201 and IPH5301 in the second half of 2019 and the first half
of 2020, respectively. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our collaborations allow us to leverage the expertise and resources of large pharmaceutical
companies and research institutions with the goal of accelerating the development of several of our product candidates while providing financing to expand the development of our proprietary product candidates. Over the last ten years we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have received an aggregate of approximately $550&nbsp;million in upfront and milestone payments and equity investments from our collaborations. Under our existing collaboration agreements and any
license agreements that become effective upon the exercise by our collaborators of options to license future product candidates, we may be eligible to receive an aggregate of approximately $5.5&nbsp;billion in future contingent payments. With
respect to the programs for which we have an existing collaboration or similar agreement, future contingent payments are dependent upon our achievement of specified development and sales milestones. With respect to the programs for which our
collaborators have been granted an option, future contingent payments are dependent upon our collaborators exercising such options, which would result in up-front option exercise fees, and upon our achievement of specified development and sales
milestones in those particular programs. The aggregate $5.5 billion in future contingent payments assumes that our collaborators exercise all of the options we have granted to them and that we achieve all related development, clinical, regulatory
and sales milestones. In April 2015, we entered into a collaboration with AstraZeneca relating to monalizumab, and in October 2018, AstraZeneca expanded this collaboration to gain full oncology rights for monalizumab and options to acquire
development rights to IPH5201 and four of our other preclinical programs. Concurrently, we acquired U.S. and EU commercial rights to Lumoxiti, and AstraZeneca acquired a 9.8% equity stake in our company. We have also entered into a collaboration
agreement with Sanofi Aventis Recherche&nbsp;&amp; D&eacute;veloppement, or Sanofi, which includes two programs based on our multi-specific, NKCE technology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Competitive Strengths </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our
key competitive strengths are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our lead product candidate, monalizumab, which we are developing in collaboration with AstraZeneca for the
treatment of SCCHN, CRC and other solid tumors, is a novel, dual-targeting checkpoint inhibitor that has shown promising clinical data.</I></B> Monalizumab is a humanized antibody that is capable of acting on NK cells and CD8+ T cells in order to
activate both innate and adaptive immune responses. We believe these properties may allow monalizumab, in combination with other therapies, to address some of the limitations of current therapies that only target T cells and potentially provide a
chemotherapy free therapeutic alternative in earlier lines of treatment. Preliminary data from a Phase II expansion cohort of 40 patients with R/M SCCHN previously treated with chemotherapy alone or chemotherapy followed by <FONT
STYLE="white-space:nowrap">PD-1/L1</FONT> checkpoint inhibitors, showed an overall response rate to monalizumab in combination with cetuximab of 27.5%, including one complete response (2.5%) and 10 partial responses (25%), and a disease control rate
at 24 weeks of 35%. Median progression-free survival and overall survival were 5.0 months and 10.3 months, respectively. In addition, we observed that there were three (18%) responders among the 17 patients who had been previously treated with <FONT
STYLE="white-space:nowrap">PD-1/L1</FONT> checkpoint inhibitors. Following these preliminary results, in 2018, AstraZeneca expanded its agreement with us by exercising its option to gain exclusive rights to
<FONT STYLE="white-space:nowrap">co-develop</FONT> and commercialize monalizumab in oncology. Under our collaboration agreement with AstraZeneca, we are eligible to receive a $100&nbsp;million milestone payment at the start of the first Phase III
clinical trial for monalizumab. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our proprietary product candidate, IPH4102, has shown single agent activity for the treatment of relapsed
or refractory S&eacute;zary syndrome</I></B>. In our Phase I clinical trial evaluating IPH4102 in CTCL, in the subgroup of 35 patients with S&eacute;zary syndrome, we observed an objective overall response rate of 42.9%, median duration of response
of 13.8 months, median progression-free survival of 11.7 months and that approximately 90% of patients experienced improved quality of life. IPH4102 has also been granted orphan drug designation in the European Union and in the United States for the
treatment of CTCL. In January 2019, the FDA granted Fast Track designation to IPH4102 for the treatment of adults with R/R S&eacute;zary syndrome who have received two prior systemic therapies. The results of the dedicated S&#233;zary syndrome
cohort may support a future Biologics License Application, or BLA, submission to the FDA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>We believe that by targeting C5a receptors, IPH5401 has potential as a novel target in cancer treatment and
as a scientifically validated pathway to reduce inflammation.</I></B> IPH5401 binds to and blocks C5a receptors expressed on subsets of myeloid derived suppressor cells, or MDSCs, and neutrophils. Part of the innate immune system, these types of
cells promote tumor growth by secreting inflammatory and angiogenic </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
factors. They potently suppress T and NK cells and hamper the activities of PD-1 checkpoint inhibitors and chemotherapy. We are currently conducting a Phase I clinical trial of IPH5401 in
combination with durvalumab, initially in patients with select advanced solid tumors, and plan to initiate a subsequent cohort expansion trial to evaluate IPH5401 in combination with durvalumab in patients with NSCLC or HCC. We also plan to explore
the potential of IPH5401 in inflammation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our commercial stage product, Lumoxiti, is the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
treatment for HCL in over 20 years</I></B>. Lumoxiti was approved by the FDA under priority review in September 2018 based on positive data in a Phase II clinical trial. In this trial, 75% of patients receiving Lumoxiti achieved an overall response,
30% had a complete response and 34% achieved a complete durable response with a negative minimal residual disease. A negative minimal residual disease complete response has been shown to be a surrogate for long-term disease control and potentially
survival in several hematological malignancies. Following our <FONT STYLE="white-space:nowrap">in-licensing</FONT> of Lumoxiti in the United States and the European Union from AstraZeneca, we are leveraging AstraZeneca&#146;s capabilities to advance
commercialization efforts through a transition period while we build our commercial organization. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>We believe that our broad, early stage pipeline of innovative immunotherapies targeting innate immunity
pathways provides us with multiple opportunities for future value creation</I></B>. Our expertise and leadership in the field of innate immunity has allowed us to create a diversified and differentiated portfolio in immuno-oncology<B><I>. </I></B>We
have developed a large panel of molecular and cellular assays and <I>in vivo</I> models for assessing the pharmacodynamics, toxicology and the therapeutic activity of product candidates targeted towards the innate immune system. In many cases, our
product candidates are among a limited number of therapeutic antibodies in development for a given biological target. As a result, our differentiated approach has allowed us to forge collaborations with the leading academic institutions, cancer
centers and industry partners to evaluate and advance our product candidates either alone or in combination with other investigational or approved therapies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our diversified business model provides us with a strong financial base and strategic flexibility</I></B>.
In addition to our internally developed pipeline, we have a track record of acquiring the rights to product candidates at different stages of development, including monalizumab, Lumoxiti, IPH5401 and our IPH52 program. We have already derived
substantial value from these acquisitions and subsequent business development transactions relating to these assets. Our collaborations have also allowed us to leverage development capabilities and financial resources of leading biopharmaceutical
companies, while retaining optionality to <FONT STYLE="white-space:nowrap">co-develop</FONT> and potentially <FONT STYLE="white-space:nowrap">co-promote</FONT> certain assets. At the same time, we have retained or acquired exclusive development and
commercialization rights to other product candidates. We believe that our strategic collaborations, our current financial position and the proceeds from this global offering will position us to continue to develop our proprietary portfolio of assets
and build our commercial infrastructure, while maintaining our leadership in the development of novel immunotherapies. As of June&nbsp;30, 2019, we had
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million in cash, cash equivalents, short term investments and <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets.<B><I> </I></B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Experienced management team with a track record in the development and commercialization of cancer
therapeutics. </I></B>Our management team and board of directors have substantial experience in the biopharmaceutical industry, including in drug discovery, clinical development and commercialization. Our Chief Executive Officer, Mondher Mahjoubi,
MD, has 28 years of oncology development, product strategy and commercial management experience.&nbsp;Previously, he was the Oncology Global Manager at AstraZeneca and had tenures at Genentech and Roche. Pierre Dodion, MD, MBA, Chief Medical
Officer, has 24 years of experience in clinical and regulatory development efforts and medical affairs. He previously held positions at ARIAD Pharmaceuticals, Pfizer, Novartis and Aventis.&nbsp;Our Chief Scientific Officer, Eric Vivier, DVM, PhD,
has over 25 years of immuno-oncology experience and a substantial track record of publications in key scientific journals.&nbsp;Jennifer Butler, Executive Vice President and General Manager of Innate Pharma U.S., Inc., has over 20 years of
experience in&nbsp;strategic marketing and commercial leadership expertise across several therapeutic areas. Ms.&nbsp;Butler has led and built multiple global and US commercial teams, including the product launch of durvalumab, while serving at
AstraZeneca.<B><I> </I></B><B><I></I></B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to harness the immune system for the treatment of conditions with serious unmet medical needs in oncology. By leveraging our
extensive experience in immuno-oncology research and development, we strive to continue to internally discover, externally identify and develop a broad and diversified portfolio of first and <FONT STYLE="white-space:nowrap">best-in</FONT> class
immunotherapies across various therapeutic modalities. The key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Deliver our clinical programs and improve patient outcomes in indications with high unmet medical need by
building on our scientific discoveries. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complete our ongoing clinical trial of monalizumab for the treatment of SCCHN, which, together with the data from
the CRC clinical trial, will inform further development and the potential path to market. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Execute the clinical development of our wholly owned product candidate, IPH4102, for the treatment of patients
with S&eacute;zary syndrome, MF and PTCL. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Progress the clinical development of our wholly owned product candidate, IPH5401, for the treatment of patients
with cancer and explore its potential to treat inflammation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance our pipeline of other proprietary product candidates, including IPH5301. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Build a commercial stage oncology-focused biotechnology company. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Build a commercial infrastructure for Lumoxiti in the United States and, if approved, in the European Union.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leverage our commercial infrastructure for future approved products in order to build a hemato-oncology focused
commercial franchise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Retain optionality to <FONT STYLE="white-space:nowrap">co-promote</FONT> product candidates in strategic regions
for select partnered assets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continue to invest in our proprietary and partnered portfolio by leveraging our strong financial position and
revenue from our existing collaborations. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximize the value of our partnered product candidates under existing collaborations, under which we may be
eligible to receive up to an aggregate of approximately $5.5&nbsp;billion in future contingent payments, including up-front option exercise fees and payments upon the achievement of specified development and sales milestones. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to explore opportunities to accelerate the development of our proprietary pipeline programs through
additional collaborations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combine our disciplined business development strategy with our immuno-oncology research and development
capabilities to further expand our product portfolio. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand our pipeline of proprietary product candidates that target novel pathways in immuno-oncology using our
internal development engine. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Activating Innate Immunity: Harnessing the Power of Immunotherapy to Treat Cancer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The Innate Immune System: Gatekeeper of the Adaptive Immune System </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The immune system is the body&#146;s defense against invading organisms and pathogens and is comprised of two arms: the innate immune system
and adaptive immune system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The innate immune system represents the first barrier of immune defense because it reacts almost immediately
against threats and serves as a catalyst to mobilize other components of the immune system. The innate immune system functions to identify, attack and kill pathogens or cancer cells, produce cytokines and activate the complement cascade and the
adaptive immune system through antigen presentation. These functions involve a variety of cells, including NK cells, dendritic cells, monocytes, macrophages and neutrophils. These cells then launch adaptive immune responses while also mounting their
own effector responses. Throughout the body, cells of the innate immune system play a critical role in the immunosurveillance and detection of the formation of cancer cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once activated, the adaptive immune system responds with large numbers of effector cells
directed against specific antigens and can provide durable immune memory. An adaptive immune response is highly specific to particular antigens expressed by pathogens or cancer cells, but it requires time to develop in a process known as priming.
Key components of the adaptive immune system include antibodies, which are produced by B cells and that bind to antigens and mark them for destruction by other immune cells, and T&nbsp;cells, which recognize antigens on diseased cells and then
attack and eliminate them. The adaptive immune response is targeted and potent and has the potential to provide a long-lasting immune memory. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g06k36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The graphic above shows the interaction of the cells in the innate immune system and adaptive immune system
in the presence of microbial infections and tumors. The various cells in the innate immune system rapidly launch their own effector response to fight the infection or tumor while also activating the B cells and T cells in the adaptive immune system.
Once activated, the adaptive immune system launches a slower but more targeted effector response against the infection or tumor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Key Elements to Modulating the Activity of Immune Cells to Treat Cancer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cells implicated in innate and adaptive immunity can have different impacts on the treatment of cancer. While cytotoxic CD8+ T cells and NK
cells help eliminate tumors, subsets of T cells, such as regulatory T cells, and subsets of myeloid cells, such as myeloid-derived suppressor cells (MDSCs), can be harmful to the host by contributing to an immunosuppressive environment and promoting
tumor growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immune cell activity is controlled by many activating and inhibitory factors, including activating receptors and inhibitory
receptors, called checkpoints, which are expressed at the surface of these cells. <FONT STYLE="white-space:nowrap">PD-1,</FONT> <FONT STYLE="white-space:nowrap">LAG-3,</FONT> TIGIT and NKG2A are examples of inhibitory checkpoints while <FONT
STYLE="white-space:nowrap">OX-40,</FONT> CD137, NKG2D and NKp46 are examples of activating checkpoints. When engaged, the inhibitory checkpoints can impair anti-tumor immunity of adaptive and innate immune cells such as CD8+ T cells or NK cells,
thereby contributing to tumor escape from immune control. Inhibitory checkpoints are potential therapeutic targets for restoring anti-cancer immunosurveillance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The Role of the Innate Immune System as a Modality for Cancer Therapies with
Significant Potential </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer has historically been treated with surgery, radiation therapy, chemotherapy, targeted therapy,
hormone therapy or a combination of these treatments that are directed at the tumor itself. More recently, advances in the understanding of the immune system&#146;s role in cancer have led to immunotherapy becoming an important therapeutic modality,
shifting the therapeutic target from the tumor to the host and focusing on the immune system and the TME in order to reactivate its immunosurveillance against cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer immunotherapy began with treatments that nonspecifically activated the immune system, such as
<FONT STYLE="white-space:nowrap">IL-2</FONT> and IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> cytokines therapies, which had limited efficacy, significant toxicity or both. More recent immunotherapy developments have instead focused on the
generation of a tumor antigen-specific T cell response, in particular by modulating the activity of inhibitory receptors expressed by T cells. This modulation can limit T cells expansion, such as with
<FONT STYLE="white-space:nowrap">anti-CTLA-4</FONT> therapy, or limit their effector properties, such as with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> therapies. The therapeutic targeting of inhibitory receptors controlling T cell function has led to an unprecedented change in the treatment paradigm of many cancers in solid tumors, such as
melanoma, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer and renal cell carcinoma, and in hematopoietic malignancies, such as Hodgkin lymphoma. Despite these successes, the breadth and durability of clinical benefit achieved has
been limited to a subset of patients and tumor types. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The onset, maintenance and development of long-lasting, protective T cell responses
are dependent on innate immune cells and NK cells in particular. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Harnessing Innate Immunity in Cancer: NK Cells as a Key Player in
the Anti-Tumor Immune Response </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NK cells are part of the innate immune system and represent a significant fraction of the total
number of cytotoxic cells in the body. They are active in many hematological and solid tumors and play a key role in the initiation of the T&nbsp;cell response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Checkpoints expressed on NK cells include inhibitory cell surface receptors, such as NKG2A, and activating NK cell receptors, such as NKp46.
NKp46 is the most specific NK cell marker identified to date across organs and species. Other receptors, such as NKG2A, are more prevalent in certain subsets of NK cells, including NK cells infiltrating the tumor, and are also present on tumor
infiltrating CD8+ T cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NK cells are involved in the anti-cancer immunosurveillance through a variety of direct and indirect effects.
The figure below provides an illustration of anti-cancer functions of NK cells. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;&nbsp;&nbsp;


<IMG SRC="g752656g07h45.jpg" ALT="LOGO">
&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">NK cells are able to directly and selectively kill cells undergoing stress caused by a cancerous transformation or pathogen
infection, a process called natural cytotoxicity.</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3" ALIGN="center">


<IMG SRC="g752656g34u16.jpg" ALT="LOGO">
 <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">


<IMG SRC="g752656g78x43.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">NK cells can also kill target cells when they are coated by antibodies in a process called antibody-dependent cellular cytotoxicity (ADCC).</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g752656g14z14.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NK cells are also potent producers of cytokines, which are soluble
molecules that recruit and activate an adaptive immune response by T&nbsp;cells through dendritic or other antigen-presenting cells, which in turn may enable the generation of immune memory against tumor cells.</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By providing the initial catalyst for the multilayered immune response, the activation of the innate immune
system through the targeting of NK cells could potentially result in an enhanced anti-tumoral T cell response. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The Tumor and its Host: The Immune System and the Tumor Microenvironment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent years, the pursuit of understanding the resistance to immune checkpoint inhibitors has led to an increased focus on the TME, which
plays an important role in the inhibition of both the innate and adaptive immune system. The TME contains a complex interplay of immunosuppressive biological pathways, cells and other components surrounding the tumor that often act together to
profoundly suppress the body&#146;s anticancer immune response, thereby allowing tumors to evade the immune system. More specifically, the TME can inhibit immune responses through the following means: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlling oxygen availability to cells, resulting in hypoxia; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">producing or degrading key metabolites regulating cell survival or activation, such as PGE2, adenosine,
tryptophan and <FONT STYLE="white-space:nowrap">L-Arginine;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">producing immunosuppressive cytokines, such as <FONT STYLE="white-space:nowrap">TGF-&szlig;;</FONT> and
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruiting suppressive cells such as MDSCs and regulatory T cells. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preclinical data has shown that targeting the TME and neutralizing its immunosuppressive, cancer-promoting effects could play a key role
in the fight against cancer in combination with other immunotherapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Differentiated Approach: Three Pillars to Harness the Potential of the
Innate Immune System </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Anti-tumor immune response results from complex interactions between many different cells, including innate
immune cells, adaptive immune cells and cancer cells. While T cells, particularly CD8+ T cells, are critical to many protective anti-tumor immune responses, they do not act autonomously and require the activation of innate immune cells to achieve
full potential. More specifically, T cells expand upon the presentation of antigens by activated dendritic cells, a process that can be enhanced by the activation of NK cells through the production of development factors, chemokines or cytokines. In
addition, innate immune cells can also have anti-tumor activity independent of their impact on T cells and other adaptive immune cells, including for example, the cytotoxic activity of NK cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our scientific expertise, strategic collaborations and discovery engine allow us to harness the potential of the innate immune system across
three pillars: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Broad spectrum immune checkpoint inhibitors</B>. We are targeting checkpoints expressed on several immune
system cell types including NK cells and myeloid cells, rather than focusing solely on T cells, in order to increase the pool of anti-tumor effector cells and potentially mount a larger anti-tumor response. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Tumor antigen targeting</B>. We are developing antibodies designed to target tumor antigens, in either
ADCC-inducing or ADC formats, and unique antibody-based multi-specific NKCEs, with the goal of combining the direct effect of tumor cell killing with the indirect priming and amplification of the T cell response by releasing tumor antigens and
mobilizing innate immune cells such as NK cells. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Suppressive factors of the TME</B>. We are developing product candidates that relieve the immunosuppression of
the innate and adaptive immune responses. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g47j52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pipeline is balanced between these three pillars and each pillar is designed to harness the potential
of the innate immune system. More specifically, for each of these pillars, we are advancing the following innovative approaches: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"><B><I>The targeting of inhibitory checkpoints includes the generation of broad-spectrum immune checkpoint inhibitors, such as monalizumab, that have been designed
to unleash several immune cell types such as NK cells and CD8+ T cells. By unleashing both types of cells, broad spectrum immune checkpoint inhibitors may provide a more effective anti-tumor response when combined with other
therapies.</I></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the greatest advances in immuno-oncology has been the development of antibodies that target T cell
checkpoints, most notably the <FONT STYLE="white-space:nowrap">CTLA-4</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> pathways. These treatments have shown an ability to activate T cells, shrink
tumors and improve patient survival in a broad range of tumors. In 2011, Yervoy (ipilimumab, anti-CTLA4) became the first checkpoint inhibitor approved by the FDA, followed by Opdivo (nivolumab, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1)</FONT></FONT> in 2014 and Keytruda (pembrolizumab, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1)</FONT></FONT> in 2015. Other recently approved checkpoint inhibitors include
Tecentriq (atezolizumab, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1),</FONT></FONT> Bavencio (avelumab, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1),</FONT></FONT> Imfinzi
(durvalumab, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1)</FONT></FONT> and Libtayo (cemiplimab, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1).</FONT></FONT> However, the breadth and
durability of clinical benefit achieved has been limited to a subset of patients and tumor types. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing broad spectrum
checkpoint inhibitors targeting inhibitory checkpoints expressed on several cell types in order to potentially increase the breadth and quality of anti-tumor response. Our most advanced checkpoint inhibitor product candidate, monalizumab, is a
potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> dual checkpoint inhibitor designed to activate both tumor-infiltrating NK cells and CD8+ T cells, potentially resulting in increased effector
functions and greater killing of the tumor by the immune system. Our preclinical data provide evidence for this dual mechanism of action, the potential of this approach to induce long-lasting anti-tumoral immunity when combined with <FONT
STYLE="white-space:nowrap">PD-(L)1</FONT> blockers and the ability to increase the activity of ADCC inducing tumor-targeting antibodies such as cetuximab. Our preclinical checkpoint inhibitor programs include a program targeting <FONT
STYLE="white-space:nowrap">Siglec-9</FONT> receptors, which is expressed on tumor-infiltrating T cells, NK cells and innate myeloid cells. We also plan to continue to discover and explore the potential of developing other novel broad spectrum
checkpoint inhibitors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"><B><I>Targeting tumor antigens, including innovative <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT>
antibody-derived drug candidates such as NKCEs, to harness the anti-tumor activity of NK cells.</I></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Antigen-targeting antibody development is highly dependent upon several factors, including the pattern of
expression of the target and the intended mechanism of action. For example, to be effective through ADCC, antibodies should be used in an immunocompetent setting, whereas to be effective by disrupting a signal, antibodies should target a driver of
the oncogenic process. We are targeting tumor antigens that are generally highly-expressed in tumor tissues but poorly-expressed in healthy tissues in order to develop product candidates through three approaches: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The first approach is to directly kill tumor cells using either an ADC, such as with our IPH43 program or an
immunotoxin, such as our commercial-stage product Lumoxiti. This approach is particularly well suited when the tumor bed is not sufficiently infiltrated by immune cells. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The second approach is to develop antibodies that activate cells of the innate immune system, such as NK cells,
that favor an immune-mediated mechanism of action. Our most advanced product candidate that utilizes this approach is IPH4102, a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody
targeting KIR3DL2. IPH4102 seeks to induce tumor killing through ADCC, and we are developing IPH4102 for the treatment of various forms of TCL, such as CTCL, including its aggressive subtype, S&eacute;zary syndrome, and PTCL. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The third approach is to develop multi-specific antibodies that leverage an activating checkpoint, NKp46. Our
multi-specific antibodies co-engage both NKp46, with or without CD16, and the tumor antigen. This approach has the potential to more effectively mobilize NK cells because, in the TME of many solid tumors, CD16, the receptor mediating the ADCC of
antibodies, can be downregulated on NK cells and whereas NKp46 expression is conserved on tumor-infiltrating NK cells. We are currently pursuing this innovative approach for two undisclosed targets with Sanofi and for one undisclosed target with
AstraZeneca. We believe that bridging innate effector cells with the tumor antigen through a multi-specific molecule has the potential to overcome limitations of current strategies focused on artificially redirecting T cells towards the tumors,
either with chimeric antigen receptor (CAR) T cells or T cell engagers. Although these current strategies have had significant success in certain hematologic malignancy indications, they are often associated with serious adverse events including
cytokine release syndrome and neurologic complications. Data from our preclinical studies suggest that NKCEs are not associated with inflammatory cytokine release and exhibit anti-tumoral activity in solid tumor mouse models, providing a rationale
to investigate the impact of NKCE in patients beyond hematologic malignancies. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"><B><I>Targeting the immunosuppressive TME to render it more immuno-competent through the disruption of the adenosine pathway, such as with IPH5201, an
anti-CD39, and with IPH5301, an anti-CD73, and the complement pathway, such as with IPH5401, an anti-C5aR.</I></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also focusing our development on the role of the TME in suppressing anti-tumoral immunity. The TME can
inhibit both innate and adaptive immune responses by producing or degrading key metabolites or by recruiting suppressive cells, or both. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adenosine is one of the components of the TME that most broadly affects immune response. It is produced by the sequential degradation of
extracellular adenosine triphosphate, or ATP, by two enzymes: first CD39, which degrades the ATP into adenosine monphosphate, or AMP, and then CD73, which impairs the AMP into adenosine. For this reason, this pathway has attracted significant
development efforts that have been focused primarily on the downstream part of the adenosine degradation cascade, CD73 and the adenosine receptors. We are developing a potentially
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> anti-CD73 antibody, and have also focused on the upstream part of the cascade, CD39, in order to block the production of immunosuppressive adenosine and
increase the pool of immuno-stimulatory extracellular ATP. We believe this approach is also potentially mechanistically synergistic with many therapies, particularly with our checkpoint inhibitor and tumor-targeting product candidates and programs.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the most abundant cell populations within the TME is the myeloid cell subset.
Increasing evidence shows that MDSCs accumulate in most individuals with cancer, where they promote tumor progression, inhibit anti-tumor immunity and are an obstacle to many cancer immunotherapies. Additionally, data from mouse models suggests that
chronic inflammation and complement pathway activation eventually promotes an immuno-suppressive TME through MDSCs that impair anti-tumor T cell response and chemotherapy efficacy. In particular, one of the complement proteins, referred to as C5a,
can be produced at the tumor bed where it attracts and activates MDSCs. Our anti-C5aR program, designed to block the migration and activation of MDSCs, is an opportunity to test a differentiated approach targeting this cell population in cancer. In
inflammation, the role of the C5a/C5aR pathway is well established and other companies are currently exploring the efficacy of blockers in several rare, inflammatory diseases. Other neutrophil-driven more frequent diseases such as sepsis, acute lung
injury, ischemia-reperfusion injury and asthma, offer the possibility of exploring a scientifically validated pathway in these conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product
Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Monalizumab, a Dual Checkpoint Inhibitor Targeting T Cells and NK Cells </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Overview and Mechanism of Action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing monalizumab, a humanized IgG4 monoclonal antibody targeting NKG2A, in collaboration with AstraZeneca. Monalizumab is being
investigated for the treatment of SCCHN, CRC and other tumor types. NKG2A is an inhibitory receptor that is expressed on a subset of peripheral and tumor-infiltrating NK cells and tumor-infiltrating cytotoxic CD8+ T cells. Monalizumab acts to block
the binding of NKG2A to its ligand, <FONT STYLE="white-space:nowrap">HLA-E,</FONT> which is overexpressed in many tumors and is often associated with a poor prognosis. Monalizumab enables NK cells and CD8+ T cells to kill cancer cells despite
expression of <FONT STYLE="white-space:nowrap">HLA-E,</FONT> thereby promoting effector T cell responses in combination with an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> antibody and enhancing NK
cell effector functions and ADCC. The following illustration provides an overview of monalizumab&#146;s mechanism of action: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g23f14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As depicted above, in the absence of a blockade by monalizumab, the inhibitory receptor NKG2A recognizes
its ligand, <FONT STYLE="white-space:nowrap">HLA-E,</FONT> on the tumor cell. This recognition inhibits or diminishes the activity of the NK cell and CD8+ T cell against the tumor cell because the inhibitory signal from the NKG2A receptor
counterbalances the signal of the activating receptors, shown in green in the illustration above. When NKG2A is blocked from recognizing its ligand by monalizumab, the signal from the activating receptors can prevail and thereby trigger the NK cell
and CD8+ T&nbsp;cell to eliminate the cancerous cells. Activation of NK cells at the tumor site appears to initiate the sequence of immune events that allows tumors to be detected and killed by CD8+ T cells through a combination of direct
cytotoxicity and the promotion of adaptive responses by inducing recruitment of dendritic cells that present tumor antigens via <FONT STYLE="white-space:nowrap">MHC-I</FONT> on the surface of those cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Development Strategy and Opportunity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expression of <FONT STYLE="white-space:nowrap">HLA-E</FONT> in several cancer types suggests that it plays a key role in suppressing or
inhibiting an immune response to the tumor, thereby allowing tumor progression. <FONT STYLE="white-space:nowrap">HLA-E</FONT> is expressed in <FONT STYLE="white-space:nowrap">70-90%</FONT> of patients with SCCHN, CRC, cancers of the ovary,
endometrium, cervix and lung, and various types of leukemia and lymphoma, as well as in up to 50% of all cases of melanoma and esophageal cancers. We are evaluating monalizumab in clinical trials in collaboration with AstraZeneca in multiple
advanced solid tumors. Currently, the most advanced clinical programs are for the treatment of SCCHN and CRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SCCHN accounts for
approximately 4% of all cancers in the United States. The American Cancer Society estimates that in 2019, over 65,000 Americans will develop head and neck cancer and over 14,500 will die from the disease. The survival rate in patients with SCCHN
varies greatly depending on the stage of the cancer at diagnosis. Among patients with more advanced disease (stages III and IV), up to 50% develop locoregional relapses and/or distant metastases. Once this occurs, the five-year survival rate drops
significantly. Cetuximab (marketed as Erbitux), an EGFR inhibitor, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> checkpoint inhibitors, including nivolumab (marketed as Opdivo) and pembrolizumab
(marketed as Keytruda), have been approved by the FDA for the treatment of SCCHN in the second line setting. However, many patients continue to fail to respond to these treatments and patients with SCCHN who have received prior immuno-oncology
treatments have few treatment options and represent a group with a significant unmet medical need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CRC is the third most common cancer in
men and the second most common cancer in women globally. The American Cancer Society estimates that in 2019, over 145,000 Americans will develop CRC and over 51,000 will die from the disease. The five-year survival rate varies greatly depending on
the stage of the cancer: for localized colorectal cancer, the five-year survival rate is as high as 90%, but if the cancer has metastasized, the five-year survival rate drops to 14%. Patients with metastatic CRC typically receive multi-agent
chemotherapy with or without antiangiogenic therapy. Approximately 50% of CRC patients have a mutation of the KRAS oncogene. Patients without this mutation typically receive an EGFR inhibitor. With these regimens, median overall survival reaches 30
months, but the five-year survival rate is less than 15%. If these treatments fail, patients may receive third and later lines of treatment, such as regorafenib (marketed as Stivarga) and the trifluridine/tipiracil combination (marketed as Lonsurf).
While both of these drugs have been approved by the FDA, their response rate is less than 15% and overall survival was observed to be longer than placebo by less than two months. More substantial activity has been reported for checkpoint inhibitors
in patients with the microsatellite instable, or MSI, subtype of CRC, referred to as <FONT STYLE="white-space:nowrap">MSI-CRC.</FONT> However, the MSI subtype comprises only <FONT STYLE="white-space:nowrap">5-15%</FONT> of all CRC cases. Among the <FONT
STYLE="white-space:nowrap">85-95%</FONT> of CRC patients with the microsatellite stable, or MSS, subtype of CRC, referred to as <FONT STYLE="white-space:nowrap">MSS-CRC,</FONT> patients in the third and later lines of treatment represent a
significant unmet medical need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are primarily focused on investigating monalizumab in combination with other approved anti-cancer
agents, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cetuximab</B>, an antibody directed against EGFR, is used for the treatment of metastatic CRC and SCCHN. In
preclinical models, cetuximab has been observed to bind to EGFR on tumor cells and thereby trigger ADCC by NK cells. However, the efficacy of ADCC is inhibited by NKG2A engagement with <FONT STYLE="white-space:nowrap">HLA-E.</FONT> Our preclinical
data support our hypothesis that monalizumab, by blocking the binding of NKG2A to <FONT STYLE="white-space:nowrap">HLA-E,</FONT> could enhance the therapeutic activity of cetuximab. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Durvalumab</B> is an antibody directed against <FONT STYLE="white-space:nowrap">PD-L1.</FONT> <FONT
STYLE="white-space:nowrap">PD-L1</FONT> and <FONT STYLE="white-space:nowrap">HLA-E</FONT> are both <FONT STYLE="white-space:nowrap">up-regulated</FONT> on many cancer cells, and they have both been observed to suppress tumor immune response and
contribute to tumor progression. Our preclinical data support our hypothesis that a monalizumab and durvalumab combination therapy may result in a greater anti-tumor immune response than durvalumab alone by blocking both the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> and the <FONT STYLE="white-space:nowrap">NKG2A/HLA-E</FONT> inhibitory pathways. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specificity of the combination of cetuximab and monalizumab is produced by the dual
targeting of both activating receptors and inhibitory receptors. Immune checkpoint inhibitors unleash lymphocytes by blocking inhibitory receptors and rely on endogenous activating receptors expressed on these lymphocytes to mediate the attack of
the tumor cells. In contrast, we believe the combination of cetuximab and monalizumab will not only unleash NK cells by blocking the inhibitory function of NKG2A, but also trigger NK cell cytotoxicity via the recognition of cetuximab-coated tumor
cells through the CD16 receptor. The following illustration depicts the way in which monalizumab, in combination with cetuximab or durvalumab, is designed to result in greater anti-tumor activity. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g01r15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rationale for these combinations is further supported by the favorable tolerability profile of
monalizumab that we observed in preclinical studies and earlier clinical trials, suggesting that monalizumab is generally not expected to negatively impact the safety profile of the combination partner drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety of monalizumab was investigated by Novo Nordisk in two Phase I trials in patients with rheumatoid arthritis and one Phase I/II
dose-ranging monotherapy trial in advanced, heavily pretreated ovarian cancer patients. Although short in duration and in a different patient population, the rheumatoid arthritis trial provided valuable dose escalation data that we were able to
leverage in order to accelerate development of monalizumab in oncology indications. In the ovarian cancer dose-ranging trial, 18 patients were randomized to three monalizumab treatments groups: 1 mg/kg, 4 mg/kg and 10 mg/kg. Monalizumab was well
tolerated in each of the three groups with no dose limiting toxicities, or DLTs, and no serious adverse events, or SAEs, reported. The most frequent adverse events, or AEs, were headache, fatigue, dry mouth, nausea/vomiting, hot flashes and
arthromyalgia. In a dose-ranging trial performed by NCIC in patients with ovarian cancer, the only AEs equal or above grade 3 were two cases of fatigue, three cases of nausea/vomiting and one case of dehydration. There was no observed dose
relationship between AEs and dosage of monalizumab. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development of Monalizumab </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a summary of the ongoing clinical trials that we or our collaborator, AstraZeneca, are conducting, as well as investigator-sponsored
trials evaluating monalizumab. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Trial</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Sponsor</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of<BR>Patients<BR>Receiving<BR>Monalizumab</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase Ib/II clinical trial in combination with cetuximab</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Innate&nbsp;Pharma</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 140</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">R/M SCCHN</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase I/II clinical trial in combination with durvalumab</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AstraZeneca</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 501</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Advanced&nbsp;Solid&nbsp;Tumors, including CRC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase II clinical trial in combination with durvalumab</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AstraZeneca</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 60</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Unresectable, Stage III NSCLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase II clinical trial in combination with durvalumab</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AstraZeneca</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 40</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Resectable, Early-Stage NSCLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">PIONeeR Phase II clinical trial in combination with durvalumab</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Not&nbsp;yet&nbsp;recruiting</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Marseille&nbsp;Public&nbsp;University Hospital System</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 30</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">NSCLC with <FONT STYLE="white-space:nowrap">PD-1</FONT> Resistance</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase II clinical trial in combination with durvalumab</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">European Organisation for Research and Treatment of&nbsp;Cancer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 76</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">R/M SCCHN</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase I clinical trial</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Innate Pharma and Institut Paoli-Calmettes</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 18</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Post-Allogenic Stem Cell Transplantation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Phase II clinical trial</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Recruitment completed;&nbsp;ongoing <FONT STYLE="white-space:nowrap">follow-up</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">European Organisation for Research and Treatment of&nbsp;Cancer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">up to 34</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">R/M SCCHN</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our collaboration agreement with AstraZeneca, we are eligible to receive a $100 million milestone
payment at the start of a Phase III clinical trial for monalizumab. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase Ib/II Clinical Trial in Relapsed/Metastatic SCCHN (in combination with cetuximab)
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and AstraZeneca are currently evaluating monalizumab in an open-label, Phase Ib/II clinical trial in combination with cetuximab in
patients with R/M SCCHN. The trial is currently being conducted at five sites in the United States pursuant to an investigational new drug application, or IND, that was accepted by the FDA in August 2015, and in nine sites in France, where it was
approved by the <I>Agence Nationale de la S&eacute;curit&eacute; du M&eacute;dicament et des Produits de Sant&eacute;</I>, or ANSM, in September 2015. The trial is expected to enroll up to 140 patients. The following graphic shows the trial design:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g10m39.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Phase Ib dose-escalation portion of the clinical trial, 17 patients with R/M SCCHN were evaluated
across five dose levels of monalizumab (0.4, 1.0, 2.0, 4.0 and 10.0 mg/kg), administered every two weeks, in combination with cetuximab, administered intravenously with an initial dose of 400
mg/m<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> and subsequent doses of 250 mg/m<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>. For the Phase Ib dose-escalation portion of the trial, the primary endpoint was to assess the
occurrence of DLTs in order to determine the recommended dose level of monalizumab for the Phase II portion of the trial. The secondary endpoint was objective response rate, which is measured as the rate of patients who had a complete or partial
response according to RECIST 1.1, a widely used guideline to measure anti-tumor response in oncology. The response categories defined under RECIST 1.1 are summarized in the table below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="72%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Response category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Definition according to RECIST 1.1</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Definitions&nbsp;of&nbsp;measurable&nbsp;and <FONT STYLE="white-space:nowrap">non-measurable</FONT> disease; numbers and site of target disease</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Measurable lesions are 10 mm or more in long diameter (15 mm for nodal lesions); maximum of 5 lesions (2 per organ). All other disease considered <FONT STYLE="white-space:nowrap">non-target</FONT> (must be 10 mm or longer in short
axis for nodal disease).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CR, PR or SD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cannot have met criteria for PD prior to CR, PR or SD.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Confirmation of CR, PR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Only required for <FONT STYLE="white-space:nowrap">non-randomized</FONT> trials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Confirmation of SD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Not required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New lesions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Results in PD. Recorded but not measured.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Confirmation of PD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Not required (unless equivocal).</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seventeen patients were enrolled in the dose escalation portion of the Phase Ib trial. Two patients were not evaluable for DLTs as they
withdrew from the trial within three weeks of first treatment for reasons other than DLTs. In the 15 evaluable patients, no DLTs, infusion-related reactions or immune-related disorders were observed,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and no discontinuations from the trial attributable to treatment-related AEs or treatment-related deaths occurred. The combination was reported to be well tolerated with no AEs beyond those
observed with monalizumab or cetuximab administered as monotherapies. The most common treatment-related AEs were asthenia/fatigue (24%) and headache (18%). All AEs related to treatment with monalizumab were grade 1 or 2 except for one case of grade
3 fatigue experienced by a patient in the 0.4 mg/kg treatment group. Based on the results observed in the Phase Ib dose- escalation portion of the trial, the recommended Phase II dose of monalizumab, in combination with cetuximab, was established as
10 mg/kg, administered intravenously every two weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary endpoint for the Phase II portion of the trial is objective response
rate, which is measured as the rate of patients who had a complete or partial response according to RECIST 1.1. Secondary endpoints for the Phase II portion of the trial include duration of response, progression-free survival and overall survival.
The Phase II portion of the trial is comprised of three expansion cohorts: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Expansion Cohort 1,</U> which enrolled 40 patients, evaluated the combination of monalizumab and cetuximab in
patients with R/M SCCHN who had been previously treated with chemotherapy alone or chemotherapy followed by checkpoint inhibitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Expansion Cohort 2</U>, which is expected to enroll 40 patients, began recruiting in September 2018 and is
evaluating the combination of monalizumab and cetuximab in patients with R/M SCCHN who have received a maximum of two prior systemic regimens in the R/M setting and with prior exposure to a <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> inhibitor
(who we refer to as <FONT STYLE="white-space:nowrap">IO-pretreated</FONT> patients); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Expansion Cohort 3</U>, which is expected to enroll up to 40 patients, began recruiting in April 2019 and is
evaluating the combination of monalizumab, cetuximab and a <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> inhibitor in patients with R/M SCCHN who have not received prior systemic regimens in the R/M setting and without prior exposure to <FONT
STYLE="white-space:nowrap">PD-(L)1</FONT> inhibitors (who we refer to as <FONT STYLE="white-space:nowrap">IO-na&iuml;ve</FONT> patients). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preliminary clinical efficacy data from the first expansion cohort was presented at the American Association for Cancer Research, or AACR,
2018 annual meeting and at the European Society for Medical Oncology, or ESMO, 2018 annual meeting. Further subset analyses were presented at the 2018 annual meeting of the Society for Immunotherapy of Cancer. As of August&nbsp;31, 2018, a total of
40 patients with R/M SCCHN were evaluable for safety. Thirty-nine patients were evaluable for efficacy, while one patient was not evaluable for efficacy because of fatal tumor progression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the efficacy results as of August&nbsp;31, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Best overall response</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>n=40,&nbsp;n&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Complete Response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(2.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial Response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;(25.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stable Disease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22 (55.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Progressive Disease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6 (15.0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subtotal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39 (97.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Early death from progression</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (2.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Outcome Measure</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Patients&nbsp;(n=40)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">IO-Na&iuml;ve&nbsp;Patients</FONT></B><br><B>(n=23)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">IO-Pretreated&nbsp;Patients</FONT></B><br><B>(n=17)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Overall Response Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">27.5%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">35.0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18.0%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median Progression-Free Survival</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0&nbsp;months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4.0 months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0 months</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median Overall Survival</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10.3&nbsp;months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10.3&nbsp;months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12.8&nbsp;months</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disease Control Rate at 24 Weeks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">35%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">39%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">29%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median Time to Response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.6 months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.7 months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.6&nbsp;months</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median Duration of Response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.6 months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.3 months</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.6 months</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Progression-Free Survival (PFS) and Overall Survival (OS) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g13o50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although preliminary, the activity of the monalizumab and cetuximab combination appears to occur across
Human Papillomavirus, or HPV, status, tumor burden and <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> expression. We believe our preliminary results of the monalizumab and cetuximab combination are encouraging when viewed in light of the clinical
results of currently approved treatment options for R/M SCCHN: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cetuximab was approved by the FDA for patients previously treated with platinum-based chemotherapy on the basis
of a <FONT STYLE="white-space:nowrap">single-arm</FONT> Phase II clinical trial in which patients treated with cetuximab achieved an overall response rate of 12.6%, median time to progression of 2.3 months and overall survival of 5.8 months.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pembrolizumab was approved by the FDA for the treatment of patients previously treated with platinum-based
chemotherapy on the basis of a <FONT STYLE="white-space:nowrap">single-arm</FONT> Phase II clinical trial <FONT STYLE="white-space:nowrap">(KEYNOTE-012)</FONT> in which patients treated with pembrolizumab achieved an overall response rate of 16%.
The median <FONT STYLE="white-space:nowrap">follow-up</FONT> time was 8.9 months. Among the 28 responding patients, the median duration of response had not been reached (range: 2.4+ to 27.7+ months), with 23 patients having responses of six months
or longer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nivolumab was approved by the FDA for the treatment of patients previously treated with platinum-based
chemotherapy on the basis of a randomized, active-controlled, open-label clinical trial <FONT STYLE="white-space:nowrap">(CHECKMATE-141).</FONT> Patients were randomized to receive nivolumab or the investigator&#146;s choice of cetuximab,
methotrexate or docetaxel. Patients treated with nivolumab achieved an overall response rate of 13.3%. Median overall survival was 7.5 and 5.1 months in the nivolumab and investigator&#146;s choice arms, respectively. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe the preliminary results of this trial are promising, no definitive conclusions regarding safety or effectiveness can be
drawn between this trial and those of the approved drugs discussed above due to the development stage of monalizumab, differences in trial designs and other factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the 40 patients evaluable for safety in the first expansion cohort of our Phase II trial, all experienced one or more treatment-emergent
adverse events, or TEAEs, of which half were grade 3 or 4. Thirty (75%) of TEAEs were deemed to be related to treatment with monalizumab, and of these, seven (18%) were grade 3 or 4. Of the 40 evaluable patients, 16 (40%) patients experienced SAEs,
12 (30%) of which were grade <FONT STYLE="white-space:nowrap">3-4.</FONT> Of these SAEs, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
three (8%) were deemed to be related to treatment with monalizumab and were grade 3 or 4. These SAEs consisted of colitis, interstitial lung disease and hypophosphatemia, each experienced by one
separate patient. Only one patient discontinued participation in the trial due to an AE. Cetuximab monotherapy is associated with significant toxicity. In the pivotal clinical trial of cetuximab in SCCHN, AEs were reported for 99% of the patients
and SAEs, mostly grade 3 or 4, were reported in 46% of the 47 patients. The most common cetuximab-related AEs were rash, acne and asthenia. In our trial investigating the monalizumab and cetuximab combination, there has been no indication to date
that the addition of monalizumab has a negative impact on the tolerability of cetuximab or vice-versa, consistent with the favorable tolerability profile of monotherapy observed in prior preclinical studies and clinical trials to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to report <FONT STYLE="white-space:nowrap">follow-up</FONT> data from the first expansion cohort in the second half of 2019 and
preliminary data from the second expansion cohort in 2020. We believe that data from the second cohort expansion testing monalizumab in combination with cetuximab in patients having been treated by a previous line of
<FONT STYLE="white-space:nowrap">PD-(L)1</FONT> will inform the next steps of the development of the combination.<I> </I>We estimate that there are approximately 15,000 patients that have received at least two prior lines of treatment in the United
States, Europe, Japan and China. We also believe that there will be a paradigm shift in the frequency and stage of use for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> treatments, which we believe will
be utilized more frequently in earlier lines of treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The third expansion cohort was initiated in April 2019 and will provide
initial data in <FONT STYLE="white-space:nowrap">IO-na&iuml;ve</FONT> patients. We believe these data will inform the design of potential future clinical trials in early settings, such as the first line or locally advanced setting. We estimate that
in the United States, Europe, Japan and China, there are approximately 65,000 and 40,000 patients in the first line and locally advanced settings, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase I/II Clinical Trial in Solid Tumors, including Colorectal Cancer (in combination with durvalumab) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AstraZeneca is evaluating monalizumab in a Phase I/II, multi-center, <FONT STYLE="white-space:nowrap">single-arm,</FONT> 3+3 dose-escalation
and cohort expansion clinical trial in combination with durvalumab in up to 501 adults with advanced solid tumor malignancies, including CRC. This trial, which commenced in February 2016, is being conducted at 28 sites in the United States pursuant
to an IND that was accepted by the FDA in January 2016, as well as over 40 sites in Australia, Belgium, Brazil, Canada, France, Hungary, Italy, South Korea, New Zealand, Spain and the United Kingdom. The primary endpoint of the trial is safety, with
anti-tumor efficacy being a key secondary endpoint. Other secondary endpoints include response duration, progression-free survival, overall survival, pharmacokinetics, pharmacodynamics, and immunogenicity of a monalizumab and durvalumab combination.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, at the annual meeting of the American Society of Clinical Oncology, or ASCO, the trial investigators presented clinical
data showing preliminary anti-tumor activity in patients with R/M <FONT STYLE="white-space:nowrap">MSS-CRC,</FONT> a population historically unresponsive to <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> blockade. At the most recent measurement
date in April of 2018, 40 patients were evaluable for safety and 39 were evaluable for efficacy. Thirty-five (88%) patients had two or more prior lines of therapy. The key efficacy data from this Phase I/II clinical trial are summarized in the table
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Efficacy parameter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;patients&nbsp;(%)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of patients</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">39&nbsp;(100%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Complete response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0&nbsp;(0%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3&nbsp;(8%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stable disease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11&nbsp;(28%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Progression</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">22&nbsp;(56%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not evaluable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3&nbsp;(8%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Overall response rate (95% Confidence interval)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">3&nbsp;(8%)&nbsp;(2-22)</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disease control rate at 16 weeks (95% Confidence interval)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">12&nbsp;(31%)&nbsp;(17-48)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Efficacy parameter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weeks&nbsp;(range)</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median duration of response</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">16.1&nbsp;weeks&nbsp;(15.9-not&nbsp;estimable)</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical results of the currently approved treatment options for R/M <FONT
STYLE="white-space:nowrap">MSS-CRC,</FONT> regorafenib and trifluridine, are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regorafenib (marketed as Stivarga) was approved by the FDA for the treatment of patients who have been previously
treated with chemotherapy, an anti-vascular endothelial growth factor, or VEGF, therapy and, if KRAS wild type, an anti-EGFR therapy, based on a randomized, placebo-controlled Phase III clinical trial. In this trial, patients with metastatic CRC who
were treated with regorafenib achieved an overall response rate of 1%. Median overall survival was 6.4 months in the regorafenib group versus 5.0 months in the placebo group. Progression-free survival was 2.0 months in the regorafenib group versus
1.7 months in the placebo group, and 41% of patients in the regorafenib group achieved disease control compared to 15% in the placebo group. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Trifluridine/tipiracil combination (marketed as Lonsurf) was approved by the FDA for the treatment of patients
who have been previously treated with the same prior treatments as regorafenib, based on a randomized, placebo-controlled Phase III clinical trial. Patients treated with trifluridine/tipiracil combination achieved an overall response rate of 1.6%.
Median overall survival was 7.2 months in the trifluridine/tipiracil combination group versus 5.2 months in the placebo group. Progression-free survival was 2.0 months in the trifluridine/tipiracil combination group compared to 1.7 months in the
placebo group. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These data indicate that there remains a significant medical need for metastatic CRC in the third or
later line setting with response rates to available treatments of less than 5% and median overall survival only minimally exceeding that seen with placebo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety results of the monalizumab and durvalumab combination from this trial have been consistent with the monotherapy profiles of each
agent. Dose-escalation was completed with no DLTs and the maximum tolerated dose was not reached. No fatal AEs or AEs leading to treatment discontinuation were reported. In the <FONT STYLE="white-space:nowrap">MSS-CRC</FONT> expansion cohort, the
most common treatment-related AEs included arthralgia (7.5%), increased levels of alkaline phosphatase, or AST (7.5%), hypothyroidism (7.5%), pruritus (7.5%) and rash (7.5%). Grade 3 or 4 AEs that occurred in three patients were limited to one case
each of sepsis (grade 4) and increased lipase (grade 3), that both were resolved, and increased AST (grade 3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based in part on the
clinical trial results observed to date, AstraZeneca has decided to pursue additional expansion cohorts to assess the safety and efficacy of monalizumab in combination with durvalumab in first and third line settings in treating metastatic CRC.
These additional expansion cohorts are ongoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect AstraZeneca will use clinical trial data observed to date to inform the design
of potential future clinical trials in CRC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Additional Exploratory Clinical Trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Monalizumab is also being evaluated by us, AstraZeneca and investigator sponsors in several exploratory trials: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>AstraZeneca&#146;s two clinical trials in NSCLC</I>. AstraZeneca is conducting two separate Phase II clinical
trials assessing the efficacy and safety of durvalumab monotherapy as compared to durvalumab in combination with various novel agents, including monalizumab, in NSCLC. The first trial is expected to enroll up 60 patients with unresectable, stage III
NSCLC and the second trial is expected to enroll 40 patients with resectable NSCLC. The primary endpoint of the first trial is objective response rate at 16 weeks according to RECIST 1.1, and secondary endpoints include incidence of AEs, duration of
response, disease control and progression-free survival. The primary endpoint of the second trial is major pathological response rate and key secondary endpoints include safety and pathological complete response rate. These trials began in January
2019 and are being conducted in the United States, Canada, France, Hong Kong, Italy, Poland, Portugal, Spain, Switzerland and Taiwan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>The PIONeeR clinical trial</I>, <I>a Phase II clinical trial sponsored by Marseille Public University Hospital
System</I>. The purpose of this trial is to assess how to overcome resistance to immune checkpoint inhibitor monotherapies with experimental precision immunotherapies combined with durvalumab in third or fourth line treatment, in patients with
advanced NSCLC. The PIONeeR trial includes multiple trial arms, each testing a different therapy in combination with durvalumab. In the monalizumab arm, up to 30 patients will receive durvalumab in combination with 750 mg of monalizumab every four
weeks. The <FONT STYLE="white-space:nowrap">12-week</FONT> disease control rate is the primary endpoint, and there are multiple key secondary endpoints including overall response rate, progression-free survival, overall survival and duration of
response. The trial is being conducted in France. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase I clinical trial evaluating monalizumab as a single agent in patients with hematological malignancies in
a post-transplantation setting sponsored by Institut Paoli-Calmettes.</I> The objective of this trial is to identify the maximum tolerated dose, if any, and to select a recommended Phase II dose in this particular population. The trial will enroll
up to 18 patients and will include patients who have received allogenic hematopoietic stem cell transplantation. Four sequential cohorts of patients will receive a single escalating dose of monalizumab 75 to 100 days after stem cell transplantation.
The primary endpoint is the occurrence ratio of DLTs within four weeks of treatment. Secondary endpoints include incidence of acute and chronic graft-versus-host disease, probabilities of <FONT STYLE="white-space:nowrap">non-relapse</FONT>
mortality, cumulative incidence of relapse, probability of disease-free survival and probability of overall survival, each measured at one year after administration of monalizumab. This trial began in December 2016<I> </I>and is being conducted in
France. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase II clinical trial evaluating monalizumab in patients with R/M SCCHN sponsored by the European
Organisation for Research and Treatment for Cancer</I>. The objective of this trial is to evaluate biomarker-based treatment of patients with R/M SCCHN. The trial groups patients into different biomarker-driven cohorts, each receiving a different
study drug. Monalizumab will be evaluated in a single arm Phase II cohort of approximately 40 patients who are <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> na&iuml;ve or resistant. The primary
endpoints of the trial are progression-free survival at 16 weeks and objective response rate at six months. Secondary endpoints include progression-free survival, response duration, overall survival and toxicity, each measured at 54 months after
first patient in, as well as objective response rate measured at 48 months after first patient in. The trial began in March 2017 and is being conducted in Belgium, France, Italy and the United Kingdom. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Lumoxiti, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class,</FONT></FONT> Marketed Product <FONT
STYLE="white-space:nowrap">In-Licensed</FONT> from AstraZeneca for the Treatment of Hairy Cell Leukemia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lumoxiti (moxetumomab
pasudotox-tdfk) is a marketed, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> CD22-directed cytotoxin for the treatment of HCL which was approved by the FDA under priority review in September 2018 as a
treatment for adult patients with R/R HCL who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog, or PNA. Lumoxiti has been granted orphan drug designation by the FDA for the treatment of HCL.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HCL is a rare, chronic and slow-growing leukemia in which the bone marrow over-produces abnormal B cell lymphocytes. Untreated, HCL can
result in serious conditions, including infections, bleeding, anemia and potentially may lead to death. Approximately 1,000 people are diagnosed with HCL in the United States each year. HCL accounts for up to 3% of all adult leukemias. While many
patients initially respond to treatment, approximately <FONT STYLE="white-space:nowrap">30-40%</FONT> will relapse within five to ten years after their first treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PNAs, such as cladribine and pentostatin, are the established first line treatments for patients with HCL. Up to 90% of the patients treated
with PNAs achieve a complete remission. However, PNAs are associated with AEs linked to myelosuppression, which is a condition in which bone marrow activity is decreased, resulting in fewer red blood cells, and immunosuppression. Most patients who
relapse more than two years after their initial treatments receive a second course of PNAs with a similar overall response rate to initial therapy but with a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shorter duration. Patients who relapse earlier often receive PNAs combined with rituximab. When a patient relapses a second time, reaching the third line setting, PNAs are less effective, with a
significantly lower response rate and shortened duration of response. The third and later line setting represents a significant medical challenge, with no established standard of care and very few treatment options available. The National
Comprehensive Cancer Network, or NCCN, guidelines for HCL, updated in January 2019, recommend that patients who are third line or later in treatment be considered for Lumoxiti or participate in clinical trials of vemurafenib, with or without
rituxan, or ibrutinib. Vemurafenib and ibrutinib have shown limited activity. The third and later line setting represents a significant medical challenge, with no established standard of care and very few treatment options available. To date,
Lumoxiti is the only approved drug in the United States for those patients in third line or later treatment. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The approval of
Lumoxiti was based on data from the open-label &#145;1053&#146; trial, which was a <FONT STYLE="white-space:nowrap">single-arm,</FONT> multi-center Phase II clinical trial assessing the efficacy, safety, immunogenicity and pharmacokinetics of
Lumoxiti monotherapy in patients with R/R HCL who had received at least two prior therapies, including one PNA. The trial enrolled 80 patients and was conducted at 34 sites in 14 countries. The primary endpoint was durable complete response, defined
as complete response with hematologic remission (blood count normalization) for more than 180 days. Secondary endpoints included overall response rate, relapse-free survival, progression-free survival, time to response, safety, pharmacokinetics and
immunogenic potential. In this trial, of the patients treated with Lumoxiti, 75% achieved an overall response, 30% had a durable complete response and 34% achieved a complete response with no minimal residual disease. The following table summarizes
initial efficacy results of the trial at the primary readout: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Efficacy measure</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Result %, (95% CI)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Durable complete response rate<SUP STYLE="font-size:85%; vertical-align:top">a,b</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">30% (20, 41)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Overall response rate<SUP STYLE="font-size:85%; vertical-align:top">c</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">75% (64, 84)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Complete response rate<SUP STYLE="font-size:85%; vertical-align:top">d</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">41% (30, 53)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial response rate<SUP STYLE="font-size:85%; vertical-align:top">e</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">34% (24, 45)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haematologic remission rate<SUP STYLE="font-size:85%; vertical-align:top">b</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">80%</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">a</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Durable complete response is defined as patients who achieved complete response with haematologic remission for a duration of more than 180 days </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">b</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Haematologic remission is defined as haemoglobin &gt; 11g/dL, neutrophils &gt; 1500/mm<SUP STYLE="font-size:85%; vertical-align:top">3</SUP>, platelets
&gt;&nbsp;100,000/mm<SUP STYLE="font-size:85%; vertical-align:top">3</SUP> without transfusions or growth factor for at least 4 weeks </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">c</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Overall response rate is defined as best overall response of complete response or partial response </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">d</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Complete response is defined as clearing of the bone marrow of hairy cells by routine haematoxylin and eosin stain, radiologic resolution of pre-existing lymphadenopathy and/or organomegaly, and haematologic remission
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">e</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Partial response is defined as <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 50% decrease or normalisation (&lt; 500/mm<SUP STYLE="font-size:85%; vertical-align:top">3</SUP>) in peripheral blood lymphocyte count,
reduction of pre-existing lymphadenopathy and/or organomegaly, and haematologic remission </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this trial, Lumoxiti had an acceptable tolerability profile, with low rates of
treatment-related AEs leading to discontinuation. Grade 3 and 4 capillary leak syndrome and hemolytic uremic syndrome were seen in 5% and 2.5% of the patients, respectively. These AEs were reported to be manageable and reversible with close
monitoring and best supportive care. We expect additional <FONT STYLE="white-space:nowrap">follow-up</FONT> data to be available in the second half of 2019 and to be presented at an upcoming conference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We <FONT STYLE="white-space:nowrap">in-licensed</FONT> commercial rights to Lumoxiti in the United States and European Union from AstraZeneca
in 2018. As part of our agreement with AstraZeneca, we have a collaborative and staged transition for the Lumoxiti program. AstraZeneca is currently conducting all aspects of the distribution, sales and marketing in the United States on our behalf.
We are establishing a specialized medical and commercial teams in the United States </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and will transition to full commercialization responsibilities by <FONT STYLE="white-space:nowrap">mid-2020.</FONT> We plan to leverage the commercial infrastructure that we are developing for
Lumoxiti to commercialize our other product candidates targeting rare cancers, including IPH4102 in S&eacute;zary syndrome, MF and PTCL, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, in collaboration with AstraZeneca, plan to file for regulatory approval of Lumoxiti for the treatment of patients R/R HCL in the European
Union in the second half of 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>IPH4102, A Tumor Targeting Anti-KIR3DL2 Antibody </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Overview and Mechanism of Action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing our wholly owned product candidate IPH4102 for the treatment of certain subtypes of TCLs, including CTCL and PTCL. IPH4102 is
designed to bind to the KIR3DL2 receptor and to kill cancer cells by ADCC, as illustrated in the following figure. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g21p77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KIR3DL2 is a receptor of the KIR family. In our preclinical studies, we have observed that KIR3DL2 is not
expressed on healthy tissues, except on a subset of NK cells and T cells. In addition, KIR3DL2 is expressed in <FONT STYLE="white-space:nowrap">T-cell</FONT> lymphoma. In particular, 65% of CTCL patients express KIR3DL2 and KIR3DL2 is also expressed
in approximately 50% of patients with MF, the most common type of CTCL. This frequency increases to 85% for the most aggressive CTCL subtypes, including S&eacute;zary syndrome. KIR3DL2 is also expressed by approximately 50% of patients with PTCL.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2019, the FDA granted IPH4102 Fast Track Designation for the treatment of adults with R/R S&eacute;zary syndrome who have
received at least two prior systemic therapies. IPH4102 has also been granted orphan drug designation in the European Union and in the United States for the treatment of CTCL. In May 2019, we initiated a Phase II clinical trial evaluating IPH4102 in
different subtypes of TCL. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cutaneous T Cell Lymphoma </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CTCL is a heterogeneous group of <FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphomas that are characterized by the abnormal
accumulation of malignant T cells, primarily in the skin. CTCL accounts for approximately 4% of all <FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphomas and has a median age at diagnosis of 55 to 65 years. There are approximately
6,000 new CTCL cases diagnosed per year in Europe and the United States combined. The most common type of CTCL is mycosis fungoides, or MF, accounting for approximately half of all CTCLs. S&eacute;zary syndrome, characterized by the presence of
lymphoma cells in the blood, is a CTCL subtype with a particularly poor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prognosis. The following table outlines the most common CTCL types, their frequency as a percentage of all cases of CTCL, and prognosis. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>CTCL Type</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Frequency&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">5-year&nbsp;disease-specific</FONT></B><br><B>survival (%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mycosis fungoides</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Primary cutaneous CD30+ lympho-proliferative disorders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">95-99</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Primary cutaneous CD4+ small/medium <FONT STYLE="white-space:nowrap">T-cell</FONT>
lymphoproliferative disorder</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mycosis fungoides variants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S&eacute;zary syndrome</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with advanced CTCL have a poor prognosis with few therapeutic options and no standard of care.
Treatment generally includes skin-directed therapies, such as topical corticosteroids, and systemic treatments, such as steroid drugs and interferon, for patients with more advanced disease or for whom skin-directed therapies failed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two new drugs have recently been approved for the treatment of CTCL: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Brentuximab vedotin (marketed as Adcetris), has been approved by the FDA for treatment of patients with primary
cutaneous anaplastic large cell lymphoma, or pcALCL, or CD30-expressing MF who have received prior systemic therapy. In Europe, brentuximab vedotin is indicated for the treatment of adult patients with R/R CD30+ CTCL who require systemic therapy.
The response rate to brentuximab vedotin was 67% compared to 20% in the control group (physician&#146;s choice of either methotrexate or bexarotene) and the median progression-free survival was 16.7 months compared to 3.5 months for the control
group. Brentuximab vedotin was associated with a 45% risk of peripheral neuropathy, which led to treatment discontinuation in 12% of the patients and inclusion of a boxed warning on the label. Brentuximab vedotin is not approved in S&eacute;zary
syndrome. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mogamulizumab, marketed as Poteligeo, has been approved by the FDA and the EMA for the treatment of adult
patients with R/R MF or S&eacute;zary syndrome after at least one prior systemic therapy. The response rate to mogamulizumab was 28%, compared to 5% in the control group (vorinostat), and the median progression-free survival was 7.6 months compared
to 3.1 months for the control group. The most common AEs were rash, infusion-related reactions, fatigue, diarrhea, upper respiratory tract infection and musculoskeletal pain. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although these new treatments represent progress in the treatment of CTCL, they are still associated with the safety and efficacy limitations
observed in their respective clinical trials. Further, even with these options, the vast majority of these treated patients eventually relapse and overall survival remains poor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Peripheral <FONT STYLE="white-space:nowrap">T-Cell</FONT> Lymphoma </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PTCL is a diverse group of aggressive <FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphomas that develop from mature T cells and
NK cells. PTCL arises in the lymphoid tissues outside of the bone marrow, such as in the lymph nodes, spleen, gastrointestinal tract and skin. The various PTCL types, their frequency as a percentage of all TCL cases, and prognosis are shown in the
following table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>PTCL Type</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Frequency&nbsp;(%)</B><br><B>Europe&nbsp;&amp; U.S.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">5-year&nbsp;overall&nbsp;survival&nbsp;(%)</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PTCL not otherwise specified</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Angioimmunoblastic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">16-28</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anaplastic large cell lymphoma, or ALCL, ALK positive</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">6-16</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anaplastic large cell lymphoma, ALK negative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irrespective of the specific regimen used (single agent chemotherapy or combination
chemotherapy including GemOx), patients with R/R PTCL typically experience a poor outcome, with a median progression-free survival and overall survival of 3.1 months and 5.5 months, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Multi-agent chemotherapy is the recommended first line treatment for the majority of patients with PTCL. Brentuximab vedotin is approved in
combination with first line chemotherapy for patients with CD30-positive PTCL. For patients who are eligible, subsequent stem cell transplantation is a potentially curative option but it is limited to a minority of patients. Despite these
treatments, a high proportion of patients need second line therapy. Belinostat (marketed as Beleodaq), pralatrexate (marketed as Folotyn) and romidepsin (marketed as Istodax) have each been approved by the FDA in this setting, but efficacy is
generally limited. In the respective <FONT STYLE="white-space:nowrap">non-randomized</FONT> clinical registration trials, the response rate to belinostat, pralatrexate and romidepsin were each less than 30%, and the median duration of response was
approximately 10 months for belinostat and pralatrexate. None of these treatments have been approved by the EMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In fact, despite these
approvals, current treatment guidelines recommend participation in a clinical trial as a preferred option for patients with relapsed PTCL after first line. If clinical trials are not available, a chemotherapy combination of gemcitabine and
oxaliplatin, or GemOx, is listed as one of the preferred treatment combinations. Several studies have been published on the role of GemOx in patients with relapsed lymphoma and it is one of the most widely used regimens for this patient population
in the United States, Europe and Asia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development of IPH4102 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a summary of our ongoing clinical trials of IPH4102. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Trial</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sponsor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Patients in</B><br><B>Trial</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Indication(s)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Phase II clinical trial (TELLOMAK)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Innate&nbsp;Pharma</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">up&nbsp;to&nbsp;250</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">S&eacute;zary&nbsp;syndrome,&nbsp;MF&nbsp;and&nbsp;PTCL</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Phase I clinical trial</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Recruitment&nbsp;completed,&nbsp;initial<BR>data reported and <FONT STYLE="white-space:nowrap">follow-up</FONT><BR>ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Innate Pharma</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">44</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CTCL&nbsp;(including&nbsp;35&nbsp;patients&nbsp;with<BR>S&eacute;zary syndrome)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase II Clinical Trial (TELLOMAK) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2019, we initiated a global, open-label, multi-cohort Phase II clinical trial, known as TELLOMAK. This clinical trial is being conducted
at more than 10 sites in the United States, pursuant to an IND accepted by the FDA in January 2019, and at 11 sites in France, pursuant to approval by ANSM in February 2019, and in Germany, Italy and the United Kingdom. In this trial, we are
evaluating IPH4102 alone and in combination with GemOx in patients with advanced TCL. We expect to recruit up to 250 patients, with IPH4102 evaluated as a single agent in approximately 60 patients with S&eacute;zary syndrome who have received at
least two prior treatments, including mogamulizumab, as a single agent in approximately 90 patients with MF who have received at least two prior systemic therapies, and as combination with standard chemotherapy (GemOx) in approximately 100 patients
with PTCL who have received at least one prior treatment. The MF and PTCL arms will be comprised of two cohorts each, testing IPH4102 in KIR3DL2 expressing and <FONT STYLE="white-space:nowrap">non-expressing</FONT> patients. These cohorts will
follow a Simon <FONT STYLE="white-space:nowrap">2-stage</FONT> design that will terminate if treatment is considered futile. The following graphic depicts the trial design: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g59d92.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary endpoint of the trial is objective response rate, measured using the 2011 Olsen criteria for
CTCL or the Lugano criteria for PTCL, respectively. Key secondary measures include incidence of treatment-emergent AEs, the effect of skin disease on quality of life as measured by the Skindex29 questionnaire, pruritus as measured by the Visual
Analog Scale, progression-free survival and overall survival. We expect to announce the outcome of the first stage of the MF and PTCL cohorts in the second half of 2020 and report first data from the different cohorts beginning in 2021. The results
of the dedicated S&eacute;zary syndrome cohort may support a future BLA submission to the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase I Clinical Trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2015, we began a Phase I dose-escalating and cohort expansion clinical trial to evaluate IPH4102 for the treatment of advanced
CTCL. The trial enrolled 44 patients, including 35 patients with S&eacute;zary syndrome. The primary objective of the trial was to evaluate IPH4102 safety, and to identify DLTs and the maximum tolerated dose. Data from this trial were presented at
the 2018 meeting of the American Society of Hematology. We reported clinical activity in the subgroup of 35 S&eacute;zary syndrome patients, including an observed overall response rate of 42.9%, median duration of response of 13.8 months, median
progression-free survival of 11.7 months and that approximately 90% of patients experienced improved quality of life. The overall response rate appeared to be higher (53.6%) in the 28 patients with no histologic evidence of large cell
transformation. Clinical activity was associated with a substantial improvement in quality of life as assessed by the Skindex29 and Pruritus Visual Analog Scale scores. IPH4102 was generally well tolerated. The most common AEs were
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
peripheral edema (29%), asthenia (26%) and fatigue (23%), all of which were grade 1 or 2. Possibly treatment-related, grade 3 or above adverse events were observed in four patients (11%) and only
three patients (9%) stopped treatment as a result of an adverse event. One patient stopped treatment because of peripheral neuropathy, one patient stopped treatment because of general malaise and one patient stopped treatment because of several
adverse events, including renal injury, respiratory failure, dysphagia and sepsis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent preclinical data presented in June 2019 further
support the rationale of evaluating the potential of IPH4102 in larger subsets of patients with TCL. The findings demonstrate that KIR3DL2 is expressed in multiple subtypes of PTCL and that the incubation of TCL cell lines with a combination
chemotherapy regimen consisting of gemcitabine and oxaliplatin, or GemOx, enhanced KIR3DL2 expression. Moreover, we observed that the combination of IPH4102 and GemOx improved anti-tumor activity against a KIR3DL2-positive T-cell line in vitro. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we believe this preclinical data supports the potential expansion of the IPH4102 development program into Adult T-cell
leukemia/lymphoma, or ATLL, which is mostly prevalent in Asia, particularly in Japan. The data demonstrates that KIR3DL2 expression is mainly associated with the ATLL acute subtype, a subtype that is the most frequent and associated with the poorest
prognosis. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>IPH5401, An Anti-C5aR Antibody Acting on Immunosuppressive Cells in the Tumor Microenvironment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Overview and Mechanism of Action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced antibody targeting the tumor microenvironment is IPH5401, which is designed to bind to and block the C5a receptor, or C5aR, a
receptor that is expressed on MDSCs and neutrophils. Part of the innate immune system, these types of cells promote tumor growth by secreting inflammatory and angiogenic factors that promote blood vessel growth, potently suppress T cells and NK
cells and hamper the activities of <FONT STYLE="white-space:nowrap">PD-1</FONT> checkpoint inhibitors. C5a, a factor in the complement cascade, is often overexpressed in tumors, where it attracts and activates MDSCs and neutrophils in the tumor
microenvironment, promoting an immunosuppressive environment at the tumor bed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The image below depicts the mechanism of action of
IPH5401. IPH5401 is designed to bind to C5aR, thereby blocking its ability to bind to C5a. This blocking allows the CD8+ or CD4 T cells and NK cells, which would otherwise be suppressed by MDSC and neutrophils, to target and kill the tumor. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g13m51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preclinical studies support development of IPH5401 in combination with
<FONT STYLE="white-space:nowrap">PD-1</FONT> checkpoint inhibitors or other immunotherapies in cancer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development of IPH5401 </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Trial</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sponsor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Patients</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Indication(s)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phase I/II clinical trial <FONT STYLE="white-space:nowrap">(STELLAR-001)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ongoing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Innate&nbsp;Pharma</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">up&nbsp;to&nbsp;100</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Solid&nbsp;Tumors,&nbsp;NSCLC,&nbsp;HCC</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2018, we entered into a non-exclusive clinical trial collaboration with AstraZeneca with respect to
IPH5401. As part of this collaboration, we are conducting a multi-center, open label, dose-escalation and dose-expansion Phase I/II clinical trial <FONT STYLE="white-space:nowrap">(STELLAR-001)</FONT> to evaluate the safety and efficacy of IPH5401
in combination with durvalumab, an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> immune checkpoint inhibitor, as a treatment for patients with solid tumors, including
<FONT STYLE="white-space:nowrap">non-small-cell</FONT> lung carcinoma, or NSCLC, with secondary resistance to prior immuno-oncology treatment and <FONT STYLE="white-space:nowrap">IO-na&iuml;ve</FONT> hepatocellular carcinoma, or HCC. The trial is
being conducted at two sites in the United States pursuant to an IND accepted by the FDA in May 2018 and at two sites in France pursuant to approval by ANSM. The first patient in this clinical trial was enrolled in September 2018, and we expect to
enroll up to 100 patients in total. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This trial consists of a dose-escalation part and two expansion cohorts. In the dose-escalation part,
patients receive IPH5401 in combination with 1,500 mg of durvalumab every 4 weeks. The first expansion cohort will evaluate the IPH5401 and durvalumab combination in patients with NSCLC who are <FONT STYLE="white-space:nowrap">IO-pretreated</FONT>
and the second expansion cohort will evaluate the IPH5401 and durvalumab combination in patients with HCC who are <FONT STYLE="white-space:nowrap">IO-na&iuml;ve.</FONT> The primary endpoints of this trial are assessment of DLTs for up to six weeks
after treatment and AEs from screening through up to 30 days after the last dose of trial medication. Secondary endpoints include objective response rate according to RECIST 1.1, duration of response and progression-free survival. The graphic below
depicts the trial design: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g00p38.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to report preliminary safety data from this clinical trial in the second half of 2019. Pursuant
to our agreement, we and AstraZeneca are sharing the costs of this clinical trial on a 50/50 basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IPH5401 for the Treatment of Inflammation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The complement system consists of a network of more than 50 different plasma and membrane associated proteins. It is a part of the innate
immune system and plays a key role in host defense against pathogens as well as in tissue homeostasis. The anaphylatoxin C5a is formed upon cleavage of C5 during the process of complement activation. C5a is the most potent chemoattractant and
induces recruitment and activation of different immune cells to inflamed tissue, among which are neutrophils, eosinophils, monocytes, basophils, and mast cells. In addition, release of C5a increases blood vessel permeability, chemokine release from
neutrophils, and expression of adhesion molecules on endothelial cells. All of these processes facilitate further immune cell recruitment into inflamed tissue and local inflammation. Unsuitable activation of the complement cascade and production of
C5a are associated with inflammatory conditions including several types of vasculitis, systemic lupus erythematous, rheumatoid arthritis, ischemia/reperfusion injury, hydradenitis suppurativa,<U></U> psoriasis, acne, and urticaria. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>IPH5201, An Anti-CD39 Antibody Targeting the Immunosuppressive Adenosine Pathway
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a CD39-blocking monoclonal antibody known as IPH5201. In preclinical models using both primary human cells
and tumor mouse models, we observed that the blockade of CD39 could stimulate anti-tumor immunity across a wide range of tumors by preventing the production of adenosine and by promoting the accumulation of extracellular adenosine triphosphate, or
ATP, in the tumor microenvironment. CD39 is a membrane-bound extracellular enzyme that is expressed on the surface of regulatory T cells, B cells, myeloid cells and endothelial cells, and is upregulated on immune cells in tumor tissue. CD39 inhibits
the immune system by degrading ATP into adenosine monophosphate, or AMP, that is then further degraded into adenosine by CD73. Within the tumor microenvironment, ATP promotes immune-cell mediated killing of cancer cells, and accumulation of ATP is
beneficial for enhancing anti-tumor immune responses. However, ATP degradation and adenosine accumulation causes immune suppression and dysregulation of immune cells, which results in the spreading of tumors. By promoting the accumulation of
immune-stimulating ATP, and preventing the production of immune-suppressive adenosine, we believe that the blockade of CD39 may stimulate anti-tumor activity across a wide range of tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This rationale is supported by our preclinical data for IPH5201 in mouse tumor models and by the analysis of anti-tumor immune responses in
tumor-challenged CD39 <FONT STYLE="white-space:nowrap">knock-out</FONT> mice. In this model, significant tumor responses were observed in response to treatment with <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitors and ADCC-inducing
antibodies, as well as with immunogenic chemotherapy, compared to responses to these agents in wild-type mice. The following images show the results of human CD39 <FONT STYLE="white-space:nowrap">knock-in</FONT> mouse tumor model. The four graphs on
the left show changes in tumor volume over time depending on the type of treatment group, which included a control group (gray), an IPH5201 (mouse version) group (blue), an oxaliplatin group (orange) and an oxaliplatin and IPH5201 combination group
(purple). The diagram below outlines survival among these four treatment groups. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g85j93.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other preclinical data showed that, in human tumors, CD39 is strongly upregulated on the tumor infiltrating
lymphocytes, or TILS, which could contribute to immunosuppression. In in vitro preclinical models with human immune cells, IPH5201 restored T cell proliferation by blocking ATP-degradation into adenosine. Additionally, IPH5201 enhanced ATP-mediated
dendritic cell activation in preclinical models, resulting in T-cell proliferation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These data were presented at the AACR 2018 annual
meeting and were published in May 2019. We expect to file an IND for IPH5201 in the second half of 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>IPH5301, An Anti-CD73 Antibody Targeting the Immunosuppressive Adenosine Pathway
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a CD73 blocking antibody for immuno-oncology known as IPH5301. CD73 plays a significant role in promoting
immunosuppression through the pathway degrading ADP into adenosine. CD73 blockade promotes anti-tumor immunity by reducing adenosine accumulation. We have generated a panel of novel anti-CD73 antibodies and, in the first half of 2018, selected a
lead product candidate from this program, IPH5301, due to a combination of parameters including affinity for CD73, inhibition of CD73 enzymatic activity and its chemistry, manufacturing and control profile. We presented preclinical data further
supporting the rationale of developing IPH5301, including in combination with IPH5201, at the AACR 2018 annual meeting. These data were also published in May 2019. IPH5301 has been observed to have a differentiated and superior activity compared to
benchmark antibodies that are currently in clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IPH5301 is more potent in restoring CD4+ and CD8+ T cell proliferation
in an <FONT STYLE="white-space:nowrap">ATP-suppression</FONT> assay, than the most advanced clinical candidates </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g41a29.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to file an IND for IPH5301 in the first half of 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Additional Preclinical Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a robust pipeline of additional preclinical product candidates across our three development pillars. Within our preclinical pipeline,
four programs are being developed under an option agreement with AstraZeneca including IPH43, the anti-Siglec-9 program and one multi-specific NKp46 NKCE program. Another NKCE program, IPH61, is developed in collaboration with Sanofi. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>IPH43: Anti-MICA/B Antibody and Tumor Targeting Antibody Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing IPH43 as an antibody-drug conjugate targeting MICA/B for the treatment of oncology indications. MICA/B molecules bind to the
NKG2D activating receptor and are specifically expressed on several highly prevalent solid tumors types including in the breast, colon and lung. We believe an antibody that kills <FONT STYLE="white-space:nowrap">MICA/B-expressing</FONT> tumor cells
could potentially treat these cancers by eliminating tumor cells. Because MICA/B molecules are highly polymorphic and therefore frequently subject to genetic variation, we have generated a series of high affinity antibodies recognizing equivalently
the most frequent genetic variants of MICA/B. We chose to target MICA/B using an ADC format because it allows the elimination of tumor cells in the condition in which the tumor is not infiltrated by immune cells, known as an immune desert. This
program is in preclinical development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Anti-Siglec-9</FONT> &#150; Checkpoint Inhibitor Program
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exploring the possibility of developing an antibody designed to reduce the effects of the
<FONT STYLE="white-space:nowrap">Siglec-9</FONT> receptor for the treatment of cancer. <FONT STYLE="white-space:nowrap">Siglec-9</FONT> is an inhibitory checkpoint that is expressed on a broad range of immune cells, including NK cells and myeloid
cells such as dendritic cells, monocytes and neutrophils. <FONT STYLE="white-space:nowrap">Siglec-9</FONT> can interact with sialic acids expressed by tumors, leading to a reduced immune cell function that allows tumors to proliferate. In our
preclinical studies, we observed that&nbsp;antibodies designed to block <FONT STYLE="white-space:nowrap">Siglec-9&#146;s</FONT> interaction with its ligands enhanced NK cell cytotoxicity. We have also observed in our preclinical studies that <FONT
STYLE="white-space:nowrap">Siglec-9</FONT> is highly expressed on monocytes and dendritic cells and upregulated on T cells in cancer patients, suggesting a potential additional role as an inhibitory checkpoint agent. This program is in preclinical
development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>NKp46 NK Cell Engagers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Multispecific monoclonal antibodies, or multispecifics, are antibody-derived formats that can simultaneously bind to two or more different
types of molecules. A number of studies of bispecific antibodies are currently underway, such as those assessing the safety and efficacy of bispecific T cell engagers, such as BiTEs, which engage T cells via the antigen receptor on <FONT
STYLE="white-space:nowrap">one-side</FONT> of the bispecific T cell engager, and a tumor antigen on the other side of the BiTE. These molecules have demonstrated the ability to reduce or slow the growth of tumors in cancer patients, but also carry a
significant toxicity risk. This toxicity risk occurs by engaging all T cells, irrespective of their specificity and development status, potentially leading to an overt production of cytokines by these T cells, referred to as a cytokine storm. In
parallel, bispecific killer cell engagers, or BiKEs, that engage CD16 receptors found on NK cells, and trispecific killer cell engagers, or TriKEs, that engage CD16 receptors and contain <FONT STYLE="white-space:nowrap">IL-15,</FONT> a cytokine that
promotes NK cell activation and survival, have also been developed to target antigens expressed on solid tumors. BiKEs and TriKEs can be effective both in vitro and in vivo preclinical models. These multifunctional molecules that engage NK cells
could reduce the risks associated with toxicity, as NK cell counts only represent approximately 10% of T cell counts, thereby potentially limiting the likelihood of inducing a cytokine storm. However, it remains unclear whether these multifunctional
CD16 engager antibodies can activate NK cells in solid tumors since they often express low levels of CD16. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed
trifunctional NKCEs to <FONT STYLE="white-space:nowrap">co-engage</FONT> NKp46 and CD16 on NK cells together with a tumor antigen. In our preclinical studies, we observed that NKp46 NKCEs have stronger anti-tumor activity as compared to preclinical
findings from other approved anti-tumor therapeutic antibodies, such as rituximab, <FONT STYLE="white-space:nowrap">Fc-enhanced</FONT> obinutuzumab and cetuximab. Additionally, preclinical results indicate that trifunctional NKCEs promoting NKp46
and CD16 receptors simultaneously with the same molecule are more potent than a mixture of bispecific reagents activating NKP46 and CD16 separately, and can efficiently promote NK cell mediated tumor cell lysis without inducing potentially toxic
off-target effects. We believe these results support the clinical development of NKCEs for cancer immunotherapy, as a complement to existing immuno-oncology approaches. The following images depict the mechanism of action of these multifunctional NK
cell engagers and our preclinical results. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="54%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g752656g72h73.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g752656g75o68.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IPH61 is a NKp46 NKCE developed as part of our research collaboration and licensing agreement with Sanofi for
the generation and evaluation of up to two NKp46 NKCEs, using Sanofi&#146;s technology and tumor targets and our NK cell engager technology. Under the terms of the agreement, Sanofi&nbsp;is responsible for the development, manufacturing and
commercialization of products resulting from the research collaboration. We are eligible to receive payments of up to &#128;400.0&nbsp;million primarily upon the achievement of development and commercial milestone as well as royalties ranging from a
mid to high single-digit percentage on net sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industry, and notably the cancer field, is characterized by rapidly advancing technologies, products
protected by intellectual property rights and intense competition and is subject to significant and rapid changes as researchers learn more about diseases and develop new technologies and treatments. While we believe that our technology, knowledge,
experience, collaborations and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic
institutions and governmental agencies and public and private research institutions. Any approved product that we commercialize will compete with existing therapies and new therapies that may become available in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology
companies. Many of our competitors have significantly greater experience, personnel and resources as it relates to research, drug development, manufacturing and marketing. In particular, large pharmaceutical laboratories have substantially more
experience than we do in conducting clinical trials and obtaining regulatory authorizations. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller
number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors are also likely to compete with us to
recruit and retain top qualified scientific and management personnel, acquire rights for promising product candidates and technologies, establish clinical trial sites and patient registration for clinical trials, acquire technologies complementary
to, or necessary for, our programs and enter into collaborations with potential partners who have access to innovative technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have a better safety profile, are more convenient, have a broader label, have more robust intellectual property
protection or are less expensive than any products that we may develop. Our competitors also may obtain regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a
strong market position before we are able to enter the market. In addition, our competitors could be more efficient in manufacturing or more effective in marketing their own products than we or our partners may be in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our lead product candidate, monalizumab, a novel dual-targeting checkpoint inhibitor, there are several pharmaceutical
companies marketing and developing treatments for either SCCHN or <FONT STYLE="white-space:nowrap">MSS-CRC.</FONT> For SCCHN, Erbitux (cetuximab), marketed by Eli Lilly, and checkpoint inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab),
marketed by Bristol-Myers Squibb and Merck, respectively, have all been approved in the second line setting. For CRC, Stivarga (regorafenib), marketed by Bayer, and Lonsurf (trifluridine/tipiracil), marketed by Taiho Oncology, are both approved in
the third line or later setting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to Lumoxiti, our marketed product for the treatment of HCL, there is currently no
established standard of care and very few treatment options available in the third line and later setting. The National Comprehensive Cancer Network, or NCCN, guidelines for HCL, updated in January 2019, recommend that patients who are third line or
later in treatment be considered for Lumoxiti as well as participation in clinical trials of vemurafenib, with or without rituxan, or ibrutinib. Vemurafenib, rituxan and ibrutinib have not been approved by the FDA for the treatment of HCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to IPH4102, our monoclonal antibody product candidate targeting KIR3DL2, we are aware of several pharmaceutical companies
marketing and developing products for the treatment of patients with CTCL, including MF and S&eacute;zary syndrome, and PTCL. Two new drugs have been recently approved by the FDA for CTCL: Adcetris (brentuximab vedotin), marketed by Seattle Genetics
and approved in combination with chemotherapy for treatment of patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing MF who have received prior systemic therapy, and Poteligeo (mogamulizumab), marketed by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Kyowa Kirin and approved for the treatment of adult patients with R/R MF or S&eacute;zary syndrome after at least one prior systemic therapy. Zolinza (vorinostat) is the only drug approved by the
FDA for CTCL patients after two prior failures. In the second line setting of PTCL, Beleodaq (belinostat), Folotyn (pralatrexate) and Istodax (romidepsin) have all been approved by the FDA; however, none of these treatments have been approved by the
EMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are also several pharmaceutical and biotechnology companies that are focused on the tumor microenvironment, including the
complement and the adenosine pathways. The C5a and C5aR pathways have attracted efforts mainly in inflammation, but we are aware of some companies targeting C5a or C5aR in the oncology settings as well, such as MorphoSys AG and InflaRx N.V. Many
companies are active in the adenosine pathway, targeting CD73, CD39 or the adenosine receptors. For example, Bristol-Myers Squibb and AstraZeneca each have anti-CD73 product candidates in clinical development, and several other biotechnology
companies are active in the adenosine pathway area, including Tizona Therapeutics, Inc., AbbVie Inc., Corvus Pharmaceuticals, Inc., Arcus Biosciences, Inc. and Surface Oncology, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NK cells have been increasingly researched and we are aware of many companies addressing NK cells through different approaches such as cell
therapies (Fate Therapeutics, Inc., NantKwest, Inc.) and multispecifics (Affimed N.V., Dragonfly Therapeutics, Inc.) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategic Collaborations and
License Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2015 Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
April 2015, we entered into two agreements with MedImmune, a wholly owned subsidiary of AstraZeneca, which we refer to as AstraZeneca. The first agreement was a co-development and license agreement relating to certain combination products containing
monalizumab, or the Original Co-Development Agreement, and the second agreement was a development and option agreement for products containing monalizumab, including products using monalizumab as a monotherapy, or the 2015 Option Agreement. We
received an initial payment of $250 million under these agreements on June 30, 2015, of which $100 million was paid to us as an initial payment for the Original Co-Development Agreement and $150 million was paid to us as consideration for the 2015
Option Agreement described below. In October 2018, AstraZeneca exercised its option under the 2015 Option Agreement, which resulted in the automatic termination of both the Original Co-Development Agreement and the 2015 Option Agreement, and a new
co-development and license agreement relating to all products containing monalizumab, or the 2015 Co-Development Agreement, automatically came into effect. In connection with AstraZeneca&#146;s exercise of its option under the 2015 Option Agreement,
an upfront payment of $100 million was due under the 2015 Co-Development Agreement, which it paid in January 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2015
Co-Development Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2015 Co-Development Agreement, we granted to AstraZeneca a worldwide, exclusive license,
subject to certain exclusions, to certain of our patents and know-how to develop, manufacture and commercialize licensed products, including monalizumab, in the field of diagnosis, prevention and treatment of oncology diseases and conditions. We
further granted to AstraZeneca a worldwide, non-exclusive license to certain of our other patents to develop, manufacture and commercialize licensed products, including monalizumab, in the field of diagnosis, prevention and treatment of oncology
diseases and conditions. We retain the rights under the licensed patents and know-how to, among other things, co-promote licensed products in certain European countries, pursuant to our option to co-promote, and exploit the licensed patents and
know-how to research, develop and commercialize the licensed products outside of the field of diagnosis, prevention and treatment of oncology diseases and conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2015 Co-Development Agreement, we are required to collaborate with AstraZeneca to develop and commercialize licensed products.
AstraZeneca will be the lead party in developing the licensed products and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
must use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize each licensed product in certain major markets. Each party will have to use commercially
reasonable efforts to complete certain development activities in accordance with a specified development plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required for a
defined period of time to co-fund 30% of the Phase III clinical trials of licensed products, subject to an aggregate cap, in order to receive 50% of the profits in Europe. We have the option to withdraw from such co-funding requirements, in which
case we would forfeit the option to co-promote licensed products under the agreement, and our right to share in 50% of such profits would terminate and sales in Europe will instead be factored into net sales used to calculate royalty and milestone
payments to us. Additionally, Phase III and regulatory milestone payments that may be payable to us will be reduced. AstraZeneca will be responsible for the promotion of licensed products worldwide, subject to our option to co-promote the licensed
products in certain European countries. Should we elect not to co-promote, our share of profits in Europe will be reduced by a specified amount of percentage points not to exceed the mid-single digits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development by AstraZeneca of a licensed product under the 2015 Co-Development Agreement is subject to certain reciprocal non-compete
obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AstraZeneca is obligated to pay us up to $925 million in the aggregate upon the achievement of certain development and
regulatory milestones ($500 million) and commercialization milestones ($425 million). As described above, the arrangement also provides for a 50% profit share and, subject to certain deferrals of reimbursement, loss share of licensed products in
Europe if we do not opt out of our co-funding and co-promoting obligations. In addition, we will be eligible to receive tiered royalties ranging from a low double-digit to mid-teen percentage on net sales of licensed products outside of Europe. The
royalties payable to us under the 2015 Co-Development Agreement may be reduced under certain circumstances, including loss of exclusivity or lack of patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our right to receive royalties under the 2015 Co-Development Agreement expires, on a licensed product-by-licensed product and
country-by-country basis, on the latest of: (i) the tenth anniversary of the first commercial sale of such licensed product in such country, or in the case of European countries, in any European country, (ii)&nbsp;the expiration of regulatory
exclusivity for such licensed product in such country and (iii) the expiration of the last-to-expire valid licensed patent claim subject to the agreement that covers such licensed product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the term of the 2015 Co-Development Agreement will expire on the date on which all of AstraZeneca&#146;s payment
obligations have expired. We may terminate the 2015 Co-Development Agreement if AstraZeneca challenges any patent licensed to it under the agreement. AstraZeneca may terminate the 2015 Co-Development Agreement in its entirety for convenience at any
time effective upon 120 days&#146; prior written notice to us. Either party may terminate the 2015 Co-Development Agreement in the event of an uncured material breach by the other party or for certain bankruptcy or insolvency events involving the
other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the 2015 Co-Development Agreement is terminated by AstraZeneca for convenience or by us for AstraZeneca&#146;s material
breach, insolvency or a patent challenge by AstraZeneca, all licenses and rights granted under the agreement terminate, however, upon any such termination, AstraZeneca would grant us an exclusive, worldwide, royalty-bearing right and license, with
the right to grant sublicenses, under technology developed by AstraZeneca and incorporated into or necessary for the exploitation of licensed products, except for certain manufacturing technology that would require a separate agreement. If the 2015
Co-Development Agreement is terminated by AstraZeneca for our material breach or insolvency, AstraZeneca has the right to continue the agreement by providing written notice to us. If AstraZeneca provides us with such written notice, among other
things, our rights under the co-promote option will terminate and we must cease any development, manufacture or commercialization activities under the agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we entered into three additional agreements with AstraZeneca. The first agreement is a collaboration and option agreement
relating to IPH5201, or the 2018 CD39 Option Agreement. We received an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
initial payment of $50 million under this agreement, $26 million of which was received in October 2018 and $24&nbsp;million of which was received in January 2019. The second agreement is an
option agreement relating to four pre-clinical programs, which we refer to as the 2018 Future Programs Option Agreement. We received an initial payment of $20 million under this agreement in October 2018. The third agreement is a license agreement
with AstraZeneca relating to Lumoxiti, or the Lumoxiti Agreement. We made an initial payment to AstraZeneca of $50 million under this agreement in January 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 CD39 Option Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the 2018 CD39 Option Agreement, we granted to AstraZeneca an exclusive option to obtain an exclusive license to certain of our
patents and know-how to develop and commercialize licensed products, including IPH5201 in the field of the diagnosis, prevention and treatment of all diseases and conditions in humans or animals, subject to certain limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2018 CD39 Option Agreement, we must collaborate with AstraZeneca to develop CD39 option products. Prior to the expiration of the
option period, we and AstraZeneca are subject to certain non-compete obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AstraZeneca is responsible for funding the research and
development costs of CD39 option products contemplated in the joint development plan. Additionally, we may conduct certain exploratory clinical studies at our own cost, subject to reimbursement by AstraZeneca with a premium under certain
circumstances related to subsequent development by AstraZeneca. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the 2018 CD39 Option Agreement, AstraZeneca is obligated to
pay us up to $10 million in the aggregate upon the achievement of certain development milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the term of
the 2018 CD39 Option Agreement will expire on the earlier of exercise of the option or expiration of the option period in the event that AstraZeneca does not exercise the option. We may terminate the 2018 CD39 Option Agreement if AstraZeneca
challenges any option patent. AstraZeneca may terminate the 2018 CD39 Option Agreement in its entirety for convenience at any time effective upon three months&#146; prior written notice to us. Either party may terminate the 2018 CD39 Option
Agreement in the event of an uncured material breach by the other party or for certain bankruptcy or insolvency events involving the other party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>CD39 Co-Development and License Agreement Upon Option Exercise by AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon exercise of the option under the 2018 CD39 Option Agreement, we would enter into a co-development and license agreement with AstraZeneca,
or the CD39 Potential License Agreement. Under the CD39 Potential License Agreement, we would grant to AstraZeneca a worldwide, exclusive license, subject to certain exclusions, to certain of our patents and know-how regarding, among other things,
our IPH5201 candidate, to develop, manufacture and commercialize licensed products in the field of diagnosis, prevention and treatment of diseases and conditions in humans and in animals, subject to certain limitations. We would retain certain
rights under the licensed patents and know-how to, among other things, co-promote licensed products in certain European countries, pursuant to our option to co-promote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CD39 Potential License Agreement provides for a payment of $25 million upon exercise. Additionally, AstraZeneca would be obligated to pay
us up to $800 million in the aggregate upon the achievement of certain development and regulatory milestones ($300 million) and commercialization milestones ($500 million). The arrangement also provides for a 50% profit share in Europe if we opt
into certain co-promoting and late stage co-funding obligations. In addition, we would be eligible to receive tiered royalties ranging from a high-single digit to mid-teen percentage on net sales of IPH5201, or from a mid-single digit to low-double
digit percentage on net sales of other types of licensed products, outside of Europe. The royalties payable to us under the CD39 Potential License Agreement may be reduced under certain circumstances, including loss of exclusivity or lack of patent
protection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CD39 Potential License Agreement, unless we have elected not to co-fund, we would
be required to collaborate with AstraZeneca to develop and commercialize licensed products. AstraZeneca would be the lead party in developing and commercializing the licensed products and each party must use commercially reasonable efforts to
develop, obtain regulatory approval and commercialize at least one licensed product in certain major markets. Each party would have to use commercially reasonable efforts to complete its development activities in accordance with a specified
development plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We would have the option to co-fund 30% of the Phase III clinical trials of licensed products in order to share in 50%
of the profits and losses of licensed products in Europe. If we do not exercise this co-funding option, among other things, our right to share in 50% of the profits and losses in Europe and right to co-promote in certain European countries will
terminate and will be replaced by rights to receive royalties on net sales at the rates applicable to outside of Europe. Additionally, certain milestone payments that may be payable to us would be reduced. AstraZeneca would be responsible for the
promotion of licensed products worldwide, subject to our option to co-promote the licensed products in certain European countries if we elect to co-fund. Additionally, we would have a right of first negotiation in the event that AstraZeneca wishes
to grant a third party the right to commercialize licensed products in Europe or the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development by AstraZeneca of a
licensed product under the Potential License Agreement is subject to certain reciprocal non-compete obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our right to receive
royalties under the CD39 Potential License Agreement expires, on a licensed product-by-licensed product and country-by-country basis, on the latest of: (i) the tenth anniversary of the first commercial sale of such licensed product in such country,
or, in the case of European countries, in any European country, (ii) the expiration of regulatory exclusivity for such licensed product in such country and (iii) the expiration of the last-to-expire valid licensed patent claim subject to the
agreement that covers such licensed product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the term of the CD39 Potential License Agreement
would expire on the date on which all of AstraZeneca&#146;s payment obligations have expired. We may terminate the CD39 Potential License Agreement if AstraZeneca challenges any patent licensed to it under the agreement. AstraZeneca may terminate
the CD39 Potential License Agreement in its entirety for convenience at any time effective upon 120 days&#146; prior written notice to us. Either party may terminate the CD39 Potential License Agreement in the event of an uncured material breach by
the other party or for certain bankruptcy or insolvency events involving the other party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 Future Programs Option Agreement
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the 2018 Future Programs Option Agreement, we granted to AstraZeneca four exclusive options that are exercisable until
IND approval to obtain a worldwide, royalty-bearing, exclusive license to certain of our patents and know-how relating to certain specified pipeline candidates to develop and commercialize optioned products in all fields of use. Upon exercise of an
option, we would be entitled to an option exercise payment of $35 million, as well as development and regulatory milestone payments ($320 million) and commercialization milestone payments ($500 million) and tiered, mid-single digit to mid-teen
percentage royalties on net sales of the applicable product. The royalties payable to us may be reduced under certain circumstances, including loss of exclusivity, lack of patent protection or the specific nature of the compound included within the
applicable product. Additionally, we would have rights to co-fund certain development costs in order to obtain profit and loss sharing in Europe. So long as we elect to co-fund such development costs, we also will have a right to co-promote optioned
products in Europe. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement for Lumoxiti </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Lumoxiti Agreement, we obtained an exclusive license under certain patents and know-how of AstraZeneca to develop, manufacture
and commercialize Lumoxiti for all uses in humans and animals </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the United States, the European Union and Switzerland. We are obligated to pay AstraZeneca up to $25&nbsp;million in the aggregate upon the achievement of certain regulatory and commercial
milestones. In connection with the Lumoxiti Agreement, we also obtained an exclusive sublicense from AstraZeneca under certain third-party intellectual property rights. In consideration for such sublicense we are obligated to pay a low single digit
royalty on our net sales of Lumoxiti, as well as milestone payments up to approximately $1&nbsp;million in the aggregate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
Lumoxiti Agreement, AstraZeneca is obligated to provide support for the continued development and commercialization of Lumoxiti in the European Union and Switzerland prior to regulatory submission and approval as well as support for the continued
commercialization of Lumoxiti in the United States for a specified period. We will reimburse AstraZeneca for the development, production and commercialization costs it will incur during the transition period, subject to certain limitations for the
year ending December 31, 2019. In addition, pursuant to the Lumoxiti Agreement we will enter into a supply agreement with AstraZeneca for the continued supply of Lumoxiti for sale in the United States, the European Union and Switzerland. Under the
Lumoxiti Agreement, each party is obligated to use commercially reasonable efforts to conduct a number of activities under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Lumoxiti Agreement, we have a right of first negotiation in the event that AstraZeneca intends to grant rights to commercialize
Lumoxiti outside of the United States, the European Union and Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lumoxiti Agreement will expire on a country-by-country
basis upon the latest of (i) the expiry of the last exclusively licensed patent in such country, (ii) expiration of any regulatory exclusivity in such country, and (iii) the fifteenth anniversary of the first commercial sale of Lumoxiti in such
country. Either party may terminate the Lumoxiti Agreement upon any uncured material breach of such party&#146;s obligations under the agreement or upon a bankruptcy or insolvency of the other party. Additionally, AstraZeneca may terminate the
agreement in the event we challenge any patent exclusively licensed under the agreement or cease to perform all commercial activities with respect to Lumoxiti in the United States or the European Union for a specified period of time. We may
terminate the Lumoxiti Agreement upon certain prior notice to AstraZeneca. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Additional agreements related to Monalizumab
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Novo Nordisk A/S </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2014, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> the full development and commercialization rights to
monalizumab relating to the modulation of the activity of isolated NK cells from Novo Nordisk A/S. In consideration for these rights, we paid Novo Nordisk A/S &#128;2&nbsp;million in cash and 600,000 of our ordinary shares at a price of &#128;8.33
per share. Novo Nordisk A/S is eligible to receive a total of &#128;20&nbsp;million in potential regulatory milestones and tiered <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-to-high</FONT></FONT> single-digit percentage
royalties on future net sales. The agreement with Novo Nordisk A/S included a right to additional consideration in the event of an <FONT STYLE="white-space:nowrap">out-licensing</FONT> agreement. Consequently, following the agreement signed with
AstraZeneca in April 2015, we paid Novo Nordisk A/S an additional consideration amount of &#128;6.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018
AstraZeneca exercised its option under the 2015 Option Agreement to acquire an exclusive license to monalizumab. Pursuant to this option exercise, AstraZeneca paid $100&nbsp;million to us and, as a result, Novo Nordisk A/S became entitled to a
second and final payment amounting to $15.0 million (&#128;13.1 million). If the AstraZeneca agreement is terminated for any reason, we will pay to Novo Nordisk A/S a portion of any amounts that have been budgeted but have not been spent or will not
be spent under the initial research and development budget. In light of current development plans and research and development costs incurred to date, we do not currently expect any amounts to be paid pursuant to this provision. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Novo Nordisk for IPH5401 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July of 2017 we entered into an exclusive license agreement with Novo Nordisk A/S relating to IPH5401, or the 2017 Novo Agreement, pursuant
to which we obtained a worldwide, exclusive license under certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents and know-how of Novo Nordisk A/S to develop, manufacture and commercialize pharmaceutical products that contain or comprise an Anti-C5aR antibody. We made an initial payment to Novo
Nordisk A/S of &#128;40.0 million under the 2017 Novo Agreement which was offset against Novo Nordisk A/S&#146;s subscription in new shares. We are obligated to pay Novo Nordisk A/S in the aggregate up to &#128;370.0 million upon achievement of
certain development, regulatory and sales milestones and tiered royalties ranging from a low double-digit to low teen percentage on net sales. Our royalty payment obligations are subject to certain reductions and expire on a product-by-product and
country-by-country basis upon the later of the date the exploitation of a licensed product is no longer covered by a claim of a licensed patent in such country, loss of data or regulatory exclusivity in such country, and the twelfth anniversary of
the first commercial sale of such product in such country. In connection with the 2017 Novo Agreement, we obtained an exclusive sublicense from Novo Nordisk A/S under certain third-party intellectual property rights. In consideration for such
sublicense we may be obligated to pay a mid-single digit royalty on our net sales of a licensed product, however, we will be entitled to offset such payments against royalties payable to Novo Nordisk A/S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2017 Novo Agreement, we are obligated to use commercially reasonable efforts to develop and seek regulatory approval for a licensed
product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2017 Novo Agreement shall expire upon expiration of the last royalty payment obligation under the agreement. Either party
may terminate the 2017 Novo Agreement upon any uncured material breach of the agreement by the other party or upon a bankruptcy or insolvency of the other party. Additionally, Novo Nordisk A/S may terminate the agreement in the event we challenge
any patent licensed under the agreement. We may terminate the 2017 Novo Agreement upon prior notice to Novo Nordisk A/S. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration and licensing agreement with Sanofi </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a research collaboration and licensing agreement with Sanofi in January 2016 to apply our proprietary technology to the
development of bispecific antibody formats engaging NK cells to kill tumor cells through the activating receptor NKp46. We granted to Sanofi under certain of our intellectual property a non-exclusive, worldwide, royalty-free research license, as
well as an exclusive, worldwide license to research, develop and commercialize products directed against two specified targets, for all therapeutic, prophylactic and diagnostic indications and uses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will work together with Sanofi on the generation and evaluation of up to two bispecific NK cell engagers, using our technology and
Sanofi&#146;s tumor targets. Under the terms of the license agreement, Sanofi will be responsible for the development, manufacturing and commercialization of products resulting from the research collaboration. We will be eligible for up to
&#128;400.0&nbsp;million in payments, primarily upon the achievement of development and commercial milestones, as well as royalties ranging from a mid to high single-digit percentage on net sales. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Orega License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our licensing agreement with Orega Biotech, we acquired an exclusive license to Orega Biotech&#146;s intellectual property rights
relating to its anti-CD39 checkpoint inhibitor program. As of December 31, 2018, we had paid a total amount of &#128;1.8&nbsp;million to Orega Biotech for the acquisition of these intellectual property rights, and in June of 2019 we paid Orega
Biotech &#128;7.0 million as consideration relating to the collaboration and option agreement signed on October 22, 2018 with AstraZeneca for IPH5201. We may also be obligated to pay Orega Biotech up to an additional &#128;51.5 million in the
aggregate upon the achievement of development and regulatory milestones, and mid-single digit to low-teen percentage payments, depending on determinations relating to Orega Biotech&#146;s intellectual property rights for certain patents, on
sublicensing revenues we receive pursuant to our agreement with AstraZeneca relating to IPH5201. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on obtaining and maintaining patent, trade secret and other intellectual property and proprietary
protection of our technology, current and future products and product candidates and methods used to develop and manufacture them. We cannot be sure that patents will be granted with respect to any of our pending patent applications or to any patent
applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be sufficient to protect our technology or will not be challenged, invalidated or circumvented.
Our success also depends on our ability to operate our business without infringing, misappropriating or otherwise violating any patents and other intellectual property or proprietary rights of third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek to
protect our trade secrets, in part, by confidentiality agreements with our employees, consultants, scientific advisors and contractors. These agreements may not provide meaningful protection or may be breached, and we may not have an adequate remedy
for any such breach. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.
Notwithstanding these measures, these agreements and systems may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors, or
misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or drug candidates or obtain or use information that
we regard as proprietary. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. To the extent that our employees, consultants, contractors or partners use intellectual property owned by others in their
work for us, disputes may arise as to the rights in related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. For more information regarding the risks related to intellectual property, please see &#147;Risk
Factors&#151;Risks Related to Intellectual Property Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file patent applications to protect our product candidates, technical processes and the processes used to prepare our product candidates,
the compounds or molecules contained in these product candidates and medical treatment methods. We also license rights to patents owned by third parties, academic partners or other companies in our field. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Moxetumab pasudotox-tdfk (Lumoxiti) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, the principal intellectual property rights related to Lumoxiti<I> </I>are
<FONT STYLE="white-space:nowrap">in-licensed</FONT> from AstraZeneca and include U.S. Patent No.&nbsp;10,072,083, which covers the composition of matter of Lumoxiti, and its counterpart European patent EP 2&nbsp;613 857 B1, which covers the
manufacture of Lumoxiti. These patents have a statutory expiration date in 2031, not including patent term adjustment or any potential patent term extension. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Monalizumab/IPH22 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, the principal intellectual property rights related to the monalizumab compound are
<FONT STYLE="white-space:nowrap">in-licensed</FONT> from Novo Nordisk A/S and include U.S. Patent Nos. 8,206,709 and 8,901,283, European patents EP&nbsp;2&nbsp;038&nbsp;306 B1 and EP 2&nbsp;426&nbsp;150 B1 and counterpart patents in certain other
countries. These patents cover the composition of matter of monalizumab and have a statutory expiration date in 2027, not including patent term adjustment or any potential patent term extension. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>IPH4102/Anti-KIR3DL2 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, the principal intellectual property rights related to IPH4102 are wholly owned by us and include U.S. Patent
No.&nbsp;10,280,222, European patent EP&nbsp;3&nbsp;116&nbsp;908&nbsp;B1 and counterpart patent applications in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain other countries. These patents and patent applications cover the composition of matter of IPH4102, and such patents have, and any patents that issue from such applications would have, a
statutory expiration date in 2035, not including patent term adjustment or any potential patent term extension. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>IPH5401/Anti-C5aR
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, the principal intellectual property rights related to IPH5401 are
<FONT STYLE="white-space:nowrap">in-licensed</FONT> from Novo Nordisk A/S and include U.S. Patent Nos. 8,613,926, 8,846,045 and 10,323,097, European patent EP 2 718 322 B1 and counterpart patents and patent applications in certain other countries.
These patents and patent applications cover the composition of matter of IPH5401, and such patents have, and any patents that issue from such applications would have, a statutory expiration date in 2032, not including patent term adjustment or any
potential patent term extension. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>IPH5201/Anti-CD39 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2019, the principal intellectual property rights related to IPH5201 are wholly owned by us and include one U.S. non-provisional
patent application. If a patent covering IPH5201 issues from such U.S. patent application, it would have a statutory expiration date in 2039, not including patent term adjustment or any potential patent term extension. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of patents in the countries in which they are obtained. In most countries,
including the United States, the patent term is 20 years from the earliest claimed filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application or its foreign equivalent in the applicable country. In the United States,
a patent&#146;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed
over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. In the United States, a patent may also be eligible for limited patent term extension under the Drug Price Competition and Patent Term
Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend
the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it, or a
method for manufacturing it may be extended. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own the mark INNATE PHARMA in the United States, Australia and Europe (EU community trademark), and INNATE in Europe (EU community
trademark) as well as the mark LUMOXITI and a figurative mark associated with the Lumoxiti product in the United States, Europe (EU community trademark) and other countries throughout the world. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development
work, preclinical tests, clinical studies, facilities, and the manufacture and sale of our products are and will continue to be subject to the complex legislative and regulatory provisions implemented by the various public authorities in Europe, the
United States and other countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EMA, FDA and the various national regulatory authorities impose considerable constraints on the
development, manufacture and sale of products that we develop and clinical trials we conduct. In case of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these regulations, the regulatory authorities may impose fines, seize or remove
products from the market or even partially or totally suspend their production. They may also revoke previously granted marketing authorizations, reject authorization applications. These regulatory constraints are important in considering whether an
active ingredient can ultimately become a drug, as well as for recognizing the time and investments necessary for such development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although there are differences from one country to another, the development of therapeutic
products for human use is subject to similar procedures and must comply with the same types of regulations in all ICH&nbsp;countries (countries part of the International Council for Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use). In order to obtain marketing authorization for a product, proof of its efficacy and safety should be provided by the applicant, along with detailed information on its composition and manufacturing process. This
entails significant pharmaceutical and preclinical developments, clinical trials and laboratory tests. The development of a new drug from fundamental research to marketing comprises five&nbsp;steps: (i)&nbsp;research, (ii) preclinical trials,
(iii)&nbsp;clinical trials in humans, (iv)&nbsp;marketing authorization and (v)&nbsp;marketing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of the purity and stability of the manufactured substance or active pharmaceutical ingredient
and the formulated product, as well as in vitro and animal studies to assess the safety and activity of the product candidate for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is
subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies,
among other things, are submitted to the applicable regulatory agency in connection with the application to begin human testing. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and
long-term toxicity studies, may continue after submission of the application. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of clinical trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In humans, clinical trials are usually carried out in three phases that are generally sequential, but under unique circumstances phases of
trials can overlap or even be skipped, following a specific review and determination by regulatory agencies. Clinical trials are sometimes necessary after marketing authorization to explain certain side-effects, investigate a specific
pharmacological effect, obtain more accurate or additional data. Additional trials are also commonly conducted to explore new indications. Regulatory authorization is needed to carry out clinical trials. The regulatory authorities may block, suspend
or require significant modifications to the clinical study protocols submitted by companies seeking to test products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical
trial authorization in the European Union </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current regulation relating to clinical trials is governed by European Directive
2001/20/EC of 4&nbsp;April 2001 on clinical trials, which has been transposed into national legislation by all European Union Member States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2001 Directive cited above has been revised and replaced by the Clinical Trials Regulation&nbsp;EU No.&nbsp;536/2014 of 16&nbsp;April
2014, which aims at harmonizing and streamlining the clinical trials authorization process. The Clinical Trial Regulation&nbsp;EU No.&nbsp;536/2014 of 16&nbsp;April 2014 entered into force on 16&nbsp;June 2014. However, the regulation will not
become applicable until the publicly available EU database and EU portal are fully functional and have been confirmed through an independent audit. The new regulation will become applicable six months after the European Commission publishes notice
of this confirmation. Due to technical difficulties with the development of the IT systems, the portal&#146;s <FONT STYLE="white-space:nowrap">go-live</FONT> date had to be postponed and therefore the Clinical Trials Regulation will come into
application in the course of 2020 instead of October 2018, as previously scheduled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When it will become applicable, the Clinical Trials
Regulation will be directly applicable (for instance under French law). Some national provisions specifying the national rules will remain applicable. It will apply to interventional clinical trials on medicinal products and to clinical trials
authorized under the current 2001 Directive still ongoing three years after the Clinical Trial Regulation has come into operation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Clinical Trial Regulation will allow better consistency throughout EU Member States:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Single submission of the clinical trial application dossier through the EU Portal (Article 5) including a common
part assessed jointly by all participating EU Member States, and a national part covering the ethical and operational aspects of the trial assessed by each EU Member State independently. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A clinical trial authorization will be issued in the form of a single decision by each EU Member State concerned
(Article 4). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This new regulation will also increase transparency of authorized clinical trials in the European Union:
the European Union database will serve as the source of public information, without prejudice of personal data protection, commercially confidential information protection, and protection of confidential communication between Member State and trial
supervision between Member States. Public information will include clinical trial authorization information, protocol data, and a summary of the results 12 months after the end of the trial (or six months in case of pediatric clinical trials). The
regulation will apply in the Member States without the requirement for separate implementing legislation by each Member State. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trial authorization in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, an Investigational New Drug application, or IND, must be submitted to the FDA and accepted before clinical trials can
start on humans. An IND is an exemption from the Federal Food, Drug, and Cosmetic Act, or FDCA, that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA
authorization to administer an investigational product to humans. This application contains early research data as well as the pharmaceutical dossier, preclinical and clinical data (if any) and includes the clinical protocol. If there is no
objection from the FDA, the IND application becomes valid 30 days after it is received by the FDA. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health
risks. At any time during or subsequent to this <FONT STYLE="white-space:nowrap">30-day</FONT> period, the FDA may request the suspension of clinical trials, whether such trials are planned or in progress, and request additional information. This
temporary suspension continues until the FDA receives the information it has requested. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing IND
requirements, an independent institutional review board, or IRB, representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must
conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with
FDA regulations An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the product candidate
has been associated with unexpected serious harm to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s primary objectives in reviewing an IND are to assure the
safety and rights of patients and to help assure that the quality of the investigation will be adequate to permit an evaluation of the biological product&#146;s safety, purity and potency. The decision to terminate development of an investigational
biological product may be made by either a health authority body such as the FDA, an IRB or ethics committee, or by us for various reasons. Additionally, some trials are overseen by an independent group of qualified experts organized by the trial
sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study.
Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by
us based on evolving business objectives and/or competitive climate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Good clinical practices </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In most countries, clinical trials must comply with the cGCP standards as defined by the International Council for Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use, or ICH. Directive 2005/28/EC dated 8&nbsp;April 2005 adopted the cGCP principles in the context of strengthening the regulatory structure specified by Directive 2001/20/EC. The
competent authority designated in each Member Country to authorize clinical trials must take into consideration, among other factors, the scientific value of the study, the safety of the participants and the possible responsibility of the clinical
site. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conducting clinical trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials must be carried out in compliance with complex regulations throughout the various phases of the process, based on the principle
of informed consent by the patient to whom the products will be administered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trial phases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials may be conducted in the United States, in Europe or in other parts of the world as long as such trials have been approved by
health authorities and ethics committees in each country where the trial is conducted. There are three well-established and internationally-recognized clinical phases: Phase I, II and III. This classification is used by the FDA and the EMA as well
as other regulatory agencies. Each of these clinical phases is described below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase I:&nbsp;The product candidate is initially introduced into healthy human subjects and tested for safety,
dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy
volunteers, the initial human testing is often conducted in patients. Sponsors sometimes designate their Phase I trials as Phase Ia or Phase Ib. Phase Ib trials are typically aimed at confirming dosing, pharmacokinetics and safety in larger number
of patients. Some Phase Ib studies evaluate biomarkers or surrogate markers that may be associated with efficacy in patients with specific types of diseases. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase II:&nbsp;This phase involves clinical trials in a limited patient population to identify possible adverse
effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and appropriate dosage. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase III:&nbsp;Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an
expanded patient population at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product
labeling. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase IV studies, may be conducted after initial marketing
approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the applicable regulator may mandate the performance of Phase IV clinical trials as a
condition of approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In specific situations, certain phases of development can be merged or even skipped when clear signs of efficacy
emerge in the early phases of development and the product candidate is designed for patients with major unmet medical needs. However, these deviations from the standard pattern of development must be discussed and approved by health authorities.
Given the high unmet medical need for certain cancer patients, deviations from the typical phases of development are frequent in oncology and in particular, in the field of immunotherapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure of clinical trial information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sponsors of clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> drugs are required to register and disclose certain
clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose
the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly available information to gain
knowledge regarding the progress of development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Regulations concerning marketing authorizations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to be marketed, a drug product must have regulatory authorization (known as approval of a New Drug Application, or NDA, or a Biologics
License Application, or BLA, in the United States and a Marketing Authorization, or MA, in the European&nbsp;Union). The competent authorities are the FDA in the United States and the EMA in Europe. Companies apply for an NDA/BLA or an MA based on
quality, safety and efficacy. In Europe, the United States and Japan, the dossier is a standard dossier referred to as a CTD, or Common Technical Document. The file relating to the NDA/MA describes the manufacturing of the active substance, the
manufacturing of the final product and the clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>United States
review and approval process for biological products </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA approves complex biological products under the
Public Health Service Act, or PHSA. In order to obtain approval to market a biological product in the United States, a marketing application must be submitted to the FDA that provides data establishing the safety, purity and potency of the proposed
biological product for its intended indication. The application includes all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed
information relating to the product&#146;s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or
from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety, purity and potency of the biological product to
the satisfaction of the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLA is thus a vehicle through which applicants formally propose that the FDA approve a new product for
marketing and sale in the United States for one or more indications. Every new product candidate must be the subject of an approved BLA before it may be commercialized in the United States. Under federal law, the submission of most BLAs is subject
to an application user fee and the sponsor of an approved BLA is also subject to annual program user fees. These fees are typically increased annually. Certain exceptions and waivers are available for some of these fees, such as an exception from
the application fee for products with orphan designation and a waiver for certain small businesses, an exception from the establishment fee when the establishment does not engage in manufacturing the product during a particular fiscal year, and an
exception from the product fee for a product that is the same as another product approved under an abbreviated pathway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following
submission of a BLA, the FDA conducts a preliminary review of the application generally within 60 calendar days of its receipt and strives to inform the sponsor by the 74th day after the FDA&#146;s receipt of the submission to determine whether the
application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept the application for filing. In this event, the application must be resubmitted with the additional information. The
resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review. The FDA has agreed to
specified performance goals in the review process of BLAs. Under that agreement, 90% of applications seeking approval of New Molecular Entities, or NMEs, are meant to be reviewed within ten months from the date on which FDA accepts the application
for filing, and 90% of applications for NMEs that have been designated for &#147;priority review&#148; are meant to be reviewed within six months of the filing date. For applications seeking approval of products that are not NMEs, the <FONT
STYLE="white-space:nowrap">ten-month</FONT> and <FONT STYLE="white-space:nowrap">six-month</FONT> review periods run from the date that FDA receives the application. The review process and the Prescription Drug User Fee Act goal date may be extended
by the FDA for three additional months to consider new information or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an application, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections may cover all facilities associated with a BLA submission, including component manufacturing, finished product manufacturing, and control testing laboratories. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a
BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. In addition, as a condition of approval, the FDA may require an applicant to develop a Risk Evaluation and Mitigation Strategy, or REMS. REMS use risk
minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product,
seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel product to an advisory committee or explain why such referral was not made. Typically, an
advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not
bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the
basis of the FDA&#146;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter
authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or
information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing
such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications,
warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the product&#146;s safety after approval, require testing and surveillance programs to
monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. The
FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Registration procedures in Europe </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To access the European markets through community procedures, drug products must be submitted through the Centralized Procedure, the Mutual
Recognition Procedure or the Decentralized Procedure. The process for doing this depends, among other things, on the nature of the medicinal product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31&nbsp;March 2014 provides for the Centralized Procedure. The
Centralized Procedure results in a single marketing authorization (MA), granted by the European Commission that is valid across the European Economic Area or EEA (<I>i.e.</I>, the European Union as well as Iceland, Liechtenstein and Norway). The
Centralized Procedure is compulsory for human drugs that are: (i)&nbsp;derived from biotechnology processes, such as genetic engineering, (ii)&nbsp;contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS,
cancer, diabetes, neurodegenerative diseases, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
autoimmune and other immune dysfunctions and viral diseases, (iii)&nbsp;officially designated orphan medicines and (iv)&nbsp;advanced-therapy medicines, or ATMPs, such as gene therapy, somatic
cell therapy or tissue-engineered medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Article 3 of the Regulation (EC) No 726/2004, the Centralized Procedure is optional
for any medicinal product not appearing in the Annex if: (1)&nbsp;the medicinal product contains a new active substance which, on the date of entry into force of this Regulation, was not authorized in the EU; or (2)&nbsp;the applicant shows that the
medicinal product constitutes a significant therapeutic, scientific or technical innovation or that the granting of authorization in accordance with this Regulation is in the interests of patients or animal health at EU level. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Centralized Procedure in the European Union, the European Medicines Agency, or EMA, shall ensure that the opinion of the Committee
for Medicinal Products for Human Use, or CHMP, is given within 210 days (Article 6.3). This excludes <FONT STYLE="white-space:nowrap">so-called</FONT> clock stops, during which additional written or oral information is to be provided by the
applicant in response to questions asked by the Committee for Medicinal Products for Human Use, or CHMP (Article 7). At the end of the review period, the CHMP provides an opinion to the European Commission. If this is opinion favorable, the
Commission may then adopt a decision to grant an MA. When an application is submitted for a MA in respect of medicinal products for human use which are of major interest from the point of view of public health and in particular from the viewpoint of
therapeutic innovation, the applicant may request an accelerated assessment procedure. The request shall be duly substantiated. If the CHMP accepts the request, the time-limit laid down in Article 6(3), first subparagraph, shall be reduced to 150
days (Article 14(9)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">National MAs, issued by the competent authorities of the member states of the EEA, are also available; however
these only cover their respective territory. National MAs may be applied for through the Mutual Recognition Procedure or Decentralized Procedure in order that multiple competent authorities in different member states of the EEA may each issue a
national MA in their territory for the same product on the back of the same application. National MAs are only available for products not falling within the mandatory scope of the Centralized Procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since 2008, as a consequence of a European directive, a marketing authorization is now renewed only once, five years after the initial
registration (Article 14, paragraph 2). The marketing authorization shall be then valid for an unlimited period, unless the Commission decides, on justified grounds, relating to pharmacovigilance, to proceed with one additional five-year renewal in
accordance with paragraph 2 (Article 14, paragraph 3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible for a drug to be withdrawn from the market, upon the request of the
health authorities, if a serious problem arises, in particular a safety-related problem. The marketing authorization is then cancelled. There can be various reasons for the withdrawal of drugs from the market, with the main reasons being public
health, major undesirable side effects and <FONT STYLE="white-space:nowrap">non-compliance</FONT> with manufacturing rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">Non-standard</FONT> registration procedures </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aside from the standard procedure of granting a marketing
authorization, as described above, there are <FONT STYLE="white-space:nowrap">non-standard</FONT> registration procedures that allow a shorter <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-market</FONT></FONT> for new
medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Europe, <FONT STYLE="white-space:nowrap">non-standard</FONT> registration procedures under the Centralized Procedures are
as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Conditional approval: valid only one year instead of five. It is granted only if the benefit / risk ratio is
positive, that is if the product responds to unmet medical needs, and if the benefits to public health outweigh the risks associated with uncertainty because of an incomplete evaluation of the drug (for instance, because of clinical trials still
ongoing at the time of the evaluation, or when additional clinical trials are needed). This temporary character may be renewed if an appropriate report to support this is provided by the sponsor. Once the pending studies are provided, it can become
a &#147;normal&#148; marketing authorization. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approval in exceptional circumstances: a marketing authorization may be granted in exceptional cases, reviewed
each year to reassess the risk-benefit balance when the initial dossier for assessment of the drug cannot contain all required data, when for instance the condition to be treated is rarely encountered. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Accelerated approval: the evaluation process is accelerated (150 days instead of 210 days) when a drug is of
major interest from the standpoint of public health. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following expedited approval programs are in place in the
United States: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Accelerated Approval is a program<B> </B>that is intended to make promising products for life threatening
diseases available on the market on the basis of preliminary evidence prior to formal demonstration of patient benefit. The FDA evaluation is performed on the basis of a surrogate marker (a measurement intended to substitute for the clinical
measurement of interest) that is considered likely to predict patient benefit. A result of substitution or marker (&#147;surrogate endpoint&#148;) is a result of laboratory or physical sign that is not in itself a direct measure of the
patient&#146;s feelings, its functions or survival, but which allows to anticipate a therapeutic benefit. The approval that is granted may be considered as a provisional approval with a written commitment to complete clinical studies that formally
demonstrate patient benefit. This procedure is equivalent to the &#147;conditional approval&#148; in Europe. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Priority&nbsp;Review is given to drugs that offer major advances in treatment, or provide a treatment where
no adequate therapy exists. A Priority&nbsp;Review means that the time it takes FDA to review a new drug application is reduced to six months rather than 10 months. This procedure is equivalent to the &#147;accelerated approval&#148; in Europe.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Fast Track&nbsp;Program&nbsp;refers to a process for interacting with FDA to facilitate the development and
expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. The advantages of this process include scheduled meetings to seek FDA input into
clinical development plans and to collect appropriate data that will be needed to support approval. Fast Track designation does not necessarily lead to a Priority Review or Accelerated Approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Breakthrough Therapy Designation is aimed at accelerating the development and examination of drugs which are
intended to treat serious illnesses and where the preliminary clinical evidence indicates that the drug may exhibit a substantial improvement over the available therapies with regard to clinically significant criterion (criteria).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A drug which is given the designation &#147;Breakthrough Therapy&#148; can benefit from the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All of the features of the designation &#147;Fast Track&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Intensive support on a program for the development of effective drugs, from Phase I onwards; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Organizational commitment involving &#147;FDA senior managers.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If research or additional studies show that a product presents a risk when it is marketed, the FDA may require its immediate withdrawal. In
addition, FDA may withdraw approval for placing on the market for other reasons, especially if the studies after approval are not made with due care. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Orphan drugs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan
drugs are drugs used for the prevention or treatment of deadly or serious rare conditions. A special authorization procedure is used for orphan drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the 1983 Orphan Drug Act is intended to encourage the development of treatments for orphan diseases. The FDA grants the
status of orphan drug to any drug aimed at treating diseases affecting fewer than 200,000 people a year in the United States, or more in cases in which there is no reasonable expectation that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the cost of developing and making a product available in the United States for treatment of the disease or condition will be recovered from sales of the product. The Orphan Drug Act also provides
the possibility of obtaining grants from the American government to cover clinical trials, tax credits to cover research costs, a possible exemption from application fees when filing for registration with the FDA, and a seven-year exclusivity if a
marketing authorization is granted. If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which
it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#146;s marketing application for the same drug for the same indication for seven years, except
in certain limited circumstances. Orphan exclusivity does not block the approval of a different product for the same rare disease or condition, nor does it block the approval of the same product for different indications. If a biologic designated as
an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of another product under certain
circumstances, including if a subsequent product with the same biologic for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care,
or if the company with orphan drug exclusivity is not able to meet market demand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Europe, equivalent legislation has been adopted to
promote treatments for rare diseases. Under Article 8 of the Regulation (EC) No 141/2000, products receiving orphan designation in the European Union can receive ten years of market exclusivity, during which time no similar medicinal product may be
placed on the market for the same therapeutic indication. Under Article 37 of the Regulation (EC) No 1901/2006, an orphan product can also obtain an additional two years of market exclusivity in the European Union for pediatric studies (in this case
for orphan drugs no extension to any supplementary protection certificate can be granted, see further detail below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of
Article 3 of Regulation 141/2000/EC of 16&nbsp;December 1999, as amended by Regulation 847/2000/EC of 27&nbsp;April 2000, a medicinal product may be designated as orphan if: (1) (a) it is intended for the diagnosis, prevention or treatment of a
life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union when the application is made, or (b)&nbsp;that is intended for the diagnosis, prevention or treatment of a life-threatening,
seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the medicinal product in the European Union would generate sufficient return to justify the necessary
investment; and (2)&nbsp;for either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method
exists, the medicinal product will be of significant benefit to those affected by that condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and scientific assistance for study proposals
(Articles 6 and 9 of the above-mentioned regulation). The application for orphan drug designation must be submitted before the application for marketing authorization (Article 5). The applicant will receive a fee reduction for the marketing
authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan drug designation does not convey any advantage in, or shorten the
duration of, the regulatory review and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the product obtains orphan drug status, it is granted an exclusive <FONT
STYLE="white-space:nowrap">10-year</FONT> marketing period during which no similar product may apply for a marketing authorization in the European Union for the same indication, as well as an exemption from regulatory fees and other advantages. The <FONT
STYLE="white-space:nowrap">10-year</FONT> market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is
sufficiently profitable not to justify maintenance of market exclusivity (Article 8). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, marketing authorization may be granted to a similar medicinal product for the same
indication at any time if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder of the MA for the original orphan medicinal product has given its consent to the second applicant;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder of the MA for the original orphan medicinal product cannot supply sufficient quantities of the orphan
medicinal product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the second applicant can establish in the application that its product, although similar to the orphan medicinal
product already authorized, is safer, more effective or otherwise clinically superior. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketing authorization may also
be granted to a similar medicinal product with the same orphan indication if the product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be
reduced to six years if it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Registration procedures outside of Europe and the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulation in the United States and Europe, a variety of foreign regulations govern clinical trials, commercial sales and
distribution of drugs. Pharmaceutical firms who wish to market their medicinal drugs outside the European Union and the United States must submit marketing authorization application to the national authorities of the concerned countries, such as the
Pharmaceutical and Medical Device Agency, or PMDA in Japan. The approval process varies from jurisdiction to jurisdiction and the time to approval may be longer or shorter than that required by the FDA or European Commission. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Post-approval regulations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Post-approval regulation in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biologics manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such
as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as
well as new application fees for supplemental applications with clinical data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers and other entities involved in
the manufacture and distribution of approved products are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP
requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and
documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain
cGMP compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards
is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure
to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, suspension of the approval, or complete withdrawal
of the product from the market or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved BLAs, or suspension or revocation
of product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted
only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses.
Prescription products may be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may also share truthful and not misleading information that is otherwise consistent with the
labeling. A company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, and its
implementing regulations, as well as the Drug Supply Chain Security Act, or DSCA, which regulate the distribution and tracing of prescription drug samples at the federal level, and set minimum standards for the regulation of distributors by the
states. The PDMA, its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCA imposes requirements to ensure accountability in distribution and to identify and remove counterfeit
and other illegitimate products from the market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Patent term restoration and extension in the United States </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A patent claiming a new biologic product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent
restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted on a patent covering a product is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time
between the effective date a clinical investigation involving human beings is begun and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. Patent term extension cannot
be used to extend the remaining term of a patent past a total of 14 years from the product&#146;s approval date. Only one patent applicable to an approved product is eligible for the extension, the application for the extension must be submitted
prior to the expiration of the patent in question, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. A patent that covers multiple products for which approval is sought can
only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA. For more information regarding the risks related to patent term
restoration and extension, please see &#147;Risk Factors&#151;Risks Related to Intellectual Property Rights&#151;If we do not obtain protection under the Hatch-Waxman Amendments and similar <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Healthcare law and regulation in the United States </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of biologic products that are granted
marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transparency laws and patient data privacy laws and regulations and other healthcare laws and regulations that may constrain business and/or financial arrangements. Restrictions under applicable
federal and state healthcare laws and regulations, include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and
willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service,
for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties
laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent or knowingly making, using or causing to
made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal
criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective
implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations on covered entities and their business associates, including mandatory contractual terms, with respect to safeguarding the privacy,
security and transmission of individually identifiable health information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient
Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for
Medicare&nbsp;&amp; Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians and teaching hospitals, as well as
ownership and investment interests held by physicians and their immediate family members; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may
apply to healthcare items or services that are reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the
relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Certain state laws require
the reporting of information relating to drug and biologic pricing; and some state and local laws require the registration of pharmaceutical sales representatives. State and foreign laws also govern the privacy and security of health information in
some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with these laws or any other governmental regulations as applicable, could result in the imposition of significant civil,
criminal and administrative penalties, damages, fines, disgorgement, imprisonment, possible exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional integrity reporting requirements and oversight, as well as
contractual damages, reputational harm, diminished profits and future earnings, and curtailment of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Healthcare reform in the United States </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A primary trend in the United States healthcare industry and elsewhere is cost containment. There have been a number of federal and state
proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for biologics and other medical products, government control and other changes to the healthcare system
in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By way of example, the United States and state governments continue to propose and pass legislation designed to
reduce the cost of healthcare. In March 2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government health care programs. Among the provisions of the ACA of
importance to potential product candidates are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription biologic
agents, apportioned among these entities according to their market share in certain government healthcare programs, although this fee would not apply to sales of certain products approved exclusively for orphan indications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded manufacturers&#146; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum
rebate for both branded and generic products and revising the definition of &#147;average manufacturer price,&#148; or AMP, for calculating and reporting Medicaid rebates on outpatient prescription product prices and extending rebate liability to
prescriptions for individuals enrolled in Medicare Advantage plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are
calculated for products that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded the types of entities eligible for the 340B drug discount program; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established the Medicare Part D coverage gap discount program by requiring manufacturers to now provide a 70% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale-discount</FONT></FONT> off the negotiated price of applicable brand products to eligible beneficiaries during their coverage gap period as a condition for the
manufacturers&#146; outpatient products to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service
delivery models to lower Medicare and Medicaid spending, potentially including prescription product spending. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There
have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal and replace certain aspects of the ACA, and we expect such challenges to continue. Since January 2017,
President Trump has signed two executive orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered
legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts
and Jobs Act of 2017 includes a provision that repealed, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying
health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; Additionally, on January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed
the implementation of certain fees mandated by the ACA, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on
<FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug plans,
commonly referred to as the &#147;donut hole.&#148; In July and December 2018, CMS published final rules with respect to permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under
its risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the ACA is
unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by the U.S. Congress as part of the Tax Cuts and Jobs Act of 2017 Act. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS,
have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the
Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2012
through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which
went into effect in April 2013 and will remain in effect through 2027 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further
reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices.
Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and
manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration&#146;s budget proposals for fiscal years 2019 and 2020
contain further drug price control measures that could be enacted during the budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part
B, to allow some states to negotiate drug prices under Medicaid and to eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT> patients. The Trump administration also released a &#147;Blueprint&#148; to lower
drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of
their products and reduce the out of pocket costs of drug products paid by consumers. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.
This final rule codified CMS&#146;s policy change that was effective January 1, 2019. The U.S. Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug
costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts,
restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pharmacovigilance system in Europe </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holder of a European MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for
pharmacovigilance, or QPPV, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All new European MA applications must include a risk management plan, or RMP, describing the
risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such
risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. RMPs and PSURs are routinely
available to third parties requesting access, subject to limited redactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Advertising regulation in Europe </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and
therefore all <FONT STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is also prohibited in
the European Union. Although general requirements for advertising and promotion of medicinal products are established under European Union directives, the details are governed by regulations in each European Union Member State and can differ from
one country to another. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things,
fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Pharmaceutical coverage, pricing and reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>European Union </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional
studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides
options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a
specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor
and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries
attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on health care costs in general, particularly prescription products, has
become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after
reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade, i.e., arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states, can further reduce prices.
There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>United States </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the United States, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Significant uncertainty
exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Thus, even if a product candidate is approved, sales of the product will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care
organizations, provide coverage, and establish adequate reimbursement levels for, the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement
rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and
imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be
considered medically necessary or cost effective. A decision by a third-party payor not to cover a product candidate could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations
and financial condition. Additionally, a payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for a product does not
assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of products have been
a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls
and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any approved products. Coverage policies and
third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies
and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-corruption, anti-kickback and transparency regulations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Arrangements with healthcare providers, physicians, third-party payors and customers can expose pharmaceutical manufactures to broadly
applicable anti-bribery, fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More specifically, each of the above-mentioned steps of the development of therapeutic products for human use is heavily regulated and
therefore involves significant interaction with public officials which is likely to cause a risk of corruption or bribery. For instance, in many countries, hospitals are operated by the government, and doctors and other hospital employees are
considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to enforcement actions. That is why business activity may be
subject to anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including without limitation the Foreign Corrupt Practices Act, the U.K. Bribery Act or the French Sapin 2 Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All these statutes generally prohibit offering, promising, giving, or authorizing others to give anything of value, either directly or
indirectly, to a government or a foreign government official or employees of public international organizations in order to influence official action, or otherwise obtain or retain business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The implementation of these statutes may also impose to develop internal compliance
programs, procedures and guidelines to detect and report any suspicious activities and to mitigate any risks of noncompliance which may occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to specific healthcare regulations, including, without limitation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the French &#147;transparency&#148; provisions, or &#147;French Sunshine Act&#148; (Articles L. <FONT
STYLE="white-space:nowrap">1453-1</FONT> and D. <FONT STYLE="white-space:nowrap">1453-1</FONT> and seq. of the French Public Health Code or PHC), which contains provisions regarding transparency of fees received by some healthcare professionals from
industries, i.e. companies manufacturing or marketing healthcare products (medicinal products, medical devices, etc.) in France. According to the provisions, these companies shall publicly disclose (on a specific public website available at
www.entreprises-transparence.sante.gouv.fr) the advantages and fees paid to healthcare professionals amounting to &#128;10 or above, as well as the agreements concluded with the latter, along with detailed information about each agreement (the
precise subject matter of the agreement, the date of signature of the agreement, its end date, the total amount paid to the healthcare professional, etc.); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the French &#147;anti-gift&#148; provisions (Articles <FONT STYLE="white-space:nowrap">L.1453-3</FONT> to <FONT
STYLE="white-space:nowrap">L.1453-12</FONT> PHC), setting out a general prohibition of payments and rewards from industries, i.e. companies manufacturing or marketing health products, to healthcare professionals, with limited exceptions and strictly
defines the conditions under which such payments or awards are lawful. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Data protection rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Regulation 2016/679, known as the General Data Protection Regulation, or GDPR, as well as EU Member State implementing legislations, apply
to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals located
in the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws impose strict obligations on the ability to process personal data, including health-related information, in
particular in relation to their collection, use, disclosure and transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, in certain countries, in particular France, the conduct
of clinical trials is subject to compliance with specific provisions of the Act <FONT STYLE="white-space:nowrap">No.78-17</FONT> of 6&nbsp;January 1978 on Information Technology, Data Files and Civil Liberties, as amended, and in particular Chapter
IX relating to the processing of personal data in the health sector. These provisions require, among others, the filing of compliance undertakings with &#147;standard methodologies&#148; adopted by the French Data Protection Authority (the CNIL),
or, if not complying, obtaining a specific authorization from the CNIL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most common standard methodologies are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Decision <FONT STYLE="white-space:nowrap">No.&nbsp;2018-154</FONT> of May&nbsp;3, 2018 concerning the approval of
a standard methodology for processing personal data in the context of research in the field of health, which does not require the express consent of the person involved (methodology <FONT STYLE="white-space:nowrap">MR-003);</FONT> and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Decision <FONT STYLE="white-space:nowrap">No.&nbsp;2018-153</FONT> of May&nbsp;3, 2018 concerning the approval of
a standard methodology for the processing of personal data carried out within the context of research in the field of clinical trials, which requires the express consent of the person involved (standard methodology
<FONT STYLE="white-space:nowrap">MR-001).</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In certain specific cases, entities processing health personal data
may have to comply with article <FONT STYLE="white-space:nowrap">L1111-8</FONT> of the French Public Health Code which imposes certain certifications for the hosting service providers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Raw Materials and Supplies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
dependent on specialized third parties, who are subject to cGMP requirements and regulations, for the supply and control of various biological materials. We do not have any internal manufacturing and control
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capabilities. We source the materials for our product candidates and preclinical programs on a purchase order basis but will also have long-term supply contracts in place for one commercial-stage
product and for one clinical-stage product candidate, in preparation for the supply we will need for a clinical pivotal trial. However, we believe that competitive pricing is achieved because there are a number of potential long-term replacements
for each of our suppliers. Generally, the prices of the principal biological raw materials that we purchase are stable. To the extent that we are exposed to price fluctuations, we generally do not expect, in the near term, to be able to pass on cost
increases because of the early development stage of our product candidates and because our commercial product is marketed for a rare disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2019, we
had 208 full-time employees. None of our employees are represented by collective bargaining agreements. We believe that we maintain good relations with our employees. As of April&nbsp;30, 2019, of our 208 full-time employees, 206 were based in
France and two were based in the United States. The following chart shows the number of employees as of April&nbsp;30, 2019 broken out by department: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Full-time equivalent employees</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;April&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate offices and laboratories are located in Luminy, near Marseille, France. In 2008, we signed a lease-financing agreement with
SOGEBAIL, a subsidiary of Soci&eacute;t&eacute; G&eacute;n&eacute;rale, for &#128;6.6&nbsp;million to finance the acquisition of our offices. The lease-financing agreement has a 12-year term. We have a purchase option for all of the buildings and
land for the lump sum of &#128;1 at the end of the term of the contract. We believe that our existing facilities are adequate to meet our current needs and that suitable additional alternative facilities will be available in the future on
commercially reasonable terms to meet our future needs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not
currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement
costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors and Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth information concerning the members of our Executive Board and Supervisory Board and our other executive officers as of July 1, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Board Members</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mondher Mahjoubi, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">60</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman&nbsp;of&nbsp;the&nbsp;Executive&nbsp;Board,&nbsp;Chief&nbsp;Executive&nbsp;Officer, Member of the Executive Committee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yannis Morel, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">45</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Executive Board, EVP, Product Portfolio Strategy &amp; Business Development, Member of the Executive Committee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne</FONT> Mercier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">41</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Executive Board, EVP, Chief Financial Officer, Member of the Executive Committee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supervisory Board Members</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Herv&eacute; Brailly, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Irina Staatz-Granzer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member and Vice Chairman of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Yves Blay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilles Brisson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">67</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">V&eacute;ronique Chabernaud, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ma&iuml;lys Ferrere<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Langlois, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">73</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcus Schindler, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Executive Officers</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pierre Dodion, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">64</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Executive Committee, EVP, Chief Medical Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Odile Belzunce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">38</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Executive Committee, VP Compliance, IT and Portfolio Management</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Butler</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">42</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Executive Committee, EVP, U.S. General Manager of Innate Pharma US Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fr&#233;d&#233;rique Brune</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Executive Committee, VP Development, CMC and Supply Chain</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Vivier, D.V.M., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Permanent Guest to the Executive Committee, SVP, Chief Scientific Officer</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As representative of Bpifrance Participations, the legal entity that holds this Supervisory Board seat. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As representative of Novo Nordisk A/S, the legal entity that holds this Supervisory Board seat. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Executive Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mondher Mahjoubi, M.D.</I>, Chief Executive Officer and Chairman of our Executive Board, was appointed as our Chief Executive Officer and
Chairman of our Executive Board on December&nbsp;30, 2016. Prior to joining us, Dr.&nbsp;Mahjoubi led the Oncology area at AstraZeneca beginning in November 2013 where he focused on the cancer pipeline and global strategy before becoming
AstraZeneca&#146;s Oncology Global Manager in August 2016. In that role, he had direct responsibility for oncology global medical affairs and United States medical affairs. Prior to AstraZeneca, he was the Senior Vice President of Global Product
Strategy in Oncology at Genentech and he previously held positions in marketing and medical affairs for Sanofi-Aventis. Dr.&nbsp;Mahjoubi holds a M.D. from the University of Tunis (Tunisia) and certifications in Medical Oncology from the University
of Tunis and University of Paris Sud (France) and in Clinical Research and Methodology from the University of Lariboisiere-Saint Louis (France). He is trained as a medical oncologist and is a member of the American Society of Clinical Oncology and
European Society of Medical Oncology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Yannis Morel, Ph.D.</I>, member of the Executive Board and EVP, Product Portfolio
Strategy and Business Development, joined us in 2001 and has held his current position since 2007 and was appointed as a member of our Executive Board on May&nbsp;25, 2015. He was employed in various positions in our Research and Development
Department, including immunology researcher and program manager, from 2001 to 2007. He received a Ph.D. in Oncology from <FONT STYLE="white-space:nowrap">Aix-Marseille</FONT> University (France) and a B.S. in Molecular Physical Chemistry from Ecole
Normale Sup&eacute;rieure de Cachan (France). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne</FONT> Mercier</I>, member
of the Executive Board and Chief Financial Officer, joined us in 2007, was appointed Chief Financial Officer on December&nbsp;30, 2016 and was appointed as a member of our Executive Board on January&nbsp;31, 2019. Prior to her current position,
Ms.&nbsp;Mercier served as Executive Vice President Finance and was previously our Director of Investor Relations. Prior to joining us, Ms.&nbsp;Mercier held positions as an equity analyst at Oddo Securities and Natexis Bleichroeder. She has a MSc.
(DEA) in Neurosciences from Universit&eacute; <FONT STYLE="white-space:nowrap">Aix-Marseille</FONT> (France) and a M.B.A. from ESSEC Business School (France). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Herv&eacute; Brailly, Ph.D.</I>, Chairman of the Supervisory Board, is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and chaired
our Executive Committee from the time of our founding in 1999 until we were converted into a <I>soci&eacute;t&eacute; anonyme</I> with an executive board and supervisory board on June&nbsp;13, 2005. Dr.&nbsp;Brailly served as our Chief Executive
Officer until December&nbsp;30, 2016. Prior to joining us, he spent his entire career at Immunotech SA, a biotechnology company acquired in 1995 by Beckman-Coulter, where he held various leadership positions. Dr.&nbsp;Brailly also serves as a member
of the bureau and as the treasurer of EuroBioMed association and is a <FONT STYLE="white-space:nowrap">co-founder</FONT> and Partner of Asajes Ventures (Tokyo). Dr.&nbsp;Brailly has served on the boards of directors of Deinove SA (ALDEI) since May
2017. Dr.&nbsp;Brailly received a Ph.D.&nbsp;in Immunology, with a specialization in immuno-pharmacology, from the Ecole des Mines de Paris (France). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Irina Staatz-Granzer, Ph.D.</I>, Vice Chairman and member of the Supervisory Board, has served on our Supervisory Board since 2009.
Dr.&nbsp;Staatz-Granzer has held business development positions at Hermal, Boots Healthcare International, Knoll, Scil Biomedicals and was CEO of Scil Technology Gmbh and U3 Pharma AG. She founded and is currently CEO of Staatz Business
Development&nbsp;&amp; Strategy. Dr.&nbsp;Staatz-Granzer also serves as Chairman of Talix Therapeutics NV and Blink Biomedicals SAS and as President of PLCD (German Pharma Licensing Club). Dr.&nbsp;Staaz-Granzer received a degree in pharmacy from
Philipps-Universit&auml;t Marburg (Germany) and a Ph.D. from the University of T&uuml;bingen (Germany). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Jean-Yves Blay, Ph.D.</I>,
member of the Supervisory Board, has served on our Supervisory Board since 2017. Prof. Blay has held the post of General Director of the Centre L&eacute;on B&eacute;rard in Lyon, France, since 2014 and in 2016 became Secretary of the Oncology
Commission of the French Academy of Medicine. Previously, he held the position of President of the European Organization for Research and Treatment of Cancer. Prof. Blay is a trained medical oncologist and received a Ph.D. from the University Claude
Bernard in Lyon (France). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Gilles Brisson</I>, member of the Supervisory Board, has served on our Supervisory Board since 2007 and was
the Chairman until December&nbsp;30, 2016. Mr.&nbsp;Brisson has worked in management positions at <FONT STYLE="white-space:nowrap">Rh&ocirc;ne-Poulenc</FONT> and then at Aventis Pharma, where he served as Chairman of the Executive Board, Chairman of
the Supervisory Board and Europe Manager. Mr.&nbsp;Brisson also serves as Chairman of the Supervisory Board of Ethypharm SA and Financiere Verdi III and member of the Board of Directors of LFB SA. He received a degree from Hautes Etudes Commerciales
de Paris (France).<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>V&eacute;ronique Chabernaud, M.D.</I>, member of the Supervisory Board, has served on our Supervisory Board
since 2015. Dr.&nbsp;Chabernaud is an oncologist and has worked for 20 years in the pharmaceutical industry. In particular, she was the Director of the French Oncological Operational Unit at Sanofi Aventis, a Vice President of Marketing and Sales at
Aventis Intercontinental and Europe, and Director of Oncology Global Medical Affairs at Rh&ocirc;ne Poulenc Rorer. She has also consulted with companies in France and abroad. Such companies include </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Genomic Health, BioSystems International, MaunaKea Technologies and Ariana Pharma. In 2007, Dr.&nbsp;Chabernaud founded Cr&eacute;er la Vitalit&eacute;, which helps companies and organizations in
the development of a global health approach. Dr.&nbsp;Chabernaud also founded the association &#147;Enfance et Vitalit&eacute;&#148; which offers health workshops to children. She is a graduate of ESSEC Business School (France) and has a M.D. in
Medicine, Oncology and Cancer Biology from Facult&eacute; Xavier Bichat in Paris (France). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Ma&iuml;lys Ferrere</I>, member of the
Supervisory Board, has served on our Supervisory Board since 2017 when she was appointed after being proposed by our shareholder Bpifrance. Ms.&nbsp;Ferrere has been Director of the Large Venture Investment team, Innovation Division of Bpifrance
since 2012. Previously, Ms.&nbsp;Ferrere was an Investment Director at the Strategic Investment Fund between 2009 and 2012 and served as a member of the Board of Pixium Vision and Gensight Biologics. Ms.&nbsp;Ferrere also serves as member of the
supervisory board of Valneva SE and member of the Board of DBV Technologies SA, Sequans Communications SA and Euronext Paris. She received a Bachelor degree in Business Law from Pantheon-Sorbonne University, Paris (France) and graduated from IEP
(School of Higher Education for Political Studies), France and the French Society for Financial Analysts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Patrick Langlois, Ph.D.</I>,
member of the Supervisory Board, has served on our Supervisory Board since 2010. Dr.&nbsp;Langlois has been Associate Managing Director of PJL Conseils since 2005. Dr.&nbsp;Langlois worked for the
<FONT STYLE="white-space:nowrap">Rh&ocirc;ne-Poulenc</FONT> group starting in 1975 and was appointed the Financial Director in 1997, where he served until 1999. From 2000 through 2004, he worked at Aventis. Dr.&nbsp;Langlois also serves as the
chairman of the board of directors of French company Sensorion SA and also serves as a director of Newron (Italy). He received a Ph.D. in Economics from the University of Rennes (France). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Marcus Schindler, Ph.D.</I>, member of the Supervisory Board, has served on our Supervisory Board since 2018 when he was appointed after
being proposed by our shareholder Novo Nordisk A/S. Dr.&nbsp;Schindler has been Senior Vice President and Head of Global Drug Discovery at Novo Nordisk A/S since April 2018. Dr.&nbsp;Schindler has close to 20 years of experience in leadership roles
in the pharmaceutical industry, working both in international large pharma and biotechnology companies, including Astra Zeneca (Sweden), Boehringer Ingelheim (Germany) and (OSI) Prosidion (UK). He received a Ph.D. in Pharmacology from the University
of Cambridge. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pierre Dodion, M.D.</I>, Member of the Executive Committee, Executive Vice President and Chief Medical Officer, joined us in that role in
2014. Prior to joining us, Dr.&nbsp;Dodion served as Senior Vice President, Chief Medical Officer and later as Senior Vice President of Corporate Development and Operations at Nasdaq-listed ARIAD Pharmaceuticals from 2007 until 2013. He previously
held positions at Pfizer, Novartis and Aventis. Dr.&nbsp;Dodion received a M.D. from Free University of Brussels (Belgium) and a M.B.A. from Saint Joseph University in Philadelphia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Odile Belzunce</I>, Member of the Executive Committee, Senior Vice President, Compliance, IT and Portfolio Management, was appointed as a
member of our Executive Committee on January&nbsp;31, 2019. During the ten years prior to Ms.&nbsp;Belzunce joining our Executive Committee, Ms.&nbsp;Belzunce served as our Quality Manager and Head of Compliance. Ms.&nbsp;Belzunce received a DESS
&#147;Analyse&nbsp;&amp; Qualit&eacute;&#148; from <FONT STYLE="white-space:nowrap">Aix-Marseille</FONT> University (France). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Jennifer
Butler</I>, Member of the Executive Committee, Executive Vice President and U.S. General Manager, joined us in that role in 2019. Prior to joining us, Ms.&nbsp;Butler served as Chief Business Officer, Chief Commercial Officer and Head of U.S.
Operations at Tessa Therapeutics from July 2017 until March 2019. Prior to Tessa Therapeutics, Ms.&nbsp;Butler served for more than ten years in various commercial roles with increasing responsibility at AstraZeneca and MedImmune. Ms.&nbsp;Butler
received a B.A. Biological Basis of Behavior with a concentration in the Physiology of Neural Systems from University of Pennsylvania. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fr&#233;d&#233;rique Brune</I>, Member of the Executive Committee, Vice President
Development, CMC and Supply Chain, was appointed as a member of our Executive Committee on July 1, 2019 after previously serving as our Senior Director of Development, CMC and Pharmaceutical Operations since March 2017. Prior to joining us, Ms.
Brune served as Quality Director of Bioproduction at LFB-Biotechnologies from March 2016 to March 2017. From September 2007 to March 2016, she worked as Director of Development programs as well as Interim Head Pharmacist at LFB-Biotechnologies.
Prior to LFB-Biotechnologies, Ms. Brune served in various roles and responsibilities from 2001 to 2007 at Pierre Fabre Research Institute, including as Analytical Development and Quality Control Director, Pharmacist delegate and Program Director.
Ms. Brune graduated from the faculty of Pharmacy Paris XI and holds a Master of Science in Experimental and Clinical Pharmacology from University Paris VI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eric Vivier, D.V.M., Ph.D.</I>, Permanent guest to the Executive Committee, Senior Vice President, Chief Scientific Officer, joined us in
that role in 2018. Prior to joining us, Dr.&nbsp;Vivier joined the Center of Immunology at Marseille-Luminy (CIML) in 1993, becoming its Director in 2008 until 2017. Dr.&nbsp;Vivier received a Doctor of Veterinary Medicine from Ecole Nationale
V&eacute;t&eacute;rinaire de Maisons-Alfort (France) and holds a Ph.D. in Immunology from the Paris University (Paris XI) (France). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Supervisory Board
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory Board is made up of a minimum of three members and a maximum of eighteen. The members of the Supervisory Board are
appointed for a renewable term of two years at the general meeting of shareholders. The general meeting of shareholders may revoke the appointments of the members of the Supervisory Board at any time during the meeting by a simple majority vote. The
appointees are selected by the shareholders and may be individuals or companies. Each member must own at least one of our ordinary shares for the entire term of the appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The age limit for being a member of the Supervisory Board and the limitations on holding such an appointment concurrently with an appointment
in another company are subject to the applicable legal and regulatory provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Supervisory Board in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Supervisory Board is primarily responsible for the oversight of our risk management activities and has delegated to the audit committee the
responsibility to assist our Supervisory Board in this task. While our Supervisory Board oversees our risk management, our management, through the Executive Board is responsible for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> risk management processes. Our Supervisory Board expects our management to consider risk and risk management in each business decision, to proactively develop
and monitor risk management strategies and processes for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and to effectively implement risk management strategies adopted by the Supervisory Board.
We believe this division of responsibilities is the most effective approach for addressing the risks we face. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Supervisory Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory Board has established an audit committee, a compensation and nomination committee and a transactions committee, which operate
pursuant to rules of procedure adopted by our Supervisory Board. Subject to available exemptions, the composition and functioning of all of our committees will comply with all applicable requirements of the French Commercial Code, the Exchange Act,
the Nasdaq listing rules and SEC rules and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with French law, committees of our Supervisory Board will only have
an advisory role and can only make recommendations to our Supervisory Board. As a result, decisions will be made by our Supervisory Board taking into account <FONT STYLE="white-space:nowrap">non-binding</FONT> recommendations of the relevant
Supervisory Board committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee assists our Supervisory Board in its oversight of our corporate accounting and financial reporting and oversees the
selection of our auditors, their remuneration and independence and keeps the Supervisory Board informed on control systems, key processes and procedures, security and risks. From the Supervisory Board of May&nbsp;22, 2019, the members of the audit
committee as of the date of this prospectus are Patrick Langlois, Irina Staatz-Granzer and Mailys Ferrere as representative of Bpifrance Participations. Dr.&nbsp;Langlois is the Chairman of the audit committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Supervisory Board has determined that Dr.&nbsp;Langlois and Dr.&nbsp;Staatz-Granzer are independent within the meaning of the applicable
listing rules and the independence requirements contemplated by Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. Our Supervisory Board has further determined that Dr.&nbsp;Langlois is an &#147;audit committee financial
expert&#148; as defined by the Nasdaq listing rules and that each of the members qualifies as financially sophisticated under the Nasdaq listing rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal responsibility of our audit committee is to monitor the existence and efficacy of our financial audit and risk control
procedures on an ongoing basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Supervisory Board has specifically assigned the following duties to the audit committee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legal control of the half-year and annual accounts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating internal control practices, risk analysis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">supervising the creation of the financial statements published by us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assessing accounting methods; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting statutory auditors, negotiating their fees, reviewing of their conclusions and reviewing their
independence. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee reviews and approves the report from the Chairman of the Supervisory Board on
internal control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation and Nomination Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation and nomination committee assists our Supervisory Board in reviewing and making recommendations to our Supervisory Board with
respect to the appointment and the compensation of the members of our Executive Board, Supervisory Board and Executive Committee and other key employees. In accordance with operating rules adopted by the Supervisory Board, the nomination and
compensation committee is composed of at least two members appointed by the Supervisory Board. Following the Supervisory Board on May&nbsp;22, 2019, the members of the committee are Patrick Langlois, Herv&eacute; Brailly and V&eacute;ronique
Chabernaud. Currently, Dr.&nbsp;Langlois and Dr.&nbsp;Chabernaud are independent members of the compensation and nomination committee. Dr.&nbsp;Chabernaud is the Chairman of the committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Supervisory Board has specifically assigned the following duties to the compensation and nomination committee: reviewing our remuneration
policy, in particular the description of our collective objectives (applicable company-wide) and individual objectives (for members of the Executive Board and the Executive Committee), reviewing the compensation of the members of our Executive Board
and the Executive Committee, the policy concerning the distribution of equity such as warrants, stock options, grants and capital increases reserved for members of our savings plan, examining the amount of attendance fees (<I>jetons de
pr&eacute;sence</I>) among the Supervisory Board and the committees members, assisting the Supervisory Board in the selection of the members of the Executive Board and committees, making recommendations with respect to the independence of the
members of the Supervisory Board and committees and preventing conflicts of interest within the Supervisory Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Transactions Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our transactions committee assists our Supervisory Board in examining the business and corporate development opportunities available to us,
which may include the acquisition of rights to products or the acquisition of other companies as well as <FONT STYLE="white-space:nowrap">out-licensing</FONT> opportunities. The members of this committee are Irina Staatz-Granzer, Herv&eacute;
Brailly and Marcus Schindler. Currently, Dr.&nbsp;Staatz-Granzer is an independent member and Chairman of the transactions committee. Our Supervisory Board has specifically assigned the following duties to the transactions committee: to analyze the
fundamentals of the products and/or companies targeted by us, the feasibility of targeted acquisitions and to participate in the selection of investment bankers and/or consultants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Observer to the Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Olivier Martinez is an observer to the Supervisory Board. Dr.&nbsp;Martinez is a Senior Investments Director for Bpifrance
Participations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The Strategic Advisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have a Strategic Advisory Board composed of six external consultants, consisting of three individuals from the medical community and
three individuals from the scientific community. The Strategic Advisory Board is not a committee of the Supervisory Board within the meaning of Article <FONT STYLE="white-space:nowrap">R.225-29</FONT> of the French Commercial Code; its members are
chosen by the Executive Board. This kind of advisory committee is common in French companies in the biotechnology sector. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Strategic
Advisory Board&#146;s role is to assist us in our strategic choices in scientific and technical fields. Its main missions are to evaluate the relevance of our choices in terms of product development and to propose, if necessary, changes to strategic
or technical approaches; to advise management and guide our scientific direction in identifying strategies and selecting product candidates, based, in particular, on the scientific results obtained by us, including new targets and new compounds and
to promote and advise us in our alliance strategies, such as external growth supporting synergies, including acquisition of new competences, purchase of operating rights, product candidates and innovative technologies. The Strategic Advisory Board
is comprised of Sebastian Amigorena, Aur&eacute;lien Marabelle, Ruslan Medzhitov, Miriam Merad, Tanguy Seiwert and Mario Sznol. Dr.&nbsp;Merad is the Chairman of the Strategic Advisory Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sebastian Amigorena, Ph.D.</I>, is the &#147;Directeur de Recherche de Classe Exceptionnelle&#148; at the Centre National de la Recherche
Scientifique. He also leads the Immunology Department and the newly created Cancer Immunotherapy Center at Institut Curie in Paris (France). Dr.&nbsp;Amigorena has made significant contributions to immunology and cell biology at every stage of his
career. His findings have helped advance the understanding of antigen presentation and T cell priming by dendritic cells, with applications in the fields of cancer immunotherapy and vaccination. Dr.&nbsp;Amigorena has received numerous national and
international prizes and awards, including the prestigious senior European Research Council award in 2008 and in 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Aur&eacute;lien
Marabelle, MD, Ph.D.</I>, is the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy Cancer Center in Villejuif, France. Dr.&nbsp;Marabelle&#146;s clinical practice is dedicated to early phase clinical trials in cancer
immunotherapy and his translational research is focused on mechanisms of action of immune checkpoint monoclonal antibodies. He works as a senior medical oncologist and an investigator in the Drug Development Department. He is coordinating a team
focused on cancer immunotherapy translational research projects at INSERM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Ruslan Medzhitov, Ph.D.</I>, is a Sterling Professor at
Yale University School of Medicine in New Haven, Connecticut and an Investigator of the Howard Hughes Medical Institute. His research interests include biology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of inflammation, biological bases of diseases and evolutionary design of biological systems. Dr.&nbsp;Medzhitov is a member of the National Academy of Sciences, National Academy of Medicine and
European Molecular Biology Organization. He is a fellow of the American Academy of Microbiology and a foreign member of the Russian Academy of Sciences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Miriam Merad, M.D., Ph.D.</I>, is the Mount Sinai Chair professor in Cancer Immunology and the Director of the Precision Immunology
Institute at Mount Sinai School of Medicine in New York. Dr.&nbsp;Merad&#146;s laboratory studies the contribution of macrophages and dendritic cells to Cancer and Inflammatory diseases in mice and humans. She has shown that tissue macrophages have
unique functional attributes that contribute to tumor outcome and response to treatment. Dr.&nbsp;Merad pioneered mapping the regulatory network of dendritic cells resulting in the identification of a lineage of dendritic cells, the CD103+ DC, that
is now considered to be a key target to improve antiviral and antitumor immunity. Dr.&nbsp;Merad receives generous funding from the National Institutes of Health, or NIH, for her research on innate immunity and their contribution to human disease
and belongs to several NIH consortia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Tanguy Seiwert, M.D.</I>, is Assistant Professor of Medicine, Section of Hematology and Oncology
in the Department of Medicine at the University of Chicago. Dr.&nbsp;Seiwert&#146;s research focuses on the biology of head and neck cancer and lung cancer. In the laboratory, he studies targeted therapies that disrupt specific pathways vital to
cancer growth and metastasis. More specifically, he focuses on which novel drugs appear most promising, which individual tumors are more likely to respond to these treatments and how to successfully combine therapies. Dr.&nbsp;Seiwert uses this
preclinical knowledge to develop new treatments for use in clinical trials, and to ultimately improve patient care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mario Sznol,
M.D.</I>, is a Professor of Medicine, Leader, Melanoma/RCC Disease-Associated Research Team, and <FONT STYLE="white-space:nowrap">co-leader,</FONT> Cancer Immunology Program at the Yale Cancer Center in New Haven, Connecticut. Recently, he was
appointed the incoming President of the Society for Immunotherapy of Cancer. Dr.&nbsp;Sznol&#146;s interests include cancer immunotherapy, drug development for cancer and treatment of patients with melanoma and renal cell carcinoma. After completing
a fellowship in medical oncology at Mount Sinai College of Medicine in New York in 1987, he joined the National Cancer Institute, or NCI, as a Senior Investigator in the Investigational Drug Branch, or IDB, Cancer Therapy Evaluation Program, or
CTEP. He was Head of the Biologics Evaluation Program, IDB, CTEP, from 1994 to 1999, and in 1999, was appointed Vice President of Clinical Development for Vion Pharmaceuticals in New Haven, Connecticut. He joined the Yale faculty in medical oncology
in 2004. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Executive Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have an Executive Committee composed of members with significant experience in strategy, financial management, medical research,
research and development project management, the negotiation of industrial and commercial agreements in the field of innovative companies, including biotechnology companies, compliance and regulations and in business development. The Executive
Committee meets at least once a month and deals with all subject regarding the activities and the management of the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current
members of the Executive Committee are Mondher Majoubi, Yannis Morel, Laure-H&eacute;l&egrave;ne Mercier, Pierre Dodion, Odile Belzunce, Jennifer Butler and Fr&eacute;d&eacute;rique Brune. Eric Vivier, our Senior Vice President, Chief Scientific
Officer, is a permanent guest to the meetings of the Executive Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance Practices </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a French <I>soci&eacute;t&eacute; anonyme</I>, we are subject to various corporate governance requirements under French law. We are a
&#147;foreign private issuer&#148; under the U.S. federal securities laws and the Nasdaq listing rules. The foreign private issuer exemption will permit us to follow home country corporate governance practices instead of certain Nasdaq listing
requirements. A foreign private issuer that elects to follow a home country practice instead </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Nasdaq listing requirements must submit to Nasdaq a written statement from an independent counsel in such issuer&#146;s home country certifying that the issuer&#146;s practices are not
prohibited by the home country&#146;s laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We apply the AFEP/MEDEF code, which recommends that a majority of the members of the
Supervisory Board be independent (as such term is defined under the code). Neither the corporate laws of France nor our bylaws requires that (i)&nbsp;our compensation committee include only independent members of the Supervisory Board,
(ii)&nbsp;each committee of the Supervisory Board have a formal written charter or (iii)&nbsp;our independent members of the Supervisory Board hold regularly scheduled meetings at which only independent members of the Supervisory Board are present.
We intend to follow French corporate governance practices in lieu of Nasdaq listing requirements for each of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
exemptions do not modify the independence requirements for the audit committee, and we intend to comply with the requirements of the Sarbanes-Oxley Act and the Nasdaq listing rules, which require that our audit committee be composed of at least
three independent members. Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act provides that the audit committee must have direct responsibility for the nomination, compensation and choice of our auditors, as well as control
over the performance of their duties, management of complaints made, and selection of consultants. Under Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> if the laws of a foreign private issuer&#146;s home country require that any such matter be
approved by the board of directors or the shareholders of the Company, the audit committee&#146;s responsibilities or powers with respect to such matter may instead be advisory. Under French law, the audit committee may only have an advisory role
and appointment of our statutory auditors, in particular, must be decided by our shareholders at our annual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Nasdaq
rules require that a listed company specify that the quorum for any meeting of the holders of share capital be at least 33 1/3% of the outstanding shares of the company&#146;s ordinary voting shares. We intend to follow our French home country
practice, rather than complying with this Nasdaq rule. Consistent with French Law, our bylaws provide that when first convened, general meetings of shareholders may validly convene only if the shareholders present or represented hold at least (1)
20% of the voting shares in the case of an ordinary general meeting or of an extraordinary general meeting where shareholders are voting on a capital increase by capitalization of reserves, profits or share premium, or (2) 25% of the voting shares
in the case of any other extraordinary general meeting. If such quorum required by French law is not met, the meeting is adjourned. There is no quorum requirement under French law when an ordinary general meeting or an extraordinary general meeting
is reconvened where shareholders are voting on a capital increase by capitalization of reserves, profits or share premium, but the reconvened meeting may consider only questions that were on the agenda of the adjourned meeting. When any other
extraordinary general meeting is reconvened, the required quorum under French law is 20% of the shares entitled to vote. If a quorum is not met at a reconvened meeting requiring a quorum, then the meeting may be adjourned for a maximum of two
months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
adopted a Code of Ethics applicable to all of our employees and members of our Executive Board and Supervisory Board. Following the completion of this global offering, the Code of Ethics will be available on our website. We expect that any
amendments to the Code of Ethics, or any waivers of its requirements, will be disclosed on our website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the members of our Executive Board and Supervisory Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation of Members of the Executive and Supervisory Boards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the entry into force of the Sapin 2 Law (French law no. 2016-1691 of December 9, 2016), the payment of any variable or exceptional
compensation attributed for a financial year to the Chairman of the Supervisory Board, the Chairman of the Executive Board and members of the Executive Board, is subject to approval at the next ordinary general meeting (ex-post vote). The payments
of the below variable compensations, for the year ending December 31, 2018, were approved by the ordinary and extraordinary shareholder meeting held on May 22, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of Members of the Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Attendance Fees </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
pay attendance fees to the members of the Supervisory Board, except for the permanent representatives of Novo Nordisk A/S and Bpifrance Participations and the Chairman of the Supervisory Board. At our general meeting of shareholders held on
May&nbsp;29, 2018, shareholders set the total attendance fees to be distributed among the members of the Supervisory Board at &#128;200,000. The attendance fees consist of a fixed portion and a variable portion based on attendance at meetings of the
Supervisory Board and its committees. The following table shows the framework for our attendance fees for the year ended December&nbsp;31, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Member Role</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attendance&nbsp;Fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fixed Portion</B> (annual fee)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Supervisory&nbsp;Board&nbsp;Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Supervisory Board Member</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&#128;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Variable Portion</B> (attendance fee at
each<BR>meeting of the Supervisory Board)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Committee Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Other&nbsp;Members&nbsp;of&nbsp;the&nbsp;Supervisory&nbsp;Board</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&#128;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Variable Portion</B> (attendance fee at each<BR>meeting of a committee of the
Supervisory Board)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Committee Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Other Committee Members</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the attendance fees earned by members of the Supervisory
Board during the year ended December&nbsp;31, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Member</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attendance&nbsp;Fees</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilles Brisson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">43,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Langlois</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">43,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Irina Staatz-Granzer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">28,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">V&eacute;ronique Chabernaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">28,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Yves Blay</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our general meeting of shareholders held on May&nbsp;22, 2019, shareholders set the total attendance fees
to be distributed among the members of the Supervisory Board at &#128;240,000. The following table shows the framework for our attendance fees for the year ending December&nbsp;31, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Member Role</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Attendance&nbsp;Fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fixed Portion</B> (annual fee)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Supervisory Board Member</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&#128;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Variable Portion</B> (attendance fee at
each meeting of the Supervisory Board)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Supervisory Board Chairman and Committee Chairman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Other Members of the Supervisory Board</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&#128;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"> 2,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Variable Portion</B> (attendance fee at each meeting of a committee of the
Supervisory Board)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Committee Chairman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Other Committee Members</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Chairman Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2016, the Supervisory Board decided that Herv&eacute; Brailly, the Chairman of the Supervisory Board, would receive
specific compensation pursuant to article <FONT STYLE="white-space:nowrap">L.225-84</FONT> of the French Commercial Code for his duties as Chairman of the Supervisory Board. During the year ended December&nbsp;31, 2018, we paid Mr.&nbsp;Brailly
&#128;50,000 as specific compensation for his performance of these duties. The Supervisory Board of January&nbsp;31, 2019 decided to increase the fixed compensation of Mr.&nbsp;Brailly by &#128;50,000 to a total of &#128;100,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on December&nbsp;14, 2016, we entrusted Mr.&nbsp;Brailly with a specific
mission pursuant to article <FONT STYLE="white-space:nowrap">L.225-84</FONT> of the French Commercial Code. This mission, renewed by the Supervisory Board on December&nbsp;13, 2017, consists of ensuring the transition to our new executive team and
providing strategic advice. This agreement expired on December 31, 2018. During the year ended December&nbsp;31, 2018, we paid Mr.&nbsp;Brailly &#128;100,000 for his performance of these additional duties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with Jean-Yves Blay </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;14, 2018, we entrusted Jean-Yves Blay, a member of our Supervisory Board, with a specific mission pursuant to article <FONT
STYLE="white-space:nowrap">L.225-84</FONT> of the French Commercial Code. Based on Mr.&nbsp;Blay&#146;s scientific and medical qualifications, we have agreed that he will attend meetings of our Strategic Advisory Board consisting of at least one
meeting that he attends <FONT STYLE="white-space:nowrap">in-person</FONT> and approximately two conference calls per year. Mr.&nbsp;Blay will participate in these Strategic Advisory Board meetings and then present a report to the Supervisory Board,
at least once a year, on his opinions of the Strategic Advisory Board&#146;s proceedings. This agreement will remain in place for the duration of Mr.&nbsp;Blay&#146;s term of office as a member of the Supervisory Board, including any renewal terms.
We have agreed to pay Mr.&nbsp;Blay &#128;10,000 in compensation for his performance of these additional duties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of
Members of the Executive Board </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Framework for Executive Board Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, the Executive Board consisted of Mondher Mahjoubi and Yannis Morel. Dr.&nbsp;Mahjoubi served as
Chairman of the Executive Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation of members of the Executive Board is decided by the Supervisory Board upon
recommendation by the compensation and nomination committee. The compensation of Dr.&nbsp;Mahjoubi, the Chairman of the Executive Board, is paid under his social mandate, whereas the compensation of Dr.&nbsp;Morel is paid under his employment
contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation of members of the Executive Board includes the following components: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fixed Compensation</I>. The members of the Executive Board receive fixed compensation pursuant to their
employment agreement or, in the case of the Chairman, his social mandate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Annual Variable Compensation</I>. The members of the Executive Board are eligible to receive annual variable
compensation upon the recommendation of the compensation and nomination committee based on the achievement of <FONT STYLE="white-space:nowrap">pre-specified</FONT> objectives. For the year ended December&nbsp;31, 2018, such objectives were
Scientific Leadership, Financial Discipline, Organization Readiness and Great Place to Work, which were divided for each member of the Executive Board into <FONT STYLE="white-space:nowrap">sub-criteria</FONT> with an achievement percentage. The
members of the Executive Board are able to opt to receive a portion of their annual variable compensation in the form of free shares, increased by a 30% premium. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Performance Free Shares</I>. The members of the Executive Board are able to receive, upon authorization of the
Supervisory Board and upon recommendation of the compensation and nomination committee, equity compensation in the form of performance free shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Other Benefits</I>. The members of the Executive Board receive other benefits consisting of a supplementary
pension plan, <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits and, for the Chairman of the Executive Board, unemployment insurance. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 Compensation of Mondher Mahjoubi </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the compensation earned by Dr.&nbsp;Mahjoubi during the year ended December&nbsp;31, 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="54%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Type of Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount of<BR>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;</TD>
<TD VALIGN="top" ALIGN="right">470,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gross fixed compensation pursuant to Dr.&nbsp;Mahjoubi&#146;s social mandate.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Variable Compensation&#151;<I>Cash </I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#128;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">155,100</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">This amount represents 50% of Dr.&nbsp;Mahjoubi&#146;s annual variable compensation, based on his achievement of 100% of the annual
objectives increased by 5% over-performance. Dr.&nbsp;Mahjoubi elected to receive the other 50% of his variable compensation in the form of free shares.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Variable Compensation&#151;<I>Free Shares</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#128;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">269,152</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Mahjoubi opted for the payment of 50% of his annual variable compensation in free shares, increased by a 30% premium. The
Executive Board of July 3, 2018 attributed 36,225 free shares (AGA Bonus 2018) to Dr.&nbsp;Mahjoubi. The number of free shares was calculated on the basis of the weighted-average price per ordinary share for the 20 trading days preceding July 3,
2018, amounting to &#128;5.06 per share. These 36,225 free shares are valued at &#128;269,152 on the basis of the stock price on December 31, 2018, or &#128;7.43 per ordinary share.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Variable Compensation&#151;<I>Exceptional Premium</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#128;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">116,129</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Supervisory Board granted this amount as an exceptional premium to Dr.&nbsp;Mahjoubi based on his crucial role during the
company&#146;s development collaboration with AstraZeneca in October 2018.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance Free Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;</TD>
<TD VALIGN="top" ALIGN="right">233,100</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">This amount was calculated in accordance with the IFRS&nbsp;2 valuation of the grant to Dr.&nbsp;Mahjoubi of 70,000 performance free shares.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits in Kind</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;</TD>
<TD VALIGN="top" ALIGN="right">21,302</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Primarily represents amounts paid for unemployment insurance and use of a company car, among other benefits.</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"><B>&#128;</B></TD>
<TD VALIGN="middle" ALIGN="right"><B>1,264,783</B></TD>
<TD NOWRAP VALIGN="middle"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 Compensation of Yannis Morel </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the compensation earned by Dr.&nbsp;Morel during the year ended December&nbsp;31, 2018: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="54%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Type of Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount of<BR>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;</TD>
<TD VALIGN="top" ALIGN="right">216,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Gross fixed compensation pursuant to Dr.&nbsp;Morel&#146;s employment contract.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Variable Compensation&#151;<I>Cash </I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#128;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">35,510</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">This amount represents 50% of Dr.&nbsp;Morel&#146;s annual variable compensation, based on his achievement of 100% of the annual
objectives increased by 4.8% over-performance. Dr.&nbsp;Morel elected to receive the other 50% of his variable compensation in the form of free shares.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Variable Compensation&#151;<I>Free Shares</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#128;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">61,847</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Morel opted for the payment of 50% of his annual variable compensation in free shares, increased by a 30% premium. The Executive
Board of July 3, 2018 attributed 8,324 free shares (AGA Bonus 2018) to Dr. Morel. The number of free shares was calculated on the basis of the weighted-average price per ordinary share for the 20 trading days preceding July 3, 2018, amounting to
&#128;5.06 per share. These 8,324 free shares are valued at &#128;61,847 on the basis of the stock price on December 31, 2018, or &#128;7.43 per ordinary share.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Variable Compensation&#151;<I>Exceptional Premium</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#128;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">27,450</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Supervisory Board granted this amount as an exceptional premium to Dr.&nbsp;Morel based on his crucial role during the company&#146;s
development collaboration with AstraZeneca in October 2018.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance Free Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;</TD>
<TD VALIGN="top" ALIGN="right">166,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">This amount was calculated in accordance with the IFRS&nbsp;2 valuation of the grant to Dr.&nbsp;Morel of 50,000 performance free shares.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits in Kind</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;</TD>
<TD VALIGN="top" ALIGN="right">3,922</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Primarily represents amounts paid for use of a company car, among other benefits.</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"><B>&#128;</B></TD>
<TD VALIGN="middle" ALIGN="right"><B>511,229</B></TD>
<TD NOWRAP VALIGN="middle"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2019 Executive Board Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our general meeting of shareholders held on May&nbsp;22, 2019, shareholders approved the compensation of the members of the Executive Board
set forth in the following table for the year ending December&nbsp;31, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Type of Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Mondher&nbsp;Mahjoubi</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Yannis&nbsp;Morel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne&nbsp;Mercier</FONT><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">216,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maximum Annual Variable Compensation if 100% of the objectives are reached<I> </I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">282,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">64,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">54,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maximum Annual Variable Compensation if case of over-performance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">352,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">82,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">68,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne</FONT> Mercier was appointed as a member of the Executive Board on January&nbsp;31, 2019. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The variable compensation for the year ending December&nbsp;31, 2019 is based on the achievement of the following <FONT
STYLE="white-space:nowrap">pre-specified</FONT> objectives, which are divided for each member of the Executive Board into <FONT STYLE="white-space:nowrap">sub-criteria</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with an achievement percentage: Scientific Leadership, Finance, Commercial Performance, Preparation and Adequacy of the Organization and Great Place to Work. Members of the Executive Board may
opt for the payment of 50% of their annual variable compensation in free shares, in which case it will be increased by a 30% premium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
our general meeting of shareholders held on May&nbsp;22, 2019, shareholders also approved the allocation of free performance shares subject to stock market value and internal conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, provisions of bylaws that limit the liability of the members of Executive and Supervisory Boards are prohibited. However,
French law allows <I>soci&eacute;t&eacute;s anonymes</I> to contract for and maintain liability insurance against civil liabilities incurred by members of Executive and Supervisory Boards involved in a third-party action, provided that they acted in
good faith and within their capacities as members of such board of the company. Criminal liability cannot be indemnified under French law, whether directly by the company or through liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have liability insurance for our Executive and Supervisory Board members, and intend to obtain insurance coverage for liability under the
Securities Act. We also intend to enter into agreements with our Executive and Supervisory Board members to provide contractual indemnification. With certain exceptions and subject to limitations on indemnification under French law, these agreements
will provide for indemnification for damages and expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding arising out of his or her actions
in that capacity. We believe that this insurance and these agreements are necessary to attract qualified Executive and Supervisory Board members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These agreements may discourage shareholders from bringing a lawsuit against our Executive and Supervisory Board members for breach of their
fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against our Executive and Supervisory Board members, even though such an action, if successful, might otherwise benefit us and our
shareholders. Furthermore, a shareholder&#146;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against our Executive and Supervisory Board members pursuant to these insurance agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentives </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our ability
to grant equity incentives is a valuable and necessary compensation tool that allows us to attract and retain the best personnel for positions of substantial responsibility, provides additional incentives to employees and promotes the success of our
business. Due to French corporate law and tax considerations, we have historically granted several different equity incentive instruments to our Executive Board and Supervisory Board members, employees and consultants, including (i)&nbsp;BSAs, which
have historically only been granted to independent members of the Supervisory Board and consultants, (ii)&nbsp;BSAARs and (iii)&nbsp;free shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Executive Board&#146;s authority to grant these warrants and free shares and the aggregate amount authorized to be granted must be
approved by a majority of the shareholders present at the relevant extraordinary shareholders&#146; meeting. Once approved by our shareholders, our Executive Board can continue to grant such awards for a specified period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have various compensation plans for our Executive Board members, Supervisory Board members, employees and consultants that have been
approved by our shareholders. The last allocation in 2015 of BSAARs no longer continue to vest following termination of the employment, office or service of the holder within the first two years and all vested warrants must be exercised within
post-termination exercise periods set forth in the grant documents. In the event of certain changes in our share capital structure, such as a consolidation or share split or dividend, French law and applicable grant documentation provides for
appropriate adjustments of the numbers of ordinary shares issuable and/or the exercise price of the outstanding warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2019, we had the following equity awards, warrants and free shares
outstanding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of share warrants (BSA) outstanding as of June 30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of redeemable share warrants (BSAAR) outstanding as of June 30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2017) outstanding as of June 30, 2019 assuming all related performance conditions are met; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
vesting of free shares (AGA) outstanding as of June 30, 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2016) as of June&nbsp;30, 2019, assuming all performance conditions are met. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Equity Warrants and Redeemable Share Subscription Warrants </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Share Warrants (BSA) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share warrants, or BSA, are granted at a <I>de minimis</I> price and entitle the holder of one BSA to exercise the warrant for one underlying
share, at an exercise price per share determined by our Executive Board at the time of grant by reference to the then prevailing share price. We have granted BSA to Supervisory Board members and certain consultants of the Company. Our share warrants
plans include provisions that allow for the adjustment of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> exercise ratio to compensate for certain modifications of our share capital, such as rights
issues, stock splits, mergers and other events affecting all existing shareholders. None of those events have occurred yet. Our BSA have an exercise period of 10 years &#150; BSA not exercised after that time lapse and are automatically cancelled.
Our share warrants cannot be sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the BSA outstanding as of June&nbsp;30, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Plan title</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA 2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA <FONT STYLE="white-space:nowrap">2015-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA <FONT STYLE="white-space:nowrap">2015-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA 2017</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">General assembly meeting date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;29,&nbsp;2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;28,&nbsp;2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;27,&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;27,&nbsp;2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;27,&nbsp;2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,&nbsp;2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Date of grant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;29, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;17, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;16, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;27, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;1, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;20,&nbsp;2017</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total number of BSA authorized</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">350,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">300,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">150,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">150,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">25,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">150,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total number of BSA granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">225,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">237,500</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">150,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">70,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14,200</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">37,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Start date of the exercise period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;29, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;17, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;16, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;27, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;1, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;20,&nbsp;2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">End date of the exercise period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;29, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;17, 2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;16, 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;26, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;30, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;20,&nbsp;2027</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise price per BSA/share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;1.77</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;2.36</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;8.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;9.59</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;14.05</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;11</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Number of BSA exercised as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">BSA cancelled or lapsed as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">BSA remaining as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Share Warrants (BSAAR) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Redeemable share warrants, or BSAAR, are identical to our share warrants of BSA (including the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> exercise ratio, its potential adjustment for certain modifications of our share capital and the exercise period of 10 years), except for the following features: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BSAAR are initially purchased by the beneficiary at their fair value, as determined by an expert, and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the BSAAR plans include a &#147;forcing&#148; clause making it possible to encourage holders to exercise their
BSAAR when the market price exceeds the exercise price and reaches a threshold defined in the BSAAR plan. We can then, subject to a time period for notifying the holders that will permit them to exercise their BSAAR, decide to purchase the
unexercised BSAAR at a unit price equal to the BSAAR acquisition price initially paid by its holder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our redeemable
share warrants cannot be sold. Our BSAAR have been granted to certain of our executive officers and employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows
the BSAAR outstanding as of June&nbsp;30, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Plan title</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSAAR 2011</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSAAR 2012</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSAAR 2015</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General assembly meeting date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;29, 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;28,&nbsp;2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;27,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;9,&nbsp;2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;27, 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;1, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of BSAAR granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">650,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">146,050</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,050,382</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Start date of the exercise period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;9, 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;27, 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;1, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">End date of the exercise period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;9, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;27, 2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;30, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAAR initial purchase price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;0.05</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;0.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;1.15</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price per BSAAR/share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;2.04</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;2.04</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;7.20</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of BSAAR exercised as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAAR cancelled or lapsed as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAAR remaining as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Free Shares (AGA) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Free shares, or AGA, are employee equity incentive instruments pursuant to which the beneficiaries are granted, for free, the possibility to
receive our ordinary shares under certain conditions. Upon grant by our Executive Board, the AGA are subject to an acquisition, or vesting, period of at least one year. At the end of this period, the free shares vest and the beneficiary becomes a
full shareholder. However, if the vesting period is less than a certain period set by law of currently two years (but three years under previous law), it must be followed by a <FONT STYLE="white-space:nowrap">lock-up</FONT> period, so that the sum
of the two periods is equal to a minimum total period also set by law of currently two years (but three years under previous law). Vesting can be conditional or not. The vesting of all or our AGA is subject to a presence condition at the end of the
vesting period. Some of our AGA are also subject to performance conditions. Over the years, we have established several AGA plans, for all of our employees or for management only, sometimes as a &#147;welcome package&#148; (with no performance
conditions). Our free share plans include provisions that allow for the adjustment of the number of ordinary shares to which a beneficiary is entitled at the end of the vesting period to compensate for certain modifications of our share capital,
such as rights issues, stock splits, mergers and other events affecting all existing shareholders, during the vesting period. Certain of our plans also provide for an accelerated vesting in case of a tender offer on the Company during the vesting
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One particular AGA plan, the &#147;AGA Bonus,&#148; entitles our management to opt for the payment of up to 50% of their annual
variable compensation in free shares. Those who take this option benefit from a matching compensation equal to 30% of the corresponding portion of the annual variable compensation, also payable in free shares. The AGA Bonus are subject to the same
performance conditions, after a <FONT STYLE="white-space:nowrap">one-year</FONT> vesting period, as the annual variable compensation. The number of AGA Bonus is determined by dividing the euro amount of the annual variable compensation for which the
election is made and of the matching contribution, by an average of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the trading price of our shares. Once vested, the AGA Bonus are subject to the minimum <FONT STYLE="white-space:nowrap">one-year</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the AGAs outstanding as of June&nbsp;30, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom" NOWRAP><B>Plan title</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Employees<BR><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Employees<BR><FONT STYLE="white-space:nowrap">2016-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA Bonus<BR><FONT STYLE="white-space:nowrap">2017-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Employees<BR><FONT STYLE="white-space:nowrap">2017-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>New<BR>Members<BR><FONT STYLE="white-space:nowrap">2017-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Bonus<BR><FONT STYLE="white-space:nowrap">2018-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Employees<BR><FONT STYLE="white-space:nowrap">2018-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA Perf<BR>Employees<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA Perf<BR>Management<BR>2018</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">General assembly meeting date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;23,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;23,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;23,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;29,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;29,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;29,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;29,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">2018</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Date of grant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October&nbsp;21,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October&nbsp;21,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;30,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;30,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;30,<BR>2017<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;3,<BR>2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;29,<BR>2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;3,<BR>2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">January&nbsp;14,<BR>2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">November&nbsp;20,<BR>2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">November&nbsp;20,<BR>2018</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Vesting Period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Lock-up</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Performance Conditions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Number of AGA granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">50,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">99,932</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">250,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">149,943</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">28,556</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">114,500</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">25,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">67,028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">90,650</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">327,500</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">260,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Number of AGA vested as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Number of AGA lapsed as of June&nbsp;30,
2019<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Number of AGA remaining to be vested as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The annual variable compensation performance conditions are determined on or about the beginning of the fiscal year and executives make their election at about that time. However, because we need the shareholders&#146;
vote on the total number of free shares available for granting AGA Bonus (like all other free shares), we wait until our annual shareholders meeting (generally during the second half of the second quarter of the year) to grant the AGA
Bonus&nbsp;&#150; hence a granting, vesting and <FONT STYLE="white-space:nowrap">lock-up</FONT> calendar different from that of the payment of the annual variable compensation, which takes place towards the end of the fiscal year or at the beginning
of the next fiscal year. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Usually after the end of the vesting period, the Executive Board will convene and acknowledge the number of free shares that have vested and the number of those that have not because the presence condition and, as
applicable, the performance conditions, have not been met. For the purpose of computing the amount of share-based compensation in our consolidated financial statements, AGA that have lapsed because the presence condition has not been met, are
excluded from the computation, even though the Executive Board has not met yet and formally acknowledged this fact. As a result, certain of the numbers above are different from those in our consolidated financial statements. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general assembly held on May&nbsp;22, 2019 authorized the allocation of (i)&nbsp;up to 50,000 free shares without performance conditions
to the benefit of new executives (employees and/or executive officers), (ii)&nbsp;up to 75,000 free shares to the benefit of employed members of the Executive Committee, employed senior executives and/or corporate officers (AGA Bonus), (iii)&nbsp;up
to 400,000 free shares with performance conditions to the benefit of executive officers, employed members of the Executive Committee, employed senior executives and/or corporate officers and (iv)&nbsp;up to 675,000 free shares with performance
conditions to the benefit of employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Free Preferred Shares (AGAP) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Free preferred shares, or AGAP, are another employee equity incentive instrument similar to the free shares or AGA, except that, after a <FONT
STYLE="white-space:nowrap">one-year</FONT> vesting period, the beneficiaries receive a preferred shares (shares B) which will become convertible into ordinary shares following a <FONT STYLE="white-space:nowrap">lock-up</FONT> period of two
additional years, if the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
performance conditions (and a presence condition) are met at the end of this <FONT STYLE="white-space:nowrap">lock-up</FONT> period. Each free preferred share is convertible into a number of our
ordinary shares &#150; which number depends upon the degree of fulfilment of the performance conditions. The free preferred shares remain convertible into ordinary shares for a period of six years and six months. Free preferred shares not converted
at the end of this conversion period can be repurchased by us and cancelled. Our AGAP cannot be sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established several AGAP
plans in 2016 and 2017 for all of our employees or for management only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the acquisition and
<FONT STYLE="white-space:nowrap">lock-up</FONT> periods, beneficiaries of the 2016 AGAP are not entitled to vote at our shareholders&#146; meetings, to dividends or to preferential subscription rights. On the contrary, during the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, beneficiaries of the 2017 AGAP are entitled to vote at our shareholders&#146; meetings, to dividends and to preferential subscription rights, as if they held the same number of ordinary shares as
their number of vested AGAP. After the end of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, holders of all of our AGAP that have not yet converted them into our ordinary shares, are entitled to vote at our shareholders&#146; meetings,
to dividends and to preferential subscription rights, on the basis of the number of ordinary shares to which they are entitled if they convert their AGAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our free preferred share plans include provisions that allow for the adjustment of the number of ordinary shares to which a beneficiary is
entitled upon conversion of his or her AGAP at the end of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, to compensate for certain modifications of our share capital, such as rights issues, stock splits, mergers and other events
affecting all existing shareholders. The 2017 AGAP plan provides for an accelerated vesting with a waiver of the performance conditions in case of a tender offer on the Company during the vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the AGAPs outstanding as of June&nbsp;30, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Plan title</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP Management<BR><FONT STYLE="white-space:nowrap">2016-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP Employees<BR><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Management<BR>2017-1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Employees<BR>2017-1</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">General assembly meeting date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,&nbsp;2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;2,&nbsp;2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;23,&nbsp;2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;23,&nbsp;2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Date of grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October&nbsp;21,&nbsp;2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;30,&nbsp;2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October&nbsp;21,&nbsp;2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;3, 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;3, 2018</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Number of AGAP granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,486</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,400</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5,725</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Maximum number of ordinary shares into which each AGAP can be converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">100</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">100</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Number of AGAP vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,550</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,381</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5,581</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Number of AGAP lapsed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">450</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">105</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">400</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">144</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Since January&nbsp;1, 2016, we have engaged in the following transactions with members of our Executive and Supervisory Boards and holders
of more than 5% of our outstanding voting securities, and their respective affiliates, which we refer to as our related parties. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transactions With
Our Principal Shareholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2015, we entered into two agreements with MedImmune, a wholly owned subsidiary of AstraZeneca, which we refer to as AstraZeneca. The
first agreement was a <FONT STYLE="white-space:nowrap">co-development</FONT> and license agreement relating to certain combination products containing monalizumab, or the Original <FONT STYLE="white-space:nowrap">Co-Development</FONT> Agreement, and
the second agreement was a development and option agreement for products containing monalizumab, including products using monalizumab as a monotherapy, or the 2015 Option Agreement. In October 2018, AstraZeneca exercised its option under the 2015
Option Agreement, which resulted in the automatic termination of both of the Original <FONT STYLE="white-space:nowrap">Co-Development</FONT> Agreement and the 2015 Option Agreement, and a new <FONT STYLE="white-space:nowrap">co-development</FONT>
and license agreement relating to all products containing monalizumab, or the 2015 <FONT STYLE="white-space:nowrap">Co-Development</FONT> Agreement, automatically came into effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we entered into additional agreements with AstraZeneca. The first agreement is a collaboration and option agreement relating
to IPH5201, or the 2018 CD39 Option Agreement. The second agreement is an option agreement relating to four preclinical programs, which we refer to as the 2018 Future Programs Option Agreement. On October&nbsp;25, 2018, we issued an aggregate of
6,260,500 ordinary shares to MedImmune Limited, at a purchase price of &#128;10.00 per share, pursuant to an equity investment agreement. As in connection with this agreement, AstraZeneca agreed to a five-year standstill, which can be waived by us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Business&#151;Our Strategic Collaborations and License Agreements&#151;AstraZeneca&#148; for more detailed information about
our agreements with AstraZeneca. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Novo Nordisk A/S </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have entered into several agreements with Novo Nordisk A/S, including as described in detail in &#147;Business&#151;Our
Strategic Collaborations and License Agreements&#151;Additional agreements related to Monalizumab&#151;Novo Nordisk A/S&#148; and &#147;Business&#151;Our Strategic Collaborations and License Agreements&#151;License Agreement with Novo Nordisk for
IPH5401.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>AstraZeneca <FONT STYLE="white-space:nowrap">Co-Development</FONT> Agreement Payment Resolution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, we and Novo Nordisk A/S agreed on the amounts owed by us to Novo Nordisk A/S as a result of the
<FONT STYLE="white-space:nowrap">co-development</FONT> agreement entered into with AstraZeneca in April 2015. Under such agreement, we paid to Novo Nordisk A/S &#128;6,500,000. In addition, we agreed that if AstraZeneca pays us the $100,000,000
pursuant to the exercise of its licensing option, we would pay an additional $15,000,000 to Novo Nordisk&nbsp;A/S. This $15,000,000 was paid to Novo Nordisk A/S in February 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contribution In Kind Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2017, we entered into a contribution in kind agreement with Novo Nordisk&nbsp;A/S under which Novo Nordisk A/S agreed to transfer
shares to us by way of contribution, which contribution relates to all the shares held by Novo Nordisk A/S in a company named NN&nbsp;C5aR&nbsp;S.A.S, set up for the purpose of acquiring the exclusive development and commercial rights in the
anti-C5aR antibody by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the transaction described above, we entered into the following agreements
with Novo Nordisk A/S: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exclusive license agreement dated July&nbsp;4, 2017; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Side letter dated June&nbsp;23, 2017 pursuant to which we and Novo Nordisk A/S agreed on the transaction terms
and the payment by us of specified external advisory costs and other costs relating to the manufacturing of a first batch; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An indemnity agreement dated July&nbsp;13, 2017, relating to the reimbursement of certain tax credits.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arrangements with the Members of our Executive and Supervisory Boards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Director and Executive Officer Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Management&#151;Compensation of Members of the Executive and Supervisory Boards&#148; for information regarding compensation of the
members of our Supervisory and Executive Boards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with Jean-Yves Blay </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;14, 2018, we entrusted Jean-Yves Blay, a member of our Supervisory Board, with a specific mission pursuant to article <FONT
STYLE="white-space:nowrap">L.225-84</FONT> of the French Commercial Code. Based on Mr.&nbsp;Blay&#146;s scientific and medical qualifications, we have agreed that he will attend meetings of our Strategic Advisory Board consisting of at least one
meeting that he attends <FONT STYLE="white-space:nowrap">in-person</FONT> and approximately two conference calls per year. Mr.&nbsp;Blay will participate in these Strategic Advisory Board meetings and then present a report to the Supervisory Board,
at least once a year, on his opinions of the Strategic Advisory Board&#146;s proceedings. This agreement will remain in place for the duration of Mr.&nbsp;Blay&#146;s term of office as a member of the Supervisory Board, including any renewal terms.
We have agreed to pay Mr.&nbsp;Blay &#128;10,000 in compensation for his performance of these additional duties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with
Herv&eacute; Brailly </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2016, we entrusted Mr.&nbsp;Brailly with a specific mission pursuant to article <FONT
STYLE="white-space:nowrap">L.225-84</FONT> of the French Commercial Code. This mission, renewed by the Supervisory Board on December&nbsp;13, 2017, consists of ensuring the transition to our new executive team and providing strategic advice. This
agreement expired on December&nbsp;31, 2018. During the year ended December&nbsp;31, 2018, we paid Mr.&nbsp;Brailly &#128;100,000 for his performance of these additional duties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this global offering, we intend to enter into indemnification agreements with each of our Executive Board and Supervisory
Board members. See the section of this prospectus titled &#147;Management&#151;Limitations on Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us
pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction with Related Companies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From
time to time, in the ordinary course of our business, we may contract for services from companies or institutions in which certain members of our Executive Board or Supervisory Board may serve as a director or advisor. The cost and provision of
these services are negotiated on an arms-length basis and none of these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person Transaction Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We comply with French law regarding approval of transactions with related parties. Prior to the closing of this global offering, we expect that
the Supervisory Board will adopt a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. The policy will become effective
immediately upon the execution of the underwriting agreement for this offering. For purposes of our policy only, a related person transaction is a transaction, arrangement or similar contractual relationship, or any series of similar transactions,
arrangements or relationships, in which we and any related person are, were or will be participants and the amount involved in the transaction exceeds $120,000, with the exception of usual transactions concluded under normal conditions. A related
person is any member of the Executive Board or Supervisory Board or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related
person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to the
Supervisory Board for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the
transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem
reasonably necessary from each member of our Executive Board and Supervisory Board and, to the extent feasible, significant shareholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the
policy. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under our Code of Business Conduct and Ethics, which we intend to adopt in connection with this global
offering, our employees and Executive and Supervisory Board members have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering related person transactions, the Supervisory Board, will take into account the relevant available facts and circumstances
including, but not limited to: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on the independence of a member of the Executive Board or Supervisory Board in the event that the
related person is a member of the Executive Board or Supervisory Board, immediate family member of a member of the Executive Board or Supervisory Board or an entity with which a member of Executive Board or Supervisory Board is affiliated;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related person transaction, the
Supervisory Board must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our shareholders, as the Supervisory Board determines in the good faith exercise of its
discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the transactions described above were entered into prior to the adoption of the written policy, but our Supervisory
Board evaluated and approved all transactions that were considered to be related party transactions under French law at the time at which they were consummated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_15"></A>PRINCIPAL SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table and accompanying footnotes sets forth, as of May&nbsp;1, 2019 and following the completion of the global offering,
information regarding beneficial ownership of our ordinary shares by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our ordinary shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our Executive Board and Supervisory Board members individually; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our Executive Board and Supervisory Board members as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To our knowledge, as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our ordinary shares were held of record by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; residents of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security
if he, she or it possesses sole or shared voting or investment power of that security, including free shares that vest within 60 days of May&nbsp;1, 2019 and options and warrants that are currently exercisable or exercisable within 60 days of
May&nbsp;1, 2019. Ordinary shares subject to free shares, options and warrants currently exercisable or exercisable within 60 days of May&nbsp;1, 2019 are deemed to be outstanding for computing the percentage ownership of the person holding these
free shares, options or warrants and the percentage ownership of any group of which the holder is a member, but are not deemed outstanding for computing the percentage of any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage ownership information shown in the table prior to the global offering is based upon 64,043,905 ordinary shares outstanding as
of May&nbsp;1, 2019. The percentage ownership information shown in the table after the global offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding, assuming
the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares (including ordinary shares in the form of ADSs) by us in the global offering and no exercise of the underwriters&#146;
option to purchase additional ordinary shares (including ordinary shares in the form of ADSs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as indicated by the footnotes
below, we believe, based on the information furnished to us, that the persons named in the table below have sole voting and investment power with respect to all ordinary shares shown that they beneficially own, subject to community property laws
where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections 13(d) and 13(g) of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address of each beneficial owner listed in the table below
is c/o Innate Pharma S.A., 117, Avenue de Luminy &#150; BP 30191, 13009 Marseille, France. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD style="width:132pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:132pt"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD style="width:39pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:39pt"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD style="width:40pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:40pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Ordinary<BR>Shares&nbsp;Beneficially&nbsp;Owned<BR>Before Global Offering</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Ordinary&nbsp;Shares<BR>Beneficially Owned</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before Global<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After Global<BR>Offering</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Shareholders</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo Nordisk A/S<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,908,456</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.9</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MedImmune Limited<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,260,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bpifrance Participations<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,396,682</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Board and Supervisory Board members and other executive officers</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mondher Mahjoubi, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,218</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yannis Morel, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,593</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laure-H&#233;l&#232;ne Mercier<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,599</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Herv&#233; Brailly, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,374,784</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Irina Staatz-Granzer<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,100</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Yves Blay<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilles Brisson<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,059</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">V&#233;ronique Chabernaud<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,210</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ma&iuml;lys Ferrere</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Langlois<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,141</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcus Schindler</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pierre Dodion, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,372</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Odile Belzunce<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,275</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Butler</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fr&eacute;d&eacute;rique Brune</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Vivier, D.V.M.<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,400</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All members of our Executive Board and Supervisory Board and other executive officers as a
group</B><SUP STYLE="font-size:85%; vertical-align:top"></SUP><FONT STYLE="font-size:6.5pt"><SUP STYLE="font-size:85%; vertical-align:top">(16)<B></B></SUP><B></B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">1,872,801<BR></TD>
<TD NOWRAP VALIGN="bottom"><BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2.9</P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than 1%. </TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 8,908,456 ordinary shares. The principal business address for Novo Nordisk A/S is Novo All&#233;, 2880 Bagsvaerd, Danemark. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 6,260,500 ordinary shares. The principal business address for MedImmune Limited is Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 4,396,682 ordinary shares. The principal business address for Bpifrance Participations is 27-31, avenue du G&#233;n&#233;ral Leclerc, 94 710 Maisons Alfort Cedex. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 15,218 ordinary shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 57,593 ordinary shares and 88,000 ordinary shares issuable upon the exercise of redeemable share warrants (BSAAR) that are exercisable within 60 days of May 1, 2019. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 8,099 ordinary shares and 44,500 ordinary shares issuable upon the exercise of redeemable share warrants (BSAAR) that are exercisable within 60 days of May 1, 2019. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,024,784 ordinary shares and 350,000 ordinary shares issuable upon the exercise of redeemable share warrants (BSAAR) that are exercisable within 60 days of May 1, 2019. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 100 ordinary shares and 35,000 ordinary shares issuable upon the exercise of share warrants (BSA) that are exercisable within 60 days of May 1, 2019. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 50 ordinary shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(10)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 48,059 ordinary shares and 40,000 ordinary shares issuable upon the exercise of share warrants (BSA) that are exercisable within 60 days of May 1, 2019. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(11)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 10 ordinary shares and 14,200 ordinary shares issuable upon the exercise of share warrants (BSA) that are exercisable within 60 days of May 1, 2019. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(12)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 8,141 ordinary shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(13)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 372 ordinary shares and 57,000 ordinary shares issuable upon the exercise of redeemable share warrants (BSAAR) that are exercisable within 60 days of May 1, 2019. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(14)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 5,275 ordinary shares and 15,000 ordinary shares issuable upon the exercise of redeemable share warrants (BSAAR) that are exercisable within 60 days of May 1, 2019. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(15)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 61,400 ordinary shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(16)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,229,101 ordinary shares, (ii) 89,200 ordinary shares issuable upon the exercise of share warrants (BSA) that are exercisable within 60 days of May 1, 2019 and (iii) 554,500 ordinary shares issuable
upon the exercise of redeemable share warrants (BSAAR) that are exercisable within 60 days of May 1, 2019. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_16"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our
share capital summarizes certain provisions of our bylaws. Such summaries do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all of the provisions of our bylaws, a copy of which has been filed as
an exhibit to the Registration Statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2019, our outstanding share capital
consisted of a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares with a nominal value of &#128;0.05 per share and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; preferred shares with a nominal value of &#128;0.05 per share. As of June&nbsp;30, 2019, we had the following equity warrants, redeemable share subscription warrants, and free
shares and convertible preferred shares outstanding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of share warrants (BSA) outstanding as of June&nbsp;30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
exercise of redeemable share warrants (BSAAR) outstanding as of June&nbsp;30, 2019 at a weighted average exercise price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2017) outstanding as of June&nbsp;30, 2019 assuming all related performance conditions are met; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon the
vesting of free shares (AGA) outstanding as of June&nbsp;30, 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon conversion
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; free preferred shares (AGAP 2016) as of June&nbsp;30, 2019 assuming all performance conditions are met. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, our bylaws set forth only our issued and outstanding share capital as of the date of the bylaws. Our fully diluted share
capital represents all issued and outstanding ordinary shares, as well as all potential ordinary shares which may be issued upon exercise of outstanding equity warrants and redeemable share subscription warrants and following the vesting of free
shares, as approved by our shareholders and granted by our Executive Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2018, our share capital as set forth in
our bylaws is &#128;3,196,979.30, representing 63,932,655 ordinary shares with a nominal value of &#128;0.05 per share and 6,931 preferred shares with a nominal value of &#128;0.05. An increase of our share capital may only be approved by an
extraordinary meeting of shareholders or as delegated to the Executive Board by an extraordinary meeting of shareholders. At an extraordinary meeting of shareholders held May&nbsp;22, 2019, our shareholders delegated authority to our Executive
Board, subject to certain conditions and approvals of the Supervisory Board, to authorize an increase of our share capital of up to 23,620,445 ordinary shares. This authorization includes a global authorization for an issuance of up to 22,420,445
ordinary shares and issuance of up to 1,200,000 ordinary shares as free shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon closing of the global offering, our outstanding
share capital will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares, nominal value &#128;0.05 per share (or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the underwriters exercise their option to purchase in full). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reconciliation of the Ordinary Shares Outstanding Prior to This Global Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the reconciliation of the number of ordinary shares issued and outstanding as of December&nbsp;31, 2016, 2017 and
2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ordinary Shares outstanding at December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,921,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with purchase by Novo Nordisk A/S</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,343,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the vesting of free shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ordinary Shares outstanding at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,600,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the vesting of free shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with purchase by MedImmune Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,260,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ordinary Shares outstanding at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,932,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the exercise of warrants and vesting of free
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ordinary Shares outstanding at May&nbsp;1, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,043,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>History of Securities Issuances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From January&nbsp;1, 2016 through May&nbsp;1, 2019, the following events have changed the number of our issued and outstanding ordinary shares:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On January&nbsp;6, 2016, we issued an aggregate of 2,700 ordinary shares to employees in connection with the
exercise of redeemable share warrants, for aggregate gross proceeds of &#128;5,508. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On May&nbsp;30, 2016, we issued an aggregate of 58,940 ordinary shares to employees and executive managers in
connection with the exercise of redeemable share warrants and share warrants, for aggregate gross proceeds of &#128;138,248. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2016, we issued an aggregate of 4,486 free preferred shares (AGAP <FONT
STYLE="white-space:nowrap">2016-1)</FONT> to employees and executive managers, convertible into 897,200 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2016, we issued an aggregate of 99,932 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-1)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2016, we issued an aggregate of 50,000 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November&nbsp;3, 2016, we issued an aggregate of 25,650 ordinary shares to employees in connection with the
exercise of redeemable share warrants, for aggregate gross proceeds of &#128;52,326. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2016, we issued an aggregate of 250,000 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-2)</FONT> to an executive manager. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2016, we issued an aggregate of 149,943 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-2)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2016, we issued an aggregate of 3,000 free preferred shares (AGAP <FONT
STYLE="white-space:nowrap">2016-2)</FONT> to an executive manager, convertible into 600,000 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On January&nbsp;24, 2017, we issued an aggregate of 38,950 ordinary shares to executive managers in connection
with the exercise of redeemable share warrants and share warrants, for aggregate gross proceeds of &#128;327,144. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On February&nbsp;10, 2017, we issued an aggregate of 50,500 ordinary shares to employees and executive managers
in connection with the exercise of redeemable share warrants and share warrants, for aggregate gross proceeds of &#128;119,020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On June&nbsp;14, 2017, we issued an aggregate of 1,850 ordinary shares to employees in connection with the
exercise of redeemable share warrants, for aggregate gross proceeds of &#128;3,774. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On July&nbsp;13, 2017, we issued an aggregate of 3,343,748 ordinary shares to Novo Nordisk A/S, at a purchase
price of &#128;11.12 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On September&nbsp;20, 2017, we issued an aggregate of 28,556 bonus free shares (AGA Bonus <FONT
STYLE="white-space:nowrap">2017-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On September&nbsp;20, 2017, we issued an aggregate of 37,000 share warrants (BSA
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to members of the Supervisory Board, convertible into 37,000 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2017, we issued an aggregate of 98,770 ordinary shares and 3,931 free preferred shares to
employees and executive managers in connection with the vesting of free shares (AGA <FONT STYLE="white-space:nowrap">2016-1</FONT> and AGAP <FONT STYLE="white-space:nowrap">2016-1),</FONT> for aggregate gross proceeds of &#128;5,135.05.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2017, we issued an aggregate of 144,978 ordinary shares and 3,000 free preferred shares to
employees and executive managers in connection with the vesting of free shares (AGA <FONT STYLE="white-space:nowrap">2016-2</FONT> and AGAP <FONT STYLE="white-space:nowrap">2016-2),</FONT> for aggregate gross proceeds of &#128;7,398.90.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;3, 2018, we issued an aggregate of 5,725 free preferred shares (AGAP
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to employees convertible into 572,500 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;3, 2018, we issued an aggregate of 2,400 free preferred shares (AGAP
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to executive managers convertible into 240,000 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;3, 2018, we issued an aggregate of 114,500 free shares (AGA
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November 20, 2018, we issued an aggregate of 327,500 performance free shares (AGA Performance <FONT
STYLE="white-space:nowrap">2018-1)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November 20, 2018, we issued an aggregate of 260,000 performance free shares (AGA Performance <FONT
STYLE="white-space:nowrap">2018-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On July&nbsp;3, 2018, we issued an aggregate of 67,028 bonus free shares (AGA Bonus <FONT
STYLE="white-space:nowrap">2018-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On September&nbsp;20, 2018, we issued an aggregate of 22,055 ordinary shares to executive managers in connection
with the vesting of free shares (AGA Bonus <FONT STYLE="white-space:nowrap">2017-1),</FONT> for aggregate gross proceeds of &#128;1,102.75. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;25, 2018, we issued an aggregate of 6,260,500 ordinary shares to MedImmune Limited, at a purchase
price of &#128;10.00 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November&nbsp;29, 2018, we issued an aggregate of 50,000 ordinary shares to employees and executive managers
in connection with the exercise of share warrants, for aggregate gross proceeds of &#128;2,500. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;18, 2019, we issued an aggregate of 111,250 ordinary shares and 7,581 preferred shares to employees
and executive managers in connection with the exercise of redeemable share warrants and the vesting of free shares (AGA <FONT STYLE="white-space:nowrap">2017-1</FONT> and AGAP <FONT STYLE="white-space:nowrap">2017-1),</FONT> for aggregate gross
proceeds of &#128;5,941.55. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January&nbsp;1, 2016 through May&nbsp;1, 2019, an aggregate of 66,140 redeemable share warrants (BSAAR) were
exercised at prices ranging from &#128;2.04 to &#128;7.20 per ordinary share. Pursuant to these exercises, we issued an aggregate of 66,140 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January&nbsp;1, 2016 through May&nbsp;1, 2019, an aggregate of 163,200 share warrants (BSA) were exercised
at prices ranging from &#128;1.77 to &#128;8.65 per ordinary share. Pursuant to these exercises, we issued an aggregate of 163,200 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January&nbsp;1, 2016 through May&nbsp;1, 2019, an aggregate of 14,512 free preferred shares (AGAP) were
vested. Pursuant to these free preferred shares vesting, we issued an aggregate of 6,931 preferred shares 2016 and 7,581 preferred shares 2017. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January&nbsp;1, 2016 through May&nbsp;1, 2019, an aggregate of 376,303 free shares (AGA) were vested.
Pursuant to these free shares vesting, we issued an aggregate of 376,303 ordinary shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Provisions of Our Bylaws and French Law Affecting Our Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description below reflects the terms of our bylaws and summarizes the material rights of holders of our ordinary shares under French law.
Please note that this is only a summary and is not intended to be exhaustive. For further information, please refer to the full text of our bylaws, a copy of which has been filed as an exhibit to the Registration Statement of which this prospectus
forms a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Purpose (Article 4 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business purpose, directly or indirectly, in France or other countries is to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perform, for our self or on behalf of third parties, any and all operations involving research, development,
studies, perfecting of production processes and marketing products of pharmaceutical interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register or grant any patents or licenses relating directly or indirectly to our business; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">more generally, perform any operation of any kind, whether economic, legal, financial, civil or commercial, which
may be directly or indirectly related to our business purpose or any similar, associated or complementary purpose. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Board
(Articles 14 to 16 of the Bylaws) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Executive Board is responsible for our management and is composed of a minimum of two members
and a maximum of five members who perform their duties under the supervision of the Supervisory Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Members of the Executive
Board </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the Executive Board are appointed or have their appointments renewed by the Supervisory Board. The members of
the Executive Board must be individuals. They are not required to be shareholders. They may be French citizens or citizens of other countries. Members of the Executive Board cannot be members of the Supervisory Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum age for being a member of the Executive Board and the limitations on having such an appointment concurrently with an appointment
in another company are subject to the applicable legal and regulatory provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of office for the members of the Executive
Board is three years and may be renewed. If there is a vacancy, the Supervisory Board must fill the vacancy within two months. The replacement is appointed for the time remaining until the Executive Board is up for renewal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the Executive Board may be removed from office, with or without cause and without notice, by the Supervisory Board or at any
General Meeting of shareholders, by a simple majority vote of the shareholders present and voting at the meeting in person or by proxy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Chairman of the Executive Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory Board elects a Chairman from among the members of the Executive&nbsp;Board to serve for the duration of his appointment as a
member of the Executive Board. The Chairman of the Executive Board represents us in our relations with third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory
Board may assign this power of representation to one or more other members of the Executive Board. Assignees have the title of General Manager. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Meetings and Powers of the Executive Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Executive Board meets as often as is in our interest, but at least once per quarter. Meetings are called by the Chairman or a member of the
Executive Board appointed for this purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At least half of the members of the Executive Board must be present to constitute a quorum
and decisions are made by a majority of the members of the Executive Board present or represented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Executive Board has broad power to
act under all circumstances on our behalf. It exercises this power within the limits of our business purpose and subject to any powers expressly given to the Supervisory Board and Shareholders&#146; Meetings by law and according to our bylaws, and
abiding by any restrictions on powers decided by the Supervisory Board. There are currently no limits imposed on the amounts of loans or borrowings that the Executive Board may approve. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of the Executive Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The method and amount of compensation for each member of the Executive Board is determined by the Supervisory Board when appointing such
member. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Supervisory Board (Articles 17 to 21 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Members of the Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Executive Board is supervised by a Supervisory Board made up of a minimum of three members and a maximum of eighteen. The members of the
Supervisory Board are appointed for a renewable term of two years at the General Meeting of shareholders, which may revoke their appointments at any time. The appointees are selected from among the shareholders and may be individuals or companies.
Each member must own at least one of our ordinary shares for the entire term of the appointment. Members of the Supervisory Board cannot be members of the Executive Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of members of the Supervisory Board who have reached the age of seventy years cannot be higher than a third of the members of the
Supervisory Board. If the age limitation is exceeded, the eldest member is deemed to have resigned automatically. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Chairman of the
Supervisory Board </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory Board appoints from its members who are individuals a Chairman and a Vice-Chairman, who are in
charge of convening the Supervisory Board and leading the debates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a report to the General Meeting of shareholders attached to the
Executive Board&#146;s Management Report, the Chairman of the Supervisory Board reports on the conditions for preparing and organizing the work of the Supervisory Board as well as the internal control procedures set up by us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Meetings and Powers of the Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory Board meets as often as is in our interests but least once per quarter. Meetings are called by the Chairman or Vice-Chairman,
or by a member of the Executive Board or <FONT STYLE="white-space:nowrap">one-third</FONT> of the members of the Supervisory Board, under the circumstances and according to the conditions set forth in the bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At least half of the members of the Supervisory Board must be present to constitute a quorum and decisions are made by a majority of the
members of the Supervisory Board present or represented, it being specified that in a case of a split-vote, the Chairman of the Supervisory Board shall have the deciding vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Supervisory Board exercises permanent control over our management by the Executive Board
and the powers explicitly conferred on it by the French laws. It alone has the authority to authorize certain significant transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, any agreement entered into, directly or through an intermediary, between us and one of the members of the Executive Board or
Supervisory Board, or a shareholder that holds over 10% of the voting rights, or, if such shareholder is a company, the controlling company thereof, must be subject to prior authorization from the Supervisory Board. The interested member cannot vote
on such decision. The same applies to agreements in which a person referred above has an indirect interest. Such prior authorization also applies to agreements between us and another company if one of the members of our Executive Board or
Supervisory Board is the owner, a partner with unlimited liability, manager, director, managing director, member of the Executive Board or of the Supervisory Board, or, in a general manner is in a position of responsibility within the other company.
These provisions are not applicable to agreements concerning <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations entered into under normal conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of the Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation for attendance at board meetings (<I>jetons de pr&eacute;sence</I>) is determined at the annual ordinary General Meeting. The
General Meeting of shareholders may allocate an annual fixed sum and our Supervisory Board allocates this sum among its members as it sees fit. In addition, the Supervisory Board may allocate exceptional compensation (<I>r&eacute;mun&eacute;ration
exceptionnelle</I>) for missions or mandates entrusted to its members; in this case, this remuneration is subject to the provisions regarding related-parties agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Committees </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Supervisory Board may decide to establish committees responsible for reviewing matters which the Supervisory Board or its Chairman wish to submit to them for examination and advice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Observers (Article 23 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the General Meeting of shareholders, one or more shareholders&#146; observers may be appointed, at the discretion of the shareholders for a
term of office expiring at the shareholders meeting convened to decide on the financial statements for the preceding financial year after the first anniversary date of their appointment. Shareholders&#146; observers may be individuals or companies
and are not required to be shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The observers attend all Supervisory Board meetings, with the right to speak but not to vote.
They hold the same information and communication rights than the Supervisory Board&#146;s members and they are bound to the same confidentiality obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rights and Obligations Attached to Ordinary Shares (Articles 12 and 41 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our ordinary shares gives the right to a share of the profits and assets in proportion to the amount of capital it represents. It also
gives the right to vote and be represented in the General Meeting of shareholders under the conditions set forth by the law and the bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are liquidated, any assets remaining after payment of the debts, liquidation expenses and all of the remaining obligations will first be
used to repay in full the par value of our ordinary shares. Any surplus will be distributed pro rata among shareholders in proportion to the number of ordinary shares respectively held by them, taking into account, where applicable, of the rights
attached to ordinary shares of different classes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders are liable for corporate liabilities only up to the par value of the
ordinary shares they hold; they are not liable to further capital calls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not issued any ordinary shares giving holders privileged rights compared to those
attached to other ordinary shares. See the section of this prospectus titled &#147;Management&#151;Equity Incentives&#148; for a description of the Free Preferred Shares (AGAP) granted to the Company&#146;s management and employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders&#146; rights may be modified as allowed by French law. Only the extraordinary shareholders&#146; meeting is<I> </I>authorized to
amend any and all provisions of our bylaws. It may not, however, increase shareholder commitments<I> </I>without the prior approval of each shareholder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights (Article 12 of the Bylaws) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The voting rights attached to the ordinary shares are in proportion to the amount of capital they represent and each share gives the right to
one vote. There is no double voting right attached to the ordinary shares. The ownership of a share implies, ipso facto, the acceptance of our bylaws and any decision of our shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, treasury shares or ordinary shares held by entities controlled by us are not entitled to voting rights and do not count for
quorum purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">They is no limitation on voting rights in our bylaws nor limit the right of
<FONT STYLE="white-space:nowrap">non-residents</FONT> of France or <FONT STYLE="white-space:nowrap">non-French</FONT> persons to own or, where applicable, to vote our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, the holders of warrants of the same class (i.e., warrants that were issued at the same time and with the same rights),
including founders&#146; warrants, are entitled to vote as a separate class at a general meeting of that class of warrant holders under certain circumstances, principally in connection with any proposed modification of the terms and conditions of
the class of warrants or any proposed issuance of preferred shares or any modification of the rights of any outstanding class or series of preferred shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends (Article 41 of the Bylaws) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may only distribute dividends out of our distributable profits, plus any amounts held in our reserves that the shareholders decide to make
available for distribution, other than those reserves that are specifically required by law. The conditions for payment of dividends in cash shall be set at the shareholders&#146; meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Distributable Profits&#148; consist of our statutory net profit in each fiscal year, calculated in accordance with accounting standards
applicable in France, as increased or reduced by any profit or loss carried forward from prior years, less any contributions to the reserve accounts. Pursuant to French law, we must allocate at least 5% of our statutory net profit for each year to
our legal reserve fund before dividends may be paid with respect to that year. Such allocation is compulsory until the amount in the legal reserve is equal to 10% of the aggregate par value of our issued and outstanding share capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends are distributed to shareholders pro rata according to their respective holdings of ordinary shares. In the case of interim
dividends, distributions are made to shareholders on the date set by our Executive Board during the meeting in which the distribution of interim dividends is approved. The actual dividend payment date is decided by the shareholders at an ordinary
general shareholders&#146; meeting or by our Executive Board in the absence of such a decision by the shareholders. Shareholders that own ordinary shares on the actual payment date are entitled to the dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to French law, dividends must be paid within a maximum of nine months after the close of the relevant fiscal year, unless extended by
court order. Dividends not claimed within five years after the payment date shall be deemed to expire and revert to the French state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders may be granted an option to receive dividends in cash or in ordinary shares, in accordance with legal conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Change in Share Capital (Article 7 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any change to the capital or the rights attached to the ordinary shares is subject to legal provisions, as our bylaws do not set forth any
particular requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Increase in Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to French law, our share capital may be increased only with shareholders&#146; approval at an extraordinary general shareholders&#146;
meeting following the recommendation of our Executive Board. The shareholders may delegate to our Executive Board either the authority (<I>d&eacute;l&eacute;gation de comp&eacute;tence</I>) or the power (<I>d&eacute;l&eacute;gation de pouvoir</I>)
to carry out any increase in share capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increases in our share capital may be effected by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuing additional shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increasing the nominal value of existing shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">creating a new class of equity securities (preference shares); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercising the rights attached to securities giving access to the share capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increases in share capital by issuing additional securities may be effected through one or a combination of the following issuances: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in consideration for cash; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in consideration for assets contributed in kind; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through an exchange offer or merger; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by conversion of previously issued debt instruments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by exercise of the rights attached to securities giving access to the share capital; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by capitalization of profits, reserves or share premium; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain conditions, by way of offset against debt incurred by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Decisions to increase the share capital through the capitalization of reserves, profits and/or share premium require shareholders&#146;
approval at an extraordinary general shareholders&#146; meeting, acting under the quorum and majority requirements applicable to ordinary shareholders&#146; meetings. Increases effected by an increase in the nominal value of shares require unanimous
approval of the shareholders, unless effected by capitalization of reserves, profits or share premium. All other capital increases require shareholders&#146; approval at an extraordinary general shareholders&#146; meeting acting under the regular
quorum and majority requirements for such meetings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Reduction in Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to French law, any reduction in our share capital requires shareholders&#146; approval at an extraordinary general shareholders&#146;
meeting following the recommendation of our Executive Board. The share capital may be reduced either by decreasing the nominal value of the outstanding shares or by reducing the number of outstanding shares. The number of outstanding shares may be
reduced by the repurchase and cancellation of shares. Holders of each class of shares must be treated equally unless each affected shareholder agrees otherwise, depending on the contemplated operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Preferential Subscription Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to French law, if we issue additional securities for cash, current shareholders will have preferential subscription rights to these
securities on a pro rata basis. Preferential subscription rights entitle the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individual or entity that holds them to subscribe pro rata based on the number of shares held by them to the issuance of any securities increasing, or that may result in an increase of, our share
capital by means of a cash payment or a <FONT STYLE="white-space:nowrap">set-off</FONT> of cash debts. Pursuant to French law, the preferential subscription rights are transferable during a period equivalent to the subscription period relating to a
particular offering but starting two days prior to the opening of the subscription period and ending two days prior to the closing of the subscription period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferential subscription rights with respect to any particular offering may be waived at an extraordinary general meeting by a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> vote of our shareholders or individually by each shareholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Executive Board and our
independent auditors are required by French law to present reports to the shareholders&#146; meeting that specifically address any proposal to waive the preferential subscription rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current shareholders waived their preferential subscription rights with respect to this global offering at an extraordinary general
shareholders&#146; general meeting held on May&nbsp;22, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Holding and Transfer of Shares (Articles 9 and 10 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Form of Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
ordinary shares are nominative or bearer, if the legislation so permits, according to the shareholder&#146;s choice. The Free Preferred Shares (AGAP) are nominative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, in accordance with applicable laws, we may request at any time from the central depository responsible for holding our Shares, the
information referred to in Article L. <FONT STYLE="white-space:nowrap">228-2</FONT> of the French Commercial Code. Thus, we are, in particular and at any time, entitled to request the name and year of birth or, in the case of a legal entity, the
name and the year of incorporation, nationality and address of holders of securities conferring immediate or long-term voting rights at its shareholders&#146; meeting and the amount of securities owned by each of them and, where applicable, the
restrictions that the securities could be affected by. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Holding of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with French law concerning the &#147;dematerialization&#148; of securities, the ownership rights of shareholders are represented
by book entries instead of share certificates. Shares issued are registered in individual accounts opened by us or any authorized intermediary, in the name of each shareholder and kept according to the terms and conditions laid down by the legal and
regulatory provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Ownership of Shares by <FONT STYLE="white-space:nowrap">Non-French</FONT> Persons </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Limitations Affecting Shareholders of a French Company.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Assignment and Transfer of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares are freely negotiable, subject to applicable legal and regulatory provisions. French law notably provides for standstill obligations and
prohibition of insider trading. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Repurchase and Redemption of Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, we may acquire our own ordinary shares. Such acquisition may be challenged on the ground of market abuse regulations.
However, Market Abuse Regulation 596/2014 of April&nbsp;16, 2014 and its delegated regulations, or MAR, provides for safe harbor exemptions when the acquisition is made (i)&nbsp;under a <FONT STYLE="white-space:nowrap">buy-back</FONT> program to be
authorized by the shareholders in accordance with the provisions of Article L. <FONT STYLE="white-space:nowrap">225-209</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the French Commercial Code and with the General Regulations of the French Financial Markets Authority, or AMF and (ii)&nbsp;for the following purposes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to decrease our share capital, with the approval of the shareholders at an extraordinary general meeting; in this
case, the ordinary shares repurchased must be cancelled within one month from the expiry of the purchase offer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to meet obligations arising from debt securities that are exchangeable into equity instruments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide ordinary shares for distribution to employees or managers under a profit-sharing, free share or share
option plan; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we benefit from a simple exemption when the acquisition is made under a liquidity contract complying with the
General Regulations of, and market practices accepted by, the AMF. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All other purposes, and especially share <FONT
STYLE="white-space:nowrap">buy-backs</FONT> made for external growth operations in pursuance of Article L. <FONT STYLE="white-space:nowrap">225-209</FONT> of the French Commercial Code, while not forbidden, must be pursued in strict compliance of
market manipulation and insider dealing rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under MAR and in accordance with the General Regulations of the AMF, a corporation shall
report to the competent authority of the trading value on which the shares have been admitted to trading or are traded, no later than by the end of the seventh daily market session following the date of the execution of the transaction, all the
transactions relating to the <FONT STYLE="white-space:nowrap">buy-back</FONT> program, in a detailed form and in an aggregated form.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No
such repurchase of ordinary shares may result in us holding, directly or through a person acting on our behalf, more than 10% of our issued share capital. Ordinary shares repurchased by us continue to be deemed &#147;issued&#148; under French law
but are not entitled to dividends or voting rights so long as we hold them directly or indirectly, and we may not exercise the preemptive rights attached to them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sinking Fund Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws do
not provide for any sinking fund provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Meeting of Shareholders (Articles 26 to 37 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Calling Meetings and Conditions for Admission (Articles 27 to 30 of the Bylaws) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General Meetings of shareholders are called by the Executive Board, or failing that, by the Supervisory Board. They can also be called by the
auditor(s) or an officer appointed by a court upon request, by any interested party or by the Works Council in an emergency, by one or more shareholders holding at least five percent of the ordinary shares or by an association of our shareholders.
Meetings are held at our registered offices or at any other location indicated in the convening notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The meeting is published in the
French Bulletin of Mandatory Legal Notices (<I>Bulletin des Annonces L&eacute;gales Obligatoires </I>or BALO) at least 35 days prior to the date of a General Meeting of shareholders. In addition to the information concerning us, the notice indicates
in particular the agenda of the General Meeting of shareholders and the draft resolutions that will be presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the 21 days
preceding the meeting, we will publish the information and documents relating to the meeting on our web site. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The General Meeting of
shareholders must be announced at least 15 days beforehand, by a notice placed in a journal that publishes legal announcements in the department where the headquarters are located, and in the BALO. Holders of registered ordinary shares who have
owned them for at least one month as of the date on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which the latest notice is published receive individual notices. When a General Meeting of shareholders is unable to take action because the requisite quorum is not present, a second meeting is
called at least ten days in advance using the same procedure as the first one. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The General Meeting of shareholders may only take action
on items on the agenda. However, it may dismiss and replace one or more members of the Supervisory Boards at any time. The General Meeting may also dismiss the members of the Executive Board. One or more shareholders representing at least the
percentage of share capital fixed by law, and acting according to the legally required conditions and deadlines, are allowed to request that items and/or draft resolutions be added to the agenda of the General Meeting of shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each shareholder has the right to attend the meetings and take part in deliberation (i)&nbsp;personally; (ii) by granting proxy to another
shareholder, his or her spouse or partner in a civil union or any other natural or legal person of his or her choice; (iii)&nbsp;by sending a proxy to the company without indication of the beneficiary; (iv)&nbsp;by voting by correspondence; or
(v)&nbsp;by videoconference or another means of telecommunication, including internet, in accordance with applicable laws and regulations that allow identification; by presenting proof of identity and ownership of ordinary shares, subject to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for holders of registered ordinary shares, an entry in the shareholder registry at least two business days before
the General Meeting of shareholders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for holders of bearer ordinary shares, filing, under the conditions provided by law, of a certificate of
participation issued by an authorized intermediary two days before the date of the General Meeting of shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
final date for returning voting ballots by correspondence is set by the Executive Board and disclosed in the notice of meeting published in the BALO. This date cannot be earlier than three days prior to the meeting as provided in the bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder who has voted by correspondence will no longer be able to participate directly in the meeting or to be represented. In the case
of returning the proxy form and the voting by correspondence form, the proxy form is taken into account, subject to the votes cast in the voting by correspondence form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder may be represented at meetings by any individual or legal entity by means of a proxy form which we send to such shareholder
either at the shareholder&#146;s request or at our initiative. A shareholder&#146;s request for a proxy form must be received at the registered office at least five days before the date of the meeting. The proxy is only valid for a single meeting,
for two meetings (an ordinary and an extraordinary meeting convened for the same day or within 15 days) or for successive meetings convened with the same agenda. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder may vote by correspondence by means of a voting form, which we send to such shareholder either at the shareholder&#146;s request
or at our initiative, or which we include in an appendix to a proxy voting form under the conditions provided for by current laws and requirements. A shareholder&#146;s request for a voting form must be received at the registered office at least six
days before the date of the meeting. The voting form is also available on our website at least 21 days before the date of the meeting. The voting by correspondence form addressed by a shareholder is only valid for a single meeting or for successive
meetings convened with the same agenda. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Bylaws and French Corporate Law Contain Provisions that May Delay or Discourage a Takeover Attempt
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions contained in our bylaws and French corporate law could make it more difficult for a third-party to acquire us, even if
doing so might be beneficial to our shareholders. In addition, provisions of our bylaws </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
impose various procedural and other requirements, which could make it more difficult for shareholders to effect certain corporate actions. These provisions include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, the owner of 90% of the share capital or voting rights of a public company listed on a
regulated market in a Member State of the European Union or in a state party to the European Economic Area, or EEA, Agreement, including from the main French stock exchange, has the right to force out minority shareholders following a tender offer
made to all shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a non-resident of France as well as any French entity controlled by non-residents of France may
have to file a declaration for statistical purposes with the Bank of France (<I>Banque de France</I>) within 20 working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such
filings are required in connection with investments exceeding &#128;15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold. See &#145;&#145;Limitations Affecting Shareholders of a
French Company&#146;&#146;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, certain investments in a French company relating to certain strategic industries by individuals
or entities not residents in a Member State of the EU are subject to prior authorization of the Ministry of Economy. See &#145;&#145;Limitations Affecting Shareholders of a French Company&#146;&#146;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger (i.e., in a French law context, a share for share exchange following which our company would be
dissolved into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the European Union would require the approval of our Executive Board as well as a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present, represented by proxy or voting by mail at the relevant meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger of our company into a company incorporated outside of the European Union would require 100% of our
shareholders to approve it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a cash merger is treated as a share purchase and would require the consent of each
participating shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders may grant in the future our Executive Board broad authorizations to increase our share capital
or to issue additional ordinary shares or other securities (for example, warrants) to our shareholders, the public or qualified investors, including as a possible defense following the launching of a tender offer for our ordinary shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders have preferential subscription rights on a <I>pro rata </I>basis on the issuance by us of any
additional securities for cash or a <FONT STYLE="white-space:nowrap">set-off</FONT> of cash debts, which rights may only be waived by the extraordinary general meeting (by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote) of our
shareholders or on an individual basis by each shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board appoints the members of the Executive Board and shall fill any vacancy within two months;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board has the right to appoint members of the Supervisory Board to fill a vacancy created by the
resignation or death of a member of the Supervisory Board for the remaining duration of such member&#146;s term of office, and subject to the approval by the shareholders of such appointment at the next shareholders&#146; meeting, which prevents
shareholders from having the sole right to fill vacancies on our Supervisory Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Executive Board can be convened by the chairman of the Executive Board or other members of the Executive
Board delegated for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board can be convened by the chairman or the vice-chairman of the Supervisory Board. A member of
the Executive Board or one-third of the members of the Supervisory Board may send a written request to the chairman to convene the Supervisory Board. If the chairman does not convene the Supervisory Board 15 days following the receipt of such
request, the authors of the request may themselves convene the Supervisory Board; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Supervisory Board meetings can only be regularly held if at least half of its members attend either
physically or by way of videoconference or teleconference enabling the members&#146; identification and ensuring their effective participation in the Supervisory Board&#146;s decisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval of at least a majority of the votes held by shareholders present, represented by a proxy, or voting by
mail at the relevant ordinary shareholders&#146; general meeting is required to remove members of the Executive Board and/or members of the Supervisory Board with or without cause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the crossing of certain ownership thresholds has to be disclosed and can impose certain obligations; see the
section of this prospectus titled &#147;Description of Share Capital&#150;Key Provisions of Our Bylaws and French Law Affecting Our Ordinary Shares;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice is required for nominations to the Supervisory Board or for proposing matters to be acted upon at
a shareholders&#146; meeting, except that a vote to remove and replace a member of the Supervisory Board can be proposed at any shareholders&#146; meeting without notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of shares shall comply with applicable insider trading rules and regulations, and in particular with
the Market Abuse Regulation 596/2014 of April&nbsp;16, 2014; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to French law, our bylaws, including the sections relating to the number of members of the Executive and
Supervisory Boards, and election and removal of members of the Executive and Supervisory Boards from office may only be modified by a resolution adopted by <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes of our shareholders present,
represented by a proxy or voting by mail at the meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Shareholder Identification (Article 9 of the Bylaws)
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ordinary Shares may be registered or bearer ordinary shares, at the option of the shareholder, subject to the applicable legal
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To identify the holders of bearer ordinary shares, we are authorized to ask in accordance with current legal and regulatory
requirements, the central depositary that maintains the records of the issue of these ordinary shares, in exchange for a fee, for the holders&#146; name or business name, year of birth or year of incorporation, address and nationality, <FONT
STYLE="white-space:nowrap">e-mail</FONT> address, number of securities held giving immediate or future access to the capital and any restrictions to which the securities are subject. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Modification of the Bylaws (Article 36 of the Bylaws) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws may only be amended by approval at an extraordinary shareholders&#146; meeting. Our bylaws may not, however, be amended to increase
shareholder commitments without the approval of each shareholder. Decisions are made by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present, represented by proxy, or voting by mail. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Crossing the Threshold Set in the Bylaws (Article 11 of the Bylaws) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without prejudice to the legal or regulatory stipulations, any natural person or legal entity who goes above or below, directly or indirectly,
acting alone or in concert (<I>de concert</I>), a percentage of the share capital or voting rights equal to or higher than 1% or a multiple of this percentage, must inform us of the total number of ordinary shares, voting rights and securities
giving access to capital or voting rights that it, he or she owns immediately or eventually, within five trading days of the date on which such ownership threshold is crossed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If shareholders fail to comply with these obligations, shares or voting rights exceeding the fraction that should have been declared are
deprived of voting rights at General Meetings of Shareholders for any meeting that would be held until the expiry of a period of two years from the date of regularization of the notification in accordance with Article L. <FONT
STYLE="white-space:nowrap">233-14</FONT> of the Commercial Code, if the failure to declare has been determined and one or several shareholders holding at least 5% of the capital make a request thereof, as recorded in the minutes of the General
Meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These requirements are without prejudice to the threshold crossing declarations provided for
under French law in Articles L. 233-7, L. 233-9 and L. 233-10 of the French Commercial Code, which impose a declaration to us and to the French Financial Markets Authority (AMF) upon crossing of the following thresholds in share capital or voting
rights no later than the fourth trading day following the crossing: 5%, 10%, 15%, 20%, 25%, 30%, 33.33%, 50%, 66.66%, 90% and 95%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, any shareholder crossing, alone or acting in concert, these 10%, 15%, 20% or 25% thresholds shall file a declaration pursuant to
which it shall set out its intention for the following 6 months, including notably whether it intends to continue acquiring shares of the company or to acquire control over the company and its intended strategy for the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, and subject to certain exemptions, any shareholder crossing, alone or acting in concert, the 30% threshold shall file a mandatory
public tender offer. Also, any shareholder holding directly or indirectly a number between 30% and 50% of the capital or voting rights and who, in less than 12 consecutive months, increases their holding of capital or voting rights by at least 1% of
the company&#146;s capital or voting rights, shall file a mandatory public tender offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Securities Exercisable for Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Equity Incentives </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section of this prospectus titled &#147;Management&#151;Equity Incentives&#148; for a description of securities granted by our
Executive Board to our members of Executive Board and of Supervisory Board, employees and consultants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Differences in Corporate Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a <I>soci&eacute;t&eacute; anonyme &agrave; directoire et conseil de surveillance</I>, or S.A., incorporated under the laws of France.
The laws applicable to French S.A.s differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the French Commercial Code applicable to us and the Delaware
General Corporation Law, the law under which many public companies in the United States are incorporated. This summary is not intended to be a complete discussion of the respective rights. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of the members of the Executive Board and of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, a <I>soci&eacute;t&eacute; anonyme &agrave; directoire et conseil de surveillance</I> must have at least three and may have up to eighteen members of the Supervisory Board. The number of members of the Executive
Board can be raised to seven if the Company is listed on a regulated exchange. Otherwise, such number cannot be greater than five. In addition, the composition of the Executive Board endeavors to seek a balanced representation of women and men. The
number of members of the Executive Board and of the Supervisory Board is fixed by or in the manner provided in the bylaws. Since January&nbsp;1, 2017, the number of members of</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the certificate of incorporation or, if the certificate is silent, in the
bylaws.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the Supervisory Board of each gender may not be less than 40%. Any appointment made in violation of this limit that is not remedied will be null and void as well as the deliberations taken by the Supervisory Board member irregularly
appointed. The members of the Supervisory Board are appointed at the shareholders&#146; general meetings.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Members of the Executive Board and of the Supervisory Board Qualifications</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, a corporation may prescribe qualifications for the members of the Executive Board and of the Supervisory Board under its bylaws. In addition, under French law, members of a supervisory board of a corporation may be
legal entities (with the exception of the chairman of the supervisory board), and such legal entities may designate an individual to represent them and to act on their behalf at meetings of the supervisory board.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation may prescribe qualifications for directors under its certificate of incorporation or bylaws.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Removal of members of the Executive Board and of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, the members of the Executive Board and of the Supervisory Board may be removed from office, with or without cause and without notice, at any shareholders&#146; meeting, by a simple</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, directors may be removed from office, with or without cause, by a majority stockholder vote, though in the case of a corporation whose board is classified, unless otherwise</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">majority vote of the shareholders present and voting at the meeting in person or by proxy. In addition, the members of the Executive Board may be removed by the Supervisory Board if provided in the bylaws. Our bylaws provide this
possibility.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">provided in the certificate of incorporation, stockholders may effect such removal only for cause.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vacancies on the Executive Board and on the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, vacancies on the Executive Board resulting from death or a resignation have to be filled by the Supervisory Board within two months. Vacancies on the Supervisory Board resulting from death or a resignation, may be
filled by the remaining members of the Supervisory Board pending ratification by the shareholders by the next shareholders&#146; meeting.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, vacancies on a corporation&#146;s board of directors, including those caused by an increase in the number of directors, unless otherwise provided in the certificate of incorporation, may be filled by a majority
of the remaining directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annual General Meeting</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, the annual general meeting of shareholders shall be held at such place, on such date and at such time as decided</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be provided by</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">each year by the Executive Board and notified to the shareholders in the convening notice of the annual meeting, within six months after the close of the relevant fiscal year unless such period is extended by court order.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the certificate of incorporation or by the bylaws, or by the board of directors if neither the certificate of incorporation or the bylaws so provide.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">General Meeting</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, general meetings of the shareholders may be called by the Executive Board or, failing that, by the statutory auditors, or by a court appointed agent (<I>mandataire ad hoc</I>) or liquidator in certain
circumstances, or by the majority shareholder in capital or voting rights following a public tender offer or exchange offer or the transfer of a controlling block on the date decided by the Executive Board or the relevant person. General meetings of
the shareholders may also be called by the Supervisory Board.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notice of General Meetings</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">A first convening notice is published in the French Bulletin of Mandatory Legal Notices (BALO) at least 35 days prior to a meeting and made available on the website of the company at least 21 days prior to the meeting. Subject to
special legal provisions, the meeting notice is sent out at least 15 days prior to the date of the meeting, by means of a notice inserted both in a legal announcement bulletin (<I>journal d&#146;annonces l&eacute;gales</I>) of the registered office
department and in the BALO. Further, the holders of registered ordinary shares for at least a month at the time of the latest of the insertions of the notice of meeting shall be summoned individually, by regular letter (or by registered letter if
they request it and include an advance of expenses) sent to their last known address. This notice to registered shareholders may also be transmitted by electronic means of telecommunication, in lieu of any such mailing, to any shareholder requesting
it beforehand by registered letter with acknowledgment of receipt in</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than 10 nor
more than 60 days before the date of the meeting and shall specify the place, date, hour, means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote, the record date for voting if it
is different from the record date determining notice and, in the case of a special meeting, purpose or purposes for which the meeting is called.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">accordance with legal and regulatory requirements, specifying his <FONT STYLE="white-space:nowrap">e-mail</FONT> address. When the shareholders&#146; meeting cannot deliberate due to lack of required quorum, the second meeting must
be called at least ten calendar days in advance in the same manner as used for the first notice. The convening notice shall specify the name of the company, its legal form, share capital, registered office address, registration number with the
French Registry of Commerce and Companies (<I>registre du commerce et des soci&eacute;t&eacute;s</I>), the place, date, hour and agenda of the meeting and its nature (ordinary and/or extraordinary meeting). The convening notice must also indicate
the conditions under which the shareholders may vote by correspondence and the places and conditions in which they can obtain voting forms by mail.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proxy</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Each shareholder has the right to attend the meetings and participate in the discussions (i)&nbsp;personally, or (ii)&nbsp;by granting proxy to another shareholder, his/her spouse, his/her partner with whom he/she has entered into a
civil union or to any natural or legal person of his/her choice; or (iii)&nbsp;by sending a proxy to the company without indication of the beneficiary (in which case, such proxy shall be cast in favor of the resolutions supported by the Executive
Board), or (iv)&nbsp;by voting by correspondence, or (v)&nbsp;by video conference or another means of telecommunication in accordance with applicable laws that allow identification. The proxy is only valid for a single meeting, for two meetings (an
ordinary and an extraordinary meeting convened for the same day or within 15 days) or for successive meetings convened with the same agenda.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy
provides for a longer period.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder action by written consent</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, shareholders&#146; action by written consent is not permitted in a <I>soci&eacute;t&eacute; anonyme</I>.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation&#146;s certificate of incorporation (1)&nbsp;may permit</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">stockholders to act by written consent if such action is signed by all stockholders, (2)&nbsp;may permit stockholders to act by written consent signed by stockholders having the minimum number of votes that would be necessary to
take such action at a meeting or (3)&nbsp;may prohibit actions by written consent.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Preemptive Rights</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, in case of issuance of additional ordinary shares or other securities for cash or <FONT STYLE="white-space:nowrap">set-off</FONT> against cash debts, the existing shareholders have preferential subscription rights
to these securities on a <I>pro rata</I> basis unless such rights are waived by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present at the extraordinary meeting deciding or authorizing the
capital increase, voting in person or represented by proxy or voting by mail. In case such rights are not waived by the extraordinary general meeting, each shareholder may individually either exercise, assign or not exercise its preferential
subscription rights. Preferential subscription rights may only be exercised during the subscription period. In accordance with French law, the exercise period shall not be less than five trading days. Preferential subscription rights are
transferable during a period equivalent to the subscription period but starting two business days prior to the opening of the subscription period and ending two business days prior to the closing of the subscription period.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, unless otherwise provided in a corporation&#146;s certificate of incorporation, a stockholder does not, by operation of law, possess preemptive rights to subscribe to additional issuances of the
corporation&#146;s stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sources of Dividends</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, dividends may only be paid by a French <I>soci&eacute;t&eacute; anonyme</I> out of &#147;distributable profits,&#148; plus any distributable reserves and &#147;distributable premium&#148; that the shareholders
decide to make available for distribution, other than those reserves that are specifically required by law. &#147;Distributable profits&#148; consist of the</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, dividends may be paid by a Delaware corporation either out of (1)&nbsp;surplus as defined in and computed in accordance with Delaware law or (2)&nbsp;in case there is no such surplus, out of its net profits for
the fiscal year in which the dividend is declared and/or the preceding fiscal year, except when the capital is diminished by depreciation in the</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">unconsolidated net profits of the relevant corporation for each fiscal year, as increased or reduced by any profit or loss carried forward
from prior years.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Distributable premium&#148; refers to the contribution paid
by the shareholders in addition to the par value of their ordinary shares for their subscription that the shareholders decide to make available for distribution.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Except in case of a share capital reduction, no distribution can be made to the shareholders when the net equity is, or would become, lower than the amount of
the share capital plus the reserves which cannot be distributed in accordance with the law or the bylaws.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">value of its property, or by losses, or otherwise, to an amount less than the aggregate amount of capital represented by issued and outstanding stock having a preference on the distribution of assets.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Repurchase of Ordinary Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under French law, a corporation may acquire its own ordinary shares. Such acquisition may be challenged on the ground of market abuse
regulations. However, Market Abuse Regulation 596/2014 of April&nbsp;16, 2014 provides for safe harbor exemptions when the acquisition is made for the following purposes:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to decrease its share capital, with the approval of the shareholders at the extraordinary general
meeting;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to meet
obligations arising from debt securities that are exchangeable into equity instruments; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;with a view to distributing the relevant shares to employees or managers under a profit-sharing,
restricted free share or share option plan.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">All other purposes, and especially share
<FONT STYLE="white-space:nowrap">buy-backs</FONT> made for external growth operations in pursuance of Article L. <FONT STYLE="white-space:nowrap">225-209</FONT> of the French Commercial Code, while not forbidden, must be pursued in strict compliance
of market manipulation and insider dealing rules.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation may generally redeem or repurchase shares of its stock unless the capital of the corporation is impaired or such redemption or repurchase would impair the capital of the
corporation.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Market Abuse Regulation 596/2014 of April&nbsp;16, 2014
(MAR) and in accordance with the General Regulations of the AMF, a corporation shall report to the competent authority of the trading value on which the shares have been admitted to trading or are traded, no later than by the end of the seventh
daily market session following the date of the execution of the transaction, all the transactions relating to the <FONT STYLE="white-space:nowrap">buy-back</FONT> program, in a detailed form and in an aggregated form.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">No such repurchase of ordinary shares may result in the company holding, directly or
through a person acting on its behalf, more than 10% of its issued share capital.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Liability of members of the Executive Board and of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, the bylaws may not include any provisions limiting the liability of members of the Executive Board. Civil liabilities of the members of the Executive Board and of the Supervisory Board may be sought for (1)&nbsp;an
infringement of laws and regulations applicable to a company, (2)&nbsp;breach of the bylaws and (3)&nbsp;management failure. Civil liabilities of the members of the Supervisory Board may be sought for the infractions committed by the members of the
Executive Board if, by knowing it, they did not reveal it to the shareholders&#146; meeting.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a corporation&#146;s certificate of incorporation may include a provision eliminating or limiting the personal liability
of a director to the corporation or its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any breach of the
director&#146;s duty of loyalty to the corporation or its stockholders;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;acts or omissions not in good faith or that involve intentional misconduct or a knowing violation
of law;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;intentional or
negligent payment of unlawful dividends or stock purchases or redemptions; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any transaction from which the director derives an improper personal benefit.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Voting Rights</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">French law provides that, unless otherwise provided in the bylaws, each shareholder is entitled to one vote for each share of capital stock held by such shareholder. As from April 2016, double voting rights are automatically granted
to the shares held in registered form for more</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such
stockholder.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">than two years, unless provided otherwise in the bylaws. Our bylaws provide that double voting rights are not applicable to our shareholders.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder Vote on Certain Transactions</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, under French law, completion of merger, dissolution, sale, lease or exchange of all or substantially all of a corporation&#146;s
assets requires:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the
approval of the Executive Board; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;approval by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the
shareholders present, represented by proxy or voting by mail at the relevant meeting or, in the case of a merger with a <FONT STYLE="white-space:nowrap">non-European</FONT> Union company, approval of all shareholders of the corporation (by
exception, the extraordinary general meeting of the acquiring company may delegate to the Executive Board authority to decide a merger-absorption or to determine the terms and conditions of the merger plan).</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of
a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#146;s assets or dissolution requires:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the approval of the board of directors; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;approval by the vote of the
holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dissent or Dissenters&#146; Appraisal Rights</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">French law does not provide for any such right but provides that a merger is subject to shareholders&#146; approval by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote as stated above.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a holder of shares of any class or series has the right, in specified circumstances, to dissent from a merger or
consolidation by demanding payment in cash for the stockholder&#146;s shares equal to the fair value of those shares, as determined by the Delaware Chancery Court in an action timely brought by the corporation or a dissenting stockholder. Delaware
law grants these appraisal rights only in the case of mergers or consolidations and not in the case of a sale or transfer of assets or a purchase of assets for stock.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Further, no appraisal rights are available for shares of any class or series that is listed on a national securities exchange or held of record by more than
2,000 stockholders, unless the agreement of a merger or consolidation</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">requires the holders to accept for their shares anything other than:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;shares of stock of the surviving corporation;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;shares of stock of another
corporation that are either listed on a national securities exchange or held of record by more than 2,000 stockholders;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;cash in lieu of fractional shares of the stock described in the two preceding bullet points;
or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any combination of the
above.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;In addition,
appraisal rights are not available to holders of shares of the surviving corporation in specified mergers that do not require the vote of the stockholders of the surviving corporation.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Standard of Conduct for members of the Executive Board and of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">French law does not contain specific provisions setting forth the standard of conduct of a member of the Executive Board and of the Supervisory Board. However, members of the Executive Board and of the Supervisory Board have a duty
to act without self-interest, on a well informed basis and they cannot make any decision against a corporation&#146;s corporate interest (<I>int&eacute;r&ecirc;t social</I>). In addition, members of the Executive Board shall take into account social
and environmental issues arising out of the Company&#146;s activity.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general,
directors have a duty to act without self-interest, on a well informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder Suits</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek indemnification from the Executive Board (but not from the Supervisory Board) of a corporation in the corporation&#146;s
interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and any legal fees relating to such action are borne by the relevant shareholder or the group of shareholders.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce
the right itself. The complaint must:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff
complains or that the plaintiff&#146;s shares thereafter devolved on the plaintiff by operation of law; and allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and
the</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The plaintiff must remain a shareholder through the duration of the
legal action.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no other case where shareholders may initiate a derivative
action to enforce a right of a corporation.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A shareholder may alternatively or
cumulatively bring individual legal action against the members of the Executive Board only, provided he has suffered distinct damages from those suffered by the corporation. In this case, any damages awarded by the court are paid to the relevant
shareholder.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">reasons for the plaintiff&#146;s failure to obtain the action; or</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;state the reasons for not
making the effort.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Additionally, the plaintiff must remain a stockholder through the
duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amendment of Certificate of Incorporation</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, corporations are not required to file a certificate of incorporation with the French Registry of Commerce and Companies (<I>registre du commerce et des soci&eacute;t&eacute;s</I>) and only have bylaws
(<I>statuts</I>) as organizational documents.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, generally a corporation may amend its certificate of incorporation if:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;its board of directors has
adopted a resolution setting forth the amendment proposed and declared its advisability; and</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the amendment is adopted by the affirmative votes of a majority (or greater
percentage as may be specified by the corporation) of the outstanding shares entitled to vote on the amendment and a majority (or greater percentage as may be specified by the corporation) of the outstanding shares of each class or series of stock,
if any, entitled to vote on the amendment as a class or series.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amendment of Bylaws</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under French law, only the extraordinary shareholders&#146; meeting is authorized to adopt or amend the bylaws.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, the stockholders entitled to vote have the power to adopt, amend or repeal bylaws. A corporation may also confer, in its certificate of incorporation, that power upon the board of directors.</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Name; Formation; Registered Office </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our legal name and commercial name is Innate Pharma S.A. We were incorporated on September&nbsp;23, 1999 as a <I>soci&eacute;t&eacute; par
actions simplifi&eacute;e</I> and converted into a <I>soci&eacute;t&eacute; anonyme</I>, or S.A., on June&nbsp;13, 2005. Our headquarters are located at 117, Avenue de Luminy, 13009 Marseille, France. We are registered at the Marseille Business and
Company Registry (<I>Registre du commerce et des soci&eacute;t&eacute;s</I>) under the number SIREN 424 365 336 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
RCS Marseille. Our telephone number at our principal executive offices is +33 4 30 30 30 30. Our agent for service of process in the United States is Corporation Service Company. Our website
address is www.innate-pharma.com. The reference to our website is an inactive textual reference only and information contained in, or that can be assessed through, our website is not part of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to have our
ADSs listed on the Nasdaq Global Market under the symbol &#147;IPHA.&#148; Our ordinary shares are currently listed on Euronext Paris under the symbol &#147;IPH.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the
completion of this global offering, the transfer agent and registrar for our ADSs will be Citibank, N.A. Soci&eacute;t&eacute; G&eacute;n&eacute;rale Securities Services is our transfer agent and registrar for our ordinary shares and currently
maintains our share register for our ordinary shares. The share register reflects only record owners of our ordinary shares. Holders of our ADSs will not be treated as one of our shareholders and their names will therefore not be entered in our
share register. The depositary, the custodian or their nominees will be the holder of the shares underlying the ADSs. Holders of our ADSs have a right to receive the ordinary shares underlying their ADSs. For discussion on our ADSs and ADS holder
rights, see &#147;Description of American Depositary Shares&#148; in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_17"></A>LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ownership of ADSs by <FONT STYLE="white-space:nowrap">Non-French</FONT> Residents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the French Commercial Code nor our bylaws currently impose any restrictions on the right of
<FONT STYLE="white-space:nowrap">non-French</FONT> residents or <FONT STYLE="white-space:nowrap">non-French</FONT> shareholders to own and vote shares. However, <FONT STYLE="white-space:nowrap">non-French</FONT> residents must file a declaration for
statistical purposes with the Bank of France (<I>Banque de France</I>) within 20 working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection
with investments exceeding &#128;15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold. Violation of this filing requirement may be sanctioned by five years of imprisonment and a
fine of up to twice the amount of the relevant investment. This amount may be increased fivefold if the violation is made by a legal entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, certain foreign investments in companies incorporated under French laws are subject to the prior authorization from the French
Minister of the Economy, where all or part of the target&#146;s business and activity relate to a strategic sector, such as energy, transportation, public health, telecommunications, etc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Exchange Controls </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under current
French foreign exchange control regulations there are no limitations on the amount of cash payments that we may remit to residents of foreign countries. Laws and regulations concerning foreign exchange controls do, however, require that all payments
or transfers of funds made by a French resident to a <FONT STYLE="white-space:nowrap">non-resident</FONT> such as dividend payments be handled by an accredited intermediary. All registered banks and substantially all credit institutions in France
are accredited intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Preferential Subscription Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our current shareholders waived their preferential subscription rights with respect to this global offering at a shareholders&#146;
general meeting held on May&nbsp;22, 2019, in the future our shareholders will have preferential subscription rights. Under French law, shareholders have preferential rights to subscribe for cash issues of new ordinary shares or other securities
giving rights to acquire additional ordinary shares on a pro rata basis. Holders of our securities in the United States (which may be in the form of ordinary shares or ADSs) may not be able to exercise preferential subscription rights for their
securities unless a registration statement under the Securities Act is effective with respect to such rights or an exemption from the registration requirements imposed by the Securities Act is available. We may, from time to time, issue new ordinary
shares or other securities giving rights to acquire additional ordinary shares (such as warrants) at a time when no registration statement is in effect and no Securities Act exemption is available. If so, holders of our securities in the United
States will be unable to exercise any preferential subscription rights and their interests will be diluted. We are under no obligation to file any registration statement in connection with any issuance of new ordinary shares or other securities. We
intend to evaluate at the time of any rights offering the costs and potential liabilities associated with registering the rights, as well as the indirect benefits to us of enabling the exercise by holders of ADSs in the United States of the
subscription rights, and any other factors we consider appropriate at the time, and then to make a decision as to whether to register the rights. We cannot assure you that we will file a registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For holders of our ordinary shares in the form of ADSs, the depositary may make these rights or other distributions available to ADS holders.
If the depositary does not make the rights available to ADS holders and determines that it is impractical to sell the rights, it may allow these rights to lapse. In that case the holders will receive no value for them. The section of this prospectus
titled &#147;Description of American Depositary Shares&#148; explains in detail the depositary&#146;s responsibility in connection with a rights offering. See also &#147;Risk Factors&#151;Risks Related to Ownership of Our Ordinary Shares and the
ADSs.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_18"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Citibank, N.A. has agreed to act as the depositary bank for the ADSs. Citibank&#146;s depositary offices are located at 388 Greenwich Street,
New York, New York 10013. ADSs represent ownership interests in securities that are on deposit with the depositary bank. ADSs may be represented by certificates that are commonly known as American Depositary Receipts, or ADRs. The depositary bank
typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank N.A., Milan Branch, via dei Mercanti, 12, 20121 Milan, Italy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will appoint Citibank as depositary bank pursuant to a deposit agreement. A copy of the deposit agreement will be filed with the SEC under
cover of a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> (Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ). You may obtain a copy of the deposit agreement from the SEC&#146;s website at
www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of
ADSs. Please remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this
summary. We urge you to review the deposit agreement in its entirety. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each ADS represents the right to receive, and to exercise the beneficial ownership interests in,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary share<B> </B>that is on deposit with the depositary bank and/or custodian. An ADS also represents the right to receive, and to exercise the
beneficial interests in, any other property received by the depositary bank or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. We and
the depositary bank may agree to change the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-Share</FONT></FONT> ratio by amending the deposit agreement. This amendment may give rise to, or change, the depositary fees payable
by ADS owners. The custodian, the depositary bank and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the
depositary bank, the custodian or their nominees. <B></B>Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the beneficial owners of the ADSs. The depositary bank, the custodian and their
respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. <B></B>A beneficial owner of ADSs may or may not be the holder of ADSs.
Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, the registered holders of the ADSs (on behalf of the applicable ADS owners)
only through the depositary bank, and the depositary bank (on behalf of the owners of the corresponding ADSs) directly, or indirectly, through the custodian or their respective nominees, in each case upon the terms of the deposit
agreement.<B></B><B>&nbsp;</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be
bound to its terms and to the terms of any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary bank. As an ADS holder
you appoint the depositary bank to act on your behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of
France, which may be different from the laws in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, applicable laws and regulations may require you to
satisfy reporting requirements and obtain regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary bank, the custodian, us or any of
their or our respective agents or affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>As an owner of ADSs, we will not treat you as one of our shareholders and you will not
have direct shareholder rights. The depositary bank will hold on your behalf the shareholder rights attached to the</I><B><I> </I></B><I>ordinary shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights
for the</I><B><I> </I></B><I>ordinary shares represented by your ADSs through the depositary bank only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an
ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manner in which you own the ADSs
(e.g., in a brokerage account vs. as registered holder, or as holder of certificated vs. uncertificated ADSs) may affect your rights and obligations, and the manner in which, and extent to which, the depositary bank&#146;s services are made
available to you. As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or through an account established by the depositary bank in your name reflecting the
registration of uncertificated ADSs directly on the books of the depositary bank (commonly referred to as the &#147;direct registration system&#148; or &#147;DRS&#148;). The direct registration system reflects the uncertificated (book-entry)
registration of ownership of ADSs by the depositary bank. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the depositary bank to the holders of the ADSs. The direct registration system includes
automated transfers between the depositary bank and The Depository Trust Company (&#147;DTC&#148;), the central book-entry clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs through your
brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The
procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning these limitations and procedures. All ADSs held
through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the &#147;holder.&#148; When we
refer to &#147;you,&#148; we assume the reader owns ADSs and will own ADSs at the relevant time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration of the ordinary shares
in the name of the depositary bank or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary bank or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights
and interests in such ordinary shares being at all times vested with the beneficial owners of the ADSs representing the ordinary shares. The depositary bank or the custodian shall at all times be entitled to exercise the beneficial ownership rights
in all deposited property, in each case only on behalf of the holders and beneficial owners of the ADSs representing the deposited property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends
and Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited
with the custodian. Your receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number
of ADSs held as of the specified record date, after deduction of the applicable fees, taxes and expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Distributions of Cash
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the
custodian. Upon receipt of confirmation of the deposit of the requisite funds, the depositary bank will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S.
dollars to the holders, subject to French laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conversion into U.S. dollars will take place only if practicable and
if the U.S. dollars are transferable to the United States. The depositary bank will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on
deposit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of cash will be made net of the fees, expenses, taxes and governmental
charges payable by holders under the terms of the deposit agreement. The depositary bank will hold any cash amounts it is unable to distribute in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account for the benefit of the
applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary bank holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Distributions of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we make a free distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number
of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will <U>either</U> distribute to holders new ADSs representing the ordinary shares deposited <U>or</U> modify the
<FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT> shares ratio, in which case each ADS you hold will represent rights and interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional
entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of
new ADSs or the modification of the <FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT> shares ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms
of the deposit agreement. In order to pay such taxes or governmental charges, the depositary bank may sell all or a portion of the new ordinary shares so distributed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No such distribution of new ADSs will be made if it would violate a law (<I>e.g.</I>, the U.S. securities laws) or if it is not operationally
practicable. If the depositary bank does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a
distribution of cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Distributions of Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute rights to subscribe for additional ordinary shares, we will give prior notice to the depositary bank and we
will assist the depositary bank in determining whether it is lawful and reasonably practicable to distribute rights to subscribe for additional ADSs to holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will establish procedures to distribute rights to subscribe for additional ADSs to holders and to enable such holders to
exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the
transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary bank is not obligated to establish procedures to facilitate the distribution and
exercise by holders of rights to subscribe for new ordinary shares other than in the form of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will <I>not</I>
distribute the rights to you if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not timely request that the rights be distributed to you or we request that the rights not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We fail to deliver satisfactory documents to the depositary bank; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is not reasonably practicable to distribute the rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The
proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary bank is unable to sell the rights, it will allow the rights to lapse. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Elective Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior
notice thereof to the depositary bank and will indicate whether we wish the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
elective distribution to be made available to you. In such case, we will assist the depositary bank in determining whether such distribution is lawful and reasonably practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will make the election available to you only if it is reasonably practicable and if we have provided all of the
documentation contemplated in the deposit agreement. In such case, the depositary bank will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in France would
receive upon failing to make an election, as more fully described in the deposit agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute property other than cash, ordinary shares or rights to subscribe for additional ordinary shares, we will
notify the depositary bank in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary bank in determining whether such distribution to holders is lawful and reasonably practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it is reasonably practicable to distribute such property to you and if we provide to the depositary bank all of the documentation
contemplated in the deposit agreement, the depositary bank will distribute the property to the holders in a manner it deems practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit
agreement. In order to pay such taxes and governmental charges, the depositary bank may sell all or a portion of the property received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will <I>not</I> distribute the property to you and will sell the property if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not request that the property be distributed to you or if we request that the property not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not deliver satisfactory documents to the depositary bank; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary bank determines that all or a portion of the distribution to you is not reasonably practicable.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we decide to redeem
any of the securities on deposit with the custodian, we will notify the depositary bank in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary bank will provide notice of the
redemption to the holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The custodian will be instructed to surrender the shares being redeemed against payment of the applicable
redemption price. The depositary bank will convert into U.S. dollars upon the terms of the deposit agreement the redemption funds received in a currency other than U.S. dollars and will establish procedures to enable holders to receive the net
proceeds from the redemption upon surrender of their ADSs to the depositary bank. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be
retired will be selected by lot or on a <I>pro rata</I> basis, as the depositary bank may determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes Affecting Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, <FONT
STYLE="white-space:nowrap">split-up,</FONT> cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any such change were to occur, your ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive
the property received or exchanged in respect of the ordinary shares held on deposit. The depositary bank may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form <FONT
STYLE="white-space:nowrap">F-6,</FONT> call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the Shares. If the depositary bank may not lawfully
distribute such property to you, the depositary bank may sell such property and distribute the net proceeds to you as in the case of a cash distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance of ADSs upon Deposit of Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the global offering, the ordinary shares being offered pursuant to the prospectus will be deposited by us with the
custodian.&nbsp;Upon receipt of confirmation of such deposit, the depositary bank will issue ADSs to the underwriters named in the prospectus. After the completion of the global offering, the ordinary shares that are being offered for sale pursuant
to the prospectus will be deposited by us with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will issue ADSs to the underwriters named in the prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the closing of the offer, the depositary bank may create ADSs on your behalf if you or your broker deposit ordinary shares with the
custodian. The depositary bank will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian. Your ability to deposit
ordinary shares and receive ADSs may be limited by U.S. and French legal considerations applicable at the time of deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance
of ADSs may be delayed until the depositary bank or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the custodian. The depositary bank will only issue ADSs in
whole numbers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the
depositary bank. As such, you will be deemed to represent and warrant that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares are duly authorized, validly issued, fully paid,
<FONT STYLE="white-space:nowrap">non-assessable</FONT> and legally obtained. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or
exercised. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You are duly authorized to deposit the ordinary shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge,
mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#147;restricted securities&#148; (as defined in the deposit agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares presented for deposit have not been stripped of any rights or entitlements.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the representations or warranties are incorrect in any way, we and the depositary bank may, at your cost and
expense, take any and all actions necessary to correct the consequences of the misrepresentations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer, Combination and Split Up of ADRs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you
will have to surrender the ADRs to be transferred to the depositary bank and also must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide such proof of identity and genuineness of signatures as the depositary bank deems appropriate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide any transfer stamps required by the State of New York or the United States; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to
the terms of the deposit agreement, upon the transfer of ADRs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To have your ADRs either combined or split up, you must
surrender the ADRs in question to the depositary bank with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a
combination or split up of ADRs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withdrawal of Ordinary shares Upon Cancellation of ADSs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder, you will be entitled to present your ADSs to the depositary bank for cancellation and then receive the corresponding number of
underlying ordinary shares<B> </B>at the custodian&#146;s offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and French law considerations applicable at the time of withdrawal. In order to
withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary bank the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery
of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold
ADSs registered in your name, the depositary bank may ask you to provide proof of identity and genuineness of any signature and such other documents as the depositary bank may deem appropriate before it will cancel your ADSs. The withdrawal of the
ordinary shares represented by your ADSs may be delayed until the depositary bank receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary bank will only accept ADSs for
cancellation that represent a whole number of securities on deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will have the right to withdraw the securities represented by
your ADSs at any time except for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed,
or (ii)&nbsp;ordinary shares are immobilized on account of a shareholders&#146; meeting or a payment of dividends. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obligations to pay fees, taxes and similar charges. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on
deposit. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your
ADSs except to comply with mandatory provisions of law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder, you generally have the right under the deposit agreement to instruct the depositary bank to exercise the voting rights for the
ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in<B> </B>the section of this prospectus entitled &#147;Description of Share Capital&#151;Voting Rights (Article 12 of the Bylaws).&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the depositary bank will distribute to you any notice of shareholders&#146;
meeting received from us together with information explaining how to instruct the depositary bank to exercise the voting rights of the securities represented by ADSs. In lieu of distributing such materials, the depositary bank may distribute to
holders of ADSs instructions on how to retrieve such materials upon request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the depositary bank timely receives voting instructions
from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder&#146;s ADSs in accordance with such voting instructions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities for which no voting instructions have been received will not be voted (except as otherwise contemplated in the deposit agreement).
Please note that the ability of the depositary bank to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to
enable you to return voting instructions to the depositary bank in a timely manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fees and Charges </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADS holder, you will be required to pay the following fees under the terms of the deposit agreement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Service</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Fees</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares, upon a change in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADSs-to-ordinary</FONT></FONT> shares ratio, or for any other
reason), excluding ADS issuances as a result of distributions of ordinary shares)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS issued</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the <FONT STYLE="white-space:nowrap">ADSs-to</FONT> ordinary shares ratio, or for any other reason)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS cancelled</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of ADSs pursuant to (i)&nbsp;stock dividends or other free stock distributions, or (ii)&nbsp;exercise of rights to purchase additional ADSs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a <FONT STYLE="white-space:nowrap">spin-off)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ADS Services</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held on the applicable record date(s) established by the depositary bank</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Registration of ADS transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and <I>vice versa</I>, or for any other reason)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) transferred</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Conversion of ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs (each as defined in the Deposit Agreement) into freely
transferable ADSs, and <I>vice versa</I>).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) converted</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADS holder you will also be responsible to pay certain charges such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">taxes (including applicable interest and penalties) and other governmental charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share
register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary bank or any nominees upon the making of deposits and withdrawals, respectively; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain cable, telex and facsimile transmission and delivery expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fees, expenses, spreads, taxes and other charges of the depositary bank and/or service providers (which may
be a division, branch or affiliate of the depositary bank) in the conversion of foreign currency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the reasonable and customary
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by the depositary bank in connection with compliance with exchange control regulations and other regulatory requirements applicable to
ordinary shares, ADSs and ADRs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fees, charges, costs and expenses incurred by the depositary bank, the custodian, or any nominee in
connection with the ADR program. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ADS fees and charges for (i)&nbsp;the issuance of ADSs, and (ii)&nbsp;the cancellation
of ADSs are charged to the person for whom the ADSs are issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in the case of ADS cancellations). In the case of ADSs issued by the depositary bank into DTC, the ADS
issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may
be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees
and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being
distributed. In the case of (i)&nbsp;distributions other than cash and (ii)&nbsp;the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from
distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in
accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs. In the case of (i)&nbsp;registration of ADS transfers,
the ADS transfer fee will be payable by the ADS Holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii)&nbsp;conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be
payable by the Holder whose ADSs are converted or by the person to whom the converted ADSs are delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of refusal to pay
the depositary bank fees, the depositary bank may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary bank fees from any distribution to be made to the ADS
holder. Certain depositary fees and charges (such as the ADS services fee) may become payable shortly after the closing of the ADS offering.<B> </B>Note that the fees and charges you may be required to pay may vary over time and may be changed by us
and by the depositary bank. You will receive prior notice of such changes. The depositary bank may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of
the ADR program or otherwise, upon such terms and conditions as we and the depositary bank agree from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendments and Termination
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may agree with the depositary bank to modify the deposit agreement at any time without your consent. We undertake to give holders
30 days&#146; prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or
supplements that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we
may not be able to provide you with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be bound by the modifications to the deposit agreement if you continue to hold your
ADSs after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the right to direct the depositary bank to terminate the deposit agreement. Similarly, the depositary bank may in certain
circumstances on its own initiative terminate the deposit agreement. In either case, the depositary bank must give notice to the holders at least &nbsp;&nbsp;&nbsp;&nbsp; days before termination. Until termination, your rights under the deposit
agreement will be unaffected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After termination, the depositary bank will continue to collect distributions received (but will not
distribute any such property until you request the cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary bank will hold the proceeds from such sale and any other funds then held for the holders of
ADSs in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account. At that point, the depositary bank will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding
(after deduction of applicable fees, taxes and expenses). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with any termination of the deposit agreement, the depositary
bank may make available to owners of ADSs a means to withdraw the ordinary shares represented by ADSs and to direct the depositary of such ordinary shares into an unsponsored American depositary share program established by the depositary bank. The
ability to receive unsponsored American depositary shares upon termination of the deposit agreement would be subject to satisfaction of certain U.S. regulatory requirements applicable to the creation of unsponsored American depositary shares and the
payment of applicable depositary fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Books of Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular
business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will maintain in New York facilities to record and process the issuance, cancellation, combination, <FONT
STYLE="white-space:nowrap">split-up</FONT> and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Obligations and Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement limits our obligations and the depositary bank&#146;s obligations to you. Please note the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank are obligated only to take the actions specifically stated in the deposit agreement
without negligence or bad faith. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary bank disclaims any liability for any failure to carry out voting instructions, for any manner in
which a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary bank disclaims any liability for any failure to determine the lawfulness or practicality of any
action, for the content of any document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary
shares, for any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our
failure to give notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank will not be obligated to perform any act that is inconsistent with the terms of the
deposit agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank disclaim any liability if we or the depositary bank are prevented or forbidden from or
subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by
reason of present or future provision of any provision of our Articles of Incorporation, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank disclaim any liability by reason of any exercise of, or failure to exercise, any
discretion provided for in the deposit agreement or in our Articles of Incorporation<B> </B>or in any provisions of or governing the securities on deposit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank further disclaim any liability for any action or inaction in reliance on the advice or
information received from legal counsel, accountants, any person presenting Shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice
or information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank also disclaim liability for the inability by a holder to benefit from any
distribution, offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank may rely without any liability upon any written notice, request or other document
believed to be genuine and to have been signed or presented by the proper parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank also disclaim liability for any consequential or punitive damages for any breach of
the terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nothing in the deposit agreement gives rise to a partnership or joint venture, or establishes a fiduciary
relationship, among us, the depositary bank and you as ADS holder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nothing in the deposit agreement precludes Citibank (or its affiliates) from engaging in transactions in which
parties adverse to us or the ADS owners have interests, and nothing in the deposit agreement obligates Citibank to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to
account for any payment received as part of those transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the
depositary bank and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable
for any deficiency if the sale proceeds do not cover the taxes that are due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank may refuse to issue ADSs, to deliver,
transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary bank and the custodian may take reasonable administrative actions to obtain tax refunds and reduced
tax withholding for any distributions on your behalf. However, you may be required to provide to the depositary bank and to the custodian proof of taxpayer status and residence and such other information as the depositary bank and the custodian may
require to fulfill legal obligations. You are required to indemnify us, the depositary bank and the custodian for any claims with respect to taxes based on any tax benefit obtained for you. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Currency Conversion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
depositary bank will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable
at a reasonable cost or within a reasonable period, the depositary bank may take the following actions in its discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders
for whom the conversion and distribution is lawful and practical. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Distribute the foreign currency to holders for whom the distribution is lawful and practical.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hold the foreign currency (without liability for interest) for the applicable holders. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law/Waiver of Jury Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
deposit agreement, the ADRs and the ADSs will be interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary shares (including<B> </B>ordinary shares represented by ADSs) is governed by the laws of France.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>AS A PARTY TO THE DEPOSIT AGREEMENT, YOU IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, YOUR RIGHT TO TRIAL BY
JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADRs AGAINST US AND/OR THE DEPOSITARY BANK. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit
agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement,
including any claim under U.S. federal securities laws. <I>If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in
accordance with applicable case law. However, you will not be deemed, by agreeing to the terms of the deposit agreement, to have waived our or the depositary&#146;s compliance with U.S. federal securities laws and the rules and regulations
promulgated thereunder.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_19"></A>SHARES AND ADSs ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the global offering, while our ordinary shares have been listed on Euronext Paris since 2006, there has been no public market on a
U.S. national securities exchange for our ordinary shares or ADSs and we cannot assure you that a significant public market in the United States for the ordinary shares or ADSs will be sustained after this global offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future sales of ADSs in the U.S. public market after this global offering, and the availability of ADSs for future sale, could adversely
affect the market price of the ADSs prevailing from time to time. As described below, a significant number of currently outstanding ordinary shares will not be available for sale shortly after this global offering due to contractual restrictions on
transfers of ordinary shares and ADSs. However, sales of substantial amounts of ADSs or ordinary shares, or the perception that these sales could occur, could adversely affect prevailing market prices for the ADSs and could impair our future ability
to raise equity capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of ordinary shares outstanding on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2019, upon completion of the global offering, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ordinary shares (including ordinary shares in the form of ADSs) will be outstanding (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise in full their option to
purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ordinary shares, which may be in the form of ADSs, in connection with the global offering), assuming no outstanding warrants
or options are exercised and assuming no free shares become vested. All of the ADSs sold in the U.S. offering will be freely tradable without restrictions or further registration under the Securities Act, except for any ADSs sold to our
&#147;affiliates,&#148; as that term is defined under Rule 144 under the Securities Act. The ordinary shares held by existing shareholders are &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act.
Restricted securities may be sold in the United States on the Nasdaq Global Market only if registered or if their resale qualifies for exemption from registration described below under Rule 144 or Rule 701 promulgated under the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a person who has
beneficially owned restricted ordinary shares for at least six months would be entitled to sell their securities pursuant to Rule 144 under the Securities Act provided that (1)&nbsp;such person is not deemed to have been one of our affiliates at the
time of, or at any time during the 90 days preceding, a sale and (2)&nbsp;we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Persons who have beneficially owned restricted ordinary shares
for at least six months, but who are our affiliates at the time of, or at any time during the 90 days preceding a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a
number of securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1.0% of the number of ordinary shares (including ordinary shares in the form of ADSs) then outstanding, which
will equal approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares immediately after the completion of the global offering based on the number of ordinary shares outstanding as
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of the ADSs on the Nasdaq Global Market during the four calendar weeks
preceding the filing of a notice on Form 144 with respect to the sale; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, in each case, that we have been subject to the
Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and
notice provisions of Rule 144. <FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales of restricted shares under Rule 144 also are subject to the availability of current public information about us until a period of one year has elapsed since
the securities were acquired from the issuer or an affiliate of the issuer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 701 under the Securities Act permits resales of shares in reliance upon Rule 144 but without compliance with certain restrictions of Rule
144, including the holding period requirement. Most of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees or members of the Supervisory and Executive Boards who purchased shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule 701, but
all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling their shares subject also to French law, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC has indicated that Rule 701 will apply to typical stock options granted by an issuer before it becomes subject to the reporting
requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the members of our Executive and Supervisory Board and certain of our shareholders have agreed that, without the prior written consent of
Citigroup Global Markets Inc., SVB Leerink LLC and Evercore Group L.L.C., or, collectively, the Representatives, on behalf of the underwriters, we and they will not, during the period ending 90 days after the date of this prospectus (i)&nbsp;offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any ordinary shares,
ADSs or any securities convertible into or exercisable or exchangeable for our ordinary shares or ADSs; or (ii)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of the ordinary shares or ADSs. In addition, we have agreed that, without the prior written consent of the Representatives on behalf of the underwriters, we will not, during the restricted period, file any registration statement with the
SEC relating to the offering of any ordinary shares or ADSs or any securities convertible into or exercisable or exchangeable for ordinary shares or ADSs. The restrictions described in this paragraph are subject to certain exceptions. See <FONT
STYLE="white-space:nowrap">&#147;Underwriting&#151;Lock-up</FONT> Agreements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Representatives, in their sole discretion, may
release the ADSs and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently expect any release of ordinary shares or ADSs subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements prior
to the expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> periods. Upon the expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> periods, substantially all of the ordinary shares and ADSs subject to
such <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>French
Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, and notably under the General Regulation (<I>R&egrave;glement G&eacute;n&eacute;ral</I>) issued by the AMF, as
well as under Market Abuse Regulation 596/2014 of 16&nbsp;April 2014, or MAR, any person that holds inside information shall, until such information is made public, refrain from (1)&nbsp;carrying out any transactions relating to securities issued by
the company, (2)&nbsp;recommending that another person engage in insider dealing or induce another person to engage in insider dealing, (3)&nbsp;unlawfully disclosing inside information outside of the normal exercise of an employment, a profession
or duties. The use of inside information by cancelling or amending an order concerning a financial instrument to which the information relates where the order was placed before the person concerned possessed the inside information, shall also be
considered to be insider dealing. These rules apply to all persons who hold inside information as a result of (1)&nbsp;their status as board member, executive officer, manager, employee of the company, third parties acting on behalf of the company
and having access to privileged information as party of their professional relations with the company during the preparation or the completion of a particular transaction, such as investor services providers, lawyers or public relations agencies,
(2)&nbsp;their holding of securities in the share capital of the company, and/or (3)&nbsp;their access to information because of their employment, profession or duties or their participation in the preparation of a financial transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under MAR and the General Regulation of the AMF, it is also prohibited for a person to engage or attempt to engage in market manipulation.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prohibited transactions include all transactions related to securities: stocks, securities
convertible, options, warrants, bonds, and in particular, (1)&nbsp;transfer of securities, (2)&nbsp;exercise of options, warrants or any securities giving access to the capital, (3)&nbsp;transfer of free shares and (4)&nbsp;acquisition of
securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulation S </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation
S provides generally that sales made in offshore transactions are not subject to the registration or prospectus delivery requirements of the Securities Act. Accordingly, restricted securities may be sold in offshore transactions in compliance with
Regulation S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_20"></A>MATERIAL UNITED STATES FEDERAL INCOME AND FRENCH TAX
CONSIDERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following describes material U.S. federal income tax considerations relating to the acquisition, ownership and disposition of our ordinary
shares or ADSs by a U.S. holder (as defined below). This summary addresses these tax considerations only for U.S. holders that are initial purchasers of our ordinary shares or ADSs pursuant to the global offering and that will hold such ordinary
shares or ADSs as capital assets (generally, property held for investment). This summary does not address all U.S. federal income tax matters that may be relevant to a particular U.S. holder. This summary does not address tax considerations
applicable to a holder of our ordinary shares or ADSs that may be subject to special tax rules including, without limitation, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, financial institutions or insurance companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities, currencies, commodities, or notional principal contracts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities or organizations, including an &#147;individual
retirement account&#148; or &#147;Roth IRA&#148; as defined in Section&nbsp;408 or 408A of the Code (as defined below), respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts, regulated investment companies or grantor trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our ordinary shares or ADSs as part of a &#147;hedging,&#148; &#147;integrated,&#148;
&#147;wash sale&#148; or &#147;conversion&#148; transaction or as a position in a &#147;straddle&#148; for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">S corporations, partnerships, or other entities or arrangements classified as partnerships for U.S. federal
income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that received our ordinary shares or ADSs as compensation for the performance of services;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons acquiring our ordinary shares or ADSs in connection with a trade or business conducted outside of the
United States, including a permanent establishment or a fixed base in France; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders that own directly, indirectly, or through attribution 10% or more of the voting power or value of our
ordinary shares or ADSs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders that have a &#147;functional currency&#148; other than the U.S. dollar. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our ordinary shares or ADSs who fall within one of the categories above are advised to consult their tax advisor regarding the
specific tax consequences which may apply to their particular situation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this description, a &#147;U.S. holder&#148;
is a beneficial owner of our ordinary shares or ADSs that is (or is treated as), for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United
States, any state therein or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust, if a court within the United States is able to exercise primary supervision over its administration and
one or more U.S. persons have the authority to control all of the substantial decisions of such trust, or if such trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (or any other entity treated as a partnership for U.S. federal income tax purposes) holds our ordinary shares or ADSs, the
tax consequences relating to an investment in our ordinary shares or ADSs will depend in part upon the status of the partner and the activities of the partnership. Such a partner or partnership should consult its tax advisor regarding the specific
tax considerations of acquiring, owning and disposing of our ordinary shares or ADSs in its particular circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion in this section is based in part upon the representations of the depositary
and the assumption that each obligation in the deposit agreement and any related agreement will be performed in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Persons considering an investment in our ordinary shares or ADSs should consult their own tax advisors as to the particular tax
consequences applicable to them relating to the acquisition, ownership and disposition of our ordinary shares or ADSs, including the applicability of U.S. federal, state and local tax laws, French tax laws and other
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This description does not address the U.S. federal estate, gift, or
alternative minimum tax considerations, or any U.S. state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax considerations of the acquisition, ownership and disposition of our ordinary shares or ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This description is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, existing, proposed and temporary U.S. Treasury
Regulations promulgated thereunder and administrative and judicial interpretations thereof, in each case as in effect and available on the date hereof. All the foregoing is subject to change, which change could apply retroactively, and to differing
interpretations, all of which could affect the tax considerations described below. There can be no assurances that the U.S. Internal Revenue Service, or the IRS, will not take a position concerning the tax consequences of the acquisition, ownership
and disposition of our ordinary shares or ADSs or that such a position would not be sustained by a court. We have not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax considerations in the purchase,
ownership or disposition of our ordinary shares or ADSs. Accordingly, holders should consult their own tax advisors concerning the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of acquiring, owning
and disposing of our ordinary shares or ADSs in their particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As indicated below, this discussion is subject to U.S.
federal income tax rules applicable to a &#147;passive foreign investment company,&#148; or a PFIC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, and taking into account
the earlier assumptions, for U.S. federal income tax purposes, a U.S. holder holding ADSs will be treated as the owner of the ordinary shares represented by the ADSs. Exchanges of ordinary shares for ADSs, and ADSs for ordinary shares, generally
will not be subject to U.S. federal income tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Distributions</I></B>. Subject to the discussion under &#147;&#151;Passive Foreign
Investment Company Considerations,&#148; below, the gross amount of any distribution (including any amounts withheld in respect of foreign tax) actually or constructively received by a U.S. holder with respect to our ordinary shares or ADSs will
generally be taxable to the U.S. holder as a dividend to the extent of the U.S. holder&#146;s pro rata share of our current or accumulated earnings and profits as determined under U.S. federal income tax principles. Distributions in excess of
earnings and profits will generally be <FONT STYLE="white-space:nowrap">non-taxable</FONT> to the U.S. holder to the extent of, and will be applied against and reduce, the U.S. holder&#146;s adjusted tax basis in our ordinary shares or ADSs.
Distributions in excess of earnings and profits and such adjusted tax basis will generally be taxable to the U.S. holder as either long-term or short-term capital gain depending upon whether the U.S. holder has held our ordinary shares or ADSs for
more than one year as of the time such distribution is received. However, since we do not calculate our earnings and profits under U.S. federal income tax principles, it is expected that any distribution will be reported as a dividend, even if that
distribution would otherwise be treated as a <FONT STYLE="white-space:nowrap">non-taxable</FONT> return of capital or as capital gain under the rules described above. <FONT STYLE="white-space:nowrap">Non-corporate</FONT> U.S. holders may qualify for
the preferential rates of taxation with respect to dividends on our ordinary shares or ADSs applicable to long-term capital gains (i.e., gains from the sale of capital assets held for more than one year) and qualified dividend income (as discussed
below) if we are a &#147;qualified foreign corporation&#148; and certain other requirements (discussed below) are met. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation (other than a corporation that is classified as a PFIC for the
taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation (a)&nbsp;if it is eligible for the benefits of a comprehensive tax treaty with the United States which the
Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of information </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provision, or (b)&nbsp;with respect to any dividend it pays on ADSs which are readily tradable on an established securities market in the United States. We have applied to list our ADSs on the
Nasdaq Global Market, which is an established securities market in the United States, and we expect the ADSs to be readily tradable on the Nasdaq Global Market. There can be no assurance that the ADSs will be considered readily tradable on an
established securities market in the United States in later years. The Company, which is incorporated under the laws of France, believes that it qualifies as a resident of France for purposes of, and is eligible for the benefits of, the Convention
between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital, signed on August&nbsp;31, 1994,
as amended and currently in force, or the U.S.-France Tax Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the U.S.-France Tax Treaty is satisfactory for purposes of the qualified dividend rules and
that it includes an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">exchange-of-information</FONT></FONT> program. Therefore, subject to the discussion under &#147;&#151;Passive Foreign Investment Company Considerations,&#148;
below, such dividends will generally be &#147;qualified dividend income&#148; in the hands of individual U.S. holders, provided that a holding period requirement (more than 60 days of ownership, without protection from the risk of loss, during the <FONT
STYLE="white-space:nowrap">121-day</FONT> period beginning 60 days before the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date) and certain other requirements are met. The dividends will not be eligible for the dividends-received deduction
generally allowed to corporate U.S. holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. holder generally may claim the amount of any French withholding tax as either a
deduction from gross income or a credit against its U.S. federal income tax liability. The foreign tax credit is subject to numerous complex limitations that must be determined and applied on an individual basis. Generally, the credit cannot exceed
the proportionate share of a U.S. holder&#146;s U.S. federal income tax liability that such U.S. holder&#146;s taxable income bears to such U.S. holder&#146;s worldwide taxable income. In applying this limitation, a U.S. holder&#146;s various items
of income and deduction must be classified, under complex rules, as either &#147;foreign source&#148; or &#147;U.S. source.&#148; In addition, the creditability of foreign taxes could be affected by actions taken by intermediaries in the chain of
ownership between the holders of our ordinary shares or ADSs and our company if, as a result of such actions, the holders of our ordinary shares or ADSs are not properly treated as beneficial owners of the underlying ordinary shares. Each U.S.
holder should consult its own tax advisors regarding the foreign tax credit rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, the amount of a distribution paid to a
U.S. holder in a foreign currency will be the U.S. dollar value of the foreign currency calculated by reference to the spot exchange rate on the day the depositary receives the distribution, in the case of the ADSs, or on the day the distribution is
received by the U.S. holder, in the case of ordinary shares, regardless of whether the foreign currency is converted into U.S. dollars at that time. Any foreign currency gain or loss a U.S. holder realizes on a subsequent conversion of foreign
currency into U.S. dollars will be U.S. source ordinary income or loss. If dividends received in a foreign currency are converted into U.S. dollars on the day they are received, a U.S. holder should not be required to recognize foreign currency gain
or loss in respect of the dividend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sale, Exchange or Other Taxable Disposition</I></B>. A U.S. holder will generally recognize
gain or loss for U.S. federal income tax purposes upon the sale, exchange or other taxable disposition of our ordinary shares or ADSs in an amount equal to the difference between the U.S. dollar value of the amount realized from such sale or
exchange and the U.S. holder&#146;s adjusted tax basis in those ordinary shares or ADSs, determined in U.S. dollars. Subject to the discussion under &#147;&#151;Passive Foreign Investment Company Considerations&#148; below, this gain or loss will
generally be a capital gain or loss. The adjusted tax basis in our ordinary shares or ADSs generally will be equal to the cost of such ordinary shares or ADSs. Capital gain from the sale, exchange or other taxable disposition of our ordinary shares
or ADSs by a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder is generally eligible for a preferential rate of taxation applicable to capital gains, if the <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder&#146;s
holding period determined at the time of such sale, exchange or other taxable disposition for such ordinary shares or ADSs exceeds one year (i.e., such gain is long-term taxable gain). The deductibility of capital losses for U.S. federal income tax
purposes is subject to limitations. Any such gain or loss that a U.S. holder recognizes generally will be treated as U.S. source gain or loss for foreign tax credit limitation purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a cash basis taxpayer, units of foreign currency paid or received are translated into
U.S. dollars at the spot rate on the settlement date of the purchase or sale. In that case, no foreign currency exchange gain or loss will result from currency fluctuations between the trade date and the settlement date of such a purchase or sale.
An accrual basis taxpayer, however, may elect the same treatment required of cash basis taxpayers with respect to purchases and sales of our ordinary shares or ADSs that are traded on an established securities market, provided the election is
applied consistently from year to year. Such election may not be changed without the consent of the IRS. For an accrual basis taxpayer who does not make such election, units of foreign currency paid or received are translated into U.S. dollars at
the spot rate on the trade date of the purchase or sale. Such an accrual basis taxpayer may recognize exchange gain or loss based on currency fluctuations between the trade date and the settlement date. Any foreign currency gain or loss a U.S.
holder realizes will be U.S. source ordinary income or loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Medicare Tax</I></B>. Certain U.S. holders that are individuals,
estates or trusts are subject to a 3.8% tax on all or a portion of their &#147;net investment income,&#148; which may include all or a portion of their dividend income and net gains from the disposition of our ordinary shares or ADSs. Each U.S.
holder that is an individual, estate or trust is urged to consult its tax advisors regarding the applicability of the Medicare tax to its income and gains in respect of its investment in our ordinary shares or ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Considerations</I></B>. If we are classified as a PFIC in any taxable year, a U.S. holder will be
subject to special rules generally intended to reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. holder could derive from investing in a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company that does not
distribute all of its earnings on a current basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be classified as a PFIC for U.S. federal income tax purposes in any taxable
year in which, after applying certain look-through rules with respect to the income and assets of our subsidiaries, either: (1)&nbsp;at least 75% of the gross income is &#147;passive income&#148; or (2)&nbsp;at least 50% of the average quarterly
value of our total gross assets (which would generally be measured by fair market value of our assets, and for which purpose the total value of our assets may be determined in part by the market value of the ADSs and our ordinary shares, which are
subject to change) is attributable to assets that produce &#147;passive income&#148; or are held for the production of &#147;passive income.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities and securities transactions,
the excess of gains over losses from the disposition of assets which produce passive income, and includes amounts derived by reason of the temporary investment of funds raised in offerings of our ordinary shares or ADSs. If a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> corporation owns directly or indirectly at least 25% by value of the stock of another corporation, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation is treated for purposes of the PFIC tests
as owning its proportionate share of the assets of the other corporation and as receiving directly its proportionate share of the other corporation&#146;s income. The determination of whether we are a PFIC is a fact-intensive determination made on
an annual basis and the applicable law is subject to varying interpretation. If we are classified as a PFIC in any taxable year during which a U.S. holder owns our ordinary shares or ADSs, such U.S. holder will be subject to special tax rules
discussed below and could suffer adverse tax consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market value of our assets may be determined in large part by reference to
the market price of the ADSs and our ordinary shares, which is likely to fluctuate after the global offering. Therefore, fluctuations in the market price of our ordinary shares or ADSs may result in our being a PFIC for any taxable year. In
addition, the composition of our income and assets will be affected by how, and how quickly, we use the cash proceeds from the global offering in our business. Whether we are a PFIC for any taxable year will depend on income, assets, activities and
market capitalization in each year, and because this is a factual determination made annually after the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable year. We do not believe we were
characterized as a PFIC in our taxable year ended December&nbsp;31, 2018. Based on the expected nature and composition of our income, assets, activities and market capitalization for our taxable year ending December 31, 2019, we believe that we will
not be classified as a PFIC for our taxable year ending </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&nbsp;31, 2019; however, there can be no assurance that we will not be considered a PFIC in the current year or for any future taxable year. Our U.S. counsel expresses no opinion
regarding our conclusions or our expectations regarding our PFIC status. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are classified as a PFIC in any year with respect to which
a U.S. holder owns our ordinary shares or ADSs, we will continue to be treated as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns the ordinary shares or ADSs, regardless of whether we continue to
meet the tests described above unless we cease to be a PFIC and the U.S. holder has made a &#147;deemed sale&#148; election under the PFIC rules or is eligible to make and makes a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election (as described below), with respect to all taxable years during such U.S. holder&#146;s holding period in which we are a PFIC. If the &#147;deemed
sale&#148; election is made, a U.S. holder will be deemed to have sold the ordinary shares or ADSs the U.S. holder holds at their fair market value as of the date of such deemed sale and any gain from such deemed sale would be subject to the rules
described below. After the deemed sale election, so long as we do not become a PFIC in a subsequent taxable year, the U.S. holder&#146;s ordinary shares or ADSs with respect to which such election was made will not be treated as shares in a PFIC and
the U.S. holder will not be subject to the rules described below with respect to any &#147;excess distribution&#148; the U.S. holder receives from us or any gain from an actual sale or other disposition of the ordinary shares or ADSs. U.S. holders
should consult their tax advisors as to the possibility and consequences of making a deemed sale election if such election becomes available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC, and you are a U.S. holder that does not make one of the elections described above (and below in further detail), a special
tax regime will apply to both (a)&nbsp;any &#147;excess distribution&#148; by us to you (generally, your ratable portion of distributions in any year which are greater than 125% of the average annual distribution received by you in the shorter of
the three preceding years or your holding period for our ordinary shares or ADSs) and (b)&nbsp;any gain realized on the sale or other disposition of our ordinary shares or ADSs. Under this regime, any excess distribution and realized gain will be
treated as ordinary income and will be subject to tax as if (a)&nbsp;the excess distribution or gain had been realized ratably over your holding period, (b)&nbsp;the amount deemed realized in each year had been subject to tax in each year of that
holding period at the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. holder&#146;s regular ordinary income rate for the
current year and would not be subject to the interest charge discussed below), and (c)&nbsp;the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition,
dividend distributions made to you will not qualify for the lower rates of taxation applicable to qualified dividends discussed above under &#147;Distributions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain elections may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment of our ordinary
shares or ADSs. If a U.S. holder makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, the U.S. holder generally will recognize as ordinary income any excess of the fair market value of our
ordinary shares or ADSs at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of our ordinary shares or ADSs over their fair market value at the end of
the taxable year (but only to the extent of the net amount of income previously included as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). If a U.S. holder makes the
election, the U.S. holder&#146;s tax basis in our ordinary shares or ADSs will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of our ordinary shares or ADSs in a year in which we are a PFIC
will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available only if we are a PFIC
and our ordinary shares or ADSs are &#147;regularly traded&#148; on a &#147;qualified exchange.&#148; Our ordinary shares or ADSs will be treated as &#147;regularly traded&#148; in any calendar year in which more than a de minimis quantity of our
ordinary shares or ADSs are traded on a qualified exchange on at least 15 days during each calendar quarter (subject to the rule that trades that have as one of their principal purposes the meeting of the trading requirement are disregarded). The
Nasdaq Global Market is a qualified exchange for this purpose and, consequently, if the ADSs are regularly traded, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election will be available to a
U.S. holder. It should be noted that it is intended that only the ADSs and not our ordinary shares will be listed on the Nasdaq Global Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Consequently, our ordinary shares may not be marketable if Euronext Paris (where our ordinary shares are listed) does not meet the applicable requirements. U.S. holders should consult their tax
advisors regarding the availability of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election for ordinary shares that are not represented by ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election generally cannot be made
for equity interests in any lower-tier PFICs that we own, unless shares of such lower-tier PFIC are themselves &#147;marketable.&#148; As a result, even if a U.S. holder validly makes a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to our ordinary shares or ADSs, the U.S. holder may continue to be subject to the PFIC rules (described above) with respect to its
indirect interest in any of our investments that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. U.S. holders should consult their tax advisors as to the availability and desirability of a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, as well as the impact of such election on interests in any lower-tier PFICs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently intend to provide the information necessary for U.S. holders to make qualified electing fund elections if we were treated
as a PFIC for any taxable year. U.S. holders should consult their tax advisors to determine whether any of these elections would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are determined to be a PFIC, the general tax treatment for U.S. holders described in this section would apply to indirect
distributions and gains deemed to be realized by U.S. holders in respect of any of our subsidiaries that also may be determined to be PFICs. U.S. holders should consult their tax advisors regarding the application of the PFIC rules to our
subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. holder owns our ordinary shares or ADSs during any taxable year in which we are a PFIC, the U.S. holder generally
will be required to file an IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) with respect to the company, generally with the U.S. holder&#146;s federal income tax return for that
year. If our company were a PFIC for a given taxable year, then you should consult your tax advisor concerning your annual filing requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The U.S. federal income tax rules relating to PFICs are complex. Prospective U.S. investors are urged to consult their own tax advisors
with respect to the acquisition, ownership and disposition of our ordinary shares or ADSs, the consequences to them of an investment in a PFIC, any elections available with respect to our ordinary shares or ADSs and the IRS information reporting
obligations with respect to the acquisition, ownership and disposition of our ordinary shares or ADSs. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Backup Withholding and
Information Reporting</I></B>. U.S. holders generally will be subject to information reporting requirements with respect to dividends on our ordinary shares or ADSs and on the proceeds from the sale, exchange or disposition of our ordinary shares or
ADSs that are paid within the United States or through U.S.-related financial intermediaries, unless the U.S. holder is an &#147;exempt recipient.&#148; In addition, U.S. holders may be subject to backup withholding on such payments, unless the U.S.
holder provides a taxpayer identification number and a duly executed IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> or otherwise establishes an exemption. Backup withholding is not an additional tax, and the amount of any backup withholding
will be allowed as a credit against a U.S. holder&#146;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Certain Reporting Requirements With Respect to Payments of Offer Price</I></B>. U.S. holders paying more than $100,000 for our ordinary
shares or ADSs generally may be required to file IRS Form 926 reporting the payment of the offer price for our ordinary shares or ADSs to us. Substantial penalties may be imposed upon a U.S. holder that fails to comply. Each U.S. holder should
consult its own tax advisor as to the possible obligation to file IRS Form 926. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Asset Reporting</I></B>. Certain individual
U.S. holders are required to report information relating to an interest in our ordinary shares or ADSs, subject to certain exceptions (including an exception for shares held in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accounts maintained by U.S. financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their federal income tax return. U.S. holders are urged to
consult their tax advisors regarding their information reporting obligations, if any, with respect to their ownership and disposition of our ordinary shares or ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE DISCUSSION ABOVE IS A SUMMARY OF THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs AND IS BASED
UPON LAWS AND RELEVANT INTERPRETATIONS THEREOF IN EFFECT AS OF THE DATE OF THIS PROSPECTUS, ALL OF WHICH ARE SUBJECT TO CHANGE, POSSIBLY WITH RETROACTIVE EFFECT. EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX
CONSEQUENCES TO IT OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs IN LIGHT OF THE INVESTOR&#146;S OWN CIRCUMSTANCES. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material French Tax
Considerations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following describes the material French income tax consequences to U.S. holders of purchasing, owning and disposing
of our ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not purport to be a complete analysis or listing of all potential tax effects of the acquisition,
ownership or disposition of our ADSs to any particular investor, and does not discuss tax considerations that arise from rules of general application or that are generally assumed to be known by investors. All of the following is subject to change.
Such changes could apply retroactively and could affect the consequences described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2011, France introduced a comprehensive set
of tax rules applicable to French assets that are held by or in foreign trusts. These rules provide inter alia for the inclusion of trust assets in the settlor&#146;s net assets for the purpose of applying the former French wealth tax (replaced by
the French real estate wealth tax as from January&nbsp;1, 2018), for the application of French gift and death duties to French assets held in trust, for a specific tax on capital on the French assets of foreign trusts not already subject to the
former French wealth tax (replaced by the French real estate wealth tax as from January&nbsp;1, 2018) and for a number of French tax reporting and disclosure obligations. The following discussion does not address the French tax consequences
applicable to securities (including ADSs) held in trusts. If ADSs are held in trust, the grantor, trustee and beneficiary are advised to consult their own tax advisor regarding the specific tax consequences of acquiring, owning and disposing of such
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description of the French income tax and real estate wealth tax consequences set forth below is based on the double tax
treaty entered into between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital of
August&nbsp;31, 1994 (the &#147;Treaty&#148;), which came into force on December&nbsp;30, 1995 (as amended by any subsequent protocols, including the protocol of January&nbsp;13, 2009), and the tax guidelines issued by the French tax authorities in
force as of the date of this prospectus, or the Treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion applies only to investors that are entitled to Treaty benefits
under the &#147;Limitation on Benefits&#148; provisions contained in the Treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership holds ADSs, the tax treatment of the
partnership and a partner in such partnership generally will depend on the status of the partner and the activities of the partnership. Such partner or partnership is urged to consult its own tax advisor regarding the specific tax consequences of
acquiring, owning and disposing of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion applies only to investors that hold ADSs as capital assets that are entitled to
Treaty benefits under the &#147;Limitation on Benefits&#148; provision contained in the Treaty, and whose ownership of the ADSs is not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effectively connected to a permanent establishment or a fixed base in France. Certain U.S. holders may be subject to special rules not discussed below, and are advised to consult their usual tax
advisor regarding the specific tax consequences which may apply to their particular situation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. holders are advised to consult their
own tax advisor regarding the tax consequences of the purchase, ownership and disposition of ADSs in light of their particular circumstances, especially with regard to the &#147;Limitations on Benefits&#148; provision contained in the Treaty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Tax on Sale or other Disposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a matter of principles, under French tax law, a U.S. holder should not be subject to any French tax on any capital gain from the sale,
exchange, repurchase or redemption by us of ordinary shares or ADSs, provided such U.S. holder is not a French tax resident for French tax purposes and has not held more than 25% of our dividend rights, known as <I>&#147;droits aux benefices
sociaux,&#148; </I>at any time during the preceding five years, either directly or indirectly, and, as relates to individuals, alone or with relatives (as an exception, a U.S. holder resident, established or incorporated in certain <FONT
STYLE="white-space:nowrap">non-cooperative</FONT> States or territories as defined in Article <FONT STYLE="white-space:nowrap">238-0</FONT> A of the French tax code (<I>Code g&eacute;n&eacute;ral des imp&ocirc;ts</I>, the &#147;FTC&#148;) should be
subject to a 75% withholding tax in France on any such capital gain, regardless of the fraction of the dividend rights it holds). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
application of the Treaty, a U.S. holder who is a U.S. resident for purposes of the Treaty and entitled to Treaty benefits will not be subject to French tax on such capital gain unless the ordinary shares or the ADSs form part of the business
property of a permanent establishment or fixed base that the U.S. holder has in France. U.S. holders who own ordinary shares or ADSs through U.S. partnerships that are not resident for Treaty purposes are advised to consult their own tax advisor
regarding their French tax treatment and their eligibility for Treaty benefits in light of their own particular circumstances.&nbsp;A U.S. holder that is not a U.S. resident for Treaty purposes or is not entitled to Treaty benefits (and in both
cases is not resident, established or incorporated in certain <FONT STYLE="white-space:nowrap">non-cooperative</FONT> States or territories as defined in Article <FONT STYLE="white-space:nowrap">238-0</FONT> A of the FTC) and has held more than 25%
of our dividend rights, known as <I>&#147;droits aux benefices sociaux&#148; </I>at any time during the preceding five years, either directly or indirectly, and, as relates to individuals, alone or with relatives will be subject to a levy in France
(i)&nbsp;at the rate of 12.8% for individuals, and (ii)&nbsp;a rate corresponding to the standard corporate income tax rate set forth in Article <FONT STYLE="white-space:nowrap">219-I</FONT> of the FTC for legal persons. Special rules apply to U.S.
holders who are residents of more than one country. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Financial Transactions Tax and Registration Duties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Article 235 <I>ter </I>ZD of the FTC, purchases of shares or ADSs of a French company listed on a regulated market of the European
Union or on a foreign regulated market formally acknowledged by the AMF are subject to a 0.3% French tax on financial transactions provided that the issuer&#146;s market capitalization exceeds 1&nbsp;billion euros as of December&nbsp;1 of the year
preceding the taxation year. A list of companies whose market capitalization exceeds 1&nbsp;billion euros as of December&nbsp;1 of the year preceding the taxation year, within the meaning of Article 235<I> ter</I> ZD of the FTC, is published
annually by the French tax authorities in their official guidelines. As at 1 December&nbsp;2018, our market capitalization did not exceed 1&nbsp;billion euros, pursuant to <FONT STYLE="white-space:nowrap">BOI-ANNX-000467-20181217.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, Nasdaq Global Market, on which ADSs will be listed, is not currently acknowledged by the AMF but this may change in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a consequence, neither the ADSs nor the ordinary shares are currently within the scope of the French tax on financial transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following this global offering, purchases of our ADSs may be subject to such tax in the future provided that our market capitalization exceeds
1&nbsp;billion euros in the year preceding the taxation year and that the Nasdaq Global Market is acknowledged by the French AMF. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case where Article 235 <I>ter</I> ZD of the FTC is not applicable, transfers of
shares issued by a French company which are listed on a regulated or organized market within the meaning of the French monetary code (<I>Code mon&eacute;taire et financier</I>) are subject to uncapped registration duties at the rate of 0.1% if the
transfer is evidenced by a written statement (&#147;<I>acte</I>&#148;) executed either in France or outside France. As ordinary shares of our company are listed on Euronext Paris, which is an organized market within the meaning of the French
monetary code, their transfer should be subject to uncapped registration duties at the rate of 0.1% subject to the existence of a written statement (&#147;<I>acte</I>&#148;), and provided that Article 235 <I>ter</I> ZD of the FTC is not applicable.
Although there is no case law or official guidelines published by the French tax authorities on this point, transfer of ADSs should remain outside of the scope of the aforementioned 0.1% registration duties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid by a French corporation to <FONT STYLE="white-space:nowrap">non-residents</FONT> of France are generally subject to French
withholding tax at a rate of (i) 30% (to be aligned on the standard corporate income tax rate set forth in Article <FONT STYLE="white-space:nowrap">219-I</FONT> of the FTC for fiscal years beginning as from January&nbsp;1, 2020) for payment
benefiting legal persons which are not French tax residents, and (ii) 12.8% for payment benefiting individuals who are not French tax residents. Dividends paid by a French corporation in certain
<FONT STYLE="white-space:nowrap">non-cooperative</FONT> States or territories, as defined in Article <FONT STYLE="white-space:nowrap">238-0</FONT> A of the FTC, will generally be subject to French withholding tax at a rate of 75%. However, eligible
U.S. holders entitled to Treaty benefits under the &#147;Limitation on Benefits&#148; provision contained in the Treaty who are U.S. residents, as defined pursuant to the provisions of the Treaty, will not be subject to this 30% (to be aligned on
the standard corporate income tax rate set forth in Article <FONT STYLE="white-space:nowrap">219-I</FONT> of the FTC for fiscal years beginning as from January&nbsp;1, 2020) or 75% withholding tax rate, but may be subject to the withholding tax at a
reduced rate (as described below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Treaty, the rate of French withholding tax on dividends paid to an eligible U.S. holder who
is a U.S. resident as defined pursuant to the provisions of the Treaty and whose ownership of the ordinary shares or ADSs is not effectively connected with a permanent establishment or fixed base that such U.S. holder has in France, is generally
reduced to 15%, or to 5% if such U.S. holder is a corporation and owns directly or indirectly at least 10% of the share capital of the issuer; such U.S. holder may claim a refund from the French tax authorities of the amount withheld in excess of
the Treaty rates of 15% or 5%, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For U.S. holders that are not individuals but are U.S. residents, as defined pursuant to the
provisions of the Treaty, the requirements for eligibility for Treaty benefits, including the reduced 5% or 15% withholding tax rates contained in the &#147;Limitation on Benefits&#148; provision of the Treaty, are complex, and certain technical
changes were made to these requirements by the protocol of January&nbsp;13, 2009. U.S. holders are advised to consult their own tax advisor regarding their eligibility for Treaty benefits in light of their own particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid to an eligible U.S. holder may immediately be subject to the reduced rates of 5% or 15% provided that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holder establishes before the date of payment that it is a U.S. resident under the Treaty by completing and
providing the depositary with a treaty form (Form 5000) in accordance with French guidelines (BOI-INT-DG-20-20-20-20-20120912 dated September 12, 2012); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary or other financial institution managing the securities account in the U.S. of such holder provides
the French paying agent with a document listing certain information about the U.S. holder and its ordinary shares or ADSs and a certificate whereby the financial institution managing the U.S.&nbsp;holder&#146;s securities account in the United
States takes full responsibility for the accuracy of the information provided in the document. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Otherwise, dividends
paid to a U.S. holder, if such U.S. holder is a legal person, will be subject to French withholding tax at the rate of 30% (to be aligned on the standard corporate income tax rate set forth in Article
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">219-I</FONT> of the FTC for fiscal years beginning as from January&nbsp;1, 2020), or 75% if paid in certain
<FONT STYLE="white-space:nowrap">non-cooperative</FONT> States or territories (as defined in Article <FONT STYLE="white-space:nowrap">238-0</FONT> A of the FTC), and then reduced at a later date to 5% or 15%, provided that such holder duly completes
and provides the French tax authorities with the treaty forms Form 5000 and Form 5001 before December&nbsp;31 of the second calendar year following the year during which the dividend is paid. Certain qualifying pension funds and certain other <FONT
STYLE="white-space:nowrap">tax-exempt</FONT> entities are subject to the same general filing requirements as other U.S. holders except that they may have to supply additional documentation evidencing their entitlement to these benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Form 5000 and Form 5001, together with instructions, will be provided by the depositary to all U.S. holders registered with the depositary.
The depositary will arrange for the filing with the French tax authorities of all such forms properly completed and executed by U.S. holders of ordinary shares or ADSs and returned to the depositary in sufficient time so that they may be filed with
the French tax authorities before the distribution in order to immediately obtain a reduced withholding tax rate. Otherwise, the depositary must withhold tax at the full rate of 30% (to be aligned on the standard corporate income tax rate set forth
in Article <FONT STYLE="white-space:nowrap">219-I</FONT> of the FTC for fiscal years beginning as from January&nbsp;1, 2020) or 75% as applicable. In that case, the U.S. holders may claim a refund from the French tax authorities of the excess
withholding tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any case, individual taxpayers who are not fiscally domiciled in France should not have to comply with these
procedures if the French withholding tax applying to them is lower than 15%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Estate and Gift Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a transfer of securities by gift or by reason of death of a U.S. holder that would otherwise be subject to French gift or
inheritance tax, respectively, will not be subject to such French tax by reason of the double tax treaty entered into between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double
Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Estates, Inheritances and Gifts, dated November&nbsp;24, 1978, unless (i)&nbsp;the donor or the transferor is domiciled in France at the time of making the gift or at the time of
his or her death, or (ii)&nbsp;the ADSs were used in, or held for use in, the conduct of a business through a permanent establishment or a fixed base in France. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Wealth Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
from January&nbsp;1, 2018, the French wealth tax <I>(imp&ocirc;t de solidarit&eacute; sur la fortune) </I>is repealed and replaced by the French real estate wealth tax<I> (imp&ocirc;t sur la fortune immobili&egrave;re). </I>The scope of such new tax
is narrowed to real estate assets (and certain assets deemed to be real estate assets) or rights, held directly or indirectly through one or more legal entities and whose net taxable assets amount at least to &#128;1,300,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broadly, subject to provisions of double tax treaties and to certain exceptions, individuals who are not residents of France for tax purposes
within the meaning of Article 4 B of the FTC, are subject to real estate wealth tax <I>(imp&ocirc;t sur la fortune immobili&egrave;re) </I>in France in respect of the portion of the value of their shares of our company representing real estate
assets (Article 965, 2&deg; of the FTC). Some exceptions are provided by the FTC<I>. </I>For instance, any participations representing less than 10% of the share capital of an operational company and shares representing real estate for the
professional use of the company considered shall not fall within the scope of the French real estate wealth tax <I>(imp&ocirc;t sur la fortune immobili&egrave;re).</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Treaty (the provisions of which should be applicable to this new real estate wealth tax <I>(imp&ocirc;t sur la fortune
immobili&egrave;re) </I>in France), the French real estate wealth tax <I>(imp&ocirc;t sur la fortune immobili&egrave;re</I>) will however generally not apply<I> </I>to securities held by an eligible U.S. holder who is a U.S. resident, as defined
pursuant to the provisions of the Treaty, provided that such U.S. holder (i)&nbsp;does not own directly or indirectly more than 25% of the issuer&#146;s financial rights and (ii)&nbsp;that the ADSs do not form part of the business property of a
permanent establishment or fixed base in France. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. holders are advised to consult their own tax advisor regarding the specific tax
consequences which may apply to their particular situation with respect to such French real estate wealth tax <I>(imp&ocirc;t sur la fortune immobili&egrave;re</I>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_21"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a corporation organized under the laws of France. The majority of our members of the Executive Board and Supervisory Board are citizens
and residents of countries other than the United States, and the majority of our assets are located outside of the United States. We have appointed an agent for service of process in the United States; however, it may be difficult for investors:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to obtain jurisdiction over us or our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident members of the
Executive Board and Supervisory Board in U.S. courts in actions predicated on the civil liability provisions of the U.S.&nbsp;federal securities laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to enforce judgments obtained in such actions against us or our <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
resident members of the Executive Board and supervisory; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to bring an original action in a French court to enforce liabilities based upon the U.S. federal securities laws
against us or our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident members of the Executive Board and Supervisory Board; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to enforce against us or our Executive Board in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> courts,
including French courts, judgments of U.S. courts predicated upon the civil liability provisions of the U.S. federal securities laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nevertheless, a final judgment for the payment of money rendered by any federal or state court in the United States based on civil liability,
whether or not predicated solely upon the U.S. federal securities laws, would be recognized and enforced in France provided that a French judge considers that this judgment meets the French legal requirements concerning the recognition and the
enforcement of foreign judgments and is capable of being immediately enforced in the United States. A French court is therefore likely to grant the enforcement of a foreign judgment without a review of the merits of the underlying claim, only if (1)
that judgment is enforceable in the jurisdiction of the U.S. court which rendered it, (2) that judgment was rendered by a court having jurisdiction over the dispute (the condition will be met if the dispute is clearly connected to the jurisdiction
of the U.S. court and French courts did not have exclusive jurisdiction over the matter), (3) that judgment does not contravene French international public order and public policy, including the right to due process, and (4) the U.S. judgment is not
tainted with fraud and is not incompatible with a judgment rendered by a French court in the same matter, or with an earlier judgment rendered by a foreign court in the same matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, French law guarantees full compensation for the harm suffered but is limited to the actual damages, so that the victim does not
suffer or benefit from the situation. Such system excludes damages such as, but not limited to, punitive and exemplary damages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a
result, the enforcement, by U.S. investors, of any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities law against us or members of our Executive Board and Supervisory Board or
certain experts named herein who are residents of France or countries other than the United States would be subject to the above conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, there may be doubt as to whether a French court would impose civil liability on us, the members of our Executive Board and
Supervisory Board or certain experts named herein in an original action predicated solely upon the U.S. federal securities laws brought in a court of competent jurisdiction in France against us or such members, officers or experts, respectively.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_22"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This global offering consists of a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares,
consisting of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an offering of a total
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in the form of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs in the United
States, referred to as the U.S. offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a concurrent private offering of a total
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in Europe (including France) and countries outside of the United States, referred to as the European private placement.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc., SVB Leerink LLC and Evercore Group L.L.C. are acting as representatives of the
underwriters in the U.S. offering. Citigroup Global Markets Limited is acting as a representative in the European private placement. As used herein, with respect to the U.S. offering, the term &#147;underwriters&#148; refers to the underwriters
offering ordinary shares in the form of ADSs in the United States and, with respect to the European private placement, the underwriter offering ordinary shares in Europe, as the case may be. The underwriters in the U.S. offering and the underwriter
in the European private placement are collectively referred to herein as the &#147;underwriters.&#148; Under the terms and subject to the conditions of an underwriting agreement dated the date of this prospectus, the underwriters named below have
severally agreed to purchase, and we have agreed to sell to them, severally, the number of ADSs (including underlying ordinary shares) and/or ordinary shares (exclusive of ordinary shares underlying ADSs), as the case may be, indicated below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>ADSs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters in each offering are offering the ADSs or ordinary shares, as the case may be, subject to
their acceptance of the ADSs and ordinary shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the ADSs or ordinary shares, as the case may
be, offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the ADSs and ordinary shares offered by this prospectus
if any such ADSs or ordinary shares, as the case may be, are taken. However, the underwriters are not required to take or pay for the ADSs and ordinary shares covered by the underwriters&#146; option to purchase additional ADSs and ordinary shares
described below. The total number of ADSs in the U.S. offering and ordinary shares in the European private placement (including any ADSs or ordinary shares purchased pursuant to the underwriters&#146; option to purchase additional ADSs and ordinary
shares described below) is subject to reallocation between these offerings to the extent permitted under applicable law and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ADSs and ordinary shares sold by the underwriters will be offered at the offering price set forth on the cover of this prospectus. Any ADSs
and ordinary shares sold by the underwriters to securities dealers may be sold at a discount from the offering price not to exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS and &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
ordinary share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares (which may be in the form of ADSs) at the offering price listed on the cover page of this prospectus, less underwriting discounts. To the extent the
option is exercised, each underwriter must purchase a number of additional ADSs or additional ordinary shares, as the case may be, approximately proportionate to that underwriter&#146;s initial purchase commitment. Any ADSs or ordinary shares issued
or sold under the option will be issued and sold on the same terms and conditions as the other ADSs and ordinary shares that are the subject of this global offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per ADS, per ordinary share and total offering price,
underwriting discounts, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Ordinary Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>ADSs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Option to<BR>Purchase<BR>Additional<BR>ADSs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Option to<BR>Purchase<BR>Additional<BR>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>ADSs&nbsp;and/or<BR>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>ADSs&nbsp;and/or<BR>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts to be paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated expenses payable by us in connection with the global offering, exclusive of the underwriting
discounts, are approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have agreed to reimburse the underwriters for expenses relating to clearance of this global offering with the Financial Industry Regulatory Authority up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have informed us that they do not intend sales to discretionary
accounts to exceed 5% of the total number of ADSs offered by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to list the ADSs on the Nasdaq Global Market under
the trading symbol &#147;IPHA.&#148; Our ordinary shares are listed on Euronext Paris under the trading symbol &#147;IPH.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed that, without the prior written consent of Citigroup Global
Markets Inc., SVB Leerink LLC, Evercore Group L.L.C. and Citigroup Global Markets Limited on behalf of the respective underwriters in the global offering, we will not, during the period ending 90 days after the date of this prospectus (the
&#147;restricted period&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any ordinary shares, ADSs or any securities convertible into or exercisable or exchangeable for ADSs or ordinary shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">file any registration statement with the SEC (or the equivalent thereof in
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions) relating to the global offering of any ordinary shares, ADSs or any securities convertible into or exercisable or exchangeable for ADSs or ordinary shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of ADSs or ordinary shares, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whether any such transaction described above is to be settled by delivery of ADSs
or ordinary shares, in cash or otherwise. In addition, we and each such person agrees that, without the prior written consent of Citigroup Global Markets Inc., SVB Leerink LLC, Evercore Group L.L.C. and Citigroup Global Markets Limited, we will not,
during the restricted period, make any demand for, or exercise any right with respect to, the registration of any ADSs or ordinary shares or any security convertible into or exercisable or exchangeable for any ADSs or ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions contained in the preceding paragraph shall not apply to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the securities to be issued or sold under the underwriting agreement, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) the issuance by us of ordinary shares or ADSs upon the exercise of an option or warrant or the conversion of a security outstanding on the
date of the underwriting agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) the issuance by us of any options or warrants pursuant to any employee equity
incentive plan or share ownership plan described herein; <I>provided</I> that any such options or warrants cannot be vested or exercisable during the restricted period; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) the filing by us of a registration statement with the Commission on Form S-8 in respect of any shares issued under or the grant of any
award pursuant to an employee equity incentive plan or share ownership plan described herein; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) the establishment, amendment or
termination by us of a trading plan pursuant to Rule 10b5-1 of the Exchange Act for the transfer of ordinary shares or ADSs; <I>provided</I> that (i) our plan does not provide for the transfer of securities during the restricted period and (ii) no
voluntary announcement is made by us, and to the extent a public announcement or filing under the Exchange Act or applicable provisions of the General Regulation of the AMF, if any, is required to be made by any party or on such party&#146;s behalf
regarding the establishment, amendment or termination of such plan, such announcement or filing shall include a statement to the effect that no transfer of our securities may be made under such plan during the restricted period; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(F) the sale or issuance of or entry into an agreement to sell or issue ordinary shares, ADSs or securities convertible into or exercisable for
ordinary shares or ADSs in connection with any (i) mergers, (ii) acquisitions of securities, businesses, property, technologies or other assets, (iii) joint ventures, (iv) strategic alliances, commercial relationships or other collaborations, or (v)
the assumption of employee benefit plans in connection with mergers or acquisitions; <I>provided</I> that the aggregate number of ordinary shares, ADSs or securities convertible into or exercisable for ordinary shares or ADSs (on an as-converted or
as-exercised basis, as the case may be) that we may sell or issue or agree to sell or issue pursuant to this clause (F), shall not exceed 5% of the total number of our ordinary shares, including in the form of ADSs, issued and outstanding
immediately following the completion of this offering (determined on a fully-diluted basis and as adjusted for stock splits, stock dividends and other similar events after the date hereof); and <I>provided further</I>, that each recipient of
ordinary shares, ADSs or securities convertible into or exercisable for our common stock shall, on or prior to such issuance, execute a lock-up letter substantially similar to those executed by the members of our Supervisory Board and Executive
Board and certain of our shareholders with respect to the remaining portion of the restricted period. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, each of the
members of our Supervisory Board and Executive Board and certain of our shareholders have agreed that, without the prior written consent of Citigroup Global Markets Inc., SVB Leerink LLC, Evercore Group L.L.C. and Citigroup Global Markets Limited,
on behalf of the respective underwriters in the offerings, they will not, during the restricted period, (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any ADSs or ordinary shares beneficially owned (as such term is used in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange
Act), by such person or any other securities so owned that are convertible into or exercisable or exchangeable for ordinary shares or ADSs; or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of
the economic consequences of ownership of the ordinary shares or ADSs, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of ordinary shares, ADSs or such other securities, in cash or otherwise. The
foregoing restrictions shall not apply to: </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the securities to be sold pursuant to our global offering or other securities acquired
in open market transactions after the completion of the global offering, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;transfers of ADSs or ordinary shares as a bona fide gift
or gifts, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;transfers of ADSs or ordinary shares to any immediate family member or any trust for the direct or indirect benefit of
the party to the lock-up agreement, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) distributions of ADSs or ordinary shares to members or stockholders of the parties, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) transfers of ADSs or ordinary shares by will, intestate succession upon the death of the party to the lock-up agreement, by operation of
law or by court </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(F) transfers of ADSs or ordinary shares to us to satisfy the exercise price of any
option or warrant outstanding granted pursuant to our equity incentive plans, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(G) transfers of ADSs or ordinary shares solely to us in
connection with the termination of an individual providing services to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U> that in the case of any transfer or distribution pursuant to
clause (B) (C) or (D), each donee or distributee shall execute and deliver a lock-up letter in the form of those executed by the members of the Company&#146;s Supervisory Board and Executive Board and certain of its shareholders; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>, <U>further</U>, that in the case of any transfer or distribution pursuant to clause (B) (C) or (D), no filing by any party (donor, donee,
transferor or transferee) under the Securities Exchange Act of&nbsp;1934, as amended, or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form&nbsp;5
made after the expiration of the restricted period). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing paragraph, &#147;Change of Control&#148; means
the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an underwriter pursuant to this global
offering), of our voting securities if, after such transfer, such person or group of affiliated persons would hold more than 50% of our outstanding voting securities (or our surviving entity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, such person has agreed that, without the prior written consent of Citigroup Global Markets Inc., SVB Leerink LLC, Evercore Group
L.L.C. and Citigroup Global Markets Limited, on behalf of the respective underwriters in the offerings, it will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any ADSs, ordinary
shares or any security convertible into or exercisable or exchangeable for ADSs or ordinary shares. Such person also agrees and consents to the entry of stop transfer instructions with our transfer agent, registrar and depositary against the
transfer of such person&#146;s ADSs or ordinary shares except in compliance with the foregoing restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets
Inc., SVB Leerink LLC, Evercore Group L.L.C. and Citigroup Global Markets Limited, in their sole discretion, may release the ADSs and ordinary shares and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements
described above in whole or in part at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the ADSs and ordinary shares, the underwriters
may engage in transactions that stabilize, maintain or otherwise affect the price of the ADSs and ordinary shares. Specifically, the underwriters may sell more ADSs and ordinary shares than they are obligated to purchase under the underwriting
agreement, creating a short position. A short sale is covered if the short position is no greater than the number of ADSs and ordinary shares available for purchase by the underwriters under the option to purchase additional ADSs and ordinary
shares. The underwriters can close out a covered short sale by exercising the option or purchasing ADSs and ordinary shares in the open market. In determining the source of ADSs and ordinary shares to close out a covered short sale, the underwriters
will consider, among other things, the open market price of ADSs and ordinary shares compared to the price available under the option. The underwriters may also sell ADSs and ordinary shares in excess of the option, creating a naked short position.
The underwriters must close out any naked short position by purchasing ADSs and ordinary shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the
price of the ADSs and ordinary shares in the open market after pricing that could adversely affect investors who purchase in this global offering. As an additional means of facilitating this global offering, the underwriters may bid for, and
purchase, ADSs and ordinary shares in the open market to stabilize the price of the ADSs and ordinary shares. These activities may raise or maintain the market price of the ADS and ordinary shares above independent market levels or prevent or retard
a decline in the market price of the ADS and ordinary shares. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters have agreed to indemnify each other against certain liabilities,
including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on websites maintained by one or
more underwriters participating in this global offering. Citigroup Global Markets Inc., SVB Leerink LLC, Evercore Group L.L.C. and Citigroup Global Markets Limited, on behalf of the respective underwriters in the offerings, may agree to allocate a
number of ADSs and ordinary shares to underwriters for sale to their online brokerage account holders. Such Internet distributions will be allocated to underwriters that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging. financing and brokerage activities. Certain of the underwriters and their respective affiliates
have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a
broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long
and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or
express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Citibank, N.A., an affiliate of Citibank Global Markets Inc. and Citigroup Global Markets Limited, is acting as depositary in
this global offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Global Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this global offering, there has been no public market for the ADSs. The offering price of the ADSs and ordinary shares was determined
by negotiations between us and Citigroup Global Markets Inc., SVB Leerink LLC, Evercore Group L.L.C. and Citigroup Global Markets Limited, on behalf of the respective underwriters in the offerings, and by reference to the prevailing market prices of
our ordinary shares on Euronext Paris after taking into account market conditions and other factors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than
in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this
prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction,
except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions
relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a
solicitation is unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each, a &#147;Member State&#148;) an offer to the public of any ADSs and
ordinary shares which are the subject of the global offering contemplated by this prospectus may not be made in that Member State, except that an offer to the public in that Member State of any ADSs and ordinary shares may be made at any time under
the following exemptions under the Prospectus Directive: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investor as defined in the Prospectus
Directive), subject to obtaining the prior consent of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of ADSs and ordinary shares shall result in a requirement for the publication by the Company or any underwriter of a prospectus
pursuant to Article 3 of the Prospectus Directive or a supplement of a prospectus pursuant to Article&nbsp;16 of the Prospectus Directive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any ADSs and ordinary shares in any
Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ADSs and ordinary shares to be offered so as to enable an investor to decide to purchase any ADSs and ordinary shares, as
the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>MiFID II Product Governance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for the purposes of each manufacturer&#146;s product approval process, the target market assessment in respect of the ADSs and ordinary
shares has led to the conclusion that: (i)&nbsp;the target market for the ADSs and ordinary shares is eligible counterparties and professional clients only, each as defined in Directive 2014/65/EU (as amended, &#147;MiFID II&#148;); and
(ii)&nbsp;all channels for distribution of the ADSs and ordinary shares to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the ADSs and ordinary shares (a
&#147;distributor&#148;) should take into consideration the manufacturers&#146; target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the ADSs and ordinary
shares (by either adopting or refining the manufacturers&#146; target market assessment) and determining appropriate distribution channels. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>France </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs
and the ordinary shares have not been and will not be offered or sold to the public in the Republic of France, and no offering or this prospectus or any marketing materials relating to the ADSs and the ordinary shares must be made available or
distributed in any way that would constitute, directly or indirectly, an offer to the public in the Republic of France. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs and the
ordinary shares may only be offered or sold in the Republic of France pursuant to article&nbsp;L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">411-2-II</FONT></FONT> of the French <I>Code mon&eacute;taire et financier</I> to
(i)&nbsp;providers of third party portfolio management investment services, (ii)&nbsp;qualified investors (i<I>nvestisseurs qualifi&eacute;s</I>) acting for their own account and/or (iii)&nbsp;a limited group of investors (<I>cercle restreint
d&#146;investisseurs</I>) acting for their own account, all as defined in and in accordance with articles L. <FONT STYLE="white-space:nowrap">411-1,</FONT> L. <FONT STYLE="white-space:nowrap">411-2</FONT> and D.
<FONT STYLE="white-space:nowrap">411-1</FONT> to <FONT STYLE="white-space:nowrap">D.411-4,</FONT> <FONT STYLE="white-space:nowrap">D.744-1</FONT> and D. <FONT STYLE="white-space:nowrap">754-1</FONT> and D.
<FONT STYLE="white-space:nowrap">764-1</FONT> of the French <I>Code mon&eacute;taire et financier</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective investors are informed
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither this prospectus nor any other offering materials relating to the ADSs and the ordinary shares described
in this prospectus has been submitted for clearance to the French financial market authority (<I>Autorit&eacute; des march&eacute;s financiers</I>); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither this prospectus, nor any offering material relating to the ADSs and the ordinary shares has been or will
be released, issued, distributed or caused to be released, issued or distributed to the public in France or used in connection with any offer for subscription or sale of the ADSs and the ordinary shares to the public in France within the meaning of
article L. 411-1 of the French <I>Code mon&eacute;taire et financier</I>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">individuals or entities referred to in article L. 411-2-II of the French <I>Code mon&eacute;taire et
financier</I> may participate in the global offering, as provided under articles D.411-1, D.411-2, D.744-1, D.754-1 and D.764-1 of the French <I>Code mon&eacute;taire et financier</I>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direct and indirect distribution or sale to the public of the ADSs and the ordinary shares acquired by them
may only be made in compliance with articles L. 411-1, L. 411-2, L. 412-1 and L. 621-8 to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.&nbsp;621-8-3</FONT></FONT> of the French <I>Code mon&eacute;taire et financier</I>.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs and ordinary shares may not be offered or sold by means of any document other than (i)&nbsp;in circumstances that do not constitute an
offer to the public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), or (ii)&nbsp;to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules
made thereunder, or (iii)&nbsp;in other circumstances that do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation or document relating
to the ordinary shares or ADSs may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by,
the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to ordinary shares or ADSs that are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional
investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan, or the Financial Instruments and Exchange Law, and each underwriter has agreed that it will not offer or sell any securities, directly or
indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term, as used in this prospectus means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments
and Exchange Law and any other applicable laws, regulations and ministerial guidelines of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs and ordinary shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any
other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure
standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document, nor any other offering or marketing material relating
to the ADSs and ordinary shares or this global offering, may be publicly distributed or otherwise made publicly available in Switzerland. Neither this document nor any other offering or marketing material relating to this global offering, the
Company, or the ordinary shares or ADSs has been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of the ADSs and ordinary shares will not be supervised by, the
Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of the ADSs and ordinary shares has not been and will not be authorized under the Swiss Federal Act on Collective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of ordinary shares or ADSs.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>United Arab Emirates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or DFSA.
This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying
any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for this prospectus. The ADSs and ordinary shares to which this prospectus
relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the ordinary shares or ADSs offered should conduct their own due diligence on the ADSs and ordinary shares. If you do not understand the contents of
this prospectus, you should consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19 (5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the
Order (all such persons together being referred to as &#147;relevant persons&#148;).</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person in the United Kingdom that is not a
relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively
by relevant persons. Any person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs
and ordinary shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or
subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of
the ADSs and ordinary shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this global
offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_23"></A>EXPENSES RELATING TO THE GLOBAL OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the costs and expenses, other than underwriting discounts, payable in connection with the sale of ordinary
shares and ADSs in the global offering. All amounts are estimated except the SEC registration fee, the Nasdaq initial listing fee and the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee. Except as otherwise noted, all the
expenses below will be paid by us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq initial listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be completed by amendment. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_24"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley&nbsp;LLP, Boston, Massachusetts, is representing us in connection with this global offering. The validity of the ordinary shares and
certain other matters of French law will be passed upon for us by Linklaters LLP. Legal counsel to the underwriters in connection with this global offering are Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP and Gide Loyrette Nouel A.A.R.P.I. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_25"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements as of December&nbsp;31, 2018 and 2017 and for each of the two years in the period ended
December&nbsp;31, 2018 included in this prospectus have been audited by Deloitte&nbsp;&amp; Associ&eacute;s, an independent registered public accounting firm, as stated in their report appearing herein (which report expresses an unqualified opinion
on the consolidated financial statements and includes an explanatory paragraph referring to the adoption of IFRS 15 <I>Revenue from Contracts with Customers </I>and IFRS 9 <I>Financial instruments</I>). Such consolidated financial statements are
included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offices of
Deloitte&nbsp;&amp; Associ&eacute;s are located at Les Docks &#150; Atrium 10.4, 10 place de la Joliette, 13002 Marseille, France. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc752656_26"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> under the Securities Act with respect
to the ordinary shares and ADSs offered in this prospectus. A related registration statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> will be filed with the SEC to register the ADSs. This prospectus, which forms a part of the Registration
Statement, does not contain all of the information included in the Registration Statement. Certain information is omitted and you should refer to the Registration Statement and its exhibits for that information. With respect to references made in
this prospectus to any contract or other document of Innate Pharma S.A., such references are not necessarily complete and you should refer to the exhibits attached to the Registration Statement for copies of the actual contract or document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this global offering, we will become subject to periodic reporting and other informational requirements of the Exchange Act
as applicable to foreign private issuers. Accordingly, we will be required to file reports, including annual reports on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> periodic reports and other information, with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are allowed four months after the end of our fiscal year to file our annual report with the SEC, and we are not required to disclose
certain detailed information regarding executive compensation that is required from U.S. domestic issuers. Also, as a foreign private issuer, we are exempt from the rules of the Exchange Act prescribing the furnishing of proxy statements to
shareholders, and the members of our Supervisory Board and Executive Board and our principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, we are also exempt from the requirements of Regulation FD (Fair Disclosure) which, generally, are meant to ensure
that select groups of investors are not privy to specific information about an issuer before other investors. We are, however, still subject to the anti-fraud and anti-manipulation rules of the SEC, such as Rule
<FONT STYLE="white-space:nowrap">10b-5.</FONT> Since many of the disclosure obligations required of us as a foreign private issuer are different than those required of U.S. domestic reporting companies, our shareholders, potential shareholders and
the investing public in general should not expect to receive information about us in the same amount, or at the same time, as information is received from, or provided by, other U.S. domestic reporting companies. We are only liable for violations of
the rules and regulations of the SEC that apply to us as a foreign private issuer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC maintains a website at www.sec.gov that
contains reports and information statements and other information regarding registrants like us that file electronically with the SEC. You also can inspect our registration statement, as well as any other information we file with or furnish to the
SEC, on this website. This reference to the SEC&#146;s website is an inactive textual reference only and is not a hyperlink. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to
make our annual reports and other information filed with or furnished to the SEC available, free of charge, through our website at www.innate-pharma.com as soon as reasonably practicable after those reports and other information are filed with or
furnished to the SEC. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated into, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A><A NAME="toc752656_27"></A><A NAME="toc752656_27"></A>INDEX TO
CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Consolidated Financial Statements as of and for the Years Ended December&nbsp;31, 2018 and 2017</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_1">Report&nbsp;of&nbsp;Independent&nbsp;Registered&nbsp;Public&nbsp;
Accounting&nbsp;Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_2">Consolidated Statements of Financial Position as of December&nbsp;
31, 2018 and 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_3">Consolidated Statements of Income (Loss) for the Years Ended December&nbsp;
31, 2018 and 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_4">Consolidated Statements of Comprehensive Income (Loss) for the Years Ended December&nbsp;31,
 2018 and 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_6">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;
31, 2018 and 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_5">Consolidated Statements of Changes in Shareholders&#146; Equity for the Years
 Ended December&nbsp;31, 2018 and 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin752656_7">Notes to the Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin752656_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">To the shareholders and the Board of Directors of Innate Pharma S.A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated statements of financial position of Innate Pharma S.A. and subsidiaries (the &#147;Company&#148;) as of December&nbsp;31, 2018 and 2017, the related consolidated statements of income (loss), comprehensive income (loss),
changes in shareholders&#146; equity, and cash flows, for each of the two years in the period ended December&nbsp;31, 2018, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2018 and 2017, and the results of its operations and its cash flows for each of the two years in the period ended December&nbsp;31,
2018, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board (IASB). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Change in
Accounting Principle </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 2a to the consolidated financial statements, the company implemented accounting changes relating to the
adoption of IFRS 15 Revenue from Contracts with Customers and IFRS 9 Financial Instruments, as adopted by the IASB and applicable to periods starting on or after January&nbsp;1, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As
part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting.
Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Associ&eacute;s </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Marseille, France </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">June 6, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as
the Company&#146;s auditor since 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin752656_2"></A>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(amounts in thousands of euro) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>319,643</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>137,522</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>131,574</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>117,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>451,216</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>255,023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration liabilities<B>&#151;</B>current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities<B>&#151;</B>current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue<B>&#151;</B>current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>196,737</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,909</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities<B>&#151;</B>non-current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration liabilities<B>&#151;</B><FONT STYLE="white-space:nowrap">non-current</FONT>
portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue<B>&#151;</B><FONT STYLE="white-space:nowrap">non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>87,238</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>95,158</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,595</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85,956</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>451,216</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>255,023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 include the impacts of the first application of IFRS 9 and IFRS 15 standards that became applicable on January&nbsp;1, 2018. The
comparative consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. See Note 2.a for more details on transition measures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin752656_3"></A>CONSOLIDATED STATEMENTS OF INCOME (LOSS) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(amounts in thousands of euro, except per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government financing for research expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue and other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>93,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from distribution agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(39,983</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net financial loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,034</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss) before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,718</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,016</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss) per share:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,776,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,351,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in &#128; per share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 include the impacts of the first application of IFRS 9 and IFRS 15 standards that became applicable on January&nbsp;1, 2018. The
comparative consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. See Note 2.a for more details on transition measures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin752656_4"></A>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(amounts in thousands of euro) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss) for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Items which will be reclassified in the consolidated statement of income (loss):</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of short-term investments and
<FONT STYLE="white-space:nowrap">non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation gain (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Items which will not be reclassified in the consolidated statement of income
(loss):</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains and (losses) related to defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(625</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>683</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,424</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(47,702</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 include the impacts of the first application of IFRS 9 and IFRS 15 standards that became applicable on January&nbsp;1, 2018. The
comparative consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. See Note 2.a for more details on transition measures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin752656_6"></A><A NAME="fin752656_6"></A>CONSOLIDATED STATEMENT OF CASH FLOWS
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(amounts in thousands of euro) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6, 7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee benefit costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in provisions for charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains (losses) on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance on financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(204</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains (losses) on assets and other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating cash flow before change in working capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(31,080</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from (used in) operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,531</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,060</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition of intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6, 8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition of property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7,&nbsp;8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of current financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,543</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of <FONT STYLE="white-space:nowrap">non-current</FONT> financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,728</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of tangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of current financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of <FONT STYLE="white-space:nowrap">non-current</FONT> financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest received on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from (used in) investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,279</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(29,460</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the exercise / subscription of equity instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in capital, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,222</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>915</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of the exchange rate changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>52,947</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(76,539</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents at the end of the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>152,314</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>99,367</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 include the impacts of the first application of IFRS 9 and IFRS 15 standards that became applicable on January&nbsp;1, 2018. The
comparative consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. See Note 2.a for more details on transition measures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Change&nbsp;in&nbsp;working&nbsp;capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15<BR>restatements<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variance<BR>excluding&nbsp;IFRS&nbsp;15<BR>restatements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables and others (excluding rebates related to capital expenditures)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others (excluding payables related to capital expenditures)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration liabilities&#151;current and <FONT STYLE="white-space:nowrap">non-current</FONT>
portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,751</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue&#151;current and <FONT STYLE="white-space:nowrap">non-current</FONT>
portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total working capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(77,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(138,085</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,584</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,488</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(47,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 include the impacts of the first application of IFRS 9 and IFRS 15 standards that became applicable on January&nbsp;1, 2018. The
comparative consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. See Note 2.a for more details on transition measures. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Change&nbsp;in&nbsp;working&nbsp;capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others (excluding payables related to capital expenditures)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Change in working capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(138,085</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(155,066</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(16,980</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reconciliation in change in financial liability and equity </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash-flows</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT><BR>variations</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(+)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(-)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Current</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-current</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Borrowing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BPI France -PTZI IPH41<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing<B>&#151;</B>Property transaction</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing<B>&#151;</B>Property transaction (down-payment)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing<B>&#151;</B>Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(173</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Borrowing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Borrowing<B>&#151;</B>Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Borrowing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Borrowing<B>&#151;</B>Property transaction</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B><FONT STYLE="white-space:nowrap">Sub-total</FONT><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,864</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,343</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,348</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,172</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Increase in capital, net</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Subscription of equity instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B><FONT STYLE="white-space:nowrap">Sub-total</FONT><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>62,668</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Leasing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Interests</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B><FONT STYLE="white-space:nowrap">Sub-total</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(102</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>62,668</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interest-free loan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 9, &#147;Financial liabilities.&#148; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Consolidated statement of changes in shareholders&#146; equity. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin752656_5"></A>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS&#146; EQUITY
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(amounts in thousands of euro, except share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Retained<BR>earnings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other<BR>comprehensive<BR>income</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net<BR>income<BR>(loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>January&nbsp;1, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,921,304</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,696</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>187,571</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(116,235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(503</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>86,169</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of short-term investments and
<FONT STYLE="white-space:nowrap">non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Actuarial gains on defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation gain</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total comprehensive loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>683</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(47,702</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Allocation of prior period income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise and subscription of equity instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Shares issued for the acquisition of C5aR intangible asset</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11,&nbsp;1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,343,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,607,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,880</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>234,874</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(103,593</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>180</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85,956</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restatement related to the first application of IFRS&nbsp;9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.a</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; <B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restatement related to the first application of IFRS&nbsp;15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.a</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>January&nbsp;1, 2018 (after restatement)(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,607,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,880</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>234,874</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(89,454</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(473</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>99,444</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Actuarial losses on defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total comprehensive income for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(625</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,424</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Allocation of prior period loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise and subscription of equity instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase in capital, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,260,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>63,939,586</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,197</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>299,932</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(137,840</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,099</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consolidated financial statements as of and for the year ended December&nbsp;31, 2018 include the impacts of the first application of IFRS 9 and IFRS 15 standards that became applicable on January&nbsp;1, 2018. The
comparative consolidated financial statements as of and for the year ended December&nbsp;31, 2017 have not been restated. See Note 2.a for more details on transition measures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin752656_7"></A>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1) The Company, significant agreements description and key events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Innate Pharma S.A. (the &#147;Company&#148; and together with its subsidiaries, referred to as the &#147;Group&#148;) is a biotechnology
company focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has extensive experience in research and development in immuno-oncology, having been pioneers in the understanding of natural
killer cell, or NK cell, biology, and later expanding its expertise in the tumor microenvironment, tumor antigens and antibody engineering fields. The Company has built, internally and through its business development strategy, a broad and
diversified portfolio including an approved product, three clinical product candidates and a robust preclinical pipeline. The Company has entered into collaborations with leaders in the biopharmaceutical industry, such as AstraZeneca and Sanofi.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From its inception, the Company has incurred losses due to its research and development (&#147;R&amp;D&#148;) activity. The financial
year ended December&nbsp;31, 2018 generated a &#128;3,049&nbsp;thousand net income. As of December&nbsp;31, 2018, the shareholders&#146; equity amounted to &#128;167,240&nbsp;thousand. Subject to potential new milestone payments related to its
collaboration agreements, the Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates in development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s future operations are highly dependent on a combination of factors, including: (i)&nbsp;the success of its R&amp;D;
(ii)&nbsp;regulatory approval and market acceptance of the Company&#146;s future product candidates; (iii)&nbsp;the timely and successful completion of additional financing; and (iv)&nbsp;the development of competitive therapies by other
biotechnology and pharmaceutical companies. As a result, the Company is and should continue, in the short to <FONT STYLE="white-space:nowrap">mid-term,</FONT> to be financed through partnership agreements for the development and commercialization of
its drug candidates and through the issuance of new equity instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s activity is not subject to seasonal
fluctuations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2018, the Company had two wholly owned subsidiaries: Innate Pharma, Inc., incorporated under the laws of
Delaware in 2009, and Innate Pharma France SAS, incorporated under the laws of France in 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Innate Pharma, Inc. nor Innate
Pharma France SAS had engaged in any material operations as of December 31, 2018. Both of the Company&#146;s subsidiaries are fully consolidated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.
1. Significant contracts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following paragraphs describe the key provisions of significant contracts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>a) Agreements related to monalizumab with Novo Nordisk A/S and with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>2014 Novo Nordisk A/S monalizumab agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2014, the Company acquired from Novo Nordisk A/S full development and commercialization rights to monalizumab. Novo Nordisk
A/S received &#128;2.0&nbsp;million in cash and 600,000 ordinary shares at a price of &#128;8.33 per share (&#128;5.0 million). Novo Nordisk A/S is eligible to receive up to &#128;20.0&nbsp;million in potential regulatory milestones and single-digit
tiered royalties on sales of monalizumab products. The agreement with Novo Nordisk A/S included a right to additional consideration in the event of an <FONT STYLE="white-space:nowrap">out-licensing</FONT> agreement. Consequently, following the
agreement signed with AstraZeneca in April 2015 (as described below), the Company paid to Novo Nordisk A/S additional consideration of &#128;6.5&nbsp;million (paid in April 2016). Following the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise of the option by AstraZeneca in October 2018 (as described below), Novo Nordisk A/S became entitled to a second and final additional payment amounting to $15.0&nbsp;million (&#128;13.1
million) which was recognized as a liability as of December&nbsp;31, 2018 and was paid in February 2019. There are no other potential additional payments due to Novo Nordisk A/S. These amounts were added to the net book value of the intangible asset
and are amortized according to the same amortization plan as the initial &#128;7.0&nbsp;million recognized in 2014. The net book value of the license amounted to &#128;12.7&nbsp;million as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.g, 2.i and 6 for accounting description. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>2015 AstraZeneca monalizumab agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under co-development and option agreements signed with AstraZeneca in 2015, the Company granted to AstraZeneca an exclusive license, subject to
certain exclusions, to certain of its patents and know-how to develop, manufacture and commercialize licensed products, including monalizumab, in the field of diagnosis, prevention and treatment of oncology diseases and conditions. The Company
further granted to AstraZeneca a worldwide, non-exclusive license to certain of its other patents to develop, manufacture and commercialize licensed products, including monalizumab, in the field of diagnosis, prevention and treatment of oncology
diseases and conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received an initial payment of $250 million under these agreements in June 2015, of which $100
million was paid to the Company as an initial payment for the co-development agreement and $150 million was paid to the Company as consideration for the option agreement. On October&nbsp;22, 2018, AstraZeneca exercised this option, triggering the
payment of $100.0&nbsp;million, which was received by the Company in January 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the option exercise, AstraZeneca became the
lead party in developing the licensed products and must use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize each licensed product in certain major markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the initial payment and option exercise payment, AstraZeneca is obligated to pay the Company up to $925 million in the
aggregate upon the achievement of certain development and regulatory milestones ($500 million) and commercialization milestones ($425 million). The Company is eligible to receive tiered royalties ranging from a low double-digit to mid-teen
percentage on net sales of licensed products outside of Europe. The Company is required for a defined period of time to co-fund 30% of the Phase III clinical trials of licensed products, subject to an aggregate cap, in order to receive 50% of the
profits in Europe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company opts out of its co-funding obligations, it would forfeit the option to co-promote licensed products
under the agreement, and its right to share in 50% of such profits would terminate and sales in Europe will instead be factored into net sales used to calculate royalty and milestone payments to it. Additionally, Phase&nbsp;III and regulatory
milestone payments that may be payable to the Company will be reduced and AstraZeneca will be responsible for the promotion of licensed products worldwide, subject to the Company&#146;s option to co-promote the licensed products in certain European
countries. Should the Company elect not to co-promote, its share of profits in Europe will be reduced by a specified amount of percentage points not to exceed the mid-single digits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.a, 2.o and 13.a for accounting description. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>b) Agreement related to Lumoxiti with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the Company obtained an exclusive license from AstraZeneca under certain patents and know-how of AstraZeneca to develop,
manufacture and commercialize Lumoxiti for all uses in humans and animals in the United States, the European Union and Switzerland. Under this Agreement, AstraZeneca is obligated to provide support for the continued development and commercialization
of Lumoxiti in the European Union and Switzerland prior to regulatory submission and approval as well as support for the continued </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialization of Lumoxiti in the United States for a specified period. The Company is scheduled to transition to full commercialization responsibilities by mid-2020. Under the agreement, the
Company was obligated to pay a $50.0 million initial payment (&#128;43.8 million), which it paid in January 2019, and is obligated to pay conditional payments up to $25.0 million in the aggregate upon the achievement of certain commercial and
regulatory milestones. The Company will reimburse AstraZeneca for the development, production and commercialization costs it incurs during the transition period, subject to certain limitations for the year ending December 31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.p and 15 for accounting description. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>c) Agreement related to IPH5201 with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the Company signed a collaboration and option agreement with AstraZeneca for co-development and co-commercialization of
IPH5201. Under the agreement, AstraZeneca paid the Company a $50.0 million upfront payment ($26.0 million paid in October 2018 and $24.0 million paid in January 2019), and is obligated to pay the Company up to an aggregate of $10.0 million upon the
achievement of certain development milestones. Upon exercise of its option under the agreement, AstraZeneca is committed to pay an option exercise fee of $25.0 million and up to $800.0 million in the aggregate upon the achievement of certain
development and regulatory milestones ($300 million) and commercialization milestones ($500 million). The arrangement also provides for a 50% profit share in Europe if the Company opts into certain co-promoting and late stage co-funding obligations.
In addition, we would be eligible to receive tiered royalties ranging from a high-single digit to mid-teen percentage on net sales of IPH5201, or from a mid-single digit to low-double digit percentage on net sales of other types of licensed
products, outside of Europe. The royalties payable to us under the agreement may be reduced under certain circumstances, including loss of exclusivity or lack of patent protection. The Company recognized &#128;15.6 million as revenue from proceeds
related to this agreement for the year ended December 31, 2018, and was also reimbursed by AstraZeneca for certain research and development expenses related to IPH5201. The Company has the option to co-fund 30% of the shared development expenses
related to the Phase III clinical trials in order to acquire co-promotion rights and to share in 50% of the profits and losses of licensed products in Europe. If the Company does not opt into the co-funding obligations, among other things, its right
to share in 50% of the profits and losses in Europe and right to co-promote in certain European countries will terminate and will be replaced by rights to receive royalties on net sales at the rates applicable to outside of Europe. Additionally,
certain milestone payments that may be payable to the Company would be materially reduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.o and 13.b for accounting
description. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>d) Agreement related to additional preclinical molecules with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the Company granted to AstraZeneca four exclusive options that are exercisable until IND approval to obtain a worldwide,
royalty-bearing, exclusive license to certain of the Company&#146;s patents and know-how relating to certain specified pipeline candidates to develop and commercialize optioned products in all fields of use. Pursuant to the agreement, AstraZeneca
paid the Company a $20.0 million upfront payment (&#128;17.5&nbsp;million) in October 2018. The Company recognizes this upfront payment in the consolidated statement of financial position as deferred revenue as of December 31, 2018, until the
exercise or the termination of each option at the earliest. Upon exercise of an option, the Company would be entitled to an option exercise payment of $35 million, as well as development and regulatory milestone payments ($320 million) and
commercialization milestone payments ($500&nbsp;million) and tiered, mid-single digit to mid-teen percentage royalties on net sales of the applicable product. The royalties payable to the Company may be reduced under certain circumstances, including
loss of exclusivity, lack of patent protection or the specific nature of the compound included within the applicable product. Additionally, the Company would have rights to co-fund certain development costs in order to obtain profit and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
loss sharing in Europe. So long as the Company elects to co-fund such development costs, it will have a right to co-promote optioned products in Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.o and 13.c for accounting description. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>e) Agreements related to IPH5401 with Novo Nordisk and with AstraZeneca </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>2017 IPH5401 <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreement with Novo Nordisk A/S </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2017, the Company signed an exclusive license agreement with Novo Nordisk A/S relating to IPH5401. Under the agreement, Novo Nordisk
A/S granted the Company a worldwide, exclusive license to develop, manufacture and commercialize pharmaceutical products that contain or comprise an anti-C5aR antibody, including IPH5401. The Company made an upfront payment of &#128;40.0 million,
&#128;37.2 million of which was contributed in new shares and &#128;2.8 million of which in cash. The Company is obligated to pay up to an aggregate of &#128;370.0 million upon the achievement of development, regulatory and sales milestones and
tiered royalties ranging from a low double-digit to low-teen percentage of net sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.g, 2.i and 6 for accounting
description. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>2018 IPH5401 AstraZeneca agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 1, 2018, the Company entered into a clinical trial collaboration agreement with AstraZeneca to sponsor a Phase I/II clinical trial
(STELLAR-001) to evaluate the safety and efficacy of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in combination with IPH5401, as a treatment for patients with select solid tumors. The Company is the sponsor of the trial and the costs are
equally shared between the two partners. This collaboration is a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> agreement and does not include any licensing rights on IPH5401 to AstraZeneca. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Notes 2.o and 13.d for accounting description. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.2 Key events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>a) Key events for
the year ended December&nbsp;31, 2018 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December 31, 2018, AstraZeneca exercised its option related to
monalizumab. See the description of the agreement related to monalizumab with AstraZeneca as presented in Note 1.1.a. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
several agreements were signed during the year with AstraZeneca. See the description of the agreement related to Lumoxiti, agreement related to IPH5201, agreement related to additional preclinical molecules and agreement related to IPH5401 as
presented in Note 1.1.b, Note 1.1.c, Note 1.1.d and Note 1.1.e, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;22, 2018, AstraZeneca acquired 9.8% of the
capital of the Company through the issuance by the Company of 6,260,500 new ordinary shares for a total amount of &#128;62,605&nbsp;thousand, with a nominal value of &#128;0.05 per share and an issue price of &#128;10.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This issuance was contingent upon, and concurrent with, the execution of the agreements described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>b) Key events for the year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See 2017 IPH5401 <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreement with Novo Nordisk A/S in Note 1.1.c. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February 6, 2017, the Company announced top-line results from the Effikir trial evaluating the efficacy of lirilumab as a single agent in
elderly patients with acute myeloid leukemia. The trial did not meet the primary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
efficacy endpoint but confirms the tolerance profile of lirilumab as a monotherapy. On November 22, 2017, the Company published an update on the clinical study program of lirilumab, stating that
while lirilumab was shown to be well-tolerated, the assessment of efficacy from the ongoing exploration of doublet combinations did not provide clear evidence of benefit to patients or an obvious development path. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;3, 2017, the Company entered into a loan agreement with Soci&eacute;t&eacute; G&eacute;n&eacute;rale in order to finance the
construction of its planned future headquarters. The loan, amounting to a maximum of &#128;15.2&nbsp;million, will be drawn upon during the period of the construction in order to make payments to suppliers as they become due. This period during
which the Company may draw funds ends on August&nbsp;30, 2019. The repayment of the loan will occur beginning on August 30, 2019 and for a period of 12 years thereafter. In connection with this loan, the Company authorized collateral of its
financial Soci&eacute;t&eacute; G&eacute;n&eacute;rale instruments amounting to &#128;15.2&nbsp;million. The security interest on the pledge of financial instruments will be released in accordance with the following schedule: &#128;4.2&nbsp;million
in July 2024, &#128;5.0&nbsp;million in July 2027 and &#128;6.0&nbsp;million in July 2031. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not yet begun this
construction. Until construction begins, the proceeds of the loan will be used to finance several projects (e.g., extension of the current building, improvement of the Company&#146;s information systems and development of a commercial
infrastructure). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2) Accounting policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>a) Basis of preparation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union&#146;s regulation
No.&nbsp;1606/2002 of July&nbsp;19, 2002, the consolidated financial statements of the Company for the years ended December&nbsp;31, 2018 and 2017 (the &#147;Consolidated Financial Statements&#148;) have been prepared in accordance with both
International Financial Reporting Standards (&#147;IFRS&#148;) as issued by the International Accounting Standard Board (&#147;IASB&#148;) and IFRS as approved by the European Union (&#147;EU&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comparative figures are presented as of and for the year ended December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IFRS includes International Financial Reporting Standards, International Accounting Standards (the &#147;IAS&#148;) and the interpretations
issued by the Standing Interpretations Committee (the &#147;SIC&#148;) and the International Financial Reporting Interpretations Committee (&#147;IFRIC&#148;). The main accounting methods used to prepare the Consolidated Financial Statements are
described below. These methods were used for the two years presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Consolidated Financial Statements have been prepared under the
historical cost convention, with the exception of certain asset and liability categories and in accordance with the provisions set forth in IFRS such as employee benefits measured using the projected unit credit method, borrowings measured at
amortized cost and derivative financial instruments measured at fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumption of going concern was used given the
Company&#146;s financial position and liquidity to meet its financing needs for the 12 months following December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
preparation of financial statements in accordance with IFRS requires the Company to make certain estimates and assumptions that are detailed in Note 2.v. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for share data and per share amounts, the Consolidated Financial Statements are presented in thousands of euro. Amounts are rounded up
or down to the nearest whole number for the calculation of certain financial data and other information contained in these accounts. Accordingly, the total amounts presented in certain tables may not be the exact sum of the preceding figures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Adoption of IFRS 15 </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IFRS 15 <I>Revenue from contracts with customers</I>, or IFRS 15, which supersedes IAS 11 <I>Construction contracts</I>, or IAS 11, and IAS 18
<I>Revenue</I>, or IAS 18, came into effect on January&nbsp;1, 2018. The amended accounting policy applied to revenue is presented in Note 2.o. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company decided to apply the modified retrospective approach without any of the practical expedients allowed by IFRS 15. According to this
approach, the comparative information is not restated and the cumulative impact of the first application is presented as an adjustment of the opening equity of the year of first application. The modified retrospective approach does not present
comparative information, but requires a comparison for the first application year of each financial statement line item affected by the application of this standard as compared to IAS 11, IAS 18 and related interpretations that were in effect before
the change. This comparison is presented below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of the adoption of IFRS 15 is limited to the accounting treatment of the
contributions paid by the Company pursuant to its <FONT STYLE="white-space:nowrap">co-financing</FONT> under the collaboration agreement with AstraZeneca related to monalizumab. Until December&nbsp;31, 2017, under IAS 18, the Company&#146;s <FONT
STYLE="white-space:nowrap">co-financing</FONT> share of R&amp;D expenses incurred by AstraZeneca were recognized as R&amp;D expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the context of the collaboration agreement with AstraZeneca, the Company and AstraZeneca make quarterly-cost sharing payments to one another to ensure that each party <FONT STYLE="white-space:nowrap">co-finances</FONT> the R&amp;D performed by
AstraZeneca. Consequently, under IFRS 15, amounts due to the partner: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Are no longer recognized as R&amp;D expenses, but are recorded as a reduction of the transaction price recorded
as revenue following the identified performance obligation under the collaboration agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Are classified in collaboration liability in the consolidated statement of financial position (instead of a
classification in deferred revenue under IAS 18). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a collaboration liability is denominated in a foreign currency,
which is the case in the context of this AstraZeneca agreement, it is translated at each reporting date with the appropriate exchange rate, resulting in foreign exchange gains or losses recorded in the consolidated statement of income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Application of IFRS 15 generated a deferred tax liability of &#128;3,098&nbsp;thousand as of January&nbsp;1, 2018. The Company recorded a
deferred tax asset equaling the amount of deferred tax liability as of January&nbsp;1, 2018 as a result of tax losses carryforward. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of the first adoption of IFRS 15 on the statement of financial position as of
January&nbsp;1, 2018 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(amounts&nbsp;in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B><br><B>as&nbsp;published</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15<BR>restatement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,&nbsp;2018</B><br><B>restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>137,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>137,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>117,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,098</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>120,599</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>255,023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,098</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>258,121</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration liabilities&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,909</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,556</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>68,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT>
portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred <FONT STYLE="white-space:nowrap">revenue&#151;non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>95,158</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,834</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>90,324</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,595</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85,956</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,488</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>99,444</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>255,023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,098</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>258,121</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the tables below provide a comparison between the published Consolidated
Financial Statements and the figures as they would have been had the Company continued to apply IAS 18 during the 2018 financial year: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(amounts&nbsp;in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>December&nbsp;31,<BR>2018</B><br><B>as&nbsp;published</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15&nbsp;impact</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>December&nbsp;31,<BR>2018,&nbsp;excluding<BR>IFRS&nbsp;15&nbsp;impacts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>319,643</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>319,643</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,561</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>131,574</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,561</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>130,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>451,216</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,561</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>449,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration liabilities&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,987</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>196,095</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,850</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>204,945</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT>
portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred <FONT STYLE="white-space:nowrap">revenue&#151;non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,561</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>87,890</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,272</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83,618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(138,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(152,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,139</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>161,101</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>451,216</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,561</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>449,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(amounts&nbsp;in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,&nbsp;2018</B><br><B>as&nbsp;published</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15<BR>impact</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,&nbsp;2018,</B><br><B>excluding&nbsp;IFRS&nbsp;15<BR>impact</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government financing for research expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue and other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>93,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>114,985</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(15,542</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(103,293</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from distribution agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,491</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,637</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net financial income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,858</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(569</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,718</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,349</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,067</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,349</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,397</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in &#128; per share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic income per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted income per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Adoption of IFRS 9 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IFRS 9 <I>Financial instruments</I>, or IFRS 9, which supersedes IAS 39 <I>Financial instruments: recognition and measurement</I>, or IAS 39,
came into effect on January&nbsp;1, 2018. IFRS 9 defines new principles covering the classification and measurement of financial instruments, the recognition of impairment provisions for credit risk on financial assets and hedge accounting. The
Company has applied IFRS 9 as of January&nbsp;1, 2018 by recording the cumulative impact in opening equity at this transition date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regarding financial instruments, IFRS 9 requires, for <FONT STYLE="white-space:nowrap">non-derivative</FONT> financial assets, a change of
name of the <FONT STYLE="white-space:nowrap">sub-categories</FONT> of financial assets without, however, modifying the valuation principles of these assets, which remain either at fair value or amortized cost. The valuation models used by the
Company remain unchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The modification of the depreciation principles for financial assets measured at amortized cost, which now
consists of adopting an approach based on expected losses, in practice has resulted in the Company not recognizing impairment and mainly impacts trade receivables, which were nil as of January&nbsp;1, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The only impact of IFRS 9 on the financial statements of the Company concerns the recognition of the variance in fair value of the mutual
funds. Under IAS 39, the variance in fair value of these financial assets was recognized in other comprehensive income. Under IFRS 9, it will be recognized in the statement of income. Following the application of the standard, the impact on the
opening statement of financial position is a reclassification from the cumulated comprehensive income to retained earnings in an amount of &#128;653&nbsp;thousand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amended accounting policy applied to financial instruments is presented in Note 2.f. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>b) Recently issued accounting standards and interpretations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The recently issued standards and interpretations whose application is mandatory as of January&nbsp;1, 2018 are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IFRS 9, which supersedes IAS 39; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IFRS 15, which supersedes IAS 11, IAS 18 and the corresponding interpretations (IFRIC 13, IFRIC 15, IFRIC 18 and
SIC 31). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New standards, amendments to existing standards and subsequent interpretations have been published but are not
applicable in 2018. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IFRS 16<I> Leases</I>, or IFRS 16, mandatory for financial years beginning on or after January&nbsp;1, 2019. IFRS
16 replaces the IAS 17 <I>Leases</I>, or IAS 17, and the corresponding interpretations (IFRIC 4, SIC 15 and SIC 27); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IFRIC 23 <I>Uncertainty over income tax treatments</I>, mandatory for financial years beginning on or after
January&nbsp;1, 2019. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not early adopted the new accounting standards, amendments and interpretations.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>IFRS 16 </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IFRS 16 was issued in January 2016 and replaces IAS 17, IFRIC 4 Determining whether an Arrangement contains a Lease, <FONT
STYLE="white-space:nowrap">SIC-15</FONT> Operating Leases-Incentives and <FONT STYLE="white-space:nowrap">SIC-27</FONT> Evaluating the Substance of Transactions Involving the Legal Form of a Lease. IFRS 16 sets out the principles for the
recognition, measurement, presentation and disclosure of leases and requires lessees to account for all leases under a single <FONT STYLE="white-space:nowrap">on-balance</FONT> sheet model similar to the accounting for finance leases under IAS 17.
The standard includes two recognition exemptions for lessees&#151;leases of <FONT STYLE="white-space:nowrap">&#147;low-value&#148;</FONT> assets (e.g., personal computers) and short-term leases (i.e., leases with a lease term of 12 months or less).
At the commencement date of a lease, a lessee recognizes a liability to make lease payments (i.e., the lease liability) and an asset representing the right to use the underlying asset during the lease term (i.e., the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset). Lessees are required to separately recognize the interest expense on the lease liability and the depreciation expense on the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset. The change in presentation of operating lease expenses results in a corresponding increase in cash flows from operating activities and a decrease in cash
flows from financing activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the new standard, the Company determined the lease term including any lessee&#146;s
extension or termination option that is deemed reasonably certain. The assessment of such options was performed at the commencement of a lease and required judgment by the management. Measuring the lease liability at the present value of the
remaining lease payments required using an appropriate discount rate in accordance with IFRS 16. The discount rate is the interest rate implicit in the lease or if that cannot be determined, the incremental borrowing rate at the date of the lease
commencement. The incremental borrowing rate can have a significant impact on the net present value of the <FONT STYLE="white-space:nowrap">right-of</FONT> use asset and lease liability recognized and requires judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lessees remeasure the lease liability upon the occurrence of certain events (e.g., a change in the lease term, a change in future lease
payments resulting from a change in an index or rate used to determine those payments). The lessee generally recognizes the amount of the remeasurement of the lease liability as an adjustment to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Progress of work to estimate the impacts of IFRS 16 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has carried out an analysis of the impacts of IFRS 16. The contracts impacted by this new standard mainly relate to the rental of
premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the transition method, the Company will opt for the modified retrospective
approach to contracts previously reported as leases under IAS 17 or IFRIC 4, and, therefore, will only recognize leases on the balance sheet as of January&nbsp;1, 2019. Accordingly, comparative information will not be restated and the cumulative
effect of initially applying IFRS 16 will be presented as an adjustment to opening reserves. As of January&nbsp;1, 2019, the right-of-use will be recognized as assets for their net value (as if IFRS 16 had always been applied) and the present value
of the remaining payments will be recognized as a liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies the following practical expedients as allowed by IFRS
16: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">apply a single discount rate to assets with similar characteristics; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exclude lease contracts for which the lease term ends within 12 months of the date of initial application, thus
considering them short-term leases; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exclude leases of assets with a replacement value of less than approximately &#128;5 thousand.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company excludes initial direct costs from the measurement of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets at the date of initial application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates that the effect on
the opening consolidated statement of financial position as of January&nbsp;1, 2019 to be between &#128;600&nbsp;thousand and &#128;900&nbsp;thousand resulting from the recognition of the lease obligation and the right of use associated with leases
contracts. The effect on equity as of January&nbsp;1, 2019 is not expected to be material. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>c) Change in accounting policies
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for the adoption of IFRS 9 and IFRS 15 as of January&nbsp;1, 2018, there has been no change in accounting policies for any
of the years presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>d) Translation of transactions denominated in foreign currency </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to IAS 21 <I>The effects of changes in foreign exchange rates</I>, transactions performed by consolidated entities in currencies other
than their functional currency are translated at the prevailing exchange rate on the transaction date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trade receivables and payables and
liabilities denominated in a currency other than the functional currency are translated at the <FONT STYLE="white-space:nowrap">period-end</FONT> exchange rate. Unrealized gains and losses arising from translation are recognized in net operating
income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foreign exchange gains and losses arising from the translation of inter-Group transactions or receivables or payables denominated
in currencies other than the functional currency of the entity are recognized in the line &#147;net financial income (loss)&#148; of the consolidated statements of income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foreign currency transactions are translated into the presentation currency using the following exchange rates: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>&#128;1&nbsp;EQUALS&nbsp;TO</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OPENING<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AVERAGE<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CLOSING<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AVERAGE<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CLOSING<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>USD</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>e) Consolidation method </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Group applies IFRS 10 <I>Consolidated financial statements</I>, or IFRS 10. IFRS 10 presents a single consolidation model identifying
control as the criteria for consolidating an entity. An investor controls an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investee if it has the power over the entity, is exposed or has rights to variable returns from its involvement with the entity and has the ability to use its power over the entity to affect the
amount of the investor&#146;s returns. Subsidiaries are entities over which the Company exercises control. They are fully consolidated from the date the Group obtains control and are deconsolidated from the date the Group ceases to exercise control.
Intercompany balances and transactions are eliminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>f) Financial instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Financial assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets are initially measured at fair value plus directly attributable transaction costs in the case of instruments not measured at
fair value through profit or loss. Directly attributable transaction costs of financial assets measured at fair value through profit or loss are recorded in the consolidated statement of income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under IFRS 9, financial assets are classified in the following three categories: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Financial assets at amortized cost; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Financial assets at fair value through other comprehensive income (&#147;FVOCI&#148;); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Financial assets at fair value through profit or loss. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The classification of financial assets depends on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The characteristics of the contractual cash flows of the financial assets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The business model that the entity follows for the management of the financial asset. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Financial assets at amortized cost </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets are measured at amortized cost when (i)&nbsp;they are not designated as financial assets at fair value through profit or loss,
(ii)&nbsp;they are held within a business model whose objective is to hold assets in order to collect contractual cash flows and (iii)&nbsp;they give rise to cash flows that are solely payments of principal and interest on the principal amount
outstanding (&#147;SPPI&#148; criterion). They are subsequently measured at amortized cost, determined using the effective interest method (&#147;EIR&#148;), less any expected impairment losses in relation to the credit risk. Interest income,
exchange gains and losses, impairment losses and gains and losses arising on derecognition are all recorded in the consolidated statement of income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This category primarily includes trade receivables, as well as other loans and receivables. Long-term loans and receivables that are not
interest-bearing or that bear interest at a below-market rate are discounted when the amounts involved are material. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Financial assets
at fair value through other comprehensive income </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets at fair value through other comprehensive income is mainly comprised
is composed of debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair
value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for
the period within the line items Financial income or Financial expenses. The Company did not hold this type of instrument as of January&nbsp;1, 2018 or as of December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Financial assets at fair value through profit or loss </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets at fair value through profit or loss is comprised of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">instruments whose contractual cash flows represent payments of interest or repayments of principal, but which are
managed other than with a view to collecting cash flows and/or selling the asset; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">instruments that management has designated as &#147;fair value through profit or loss&#148; on initial
recognition. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gains and losses arising from changes in fair value are recognized in profit or loss within the line items
financial income or financial expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Impairment of financial assets measured at amortized cost </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main assets involved are trade receivables and others. Trade receivables are recognized when the Company has an unconditional right to
payment by the customer. Impairment losses on trade receivables and others are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is
estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are
indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a
reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within Operating expenses in the consolidated statement of income (loss). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Financial liabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial liabilities comprise deferred revenue, collaboration liabilities, loans and trade and other payables. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial liabilities are initially recognized on the transaction date, which is the date that the Company becomes a party to the contractual
provisions of the instrument. They are derecognized when the Company&#146;s contractual obligations are discharged, cancelled or expire. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loans are initially measured at fair value of the consideration received, net of directly attributable transaction costs. Subsequently, they
are measured at amortized cost using the EIR method. All costs related to the issuance of loans, and all differences between the issuance proceeds net of transaction costs and the value on redemption, are recognized within financial expenses in the
consolidated statement of income (loss) over the term of the debt using the EIR method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other financial liabilities include trade
accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Cash and cash equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash equivalents are short-term, highly liquid investments, that are readily convertible to known amounts of cash and which are subject to an
insignificant risk of changes in value. Cash and cash equivalents comprise the cash that is held at the bank and petty cash as well as the short-term fixed deposits for which the maturity is less than three months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purpose of establishing the statement of cash flows, cash and cash equivalents include cash in hand, demand deposits and short
fixed-term deposits with banks and short-term highly liquid investments with original maturities of three months or less, net of bank overdrafts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents are initially recognized at their purchase costs on the transaction date, and are subsequently measured at fair
value. Changes in fair value are recognized in profit or loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Fair value of financial instruments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under IFRS 13 <I>Fair value measurement</I> and IFRS 7 <I>Financial instruments: disclosures</I>, or IFRS 7, fair value measurements must be
classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level 2: fair value calculated using valuation techniques based on observable market data such as prices of
similar assets and liabilities or parameters quoted in an active market; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level 3: fair value calculated using valuation techniques based wholly or partly on unobservable inputs such as
prices in an inactive market or a valuation based on multiples for unlisted securities. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>g) Intangible assets
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Research and development (R&amp;D) expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with IAS 38 <I>Intangible assets</I>, or IAS 38, expenses on research activities are recognized as an expense in the period in
which it is incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An internally generated intangible asset arising from the Company&#146;s development activities is recognized only
if all of the following conditions are met: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Technically feasible to complete the intangible asset so that it will be available for use or sale;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company has the intention to complete the intangible assets and use or sell it; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company has the ability to use or sell the intangible assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The intangible asset will generate probable future economic benefits, or indicate the existence of a market;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adequate technical, financial and other resources to complete the development are available; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company is able to measure reliably the expenditure attributable to the intangible asset during its
development. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the risks and uncertainties related to regulatory approval, the R&amp;D process and the
availability of technical, financial and human resources necessary to complete the development phases of the product candidates, the six criteria for capitalization are usually considered not to have been met until the product candidate has obtained
marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical trials, are generally expensed as incurred within Research
and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, some clinical trials, for example those undertaken to obtain a geographical extension for a molecule
that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS 38, in which case the related expenses are recognized as an intangible asset. These related costs are
capitalized when they are incurred and amortized on a straight line basis over their useful lives beginning when marketing approval is obtained. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Licenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments for
separately acquired research and development are capitalized within &#147;Other intangible assets&#148; provided that they meet the definition of an intangible asset: a resource that is (i)&nbsp;controlled by the Group, (ii)&nbsp;expected to provide
future economic benefits for the Group and (iii)&nbsp;identifiable (i.e. it is either separable or arises from contractual or legal rights). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with paragraph 25 of IAS 38, the first recognition criterion, relating to the
likelihood of future economic benefits generated by the intangible asset, is presumed to be achieved for research and development activities when they are acquired separately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this context, amounts paid to third parties in the form of initial payments or milestone payments relating to product candidates that have
not yet obtained a regulatory approval are recognized as intangible assets. These rights are amortized on a straight-line basis: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">after obtaining the regulatory approval, over their useful life; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">after entering in an <FONT STYLE="white-space:nowrap">out-license</FONT> collaboration agreement with a third-party partner, over their estimated useful life. This estimated useful life takes into consideration the
period of protection of the <FONT STYLE="white-space:nowrap">out-licensed</FONT> exclusivity rights and the anticipated period over which the Company will receive the economic benefits of the asset. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unamortized rights (before marketing authorization) are subject to impairment tests in accordance with the method defined in Note 5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When intangible assets acquired separately are acquired through variable or conditional payments, these payments are recognized as an increase
of the carrying amount of the intangible asset when they become due. Royalties due by the Company related to acquired licenses are recognized as operating expenses when the Company recognizes sales subject to royalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Other intangible assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other intangible assets consist of acquired software. Costs related to the acquisition of software licenses are recognized as assets based on
the costs incurred to acquire and set up the related software. Software is amortized using the straight-line method over a period of one to three years depending on the anticipated period of use. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>h) Property and equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are carried at acquisition cost. Major renewals and improvements are capitalized while repairs and maintenance are
expensed as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are depreciated over their estimated useful lives using the straight-line depreciation
method. Leasehold improvements are depreciated over the life of the improvement or the remaining lease term, whichever is shorter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
headquarters of the Company was split into several components (e.g., foundations, structure, electricity, heating and ventilation systems) which are depreciated over different useful lives according to the anticipated useful life of these elements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation periods are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buildings&nbsp;and&nbsp;improvements&nbsp;on&nbsp;buildings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20&nbsp;to&nbsp;40&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Installations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5 to 20 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Technical installations and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment and office furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers and IT equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>i) Impairment of intangible assets, property, and equipment, </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Group assesses at the end of each reporting period whether there is an indication that intangible assets, property and equipment may be
impaired. If any indication exists, the Group estimates the recoverable amount of the related asset. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not there is any indication of impairment, intangible assets not yet available
for use are tested for impairment annually by comparing their carrying amount with their recoverable amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to IAS
36&#151;<I>Impairment of Assets</I>, criteria for assessing indication of loss in value may notably include performance levels lower than forecast, a significant change in market data or the regulatory environment, or obsolescence or physical damage
of the asset not included in the amortization/depreciation schedule. The recognition of an impairment loss alters the amortizable/depreciable amount and potentially, the amortization/depreciation schedule of the relevant asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Impairment losses on intangible assets, property and equipment shall be reversed subsequently if the impairment loss no longer exists or has
decreased. In such case, the recoverable amount of the asset is to be determined again so that the reversal can be quantified. The asset value after reversal of the impairment loss may not exceed the carrying amount net of depreciation/amortization
that would have been recognized if no impairment loss had been recognized in prior periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Group does not have any intangible assets
with an indefinite useful life. However, as explained in Note 2.g, the Group recognized intangible assets in progress, which will be amortized once marketing authorization is received. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>j) Employee benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Long-term pension benefits </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Company employees are entitled to pension benefits required by French law: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pension benefit, paid by the Company upon retirement (i.e. defined benefit plan); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pension payments from social security entities, financed by contributions from businesses and employees (i.e.
defined contribution plan&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company has implemented an additional, <FONT
STYLE="white-space:nowrap">non-mandatory,</FONT> pension plan (&#147;Article 83&#148;), initially for the benefit of executives only. This plan was extended to the <FONT STYLE="white-space:nowrap">non-executive</FONT> employees starting on
January&nbsp;1, 2014. This plan meets the definition of defined contribution plan and is financed through a contribution that corresponds to 2.2% of the employee&#146;s annual wage, with the Company paying 1.4% and the employee paying 0.8%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the defined benefit plan, the costs of the pension benefit are estimated using the &#147;projected unit credit&#148; method. According to
this method, the pension cost is accounted for in the consolidated statement of income (loss), so that it is distributed uniformly over the term of the services of the employees. The pension benefit commitments are valued using the actual present
value of estimated future payments, adopting the rate of interest of long-term bonds in the private sector (i.e. Euro zone AA or higher rated corporate bonds + 10 years). The difference between the amount of the provision at the beginning of a
period and at the close of that period is recognized in the consolidated statement of income (loss) for the portion representing the costs of services rendered and the net interest costs, and through other comprehensive income for the portion
representing the actuarial gains and losses. The Company&#146;s commitments under the defined benefit plan are not covered by any plan assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments made by the Company for defined contribution plans are accounted for as expenses in the consolidated statement of income (loss) in
the period in which they are incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Other long-term benefits </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company pays seniority bonuses to employees reaching 10, 15 and 20 years of seniority. These bonuses represent long-term employee benefits.
Under IAS 19R &#147;Employee benefits&#148;, they are recording as a defined benefit obligation in the consolidated statement of financial position, but their remeasurements is not recognized in the consolidated statement of other comprehensive
income (loss). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Other short-term benefits </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An accrued expense is recorded for the amount the Company expects to pay its eligible employees in relation to services rendered during the
reporting period (actual legal or implicit obligation to make to these payments on a short-term basis). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>k) Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Finance leases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leases of
property and equipment where the Company has substantially all the risks and rewards of ownership are classified as finance lease arrangements under IAS 17&#151;Leases. Property and equipment acquired under finance-leases are capitalized at the
inception of the lease at the lower of the fair value of the leased property or the present value of the minimum lease payments. Each lease payment is divided between principal repayment and interest expense so as to achieve a constant rate on the
outstanding amount due. The corresponding rental obligations, net of interest expenses, are classified as financial liabilities in the consolidated statements of financial position. Property and equipment acquired under finance leases are
depreciated over the useful life of the asset. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Operating leases </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leases where a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating lease
arrangements under IAS 17. Payments made under operating-leases, net of any incentives received from the lessor, are recognized as expenses on the consolidated statements of income (loss) on a straight-line basis over the period of the lease. When a
lease contract includes rent-free periods or when the paid rents are not equal on the contract duration, the minimum payments are deferred on a straight-line basis over the leasing period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>l) Provisions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the course of its business, the Company could be exposed to certain risks and litigations, notably in relation to contractual arrangements. Provisions are recognized when the Company has a present legal or constructive obligation as a result of past
events, it is probable that the Company is subject to a release of outflow representatives of economic benefits to settle the obligation and a reliable estimate of the amount of the obligation can be made. Management of the Company estimates the
probability and the expected amount of a cash outflow associated with risks, together with the other information to be provided on possible liabilities. Where the Company expects a provision to be reimbursed, for example under an insurance contract,
the reimbursement is recognized as a separate asset but only when the reimbursement is certain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>m) Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ordinary shares are classified in shareholders&#146; equity. Costs associated with the issuance of new shares are directly accounted for in
shareholders&#146; equity in diminution of issuance premium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s own shares bought in the context of a brokering/liquidity
agreement are presented as a reduction in shareholders&#146; equity until their cancellation, their reissuance or their disposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>n) Share-based compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its inception, the Company has established several plans for compensation paid in equity instruments in the form of free shares
(&#147;<I>Attributions gratuites d&#146;actions</I>,&#148; or &#147;AGA&#148;), free preferred shares convertible into ordinary shares (&#147;<I>Attributions gratuites d&#146;actions de pr&eacute;f&eacute;rence convertibles en actions
ordinaires</I>,&#148; or &#147;AGAP&#148;), free performance shares (&#147;<I>Attributions gratuites d&#146;actions de performance</I><I></I>,&#148; or &#147;AGA Perf&#148;), share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subscription warrants (&#147;<I>Bons de souscription d&#146;actions</I>,&#148; or &#147;BSA&#148;), redeemable share subscription warrants (&#147;<I>Bons de Souscription et/ou d&#146;Acquisition
d&#146;Actions Remboursables</I>,&#148; or &#147;BSAAR&#148;), granted to its employees, executives, members of the Executive Board and scientific consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to IFRS 2&#151;<I>Share-based Payment, </I>these awards are measured at their fair value on the date of grant. The fair value is
calculated with the most relevant formula regarding the conditions and the settlement of each plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For share-based compensation granted
to employees, executives, members of the Executive Board and scientific consultants, the Company uses the Black-Scholes and Monte Carlo approach pricing models to determine the fair value of the share-based compensation. For scientific consultants
providing similar services, as the Company cannot estimate reliably the fair value of the goods or services received, it measures the value of share-based compensation and the corresponding increase in equity, indirectly, by reference to the fair
value of the equity instruments granted also using the Black-Scholes option pricing model. The fair value of free shares included in the model is determined using the value of the shares at the time of their distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In calculating the fair value of share-based compensation, the Company also considers the vesting period and the employee turnover weighted
average probability as described in Note 14. Other assumptions used are also detailed in Note 14. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes the fair value
of these awards as a share-based compensation expense over the period in which the related services are received with a corresponding increase in shareholders&#146; equity. Share-based compensation is recognized using the straight-line method. The
share compensation expense is based on awards ultimately expected to vest and is reduced by expected forfeitures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>o) Revenue
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Revenue from collaboration and license agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, the Company&#146;s revenue results primarily from payments received in relation to research, collaboration and licensing agreements
signed with pharmaceutical companies. These contracts generally provide for components such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payments upon signature; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments for the exercise of the option to acquire licenses of drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">milestones payments triggered following stages of development (scientific results obtained by the Company or by
the partner, obtaining regulatory marketing approvals); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments related to the Company&#146;s R&amp;D activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments triggered by the start of the commercialization of products resulting from development work or by
crossing cumulative thresholds of product sales, as well as the allocation of royalties on future sales of products or a sharing of profits on sales. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under collaboration and license agreements, the Company may promise its partners licenses on intellectual property, as well as research and
development services. According to IFRS 15, the Company has to determine if the promises included in the contract are distinct (therefore recognized separately as revenue) or if they have to be combined as a single performance obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When promises in a collaboration and license agreement are considered as a single performance obligation, the Company has to determine if the
combined performance obligation is satisfied over time or at point in time. If the combined performance obligation is satisfied over time, revenue recognition is based on the percentage of completion of the costs to be incurred. <FONT
STYLE="white-space:nowrap">Non-refundable</FONT> initial payments are deferred and recognized as revenue during the period the Company is engaged to deliver services to the customer on the basis of the corresponding costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When promises in a collaboration and license agreement are considered as separate
performance obligations, revenue is allocated to each obligation proportionally to its transaction price, which corresponds to a price each performance obligation would have been sold in the context of a separate transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with IFRS 15, variable considerations cannot be included in the estimated transaction price as long as it not highly probable
that the related revenue will not reversed in the future. According to the level of uncertainty relating to the results of preclinical and clinical trials and the decisions relating to the regulatory approvals, variable considerations depending on
these events are excluded from the transaction price as long as the trigger event is not highly probable. When the trigger event occurs, the corresponding milestone is added to the transaction price. Such adjustments are recorded on a cumulative <FONT
STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and net income (loss) in the period of adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues
based on royalties, completion of commercialization steps or <FONT STYLE="white-space:nowrap">co-sharing</FONT> profit from sales are recognized when the corresponding sales of products are carried out by the partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a collaboration contract grants a partner an option to acquire a licensed intellectual property (&#147;IP&#148;), the Company determines
the date of the transfer of control over the licensed IP. Depending on the Company analysis, revenue related to the option fee will be recognized (i)&nbsp;when control over the licensed IP transfers (payment related to the exercise of the option
being therefore considered as a variable consideration), or, (ii)&nbsp;deferred until the exercise of the option or its expiration period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When an agreement only promises development services, the Company will recognize the related revenue when the costs are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Up-front</FONT> and milestones payments and fees are recorded as deferred revenue upon receipt or when due,
and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts due by the Company in relation to cost-sharing are recorded as collaboration liability. Amounts payable
to the Company are recorded as accounts receivable when the Company&#146;s right to consideration is unconditional. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 13 for
accounting description of significant agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>p) Net income (expenses) from distribution agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When product sales are made by a partner in the context of collaboration or transition agreements, the Company must determine if the partner
acts as an agent or a principal. A party is recognized as a principal when it has the ability to conduct the use of the products and to obtain all the residual economic benefits previously to the transfer of the control of the products to the
customers. If the Company is a principal, sales are recognized as revenue. If the Company is an agent, it recognizes as a gain or a loss, the part of the revenue it is entitled to, which is the case under the agreement with AstraZeneca in relation
to Lumoxiti (see Note&nbsp;15). Therefore, income (loss) under the agreement are recognized in the statement of income (loss) on the line item &#147;Net income (loss) from distribution agreements&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>q) Government financing for research expenditures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Research tax credit </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
research tax credit (<I>Cr&eacute;dit d</I><I></I><I>&#146;Imp&ocirc;t Recherche</I>) (the &#147;Research Tax Credit&#148; or &#147;CIR&#148;) granted by the French tax authorities in order to encourage Companies to conduct technical and scientific
research. Companies that can justify that these expenses meet the required criteria receive such grants in the form of a refundable tax credit that can be used for the payment of taxes due for the period in which the expense was incurred and for the
next three years. These grants are presented under other income, in &#147;government financing for research expenditures&#148; line item in the consolidated statements of income (loss) , as soon as these eligible expenses were conducted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has benefited from a Research Tax Credit since its inception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received the reimbursement of the Research Tax Credit for the year 2017 during the year 2018. It has requested the reimbursement
of the 2018 Research Tax Credit in 2019 under the European Community tax rules for small and medium sized enterprises (&#147;SME&#148;) in compliance with the applicable regulations in effect. Only companies that meet the definition of SME according
to European Union criteria are eligible for early reimbursement of their CIR. Management ensured that the Company is a SME according to European Union criteria and can therefore benefit from this early reimbursement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CIR is presented under other income, in &#147;government financing for research expenditures&#148; line item in the consolidated
statements of income (loss) as it meets the definition of government grant as defined in IAS&nbsp;20&nbsp;<I>Accounting for government grants and disclosure of government assistanc</I>e. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Subsidies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government
grants are recognized when there is a reasonable assurance that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company will comply with the conditions attached to the grants; and that </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The grants will be received. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A government grant that becomes receivable as compensation for expenses or losses already incurred, or for the purpose of providing immediate
financial support to the Company with no future related costs, is recognized as other income of the period in which it becomes receivable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government grants to subsidize capital expenditures are presented in the statement of financial position as deferred income and are recognized
as income on a straight line basis over the useful life of those assets that have been financed through the grants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT
STYLE="white-space:nowrap">non-repayable</FONT> loan from the government is treated as a government grant when there is a reasonable assurance that the Company will meet the terms for <FONT STYLE="white-space:nowrap">non-repayment</FONT> of the
loan. When there is no such assurance, the loan is recorded as a liability under borrowings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>r) Income tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and
liabilities and their carrying amounts in the financial statements. Main temporary differences are generally associated with the depreciation of property and equipment, provisions for pension benefits and tax losses carried forward and also with the
deferred tax liabilities / assets generated by the application of IFRS 15 (see Note 2.a &#147;Adoption of IFRS 15&#148;). Currently enacted tax rates are used in the determination of deferred income tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary
differences can be utilized. Due to Company&#146;s early stage of development, it is not probable that future taxable profit will be available against which the unused tax losses can be utilized. As a consequence, deferred tax assets are recognized
up to deferred tax liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>s) Earnings (loss) per share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with IAS 33 <I>Earnings per share</I>, basic income (loss) per share is calculated by dividing the income (loss) attributable to
equity holders of the Group by the weighted average number of outstanding shares for the period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diluted income (loss) per share is measured by dividing the income (loss) attributable to
holders of equity and dilutive instruments by the weighted average number of outstanding shares and dilutive instruments for the period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If in the calculation of diluted income (loss) per share, instruments giving deferred rights to capital such as warrants generates an
antidilutive effect, then these instruments are not taken into account. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>t) Other comprehensive income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Items of income and expenses for the period that are recognized directly in equity are presented under &#147;other comprehensive income.&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>u) Segment information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For internal reporting purposes, and in order to comply with IFRS 8 <I>Operating segments</I>, the Company performed an analysis of operating
segments. Following this analysis, the Company considers that it operates within a single operating segment being the R&amp;D of pharmaceutical products in order to market them in the future. All R&amp;D activities of the Company are located in
France. Key decision makers (the executive committee of the Company) monitor the Company&#146;s performance based on the cash consumption of its activities. For these reasons, the Management of the Group considers it not appropriate to set up
separate business segments in its internal reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2018 and 2017, revenue was entirely generated by one customer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>v) Critical accounting estimates and assumptions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the consolidated financial statements under IFRS requires management to make estimates, assumptions and judgments that
affect the reported amounts of assets, liabilities, income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under
the circumstances. The Company&#146;s actual results may differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
estimates and judgments involve mainly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the accounting for collaboration and licensing agreements</B>: the revenue results primarily from payments
based on several components (e.g., upfront payments, milestone payments) received in relation to research, collaboration and licensing agreements signed with pharmaceutical or other companies. When the Company is committed to perform R&amp;D
services, revenue is spread over the period the Company is engaged to deliver these services, more particularly on the basis of the Company&#146;s inputs to the satisfaction of a performance obligation relative to the total expected inputs to the
satisfaction of that performance obligation. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Milestone payments are dependent upon the achievement of certain
scientific, regulatory, or commercial milestones. These variable payments are recognized when the triggering event has occurred, there are no further contingencies or services to be provided with respect to that event, and the counterparty has no
right to refund of the payment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">The changes in estimate regarding the completion of the works and the variable consideration relating to
the contracts signed with customers are described in Note 13. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the measurement of the subcontracting costs relating to the clinical trial costs</B>: the completion of the
subcontracting costs related to clinical trials is based on two allocation keys: (i)&nbsp;time, for the services defined as fixed and linear and/or (ii)&nbsp;the number of visits for services resulting from the recruitment rate. If the Company is
not sponsor of the trial, the criteria &#147;visits&#148; is replaced by the criteria &#147;patients.&#148; For </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
each clinical trial, these allocation keys are applied to the budget of the clinical trial. These allocations keys required three types of estimates: (i)&nbsp;the budget and length of the
clinical trial for the allocation key &#147;time&#148;, and (ii)&nbsp;the total number of visits (or &#147;patients&#148;) for the criteria &#147;visit&#148; or (&#147;patient&#148;). These estimated data are defined by the clinical operations
department and validated by the management. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the estimation of shared development costs and transition costs under the 2015 AstraZeneca monalizumab
agreement and the AstraZeneca Lumoxiti <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreement</B>: quarterly invoices submitted by AstraZeneca under these agreements are based on estimates made by AstraZeneca management as a result of its
accounting work. This implies estimates from AstraZeneca regarding the advancement of their clinical costs. AstraZeneca submits to the Company an update of their budgets which is reviewed by the Company in order to identify potential deviations.
These estimates of shared development costs and transition costs have a significant impact on the Company&#146;s operating income (loss), trade payables and collaboration liabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the</B> <B>measurement of the fair value of warrants</B>: the measurement of the fair value of warrants
granted to employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the Executive Board, scientific consultants, determined on the basis of Black-Scholes option and Monte Carlo approach pricing models; these models require the use
by the Company of certain calculation assumptions such as the expected volatility of the underlying share or the employee turnover weighted average rate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the</B> <B>measurement of employee benefits obligations</B>: inherent in these valuations are key actuarial
assumptions such as the discount rate, mortality tables and rates of turnover in employee personnel. These assumptions are provided in Note 10 and a change in these actuarial assumptions could have a material impact on the consolidated financial
statements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the</B> <B>measurement of provision for risk</B>: as part of its activities, the Company may be exposed to
some risks, in particular those related to contractual commitments. It is required that the Management of the Company to exercise its judgment to estimate the probability of cash outflow and, if applicable, the amount of this cash outflow and the
information to provide on the contingent liabilities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the</B> <B>estimate of the recoverable amount of the acquired and under progress licenses</B>: impairment
tests are performed on a yearly basis for the intangible assets which are not amortized (such as intangible assets in progress). Amortizable intangible assets are tested for impairment when there is an indicator of impairment. Impairment tests
involve comparing the recoverable amount of the licenses to their net book value. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. If the carrying amount of any asset is below its
recoverable amount, an impairment loss is recognized to reduce the carrying amount to the recoverable amount. The main assumptions used for the impairment test include (a)&nbsp;the amount of cash flows that are set on the basis of the development
and commercialization plans and budgets approved by Management, (b)&nbsp;assumptions related to the achievement of the clinical trials and the launch of the commercialization, (c)&nbsp;the discount rate, (d)&nbsp;assumptions on risk related to the
development and (e)&nbsp;for the commercialization, selling price and volume of sales, Any change in these assumptions could lead to the recognition of an impairment charge that could have a significant impact on the Company&#146;s consolidated
financial statements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>the</B> <B>estimate of the useful life of the acquired licenses</B>: intangible assets are amortized on a
straight line basis over their anticipated useful life. The estimated useful life is the period over which the asset provides future economic benefits. It is estimated by management and is regularly revised by taking into consideration the period of
development over which it expects to receive economic benefits such as collaboration revenues, royalties, product of sales, etc. However, given the uncertainty surrounding the duration of the R&amp;D activities for the programs in development and
their likelihood to generate future economic benefits to the Company, the estimated useful life of the rights related to these programs is rarely longer than the actual development phase of the product candidate. When a program is in
commercialization phases, the useful life takes into account the protection of the exclusivity rights and the anticipated period of commercialization without taking into account any extension or additional patents.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
The prospective amendment of the amortization plan of the monalizumab intangible asset, which is modified according to the estimate ending date of the Phase II clinical trial is described in Note
6. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3) Management of financial risks and fair value </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal financial instruments held by the Company are cash, cash equivalents and marketable securities. The purpose of holding these
instruments is to finance the ongoing business activities of the Company. It is not the Company&#146;s policy to invest in financial instruments for speculative purposes. The Company does not utilize derivatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal risks to which the Company is exposed are liquidity risk, foreign currency exchange risk, interest rate risk and credit risk.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Liquidity risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s cash management is performed by the Finance department, in charge of monitoring the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> financing and the short-term forecast and enabling the
Company to face its financial commitments by maintaining an amount of available cash consistent with the maturities of its liabilities. As of December&nbsp;31, 2018, cash, cash equivalents and short-term investments were &#128;167,531 thousand,
which represents more than a year of cash consumption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main characteristics of the financial instruments owned by the Company
(including liquidity) are presented in Note 4. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Foreign currency exchange risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is exposed to foreign exchange risk inherent in certain subcontracting activities relating to its operations in the United States,
which have been invoiced in U.S. dollars. The Company does not currently have recurring revenues in euros, dollars or in any other currency. As the Company further increases its business, particularly in the United States, it is expected to face
greater exposure to exchange rate risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The revenue denominated in U.S. dollars has represented approximately 100% of revenue in the
years ended December&nbsp;31, 2018 and 2017, respectively. Payments in U.S. dollars represented approximately 31.9% and 15.1% of the payments in the years ended December&nbsp;31, 2018 and 2017, respectively. In order to cover this risk, the Company
kept in U.S. dollars a part of the consideration received from AstraZeneca in June 2015 and January 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s foreign
exchange policy does not include the use of hedging instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Interest rate risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has very low exposure to interest rate risk. Such exposure primarily involves money market funds and time deposit accounts. Changes
in interest rates have a direct impact on the rate of return on these investments and the cash flows generated. The Company has no credit facilities. The repayment flows of the advances from <I>Banque Publique d&#146;Investissement</I> (&#147;BPI
France&#148;) and the borrowings subscribed in 2017 are not subject to interest rate risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Credit risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The credit risk related to the Company&#146;s cash equivalents, short-term investments and <FONT STYLE="white-space:nowrap">non-current</FONT>
financial assets is not significant in light of the quality of the issuers. The Company deemed that none of the instruments in its portfolio are exposed to credit risk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Fair value </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of financial instruments traded on an active market is based on the market rate as of December&nbsp;31, 2018. The market prices
used for the financial assets owned by the Company are the bid prices in effect on the market as of the valuation date. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4) Cash, cash equivalents and
financial assets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Cash and cash equivalents and short-term investments</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>167,531</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>116,110</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash, cash equivalents and financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>202,712</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>176,578</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The variation of short-term investments and <FONT STYLE="white-space:nowrap">non-current</FONT> financial
assets for the periods 2017 and 2018 are the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Acquisitions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Disposals</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variation&nbsp;of<BR>fair&nbsp;value&nbsp;through<BR>the&nbsp;consolidated<BR>statement&nbsp;of<BR>income&nbsp;(loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variation<BR>of&nbsp;fair<BR>value&nbsp;by<BR>OCI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variation<BR>of</B><br><B>accrued</B><br><B>interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Foreign<BR>currency<BR>effect</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT><B> </B>financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>77,212</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(24,217</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,786</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(152</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,341</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,398</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Acquisitions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Disposals</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variation&nbsp;of<BR>fair&nbsp;value&nbsp;through<BR>the&nbsp;consolidated<BR>statement&nbsp;of<BR>income&nbsp;(loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variation<BR>of fair<BR>value&nbsp;by<BR>OCI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variation<BR>of</B><br><B>accrued</B><br><B>interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Currency<BR>translation<BR>difference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,103</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT><B> </B>financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>54,757</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43,271</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17,541</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(41</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>447</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>261</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,943</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>77,212</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents are mainly composed of current bank accounts, interest-bearing accounts and fixed-term accounts. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at hand</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest-bearing accounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed-term accounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares in mutual funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>152,314</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>99,367</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest-bearing accounts, fixed-term accounts and shares in mutual funds meet the criteria
to be considered as cash equivalents. For an investment to qualify as a cash equivalent it must be readily convertible to a known amount of cash and be subject to an insignificant risk of changes in value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-current</FONT> financial assets and short-term investments </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares in mutual funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Short-term investments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,217</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,743</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medium-term notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35,181</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60,469</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the year ended December 31, 2017, shares in mutual funds are defined by the Company as assets available for
sale measured at fair value through other comprehensive income. From January 1, 2018 and the first application of IFRS 9, they are accounted for as financial assets at fair value through profit and loss. The Company only invests into funds with a
very low level of risk. As of December&nbsp;31, 2018, the Company owns shares of four mutual funds. The risk profiles of these funds are rated 1 to 7 by the financial institution who manages and commercializes these funds (1 being the lowest risk
profile). When the maturity of shares in mutual funds is longer than one year, they are classified as <FONT STYLE="white-space:nowrap">non-current</FONT> financial instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets generally include a guarantee of capital at the maturity date
(which is always longer than one year). These instruments are defined by the Company as financial assets at fair value through profit or loss and classified as <FONT STYLE="white-space:nowrap">non-current</FONT> due to their maturity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cash, cash equivalents and financial assets per currency </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments and other <FONT STYLE="white-space:nowrap">non-current</FONT> financial
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>128,270</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>74,442</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>202,712</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>117,231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>59,348</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>176,578</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The portion of the financial assets held and denominated in U.S. dollars will be used by the Company to pay
for services provided in the United States, which will be invoiced in U.S. dollars during the next years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Variance in fair value of
financial instruments </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value through profit or loss(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value through other comprehensive income(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In 2018 and 2017, change in fair value through profit or loss is made of &#128;4,248&nbsp;thousand (&#128;651 thousand) of unrealized gains, less &#128;462&nbsp;thousand (&#128;691 thousand) of unrealized losses,
respectively, which are recognized in Net financial loss, respectively (see Note 16). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In 2017, financial instruments for which change in fair value is recognized through other comprehensive income are related to mutual funds </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5) Trade receivables and others </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trade
receivables and others are analyzed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued receivables excluding rebates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CIR(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other tax credits (e.g. CICE)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAT refund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade account receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments made to suppliers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refund to be received (&#147;CVAE&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Trade receivables and others excluding rebates</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>139,012</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,412</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rebate related to capital expenditures(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Trade receivables and others</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>152,112</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,412</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;Other receivables&#148; as of December&nbsp;31, 2018, are mainly related to AstraZeneca as a result of the exercise of the monalizumab exclusive license option ($100,000&nbsp;thousand or &#128;87,655 thousand) and
option granted on IPH5201 ($24,000&nbsp;thousand or &#128;20,961 thousand). These amounts are due in the first quarter of 2019, see Note 1.1.a and Note 1.1.c for agreements description. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The rebate refers to an estimated rebate of $15.0&nbsp;million (&#128;13.1 million) granted by AstraZeneca in connection with the acquisition of Lumoxiti rights and that will be paid in 2019, see Note 6.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In accordance with the principles described in Note 2.q, the CIR is recognized as other operating income in the year to which the eligible research expenditure relates. The Company obtained the repayment of the CIR for
the tax year 2017 in the amount of &#128;11,022&nbsp;thousand in 2018 and will apply for the refund of the CIR for the tax year 2018 of &#128;13,503&nbsp;thousand in 2019. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net book value of the receivables is considered to be a reasonable approximation of their estimated fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trade receivables and others have payment terms of less than one year. No valuation allowance was recognized on trade receivables and others
as the credit risk of each of debtors was considered as not significant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6) Intangible assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets can be broken down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Purchased<BR>licenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other&nbsp;intangible<BR>assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>In&nbsp;Progress</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>January&nbsp;1, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,022</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,075</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions (amended)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2017
</B>(amended)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,192</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>January&nbsp;1, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,192</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,801</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,630</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,184</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>84,529</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">This amount is an upfront payment for acquisition of IPH5401 rights under the <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreement signed in 2017 with Novo Nordisk A/S. The classification of this amount has
been amended compared to the 2017 consolidated financial statements since it is in progress and thus not amortized. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">This amount mainly includes (i)&nbsp;an upfront payment of &#128;43,501&nbsp;thousand, less an accrued receivables of &#128;13,050&nbsp;thousand relating to the rights acquired from AstraZeneca in 2018 under the
Lumoxiti <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreement and (ii)&nbsp;a &#128;13,050&nbsp;thousand additional consideration to be paid to Novo Nordisk A/S following the exercise of the option by AstraZeneca for the monalizumab
rights. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the agreement inception, acquired rights were recorded as intangible asset for an amount of &#128;7,000&nbsp;thousand. The Company recorded
an additional consideration of &#128;6,325&nbsp;thousand in 2015 and a final consideration of $15,000&nbsp;thousand (&#128;13,050 thousand) due in 2018 (see Note&nbsp;1.1.a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, this asset is amortized on a straight-line basis over the anticipated residual duration of the Phase&nbsp;II trials. As of
December 31, 2018, the Company estimated that it would be fully amortized by the end of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net book values of the monalizumab
rights were &#128;12,733&nbsp;thousand and &#128;4,513&nbsp;thousand as of December&nbsp;31, 2018 and December&nbsp;31, 2017, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>IPH5201 (Anti-CD39) rights acquired from Orega Biotech </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;4, 2016, the Company and Orega Biotech entered into an exclusive licensing agreement by which Orega Biotech granted the Company
full worldwide rights to its program of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> anti-CD39 checkpoint inhibitors. The undisclosed upfront payment paid by the Company to Orega Biotech has been
recognized as an intangible asset in the consolidated financial statements for the year ended December&nbsp;31, 2016. Criteria relating to the first development milestone were reached in December 2016. Consequently, the amount of this milestone was
recognized as an intangible asset in addition to the initial payment, for a total of &#128;1.8&nbsp;million as of December&nbsp;31, 2018. In June of 2019, the Company also paid Orega Biotech &#128;7.0&nbsp;million as consideration following the
collaboration and option agreement signed on October&nbsp;22, 2018 with AstraZeneca regarding IPH5201. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This asset is amortized on a straight-line basis since November&nbsp;1, 2018 (corresponding
to the effective beginning date of the collaboration) until the date the Company expects to fulfill its commitment (submission of an IND expected in 2019). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may also be obligated to pay Orega Biotech up to &#128;51,500 thousand upon the achievement of development and regulatory
milestones. In addition, the Company will be obligated to pay mid-single digit to low-teen percentage payments, depending on determinations relating to Orega Biotech&#146;s intellectual property rights for certain patents, on sublicensing revenues
the Company receives pursuant to its agreement with AstraZeneca relating to IPH5201. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>IPH5401 (anti-C5aR) rights acquired from Novo
Nordisk A/S </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the agreement inception, an upfront payment of &#128;40&nbsp;million for acquired rights were recorded as
intangible asset. As IPH5401 is still in clinical trial, the acquired rights are classified as intangible asset in progress. They were subject to annual impairment test. No impairment were recorded since inception. These acquired rights will be
amortized when the Company obtains economic benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the agreement, the Company will pay additional payments according to
the reach of specific steps. As of December&nbsp;31, 2018, according to the uncertainty of these potential payments, no liability was recognized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development costs incurred by the Company are recognized as research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main assumptions used for the impairment test are the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cash flows are set on the basis of the development and commercialization plans and budgets approved by
Management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A discount rate of 12%; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A risk of development is taken into consideration by applying probabilities of success of reaching future phases
of development to cash flows related to each development phases Those average probabilities of success of R&amp;D projects are based on an article published in Nature Biotechnology journal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the commercialization phase, selling price and sales volume are estimated on the basis of the potential
market and the observed performances of comparable drugs currently on the market. An attrition rate is applied to anticipated revenue once the related rights fall <FONT STYLE="white-space:nowrap">off-patent.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of failure of the clinical trials in progress, the Company may have to fully depreciate the intangible asset corresponding to the
IPH5401 rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company did not identify any reasonable potential variance in the key assumptions that may generate a depreciation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sensitivity testing regarding the actuarial assumptions and other assumptions such as: discount rate
<FONT STYLE="white-space:nowrap">(+/-&nbsp;2&nbsp;points),</FONT> attrition rate <FONT STYLE="white-space:nowrap">(+/-&nbsp;2&nbsp;points)</FONT> and selling price <FONT STYLE="white-space:nowrap">(-50/+25</FONT> points) were performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IPH5401 does not generate economic benefits yet for the Company. In accordance with IAS&nbsp;38, it will be amortized when it generates
economic benefits, which can result from: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The commercialization the drug candidate; or, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An <FONT STYLE="white-space:nowrap">out-licensed</FONT> agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company commercialize the drug product on its own, it will have to determine the amortization period of the related capitalized rights.
It will have to estimate their useful life, considering the date when they fall off patent. Those capitalized rights will be amortized on a straight line basis during the estimated useful life. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company entered in an <FONT STYLE="white-space:nowrap">out-licensed</FONT> agreement,
the Company will have to perform an analysis to determine if the control of the rights are transferred to a third party, and thus will have to derecognize the capitalized rights. If the Company conclude that it keeps the control of the rights, it
will determine their useful life and will amortize them on a straight line basis during this useful life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Lumoxiti rights acquired
from AstraZeneca under the 2018 AstraZeneca multi-term agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As mentioned above, Lumoxiti rights are capitalized in 2018 for a
total amount of &#128;30,451&nbsp;thousand (see Note 1.1.b for agreement description). The Company will reimburse AstraZeneca for the development, production and commercialization costs incurred by AstraZeneca during the transition period, after
deduction of an amount up to &#128;13.1&nbsp;million ($15 million) accrued receivable. Thus, this accrued receivable is not included the value of capitalized rights and is recorded in trade receivables and others in the consolidated statement of
financial position as of December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The license is amortized on a straight line basis until July&nbsp;31, 2031, which
corresponds to the expiration of the current composition of matter patent, not including any additional patent extensions or patents. The net book value of the asset amounts to &#128;29,987&nbsp;thousand as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development costs invoiced by AstraZeneca since the acquisition of the license mainly relate to the generation of additional data for
regulatory purposes. These costs are recognized as research and development expenses as incurred (see Note 14). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7) Property and equipment </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lands&nbsp;and<BR>buildings<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Laboratory<BR>equipment&nbsp;and&nbsp;other</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>In&nbsp;Progress</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year ended December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net opening balance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,900</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(987</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net closing balance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,093</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,602</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,729</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year ended December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net opening balance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,093</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,602</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,729</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,532</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net closing balance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,101</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>320</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,216</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Company owns two properties. The one on which stands the buildings purchased in 2008 (gross value &#128;772 thousand), and a second one, adjacent to the first one, acquired in December 2017 (gross value &#128;491
thousand). They are not amortized. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Of which &#128;930&nbsp;thousand financed through loans (&#128;491&nbsp;thousand for a land and &#128;439&nbsp;thousand for the acquisition of R&amp;D equipment). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes assets under finance-lease agreements as broken down below: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Land and building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net book value of lands and buildings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,290</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,581</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net book value of equipment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,904</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8) Trade payables and others </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This line item is analyzed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Suppliers (excluding payables related to capital expenditures)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax and employee-related payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Trade payables and others (excluding payables related to capital expenditures)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34,662</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payables related to capital expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Trade payables and others</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>91,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,657</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The book value of trade payables and others is considered to be a reasonable approximation of their fair
value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9) Financial liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This line item was broken down per maturity and is analyzed as follows : </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proceeds<BR>from<BR>borrowings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Repayments<BR>of</B><br><B>borrowings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI PTZI IPH41(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Real estate property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Down-payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(173</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan&#151;Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total&#151;Financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,864</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,342</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,522</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interest-free loan </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands of euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proceeds<BR>from<BR>borrowings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Repayments<BR>of<BR>borrowings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI PTZI IPH41(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Real estate property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(861</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Down-payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(530</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan&#151;Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total&#151;Financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,327</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,739</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,201</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,864</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interest free loan </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI PTZI IPH41</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Real estate property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total&#151;Current financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,347</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,343</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI PTZI IPH41(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Real estate property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Total&#151;Non-Current</FONT> financial
liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,522</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,864</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013, the Company was granted an interest-free loan for innovation (&#147;PTZI&#148;) by BPI France
relating to the program IPH4102 for an amount of &#128;1,500&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finance lease obligations relate primarily to real estate
property in relation to the acquisition in 2008 of the Company&#146;s headquarters and main laboratories. They are presented in the above table net of the cash collateral paid to Sogebail, the lessor. In the context of this operation, the Company
paid a guarantee in the form of a down-payment. This down-payment amounts to &#128;234&nbsp;thousand as of December&nbsp;31, 2018 (&#128;386&nbsp;thousand as of December&nbsp;31, 2017). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;3, 2017, the Company borrowed from the Bank &#147;Soci&eacute;t&eacute; G&eacute;n&eacute;rale&#148; in order to finance the
construction of its future headquarters. This loan amounting to a maximum of &#128;15,200&nbsp;thousand will be raised during the period of the construction in order to pay the supplier payments as they become due. This period of raising is limited
to August&nbsp;30, 2019. The reimbursement of the capital will begin from August 30, 2019 to August&nbsp;30, 2031 (12 years). The Company authorized collateral over financial &#147;Soci&eacute;t&eacute; G&eacute;n&eacute;rale&#148; instruments
amounting to &#128;15,200&nbsp;thousand. The security interest on the pledge financial instruments will be released in accordance with the following schedule: &#128;4,200&nbsp;thousand in July 2024, &#128;5,000&nbsp;thousand in July 2027 and
&#128;6,000&nbsp;thousand in July 2031. As of December&nbsp;31, 2018 the loan was raised at an amount of &#128;1,300&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
loan bears a fixed interest rate of 2.01%. It is subject to a covenant based on the assumption that the total cash, cash equivalents and current and <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets are at least equal to principal
as of financial year end. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the schedule for repayment of financial liabilities (principal only).
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Repayment&nbsp;schedule&nbsp;(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&lt;1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2&nbsp;to&nbsp;5&nbsp;years<BR>included</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&gt;&nbsp;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI France&#151;IPH41</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Real estate property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Down-payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;</B><B>&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(234</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>987</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>372</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan&#151;Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,300</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,347</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,112</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,062</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,522</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the schedule for the contractual flows (being principal and interest payments,): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Repayment&nbsp;schedule&nbsp;(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&lt;1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2&nbsp;to&nbsp;5&nbsp;years<BR>included</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&gt;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BPI France&#151;PTZI IPH41</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Real estate property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,376</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Down-payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(241</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease finance obligations&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>992</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans&#151;Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan&#151;Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,463</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,365</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,228</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,132</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,725</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair value of financial liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of financial liabilities, calculated on the basis of discounted future cash flow, was &#128;4,427&nbsp;thousand and
&#128;5,402&nbsp;thousand as of December&nbsp;31, 2018 and 2017, respectively, using level 3 fair value measurements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10) Employee benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Defined benefit obligations </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Defined&nbsp;benefit&nbsp;obligations&nbsp;(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allowance for retirement defined benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allowance for seniority awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total&#151;Defined benefit obligations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,621</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">French law requires payment of a lump sum retirement indemnity to employees based on years of service and
annual compensation at retirement. Benefits do not vest prior to retirement. The Company pays for this defined benefit plan. It is calculated as the present value of estimated future benefits to be paid, applying the projected unit credit method
whereby each period of service is seen as giving rise to an additional unit of benefit entitlement, each unit being measured separately to build up the final. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;24, 2016, the Company entered into an internal labor agreement with the employees representatives whereby the Company is
committed to paying a seniority award after 15 years and 20 years of employment. This award is paid on the anniversary date. A similar award existed for employees having a seniority of 10 years but was not booked due to its insignificant amount. As
such, in 2016 the Company recorded </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a provision for seniority awards and a corresponding charge included in &#147;Staff costs other than share-based payments&#148; (see Note 14) other than payments in shares. These awards meet the
definition of other long-term benefits under IAS 19. This provision is determined by an external actuary firm based on the assumptions disclosed hereafter and amounts to &#128;415&nbsp;thousand as of December&nbsp;31, 2018 (&#128;366&nbsp;thousand
as of December&nbsp;31, 2017). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main actuarial assumptions used to evaluate retirement benefits are the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Economic assumptions</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate (iBoxx Corporate AA) for retirement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual rate of increase in wages</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Demographical assumptions</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Type of retirement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">At&nbsp;the&nbsp;initiative&nbsp;of<BR>the employee</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">At&nbsp;the&nbsp;initiative&nbsp;of<BR>the employee</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rate of tax and social charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Age at retirement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Executives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- <FONT STYLE="white-space:nowrap">Non-executives</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mortality table</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">TH-TF</FONT> <FONT STYLE="white-space:nowrap">00-02</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">TH-TF</FONT> <FONT STYLE="white-space:nowrap">00-02</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual turnover by tranche of age</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">All personnel</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">All personnel</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">16-24</FONT> years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">25-29</FONT> years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">30-34</FONT> years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">34-39</FONT> years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">40-44</FONT> years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">45-49</FONT> years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+50 years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in the projected benefit obligation for the periods presented were as follows (in thousands of euro):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As&nbsp;of&nbsp;January&nbsp;1,&nbsp;2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,418</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial (gain) / loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,621</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial (gain) / loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no asset covering the defined benefit obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An increase/decrease of +/- 50 basis point of the discount rate would result in a decrease/increase of the total benefit obligation of
&#128;300&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main actuarial assumptions used to evaluate seniority awards at December&nbsp;31, 2018 are the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Discount rate: 1.14% (difference with the rate used for pension benefit provision results from the difference of
maturity) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rate of annual increase in wages: 4.5% </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rate of contributions: 45.20% </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rate of wage costs: 23.29% </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Age of retirement: 64 years for executives, 62 years for <FONT STYLE="white-space:nowrap">non-executives</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mortality Table: TH&#151;TF <FONT STYLE="white-space:nowrap">00-02</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual mobility rate: 2.1% on average </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Defined contribution plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In France, pension funds are generally financed by employer and employee contributions and are accounted for as defined contribution plans with
the employer contributions recognized as expensed as incurred. They amounted &#128;1,277&nbsp;thousand and &#128;982&nbsp;thousand in the years ended December&nbsp;31, 2018 and 2017, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11) Share capital and share base payments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>a) Share capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company manages its capital to ensure that the Company will be able to continue as a going concern while maximizing the return to
shareholders through the optimization of the debt and equity balance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company&#146;s share capital
amounted to &#128;3,196,979 divided into 63,939,586 shares with a par value of &#128;0.05 each, fully paid up, after taking into account the various capital increases that took place since the inception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share capital does not include BSAs, BSAAR, AGAs and AGAPs that have been granted to certain investors or natural persons, both employees and <FONT
STYLE="white-space:nowrap">non-employees</FONT> of the Company, but not yet exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Group issued preferred shares (share B) which
will become convertible into ordinary shares following a vesting period of one year and a retention period of two years if the performance criteria are met at the end of the retention period. The number of ordinary shares to which the conversion of
one preferred share will be entitled will be determined according to the fulfillment of the performance criteria. The holders of preferred shares are not entitled to voting rights nor dividend payment until the date at which the preferred shares
become convertible into ordinary shares. The preferred shares give no preferential subscription right to any capital increase and are not transferrable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents the historical changes in the share capital of the Company as of
December&nbsp;31, 2018 and 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Number&nbsp;of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Nature&nbsp;of&nbsp;the&nbsp;Transactions</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share&nbsp;Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nominal<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance&nbsp;as&nbsp;of&nbsp;January&nbsp;1,&nbsp;2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,880,352</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>234,874,392</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,600,100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">September&nbsp;20, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary shares (definitive acquisition of free shares)</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;25, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary shares to AstraZeneca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,291,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,260,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;25, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,078</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">November&nbsp;29, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary shares (Exercise of shares warrants)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,706,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,196,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>299,932,221</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>63,932,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Number&nbsp;of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Nature&nbsp;of&nbsp;the&nbsp;Transactions</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share&nbsp;Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nominal<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance&nbsp;as&nbsp;of&nbsp;January&nbsp;1,&nbsp;2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,696,065</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>187,571,429</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,921,304</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">January&nbsp;24,<BR>2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary shares (exercise of share warrants)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">February&nbsp;10,<BR>2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary shares (exercise of share warrants)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">June&nbsp;14, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary shares (exercise of share warrants)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;13, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Contribution in kind in the context of the acquisition of C5aR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,999,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,343,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;21, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary and preferred shares (definitive acquisition of free
shares and free preferred shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">December&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase by issuance of ordinary and preferred shares (definitive acquisition of free
shares and free preferred shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,399</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,829,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">December&nbsp;7, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Subscription of share warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,880,352</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>234,874,392</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,600,100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Holding by the Company of its own shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company held 18,575 of its own shares as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>b) Share based payments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has issued BSAs, BSAARs, stock options, AGAs and AGAPs as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Types</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>issued&nbsp;as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants&nbsp;void<BR>as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>exercised&nbsp;as<BR>of</B><br><B>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>outstanding<BR>as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>number&nbsp;of<BR>shares&nbsp;to&nbsp;be<BR>issued&nbsp;as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercice<BR>price&nbsp;per<BR>share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Sept. 9, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSAAR 2011</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 2.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">May&nbsp;27, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSAAR 2012</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 2.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSAAR 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 7.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;21,&nbsp;2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGAP Management <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;21, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGAP Employees <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;21, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Management <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Types</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>issued&nbsp;as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants&nbsp;void<BR>as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>exercised&nbsp;as<BR>of</B><br><B>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>outstanding<BR>as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>number&nbsp;of<BR>shares&nbsp;to&nbsp;be<BR>issued&nbsp;as&nbsp;of<BR>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercice<BR>price&nbsp;per<BR>share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">October&nbsp;21, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Employees <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">December&nbsp;30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGAP <FONT STYLE="white-space:nowrap">2016-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">nil</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">December&nbsp;30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Management <FONT STYLE="white-space:nowrap">2016-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">December&nbsp;30,&nbsp;2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Employees <FONT STYLE="white-space:nowrap">2016-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">September&nbsp;20,&nbsp;2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Bonus 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">April&nbsp;3,2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGAP Employees 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">April&nbsp;3,2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGAP Management 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">April&nbsp;3,2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Employees 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;3, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Bonus Management 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">November&nbsp;20, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Perf Employees 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">November&nbsp;20, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AGA Perf Management 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;29, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSA 2011</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 1.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;17, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSA 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 2.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;16, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSA 2014</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">April&nbsp;27, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSA <FONT STYLE="white-space:nowrap">2015-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 9.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">July&nbsp;1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSA <FONT STYLE="white-space:nowrap">2015-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">September&nbsp;20, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSA 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,943,202</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,145,643</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,747,038</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,862,100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Types</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>issued&nbsp;as&nbsp;of<BR>12/31/2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants&nbsp;void</B><br><B>as&nbsp;of<BR>12/31/2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>exercised&nbsp;as</B><br><B>of<BR>12/31/2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>warrants<BR>outstanding</B><br><B>as&nbsp;of<BR>12/31/2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>number&nbsp;of<BR>shares&nbsp;to&nbsp;be<BR>issued&nbsp;as&nbsp;of<BR>12/31/2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercice<BR>price&nbsp;per<BR>share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">Sept. 9, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSAAR 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">May&nbsp;27, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSAAR 2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">July&nbsp;1, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSAAR 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">October&nbsp;21,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGAP Management <FONT STYLE="white-space:nowrap">2016-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">October&nbsp;21,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGAP Employees <FONT STYLE="white-space:nowrap">2016-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">October&nbsp;21,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGA Management <FONT STYLE="white-space:nowrap">2016-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">October&nbsp;21,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGA Employees <FONT STYLE="white-space:nowrap">2016-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">December&nbsp;30,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGAP <FONT STYLE="white-space:nowrap">2016-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">December&nbsp;30,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGA Management <FONT STYLE="white-space:nowrap">2016-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">December&nbsp;30,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGA Employees <FONT STYLE="white-space:nowrap">2016-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">September&nbsp;20,<BR>2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGA Bonus 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">July&nbsp;29, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSA 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">July&nbsp;17, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSA 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">July&nbsp;16, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSA 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">April&nbsp;27,<BR>2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSA <FONT STYLE="white-space:nowrap">2015-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">July&nbsp;1, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSA <FONT STYLE="white-space:nowrap">2015-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">September&nbsp;20,<BR>2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BSA 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,288,674</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,073,588</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,079,482</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,458,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>AGA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Details of AGA </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP</B><br><B>Employees</B><br><B><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA</B><br><B>Employees</B><br><B><FONT STYLE="white-space:nowrap">2016-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of grant (Executive Board)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;21,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;21,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;21,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;21,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">December&nbsp;30,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting period (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-transferability</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years after<BR>vesting&nbsp;period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years after<BR>vesting&nbsp;period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years after<BR>vesting&nbsp;period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years after<BR>vesting period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of AGA granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share entitlement per free share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant date share fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">No</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">No</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected turnover (yearly basis)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per AGA at grant date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>Management<BR><FONT STYLE="white-space:nowrap">2016-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA</B><br><B>Employees<BR><FONT STYLE="white-space:nowrap">2016-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA&nbsp;Bonus</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Employees</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAP<BR>Management<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of grant (Executive Board)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">December&nbsp;30,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">December&nbsp;30,<BR>2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;20,<BR>2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;3,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2018</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;3,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2018</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting period (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-transferability</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years after<BR>vesting period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR><BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years<BR>after<BR>vesting<BR>period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR><BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">2 years<BR>after<BR>vesting<BR>period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of AGA granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share entitlement per free share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant date share fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected turnover (yearly basis)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per AGA at grant date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA</B><br><B>Employees</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA&nbsp;Bonus</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA&nbsp;Perf<BR>Employees</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA&nbsp;Perf<BR>Management</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of grant (Executive Board)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;3,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2018</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;3,<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2018</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">November&nbsp;20,<BR>2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">November&nbsp;20,<BR>2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting period (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-transferability</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">1 years after<BR>vesting period<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">end</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom" ALIGN="right">1 years after<BR>vesting period<BR>end</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number&nbsp;of&nbsp;AGA&nbsp;granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share entitlement per free share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant date share fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Yes</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected turnover (yearly basis)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.70%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per AGA at grant date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Change in Number of AGAs Outstanding </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number&nbsp;of&nbsp;AGAs</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>331,910</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>557,361</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">777,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,055</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(243,748</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,682</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,049,466</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>331,910</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Breakdown of the Closing Balance </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number&nbsp;of&nbsp;AGAs</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP Management <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP Employees <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Management <FONT STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP <FONT STYLE="white-space:nowrap">2016-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Management <FONT STYLE="white-space:nowrap">2016-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Bonus 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP Employees 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP Management 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Employees 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Bonus 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Perf Employees 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Perf Management <FONT STYLE="white-space:nowrap">2018-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,049,466</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>331,910</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of granted free shares is based on the closing price of the Company&#146;s
share at grant date, reduced when necessary by an estimated turn-over rate. This estimated fair value is recognized as operating expenses on a straight-line basis over the vesting period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>AGA Management <FONT STYLE="white-space:nowrap">2016-1</FONT> / AGA Management <FONT STYLE="white-space:nowrap">2016-2&nbsp;/</FONT> AGA
Employees <FONT STYLE="white-space:nowrap">2016-1</FONT> / AGA Employees <FONT STYLE="white-space:nowrap">2016-2</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses
related to those plans were &#128;1,392&nbsp;thousand and &#128;4,383&nbsp;thousand for the financial years ended December&nbsp;31, 2018 and 2017, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>AGA <FONT STYLE="white-space:nowrap">2017-1</FONT> (Employees) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses were &#128;456&nbsp;thousand for the financial year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Free preferred shares convertible into ordinary shares: AGAP Management <FONT STYLE="white-space:nowrap">2016-1&nbsp;/</FONT> AGAP
Employees <FONT STYLE="white-space:nowrap">2016-1</FONT> / AGAP Management <FONT STYLE="white-space:nowrap">2016-2</FONT> / AGAP Management 2017&nbsp;/ AGAP Employees 2017 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AGAP Management <FONT STYLE="white-space:nowrap">2016-1,</FONT> <FONT STYLE="white-space:nowrap">2016-2</FONT> and AGAP Employees <FONT
STYLE="white-space:nowrap">2016-1</FONT> are subject to internal and share price conditions. AGAP Management <FONT STYLE="white-space:nowrap">2017-1</FONT> and AGAP Employees <FONT STYLE="white-space:nowrap">2017-1</FONT> are subject to share value
condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of these free preferred shares is based on a third party valuation report. The valuation method used to
estimate the fair value of these free preferred shares is presented below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a
Capital Asset Pricing (&#147;CAPM&#148;) model of the share price using a Monte Carlo approach; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adjustment of the estimation by applying expected turnover rates; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in internal conditions are taken into account in the revision of the estimated number of free shares expected to vest during the
vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has recognized an expense over a period of one year on a straight-line basis, this period being the vesting
period. Expenses were &#128;567&nbsp;thousand and &#128;5,327&nbsp;thousand for the financial year ended December&nbsp;31, 2018 and 2017, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>AGA Bonus 2017 and AGA Bonus 2018 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AGA Bonus 2017 and 2018 were granted to the Executive members Committee who opted for these compensation plans. For each recipient, the number
of shares definitely acquired is equal to the cash equivalent of 50% of the annual variable compensation increased by a 30% premium. In the event of an over-performance (i.e. achieved target above 100%), the surplus is paid in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses were &#128;208&nbsp;thousand and &#128;189&nbsp;thousand for the financial years ended December&nbsp;31, 2018 and 2017, respectively.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Free performance shares (AGA Perf Employees 2018 / AGA Perf Management 2018) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Free performance shares granted in 2018 are subject to share price conditions and a vesting kicker triggered by the performance of an internal
condition, which is the success of certain clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of these free performance shares is based on a third party
valuation report. The valuation method used to estimate the fair value of these free performance shares is presented below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a
CAPM model of the share price using a Monte Carlo approach; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adjustment of the estimation by applying expected turnover rates. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in internal conditions are taken into account in the revision of the estimated
number of free performance shares expected to vest during the vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses were &#128;84.0&nbsp;thousand the financial year
ended 31, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>BSA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Details of BSA </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA&nbsp;2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA&nbsp;2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">BSA&nbsp;2015-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">BSA&nbsp;2015-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSA&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date&nbsp;of&nbsp;grant (Executive Board)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;29,&nbsp;2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;17,&nbsp;2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;16,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;27,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;1,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;20,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting period (years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plan expiration date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;29,<BR>2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;17,<BR>2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;16,<BR>2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;26,<BR>2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">June&nbsp;30,<BR>2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;20,<BR>2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of BSA granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share entitlement per BSA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 11.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation method used</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="21" ALIGN="center">Black&#151;Scholes</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant date share fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">6.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46.72</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.08</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47.83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average life of BSA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0,20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance conditions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value per BSA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.62</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.87</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2.51</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6.59</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4.73</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.57</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Change in Number of BSA Outstanding </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number&nbsp;of&nbsp;BSA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">384,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">435,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>334,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>384,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Breakdown of the Closing Balance </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number&nbsp;of&nbsp;BSA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA <FONT STYLE="white-space:nowrap">2015-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA <FONT STYLE="white-space:nowrap">2015-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>334,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>334,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>384,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>384,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>BSAAR </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>BSAAR </B>are securities whose subscription price and exercise price are fixed at their fair value as determined by an expert. The BSAAR
subscription therefore represents an investment on the part of the beneficiary. At the end of the exercise period, if they have not been exercised, the BSAAR becomes void. The Company benefits from a clause called &laquo;forcing&raquo; making it
possible to encourage holders to exercise their redeemable equity warrants when the market price exceeds the exercise price and reaches a threshold defined in the BSAAR issuance agreement. The Company may, then, subject to a time period for
notifying holders that will permit them to exercise the BSAAR, decide to reimburse the warrants not exercised at a unit price equal to the BSAAR acquisition price paid by its holder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Details of BSAAR </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>BSAAR</I>. The methodology used to estimate the fair value of the BSAAR is similar to the one used to estimate the fair value of the BSA,
except for the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Term</I>. Unlike the BSA, the Company does not have sufficient historical experience for the BSAAR.
Consequently, the expected term used for the valuation of the fair value is the legal maturity of the instrument (10 years). </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No
share-based payment compensation expense was recognized relating to the BSAAR since the amount paid by the beneficiaries is equal to the fair value. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BSAAR 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date&nbsp;of&nbsp;grant&nbsp;(Executive&nbsp;Board)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;1,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting period (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plan expiration date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June&nbsp;30,&nbsp;2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of BSAAR granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share entitlement per BSAAR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 7.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation method used</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">Black-Scholes</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant date share fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average life of BSAAR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.22</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">None</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per BSA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Change in Number of BSAAR Outstanding </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number&nbsp;of&nbsp;BSAAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,363,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,366,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,363,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,363,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Breakdown of the Closing Balance </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number&nbsp;of&nbsp;BSAAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAAR 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAAR 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAAR 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,363,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,363,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,363,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,363,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Breakdown of expenses per financial year </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The share-based compensation expenses are broken down as follows (in thousands of euro): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Employees <FONT STYLE="white-space:nowrap">2016-1&amp;2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Management <FONT STYLE="white-space:nowrap">2016-1&amp;2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP Management <FONT STYLE="white-space:nowrap">2016-1&amp;2</FONT> / AGAP Employees <FONT
STYLE="white-space:nowrap">2016-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Employees 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAP Management 2017 / AGAP Employees 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Bonus 2018 / AGA Bonus 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA Perf Management 2018 / AGA Perf Employees 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Share-based compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,707</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,830</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, employers&#146; social security contributions relating to free shares were paid
for an amount of &#128;68&nbsp;thousand (&#128;334&nbsp;thousand for the year ended December&nbsp;31, 2017). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12) Financial instruments recognized in
the statement of financial position and related effect on the income statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables show the carrying amounts and fair
values of financial assets and financial liabilities. The tables do not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>As of&nbsp;December&nbsp;31,&nbsp;2018</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Book&nbsp;value&nbsp;on&nbsp;the<BR>statement&nbsp;of<BR>financial&nbsp;position</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>profit&nbsp;and&nbsp;loss(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>comprehensive<BR>income(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Receivables(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables and others</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>354,824</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>200,669</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>154,155</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>354,824</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2018</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands of euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Book&nbsp;value&nbsp;on&nbsp;the<BR>statement of<BR>financial position</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>profit and loss(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>comprehensive<BR>income(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Debt&nbsp;at</B><br><B>amortized&nbsp;costs(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>96,175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>96,175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>96,175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>As of&nbsp;December&nbsp;31,&nbsp;2017</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Book&nbsp;value&nbsp;on&nbsp;the<BR>statement&nbsp;of<BR>financial&nbsp;position</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>profit&nbsp;and&nbsp;loss(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>comprehensive<BR>income(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Receivables</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>197,990</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>125,397</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,135</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,458</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>197,990</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2017</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands of euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Book&nbsp;value&nbsp;on&nbsp;the<BR>statement of<BR>financial position</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>profit and loss(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;through<BR>comprehensive<BR>income(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Debt&nbsp;at&nbsp;amortized<BR>costs(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The fair value of financial assets classified as fair value through comprehensive income corresponds to the market value of the assets, which are primarily determined using level 1 measurements. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the amendments to IFRS 7, financial instruments are presented in three categories based on a hierarchy of methods used to
determine fair value: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;1: fair value determined based on quoted prices in active markets for assets or liabilities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;2: fair value determined on the observable database for the asset or liability concerned either directly or indirectly; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3: fair value determined on the basis of evaluation techniques based in whole or in part on unobservable data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13) Revenue and government financing for research expenditures </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from collaboration and licensing agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>of which monalizumab agreement</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>61,546</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>32,346</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>of which IPH5201 agreement</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>15,632</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invoicing of research and development costs (IPH5201 and IPH5401 agreements)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange gains on collaboration agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue from collaboration and licensing agreements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>79,892</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,631</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The impact of the application of the IFRS 15 standard is presented in Note 2.a. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>a)
Revenue recognition related to monalizumab AstraZeneca agreements and amendments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company identified the following promises
under the monalizumab AstraZeneca agreements and amendments: (1)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license related to monalizumab restricted to two applications, with an option for an exclusive license related to
monalizumab including all applications, (2)&nbsp;the performance of certain initial studies related to phases I/II trials, and participation in certain studies of phases I/II trials and phase III clinical trials through a <FONT
STYLE="white-space:nowrap">co-financing.</FONT> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considered the license has a standalone functionality and is capable of
being distinct. However the Company determined that the license is not distinct from the performance of initial studies and participation to phase III clinical trials because they increased the utility of the licensed IP. Thus, the licensed IP, the
performance of initial studies and participation to phase III clinical trials are combined into a single performance obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This performance obligation was considered as satisfied over time as AstraZeneca controls the licensed IP which is being enhanced during the
agreement. The revenue is recognized over time, based on the input method (costs incurred). As a result, the Company recognizes the price of the transaction as a revenue on the basis of the progress of studies that the Company has undertaken to
carry out under the agreement. Progression is assessed following to actual costs incurred relative to the total budgeted costs to fulfill the obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction price was initially estimated to the initial payment of $250,000&nbsp;thousand, less the amounts that the Company expected to
pay to AstraZeneca for <FONT STYLE="white-space:nowrap">co-financing</FONT> Phase I/II clinical studies. The additional payment of $100,000&nbsp;thousand triggered by AstraZeneca&#146;s exercise of the exclusivity option was treated as a change in
the price estimate of the transaction. In addition, the amendment of the contract, which modified the scope and budget of the studies to be carried out by the Company as well as the arrangements for sharing the cost of the other studies, led to a
revision of the degree of progress and the price of the transaction. Thus, the exercise of the option and the amendment of the contract resulted in the recognition of a favorable cumulative adjustment of &#128;31,966&nbsp;thousand in revenue for the
year ended December&nbsp;31, 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The subsequent milestones and potential royalty payments are excluded from the transaction price
due to the uncertainties of clinical trials results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company used the most likely amount to determine variable consideration.
Variable consideration for cost-sharing payments related to certain studies of phases I/II trials and phase III clinical trials when applicable are included in the transaction price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and AstraZeneca make quarterly cost-sharing payments to one another in amounts necessary to ensure that each party bears its
contractual share of the overall shared development costs incurred. Costs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incurred by the Company related to agreed-upon services under the agreement are recorded as research and development expenses in its consolidated statements of financial income (loss). The
Company accounts for cost sharing payments from AstraZeneca as increase in revenue in its consolidated statements of income (loss), while cost sharing payments to AstraZeneca are recorded as payments to customer which reduce the transaction price
recorded as revenue from the collaboration agreement. As described in Note&nbsp;2.a, the expected payments to AstraZeneca are classified as collaboration liability in the consolidated statement of financial position. Quarterly invoices received from
AstraZeneca reduce the collaboration liability and have no impact on the consolidated statement of income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Change in monalizumab
deferred revenue (in thousands of euro): </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167,260</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue for the 2017 financial year <I></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2017, as published</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>134,914</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restatement related to the first application of IFRS 15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2018 restated</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>81,831</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue for the 2018 financial year(1)-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in deferred revenue resulting from the exercise of the $100M option.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer to collaboration liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(717</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>104,925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Without exercise of the option, the amount recognized as revenue would have amounted to &#128;29,581&nbsp;thousand. The impact of the exercise on 2018 revenue amounted to &#128;31,966&nbsp;thousand. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The exercise of the $100,000&nbsp;thousand option was converted to &#128;87,002&nbsp;thousand, of which &#128;85,358&nbsp;thousand was recognized as deferred revenue and &#128;1,644&nbsp;thousand recognized in
collaboration liabilities. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Change in monalizumab collaboration liabilities (in thousands of euro) : </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2017,&nbsp;as&nbsp;published</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restatement related to the first application of IFRS 15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2018 restated</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deductions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31,656</B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Of which &#128;20,987 thousand of current portion and &#128;10,669 of non-current portion. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>b) Revenue recognition related to IPH5201 AstraZeneca collaboration and option agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that IPH5201 AstraZeneca collaboration and option agreement is an enforceable contract under IFRS 15 as the upfront
payment is <FONT STYLE="white-space:nowrap">non-refundable</FONT> and thus AstraZeneca will incur significant loss if it doesn&#146;t exercise its licensed option. The Company considered that the exercise price of the option granted to AstraZeneca
for an exclusive license is a variable consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company identified the following promises under the IPH5201 AstraZeneca
collaboration and option agreement: (1) an option for an exclusive license related to IPH5201 and (2) the performance of research and development services in conformity with the defined development plan for preclinical studies. The Company
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determined that the option is not distinct from the performance of research and development services because they increased the utility of the licensed IP. Thus, the option and the performance of
research and development services are combined into a single performance obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction price was initially estimated to the
initial upfront payment of $50,000&nbsp;thousand (received in October 2018 for $26,000&nbsp;thousand and in January 2019 for $24,000 thousand) and estimated quarterly payment received in relation to costs incurred by the Company for preclinical
studies. Development and commercial milestones and potential royalties payments were excluded from the transaction price due to uncertainties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The performance obligation was considered as satisfied over time as the IP in development has no alternate use for the Company as it is an
exclusive license and that the Company has an enforceable right to payment for completed research and development services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
applied the input method and recognized the price of the transaction as a revenue percentage of completion of the costs of the preclinical studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Change in IPH5201 deferred revenue (in thousands of euro): </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The variance of the <B>deferred revenue</B> relating to this agreement is presented in the following schedule (in thousands of euro): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upfront payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue for the 2018 financial year <I></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27,869</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>c) Revenue related to collaboration and option agreement related to four
<FONT STYLE="white-space:nowrap">to-be-agreed</FONT> upon molecules (preclinical molecules) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the option
to acquire an exclusive license provides a material right to AstraZeneca that it would not receive without entering into that contract. The Company will recognize revenue when those future goods or services are transferred or when the option
expires. Thus, the upfront payment is recorded as a deferred revenue for an amount of &#128;17,400&nbsp;thousand as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>d) Revenue recognition related to IPH5401 AstraZeneca agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenue as research and development expenses are incurred (see Note 1.1.c for agreement description). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>e) Schedule of variance of deferred revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The variance of the global deferred revenue is presented in the following schedule: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017&nbsp;as<BR>published</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Impact<BR>IFRS&nbsp;15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017&nbsp;as<BR>restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proceeds</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Recognition<BR>in&nbsp;P&amp;L</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transfer&nbsp;to</B><br><B>collaboration</B><br><B>liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Monalizumab</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>81,831</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(715</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>104,925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPH5201</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27,869</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical molecules</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>134,914</B></TD>
<TD NOWRAP VALIGN="bottom"><B>(1)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(53,083</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>81,831</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>146,259</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(77,180</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(715</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>150,195</B></TD>
<TD NOWRAP VALIGN="bottom"><B>(2)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Of which &#128;47,909&nbsp;thousand of current deferred revenue and &#128;87,005&nbsp;thousand of <FONT STYLE="white-space:nowrap">non-current</FONT> deferred revenue. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Of which &#128;82,096&nbsp;thousand of current deferred revenue and &#128;68,098&nbsp;thousand of <FONT STYLE="white-space:nowrap">non-current</FONT> deferred revenue. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Monalizumab</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue for the 2017 financial year <I></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>134,914</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>f) Government financing for research expenditures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company receives grants from the European Commission and the French government and state organizations in several different forms: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investment and operating grants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Research Tax Credits. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total amount for government financing for research expenditures recorded as other income in the income statement can be analyzed as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research Tax Credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Government financing for research expenditures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,060</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,402</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14) Operating expenses </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>R&amp;D</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>G&amp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>R&amp;D</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>G&amp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subcontracting costs(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,327</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(37,996</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of supplies and consumable materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,819</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,287</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses other than share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,520</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(19,121</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,995</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(15,163</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,707</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,985</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Personnel expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(14,226</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(7,601</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B><I>&nbsp;</I></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><I>(21,828</I></B></TD>
<TD NOWRAP VALIGN="bottom"><B><I>)&nbsp;</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(14,692</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(10,456</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B><I>&nbsp;</I></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B><I>(25,148</I></B></TD>
<TD NOWRAP VALIGN="bottom"><B><I>)&nbsp;</I></B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-scientific</FONT> advisory and consulting(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,301</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,794</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,357</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasing and maintenance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(887</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,968</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,781</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travel expenses and meeting attendance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(992</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,294</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketing, communication and public relations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(399</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(518</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(649</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scientific advisory and consulting(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(349</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(845</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other purchases and external expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(311</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(687</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,402</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,396</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual property expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,087</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,499</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income and (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,502</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,076</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total net operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(69,555</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(18,142</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(67,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Company subcontracts a significant part of its preclinical (pharmaceutical development, tolerance studies and other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) to
third parties. Associated costs are recorded in subcontracting on the basis of the level of completion of the clinical trials. The increase between 2017 and 2018 is essentially due to the progress of the preclinical and clinical programs but also
for &#128;1,094&nbsp;thousand of R&amp;D costs related to Lumoxiti following the agreement signed with AstraZeneca in October 2018. In accordance with this agreement, AstraZeneca will invoice the Company development costs during the transition.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Non-scientific</FONT> advisory and consulting are services performed to support the selling, general and administration activities of the Company, such as legal, accounting and audit
fees as well as business development support. The increase results from advisory fees in relation with the Company&#146;s structuring in a context of strong growth. The following schedule presents the breakdown per audit firm of the audit fees.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Audit&nbsp;Conseil<BR><FONT STYLE="white-space:nowrap">Expertise&nbsp;-&nbsp;PKF</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deloitte&nbsp;&amp;<BR>Associ&eacute;s</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Audit&nbsp;Conseil<BR><FONT STYLE="white-space:nowrap">Expertise&nbsp;-&nbsp;PKF</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deloitte&nbsp;&amp;<BR>Associ&eacute;s</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>800</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>867</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-audit</FONT> fees*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>205</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>605</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>810</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>166</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>731</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>897</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Non-audit</FONT> fees: these fees correspond to services performed by the auditors related to the production of certification in the context of the declaration of expenses for the
obtention of grants; to the verification report of social and environmental information, special reports within the framework of operations on the Company&#146;s capital </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Personnel expenses other than share-based compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The line item amounted to &#128;19,121&nbsp;thousand and &#128;15,163&nbsp;thousand for the years ended December&nbsp;31, 2018 and 2017
respectively. The Company had 195 employees as of December&nbsp;31, 2018, compared to 188 as of December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
benefited from the &#147;competitiveness and employment tax credit&#148; (CICE) of &#128;180.0&nbsp;thousand and &#128;233.0&nbsp;thousand for the financial year ended December&nbsp;31, 2018 and 2017, respectively. This tax credit will be mainly
used to reinforce the research teams. It is deducted from the line item &#147;Personnel expenses other than share-based compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Depreciation and amortization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The line item is mainly composed of the amortization of the monalizumab, IPH5201 and Lumoxiti intangible assets (see Note 6). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Cost of supplies and consumable materials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of supplies and consumable materials consists mainly of the cost of procurement of the Company&#146;s drug substance and/or drug product
that is manufactured by third-parties. This line item amounts to &#128;3,819&nbsp;thousand and &#128;4,287&nbsp;thousand for the years ended December&nbsp;31, 2018 and 2017, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Intellectual property expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intellectual property expenses amounted to &#128;1,380&nbsp;thousand and &#128;1,499&nbsp;thousand for the financial years ended
December&nbsp;31, 2018 and 2017, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the acquisition of intellectual property rights from third parties, excluding the
acquisitions of patents by way of assignation, the Company has three different types of agreements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exclusive option agreements, which correspond to an exclusive period during which the Company evaluates the
opportunity to acquire the licensing rights of the intellectual property subject to the option agreement. The Company generally pays an option fee and bears the past and/or present intellectual property expenses related to the invention subject to
the option agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exclusive licensing agreements of which the duration varies according to contractual conditions but which is
generally the same as the life of the underlying intellectual property. The Company pays the past and/or present expenses related to the intellectual property and also costs related to access to technology, milestone payments when they are achieved
and in the case of marketing of the products/technologies covered by the intellectual property, royalties on sales; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exclusive collaboration and licensing agreements including some exclusive collaboration on a specific work
program or for a specific area of which the duration is limited in time, and an exclusive license of a varying duration according to contractual conditions but which generally coincides with the life of the underlying intellectual property. The
Company agrees to bear research and development expenses for the exclusive collaboration part, and, for the exclusive license part, pays fees to access technology, intellectual property expenses, milestone payments when they are achieved and in the
case of marketing of the products/technologies covered by the intellectual property, royalties on sales. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15) Net income / (loss)
from distribution agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the transition period, Lumoxiti products are commercialized in the United States by AstraZeneca
who is the owner of the regulatory approval. As explained in Note 2.p, the Company concluded that it did not meet the criteria for being principal under IFRS 15. Consequently, the net loss resulting from all Lumoxiti marketing&#146;s operations are
disclosed in the item line &#147;Net income / (loss) from distribution agreements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized a
&#128;1,109&nbsp;thousand net loss, corresponding to production and marketing costs, net of sales proceeds, as invoiced by AstraZeneca in relation to the Lumoxiti distribution agreement for the period. Sales of Lumoxiti products in the year ended
December&nbsp;31, 2018 were not significant considering that the first commercialization in the United States happened in the last quarter of 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16) Net financial loss </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net financial
loss can be analyzed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange gains</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,002</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized losses on financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,942</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,851</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,429</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,535</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net financial loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,034</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the financial years ended December&nbsp;31, 2017 and 2018, the foreign exchange gains
and losses mainly result from the variance of the exchange rate between the Euro and the U.S. dollar on U.S. dollars denominated cash and cash equivalent and financial assets accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unrealized losses on financial assets relate to unquoted instruments, the fair value of which is determined using level 2 measurements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17) Income Tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the Company&#146;s
early stage of development, it is not probable that future taxable profit will be available against which the unused tax losses can be utilized. As a consequence, deferred tax assets are recognized up to deferred tax liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Temporary differences mainly result from finance leases, provision for defined benefit obligation and tax losses carryforwards. As of
December&nbsp;31, 2018 and 2017, deferred tax liabilities and deferred tax assets each amounted to &#128;19&nbsp;thousand and &#128;250&nbsp;thousand, respectively, resulting in a net amount of zero in the consolidated statements of financial
positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the accumulated tax losses carryforwards of Innate Pharma SA were &#128;219,563&nbsp;thousand
with no expiration date (&#128;218,670&nbsp;thousand as of December&nbsp;31, 2017). As of December&nbsp;31, 2018, the accumulated tax losses carryforwards of Innate Pharma Inc. was &#128;493&nbsp;thousand, or $564&nbsp;thousand,
(&#128;446&nbsp;thousand, or $535&nbsp;thousand as of December&nbsp;31, 2017), with a <FONT STYLE="white-space:nowrap">20-year</FONT> period expiration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the financial year ended December&nbsp;31, 2017, the Company recognized a &#128;368&nbsp;thousand prior period tax adjustment for a tax
regime that was no more applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the financial year 2018, the Company opted for the carry back mechanism which gave rise to a
&#128;333&nbsp;thousand tax credit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Tax rate reconciliation </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income before taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(48,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tax benefit / (loss) calculated at statutory tax rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,016</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase/decrease in tax expense arising from:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research Tax Credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for defined benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(902</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborations with customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-recognition</FONT> of deferred tax assets related to tax
losses and temporary differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carry-back</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effective tax expense (a)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>333</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax income / (loss) (b)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(368</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income tax expense (a)+(b)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>333</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(368</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18) Commitments, contingencies and litigations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Commitments </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Consumable purchases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
part of a supply of scientific equipment, the Company was committed towards a supplier to minimum annual purchases of consumables. As of December&nbsp;31, 2018, the overall commitment was amounting to &#128;281 thousand for the period from January
2019 to June 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Operating lease commitments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the increase of employees, the Company signed on June&nbsp;30, 2017 a lease to rent a new building. The lease covers a period of nine
years with possibility for termination after three and six years. At December&nbsp;31, 2018, the commitment related to the rent until June&nbsp;30, 2020 (which is the end of the three-years <FONT STYLE="white-space:nowrap">non-terminable</FONT>
period) amounts to &#128;449&nbsp;thousand. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;to&nbsp;3<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3&nbsp;to&nbsp;5<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease&#151;Building &#147;Le Virage&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease&#151;Vehicles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>340</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>421</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>769</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Loan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July&nbsp;17, 2017, the Company took out a loan amounting to &#128;15,200&nbsp;thousand in order to finance the acquisition of a land and
the construction of its future headquarters to be fully drawn before August&nbsp;31, 2019. As of December&nbsp;31, 2018, the Company has partially drawn an amount of &#128;1,300&nbsp;thousand, resulting in a remaining amount to be drawn of
&#128;13,900&nbsp;thousand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Licensing and collaboration agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commitments related the Company&#146;s licensing and collaboration agreements are disclosed in Note 1.1. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Contingencies and litigations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2012, Platine Pharma Services SAS, the Company&#146;s former subsidiary, received a tax notice suggesting that it should pay a
tax on salaries of &#128;91&nbsp;thousand. The management of Platine Pharma Services does not agree with this position on the ground that the status of Platine Pharma Services is exempt from such tax as it is a commercial company. The period subject
to the tax audit was prior to the acquisition by Transgene of an equity interest in Platine Pharma Services which was at the time a wholly-owned subsidiary. Therefore, in accordance with the liabilities guarantee clause, the contingent liability
resulting from this adjustment would be borne by the former parent company. Based on an assessment of the technical merits of this position, the Company believes that it is not probable that an outflow of resources embodying economic benefits will
be required to settle the contingency and, as a result, has not recognized a provision in the consolidated financial statements. This litigation ended as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is exposed to contingent liabilities relating to legal actions before the labor court or intellectual property issues happening in
the ordinary course of its activities. Each <FONT STYLE="white-space:nowrap">pre-litigation,</FONT> known litigation or procedure in ordinary course the Company is involved in was analyzed at the closing date after consultation of advisors. There is
no acknowledged litigation as of December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions amounted to &#128;690&nbsp;thousand and &#128;1,012&nbsp;thousand as of December&nbsp;31, 2018 and 2017, respectively. They
consisted solely of the employer contribution in respect of the grants of employee equity instruments. In accordance with IFRS 2, when a Company decides to provide its employees with shares bought back on the market, a provision has to be recognized
upon the decision to allocate free shares that are spread over the vesting period when the plan conditions actions for employees when they join the Company at the end of the plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19) Related party transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Members of the Executive Board and Executive Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each of the periods presented, the following compensation was granted to the members of the Executive Committee of the Company and were
recognized as expense: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses and other short-term employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Extra pension benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Committee members compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,208</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,584</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, two members of the Executive Committee were also members of the Executive Board.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Personnel expenses and other short-term employee benefits correspond to amounts effectively paid during the calendar year to which they
relate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;31, 2018, J&eacute;r&ocirc;me Tiollier resigned from his function as a member of the Executive Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calculation of share-based compensation is detailed in Note 11.b. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Members of the Supervisory Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized a provision of &#128;216&nbsp;thousand for attendance fees (<I>jetons de presence</I>)<I> </I>relating to the year ended
December&nbsp;31, 2018 which should be paid in 2019. This amount includes the compensation for the Chairman of the Supervisory Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Related parties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Novo Nordisk A/S is a board member and is related to the Company by three licensing agreements related to the drug-candidates lirilumab,
monalizumab and IPH5401. Under the terms of the agreements, Novo Nordisk A/S is eligible to receive milestone payments as well as royalties on future sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company has a &#128;13,050&nbsp;thousand additional consideration to be paid to Novo Nordisk A/S relating to
the additional consideration for monalizumab following the exercise of the option by AstraZeneca and a &#128;756&nbsp;thousand liability relating to a production delivery of IPH5401. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AstraZeneca is a shareholder and is related to the Company through several collaboration and option licensing or license agreements for
different drug candidates (monalizumab, IPH5401, IPH5201 and preclinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
molecules) and a license agreement for the rights of the drug Lumoxiti. The payments between the two companies as well as the liabilities and receivables as of 31&nbsp;December 2018 are as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assets/<BR>Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collection (AstraZeneca to the Company) / Receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments (the Company to AstraZeneca) / Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,314</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85,560</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,368</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In addition, the Company recognized in the income statement a net expense of &#128;1,109&nbsp;thousand as net result from distribution agreements (see Note 15) and an R&amp;D expense of &#128;1.1&nbsp;million as
operating expenses (see Note&nbsp;14) </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BPI France is a board member and has granted the Company a &#128;1,500&nbsp;thousand
interest-free loan (<I>Pr&ecirc;t &agrave; Taux Z&eacute;ro Innovation</I>, or &#147;PTZI&#148;). This loan will be reimbursed starting September 2016 over a 5-year period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Subsidiaries </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
business relationships between the Company and its subsidiaries are governed by intra-group agreements, conducted at standard conditions on an arm&#146;s length basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20) Income (loss) per share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Basic
income (loss) per share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic income (loss) per share is calculated by dividing the net income (loss) attributable to equity
holders of the Company by the weighted average number of ordinary shares in circulation during the corresponding period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro,&nbsp;except&nbsp;for&nbsp;share&nbsp;data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares in circulation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,776,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,351,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic income (loss) per share (&#128; per share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(0.89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Diluted income (loss) per share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diluted income (loss) per share is calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted
average number of ordinary shares in circulation during the corresponding period, increased by all dilutive potential ordinary shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in&nbsp;thousands&nbsp;of&nbsp;euro,&nbsp;except&nbsp;for&nbsp;share&nbsp;data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares in circulation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,776,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,351,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments for share warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Diluted income (loss) per share (&#128; per share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(0.89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21) Events after the reporting date </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;14, 2019, the Executive Board granted 90,650 free shares to employees of the Company (AGA Employees <FONT
STYLE="white-space:nowrap">2018-1).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;18, 2019, subsequent to the definitive acquisitions of (i)&nbsp;110,500 free
shares granted on April&nbsp;3, 2018 under the &#147;AGA Employees 2017&#148; plan, (ii)&nbsp;5,581 free preferred shares convertible into ordinary share granted on April&nbsp;3, 2018 under the &#147;AGAP Employees 2017&#148; plan, (iii)&nbsp;2,000
free preferred shares convertible into ordinary shares granted on April&nbsp;3, 2018 under the &#147;AGAP Management 2017&#148; plan and (iv)&nbsp;the exercise of 750 &#147;2012&#148; BSAAR, the Executive Board carried out a capital increase of
&#128;7,434 (including share premium). As a result, (i)&nbsp;110,500 ordinary shares were created, with a nominal value of &#128;0.05, for an issue price of &#128;0.05 per share, (ii)&nbsp;750 ordinary shares were created, with a nominal value of
&#128;0.05, for an issue price of &#128;2.04 per share and (iii)&nbsp;7,581 &#147;2017&#148; preferred shares were created, with a nominal value of &#128;0.05, for an issue price of &#128;0.05 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;29, 2019, the Executive Board granted 25,000 free shares to an employee of the Company&#146;s subsidiary (AGA New Members
2017-1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following these transactions, the share capital amounted to &#128;3,202,920 divided into: (i)&nbsp;64,043,905 ordinary shares,
each with a nominal value of &#128;0.05; (ii)&nbsp;6,931 &#147;2016&#148; preferred shares, each with a nominal value of &#128;0.05, and (iii)&nbsp;7,581 &#147;2017&#148; preferred shares, each with a nominal value of &#128;0.05, respectively, fully
paid up. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;3, 2019, the Company signed an agreement with Orega Biotech amending the license agreement signed on
January&nbsp;4, 2016. Pursuant to this agreement, the Company was required to pay Orega Biotech an amount of &#128;7,000 thousand as consideration following the collaboration and option agreement signed on October&nbsp;22, 2018 with AstraZeneca
regarding IPH5201. The payment was made in June 2019 and will be accounted for as an increase of the Company&#146;s intangible asset related to anti-CD39. The agreement also includes potential additional payments in the aggregate of &#128;51,500
thousand by the Company to Orega Biotech in connection with the completion of development and regulatory milestones, as well mid-single digit to low-teen percentage payments, depending on determinations relating to Orega Biotech&#146;s intellectual
property rights for certain patents, on sublicensing revenues the Company receives pursuant to its agreement with AstraZeneca relating to IPH5201. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:36pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Until
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 (25 days after the date of this prospectus), all dealers that buy, sell, or trade our ordinary shares, whether or not
participating in this global offering, may be required to deliver a prospectus. This is in addition to a dealers&#146; obligation to deliver a prospectus when acting as underwriter and with respect to their unsold allotments or subscriptions.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ORDINARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Including Ordinary Shares in the Form of American Depositary Shares) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g752656g14p44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per American Depositary Share </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Ordinary Share </B></P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P></center>
<P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 </B></P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P></center>
<P STYLE="font-size:54pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:20pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:20pt">
<TD VALIGN="bottom"><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>SVB Leerink&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Evercore ISI</B></TD></TR>
</TABLE> <P STYLE="font-size:54pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;6. Indemnification of Members of the Executive and Supervisory Board. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, provisions of bylaws that limit the liability of directors are prohibited. However, French law allows
<I>soci&eacute;t&eacute;s anonymes</I> to contract for and maintain liability insurance against civil liabilities incurred by any of their directors and officers involved in a third-party action, provided that they acted in good faith and within
their capacities as directors or officers of the company. Criminal liability cannot be indemnified under French law, whether directly by the company or through liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain liability insurance for the members of our Supervisory Board and Executive Board, including insurance against liability under the
Securities Act of 1933, as amended, and we intend to enter into agreements with the members of our Supervisory Board and Executive Board to provide contractual indemnification. With certain exceptions and subject to limitations on indemnification
under French law, these agreements will provide for indemnification for damages and expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or
proceeding arising out of his or her actions in that capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the members of our Supervisory Board may, through their
relationships with their employers or partnerships, be insured and/or indemnified against certain liabilities in their capacity as members of our Supervisory Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any underwriting agreement we enter into in connection with the sale of ADSs being registered hereby, the underwriters will agree to
indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act against certain liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;7. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding share capital issued and options, warrants and free shares granted by us since January&nbsp;1, 2016.
None of the transactions described below involved any underwriters, underwriting discounts or commissions, or any public offering. Some of the transactions described below involved members of our Supervisory Board and Executive Board and 5%
shareholders and are more fully described under the section of the prospectus titled &#147;Certain Relationships and Related Party Transactions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From January&nbsp;1, 2016 through May 1, 2019, we have issued securities in the following transactions that were not registered under the
Securities Act: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On January&nbsp;6, 2016, we issued an aggregate of 2,700 ordinary shares to employees in connection with the
exercise of redeemable share warrants, for aggregate gross proceeds of &#128;5,508. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On May&nbsp;30, 2016, we issued an aggregate of 58,940 ordinary shares to employees and executive managers in
connection with the exercise of redeemable share warrants and share warrants, for aggregate gross proceeds of &#128;138,248. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2016, we issued an aggregate of 4,486 free preferred shares (AGAP <FONT
STYLE="white-space:nowrap">2016-1)</FONT> to employees and executive managers, convertible into 897,200 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2016, we issued an aggregate of 99,932 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-1)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2016, we issued an aggregate of 50,000 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November&nbsp;3, 2016, we issued an aggregate of 25,650 ordinary shares to employees in connection with the
exercise of warrants, for aggregate gross proceeds of &#128;52,326. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2016, we issued an aggregate of 250,000 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-2)</FONT> to an executive manager. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2016, we issued an aggregate of 149,943 free shares (AGA
<FONT STYLE="white-space:nowrap">2016-2)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2016, we issued an aggregate of 3,000 free preferred shares (AGAP <FONT
STYLE="white-space:nowrap">2016-2)</FONT> to an executive manager, convertible into 600,000 ordinary shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On January&nbsp;24, 2017, we issued an aggregate of 38,950 ordinary shares to executive managers in connection
with the exercise of redeemable share warrants and share warrants, for aggregate gross proceeds of &#128;327,144. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On February&nbsp;10, 2017, we issued an aggregate of 50,500 ordinary shares to employees and executive managers
in connection with the exercise of redeemable share warrants and share warrants, for aggregate gross proceeds of &#128;119,020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On June&nbsp;14, 2017, we issued an aggregate of 1,850 ordinary shares to employees in connection with the
exercise of redeemable share warrants, for aggregate gross proceeds of &#128;3,774. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On July&nbsp;13, 2017, we issued an aggregate of 3,343,748 ordinary shares to Novo Nordisk A/S, at a purchase
price of &#128;11.12 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On September&nbsp;20, 2017, we issued an aggregate of 28,556 bonus free shares (AGA Bonus <FONT
STYLE="white-space:nowrap">2017-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On September&nbsp;20, 2017, we issued an aggregate of 37,000 share warrants (BSA
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to members of the Supervisory Board, convertible into 37,000 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;21, 2017, we issued an aggregate of 98,770 ordinary shares and 3,931 free preferred shares to
employees and executive managers in connection with the vesting of free shares (AGA <FONT STYLE="white-space:nowrap">2016-1</FONT> and AGAP <FONT STYLE="white-space:nowrap">2016-1),</FONT> for aggregate gross proceeds of &#128;5,135.05.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;30, 2017, we issued an aggregate of 144,978 ordinary shares and 3,000 free preferred shares to
employees and executive managers in connection with the vesting of free shares (AGA <FONT STYLE="white-space:nowrap">2016-2</FONT> and AGAP <FONT STYLE="white-space:nowrap">2016-2),</FONT> for aggregate gross proceeds of &#128;7,398.90.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;3, 2018, we issued an aggregate of 5,725 free preferred shares (AGAP
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to employees convertible into 572,500 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;3, 2018, we issued an aggregate of 2,400 free preferred shares (AGAP
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to executive managers convertible into 240,000 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;3, 2018, we issued an aggregate of 114,500 free shares (AGA
<FONT STYLE="white-space:nowrap">2017-1)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November 20, 2018, we issued an aggregate of 327,500 performance free shares (AGA Performance <FONT
STYLE="white-space:nowrap">2018-1)</FONT> to employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November 20, 2018, we issued an aggregate of 260,000 performance free shares (AGA Performance <FONT
STYLE="white-space:nowrap">2018-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On July&nbsp;3, 2018, we issued an aggregate of 67,028 bonus free shares (AGA Bonus <FONT
STYLE="white-space:nowrap">2018-1)</FONT> to executive managers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On September&nbsp;20, 2018, we issued an aggregate of 22,055 ordinary shares to executive managers in connection
with the vesting of free shares (AGA Bonus <FONT STYLE="white-space:nowrap">2017-1),</FONT> for aggregate gross proceeds of &#128;1,102.75. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;25, 2018, we issued an aggregate of 6,260,500 ordinary shares to MedImmune Limited, at a purchase
price of &#128;10.00 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November&nbsp;29, 2018, we issued an aggregate of 50,000 ordinary shares to employees and executive managers
in connection with the exercise of share warrants, for aggregate gross proceeds of &#128;2,500. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;18, 2019, we issued an aggregate of 111,250 ordinary shares and 7,581 preferred shares to employees
and executive managers in connection with the exercise of redeemable share warrants and the vesting of free shares (AGA <FONT STYLE="white-space:nowrap">2017-1</FONT> and AGAP <FONT STYLE="white-space:nowrap">2017-1),</FONT> for aggregate gross
proceeds of &#128;5,941.55. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January 1, 2016 through May 1, 2019, an aggregate of 66,140 redeemable share warrants (BSAAR) were exercised
at prices ranging from &#128;2.04 to &#128;7.20 per ordinary share. Pursuant to these exercises, we issued an aggregate of 66,140 ordinary shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January 1, 2016 through May 1, 2019, an aggregate of 163,200 share warrants (BSA) were exercised at prices
ranging from &#128;1.77 to &#128;8.65 per ordinary share. Pursuant to these exercises, we issued an aggregate of 163,200 ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January 1, 2016 through May 1, 2019, an aggregate of 14,512 free preferred shares (AGAP) were vested.
Pursuant to these free preferred shares vesting, we issued an aggregate of 6,931 preferred shares 2016 and 7,581 preferred shares 2017. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From January 1, 2016 through May 1, 2019, an aggregate of 376,303 free shares (AGA) were vested. Pursuant to
these free shares vesting, we issued an aggregate of 376,303 ordinary shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offers, sales and issuances of the
securities described above were exempt from registration either (a)&nbsp;under Section&nbsp;4(a)(2) of the Securities Act in that the transactions were between an issuer and sophisticated investors or members of its senior executive management and
did not involve any public offering within the meaning of Section&nbsp;4(a)(2), (b) under Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling
efforts were made in the United States or (c)&nbsp;under Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans and contracts relating to compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;8. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>(a) Exhibits </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;1.1*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;3.1#</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Bylaws (<I>statuts</I>) of the Registrant (English translation).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;4.1*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Deposit Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;4.2*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of American Depositary Receipt (included in Exhibit 4.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;5.1*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Opinion of Linklaters LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.1&#134;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Co-Development</FONT> and License Agreement between Innate Pharma S.A. and MedImmune Limited, dated April&nbsp;24, 2015, as amended to date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.2&#134;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lumoxiti License Agreement, between Innate Pharma S.A. and MedImmune Limited, dated October&nbsp;22, 2018.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.3&#134;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Amendment and Restatement Agreement of the Collaboration and Option Agreement Relating to CD39, between Innate Pharma S.A. and MedImmune Limited, dated April 16, 2019.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.4&#134;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Joint Research, Development, Option and License Agreement between Innate Pharma S.A. and Novo Nordisk A/S, dated March&nbsp;28, 2006, as amended to date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.5#</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Finance Lease Agreement between Innate Pharma S.A. and Sogebail S.A., dated June&nbsp;9, 2008 (English translation).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.6#</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Amendment to Finance Lease Agreement between Innate Pharma S.A. and Sogebail S.A., dated September&nbsp;29, 2016 (English translation).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">21.1#</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">List of subsidiaries.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23.1*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Consent of Deloitte&nbsp;&amp; Associ&eacute;s.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23.2*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Consent of Linklaters LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24.1*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Power of Attorney (included on signature page).</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">#</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Previously submitted. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Certain portions of this exhibit have been omitted because they are not material and would likely cause competitive harm to the registrant if disclosed. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>(b) Financial Statement Schedules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All schedules have been omitted because the information required to be set forth therein is not applicable or has been included in the
consolidated financial statements and notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;9. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreement certificates
in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as
indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the
registrant has been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities, other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding, is asserted
by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless, in the opinion of its counsel, the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question, whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) if the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration
statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first
used after effectiveness, provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was
part of the registration statement or made in any such document immediately prior to such date of first use. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) for
purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A, and contained in the form of prospectus filed by the
registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act, as amended, shall be deemed to be part of this registration statement as of the time it was declared effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form
of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial
distribution of the securities, that in a primary offering of securities of the undersigned registrant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of
any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed
pursuant to Rule 424; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) any free writing prospectus relating to the offering prepared by or on behalf of the
undersigned registrant or used or referred to by the undersigned registrant; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the portion of any other free writing
prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">F-1</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Marseille, France
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>INNATE PHARMA S.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the undersigned members of the directors, officers and authorized representative of Innate Pharma S.A. hereby severally constitute and
appoint Mondher Mahjoubi and <FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne</FONT> Mercier, and each of them singly, his or her true and lawful agent, proxy and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to (i)&nbsp;act
on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this Registration Statement together with all schedules and exhibits thereto and any subsequent registration statement
filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii)&nbsp;act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or
appropriate in connection therewith, (iii)&nbsp;act on and file any supplement to any prospectus included in this Registration Statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the
Securities Act of 1933, as amended, and (iv)&nbsp;take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming
all that such agent, proxy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> or any of his substitutes may lawfully do or cause to be done by virtue thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons
in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mondher Mahjoubi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Executive Officer and Chairman of the Executive Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne</FONT> Mercier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Financial Officer and Member of the Executive Board (principal&nbsp;financial officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Herv&eacute; Brailly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Irina Staatz-Granzer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Vice-Chairman of Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jean-Yves Blay</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Gilles Brisson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">V&eacute;ronique Chabernaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ma&iuml;lys Ferrere</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Patrick Langlois</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Marcus Schindler</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Member of the Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Representative in the United States</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i)&nbsp;is not material and (ii)&nbsp;would be
competitively harmful if publicly disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:11pt; font-family:ARIAL">Private&nbsp;&amp; Confidential </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:5%; font-size:11pt; font-family:ARIAL">EXECUTION VERSION </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>DATED April&nbsp;24, 2015
</B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:7.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000;width:42%">&nbsp;</P></center>
<P STYLE="font-size:45pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>INNATE PHARMA S.A.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(1)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>and</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>MEDIMMUNE LIMITED</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(2)</B></TD></TR>
</TABLE> <P STYLE="font-size:55pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:42%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CO-DEVELOPMENT</FONT> AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>RELATING TO IPH2201 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:42%">&nbsp;</P></center>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">CONSTRUCTION; COMPETITION LAW CLEARANCE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">GRANT OF RIGHTS AND LICENSES; EXCLUSIVITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">DEVELOPMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">JOINT PROJECT TEAM AND DEVELOPMENT COLLABORATION COMMITTEE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">GENERAL PROVISIONS ON DEVELOPMENT AND COMMERCIALIZATION AND REGULATORY MATTERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">CO-FUNDING</FONT> OF DEVELOPMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">COMMERCIALIZATION, <FONT STYLE="white-space:nowrap">CO-PROMOTION</FONT> IN THE [***] AND SALES COLLABORATION COMMITTEE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">MANUFACTURE AND SUPPLY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">CONSIDERATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">CONFIDENTIALITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">REPRESENTATIONS, WARRANTIES AND COVENANTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">RECORD RETENTION, AUDIT AND USE OF NAME</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">TERM AND TERMINATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">INDEMNIFICATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">GOVERNING LAW AND ARBITRATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="6"></TD>
<TD HEIGHT="6" COLSPAN="2"></TD>
<TD HEIGHT="6" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">18</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ASSIGNMENT; PERFORMANCE BY AFFILIATES; GENERAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>SCHEDULES </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 1.8</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Current Back up</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule
1.66</P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Formulation
Patent</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 1.85</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Current IPH2201</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule
1.92</P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Licensed
Shared Patents</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 1.95</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Listed Patents</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule
1.109</P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">NKG2A</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 1.110</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt"><FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed
Patents</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule
1.124</P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Profit/Loss
Reporting Schedule</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 1.147</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Third Party Agreements</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule
3.11</P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Form
Confirmatory Patent License</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 4.11(a)</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Approved Third Parties</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule
4.11(b)</P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">MedImmune
Code of Conduct</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 5.3</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Parties Representation on JPT</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 5.7</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Parties
Representation on DCC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 7.1</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Development Costs Sharing Example</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 7.4</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Form
Development Costs Report</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 8.14</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Form Commercialization Costs Report</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule
13.2(a)(i)</P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Owned
Patents</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 13.2(a)(ii)</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Exclusively Licensed Patents</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule
13.2(a)(iv)</P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Listed <FONT
STYLE="white-space:nowrap">Know-How</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 13.2(m)</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Current Manufacturing
Specification</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Schedule 13.2(n)</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Current Contract Manufacturing
Organisations</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">This <FONT STYLE="white-space:nowrap">Co-Development</FONT> and License Agreement (the
&#147;<B>Agreement</B>&#148;) is made as of the <B>Signing Date</B> by and between: </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">INNATE PHARMA S.A., a company incorporated in France and with its principal place of business at 117, Avenue de Luminy
&#150; BP 30191 13 009 Marseille, France (&#147;<B>Innate</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MEDIMMUNE LIMITED, a company incorporated in England and Wales with company number 2451177 and with its registered
office at Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom (&#147;<B>MedImmune</B>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Background </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate is the owner of certain propriety technology relating to IPH2201, its first in class NKG2A monoclonal antibody,
and is the owner or exclusive licensee or sublicensee of certain Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> associated therewith, including Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> exclusively licensed to Innate
by Novo Nordisk pursuant to an agreement dated 28&nbsp;March 2006 (as amended) (capitalised terms are defined below); </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate has developed and studied IPH2201 for the treatment of cancer, in particular head and neck cancer, chronic
lymphocytic leukaemia and ovarian cancer, both alone and in combination with other compounds; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune is, directly or indirectly, a wholly owned subsidiary of AstraZeneca PLC. MedImmune and its Affiliates have
experience in the research, development, manufacturing and commercialisation of pharmaceutical products worldwide, including treatments for cancer both using small molecules and large molecules, some of which, have the potential for use in
combination with IPH2201 (capitalised terms are defined below); </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate granted an exclusive option to MedImmune pursuant to a Development and Option Agreement entered into on the
same date as this Agreement (the &#147;<B>Development and Option Agreement</B>&#148;) and MedImmune desires to exercise such option and take such license, under Innate&#146;s rights in and to the Licensed
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Antibodies, IPH2201, <FONT STYLE="white-space:nowrap">Back-Up</FONT> Licensed Antibodies and associated Patents and Intellectual Property Rights to Exploit one or several of the Licensed
Antibodies for the treatment of cancer or any other indication, in accordance with the terms and conditions set forth below (as such capitalised terms are defined below). </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties are interested in <FONT STYLE="white-space:nowrap">co-developing</FONT> and
<FONT STYLE="white-space:nowrap">co-commercialising</FONT> Licensed Products and in collaborating and sharing certain expenses and revenues, with respect to the Development and Commercialisation of Licensed Products, in accordance with the terms and
conditions set forth below (as such capitalised terms are defined below). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The intent of the Parties is that Medimmune will, as needed, involve the resources of its Affiliates in the activities
contemplated hereunder. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of Innate and MedImmune, intending to be legally bound, agree as follows: </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>DEFINITIONS</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;Unless otherwise specifically provided in this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;</B><B>Affiliate</B><B>&#148;</B> means, with respect to a Person, any Person that from time to time
directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such first Person. For purposes of the definition in this Section&nbsp;1.1 only, &#147;control&#148;, and with correlative
meanings, the terms &#147;controlled by&#148; and &#147;under common control with&#148; mean (a)&nbsp;to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities, by
contract relating to voting rights or corporate governance, resolution, regulation or otherwise, or (b)&nbsp;to own, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities or other ownership interest of such
Person. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Annual Net Sales</B>&#148; means the Net Sales made during any given Calendar Year. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Anti-Corruption Laws</B>&#148; means the US Foreign Corrupt Practices Act 1977, the UK Bribery Act 2010 and
any other Applicable Laws for the prevention of fraud, corruption, racketeering, money laundering or terrorism. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Applicable Laws</B>&#148; means the laws, rules, regulations and guidelines in the world, including any
rules, regulations, guidelines or other requirements of the Governmental Bodies that are applicable to the Parties or any particular activity under this Agreement, in each case as may be in effect from time to time, including, without limitation,
(i)&nbsp;GCP, (ii) GMP and (iii)&nbsp;the principles that form the basis of the Helsinki Declaration of the World Medical Association, in each case to the extent they apply to a Party&#146;s performance of its obligations under this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Arising IP</B>&#148; means any <FONT STYLE="white-space:nowrap">Know-How,</FONT> inventions, Patents or other
IPR arising after the Effective Date, as a result of the performance of rights or obligations under this Agreement, including the conduct of the Development Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Arising Patent&#148;</B> shall have the meaning assigned in Section&nbsp;12.3. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Assigned Activities</B>&#148; shall have the meaning assigned in Section&nbsp;3.5. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B><FONT STYLE="white-space:nowrap">Back-Up</FONT> Licensed Antibodies</B>&#148; means antibodies
(i)&nbsp;described in <U>Schedule 1.8</U> (the &#147;<B>Current Back up</B>&#148;), (ii) that bind to NGK2A and are within the scope of the claims of the Licensed Patents in any country at any time, or (iii)&nbsp;that bind to NGK2A and are under the
Control of Innate or its Affiliates, and including any fragment or derivative of such an antibody, but excluding IPH2201. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Bankruptcy Code</B>&#148; means Title 11, United States Code, as amended, or analogous provisions of
Applicable Laws outside the United States. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Breaching Party</B>&#148; shall have the meaning assigned in Section&nbsp;15.2(i). </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Breach Invoking Party</B>&#148; shall have the meaning assigned in Section&nbsp;15.2(i).
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Business Day</B>&#148; means a day other than Saturday or Sunday or a public holiday in England or France.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Calendar Quarter</B>&#148; means each successive period of three (3)&nbsp;consecutive calendar months
commencing on 1st January, 1st April, 1st July and 1st October. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Calendar Year</B>&#148; means each successive period of twelve (12)&nbsp;consecutive calendar months
commencing on 1st January. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Change of Control</B>&#148; means any of the following with respect to Innate: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the sale or disposition of all or substantially all of its assets to an Industrial Competing Party;
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the acquisition by an Industrial Competing Party, acting alone or in concert with other Person(s), of more than fifty
percent (50%) of the combined voting power of Innate&#146;s outstanding voting securities or otherwise the power to control the appointment of the Board of Directors of Innate; or </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">a merger, consolidation, share exchange or other similar transaction of Innate and any Industrial Competing Party
which results in the holders of the outstanding voting securities of Innate immediately prior to such merger, consolidation, share exchange or other similar transaction ceasing to hold more than fifty percent (50%) of the combined voting power of
the surviving, purchasing or continuing entity immediately after such merger, consolidation, share exchange or other similar transaction; </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">other than, in each case of subsection (a), (b) and (c), where such transaction is to be entered into between Innate and MedImmune or an
Affiliate of MedImmune. Notwithstanding the foregoing, a Change of Control shall not be deemed to occur solely on account of an (x)&nbsp;initial public or secondary offering, or (y)&nbsp;the acquisition of securities of Innate by one or more
institutional investors, or Affiliates thereof, which are not Industrial Competing Parties, that acquire Innate&#146;s securities in a transaction or series of related transactions (i) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify">
primarily for purposes of equity investment, or (ii)&nbsp;as a sale of assets, merger or other transaction effected exclusively for the purpose of obtaining tax or other fiscal benefit or
changing the corporate domicile of Innate. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Clinical Trials</B>&#148; means Phase 1 Clinical Trials, Phase 2 Clinical Trials, Phase 3 Clinical Trials,
Phase 4 Clinical Trials, or variations of such trials (for example, Phase 2/3 and Phase 2b), and any other clinical study conducted in human subjects in connection with the Development of a Licensed Product. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CMC</B>&#148; means optimization of Manufacturing processes to provide reproducible supply of drug substance
at commercialization scale, including formulation and development work to ensure stability and purity, and to otherwise meet the requirements under Applicable Law to be approved by a Regulatory Health Authority for marketing, sale and distribution.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B><FONT STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice</B>&#148; shall have the meaning
assigned in Section&nbsp;7.1. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Committees</B>&#148; shall mean the DCC, the SCC and the JTC. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Competition Law Clearance</B>&#148; means the first date upon which all of the following have been met:
(i)&nbsp;the waiting period provided by the HSR Act and all other applicable national legislation has expired or been terminated and all required antitrust clearances have been obtained, (ii)&nbsp;no court or administrative challenges to the
transaction contemplated by this Agreement are pending, and (iii)&nbsp;no court or administrative orders are outstanding blocking the completion of the transactions. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B><FONT STYLE="white-space:nowrap">Co-Promote</FONT> Agreement</B>&#148; shall have the meaning assigned in
Section&nbsp;8.12. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B><FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option</B>&#148; shall have the meaning assigned in
Section&nbsp;8.3. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B><FONT STYLE="white-space:nowrap">Co-Promote</FONT> Product</B>&#148; means a Licensed Product marketed and <FONT
STYLE="white-space:nowrap">Co-Promoted</FONT> in [***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B><FONT STYLE="white-space:nowrap">&#147;Co-Promotion&#148;</FONT> </B>means the conduct of Promotion with respect to
the Licensed </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Products in the Field, in [***] by each of the Parties, or their Affiliates, under the same Product trademark in a given country, and
&#147;<B><FONT STYLE="white-space:nowrap">Co-Promote</FONT></B>&#148; shall have a corresponding meaning. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B><FONT STYLE="white-space:nowrap">Co-Promotion</FONT> Withdrawal</B>&#148; shall have the meaning assigned to
it in Section&nbsp;8.4. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.26</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Combination&#148; </B>or<B> </B>&#147;<B>Combination Product</B>&#148; means the combination of a Licensed
Antibody as an active ingredient with one or more other active ingredients including but not limited to MedImmune Compounds, whether sold or anticipated to be sold as a fixed dose or as separate <FONT STYLE="white-space:nowrap">co-prescribed</FONT>
doses or in a physically <FONT STYLE="white-space:nowrap">co-packaged</FONT> form. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.27</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Commercialization</B>&#148; means all activities undertaken relating to the preparation for and conduct of
marketing and sale of a Licensed Product, including without limitation <FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Activities, advertising, education, planning, marketing, promotion, distribution, market and product support, seeking pricing
and reimbursement approvals and Phase 4 Clinical Trials anywhere in the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.28</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Commercialization Costs</B>&#148; means, with respect to a Licensed Product during any given period, all
Costs that are incurred [***]. Subject to the foregoing, Commercialization Costs for a Licensed Product shall consist of Costs with respect to such Licensed Product incurred for: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]and </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.29</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Commercialize</B>&#148; means the conduct of Commercialization activities. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.30</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Commercially Reasonable Efforts</B>&#148; means, with respect to the efforts to be expended by a Party [***]
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.31</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Competing Product</B>&#148; a small molecule or protein used in the Field, including but not limited to an
antibody, that binds [***], but excluding a Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.32</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Compulsory License</B>&#148; shall have the meaning assigned in Section&nbsp;10.17. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.33</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Confidential Information</B>&#148; means any and all <FONT STYLE="white-space:nowrap">Know-How</FONT> and
Materials, whether oral or in writing or in any other form, disclosed before, on or after the date of this Agreement by one Party to the other Party that is either marked or identified as confidential or proprietary or that is of such a nature that
would be considered by a reasonable person to be confidential or proprietary. The Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> shall be deemed Innate&#146;s Confidential Information. MedImmune
<FONT STYLE="white-space:nowrap">Know-How</FONT> shall be deemed MedImmune&#146;s Confidential Information. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.34</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Control</B>&#148; means, with respect to an item of <FONT STYLE="white-space:nowrap">Know-How</FONT> or a
Patent, the ability and authority of a Party or its Affiliates, whether arising by ownership, possession, or pursuant to a license or sublicense, to assign, disclose, grant licenses, sublicenses, or other rights to the other Party under or to such
item of <FONT STYLE="white-space:nowrap">Know-How</FONT> or such Patent as provided for in this Agreement, without breaching the terms of any agreement between such Party and any Third Party and subject to Section&nbsp;18.2. Notwithstanding the
foregoing, with respect to any Patent or item of <FONT STYLE="white-space:nowrap">Know-How</FONT> <FONT STYLE="white-space:nowrap">in-licensed</FONT> or otherwise acquired by Innate after the Effective Date, the exercise or use of which would result
in a payment obligation to any Third Party, such Patent or item of <FONT STYLE="white-space:nowrap">Know-How</FONT> shall be deemed to be Controlled by Innate for purposes of this Agreement only if MedImmune agrees in writing to reimburse all
amounts owed to such Third Party as a result </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
of its exercise of such right, license or sublicense excluding any sums which are payable pursuant to the Third Party Agreements. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.35</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Controlled Patents</B>&#148; shall have the meaning assigned in Section&nbsp;12.3. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.36</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Costs</B>&#148; means both internal and external costs and expenses (including the cost of allocated FTEs at
the FTE Rate). Unless otherwise mutually agreed between the Parties, internal costs incurred by a Party shall be determined by multiplying the applicable FTE Rate by the number of FTEs utilized to conduct the applicable activities.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.37</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Covenant Period 1</B>&#148; shall have the meaning assigned in Section&nbsp;3.13. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.38</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Covenant Period 2</B>&#148; shall have the meaning assigned in Section&nbsp;3.14. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.39</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Damages</B>&#148; means any and all direct liabilities, claims, actions, damages, losses or expenses,
including interest, penalties, and reasonable lawyers&#146; fees and disbursements. In calculating Damages, the legal duty to mitigate on the part of the Party suffering the loss shall be taken into account. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.40</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Detail</B>&#148; means a sales presentation or interaction by a professional sales representative to or with
a target physician or other professional with prescribing authority involved in prescribing a <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Product or to other individuals influencing prescription activity with respect to a <FONT
STYLE="white-space:nowrap">Co-Promote</FONT> Product, in any case, in which the primary purpose is to discuss the benefits and features of the <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Product. The term Detail will be further defined in the
<FONT STYLE="white-space:nowrap">Co-Promote</FONT> Agreement. When used as a verb, &#147;<B>Detail</B>&#148; or &#147;<B>Detailing</B>&#148; means to perform a Detail. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.41</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Develop</B>&#148; means the conduct of Development activities. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.42</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Development</B>&#148; means all activities relating to obtaining Regulatory Approval of a Licensed Product,
Licensed Product line extensions, alternative delivery systems and new indications therefor, and all activities relating to developing the ability to Manufacture the same, including CMC. This includes, for example,
<FONT STYLE="white-space:nowrap">(i)&nbsp;non-clinical</FONT> testing, toxicology, formulation, clinical studies, regulatory </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
affairs, and outside counsel regulatory legal services, (ii)&nbsp;manufacturing process development for bulk and finished forms of Licensed Antibodies and Licensed Products, and manufacturing and
quality assurance technical support activities prior to the First Commercial Sale of a Licensed Product anywhere in the Territory and (iii)&nbsp;the conduct of advisory boards with relevant experts, e.g. clinical experts or payer representatives.
Development shall not include activities associated with Phase 4 Clinical Trials in respect of a Licensed Product commenced after First Commercial Sale of such Licensed Product anywhere in the Territory unless (x)&nbsp;required or requested by a
Regulatory Health Authority as a condition of obtaining, maintaining or extending Regulatory Approval or (y)&nbsp;performed to explore additional indications or alternative formulations of such Licensed Products. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.43</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Development and Option Agreement</B>&#148; means the Development and Option Agreement between the Parties
dated 24&nbsp;April 2015. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.44</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Development Budget</B>&#148; shall have the meaning set forth in Section&nbsp;4.5. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.45</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Development Collaboration Committee</B>&#148; or &#147;<B>DCC</B>&#148; means the committee described in
Section&nbsp;5.5. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.46</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Development Costs</B>&#148; means, with respect to each Licensed Product [***]: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Except to the extent included in subsection (ii)&nbsp;above, Development Costs shall not include either Party&#146;s
Costs to the extent they solely relate to activities associated with overseeing execution of and compliance with this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.47</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Development Plan</B>&#148; means the plan for Development of Licensed Product, as mutually agreed by the
Parties and approved by the DCC in accordance with Section&nbsp;4.5. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.48</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Development Term</B>&#148; means the period during which Development activities are being performed with
respect to any Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.49</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Distributor</B>&#148; shall have the meaning assigned in Section&nbsp;3.3. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.50</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Drug Approval Application</B>&#148; means an application for Regulatory Approval required before commercial
sale or use of a Licensed Product as a drug in a regulatory jurisdiction, but excluding pricing and reimbursement approvals. Drug Approval Application includes a Marketing Approval Application (MAA) in Europe or an New Drug Application (NDA) in the
United States. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.51</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Effective Date</B>&#148; means the (i)&nbsp;date of the Competition Law Clearance or (ii)&nbsp;if the Parties
agree in accordance with Section&nbsp;2.2 that no Competition Law Clearance is required, the Signing Date. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.52</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;EMA</B>&#148; means the European Medicines Agency or any successor thereto. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.53</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;</B><B>Employees</B><B>&#148;</B><B> </B>shall have the meaning in<B> </B>Section&nbsp;16.7.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.54</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Employment Liabilities&#148; </B>means any Damages resulting from any Unexpected Transferring Employees as
well as any other liability, damage or loss and reasonable costs of legal defence due to or in connection with Applicable Laws or the (possible) violation or the termination of the employment of any Unexpected Transferring Employees.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.55</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Exploit</B>&#148; means to undertake, or have undertaken, any or all of the following activities: to make,
import, use, sell, or offer for sale, Research, study, Develop, register, modify, enhance, improve, Manufacture, Commercialize, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
hold or keep (whether for disposal or otherwise), formulate, optimise, use, export, transport, distribute, promote, market or otherwise dispose or offer to dispose of, a product or process.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.56</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Exploitation</B>&#148; means the act of Exploiting a product or process. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.57</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Europe&#148;</B> or <B>&#147;EU&#148;</B> means the European Economic Area as it may be constituted from time
to time. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.58</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;</B>[***]<B>&#148;</B>means [***]<I>. </I> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.59</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>EU Commercialization Budget</B>&#148; shall have the meaning assigned in Section&nbsp;8.5.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.60</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>EU</B> <B>Commercialization Plans</B>&#148; shall have the meaning assigned in Section&nbsp;8.5.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.61</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>FDA</B>&#148; means the United States Food and Drug Administration or any successor thereto.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.62</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>FFDCA</B>&#148; means the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167;&#167; 301, et seq., as
amended from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.63</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Field</B>&#148; means the diagnosis, prevention, and treatment of oncology diseases and conditions in humans
or animals. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.64</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Filing Date</B>&#148; means, with respect to a submission to a Regulatory Health Authority, the date that
such submission is confirmed to have been received by the relevant Regulatory Health Authority. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.65</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>First Commercial Sale</B>&#148; means, with respect to any Licensed Product, the first sale of such Licensed
Product for value by MedImmune, its Affiliate, or its Sublicensees to a Third Party after Regulatory Approval of such Licensed Product has been obtained by MedImmune, its Affiliates, or its Sublicensees; <U>provided</U>, <U>however</U>, that in no
event shall any sale or distribution of a Licensed Product for <FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Activities or use in a Clinical Trial or otherwise any sales prior to receipt of all Regulatory Approvals necessary to commence
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
regular commercial sales (including <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;treatment IND sales&#148; and &#147;compassionate use sales&#148;) be deemed a First Commercial Sale.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.66</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Formulation Patent</B>&#148; means the Licensed Patent listed in <U>Schedule 1.66</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.67</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>FTE</B>&#148; means a full time equivalent person year of [***] of scientific, technical or operational work
(excluding administrative services). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.68</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>FTE Rate</B>&#148; means, for the period commencing on the Signing Date until such time as adjusted pursuant
to the following sentence or the Parties agree otherwise, [***] for all activities. The FTE Rate will be increased or decreased on each anniversary of the Signing Date by a percentage equivalent to the change over the preceding twelve month period
in the Consumer Price Index for Urban Wage Earners and Clerical Workers with respect to MedImmune and the index of salaries of the pharmaceutical industry published by LEEM with respect to Innate. The FTE Rate shall include costs of salaries,
benefits, supplies, travel, other employee costs, and supporting general and administration allocations. For clarity, the FTE Rate will not apply to any employee that performs activities related to manufacturing (excluding pharmaceutical development
activities conducted in accordance with the Development Plan), and any costs related to such employee will be included only to the extent consistent with the definition of Transfer Price. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.69</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>GCP</B>&#148; or &#147;<B>Good Clinical Practices</B>&#148; means, to the extent applicable in the country
where Regulatory Approval is sought, the current standards for good clinical practices relating to clinical trials for pharmaceuticals, as set forth in the United States Code of Federal Regulations or ICH guidelines and applicable regulations, laws
or rules as promulgated thereunder, in each case as amended from time to time, and all other standards of good clinical practice as are required by any Regulatory Health Authority. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.70</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Generic Product</B>&#148; means with respect to a Licensed Product in a particular country any product
(i)&nbsp;that is sold in such particular country by a Third Party who is not a Sublicensee or a Distributor selling such product under authorization from MedImmune or its Affiliates, (ii)&nbsp;that has received Regulatory Approval necessary for sale
in such country, (iii)&nbsp;that (a) is </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="right">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
substantially the same as the Licensed Product in dosage form, strength, route of administration, quality and performance characteristics, and intended use or (b)&nbsp;has received Regulatory
Approval based on a reference to a Regulatory Approval of the Licensed Product held by MedImmune, its Affiliates, or Sublicensees, and (iv)&nbsp;that contains as an active ingredient the same compound or substantially the same compound (such as a
biosimilar) (or, solely for products that are described by subsection (iii)(b), an equivalent or biosimilar thereof), as is contained in such Licensed Product. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.71</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Global</B> <B>Commercialization Plan</B>&#148; shall have the meaning assigned in Section&nbsp;8.2.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.72</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>GLP</B>&#148; or &#147;<B>Good Laboratory Practices</B>&#148; means good laboratory practices required under
the regulations set forth in 21 C.F.R. Part 58, as in effect during the Term, and the requirements thereunder imposed by the FDA, and the equivalent thereof in any jurisdiction. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.73</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>GMP</B>&#148; or &#147;<B>Good Manufacturing Practice</B>&#148; means the principle of good manufacturing
practice in respect of medicinal products for human use and investigational medicinal products for human use as required by Applicable Laws and Requirements, including the laws of the European Community and Directive 2003/94/EC as well as any
national legislation implementing the aforesaid Directive and any relevant guidance relating thereto. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.74</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Governmental Body</B>&#148; means any: (i)&nbsp;nation, state, commonwealth, province, territory, county,
municipality, district or other jurisdiction of any nature; (ii)&nbsp;federal, state, local, municipal, foreign or other government; (iii)&nbsp;governmental or quasi-governmental authority of any nature (including any governmental division,
department, agency, commission, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and any court or other tribunal); or (iv)&nbsp;self-regulatory organization (including the NASDAQ Global Market and the
NASDAQ Global Select Market). For the avoidance of doubt, Governmental Bodies includes Regulatory Health Authorities. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.75</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Government Official</B>&#148; means any Person employed by or acting on behalf of a
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Governmental Body, government-controlled entity or public international organization. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.76</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>HSR Act</B>&#148; means the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended,
including all rules promulgated thereunder. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.77</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>ICH</B>&#148; means the International Conference on Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.78</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>IFRS</B>&#148; means International Financial Reporting Standards, or the future equivalent of such reporting
standards, as consistently applied by the applicable Party in the manner used for external reporting. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.79</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>IND</B>&#148; means an Investigational New Drug Application (as defined in the FFDCA and applicable
regulations promulgated thereunder by the FDA) or an equivalent application filed with or submitted to any Regulatory Health Authority, the filing of which is required for authorization to commence human clinical trials. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.80</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Indirect Taxes</B>&#148; means value added taxes, sales taxes, consumption taxes and other similar taxes.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.81</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Industrial Competing Party</B>&#148; means a Person that is in the top [***] pharmaceutical companies in the
world measured by global sales of prescription drugs based on readily available data from an independent data source such as IMS and which clinically Develops or Commercialize a Competing Product or any product in the specifically directed to
components of the immune checkpoint targets and cell-based therapies supplementing the immune system. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.82</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Initial Study</B>&#148; shall have the meaning given in the Development and Option Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.83</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Initial Supply</B>&#148; shall have the meaning assigned in Section&nbsp;9.1. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.84</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Intellectual Property Rights</B>&#148; or &#147;<B>IPR</B>&#148; means Patents, trademarks, service marks,
trade secrets (including patentable inventions), trade names, registered </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
designs, design rights, copyrights (including rights in computer software), domain names, database rights and any rights or property similar to any of the foregoing in any part of the world,
whether registered or not, together with the right to apply for the registration of any such rights. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.85</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>IPH2201</B>&#148; means the monoclonal antibody to NKG2A (i)&nbsp;as particularised in <U>Schedule 1.85</U>
(the &#147;<B>Current IPH2201</B>&#148;), or (ii)&nbsp;a molecule that binds to NKG2A containing the CDRs (Complimentary Determining Regions) of IPH2201 as noted in <U>Schedule 1.85</U> and any derivative or fragment thereof and any formulation of
the foregoing. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.86</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all inventions, discoveries, data,
information (including scientific, technical or regulatory information), trade secrets, processes, means, methods, practices, formulae, instructions, procedures, techniques, materials, technology, results, analyses, designs, drawings, computer
programs, apparatuses, specifications, technical assistance, laboratory, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data (including laboratory notes and notebooks), and other material or
<FONT STYLE="white-space:nowrap">know-how,</FONT> in written, electronic or any other form, whether or not confidential, proprietary or patentable, including without limitation: development technology; biology, chemistry, pharmacology, toxicology,
drug stability, Manufacturing and formulation, test procedures, synthesis, purification and isolation techniques, quality control data and information, methodologies and techniques; information regarding clinical and
<FONT STYLE="white-space:nowrap">non-clinical</FONT> safety and efficacy studies, including study designs and protocols, marketing studies, absorption, distribution, metabolism and excretion studies; assays and biological methodology.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.87</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>knowledge</B>&#148; means the good faith understanding of the officers of Innate and its Affiliates, with
respect to relevant facts and information after performing a commercially reasonable inquiry of the employees having responsibilities in Innate&#146;s organisation with respect to the relevant subject matters and external patent agents of Innate and
its Affiliates with respect to such facts and information relating to the Licensed Patents, that the patent agent is responsible for prosecuting and maintaining. For purposes of the foregoing, Innate will not be deemed to have knowledge of any given
fact or information, which (i)&nbsp;was known or should have been known by any external patent agents </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
of Innate and its Affiliates but was not disclosed to Innate&#146;s officers or (ii)&nbsp;was not known by the employees of Innate and its Affiliates. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.88</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Legal Proceeding</B>&#148; means any action, suit, litigation, arbitration, proceeding (including any civil,
criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Body or any
arbitrator or arbitration panel. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.89</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Licensed Antibodies</B>&#148; means IPH2201 and all <FONT STYLE="white-space:nowrap">Back-Up</FONT> Licensed
Antibodies. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.90</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all
<FONT STYLE="white-space:nowrap">Know-How</FONT> which is Controlled by Innate or its Affiliates, as of the Effective Date or at any time during the term of this Agreement, that may be necessary or useful for the Research, Development,
Commercialization and/or Exploitation of any Licensed Antibody, Licensed Product or Combinations, including Study Results, but excluding in each case, any <FONT STYLE="white-space:nowrap">Know-How</FONT> related to any active ingredient within a
Combination other than the Licensed Antibody. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.91</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Licensed Patents</B>&#148; means all of the Patents which are Controlled by Innate or its Affiliates, as of
the Effective Date or at any time during the Term, that (a)&nbsp;claim any Licensed Antibody, Licensed Product or Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> or (b)&nbsp;claim any invention that is necessary or useful for the Research,
Development, Commercialization or Exploitation of any Licensed Antibody, Licensed Product or Combination, but excluding in each case, any (x)&nbsp;Patent related to any active ingredient within a Combination other than the Licensed Antibody and
(y)&nbsp;the <FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Patents. For the avoidance of doubt, Licensed Patents includes the Listed Patents, the Novo Nordisk Patents and the Patents within the Arising IP when such Patents are
owned or <FONT STYLE="white-space:nowrap">co-owned</FONT> by Innate pursuant to Section&nbsp;12.2. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.92</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Licensed Shared Patents</B>&#148; means those listed Patents listed in <U>Schedule 1.92</U>, which refer to
NKG2A but also to other targets, as such schedule may be updated from time to time by agreement of the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.93</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Licensed Product</B>&#148; shall mean any and all pharmaceutical products including
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
a Licensed Antibody as an active ingredient, including Combinations. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.94</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Licensed Technology</B>&#148; means all Licensed Patents and Licensed
<FONT STYLE="white-space:nowrap">Know-How.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.95</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Listed Patents</B>&#148; means the Patents listed in <U>Schedule 1.95</U>, and any Patents filed after the
Signing Date claiming priority to the Patents listed on <U>Schedule 1.95</U>, as such schedule may be updated from time to time by agreement of the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.96</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Major Market</B>&#148; means [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.97</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Manufacture</B>&#148; or &#147;<B>Manufacturing</B>&#148; means activities in connection with the synthesis,
manufacture, processing, formulating, testing (including, without limitation quality control, quality assurance and lot release testing), bulk packaging, labeling or storage and delivery of Licensed Antibody or Licensed Product (including any
component thereof). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.98</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Manufacturing Costs&#148;</B> means the <FONT STYLE="white-space:nowrap">fully-burdened</FONT> aggregate
Costs incurred and recorded by a Party (in accordance with IFRS) as a result of Manufacturing a Licensed Product or component thereof consisting solely of: </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(i) [***]; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(ii)
[***]; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(iii) [***]; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(iv) [***]; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(v)
[***]; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(vi) [***]; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(vii) [***]; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(viii) [***]; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; text-indent:3%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(ix) [***]. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:3%; text-indent:3%; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***]. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.99</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Material Anti-Corruption Law Violation</B>&#148; means a violation of an Anti-Corruption Law relating to the
subject matter of this Agreement which would, if it were publicly known, be reasonably expected to have an adverse effect on the Party committing such violation or on the reputation of the other Party because of its relationship with the Party
committing such violation. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.100</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Materials</B>&#148; means compounds, compositions of matter, assays, and biological materials useful for the
Exploitation of Licensed Antibodies or Licensed Products. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.101</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>MedImmune Compound</B>&#148; means any small molecule, large molecule, antibody or other molecule or compound
that is Controlled by MedImmune or any of its Affiliates. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.102</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>MedImmune Compound Arising IP</B>&#148; means any IPR arising after the Effective Date to the extent solely
relating to the MedImmune Compounds. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.103</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>MedImmune <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means
<FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by MedImmune or its Affiliates at any time during the Term that may be necessary or useful for the Exploitation of any Licensed Antibody, Licensed Product or Combinations, including any
such MedImmune Compound Arising IP and Study Results. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.104</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>MedImmune Patents</B>&#148; means all Patents (i)&nbsp;that are Controlled by MedImmune or its Affiliates as
of the Effective Date or that come into the Control of MedImmune or its Affiliates at any time during the Term, including Patents claiming MedImmune Compound Arising IP, and (ii)&nbsp;that claim any MedImmune Compound or any other inventions that
are necessary or useful for the Exploitation of any Licensed Antibody, Licensed Product or Combination, or that claim any Licensed Antibody, Licensed Product, Combination or Study Result. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.105</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>MedImmune Technology</B>&#148; means MedImmune <FONT STYLE="white-space:nowrap">Know-How</FONT> and MedImmune
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Patents. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.106</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>MedImmune</B> <B>Product Data</B>&#148; shall have the meaning assigned in Section&nbsp;15.3(viii).
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.107</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;MedImmune Triggered Termination</B>&#148; shall have the meaning assigned in Section&nbsp;15.3.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.108</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Net Sales</B>&#148; [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.109</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>NKG2A</B><B>&#148;</B><B> </B>means the human NKG2-Atype II integral membrane protein (also known as CD159
antigen-like family member A, NK cell receptor A, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NKG2-A-activating</FONT></FONT> NK receptor, or CD159a) and all isoforms, fragments or derivatives thereof (including homologs and
orthologs of the human sequence) including the protein described in <U>Schedule 1.109</U><B>.</B><B><I> </I></B> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.110</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B><FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Patents</B>&#148; means the Licensed Patents
listed in <U>Schedule 1.110</U>. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.111</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Novo Nordisk Patents</B>&#148; shall mean those patents licensed to Innate under an agreement with Novo
Nordisk A/S dated 28&nbsp;March 2006 (as amended), being those patents owned by Novo Nordisk as listed in Schedule 1.95. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.112</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Other Promotional Activities</B>&#148; means both off line and online activities including but not limited
to, sales activities, other than Detailing, such as sales training, sales meetings; marketing activities such as advertising and promotion; and medical or scientific affairs activities such as conferences, speakers bureaus, and continuing medical
education activities; provided that all such activities shall be in accordance with the USFDA Office of Prescription Drug Promotion. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.113</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Patents</B>&#148; means (a)&nbsp;all national, regional and international patents and patent applications,
including provisional patent applications, (b)&nbsp;all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals,
continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> <FONT STYLE="white-space:nowrap">non-provisional</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
applications, and continued prosecution patent applications, (c)&nbsp;any and all patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including
utility models, petty patents and design patents and certificates of invention, (d)&nbsp;any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, <FONT
STYLE="white-space:nowrap">re-examinations</FONT> and extensions (including any supplementary protection certificates, patent term extensions and the like) of the foregoing patents or patent applications (a), (b) and (c)), and (e)&nbsp;any similar
rights, including <FONT STYLE="white-space:nowrap">so-called</FONT> pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent applications
and patents. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.114</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Payments</B>&#148; shall have the meaning assigned in Section&nbsp;10.26. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.115</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Person</B>&#148; means any individual, sole proprietorship, corporation, partnership, association,
joint-stock company, trust, unincorporated organization, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.116</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Phase 1 Clinical Trial</B>&#148; means any clinical study conducted on human subjects [***].
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.117</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Phase 2 Clinical Trial</B>&#148; means any clinical study that is not intended to be used as a pivotal study
for purposes of seeking Regulatory Approval in any country within the Territory that is conducted on human patients [***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.118</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Phase 3 Clinical Trial</B>&#148; means any clinical study used as a pivotal study for purposes of seeking
Regulatory Approval, [***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.119</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Phase 4 Clinical Trial</B>&#148; means any clinical study of a pharmaceutical product on human subjects
commenced [***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.120</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B><FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Activities</B>&#148; means all activities undertaken
with respect to a Licensed Product prior to First Commercial Sale and in preparation for the launch of such Licensed Product in the EU. <FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Activities shall include without limitation advertising,
education, product-related public relations, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
health care economic studies, governmental affairs activities for reimbursement and formulary acceptance, sales force training, trademark selection, filing, prosecution, and enforcement, and
other activities included within the Global Commercialization Plan or (as applicable) EU Commercialization Plan prior to the First Commercial Sale of a Licensed Product. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.121</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Principal Investigator</B>&#148; means the person responsible for the conduct of a Clinical Trial at a
Clinical Trial site. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.122</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Product Information</B>&#148; shall have the meaning assigned in Section&nbsp;11.2. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.123</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Product Trademark</B>&#148; shall have the meaning assigned in Section&nbsp;12.16(i). </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.124</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Profit/Loss&#148; </B>means the Net Sales of the Licensed Product in Europe less [***].
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.125</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Promotion</B>&#148; means solely for the purposes of this Agreement and notwithstanding any more general
meaning of the word &#147;promote&#148; in common parlance or as an industry term, means: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the conduct of activities of the Parties to promote the use, prescription, dispensing, administration or sale of the
Licensed Products under the Licensed Product trademark in the Field in the Territory, for commercial purposes, all in accordance with the approved Licensed Product labelling information, including Detailing; and </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Medical science liaison and Medical Education Activities related to the Licensed Products in the Field in the
Territory, </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:17%; font-size:11pt; font-family:ARIAL" ALIGN="justify">in each case in accordance with the applicable EU Commercialization Plan and having such activities
undertaken by an Affiliate or, to the extent permitted under this Agreement and in accordance with the terms of this Agreement, a Third Party. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify">&#147;<B>Promote</B>&#148; shall have a corresponding meaning. For the avoidance of doubt,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Promotion shall not include any Development activities. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.126</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Promotion Proposal</B>&#148; shall have the meaning assigned in Section&nbsp;8.11. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.127</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Regulatory Approval</B>&#148; means any and all approvals (including without limitation pricing and
reimbursement approvals), product or establishment licenses, registrations, or authorizations of any regional, federal, state, or local Regulatory Health Authority, department, bureau, or other governmental entity, necessary to commercially
distribute, sell or market a Licensed Product in a regulatory jurisdiction, including, where applicable, (a)&nbsp;pricing or reimbursement approval in such jurisdiction if necessary or desirable, <FONT STYLE="white-space:nowrap">(b)&nbsp;pre-</FONT>
and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto), and (c)&nbsp;labelling approval. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.128</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Regulations</B>&#148; means The Transfer of Undertakings (Protection of Employment) Regulations 2006 or any
equivalent laws in the applicable country. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.129</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Regulatory Documentation</B>&#148; means all applications, registrations, licenses, authorizations and
approvals, all correspondence submitted to or received from Regulatory Health Authorities (including minutes and official contact reports relating to any communications with any Regulatory Health Authority) and all supporting documents, including
documentation arising in the course of all Clinical Trials, in each case relating to obtaining or maintaining Regulatory Approval of Licensed Products, including all INDs, regulatory drug lists, advertising and promotion documents, adverse event
files and complaint files. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.130</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Regulatory Exclusivity</B>&#148; shall mean any exclusive marketing rights or data exclusivity rights
conferred by any applicable Regulatory Health Authority, other than an issued and unexpired Patent, including any regulatory data protection exclusivity (including, where applicable, pediatric exclusivity or orphan drug exclusivity) or any other
exclusivity afforded by restrictions which restrict the granting by a Regulatory Health Authority of Regulatory Approval to market a Generic Product. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.131</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Regulatory Health Authority</B>&#148; means any applicable national (for example,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
FDA or Japan&#146;s Pharmaceuticals and Medical Devices Agency), supranational (for example, the EMA), regional, state, provincial or local regulatory health authority, department, bureau,
commission, council, or other government entity regulating or otherwise exercising authority with respect to the Exploitation of Licensed Antibodies or Licensed Products in the Territory, including any such entity involved in the granting of
Regulatory Approval for pharmaceutical products. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.132</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Research</B>&#148; means the discovery, identification, research, characterisation, modification,
derivatisation, optimisation and preclinical testing of pharmaceutical products. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.133</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Safety Agreement</B>&#148; shall have the meaning assigned in Section&nbsp;4.24. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.134</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Sales Collaboration Committee</B>&#148; or &#147;<B>SCC</B>&#148; means the committee described in
Section&nbsp;8.6. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.135</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Senior Executives</B>&#148; means (i) [***] and (ii) [***]. A Party shall be entitled, effective upon written
notice thereof to the other Party, to designate one of its other representatives having equivalent seniority and experience to replace such foregoing representative as that Party&#146;s Senior Executive for the purpose of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.136</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Serious Adverse Event</B>&#148; means any untoward medical occurrence that at any dose results in death, is
life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect (CPMP/ICH/377/95). Serious Adverse Event includes
any event affecting patient safety that Applicable Law requires reporting to a Regulatory Health Authority. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.137</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Signing Date</B>&#148; means the date of the exercise of the Option by MedImmune pursuant to the Development
and Option Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.138</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Specification</B>&#148; means the specification applicable to the Manufacture, packaging, labelling and
storage of any Licensed Antibody or Licensed Products, in effect at a given time. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.139</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Statistical Analysis Plan</B>&#148; shall have the meaning assigned in Section&nbsp;4.11.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.140</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Study Results&#148; </B>means any data and information generated as a result of the Clinical Trials performed
as part of the Development Plan. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.141</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Sublicensee</B>&#148; shall have the meaning assigned in Section&nbsp;3.2. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.142</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Tax</B>&#148; or &#147;<B>Taxation</B>&#148; means any form of tax or taxation, levy, duty, charge, social
security charge, contribution or withholding of whatever nature (including any related fine, penalty, surcharge or interest) imposed by, or payable to, a Tax Authority. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.143</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Tax Authority</B>&#148; means any Governmental Body authorized to levy Tax. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.144</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Term</B>&#148; shall have the meaning assigned in Section&nbsp;15.1. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.145</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Territory</B>&#148; means the world. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.146</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Third Party</B>&#148; means any Person other than Innate or MedImmune, or their respective Affiliates.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.147</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Third Party Agreements&#148;</B> shall mean those agreements listed in <U>Schedule 1.147</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.148</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Third Party Claims</B>&#148; shall have the meaning assigned in Section&nbsp;16.2. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.149</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Third Party Payments</B>&#148; shall have the meaning assigned in Section&nbsp;10.20. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.150</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Transfer Price</B>&#148; means the Manufacturing Cost of the transferred Licensed Antibody or Licensed
Product. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.151</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Triggered Termination</B>&#148; means, as the context requires, either a MedImmune Triggered Termination or
(ii)&nbsp;termination by MedImmune for Innate&#146;s uncured material breach pursuant to Section&nbsp;15.1(i) or Innate&#146;s insolvency pursuant to Section&nbsp;15.2(iii). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.152</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Unexpected Transfer Employee</B>&#148; shall have the meaning set out in Section&nbsp;16.7.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.153</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Valid Claim</B>&#148; means a claim of an issued and unexpired patent or pending patent application within
the Licensed Patents that has not been held unpatentable, invalid, or unenforceable by a court or other government agency of competent jurisdiction in an unappealed or unappealable decision or has not been admitted to be invalid or unenforceable
through reissue, <FONT STYLE="white-space:nowrap">re-examination,</FONT> disclaimer, or otherwise. Notwithstanding the foregoing, if a claim of a pending patent application has not issued as a claim of a patent within [***] after the filing date,
such claim shall not be a Valid Claim for the purposes of this Agreement, unless and until such claim issues as a claim of any issued patent (from and after which time the same would be deemed a Valid Claim subject to the first sentence of the
definition above). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.154</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Written Disclosure</B>&#148; shall have the meaning assigned in Section&nbsp;14.3. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>CONSTRUCTION; COMPETITION LAW CLEARANCE</B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Except where the context requires otherwise, whenever used the singular includes the plural, the plural includes the
singular, the use of any gender is applicable to all genders and the word &#147;or&#148; has the inclusive meaning represented by the phrase &#147;and/or&#148;. Whenever this Agreement refers to a number of days, unless otherwise specified, such
number refers to calendar days. The headings of this Agreement are for convenience only and do not define, describe, extend or limit the scope or intent of any provision in this Agreement. The term &#147;including&#148; or &#147;includes&#148; as
used in this Agreement means including, without limiting the generality of any description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the Parties and no rule of strict construction shall
be applied against any Party. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">No later than five (5)&nbsp;Business Days following the Signing Date or such later date as the Parties may agree, the
Signing Date, the Parties shall jointly determine whether a filing under the HSR Act or any equivalent competition law statute or regulation (a &#147;Competition Law Filing&#148;) is required for the performance of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
this Agreement. Upon a joint determination that one or more Competition Law Filings are required, the Parties shall prepare and submit the required notification forms as soon as reasonably
practicable (and for any filing under the HSR Act within ten (10)&nbsp;Business Days after such determination) and use reasonable efforts to obtain clearance for the transactions contemplated hereunder as soon as practicable. Subject to Applicable
Law relating to the exchange of information, MedImmune shall have the right to direct all matters with respect to Competition Law Filings hereunder, consistent with its obligations hereunder, after consultation with Innate. Each Party will consult
with the other on, and consider in good faith the views of the other Party in connection with, all of the information relating to such other Party that appears in any Competition Law Filing.&nbsp;&nbsp;&nbsp;&nbsp;MedImmune shall bear all fees in
connection with any Competition Law Filing and each Party shall bear their respective attorneys&#146; fees in connection therewith. This Agreement shall bind the Parties upon execution and continue in full force and effect unless and until the
termination or expiration of the Agreement by its terms, provided, however, that each Party&#146;s grant of license rights hereunder, MedImmune&#146;s obligation to make the payments hereunder, and the Parties&#146; other rights and obligations
hereunder in connection with the Development and Commercialization of the Licensed Antibodies and Licensed Products shall not become effective unless and until the date of either: 1) the receipt of all Competition Law Clearances or 2) the conclusion
by the Parties pursuant to this Section&nbsp;2.2 that no Competition Law Clearance is necessary for the implementation of this Agreement. Nothing in this Agreement shall require or be deemed to require either Party (or their Affiliates) to commit to
any divestitures or licenses or agree to hold separate any assets or agree to any similar arrangements or commit to conduct its business in a specified manner, or to submit and respond to a formal discovery procedure initiated by the FTC or DOJ
(i.e., a &#147;Request for Additional Information and Documentary Materials&#148; also known as a &#147;second request&#148;, or Civil Investigative Demand if a filing is not required under the HSR Act), in each case as a condition to obtaining
antitrust clearance for the transactions contemplated hereunder. If Competition Law Clearance is not received in relation to both this Agreement and the Development and Option Agreement on or before ninety (90)&nbsp;days after the date on which both
Parties have submitted to the FTC and DOJ their respective initial filings to request Competition Law Clearance of the transactions hereunder, then either Party </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
shall have the right to terminate this Agreement without liability therefor at any time thereafter, but prior to receipt of Competition Law Clearance of the transactions contemplated hereunder,
by written notice to the other Party. If Competition Law Clearance is obtained by the Parties in relation to this Agreement prior to the Signing Date this Section&nbsp;2.2 shall have no effect and the Signing Date and Effective Date shall be the
same date. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>GRANT OF RIGHTS AND LICENSES; EXCLUSIVITY</B><B> </B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Exclusive License to MedImmune. </B>Subject to the terms of this Agreement, Innate grants to MedImmune and its
Affiliates: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">an exclusive (including with regard to Innate and its Affiliates, except with respect to the retained rights set forth
in Section&nbsp;3.5 below) right and license under the Licensed Technology to Develop, Manufacture and Commercialize Licensed Antibodies and Licensed Products in the Field in the Territory; </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right and sublicense, under the
<FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Patents, to the extent necessary to Develop, Manufacture and Commercialize Licensed Antibodies and Licensed Products in the Field in the Territory; and </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">an exclusive (including with regard to Innate and its Affiliates, except with respect to the retained rights set forth
in Section&nbsp;3.5 below), right and license and right of reference in the Territory under Innate&#146;s and its Affiliates&#146; rights, titles and interests in and to the Regulatory Documentation, INDs and Regulatory Approvals, to all other
clinical and preclinical data and results contained in the Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> to Develop, Manufacture and Commercialize the Licensed Antibodies and Licensed Products in the Field in the Territory.
</P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">MedImmune shall be responsible for its Affiliates compliance with the terms of this Agreement as if MedImmune
hereunder. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Sublicenses</B>. Subject to Section&nbsp;3.4, MedImmune and its Affiliates shall have
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
the right to grant sublicenses, through multiple tiers of sublicenses, under the licenses granted under Section&nbsp;3.1, to any other Person other than a Person Exploiting a Competing Product,
provided that, in the event of a sublicense to anyone other than a MedImmune Affiliate, MedImmune shall provide Innate with at least [***] prior written notice and any such sublicense shall be consistent with the provisions of this Agreement. Where
MedImmune or its Affiliates grants such sublicense to a Person that is not an Affiliate of MedImmune, and such Person is not a Distributor, such Person shall be a &#147;<B>Sublicensee</B>&#148; for the purposes of this Agreement, and any Person to
which a Sublicensee grants a further sublicense shall also be a Sublicensee; <U>provided</U>, <U>however</U>, that any Person that (i)&nbsp;is granted a sublicense under the license granted to MedImmune and its Affiliates pursuant to
Section&nbsp;3.1 solely to enable such Person to provide contract research or development services or contract manufacturing services for MedImmune, its Affiliates or Sublicensees, and (ii)&nbsp;does not have the right to distribute, market or sell
the Licensed Products, shall not be a &#147;<B>Sublicensee</B>&#148; for purposes of this Agreement. MedImmune, its Affiliates and its Sublicensees shall ensure that all Persons to which they grant sublicenses comply with all relevant terms and
conditions of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Distributorships. </B>Subject to Innate&#146;s rights under the <FONT STYLE="white-space:nowrap">Co-Promote</FONT>
Option<B>, </B>MedImmune and its Sublicensees shall have the right, in their sole discretion, to appoint any other Persons, in the Territory or in any country of the Territory, to distribute, market and sell the Licensed Products, with or without
packaging rights. In circumstances where such appointed Person purchases its requirements of Licensed Products from MedImmune, its Affiliates or its Sublicensees, but does not otherwise make any royalty or other payment to MedImmune, its Affiliates
or its Sublicensees with respect to Intellectual Property Rights, and where such Person is not an Affiliate of MedImmune and neither MedImmune nor any of its Affiliates or Sublicensees shares in the profits from, or has an equivalent interest in the
proceeds from, the sale of Licensed Products by such Person, that Person shall be a &#147;<B>Distributor</B>&#148; for purposes of this Agreement. The term &#147;packaging rights&#148; in this Section&nbsp;3.3 means the right for the Distributor to
package Licensed Products supplied in unpackaged bulk form into individual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-for-sale</FONT></FONT> packs. MedImmune shall remain liable for any action or failure to act by the
Distributor that would constitute a breach of this Agreement as if such action or failure were committed by MedImmune. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B><FONT STYLE="white-space:nowrap">Co-Promotion</FONT> Rights</B>. MedImmune and its Affiliates shall have the right,
in their sole discretion, to <FONT STYLE="white-space:nowrap">co-promote</FONT> the Licensed Products with any other Person(s), or to appoint one or more Third Parties to promote the Licensed Products without MedImmune in all or any part of the
Territory outside of [***] for which Section&nbsp;8 shall apply. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Rights Retained by Innate</B>. Notwithstanding the foregoing, Innate retains the right under the Licensed
Technology to (i)&nbsp;conduct the Development activities that may be assigned to be performed by Innate under the Development Plan; (ii)&nbsp;Manufacture or have Manufactured the Licensed Product in satisfaction of its obligations under
Section&nbsp;9; (iii) following the exercise of the <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option, promote the <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Product in [***] subject to Section&nbsp;8; (iv) conduct any other
activities expressly assigned to Innate by the DCC under this Agreement or as the Parties may otherwise mutually agree (collectively, the activities referred to in (i)&nbsp;to (iv) are the &#147;<B>Assigned Activities</B>&#148;); and (v)&nbsp;to
Exploit the Licensed Technology to Research, Develop and Commercialize Licensed Products outside the Field, subject to the provisions of Section&nbsp;3.17. Furthermore, Innate retains all rights under the Licensed Shared Patents with respect to all
activities not related to Research, Development, Commercialisation or Exploitation of Licensed Products or any Competing Product, and/or all activities related to antibodies that bind KIR2DL1, <FONT STYLE="white-space:nowrap">-2</FONT> and/or <FONT
STYLE="white-space:nowrap">-3.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Covenant not to Sue</B>. MedImmune shall not, and shall procure that its Affiliates and Sublicensees shall not,
anywhere in the world, institute or prosecute (or in any way aid any Third Party in instituting or prosecuting), at law or in equity, any claim, demand, action or cause of action for damages, costs, expenses or compensation, or for an enjoinment,
injunction, or any other equitable remedy, against Innate alleging the infringement of any MedImmune Technology by Innate due to Innate&#146;s performance of the Assigned Activities or its rights in compliance with this Agreement. For the avoidance
of doubt, the covenant not to sue set forth in this Section&nbsp;3.6 shall not apply in respect of any activities conducted by or on behalf of Innate or its Affiliates in conflict with this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>No Implied Rights.</B> This Agreement confers no right, license, or interest by
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
implication, estoppel, or otherwise under any Patents, <FONT STYLE="white-space:nowrap">Know-How,</FONT> or other Intellectual Property Rights of either Party except as expressly set forth in
this Agreement. Each Party hereby expressly retains and reserves all rights and interests with respect to Patents, <FONT STYLE="white-space:nowrap">Know-How,</FONT> or other Intellectual Property Rights not expressly granted to the other Party
hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>No Encumbrance</B>. During the Term, Innate shall not assign, transfer, convey or otherwise encumber its rights to
the Licensed Technology, or Regulatory Approvals, and shall not use any of the foregoing itself or grant any right, title or interest therein with respect to the Licensed Product in the Field to any Person, in all cases in a manner that is
inconsistent with the exclusive licenses or other rights granted to MedImmune under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Exclusivity Term</B>. MedImmune&#146;s exclusive licenses granted under Section&nbsp;3.1, shall expire [***]. Upon
expiry of MedImmune&#146;s exclusive licenses [***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Assignment of Regulatory Documentation</B>. MedImmune or its nominated Affiliate shall be the lead regulatory party
and hold all Regulatory Documentation and Regulatory Approvals relating to Licensed Products. Innate hereby assigns to MedImmune all of its rights, titles and interests in and to all Regulatory Documentation, including, to the extent permitted by
Applicable Laws, all INDs and Regulatory Approvals Controlled by Innate or its Affiliates as of the Effective Date and from time to time during the Term that relate to the Licensed Antibodies or Licensed Products. Innate shall duly execute and
deliver, or cause to be duly executed and delivered such instruments and shall do and cause to be done such acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary to complete such
assignment, or as MedImmune may reasonably request in connection therewith, or to carry out more effectively the purpose thereof, or to better assure and confirm to MedImmune its rights under this Section&nbsp;3.10, at MedImmune&#146;s cost and
expense. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Confirmatory Patent Licenses</B>. Innate shall, if requested to do so by MedImmune, immediately enter into short
form confirmatory license agreement(s) in the form or substantially the form set out in <U>Schedule 3.11</U> for purposes of (i)&nbsp;recording the licenses granted under this Agreement with such
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Patent authorities in the Territory as MedImmune considers appropriate or (ii)&nbsp;otherwise being able to demonstrate the existence of the licenses granted to MedImmune under this Agreement to
relevant authorities, including courts and other bodies, where required without having to disclose this Agreement in its entirety. Until the execution of any such confirmatory licenses, so far as may be legally possible, Innate and MedImmune shall
have the same rights in respect of the licenses granted under this Agreement and be under the same obligations to each other in all respects as if such confirmatory licenses had been executed. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:2%; text-indent:3%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U><FONT STYLE="white-space:nowrap">Non-</FONT></U><U>compete and Restrictive Covenants</U> </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The words &#147;Develop&#148; and &#147;Commercialize&#148; and all variations thereof included in the below Sections
3.13 to 3.16 with reference to Competing Products shall include the activities described in the definitions of such words in Section&nbsp;1, but with such activities being with respect to Competing Products rather than with respect to Licensed
Product as set forth in the definition. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">During the period starting on the Effective Date and continuing until the earlier to occur of (i) [***] and (ii)
[***](such period, &#147;<B>Covenant Period 1</B>&#148;), neither Party nor any of its Affiliates (each, a &#147;Restricted Party&#148;) shall, either by itself or through a Third Party, except as otherwise expressly permitted in this Agreement,
conduct any research or Development in respect of any Competing Product. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">During the period starting on the Effective Date and continuing until [***] (such period, &#147;<B>Covenant Period
2</B>&#148;), no Restricted Party shall, either by itself or through a Third Party, except as otherwise expressly permitted in this Agreement, Commercialize any Competing Product in the Territory; <U>provided</U> <U>that</U> if this Agreement is
terminated as a result of such Restricted Party&#146;s Triggered Termination, then for the purpose of this Section&nbsp;3.14, Covenant Period 2 shall expire on the first to occur of (i) [***] and (ii) [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding the foregoing, a Restricted Party&#146;s&#146; direct or indirect acquisition by/of, or merger with,
in whole or in part, a Person (or group of companies) or the business of a Person (or group of companies) having any activity contravening the covenants set forth above in Sections 3.13 and 3.14,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
shall not constitute a breach of such covenants, if: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">within [***] following the closing of such acquisition or merger transaction, the Restricted Party shall provide the
other Party with written notice of such transaction and the nature and stage of development of the Competing Product. The Parties will discuss in good faith whether it will be mutually beneficial that the Competing Product be included in their
collaboration and the related terms. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If the Restricted Party is Medimmune, if the Competing Product has [***], and the Parties cannot reach an agreement
pursuant to <FONT STYLE="white-space:nowrap">sub-Section</FONT> (a)&nbsp;within [***] of the closing of the acquisition or merger transaction, then Medimmune shall notify Innate of its intention to either to either (i)&nbsp;divest of the relevant
part of the Competing Product business or (b)&nbsp;terminate this Agreement. In such event, if MedImmune has elected to divest the Competing Product business, MedImmune (or, as the case may be, MedImmune shall cause its relevant Affiliate to)
diligently pursues the sale or transfer to a Third Party of such business, and enter into (or, as the case may be, cause its relevant Affiliate to enter into) a binding definitive agreement with a Third Party for such sale or transfer no later than
[***] after the closing of the acquisition or merger transaction under which the relevant business was acquired. If the Competing Product has [***], then, the provisions of this subclause (b)&nbsp;shall apply, <I>mutatis mutandis</I>, from the day
on which Medimmune or its Affiliates decides to [***] with respect to such Competing Product and the reference date for computing the [***] and the [***] timelines shall be the date of such decision. Until consummation of the sale of transfer of the
business relating to a Competing Product, for purposes of determining MedImmune&#146;s diligence obligations under Sections 4.12 - 4.17, MedImmune&#146;s Commercially Reasonable Efforts shall not take into account the existence of another MedImmune
development program for a Competing Product, the Licensed Product&#146;s competitive position with respect to such Competing Product, the relative profitability of the Competing Product or any other factors relating to such Competing Product.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">If the Restricted Party is Innate, the DCC and other committees should be dismantled and, if MedImmune so requests,
Innate shall cease to have an active role in the Development and <FONT STYLE="white-space:nowrap">Co-Promotion</FONT> of the Licensed Product, provided that Innate shall retain its right to <FONT STYLE="white-space:nowrap">co-fund</FONT> the
Development of the Licensed Product and, if Innate does not provide its <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice, to share the Profit in accordance with Section&nbsp;10.21. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Restricted Party shall take appropriate steps and actions necessary (including by following commercially
reasonable policies and procedures that are no less stringent than those customarily followed in the pharmaceutical industry when establishing firewalls) to ensure that, as applicable, there is no, direct or indirect, as applicable, disclosure,
sharing or other use of any information obtained or discussed in connection with the Licensed Product and the Competing Product program. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties agree that the restrictions contained in these Sections 3.13 to 3.15 are reasonable and necessary for the
protection of the other Party&#146;s and its&#146; Affiliates&#146; respective Confidential Information and business and investment in the Licensed Products, that such restrictions are reasonable in all the circumstances and that the Parties would
not have entered into this Agreement without the protections afforded to them under these Sections 3.13 to 3.15. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate grants to MedImmune a first right to negotiate terms pursuant to which MedImmune&#146;s rights under this
Agreement could be expanded to include all fields of use in humans and animals outside the Field. MedImmune shall be entitled to exercise this right of first negotiation at any time during the term of this Agreement by written notice to Innate
(&#147;<B>ROFN Notice</B>&#148;). If MedImmune serves an ROFN Notice the Parties will negotiate in good faith for a period of [***] following the date of the ROFN Notice the terms of such and expanded agreement. Innate shall not, and shall ensure
that its Affiliates shall not, sell, transfer, assign, <FONT STYLE="white-space:nowrap">out-license,</FONT> encumber or otherwise grant or offer any rights to (in whole or in part) the Licensed Technology in any field outside the Field without first
offering to MedImmune the right to negotiate terms in accordance with this Section&nbsp;3.17. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>DEVELOPMENT</B><B> </B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The purpose of the collaboration undertaken by the Parties under this Agreement (&#147;<B>Collaboration</B>&#148;) is
for the Parties to collaborate in the development of Licensed Products in the Field in the Territory and for the Parties to share in certain costs and revenues related to the Licensed Products, as described in more detail herein. The Parties desire
to establish the following committees to oversee the Collaboration and to provide a forum for discussion of matters relating to the Collaboration: Joint Project Team, Development Collaboration Committee and Sales Collaboration Committee.
</P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><U>Initial Studies under the Development and Option Agreement </U></P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding Section&nbsp;4.1, if MedImmune exercises the Option before the final Initial Study has been completed
(i.e., before the final study report for such Clinical Trial is completed and approved in accordance with Innate&#146;s quality assurance procedures), Innate shall use Commercially Reasonable Efforts, at its cost in accordance with the Development
Plan (as such terms are defined in the Option Agreement), regardless of its receipt of an Option Notice within the Option Period, continue or commence, as applicable, all of the Initial Studies or any part of them, in accordance with the provisions
of Section&nbsp;3 of the Development and Option Agreement as if the Option had not been exercised, provided that MedImmune may, subject to Applicable Law, elect to assume the responsibilities and obligations of Innate in relation to the Initial
Studies in which case the provisions of Section&nbsp;4.4 will apply. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In the event that MedImmune exercises the Option as a result an S/R Notice, except to the extent, and for as long as,
otherwise required under Applicable Laws or otherwise to protect the safety, health or well-being of any patient, upon its receipt of an Option Notice within the Option Period in accordance with the Development and Option Agreement, Innate shall
discontinue any then remaining Initial Studies and any part of them at MedImmune&#146;s request. MedImmune may elect to assume the responsibilities and obligations of Innate in relation to the Initial Studies, and any such Initial Studies shall be
conducted at Innate&#146;s cost in accordance with the Development Plan (as such term is defined in the Option Agreement). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In the event that, following exercise of its Option before the final Initial Study has been completed, MedImmune makes
an election to take control of the Initial Studies, (i)&nbsp;the Parties will agree in good faith a detailed plan for transitioning such responsibilities and obligations from Innate to MedImmune, including estimated timelines for such activities,
and shall use Commercially Reasonable Efforts in carrying out such transition plan, (ii)&nbsp;MedImmune will keep Innate regularly informed about the progress and results of the Initial Studies through the DCC, (iii)&nbsp;both Parties shall take
such actions as may be reasonably required or useful to ensure a smooth and orderly transition of the Initial Studies to MedImmune, and (iv)&nbsp;the Parties shall cooperate in good faith to prepare as promptly as possible after the Effective Date
all filings and other actions required by Applicable Laws to be made and taken in order to commence and conduct the Development of Option Products. All such filings and actions shall be approved in advance by MedImmune and be made and taken by or on
behalf of MedImmune. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Development Plan and Development Budget </U> </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Development of the Licensed Products shall be governed by a global Development Plan, which includes development
plans approved by the DCC as set forth in this Section&nbsp;4, and costs and expenses relating to the Development of Licensed Products shall be governed by a development budget approved by the DCC and set forth in the Development Plan
(&#147;<B>Development Budget</B>&#148;). The Development Budget shall be broken down by Clinical Trials or other activities and by Calendar Quarter. Within [***] after the Effective Date, the parties, acting through the DCC, shall review and approve
a Development Plan and Development Budget. The Development Plan will include, among other things, (i)&nbsp;the initial indication(s) for which the Licensed Product is planned to be Developed, (ii)&nbsp;other indications for which the Licensed
Product may be developed, (iii)&nbsp;the proposed overall program of Development for the Licensed Product for any indications elected by MedImmune in each applicable Major Market, and any other applicable countries, including without limitation all
material nonclinical studies, toxicology, pharmacology studies, formulation, process development, CMC, clinical studies, and regulatory plans and other main elements of obtaining Regulatory Approval in each applicable Major Market, and any other
applicable country, (iv)&nbsp;critical activities anticipated to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
be undertaken, estimated timelines, decision points and relevant decision criteria, and (v)&nbsp;allocation of responsibilities between the Parties for the various activities to be undertaken
under the Development Plan and estimated timelines; all based on what can reasonably be foreseen and planned at the time of preparation of the Development Plan. MedImmune shall review and submit an updated Development Plan and Development Budget to
the DCC for approval at least annually during the Development Term. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Development Plan and Development Budget shall also include the (i)&nbsp;allocation of Development and regulatory
activities between the Parties on a country-specific or activity-specific basis, taking into consideration all relevant factors (including the strategic objectives and capabilities of each Party) and (ii)&nbsp;those activities in relation to which
operational responsibility should be held by either MedImmune or Innate. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties may, at any time, produce and submit to the DCC for comment a revised Development Plan and Development
Budget in accordance with this Section&nbsp;4. While the DCC is in effect, the DCC shall approve the Development Plan and Development Budget, and any revised Development Plan and Development Budget. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Development Lead</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall take the lead in Developing the Licensed Products, with Innate performing such activities as may be
allocated to it under the Development Plan. Each Party shall have primary responsibility for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and decisions relating to such Party&#146;s allocated
responsibilities, provided that such activities and decisions are consistent with the Development Plan and the authority granted to such Party thereunder. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Performance of Development Plan and Reporting</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">During the Development Term, each Party will report on the Development activities, if any, undertaken by it in
accordance with the Development Plan at each meeting of the DCC or at such other intervals as may be set forth in the Development Plan. Whether provided during the period the DCC is in effect, or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
thereafter, the Development reports shall include a reasonably detailed summary of all results, data and material inventions and <FONT STYLE="white-space:nowrap">Know-How,</FONT> if any, obtained
from such Development activities. In addition, each Party will, at its own expense, make appropriate scientific and regulatory personnel available to the other Party, either by telephone or in person as the Parties may mutually agree, as reasonably
required to keep the other Party informed of Development activities conducted by such Party. Innate shall provide MedImmune with (i)&nbsp;access, upon MedImmune&#146;s request, to all raw data and individual datasets obtained in relation to the
Assigned Activities from such time when such data becomes available to Innate; (ii)&nbsp;the Study Results &#150; as outlined in the relevant Statistical Analysis Plan within [***] after database lock of the respective study; and (iii)&nbsp;the
relevant final report within [***] after database lock of the respective study. For the purpose of this Agreement &#147;Statistical Analysis Plan&#148; means a document that is prepared for the purpose of a Clinical Trial, that is approved by the
DCC and that <FONT STYLE="white-space:nowrap">pre-specifies</FONT> the statistical analyses to be performed (statistical methods, endpoint definitions, analysis sets and principles for the handling of missing data) and how the results from the
relevant Clinical Trial will be presented. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party shall provide all Clinical Trial results to the DCC in draft form as soon as reasonably practicable and
shall provide each final report to the DCC, within [***] after finalization of the Clinical Trial report. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party will have the right to use its Affiliates or Third Parties to perform Development activities allocated to
it under the Development Plan, provided that any Affiliate or Third Party retained by Innate for such purpose that is not listed in <U>Schedule 4.11(a)</U> (as such Schedule may be amended by the DCC from time to time after the Effective Date) shall
first have been approved by MedImmune, such approval not to be unreasonably withheld, and further provided that Innate will use Commercially Reasonable Efforts to obtain agreement by the Third Parties listed on Schedule 4.11(a) to comply with the
MedImmune Code of Conduct (as set forth in the website set forth in <U>Schedule 4.11(b)</U>) within [***] after the Effective Date, and Innate shall confer with the DCC if it is unable to obtain such agreement by any such Third Party.
</P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Diligence </U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall use Commercially Reasonable Efforts to (i)&nbsp;continue Development of each Licensed Product in
respect of which clinical Development has been initiated and (ii)&nbsp;Develop and obtain Regulatory Approval for each such Licensed Product at least in each country of the Major Markets and [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The responsible Party (as set forth in each Development Plan) shall use Commercially Reasonable Efforts to Manufacture
or have Manufactured Licensed Antibody and Licensed Product for use in the Development and Commercialization thereof in accordance with Section&nbsp;9. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Upon approval of a Drug Approval Application in each of [***], (i) if pricing and reimbursement approval is not
necessary in any country in such jurisdiction, MedImmune shall use Commercially Reasonable Efforts to achieve First Commercial Sale of such Licensed Product in such country(ies) within [***] after approval of the Drug Approval Application, or
(ii)&nbsp;if pricing and reimbursement approval is necessary in such jurisdiction, MedImmune shall use Commercially Reasonable Efforts to obtain such pricing and reimbursement approval in such country(ies) as soon as possible, and shall use
Commercially Reasonable Efforts to achieve First Commercial Sale in such country(ies) within [***] after receipt of pricing and reimbursement approval. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall use Commercially Reasonable Efforts to Commercialize Licensed Products in at least each country of the
Major Market [***]. Subject to its exercise of the <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option, Innate shall use Commercially Reasonable Efforts to <FONT STYLE="white-space:nowrap">Co-Promote</FONT> the
<FONT STYLE="white-space:nowrap">Co-Promote</FONT> Licensed Product in [***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall perform, or cause its Affiliates or Third Party contractors to perform, its responsibilities under
this Agreement, and Innate shall perform, or cause its Affiliates or Third Party contractors to perform, the Assigned Activities, in each case, in compliance with this Agreement and all Applicable Laws. For the avoidance of doubt, MedImmune shall
not be obligated to obtain Regulatory Approvals for, or Commercialize, a Licensed Product which has not been the subject of a Development Plan. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party shall use Commercially Reasonable Efforts to complete its Development activities in accordance with the
Development Plan. With respect </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
to each Clinical Trial, each Party shall (i)&nbsp;cause the relevant Principal Investigators, relevant study sites and any contractors involved in the performance of such study to conduct the
respective study in accordance with this Agreement, including the provisions set out in this Section&nbsp;4.17, and (ii)&nbsp;shall, and shall cause the relevant Principal Investigators, relevant Clinical Trial study sites and any contractors
involved in the performance of the Clinical Trial to, comply with all safety reporting procedures set forth in the Safety Agreement in connection with its performance of such studies. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">A Party shall not be liable for any failure to comply with its obligations under this Agreement to the extent caused
by a breach by the other Party of its obligations hereunder and provided that the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party shall use Commercially Reasonable Efforts to mitigate such situation. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U><FONT STYLE="white-space:nowrap">Back-Up</FONT> Licensed Antibodies</U> </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Either Party may propose that the Development Plan should include the Development of a
<FONT STYLE="white-space:nowrap">Back-Up</FONT> Licensed Antibody. The Parties will discuss any such proposal in good faith and in particular whether Innate should bear [***] of the Development Costs associated with Developing such a <FONT
STYLE="white-space:nowrap">Back-Up</FONT> Licensed Antibody and the revised financial terms applicable to any Licensed Product containing such a <FONT STYLE="white-space:nowrap">Back-Up</FONT> Licensed Antibody to replace those set out in
Section&nbsp;10. If Innate does not want to <FONT STYLE="white-space:nowrap">co-fund</FONT> the Development Costs of such a <FONT STYLE="white-space:nowrap">Back-Up</FONT> Licensed Antibody, MedImmune shall be entitled to Develop such <FONT
STYLE="white-space:nowrap">Back-Up</FONT> Licensed Antibody on its own and shall bear all associated Development Costs. The Parties will negotiate in good faith for a period of [***] the financial terms applicable to any Licensed Product containing
such a <FONT STYLE="white-space:nowrap">Back-Up</FONT> Licensed Antibody to replace those set out in Section&nbsp;10. A failure by the Parties to reach agreement on such terms shall not preclude MedImmune from developing or commercializing a <FONT
STYLE="white-space:nowrap">Back-Up</FONT> Licensed Antibody or from otherwise exercising the rights and licenses granted to it by Innate under this Agreement. However, in the event of a failure by the Parties to reach such agreement within the
aforementioned [***] period or any extension of such period mutually agreed by the Parties or otherwise in the event of a dispute as to the financial terms for such a <FONT STYLE="white-space:nowrap">Back-Up</FONT> Licensed Antibody, each Party
shall be entitled to escalate the matter in accordance with Section&nbsp;17.2 and, if applicable, to refer the matter </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
to arbitration in accordance with Section&nbsp;17.3. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Transition</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Following the Effective Date, the Parties will promptly meet to coordinate the transition of Development and
regulatory activities from Innate, its Affiliates or Third Parties to MedImmune, its Affiliates or its designated Third Parties in a manner so as not to unduly delay or hamper the Development of Licensed Products. The Parties will agree a detailed
transition plan which plan will set out in detail the activities to be undertaken, the Party responsible for the activity and an estimated timeframe for the completion of the activity. Unless otherwise agreed, the Parties will each bear their own
costs associated with carrying out the activities in the transition plan. Without prejudice to the foregoing, each Party shall at its cost do all things required in order to achieve a smooth transfer of the Development of the Licensed Products to
MedImmune as a quickly as possible following the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties shall cooperate in good faith to prepare as promptly as possible after the Effective Date all filings and
other actions required by Applicable Laws to be made and taken in order to commence and conduct the Development. All such filings and actions shall be approved in advance by MedImmune and be made and taken by or on behalf of MedImmune.
</P></TD></TR></TABLE> <P STYLE="margin-top:48pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Manufacturing</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall use Commercially Reasonable Efforts to maintain in full force and effect all agreements with contract
manufacturing organisations and Third Parties undertaking Clinical Trials and studies on its behalf, in both cases in relation to the Licensed Antibodies, in place as at the Effective Date and shall not act or fail to act in manner which it knows or
should reasonably anticipate may lead to termination or material breach of such agreements. If requested by MedImmune and consistent with the Development Plan, Innate will use Commercially Reasonable Efforts to permit MedImmune to purchase Licensed
Antibody pursuant to such agreements. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Supply of Materials for Development</U> </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In the event that it becomes reasonably necessary for one Party to provide the other Party with tangible research or
biological Materials (other than a Licensed Product for clinical or commercial use) in connection with the performance of activities hereunder, the Parties may enter into an appropriate material transfer agreement related thereto, which agreement
will be subject to this Agreement and will be interpreted in a manner consistent with the terms hereof. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Adverse Event Reporting and Product Recall</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune will hold the safety database for the Licensed Antibodies and the Licensed Products and Innate will provide
safety information as required by Applicable Laws, in a timely manner. Within [***] of the Effective Date and in any event prior to the initiation of the Development, the Parties will enter into a detailed safety agreement (the &#147;<B>Safety
Agreement</B>&#148;), governing, among other things, appropriate adverse event reporting procedures relating to Licensed Products and reflecting the provisions set forth above in this Section 4.24. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In the event that any Regulatory Health Authority issues or requests a recall or takes similar action in connection
with the Licensed Antibodies or the Licensed Products, or in the event either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall or market withdrawal, the Party notified of or desiring such
recall or market withdrawal shall promptly advise the other Party thereof. Following notification of a recall, MedImmune shall have the right to decide whether to conduct a recall or market withdrawal (except in the case of a recall required by
Regulatory Health Authority) in the Territory and shall have control of the manner in which any such recall or market withdrawal shall be conducted. MedImmune shall bear the expenses of any recall of a Licensed Product. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>JOINT PROJECT TEAM AND DEVELOPMENT COLLABORATION COMMITTEE</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Joint Project Team </U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Provided that Innate has not issued a <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice within the
Opt Out Period, MedImmune and Innate shall establish and maintain a Joint Project Team (the &#147;<B>JPT</B>&#148;) and appoint Alliance Managers pursuant to Section&nbsp;5.4. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The JPT shall remain in effect as from the Effective Date and for as long as Innate is actively performing any
Development activities assigned to Innate under the Development Plan or any <FONT STYLE="white-space:nowrap">Co-Promotion</FONT> in accordance with Section&nbsp;3.4. The JPT shall serve as a joint working group for the purpose of implementing the
Development Plan, coordinating the practical aspects of the Parties&#146; collaboration and <FONT STYLE="white-space:nowrap">Co-Promotion</FONT> under this Agreement, handling
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> issues in relation thereto, facilitating communication between the Parties in respect thereof and otherwise performing such specific tasks as may be assigned
to it by the DCC. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The JPT shall consist of two project leaders, one appointed by MedImmune and the other by Innate, and such additional
members as each Party may appoint from time to time as necessary or useful for the performance of the JPT&#146;s responsibilities hereunder. Each Party shall have the right to withdraw or replace its JPT representatives upon written notice to the
other Party, provided that any such substitute representative shall have substantially the equivalent position and experience as the representative that such person replaces. MedImmune and Innate shall each bear all expenses of its JPT members
related to such members&#146; participation on the JPT. Each Party&#146;s representatives on the JPT as of the Effective Date are set forth in <U>Schedule 5.3</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Alliance Managers. Within [***] following the Effective Date, each Party shall appoint a representative
(&#147;Alliance Manager&#148;) to facilitate communications between the Parties (and to act as a liaison between the Parties with respect to such other matters as the Parties may mutually agree in order to maximize the efficiency of the
collaboration). Each Party may replace its Alliance Manager with an alternative representative at any time with prior written notice to the other Party. Each Party&#146;s Alliance Managers shall be entitled to attend all Committee meetings. Each
Alliance Manager may bring any matter to the attention of the Committees where such Alliance Manager reasonably believes that such matter requires attention of the Committees. Each Alliance Manager
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
shall be responsible with creating and maintaining a collaborative work environment within and among the Committees. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Development Collaboration Committee </U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate and MedImmune shall establish a development collaboration committee in accordance with this Section&nbsp;5 (the
&#147;<B>DCC</B>&#148;). The DCC shall remain in effect as from the Effective Date through the end of the Development Term. If the DCC is disbanded pursuant to the preceding sentence and the Parties thereafter decide to commence or <FONT
STYLE="white-space:nowrap">re-commence</FONT> any Development activities, the DCC shall be <FONT STYLE="white-space:nowrap">re-established</FONT> and remain in effect until for the duration of performance of such Development activities.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The DCC shall serve as a forum for discussing and sharing Information and materials; discussing strategy regarding the
Development of the Licensed Products; and discussing the allocation of Development activities to be conducted by Innate and MedImmune. The DCC&#146;s responsibilities are more fully set forth in Section&nbsp;5.7 below. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party shall appoint three (3)&nbsp;representatives as its voting members of the Development Collaboration
Committee. Each Party&#146;s representatives on the DCC as of the Effective Date are set forth in <U>Schedule 5.7</U>. The DCC shall be chaired by a representative of MedImmune. The chairperson shall be responsible for calling meetings, setting the
agenda, circulating the agenda at least [***] prior to each meeting and distributing minutes of the meetings within [***] following such meetings (provided that the chairperson may elect to delegate the performance of its responsibilities to other
members of the DCC from time to time), but will not otherwise have any greater power or authority than any other member of the DCC. The chairperson shall coordinate with each Party to schedule each DCC meeting in good time in advance of such
meeting. Each Party shall disclose to the chairperson any proposed agenda items, along with appropriate information and materials as early as reasonably practicable in advance of such meeting, but no less than three (3)&nbsp;Business Days. The
chairperson shall not unreasonably reject any proposed call for a DCC meeting or proposed agenda items made by either Party. At least one (1)&nbsp;member of the DCC selected by Innate and one (1)&nbsp;member of the DCC selected by MedImmune
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
shall have substantial experience in pharmaceutical product research and development, and all of the members of the DCC shall have such expertise as appropriate to the activities of the DCC. Each
Party may replace its members of the DCC upon written notice to the other Party, provided that any such substitute member shall have substantially the equivalent functional expertise, experience and seniority as the member that such person replaces
provided that the Parties shall use Commercially Reasonable Efforts to keep replacements to a minimum. From time to time, the DCC may invite <FONT STYLE="white-space:nowrap">non-voting</FONT> personnel of either Party to participate in discussions
of the DCC. An alternate voting member designated by a Party may serve temporarily in the absence of a permanent voting member appointed by such Party, and either Party may also designate one or more
<FONT STYLE="white-space:nowrap">non-voting</FONT> consultants to such Party who are under written obligations of confidentiality to such Party as DCC observers who may attend the DCC meetings in an observational or advisory capacity only.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The DCC shall hold meetings at such times and places as shall be determined by a majority of the entire membership of
the committee, but in no event shall such meetings be held less frequently than once every three (3)&nbsp;months. Meetings of the DCC will alternate between the offices of the Parties, unless otherwise agreed upon by the members of the DCC, or may
be held via internet, telephonically or by videoconference; provided that at least two (2)&nbsp;meetings per year shall be held in person. Meetings of the DCC will be effective only if at least two DCC members of each Party are in attendance or
participating in the meeting. Each Party will be responsible for the expenses incurred in connection with its employees, consultants and its members of the DCC attending or otherwise participating in DCC meetings. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Responsibilities of the DCC</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The DCC&#146;s responsibilities will include, among others, (i)&nbsp;reviewing and approving the Development Plan and
Development Budget, and any amendments thereto, (ii)&nbsp;reviewing and approving protocols for nonclinical studies and Clinical Trials and any amendments or modifications to such protocols or studies, (iii)&nbsp;performing quarterly reviews of the
progress of Development and considering any proposed additional studies, (iv)&nbsp;facilitating the exchange of information and materials, (iv)&nbsp;facilitating the timely transfer
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
of Manufacturing responsibility to MedImmune in accordance with Section&nbsp;9, (v) reviewing and advising on a proposal by either Party to stop a Clinical Trial of a Licensed Product,
(vi)&nbsp;reviewing and commenting on allocation of responsibility for Development activities between the Parties, (vii)&nbsp;discussing each Party&#146;s progress under the Development Plan, including reviewing progress toward timelines and budget,
Study Results and the status of achieving Regulatory Approval; (viii)&nbsp;providing strategic direction and consultation with respect to Development of Licensed Products; (ix)&nbsp;coordinating communication between the Parties; (x)&nbsp;resolving
disputes between the Parties relating to the Development Plan, and (xi)&nbsp;performing such other functions as designated to the DCC under this Agreement or mutually agreed between the Parties. Notwithstanding anything to the contrary set forth in
this Agreement, the DCC will have no authority to (a)&nbsp;amend, modify or waive compliance with this Agreement or otherwise impose any obligation on the Parties in deviation from this Agreement, or (b)&nbsp;resolve any dispute concerning the
validity, compliance with, or breach of, this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The DCC shall make decisions on all matters within the scope it its authority only by unanimous consent, with the
MedImmune voting members cumulatively having one (1)&nbsp;vote and the Innate voting members cumulatively having one (1)&nbsp;vote, irrespective of the number of members actually in attendance at a meeting. In the event that unanimity cannot be
reached by the DCC on a matter before it for decision within [***] after the matter was first considered by it then the matter may be referred by either Party to the Senior Executives, who shall meet (in person, via internet, telephonically or by
videoconference) and attempt to resolve the matter within [***] of such referral. In the event that the Senior Executives are unable to reach consensus within such [***] period, [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>GENERAL PROVISIONS ON DEVELOPMENT AND COMMERCIALIZATION</B><B> AND REGULATORY MATTERS</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Information Disclosure; Assistance; Record Keeping</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate acknowledges that it has, prior to the Effective Date, made available to MedImmune all material Regulatory
Documentation Controlled by Innate or its </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Affiliates and tangible and electronic embodiments of all material Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> existing as of the Effective Date. After the Effective Date, and
promptly following MedImmune&#146;s request to do so, Innate shall transfer to MedImmune copies of all of the Essential Documents (as defined in Chapter 8 of <FONT STYLE="white-space:nowrap">ICH-GCP)</FONT> that are Controlled by Innate relating to
IPH2201 (the &#147;<B>Essential Documents</B>&#148;). Innate will have the right to retain original copies of the foregoing but shall make such original copies available to MedImmune at Innate&#146;s site of business for inspection upon reasonable
advance written notice by MedImmune. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">After the Effective Date, to the extent not done so already, Innate shall, and shall cause its Affiliates to, without
additional compensation, disclose and make available to MedImmune, in whatever form MedImmune may reasonably request, as soon as reasonably practicable after the earlier of the development, making, conception or reduction to practice of each of the
following: copies or tangible embodiments of all Regulatory Documentation Controlled by Innate. Subject to Section&nbsp;6.5 Innate will have the right to retain original copies of the foregoing, and shall make such original copies available to
MedImmune at Innate&#146;s site of business for inspection upon reasonable advance written notice by MedImmune. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Without prejudice to its other obligations under this Agreement, including activities explicitly assigned by the DCC
to be performed by Innate in connection with the Development hereunder, Innate shall, at its cost and expense, provide MedImmune with all reasonable assistance required in order to transfer the Licensed
<FONT STYLE="white-space:nowrap">Know-How</FONT> to MedImmune in a timely manner or, at the cost and expense of Innate, assist MedImmune with respect to the practice of the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> in connection with
Development, Manufacture or Commercialization of the Licensed Products. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">From and after the Effective Date, each Party shall maintain, or cause to be maintained, records of its Development
activities under this Agreement, including the Essential Documents and including records in the form of laboratory notebooks, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes including GLP and GCP,
which shall be complete and accurate and shall fully and properly reflect all work </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
done and results achieved in the performance of its activities hereunder, which shall record only such activities and shall not include or be commingled with records of activities outside the
scope of this Agreement, and which shall be retained by such Party for at least five (5)&nbsp;years after the termination of this Agreement, or for such longer period as may be required by Applicable Laws. Each Party shall have the right, during
normal business hours and upon reasonable prior notice, to inspect any such records of the other Party. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Regulatory Matters</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Following the transfer of the Regulatory Documentation, including INDs to MedImmune pursuant to Section&nbsp;3.9,
subject to the terms set forth below, MedImmune shall be solely responsible for all regulatory filings and communications with each Regulatory Health Authority with respect to that Regulatory Documentation including any INDs relating to the Licensed
Product, and MedImmune shall be solely responsible for any and all subsequent filings and communications with the Regulatory Health Authority including, without limitation, for the preparation and filing of all additional INDs relating to the
Licensed Product and for providing, in the format required by Regulatory Health Authorities, the data and information required to be submitted to such Regulatory Health Authorities for Regulatory Approval of Licensed Products, including without
limitation data from all Clinical Trials and all Manufacturing and controls information required for Regulatory Approval of such Licensed Product by the Regulatory Health Authorities. Notwithstanding the foregoing, MedImmune shall (i)&nbsp;provide
Innate with copies of all material Regulatory Documentation received from Regulatory Health Authorities, (ii)&nbsp;provide Innate with advance copies of all material Regulatory Documentation for submission to Regulatory Health Authorities in the
Major Markets, with sufficient time for Innate to review and provide comment, and give reasonable, good faith consideration to Innate&#146;s suggestions therefor, (iii)&nbsp;permit at least one Innate representative to be present at all discussions
and meetings with the EMA and the FDA relating to Licensed Products subject to Applicable Law and any applicable restrictions imposed by the FDA or EMA and (iv)&nbsp;generate true and accurate minutes of all discussions and meetings with Regulatory
Health Authorities relating to Licensed Products in the Major Markets and provide copies of such minutes to Innate as promptly as possible following any such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
meeting. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">During the Development Term, MedImmune shall keep Innate reasonably informed of the status of each pending or proposed
IND application or Drug Approval Application covering a Licensed Product in the Territory through the DCC. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall immediately (within 24 hours) inform Innate in the event that Regulatory Health Authority threatens or
initiates any action to remove a Licensed Product from any market in the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B><FONT STYLE="white-space:nowrap">CO-FUNDING</FONT></B><B> OF DEVELOPMENT</B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Subject to the remaining provisions of this Section&nbsp;7 Innate shall participate in the funding of each of the
Phase 3 Clinical Trials of Licensed Products supporting Drug Approval Application in [***], such funding to be provided by Innate in the amount of thirty percent (30%) of the total Development Costs for each of such Phase 3 Clinical Trials with the
remaining seventy (70%) percent being provided by MedImmune, provided that neither Party shall be required to contribute more than their agreed percentage share of Development Costs for the Phase 3 Clinical Trials in accordance with the Development
Budget. The Development Budget is anticipated to be [***] for each Clinical Trial in average across [***] and [***] in total based on up to [***]. To the extent that a Party&#146;s share of the Development Costs in accordance with the Development
Budget exceeds [***] in the case of Innate or [***] in the case of MedImmune of the anticipated budget of [***] per Phase 3 Clinical Trial, then the excess portion shall be payable by the Party sponsoring the applicable Phase 3 Clinical Trial. The <FONT
STYLE="white-space:nowrap">non-sponsoring</FONT> Party&#146;s share of the Development Costs of the subsequent Phase 3 Clinical Trial shall be increased by such excess amount provided that the <FONT STYLE="white-space:nowrap">non-sponsoring</FONT>
Party&#146;s share shall never exceed [***] of [***]in the case of Innate and [***] of [***] in the case of MedImmune for any given Phase 3 Clinical Trial. For the avoidance of doubt, the excess amount shall not be payable other than pursuant to the
preceding sentence and if it cannot be paid in accordance with the preceding sentence, it shall not be payable by the <FONT STYLE="white-space:nowrap">non-sponsoring</FONT> Party. The Parties have agreed that the first Phase 3 Clinical Trial will be
sponsored by MedImmune, as will any additional Phase 3 Clinical Trials related </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
to Licensed Products unless the Parties otherwise mutually agree. An example of such payment mechanism is attached as Schedule 7.1. The Parties may agree that Innate&#146;s <FONT
STYLE="white-space:nowrap">co-funding</FONT> amount pursuant to this Section&nbsp;7.1 may be used to finance other Clinical Trials than the Phase 3 Clinical Trials. Innate shall have the option, upon providing written notice to MedImmune (&#147;<B><FONT
STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice</B>&#148;) within [***] after receiving MedImmune&#146;s updated Development Plan and Development Budget in accordance with Section&nbsp;4.2 (&#147;<B>Opt Out Period</B>&#148;), to not
participate in the <FONT STYLE="white-space:nowrap">Co-Funding.</FONT> Such right to withdraw shall be exercisable once only in respect of the first Licensed Product. If Innate does not provide a <FONT STYLE="white-space:nowrap">Co-Funding</FONT>
Withdrawal Notice within the Opt Out Period described above Innate will be obliged to provide <FONT STYLE="white-space:nowrap">co-funding</FONT> with respect to the applicable Licensed Product as described in this Section&nbsp;7.1.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If Innate provides a <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice, the following provisions
shall apply: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate&#146;s role on the DCC shall be limited to discussing with MedImmune the matters within the remit of the DCC
but Innate shall have no rights to vote on any such matter and MedImmune shall have final say; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate&#146;s <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option shall terminate and be of no further effect;
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate&#146;s right to share in 50% of the Profit in Europe shall terminate. Instead Net Sales in Europe will be
included for the purposes of the Sales Related Payments due under Section&nbsp;10.5 and royalties under Section&nbsp;10.11 and the first five subsequent Phase 3 Clinical Trial milestones payable pursuant to Section&nbsp;10.2 shall each be reduced by
[***] and all [***] milestones shall be extinguished entirely.<B><I> </I></B>For the avoidance of doubt, any other Payments shall remain unchanged. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Expense Sharing</B>. The provisions set out in this Section&nbsp;7.3 and in Section&nbsp;7.4 <FONT
STYLE="white-space:nowrap">-7.9</FONT> shall apply if Innate has not served MedImmune with a <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice within the Opt Out Period. The Parties will share all Development Costs related to the
Phase 3 Clinical Trials of Licensed Products under the Development Plan and in accordance with the Development Budget (the &#147;<B>Shared Development Costs</B>&#148;) so that subject to Section&nbsp;7.1, Innate pays thirty percent (30%) and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
MedImmune shall pay the remainder as set out below in this Section&nbsp;7. <B></B> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Development Costs.</B> Within [***] days after the end of each Calendar Quarter each Party will provide the other
Party with detailed, itemized accounting of the Shared Development Costs incurred by it in undertaking its Development activities, which report shall be itemized on a Licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis in such quarter in the form set forth in <U>Schedule 7.4</U> or in such other form as the Parties may mutually agree from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time.</FONT></FONT> For clarity, for calculation of Costs pursuant to this Section with respect to any activity performed by a Third Party (including any subcontracted Third Party),
the Costs shall be the pass-through costs, with no <FONT STYLE="white-space:nowrap">mark-up,</FONT> charged to the applicable Party by such Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Income Taxes</B>. Subject to Section&nbsp;10.26 (Taxes), income and withholding taxes imposed on either of the
Parties hereunder will not be included in cost sharing hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Exchange Rate. </B>For the purposes of calculating the Shared Development Costs, the Parties&#146; Development
Costs will be converted from local currency (if different from US Dollars) to US Dollars in accordance with Section&nbsp;10.30 (Payment Currency).<B> </B> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Overruns.</B> Each Party will promptly notify the other Party upon becoming aware that the anticipated Costs to be
incurred by such Party for a given Calendar Year will be in excess of [***] of the aggregate amounts budgeted to be incurred by or on behalf of such Party for its activities for such Product in such Calendar Year in the then-current applicable
Development Budget respectively (&#147;<B>Excess Costs</B>&#148;), will not be included in the calculation of the Development Costs for the purposes of this Section provided, that a given Excess Cost will be included to the extent such Excess Cost
is or was attributable to: (i)&nbsp;a change in Applicable Law; (ii)&nbsp;a Force Majeure event; (iii)&nbsp;variation in actual patient enrolment from projected patient enrolment not caused by the default of the relevant Party; (iv)&nbsp;a change to
a clinical trial protocol required or requested by any Regulatory Health Authority; (v)&nbsp;increases in the cost of raw materials; (vi)&nbsp;is approved by the DCC. Notwithstanding the foregoing, in no circumstance shall Innate be liable for
Shared Development Costs with respect to any given </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Clinical Trial or other activity in accordance with the Development Plan or any Development Costs other than in accordance with Section&nbsp;7.1. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Reconciliation Discussion. </B>In the event that either Party has any questions or concerns regarding the
Development Costs reported by the other Party pursuant to this Section&nbsp;7 it shall promptly notify the other Party with respect thereto and the Parties shall work together in good faith, including through involving any applicable Committee, to
resolve such questions and concerns within [***] the end of each Calendar Quarter. In the event that a Party disagrees with, or identifies a discrepancy in, the Development Costs submitted by the other Party and the disagreement or discrepancy
cannot be resolved or rectified between the Parties within a period of [***] of the matter being first raised by a Party, the Parties shall appoint an independent, internationally recognised accountant to review the alleged discrepancy. The costs of
carrying out such review shall be borne by the Party requesting it unless the accountant finds a discrepancy in favour of the Party requesting of greater than [***] in which case the other Party will bear the costs<B> </B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B><FONT STYLE="white-space:nowrap">True-up.</FONT> </B>Within [***] after the end of each Calendar Quarter, the Party
having paid more than its share of the Shared Development Costs (on a cumulative basis) shall deliver to the other Party an invoice for amounts to be reimbursed by the other Party, and the other Party shall make a balancing payment in order to
effect the sharing of Development Costs as set forth in this Section within [***] after its receipt of such invoice. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>COMMERCIALIZATION, <FONT STYLE="white-space:nowrap">CO-PROMOTION</FONT> IN THE [***] AND SALES COLLABORATION
COMMITTEE</B> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall be responsible for all Promotion of the Licensed Products outside of [***] and, subject to the
operation of Innate&#146;s <FONT STYLE="white-space:nowrap">Co-Promotion</FONT> rights in this Section&nbsp;8, shall be responsible for all Promotion of the Licensed Products in [***]. In the event that Innate elects not to <FONT
STYLE="white-space:nowrap">Co-Promote</FONT> the Licensed Products in [***], in accordance with Section&nbsp;8.3 below, all such activities shall be conducted, as between the Parties, solely by MedImmune (whether directly or by its Affiliates,
Sublicensees or contractors (excluding Innate)) upon expiration of the notice period in accordance with Section&nbsp;8.3. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Sole Promotion by MedImmune</U> </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">With respect to Commercialization of Licensed Products (other than with respect to a
<FONT STYLE="white-space:nowrap">Co-Promote</FONT> Product in [***]), such Commercialization shall be conducted independently of Innate by MedImmune, its Affiliates and Sublicenses, and MedImmune shall provide to Innate its overall plans for
Commercialization and launch of Licensed Products in the Territory (each a &#147;<B>Global</B> <B>Commercialization Plan</B>&#148;), which plans shall contain reasonable details as to the commercialization resources committed by MedImmune, timelines
for launch and sale projections over [***] with respect to the Major Markets. MedImmune shall provide to Innate the first Global Commercialization Plan as soon as reasonably practicable following the Filing Date of the first Drug Approval
Application for a Licensed Product in the Territory and updates within [***] from the beginning of each Calendar Year. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U><FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option</U> </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Subject to the remaining provisions of this Section&nbsp;8, Innate shall have the right to <FONT
STYLE="white-space:nowrap">Co-</FONT> Promote the Licensed Products in [***], (&#147;<B><FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Promptly following the date on which MedImmune has filed for the first Drug Approval Application, the Parties shall
meet to discuss whether or not Innate is interested in principle in exercising its <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option. MedImmune shall provide Innate with reasonable details of its plans for Commercialization of the Licensed
Product in [***] in advance of such meeting. No later than ninety (90)&nbsp;days after MedImmune notifies Innate that it has filed for the first Drug Approval Application for a Licensed Product in the EU, Innate shall provide to MedImmune a written
notice confirming whether or not Innate is opting in to <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Licensed Products in the [***]. If Innate confirms in such notice that it is not exercising its
<FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option, such notice shall be deemed to be a &#147;<B><FONT STYLE="white-space:nowrap">Co-Promotion</FONT> Withdrawal</B>&#148;. Any failure by Innate to notify MedImmune as to whether or not it is
exercising its <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option in [***] within such [***] shall also be deemed to be a <FONT STYLE="white-space:nowrap">Co-Promotion</FONT> Withdrawal. Such right to withdraw shall be exercisable once only
and must be exercised by way of a <FONT STYLE="white-space:nowrap">Co-Promotion</FONT> Withdrawal pursuant to this Section&nbsp;8.4 in respect of the first Drug Approval Application for the first Licensed Product. If Innate makes a <FONT
STYLE="white-space:nowrap">Co-Promotion</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Withdrawal, Innate&#146;s right to share in the Profit/Loss shall be adjusted so that MedImmune receives/bears [***] and Innate receives/bears [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If Innate confirms to MedImmune in writing within the [***] referred to in Section&nbsp;8.4 above that it does wish to
exercise the <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option MedImmune shall prepare detailed plans for Commercialization in the EU including plans for the launch of the Licensed Product in the EU (&#147;<B>EU Commercialization
Plans</B>&#148;), and related budgets (the &#147;<B>EU</B> <B>Commercialization Budgets</B>&#148;), and shall furnish the SCC for discussion with such plans. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Sales Collaboration Committee </U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If Innate exercises its <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option, Innate and MedImmune shall create,
within [***] after such exercise, a Sales Collaboration Committee (&#147;<B>SCC</B>&#148;). The SCC shall remain in effect throughout the Term unless and until the Parties cease <FONT STYLE="white-space:nowrap">Co-Promotion</FONT> of the <FONT
STYLE="white-space:nowrap">Co-Promote</FONT> Product in [***]. The SCC shall serve as a forum for discussing and sharing information and materials; discussing strategy regarding the Commercialization of the
<FONT STYLE="white-space:nowrap">Co-Promote</FONT> Product in the [***]; and discussing the allocation of Commercialization activities to be conducted by Innate and MedImmune, all in accordance with the
<FONT STYLE="white-space:nowrap">Co-Promote</FONT> Agreement and the provisions set forth below in this Section&nbsp;8. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Composition of SCC.</B> Each Party shall appoint three (3)&nbsp;representatives as its voting members of the Sales
Collaboration Committee. The SCC shall be chaired by a representative of MedImmune. The chairperson shall be responsible for calling meetings, setting the agenda, circulating &#150; where reasonably possible given the urgency of the matter at hand
&#150; the agenda at least ten (10)&nbsp;days prior to each meeting and distributing minutes of the meetings within thirty (30)&nbsp;days following such meetings (provided that the chairperson may elect to delegate the performance of such
responsibilities to other members of the SCC from time to time), but will not otherwise have any greater power or authority than any other member of the SCC. The chairperson shall coordinate with Innate&#146;s SCC members to schedule each SCC
meeting in good time in advance of such meetings. Each Party shall disclose to the chairperson any proposed agenda items, along with appropriate information and materials as early as reasonably practical before each meeting of the SCC, but no less
than three (3) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Business Days. The chairperson shall not unreasonably reject any proposed call for a meeting or proposed agenda items proposed by either Party. The chairperson shall coordinate with the Parties
to schedule SCC meetings in good time in advance of the meetings. The members of the SCC shall have substantial experience in pharmaceutical sales and marketing and all of the members of the SCC shall have such expertise as appropriate to the
activities of the SCC. Each Party may replace its members of the SCC upon written notice to the other Party, provided that any such substitute member shall have substantially the equivalent functional expertise, experience and seniority as the
member that such person replaces provided that the Parties shall use Commercially Reasonable Efforts to keep replacements to a minimum. From time to time, the SCC may invite <FONT STYLE="white-space:nowrap">non-voting</FONT> personnel of either
Parties to participate in discussions of the SCC. An alternate voting member designated by a Party may serve temporarily in the absence of a permanent voting member appointed by such Party, and either Party may also designate one or more <FONT
STYLE="white-space:nowrap">non-voting</FONT> consultants to such Party, who are under written obligations of confidentiality to such Party, as SCC observers who may attend the SCC meetings in an observational or advisory capacity only.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Responsibilities of the SCC</B>. The SCC&#146;s responsibilities will include, (i)&nbsp;reviewing and approving the
EU Commercialization Plans and EU Launch Plans and related budgets, and reviewing plans for trademark selection for the Licensed Product in the EU, such plans shall be prepared and updated by MedImmune, (ii)&nbsp;receiving and providing to the
Parties all sales, pricing, and financial reports pertaining to <FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Activities and Commercialization of the Licensed Product in the EU, (iii)&nbsp;facilitating the flow of information and materials
with respect to the Commercialization of the Licensed Product in the EU, (iv)&nbsp;performing quarterly reviews of the progress of launch and Commercialization activities in the EU with respect to the Product, and (v)&nbsp;coordinating the efforts
of the Parties in connection with Commercialization of the Licensed Product in the EU. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Meetings of the SCC</B>. The SCC shall hold meetings at such times and places as shall be determined by a majority
of the entire membership of the committee, but in no event shall such meetings be held less frequently than once every six (6)&nbsp;months. Meetings of the SCC will alternate between the offices of the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Parties, unless otherwise agreed upon by the members of the SCC, or may be held via internet telephonically or by video conference; provided that at least two (2)&nbsp;meetings per year shall be
held in person. Meetings of the SCC will be effective only if at least two (2)&nbsp;SCC representatives of each Party are in attendance or participating in the meeting. Each Party will be responsible for the expenses incurred by its employees,
consultants and its members of the SCC attending or otherwise participating in SCC meetings. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>SCC Decision Making</B>. The SCC shall endeavour to make decisions within its remit by unanimous consent, with the
MedImmune members cumulatively having one (1)&nbsp;vote and the Innate members cumulatively having one (1)&nbsp;vote, irrespective of the number of members in attendance at a meeting. [***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Allocation of <FONT STYLE="white-space:nowrap">Co-Promote</FONT> activities in [***]</U> </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Within thirty (30)&nbsp;days of the later of: (a)&nbsp;creation of the SCC, and (b)&nbsp;receipt of the EU
Commercialization Plans and EU Launch Plan, the Parties shall, based on such plans, provide to the SCC a joint proposal (&#147;<B>Promotion Proposal</B>&#148;) describing the Detail commitments and Other Promotional Activities proposed to be
undertaken by Innate in connection with the Commercialization of the Licensed Product in [***]. Such Promotion Proposal shall include, among other things, (i)&nbsp;the level of, and target audience, for the Detailing to be performed by Innate in
[***], which shall be [***] of the total Detailing efforts required in [***] for the <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Product, and (ii)&nbsp;any <FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Activities and Other Promotional
Activities that the Parties propose Innate conduct in [***] which shall be [***] with respect to Medical Scientific Liaisons and, to the extent reasonably practicable, any Other Promotional Activities. In allocating these activities, Innate shall be
given a meaningful role with respect to key opinions leaders in France. The Promotion Proposal shall be considered, discussed and approved by the SCC and the Parties or the SCC may propose further or alternative promotional activities to be
undertaken by Innate. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Based on such discussions, Innate and MedImmune (or, at MedImmune&#146;s option, one of MedImmune&#146;s Affiliates)
shall negotiate in good faith to execute as promptly as possible a separate agreement (the &#147;<B><FONT STYLE="white-space:nowrap">Co-Promote</FONT> Agreement</B>&#148;) that shall regulate the detailed activities and responsibilities of Innate in
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
respect of the marketing and promotion of the Licensed Product in [***]. The <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Agreement shall contain such reasonable terms and conditions as the
Parties deem appropriate. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall be entitled and obligated to carry out those promotional tasks agreed in the <FONT
STYLE="white-space:nowrap">Co-Promote</FONT> Agreement within [***] in respect of the <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Products, subject to relevant EU Launch Plans and EU Commercialization Plans. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Reimbursement of Commercialization Costs </U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Commercialization Costs. </B>Within [***] after the end of each Calendar Quarter, each Party will provide the other
Party with detailed, itemized accounting of its Commercialization Costs in accordance with the Global Commercialization Plan and EU Commercialization Budget, in such quarter in the form set forth in <U>Schedule 8.14</U> or in such other form as the
Parties may mutually agree from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time.</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Reimbursement.</B> Within [***] after the end of each Calendar Quarter, Innate shall deliver to MedImmune an
invoice for its Commercialization Costs incurred in such Calendar Quarter in accordance with the EU Commercialization Budget, and MedImmune shall pay such costs within [***] after its receipt of such invoice. In addition, within [***]after the end
of each Calendar Quarter, Innate shall deliver to MedImmune an invoice for the total of any royalties or other sums payable by Innate to any Third Party with respect to Intellectual Property Rights that become Controlled by Innate and which
MedImmune has agreed to reimburse Innate according to Section&nbsp;1.34 after the Effective Date in connection with the Licensed Product, and MedImmune shall pay such costs within [***] after its receipt of such invoice. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Calculation</B>. The procedures set forth in Section&nbsp;7.8 shall apply <I>mutatis </I><I>mutandis</I> to the
reimbursement of Innate&#146;s Commercialization Costs.<B> </B> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune (or, as the case may be, its Affiliates or Sublicensees) shall book all of their sales of each Licensed
Product, coordinate the Manufacture and supply of all Licensed Products required for Commercialization, invoice Third Parties (including Distributors) that purchase Licensed Products from
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
MedImmune (or its Affiliates or Sublicensees), and collect payment for all Licensed Products sold by MedImmune (or its Affiliates or Sublicensees) both in the EU and outside of the EU.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B><U>MANUFACTURE AND SUPPLY</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Initial Supply</B><B> of Licensed Product</B>. Innate shall assume initial responsibility for supplying IPH2201 for
use in the Development of IPH2201 under this Agreement until such time as the Parties agree, but no later than the point at which manufacturing for the first Phase 3 Clinical Trial is due to start, MedImmune shall assume responsibility for such
supply hereunder (the &#147;<B>Initial Supply</B>&#148;). Innate shall use Commercially Reasonable Efforts to procure, from its current contract manufacturing organization, such Initial Supply of IPH2201 as MedImmune may reasonably require in
relation to the Development of the Licensed Product and in accordance with the Development Plan. Innate shall deliver the Initial Supply and perform the activities in such a manner and within such timelines as are required under the Development
Plan. Innate will ensure that the Initial Supply is Manufactured, packaged, stored and labelled in accordance with Applicable Laws and the Specification. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Initial Supply of MedImmune Compound. </B>MedImmune shall be responsible for the provision of such GMP quantities
of the MedImmune Compound as are specified in the Development Plan or otherwise required for the conduct of the Development. In the event that Development activities involving MedImmune Compound are Innate&#146;s Assigned Activities, MedImmune shall
supply MedImmune Compound to Innate in accordance with the terms of a combination supply agreement which will be agreed by the Parties in good faith prior to any such supply being made<B>. </B>MedImmune will be responsible for any costs and payments
(including without limitation upfront fees, annual fees, milestone payments and royalties) due to any Third Party in connection with the use of an MedImmune Compound in accordance with this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Costs. </B>The Parties will discuss and agree the Transfer Price on an annual basis. The Transfer Price for any
Licensed Products or Licensed Antibodies supplied by Innate will be treated as a Development Cost. In the event that Innate is <FONT STYLE="white-space:nowrap">co-funding</FONT> Development in accordance with Section&nbsp;7, the Transfer Price shall
be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
included in the calculation of Innate&#146;s contribution in Section&nbsp;7.4. In the event that Innate is not <FONT STYLE="white-space:nowrap">co-funding</FONT> Development, the Transfer Price
shall be reimbursed by MedImmune within [***] of the receipt of an invoice for the Transfer Price for Licensed Product supplied from Innate. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Manufacturing and Supply Agreement.</B> If a manufacturing and supply agreement (&#147;<B>MSA</B>&#148;) is
required with regard to the supply of Initial Supply by Innate, the Parties shall negotiate and agree in good faith the terms of such agreement. The Parties shall also enter into a separate Quality Assurance Agreement (&#147;<B>QAA</B>&#148;) that
shall define the manufacturing and supply quality responsibilities of the Parties. The QAA shall further include provisions obligating Innate to report to MedImmune any regulatory compliance issues with its suppliers as well as any critical quality <FONT
STYLE="white-space:nowrap">non-conformances</FONT> relating to IPH2201. The MSA and the QAA shall be negotiated in good faith between the Parties and be executed within ninety (90)&nbsp;days following the Effective Date. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Transfer of responsibility. </B>Subject to Section&nbsp;9.1, MedImmune shall use Commercially Reasonable Efforts to
assume responsibility for the supply of all Licensed Antibodies and Licensed Products for use in the Development and Commercialization of Licensed Products beginning with the supplies of drug substance necessary to conduct Phase 3 Clinical Trials of
the Licensed Product and continuing thereafter for the remainder of the Term; <U>provided</U>, <U>however</U>, that MedImmune may, by written notice to Innate, elect to assume responsibility for Development work associated with the Manufacture of
the Licensed Product or Licensed Antibody at any earlier time after the Effective Date. In such case, the timing of the transition of such activities, and the impact of the transition of such Development work on the supply of Licensed Product or
Licensed Antibody for Clinical Trials, shall be determined by the DCC, taking into account, among other things, the contractual obligations that Innate may have to its current suppliers. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Material Transfer</B>. The DCC shall coordinate the transfer of all Licensed
<FONT STYLE="white-space:nowrap">Know-How</FONT> and Materials Controlled by Innate that are necessary or useful to Manufacture Licensed Antibodies and Licensed Products. Such transfer shall take place in a manner and at such time as not to disrupt
the manufacture and delivery of any Initial Supplies under Section&nbsp;9.1. At such time as is determined </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
by the DCC, Innate shall, and shall cause its manufacturing contractors at its own cost and expense to, provide to MedImmune or its designee, all reasonable assistance, including the right to
observe the Manufacturing at a facility of Innate&#146;s manufacturing contractors, and transfer all Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and Materials Controlled by Innate, that are necessary or useful to Manufacture the
Licensed Antibodies and the Licensed Products, including without limitation all production and quality control Specification and process and manufacturing technology, for the purpose of allowing MedImmune or its designee to develop and establish
such Manufacturing. MedImmune shall have the right to disclose all such information to Third Parties for purposes of allowing MedImmune to assess the feasibility of such Third Parties Manufacturing the Licensed Antibodies and the Licensed Products
and to allow such Manufacturing. The Parties shall cooperate to obtain all necessary assurances and cooperation from any Third Party contract manufacturers of Licensed Antibodies or Licensed Products with respect to the foregoing material transfer
activities. Innate covenants to MedImmune that any Third Party agreements under which Innate engages such Third Party to Manufacture Licensed Antibodies or Licensed Products contain provisions regarding the allocation of Intellectual Property Rights
and rights in work product that are consistent with the terms of this Agreement and will enable Innate to fulfil its obligations to MedImmune under this Section&nbsp;9. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Other Supply</B>. MedImmune may supply Licensed Antibody or Licensed Products to any Third Party for any Third
Party solely for use in the Field. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>CONSIDERATION</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Upfront fee</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">As partial payment for the rights and licenses granted to MedImmune by Innate under this Agreement, MedImmune shall
pay to Innate a nonrefundable one-time upfront payment of one hundred million US dollars (USD 100,000,000) within [***] the Effective Date. The upfront payment shall not be refundable or creditable against any other payments MedImmune is obligated
to make to Innate under this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Milestone Payments</U> </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall make the following <FONT STYLE="white-space:nowrap">one-time,</FONT> nonrefundable and <FONT
STYLE="white-space:nowrap">non-creditable</FONT> milestone payments to Innate within [***] receipt of an invoice from Innate (fulfilling the requirements set forth in Section&nbsp;10.27) following the first achievement of each of the following
milestone events for a Licensed Product containing IPH2201, subject to the limitations and additional provisions set forth below in this Section&nbsp;10. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="97%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER:1.50pt solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>Milestone Event for a Licensed Product Containing IPH2201</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;Milestone&nbsp;Payment&nbsp;&nbsp;&nbsp;&nbsp;
</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" ROWSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-right:1.00em; font-size:11pt; font-family:ARIAL" ALIGN="justify">I. Dosing of the first patient in the first Phase 3 Clinical Trial</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; margin-right:1.00em; text-indent:-1.50em; font-size:11pt; font-family:ARIAL" ALIGN="justify">A.&#8194;For the first Phase 3 Clinical Trial to support a Drug Approval Application in a
Major Market</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">US $100,000,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:11pt; font-family:ARIAL" ALIGN="justify">B.&#8194;[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:16pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&#8201;&#8201;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL" ALIGN="center">[***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">II.[***]</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:16pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:11pt; font-family:ARIAL" ALIGN="justify">A.&#8194;[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"><FONT STYLE="font-size:11pt">[***]</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">III.[***]</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:16pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:11pt; font-family:ARIAL" ALIGN="justify">A.&#8194;[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"><FONT STYLE="font-size:11pt">[***]</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***] </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">None of the milestone payments set forth in Section&nbsp;10.2 shall be payable more than once, irrespective of the
number of Licensed Products or indications that have achieved the milestone events or the number of countries in which such milestone events have been achieved, provided that milestone I(B) shall be payable up to [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Except as permitted in Section&nbsp;10.2, no payments pursuant to Section&nbsp;10.2 shall be creditable against any
other payments MedImmune is obligated to make to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Innate under this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Sales Related
Milestones</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall make the following <FONT STYLE="white-space:nowrap">one-time,</FONT>
<FONT STYLE="white-space:nowrap">non-refundable</FONT> milestone payments to Innate within [***] after receipt of an invoice from Innate, fulfilling the requirements set forth in Section&nbsp;10.29, following the first achievement of each of the
following milestones in respect of Annual Net Sales of all Licensed Products containing IPH2201 in all countries subject to Section&nbsp;10.8 below and subject to the limitations and additional provisions set forth below in this Section&nbsp;10,
including Section&nbsp;1 0.21: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">[***]</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">[***]</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">[***]</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">[***]</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">[***]</TD></TR>
</TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In the event that more than one of the sales milestones set forth in Section&nbsp;10.5
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
are achieved in the same Calendar Quarter, the payment associated with each sales milestone achieved in such Calendar Quarter shall be due and payable [***] after MedImmune&#146;s receipt of an
invoice from Innate following the end of such Calendar Quarter. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding anything else set forth herein, no milestone payment pursuant to Section&nbsp;10.5 will be made more
than once. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Territory shall exclude Europe for the purposes of the calculation of Annual Net Sales if Innate has not provided
its <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune will notify Innate as soon as reasonably practicable and not later than within [***] of the end of each
Calendar Quarter if any of the milestones events set out above in Section&nbsp;10.5 have been achieved in that Calendar Quarter. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Except as provided in Section&nbsp;10.21, no payments pursuant to Section&nbsp;10.5 shall be creditable against any
other payments MedImmune is obligated to make to Innate under this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Royalties</U> </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Subject to the provisions set forth below in Sections 10.12, 10.13, 10.14, 10.15, 10.16, 10.17, 10.18, 10.19, 10.20
and 10.22, MedImmune shall pay to Innate, with respect to each Licensed Product containing IPH2201, an incremental royalty on aggregate Annual Net Sales of each such Licensed Product containing IPH2201 made by MedImmune, its Affiliates, or its
Sublicensees as follows: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">Portion of aggregate Annual Net Sales of relevant Licensed Product</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalty&nbsp;Rate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">[***]</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">[***]</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">[***]</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***] </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The calculation of royalties under Section&nbsp;10.11 shall be conducted separately for each Licensed Product. Thus,
if MedImmune sells more than one Licensed Product in the Territory, the thresholds and ceilings in Section&nbsp;10.11 shall apply separately to each Licensed Product. For purposes of the foregoing, all Licensed Products containing IPH2201 shall be
deemed the same Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Territory shall exclude Europe for the purposes of calculating royalties above if Innate has not provided its <FONT
STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Sales between MedImmune, its Affiliates and Sublicensees shall not be subject to royalties hereunder. Royalties shall
be calculated on MedImmune&#146;s, its Affiliates&#146; and Sublicensees&#146; sales of the Licensed Products to a Third Party, including Distributors (but excluding, for the avoidance of doubt, Affiliates and Sublicensees). Royalties shall be
payable only once for any given batch of the Licensed Products. For the purpose of determining Net Sales, the Licensed Product shall be deemed to be sold when invoiced and a &#147;sale&#148; shall not include, and no royalties shall be payable on,
transfers by MedImmune, its Affiliates or Sublicensees of free samples of Licensed Product or clinical trial materials, or other transfers or dispositions for charitable, promotional, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical,
manufacturing, testing or qualification, regulatory or governmental purposes to the extent that such transfer is made at the Transfer Price or less. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If, at any time, in any particular country in the Territory, a given Licensed
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Product [***], then, the royalty rates set forth in the table in Section&nbsp;10.11 shall be reduced by [***] for the purposes of calculating royalties due under this Agreement as from the first
Calendar Quarter in which this Section&nbsp;10.15 applies, and thereafter for so long as this Section&nbsp;10.15 applies in such particular country. The calculation of the royalty reduction under this Section&nbsp;10.15 shall be conducted separately
for each Licensed Product in each country. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If, at any time, in any particular country in the Territory, (i)&nbsp;a Generic Product receives Regulatory Approval
in such country and (ii)&nbsp;in any two consecutive Calendar Quarters such Generic Product(s), by unit equivalent volume in such country, exceed a [***] share of the market for the Licensed Product and relevant Generic Products; then, the royalty
rates set forth in the table in Section&nbsp;10.11 shall be reduced by [***] as from the first Calendar Quarter in which this Section&nbsp;10.16 applies and thereafter for the remainder of the period during which royalties are payable with regard to
such Licensed Product in such country. The calculation of the royalty reduction under this Section&nbsp;10.16 shall be conducted separately for each Licensed Product in each country. For purposes of this Section &#147;market&#148; refers to the
aggregate of the sales of the Generic Product(s) and the applicable Licensed Product in a country. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If, at any time, in any particular country in the Territory, a court or a governmental agency of competent
jurisdiction requires MedImmune or its Affiliate or Sublicensee to grant a compulsory license to a Third Party permitting such Third Party to make and sell Licensed Product containing IPH2201 in one or more countries in the Territory (a
&#147;<B>Compulsory License</B>&#148;), and the royalty rate for royalties payable to MedImmune, its Affiliate or Sublicensee on Net Sales (which term for the purpose of this Section&nbsp;10.17 shall apply <I>mutatis mutandis</I> to sales by such
grantee) of Licensed Product containing IPH2201 by or on behalf of such grantee of the Compulsory License is less than the royalty rate for royalties on Net Sales due to Innate pursuant to Section&nbsp;10.11 in such country, then if MedImmune has in
due time informed Innate of the start of such action or proceedings by such court or governmental agency of competent jurisdiction and taken into account Innate&#146;s reasonable comments, the royalty rate applicable to Net Sales for royalties due
to Innate in such country shall be reduced to be equal to the royalty rate for royalties payable by the grantee of the Compulsory License. The royalty rate reduction </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
set forth herein shall be effective as from the first Calendar Quarter in which this Section&nbsp;10.17 applies and thereafter for so long as this Section&nbsp;10.17 applies. The calculation of
the royalty rate reduction under this Section&nbsp;10.17 shall be conducted separately for each Licensed Product in each country. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Any reductions set forth in this Section&nbsp;10 shall be applied in the order in which the event triggering such
reduction occurs, provided that in no event shall, due to the cumulative reductions set out in Sections 10 the royalties that would otherwise have been payable to Innate in application of the royalty rates set forth in the table in
Section&nbsp;10.11 be reduced by more than [***] in any given country. Credits not exhausted in any Calendar Quarter in any given country may however be carried into future Calendar Quarters in such country, subject to the foregoing sentence.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune&#146;s obligation to pay royalties due under Section&nbsp;10.11 shall expire, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, with respect to such Licensed Product, at the latest of: (i)&nbsp;the tenth (10th) anniversary of the First Commercial Sale of such Licensed Product
in such country (or, in the case of any country in Europe, the tenth (10th) anniversary of the First Commercial Sale of such Licensed Product in any country in Europe), (ii) the expiry of the Regulatory Exclusivity covering the Licensed Product in
such country and (iii)&nbsp;the date on which there is no longer a Valid Claim covering the use, manufacture or sale of Licensed Product in such country. At such time as MedImmune&#146;s obligation to pay royalties under Section&nbsp;10.11 have
terminated in a country, the Net Sales of such Licensed Product in such country shall be excluded from royalty calculations under Section&nbsp;10.11 (including for purposes of applying thresholds and ceilings). </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Subject to Sections 12.9 and 12.10, if (i)&nbsp;MedImmune, [***] (&#147;Third Party Payment&#148;), then for the
period during which MedImmune owes royalties to Innate hereunder, the amounts that would otherwise have been payable as royalties to Innate under this Agreement shall be reduced by [***] of all Third Party Payment payable by or on behalf of
MedImmune to such Third Party. As used herein, [***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In consideration of Innate paying thirty percent (30%) of the Shared Development Costs in accordance with
Section&nbsp;7.1 (including the limitations </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
therein), Innate will be entitled to receive fifty percent (50%) of the Profit/Loss earned by MedImmune and its Affiliates on sales of the Licensed Products in Europe. MedImmune will provide a
report to Innate within [***] of the end of each Calendar Quarter setting out the Profit /Loss in that quarter and if such calculation shows a Profit shall pay fifty percent (50%) of such amount to Innate within [***] of receiving an invoice for
such amount from Innate. Any Loss shall be carried forward and offset against (i)&nbsp;subsequent Profits, (ii)&nbsp;any other sums due to Innate under this Agreement other than reimbursement of Development Costs and Commercialization Costs in
accordance with this Agreement, provided that Innate shall always be entitled to receive, and MeImmune shall pay to Innate, any amount corresponding to payments which Innate is obliged to pass through to the applicable counter Party under the Third
Party Agreements. Subject to the foregoing, no Profit will be shared hereunder until all Losses have been recouped by MedImmune. If after all Losses have been recouped pursuant to the preceding sentence, a Profit is made and shared equally between
the Parties in [***] consecutive Calendar Quarters, any Loss which may be made in any period after such three (3)&nbsp;consecutive Calendar Quarters of Profit shall be borne by the Parties in equal shares and a balancing payment shall be payable by
the applicable Party within [***] of receipt of an invoice from the Party which has borne more than fifty percent (50%) of any such Loss in any applicable Calendar Quarter. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><U>Provisions affecting consideration </U></P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Combination Products. With regard to sales of the Licensed Antibodies when incorporated in or combined with another
article, composition or product, which [***], and sold or otherwise supplied as a Combination Product [***], the Net Sales of the Licensed Product, for the purposes of determining royalty payments, shall be determined by [***].
</P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">In the event that, with respect to any Combination Product, [***], Net Sales for purposes of determining royalty
payments shall be calculated by [***]. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***] </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***]. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***]. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify">For
purposes of the calculations set forth in this Section&nbsp;10.22, [***]. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Separate Licensed Product</B>. Notwithstanding anything else set forth in this Agreement to the contrary, the
milestones and royalties in this Section&nbsp;10shall not apply to development or commercialization of a Licensed Product for diagnostic, veterinary or any other use other than as a therapeutic pharmaceutical product in humans<I> </I>(&#147;Separate
Licensed Product&#148;). If MedImmune develops a Separate Licensed Product, MedImmune shall pay to Innate such separate milestones and royalties for the development, commercialization or sale of such Separate Licensed Product as are commercially
reasonable taking into account each Party&#146;s respective investment to date in the Separate Licensed Product, the commercial potential of such product, the future cost of developing and commercializing such product, the then current stage of
development and the probability of successfully launching such product. In the event that MedImmune decides to initiate development of a Separate Licensed Product, MedImmune shall notify Innate thereof in writing and the Parties shall thereafter
negotiate in good faith within a period of [***] from such notice to agree on such separate milestones and royalties. A failure by the Parties to reach such agreement shall not preclude MedImmune from developing or commercializing a Separate
Licensed Product or from otherwise exercising the rights and licenses granted to it by Innate under this Agreement. However, in the event of a failure by the Parties to reach such agreement within the aforementioned [***] period or any extension of
such period mutually agreed by the Parties or otherwise in the event of a dispute as to the separate milestones and royalties for a Separate Licensed Product, each Party shall be entitled to escalate the matter in accordance with Section&nbsp;17.2
and, if applicable, to refer the matter to arbitration in accordance with Section&nbsp;17.1. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Sales by Sublicensees</B>. In the event MedImmune grants sublicenses to one or more Sublicensees to make or sell
Licensed Products to the extent permitted hereunder, such sublicenses shall include without limitation an obligation for </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
the Sublicensee to account for and report its Net Sales of such Licensed Products on the same basis as if such sales were Net Sales by MedImmune, and MedImmune shall pay royalties to Innate as if
the Net Sales of the Sublicensee were Net Sales of MedImmune. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Royalty Payments and Reports</B>. The royalties payable under Section&nbsp;10.11 shall be calculated quarterly as
of the last day of each Calendar Quarter, for the Calendar Quarter ending on that date. MedImmune shall deliver to Innate a report summarizing the Net Sales of Licensed Products during each Calendar Quarter following the First Commercial Sale of a
Licensed Product in the Territory. Such report shall be delivered within [***] following the end of each Calendar Quarter for which royalties are due from MedImmune. Any royalties payable to Innate or its designee under this Agreement shall be paid
on the due date for the report in the foregoing sentence of this Section&nbsp;10.25. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.26</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Taxes. </B>The royalties, milestones and other amounts payable by MedImmune to Innate pursuant to this Agreement
(&#147;<B>Payments</B>&#148;) shall [***] (and, if necessary, the receipt by MedImmune of appropriate governmental authorization) at least [***] prior to the time that the Payments are due. If MedImmune [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.27</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding anything to the contrary contained in this Section&nbsp;10 or elsewhere in this Agreement, the
following shall apply with respect to Indirect Taxes. All Payments are stated exclusive of Indirect Taxes. If any Indirect Taxes are chargeable in respect of any Payments, MedImmune shall pay such Indirect Taxes at the applicable rate in respect of
any such Payments following the receipt, where applicable, of an Indirect Taxes invoice issued in the appropriate form by Innate in respect of those Payments, such Indirect Taxes to be payable on the due date of the payment of the Payments to which
such Indirect Taxes relate or at the time such Indirect Taxes are required to be collected by Innate, in the case of payment of Indirect Taxes to Innate. The Parties shall issue invoices for all goods and services supplied under this Agreement
consistent with Indirect Tax requirements, and to the extent any invoice is not initially issued in an appropriate form, MedImmune shall promptly inform Innate and shall cooperate with Innate to provide such information or assistance as may be
necessary to enable the issuance of such invoice consistent with Indirect Tax requirements. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.28</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Payments or Reports by Affiliates</B>. Any Payment required under any provision of this Agreement to be made to
Innate or any report required to be made by MedImmune shall be made by an Affiliate of MedImmune if such Affiliate is designated by MedImmune as the appropriate payer or reporting entity. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.29</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Mode of Payment and Invoice Requirements</B>. All payments set forth in this Section&nbsp;10, or otherwise in this
Agreement due from MedImmune to Innate, shall be remitted by wire transfer to the bank account of Innate as designated in writing to MedImmune. All invoices submitted by Innate to MedImmune as provided in this Agreement shall fulfil the requirements
set forth in this Section&nbsp;10. Unless otherwise instructed by MedImmune, Innate&#146;s invoices to MedImmune shall be sent to MedImmune Limited, Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom , and shall contain
(a)&nbsp;MedImmune&#146;s Agreement ID number or purchase order number, (b)&nbsp;the number and date of the invoice, (c)&nbsp;the latest date of payment, not to be less than [***] following MedImmune&#146;s receipt of the invoice and in no event
prior to the due date, (d)&nbsp;name and address of Innate, (e)&nbsp;invoice amount and currency (USD), (f) bank details, i.e. bank number and bank code, and (g)&nbsp;SWIFT-address and (h)&nbsp;contain Innate&#146;s VAT number. All payments set
forth in this Section&nbsp;10, or otherwise in this Agreement due from Innate to MedImmune, shall be remitted by wire transfer to the bank account of MedImmune as designated in writing to Innate. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.30</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Payment Currency</B>. All payments and reports required from MedImmune or Innate under this Agreement shall be paid
and stated respectively in US dollars. With respect to amounts required to be converted into US dollars from another currency for calculation or payment hereunder, such amounts will be converted using a rate of exchange which corresponds to the rate
used for conversion between the relative currencies by whichever Party recorded the relevant receipt or expenditure, for the respective reporting period in its books and records that are maintained in accordance with IFRS, as applicable, and used
for its external reporting. If a Party is not required to perform such a currency conversion for its IFRS reporting with respect to the applicable period, then for such period such Party will make such conversion using the rate of exchange
calculated using the Foreign Exchange rates set at 14:15 CET and as published by the European Central Bank </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
(https://www.ecb.europa.eu/stats/exchange/eurofxref/html/index.en.html) on the second to last business day of the calendar month (or such other publication as
<FONT STYLE="white-space:nowrap">agreed-upon</FONT> by the Parties) in which such receipt or expenditure was incurred. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.31</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B><FONT STYLE="white-space:nowrap">Set-off</FONT></B>. Where a Party is due to make a payment to the other in
accordance with the terms of this Agreement, that Party shall be entitled to <FONT STYLE="white-space:nowrap">set-off</FONT> against such payment any amount owed to it from the other Party or that other Party&#146;s Affiliates, under this Agreement
or otherwise, provided that <FONT STYLE="white-space:nowrap">set-off</FONT> shall not be permitted in respect of sums that are disputed, until such disputed payments have been agreed or finally determined by arbitration. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.32</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Imports</B>. For the avoidance of doubt, the Parties acknowledge and agree that none of the milestones or royalties
payable under this Agreement are related to the license (or right) to import or any import of Licensed Products. The receiving Party shall be responsible for any import clearance, including payment of any import duties and similar charges, in
connection with any Licensed Products transferred to such Party under this Agreement. The Parties shall <FONT STYLE="white-space:nowrap">co-operate</FONT> in accordance with Applicable Laws to ensure where permissible that no import duties are paid
on imported materials. Where import duties are payable, the Parties shall <FONT STYLE="white-space:nowrap">co-operate</FONT> to ensure that the Party responsible for shipping values the materials in accordance with Applicable Laws and minimizes
where permissible any such duties and any related import taxes that are not reclaimable from the relevant authorities. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>CONFIDENTIALITY</B> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">At all times during the Term and for a period of [***] following termination or expiration thereof, each Party (the
&#147;<B>Receiving Party</B>&#148;) shall (i)&nbsp;keep confidential and not disclose to any Third Party, other than its and its Affiliates&#146; officers, directors, other employees, contractors and advisors on a need to know basis, any
Confidential Information provided to it by the other Party (the &#147;<B>Disclosing Party</B>&#148;) and (ii)&nbsp;not publish or otherwise use, directly or indirectly, for any purpose, such Confidential Information, except to the extent permitted
by the terms of this Agreement or to the extent such use is necessary for the fulfilment of the Receiving Party&#146;s obligations under this Agreement. The </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Receiving Party shall cause all of its and its Affiliates&#146; officers, directors, other employees, contractors and advisors to whom the Receiving Party has disclosed Confidential Information
to comply with confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations at least as restrictive as those set out in this Agreement and shall be liable to the Disclosing Party for any breach thereof by such Affiliates,
officers, directors, other employees, contractors and advisors. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate recognizes that by reason of, among other things, MedImmune&#146;s status as an exclusive licensee pursuant to
the grants under Section&nbsp;3, MedImmune has an interest in Innate&#146;s retention in confidence of information relating to the Licensed Antibodies or Licensed Products, and the Exploitation thereof. Innate shall, and shall cause its Affiliates
and their respective officers, directors, employees and agents to, until the expiration of MedImmune&#146;s obligation to pay royalties hereunder, keep confidential and not publish or otherwise disclose, and not use directly or indirectly for any
purpose other than to perform Innate&#146;s obligations under this Agreement or as expressly permitted hereunder, any Confidential Information relating to any Licensed Antibody or Licensed Product that is Controlled by Innate (&#147;<B>Product
Information</B>&#148;). In the event this Agreement is terminated in its entirety, this Section shall have no continuing force or effect. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> herein shall not extend to any
Confidential Information that, in the case of Sections 11.1 and 11.2, (a) is or comes into the public domain without breach of this Agreement, (b)&nbsp;is received by a Party from a Third Party (other than an Affiliate of Disclosing Party) without
any obligation of confidentiality and without breach of this Agreement, or, in the case of Sections 11.1 and 11.2, or (c)&nbsp;in the case of Section&nbsp;11.1, the Receiving Party can prove was already in its possession without any limitation on
use or disclosure prior to the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Nothing in this Section&nbsp;11 shall prevent either Party from using and disclosing Confidential Information to the
extent reasonably required for te Receiving Party&#146;s performance of its obligations and exercise of its rights granted to it under this Agreement or other agreement between the Parties. In particular either Party shall be entitled to use and
disclose Confidential Information of Innate relating to Licensed Products for Patent filing and prosecution purposes, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
for the purposes of making Drug Approval Applications and for the purposes of appointing Third Parties to manufacture Licensed Products; <U>provided</U>, <U>however</U>, that MedImmune may [***].
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In addition each Party shall be entitled to disclose the terms of this Agreement on a confidential basis to actual or
potential investors or in connection with any permitted assignment under this Agreement or in connection with any proposed grant of a <FONT STYLE="white-space:nowrap">sub-license</FONT> by MedImmune as permitted by this Agreement, provided that in
each case the Receiving Party shall cause any and all parties to whom such disclosure is made to comply with confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations at least as restrictive as those set out in this Agreement
and shall be liable to the Disclosing Party for any breach thereof by such parties. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">This Agreement shall not restrict the Receiving Party from complying with a lawfully issued governmental order or
legal requirement or requirement under applicable stock exchange rules to produce or disclose Confidential Information; <U>provided</U>, <U>however</U>, that, in the event of governmental orders, the Receiving Party shall promptly notify the
Disclosing Party to enable the Disclosing Party to oppose the order or obtain a protective order and the Receiving Party shall cooperate fully with the Disclosing Party in any such proceeding. If the Receiving Party is legally required or required
under applicable stock exchange rules to disclose Confidential Information, the Receiving Party and the Disclosing Party will endeavour to agree to a mutually satisfactory means to disclose such information. Nothing contained herein shall prohibit
either of the Parties from immediately disclosing results of any Clinical Trial to the extent necessary to prevent or mitigate a serious health hazard; <U>provided</U>, <U>however</U>, that the Party intending to make such disclosure shall notify
the other Party prior to and immediately after such disclosure and, to the extent it is reasonably practicable to do so, the nature and content of such disclosure shall be agreed between the Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties acknowledge that each of them shall use Commercially Reasonable Efforts to monitor scientific publications
to prevent any adverse effect from premature publication relating to the Licensed Antibodies or Licensed Products. The Party wishing to make a publication or communication on shall provide a draft to the other Party, which will have [***] to provide
comments. The Party </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
proposing to make a publication or communication shall, in good faith, consider the comments made by the other Party and shall defer the publication or communication for a period of time not
exceeding [***] if a Patent may be filed using the Data or Know How covered in the proposed publication or communication. MedImmune shall have the final decision making with respect to any proposed publication or communication, provided that
MedImmune shall acknowledge the contribution of Innate to the development of the Licensed Product. Publications by Innate relating to Licensed Products following First Commercial Sale of the first Licensed Product by Innate shall only to be made
with MedImmune&#146;s prior written approval. MedImmune will use Commercially Reasonable Efforts to provide a copy of any proposed publication to be made following First Commercial Sale of the first Licensed Product to Innate before it is published.
Notwithstanding the foregoing, neither Party will publish or present any Confidential Information of the other Party without such other Party&#146;s prior written consent. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">This Section&nbsp;11 (other than Section&nbsp;11.2) shall survive the termination or expiration of this Agreement for
a period of ten (10)&nbsp;years. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Disclosure</B>. During the Term, each Party shall promptly disclose to the other Party all Arising IP (whether
patentable or not) which is created by or on behalf of such Party as a result of carrying out the activities assigned to it under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Ownership</U> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall retain all rights, title and interest in and to any and all Licensed Technology, subject only to the
licenses granted to MedImmune in this Agreement. MedImmune shall retain all rights, title and interest in and to any and all MedImmune Technology. Subject to such licenses and the remainder of this Agreement, (a)&nbsp;if Innate has not provided its <FONT
STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice, any Arising IP conceived or made by any Party or their employees or independent contractors (including those of its Affiliates, Sublicensees and other Third Parties) shall be jointly
owned by the Parties and the relevant Party </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
shall assign which shall transfer a [***] <FONT STYLE="white-space:nowrap">co-ownership</FONT> interest in such Arising IP to the other Party, and (b)&nbsp;if Innate has provided its <FONT
STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice, any Arising IP conceived or made by a Party or its employees or independent contractors (including those of its Affiliates, Sublicensees and other Third Parties) shall belong to such
Party and any Arising IP conceived or made by both Parties or their employees or independent contractors (including those of its Affiliates, Sublicensees and other Third Parties) shall be jointly owned by the Parties as determined based on
inventorship in accordance with US patent laws; provided that in either case any Arising IP arising from either Party&#146;s conduct of CMC development work and solely related to such Party&#146;s proprietary CMC technology shall be owned by such
Party, and further provided that in either case any MedImmune Compound Arising IP conceived or made by a Party or its employees or independent contractors (including those of its Affiliates, Sublicensees and other Third Parties) shall belong to
MedImmune. To the extent permissible under Applicable Laws, each Party will cause each employee and contractor (including those of its Affiliates, Sublicensees and other Third Parties) conducting work on its behalf under this Agreement to sign a
contract that (i)&nbsp;compels prompt disclosure of all Arising IP, (ii)&nbsp;automatically assigns to such Party all right, title and interest in and to such Arising IP, and (iii)&nbsp;obligates such persons to maintain confidentiality in respect
of the Arising IP (on terms at least as restrictive as those contained herein). Each Party will require each employee and contractor conducting work on its behalf under this Agreement to maintain records in sufficient detail and in a good scientific
manner appropriate for regulatory purposes and purposes of pursuing Patent protection on inventions to properly reflect all work done. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Prosecution and Maintenance of Patent Rights</U> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties will each appoint a patent coordinator for the purposes of coordinating their activities under this
Section&nbsp;12. MedImmune (the &#147;Responsible Party&#148;) shall be primarily responsible for and shall use Commercially Reasonable Efforts in control the preparation, filing, prosecution (including without limitation conducting or handling any
interferences, oppositions, action for declaratory judgment, nullity actions, reissue proceedings, reexaminations and challenges to title) and maintenance of the Licensed Patents (other than the Formulation Patent, the
<FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Licensed Patents and the Licensed Shared Patents)<I> </I>and Patents claiming Arising IP <B>(&#147;Arising Patents</B>&#148;) (collectively, the &#147;<B>Controlled Patents</B>&#148;); provided
that the Responsible Party shall provide the other Party with advance copies of, and a reasonable opportunity to comment upon, proposed patent filings, related prosecution strategies and proposed correspondence with patent officials or other Third
Parties relating to any Controlled Patents (excluding any such Patents protecting MedImmune Compound Arising IP or any Arising IP relating to MedImmune&#146;s proprietary CMC technology), and will consider comments received from the other Party with
respect to such proposed filings, strategies and correspondence in good faith. Innate shall use Commercially Reasonable Efforts to explore [***] and, to the extent reasonably practicable, ensure [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Responsible Party shall further be responsible for all costs and expenses associated with the filing, prosecution
and maintenance of the Controlled Patents, and where applicable, the Licensed Shared Patents. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If the Responsible Party decides not to file, prosecute or maintain a Controlled Patent (excluding any such Patents
protecting MedImmune Compound Arising IP or any Arising IP relating to MedImmune&#146;s proprietary CMC technology), it shall give the other Party reasonable notice to that effect sufficiently in advance of any deadline for any filing with respect
to such Patent. After receiving such notice, the other Party may elect by written notice to the Responsible Party within [***] after receiving such notice from the Responsible Party to file, prosecute and maintain the relevant Licensed Patent, at
its sole cost and expense. If the other Party does so elect, the Responsible Party shall cooperate with Innate as necessary to enable Innate to perform such acts as may be reasonably necessary for Innate to file, prosecute or maintain such Patent,
including the execution and filing of appropriate instruments and to facilitate the transition of such patent activities to Innate. For the avoidance of doubt, Innate shall not have any comment rights or rights to assume prosecution of any Arising
Patents claiming MedImmune Compound Arising IP or any Arising IP relating to MedImmune&#146;s proprietary CMC technology. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Responsible Party shall be responsible for and shall control, in consultation with the other Party, the selection
of the appropriate Controlled Patents as listed in the patent information section of the Drug Approval Application for </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Licensed Products for filing to obtain a Patent Term Extension (&#147;<B>PTE</B>&#148;) pursuant to all Applicable Laws, including without limitation supplementary protection certificates and any
other extensions that are now or become available in the future wherever applicable to Controlled Patents that are applicable to the Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Promptly after the Effective Date, Innate shall (a)&nbsp;provide to MedImmune all information, including a correct and
complete list of all Patents covering the Licensed Product(s) or otherwise necessary or reasonably useful to enable MedImmune to make filings with Regulatory Health Authorities with respect to the Licensed Patents, including as required or allowed
in connection with (i)&nbsp;in the United States, the FDA&#146;s Purple Book and (ii)&nbsp;outside the United States, under the national implementations of Section&nbsp;10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents, and
(b)&nbsp;cooperate with MedImmune at MedImmune&#146;s reasonable request in connection therewith, including meeting submission deadlines, in each case, to the extent required or permitted by Applicable Laws. Promptly after the Effective Date and not
less than [***] prior to any subsequent deadline with respect to the foregoing, the Parties shall discuss and identify those Patents claiming or covering the Licensed Product and the process of review of such Patents for submission to the applicable
Regulatory Health Authorities. MedImmune shall have the right, at its sole discretion, to submit or <FONT STYLE="white-space:nowrap">de-list</FONT> any Licensed Patent with respect to any Regulatory Health Authority with prior notice to Innate.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding anything to the contrary in this Section&nbsp;11, neither Party shall have the right to make an
election under the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. 103(c)(2)-(c)(3) (the &#147;<B>CREATE Act</B>&#148;) when exercising its rights under this Section&nbsp;11 without the prior written consent of the other
Party. With respect to any such permitted election, the Parties shall use reasonable efforts to cooperate and coordinate their activities with respect to any submissions, filings or other activities in support thereof. The Parties acknowledge and
agree that this Agreement is a &#147;joint research agreement&#148; as defined in the CREATE Act. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U><FONT STYLE="white-space:nowrap">In-licensed</FONT> IP and Third-Party Patent Rights</U> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall, during the Term, not make any material changes or alterations to the Third Party Agreements adversely
impacting MedImmune&#146;s rights under this Agreement except with the prior written consent of MedImmune. Innate will be responsible for any costs and payments (including without limitation upfront fees, annual fees, milestone payments and
royalties) due to any Third Party in relation to the Third Party Agreements. Innate shall notify MedImmune immediately if Innate becomes aware of any dispute arising under a Third Party Agreement. In the event that [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune will be responsible for any costs and payments (including without limitation upfront fees, annual fees,
milestone payments and royalties) due to any Third Party in connection with the use of an MedImmune Compound in a Combination which is Researched, Developed, Commercialized and/or Exploited under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Defense of Third Party Claims. </B>Except as otherwise provided in Section&nbsp;13, neither Party makes any
warranty with respect to the validity, perfection, or dominance of any Patent or proprietary right or with respect to the absence of rights in Third Party Patents which may be infringed by the manufacture or sale of any Licensed Antibody or Licensed
Product. If a Third Party asserts a Patent or other right owned by it is infringed by the Development, Manufacture or Exploitation of any Licensed Antibody or Licensed Product, or either Party discovers such a Patent or right, the Party first
obtaining knowledge of such a claim or potential claim shall immediately provide the other Party written notice and the related facts in reasonable detail. In the event the Parties cannot agree on the defense of any such claim, such defense shall be
controlled by the Responsible Party; provided that the other Party shall have the right to participate and to be represented in any such action by counsel of its selection at its sole discretion. The Responsible Party shall also have the right to
control settlement of such claim; if such settlement requires the Responsible Party to pay a royalty to the Third Party, such expense shall be treated pursuant to Section&nbsp;10.20. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Oppositions. </B>Either Party may commence an opposition, action for declaratory judgment, nullity action,
interference, <FONT STYLE="white-space:nowrap">re-examination,</FONT> or other attack upon the validity, title, or enforceability of any Patents Controlled by a Third Party </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
that cover the Manufacture, use, or sale or other Exploitation of any Licensed Antibody or Licensed Product and are not Licensed Patents, MedImmune Patents or Patents in the Arising IP, at its
own expense, but shall notify the other before commencing such action to enable the Parties to cooperate, if they see fit. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Infringement by Third Parties </U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Party first having knowledge that any Controlled Patent has been infringed or misappropriated by a Third Party in
any country in the Territory shall promptly notify the other in writing, such notice setting forth the facts of that infringement in reasonable detail. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Responsible Party shall have the first right, but not the obligation, to institute, prosecute, and control any
action or proceeding or negotiation of any settlements with respect to any infringement of Controlled Patents (with the other Party having the right to participate in such action or negotiations at its expense and be represented if it so desires).
If necessary, the other Party agrees in any such action to be joined as a claimant and to give the Responsible Party reasonable assistance and any needed authority to control, file, and to prosecute such action, at the Responsible Party&#146;s
expense. If the Responsible Party elects not to institute and prosecute such action or proceeding or to conduct such negotiation, the Responsible Party will discuss with the other Party the reasons for this decision and the other Party may step in
the Responsible Party&#146;s rights for purposes of this Section&nbsp;12.14, with the consent of the Responsible Party not to be unreasonably withheld. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Compensation.</B> Any damages or monetary awards relating to the Controlled Patents shall be applied as follows:
(a)&nbsp;to reimburse any and all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred by the Responsible Party in bringing suit; (b)&nbsp;to reimburse any and all <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred by the other Party in relation to the suit; and (c)&nbsp;any remaining damages shall be allocated at [***] to the Responsible Party and [***] to
the other Party. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Trademarks, Packaging and Labelling</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall have the sole right and discretion to: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">select the trademarks to be used specifically for the marketing and sale of all Licensed Products in the Territory
(each a &#147;<B>Product Trademark</B>&#148;). MedImmune shall own all rights, title and interests in and to the Product Trademarks and all IP rights and other rights and goodwill associated therewith. Innate shall not use any trademark that is the
same or confusingly similar to, misleading or deceptive with respect to, or that dilutes any of the Product Trademarks. MedImmune shall have the right; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">use internal or external counsel of its own choosing and at its sole expense to, file, prosecute, maintain, protect,
defend and enforce the Product Trademarks; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">design and procure packaging and labeling of the Licensed Products. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Each Party shall notify the other Party promptly in writing upon learning of any actual, alleged, or threatened infringement of a
Product Trademark used in connection with the Licensed Products or in relation to the indications for which they are marketing, of any unfair trade practices, trade dress imitation, passing off of counterfeit goods, or like offenses. Innate shall
cooperate as reasonably requested by MedImmune in any actions or proceedings brought by MedImmune to halt the infringement. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>REPRESENTATIONS, WARRANTIES AND COVENANTS</B><B> </B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Mutual Warranties</U>. Each Party provides the following representations and warranties to the other as at the
Effective Date: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">Corporate Power. It is duly organized, validly existing and in good standing under the laws of its jurisdiction of
incorporation or formation, has full legal power to grant the rights granted to the other Party under this Agreement, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">Due Authorisation. The execution, delivery, and performance of the Agreement by it does not conflict with any agreement,
instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any material law or regulation of any court, Governmental Body, or administrative or other agency having jurisdiction over it.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">Binding Agreement. This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance
with its terms. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Innate Warranties</U>. Innate provides the following representations, warranties and covenants to MedImmune as of
the date of signing of the Development and Option Agreement (or as of such other dates or time periods as may be specified below). Such representations, warranties and covenants shall be considered to be restated by Innate as at the Effective Date,
subject to Innate&#146;s right to make disclosures against such representations, warranties and covenants with respect to matters which have arisen or come to the knowledge of Innate (with respect to representations made to Innate&#146;s knowledge)
between the date of signing of the Development and Option Agreement and the Effective Date of this Agreement. For the avoidance of doubt, Innate shall not be liable for facts and circumstances fairly disclosed to MedImmune in accordance with the
preceding sentence. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate is: (i)&nbsp;the sole and exclusive owner of the entire right, title and interest in the Licensed Patents
listed in <U>Schedule 13.2(a)(i)</U> (the &#147;Owned Patents&#148;), (ii) the sole and exclusive licensee of the Licensed Patents listed in <U>Schedule 13.2(a)(ii) (the &#147;Exclusively Licensed Patents&#148;)</U>, in connection with the Licensed
Antibodies, and (iii)&nbsp;the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licensee of the <FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Patents, in connection with the Licensed Antibodies, and (iv)&nbsp;either itself or
through its Affiliates, the sole and exclusive owner or licensee of the entire right, title and interest in the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> listed in <U>Schedule 13.2(a)(iv)</U> and has the right to grant an exclusive
license to MedImmune in connection with the Development and Commercialization of the Licensed Antibodies in the Field under the other Licensed Know How. To the extent any rights, title or interests in the Licensed
<FONT STYLE="white-space:nowrap">Know-How</FONT> are owned by its Affiliates, Innate </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
shall procure that such rights are transferred to Innate such that MedImmune shall receive from Innate all rights and licenses granted to it under this Agreement and such that Innate shall be
entitled without restriction to grant the rights to MedImmune specified in the License Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Other than for the restrictions set forth in the Third Party Agreements, which have been disclosed to MedImmune prior
to the date of signing of the Development and Option Agreement, and the licenses granted to the Licensed Shared Patents for use in connection with [***], none of the Licensed Patents is subject to any encumbrance or lien permitted by Innate and none
of the Owned Patents is subject to any encumbrance or lien permitted by Innate or, to Innate&#146;s knowledge, to any claim of ownership by any Third Party. For the duration of the Term, Innate shall not encumber the rights granted to MedImmune
hereunder with respect to the Licensed Technology in a manner that would have an material adverse effect on MedImmune&#146;s rights hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Third Party Agreements are in full force and effect and Innate has no knowledge of any circumstances that may lead
to the termination of such agreements. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">As at the Effective Date, Innate does not own or Control any Product Trademarks,
<FONT STYLE="white-space:nowrap">Know-How</FONT> or Patents, other than the Licensed Technology, that are necessary for the Research, Development and Exploitation of the Licensed Products. The Patents specified in <U>Schedules 9.2(a)(i) and
9.2(a)(ii)</U> constitute all of the Licensed Patents existing at the Effective Date. To Innate&#146;s and its Affiliates&#146; knowledge, the Licensed Patents have as of the Effective Date been diligently and properly filed, prosecuted and
maintained in accordance with Applicable Law where applicable in the course of normal patent prosecution of patents that are intended to be maintained, and all applicable fees have been paid on or before the due date for payment.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">To the knowledge of Innate&#146;s and its Affiliates&#146; personnel responsible for patent matters, in respect of all
US patent applications in the Listed </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Patents, Innate (or, as appropriate, its licensor) has submitted all material prior art of which it is aware in accordance with the requirements of the United States Patent and Trademark Office.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">To Innate&#146;s and its Affiliates&#146; knowledge, as of the Effective Date, the Licensed Patents properly identify
each and every inventor of the claims of the Licensed Patents. To Innate&#146;s and its Affiliates&#146; knowledge, each Person who has contributed to the conception of inventions claimed in the Licensed Patents owned by Innate and existing as of
the Effective Date, has duly assigned and has executed an agreement assigning to Innate, or as appropriate, Innate&#146;s licensor, such Person&#146;s entire right, title and interest in and to such Licensed Patents. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B><I></I></B>Where Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> has been disclosed to a Third Party
under terms of confidentiality, to Innate&#146;s knowledge no breach of such confidentiality obligations has been committed by any such Third Party. MedImmune shall not, before, on or after the Effective Date, have any obligation to contribute to
any remuneration of any inventor employed or previously employed by Innate or any of its Affiliates in respect of the Current IPH2201, Licensed Patents or Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> Innate or its Affiliates are solely
responsible for paying all such remuneration and neither Innate nor any of its Affiliates has received notification that such payments are insufficient compensation. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate and its Affiliates have not been notified of any actual or threatened infringements or misappropriation of the
Licensed Technology. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate and its Affiliates have not been notified of any threatened or pending proceedings in any court, arbitration,
patent office, administrative or other tribunal which are concerned with (a)&nbsp;the ownership of any of the Licensed Technology, or (b)&nbsp;the validity of any of the Licensed Patents (other than pending Patent applications), and, in both cases,
to Innate&#146;s and its Affiliates&#146; knowledge, there have been no allegations or assertions by a Third Party which are likely to give rise to a claim by such Third Party for ownership or invalidity of the Licensed Patents.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Third Party Rights</U> </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The conception, development and reduction to practice of the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT>
and Licensed Patents existing as of the Effective Date has not, to Innate&#146;s knowledge, constituted or involved the misappropriation of trade secrets of any Person. Other than the amounts owed by Innate under the Third Party Agreements, there
are no claims, judgments or settlements against or amounts with respect thereto owed by Innate or any of its Affiliates as of the Effective Date relating to the Regulatory Documentation, Listed Patents or Licensed
<FONT STYLE="white-space:nowrap">Know-How,</FONT> or amounts owed by Innate or its Affiliates with respect to any such claims, judgments or settlements. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">To Innate&#146;s and its Affiliates&#146; knowledge, as of the Effective Date, the Development and the
Commercialization of the Current IPH2201 does not infringe or misappropriate the Patents, of any Third Party, and no claim or litigation has been brought or threatened by written notice to Innate as of the Effective Date by any Person making such
allegations. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall not, before, on or after the Effective Date, have any obligation to pay any fees, charges or other
sums due to a Third Party under the Third Party Agreements in relation to Licensed Products containing the Current IPH2201. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Development and Manufacture</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">As at the Effective Date, since the adoption of the Specification in <U>Schedule 13.2(m)</U>, all Current IPH2201
produced by, to Innate&#146;s knowledge, on behalf of Innate, has been, Manufactured, packaged, stored and labelled (as applicable) in accordance with all Applicable Laws and the Specification in <U>Schedule </U><U>13.2(m)</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">As at the Effective Date, Innate&#146;s contract manufacturing organizations for the Licensed Product are those
specified in <U>Schedule 13.2(n)</U> and the manufacturing agreements listed on that schedule are in full force and effect and Innate has no knowledge any circumstances that would lead to
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
the termination of such agreements. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Regulatory and
Compliance</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">As of the Effective Date, Innate, its Affiliates and, to their knowledge, their contractors, have at all times
(a)&nbsp;researched and developed the Licensed Product in accordance with all Applicable Laws, and (b)&nbsp;undertaken clinical trials and prepared, maintained and retained all Regulatory Documentation in accordance with GLP, GCP, regulations and
other Applicable Laws. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate has made available to MedImmune all Regulatory Documentation, Licensed
<FONT STYLE="white-space:nowrap">Know-How</FONT> and other information in its possession or Control as of the Effective Date regarding or related to any Licensed Antibody or Licensed Product that MedImmune has specifically requested, with reasonable
clarity, in writing to Innate to make available or that Innate would reasonably consider based on the information available at the Effective Date to be material to MedImmune&#146;s evaluation of whether to enter this Agreement and all such items are
true, complete and correct. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">All Regulatory Documentation that are the material regulatory filings or approvals held by Innate or its Affiliates in
relation to the Research, Development and Manufacture of the Licensed Products have been provided to MedImmune prior to the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate and its Affiliates have not knowingly withheld from a Regulatory Health Authority or from MedImmune any
material information, including CMC <FONT STYLE="white-space:nowrap">Know-How,</FONT> Serious Adverse Events and results from Clinical Trials (whether or not completed) relating to the safety, toxicity, quality or efficacy of the Licensed Products.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(s)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate and its Affiliates have the right to refer to and use any data that has been created by the manufacturers of
the Licensed Product which is necessary for the use and registration of the Licensed Product and MedImmune will have the same rights under this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(t)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In the course of the Development of the Licensed Product, Innate has not knowingly used, any employee or consultant
that is debarred by any Regulatory Health Authority or, to its knowledge, is the subject of debarment proceedings by any Regulatory Health Authority. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(u)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The information provided by Innate to MedImmune (for the purposes of MedImmune&#146;s assessment as to whether or not
filing is required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to this Agreement or the transactions contemplated herein) regarding Innate&#146;s and its Affiliates&#146; corporate structure and financial
status is correct, complete and not misleading. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>General</U> </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Neither Innate nor any Innate Affiliate is engaged in any litigation, opposition or arbitration affecting or relating
to the Current IPH2201 and, as to Innate and its Affiliates&#146; knowledge as at the Effective Date, there are no such litigation, opposition or arbitration pending or threatened by written notice to Innate and no material facts which are likely to
result in a material judgment against Innate or its Affiliates relating to the Licensed Products. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(w)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The rights granted to MedImmune under this Agreement are not subject to any right, license or interest under the
Licensed Patents in favour of any government due to funding obtained with respect to Licensed Products or clinical trials carried out in government owned hospitals which would conflict with the rights granted to MedImmune under this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>MedImmune Warranties</B>. MedImmune provides the following representations, warranties and covenants to Innate as
of the date of signing of the Development and Option Agreement (or as of such other dates or time periods as may be specified below). Such representations, warranties and covenants shall be considered to be restated by MedImmune as at the Effective
Date, subject to MedImmune&#146;s right to make disclosures against such representations, warranties and covenants with respect to matters which have arisen or come </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
to the knowledge of Innate (with respect to representations made to MedImmune&#146;s knowledge) between the effective date of the Development and Option Agreement and the Effective Date of this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">No claim or litigation has been brought or threatened as of the Effective Date in relation to an MedImmune Compound by
any Person making such allegations by written notice to MedImmune. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune will not knowingly use in any capacity, in connection with the Development of the Licensed Product, any
employee or consultant that is debarred by any Regulatory Health Authority or, to the best of such its knowledge, is the subject of debarment proceedings by any Regulatory Health Authority. If either Party learns that any employee or consultant
performing on its behalf under this Agreement has been debarred by any Regulatory Health Authority, or has become the subject of debarment proceedings by any Regulatory Health Authority, such Party shall promptly notify the other Party and shall
prohibit such employee or consultant from performing on its behalf under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The information provided by MedImmune to Innate (for the purposes of Innate&#146;s assessment as to whether or not
filing is required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to this Agreement or the transactions contemplated herein) regarding MedImmune&#146;s and its Affiliates&#146; corporate structure and
financial status is correct, complete and not misleading. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune is not researching, Developing or otherwise Exploiting a Competing Product. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Mutual Covenants</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If either Party learns that any employee or consultant performing on its behalf under this Agreement has been debarred
by any Regulatory Health Authority, or has become the subject of debarment proceedings by any Regulatory Health Authority, such Party shall promptly notify the other Party and shall prohibit such employee or consultant from performing on its behalf
under this </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Agreement.<B><I> </I></B> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party shall, and shall procure that its Affiliates and its/their contractors shall, during the Term,
(a)&nbsp;Manufacture, research and develop the Licensed Product in accordance with all Applicable Laws, and (b)&nbsp;undertake clinical trials and prepare, maintain and retain all Regulatory Documentation in accordance with GLP, GCP, regulations and
other Applicable Laws. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Anti-Corruption Laws</U> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Both Parties shall ensure that in connection with this Agreement, they shall conduct their activities in a manner that
is consistent with the Anti-Corruption Laws. Each Party further undertakes that none of its or its Affiliates&#146; employees, directors or officers shall, directly or indirectly, engage in any activities that violate any Anti-Corruption Law
(a)&nbsp;in order to influence official action of any Government Official, or (b)&nbsp;with the intention of or as a condition to inducing any person to carry out a duty or function improperly or to reach a favourable decision on an improper basis,
in each case in connection with the activities contemplated under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party shall promptly provide the other Party with written notice of (a)&nbsp;becoming aware of a Material
Anti-Corruption Law Violation by it or any of its or its Affiliates&#146; employees, directors or officers with respect to the subject matter of this Agreement, or (b)&nbsp;upon receiving a formal notification that it or any of its or its
Affiliates&#146; employees, directors or officers is the target of a formal investigation by any Governmental Authority for a Material Anti-Corruption Law Violation. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate acknowledges that its undertakings given in this Section (c)&nbsp;are material to MedImmune in entering into
this Agreement. Notwithstanding any other provision of this Agreement, if MedImmune becomes aware of what it determines, acting reasonably, to be a breach of these undertakings, then MedImmune shall be entitled to terminate this Agreement in its
entirety, and to terminate any other agreement between the Parties, on notice with immediate effect. Subject to the accrued </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:11pt; font-family:ARIAL" ALIGN="justify">
rights of the Parties pursuant to termination, MedImmune shall have no liability to Innate for any fees, reimbursements or other compensation or for any loss, cost, claim or damage resulting,
directly or indirectly, from such termination. At the sole discretion of MedImmune, any breach of an Innate obligation with respect to its obligation in this subsection (c)&nbsp;may be cured (if capable of being cured) within a reasonable period of
time after learning of such material breach or Material Anti-Corruption Law Violation. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>13.4 DISCLAIMER OF WARRANTY.</U> EXCEPT
FOR THE EXPRESS WARRANTIES SET FORTH IN SECTION 13 NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER
WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE
<FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>RECORD RETENTION, AUDIT AND USE OF NAME</B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Records Retention; Audit</U> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party shall keep or cause to be kept accurate records of account in accordance with IFRS, showing information
that is necessary for the accurate determination of the royalties and other payments due under Section&nbsp;10, or any other payment due hereunder. Such records or books of account shall be kept until the third (3rd) anniversary of December&nbsp;31
of the Calendar Year in which the relevant Licensed Product is sold (in the case of royalty or other payments due under Section&nbsp;10) or in the period for which any other payment hereunder is required to be made. For clarity, each Party shall
cause its Affiliates to keep, and shall require pursuant to a written agreement that any Sublicensee, other sublicensee or subcontractor performing activities hereunder keep accurate records or books of account in a manner that will permit such
Party to comply with its obligations under the foregoing sentence. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Upon the written request of the other Party, each Party shall permit a qualified accountant or a person possessing
similar professional status and associated with an independent accounting firm acceptable to the Parties to inspect during regular business hours and no more than once a year and once in any given Calendar Year, and going back no more than three
(3)&nbsp;years preceding the current Calendar Year, all or any part of the audited Party&#146;s records and books necessary to check the accuracy of any payments made or required to be made hereunder. The accounting firm shall disclose to Innate and
MedImmune only whether the payments made are correct and details concerning any discrepancies, but no other information. The charges of the accounting firm shall be paid by the Party requesting the inspection, except that if the payments being
audited have been underpaid or the costs being reimbursed have been overstated by more than [***], the charges will be paid by the Party whose records and books are being inspected. Any failure by a Party to exercise its rights under this
Section&nbsp;14.2 with respect to a Calendar Year within the three (3)&nbsp;year period allotted therefor shall constitute a waiver by such Party of its right to later object to any payments made by the other Party under this Agreement during such
Calendar Year. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Publicity Review</U> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Subject to the remainder of this Section&nbsp;14.3 and to Section&nbsp;11, no Party shall originate any written
publicity, news release, or other announcement relating to this Agreement or the existence of it or to performance hereunder (collectively, &#147;<B>Written Disclosure</B>&#148;), without the prior written approval of the other, which approval shall
not be unreasonably withheld or delayed. Notwithstanding the foregoing, any Party may make public Written Disclosures it believes in good faith are required by Applicable Laws or any listing or trading agreement concerning its publicly traded
securities, provided that, prior to such Written Disclosure, the disclosing Party shall where reasonably practicable provide the other Party with a copy of the materials proposed to be disclosed and an opportunity to promptly review and comment. If
the receiving Party reasonably requests that any information in the materials proposed to be disclosed be deleted, the disclosing Party shall use reasonable efforts to request confidential treatment of such information pursuant to any applicable
regulation relating to the confidential treatment of information. The terms of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
this Agreement may be disclosed to (a)&nbsp;Government Agencies where required by Applicable Laws, provided that the Party making such disclosure seeks a protective order or confidential
treatment of this Agreement to the extent allowed under Applicable Laws, (b)&nbsp;Third Parties having a need to know information for purposes of performing under this Agreement or advising a Party with respect to its performance under this
Agreement or its business or legal obligations, or (c)&nbsp;Third Party investment bankers, financial advisors, actual or potential Third Party partners, licensors, investors, licensees, sublicensees or acquirers of any of the assets to which this
Agreement relates; provided, that, disclosures under subsections (b)&nbsp;or (c) shall be made on a need to know basis under confidentiality obligations at least as strict as those contained herein and the Party having made such disclosures shall be
liable to the other for any breach of such confidentiality obligation by the Third Party recipient. Notwithstanding the foregoing, the Parties intend to issue jointly press releases regarding material events occurring with respect to the Development
or Commercialization of Licensed Products pursuant to this Agreement. Such material events may include without limitation the commencement or completion of a Phase 3 Clinical Trial for Licensed Products, the filing of a Drug Approval Application,
and the receipt of Regulatory Approval for Licensed Products. The content of any such press releases shall be agreed upon by the Parties in advance of any such announcement being provided to any Third Party. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Use of Names</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Neither Party shall use the name, insignia, symbol, trademark, trade name or logotype of the other Party or its
Affiliates in relation to this transaction or otherwise in any public announcement, press release, or other public document without the prior written consent of such other Party, which consent shall not be unreasonably withheld, delayed or
conditioned, except for those disclosures for which consent has previously been obtained; <U>provided</U>, <U>however</U>, that either Party may use the name of the other Party in any document required to be filed with any government authority,
including without limitation the FDA and the Securities and Exchange Commission or otherwise as may be required by Applicable Laws, provided that such disclosure shall be governed by Section&nbsp;11. Further, the restrictions imposed on each Party
under this Section&nbsp;14.4 are not intended, and shall not be construed, to prohibit a Party from identifying the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
other Party in its internal business communications, provided that any Confidential Information in such communications remains subject to Section&nbsp;11. Moreover, and notwithstanding the
foregoing, MedImmune and its Affiliates and Sublicensees and Innate and its Affiliates shall have the right to use the name of Innate and its Affiliates to the extent necessary or useful in connection with the Exploitation of the Licensed Products
or perform the activities as contemplated by this Agreement in their negotiations and work with subcontracting and sublicensing transactions in connection therewith provided that any Confidential Information in such communications remains subject to
Section&nbsp;11. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>TERM AND TERMINATION</B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Term. </B>The term of this Agreement shall commence as of the Effective Date and, unless sooner terminated as
provided herein, shall continue in effect until the date on which all of MedImmune&#146;s payment obligations under Section&nbsp;10 have been performed or have expired (the &#147;<B>Term</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Termination Rights</B> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Termination for Cause</U> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Subject to the provisions of this Section&nbsp;15.2(i), if either Party (the &#147;<B>Breaching Party</B>&#148;) shall
have committed a material breach of any of its material obligations under this Agreement, and such material breach shall remain uncured and shall be continuing for a period of [***] following the Breaching Party&#146;s receipt of notice of such
breach from the other Party (the &#147;<B>Breach Invoking Party</B>&#148;) stating the Breach Invoking Party&#146;s intent to terminate this Agreement in its entirety pursuant to this Section&nbsp;15.2(i) if such breach remains uncured, then, in
addition to any and all other rights and remedies that may be available, the Breach Invoking Party shall have the right to terminate this Agreement effective upon the expiration of such [***] period (subject, however, to the provisions set forth
below in this Section&nbsp;15.2(i). Notwithstanding the above, if (i)&nbsp;such material breach cannot reasonably be cured within such [***], (ii) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
the Breaching Party provides, within such [***], the Breach Invoking Party with a written detailed plan that contains measures that can be reasonably expected to cure such breach as soon as
reasonably practicable but no later than within [***], and (iii)&nbsp;the Breaching Party commences to perform such measures in accordance with such plan, and (iv)&nbsp;the Breaching Party thereafter diligently continues to perform such measures as
detailed in such plan, then the Breach Invoking Party shall not be entitled to terminate this Agreement (and any notice of termination issued pursuant to the foregoing sentence shall not become effective) unless and until the Breaching Party ceases
to diligently perform such measures despite then not having cured the breach or does not cure the breach during the timeframe set forth in the plan. Notwithstanding the above, if within the aforementioned [***] period either Party takes measures to
resolve the dispute (for which termination is being sought) pursuant to Section&nbsp;17.2 and thereafter (if the dispute then remains unresolved) within a period of [***] after the expiry of the time period set forth in Section&nbsp;17.2, initiates
arbitration as permitted under Section&nbsp;17.3 to resolve the dispute and diligently pursues such procedure, then termination shall be suspended until the arbitration tribunal determines through its final resolution of the dispute that such breach
exists. This Section&nbsp;15.2(i) defines exclusively the Parties&#146; right to terminate this Agreement for any material breach of contract. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Termination for Convenience&nbsp;&nbsp;</U> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Prior to its expiration, this Agreement may be terminated in its entirety at any time by MedImmune effective upon one
hundred and twenty (120)&nbsp;days (or such longer period as MedImmune may elect at its sole discretion) prior written notice to Innate. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Termination for Insolvency&nbsp;&nbsp;</U> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">A Party may terminate this Agreement effective immediately upon written notice to the other Party if at any time
during the Term, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
the other Party (the &#147;Debtor&#148;) (i) becomes insolvent, (ii)&nbsp;files for or is subject to the institution of bankruptcy, liquidation or receivership proceedings, (iv)&nbsp;assigns all
or a substantial portion of its assets for the benefit of creditors, (v)&nbsp;has a receiver or custodian appointed for the Debtor&#146;s business, or (vi)&nbsp;has a substantial part of its business being subject to attachment or similar process;
provided, however, that in the event of any involuntary case the first Party shall not be entitled to terminate this Agreement pursuant to this subsection 15.2(iii) if the case is dismissed within sixty (60)&nbsp;days after the commencement thereof.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Termination for Patent Challenge</U> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Termination by Innate for Patent Challenge. Except to the extent the following is not enforceable under the law of a
particular jurisdiction, this Agreement may be terminated by Innate in its entirety upon written notice to that effect to MedImmune, if MedImmune or any of its Affiliates has challenged the validity, enforceability or scope of any Licensed Patent
(an &#147;<B>IP Challenge</B>&#148;) and failed to withdraw the IP Challenge within [***] after having received Innate&#146;s written notice of the IP Challenge requiring such IP Challenge to be withdrawn (including notice of Innate&#146;s intention
to otherwise terminate this Agreement). This Section&nbsp;15.3(iv) shall not apply in relation to any IP Challenge made by MedImmune as a counterclaim or defence in response to an action brought by Innate, its Affiliates or any Third Party licensee
or licensor of Innate or its Affiliates alleging infringement of a Licensed Patent by MedImmune for activities that do not relate to NKG2A. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Consequences of a MedImmune Triggered Termination </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In the event (a)&nbsp;Innate terminates this Agreement pursuant to Section&nbsp;15.2(i) for MedImmune&#146;s material
breach; (b)&nbsp;Innate terminates this Agreement </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
pursuant to Section&nbsp;15.2(iii) for MedImmune&#146;s insolvency; (c)&nbsp;Innate terminates this Agreement pursuant to Section&nbsp;15.2(iv); or (d)&nbsp;MedImmune terminates this Agreement
pursuant to Section&nbsp;15.2(ii) for convenience; (a termination as per (a)&nbsp;through (d) being an &#147;<B>MedImmune Triggered Termination</B>&#148;), MedImmune shall, subject to Section&nbsp;15.4(i), continue to be obligated during the
termination notice period (as applicable) to perform as far as reasonably practicable all of its obligations under this Agreement, except in the event of a termination pursuant to Section&nbsp;15.2(ii) for material safety concerns. For purposes of
this Section&nbsp;15.3 and Section&nbsp;15.4, &#147;material safety concerns&#148; shall the reasonable belief, based upon new scientific data that there are safety and public health issues relating to the Licensed Product such that the medical
benefit/risk ratio of such Product is sufficiently unfavorable as to materially compromise the welfare of patients. If a MedImmune Triggered Termination occurs after the first Regulatory Approval of a Licensed Product, MedImmune shall continue to
use Commercially Reasonable Efforts to Commercialize such Licensed Product until the earlier of (i), if applicable, the expiration of the one hundred twenty (120)&nbsp;day notice period, in the event of a termination by MedImmune pursuant to
Section&nbsp;15.2(ii) other than for material safety concerns; (ii)&nbsp;receipt of Innate&#146;s written notice that MedImmune may cease such Commercialization activities; or (iii), if applicable, the effective date of the termination notice. In
addition, as a result of a MedImmune Triggered Termination the following shall apply: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">All licenses and rights to the Licensed Technology granted to MedImmune hereunder shall terminate as of the effective
date of such termination, except to the extent and for so long as is necessary to permit MedImmune to meet its obligations under this Agreement, to finish
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-in-progress</FONT></FONT> and sell any inventory as per Section&nbsp;15.3(xi) and to otherwise perform any responsibilities in connection with any then ongoing Clinical Trial or
other activity that cannot be terminated as of such date under Applicable Laws, including GCP, it being agreed that all such activities and responsibilities shall be discontinued and ceased (unless otherwise agreed or required under Applicable Laws
by transitioning such activities and responsibilities to Innate) as promptly as possible, subject to Applicable Laws, including GCP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If the notice of the MedImmune Triggered Termination is given at a time when the Clinical Trials or any other Assigned
Activities have been initiated but not yet completed, then the Parties shall work together in good faith during the termination notice period to ensure that MedImmune&#146;s involvement in and responsibilities for such activities will be
discontinued and ceased as efficiently and promptly as possible (by way of transitioning such involvement and responsibilities to Innate or by other means agreed to by the Parties), subject to Applicable Laws, including GCP, and provided that the
foregoing shall be without prejudice to MedImmune&#146;s obligations under this Agreement and rights under Section&nbsp;15.3(xi) and that provided further that, with respect to any Clinical Trial related to the Licensed Product for which a Contract
Research Organisation has been contracted or the first patient has been dosed, whichever is the earlier, MedImmune shall pay to Innate, upon the effective date of termination, its unpaid portion of the Shared Development Costs, as budgeted in the
corresponding Development Budget until completion of such Clinical Trial (i.e., final report sent to the Regulatory Authorities). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall grant, and hereby grants to Innate an exclusive, worldwide, royalty-bearing right and license, with
the right to grant sublicenses, under any MedImmune Technology solely to the extent incorporated into or necessary for the Exploitation of the Licensed Products, or applicable to the use, formulation, method of making or method of treatment of
Licensed Products as they exist as of the effective date of the MedImmune Triggered Termination solely to Exploit Licensed Antibodies and Licensed Products in the Territory, provided that Innate shall indemnify, defend and hold harmless MedImmune,
its Affiliates and each of its and their respective employees, officers, directors and agents as set forth in Section&nbsp;16.3 from and against any Damages arising out of or resulting from Third Party Claims that arise or result from Innate&#146;s
or its sublicensees&#146; activities performed under the foregoing license and further provided that such license shall not include a license to any confidential manufacturing or CMC related
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Information (&#147;MedImmune Manufacturing Technology&#148;) related to the Licensed Products. If any MedImmune Manufacturing Technology is being used in relation to the Licensed Products at the
date of termination the Parties will negotiate in good faith to agree within [***] of the notice of termination terms under which MedImmune will continue to make the Licensed Products on behalf of Innate, which terms shall include a supply price
equal to the Transfer Price plus a <FONT STYLE="white-space:nowrap">mark-up</FONT> of [***], or such technology will be provided to a CMO on terms satisfactory to MedImmune to allow the CMO to make the Licensed Product on behalf of Innate, provided
that such technology transfer (including any comparability studies costs) shall be at MedImmune&#146;s costs. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party shall return all data, files, records and other materials in its possession or Control containing or
comprising the other Party&#146;s Confidential Information to which such first Party does not retain rights hereunder (except one copy thereof, which may be retained by the returning Party solely for legal archive purposes). </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall, where permitted under Applicable Laws, as promptly as reasonably practical transfer to Innate all
INDs, Drug Approval Applications, and Regulatory Approvals with respect to Licensed Antibodies and Licensed Products (but not with respect to any other compounds or products), and shall take such other actions and execute such other instruments,
assignments, and documents as may be necessary to effect the transfer of rights hereunder to Innate or its designee at MedImmune&#146;s expense. Innate shall indemnify and hold harmless MedImmune, its Affiliates and each of its and their respective
employees, officers, directors, and agents as set forth in Section&nbsp;16.3 from and against any Losses arising out of or resulting from Third Party Claims that arise or result from Innate&#146;s, its Affiliates&#146; or its sublicensees&#146;
Exploitation of the Licensed Antibodies or Licensed Products under any INDs, Drug Approval Applications or Regulatory Approvals transferred hereunder. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune will assign (or cause its Affiliates to assign) to Innate or its designee, at Innate&#146;s request, all of
MedImmune&#146;s (or its Affiliates&#146;) rights and obligations under agreements with Third Parties with respect to (i)&nbsp;the conduct of Clinical Trials for each Licensed Product, including Agreements with contract research organizations,
clinical sites and investigators that relate to Clinical Trials in support of Regulatory Approvals in the Territory, (ii)&nbsp;the Manufacture of Licensed Antibodies or Licensed Product (subject to MedImmune&#146;s obligations to manufacture after
termination), and (iii)&nbsp;any other Third Party agreements involving the Development or Commercialization of the Licensed Products, unless in each of (i)&nbsp;through (iii), such agreement is not permitted to be assigned pursuant to its terms or
relates to products other than Licensed Products, in which case MedImmune will cooperate with Innate in all reasonable respects to transfer as promptly as reasonably practical to Innate the benefit of such contract (against Innate undertaking to
perform all the obligations and assume all liabilities under such contract) in another mutually acceptable manner and upon Innate&#146;s request facilitate discussions between Innate and such Third Parties to assist Innate in entering into a direct
agreement with such Third Parties. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall at MedImmune&#146;s sole cost and expense assign all of its rights in and to all Product Trademarks
for Licensed Products (and all registrations and applications for registration therefor) that it owns pursuant to Section&nbsp;12.6 (trademarks packaging and labelling) to Innate or its designee and Innate shall have the exclusive right (but not the
obligation) to enforce the Product Trademark rights against infringers. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Upon Innate&#146;s request, MedImmune shall transfer to Innate copies of all materials, data, results, analyses,
reports, websites, marketing materials, technology, regulatory filings and other Information and Materials existing in tangible or electronic form at the effective date of the MedImmune Triggered Termination, that is Controlled by MedImmune and has
been generated on or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
before the effective date of such termination by or on behalf of MedImmune, its Affiliates or Sublicensees with respect to the Licensed Products (&#147;<B>MedImmune Product Data</B>&#148;) and
Innate shall have the right to use on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis such MedImmune Product Data solely related to the Licensed Products and non-exclusive basis all other MedImmune Product Data to the extent necessary
or useful to enable Innate to proceed to Develop, Manufacture and Commercialize Licensed Products upon and after termination of this Agreement, provided that Innate shall indemnify and hold harmless MedImmune, its Affiliates and each of its and
their respective employees, officers, directors and agents as set forth in Section&nbsp;16.3 from and against any Damages arising out of or resulting from Third Party Claims that arise or result from the use of any MedImmuna Product Data hereunder.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">As the sole consideration of the foregoing transfer of MedImmune Product Data and, if applicable, INDs, Drug Approval
Applications, Regulatory Approvals, Product Trademarks and license and any other rights granted under the above provisions in this Section&nbsp;15.4, Innate shall pay to MedImmune royalty payments pursuant to Section&nbsp;10 at rates reduced by
[***] if the Agreement is terminated [***] or reduced by [***] if this Agreement is terminated [***], calculated as if all Net Sales by Innate or its Affiliates or sublicensees in the Territory were Net Sales by MedImmune, provided that in the event
that the Agreement has been terminated by Innate pursuant to Section&nbsp;15.2(i) due to MedImmune&#146;s material breach no royalty shall be due by Innate to MedImmune; </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">For the avoidance of doubt the rights granted to Innate under this Section&nbsp;15.3 are restricted to Licensed
Antibodies and Licensed Products and MedImmune does not grant any rights whatsoever to any other compounds or products (other for the avoidance of doubt than the MedImmune Compounds forming part of the Licensed Product prior to the effective date of
termination as a fixed dose combination or in a <FONT STYLE="white-space:nowrap">co-packaged</FONT> form, in relation to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
which the Parties will agree reasonable terms relating to the supply by MedImmune of the MedImmune Compound contained in such fixed dose combination or
<FONT STYLE="white-space:nowrap">co-packaged</FONT> form within [***] of the date of notice of termination and at a supply price equal to the Transfer Price plus a <FONT STYLE="white-space:nowrap">mark-up</FONT> of [***] or to any Intellectual
Property Rights other than as set forth in this Agreement. If the Licensed Product is being promoted to be <FONT STYLE="white-space:nowrap">co-prescribed</FONT> with a MedImmune Compound, Innate&#146;s rights under this Section&nbsp;15.3 shall be
limited to being able to promote the Licensed Product in such <FONT STYLE="white-space:nowrap">co-prescribed</FONT> combination. Moreover, MedImmune shall not be obligated to provide Innate with any other IPR or other rights or services than that
which is explicitly provided for under this Section&nbsp;15.3. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall be entitled, during a period of [***] following the MedImmune Triggered Termination, to finish any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-in-progress</FONT></FONT> to sell any inventory of the Licensed Product that remains on hand as of the date of the termination, so long as MedImmune pays to Innate the royalties
applicable to said subsequent sales in accordance with the terms and conditions set forth in this Agreement; provided that MedImmune&#146;s rights under this Section&nbsp;15.3(xi) shall be subject to Innate&#146;s prior written consent, which shall
not be unreasonably withheld, delayed or conditioned, further provided that Innate&#146;s consent shall not be required if MedImmune is selling Licensed Product to satisfy existing obligations to MedImmune customers. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding anything else set forth in this Agreement but without prejudice to MedImmune&#146;s obligations
pursuant to Section&nbsp;15.3 (ii), (i) MedImmune shall not have any obligations to continue any Development, Manufacture or Commercialization of the relevant Licensed Antibody or Licensed Product if MedImmune has terminated this Agreement pursuant
to Section&nbsp;15.2(ii) with reference to any material safety concerns; and (ii)&nbsp;should Innate elect to pursue any Development, Manufacture or Commercialization of the relevant Licensed Antibody or Licensed
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Product following any such termination by MedImmune, Innate shall - without prejudice to or limitation of any other or further obligations Innate may have to MedImmune under this Agreement
(including Section&nbsp;16.3) - indemnify MedImmune for any Third Party claims arising from Innate&#146;s Development, Manufacture or Commercialization after the effective date of the termination of the relevant Licensed Antibody or Licensed Product
as set forth in Section&nbsp;16. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xiii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The provisions of this Section&nbsp;15 shall be Innate&#146;s exclusive remedy in the event of MedImmune&#146;s
termination pursuant to Section&nbsp;15.2 (ii). </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>Consequences of Termination (or Right to Terminate) by
MedImmune for Innate&#146;s breach or insolvency</U> </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If MedImmune is entitled to terminate this Agreement pursuant to Section&nbsp;15.2(ii) as a result of a material
breach by Innate or Section&nbsp;15.2(iii) for an insolvency or other transaction described therein affecting Innate, MedImmune may elect to terminate this Agreement subject to the provisions set forth in Section&nbsp;15.4(i), or to continue the
Agreement subject to the provisions set forth in Section&nbsp;15.4 (ii). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If MedImmune terminates the Agreement under Section&nbsp;15.2(i) or under Section&nbsp;15.2(iii), the Parties will
negotiate in good faith the transfer of rights back to Innate in respect of Licensed Products consistent with the terms of Section&nbsp;15.3, provided that such transfer shall be at Innate&#146;s cost. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If MedImmune has the right to terminate this Agreement under Section&nbsp;15.2(i) or Section&nbsp;15.2(iii), MedImmune
may elects to continue this Agreement by providing written notice to Innate that it is invoking this clause. In such event, this Agreement shall continue in full force and effect except as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate&#146;s rights under the <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option (whether or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
not exercised prior to the termination) shall terminate and the Profit/Loss share will be adjusted in accordance with Section&nbsp;8.4. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall, at MedImmune&#146;s request, cease any Development, Manufacturing or Commercialization activities
performed by Innate pursuant to this Agreement (but Innate&#146;s right to <FONT STYLE="white-space:nowrap">co-fund</FONT> the Development pursuant to this Agreement and share Profit shall continue in full force and effect subject to any adjustment
made pursuant to (A)&nbsp;above), Innate shall cease to have the right to participate in the DCC and SCC, and, upon such request, Innate shall furnish MedImmune with reasonable cooperation to assure a smooth transition to MedImmune (or its designee)
of any such activities then being conducted or performed by Innate. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall return all data, files, records and other materials in its possession or Control containing or comprising
MedImmune&#146;s Confidential Information to which Innate does not retain rights hereunder (except one copy thereof, which may be retained by Innate solely for legal archive purposes). </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Except where expressly provided for otherwise in this Agreement, termination of this Agreement by either Party shall
not relieve the Parties of any liability, including without limitation any obligation to make payments hereunder, which accrued hereunder prior to the effective date of such termination, nor preclude any Party from pursuing all rights and remedies
it may have hereunder or at law or in equity with respect to any breach of this Agreement, nor prejudice any Party&#146;s right to obtain performance of any obligation. In the event of such termination, this Section&nbsp;15.5 shall survive in
addition to others specified in this Agreement to survive in such event. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Bankruptcy</B>. All rights and licenses granted under or pursuant to this Agreement by a Party are, and shall
otherwise be deemed to be, for the purposes of Section </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
365(n) of the United States Bankruptcy Code, licenses of rights to &#147;intellectual property&#148; as defined under Section&nbsp;101 of the United States Bankruptcy Code or equivalent
provisions of applicable legislation in any other jurisdiction. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the United States
Bankruptcy Code, or equivalent provisions of applicable legislation in any other jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the Unites States Bankruptcy
Code or equivalent provisions of applicable legislation in any other jurisdiction, the Party that is not a party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property
and all embodiments of such intellectual property, which, if not already in the <FONT STYLE="white-space:nowrap">non-subject</FONT> Party&#146;s possession, shall be promptly delivered to it (a)&nbsp;upon any such commencement of a bankruptcy
proceeding upon the <FONT STYLE="white-space:nowrap">non-subject</FONT> Party&#146;s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement, or (b)&nbsp;if not
delivered under subsection (a)&nbsp;above, following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the <FONT STYLE="white-space:nowrap">non-subject</FONT> Party.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Change of Control of Innate.</B> Innate shall provide to MedImmune written notice of any Change of Control of
Innate as soon as practicable after the effective date of an agreement pursuant to which such Change of Control would be effected, but in any event within [***] of the closing of the Change of Control transaction. Upon any Change of Control of
Innate, the following shall apply [***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Surviving Rights and Obligations. </B>The rights and obligations set forth in this Agreement shall extend beyond
the expiration or termination of the Agreement only to the extent expressly provided for herein, or to the extent that the survival of such rights or obligations are necessary to permit their complete fulfilment or discharge. Without limiting the
foregoing, the Parties have identified various rights and obligations which are understood to survive, as follows: In the event of expiration or termination of this Agreement for any reason, the following provisions shall survive in addition to
others specified in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
this Agreement to survive in such event: Sections 1, 2.1, 3.14, 6.4, 10 (solely to the extent provided in Sections 15.3 and 15.4), 11, 12.2, 14.1, 14.2, 15.3, 15.4, 15.5, 15.8, 15.9, 16 (solely
as to actions arising during the term of this Agreement, or as to activities conducted in the course of a Party&#146;s exercise of licenses surviving after the term of this Agreement), 17 and 18.6 to 18.12. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B><U>Accrued Rights.</U></B> Termination, relinquishment, or expiration of the Agreement for any reason shall be
without prejudice to any rights that shall have accrued to the benefit of either Party prior to such termination, relinquishment, or expiration, including without limitation damages arising from any breach hereunder. Such termination,
relinquishment, or expiration shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of the Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>INDEMNIFICATION</B><B> </B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>LIMITATION OF LIABILITY</B>. EXCEPT IN CIRCUMSTANCES OF NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS
AFFILIATES, OR WITH RESPECT TO THIRD PARTY CLAIMS UNDER SECTIONS 16.1 AND 16.2, IN NO EVENT SHALL EITHER PARTY OR ITS RESPECTIVE AFFILIATES AND SUBLICENSEES BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT,
WARRANTY, TORT, STRICT LIABILITY, OR OTHERWISE. This Section&nbsp;16 shall not limit either Party&#146;s obligations under Section&nbsp;11. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Indemnification. </B>MedImmune hereby agrees to indemnify, defend, and hold harmless Innate, its Affiliates, and
each of its and their respective employees, officers, directors and agents from and against any and all Damages incurred by them resulting from or arising out of or in connection with any suits, claims, actions or demands made or brought by a Third
Party (collectively, &#147;<B>Third Party Claims</B>&#148;) against Innate, its Affiliates or their respective employees, officers, directors or agents, that result from or arise out of the Development, Manufacture, use, handling, storage,
Commercialization, or other disposition of Licensed Products by MedImmune or its Affiliates, agents, Distributors, Sublicensees or other sublicensees in the Territory (including with respect to any Product Liability Claim), except in any case, to
the extent such Damages are Damages for which Innate has an obligation to indemnify MedImmune, its </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Affiliates or their respective employees, officers, directors or agents pursuant to Section&nbsp;15.3(viii) and 15.3(xiii) or Section&nbsp;16.3, as to which Damages each Party shall indemnify the
other to the extent of their respective liability for such Damages. For purposes of the foregoing &#147;Product Liability Claim&#148; means any product liability claims asserted or filed by Third Parties (without regard to their merit or lack
thereof), seeking damages or equitable relief of any kind, relating to personal injury, wrongful death, medical expenses, an alleged need for medical monitoring, consumer fraud or other alleged economic Damages, allegedly caused by any Licensed
Product, and including claims by or on behalf of users of any Licensed Product (including spouses, family members and personal representatives of such users) relating to the use, sale, distribution or purchase of any Licensed Product sold by or on
behalf of MedImmune, its Affiliates or Sublicensees, including, but not limited to, claims by third party payers, such as insurance carriers and unions). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate hereby agrees to indemnify, defend and hold harmless MedImmune, its Affiliates, and each of its and their
respective employees, officers, directors and agents from an against any and all Damages incurred by them resulting from or arising out of or in connection with any Third Party Claims against MedImmune, its Affiliates or their respective employees,
officers, directors or agents, that result from or arise out of (i)&nbsp;the Manufacture, use, handling, storage, sale or other disposition of Licensed Products by Innate or its Affiliates, agents, distributors or sublicensees prior to the Effective
Date or (ii)&nbsp;any material breach by Innate of its obligations hereunder with respect to Innate&#146;s activities in the Development, Detailing, <FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Activities and Other Promotional Activities
related to the Licensed Product and assigned to Innate pursuant to this Agreement; except in any case, to the extent such Damages are Damages for which MedImmune has an obligation to indemnify Innate, its Affiliates or their respective employees,
officers, directors or agents pursuant to Section&nbsp;16.2, as to which Damages each Party shall indemnify the other to the extent of their respective liability for such Damages. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Mechanism.</B> In the event that a Party (the &#147;<B>Indemnified Party</B>&#148;) is seeking indemnification
under Section&nbsp;16.2 or 16.3, it shall notify the other Party (the &#147;<B>Indemnifying Party</B>&#148;) in writing of the relevant Third Party Claim and the relevant Damage for which indemnification is sought as soon as reasonably
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
practicable after becoming aware of such claim. Such notices shall contain a description of the Third Party Claim and the nature and amount of the Damage (to the extent known). The Indemnified
Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of such Third Party Claim or Damage. For the avoidance of doubt, all indemnification claims in respect of a Party, its Affiliates,
and each of its and their respective employees, officers, directors and agents shall be made solely by such Party to this Agreement. To the extent that the Indemnifying Party irrevocably commits to indemnify any Indemnified Party in respect of the
Third Party Claim, the Indemnified Party shall permit the Indemnifying Party to assume direction and control of the defense of the relevant Third Party Claim (including without limitation the right to settle the claim solely for monetary
consideration), and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of the claim. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding Section&nbsp;16.1, the failure to give timely notice to the Indemnifying Party shall not release the
Indemnifying Party from liability to the Indemnified Party to the extent the Indemnifying Party is not prejudiced thereby and, for the avoidance of doubt, the Indemnifying Party shall not be liable to the extent any Damage is caused by any delay by
the Indemnified Party in providing such notice. Notwithstanding the provisions of Section&nbsp;16.4 requiring the Indemnified Party to tender to the Indemnifying Party the exclusive ability to defend such claim, if the Indemnifying Party does not
satisfy the condition set forth in Section&nbsp;16.4 to, or declines to or fails to timely assume control of the relevant Third Party Claim, the Indemnified Party shall be entitled to assume such control, conduct the defense of, and settle such
claim, all at the sole costs and expense of the Indemnifying Party; <U>provided</U>, <U>however</U>, that neither Party shall settle or dispose of any such claim in any manner that would adversely affect the rights or interests or admit fault, of
the other Party without the prior written consent of such other Party, which shall not be unreasonably withheld, delayed or conditioned. Each Party, at the other Party&#146;s expense and reasonable request, shall cooperate with such other Party and
its counsel in the course of the defense or settlement of any such claim, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information, and witnesses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Insurance.</B> Each Party shall have and maintain such type and amounts of liability insurance covering the
Manufacture, supply, use and sale of the Licensed Antibodies and the Licensed Products as is normal and customary in the pharmaceutical industry generally for Persons similarly situated, and shall upon request provide the other Party with a copy of
its policies of insurance in that regard, along with any amendments and revisions thereto. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Employees who Transfer under the Regulations. </B>Innate<B> </B>and MedImmune do not intend that as a consequence
of the transaction effected hereunder any employees of Innate or any of its Affiliates (&#147;Employees&#148;) shall transfer to MedImmune or to Innate (or their Affiliates or successors) under this Agreement or by operation of law. If, under the
Regulations, the contract of employment of any person is found or alleged to have effect after the Effective Date as if originally made with MedImmune or Innate or their Affiliates or successors) (the &#147;Concerned Party&#148;), as a consequence
of the transaction effected hereunder and to the extent permitted by Applicable Laws (an &#147;Unexpected Transfer Employee&#148;): </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Concerned Party will, upon becoming aware of any Unexpected Transfer Employee, notify the other Party immediately
or as soon as is reasonably practicable in writing; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The other Party agrees that in consultation with the Concerned Party, it will within [***] of being so requested by
the Concerned Party (as long as the request is made no later than [***] after notification under Section&nbsp;16.7(a) above), make (or procure there is made) to that Unexpected Transfer Employee an offer in writing to employ him under a new contract
of employment to take effect upon the termination referred to below on the same terms and conditions as that person&#146;s contract of employment immediately before the Effective Date, or on terms and conditions which, when taken as a whole, do not
materially differ from the terms and conditions of employment of that person immediately before the Effective Date (save as to the identity of the employer and any terms relating to an occupational pension scheme). The Concerned Party shall give the
other Party all reasonable <FONT STYLE="white-space:nowrap">co-operation</FONT> and assistance to procure that the Unexpected Transfer Employee accepts the offer of employment; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">upon the expiry of [***] following the offer in Section&nbsp;16.7(b) being made (or on the expiry of [***] from the
Concerned Party&#146;s request under Section&nbsp;16.7(b) if the offer is not made as requested), the Concerned Party may terminate the employment of the Unexpected Transfer Employee provided that: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">it does so in accordance with all legal requirements and any procedure that may be given to it by the other Party; and
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">it takes all other steps to mitigate any payments or entitlements due to the Unexpected Transfer Employee and any
potential liability of the other Party under the indemnity at Section&nbsp;16.7(d). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Provided that the termination is effected within [***] of the notification under Section&nbsp;16.7(a) above, the other
Party shall indemnify the Concerned Party for any Employment Liabilities in relation to: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the employment of the Unexpected Transfer Employee after the Effective Date until any such termination (save to the
extent that the Concerned Party has acted unlawfully in respect thereof); and </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the termination of employment of the Unexpected Transfer Employee. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Mutual Assistance. MedImmune and Innate shall give each other any assistance that either may reasonably require to
comply with the Regulations in relation to the Unexpected Transferring Employees and in contesting any claim by any Employee at or before the Effective Date resulting from or in connection with this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>GOVERNING LAW AND ARBITRATION</B><B> </B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Governing Law. </B>The interpretation and construction of this Agreement (including
<FONT STYLE="white-space:nowrap">non-contractual</FONT> disputes) shall be governed by the laws of England and Wales excluding any conflicts or choice of law rule or principle that might
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Referral of Disputes to the Parties Senior Executives. </B>In the event of any dispute between the Parties arising
out of or in connection with this Agreement, either Party may, by written notice to the other, have such dispute referred to the Senior Executives for attempted resolution by good faith negotiations within [***] after such notice is received.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Arbitration</B>. In the event the Parties are unable to resolve a dispute in accordance with Section&nbsp;17.2 any
dispute arising out of or in connection with this Agreement, including any question regarding its existence, validity or termination, shall be referred to and finally resolved by arbitration under the Arbitration Rules of the International Chamber
of Commerce (ICC), which Rules are deemed to be incorporated by reference into this clause. The seat, or legal place, of arbitration shall be London. The language to be used in the arbitral proceedings shall be English. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Preliminary Injunctions</B>. Notwithstanding anything to the contrary, a Party may seek a temporary restraining
order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending the decision of the arbitrator(s) on the ultimate merits of any dispute.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">17.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Patent Disputes</B>. Notwithstanding anything to the contrary, any and all issues regarding the scope,
inventorship, construction, validity, or enforceability of Patents shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patents in question. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>ASSIGNMENT; PERFORMANCE BY AFFILIATES; GENERAL</B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Neither Party may assign any of its rights or obligations under this Agreement in any country in whole or in part
without the prior written consent of the other Party, except that each Party shall have the right, without such consent, (i)&nbsp;to perform any of its obligations and exercise any of its rights under this Agreement through, and to assign all of its
rights and obligations under this </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Agreement to, any of its Affiliates; and (ii)&nbsp;on written notice to the other Party, to assign all of its rights and obligations under this Agreement to a
<FONT STYLE="white-space:nowrap">non-Affiliate</FONT> successor in interest, whether by merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar transaction, to all or substantially all of the business to
which this Agreement relates (meaning a business which constitutes more than solely the Research, Development, Exploitation of Licensed Products). In the event that a Party performs its obligations or exercises its rights under this Agreement
through an Affiliate or assigns its rights and obligations to an Affiliate as permitted under this Section&nbsp;18, doing so shall not relieve the relevant Party of its responsibilities for the performance of its obligations under this Agreement,
and the relevant Party shall remain responsible for the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance). </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">This Agreement shall survive any succession of interest permitted pursuant to Section&nbsp;18, whether by merger,
consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar transaction, provided, that, in the event of such merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar
transaction, no Intellectual Property Rights of the acquiring corporation and its Affiliates (other than a Party and its Affiliates prior to such acquisition) shall be included in the technology licensed hereunder, unless such Intellectual Property
Rights arise as a result of the performance of this Agreement by such corporation after such transaction becomes effective. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties.
Any assignment not in accordance with this Agreement shall be void. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Further Actions</B>. Each Party agrees to execute, acknowledge, and deliver such further instruments, and to do all
such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Force Majeure</B>. In this Agreement, &#147;<B>Force Majeure</B>&#148; means an event which is beyond a <FONT
STYLE="white-space:nowrap">non-performing</FONT> Party&#146;s reasonable control, including an act of God, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
strike, <FONT STYLE="white-space:nowrap">lock-out</FONT> or other industrial/labour disputes (whether involving the workforce of the Party so prevented or of any other Person), war, riot, civil
commotion, terrorist act, epidemic, quarantine, fire, flood, storm, earthquake or natural disaster. A Party that is prevented or delayed in its performance under this Agreement by an event of Force Majeure (a &#147;<B>Force Majeure Party</B>&#148;)
shall, as soon as reasonably practical but no later than thirty (30)&nbsp;days after the occurrence of a Force Majeure event, give notice in writing to the other Party specifying the nature and extent of the event of Force Majeure, its anticipated
duration and any action being taken to avoid or minimize its effect. Subject to providing such notice and to this Section&nbsp;18.5, the Force Majeure Party shall not be liable for delay in performance or for
<FONT STYLE="white-space:nowrap">non-performance</FONT> of its obligations under this Agreement, in whole or in part, except as otherwise provided in this Agreement, where <FONT STYLE="white-space:nowrap">non-performance</FONT> or delay in
performance has resulted from an event of Force Majeure. The suspension of performance allowed hereunder shall be of no greater scope and no longer duration than is reasonably required and the Force Majeure Party shall exert all reasonable efforts
to avoid or remedy such Force Majeure. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Notices. </B>Any notice, request, or other communication permitted or required under this Agreement shall be in
writing, shall refer specifically to this Agreement, and shall be deemed given only if hand delivered, sent by an internationally recognised overnight delivery service, costs prepaid, or sent by email (providing such email is read receipted and such
notice is also despatched by an internationally recognised overnight delivery service, costs prepaid, on same day) to the Party to whom notice is to be given at the following address (or at such other address such Party may have provided to the
other Party in accordance with this Section&nbsp;18. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>If to MedImmune:</U> </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Address: </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:11%; font-size:11pt; font-family:ARIAL" ALIGN="justify">One
MedImmune Way </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:11%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Gaithersburg </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:11%; font-size:11pt; font-family:ARIAL" ALIGN="justify">MD20878 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">For the
attention of:&nbsp;&nbsp;[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Email address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
[***] </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><U>If to Innate:</U> </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Address: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Innate
Pharma S.A. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:11%; font-size:11pt; font-family:ARIAL" ALIGN="justify">17, Avenue de Luminy - BP 30191 </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:11%; font-size:11pt; font-family:ARIAL" ALIGN="justify">13276 Marseille Cedex 09 FRANCE </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Attention: [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Email: [***] </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Such
notice, shall be deemed to have been given as of the date delivered by hand, or on the second business day (at the place of delivery) after deposit with an internationally recognised overnight delivery service, whichever is the earlier. </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Waiver. </B>A Party&#146;s failure to enforce, at any time or for any period of time, any provision of this
Agreement, or to exercise any right or remedy shall not constitute a waiver of that provision, right or remedy or prevent such Party from enforcing any or all provisions of this Agreement and exercising any rights or remedies. To be effective any
waiver must be in writing. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Severability. </B>If any provision of this Agreement is held to be invalid, illegal or unenforceable, in any
respect, then such provision will be given no effect by the Parties and shall not form part of this Agreement. To the fullest extent permitted by Applicable Law and if the rights and obligations of a Party will not be materially and adversely
affected all other provisions of this Agreement shall remain in full force and effect and the Parties will use all reasonable efforts to negotiate a provision in replacement of the provision held invalid, illegal or unenforceable that is consistent
with Applicable Law and achieves, as nearly as possible, the original intention of the Parties. To the fullest extent permitted by Applicable Law, the Parties waive any provision of law that would render any provision in this Agreement invalid,
illegal or unenforceable in any respect. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Counterparts. </B>This Agreement may be executed in any number of counterparts, each of which shall be deemed an
original and all of which taken together shall be deemed to constitute one and the same instrument. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Entire Agreement. </B>This Agreement, including without limitation all schedules attached hereto, constitutes the
entire agreement between the Parties with respect to the subject matter of the Agreement. This Agreement supersedes all prior agreements, whether written or oral, with respect to the subject matter of the Agreement. Each Party confirms that it is
not relying on any representations, warranties or covenants of the other Party except as specifically set out in this Agreement. Nothing in this Agreement is intended to limit or exclude any liability for fraud. All Schedules referred to in this
Agreement are intended to be and are hereby specifically incorporated into and made a part of this Agreement. In the event of any inconsistency between any such Schedules and this Agreement, the terms of this Agreement shall govern.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Amendment.</B><B> </B>Any amendment or modification of this Agreement must be in writing and signed by authorised
representatives of both Parties. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>No Partnership</B>. It is expressly agreed that the relationship between Innate and MedImmune shall not constitute
a partnership, joint venture, or agency. Neither Innate nor MedImmune shall have the authority to make any statements, representations, or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior
consent of such other Party to do so. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">18.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Further Assurance. </B>Each Party shall perform all further acts and things and execute and deliver such further
documents as may be necessary or as the other Party may reasonably require to implement or give effect to this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">[Signature page overleaf] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">THIS AGREEMENT IS EXECUTED by the authorised representatives of the Parties as of the date first
written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">SIGNED for and on behalf of<BR><B>Innate Pharma S.A.</B></P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL">/s/ Mondher Mahjoubi</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">SIGNED for and on behalf of<BR><B>MedImmune Limited</B></P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL">/s/ Jane Osbourn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Signature</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Mondher Mahjoubi</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Jane Osbourn</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Title:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">CEO</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">Title:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">VP of R&amp;D</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 1.8</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Current <FONT STYLE="white-space:nowrap">Back-up</FONT></U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 1.66 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Formulation Patent </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 1.85 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Current IPH2201 </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">[***]
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 1.92 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Licensed Shared Patents </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>[***]
</B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 1.95 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Listed Patents </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 1.109</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>DEFINITION OF NKG2A</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 1.110 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U><FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Patents </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 1.124 </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Profit and Loss Reporting Schedule </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 1.147 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Third Party Agreements </U></B></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 3.11 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Confirmatory Patent License </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FORM
CONFIRMATORY PATENT LICENSE </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 4.11(a) </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Approved Third Parties </U></B></P> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 4.11(b) </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>MedImmune Code of Conduct </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 5.3 </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Parties&#146; Representation on JPT </U></B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 5.7 </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Parties&#146; Representation on DCC </U></B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 7.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Development Costs Sharing Example </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 7.4 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Form Development Costs Report </U></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***]
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 8.14 </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Form Commercialization Costs Report </U></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 13.2(a)(i) </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Owned Patents </U></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 13.2(a)(ii) </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Exclusively Licensed Patents </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***]
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 13.2(a)(iv) </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Listed <FONT STYLE="white-space:nowrap">Know-How</FONT> </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 13.2(m) </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Current Manufacturing Specification </U></B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Schedule 13.2(n) </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><U>Current Contract Manufacturing Organisations </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because
such information (i)&nbsp;is not material and (ii)&nbsp;would be competitively harmful if publicly disclosed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>AMENDMENT N&deg;1<BR>TO THE DEVELOPMENT AND OPTION AGREEMENT RELATING TO IPH2201</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:20pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>THIS AMENDMENT</B> (the &#147;<B>Amendment n</B><B>&deg;</B><B>1</B>&#148;), effective as of October
<U>22</U>, 2018 (the &#147;<B>Amendment Effective Date</B>&#148;), is made by and between; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>INNATE PHARMA S.A</B>., a company incorporated in France having its principal place of business at 117, Avenue de
Luminy &#151; BP 30191 13009 Marseille, France (&#147;<B>Innate</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>MEDIMMUNE LIMITED</B>, a company incorporated in England and Wales with company number 2451177 and with its
registered office at Milstein Building, Granta Park, Cambridge CB21 6GH, United Kingdom (&#147;<B>MedImmune</B>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Innate
and Medimmune shall hereinafter be referred to individually as a &#147;<B>Party</B>&#148; and collectively as the &#147;<B>Parties</B>&#148;. </P> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>BACKGROUND:
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">On 24&nbsp;April 2015, Innate and MedImmune entered into, <I>inter alia</I>, a Development and Option Agreement
relating to IPH2201 (the &#147;<B>Option Agreement</B>&#148;) to further develop IPH2201 and, upon MedImmune&#146;s exercise of the Option (as such term is defined in the Option Agreement), enter into an agreed form
<FONT STYLE="white-space:nowrap">Co-Development</FONT> and License Agreement relating to IPH2201, attached to the Option Agreement at Schedule 1.41 (the &#147;<B>License Agreement</B>&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Medlmmune and Innate have agreed to transfer to Medlmmune the responsibility for the manufacturing activities for
IPH2201 prior to the exercise of the Option so that Medimmune will be responsible for supplying IPH2201 after depletion of Innate&#146;s current inventory of GMP quantities of IPH2201 (the &#147;<B>Inventory</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Medimmune has indicated to Innate its intent to exercise the Option pursuant to the Option Agreement, by providing the
exercise notice set forth in Exhibit 1, immediately after the amendment of certain terms of the License Agreement pursuant to this Amendment n&deg;1. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Accordingly, the Parties have agreed to modify certain terms of the License Agreement as set forth below.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>NOW THEREFORE, THE PARTIES HAVE AGREED AS FOLLOWS: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B><U>Article 1 - Definitions </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Capitalized terms used in
this Amendment n&deg;1 shall have the meaning ascribed to them in the Option Agreement or License Agreement (as applicable), except if they are otherwise defined in this Amendment n&deg;1, in which case they shall have the meaning ascribed to them
in this Amendment n&deg;1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Article 2 &#150; Manufacturing, Revision of Development Plan </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Parties acknowledge that, prior to the Amendment Effective Date, MedImmune has elected to assume responsibility
for the Manufacturing activities of IPH2201 and that, as far as each Party is aware, Innate has transferred to MedImmune prior to the Amendment Effective Date all information and documentation necessary or useful to Manufacture IPH2201 to
MedImmune&#146;s satisfaction. Accordingly, MedImmune shall assume responsibility for the Manufacturing activities of IPH2201 (including the completion of the CMC activities specified in the Development Plan with respect to IPH2201 and the
manufacture of the Option Products), and, after depletion of the Inventory, shall supply or have supplied all of Innate&#146;s requirements for IPH2201 for (i)&nbsp;the Initial Studies (as defined in the Option Agreement) and (ii)&nbsp;any
Development activities assigned to be performed by Innate under the Development Plan (as defined in the License Agreement), all at [a Transfer Price (as defined in the License Agreement)] to be agreed upon between the Parties pursuant to
Section&nbsp;9.3 of the License Agreement (as amended below). The Parties have further agreed that Innate will perform, as part of the <FONT STYLE="white-space:nowrap">IPH2201-203</FONT> study (which forms part of the Initial Studies as defined in
the Option Agreement), a study on the combination or combinations of IPH2201 with MEDI4736 as set out in the Development Plan to the Option Agreement (as amended) and that MedImmune will supply MEDI4736 to Innate for this purpose.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL" ALIGN="justify">In view of the foregoing, Sections 9.1, 9.5 and 9.6 of the License Agreement are hereby deleted in their
entirety. Sections 9.3 and 9.4 of the License Agreement are hereby amended to read in their entirety as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><I>&#147;9.3</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><I></I><B><I>Costs</I></B><I>. The Parties will discuss and agree the Transfer Price on an annual basis. The Transfer
Price for any Licensed Products, Licensed Antibodies or MedImmune Compound supplied by MedImmune to Innate for the purposes of the Initial Studies (as defined in the Option Agreement) conducted by Innate pursuant to Section&nbsp;4.2 shall be
invoiced by MedImmune and paid by Innate within </I>[***]<I> after its receipt of such invoice. The Transfer Price for any Licensed Products or Licensed Antibodies otherwise supplied under this Agreement will be treated as </I>[***]<I>. In the event
that Innate is <FONT STYLE="white-space:nowrap">co-funding</FONT> Development in accordance with Section&nbsp;7, the Transfer Price for such Licensed Products or Licensed Antibodies shall be </I>[***]<I>.&#148;</I> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><I>&#147;9.4</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><I></I><B><I>Manufacturing and Supply Agreement</I></B><I>. If a manufacturing and supply agreement (&#147;MSA&#148;)
is required with regard to the supply of Licensed Product, Licensed Antibodies or MedImmune Compound by MedImmune to Innate, the Parties shall as soon as reasonably practicable negotiate and agree in good faith the terms of such MSA. The Parties
shall then also enter into a separate Quality Assurance Agreement(s) (&#147;QAA&#148;) that shall define the manufacturing and supply quality responsibilities of the Parties. &#147;</I> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Parties acknowledge that all Initial Studies (as defined in the Option Agreement) have not been completed on the
Amendment Effective Date and that such studies will continue or commence, as applicable, pursuant to Section&nbsp;4.2 of the License Agreement following MedImmune&#146;s exercise of the Option. [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Parties agree to <FONT STYLE="white-space:nowrap">co-fund</FONT> the Phase 1 Clinical Trials and Phase 2 Clinical
Trials outlined in Exhibit 3 to this Amendment n&deg;1 pursuant to Section&nbsp;7 of the License Agreement (as amended below). Such Clinical Trials shall form part of and be further described the Development Plan and Development Budget to be
provided by MedImmune to Innate and reviewed and approved by the Parties, acting through the DCC pursuant to Section&nbsp;4.5 of the License Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Furthermore, in view of the foregoing, Sections 7.1 and 7.3 of the License Agreement shall be amended to read in their entirety as
follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><I>&#147;7.1</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><I>It is acknowledged that on the Effective Date the </I>[***]<I> budget previously agreed by the Parties for the
Initial Combination Study under the Combination License Agreement has not been fully spent. The Parties agree that the remaining unspent portion of such budget, as at the Effective Date estimated to be </I>[***]<I>, (the &#147;</I><B><I>Residual
Budget</I></B><I>&#148;) shall be used to </I>[***]<I> (the &#147;</I><B><I><FONT STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2</I></B><I> </I><B><I>Clinical Trials</I></B><I>&#148;), some of which have been initiated prior to the date hereof,
in accordance with the below provisions in this Section&nbsp;7.1. The &#147;</I><B><I>Combination License Agreement</I></B><I>&#148; means the <FONT STYLE="white-space:nowrap">Co-Development</FONT> and License Agreement Relating to IPH2201 in
Combination with MEDI4736 and Tremelimumab entered into by the Parties on 24&nbsp;April 2015. </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify"><I>The Parties
agree to co -fund the <FONT STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2 Clinical Trials as follows: Until such time when the total Development Costs for the <FONT STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2 Clinical Trials equal the
</I>[***]<I>, each Party will provide </I>[***]<I> of the Development Costs for such trials (it being acknowledged that MedImmune&#146;s </I>[***]<I> of the </I>[***]<I> has been <FONT STYLE="white-space:nowrap">pre-paid</FONT> to Innate pursuant to
the Combination License Agreement) and thereafter Innate will provide </I>[***]<I> of the total Development Costs for the <FONT STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2 Clinical Trials, with the remaining </I>[***]<I> being provided by
MedImmune, provided, however, that Innate shall not be required to contribute more than </I>[***]<I> in accordance with the Development Budget. For clarity, Innate&#146;s current commitment for <FONT STYLE="white-space:nowrap">Co-Funded</FONT> Phase
2 Clinical Trials shall not exceed </I>[***]<I> unless </I>[***]<I>. For the avoidance of doubt, Innate&#146;s refusal to </I>[***]<I> shall not be deemed a <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice for purposes of the
License Agreement. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify"><I>The <FONT STYLE="white-space:nowrap">co-funding</FONT> arrangements in respect of the <FONT
STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2 Clinical Trials pursuant to the above provisions in this Section&nbsp;7.1 shall be separate from and without prejudice to Innate&#146;s <FONT STYLE="white-space:nowrap">co-funding</FONT> of Phase 3
Clinical Trials pursuant to the remaining provisions of this Section&nbsp;7. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL" ALIGN="justify"><I>Subject to the remaining provisions of this
Section&nbsp;7 Innate shall further participate in the funding of each of the Phase 3 Clinical Trials of Licensed Products supporting Drug Approval Application in </I>[***]<I>, such funding to be provided by Innate in the amount of thirty percent
(30%) of the total Development Costs for each of such Phase 3 Clinical Trials with the remaining seventy (70%) percent being provided by MedImmune, provided that neither Party shall be required to contribute more than their agreed percentage share
of Development Costs for the Phase 3 Clinical Trials in accordance with the Development Budget. The Development Budget is anticipated to be </I>[***]<I> for each Clinical Trial in average across </I>[***]<I>. To the extent that a Party&#146;s share
of the Development Costs in accordance with the Development Budget exceeds </I>[***]<I> in the case of Innate or </I>[***]<I> in the case of MedImmune of the anticipated budget of </I>[***]<I>, then the excess portion shall be payable by
</I>[***]<I>. For the avoidance of doubt, the excess amount shall not be payable other than pursuant to the preceding sentence and if it cannot be paid in accordance with the preceding sentence, it shall not be payable by the <FONT
STYLE="white-space:nowrap">non-sponsoring</FONT> Party. The Parties have agreed that the first Phase 3 Clinical Trial will be sponsored by MedImmune, as will any additional Phase 3 Clinical Trials related to Licensed Products unless the Parties
otherwise mutually agree. An example of such payment mechanism is attached as Schedule 7.1. The Parties may agree that Innate&#146;s co -funding amount pursuant to this final paragraph of this Section&nbsp;7.1 may be used to finance other Clinical
Trials than the Phase 3 Clinical Trials. Innate shall have the option, upon providing written notice to MedImmune (&#147;</I><B><I><FONT STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice</I></B><I>&#148;) within </I>[***]<I> after
receiving MedImmune&#146;s Development Plan and Development Budget in accordance with Section&nbsp;4.5 (&#147;</I><B><I>Opt Out Period</I></B><I>&#148;), to not participate in the <FONT STYLE="white-space:nowrap">Co-Funding.</FONT> Such right to
withdraw shall be exercisable once only in respect of the first Licensed Product. If Innate does not provide a <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice within the Opt Out Period described above Innate will be obliged to
provide co -funding with respect to the applicable Licensed Product as described in this Section&nbsp;7.1.&#148; </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><I>&#147;7.3</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><I></I><B><I>Expense Sharing.</I></B><I> The provisions set out in this Section&nbsp;7.3 and in Sections 7.4 <FONT
STYLE="white-space:nowrap">-7.9</FONT> shall apply with regard to the <FONT STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2 Clinical Trials and, if Innate has not served MedImmune with a <FONT STYLE="white-space:nowrap">Co-Funding</FONT>
Withdrawal Notice within the Opt Out Period, the Phase 3 Clinical Trials referred to in the final paragraph of Section&nbsp;7.1. The Parties will share all Development Costs related to the <FONT STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2
Clinical Trials and the Phase 3 Clinical Trials of Licensed Products under the Development Plan and in accordance with the Development Budget (the &#147;Shared Development Costs&#148;) so that subject to Section&nbsp;7.1, Innate and MedImmune each
pays its relevant percentage share of such costs.&#148;</I> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Article 3&#150; Upfront Payment Term; Preparation of the Exercise of the
Option; Effective Date of the License Agreement; Warranties; Notices </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Subject to the Option being exercised on or prior to 23&nbsp;October 2018, Section&nbsp;10.1 of the License Agreement
is hereby deleted and replaced by the following clause: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><I>&#147;10.1</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><I>As partial payment for the rights and licenses granted to MedImmune by Innate under this Agreement, MedImmune shall
pay to Innate a nonrefundable <FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment of one hundred million US dollars (USD 100,000,000) no later than on </I>[***]<I>. The upfront payment shall not be refundable or creditable against any
other payments MedImmune is obligated to make to Innate under this Agreement.&#148;</I> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Exhibit 4.1 hereto constitutes an updated set of disclosure Schedules with respect to Innate&#146;s representations
and warranties in the License Agreement. Exhibit 4.2 hereto sets out certain disclosures made by MedImmune with respect to MedImmune&#146;s warranties in Section&nbsp;13.3(a) of the License Agreement (as amended below). Exhibit 3 hereto is the
Option exercise notice in its agreed form. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The Parties have jointly determined and hereby agree that no Competition Law Filing will be required for the
performance of the License Agreement. Pursuant to Clause 2.2 of the License Agreement, the Parties acknowledge and agree that the Effective Date will be the Signing Date, as such terms are defined in the License Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The second sentence of Section&nbsp;13.3 shall be amended to read in its entirety as follows: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL" ALIGN="justify"><I>&#147;Such representations, warranties and covenants shall be considered to be restated by MedImmune as at the Effective Date,
subject to MedImmune&#146;s right to make disclosures against such representations, warranties and covenants with respect to matters which have arisen or come to the knowledge of MedImmune (with respect to representations made to MedImmune&#146;s
knowledge) between the effective date of the Development and Option Agreement and the Effective Date of this Agreement.&#148;</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Section&nbsp;13.3(a) shall be amended to read in its entirety as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#147;(a)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><I>No claim or litigation has been brought or threatened as of the Effective Date in relation to MEDI4736 (as defined
below) or Tremelimumab (as defined below) by any Person making such allegations by written notice to MedImmune.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL" ALIGN="justify"><I>&#147;</I><B><I>MEDI4736</I></B><I>&#148; means the proprietary antibody Controlled by MedImmune or its Affiliate(s) known as
MEDI4736, which is an antibody that binds <FONT STYLE="white-space:nowrap">PD-L1</FONT> and blocks the interaction of <FONT STYLE="white-space:nowrap">PD-L1</FONT> with programmed cell death protein 1. &#147;</I><B><I>Tremelimumab</I></B><I>&#148;
means the proprietary antibody Controlled by MedImmune or its Affiliate(s) known as Tremelimumab, which is an antibody that targets <FONT STYLE="white-space:nowrap">CTLA-4.&#148;</FONT> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The second paragraph of Section&nbsp;18.6 (MedImmune&#146;s address) shall be amended as follows:
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL" ALIGN="justify"><I>&#147;If to MedImmune</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL" ALIGN="justify"><I>Address:</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><I>One MedImmune Way</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><I>Gaithersburg</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><I>MD 20878</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL" ALIGN="justify">[***] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Article 4 - Miscellaneous </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">This Amendment n&deg;1 represents an amendment to the Option Agreement and except as specifically set forth in this
Amendment n&deg;1, all of the provisions of the Option Agreement remain unchanged and in full force and effect as originally agreed. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">The interpretation and construction of this Amendment n&deg;1 (including
<FONT STYLE="white-space:nowrap">non-contractual</FONT> disputes) shall be governed by the laws of England and Wales excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this
Amendment n&deg;1 to the substantive law of another jurisdiction. Any dispute arising out of or in connection with this Amendment n&deg;1 shall be resolved pursuant to the dispute resolution provisions in the Option Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">This Amendment n&deg;1 may be executed in any number of counterparts, each of which shall be deemed an original and
all of which taken together shall be deemed to constitute one and the same instrument. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, the Parties hereto have caused the Amendment n&deg;1 to be executed as of
the first date written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U><B>INNATE PHARMA S.A.</B></U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U><B>MEDIMMUNE LIMITED</B></U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="49"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">By: /s/ Mondher Mahjoubi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">By:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Name : Mondher Mahjoubi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Title : CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Title:</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, the Parties hereto have caused the Amendment n&deg;1 to be executed as of
the first date written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><U>INNATE PHARMA S.A.</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><U>MEDIMMUNE LIMITED</U></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="49"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">By:&nbsp;&nbsp;&nbsp;&nbsp;/s/ Jane Osbourn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Name :</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Name:&nbsp;&nbsp;&nbsp;&nbsp;Jane Osbourn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Title :</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VP R&amp;D</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Exhibit 1 &#150; Exercise Notice </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Exhibit 2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><U>Initial Studies </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Exhibit 3 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="white-space:nowrap">Co-funded</FONT> Phase 1 and 2 - Revised Development Plan </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Exhibit 4.1 &#150; Innate&#146;s Updated Disclosure Schedule </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Exhibit 4.2 &#150; MedImmune Disclosure Schedule </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because
such information (i)&nbsp;is not material and (ii)&nbsp;would be competitively harmful if publicly disclosed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">THIS SECOND AMENDMENT TO
THE <FONT STYLE="white-space:nowrap">CO-DEVELOPMENT</FONT> AND LICENSE AGREEMENT RELATING TO IPH2201 (this &#147;<B><I>Second</I></B><B> </B><B><I>Amendment</I></B>&#148;) is made and entered into as of July&nbsp;26, 2019 (the &#147;<B><I>Amendment
Effective Date</I></B>&#148;), by and between MedImmune Limited, a company organized under the laws of England and Wales (&#147;<B><I>MedImmune</I></B>&#148;) and Innate Pharma S.A, a company organized under the laws of France
(&#147;<B><I>Innate</I></B>&#148;). MedImmune and Innate are each referred to in this Amendment as a &#147;<B><I>Party</I></B>&#148; and collectively, as the &#147;<B><I>Parties</I></B>&#148;. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B></B>WHEREAS, MedImmune and Innate are parties to a <FONT STYLE="white-space:nowrap">Co-Development</FONT>
and License Agreement relating to IPH2201 effective as of April&nbsp;24, 2015, as amended (the &#147;<B><I>Agreement</I></B>&#148;<I>)</I>. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B></B>WHEREAS, MedImmune and Innate are parties to the
<FONT STYLE="white-space:nowrap">Co-Development</FONT> and License Agreement Relating to IPH2201 in Combination with MEDI4736 and TREMELIMUMAB, dated April&nbsp;24, 2015 (the &#147;<B><I>Combination License Agreement</I></B>&#148;).
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>C.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B></B>WHEREAS, MedImmune provided Innate with the updated Development Plan and Development Budget on
December&nbsp;18, 2018. Accordingly, pursuant to Section&nbsp;7.1 of the Agreement Innate must provide the <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice by [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>D.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B></B>WHEREAS, Innate [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>E.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B></B>WHEREAS, MedImmune has agreed to [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>F.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B></B>WHEREAS, the Parties have agreed to extend the Opt Out Period to allow Innate to consider the
Additional Study Details. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>G.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B></B>WHEREAS, in accordance with Section&nbsp;18.11 of the Agreement, the Parties hereto desire to amend
and modify the Agreement in accordance with the terms and subject to the conditions set forth in this Amendment. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>NOW, THEREFORE, IN
CONSIDERATION OF THE MUTUAL COVENANTS, CONDITIONS AND AGREEMENTS HEREIN CONTAINED, THE PARTIES HEREBY AGREE AS FOLLOWS: </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B></B><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;7.1 of the Agreement is hereby amended and restated in
its entirety to read as follows</U></B>: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>&#147;</B>7.1&nbsp;&nbsp;&nbsp;&nbsp;It is acknowledged
that on the Effective Date the [***] budget previously agreed by the Parties for the Initial Combination Study under, and as defined in the Combination License Agreement has not been fully spent. The Parties agree that the remaining unspent portion
of such budget, as at the Amendment Effective Date, estimated to be [***], (the &#147;<B><I>Residual Budget</I></B>&#148;), shall be used to [***] (the &#147;<B><I><FONT STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2 Clinical
Trials</I></B>&#148;), some of which have been initiated prior to the date hereof, in accordance with the below provisions in this Section&nbsp;7.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because
such information (i)&nbsp;is not material and (ii)&nbsp;would be competitively harmful if publicly disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">The Parties
agree to <FONT STYLE="white-space:nowrap">co-fund</FONT> the <FONT STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2 Clinical Trials as follows: Until such time when the total Development Costs for the
<FONT STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2 Clinical Trials equal [***], each Party will provide [***] of the Development Costs for such trials (it being acknowledged that MedImmune&#146;s [***] of [***] has been <FONT
STYLE="white-space:nowrap">pre-paid</FONT> to Innate pursuant to the Combination License Agreement) and thereafter Innate will provide [***] of the total Development Costs for the <FONT STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2 Clinical
Trials, with the remaining [***] being provided by MedImmune, provided, however, that Innate shall not be required to contribute more than [***] in accordance with the Development Budget. For clarity, Innate&#146;s current commitment for <FONT
STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2 Clinical Trials shall not exceed [***] unless [***]. For the avoidance of doubt, Innate&#146;s refusal to [***] shall not be deemed a <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal
Notice for purposes of the License Agreement. The <FONT STYLE="white-space:nowrap">co-funding</FONT> arrangements in respect of the <FONT STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2 Clinical Trials pursuant to the above provisions in this
Section&nbsp;7.1 shall be separate from and without prejudice to Innate&#146;s <FONT STYLE="white-space:nowrap">co-funding</FONT> of Phase 3 Clinical Trials pursuant to the remaining provisions of this Section&nbsp;7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Subject to the remaining provisions of this Section&nbsp;7 Innate shall further participate in the funding of each of the
Phase 3 Clinical Trials of Licensed Products supporting Drug Approval Application in [***], such funding to be provided by Innate in the amount of thirty percent (30%) of the total Development Costs for each of such Phase 3 Clinical Trials with the
remaining seventy (70%) percent being provided by MedImmune, provided that neither Party shall be required to contribute more than their agreed percentage share of Development Costs for the Phase 3 Clinical Trials in accordance with the Development
Budget. The Development Budget is anticipated to be [***] for each Clinical Trial in average across [***]. To the extent that a Party&#146;s share of the Development Costs in accordance with the Development Budget exceeds [***] in the case of Innate
or [***] in the case of MedImmune of the anticipated budget of [***], then the excess portion shall be payable by [***]. For the avoidance of doubt, the excess amount shall not be payable other than pursuant to the preceding sentence and if it
cannot be paid in accordance with the preceding sentence, it shall not be payable by the <FONT STYLE="white-space:nowrap">non-sponsoring</FONT> Party. The Parties have agreed that the first Phase 3 Clinical Trial will be sponsored by MedImmune, as
will any additional Phase 3 Clinical Trials related to Licensed Products unless the Parties otherwise mutually agree. An example of such payment mechanism is attached as Schedule 7.1. The Parties may agree that Innate&#146;s <FONT
STYLE="white-space:nowrap">co-funding</FONT> amount pursuant to this final paragraph of this Section&nbsp;7.1 may be used to finance other Clinical Trials than the Phase 3 Clinical Trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">The Parties agree that Innate&#146;s <FONT STYLE="white-space:nowrap">co-funding</FONT> commitment for [***] for clarity shall
be mutually agreed by the Parties and approved by the DCC in accordance with Article 4,&nbsp;shall not be [***]. With respect to these mutually agreed and DCC approved externally sponsored or investigator initiated clinical trials, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">
Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i)&nbsp;is not material and (ii)&nbsp;would be competitively harmful if
publicly disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Parties agree to support these studies using existing uncommitted stocks of monalizumab process B
drug product, to the extent such stocks are available, [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Innate shall have the option, upon providing written notice
to MedImmune (&#147;<B><I><FONT STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice</I></B>&#148;) on or prior to [***] (&#147;<B><I>Opt Out Period</I></B>&#148;), to not participate in the
<FONT STYLE="white-space:nowrap">co-funding.</FONT> Such right to withdraw shall be exercisable once only in respect of the first Licensed Product. If Innate does not provide a <FONT STYLE="white-space:nowrap">Co-Funding</FONT> Withdrawal Notice
within the Opt Out Period described above Innate will be obliged to provide <FONT STYLE="white-space:nowrap">co-funding</FONT> with respect to the applicable Licensed Product as described in this Section&nbsp;7.1.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B></B>Except as expressly set forth herein, all of the terms and conditions of the Agreement remain
unchanged and are in full force and effect. Capitalized terms not otherwise defined in this Second Amendment shall have the meanings respectively ascribed to them in the Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B></B>This Amendment, the Agreement, as previously amended, and the Combination License Agreement,
constitute the complete and final and exclusive understanding and agreement of the Parties with respect to the subject matter of the Agreement, and supersede any and all prior or contemporaneous negotiations, correspondence, understanding and
agreements, whether oral or written, between the Parties respecting the subject matter of the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify"><B></B>This Amendment may be executed in counterparts, each of which shall be deemed to be an original, and
all of which taken together shall be deemed to constitute one and the same instrument. The Parties agree that delivery of an executed counterpart of a signature page of this Amendment electronically shall be effective as delivery of a manually
executed counterpart of this Amendment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, the Parties hereto have caused this Amendment to be duly executed
by their respective authorized representatives as of the Amendment Effective Date set forth above. </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>MEDIMMUNE LIMITED</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature: s/Adrian Kemp, Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="49"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>INNATE PHARMA S.A</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature: s/Monher Mahoubi, CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Second Amendment to <FONT STYLE="white-space:nowrap">Co-Development</FONT> and License
Agreement by and between MedImmune Limited and Innate Pharma S.A. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i)&nbsp;is not material and (ii)&nbsp;would be
competitively harmful if publicly disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><I>CONFIDENTIAL </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>DATED OCTOBER 22, 2018 </B></P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>-between- </B></P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>MEDIMMUNE
LIMITED </B></P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>-and- </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>INNATE PHARMA S.A. </B></P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:74%">&nbsp;</P></center> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE
AGREEMENT </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:74%">&nbsp;</P></center>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Page</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>1.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>DEFINITIONS AND INTERPRETATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>2.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>CLOSING</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>3.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>TRANSITION OF CERTAIN ACTIVITIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>4.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>LICENCE TERM GRANT OF RIGHTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>5.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>RESTRICTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>6.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>DEVELOPMENT PLAN/GOVERNANCE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>7.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>ONGOING AND FUTURE CLINICAL TRIALS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>8.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>CERTAIN DILIGENCE OBLIGATIONS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>9.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>COMMERCIALISATION ACTIVITIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>10.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>PAYMENTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>11.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>RECORDS AND REPORTING</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>37</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>12.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>REGULATORY ACTIVITIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>38</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>13.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>INTELLECTUAL PROPERTY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>14.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>PRODUCT TRADEMARKS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>15.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>CONFIDENTIALITY AND <FONT STYLE="white-space:nowrap">NON-DISCLOSURE</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>52</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>16.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>WARRANTIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>56</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>17.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>COMPLIANCE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>18.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>INDEMNITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>62</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>19.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>LIMITATION OF LIABILITY AND INSURANCE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>65</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>20.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>TERM AND TERMINATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>65</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>21.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>MISCELLANEOUS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>69</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>SCHEDULE 1 COMMERCIALIZATION PLAN</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>77</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>SCHEDULE 2 SOTC SERVICES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>78</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>SCHEDULE 3 SUPPLY AGREEMENT TERMS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>79</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>SCHEDULE 4 LICENSED ANTIBODY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>80</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>SCHEDULE 5 EXISTING PRODUCT TRADEMARKS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>81</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>SCHEDULE 6 LICENSED MEDI PATENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>82</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>SCHEDULE 7 AZ CORPORATE MARKS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>SCHEDULE 8 INNATE CORPORATE NAMES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>84</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>SCHEDULE 9 INITIAL MEMBERS OF JDC AND JCC</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>SCHEDULE 10 DEVELOPMENT PLAN</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>86</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>SCHEDULE 11 LICENSED MEDI
<FONT STYLE="white-space:nowrap">KNOW-HOW</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>87</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>SCHEDULE 12 TRADEMARK ASSIGNMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>88</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>SCHEDULE 16.2 EXISTING RESEARCH AND COLLABORATION AGREEMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:12pt; font-family:Times New Roman; "><B>EXHIBIT A AZ PROMOTION PRINCIPLES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>90</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">-i- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>THIS LICENSE AGREEMENT</B> (the &#147;<B>Agreement</B>&#148;) is made and entered into this 22nd day of October, 2018 (the
&#147;<B>Effective Date</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>BETWEEN: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>MEDIMMUNE LIMITED</B>, a company incorporated in England and Wales with company number 2451177 and with
its registered office at Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom (&#147;<B>MedImmune</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>INNATE PHARMA S.A.</B>, a company incorporated in France and with its principal place of business at 117,
Avenue de Luminy &#150; BP 30191 13 009 Marseille, France (&#147;<B>Innate</B>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">MedImmune and Innate are
sometimes referred to herein individually as a &#147;<B>Party</B>&#148; and collectively as the &#147;<B>Parties.</B>&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>RECITALS: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, MedImmune is, directly or indirectly, a wholly owned subsidiary of AstraZeneca PLC (AstraZeneca PLC and its
Affiliates being &#147;<B>AstraZeneca</B>&#148;). MedImmune and its Affiliates have experience in the research, development, manufacturing and commercialization of pharmaceutical products worldwide, including treatments for cancer both using small
molecules and large molecules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, Innate is a biopharmaceutical company concentrating its business on
developing treatments for cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, MedImmune owns or controls certain Intellectual Property Rights (as
defined herein) with respect to the Licensed Product, so called Lumoxiti&reg; in the US (as further defined herein) in the Territories (as defined herein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, MedImmune wishes to grant Innate a license under Intellectual Property Rights owned or Controlled by MedImmune
to Develop, Manufacture, seek registration of and Commercialize the Licensed Product in conditions set forth herein. the Territories, in accordance with the terms and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, MedImmune has agreed to provide certain transition services to Innate so that the Development, Manufacturing
and regulatory activities to seek registration and Commercialization of the Licensed Product will continue in accordance with MedImmune&#146;s standard practices for a transitional period with the intention that Innate shall have built sufficient
capabilities to take over those activities at the end of the transition period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>AGREED TERMS: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>DEFINITIONS AND INTERPRETATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Unless otherwise specifically provided in this Agreement, the following terms shall have the following
meanings: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>ACCESS 360 Program Logo</B>&#148; means the Trademark and logo set forth on Part 2
of <U>Schedule</U><U></U><U>&nbsp;7</U>, used in connection with MedImmune and its Affiliates&#146; patient savings program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Affiliate</B>&#148; means, with respect to a Person, any Person that from time to time directly, or indirectly
through one or more intermediaries, controls, is controlled by or is under common control with such first Person. For purposes of the definition in this clause 1.1 only, &#147;<B>control</B>&#148;, and with correlative meanings, the terms
&#147;<B>controlled by</B>&#148; and &#147;<B>under common control with</B>&#148; mean (a)&nbsp;to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities, by
contract relating to voting rights or corporate governance, resolution, regulation or otherwise, or (b)&nbsp;to own, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities or other ownership interest of such
Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Agreement</B>&#148; has the meaning set forth in the preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Alliance Manager</B>&#148; has the meaning set forth in clause 6.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Anti-Corruption Laws</B>&#148; means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as
amended, and any other Applicable Laws including applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Applicable Law</B>&#148; means applicable laws, rules and regulations, including any rules, regulations, guidelines
or other requirements of the Regulatory Authorities or any Governmental Authority applicable to the Parties or any particular activity under this Agreement, that may be in effect from time to time, including, (i)&nbsp;GCP, (ii) GMP, (iii)&nbsp;GVP,
(iv) the principles that form the basis of the Helsinki Declaration of the World Medical Association, (v)&nbsp;the FFDCA and (vi)&nbsp;the Anti-Corruption Laws, and (vii)&nbsp;Data Protection Law, in each case to the extent they apply to a
Party&#146;s performance of its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>AstraZeneca Corporate Marks</B>&#148; means
the Trademarks and logos identified on Schedule 7 and such names or logos of AstraZeneca as MedImmune may designate in writing to Innate from time to time, including the names &#147;<B>AstraZeneca,</B>&#148; &#147;<B>AZ,</B>&#148; the AstraZeneca
corporate logo, and the ACCESS 360 Program Logo, or any other name or mark including or comprising &#147;<B>AstraZeneca</B>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>AZ&#146;s Global Ethical Interactions Policy</B>&#148; means AstraZeneca&#146;s &#147;Ethical Interactions&nbsp;&amp;
Anti-Bribery/Anti-Corruption Policy&#148;, as available on AstraZeneca&#146;s website from time to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
time at
<FONT STYLE="font-family:Times New Roman" COLOR="#0000ff"><U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://www.astrazeneca.com/sustainability/resources.html#global-policies-and-positions-0</FONT>
</FONT></FONT></U></FONT><FONT STYLE="font-family:Times New Roman">. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>AZ Promotion Principles</B>&#148;
means AstraZeneca&#146;s principles for Promotion set forth on
<FONT STYLE="font-family:Times New Roman" COLOR="#0000ff"><U>Exhibit<FONT STYLE="font-family:Times New Roman" COLOR="#0000ff">&nbsp;A</FONT></U><FONT STYLE="font-family:Times New Roman">. </FONT></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>AZ Site</B>&#148; means, with respect to drug substance for Licensed Product Manufactured or supplied by [***] under
the [***] Supply Agreement, the [***] manufacturing facility at which drug substance is manufactured and, with respect to finished Licensed Product Manufactured or supplied by [***] under the [***] Supply Agreement, the [***] manufacturing facility
located in Italy or, in each case, as otherwise agreed by the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;[***]&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;[***]<B> Supply Agreement</B>&#148; means the biologics Master Supply Agreement relating to (among other products) the
active pharmaceutical ingredient forming part of the Licensed Product entered into between AstraZeneca AB (PUBL) and [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>BLA</B>&#148; means a Biologics License Application submitted to the FDA under subsection (a)&nbsp;or (k) of
Section&nbsp;351 of the PHSA or any corresponding application outside the United States, including with respect to the European Union, a Marketing Authorisation Application filed with the EMA pursuant to the centralized approval procedure or with
Swissmedic in Switzerland, or any other applicable Regulatory Authority (if any) in Switzerland or the United Kingdom or a country in Europe with respect to mutual recognition of any other national approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Block List</B>&#148; means [***] as the same may be modified from time to time by MedImmune or one of its Affiliates
on [***] written notice to Innate or in accordance with such other procedures as may be established by the JCC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;[***]&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;[***]<B> Supply Agreement</B>&#148; means the master commercial supply agreement relating to the manufacture of the
finished Licensed Product and entered into between AstraZeneca Pharmaceuticals LP and [***] on [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Breaching
Party</B>&#148; has the meaning set forth in clause 20.2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Business Day</B>&#148; means a day other than a
Saturday or Sunday or a day on which banking institutions in London and Paris are permitted or required to be closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Calendar Quarter</B>&#148; means each successive period of three (3)&nbsp;calendar months commencing on
January&nbsp;1, April&nbsp;1, July&nbsp;1 and October&nbsp;1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on December&nbsp;31, 2018 and the last Calendar Quarter shall end on the last day of the
Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Calendar Year</B>&#148; means each successive period of twelve (12)&nbsp;calendar months commencing on
January&nbsp;1 and ending on December&nbsp;31, except that the first Calendar Year </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">3. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
of the Term shall commence on the Effective Date and end on December&nbsp;31, 2018 and the last Calendar Year of the Term shall commence on January&nbsp;1 of the year in which the Term ends and
end on the last day of the Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Clinical Trial</B>&#148; means a human clinical trial or such other tests and
studies of the Licensed Product in humans to which the applicable regulations on good clinical practice and clinical trials apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Closing</B>&#148; means the completion of the Transaction in accordance with clause 2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Commercialization</B>&#148; means any and all activities directed to or relating to the preparation for sale of,
offering for sale of or sale of the Licensed Product, including activities related to marketing, Promoting, distributing and importing the Licensed Product for commercial sale and interacting with Regulatory Authorities regarding any of the
foregoing but excluding Manufacturing. When used as a verb, &#147;<B>to Commercialize</B>&#148; and &#147;<B>Commercialising</B>&#148; means to engage in Commercialization and &#147;<B>Commercialized</B>&#148; has a corresponding meaning. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Commercialization Budget</B>&#148; means the costs and expenses related to the Commercialization of the Licensed
Product as set out in the Commercialization Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Commercialization Costs</B>&#148; means, [***]: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***];<B></B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(f)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(g)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(h)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(i)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Commercialization Plan</B>&#148; shall have the meaning set forth in clause 3.6.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Commercially Reasonable Efforts</B>&#148; means, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Committee</B>&#148; means the Joint Development Committee or the Joint Commercialization Committee, as the context
requires and &#147;<B>Committees</B>&#148; shall mean all of them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Compliance Audit</B>&#148; has the meaning
set forth in clause 17.2.4 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">4. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Concerned Party</B>&#148; has the meaning set forth in clause
21.1.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Confidential Information</B>&#148; means any and all <FONT STYLE="white-space:nowrap">Know-How</FONT>
and Materials, whether oral or in writing or in any other form, disclosed before, on or after the date of this Agreement by one Party to the other Party that is either marked or identified as confidential or proprietary or that is of such a nature
that would be considered by a reasonable person to be confidential or proprietary. The Licensed MedImmune <FONT STYLE="white-space:nowrap">Know-How</FONT> shall be deemed Innate&#146;s Confidential Information. All other <FONT
STYLE="white-space:nowrap">Know-How</FONT> owned or Controlled by MedImmune or any of its Affiliates shall be deemed MedImmune&#146;s Confidential Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Control</B>&#148; means, with respect to any item of Information, Regulatory Documentation, material, Patent or other
Intellectual Property Right, possession of the right, whether directly or indirectly and whether by ownership, licence or otherwise (other than by operation of the license and other grants in clause 4.1), to grant a licence, sublicence or other
right (including the right to reference Regulatory Documentation) to or under such Information, Regulatory Documentation, material, Patent or other Intellectual Property Right as provided for herein without violating the terms of any agreement with
any Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Costs</B>&#148; means both internal and external costs and expenses (including the cost of
allocated FTEs at the applicable FTE Rate quoted by MedImmune). Unless otherwise mutually agreed between the Parties, internal costs incurred by a Party shall be determined by multiplying the applicable FTE Rate quoted by MedImmune by the number of
FTEs utilized to conduct the applicable activities. External costs shall be invoiced [***] for the handling of the third party arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>CPP</B>&#148; has the meaning set forth in clause 4.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>CREATE Act</B>&#148; has the meaning set forth in clause 13.5.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Damages</B>&#148; means any and all direct liabilities, claims, actions, damages, losses, costs or expenses,
including interest, penalties, and reasonable lawyers&#146; fees and disbursements suffered or incurred by a Party. In calculating Damages, the legal duty to mitigate on the Party suffering the loss shall be taken into account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Data Protection Law</B>&#148; means, all applicable laws, rules and regulations, including any national implementing
legislation relating to privacy and data protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Data Subject</B>&#148; means a natural person who is
identified or identifiable natural person. An identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier
or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Detail</B>&#148; means that part of an in person,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face</FONT></FONT> sales call during which a Full Time Sales Representative makes a presentation with respect to the Licensed Product to an Eligible Prescriber, such that the
relevant characteristics of the Licensed Product are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">5. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
described by the Full Time Sales Representative in a fair and balanced manner consistent with the requirements of this Agreement and Applicable Law, in a manner that is customary in the
pharmaceutical industry in the United States for the purpose of promoting a prescription pharmaceutical product. When used as a verb, &#147;<B>Detailing</B>&#148; means to perform Details. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Development</B>&#148; means all activities related to research, <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
and other <FONT STYLE="white-space:nowrap">non-clinical</FONT> testing, test method development and stability testing, toxicology, formulation, clinical studies, statistical analysis and report writing, the preparation and submission of BLAs (and
supplements), regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of obtaining or maintaining a Regulatory
Approval but not including Manufacture. When used as a verb, &#147;<B>to Develop</B>&#148; and &#147;<B>Developing</B>&#148; means to engage in Development and &#147;<B>Developed</B>&#148; has a corresponding meaning. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Development Budget</B>&#148; means the costs and expenses related to the Development of the Licensed Product in the
EU Territory in accordance with the Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Development Costs</B>&#148; means, with respect to each
Licensed Product to the extent incurred in accordance with and after the Effective Date of this Agreement and the relevant Development Plan and Development Budget: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(f)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(g)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Except to the extent included in subsection (b)&nbsp;above, Development Costs shall not include either Party&#146;s Costs to
the extent they solely relate to activities associated with that Party&#146;s management of its own performance of and compliance with this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Development Plan</B>&#148; means the Development plan relating to the Licensed Product in the Territories, to be
agreed by the Parties in accordance with clause 6.1.1, and which may be updated or amended from time to time in accordance with clause 6.3.4 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Disclosing Party</B>&#148; has the meaning set forth in clause 15.1.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Dispute</B>&#148; has the meaning set forth in clause 21.6.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">6. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Dollars</B>&#148; or &#147;<B>$</B>&#148; means United States
Dollars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Effective Date</B>&#148; has the meaning set forth in the preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Eligible Prescriber</B>&#148; means a health care provider that has the authority to prescribe the Licensed Product
under Applicable Law and, with respect to the period prior to the MAH Transfer Date only, (a)&nbsp;is not on the Block List and (b)&nbsp;does not have an Excluded Specialty based on his or her assigned specialty in AstraZeneca&#146;s physician
classification system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>EMA</B>&#148; means the European Medicines Agency and any successor agency thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>EU MA Transfer Date</B>&#148; means the date on which the EU Marketing Approval is transferred to Innate in
accordance with clause 14.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>EU Marketing Approval</B>&#148; means an approval of the BLA for the Licensed
Product in one or more countries in the EU Territory by the relevant Regulatory Authority which is necessary for the marketing and sale of the Licensed Product, in the EU Territory, as amended as a consequence of any approved variation to the
Licensed Product in the EU Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>EU Regulatory Transition Plan</B>&#148; has the meaning set forth in
clause 12.2.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>EU Territory</B>&#148; means the United Kingdom, Switzerland and every Member State of the
European Union from time to time (regardless of whether that country ceases to be such a member during the Term). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>EU Transition Period</B>&#148; means the period commencing on the Effective Date and ending on the EU MA Transfer
Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Executives</B>&#148; means, (a)&nbsp;with respect to MedImmune, [***] and (b)&nbsp;with respect to Innate,
[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Existing Product Trademarks</B>&#148; means the Trademarks listed in <U>Schedule 5</U>; together with any
registrations thereof or any pending applications relating thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Existing Product Trials</B>&#148; means the
following Clinical Trials: (i)&nbsp;the pivotal Phase III Clinical trial (NCTO1829711)(also known as the 1053 trial), and (ii)&nbsp;the extended access trial (NCT0350615). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Existing Research and Collaboration Agreements</B>&#148; means the agreements set out in
<U>Schedule</U><U></U><U>&nbsp;16.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Exploit</B>&#148; means to make, have made, import, use, sell or offer
for sale, including to research, Develop, Commercialize, register, Manufacture, have Manufactured, hold or keep (whether for disposal or otherwise), have used, export, transport, distribute, Promote, market or have sold or otherwise dispose of.
&#147;<B>Exploitation</B>&#148; means the act of Exploiting a compound, product or process. When used as a verb, &#147;<B>to Exploit</B>&#148; and &#147;<B>Exploiting</B>&#148; means to engage in Exploitation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">7. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>FCA</B>&#148; means the UK Financial Conduct Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>FDA</B>&#148; means the United States Food and Drug Administration and any successor agency thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>FFDCA</B>&#148; means the Federal Food, Drug, and Cosmetic Act of the United States, as amended from time to time,
together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Field</B>&#148; means all uses, including any therapeutic, prophylactic, diagnostic and palliative uses in humans and
animals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Field Force</B>&#148; means Innate&#146;s field force involved in the Promotion of the Licensed Product
in the Territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>First Commercial Sale</B>&#148; means on a country by country basis the first sale of the
Licensed Product for monetary value for use or consumption by the end user following Regulatory Approval permitting such sale in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>FSMA</B>&#148; means the Financial Services and Markets Act 2000 (as amended). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>FTE</B>&#148; means the equivalent of one (1)&nbsp;full-time person, or in the case of less than a full-time person,
a full-time equivalent person, of work directly related to the Development or Commercialization of the Licensed Product that is carried out by an appropriately qualified employee or consultant of a Party or its Affiliates, based on [***] or greater
per year. For clarity, any such person who devotes less than [***] shall be treated as an FTE on a pro rata basis based upon the actual number of hours worked divided by [***], all as calculated by MedImmune. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>FTE Rate</B>&#148; means an annual rate for the time of an FTE of work, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Full Time Sales Representative</B>&#148; means a pharmaceutical sales representative employed by Innate full-time
[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>GCP</B>&#148; or &#147;<B>Good Clinical Practices</B>&#148; means, to the extent applicable in the
country where Regulatory Approval is sought, the current standards for good clinical practices relating to clinical trials for pharmaceuticals, as set forth in the United States Code of Federal Regulations or ICH guidelines and applicable
regulations, laws or rules as promulgated thereunder, in each case as amended from time to time, and all other standards of good clinical practice as are required by any Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>GMP</B>&#148; or &#147;<B>Good Manufacturing Practice</B>&#148; means the principle of good manufacturing practice in
respect of medicinal products for human use and investigational medicinal products for human use as required by Applicable Law, including the laws of the European Community and Directive 2003/94/EC as well as any national legislation implementing
the aforesaid Directive and any relevant guidance relating thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">8. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Governmental Authority</B>&#148; means any supranational,
international, federal, state or local court, administrative agency or commission or other governmental authority or instrumentality, domestic or foreign. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Government Official</B>&#148; means (a)&nbsp;any Person employed by or acting on behalf of a government, Governmental
Authority, government-controlled agency or entity or public international organisation, (b)&nbsp;any political party, party official or candidate, (c)&nbsp;any Person who holds or performs the duties of an appointment, office or position created by
custom or convention or (d)&nbsp;any Person who holds himself out to be the authorised intermediary of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>GVP</B>&#148; or &#147;<B>Good Pharmacovigilance Practices</B>&#148; means, in addition to the provisions under the
Pharmacovigilance Agreement, all applicable good pharmacovigilance practices promulgated and published by FDA, EMA or any other Regulatory Authorities having jurisdiction over the Development, Manufacture or Commercialization of the Product , as
applicable, pursuant to its regulations, guidelines or otherwise, including as applicable, major pharmacovigilance process and product and/or population specific considerations as defined in (a)&nbsp;European Commission Regulation code relating to
medicinal products for human use, Directives 2010/84/EU and 2012/26/EU respectively, as well as by the Commission Implementing Regulation (EU) No 520/2012 on the Performance of Pharmacovigilance Activities Provided for in Regulation (EC) No 726/2004
and Directive 2001/83/EC, Title IX of the Directive, Article 108a (a)&nbsp;of Directive 2001/83/EC, and principles detailed in the ICH guidelines for pharmacovigilance as well as (b)&nbsp;principles detailed in the United States 21 CFR and Guidance
for Industry Good Pharmacovigilance Practices and Pharmacoepidemiological Assessment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>IFRS</B>&#148; means
generally accepted international accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>IND</B>&#148; means (a)&nbsp;an investigational new drug
application filed with the FDA for authorisation to commence clinical studies and its equivalent in other countries or regulatory jurisdictions, including a Clinical Trial Application filed with the EMA with respect to the EU Territory or Swissmedic
with respect to Switzerland and (b)&nbsp;all supplements and amendments that may be filed with respect to the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Indirect Taxes</B>&#148; means value added, sales, consumption, goods and services taxes or other similar taxes
required by Applicable Law including, for the avoidance of doubt, any tax imposed in compliance with the Council Directive of 28&nbsp;November 2006 on the common system of value added tax (EC Directive 2006/112), to be disclosed as a separate item
on the relevant invoice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Information</B>&#148; means all technical, scientific and other <FONT
STYLE="white-space:nowrap">know-how</FONT> and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs,
drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material, including: biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical,
<FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical, safety, manufacturing and quality control data and information, including study designs and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">9. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
protocols, assays and biological methodology, in each case (whether or not confidential, proprietary, patented or patentable) in written, electronic or any other form now known or hereafter
developed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Innate</B>&#148; has the meaning set forth in the preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Innate Corporate Names</B>&#148; means the Trademarks and logos identified on <U>Schedule 8</U> and such other
corporate names or logos of Innate as Innate may designate in writing to MedImmune from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Innate <FONT
STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all <FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by Innate or any of its Affiliates or its or their Sublicensees that is developed by Innate or any of its Affiliates or its or
their Sublicensees in the course of any Development activities relating to the Licensed Product and shall include all <FONT STYLE="white-space:nowrap">Know-How</FONT> developed by either Party in accordance with clause&nbsp;13.1.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Innate Marketing Materials</B>&#148; has the meaning set forth in clause 9.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Innate Patents</B>&#148; means all of the Patents Controlled by Innate or any of its Affiliates or its or their
Sublicensees that claim or cover Innate <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Innate Regulatory
Documentation</B>&#148; means the Regulatory Documentation Controlled by Innate or any of its Affiliates or Sublicensees relating to the Exploitation of the Licensed Product in the Field in the Territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Intellectual Property Rights</B>&#148; means all Patents, Trademarks, copyrights, design rights, database rights,
domain names, rights in inventions, confidential information, know how, trade names, business names, <FONT STYLE="white-space:nowrap">get-up,</FONT> logos and trade dress, and all other rights in the nature of intellectual property rights (whether
registered or unregistered) and all applications and rights to apply for the above, anywhere in the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>IP
Manager</B>&#148; has the meaning set forth in clause 13.4.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Joint Development Committee</B>&#148; or
&#147;<B>JDC</B>&#148; has the meaning set forth in clause 6.3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means any Information which is secret and not in the
public domain, particularly not disclosed in a published Patent, and identified or identifiable in a tangible form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Knowledge</B>&#148; means the good faith actual knowledge of the officers of MedImmune and its Affiliates, within the
remit of their functions within MedImmune, with respect to relevant facts and information after performing a commercially reasonable inquiry with respect to the relevant subject matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Licensed Antibody</B>&#148; means the anti-CD22 immunotoxin as further described and set forth in <U>Schedule 4</U>
to this Agreement, so called moxetumomab pasudotox-tdfk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Licensed Livery Period</B>&#148; has the meaning set
forth in clause 14.5.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">10. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Licensed MedI
<FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means the <FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by MedImmune or any of its Affiliates that solely and exclusively relates to the Licensed Antibody and Licensed Product
and (a)&nbsp;is listed in <U>Schedule 11</U>, or (b)&nbsp;has been used by MedImmune or its Affiliates to Develop or Commercialize the Licensed Antibody or Licensed Product in the Field in the Territories prior to or on the Effective Date; or
(c)&nbsp;is developed by MedImmune or any of its Affiliates in connection with the Existing Product Trials, the Existing Research and Collaboration Agreements or any other Development activities relating to the Licensed Antibody or Licensed Product
undertaken by MedImmune or its Affiliates under this Agreement on or after the Effective Date, including Study Results, but in each case ((a), (b) and (c)) excluding any <FONT STYLE="white-space:nowrap">Know-How</FONT> licensed under the [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Licensed MedI Patents</B>&#148; means (a)&nbsp;the Patents owned or Controlled by MedImmune or its Affiliates and
listed in <U>Schedule 6</U>, and (b)&nbsp;the Patents owned or Controlled by MedImmune or its Affiliates in the Territory on or after the Effective Date that solely and exclusively relates to the Licensed Antibody or Licensed Product or otherwise
claims Licensed MedI <FONT STYLE="white-space:nowrap">Know-How,</FONT> but excluding Patents licensed under the [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Licensed </B>[***] <B>Patents</B>&#148; means the Patents listed in the [***], being the Patents licensed by
MedImmune under the [***] and sublicensed to Innate under the [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Licensed Product</B>&#148; means any
product that is comprised of or contains the Licensed Antibody as an active ingredient, whether alone or in combination with other active ingredients and includes the product that has been approved for sale in the United States pursuant to the US
Marketing Approval, so called Lumoxiti&reg; in the US. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Listing Rules</B>&#148; means the Listing Rules of the
FCA made under Part VI of FSMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>MAH</B>&#148; means, with respect to the Licensed Product in the EU Territory,
the holder of the EU Marketing Approval for the Licensed Product and, with respect to the Licensed Product in the US Territory, the holder of the US Marketing Approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>MAH Related Responsibilities</B>&#148; has the meaning set forth in clause 12.1.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>MAH Transfer Date</B>&#148; has the meaning set forth in clause 12.2.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Manufacture</B>&#148; means all activities related to the production, manufacture, processing, filling, finishing,
packaging, labelling, shipping and holding of the Licensed Antibody or Licensed Product or any intermediate thereof, including process development, process qualification and validation, <FONT STYLE="white-space:nowrap">scale-up,</FONT> <FONT
STYLE="white-space:nowrap">pre-clinical,</FONT> clinical and commercial manufacture and analytic development, product characterisation, stability testing, quality assurance and quality control. When used as a verb, &#147;<B>to Manufacture</B>&#148;
and &#147;<B>Manufacturing</B>&#148; means to engage in Manufacture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Material Agreement</B>&#148; has the
meaning given to it in clause 16.2(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Material Anti-Corruption Law Violation</B>&#148; means a violation of an
Anti-Corruption Law relating to the subject matter of this Agreement that would, if it were publicly known, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">11. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
be reasonably expected to have a material adverse effect on a Party or on the reputation of a Party because of its relationship with the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Materials</B>&#148; means compounds, compositions of matter, assays, and biological materials useful for the
Exploitation of Licensed Antibodies or Licensed Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>MedI Regulatory Documentation</B>&#148; means the Regulatory Documentation Controlled by MedImmune or any of its
Affiliates relating to the Exploitation of the Licensed Product in the Field in the Territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>MedImmune</B>&#148; has the meaning set forth in the preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Member State</B>&#148; means each other country that is currently a member state of the European Union, other than
the United Kingdom and Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;[***]&#148; means the [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;[***]&#148; has the meaning set forth in clause [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;[***]&#148; has the meaning set forth in clause [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Net Sales</B>&#148; means, [***]: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>(e)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B></B>[***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>New Product Trademarks</B>&#148; means Trademark(s) selected in accordance with clause 14.1.2 together with any
registrations thereof or any pending applications relating thereto in the Territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B><FONT
STYLE="white-space:nowrap">Non-Breaching</FONT> Party</B>&#148; has the meaning set forth in clause 20.2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B><FONT
STYLE="white-space:nowrap">Non-Business</FONT> Days</B>&#148; has the meaning set forth in clause 12.4.6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Notice
Period</B>&#148; shall have the meaning set forth in clause 20.2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Other AZ IPR</B>&#148; means any Patents or <FONT
STYLE="white-space:nowrap">Know-How</FONT> owned or Controlled by MedImmune or any of its Affiliates which are not Licensed MedI Patents or Licensed MedI <FONT STYLE="white-space:nowrap">Know-How,</FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">12. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
but which are necessary to Develop or Commercialize the Licensed Antibody or Licensed Product in the form it is formulated and approved in the US Marketing Approval at the Effective Date in the
Territories as contemplated by this Agreement and (a)&nbsp;has been used by MedImmune or its Affiliates to Develop or Commercialize the Licensed Antibody or Licensed Product in the Field in the Territories prior to or on the Effective Date; or
(b)&nbsp;is developed by MedImmune or any of its Affiliates or its or their respective licensees or sublicensees in connection with the Existing Product Trials or any other Development activities relating to the Licensed Antibody or Licensed Product
undertaken by MedImmune or its Affiliates under this Agreement or undertaken by their respective licensees or sublicensees on or after the Effective Date, but in all cases excluding any Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT>
licensed under the [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Other Licensees</B>&#148; means Third Parties that may be granted rights under the
Licensed MedI <FONT STYLE="white-space:nowrap">Know-How,</FONT> Licensed MedI Patents, Innate <FONT STYLE="white-space:nowrap">Know-How</FONT> and/or Innate Patents outside the Territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Party</B>&#148; and &#147;<B>Parties</B>&#148; have the meanings set forth in the preamble hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Patents</B>&#148; means all patents and patent applications, including, without limitation, any divisional,
continuation, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuation-in-part</FONT></FONT> or registration applications, utility models, design patents, any patent issued with respect to any such patent applications, any
reissue, <FONT STYLE="white-space:nowrap">re-examination,</FONT> renewal, amendment or extension (including any supplementary protection certificate (SPC) or paediatric extension) of any such patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Payment</B>&#148; has the meaning set forth in clause 10.9.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Person</B>&#148; means any individual, sole proprietorship, corporation, partnership, association, joint-stock
company, trust, unincorporated organization, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Personal Data</B>&#148; means any information relating to a Data Subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Pharmacovigilance Agreement</B>&#148; has the meaning set forth in clause 12.4.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>PHSA</B>&#148; means the Public Health Service Act as set forth at 42 U.S.C.,Chapter 6A, as may be amended from time
to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Product Agreement</B>&#148; means, with respect to the Licensed Product, any agreement entered into by and between
Innate or any of its Affiliates or any of its or their Sublicensees, on the one hand and one (1)&nbsp;or more Third Parties, on the other hand, that is necessary or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">13. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
reasonably useful for the Development or Commercialization of the Licensed Product in the Field in the Territories, including (a)&nbsp;clinical trial agreements, (b)&nbsp;contract research
organisation agreements and (c)&nbsp;service agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Processing</B>&#148; means any operation or set of
operations that is performed on Personal Data or on sets of Personal Data, whether or not by automated means, such as collection, recording, organisation, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by
transmission, dissemination or otherwise making available, alignment or combination, restriction, erasure or destruction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Product Copyrights</B>&#148; means all copyrightable subject matter related to the Licensed Product included in the
Product Labelling, the Promotional Materials and any Licensed Product training materials Controlled by MedImmune and provided by MedImmune to Innate in connection with this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Product Trademarks</B>&#148; means the Existing Product Trademarks and the New Product Trademarks (if any). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Product Labelling</B>&#148; means, with respect to the Licensed Product in the Territories, (a)&nbsp;the approved
summary of product characteristics or other full prescribing information for the Licensed Product, including any required patient information, (b)&nbsp;all packaging for the Licensed Product, and (c)&nbsp;all labels and other written, printed or
graphic matter upon a container, wrapper or any package insert utilised with or for the Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Product Liability Claim</B>&#148; means a Third Party Claim arising from or occurring as a result of any personal
injury (including death) arising out of or relating to the administration of (a)&nbsp;the Licensed Product, or (b)&nbsp;a procedure provided for or required by a protocol for a Clinical Trial for the Licensed Product to which the trial subject would
not have been exposed but for their participation in the Clinical Trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Project Teams</B>&#148; shall have the
meaning set forth in clause 6.3.9(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Promotion</B>&#148; means any activities undertaken by a pharmaceutical
company&#146;s field force representatives aimed at encouraging the use of a particular pharmaceutical product, including Detailing. When used as a verb, &#147;<B>to Promote</B>&#148; and &#147;<B>Promoting</B>&#148; means to engage in Promotion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Promotional Materials</B>&#148; means, with respect to the Licensed Product, all written, printed, electronic or
graphic promotional materials, other than Product Labelling. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>PTE</B>&#148; shall have the meaning set forth in
clause 13.5.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Quality Agreement</B>&#148; means the quality agreement in a form that is customary in the
pharmaceutical industry for the supply of Licensed Product for sale in the Territories entered into between the Parties in accordance with clause 12.4.7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Receiving Party</B>&#148; has the meaning set forth in clause 15.1.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">14. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Regulations</B>&#148; means The Transfer of Undertakings
(Protection of Employment) Regulations 2006. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Regulatory Approval</B>&#148; means, with respect to the Licensed
Product and a particular country in either of the Territories, any and all approvals (including approvals of BLAs), licences, registrations or authorisations of any Regulatory Authority necessary to commercially distribute, sell or market the
Licensed Product in the Territories, including, where applicable, (a)&nbsp;pricing or reimbursement approval in such country, <FONT STYLE="white-space:nowrap">(b)&nbsp;pre-</FONT> and post- approval marketing authorisations (including any
prerequisite Manufacturing approval or authorisation related thereto) and (c)&nbsp;labelling approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Regulatory Authority</B>&#148; means any applicable supra-national, federal, national, regional, state, provincial or
local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the Exploitation of the Licensed Product, including the FDA in the United States, the
EMA in the European Union, and Swissmedic in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Regulatory Documentation</B>&#148; means: all
(a)&nbsp;applications, registrations, licences, authorisations and approvals (including Regulatory Approvals) necessary for the Development or Commercialization of the Licensed Product in the Field in the Territories; (b)&nbsp;relevant
correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority) relating to the Development or Commercialization of the
Licensed Product in the Field in the Territories and all supporting documents with respect thereto, including any applicable CMC and <FONT STYLE="white-space:nowrap">non-clinical</FONT> information and all adverse event files, excluding source
documentation associated with individual case safety reports, and complaint files; and (c)&nbsp;clinical and other data contained or relied upon in any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Regulatory Exclusivity</B>&#148; shall mean any exclusive marketing rights or data exclusivity rights conferred by
any applicable Regulatory Authority, other than an issued and unexpired Patent, including any regulatory data protection exclusivity (including, where applicable, pediatric exclusivity or orphan drug exclusivity) or any other exclusivity afforded by
restrictions which restrict the granting by a Regulatory Authority of Regulatory Approval to market a generic product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Relevant Costs</B>&#148; has the meaning set forth in clause 10.4.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Retained Rights</B>&#148; means the rights of MedImmune, its Affiliates and its and their licensors, (sub)licensees
and contractors to (i)&nbsp;perform its and their obligations under this Agreement and/or, subject to the [***]; (ii) Develop, obtain and maintain Regulatory Approvals for, Manufacture, Commercialize or otherwise Exploit, Licensed Product outside
the Territories; and (iii)&nbsp;Manufacture the Licensed Product for (x)&nbsp;supply to Innate or its Affiliates or licensees for sale in the Territories, or (y)&nbsp;supply to MedImmune or its Affiliates or licensees for sale outside the
Territories; and (iv)&nbsp;with Innate&#146;s prior consent (not to be unreasonably withheld, delayed or conditioned) Develop or otherwise use the Licensed Product in the Territory for sale outside the Territories. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">15. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Regulatory Services</B>&#148; shall have the meaning set forth in
clause 12.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Representatives</B>&#148; has the meaning set forth in clause 17.2.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Service Standard</B>&#148; means, with respect to the provision of any service by MedImmune (including the Regulatory
Services or the performance of any obligation under the Development Plan or the Commercialization Plan), the provision of those services or performance of those obligations (a)&nbsp;with substantially the same degree of skill, quality and care
utilized by MedImmune (or its Affiliates) in performing such activities for itself with respect to the Licensed Antibody or Licensed Product; and (b)&nbsp;in compliance in all material respects with Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>SKU</B>&#148; means stock keeping unit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>SOTC</B>&#148; means sales order to cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>SOTC Period</B>&#148; has the meaning set forth in clause 3.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>SOTC Services</B>&#148; has the meaning set forth in clause 3.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Study Results</B>&#148; means any data and information generated as a result of any Clinical Trials performed as part
of the Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Sublicensee</B>&#148; means a Person, other than an Affiliate, that is granted a
sublicence by Innate or its Affiliate under the grants in clause 4.1, as provided in clause 4.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Supply
Agreement</B>&#148; has the meaning set forth in clause 3.2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Swissmedic</B>&#148; means the Swiss Agency for
Therapeutic Products and any successor agency thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Tax</B>&#148; or &#147;<B>Taxation</B>&#148; means any
form of tax or taxation, levy, duty, charge, social security charge, contribution or withholding of whatever nature (including any related fine, penalty, surcharge or interest) imposed by, or payable to, a Tax Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Tax Authority</B>&#148; means any Governmental Authority authorized to levy Tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Term</B>&#148; has the meaning set forth in clause 20.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Termination Notice</B>&#148; has the meaning set forth in clause 20.2.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Territories</B>&#148; means the US Territory and the EU Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Third Party</B>&#148; means any Person other than MedImmune, Innate and their respective Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Third Party Claims</B>&#148; has the meaning set forth in clause 18.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>TM Competitive Infringement</B>&#148; has the meaning set forth in clause 14.3.2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">16. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Trademark</B>&#148; means any word, name, symbol, colour, shape,
designation or any combination thereof, including any trademark, service mark, trade name, brand name, <FONT STYLE="white-space:nowrap">sub-brand</FONT> name, trade dress, product configuration, program name, delivery form name, certification mark,
collective mark, logo, tagline, slogan, design or business symbol, that functions as an identifier of source or origin, whether or not registered and all statutory and common law rights therein and all registrations and applications therefor,
together with all goodwill associated with, or symbolised by, any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Transaction</B>&#148; means
the transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Transferred Data</B>&#148; means the Personal Data transferred
by MedImmune to Innate pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Unexpected Transfer Employee</B>&#148; has the meaning set
forth in clause 21.1.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>US Marketing Approval</B>&#148; means the approval of the BLA for the Licensed Product
in the US Territory by the FDA which was granted on September&nbsp;13, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>US Territory</B>&#148; means the
United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>US Transfer Date</B>&#148; has the meaning set forth in clause 3.7.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>US Transfer Notice</B>&#148; has the meaning set forth in clause 3.7.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>US Transition Period</B>&#148; means the period commencing on the Effective Date and ending on the US Transfer Date.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In this Agreement, except where the context requires otherwise, whenever used the singular includes the
plural, the plural includes the singular, the use of any gender is applicable to all genders and the word &#147;or&#148; has the inclusive meaning represented by the phrase &#147;and/or&#148;. Whenever this Agreement refers to a number of days,
unless otherwise specified, such number refers to calendar days. The headings of this Agreement are for convenience only and do not define, describe, extend or limit the scope or intent of any provision in this Agreement. The term
&#147;including&#148; or &#147;includes&#148; as used in this Agreement means including, without limiting the generality of any description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the
Parties and no rule of strict construction shall be applied against any Party. Clause and Schedule headings shall not affect the interpretation of this Agreement. The Schedules form part of this Agreement and shall have effect as if set out in full
in the body of this Agreement. Any reference to this Agreement includes the Schedules. References to clauses and Schedules are to the clauses and Schedules of this Agreement. A reference to a statute or statutory provision is a reference to it as
amended, extended or <FONT STYLE="white-space:nowrap">re-enacted</FONT> from time to time. A reference to a statute or statutory provision shall include any subordinate legislation made from time to time under that statute or statutory provision.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">17. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>CLOSING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Closing shall take place on the Effective Date after the close of the trading day of Euronext Paris. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>TRANSITION OF CERTAIN ACTIVITIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Overview</B>. It is the intention of the Parties that, with effect from the Effective Date, Innate shall
immediately become responsible for all Development Costs and all Commercialization Costs relating to the Development and Commercialization of the Licensed Product and Licensed Antibody in the Territories incurred on or after the Effective Date, and
shall be entitled to all revenues (less agreed fees pursuant to this Agreement) generated from Exploitation of the Licensed Product in the Territories. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Supply Agreement</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">As soon as reasonably practicable after the Effective Date, the Parties shall use their respective
reasonable endeavours to agree to a supply agreement to be executed no later than [***] after the Effective Date or such later date as the Parties agree (the &#147;<B>Supply Agreement</B>&#148;). The Parties agree that the terms of the Supply
Agreement shall incorporate the terms set out in <U>Schedule 3</U>, together with such other terms that are customary in the pharmaceutical industry for supply of products similar to the Licensed Product. In negotiating the Supply Agreement, each
Party shall act reasonably and in good faith with a view to reaching agreement as soon as reasonably practicable after the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>US Transition Period</B>. During the US Transition Period, the Parties shall collaborate on the
Development and Commercialization of the Licensed Product in the US Territory, in accordance with their respective obligations set forth in the Commercialization Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>US Transition Period Committees</B>. During the US Transition Period, the performance of the
Parties&#146; respective obligations under the Commercialization Plan in the US Territory shall be overseen by the JCC. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>EU Transition Period</B>. During the period needed for Innate to take over all responsibilities in Europe
following the transfer of the EU Marketing Approval, MedImmune will provide assistance in accordance with the EU Regulatory Transition Plan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Commercialization Plan</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">An initial version of the plan for the Commercialization of the Licensed Product in the US Territory is
attached as <U>Schedule&nbsp;&nbsp; 1</U> (&#147;<B>Commercialization Plan</B>&#148;), as such Commercialization Plan may be updated from time to time by the JCC. The Parties acknowledge and agree that the initial version of the Commercialization
Plan is consistent with MedImmune and Innate&#146;s obligations under the [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">18. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Commercialization Plan must include until the end of the US Transition Period: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">general strategies for Promoting, marketing and distributing the Licensed Product in the US Territory;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">numbers of Full Time Sales Representatives, field based supervisory sales managers and medical/scientific
liaisons (expressed in FTEs) for the Licensed Product; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Promotional activities and Detailing plans, including target prescribers and frequency and coverage metrics;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">budgeted expenditure for sales and marketing; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">summary-level market and sales forecasts for the Licensed Product; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">a projection of Net Sales for the Licensed Product; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">SOV (share of voice) objectives; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">plans regarding distribution; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate&#146;s strategy with respect to pricing and reimbursement, managed care and discounts.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Following the Effective Date, each Party, through its representatives on the Joint Commercialization
Committee, may propose amendments to the Commercialization Plan at any time and the Joint Commercialization Committee shall review the Commercialization Plan at least quarterly for the purpose of considering appropriate amendments with the objective
of optimising the Commercialization of the Licensed Product in the US Territory. Provided they are consistent with the content principles set forth in clause 3.6.2, each Party shall consider all comments made by the other on the Commercialization
Plan and any proposed amendments thereto in good faith. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">During the US Transition Period, the Joint Commercialization Committee shall review and agree any proposed
amendments to the Commercialization Plan with the objective of optimising the Commercialization of the Licensed Product in the US Territory, and transitioning its Commercialization to Innate, and complying with the provisions of the [***].
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Commercial Transitional Arrangements</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Subject to clause 3.7.2, MedImmune shall be responsible for Commercialization of the Licensed Products in
accordance with the Commercialization Plan until Innate takes full responsibility for such Commercialization. Innate shall serve written notice on MedImmune of the proposed date on which it shall take full responsibility for the Commercialization of
the Licensed Product in the US Territory (the &#147;<B>US Transfer </B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">19. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
<B>Notice</B>&#148;). Unless otherwise agreed by the Parties, such date (the &#147;<B>US Transfer Date</B>&#148;) shall be the earlier of: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">[***]; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate may not serve the notice contemplated by clause 3.7.1 earlier than [***] and such notice must provide
at least [***] notice of the proposed transfer. However, the Parties agree that Innate may undertake part of Commercialization activities in accordance with the Commercialization Plan starting as of the Effective Date. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">No later than [***] prior to the US Transfer Date the Parties shall update the Commercialization Plan to
include activities intended to ensure the smooth transfer of all sales and distribution and other Commercialization activities relating to the Licensed Product in the US Territory undertaken by MedImmune or its Affiliates to Innate or its Affiliates
as soon as reasonably practicable after the US Transfer Date or in accordance with clause 3.8, by the end of the SOTC Period. The Commercialization Plan shall include any services to be provided by MedImmune in connection with such transition and,
except to the extent such services are SOTC Services paid for in accordance with clause 3.8, the fee payable (on an FTE basis and at the applicable FTE Rate quoted by MedImmune) by Innate for such activities in accordance with the budget included in
the Commercialization Plan. Innate shall also reimburse MedImmune for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs reasonably incurred by MedImmune in performing activities in accordance
with the Commercialization Plan in accordance with the budget included therein. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>SOTC Services</B>. Unless otherwise agreed by the Parties, MedImmune shall provide the SOTC services set
out in <U>Schedule 2</U> (the &#147;<B>SOTC Services</B>&#148;) until such time as (i) [***] and (ii) [***] (the &#147;<B>SOTC Period</B>&#148;), such SOTC Services to be provided on the terms described in <U>Schedule 2</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>LICENCE TERM GRANT OF RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>MedImmune Licence</B>. Subject as provided in this clause 4 (including the Retained Rights) and the other
terms and conditions of this Agreement, MedImmune hereby grants, with effect from the Effective Date, to Innate: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">an exclusive (including with regard to MedImmune and its Affiliates) licence (or sublicence) under the
Licensed MedI Patents and the Licensed MedI <FONT STYLE="white-space:nowrap">Know-How</FONT> to Develop, obtain and maintain Regulatory Approvals for, Manufacture, Commercialize or otherwise Exploit the Licensed Product and Licensed Antibody in the
Field in the Territories; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">an exclusive (including with regard to MedImmune and its Affiliates) licence (or sublicence) under the
Licensed MedI Patents and the Licensed MedI <FONT STYLE="white-space:nowrap">Know-How</FONT> to Develop and Manufacture the Licensed Product and Licensed Antibody in the Field outside the Territories solely (a)&nbsp;for Innate or its Affiliates or
licensees to Develop or Commercialize such Licensed Product and/or such Licensed Antibody </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">20. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
in the Field in the Territories, and (b)&nbsp;for Innate or its Affiliates or licensees to Manufacture Licensed Product for and supply Licensed Product to MedImmune pursuant to the Supply
Agreement. For the avoidance of doubt, the exclusivity in this grant relates and applies only to Innate&#146;s right to Develop or Commercialize Licensed Product and/or such Licensed Antibody outside the Territory in the Field for the sole purpose
of Development and Commercialization in the Territories and MedImmune and its Affiliates shall retain the right to Develop, Manufacture and Commercialize the Licensed Product and Licensed Antibody outside the Territories for all other purposes in
accordance with the other provisions of this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licence (or sublicense) under the Other AZ IPR to
Develop, obtain and maintain Regulatory Approvals for, Manufacture, Commercialize and otherwise Exploit the Licensed Product and Licensed Antibody in the Field in the Territories; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">an <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licence (or sublicence) under the Other AZ IPR to
Develop and Manufacture the Licensed Product and Licensed Antibody in the Field outside the Territories solely (a)&nbsp;for Innate or its Affiliates or licensees to Develop or Commercialize such Licensed Product and/or such Licensed Antibody in the
Field in the Territories, and (b)&nbsp;for Innate or its Affiliates or licensees to Manufacture Licensed Product for and supply Licensed Product to MedImmune pursuant to the Supply Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
<FONT STYLE="white-space:nowrap">non-transferrable,</FONT> <FONT STYLE="white-space:nowrap">non-sublicensible</FONT> royalty free <FONT STYLE="white-space:nowrap">paid-up</FONT> licence to use the AstraZeneca Corporate Marks and Product Copyrights
on Product Labelling and Innate&#146;s Promotional Materials, including the Innate Marketing Materials solely to the extent necessary for Innate to Commercialize the Licensed Product in the Territories, subject to and in accordance with the terms of
this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Subject to (i)&nbsp;Applicable Law, and (ii)&nbsp;MedImmune being compensated for any
Costs incurred in connection therewith, and to the extent practicable, Innate, its Affiliates and its Sublicensee shall be afforded access to MedImmune&#146;s Access 360 Program, and/or other related patient savings programs (<I>i.e.</I>, AZ&amp;Me)
in the US in connection with Innate&#146;s Exploitation of the Licensed Product in the US Territory. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Sublicences and Subcontracting</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Subject as provided in this clause 4.2, Innate may grant sublicences under the licences granted in clause
4.1: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">to its Affiliates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">with respect to US activities, while MedImmune holds the US Marketing Approval, to any Third Party, subject
to MedImmune&#146;s prior written consent (such consent not to be unreasonably withheld or delayed); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">21. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">without consent provided it is with respect to US activities, after such time as MedImmune (or any of its
Affiliates) ceases to hold the US Marketing Approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">without consent to any person in connection with the development, reproduction and use of Innate&#146;s
Promotional Materials for the sole purpose of Commercializing the Licensed Product in the US Territory in accordance with this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">once Innate hold the EU Marketing Approval, with respect to European activities, to any person without
consent. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">For clarity, until such time when Innate holds the US Marketing Approval or the EU Marketing
Approval (as applicable), any sublicence to an Affiliate with respect to the US activities or the EU activities (as applicable) shall automatically terminate on such Person ceasing to be an Affiliate of Innate. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Any sublicences granted under clause 4.2.1 (whether to an Affiliate or a Third Party) shall be consistent
with, and expressly made subject to, the terms and conditions of this Agreement. Innate shall cause each Sublicensee to comply with the applicable terms and conditions of this Agreement, as if such Sublicensee were a Party to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Subject to clauses 4.2.4, Innate may subcontract with an Affiliate or a Third Party to perform any or all of
its obligations hereunder without MedImmune&#146;s consent. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The appointment of a Sublicensee or other subcontractor shall not relieve Innate of its obligation hereunder
or any liability and Innate shall be and remain fully responsible and liable for the acts and omissions of its Sublicensees and subcontractors. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The agreement pursuant to which Innate grants rights to any Sublicensee or engages any subcontractor must be
consistent in all material respects with this Agreement and without limitation must (a)&nbsp;contain terms obligating such Sublicensee or subcontractor to comply with the confidentiality, intellectual property and all other relevant provisions of
this Agreement and (b)&nbsp;contain terms obligating such Sublicensee or subcontractor to permit MedImmune rights of inspection, access and audit substantially similar to those provided to MedImmune by this Agreement, while MedImmune holds the US
Marketing Approval and in the period prior to the grant of EU Marketing Approval. Innate shall ensure that each Sublicensee and subcontractor accepts and complies with all applicable terms and conditions of this Agreement (including any obligations
applicable to Affiliates). Innate hereby waives any requirement that MedImmune exhausts any right, power or remedy, or proceed against any Sublicensee or subcontractor for any obligation or performance under this Agreement prior to proceeding
directly against Innate. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Retained Rights of MedImmune</B>. Notwithstanding anything to the contrary in this Agreement and without
limitation of any rights granted or reserved to MedImmune pursuant to any other term or condition of this Agreement, MedImmune hereby expressly retains, on behalf of itself and its Affiliates (and on behalf of its licensors, (sub)licensees and
contractors) all right, title and interest in and to the Licensed MedI Patents, the Licensed MedI <FONT STYLE="white-space:nowrap">Know-How</FONT> and the Product Trademarks for purposes of performing or exercising the Retained Rights, provided
that, except with respect to the performance by </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">22. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
MedImmune of its obligations under this Agreement or [***], the performance or exercise of the Retained Rights does not conflict with the exclusivity of any exclusive licence granted to Innate
under clause 4.1 or under the [***]. [***]. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>No Other Rights Granted by MedImmune</B>. Except as expressly provided herein and without limiting the
foregoing, MedImmune grants no other right or licence, including any rights or licences to the Licensed MedI Patents, the Licensed MedI <FONT STYLE="white-space:nowrap">Know-How,</FONT> Other AZ IPR, the Product Trademarks, the AstraZeneca Corporate
Marks or any other Patent or Intellectual Property Rights not otherwise expressly granted herein. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Grants to MedImmune</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate hereby grants to MedImmune a perpetual and irrevocable,
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-free licence under the Innate Patents, the Innate <FONT STYLE="white-space:nowrap">Know-How</FONT> and the Innate Regulatory Documentation, to perform its obligations under this
Agreement and the [***] or to perform or exercise the Retained Rights. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune may grant sublicences under the licence granted in clause 4.5.1 to its Affiliates and Other
Licensees but shall otherwise not have any rights to grant sublicences under that licence without Innate&#146;s prior written consent (such consent not to be unreasonably withheld, delayed or conditioned). For clarity, any sublicence to an Affiliate
shall automatically terminate on such Person ceasing to be an Affiliate of MedImmune. MedImmune shall remain fully responsible and liable for the acts and omissions of its sublicensees. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Rights of Reference</B>. If MedImmune transfers the EU Marketing Approval or US Marketing Approval to
Innate, subject to MedImmune&#146;s securing similar right of reference for Innate, its Affiliates and Sublicensees to the Regulatory Documentation of MedImmune, its Affiliates and its Other Licensees, Innate shall and does hereby grant to MedImmune
and its Affiliates a licence and right of reference, with the right to grant sublicences and further rights of reference through multiple tiers, under such marketing approvals and any other Innate Regulatory Documentation as necessary for purposes
of exercising the Retained Rights. Innate shall not grant any such licence or right of reference to any Third Party for Commercialization of the Licensed Product outside of the Territories. Innate shall, at MedImmune&#146;s reasonable request and
cost, obtain any certificates of pharmaceutical products for the Licensed Product (&#147;<B>CPP</B>&#148;) and provide any appropriate authorisations to the applicable Regulatory Authority to permit MedImmune (or its Affiliates and designees) such
rights of reference. Innate shall not withdraw, or permit to be withdrawn, the US Marketing Approval or the EU Marketing Approval, any CPP or any other Innate Regulatory Documentation without providing at least [***] prior written notice to
MedImmune, and on request shall transfer any such marketing approval or other Innate Regulatory Documentation to MedImmune. Innate shall give Medimmune at least [***] prior written notice of any planned variations or other amendments to the US
Marketing Approval or the EU Marketing Approval or such other Innate Regulatory Documentation that would require a new CPP to be issued. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">23. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>No Other Rights Granted by Innate</B>. Except as expressly provided herein, Innate grants no other right
or licence, including any rights or licences to the Innate Patents, the Innate <FONT STYLE="white-space:nowrap">Know-How,</FONT> the Innate Regulatory Documentation or any other Patent or Intellectual Property Rights not otherwise expressly granted
herein. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><FONT STYLE="white-space:nowrap">Know-How</FONT> Transfer</B>. During the [***] period following
MedImmune&#146;s receipt of notification that Innate is ready to receive Licensed MedI <FONT STYLE="white-space:nowrap">Know-How</FONT> MedImmune shall provide Innate with electronic (or tangible embodiments, if electronic is not available) of the
Licensed MedI <FONT STYLE="white-space:nowrap">Know-How.</FONT> MedImmune shall be responsible for the cost of providing one (1)&nbsp;set of copies (electronic, where they exist) only. MedImmune shall use Commercially Reasonable Efforts to provide
Innate with all reasonable assistance required in order to transfer the Licensed MedI <FONT STYLE="white-space:nowrap">Know-How</FONT> to Innate hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>RESTRICTIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Territorial Restrictions</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate acknowledges that MedImmune has reserved to itself and its Affiliates the right to distribute,
market, Promote, offer for sale or sell the Licensed Product outside the Territories. To the extent permitted by Applicable Law, Innate shall not, and shall not permit any of its Affiliates, distributors or Sublicensees to, distribute, market,
Promote, offer for sale or sell the Licensed Product actively or passively to any Person outside the Territories. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Having granted the licences hereunder giving Innate and its Affiliates the exclusive right to distribute,
market, Promote, offer for sale or sell the Licensed Product inside the Territories, to the extent permitted by Applicable Law, save to the extent required for MedImmune to perform its obligations under this Agreement MedImmune, shall not, and shall
not permit any of its Affiliates, distributors or Sublicensees, , to, distribute, market, Promote, offer for sale or sell the Licensed Product actively or passively to any Person in the Territories. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Neither Party shall [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>DEVELOPMENT PLAN/GOVERNANCE </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">An initial version of the plan for the continued Development of the Licensed Antibody and Licensed Product
in the EU Territory and the related budget is attached as <U>Schedule 10</U> (the &#147;<B>Development Plan</B>&#148;), as such Development Plan may be updated from time to time by the JDC. The Parties acknowledge and agree that the initial version
of the Development Plan is consistent with MedImmune Innate&#146;s obligations under the [***]. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Alliance Managers</B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">With effect from the Effective Date, each Party shall appoint a person (an &#147;<B>Alliance Manager</B>&#148;) who shall
manage and facilitate communications between the Parties under this Agreement and who shall work together to resolve quickly any issues between the Parties that may arise in connection with this Agreement. Each Party may replace its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">24. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
Alliance Manager at any time by notice in writing to the other Party. In particular the Alliance Managers shall: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">attend meetings of the Committees as <FONT STYLE="white-space:nowrap">non-voting</FONT> participants;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">assist the chairperson of each Committee with respect to notifying the applicable members of such Committee
of meetings and providing agendas and related information to such members; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">assist the chairperson of each Committee to circulate for review, and obtain approval of, the minutes of
each meeting of such Committee; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">facilitate the delivery of reports relating to Development and Commercialization activities; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">otherwise coordinate the Parties&#146; activities under this Agreement, any transitional services agreement,
any supply agreement and [***]. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Committees</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Joint Development Committee</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate and MedImmune shall establish a joint development collaboration committee in accordance with this
clause 6.3.1 (the &#147;<B>JDC</B>&#148;). The JDC shall remain in effect as from the Effective Date until the EU Marketing Approval is obtained and transferred to Innate (or until such time as the JDC determines that there is no reasonable prospect
of the EU Marketing Approval being obtained). If the JDC is disbanded pursuant to the preceding sentence and the Parties thereafter decide to commence or <FONT STYLE="white-space:nowrap">re-commence</FONT> any Development activities, the JDC shall
be <FONT STYLE="white-space:nowrap">re-established</FONT> and remain in effect until for the duration of performance of such Development activities. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The JDC shall serve as a forum for discussing and sharing Information and materials; discussing strategy
regarding the Development of the Licensed Product in the Territories and, in particular, the strategies and actions required to obtain the EU Marketing Approval, and discussing the allocation of Development activities to be conducted by Innate and
MedImmune respectively. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Each Party shall appoint [***] as its voting members of the JDC. Each Party&#146;s representatives on the
JDC as of the Effective Date are set forth in <U>Schedule 9</U>. The JDC shall be chaired by a representative of Innate. The chairperson shall be responsible for calling meetings, setting the agenda, circulating the agenda at least [***] to each
meeting and distributing minutes of the meetings within [***] following such meetings (provided that the chairperson may elect to delegate the performance of its responsibilities to other members of the JDC from time to time), but will not otherwise
have any greater power or authority than any other member of the JDC. The chairperson shall coordinate with each Party to schedule each JDC meeting in good time in advance of such meeting. Each Party shall disclose to the chairperson any proposed
agenda items, along with appropriate </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">25. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
information and materials as early as reasonably practicable in advance of such meeting, but no less than [***]. The chairperson shall not unreasonably reject any proposed call for a JDC meeting
or proposed agenda items made by either Party. At least one (1)&nbsp;member of the JDC selected by Innate and one (1)&nbsp;member of the JDC selected by MedImmune shall have substantial experience in pharmaceutical product research and development,
and all of the members of the JDC shall have such expertise as appropriate to the activities of the JDC. Each Party may replace its members of the JDC upon written notice to the other Party, provided that any such substitute member shall have
substantially the equivalent functional expertise, experience and seniority as the member that such person replaces provided that the Parties shall use Commercially Reasonable Efforts to keep replacements to a minimum. From time to time, the JDC may
invite <FONT STYLE="white-space:nowrap">non-voting</FONT> personnel of either Party to participate in discussions of the JDC. An alternate voting member designated by a Party may serve temporarily in the absence of a permanent voting member
appointed by such Party, and either Party may also designate one or more <FONT STYLE="white-space:nowrap">non-voting</FONT> consultants to such Party who are under written obligations of confidentiality to such Party as JDC observers who may attend
the JDC meetings in an observational or advisory capacity only. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The JDC shall hold meetings at such times and places as shall be determined by a majority of the entire
membership of the committee, but in no event shall such meetings be held less frequently than once every [***]. Meetings of the JDC will alternate between the offices of the Parties, unless otherwise agreed upon by the members of the JDC, or may be
held via internet, telephonically or by videoconference; provided that at least [***] shall be held in person. Meetings of the JDC will be effective only if at least [***] of each Party are in attendance or participating in the meeting. Each Party
will be responsible for the expenses incurred in connection with its employees, consultants and its members of the JDC attending or otherwise participating in JDC meetings. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Either Party may convene at any time a meeting of the JDC to discuss and, if agreed, approve any increase in
the amount of Costs likely to be incurred in connection with Development activities that exceed the corresponding budgeted amount for those activities. If the JDC shall not be able to reach a decision on any additional Costs and Budgets, then
neither Party shall be liable under this Agreement to the other for any failure to achieve or delay in achieving any obligation the satisfaction of which is contingent upon the incurrence of such additional Costs. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The JDC&#146;s responsibilities will include, among others, (i)&nbsp;reviewing and approving the Development
Plan, Development Budget, Regulatory Documentation and EU Regulatory Transition Plan, and any amendments thereto, (ii)&nbsp;reviewing and approving protocols for any new Clinical Trials and any amendments or modifications to such protocols or
studies, (iii)&nbsp;performing quarterly reviews of the progress of Development and considering any proposed additional studies, (iv)&nbsp;facilitating the exchange of information and materials, (v)&nbsp;reviewing and advising on a proposal by
either Party to stop an Existing Product Trial or any new Clinical Trial of the Licensed Product, (vi)&nbsp;reviewing and commenting on allocation of responsibility for Development activities between the Parties, (vii)&nbsp;discussing each
Party&#146;s progress under the Development Plan, including reviewing progress toward timelines and budget, Study Results and the status of achieving Regulatory Approval; (viii)&nbsp;providing strategic direction and consultation with respect to
Development of Licensed </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">26. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
Products (including regulatory strategy); (ix) coordinating communication between the Parties; (x)&nbsp;resolving disputes between the Parties relating to the Development Plan or relating to any
pharmacovilance maters that cannot be resolved at the respective functional teams of the Parties, and (xi)&nbsp;performing such other functions as designated to the JDC under this Agreement or mutually agreed between the Parties. For clarity, any
and all decisions taken by JDC through the responsibilities defined in this section 6.3.5 shall be consistent with the provisions of the Development Plan, the Budget, the Costs and the Supply Agreement (including the supply forecasts for the
Licensed Products). Notwithstanding anything to the contrary set forth in this Agreement, the JDC will have no authority to (a)&nbsp;amend, modify or waive compliance with this Agreement or otherwise impose any obligation on the Parties in deviation
from this Agreement, or (b)&nbsp;resolve any dispute concerning the validity, compliance with, or breach of, this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The JDC shall make decisions on all matters within the scope of` its authority only by unanimous consent,
with the MedImmune voting members cumulatively having one (1)&nbsp;vote and the Innate voting members cumulatively having one (1)&nbsp;vote, irrespective of the number of members actually in attendance at a meeting. In the event that unanimity
cannot be reached by the JDC on a matter before it for decision within [***] after the matter was first considered by it then the matter may be referred by either Party to the Executives, who shall meet (in person, via internet, telephonically or by
videoconference) and attempt to resolve the matter within [***] of such referral. In the event that the Executives are unable to reach consensus within such [***] period, subject to clause 6.3.6 Innate shall have the final decision making authority
[***]. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Prior to and during such time as MedImmune is MAH of the US Marketing Approval or EU Marketing Approval, as
the case may be, [***]. Upon and after such time as Innate is MAH of the US Marketing Approval or EU Marketing Approval, as the case may be, [***]. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Joint Commercialization Committee</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Formation and Purpose</B>. Promptly following the Effective Date, the Parties shall form a joint
commercialisation committee (the &#147;<B>Joint Commercialization Committee</B>&#148; or &#147;<B>JCC</B>&#148;) to oversee and coordinate the Parties activities with respect to, and optimise the Commercialization of the Licensed Product in the US
Territory during the US Transition Period. The initial members of the JCC (and their functional responsibilities) are set forth on <U>Schedule 9</U>. The JCC shall be chaired by a representative of MedImmune. The chairperson shall be responsible for
calling meetings, setting the agenda, circulating the agenda at least [***] prior to each meeting and distributing minutes of the meetings within [***] following such meetings (provided that the chairperson may elect to delegate the performance of
its responsibilities to other members of the JCC from time to time), but will not otherwise have any greater power or authority than any other member of the JCC. The chairperson shall coordinate with each Party to schedule each JCC meeting in good
time in advance of such meeting. Each Party shall disclose to the chairperson any proposed agenda items, along with appropriate information and materials as early as reasonably practicable in advance of such meeting, but no less than [***]. The
chairperson shall not unreasonably reject any proposed call for a JCC meeting </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">27. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
or proposed agenda items made by either Party. At least one (1)&nbsp;member of the JCC selected by Innate and one (1)&nbsp;member of the JCC selected by MedImmune shall have substantial
experience in commercialization of pharmaceutical products in the US Territory, and all of the members of the JCC shall have such expertise as appropriate to the activities of the JCC. Each Party may replace its members of the JCC upon written
notice to the other Party, provided that any such substitute member shall have substantially the equivalent functional expertise, experience and seniority as the member that such person replaces provided that the Parties shall use Commercially
Reasonable Efforts to keep replacements to a minimum. From time to time, the JCC may invite <FONT STYLE="white-space:nowrap">non-voting</FONT> personnel of either Party to participate in discussions of the JCC. An alternate voting member designated
by a Party may serve temporarily in the absence of a permanent voting member appointed by such Party, and either Party may also designate one or more <FONT STYLE="white-space:nowrap">non-voting</FONT> consultants to such Party who are under written
obligations of confidentiality to such Party as JCC observers who may attend the JCC meetings in an observational or advisory capacity only. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Meetings</B>. The JCC shall hold meetings at such times and places as shall be determined by a majority
of the entire membership of the committee, but in no event shall such meetings be held less frequently than once every [***]. Meetings of the JCC will alternate between the offices of the Parties, unless otherwise agreed upon by the members of the
JCC, or may be held via internet, telephonically or by videoconference; provided that at least [***] shall be held in person. Meetings of the JCC will be effective only if at least two JCC members of each Party are in attendance or participating in
the meeting. Each Party will be responsible for the expenses incurred in connection with its employees, consultants and its members of the JCC attending or otherwise participating in JCC meetings. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Either Party may convene at any time a meeting of the JCC to discuss and, if agreed, approve any increase in
the amount of Costs likely to be incurred in connection with Commercialization activities that exceed the corresponding budgeted amount for those activities. If the JCC shall not be able to reach a decision on any additional Costs and Budgets, then
neither Party shall be liable under this Agreement to the other for any failure to achieve or delay in achieving any obligation the satisfaction of which is contingent upon the incurrence of such additional Costs. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Specific Responsibilities of the JCC</B>. In support of its responsibility for overseeing, coordinating
and optimising the Commercialization of the Licensed Product in the US Territory during the US Transition Period, the JCC shall: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">review and approve the Commercialization Plan and anticipated Commercialization Costs;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">facilitate the flow of information with respect to Commercialization activities being conducted for the
Licensed Product in the US Territory during the US Transition Period; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">28. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">discuss pricing, reimbursement and discount strategy for the Licensed Product in the US Territory;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">discuss and seek to finalise the draft commercial transition plan in accordance with clause 3.7 and the
provisions of the Development Plan, and oversee the implementation of the commercial transition plan; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">discuss demand planning and supply forecast (subject to the provisions of the [***] Supply Agreement and
[***] Supply Agreement). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Decision Making</B>. The JCC shall make decisions on all matters within the scope of its authority only
by unanimous consent, with the MedImmune voting members cumulatively having one (1)&nbsp;vote and the Innate voting members cumulatively having one (1)&nbsp;vote, irrespective of the number of members actually in attendance at a meeting. In the
event that unanimity cannot be reached by the JCC on a matter before it for decision, having considered the matter in good faith with a view to mutually beneficial resolution, within fifteen (15)&nbsp;days after the matter was first considered by it
then the matter may be referred by either Party to the Executives, who shall meet (in person, via internet, telephonically or by videoconference) and attempt to resolve the matter within fifteen (15)&nbsp;days of such referral. In the event that the
Executives are unable to reach consensus within such fifteen (15)&nbsp;day period, Innate shall have the final decision making authority [***]. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Disbandment</B>. The JCC shall cease to exist from the end of the US Transition Period and thereafter
responsibility for the oversight of Commercialization of the Licensed Product in the US Territory shall pass to Innate (or as otherwise agreed in the commercial transition plan). If the Parties elect to form a Committee for the oversight of
Commercialization activities in the EU Territory, then the JCC shall be reconstituted with such roles and responsibilities as the Parties may agree. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Joint Working Groups</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Parties will either directly or through the JDC or JCC establish one or more operational teams, which
may be formal or informal, including with respect to transition, supply chain, pharmacovigilance, regulatory and other matters. Such teams shall be made up of an adequate number of persons from each Party with the necessary skills to coordinate and
execute the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities required for the implementation of the decisions from each Committee (the &#147;<B>Project Teams</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Project Teams shall periodically, or at the request of the Committees, submit to the applicable
Committees progress reports in relation to its activities under the Development and Commercialization Plans. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>ONGOING AND FUTURE CLINICAL TRIALS </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Existing Product Trials</B>. Following the Effective Date, MedImmune shall continue, unless otherwise
indicated by the Commercialization Plan or Development Plan or directed by the JDC or JCC, to conduct any Existing Product Trial that commenced prior to the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">29. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
Effective Date and shall be responsible for the activities associated therewith. Innate shall be responsible for, and shall reimburse MedImmune for, any and all Costs incurred by MedImmune or its
Affiliates in connection with any Existing Product Trial (including those related to pharmacovigilance) from the Effective Date in accordance with the Commercialization Plan or the Development Plan. MedImmune shall notify Innate as soon as
reasonably practicable of any material developments or results in respect of any Existing Clinical Trial, including providing Innate with an electronic copy of such results, which shall be deemed to be Licensed MedI
<FONT STYLE="white-space:nowrap">Know-How.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Existing Research and Collaboration Agreements</B>. Prior to the Effective Date, MedImmune has entered
into the Existing Research and Collaboration Agreements. Following the Effective Date, the JDC or JCC (as relevant) shall monitor MedImmune&#146;s performance under such Existing Research and Collaboration Agreements, which shall be at Innate&#146;s
cost and expense. MedImmune shall notify Innate as soon as reasonably practicable of any material developments or results in respect of any Existing Research and Collaboration Agreements as well as the completion of the collaboration and/or the
termination of any such Existing Research and Collaboration Agreement. MedImmune shall provide Innate with a copy of such results in the format received, which shall be deemed to be Licensed MedI <FONT STYLE="white-space:nowrap">Know-How.</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Additional Trials</B>. Without limiting Innate&#146;s responsibility for all Development Costs, Innate
shall be responsible for all Costs associated with any new Clinical Trials relating to the Licensed Antibody or Licensed Product in the Territories and, subject to MedImmune agreeing to provide support to Innate in connection with such new Clinical
Trial, which agreement shall not be unreasonably withheld or delayed if such Clinical Trials are required to obtain Regulatory Approval, shall reimburse MedImmune for all such Costs incurred by it and its Affiliates in connection with any such new
Clinical Trial, provided that the protocols and supervising of such Clinical Trials have been agreed by the JDC. MedImmune shall notify Innate as soon as reasonably practicable of any request from any Regulatory Authority for any new Clinical Trial
for the Licensed Antibody or Licensed Product in the Territories and any material developments or results in respect of such trial. MedImmune shall not be under any obligation to undertake or fund any additional Clinical Trials of the Licensed
Antibody or Licensed Product in the Territories. For the avoidance of doubt, Innate shall be responsible for all Costs associated with any life cycle management related to the Licensed Product in the Territories. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>CERTAIN DILIGENCE OBLIGATIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Development Diligence: <FONT STYLE="white-space:nowrap">Pre-Transfer</FONT> of Marketing Approvals</B>.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">From the Effective Date until the MAH Transfer Date, MedImmune shall use its Commercially Reasonable Efforts
to comply with its obligations under the Commercialization Plan. For the duration of the Development Plan, MedImmune shall use its Commercially Reasonable Efforts to comply with its obligations under the Development Plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">30. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">From such time as Innate commences its first activities under the Commercialization Plan until the MAH
Transfer Date for the US Marketing Approval, Innate shall, at MedImmune&#146;s reasonable request, use Commercially Reasonable Efforts to support MedImmune to maintain the US Marketing Approval in the Field in the US Territory.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">During the period that MedImmune is providing the Regulatory Services, it shall provide (or procure the
provision of) such services in accordance with the Service Standard. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">From the Effective Date until the MAH Transfer Date for the EU Marketing Approval (provided the EU Marketing
Approval is granted), Innate shall, at MedImmune&#146;s reasonable request, use Commercially Reasonable Efforts to support MedImmune to obtain and, following grant of the EU Marketing Approval, maintain, the EU Marketing Approval in the Field in the
EU Territory. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>COMMERCIALISATION ACTIVITIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Responsibility for Commercialization</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Following the end of the US Transition Period (with respect to the US Territory), Innate shall:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">be responsible for Commercialization of the Licensed Product in the Field in the US Territory at its cost
and expense; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">subject to Applicable Law, invoice and book sales, establish all terms of sale (including pricing and
discounts) and warehouse and distribute the Licensed Product in the Field in the Territories and perform or cause to be performed all related services; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">subject to clause 12.4, handle all returns, recalls or withdrawals, order processing, invoicing, collection,
distribution and inventory management with respect to the Licensed Product in the Territories. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">From the Effective Date, Innate shall be responsible for the Commercialization of the Licensed Product in
the EU Territory (subject to the EU Marketing Approval being granted and transferred from MedImmune to Innate). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Markings</B>. Subject to any local regulatory requirements, Innate shall be identified on the Licensed
Product Labelling. All changes to the Licensed Product Labelling required to so identify Innate shall be at Innate&#146;s cost. The timing of any such changes shall be agreed by the Parties following discussions by the JCC, taking into account
existing inventory of Licensed Product and Manufacturing and regulatory requirements. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Promotional Materials</B>. Following the Effective Date and as part of the Commercialization Plan,
MedImmune shall provide to Innate MedImmune Promotional Materials so that Innate can develop its own Promotional Materials (including web and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">31. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
social media content) for the Licensed Product (collectively, the &#147;<B>Innate Marketing Materials</B>&#148;). The Innate Marketing Materials shall be consistent with the Product Labelling in
all material respects. Innate shall provide copies of the Innate Marketing Materials to the JCC for review promptly following their creation by Innate or a material amendment, and prior to their use. Innate shall be responsible for creating any
necessary local variants of the Innate Marketing Materials for use in each country in the Territories and shall ensure that such marketing materials are consistent with the Innate Marketing Materials provided to the JCC for review. Innate shall use
Promotional Materials that are consistent with the Innate Marketing Materials provided to the JCC for review (and only such marketing materials, together with Product Labelling) in Commercializing the Licensed Product in the Territories. While
MedImmune is the MAH, (a)&nbsp;all Innate Marketing Materials for the Licensed Product in the US must be approved by MedImmune in writing prior to its use (such approval not to be unreasonably withheld, delayed or conditioned) and (b)&nbsp;after any
such approval the approved Innate Marketing Materials shall, at MedImmune&#146;s reasonable request, be subject to <FONT STYLE="white-space:nowrap">re-approval</FONT> by MedImmune (such <FONT STYLE="white-space:nowrap">re-approval</FONT> not to be
unreasonably withheld, delayed or conditioned). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Promotion of Products</B>. Until such time as MedImmune (or any of its Affiliates) ceases to be the MAH
in the US with respect to Innate and during the SOTC Period with respect to MedImmune, each Party shall train the Field Force and ensure that all Promotional activities relating to the Licensed Product are undertaken in accordance with standards
equivalent to, or higher than, the AZ Promotion Principles. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>PAYMENTS </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Upfront Amount</B>. In partial consideration of the rights granted by MedImmune to Innate under this
Agreement, Innate shall pay to MedImmune a <FONT STYLE="white-space:nowrap">non-refundable</FONT> <FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment of fifty million Dollars ($50,000,000) (&#147;<B>Upfront Amount</B>&#148;) on the
later of the Effective Date and January&nbsp;31, 2019, by way of electronic transfer to the account set forth in clause 10.8. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Milestone Payments</B>. In partial consideration of the rights granted by MedImmune to Innate hereunder,
Innate shall pay MedImmune the following milestone payments within [***] after the first achievement of each of the following milestone events, which payments shall be a <FONT STYLE="white-space:nowrap">one-time</FONT> payment, <FONT
STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> and fully earned upon achievement of the relevant milestone event: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" BGCOLOR="#dadada" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#dadada"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10.5pt; font-family:Times New Roman"><B>Milestone Event</B></P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" BGCOLOR="#dadada" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#dadada"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10.5pt; font-family:Times New Roman"><B>Milestone Payment ($)</B></P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:42pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-right:0.50em; font-size:10.5pt; font-family:Times New Roman" ALIGN="justify">The date on which gross sales of Licensed Product during the 2019 Calendar Year in the US Territory equals or exceeds
[***].</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10,000,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">32. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-right:0.50em; font-size:10.5pt; font-family:Times New Roman" ALIGN="justify">Date on which MedImmune files for the BLA (or its European equivalent) with the EMA (or files for the BLA (or its
European equivalent) in [***].</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10.5pt; font-family:Times New Roman">15,000,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:22pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Determination that milestones have occurred</B>. Either Party shall notify the other promptly of the
achievement of each of the events identified as a milestone in clause 10.2. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Other Payments</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Development Plan includes that Development Budget (which includes the budget for the Regulatory
Services), and the Commercialization Plan includes, a budget for the Supply Expenses, as such budgets may be updated from time to time by mutual agreement, and may be supplemented by budgets for other services that are not included in the SOTC
Services (together the &#147;<B>Budgets</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Costs incurred by MedImmune and its Affiliates pursuant to any Budgets and pursuing the
Commercialization Plan and Development Plan, shall be reimbursed by Innate on a quarterly basis in arrears, upon receipt from MedImmune of an invoice including reasonable supporting evidence of the Costs, provided that such Costs have not already
been compensated under this Agreement. Any Costs incurred by MedImmune and its Affiliates in excess of [***] of the amount budgeted for the applicable Calendar Quarter in any given Budget (the &#147;<B>Excess Costs</B>&#148;) shall be reimbursable
by Innate only if (i)&nbsp;such Excess Costs were incurred as a result of circumstances outside MedImmune&#146;s control or otherwise by the occurrence of a force majeure event, (ii)&nbsp;the incurrence of such Excess Costs was approved by the JDC
or JCC, or (iii)&nbsp;such Excess Costs were not incurred as a result of MedImmune&#146;s failure to perform the corresponding obligations in the Development Plan or Commercialization Plan (as the case may be) in accordance with the Services
Standard. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">[***]. Innate shall make the payments set forth in, and contemplated by, the [***]. Other than those
payments, no other payments shall be due by Innate in respect of the [***]. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">[***]. Innate shall make the payments set forth in, and contemplated by, the [***]. Other than those
payments, no other payments shall be due by Innate in respect of the [***]. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>No other payments</B>. The payments referred to in this clause 10, clause 3.8 and <U>Schedule 2</U> and
clause 3.2 and <U>Schedule 3</U> are Innate&#146;s sole payment obligations to MedImmune, its Affiliates and their respective licensors or contractors in respect of the grant of licenses described in clause 4 and the Development and
Commercialization obligations undertaken by MedImmune under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Mode of Payment; Offsets</B>. All payments to MedImmune under this Agreement shall be made by deposit of
Dollars in the requisite amount to the UK bank account notified in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">33. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
advance by MedImmune to Innate, or such other account as MedImmune may from time to time designate by notice to Innate. Neither Party shall have the right to offset, set off or deduct any amounts
from or against other amounts due hereunder. For the purpose of calculating any sums due under, or otherwise reimbursable pursuant to, this Agreement (including the calculation of Net Sales expressed in currencies other than Dollars), the Parties
shall convert any amount expressed in a foreign currency into Dollar equivalents using its, its Affiliate&#146;s or Sublicensee&#146;s, as applicable, standard conversion methodology consistent with GAAP. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Taxes</B>. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>General</B>. The Upfront Amount, milestone payments and other payments payable by Innate to MedImmune
pursuant to this Agreement (each, a &#147;<B>Payment</B>&#148;) shall be paid without any deduction or withholding for or on account of any Tax, except for any such deduction or withholding required by Applicable Law. The Parties acknowledge and
agree that in accordance with Applicable laws as of the Effective Date, no withholding Tax should apply. Except as provided in this clause 10.9.1, MedImmune shall be solely responsible for paying any and all taxes (other than withholding taxes
required by Applicable Law to be deducted from Payments and remitted by Innate) levied on account of, or measured in whole or in part by reference to, any Payments it receives. Innate shall deduct or withhold from the Payments any taxes that it is
required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if MedImmune is entitled under any applicable Tax treaty to a reduction of rate of, or the elimination of, applicable withholding Tax, it may deliver to Innate or the
appropriate Governmental Authority (with the assistance of Innate to the extent that this is reasonably required and is requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Innate of its
obligation to withhold such Tax and Innate shall apply the reduced rate of withholding or dispense with withholding, as the case may be; <I>provided</I> that Innate has received evidence that MedImmune has duly delivered all applicable forms (and
that, if applicable, all governmental authorisations that are required to be received by the appropriate Party have been so received) at least [***] prior to the time that the Payments are due. If, in accordance with the foregoing, Innate withholds
any amount, it shall pay to MedImmune the balance when due, make timely payment to the proper taxing authority of the withheld amount and send to MedImmune proof of such payment within [***] following such payment. If Innate shall have transferred
(whether by way of legal or equitable assignment, declaration of trust, novation or otherwise) the benefit in whole or in part of this Agreement or shall, after the Effective Date, have changed its Tax residence or the permanent establishment to
which the rights under this Agreement are allocated and, a payment under this Agreement is subject to a requirement to withhold for or on account of Tax where the payment would not have been subject to such withholding requirement in the absence of
such transfer, change of Tax residence or permanent establishment, then Innate or its assignee (as the case may be) shall be obliged to pay to MedImmune such sum as will, after such deduction or withholding has been made, leave MedImmune with the
same amount as it would have been entitled to receive in the absence of any such requirement to make a deduction or withholding; <I>provided</I> that, upon Innate&#146;s or its assignee&#146;s reasonable request, if MedImmune is entitled under any
applicable Tax treaty to a reduction of rate of, or the elimination of, any applicable withholding Tax, it shall deliver to Innate or its assignee or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">34. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
the appropriate Governmental Authority (with the assistance of Innate or its assignee to the extent that this is reasonably required) the prescribed forms necessary to reduce the applicable rate
of withholding or to relieve Innate of its obligation to withhold such Tax. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Indirect Tax</B>. Notwithstanding anything contained in clause 10.9.1, this clause 10.9.2 shall apply
with respect to Indirect Tax. All amounts expressed to be payable under this Agreement (including the Upfront Amount) by any Party to this Agreement which (in whole or in part) constitute the consideration for any supply for Indirect Tax purposes
are deemed to be exclusive of any Indirect Tax which is chargeable on that supply, and accordingly, if any Indirect Tax is or becomes chargeable on any supply made by any Party to this Agreement (the &#147;<B>Supplier</B>&#148;) and the Supplier or
an Affiliate of the Supplier is required to account to the relevant Tax Authority for the Indirect Tax, the Party receiving such chargeable supply (the &#147;<B>Recipient</B>&#148;) shall pay to the Supplier (in addition to and at the same time as
paying any other consideration for such supply, or [***] after the receipt by the Recipient of an appropriate invoice in respect of such Indirect Tax) an amount equal to the amount of the Indirect Tax (and such Supplier must promptly provide an
appropriate invoice in respect of such Indirect Tax to the Recipient to the extent that such an invoice has not already been provided). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Tax Warranties</B>. In this clause 10.9.3: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">references to &#147;<B>committing tax evasion</B>&#148; shall include: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">fraudulently or dishonestly failing to pay any amount of tax to the relevant Tax Authority within any
applicable time limit for the payment of such tax without incurring interest and/or penalties; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">fraudulently or dishonestly claiming any relief, allowance, credit, deduction, exemption or set off in
respect of any tax (or relevant to the computation of any income, profits or gains for the purposes of any tax), or any right to or actual repayment of or saving of tax; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">&#147;<B>tax</B>&#148; or &#147;<B>taxation</B>&#148; means: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="21%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">taxes on gross or net income, profits and gains, and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="21%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">all other taxes, levies, duties, imposts, charges and withholdings of any nature, including any excise,
property, wealth, capital, value added, sales, use, occupation, transfer, franchise and payroll taxes and any national insurance or social security contributions, together with all penalties, charges, fees and interest relating to any of the
foregoing or to any late or incorrect return in respect of any of them. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Each Party represents, warrants and undertakes that </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">neither it nor its Affiliates shall commit tax evasion; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">35. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">neither it nor its Affiliates shall undertake any activities which would facilitate or otherwise result in
another person committing tax evasion; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">it and its Affiliates shall maintain reasonable procedures designed to prevent any employees, agents or
other persons who perform services for them or on their behalf from undertaking any activities which would facilitate or otherwise result in another person committing tax evasion. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Each Party shall promptly report any apparent breach of clause 10.9.3(b) to the other Party.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Each Party shall: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">answer, in reasonable detail, any written or oral inquiry from the other Party related to Innate&#146;s
compliance with clause 10.9.3(b), 10.9.3(c) and 10.9.3(d); </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">facilitate the interview of staff employed by Innate (or any agent of Innate) at any reasonable time
specified by the other arty related to compliance with this clause 10.9.3; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><FONT STYLE="white-space:nowrap">co-operate</FONT> with the other Party and/or any regulator or Governmental
Authority in relation to any investigation relating to the matters referred to in this clause. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Breach
of this clause 10.9.3 shall be deemed a material breach under clause 20.2.1, and for that purpose a breach of clause 10.9.3(b) or 10.9.3(c) shall be regarded as incapable of remedy. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Unless otherwise expressly provided, all payments due by one party to another under the Agreement shall be
made against invoices. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Interest on Late Payments</B>. If either Party fails to pay any amount payable under this Agreement by
the due date for payment then, without prejudice to any other rights or remedies that the other Party may have, interest shall accrue thereon (before and after any judgment) at an annual rate [***], as adjusted from time to time and published by
[***], such interest to run from the date on which payment of such sum became due until payment thereof in full together with such interest. Notwithstanding the previous sentence, the payable interest rate shall never be less than [***].
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The consideration paid by Innate under this Agreement shall be allocated to the Licensed MedI Patents, the
Licensed MedI <FONT STYLE="white-space:nowrap">Know-How,</FONT> the Product Trademarks and other commitments made by MedI under this Agreement. No portion of the consideration shall be allocated to the [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">36. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>RECORDS AND REPORTING </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Development Records</B>. MedImmune, with respect to its Development activities in the EU Territory (and,
if applicable, the US Territory) relating to the Licensed Product (including any Existing Product Trial), and Innate to the extent that Innate is engaged in any Development of the Licensed Product, shall, and shall cause its Affiliates to, maintain,
in good scientific manner, complete and accurate books and records pertaining to such Development activities. Such books and records shall (a)&nbsp;be appropriate for Patent and regulatory purposes, (b)&nbsp;be in compliance with Applicable Law,
(c)&nbsp;properly reflect all work done and results achieved in the performance of its Development activities hereunder, (d)&nbsp;record only such activities and not include or be commingled with records of activities outside the scope of this
Agreement and (e)&nbsp;be retained by MedImmune or Innate (as applicable) for at least [***] after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Development Reports</B>. During the period when the JDC operates between the Parties as contemplated by
this Agreement, within [***] following the end of each Calendar Quarter during which a Party is conducting Development activities with respect to the Licensed Product in the EU Territory, such Party shall provide the JDC with a report summarising
its activities to Develop the Licensed Product in the Territories, such report to include a summary of the work completed, a summary of the work in progress, and, if applicable, a summary of a current schedule of planned activities in the Calendar
Quarter following the reporting period. Such report shall contain sufficient detail to enable the JDC to assess each Party&#146;s compliance with its obligations set forth in clause 8.1. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Financial Records</B>. Each Party shall and shall cause its Affiliates (and if applicable, Innate&#146;s
Sublicensees) to, keep complete and accurate financial books and records pertaining to the Commercialization of the Licensed Product hereunder, including books and records of Development Costs, Commercialization Costs, other fees pursuant to this
Agreement and Net Sales of Licensed Product, in sufficient detail to calculate and verify all amounts payable hereunder. Such records shall be in compliance with Applicable Law. Each Party shall and shall cause its Affiliates and (if applicable,
Innate&#146;s Sublicensees) to, retain such books and records until the later of (a) [***] after the end of the period to which such books and records pertain and (b)&nbsp;the expiration of the applicable Tax statute of limitations (or any
extensions thereof) or for such longer period as may be required by Applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Commercialization Reports</B>. Within [***] following the end of each Calendar Quarter during which
MedImmune is providing SOTC Services, MedImmune will provide Innate with a report summarising MedImmune&#146;s activities to Commercialize the Licensed Product in the US Territory pursuant to the SOTC Services, such report to include a summary of
the work completed, a summary of the work in progress, and, if applicable, a summary of a current schedule of planned activities in the Calendar Quarter following the reporting period. Such report shall not be required to be any more detailed or
comprehensive than any similar report MedImmune would use for internal reporting purposes. If during the 2019 Calendar Year Innate carries out any Commercialization activities with respect to the US Territory, then it shall, within [***] following
the end of each Calendar Quarter during </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">37. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
which Innate is conducting those activities, provide MedImmune with a report summarising Innate&#146;s activities to Commercialize the Licensed Product in the US Territory, such report to include
a summary of the work completed, a summary of the work in progress, and, if applicable, a summary of a current schedule of planned activities in the Calendar Quarter following the reporting period. Each such report shall contain sufficient detail to
enable the other Party to assess the reporting Party&#146;s compliance with its obligations under the Commercial Plan and commercial transition plan, as applicable, including: (a)&nbsp;field force size and allocation; (b)&nbsp;the number and
position of Details in the applicable period; (c)&nbsp;the nature of Promotional activities and Licensed Product sampling activities; (d)&nbsp;market and sales promotional programs; and (e)&nbsp;the conduct of advertising, public relations and other
promotional programs, including professional symposia and speaker and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peer-to-peer</FONT></FONT> activity programs used in the Commercialization of the Licensed Product.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Audit</B>. In respect of any Calendar Year in which SOTC Services are being provided, at the request of
either Party, the other Party shall and shall cause its Affiliates to, permit such Party or an independent auditor designated by such Party and reasonably acceptable to the other Party, not more than once in respect of each such Calendar Year and at
reasonable times and upon reasonable notice, to audit the books and records maintained pursuant to this clause 11 to ensure the accuracy of all reports and payments made hereunder. Except as provided below, the cost of this audit shall be borne by
the auditing Party, unless the audit reveals, with respect to the period covered by the audit, a variance of more than [***] from the reported financial amounts for such period, in which case the audited Party shall bear the cost of the audit.
Unless disputed pursuant to clause 11.6, if such audit concludes that (a)&nbsp;additional amounts were owed by the audited Party, then the audited Party shall pay the additional amounts, with interest from the date originally due or (b)&nbsp;excess
payments were made by the auditing Party, the audited Party shall reimburse such excess payments, in either case ((a) or (b)), within [***] after the date on which such audit is completed by the auditing Party. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Audit Dispute</B>. In the event of a dispute arising out of or in connection with any audit under clause
11.5, the Parties agree to submit the dispute, in the first instance, to administered expert proceedings in accordance with the Rules for the Administration of Expert Proceedings of the International Chamber of Commerce. After the International
Centre for ADR&#146;s notification of the termination of the administered expert proceedings, the dispute, if it has not been resolved, shall be resolved in accordance with the dispute resolution mechanism set out in clause 21.6.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>REGULATORY ACTIVITIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Regulatory Approvals</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">During: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the US Transition Period, MedImmune or its Affiliate shall remain the MAH for the Licensed Product in the US
Territory and use Commercially Reasonable Efforts to maintain the US Marketing Approval (provided that nothing in this clause </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">38. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
12.1.1(a) shall impose any obligation on MedImmune with respect to the costs of new Clinical Trials for the Licensed Product in the US); and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the EU Transition Period, MedImmune shall in accordance with the Development Plan continue to prepare and,
once prepared, submit the BLA to the EMA and Swissmedic to obtain the EU Marketing Approval and in connection with this shall have the right (following consultation with Innate through the JDC) to conduct communications with the EMA and Swissmedic
in the EU Territory in its name, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:Times New Roman">provided that, MedImmune shall have no obligation to carry out any Development
activities with respect to the Licensed Product unless set forth in the Development Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Until the MAH Transfer Date in the US Territory or the EU Territory, as the case may be, the Parties
acknowledge that MedImmune (or an Affiliate of MedImmune) holds (or will hold) the US Marketing Approval and the EU Marketing Approval (as applicable) and has certain rights and obligations under Applicable Law as a holder of such approvals and is
required to undertake or have undertaken certain activities in connection with such approvals (the &#147;<B>MAH Related Responsibilities</B>&#148;). During such time that MedImmune is the holder of the US Marketing Approval and/or the EU Marketing
Approval, subject to the terms of this Agreement, Innate shall cooperate fully with MedImmune in the discharge of the MAH Related Responsibilities and shall use Commercially Reasonable Efforts to perform its Development and Commercialization
activities with respect to the Licensed Product under the US Marketing Approval or EU Marketing Approval, as applicable, and otherwise act under and in accordance with such approvals and the AZ Promotion Principles. During the Term, if necessary to
permit Innate or its nominee to lawfully perform all or some of the MAH Related Responsibilities on behalf of MedImmune, or its Affiliate as contemplated by this Agreement, MedImmune or its Affiliate, as holder, shall provide Innate or its nominee
with a power of attorney or delegation of authority. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Transfers of Regulatory Approvals</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Subject to Applicable Law, MedImmune shall transfer the (i)&nbsp;US Marketing Approval to Innate on the US
Transfer Date, and (ii)&nbsp;EU Marketing Approval (if obtained) to Innate in accordance with the EU Regulatory Transition Plan, (either date being a &#147;<B>MAH Transfer Date</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate and MedImmune shall ensure that the Commercialization Transition Plan contains provisions relating to
the transfer of the US Marketing Approval and shall prepare and agree, acting through the JDC, a regulatory transition plan for the transfer of the EU Marketing Approval (once approved and agreed, the &#147;<B>EU Regulatory Transition
Plan</B>&#148;). The EU Regulatory Transition Plan shall include any services to be provided by MedImmune in connection with such transition and the fee payable (on an FTE basis and at the applicable FTE Rate quoted by MedImmune) by Innate for such
activities. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Following an MAH Transfer Date, Innate shall be the MAH for the US Marketing Approval or the EU Marketing
Approval and shall assume all regulatory responsibilities </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">39. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
with respect to the Licensed Product in the US Territory or EU Territory, as the case may be. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">On or prior to the Effective Date and on an <FONT STYLE="white-space:nowrap">on-going</FONT> basis
thereafter promptly upon the creation or receipt of, or update to MedI Regulatory Documentation, MedImmune shall provide Innate with an electronic copy of the MedI Regulatory Documentation relating to the Licensed Product in the US Territory or EU
Territory, as applicable, through an electronic repository in a form agreed between the Parties. The MedI Regulatory Documentation shall not include any source documents associated with individual case safety reports and MedImmune shall not be
required to transfer any such documents or reports. For the avoidance of doubt, MedI Regulatory Documentation constitutes Licensed MedI Know How and shall remain as such notwithstanding the transfer of the US Marketing Approval or EU Marketing
Approval to Innate. Accordingly, such Information may only be used or disclosed by Innate or its Affiliates or Sublicensees in accordance with the terms and conditions of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Communications and Filings with Regulatory Authorities</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">With respect to the Licensed Product, the MAH shall be responsible for all communications with the
Regulatory Authorities in the US Territory and EU Territory (as applicable) with respect to the Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">While MedImmune is the MAH with respect to the Licensed Product, it shall wherever practicable provide
Innate with reasonable advance notice of all meetings, conferences, discussions or other communications (whether <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face</FONT></FONT> or teleconference and including any meeting
of experts convened by a Regulatory Authority concerning any topic relevant to the Licensed Product) with a Regulatory Authority concerning any matter relating to the Licensed Product in the Territories within [***] after the earliest of the
occurrence, notice or scheduling of such meeting (or as quickly as feasibly possible if the meeting is scheduled with less than a [***] prior notice), including copies of all related documents and other relevant information relating to such
meetings, conferences, discussions or other communications. Innate shall have the right to have reasonable representation present at and to participate in such meetings, conferences, discussions and other communications. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">While MedImmune is the MAH in either of the Territories, it shall promptly provide Innate with the following
, or if not practicable to provide, written summaries of the following: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">copies of all regulatory correspondence to or from the Regulatory Authorities relating to the Licensed
Product in the US Territory or EU Territory (as applicable); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">advance copies of material submissions and filings (e.g., INDs, BLAs, major supplements or amendments to the
foregoing, material labelling supplements, Regulatory Authority meeting requests and core data sheets) to the Regulatory Authorities and a reasonable opportunity to comment in advance on such submissions (which comments MedImmune shall consider in
good faith and shall be incorporated therein to the extent reasonable); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">40. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">notices of any revocations of Regulatory Approvals with respect to the Licensed Product and any Licensed
Product recalls or withdrawals in the Territories; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">reasonable responses to inquiries by Innate regarding the Regulatory Approval and Commercialization
processes for the Licensed Product in the Territories, including reasonable access to MedImmune&#146;s personnel in connection with such inquiries; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">copies of all other documents and correspondence pertaining to the Licensed Product in the Territories after
they have been submitted to, or received from, the Regulatory Authorities in the Territories; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">if and to the extent not provided in accordance with the Pharmacovigilance Agreement, any other material
safety information in relation to the Licensed Product outside the Territories to the extent that such information might reasonably be expected to be relevant to the Development or Commercialization of the Licensed Product in the Territories by
Innate. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune shall, where practicable and feasible, take into account Innate&#146;s comments provided as part
of the discussions at the JCC and JDC (where applicable) with respect to any filing with, response to, or interactions with the Regulatory Authorities relating to the Licensed Product in the US Territory or EU Territory in each case in accordance
with the Commercialization Plan and Development Plan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Recalls, Suspensions or Withdrawals</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Notification</B>. Each Party shall notify the other Party promptly (but in no event later than [***])
following its determination that any event, incident or circumstance has occurred that may result in the need for a recall, market suspension or market withdrawal of the Licensed Product (whether in the Territories or outside the Territories) and
shall include in such notice the reasoning behind such determination and any supporting facts. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Conduct</B>. As between the Parties, the MAH shall have final decision making authority with respect to
Product recalls in the Territories and shall have the right to make the final determination whether to voluntarily implement any such recall, market suspension or market withdrawal in the Field in the Territories, including any retraction of
Promotional Materials; <I>provided</I> that prior to any implementation of such a recall, market suspension or market withdrawal, including any retraction of Promotional Materials, the MAH shall consult with the other Party and shall consider the
other Party&#146;s comments in good faith. If a recall, market suspension or market withdrawal, including any retraction of Promotional Materials, is mandated by a Regulatory Authority in the Territories, as between the Parties, the MAH shall
initiate such a recall, market suspension or market withdrawal in compliance with Applicable Law. For all recalls, market suspensions or market withdrawals undertaken pursuant to this clause 12.4.2, as between the Parties, the MAH shall be solely
responsible for the execution thereof. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Costs of Recalls, Suspensions or Withdrawals</B>. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">41. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">During the Term, subject to clause 18, Innate shall be responsible for all
costs of any recall, market suspension or market withdrawal of the Licensed Product, except in the event and to the extent that such recall, market suspension or market withdrawal resulted from MedImmune&#146;s or its Affiliate&#146;s breach of its
obligations under this Agreement or the [***] or MedImmune&#146;s negligence, in which case, MedImmune shall bear the expense of such recall, market suspension or market withdrawal. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Pharmacovigilance</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">During the period during which pharmacovigilence responsibilities are transferring from MedImmune to Innate
with respect to the Licensed Product in the Territories (the &#147;<B>Pharmacovigilance Transfer Period</B>&#148;) and subject to what may be otherwise agreed by the Parties in the transition services agreement: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune shall hold and maintain the Global Safety Database for the Licensed Product and have
responsibility for maintenance of reference safety information for both Development and Commercialization use; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune shall prepare periodic/aggregate safety reports, manage signal detection/surveillance, global
(English language) literature, and other such global safety activities as are required; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune shall be responsible for consumer facing safety and pharmacovigilance activities including adverse
event collection, following up and processing, as well as medical inquiries/information, local language literature and other such local activities in the Territories as are required. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the applicable MAH will be responsible for all pharmacovigilance related submissions to Regulatory
Authorities </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">During the Pharmacovigilence Transfer Period, the Parties will work together in good faith
to transfer responsibility for pharmacovigilance in the Territories from AZ/MedI to Innate as soon as practical but not later than the earlier of 1) [***] or 2) [***]. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Following the transfer of pharmacovigilance activities in accordance with clause 12.4.4 (a):
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall hold and maintain the Global Safety Database for the Licensed Product and have responsibility
for the maintenance of reference safety information for both Developmentand Commercialization use. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall prepare periodic/aggregate safety reports, manage signal detection/surveillance, global
(English language) literature, and other such global safety activities. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall be responsible for consumer facing safety and pharmacovigilance activities including adverse
event collection and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">42. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
following up, Medical inquiries/information, local language literature and other such Local activities in the Territories as are required. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate will be responsible for all pharmacovigilance related submissions to Regulatory Authorities in any
countries where the applicable Regulatory Approval has been transferred to Innate. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Prior to the date (if any) on which the BLA is submitted to the EMA, MedImmune and Innate will appoint
pharmacovigilance transition teams to discuss any pharmacovigilance activities to be included in the EU Regulatory Transition Plan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Pharmacovigilance Agreement</B>. The Parties shall enter into a separate pharmacovigilance or safety data
exchange agreement in a form that is customary in the pharmaceutical industry (&#147;<B>Pharmacovigilance Agreement</B>&#148;) reasonably in advance of Innate taking full responsibility for any Commercialization or Development activity with respect
to the Licensed Product, outlining their respective responsibilities with respect to the exchange of safety information and the performance of pharmacovigilance activities for the Licensed Product in accordance with clause 12.4.4.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Pending execution of such Pharmacovigilance Agreement, and unless otherwise agreed: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall notify MedImmune of any adverse events or special situations (including but not limited to
reports of exposure during pregnancy or breastfeeding; overdose, abuse and misuse; <FONT STYLE="white-space:nowrap">off-label</FONT> use, mediation errors; lack of therapeutic effect, occupational exposure, unexpected therapeutic or clinical benefit
and infectious agents) associated with the Licensed Product in the Territories within [***] after the first receipt of such information (such notice to be provided to [***]); provided that (i)&nbsp;if a case is received during a period of [***]
(&#147;<B><FONT STYLE="white-space:nowrap">non-Business</FONT> Days</B>&#148;), Innate will forward details of the case on the next Business Day and (ii)&nbsp;the Parties shall put in place procedures to ensure that Innate will forward any report of
an adverse event received during a period of [***] in accordance with 12.4.6 in order to ensure the safety of patients; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">at MedImmune&#146;s request, Innate shall cooperate with MedImmune and provide such assistance as MedImmune
may reasonably require to enable it to investigate and <FONT STYLE="white-space:nowrap">follow-up</FONT> any reports of adverse events or other safety-relevant information associated with the Licensed Product; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the Parties shall put in place procedure(s) to perform reconciliation as MedImmune, as MAH, deems reasonably
necessary. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Quality Agreement</B>. The Parties shall enter into the Quality Agreement as soon as reasonably
practicable after, and in any event no later than [***] after, the Effective Date, outlining their respective quality related responsibilities with respect to the Licensed Product. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Standard Response Letters</B>. During the period commencing on the Effective Date and ending on the EU MA
Transfer Date (or the date, if any, on which the Parties determine </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">43. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
that they shall not obtain a BLA with respect to the EU Territory), MedImmune shall be responsible for developing and updating the template for standard response letters for use in connection
with the Licensed Product and shall provide a copy of such template letters to Innate. Innate shall use such template letters in preparing standard response letters for use in the Territories; provided that the MAH shall be responsible for preparing
any country-specific standard response letters for use in the Territories. Innate shall not include any information in any standard response letter that is not included in a then-current MedImmune template letter without MedImmune&#146;s prior
written consent, such consent not to be unreasonably withheld, conditioned or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Compensation for Regulatory Support and Services</B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In consideration of the performance of regulatory services being provided by MedImmune to Innate in accordance with this
clause 12 (and other provisions of this Agreement) (the &#147;<B>Regulatory Services</B>&#148;), Innate shall pay to MedImmune in accordance with clause 10.8 for the provision of those Regulatory Services. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>INTELLECTUAL PROPERTY </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Ownership of Technology</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">As between the Parties, Innate shall own and retain all right, title and interest in and to any and all
Information and inventions that are conceived, discovered, developed or otherwise made by or on behalf of either Party or its Affiliates under or in connection with this Agreement, whether or not patented or patentable and any and all Patents and
other Intellectual Property Rights with respect thereto. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The determination of whether Information and inventions are conceived, discovered, developed or otherwise
made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other Intellectual Property Rights) therein, shall, for purposes of this Agreement, be made in accordance with Applicable Law in the United States
irrespective of where or when such conception, discovery, development or making occurs. Each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, such right, title
and interest in and to any Information and inventions as well as any Intellectual Property Rights with respect thereto, as is necessary to fully effect, as applicable, the allocation of ownership provided for in clause 13.1.1. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Each Party shall cause all Persons who perform any activities for or on its behalf under this Agreement or
who conceive, discover, develop or otherwise make any Information or inventions by or on behalf of it or its Affiliates or, in the case of Innate, its Sublicensees, under or in connection with this Agreement to be under an obligation to assign (or,
if the Party is unable to cause such Person to agree to such assignment obligation despite such Party using reasonable efforts to negotiate such assignment obligation, then to grant an exclusive licence under) their rights in any Information and
inventions resulting therefrom to such Party, except where Applicable Law requires otherwise and except in the case of governmental, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> and public
institutions that have standard policies against such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">44. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
an assignment (in which case, a suitable licence or right to obtain such a licence, shall be obtained). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">[***]. Innate acknowledges that [***] all rights, title and interest in the Intellectual Property Rights
licensed to [***]. Except as expressly granted in the [***], Innate shall not acquire any right, title or interest whatsoever in or to any such Intellectual Property Rights. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Third Party Agreements</B>. The Parties acknowledges that the rights, obligations and procedures set out
in this clause 13 are subject to the terms and conditions of the [***] as they apply to the maintenance, prosecution, defence and infringement of the Intellectual Property Rights licensed thereunder and to the extent that there is an inconsistency
between the provisions of this clause 13 and the [***] with respect to such matters, the terms of the [***] shall prevail. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B><FONT STYLE="white-space:nowrap">Co-ordination</FONT></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Promptly following the Effective Date, each Party shall appoint one (1)&nbsp;patent attorney from within its
organisation (each an &#147;<B>IP Manager</B>&#148;) to act as its main point of contact between the Parties for all Patent and Trademark matters addressed under this Agreement and, in particular, the remaining provisions of this clause 13.4. The IP
Managers shall establish and oversee mutually agreeable procedures for (a)&nbsp;liaising with regard to Patent and Trademark prosecution, enforcement and defence activities under this Agreement and the [***]] and (b)&nbsp;coordinating communications
with respect to such matters. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">If MedImmune receives documents relating to [***] prosecution, maintenance or defence of the Intellectual
Property Rights licensed thereunder to MedImmune or otherwise has rights to make decisions or influence [***] decisions with respect to the Intellectual Property Rights licensed thereunder, MedImmune&#146;s IP Manager shall provide Innate with
copies of the relevant documents or notices received from [***] in so far as they relate to the Licensed Product or Licensed Antibody in the Territories and MedImmune shall consider in good faith any comments from Innate with respect thereto. To the
extent MedImmune takes over responsibility for patent prosecution under the [***], all such prosecution with respect to the [***] (the &#147;[***]&#148;) shall be coordinated by the IP Managers in accordance with clause 13.4.1.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Prosecution and Maintenance of Patent Rights</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall be primarily responsible for and shall use Commercially Reasonable Efforts to control the
preparation, filing, prosecution (including conducting or handling any interferences, oppositions, action for declaratory judgment, nullity actions, reissue proceedings, reexaminations and challenges to title) and maintenance of the Licensed MedI
Patents, and [***] subject to [***] to the extent MedImmune has the corresponding responsibility under the [***]; provided that Innate shall provide MedImmune with advance copies of, and a reasonable opportunity to comment upon, proposed patent
filings, related prosecution strategies and proposed correspondence with patent officials or other Third Parties relating to any [***] subject to [***], and will consider comments received
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">45. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
from MedImmune with respect to such proposed filings, strategies and correspondence in good faith. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall further be responsible for all Costs incurred or invoiced by either Party and its Affiliates as
of the Effective Date and thereafter associated with the Licensed MedI Patents. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">If Innate decides not to file, prosecute or maintain a Licensed MedI Patent or [***], it shall give
MedImmune reasonable notice to that effect sufficiently in advance of any deadline for any filing with respect to such Licensed MedI Patent or such [***], as applicable, in which case any and all rights under this Agreement with respect to such
Licensed MedI Patent and such [***] shall cease with respect to Innate. After receiving such notice, MedImmune may elect by written notice to Innate within [***] after receiving such notice from Innate to file, prosecute and maintain the relevant
Licensed MedI Patent or [***], at its sole cost and expense. If MedImmune does so elect, Innate shall cooperate with MedImmune as necessary to enable MedImmune to perform such acts as may be reasonably necessary for MedImmune to file, prosecute or
maintain such Licensed MedI Patent or [***], including the execution and filing of appropriate instruments and to facilitate the transition of such patent activities to MedImmune. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall be responsible for and shall control, in consultation with MedImmune, the selection of the
appropriate Licensed MedI Patents as listed in the patent information section of the BLA for the Licensed Product for filing to obtain a Patent Term Extension (&#147;<B>PTE</B>&#148;) pursuant to all Applicable Laws, including supplementary
protection certificates and any other extensions that are now or become available in the future wherever applicable to Licensed MedI Patents and [***] that are applicable to the Licensed Product in the Territory. The IP Managers shall discuss
Innate&#146;s proposed strategy for patent term extensions and patent listings and Innate shall consider MedImmune&#146;s comments with respect to such strategy in good faith, but without derogating from Innate&#146;s right to be ultimately
responsible for and to control such strategy. MedImmune shall provide prompt and reasonable assistance, if requested by Innate and at Innate&#146;s cost and expense, to obtain such extensions or listings. Notwithstanding the foregoing, MedImmune
shall continue to be responsible for and shall control the filing of the PTE application in the United States that are in process as at the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Promptly after the Effective Date, and following Innate&#146;s written request, MedImmune shall
(a)&nbsp;provide to Innate all information, including a correct and complete list of all Patents covering the Licensed Product or otherwise necessary to enable Innate to make filings with Regulatory Authorities with respect to the Licensed MedI
Patents and [***] including as required or allowed in connection with (i)&nbsp;in the United States, the FDA&#146;s Purple Book and (ii)&nbsp;outside the United States, under the national implementations of Section&nbsp;10.1(a)(iii) of Directive
2001/EC/83 or other international equivalents, and (b)&nbsp;cooperate with Innate at Innate&#146;s reasonable request and cost and expense in connection therewith, including meeting submission deadlines, in each case, to the extent required or
permitted by Applicable Laws. Promptly after the Effective Date and not less than [***] prior to any subsequent deadline with respect to the foregoing, the Parties shall discuss and identify those Patents claiming or covering the Licensed Product
and the process of review of such Patents for submission to the applicable Regulatory Authorities. Innate shall have </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">46. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
the right, at its sole discretion, to submit or <FONT STYLE="white-space:nowrap">de-list</FONT> any Licensed Medi Patent or [***] with respect to any Regulatory Authority with prior notice to
MedImmune. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Notwithstanding anything to the contrary in this clause 13, neither Party shall have the right to make an
election under the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. 103(c)(2)-(c)(3) (the &#147;<B>CREATE Act</B>&#148;) when exercising its rights under this clause 13.5.6 without the prior written consent of the other Party.
With respect to any such permitted election, the Parties shall use reasonable efforts to cooperate and coordinate their activities with respect to any submissions, filings or other activities in support thereof. The Parties acknowledge and agree
that this Agreement is a &#147;joint research agreement&#148; as defined in the CREATE Act. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Defence of Third Party Claims/Oppositions</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Except as otherwise provided in clause 19, neither Party makes any warranty with respect to the validity,
perfection, or dominance of any Patent (including the Licensed MedI Patents or [***]) or proprietary right or with respect to the absence of rights in Third Party Patents which may be infringed by the Development, Manufacture or Exploitation of any
Licensed Antibody or Licensed Product. If a Third Party asserts a Patent or other right owned by it is infringed by the Development, Manufacture or Exploitation of any Licensed Antibody or Licensed Product, or either Party discovers such a Patent or
right, the Party first obtaining knowledge of such a claim or potential claim shall immediately provide the other Party written notice and the related facts in reasonable detail. In the event the Parties cannot agree on the defense of any such
claim, such defense shall be controlled by Innate; provided that MedImmune shall have the right to participate and to be represented in any such action by counsel of its selection at its sole discretion. Innate shall also have the right to control
settlement of such claim and shall be solely responsible for paying any settlement amounts. Innate shall not settle any such claim, suit, or proceeding prior to discussing the settlement with MedImmune to the extent such proceedings may impact
MedImmune&#146;s Retained Rights. Subject to the foregoing, Innate shall consider comments received from MedImmune with respect to such settlement arrangements in good faith. If Innate chooses to settle such claim, suit or proceedings on the basis
that it takes a license from the Third Party, then Innate shall be solely responsible for all such costs associated with such license. Innate shall, as between the Parties be solely responsible for any award of damages and costs awarded against it
or MedImmune in any such proceedings. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Either Party may commence an opposition, action for declaratory judgment, nullity action, interference, <FONT
STYLE="white-space:nowrap">re-examination,</FONT> or other attack upon the validity, title, or enforceability of any Patents Controlled by a Third Party that cover the Development, Manufacture or Exploitation of any Licensed Antibody or Licensed
Product and are not Licensed MedI Patents or [***], at its own expense, but shall notify the other before commencing such action to enable the Parties to cooperate, with such cooperation not to be unreasonably withheld or delayed.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">47. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Infringement by Third Parties</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Party first having knowledge that any Licensed MedI Patent has been infringed or misappropriated by a
Third Party in any country shall promptly notify the other in writing. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall have the first right, but not the obligation, to institute, prosecute, and control any action
or proceeding or negotiation of any settlements with respect to any infringement of Licensed MedI Patents (with the other Party having the right to participate in such action or negotiations at its expense and be represented if it so desires).
Innate shall not have the right to make any admission in connection with any infringement litigation or settle any infringement in a manner that has or would reasonably be expected to have a material adverse effect on MedImmune Retained Rights or
involves any admission by, MedImmune, or which would involve any cost or expense to MedImmune or any of its Affiliates without the express written consent of MedImmune (which consent shall not be unreasonably withheld, conditioned or delayed). If
necessary, MedImmune agrees in any such action to be joined as a claimant and to give Innate reasonable assistance and any needed authority to control, file, and to prosecute such action, at Innate&#146;s expense. If Innate elects not to institute
and prosecute such action or proceeding or to conduct such negotiation, Innate will discuss with MedImmune the reasons for this decision and MedImmune may, to the extent required to ensure compliance with [***], step in Innate&#146;s rights for
purposes of this clause 13.7.2, with the consent of Innate not to be unreasonably withheld. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Any damages or monetary awards relating to the Licensed MedI Patents shall be applied as follows:
(a)&nbsp;to reimburse any and all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred by Innate in bringing suit; (b)&nbsp;to reimburse any and all <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred by MedImmune in relation to the suit; and (c)&nbsp;any remaining damages shall be [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Where Innate activities under this Agreement result in the necessity of any licences to Third Party&#146;s
Patents, and MedImmune had no Knowledge (without performing a commercially reasonable inquiry with respect to the relevant subject matters) of the need for such licenses prior to the Effective Date, Innate shall be solely responsible for obtaining
such Third Party licence(s) at its own expense and cost. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune shall not grant its Other Licensees rights in breach of the exclusive licenses granted to Innate
hereunder, and shall not grant such licenses unless each such Other Licensee agrees to contractual obligations reciprocal to those obligations of Innate whereby data and information of Innate are able to be shared and used for the benefit of such
Other Licensee on substantially similar terms. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Other AZ IPR</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise agreed by the parties, MedImmune shall have the sole right and responsibility, but not the obligation, with
regard to the maintenance, prosecution, defence and infringement of any Intellectual Property Rights, or any other matters, in connection with the Other AZ IPR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">48. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>PRODUCT TRADEMARKS </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Ownership of Corporate Names and Product Trademarks; New Product Trademarks</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Ownership</B>. As between the Parties except as otherwise expressly provided, (a)&nbsp;MedImmune (or one
of its Affiliates) shall remain the sole and exclusive owner of the AstraZeneca Corporate Names, and (b)&nbsp;Innate shall remain the sole and exclusive owner of the Innate Corporate Names. Subject to the license referred to in clause 14.1.2 being
agreed and entered into, in consideration for MedImmune&#146;s right hereunder, MedImmune shall, or shall procure that one of its Affiliates shall, assign, on the terms of the assignment attached at <U>Schedule 12</U>, the Product Trademarks to
Innate within an agreed time after the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In consideration of MedImmune&#146;s agreement to assign, and to cause its Affiliate to assign, to Innate
all of MedImmune&#146;s or its Affiliate&#146;s ownership rights in and to the Product Trademarks, Innate shall grant to MedImmune an exclusive (including with regard to Innate and its Affiliates), irrevocable, perpetual, royalty-free, fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> fully transferable, with the right to grant sublicenses through multiple tiers, license to use the Product Trademarks, including any New Product Marks, to Manufacture or have Manufactured the Licensed
Product and other products anywhere in the world and to Commercialize and otherwise Exploit the Licensed Product (and other products) outside the Territories, pursuant to a separate trademark license agreement to be negotiated between the Parties in
good faith and to be executed no later than [***] after the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>New Product Trademarks</B>. Innate shall have the right, but not the obligation, at its sole cost and
expense, to select Trademarks, other than the Existing Product Trademarks, for use in the Commercialization of the Licensed Product in the Territories subject to the following conditions: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall, at its sole cost and expense, be responsible for all activities relating to the selection and
use of such Trademark in connection with the Licensed Product in the Territories including any searches and obtaining all required approvals from Regulatory Authorities for such use; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">as long as MedImmune is the MAH, any New Product Trademark must be approved for use with the Licensed
Product in the Territories by MedImmune, such approval not to be unreasonably withheld, conditioned or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Prosecution of Product Trademarks</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Unless otherwise agreed by the Parties, Innate shall be responsible for and shall use Commercially
Reasonable Efforts to register, prosecute and maintain any registration or application for the Product Trademarks in the Territories, and such other Trademark rights in the Product Trademarks as MedImmune may require outside the Territories,
providing Innate with a list of countries in which Innate needs to secure/maintain such Trademark rights for the possible use by AZ, in a manner that is consistent with its practices for registration, prosecution and maintenance of product
trademarks for its other products, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">49. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
using counsel of its own choice. Innate shall (i)&nbsp;provide MedImmune each quarter, a detailed, written report identifying the current status of all Trademark applications and registrations
for the Product Trademarks by country; (ii)&nbsp;notify MedImmune of, and make its Commercially Reasonable Efforts to consult with MedImmune, with respect to, any substantive issue and/or any opposition or cancellation proceeding that may be raised
or asserted against any Trademark application or registration for the Product Trademarks prior to taking any action in response thereto; (iii), from time to time, upon MedImmune&#146;s request, provide MedImmune with copies of any registration
certificates, renewal applications and certificates, registration applications, pleadings, and/or other documentation or information as MedImmune may request relating to any Trademark application or registration for the Product Trademarks; and
(iv)&nbsp;use its Commercially Reasonable Efforts to consult with MedImmune prior to taking any action to (A)&nbsp;abandon or withdraw any Trademark application for a Product Trademark or (B)&nbsp;permit any Trademark registration a Product
Trademark to lapse, to expire or to be cancelled. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Subject to clause 14.2.1, if Innate decides to abandon a registration or application for a Product
Trademark, Innate shall so notify MedImmune promptly in writing at least [***] prior to any deadlines by which an action must be taken to establish or preserve all rights under such Product Trademark in the Territories (or outside the Territories
for any registration or application for a Product Trademark outside the Territories) and MedImmune may on notice to Innate assume control over, and at MedImmune&#146;s election ownership of, such application and registration and the further
prosecution (including application), administration, maintenance and defence of such Product Trademark at its sole cost and expense, and Innate shall execute such assignments, powers of attorney or other instruments and shall take such other actions
as MedImmune may reasonably request to transfer ownership of such Product Trademark registration or application to MedImmune and/or to give MedImmune control over such Product Mark registration or application so as to allow MedImmune to pursue or
resume such Trademark registration, maintenance or renewal efforts. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Infringement of the Product Trademarks</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Each Party shall provide to the other Party prompt written notice of any actual or threatened infringement
of the Product Trademarks in the Field and of any actual or threatened claim that the use of a Product Trademark violates the rights of any Third Party, in each case, of which such Party becomes aware, and the IP Managers shall promptly discuss such
notice and the potential enforcement strategies available. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">As between the Parties, Innate shall have the first right to defend against any claim by any Third Party
that the use of any of the Product Marks by Innate (or by AZ outside of the Territories) infringes, dilutes, misappropriates or otherwise violates such Third Party Trademark or constitutes unfair trade practices or another like offense (each, a
&#147;<B>TM Infringement Claim</B>&#148;) or take such action as Innate deems necessary against a Third Party based on any alleged, threatened or actual infringement, dilution, misappropriation or other violation of or unfair trade practices or any
other like offence relating to, the Product Trademarks by a Third Party in connection with the Exploitation of the Licensed Product </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">50. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
(a &#147;<B>TM Competitive Infringement</B>&#148;) at its sole cost and expense and using counsel of its own choice. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">If Innate decides to defend against a TM Infringement Claim in accordance with clause 14.3.2 or to commence
proceedings in relation to a TM Competitive Infringement in accordance with clause 14.3.2, in the case of a TM Infringement Claim with respect to the Commercialization of the Licensed Product outside the Territories or, in the case of a TM
Competitive Infringement, and the Licensed Product is Commercialized under the Product Trademark outside of the Territories, then MedImmune shall have the right to join any such defence or infringement action, and participate with its own counsel,
at its sole cost and expense; provided that Innate shall retain control of the defence or prosecution of such claim, suit or proceeding, including the response to any defence or defence of any counterclaim raised in connection therewith; provided
that MedImmune shall have right to be consulted regarding any settlement thereof and Innate shall not be able to enter into any settlement that may undermine MedImmune&#146;s rights and interest in the Product Trademarks outside the Territories. If
Innate decides not to commence proceedings in relation to a TM Competitive Infringement in accordance with clause 14.4.2 or to control the defence of a TM Infringement Claim in accordance with clause 14.4.2, MedImmune shall have the right to assume
such defence or take such action as it deems necessary against the relevant Third Party at its sole cost and expense and using counsel of its own choice and shall be entitled to retain any damages to other amounts collected in connection therewith.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Oversight of Product Trademarks</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall comply with all Trademark marking requirements as MedImmune may specify or as may be required
by Applicable Law and with all such Trademark usage guidelines as MedImmune may furnish to Innate from time to time in all jurisdictions in the Territories concerning AstraZeneca Corporate Marks. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Neither Party shall at any time use the other Party&#146;s Corporate Name, or any variation thereof, or
other word, name, letter or combination substantially similar thereto, or any other Trademark of the other Party or any of its Affiliates, except in accordance with written instructions received from the other Party, as required by Applicable Law or
as expressly provided under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Without limiting this clause 14.4, neither Party shall, and shall not permit its Affiliates or its or their
licensees to, (a)&nbsp;use in their respective businesses, any Trademark that is confusingly similar to, misleading or deceptive with respect to or that dilutes any (or any part) of the other Party&#146;s corporate marks (including AstraZeneca
Corporate Marks), (b) knowingly do any act that endangers, destroys or similarly affects, in any material respect, the value of the goodwill pertaining to the other Party&#146;s corporate marks (including AstraZeneca Corporate Marks) or
(c)&nbsp;attack, dispute or contest the validity of or ownership of the other Party&#146;s corporate marks (including AstraZeneca Corporate Marks) anywhere in the Territories or any registration applications or any registrations issued or issuing
with respect thereto. Each Party agrees and shall cause its Affiliates and licensees, to conform (i)&nbsp;to AstraZeneca&#146;s standards for the protection of the other Party&#146;s corporate marks
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">51. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
(including AstraZeneca Corporate Marks) and (ii)&nbsp;to maintain the quality standards of the other Party and its Affiliates with respect to the goods sold and services provided in connection
with the such other Party&#146;s corporate marks. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">As between the Parties, MedImmune and its Affiliates shall retain all right, title and interest in and to
the AstraZeneca Corporate Marks. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Changes to Livery and Labelling</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Concurrently with the transfer of the US Marketing Approval or the EU Marketing Approval (as the case may
be) to Innate or promptly thereafter, Innate shall file any necessary variations to such transferred approval to replace the MedImmune livery on Product Labelling of the Licensed Product with the livery of Innate; provided that Innate shall continue
to use AstraZeneca Corporate Marks as required pursuant to clause 14.5. Notwithstanding the foregoing, and subject in all respects to compliance with all Applicable Law, and the terms of, and any restrictions imposed under, all applicable Regulatory
Approvals, Innate may in each jurisdiction in the Territories, following the transfer of the relevant approval for such jurisdiction to Innate, sell any Licensed Product purchased from MedImmune in AstraZeneca&#146;s livery for the lesser of (i)
[***] after the US Transfer Date for the US Marketing Approval or EU Transfer Date (or any longer period as may be reasonably agreed between the Parties), as the case may be] and (ii) [***] (such period being the &#147;<B>Licensed Livery
Period</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>CONFIDENTIALITY AND <FONT STYLE="white-space:nowrap">NON-DISCLOSURE</FONT> </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Confidentiality Obligations</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">At all times during the Term and for a period of ten (10)&nbsp;years following termination or expiration
thereof, each Party (the &#147;<B>Receiving Party</B>&#148;) shall (i)&nbsp;keep confidential and not disclose to any Third Party, other than its and its Affiliates&#146; officers, directors, other employees, contractors and advisors on a need to
know basis, any Confidential Information provided to it by the other Party (the &#147;<B>Disclosing Party</B>&#148;) and (ii)&nbsp;not publish or otherwise use, directly or indirectly, for any purpose, such Confidential Information, except to the
extent permitted by the terms of this Agreement or to the extent such use is necessary for the fulfilment of the Receiving Party&#146;s obligations under this Agreement. The Receiving Party shall cause all of its and its Affiliates&#146; officers,
directors, other employees, contractors and advisors to whom the Receiving Party has disclosed Confidential Information to comply with confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations at least as restrictive as those
set out in this Agreement and shall be liable to the Disclosing Party for any breach thereof by such Affiliates, officers, directors, other employees, contractors and advisors. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> herein shall not
extend to any Confidential Information that, in the case of clause 15.1.1, (a) is or comes into the public domain without breach of this Agreement, (b)&nbsp;is received by a Party from a Third Party (other than an Affiliate of Disclosing Party)
without any obligation of confidentiality and without breach of this Agreement, or (c)&nbsp;the Receiving Party can prove was already in its possession without any limitation on use or disclosure prior to the Effective Date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">52. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Nothing in this clause 15 shall prevent either Party from using and disclosing Confidential Information to
the extent reasonably required for the Receiving Party&#146;s performance of its obligations and exercise of its rights granted to it under this Agreement or other agreement between the Parties. In particular either Party shall be entitled to use
and disclose Confidential Information of the other relating to the Licensed Product for Patent filing and prosecution purposes, for the purposes of making BLAs and for the purposes of appointing Third Parties to Manufacture the Licensed Product.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In addition each Party shall be entitled to disclose the terms of this Agreement on a confidential basis to
actual or potential investors or in connection with any permitted assignment under this Agreement or in connection with any proposed grant of a <FONT STYLE="white-space:nowrap">sub-license</FONT> by Innate or MedImmune as permitted by this
Agreement, provided that in each case the Receiving Party shall cause any and all parties to whom such disclosure is made to comply with confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations at least as restrictive as those
set out in this Agreement and shall be liable to the Disclosing Party for any breach thereof by such parties. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">This Agreement shall not restrict the Receiving Party from complying with a lawfully issued governmental
order or legal requirement or requirement under applicable stock exchange rules to produce or disclose Confidential Information; provided, however, that, in the event of governmental orders, the Receiving Party shall promptly notify the Disclosing
Party to enable the Disclosing Party to oppose the order or obtain a protective order and the Receiving Party shall cooperate fully with the Disclosing Party in any such proceeding. If the Receiving Party is legally required or required under
applicable stock exchange rules to disclose Confidential Information, the Receiving Party and the Disclosing Party will endeavour to agree to a mutually satisfactory means to disclose such information. Nothing contained herein shall prohibit either
of the Parties from immediately disclosing results of any Clinical Trial to the extent necessary to prevent or mitigate a serious health hazard; provided, however, that the Party intending to make such disclosure shall notify the other Party prior
to and immediately after such disclosure and, to the extent it is reasonably practicable to do so, the nature and content of such disclosure shall be agreed between the Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Parties acknowledge that each of them shall use Commercially Reasonable Efforts to monitor scientific
publications to prevent any adverse effect from premature publication relating to the Licensed Antibodies or Licensed Products. If a Party wishes to make a publication or communication with respect to any results arising out of any Clinical Trials
initiated prior to the Effective Date or, with respect to MedImmune or any of its Affiliates, with respect to any Clinical Trials conducted outside the Territories, it shall provide a draft to the other Party, which will have [***] to provide
comments. The Party proposing to make a publication or communication shall, in good faith, consider the comments made by the other Party and shall defer the publication or communication for a period of time not exceeding [***] if a Patent may be
filed using the Information or Know How covered in the proposed publication or communication. Notwithstanding the foregoing, neither Party will publish or present any Confidential Information of the other Party without such other Party&#146;s prior
written consent, such consent not to be unreasonably withheld, delayed or conditioned. Notwithstanding anything contained herein to the contrary, each Party shall be permitted to make whatever public disclosure is required by Applicable Law in
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">53. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
connection with any Clinical Trial using or involving the Licensed Antibody, including Clinical Trials transparency laws governing disclosure of results, protocols, and other items.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">As between the Parties, Innate shall have the sole right to make scientific publications with respect to
Clinical Trials initiated after the date on which MedImmune ceases to hold any Regulatory Approvals in the Territories. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Use of Name</B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Neither Party shall use the name, insignia, symbol, trademark, trade name or logotype of the other Party or its Affiliates in
relation to this transaction or otherwise in any public announcement, press release, or other public document without the prior written consent of such other Party, which consent shall not be unreasonably withheld, delayed or conditioned, except for
those disclosures for which consent has previously been obtained; provided, however, that either Party may use the name of the other Party in any document required to be filed with any Government Authority, including the FDA and the Securities and
Exchange Commission or otherwise as may be required by Applicable Laws, provided that such disclosure shall be governed by this clause 15. Further, the restrictions imposed on each Party under this clause 15.2 are not intended, and shall not be
construed, to prohibit a Party from identifying the other Party in its internal business communications, provided that any Confidential Information in such communications remains subject to this clause 15. Moreover, and notwithstanding the
foregoing, MedImmune and its Affiliates and Innate and its Affiliates and Sublicensees shall have the right to use the name of MedImmune and its Affiliates to the extent necessary or useful in connection with the Exploitation of the Licensed Product
or perform the activities as contemplated by this Agreement in their negotiations and work with subcontracting and sublicensing transactions in connection therewith provided that any Confidential Information in such communications remains subject to
this clause 15. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Public Announcements</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Neither Party shall issue any other public announcement, press release or other public disclosure regarding
this Agreement or its subject matter without the other Party&#146;s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, except for any such disclosure that is, in the opinion of the disclosing Party&#146;s
counsel, required by Applicable Law, the Listing Rules or any other rules of a stock exchange (including Paris Euronext) on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted). Without
limiting the foregoing, Innate shall be entitled to communicate with respect to the status of the Licensed Product and any activities under this Agreement, including any registration, launch, or commercialization of the Licensed Product, as long as
such communication does not include any MedImmune Confidential Information. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In the event a Party is, in the opinion of its counsel, required by Applicable Law, the Listing Rules or any
other rules of a stock exchange (including Paris Euronext) on which its securities are listed (or to which an application for listing has been submitted) to make such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">54. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
a public disclosure, such Party shall submit the proposed disclosure in writing to the other Party as far in advance as reasonably practicable (having regard to the requirements of the Applicable
Law, the Listing Rules or other stock exchange rules, as applicable) so as to provide a reasonable opportunity to comment thereon. Neither Party shall be required to seek the permission of the other Party to repeat any information regarding the
terms of this Agreement or any amendment hereto that has already been publicly disclosed by such Party or by the other Party, in accordance with this clause 15.3; <I>provided</I> that such information remains accurate as of such time and provided
the frequency and form of such disclosure are reasonable. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Return of Confidential Information</B>. Upon the expiration or termination of this Agreement for any
reason, either Party may request in writing and the <FONT STYLE="white-space:nowrap">non-requesting</FONT> Party shall either, with respect to Confidential Information to which such <FONT STYLE="white-space:nowrap">non-requesting</FONT> Party does
not retain rights under the surviving provisions of this Agreement, at the requesting Party&#146;s election, (a)&nbsp;promptly destroy all copies of such Confidential Information in the possession or control of the
<FONT STYLE="white-space:nowrap">non-requesting</FONT> Party and confirm such destruction in writing to the requesting Party or (b)&nbsp;promptly deliver to the requesting Party, at the <FONT STYLE="white-space:nowrap">non-requesting</FONT>
Party&#146;s sole cost and expense, all copies of such Confidential Information in the possession or control of the <FONT STYLE="white-space:nowrap">non-requesting</FONT> Party. Notwithstanding the foregoing, the
<FONT STYLE="white-space:nowrap">non-requesting</FONT> Party shall be permitted to retain such Confidential Information (i)&nbsp;to the extent necessary or useful for purposes of performing any continuing obligations or exercising any ongoing rights
hereunder and, in any event, a single copy of such Confidential Information for archival purposes and (ii)&nbsp;any computer records or files containing such Confidential Information that have been created solely by such <FONT
STYLE="white-space:nowrap">non-requesting</FONT> Party&#146;s automatic archiving and <FONT STYLE="white-space:nowrap">back-up</FONT> procedures, to the extent created and retained in a manner consistent with such
<FONT STYLE="white-space:nowrap">non-requesting</FONT> Party&#146;s standard archiving and <FONT STYLE="white-space:nowrap">back-up</FONT> procedures, but not for any other uses or purposes. All Confidential Information shall continue to be subject
to the terms of this Agreement for the period set forth in clause 15.1. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Privileged Communications</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In furtherance of this Agreement, it is expected that the Parties may, from time to time, disclose to one
another privileged communications with counsel, including opinions, memoranda, letters and other written, electronic and verbal communications. Such disclosures are made with the understanding that they shall remain confidential in accordance with
this clause 15, that they will not be deemed to waive any applicable attorney-client or attorney work product or other privilege and that they are made in connection with the shared community of legal interests existing between MedImmune and Innate,
including the community of legal interests in avoiding infringement of any valid, enforceable patents of Third Parties and maintaining the validity of the Licensed MedI Patents and Innate Patents. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In the event of any litigation (or potential litigation) with a Third Party related to this Agreement or the
subject matter hereof, the Parties shall, upon either Party&#146;s request, enter into a reasonable and customary joint defence agreement. In any event, each Party shall consult in a timely manner with the other Party before engaging in any conduct
(e.g., </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">55. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
producing information or documents) in connection with litigation or other proceedings that could conceivably implicate privileges maintained by the other Party. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Notwithstanding anything contained in this clause 15.5, nothing in this Agreement shall prejudice a
Party&#146;s ability to take discovery of the other Party in disputes between them relating to the Agreement and no information otherwise admissible or discoverable by a Party shall become inadmissible or immune from discovery solely by this clause
15.5. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>WARRANTIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Mutual Warranties</B>. MedImmune and Innate each warrants to the other, as of the Effective Date, and
covenants that: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">it is a corporation duly organised, validly existing and in good standing under the laws of the jurisdiction
of its organization and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">its execution of this Agreement has been duly authorised by all necessary corporate action and does not
violate: (i)&nbsp;such Party&#146;s charter documents, bylaws or other organisational documents; (ii)&nbsp;in any material respect, any agreement, instrument or contractual obligation to which such Party is bound; (iii)&nbsp;any requirement of any
Applicable Law; or (iv)&nbsp;any order, writ, judgment, injunction, decree, determination or award of any court or Governmental Authority presently in effect applicable to such Party; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">its performance and exercise in accordance with this Agreement of the obligations and transactions
contemplated hereby do not violate in any material respect, any agreement, instrument or contractual obligation to which such Party is bound; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">this Agreement is a legal, valid and binding obligation of such Party enforceable against it in accordance
with its terms and conditions, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general
principles of equity (whether enforceability is considered a proceeding at law or equity); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">it is not under any obligation, contractual or otherwise, to any Person that conflicts with or is
inconsistent in any material respect with the terms of this Agreement or that would impede the diligent and complete fulfilment of its obligations hereunder; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">neither it nor any of its Affiliates has been debarred or is subject to debarment and neither it nor any of
its Affiliates will use in any capacity, in connection with the services or activities to be performed under this Agreement, any Person who has been debarred pursuant to Section&nbsp;306 of the FFDCA or who is the subject of a conviction described
in such section. It agrees to inform the other Party in writing promptly if it or any such Person who is performing services hereunder is debarred or is the subject of a conviction described in Section&nbsp;306 or if any action, suit, claim,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">56. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
investigation or legal or administrative proceeding is pending or, to the best of its or its Affiliates&#146; Knowledge, is threatened, relating to the debarment or conviction of it or any such
Person performing services or activities hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Additional Warranties of MedImmune</B>. MedImmune further warrants to Innate, as of the Effective Date:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">it has the right to grant the licences and sublicences specified herein on the terms as specified herein;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Development of the Licensed Antibody and the Licensed Product and
<FONT STYLE="white-space:nowrap">pre-commercialization</FONT> Manufacturing and Commercialization activities with respect to the Licensed Product have been conducted by MedImmune in accordance with Applicable Laws and Regulatory Approvals in all
material respects; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">it has no Knowledge of any safety or efficacy issues with the Licensed Antibody or the Licensed Product
which have not been disclosed to the applicable Regulatory Authority with regard to its labelled indication which would materially adversely affect: (i)&nbsp;the maintenance of the US Marketing Approval, (ii)&nbsp;the application for and grant of
the EU Marketing Approval, or (iii)&nbsp;the Exploitation of the Licensed Products in the Territories; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">to its Knowledge, it has complied in all material respects with pharmacovigilance requirements in accordance
with Applicable Laws; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the [***] Supply Agreement, the [***] Supply Agreement and [***] Agreement are the only material agreements
relating to the Licensed Product in force on the Effective Date and entered into by MedImmune or one of its Affiliates and necessary to Develop, Manufacture and Commercialize the Licensed Product entered into by MedImmune or its Affiliates (the
&#147;<B>Material Agreements</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">true and updated copies of the Material Agreements, subject to redaction of terms deemed by MedImmune
commercially sensitive or confidential, have been provided by MedImmune to Innate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the Material Agreements are in force and the [***] Supply Agreement and [***] Supply Agreement have been
performed substantially in accordance with their respective terms; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune has performed its payment and diligence related obligations contained in the [***] Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">to its Knowledge, MedImmune has received no notice of breach or termination of any Material Agreement, nor
has it acted, or failed to act in any way that would reasonably be expected to lead to termination of the [***] Supply Agreement and [***] Supply Agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">57. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune has diligently prepared the Development Plan, Commercialization Plan and related Budgets in good
faith, based on reasonable assumptions and assessments; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune has no Other Licensees (excluding [***] and [***]); </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the studies under the Existing Research and Collaboration Agreements listed on <U>Schedule 16.2 Part 1</U> <FONT
STYLE="white-space:nowrap">(Non-Clinical)</FONT> are not conducted in humans. all Intellectual Property Rights relating to the Licensed Product arising therefrom will according to the terms thereof either belong to MedImmune or MedImmune has an
option to acquire a license to such Intellectual Property Rights; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune has not received any written claim or demand alleging that the Development and Commercialization
of the Licensed Product as contemplated by this Agreement infringe any Intellectual Property Rights owned by any Third Party; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">to MedImmune&#146;s Knowledge, there is no claim for revocation, opposition or rectification of any Licensed
MedI Patent; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">to MedImmune&#146;s Knowledge, no Person is infringing or threatening to infringe the Licensed MedI Patent
in the Territories; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the Licensed MedI Patents, Licensed MedI <FONT STYLE="white-space:nowrap">Know-How</FONT> and Other AZ IPR
are all of the Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> owned or Controlled by MedImmune and its Affiliates that are necessary and have been used by MedImmune for the Development and Commercialization of the Licensed Product in
the Territories as of the Effective Date; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune or one of its Affiliates is the owner of the specific registered Product Trademarks identified in
<U>Schedule 7</U> hereto; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">to MedImmune&#146;s Knowledge, none of MedImmune&#146;s current officers, directors or employees that have
been involved in the Development of the Licensed Product has been debarred; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(s)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">neither MedImmune nor to MedImmune&#146;s Knowledge, any of MedImmune&#146;s officers, directors, employees,
agents, representatives, consultants or subcontractors hired in connection with the subject matter of this Agreement, has made, solicited or received anything of value that would or has put it in violation of the Anti-Corruption Laws during the
three (3)&nbsp;years preceding the Effective Date; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(t)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune is resident in the United Kingdom for Tax purposes. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Limitation of Liability</B>. <B>In respect of the warranties set forth in clauses 16.2(a) to 16.2(r):</B>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune shall not be liable in respect of any Warranty Claim, unless [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">58. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The aggregate liability of MedImmune in respect of all Warranty Claims shall not exceed [***].
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune shall not be liable for any Warranty Claim unless and until it has received from Innate written
notice containing reasonable details of the relevant Warranty Claim including the amount of the Warranty Claim on or before the date that falls [***] after the Effective Date. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall not be entitled to make a Warranty Claim to the extent it [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall not be entitled to make a Warranty Claim to the extent that it [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Additional Warranties of Innate</B>. Innate further warrants to MedImmune, as of the Effective Date,
that: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">neither Innate nor to Innate&#146;s Knowledge, any of the Innate Representatives has made, solicited or
received anything of value that would or has put it in violation of the Anti-Corruption Laws during the [***] preceding the Effective Date; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate is resident in France for Tax purposes. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>DISCLAIMER OF WARRANTIES</B>. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, NEITHER PARTY MAKES ANY
REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL OR EXPRESS OR IMPLIED, INCLUDING ANY
WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>ADDITIONAL WAIVER</B>. SUBJECT TO CLAUSE 16.2, INNATE AGREES THAT THE LICENSED MEDI PATENTS AND THE
PRODUCT TRADEMARKS ARE LICENSED &#147;AS IS,&#148; &#147;WITH ALL FAULTS,&#148; AND &#147;WITH ALL DEFECTS,&#148; AND INNATE EXPRESSLY WAIVES ALL RIGHTS TO MAKE ANY CLAIM WHATSOEVER AGAINST MEDIMMUNE FOR BREACH OF PROMISE, GUARANTEE OR WARRANTY OF
ANY KIND RELATING TO THE LICENSED MEDI PATENTS OR THE PRODUCT TRADEMARKS. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>MedImmune Covenants</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Other Licensees</B>. The agreements entered with Other Licensees shall not materially adversely affect
Innate&#146;s rights under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">[***]<B> Supply Agreement</B> MedImmune, in so far as it relates to the Licensed Product, shall not agree to
amend the [***] Supply Agreement, in such a manner that would reasonably be expected to materially adversely affect its ability to supply the License Product to Innate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">59. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
Furthermore, MedImmune shall use its Commercially Reasonable Efforts to comply with the provisions of the [***] Supply Agreement relating to the Licensed Product and to avoid taking steps (or
omitting to take steps) that are reasonably likely to give rise to a termination of the [***] Supply Agreement insofar as it relates to the Licensed Product. MedImmune shall not terminate the [***] Supply Agreement as it relates to the Licensed
Produce without Innate&#146;s agreement prior to the end of any period during which MedImmune is supplying bulk drug substance for the Licensed Product to Innate. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">16.7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Material Agreements</B>. MedImmune shall not enter into any Material Agreement without Innate&#146;s
prior consent and review of the applicable terms and conditions. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>COMPLIANCE </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Statements and Compliance with Applicable Law</B>. Each Party shall and shall cause its respective
Affiliates to, comply with all Applicable Law with respect to the Development and Commercialization of the Licensed Product and shall avoid and shall cause its Affiliates and its and their employees, representatives, agents, and distributors to
avoid, taking or failing to take, any actions or to give information that MedImmune knows or reasonably should know would jeopardise the goodwill or reputation of Innate or the Licensed Product or any Trademark associated therewith, or would impact
the performance of the Agreement. Until such time as MedImmune and any of its Affiliates ceases to be involved in the Manufacture of the Licensed Product, Innate shall and shall cause its Affiliates to, comply with all Applicable Law with respect to
the Development and Commercialization of the Licensed Product and shall avoid and shall cause its Affiliates and its and their Sublicensees, employees, representatives, agents, and distributors to avoid, taking or failing to take, any actions or to
give information that Innate knows or reasonably should know would jeopardise the goodwill or reputation of MedImmune or the Licensed Product or any Trademark associated therewith or would impact the performance of the Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Anti-Bribery and Anti-Corruption Compliance</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Each Party agrees, on behalf of itself, its officers, directors and employees and on behalf of its
Affiliates, agents, representatives, consultants and subcontractors hired in connection with the subject matter of this Agreement (together with Innate, the &#147;<B>Representatives</B>&#148;) that for the performance of its obligations hereunder:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the Representatives shall not directly or indirectly pay, offer or promise to pay or authorise the payment
of any money or give, offer or promise to give or authorise the giving of anything else of value, to: (i)&nbsp;any Government Official in order to influence official action; (ii)&nbsp;any Person (whether or not a Government Official)&nbsp;(x) to
influence such Person to act in breach of a duty of good faith, impartiality or trust (&#147;acting improperly&#148;), (y) to reward such Person for acting improperly or (z)&nbsp;where such Person would be acting improperly by receiving the money or
other thing of value; (iii)&nbsp;any Person (whether or not a Government Official) while knowing or having reason to know that all or any portion of the money or other thing of value will be paid, offered, promised or given to or will otherwise
benefit, a Government </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">60. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
Official in order to influence official action for or against either Party in connection with the matters that are the subject of this Agreement; or (iv)&nbsp;any Person (whether or not a
Government Official) to reward that Person for acting improperly or to induce that Person to act improperly; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the Representatives shall not, directly or indirectly, solicit, receive or agree to accept any payment of
money or anything else of value in violation of the Anti-Corruption Laws. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Each Party shall and shall cause the Representatives to comply with (a)&nbsp;such Anti-Corruption Laws as
are relevant to it or the Territories; (b)&nbsp;its own internal policies relating to anti-corruption; and (c)&nbsp;in connection with activities under this Agreement, AZ&#146;s Global Ethical Interactions Policy. If MedImmune makes any material
change to AZ&#146;s Global Ethical Interactions Policy, it shall notify Innate of such change in writing. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Each Party, on behalf of itself and the other Representatives shall promptly inform the other Party upon
receiving a formal notification that it or any of its Representatives is the target of a formal investigation by a Governmental Authority for a Material Anti-Corruption Law Violation. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">For the purpose of auditing and monitoring the performance of its compliance with this clause 17.2, each
Party (the &#147;<B>Auditing Party</B>&#148;) will, subject to the terms of this clause 17.2.4 and not more than once in each Calendar Year, permit any independent auditors appointed by the other Party (the &#147;<B>Audited Party</B>&#148;) for such
purpose and any Governmental Authority to have access to any premises of the Audited Party or other Representatives used in connection with this Agreement (such access to be at reasonable times and on reasonable notice), together with a right to
access personnel and records that relate to this Agreement (&#147;<B>Compliance Audit</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">To the extent that any Compliance Audit requires access and review of any commercially or strategically
sensitive information or agreements, such independent auditor shall only report back such information as is directly relevant to informing on compliance with the particular provisions of this Agreement or the agreement being audited.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the Audited Party shall, and shall cause the Innate Representatives to, provide all cooperation and
assistance during normal working hours as reasonably requested by its independent auditor for the purposes of a Compliance Audit. The Auditing Party shall cause any substantially consistent such auditor to enter into a confidentiality agreement with
the applicable requirements of clause 15, and to cause the minimum amount of disruption to the business of the Audited Party and its Representatives and to comply with relevant building and security regulations. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Parties shall bear their own costs of a Compliance Audit or rendering assistance under this clause
17.2.4. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">If either Party becomes aware that the Other Party (or its Representative) has or may have committed a
Material Anti-Corruption Law Violation, such Party shall have the right, in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">61. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
addition to any other rights or remedies under this Agreement or to which it may be entitled in law or equity, to terminate this Agreement immediately and in its entirety upon written notice to
the other Party if the breaching Party does not cure such Material Anti-Corruption Law Violation within [***] of learning of such Material Anti-Corruption Law Violation. To cure such Material Anti-Corruption Law Violation, the breaching Party must
take such steps, additional measures, representations, warranties, undertakings and other provisions, in each case, as the other Party believes in good faith are reasonably necessary in order to avoid a subsequent violation or continuing violation
of the Anti-Corruption Laws. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Any termination of this Agreement pursuant to clause 17.2.5 shall be treated as a termination for breach and
the consequences of termination set forth in clause 20.3 shall apply. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.2.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Either Party may disclose the terms of this Agreement or any action taken under this clause 17.2 to prevent
a potential violation or continuing violation of applicable Anti-Corruption Laws, including the identity of the other Party or its Representative and the payment terms, to any Governmental Authority if such Party determines, upon advice of counsel,
that such disclosure is necessary. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>DATA PROTECTION; PRIVACY</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune and Innate agree that, for the purposes of Data Protection Law, each of MedImmune and Innate are
independent data controllers. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">If Data Protection Law requires that any notice be sent to any Data Subject or otherwise in connection with
the transfer of Personal Data under or pursuant to this Agreement, the relevant Party shall be responsible for preparing and providing such notice at its sole cost and expense; provided, that that Party shall provide a copy of any such proposed
notice to the other Party sufficiently in advance of any deadline in respect of such notice so as to allow for a reasonable opportunity for the other Party to review and approve the content of such notice, such approval not to be unreasonably
withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Each Party shall provide the other with such assistance as may be reasonably requested to ensure that each
Party complies with their obligations under applicable law, including Data Protection Law. For clarity, such assistance may include cooperating in response to requests from data subjects or supervisory authorities, or the provision of information
relating to Transferred Data, including providing copies of any relevant fair processing notices or consent forms provided to Data Subjects </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">17.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">No Transferred Data shall be transferred outside the European Economic Area unless such transfer is to a
country that the European Commission has decided from time to time ensures an adequate level of protection in accordance with Data Protection Law. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>INDEMNITY </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Indemnification of MedImmune</B>. Subject to clause 19, Innate hereby agrees to indemnify, defend, and
hold harmless MedImmune, its Affiliates, and each of its and their respective employees, officers, directors and agents from and against any and all Damages incurred </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">62. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
by them resulting from or arising out of or in connection with any suits, claims, actions or demands made or brought by a Third Party (collectively, &#147;<B>Third Party Claims</B>&#148;) against
MedImmune, its Affiliates or their respective employees, officers, directors or agents, that result from or arise out of (i)&nbsp;the Development, Manufacture, use, handling, storage, Commercialization, or other disposition of Licensed Products by
(or on behalf of, including where MedImmune or an Affiliate is providing SOTC Services) Innate or its Affiliates, agents, Distributors, Sublicensees or other sublicensees in the Territories (including with respect to the Product Liability Claim), in
each case on or after the Effective Date, (ii)&nbsp;any material breach by Innate of its obligations hereunder, (iii)&nbsp;MedImmune&#146;s performance of the Regulatory Services in accordance with this Agreement and the Development Plan, or
otherwise in accordance with any instruction or direction given by Innate or any of its Affiliates, except to the extent such Damages arise due to MedImmune&#146;s refusal to follow relevant instruction or direction given in accordance with
Applicable Law by Innate or any of its Affiliates, or (iv)&nbsp;Innate&#146;s negligence or wilful misconduct, except in any case, to the extent such Damages are Damages for which MedImmune has an obligation to indemnify Innate, its Affiliates or
their respective employees, officers, directors or agents pursuant to clause 18.2, as to which Damages each Party shall indemnify the other to the extent of their respective liability for such Damages. Notwithstanding this clause 18.1, Innate shall
not indemnify MedImmune for Damages arising as a consequence of a breach by Innate of the [***] relating to its failure to manufacture Licensed Products in accordance with the requirements of [***] or corresponding provisions of the [***].
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Indemnification of Innate</B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Subject to clause 19, MedImmune hereby agrees to indemnify, defend and hold harmless Innate, its Affiliates, and each of its
and their respective employees, officers, directors and agents from an against any and all Damages incurred by them resulting from or arising out of or in connection with any Third Party Claims (including Product Liability Claims) against Innate,
its Affiliates or their respective employees, officers, directors or agents, and also any other Damages with respect to (d)&nbsp;and (e) below, in each case that result from or arise out of: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the Manufacture, Development, Exploitation, use, handling, storage, sale or other disposition of Licensed
Product by MedImmune or its Affiliates, agents, distributors or sublicensees in each case prior to the Effective Date; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the Manufacture, Development, Commercialization, Exploitation, use, handling, storage, sale or other
disposition of Licensed Product by MedImmune or its Affiliates, agents, distributors or sublicensees outside of the Territories; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">any material breach by MedImmune of its obligations hereunder; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">any [***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">any [***]; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the conduct by MedImmune or its Affiliates of any Existing Clinical Trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">63. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the conduct by MedImmune or its Affiliates of any activities under any Existing Research and Collaboration
Agreements; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune&#146;s negligence or wilful misconduct; except in any case, to the extent such Damages are Damages
for which Innate has an obligation to indemnify MedImmune, its Affiliates or their respective employees, officers, directors or agents pursuant to clause 18.1, as to which Damages each Party shall indemnify the other to the extent of their
respective liability for such Damages. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">18.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Mechanism</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">18.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In the event that a Party (the &#147;<B>Indemnified Party</B>&#148;) is seeking indemnification under clause
18.1 or 18.2, it shall notify the other Party (the &#147;<B>Indemnifying Party</B>&#148;) in writing of the relevant Third Party Claim and the relevant Damage for which indemnification is sought as soon as reasonably practicable after becoming aware
of such claim. Such notices shall contain a description of the Third Party Claim and the nature and amount of the Damage (to the extent known). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official
documents received in respect of such Third Party Claim or Damage. For the avoidance of doubt, all indemnification claims in respect of a Party, its Affiliates, and each of its and their respective employees, officers, directors and agents shall be
made solely by such Party to this Agreement. To the extent that the Indemnifying Party irrevocably commits to indemnify any Indemnified Party in respect of the Third Party Claim, the Indemnified Party shall permit the Indemnifying Party to assume
direction and control of the defense of the relevant Third Party Claim (including without limitation the right to settle the claim solely for monetary consideration), and shall cooperate as requested (at the expense of the Indemnifying Party) in the
defense of the claim. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">18.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Notwithstanding clause 18.3.1, the failure to give timely notice to the Indemnifying Party shall not release
the Indemnifying Party from liability to the Indemnified Party to the extent the Indemnifying Party is not prejudiced thereby and, for the avoidance of doubt, the Indemnifying Party shall not be liable to the extent any Damage is caused by any delay
by the Indemnified Party in providing such notice. Notwithstanding the provisions of clause 18.3.1 requiring the Indemnified Party to tender to the Indemnifying Party the exclusive ability to defend such claim, if the Indemnifying Party does not
satisfy the condition set forth in clause 18.3.1 to, or declines to or fails to timely assume control of the relevant Third Party Claim, the Indemnified Party shall be entitled to assume such control, conduct the defense of, and settle such claim,
all at the sole costs and expense of the Indemnifying Party; provided, however, that neither Party shall settle or dispose of any such claim in any manner that would adversely affect the rights or interests or admit fault, of the other Party without
the prior written consent of such other Party, which shall not be unreasonably withheld, delayed or conditioned. Each Party, at the other Party&#146;s expense and reasonable request, shall cooperate with such other Party and its counsel in the
course of the defense or settlement of any such claim, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information, and witnesses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">64. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>LIMITATION OF LIABILITY AND INSURANCE </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">19.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Special, Indirect and Other Losses</B>. EXCEPT IN CIRCUMSTANCES OF NEGLIGENCE OR INTENTIONAL MISCONDUCT
BY A PARTY OR ITS AFFILIATES, OR WITH RESPECT TO THIRD PARTY CLAIMS UNDER CLAUSES 18.1 AND 18.2, IN NO EVENT SHALL EITHER PARTY OR ITS RESPECTIVE AFFILIATES AND SUBLICENSEES BE LIABLE FOR SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL
DAMAGES, OR FOR LOSS OF PROFITS (WHETHER DIRECT OR OTHERWISE), IN EACH CASE WHETHER IN CONTRACT, WARRANTY, TORT, STRICT LIABILITY, OR OTHERWISE. NOTWITHSTANDING THE FOREGOING, THE EXCLUSION IN THIS CLAUSE 19.1 SHALL NOT APPLY TO CLAIMS UNDER CLAUSES
18.2(d) AND 18.2(e) WITH RESPECT TO LOSS OF PROFITS. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">19.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Insurance</B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Each Party shall have and maintain such type and amounts of liability insurance covering the Manufacture, supply, use and sale
of the Licensed Product as is normal and customary in the pharmaceutical industry generally for Persons similarly situated, but in any event no less than is adequate to cover a Party&#146;s exposure given its obligations under this Agreement, and
shall upon request provide the other Party with a copy of its certificate of insurance in that regard, along with any amendments and revisions thereto. It is expressly acknowledged and agreed that, with respect to MedImmune, reasonably sufficient
and appropriate self-insurance shall satisfy MedImmune&#146;s obligations under this clause. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">19.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Nothing in this Agreement excludes or limits either Party&#146;s liability for fraud, or for death or
personal injury caused by its negligence or that of its employees or agents. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">19.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune and its Affiliates&#146; maximum aggregate liability to Innate with respect to any claim under the
indemnity in clause 18.2(d) or 18.2(e), when taken together with any liability to Innate with respect to any Warranty Claims, shall not exceed [***]. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>TERM AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">20.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Term and Expiration</B>. This Agreement shall commence on the Effective Date and, unless earlier
terminated in accordance herewith, shall continue in force and effect in any given country of the Territories until the latest of: (a)&nbsp;the expiry of the last Patent within the Licensed MedI Patents in such country, (b)&nbsp;any Regulatory
Exclusivity in such country, and (c)&nbsp;the fifteenth anniversary of the First Commercial Sale of Licensed Product in such country (the &#147;<B>Term</B>&#148;). Following the expiration of the Term for the Licensed Product in a country, the
grants in clause 4.1 shall become or remain <FONT STYLE="white-space:nowrap">non-exclusive</FONT> (as applicable), perpetual, irrevocable, fully paid and royalty-free for the Licensed Product in that country. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">20.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Termination of Agreement</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">20.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Material Breach</B>. In the event that either Party (the &#147;<B>Breaching Party</B>&#148;) shall be in
material breach in the performance of any of its obligations under this Agreement, in addition to any other right and remedy the other Party (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Breaching</FONT> Party</B>&#148;) may
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">65. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
have (including in the case of MedImmune its rights to terminate this Agreement in accordance with clause 20.2.2), the <FONT STYLE="white-space:nowrap">Non-Breaching</FONT> Party may terminate
this Agreement by providing [***] (the &#147;<B>Notice Period</B>&#148;) prior written notice (the &#147;<B>Termination Notice</B>&#148;) to the Breaching Party and specifying the breach and its claim of right to terminate; <I>provided</I> that the
termination shall not become effective at the end of the Notice Period if (a)&nbsp;the Breaching Party cures the breach specified in the Termination Notice during the Notice Period or (b)&nbsp;provided that such breach does not relate to <FONT
STYLE="white-space:nowrap">non-payment,</FONT> if such breach cannot be cured within the [***] cure period, this Agreement shall not terminate pursuant to this clause 20.2.1 if the Breaching Party has made diligent efforts to cure such breach within
such period and this Agreement shall remain in effect for such period after the Notice Period as may be reasonable in the circumstances as long as the Breaching Party continues to use diligent efforts to cure the breach with a reasonable expectation
that cure will be effected as promptly as practicable thereafter and in any event within [***] after expiration of the Notice Period. If the existence or cure of a material breach is disputed, except with respect to a material breach involving any
of the AstraZeneca Corporate Mark or Innate Corporate Mark, this Agreement cannot be terminated until the existence and absence of cure of a material breach have been determined pursuant to Section&nbsp;21.6.2 and then if such material breach is not
cured within [***] following the arbitration award. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">20.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Termination by MedImmune</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Patent Challenge</B>. In the event that Innate or any of its Affiliates or Sublicensees institutes,
prosecutes or otherwise participates in (or in any way aids any Third Party in instituting, prosecuting or participating in), at law or in equity or before any administrative or regulatory body, including the U.S. Patent and Trademark Office or its
foreign counterparts, any claim, demand, action or cause of action for declaratory relief, damages or any other remedy or for an enjoinment, injunction or any other equitable remedy, including any interference,
<FONT STYLE="white-space:nowrap">re-examination,</FONT> opposition or any similar proceeding, alleging that any claim in a Licensed MedI Patent is invalid, unenforceable or otherwise not patentable or would not be infringed by Innate&#146;s
activities absent the rights and licences granted hereunder, MedImmune shall have the right to immediately terminate this Agreement, including the rights of any Sublicensees, upon written notice to Innate. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Abandonment</B>. In the event that Innate ceases to perform all Commercialization activities with respect
to the Licensed Product in the US Territory or the EU Territory for a consecutive period of [***], and Innate does not recommence Commercialization activities within [***] of receiving from MedImmune a notice specifying that Innate must recommence
Commercialisation, MedImmune shall be entitled to immediately terminate this Agreement with respect to whichever of the Territories such activities have ceased, including the rights of any Sublicensees, upon written notice to Innate.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">20.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Termination for Convenience</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Subject to compliance with clause 20.2.3(b), Innate may terminate this Agreement at any time upon [***]
prior written notice to MedImmune. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">66. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Together with the notice of termination sent in accordance with clause 20.2.3(a), Innate shall send
MedImmune its proposed approach to ensuring an orderly and efficient transition of the Licensed Product business back to MedImmune, which may include a draft transition services agreement. The Parties shall use their respective Commercially
Reasonable Efforts to negotiate in good faith and agree to a transition plan and/or transition agreement, including how any existing stock of Licensed Product held by Innate, will be sold by Innate (including under any sales order to cash
arrangement agreed with MedImmune) during the transitional period. Notwithstanding clause 20.2.3(a), no termination shall take effect until the transition plan and/or transition services agreement has been agreed in writing by the Parties.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">20.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Termination for Insolvency</B>. In the event that either Party: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">files for protection under bankruptcy or insolvency laws; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">makes an assignment for the benefit of creditors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">has a moratorium agreed or declared in respect of, or affecting all or a material part of its indebtedness;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">appoints or suffers appointment of a receiver or trustee over substantially all of its property that is not
discharged within [***] after such filing; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">proposes a written agreement of composition or extension of its debts; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">proposes or is a party to any dissolution or liquidation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">files a petition under any bankruptcy or insolvency act or has any such petition filed against it that is
not discharged within [***] of the filing thereof; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">admits in writing its inability generally to meet its obligations as they fall due in the general course; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">suffers anything analogous to or having a substantially similar effect to any of the events specified in
clauses 20.2.4(a) to 20.2.4(h), </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">then the other Party may terminate this Agreement in its entirety
effective immediately upon written notice to such Party. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">20.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Consequences of Termination of this Agreement</B>. In the event of a termination (but not expiry) of this
Agreement by Innate or by MedImmune pursuant to clause 20.2: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">all rights and licences granted to Innate by MedImmune hereunder and the [***] shall immediately terminate
and all sublicenses granted by Innate with respect thereto shall automatically terminate; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">67. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">to the extent that the US Marketing Approval or the EU Marketing Approval have been transferred to Innate,
Innate shall transfer such marketing approvals and any other Regulatory Approvals relating to the Licensed Product in the Territories back to MedImmune or its nominee; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall and hereby does, and shall cause its Affiliates and its and their Sublicensees to, effective as
of termination, assign to MedImmune or its nominee all of its right, title and interest in and to all Innate Regulatory Documentation, the Product Trademarks and any New Product Trademarks (together with any domain names and social media identifiers
that incorporate any of the Product Trademarks or any New Product Trademarks) and any and all copyrights and any and all promotional, marketing or other materials used in connection with the Licensed Product; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">other than in cases of termination under clause 20.2.3(a), where clause 20.2.3(b) shall prevail, Innate
shall, at MedImmune&#146;s option, either sell any existing stock of Licensed Product held by Innate in the market under a sales order to cash arrangement, or shall transfer such stock to MedImmune [***], on such reasonable terms as the parties will
negotiate in good faith; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">unless otherwise requested by MedImmune, Innate shall and hereby does, and shall cause its Affiliates and
its and their Sublicensees to, effective as of termination, assign to MedImmune or its nominee all of its right, title and interest in and to any and all Trademarks that Innate has used in connection with the Licensed Product (together with any
domain names and social media identifiers that incorporate any such Trademarks) (excluding any Innate Corporate Names); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate shall and hereby does, and shall cause its Affiliates and its and their Sublicensees to, effective as
of termination, grant MedImmune a worldwide, exclusive, royalty-free licence and right of reference, with the right to grant multiple tiers of sublicenses and further rights of reference, in and to the Innate Patents, and the Innate <FONT
STYLE="white-space:nowrap">Know-How,</FONT> and Innate&#146;s rights in and to any jointly conceived information to Exploit any Licensed Product and/or exercise the Retained Rights; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">at MedImmune&#146;s written request, Innate shall, and cause its Affiliates and its and their Sublicensees
to, assign to MedImmune all Product Agreements relating to the Licensed Product, unless, with respect to any Product Agreement, the Product Agreement expressly prohibits such assignment, in which case Innate (or such Affiliate or Sublicensee, as
applicable) shall cooperate with MedImmune in all reasonable respects to secure the consent of the applicable Third Party to such assignment or the Product Agreement relates to the Licensed Product and another product and if any such consent cannot
be obtained with respect to the Product Agreement or the Product Agreement is not exclusive to the Product, Innate shall, and cause its Affiliates and its and their Sublicensees to, obtain for MedImmune substantially all of the practical benefit and
burden under the Product Agreement, including by (i)&nbsp;entering into appropriate and reasonable alternative arrangements </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">68. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
on terms agreeable to MedImmune and (ii)&nbsp;subject to the consent and control of MedImmune, enforcing, at MedImmune&#146;s cost and expense and for the account of MedImmune, any and all rights
of Innate (or such Affiliate or Sublicensee, as applicable) against the other party thereto arising out of the breach or cancellation thereof by such other party or otherwise; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">provided that if Innate terminates this Agreement pursuant to clause 20.2.1, MedImmune shall reimburse Innate for all costs
reasonably incurred by Innate in complying with its obligations under this clause 20.3 and provided further that if the termination is with respect to one of the Territories only, the obligations above shall apply only with respect to the US
Territory or EU Territory where the activities have ceased (as applicable); </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">20.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Remedies</B>. Except as otherwise expressly provided herein, termination of this Agreement in accordance
with the provisions hereof shall not limit remedies that may otherwise be available in law or equity. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">20.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Accrued Rights; Surviving Obligations</B>. Termination or expiration of this Agreement for any reason
shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations that are expressly indicated to survive the
termination or expiration of this Agreement. Without limiting the foregoing, the following provisions of this Agreement shall survive the termination or expiration of this Agreement for any reason: (a) [***]; (b) [***]; and (c)&nbsp;any other
provisions which are expressed to survive termination or expiry or which are required to give effect to such termination or expiry. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>MISCELLANEOUS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Employees who Transfer under the Regulations</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Innate and MedImmune do not intend that as a consequence of the transaction effected hereunder (including
any transfer of rights or assets that may occur upon a termination of this Agreement) any employees of Innate or any of its Affiliates (&#147;<B>Employees</B>&#148;) shall transfer to MedImmune or to Innate (or their Affiliates or successors) under
this Agreement or by operation of law. If, under the Regulations, the contract of employment of any person is found or alleged to have effect after the Effective Date as if originally made with MedImmune or Innate or their Affiliates or successors)
(the &#147;<B>Concerned Party</B>&#148;), as a consequence of the transaction effected hereunder and to the extent permitted by Applicable Laws (an &#147;<B>Unexpected Transfer Employee</B>&#148;): </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The Concerned Party will, upon becoming aware of any Unexpected Transfer Employee, notify the other Party
immediately or as soon as is reasonably practicable in writing; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">The other Party agrees that in consultation with the Concerned Party, it will within [***] of being so
requested by the Concerned Party (as long as the request is made no later than [***] after notification under clause 21.1.1(a)), make (or procure there is made) to that Unexpected Transfer Employee an offer in writing to employ him under a new
contract of employment to take effect upon the termination referred to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">69. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
below on the same terms and conditions as that person&#146;s contract of employment immediately before the Effective Date, or on terms and conditions which, when taken as a whole, do not
materially differ from the terms and conditions of employment of that person immediately before the Effective Date (save as to the identity of the employer and any terms relating to an occupational pension scheme). The Concerned Party shall give the
other Party all reasonable <FONT STYLE="white-space:nowrap">co-operation</FONT> and assistance to procure that the Unexpected Transfer Employee accepts the offer of employment; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">upon the expiry of [***] following the offer in clause 21.1.1(b) being made (or on the expiry of [***] from
the Concerned Party&#146;s request under clause 21.1.1(b) if the offer is not made as requested), the Concerned Party may terminate the employment of the Unexpected Transfer Employee provided that: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">it does so in accordance with all legal requirements and any procedure that may be given to it by the other
Party; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">it takes all other steps to mitigate any payments or entitlements due to the Unexpected Transfer Employee
and any potential liability of the other Party under the indemnity at clause 21.1.1(d). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Provided that the termination is effected within [***] of the notification under clause 21.1.1(a), the other
Party shall indemnify the Concerned Party for any employment liabilities in relation to: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the employment of the Unexpected Transfer Employee after the Effective Date until any such termination (save
to the extent that the Concerned Party has acted unlawfully in respect thereof); and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">the termination of employment of the Unexpected Transfer Employee. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">MedImmune and Innate shall give each other any assistance that either may reasonably require to comply with
the Regulations in relation to the Unexpected Transferring Employees and in contesting any claim by any Employee at or before the Effective Date resulting from or in connection with this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Force Majeure</B>. In this Agreement, &#147;<B>Force Majeure</B>&#148; means an event which is beyond a <FONT
STYLE="white-space:nowrap">non-performing</FONT> Party&#146;s reasonable control, including an act of God, strike, <FONT STYLE="white-space:nowrap">lock-out</FONT> or other industrial/labour disputes (whether involving the workforce of the Party so
prevented or of any other Person), war, riot, civil commotion, terrorist act, epidemic, quarantine, fire, flood, storm, earthquake or natural disaster. A Party that is prevented or delayed in its performance under this Agreement by an event of Force
Majeure (a &#147;<B>Force Majeure Party</B>&#148;) shall, as soon as reasonably practical but no later than [***] after the occurrence of a Force Majeure event, give notice in writing to the other Party specifying the nature and extent of the event
of Force Majeure, its anticipated duration and any action being taken to avoid or minimize its effect. Subject to providing such notice and to this clause 21.2, the Force Majeure Party shall not be liable for delay in performance or for <FONT
STYLE="white-space:nowrap">non-performance</FONT> of its obligations under this Agreement, in whole or in part, except as </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">70. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
otherwise provided in this Agreement, where <FONT STYLE="white-space:nowrap">non-performance</FONT> or delay in performance has resulted from an event of Force Majeure. The suspension of
performance allowed hereunder shall be of no greater scope and no longer duration than is reasonably required and the Force Majeure Party shall exert all reasonable efforts to avoid or remedy such Force Majeure. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Export Control</B>. This Agreement is made subject to any restrictions concerning the export of products
or technical information from the United States or other countries that may be imposed on the Parties from any technical information acquired from time to time. Neither Party shall export, directly or indirectly, the other Party under this Agreement
or any products using such technical information to a location or in a manner that at the time of export requires an export licence or other governmental approval, without first obtaining such export licence or other governmental approval.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Assignment</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Unless otherwise expressly provided herein, neither Party may assign any of its rights or obligations under
this Agreement in any country in whole or in part without the prior written consent of the other Party, except that each Party shall have the right, without such consent, (i)&nbsp;to perform any of its obligations and exercise any of its rights
under this Agreement through, and to assign all of its rights and obligations under this Agreement to, any of its Affiliates; and (ii)&nbsp;on written notice to the other Party, to assign all of its rights and obligations under this Agreement to a <FONT
STYLE="white-space:nowrap">non-Affiliate</FONT> successor in interest, whether by merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar transaction, to all or substantially all of the business relating
to the Licensed Product. In the event that a Party performs its obligations or exercises its rights under this Agreement through an Affiliate or assigns its rights and obligations to an Affiliate as permitted under this clause 21.4.1, doing so shall
not relieve the relevant Party of its responsibilities for the performance of its obligations under this Agreement, and the relevant Party shall remain responsible for the performance by its Affiliates and shall cause its Affiliates to comply with
the provisions of this Agreement in connection with such performance). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">This Agreement shall survive any succession of interest permitted pursuant to clause 21.4.1, whether by
merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar transaction, provided, that, in the event of such merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar
transaction, no Intellectual Property Rights of the acquiring corporation and its Affiliates (other than a Party and its Affiliates prior to such acquisition) shall be included in the technology licensed hereunder, unless such Intellectual Property
Rights arise as a result of the performance of this Agreement by such corporation after such transaction becomes effective. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Any attempted assignment or delegation in violation of this clause 21.4 shall be void and of no effect.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">71. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Severability</B>. If any provision of this Agreement is held to be invalid, illegal or unenforceable, in
any respect, then such provision will be given no effect by the Parties and shall not form part of this Agreement. To the fullest extent permitted by Applicable Law and if the rights and obligations of a Party will not be materially and adversely
affected all other provisions of this Agreement shall remain in full force and effect and the Parties will use all reasonable efforts to negotiate a provision in replacement of the provision held invalid, illegal or unenforceable that is consistent
with Applicable Law and achieves, as nearly as possible, the original intention of the Parties. To the fullest extent permitted by Applicable Law, the Parties waive any provision of law that would render any provision in this Agreement invalid,
illegal or unenforceable in any respect. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Dispute Resolution</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Escalation to Executives</B>. In the event of any dispute between the Parties arising out of or in
connection with this Agreement, including any question regarding its existence, validity or termination (&#147;<B>Dispute</B>&#148;), either Party may, by written notice to the other, have such Dispute referred to the Executives for attempted
resolution by good faith negotiations within [***] after such notice is received. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Arbitration</B>. In the event the Parties are unable to resolve a Dispute in accordance with clause
21.6.1 any dispute arising out of or in connection with this Agreement, shall be referred to and finally resolved by arbitration under the Arbitration Rules of the International Chamber of Commerce (ICC), which Rules are deemed to be incorporated by
reference into this clause. One or more arbitrators shall be appointed in accordance with the said Rules. The seat, or legal place, of arbitration shall be London. The language to be used in the arbitral proceedings shall be English.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Pendency of Arbitration</B>. During the period of time that any arbitration proceeding described in
clause 21.6.2 is pending under this Agreement, the Parties shall continue to comply with all those terms and provisions of this Agreement that are not the subject of, and the performance of which are not otherwise implicated by, such pending
arbitration proceeding. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Interim and Conservatory Measures</B>. Nothing contained in this Agreement shall preclude any Party from
seeking interim or other equitable or provisional relief from a court of competent jurisdiction to preserve the status quo or prevent irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing arbitration
proceeding. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Patent Disputes</B>. Notwithstanding anything to the contrary, any and all issues regarding the scope,
inventorship, construction, validity, or enforceability of Patents shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patents in question. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Confidentiality</B>. The Parties agree that any arbitration conducted pursuant to this clause 21.6 shall
be kept confidential and that the existence of the proceeding and any element of it (including any pleadings or briefs submitted by the Parties, any testimony or oral </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">72. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
submissions, and any orders or awards) shall not be disclosed beyond the arbitrators, the Parties, and their respective counsel, accountants, auditors, insurers and reinsurers, or any other
Person necessary to the conduct of the arbitration. These confidentiality obligations shall not apply if: (a)&nbsp;disclosure is required by Applicable Law, or in judicial or administrative proceedings; or (b)&nbsp;disclosure is necessary to enforce
rights arising out of an arbitral award or order. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Governing Law</B>. The interpretation and construction of this Agreement (including <FONT
STYLE="white-space:nowrap">non-contractual</FONT> disputes) shall be governed by the laws of England and Wales excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to
the substantive law of another jurisdiction. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Notices</B>. Any notice, request, or other communication permitted or required under this Agreement shall
be in writing, shall refer specifically to this Agreement, and shall be deemed given only if hand delivered, sent by an internationally recognised overnight delivery service, costs prepaid, or sent by email (providing such email is read receipted
and such notice is also despatched by an internationally recognised overnight delivery service, costs prepaid, on same day) to the Party to whom notice is to be given at the following address (or at such other address such Party may have provided to
the other Party in accordance with this clause 21.8. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Notice Requirements</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Address for Notice</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">If to Innate, to: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Innate Pharma S.A. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">17, Avenue de Luminy - BP 30191 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">13276 Marseille Cedex 09 FRANCE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Attention: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Email: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">and with a copy (which shall not constitute effective notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Email: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Attention: [***]] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Such notice, shall be deemed to have been given as of the date delivered by hand, or on the second business day (at the place
of delivery) after deposit with an internationally recognised overnight delivery service, whichever is the earlier. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">If to MedImmune, to: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">73. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">MedImmune LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">One MedImmune Way </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Gaithersburg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">MD 20878 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">USA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">with a copy (which shall not constitute effective notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">and with a copy (which shall not constitute effective notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:0%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Such notice, shall be deemed to have been given as of the date delivered by hand, or on the second business day (at the place
of delivery) after deposit with an internationally recognised overnight delivery service, whichever is the earlier. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Entire Agreement; Amendments</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">This Agreement and any document referred to in it constitutes the entire agreement between the Parties with
respect to its subject matter hereof and thereof. This Agreement supersedes all prior arrangements, undertakings, understandings and agreements, whether written or oral, with respect to its subject matter. Each Party confirms that in entering into
this Agreement it is not relying on any statements, representations, warranties, or covenants made by a Party or its representative prior to entering into this Agreement, except as specifically set out in the Agreement. Each Party waives all rights
and remedies which, but for this clause 21.9, might otherwise be available to it in respect of any such representation, warranty, collateral contract or other assurance. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">Any amendment or modification of this Agreement must be in writing and signed by authorised representatives
of both Parties. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">This clause 21.9 shall not exclude or limit liability for fraud or fraudulent misrepresentation.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify">In the event of any inconsistencies between this Agreement and any Schedules or other attachments hereto,
the terms of this Agreement shall control. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>English Language</B>. The language of this Agreement is English and all documents, notices, waivers and
all other written communications or otherwise between the Parties in connection with this Agreement shall be in English. If this Agreement is translated into any other language, the English language text shall prevail. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Waiver and <FONT STYLE="white-space:nowrap">Non-Exclusion</FONT> of Remedies</B>. A Party&#146;s failure
to enforce, at any time or for any period of time, any provision of this Agreement, or to exercise any right or remedy shall not constitute a waiver of that provision, right or remedy or prevent such Party from
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">74. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">
enforcing any or all provisions of this Agreement and exercising any rights or remedies. To be effective any waiver must be in writing. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>No Benefit to Third Parties</B>. Except for any rights and immunities granted in this Agreement to any
Affiliates, the Contracts (Rights of Third Parties) Act 1999 shall not apply to this Agreement. Any Person who is not a party to this Agreement (including any employee, officer, agent, representative or subcontractor of either Party) shall not have
the right (whether under the Contracts (Rights of Third Parties) Act 1999 or otherwise) to enforce any provision of this Agreement which expressly or by implication confers a benefit on that Person without the express prior agreement in writing of
the Parties, which agreement must refer to this clause 21.12. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Further Assurance</B>. Each Party shall perform all further acts and things and execute and deliver such
further documents as may be necessary or as the other Party may reasonably require to implement or give effect to this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Relationship of the Parties</B>. It is expressly agreed that the relationship between Innate and
MedImmune shall not constitute a partnership, joint venture, or agency. Neither Innate nor MedImmune shall have the authority to make any statements, representations, or commitments of any kind, or to take any action, which shall be binding on the
other Party, without the prior consent of such other Party to do so. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">21.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="justify"><B>Counterparts</B>. This Agreement may be executed in two (2)&nbsp;or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by PDF format via email or other electronically transmitted signatures and such signatures shall be deemed to bind
each Party hereto as if they were original signatures. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE FOLLOWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">75. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>THIS AGREEMENT IS EXECUTED</B> by the authorised representatives of the Parties as of the date first
written above. </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>MEDIMMUNE LIMITED</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>INNATE PHARMA S.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">By: /s/ Jane Osbourn</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By: /s/ Mondher Mahjoubi</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Name: Jane Osbourn</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name: Mondher Mahjoubi</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Title: VP R&amp;D</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title: CEO</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><I>Signature page to the License Agreement </I></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>COMMERCIALIZATION PLAN </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>SOTC SERVICES </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature page to the License Agreement</I>]<I> </I></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SUPPLY AGREEMENT TERMS </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>LICENSED ANTIBODY </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>EXISTING PRODUCT TRADEMARKS </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>LICENSED MEDI PATENTS </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>AZ CORPORATE MARKS </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>INNATE CORPORATE NAMES </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>INITIAL MEMBERS OF JDC AND JCC </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>DEVELOPMENT PLAN </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>LICENSED MEDI <FONT STYLE="white-space:nowrap">KNOW-HOW</FONT> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 12 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TRADEMARK ASSIGNMENT </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 16.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>EXISTING RESEARCH AND COLLABORATION AGREEMENTS </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>AZ PROMOTION PRINCIPLES </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i)&nbsp;is not material and (ii)&nbsp;would be
competitively harmful if publicly disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Private&nbsp;&amp; Confidential </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:100pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>Dated&nbsp;&nbsp;&nbsp;&nbsp;16 April&nbsp;&nbsp;&nbsp;&nbsp;2019</B></P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="81"></TD>
<TD HEIGHT="81" COLSPAN="2"></TD>
<TD HEIGHT="81" COLSPAN="2"></TD>
<TD HEIGHT="81" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>INNATE PHARMA S.A.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>(1)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="27"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>AND</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="27"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>MEDIMMUNE LIMITED</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>(2)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="68"></TD>
<TD HEIGHT="68" COLSPAN="2"></TD>
<TD HEIGHT="68" COLSPAN="2"></TD>
<TD HEIGHT="68" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>AMENDMENT&nbsp;AND&nbsp;RESTATEMENT AGREEMENT&nbsp;OF&nbsp;THE&nbsp;COLLABORATION&nbsp;AND
OPTION&nbsp;AGREEMENT&nbsp;RELATING&nbsp;TO&nbsp;CD39</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="justify"><B>CD39 OPTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">This Deed (the &#147;<B>Deed</B>&#148;) is made on ______<U>16</U><U></U><U>&nbsp;April </U>____2019 by and between: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">INNATE PHARMA S.A., a company incorporated in France having its principal place of business at 117, Avenue de Luminy -
BP 30191 13 009 Marseille, France (&#147;<B>Innate</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MEDIMMUNE LIMITED, a company incorporated in England and Wales with company number 2451177 and with its registered
office at Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom (&#147;<B>MedImmune</B>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>Background
</B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate and MedImmune entered into a Collaboration and Option Agreement relating to CD39 on 22&nbsp;October 2018
(&#147;<B>Original Agreement</B>&#148;). Under the Original Agreement, Innate has granted to MedImmune an exclusive option to take an exclusive license under the CD39 Option Technology (as defined in the Original Agreement), and the Parties agree to
collaborate to perform certain development activities with respect to the CD39 program, in each case, in accordance with the terms of the Original Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate and MedImmune now wish to amend and restate the Original Agreement in its entirety, in the form set out in the
Schedule to this Deed, in accordance with the terms of this Deed. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">NOW, THEREFORE, each of Innate and MedImmune, intending to be
legally bound, agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>DEFINITIONS</B> </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In this Deed, unless the context otherwise requires, the provisions in this Section&nbsp;1 apply. Unless otherwise
stated, terms defined in the Original Agreement shall have the same meaning in this Deed. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Amended Agreement</B>&#148; shall have the meaning set out Section&nbsp;3.1. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Effective Date</B>&#148; means 22&nbsp;October 2018. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Original Agreement</B>&#148; shall have the meaning set out in the preamble to this Deed.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>INTERPRETATION </B></P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The principles of interpretation set out in Section&nbsp;2.1 of the Original Agreement shall have effect as if set out
in this Deed, save that references to &#147;this Agreement&#148; shall be construed as references to &#147;this Deed&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">References to this Deed include its Schedule. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>AMENDMENT </B></P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In accordance with Section&nbsp;26 of the Original Agreement, the Parties agree that the Original Agreement shall be
amended and restated in its entirety, in the form set out in the Schedule to this Deed (the &#147;<B>Amended Agreement</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The amendment and restatement of the Original Agreement pursuant to Section 3.1 shall take effect from the Effective
Date, as if the Amended Agreement had been entered into on the Effective Date. Accordingly, upon this Deed being entered into, the Amended Agreement shall supersede the Original Agreement in its entirety. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>INCORPORATION OF TERMS; CONFIDENTIALITY </B></P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The provisions of Sections 11.1, 11.2 (with the reference to &#147;and the obligations set forth in
Section&nbsp;11.5&#148; deleted), 11.3 (with each reference to &#147;and the License Agreement&#148; deleted), 11.4, 18.1 (first paragraph) and 20 to 28 of the Amended Agreement shall apply to this Deed as if set out in full in this Deed and as if
references in those Sections to &#147;this Agreement&#148; shall be construed as references to this Deed. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties acknowledge and agree that the terms of this Deed shall be deemed to be each Party&#146;s Confidential
Information (and each Party shall be deemed to be the Disclosing Party and also the Receiving Party with respect to such Confidential Information). </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>IN
WITNESS </B>this Deed has been executed by the Parties as a deed and is intended to be and is delivered on the date first appearing above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>EXECUTED</B>&nbsp;as&nbsp;a&nbsp;<B>DEED&nbsp;</B>by</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>MEDIMMUNE LIMITED</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top">acting by a director:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><U>/s/ Adrian Kemp</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Name: Adrian Kemp</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL">Title: Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="68"></TD>
<TD HEIGHT="68" COLSPAN="2"></TD>
<TD HEIGHT="68" COLSPAN="2"></TD>
<TD HEIGHT="68" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top">in the presence of:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><U>/s/ Svetlana Dmuk</U><U>h</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL">Witness</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">&nbsp;&nbsp;Name of witness</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">&nbsp;&nbsp;/s/ Svetlana Dmukh</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">&nbsp;&nbsp;Address of witness</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">&nbsp;&nbsp;Academy House</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">&nbsp;&nbsp;136 Mills Road</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">&nbsp;&nbsp;Cambridge,&nbsp;CB2&nbsp;8PA,&nbsp;UK</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">&nbsp;&nbsp;Occupation of witness</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">&nbsp;&nbsp;Company Secretarial</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:ARIAL">&nbsp;&nbsp;Administrator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:ARIAL"><B>CD390PTION </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10.5pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:ARIAL"><B>EXECUTED as a DEED </B>by</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10.5pt; font-family:ARIAL"><B>INNATE PHARMA S.A.</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">/s/ Mondher Mahjoubi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10.5pt; font-family:ARIAL">acting by a person under the authority of the company in accordance with the laws of its jurisdiction of incorporation.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:ARIAL">Name: Mondher Mahjoubi</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10.5pt; font-family:ARIAL">Title: CEO</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10.5pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10.5pt">in the presence of:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Witness</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">/s/ Irene Berkowitz</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:ARIAL">Address of witness</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:ARIAL">A2 Impasse Gaveliere</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10.5pt; font-family:ARIAL">A3007 Marseille, France</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39&nbsp;&nbsp;OPTION </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>SCHEDULE </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39&nbsp;&nbsp;OPTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Private&nbsp;&amp; Confidential </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Execution version </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>Dated October&nbsp;22, 2018</B></P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="95"></TD>
<TD HEIGHT="95" COLSPAN="2"></TD>
<TD HEIGHT="95" COLSPAN="2"></TD>
<TD HEIGHT="95" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>INNATE PHARMA S.A.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>(1)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="27"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>AND</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="27"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD>
<TD HEIGHT="27" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>MEDIMMUNE LIMITED</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>(2)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="81"></TD>
<TD HEIGHT="81" COLSPAN="2"></TD>
<TD HEIGHT="81" COLSPAN="2"></TD>
<TD HEIGHT="81" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>COLLABORATION&nbsp;AND&nbsp;OPTION&nbsp;AGREEMENT RELATING TO CD39</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39&nbsp;&nbsp;OPTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">This Collaboration and Option Agreement (the &#147;<B>Agreement</B>&#148;) is made as of the 22&nbsp;October 2018 (the &#147;<B>Effective
Date</B>&#148;) by and between: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">INNATE PHARMA S.A., a company incorporated in France having its principal place of business at 117, Avenue de Luminy -
BP 30191 13 009 Marseille, France (&#147;<B>Innate</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MEDIMMUNE LIMITED, a company incorporated in England and Wales with company number 2451177 and with its registered
office at Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom (&#147;<B>MedImmune</B>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Background </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate is the owner of certain proprietary technology relating to monoclonal antibodies which allows the inhibition of
the CD39 human enzyme and is the owner or exclusive licensee or sublicensee of certain Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> associated therewith (capitalised terms are defined below); </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune, which is directly or indirectly wholly owned by AstraZeneca PLC, and its Affiliates have experience in the
research, development, manufacturing and commercialization of pharmaceutical products worldwide (capitalised terms are defined below); </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">By entering this Agreement MedImmune is obtaining an exclusive option to take an exclusive license under Patents and <FONT
STYLE="white-space:nowrap">Know-How</FONT> in and to the CD39 Lead and the CD39 <FONT STYLE="white-space:nowrap">Back-Ups</FONT> and Innate is willing to grant such option to MedImmune, in each case, on the terms and conditions set forth below and
in the License Agreement (capitalised terms are defined below); </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties intend to collaborate to perform certain Development activities (including Collaboration Studies) to
further develop the Innate&#146;s research and development programme with respect to CD39, and Innate intends to assist MedImmune in its Evaluation and determination as to whether or not to exercise CD39 Option (capitalised terms are defined below),
all in accordance with the terms and conditions set forth below. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39&nbsp;&nbsp;OPTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, each of Innate and MedImmune, intending to be legally bound, agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>DEFINITIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify">As used in this Agreement, the following terms will have the meanings set forth in this Section&nbsp;1, unless context dictates
otherwise: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Affiliate</B>&#148; means, with respect to a Person, any Person that from time to time directly, or
indirectly through one or more intermediaries, controls, is controlled by or is under common control with such first Person. For purposes of the definition in this Section&nbsp;1.1 only, &#147;control&#148;, and with correlative meanings, the terms
&#147;controlled by&#148; and &#147;under common control with&#148; mean (a)&nbsp;to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities, by contract relating to
voting rights or corporate governance, resolution, regulation or otherwise, or (b)&nbsp;to own, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities or other ownership interest of such Person.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Agreement</B>&#148; shall have the meaning set forth in the preamble to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Anti-Corruption Laws</B>&#148; means the US Foreign Corrupt Practices Act 1977, the UK Bribery Act 2010 and
any other Applicable Law for the prevention of fraud, corruption, racketeering, money laundering or terrorism. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Applicable Law</B>&#148; means the laws, rules, regulations and guidelines in the world, including any rules,
regulations, guidelines or other requirements of the Governmental Bodies that are applicable to the Parties or any particular activity under this Agreement, in each case as may be in effect from time to time, including, without limitation,
(i)&nbsp;GCP, (ii) GMP, (iii)&nbsp;GLP, (iv) GVP and (v)&nbsp;the principles that form the basis of the Helsinki Declaration of the World Medical Association, in each case to the extent they apply to a Party&#146;s performance of its obligations
under this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Background IP</B>&#148; means, with respect to a Party, the Intellectual Property Rights owned by or licensed
to such Party as of the Effective Date, and the Intellectual Property Rights that come into the ownership of or become licensed to such Party during the term of this Agreement, other than by operation of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>BLA</B>&#148; means a Biologics License Application submitted to the FDA under subsection (a)&nbsp;or (k) of
Section&nbsp;351 of the PHSA or any corresponding application outside the United States. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Business Day</B>&#148; means a day other than Saturday or Sunday or a public holiday in England or France.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39</B>&#148; means the enzyme NTPDase 1. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 [***] Bispecific</B>&#148; means those molecules (including antibodies) and any fragment or derivative
thereof, that simultaneously bind to: </P></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(i) CD39, and (ii) [***]. </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 [***] Combo</B>&#148; means any product or treatment involving sequential or concomitant administration
or otherwise a combination of (a)&nbsp;a CD39 Program Antibody; and (b)&nbsp;a molecule (including antibody) targeting any therapeutic target within [***], whether on their own or in combination with other active ingredient(s). For the avoidance of
doubt, CD39 [***] Combo includes a CD39/[***] Combination Product. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 [</B>***<B>] Studies</B>&#148; means any Clinical Trial with respect to a CD39 [***] Bispecific or a
CD39 [***] Combo. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 <FONT STYLE="white-space:nowrap">Back-Ups</FONT></B>&#148; means those (i)&nbsp;antibodies described in
<U>Schedule 1.12</U>, or (ii)&nbsp;other antibodies (or any fragment or derivative thereof) which bind to CD39, in each case (i)&nbsp;and (ii), including any fragment or derivative of such antibody, but excluding the CD39 Lead and the CD39 <FONT
STYLE="white-space:nowrap">Bi-Specific</FONT> Molecules. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 <FONT STYLE="white-space:nowrap">Bi-Specific</FONT> Molecules</B>&#148; means those molecules (including
antibodies) and any fragment or derivative thereof, that simultaneously bind to: (i)&nbsp;CD39, and (ii)&nbsp;other therapeutic target(s). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 Competing Product</B>&#148; means a protein, including an antibody (or any fragment or derivative
thereof), that [***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39/[</B>***<B>] Combination Product</B>&#148; means any product or treatment involving sequential or
concomitant administration or otherwise a combination of: (a)&nbsp;any molecule (including antibody) or any fragment or derivative thereof which binds to CD39; and (b)&nbsp;any molecule (including antibody) or any fragment or derivative thereof
which binds to [***], whether on their own or in combination with other active ingredients(s). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 Lead</B>&#148; means the CD39 Program Antibody identified as [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 Option</B>&#148; shall have the meaning set forth in Section&nbsp;4.1. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 Option Fee</B>&#148; shall have the meaning set forth in Section&nbsp;3.1. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 Option <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all <FONT
STYLE="white-space:nowrap">Know-How</FONT> which is Controlled by Innate or its Affiliates, as of the Effective Date or at any time during the term of this Agreement, that is or may become necessary or useful for the Research, Development,
commercialization or other Exploitation of the CD39 Option Products, including: (a)&nbsp;the Innate Study Results, (b)&nbsp;the <FONT STYLE="white-space:nowrap">Know-How</FONT> within the Innate Collaboration IP and (c)&nbsp;Innate&#146;s interest
in the <FONT STYLE="white-space:nowrap">Know-How</FONT> within the Joint Collaboration IP (together (a)&nbsp;to (c), the &#147;<B>Innate Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148;), but excluding <FONT
STYLE="white-space:nowrap">Know-How</FONT> licensed under the [***], unless otherwise agreed between the Parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 Option Notice</B>&#148; shall have the meaning set forth in Section&nbsp;4.8. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 Option Patents</B>&#148; means all of the Patents: (a)&nbsp;listed in Appendix A, as may be supplemented
by Innate from time to time, together with (b)&nbsp;all Patents which are Controlled by Innate or its Affiliates, as of the Effective Date or at any time during the term of this Agreement, that (i)&nbsp;claim any CD39 Option Product or
(ii)&nbsp;claim any invention that is or becomes (subject to Section&nbsp;12.12) necessary or useful for the Research, Development, commercialization or Exploitation, as applicable, of any CD39 Program Antibody, but excluding in each case
(1)&nbsp;any Patent exclusively related to any active ingredient within a Combination (other than a CD39 Program Antibody) [***], unless otherwise agreed between the Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 Option Period</B>&#148; means the period beginning upon [***] </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 Option Products</B>&#148; means any and all pharmaceutical products including a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">CD39 Program Antibody as an active ingredient (including Combinations). </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 Option Technology</B>&#148; means the CD39 Option Patents and the CD39 Option <FONT
STYLE="white-space:nowrap">Know-How.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CD39 Program Antibody</B>&#148; means any of: (a)&nbsp;the CD39 Lead, (b)&nbsp;any CD39 Back- Up; and
(c)&nbsp;CD39 <FONT STYLE="white-space:nowrap">Bi-Specific</FONT> Molecule, in each case within the scope of the claims of any of the CD39 Option Patents at any time, regardless of jurisdiction. In any case, antibodies listed as Schedule 1.12,
including any fragment or derivative thereof, shall be CD39 Program Antibodies. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.26</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;CD39 Program&#148; </B>means the programme of research and development with respect to CD39 Option Products
conducted or to be conducted under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.27</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Change of Control</B>&#148; has the meaning set forth in the License Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.28</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Clinical Trial</B>&#148; means a Phase 1 Clinical Trial, a Phase 2 Clinical Trial, or a Phase 3 Clinical
Trial. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.29</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CMC</B>&#148; means optimization of Manufacturing processes to provide reproducible supply of drug substance
at commercialization scale, including formulation and development work to ensure stability and purity, and to otherwise meet the requirements under Applicable Law to be approved by a Regulatory Health Authority for marketing, sale and distribution.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.30</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Collaboration Budget</B>&#148; means the budget set out in the Development Plan with respect to the
forecasted Innate Development Costs to be incurred by Innate during the CD39 Option Period, as amended or updated from time to time by the OC in accordance with this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.31</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Collaboration IP</B>&#148; means the <FONT STYLE="white-space:nowrap">Know-How</FONT> and other Intellectual
Property Rights arising from, generated from or reduced to practice in connection with the performance of the Development activities under the Development Plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.32</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Collaboration Study</B>&#148; means any clinical study conducted or to be conducted in accordance with the
Development Plan. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.33</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Collaboration Study Preliminary Report</B>&#148; means the preliminary report in respect of each
Collaboration Study written by or on behalf of Innate and summarising the Primary Endpoint Results of each Collaboration Study. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.34</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Collaboration Study Protocol</B>&#148; means each clinical trial protocol describing a Collaboration Study
and outlining the activities to be conducted by the Party assigned to perform such Collaboration Study under the Development Plan and the anticipated timelines for carrying out such activities, which protocol shall (i)&nbsp;be in accordance with the
Collaboration Study outline contained in the Development Plan; and (ii)&nbsp;be prepared by or on behalf of such Party and the applicable Principal Investigator, as may be amended from time to time in accordance with Section&nbsp;7.3(b).
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.35</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Combination</B>&#148; means the combination of a CD39 Program Antibody as an active ingredient with one or
more other active ingredients including but not limited to MedImmune Products, whether sold or anticipated to be sold as a fixed dose or as separate <FONT STYLE="white-space:nowrap">co-prescribed</FONT> doses or in a physically <FONT
STYLE="white-space:nowrap">co-packaged</FONT> form. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.36</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Commercially Reasonable Efforts</B>&#148; means, with respect to the efforts to be expended by a Party [***].
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.37</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Competition Law Filing</B>&#148; shall have the meaning set forth in Section&nbsp;2.2. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.38</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Confidential Information</B>&#148; means any and all <FONT STYLE="white-space:nowrap">Know-How</FONT> and
information with respect to a Party&#146;s or its Affiliates&#146; business, whether oral or in writing or in any other form, disclosed before, on or after the date of this Agreement by one Party to the other Party that is either marked or
identified as confidential or proprietary or that is of such a nature that would be considered by a reasonable person to be confidential or proprietary. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.39</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Control</B>&#148; means, with respect to any item of <FONT STYLE="white-space:nowrap">Know-How</FONT> or a
Patent, the ability and authority of a Party or its Affiliates, whether arising by ownership, possession, or pursuant to a licence or sublicense (other than pursuant to a licence or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
sublicense granted under this Agreement or the License Agreement), to assign, disclose or grant a licence, sublicence or other right to the other Party under or to such item of <FONT
STYLE="white-space:nowrap">Know-How</FONT> or such Patent as provided for herein or under the License Agreement, and without breaching the terms of any agreement between such Party and any Third Party. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.40</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Costs</B>&#148; means both internal and external costs and expenses. Unless otherwise mutually agreed between
the Parties, internal costs incurred by a Party shall be determined by multiplying the applicable FTE Rate by the number of FTEs utilized to conduct the applicable activities. Costs shall exclude any payment obligations owed to the head licensors
under any Head License. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.41</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CRO</B>&#148; means a contract research organisation selected by Innate for the performance of the
Collaboration Studies or parts thereof and identified in the relevant Collaboration Studies Protocol, including the CROs engaged by Innate in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">relation to the CD39 Program. </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.42</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CTA Materials</B>&#148; means those Clinical Trial Applications for the Collaboration Studies, together with
all supporting documentation and data, to be submitted after the Effective Date to the European Medicines Agency or other appropriate Regulatory Health Authorities in respect of the Collaboration Studies. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.43</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>CTA</B>&#148; or &#147;<B>Clinical Trial Application</B>&#148; means any and all applications to the European
Medicines Agency or other appropriate Regulatory Health Authorities for the permission to perform a clinical study as required by Applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.44</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Data Protection Law</B>&#148; means any law or regulation in force in the relevant jurisdiction from time to
time which implements or supplements the General Data Protection Regulation 2016/679 dated 27&nbsp;April and any other Applicable Law replacing adding to or amending, extending, reconstituting or consolidating it or any equivalent national laws and
regulations which otherwise regulate the processing of Personal Data, privacy, direct marketing or the interception or communication of electronic messages. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.45</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Data Subject</B>&#148; means a natural person who is an identified or identifiable natural person. An
identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the
physical, physiological, genetic, mental, economic, cultural or social identity of that natural person. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.46</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Develop</B>&#148; or &#147;<B>Development</B>&#148; means activities relating to the development of CD39
Option Products, and activities to develop manufacturing capabilities for CD39 Option Products. Development includes <FONT STYLE="white-space:nowrap">pre-clinical</FONT> activities, toxicology studies, formulation, manufacturing process development
and <FONT STYLE="white-space:nowrap">scale-up</FONT> (including bulk antibody production and CMC activities), manufacturing CD39 Option Products for clinical trials, quality assurance and quality control, initial biomarker studies, technical
support, pharmacokinetic studies, clinical studies, pharmacovigilance and regulatory affairs activities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.47</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Development Plan</B>&#148; means the Development Plan for the CD39 Program, as reviewed, updated and approved
by the OC from time to time pursuant to Section&nbsp;5.1; containing the outline of each of the currently envisaged <FONT STYLE="white-space:nowrap">pre-clinical</FONT> activities, the Collaboration Studies and timelines for the commencement and
completion of such studies, as well as certain CMC activities and the supply of CD39 Option Products, the related timelines for such activities as well as the assumptions set forth therein. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.48</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Disclosing Party</B>&#148; shall have the meaning set forth in Section&nbsp;11.1. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.49</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;EMA&#148; </B>means the European Medicines Agency, a Regulatory Health Authority for the purposes of this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.50</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Evaluation&#148; and &#147;Evaluate&#148; </B>means MedImmune&#146;s and its Affiliates&#146; internal
evaluation of the CD39 Program for purposes of determining whether or not to exercise the CD39 Option. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.51</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Exploit</B>&#148; means to undertake, or have undertaken, any or all of the following activities: to make,
import, use, sell, or offer for sale, research, study, Develop, register, modify, enhance, improve, manufacture, hold or keep (whether for disposal or otherwise), formulate, optimise, use, export, transport, distribute, promote, market or otherwise
dispose or offer to dispose of, a product or process and &#147;<B>Exploitation</B>&#148; shall have the correlative meaning. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.52</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Exploratory Study</B>&#148; shall have the meaning set forth in Section&nbsp;4.5. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.53</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;FDA&#148; </B>means the United States Food and Drug Administration, a Regulatory Health Authority for the
purposes of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.54</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Force Majeure</B>&#148; has the meaning set out in the License Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.55</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>France - UK Double Tax Treaty</B>&#148; means the convention between the Government of the United Kingdom of
Great Britain and Northern Ireland and the Government of France for the avoidance of double taxation and the prevention of fiscal evasion with respect to taxes on income and on capital gains signed in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">London on 19&nbsp;June 2008 as well as any convention that would replace it in the
future. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.56</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>FTE</B>&#148; means a full time equivalent person year of [***] of scientific, technical or operational work
(excluding administrative services). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.57</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>FTE Rate</B>&#148; means, for the period commencing on the Effective Date until such time as adjusted
pursuant to the following sentence or the Parties agree otherwise, [***] for all activities. The FTE Rate will be increased or decreased on each anniversary of the Effective Date by a percentage equivalent to the change over the preceding twelve
month period in the Consumer Price Index for Urban Wage Earners and Clerical Workers with respect to MedImmune and the index of salaries of the pharmaceutical industry published by LEEM with respect to Innate. The FTE Rate shall include costs of
salaries, benefits, supplies, travel, other employee costs, and supporting general and administration allocations. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.58</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>GCP</B>&#148; or &#147;<B>Good Clinical Practices</B>&#148; means, to the extent applicable in the country
where Regulatory Approval is sought, the current standards for good clinical practices relating to clinical trials for pharmaceuticals, as set forth in the United States Code of Federal Regulations or ICH guidelines and applicable regulations, laws
or rules as promulgated thereunder, in each case as amended from time to time, and all other standards of good clinical practice as are required by any Regulatory Health Authority. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.59</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>GLP</B>&#148; or &#147;<B>Good Laboratory Practices</B>&#148; means good laboratory practices required under
the regulations set forth in 21 C.F.R. Part 58, as in effect during the term of this Agreement, and the requirements thereunder imposed by the FDA, and the equivalent thereof in any jurisdiction. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.60</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>GMP</B>&#148; or &#147;<B>Good</B> <B>Manufacturing Practice</B>&#148; means the principle of good
manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use as required by Applicable Law, including the laws of the European Community and Directive 2003/94/EC as well as any national
legislation implementing the aforesaid Directive and any relevant </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">guidance relating thereto. </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.61</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>GVP</B>&#148; or &#147;<B>Good Pharmacovigilance Practices</B>&#148; means, in addition to the provisions
under the any pharmacovigilance agreement between the Parties, all applicable good pharmacovigilance practices promulgated and published by FDA, EMA or any other Regulatory Health Authorities having jurisdiction over the Development, Manufacture or
commercialization of the CD39 Option Products pursuant to its regulations, guidelines or otherwise, including as applicable, major pharmacovigilance process and product or population specific considerations as defined in (a)&nbsp;European Commission
Regulation code relating to medicinal products for human use, Directives 2010/84/EU and 2012/26/EU respectively, as well as by the Commission Implementing Regulation (EU) No 520/2012 on the Performance of Pharmacovigilance Activities Provided for in
Regulation (EC) No 726/2004 and Directive 2001/83/EC, Title IX of the Directive, Article 108a (a)&nbsp;of Directive 2001/83/EC, and principles detailed in the ICH guidelines for pharmacovigilance as well as (b)&nbsp;principles detailed in the United
States 21 CFR and Guidance for Industry Good Pharmacovigilance Practices and Pharmacoepidemiological Assessment. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.62</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Government Official</B>&#148; means any Person employed by or acting on behalf of a Governmental Body,
government-controlled entity or public international organization. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.63</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Governmental Body</B>&#148; means any: (i)&nbsp;nation, state, commonwealth, province, territory, county,
municipality, district or other jurisdiction of any nature; (ii)&nbsp;federal, state, local, municipal, foreign or other government; (iii)&nbsp;governmental or quasi-governmental authority of any nature (including any governmental division,
department, agency, commission, instrumentality, official, ministry, fund, foundation, centre, organization, unit, body or entity and any court or other tribunal); or (iv)&nbsp;self-regulatory organization (including the NASDAQ Global Market and the
NASDAQ Global Select Market). For the avoidance of doubt, Governmental Bodies includes Regulatory Health Authorities. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.64</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Head License</B>&#148; means any of the [***] or any license from a Third Party described under
Section&nbsp;12.12 or Section&nbsp;12.14, and &#147;Head Licenses&#148; means all of them. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.65</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>HSR Act</B>&#148; means the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended,
including all rules promulgated thereunder. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.66</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>ICH</B>&#148; means the International Conference on Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.67</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;IND&#148; </B>or <B>&#147;Investigational New Drug Application&#148; </B>means an application to the FDA for
permission to perform a clinical study as required by Applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.68</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Independent Ethics Committee</B>&#148; or &#147;<B>IEC</B>&#148; means an independent body, institutional,
regional, national or supranational committee or review board, whose responsibility it is to ensure the protection of rights, safety and well-being of human subjects in a clinical study and who is responsible for, among other things, reviewing and
approving or providing opinions on, the Collaboration Study Protocol, the suitability of the investigator(s), facilities, subject recruitment materials, methods and the information to be provided to potential Subjects in a Collaboration Study to
secure their informed consent. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.69</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Indication</B>&#148; means a cancerous condition resulting from a separate and distinct tumor type and line
of therapy that is the basis for a separate and distinct Regulatory Approval. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.70</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Indirect Taxes</B>&#148; means value added taxes, sales taxes, consumption taxes and other similar taxes.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.71</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Innate</B>&#148; shall have the meaning set forth in the preamble to this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.72</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Innate Data Room</B>&#148; means the dataroom with respect to Innate&#146;s CD39 research and development
programme which is maintained by or on behalf of Innate and to the extent available for access by MedImmune on or before the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.73</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Innate Development Costs</B>&#148; has the meaning set out in Section&nbsp;6.1. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.74</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Innate Standards</B>&#148; means, with respect to the performance of any activities allocated to Innate under
the Development Plan with respect to a CD39 Option </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Product, the performance of such activities (a)&nbsp;with substantially the same degree of skill, quality and care utilized by Innate in performing such activities for itself with respect to such
CD39 Option Product or products at a similar stage of development as such CD39 Option Product; and (b)&nbsp;in compliance in all material respects with Applicable Laws. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.75</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Innate Study Results</B>&#148; shall have the meaning set forth in Section&nbsp;12.6(a).
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.76</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Innate Third Party Claim</B>&#148; shall have the meaning set forth in Section&nbsp;15.2.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.77</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Intellectual Property Rights</B>&#148; means Patents, trademarks, service marks, trade secrets (including
patentable inventions), trade names, registered designs, design rights, copyrights (including rights in computer software), domain names, database rights and any rights or property similar to any of the foregoing in any part of the world, whether
registered or not, together with the right to apply for the registration of any such rights. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.78</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Joint Collaboration IP</B>&#148; shall have the meaning set forth in Section&nbsp;12.3(c).
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.79</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all inventions, discoveries, data,
information (including scientific, technical or regulatory information), trade secrets, processes, means, methods, practices, formulae, instructions, procedures, techniques, materials, technology, results, analyses, designs, drawings, computer
programs, apparatuses, specifications, technical assistance, laboratory, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data (including laboratory notes and notebooks), and other material or
<FONT STYLE="white-space:nowrap">know-how,</FONT> in written, electronic or any other form, whether or not confidential, proprietary or patentable, including without limitation: development technology; biology, chemistry, pharmacology, toxicology,
drug stability, CMC, Manufacturing and formulation, initial biomarker studies, test procedures, synthesis, purification and isolation techniques, quality control data and information, methodologies and techniques; information regarding clinical and <FONT
STYLE="white-space:nowrap">non-clinical</FONT> safety and efficacy studies, including study designs and protocols, marketing studies, absorption, distribution, metabolism and excretion studies; assays and biological methodology.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.80</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>knowledge</B>&#148; means the good faith understanding of the officers of Innate and its Affiliates, with
respect to relevant facts and information after performing a commercially reasonable inquiry of the employees having responsibilities in Innate&#146;s organisation with respect to the relevant subject matters and external patent agents of Innate and
its Affiliates with respect to such facts and information relating to the CD39 Option Patents, that the patent agent is responsible for prosecuting and maintaining. For purposes of the foregoing, Innate will not be deemed to have knowledge of any
given fact or information, which (i)&nbsp;was known or should have been known by any external patent agents of Innate and its Affiliates but was not disclosed to Innate&#146;s officers or (ii)&nbsp;was not known by the employees of Innate and its
Affiliates. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.81</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>License Agreement</B>&#148; shall mean the agreed form license attached at <U>Schedule 1.80</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.82</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Listed Patents</B>&#148; means the Patents listed in <U>Schedule 1.81</U>, and any Patents filed after the
Effective Date claiming priority to the Patents listed on <U>Schedule 1.81</U>, as such schedule may be updated from time to time by agreement of the Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.83</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Loss&#148; </B>or <B>&#147;Losses&#148; </B>means any and all direct liabilities, claims, actions, damages,
losses or expenses, including interest, penalties, and reasonable lawyers&#146; fees and disbursements. In calculating Losses, the legal duty to mitigate on the part of the Party suffering the Loss shall be taken into account. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.84</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Manufacture</B>&#148; or &#147;<B>Manufacturing</B>&#148; means activities in connection with the synthesis,
manufacture, processing, formulating, testing (including, without limitation quality control, quality assurance and lot release testing), bulk packaging, labelling or storage and delivery of CD39 Option Products (including any component thereof).
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.85</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Material Anti-Corruption Law Violation</B>&#148; means a violation of an Anti-Corruption Law relating to the
subject matter of this Agreement which would if it were publically known have a material adverse effect on a Party or on the reputation of a Party because of its relationship with the other Party. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.86</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Material Issues</B>&#148; means issues material to the governance of or performance of the Development Plan,
including any of the following with respect to the CD39 Program: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">discontinuing commencement of Collaboration Studies, or prolonging or postponing commencement of Collaboration Studies
by more than [***]; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">any Safety or Regulatory Issues; </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">conducting the Collaboration Studies across fewer than [***] sites per Collaboration Study; </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">selecting and using any contract research organisation that is not a CRO other than those with international
recognition for conducting the Collaboration Studies; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">delay in the CMC work set forth in the Development Plan likely to cause a delay in commencing the first Phase 3
Clinical Trial in respect of a CD39 Option Product, with reference to the target date set forth in the Development Plan, by more than [***]; and </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">review and approve supply forecast (including for Exploratory Studies). </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.87</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>MedImmune</B>&#148; shall have the meaning set forth in the preamble to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.88</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>MedImmune Collaboration IP</B>&#148; shall have the meaning set forth in Section&nbsp;12.3(a).
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.89</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>MedImmune Collaboration Studies</B>&#148; shall have the meaning set forth in Section&nbsp;9.1(a).
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.90</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>MedImmune Indemnitees</B>&#148; shall have the meaning set forth in Section&nbsp;15.1. </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.91</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;MedImmune Manufacturing Information&#148; </B>means any <FONT STYLE="white-space:nowrap">Know-How</FONT> with
respect to the Manufacture of any MedImmune Product or other proprietary product of MedImmune, including the CMC data with respect thereto. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.92</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>MedImmune Manufacturing IP</B>&#148; shall have the meaning set forth in Section&nbsp;12.4.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.93</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;MedImmune Product&#148; </B>shall mean any proprietary product of MedImmune and with which either Party
conducts a Collaboration Study or a <FONT STYLE="white-space:nowrap">pre-clinical</FONT> study under the Development Plan. For the avoidance of doubt, MedImmune Product excludes the CD39 Option Products. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.94</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>MedImmune Study Results</B>&#148; shall have the meaning set forth in Section&nbsp;12.6(b).
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.95</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>MedImmune Third Party Claim</B>&#148; shall have the meaning set forth in Section&nbsp;15.1.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.96</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Objectives</B>&#148; means the objectives of Party which are: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">providing proof of the concept of the CD39 Option Products as cancer treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">carrying out the Collaboration Studies, CMC and other activities assigned to such Party as set forth in the
Development Plan taking into account the assumptions set out in the Development Plan; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.97</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Oncology Field</B>&#148; means the treatment, diagnosis and prevention of cancer in humans and animals.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.98</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Option Committee</B>&#148; or &#147;<B>OC</B>&#148; shall have the meaning set forth in Section&nbsp;7.3.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.99</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.100</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.101</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Parties</B>&#148; means MedImmune and Innate and &#147;<B>Party</B>&#148; means either of them.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.102</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Patent Action</B>&#148; shall have the meaning set forth in Section&nbsp;12.21. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.103</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Patents</B>&#148; means (a)&nbsp;all national, regional and international patents and patent applications,
including provisional patent applications, (b)&nbsp;all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals,
continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> non- provisional applications, and continued prosecution applications, (c)&nbsp;any and all patents that have issued or in the
future issue from the foregoing patents or patent applications ((a) and (b)), including utility models, petty patents and design patents and certificates of invention, (d)&nbsp;any and all extensions or restorations by existing or future extension
or restoration mechanisms, including revalidations, reissues, <FONT STYLE="white-space:nowrap">re-examinations</FONT> and extensions (including any supplementary protection certificates, patent term extensions and the like) of the foregoing patents
or patent applications ((a), (b) and (c)), and (e)&nbsp;any similar rights, including <FONT STYLE="white-space:nowrap">so-called</FONT> pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent
or patent of additions to any such foregoing patent applications and patents. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.104</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Payments</B>&#148; shall have the meaning set forth in Section&nbsp;8.1. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.105</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Person</B>&#148; means an individual, sole proprietorship, partnership, limited partnership, limited
liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department or
agency of a government. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.106</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Personal Data</B>&#148; means any information relating to a Data Subject. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.107</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Phase 1 Clinical Trial</B>&#148; means any clinical study conducted on human subjects [***].
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.108</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Phase 2 Clinical Trial</B>&#148; means any clinical study that is not intended to be used as a pivotal study
for purposes of seeking Regulatory Approval in any country within the Territory that is conducted on human patients [***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.109</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Phase 3 Clinical Trial</B>&#148; means any clinical study used as a pivotal study for purposes of seeking
Regulatory Approval, [***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.110</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Primary End Point Results</B>&#148; means with respect to any given Clinical Trial, the primary end point
results in accordance with the applicable protocol which, for the avoidance of doubt, might include items such as overall response rate, disease control rate, durability of response, progression free survival or safety data, as will be specified in
the applicable protocol. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.111</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Principal Investigator</B>&#148; means the person(s) appointed to lead and
<FONT STYLE="white-space:nowrap">co-ordinate</FONT> one or several Collaboration Studies under this Agreement and identified as Principal Investigator on the relevant Collaboration Studies Protocol, or any other person who may be appointed to such
role. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.112</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Processing</B>&#148; means any operation or set of operations that is performed on Personal Data or on sets
of Personal Data, whether or not by automated means, such as collection, recording, organisation, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available,
alignment or combination, restriction, erasure or destruction. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.113</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Product Trademark</B>&#148; mean trademarks to be used specifically for the marketing and sale of the CD39
Option Products. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.114</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Receiving Party</B>&#148; shall have the meaning set forth in Section&nbsp;11.1. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.115</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Regulatory Approval</B>&#148; means any and all approvals, product or establishment
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
licenses, registrations, or authorizations of any regional, federal, state, or local Regulatory Health Authority, department, bureau, or other governmental entity, necessary to test, manufacture,
commercially distribute, sell or market a CD39 Option Product in a regulatory jurisdiction, including, where applicable, (a)&nbsp;pricing or reimbursement approval in such jurisdiction if necessary or desirable, (b)
<FONT STYLE="white-space:nowrap">pre-</FONT> and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto), and (c)&nbsp;labelling approval. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.116</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Regulatory Documentation</B>&#148; means all applications, registrations, licenses, authorizations and
approvals, all correspondence submitted to or received from Regulatory Health Authorities (including minutes and official contact reports relating to any communications with any Regulatory Health Authority) and all supporting documents, including
documentation arising in the course of all clinical trials, in each case relating to obtaining or maintaining Regulatory Approval of Option Products, including all INDs, regulatory drug lists, advertising and promotion documents, adverse event files
and complaint files, including safety information, excluding source documentation associated with individual case safety reports other than such source documentation that is part of the clinical trial master file. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.117</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Regulatory Exclusivity</B>&#148; shall mean any exclusive marketing rights or data exclusivity rights
conferred by any applicable Regulatory Health Authority, other than an issued and unexpired Patent, including any regulatory data protection exclusivity (including, where applicable, paediatric exclusivity or orphan drug exclusivity) or any other
exclusivity afforded by restrictions which restrict the granting by a Regulatory Health Authority of Regulatory Approval to market a generic product. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.118</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Regulatory Health Authority</B>&#148; means any applicable national (for example, FDA or Japan&#146;s
Pharmaceuticals and Medical Devices Agency), supranational (for example, the EMA), regional, state, provincial or local regulatory health authority, department, bureau, commission, council, or other government entity regulating or otherwise
exercising authority with respect to the Exploitation of Option Products in the Territory, including any such entity involved in the granting </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
of Regulatory Approval for pharmaceutical products. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.119</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Research</B>&#148; means the discovery, identification, research, characterisation, modification,
derivatisation, optimisation and preclinical testing of pharmaceutical products. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.120</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Restricted Party</B>&#148; shall have the meaning set forth in Section&nbsp;13.2. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.121</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Right of Reference</B>&#148; means the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right to cross
reference, copy, incorporate by reference or rely upon any Study Results solely for the purposes of obtaining or maintaining Regulatory Approval for a pharmaceutical product, including (1)&nbsp;a &#147;Right of Reference or Use&#148; as that term is
defined in 21 C.F.R. &#167;314.3(b) in the United States, (2)&nbsp;any analogous procedures with respect to biologics or BLAs in the United States and (3)&nbsp;any equivalents thereof outside the United States. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.122</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>S/R Notice</B>&#148; shall have the meaning set forth in Section&nbsp;9.7. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.123</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Safety or Regulatory Issue</B>&#148; means: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Serious Adverse Event; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">requirement or request by a Regulatory Health Authority that one or more of the Collaboration Studies should cease in
the interests of the health, safety or well-being of Subjects; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">a reasonable, good faith determination by Innate, as notified to the OC, that one or more of the Collaboration Studies
should cease in the interests of the health, safety or well-being of Subjects and that such issue cannot be rectified or overcome without adversely jeopardizing the aforementioned interests; or </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">any decision or requirement of a Regulatory Health Authority which occurs prior to or during any of the Collaboration
Studies and which prevents Innate from initiating or completing one or more of the Collaboration </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Studies or from causing one or more of the Collaboration Studies to be initiated or
completed. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.124</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.125</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.126</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.127</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Senior Executives</B>&#148; means (i) [***] and (ii), [***]. A Party shall be entitled, effective upon
written notice thereof to the other Party, to designate one of its other representatives having equivalent seniority and experience to replace such foregoing representative as that Party&#146;s Senior Executive for the purpose of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.128</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Serious Adverse Event</B>&#148; shall have the meaning given and defined by ICH from time to time.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.129</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Specification</B>&#148; means the specification applicable to the Manufacture, packaging, labelling and
storage of a relevant product, as current at any given time. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.130</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Study Documentation</B>&#148; means all records, accounts, notes, laboratory notebooks, reports and data,
collected, generated or used in connection with the Collaboration Studies, Exploratory Studies or where applicable, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> activities performed by a Party under the Development Plan, whether in written,
electronic, optical or other form, including all recorded original observations and notations of clinical activities such as reports and records necessary for the evaluation and reconstruction of the relevant Collaboration Study or Exploratory
Study. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.131</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Study Results</B>&#148; means any data and information generated as a result of the Collaboration Studies,
including any of the Collaboration Study Preliminary Reports. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.132</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Study Site Staff</B>&#148; means all those researchers, students, employees, agents or others who are engaged
by or on behalf of Innate in the conduct of any of the Collaboration Studies, including any <FONT STYLE="white-space:nowrap">sub-investigator</FONT> (but excluding, for the avoidance of doubt, MedImmune and its researchers, students, employees and
agents). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.133</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Subject</B>&#148; means a person recruited to participate in a Collaboration Study. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.134</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Tech Transfer Period</B>&#148; shall have the meaning set forth in Section&nbsp;17.3. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.135</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Territory</B>&#148; means the world. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.136</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>&#147;Third Party Agreements&#148; </B>means those agreements listed in <U>Schedule 1.135.</U>
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.137</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Third Party</B>&#148; means any Person other than the Parties or the Parties&#146; respective Affiliates.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.138</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Third Party Claim</B>&#148; means an Innate Third Party Claim or a MedImmune Third Party Claim.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.139</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">&#147;<B>Transferred Data</B>&#148; means the Personal Data transferred by MedImmune to Innate pursuant to this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left"><B>CONSTRUCTION; COMPETITION LAW FILING </B></P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Except where the context requires otherwise, whenever used the singular includes the plural, the plural includes the
singular, the use of any gender is applicable to all genders and the word &#147;or&#148; has the inclusive meaning represented by the phrase &#147;and/or&#148;. Whenever this Agreement refers to a number of days, unless otherwise specified, such
number refers to calendar days. The headings of this Agreement are for convenience only and do not define, describe, extend or limit the scope </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">or intent of any provision in this Agreement. The term &#147;including&#148; or
&#147;includes&#148; as used in this Agreement means including, without limiting the generality of any description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the Parties and no rule of
strict construction shall be applied against any Party. The Parties hereby agree to act in good faith with respect to their performance of the rights and obligations pursuant to this Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If MedImmune reasonably determines during the CD39 Option Period that a filing under the HSR Act or any equivalent
competition law statute or regulation (a &#147;<B>Competition Law Filing</B>&#148;) is required for the performance of this Agreement or any License Agreement, promptly upon MedImmune&#146;s request, the Parties shall prepare and submit the required
notification forms as soon as reasonably practicable (and for any filing under the HSR Act within [***] after such determination) and use reasonable efforts to obtain clearance for the transactions contemplated hereunder as soon as practicable.
Subject to Applicable Law relating to the exchange of information, MedImmune shall have the right to direct all matters with respect to Competition Law Filings hereunder, consistent with its obligations hereunder after consulting with Innate. Each
Party will consult with the other on, and consider in good faith the views of the other Party in connection with, all of the information relating to such other Party that appears in any Competition Law Filing. MedImmune shall bear all fees in
connection with any Competition Law Filing and each Party shall bear their respective attorneys&#146; fees in connection therewith. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left"><B>OPTION FEE </B></P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In consideration of the grant of the CD39 Option by Innate to MedImmune and Innate&#146;s obligations to perform the
activities contemplated under this Agreement to facilitate MedImmune&#146;s Evaluation, MedImmune shall, subject to the terms of this Agreement, pay to Innate: </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">a <FONT STYLE="white-space:nowrap">non-creditable</FONT> and <FONT STYLE="white-space:nowrap">non-refundable</FONT>
fee of fifty million US dollars ($USD 50,000,000) (the &#147;<B>CD39 Option Fee</B>&#148;); and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">the following <FONT STYLE="white-space:nowrap">non-creditable</FONT> and
<FONT STYLE="white-space:nowrap">non-refundable</FONT> fee upon the first achievement of the applicable milestone event set out below by or on behalf of MedImmune or Innate: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.00pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt"><B>Milestone Event for a CD39 Option Product</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"><B>Payment</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.00pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.00pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">[***]</P> <P STYLE="font-size:68pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-RIGHT:1.00pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:ARIAL">[***]</P> <P STYLE="font-size:78pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:4.00em; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***]</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">For the avoidance of doubt, each payment set out above shall be payable by MedImmune only once. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The CD39 Option Fee shall be payable by MedImmune in accordance with Section&nbsp;8 in cash in two lump sums.
MedImmune shall pay to Innate: (a)&nbsp;the first amount of twenty six million US dollars ($USD 26,000,000) within [***] after the Effective Date, and (b)&nbsp;the remaining amount of twenty four million US dollars ($USD 24,000,000) on [***] 2019.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Upon achievement of the corresponding milestone event by or on behalf of Innate or MedImmune set forth in
Section&nbsp;3.1(b) Innate may issue an invoice to MedImmune with respect to the corresponding payment, and MedImmune shall pay such amount to Innate no later than [forty five (45)&nbsp;days] following receipt of such invoice. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">For the avoidance of doubt, the CD39 Option Fee is in addition to those fees payable on valid exercise of the CD39
Option. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>CD39 OPTION </B></P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate hereby grants to MedImmune the exclusive option (the <B>&#147;CD39 Option</B>&#148;) to </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">obtain the rights and licenses under the CD39 Option Technology to Exploit CD39 Option Products pursuant to the terms of the License
Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">During the CD39 Option Period, each Party shall be responsible for the performance of the Development activities
assigned to it under the Development Plan, in accordance with Section&nbsp;5. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune agrees to fund and shall finance those <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies under
the Development Plan allocated to Innate, in accordance with the Collaboration Budget for such studies contained in the Development Plan. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall use its Commercially Reasonable Efforts to formulate the CMC part of any data package required for any
IND/CTA or Regulatory Approval contained in the Development Plan in accordance with the expected timeline indicated in the Development Plan. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">During the CD39 Option Period, Innate may conduct exploratory clinical trials (including any Phase 1 Clinical Trials
or Phase 2 Clinical Trials) (&#147;<B>Exploratory Studies</B>&#148;) with respect to any CD39 Option Product (other than CD39 <FONT STYLE="white-space:nowrap">Bi-Specific</FONT> Molecules), including in combination with one or more active
ingredient(s), at its discretion and own expense, provided that Innate shall, at least [***] prior to the initiation of the Exploratory Study, propose to MedImmune through the OC to include the Exploratory Study in the Development Plan, and provide
to MedImmune a copy of the study protocol for such Exploratory Study (with respect to a CD39 [***] Study, Innate shall provide a high level clinical trial design summary that includes tumor type, patient population, dose range and schedule of each
agent to be administered (a &#147;<B>CD39 </B>[***]<B> Plan</B>&#148;)). MedImmune shall consider such proposal in good faith in light of the Objectives. Within [***] after the receipt of such study protocol (or clinical trial design summary, as
applicable), MedImmune shall also indicate whether or not such Exploratory Study satisfies the criteria set forth in (a)&nbsp;to (c) below. If MedImmune does not approve the inclusion of such Exploratory Study in the Development Plan, then Innate
may perform such Exploratory Study at its Cost (subject to Section&nbsp;4.7), but only if the criteria set out in (a)&nbsp;to (c) below are satisfied (otherwise, Innate may not </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
perform such Exploratory Study): </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">[***]; and </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">[***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Notwithstanding the foregoing, clauses (a)&nbsp;to (c) shall not apply with respect to any Exploratory Study to be conducted by Innate
on a CD39/[***] Combination Product, provided that, [***]. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall use Commercially Reasonable Efforts to provide to Innate, upon Innate&#146;s reasonable request
(including reasonable manufacturing timelines) at Cost payable by Innate, and in a reasonably timely manner so as not to delay the filing of any IND/CTA or any other Regulatory Approval: </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">quantities of the CD39 Lead or other CD39 Option Product as might be required to conduct each Exploratory Study,
subject to MedImmune&#146;s then-current stock of such CD39 Option Product, its manufacturing capacity, and its obligations under Section&nbsp;5.3(a); and </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">a complete data package with respect to CMC as is required to enable </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Innate to make the relevant submission for each IND/CTA or any other Regulatory
Approval for such Exploratory Study. Provision of such data package may be in a form or method as enables MedImmune to retain its confidentiality in the MedImmune Manufacturing Information. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If a Phase 3 Clinical Trial is initiated by or on behalf of MedImmune or its Affiliates and: </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; and </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify">then MedImmune shall reimburse to Innate the reasonable and documented Costs of such Exploratory Study undertaken by Innate together
with an additional amount equal to [***] of such reasonable and documented Costs, such additional [***] being a premium reflecting the risk undertaken by Innate in conducting such Exploratory Study. Such Costs and premium shall be Payments, payable
in accordance with Section&nbsp;8 and shall be paid no later than the date of recruitment of the first Subject into such Phase 3 Clinical Trial initiated by or on behalf of MedImmune or its Affiliates. For the avoidance of doubt, any such payment
shall be in addition to any other Payment hereunder or in the License Agreement, including any milestone payments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B><U>Exercising
the CD39 Option</U> </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune may exercise the CD39 Option by giving Innate written notice that it is
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">exercising the CD39 Option (&#147;<B>CD39 Option Notice</B>&#148;) at any time within
the CD39 Option Period. No later than [***] prior to the expected expiry of the CD39 Option Period (if the CD39 Option Notice has not been given), Innate shall notify MedImmune of such occurrence through the Option Committee, and the Parties shall
discuss MedImmune&#146;s intention to exercise or not to exercise the CD39 Option. Innate will provide to MedImmune an updated set of Schedules (including disclosure Schedules with respect to Innate&#146;s representations and warranties) in the
License Agreement. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Upon Innate&#146;s receipt within the CD39 Option Period of a CD39 Option Notice, the License Agreement shall,
automatically and without any further measures having to be taken by either Party, enter into force in accordance with its terms. The Parties shall cooperate in good faith to prepare as promptly as possible after the effective date of the License
Agreement all filings and other actions required by Applicable Laws to be made and taken in order to continue to conduct the Development of CD39 Option Products. All such filings and actions shall be approved in advance by MedImmune and be made and
taken by or on behalf of MedImmune. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Upon valid exercise of the CD39 Option, MedImmune may assume from Innate the right to lead and conduct such ongoing
early-stage Development activities as Innate may have been conducting prior to exercise of the CD39 Option. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Upon valid exercise of the CD39 Option, MedImmune will assume responsibility from Innate to undertake all late-stage
development activities (which shall include sponsorship of all Phase 3 Clinical Trials), as set out in and subject to the terms of the License Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; text-indent:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B><U>Lapse of the CD39 Option</U> </B></P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If: (a)&nbsp;MedImmune has not on or prior to the expiry of the CD39 Option Period furnished Innate with a CD39 Option
Notice; or (b)&nbsp;either Party terminates this Agreement pursuant to Sections 16.2 to 16.4, then the CD39 Option shall terminate and the CD39 Option shall lapse, and shall have no force or effect, and the consequences set forth in Section&nbsp;17
applicable to such expiry or termination (as </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">applicable) shall apply. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Upon the termination of the CD39 Option pursuant to Section&nbsp;4.12, if Innate subsequently Develops, commercialises
or otherwise Exploits any CD39 Option Product or any product developed using or otherwise incorporating any Collaboration IP or Study Results (each, an &#147;<B>Innate Licensed Product</B>&#148;), then Innate shall pay to MedImmune the payments
calculated in accordance with <U>Schedule 4.13 </U>with respect to such Innate Licensed Product, up to a maximum amount equal to [***] of the aggregate of: [***] (the &#147;<B>Total Reimbursement Amount</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Upon the expiry or termination of the CD39 Option pursuant to Section&nbsp;4.12 MedImmune shall grant to Innate:
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty free, fully paid up (subject to Section&nbsp;4.15)
worldwide licence, with the right to sublicense through multiple tiers, under MedImmune&#146;s interest in the Joint Collaboration IP to research, Develop, manufacture, commercialise and otherwise Exploit any product; and </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">a royalty free, fully paid up (subject to Section&nbsp;4.15) worldwide licence, with the right to sublicense through
multiple tiers, under the MedImmune Collaboration IP (excluding any MedImmune Collaboration IP claiming or related to any CD39 <FONT STYLE="white-space:nowrap">Bi-Specific</FONT> Molecule or CD39 [***] Combo) and the MedImmune Study Results
(excluding the Study Results with respect to any CD39 <FONT STYLE="white-space:nowrap">Bi-Specific</FONT> Molecule or CD39 [***] Combo), to research, Develop, manufacture, commercialise and otherwise Exploit any CD39 Option Product, such licence
shall be exclusive with respect to any MedImmune Collaboration IP that claims the CD39 Option Products existing as of the date the termination of the CD39 Option and such licence shall be <FONT STYLE="white-space:nowrap">non-exclusive</FONT> with
respect to any other MedImmune Collaboration IP. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Upon the termination of the CD39 Option pursuant to Section&nbsp;4.12, if Innate wishes to acquire a licence under any
MedImmune Collaboration IP claiming any CD39 <FONT STYLE="white-space:nowrap">Bi-</FONT> Specific Molecule or [***] Combo or any MedImmune Study Results with respect to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
any CD39 <FONT STYLE="white-space:nowrap">Bi-Specific</FONT> Molecule or CD39-[***] Combo, Innate may notify MedImmune of such wish. If MedImmune wishes to grant to Innate such licence, the
Parties shall negotiate in good faith a licence under such Collaboration IP or Study Results, which shall include any financial terms. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>DEVELOPMENT PLAN AND REPORTING </B></P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Within [***] of the Effective Date, the OC will meet to discuss and agree on an initial version of the Development
Plan and the Collaboration Budget, recognising that in so doing, the ultimate purpose is to design a plan that gives the Parties the best opportunity to achieve the Objectives. The Development Plan shall specify which of the Parties shall be the
sponsor of each of the Collaboration Studies, and that Party&#146;s responsibilities will include compliance with all obligations imposed on study sponsors under Applicable Law. The Collaboration Budget shall be broken down by agreed activities in
applicable areas, including research, preclinical activities, Clinical Trials, pharmacovigilance or other activities. The Development Plan will include, among other things, (i)&nbsp;the initial indication(s) for which the CD39 Option Product is
planned to be Developed, (ii)&nbsp;other indications for which the CD39 Option Product may be developed, (iii)&nbsp;the proposed overall program of Development for the CD39 Option Product for any indications elected by MedImmune, including without
limitation all material nonclinical studies, toxicology, pharmacology studies, formulation, process development, CMC, clinical studies, and regulatory plans, (iv)&nbsp;critical activities anticipated to be undertaken, estimated timelines, decision
points and relevant decision criteria, and (v)&nbsp;allocation of responsibilities between the Parties for the various activities to be undertaken under the Development Plan and estimated timelines; all based on what can reasonably be foreseen and
planned at the time of preparation of the Development Plan. MedImmune shall review and submit an updated Development Plan and Collaboration Budget to the OC for approval at least </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
annually during the term of this Agreement. Each Party shall use Commercially Reasonable Efforts to perform the Collaboration Studies outlined in, and other activities (including any
Manufacturing and technology transfer activities) contemplated in, the Development Plan and assigned to such Party in the Development Plan, such performance shall be in accordance with: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">this Agreement, </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">the applicable Collaboration Study Protocols, </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">all Applicable Law; and </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">the Development Plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Without limiting the foregoing, each Party shall obtain and maintain all permissions, consents, licences and patient consents required
for the performance of its obligations under this Agreement, including the Collaboration Studies assigned to such Party under the Development Plan. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Without limiting Section&nbsp;5.1, each Party shall, with respect to Collaboration Studies assigned to it under the
Development Plan shall: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">perform, or cause to be performed, such Collaboration Studies in good scientific manner and in compliance with all
Applicable Law, as well as any condition required by a Regulatory Health Authority or an IEC; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">use Commercially Reasonable Efforts to complete such Collaboration Studies (meaning delivery of all final reports with
respect to such Collaboration Studies) within the timescales specified in the applicable Collaboration Study Protocols and the Development Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">cause the Principal Investigator and the Study Site Staff to conduct such Collaboration Studies in accordance with the
provisions set out above in this Section&nbsp;5. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
In relation to Collaboration Studies assigned to a Party under the Development Plan for which there is no detailed Collaboration Study Protocol as at the Effective Date of this Agreement or
Collaboration Studies that are conceived after the Effective Date of this Agreement, such Party shall produce Collaboration Study Protocols for such Collaboration Study, as soon as reasonably practicable after the Effective Date of this Agreement or
conception of those Collaboration Studies, respectively and provide them to the OC for review. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Medimmune shall: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">use Commercially Reasonable Efforts to provide, at its own cost, such GMP quantities of CD39 Lead as are specified in
the Collaboration Study Protocols or otherwise required for the conduct of the Collaboration Studies and the Development Plan. Without limiting the foregoing, MedImmune shall provide a near-term manufacturing slot for CD39 Lead to enable supplies of
the CD39 Lead to be Manufactured to the Specification for the purposes of GLP toxicology studies and Phase 1 Clinical Trials in accordance with the Development Plan; and </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">use Commercially Reasonable Efforts to conduct the activities assigned to MedImmune in the Development Plan, including
any Collaboration Studies assigned to MedImmune and any CMC activities as might be specified therein. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Promptly upon MedImmune&#146;s request, the Parties shall negotiate in good faith a separate quality assurance
agreement (the &#147;<B>QAA</B>&#148;) that shall define the manufacturing and supply quality responsibilities of the Parties. The QAA shall further include provisions obligating the supplying Party to report to the other any regulatory compliance
issues with its suppliers as well as any critical quality <FONT STYLE="white-space:nowrap">non-</FONT> conformances relating to the CD39 Option Product (or MedImmune Product, as applicable). </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If any Innate Collaboration Study involves the use of any MedImmune Product, the Parties shall negotiate in good faith
a clinical supply agreement providing for the supply of such MedImmune Product, which shall include terms with respect to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Intellectual Property Rights allocation and other customary terms with respect to clinical supply agreements of a similar nature. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party shall: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">obtain and maintain all filings and applications and all other actions required by Applicable Law to conduct the
Collaboration Studies (and the Exploratory Studies in the case of Innate); </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">procure that complete, current, accurate and legible Study Documentation is retained and stored in a manner consistent
with customary industry practices, for: (i)&nbsp;further Developing the CD39 Option Products, (ii)&nbsp;Patent purposes, and (iii)&nbsp;the collection of data for submission to, or review by, a Regulatory Health Authority, in full compliance with
the Collaboration Study Protocols and all Applicable Law and kept clearly separated from all records pertaining to other activities that may be carried out by or on behalf of such Party outside the scope of this Agreement. Without limiting clause
(d), except to the extent prohibited under Applicable Law, upon prior written request by MedImmune no more than twice per consecutive [***] period during the term of this Agreement, Innate shall make all Study Documentation available for
MedImmune&#146;s review pursuant to Section&nbsp;7 and for inspection, analysis and use by or on behalf of MedImmune during the term of this Agreement for the sole purpose of the Evaluation; </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">ensure that no such Study Documentation is destroyed without the prior written approval of the other Party;
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">if such Party is Innate, with respect to all Collaboration Studies assigned to Innate and all Exploratory Studies:
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">promptly provide the OC (and, in the case of Exploratory Studies, MedImmune) with copies of all relevant study
documents including protocol, annotated Case Report Forms (&#147;<B>CRFs</B>&#148;), database structure, coding dictionaries related information, Data Validation </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Plan, Statistical Analysis Plan, mock Tables, Figures, Listings (&#147;<B>TFL</B>&#148;) shells, Study Data Tabulation Model (&#147;<B>SDTM</B>&#148;) and Analysis Data Model
(&#147;<B>ADaM</B>&#148;) data specifications, existing standards (for CRFs, data, TFLs, programs, operating procedures). Innate shall retransfer any components if and when they undergo amendments; </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">promptly provide the OC (and, in the case of Exploratory Studies, MedImmune) with copies of all Dose escalation
committee (or any other study safety committee) reports, minutes and review materials including raw data snapshot, SDTM, ADaM, TFL and programs within [***] of the relevant committee meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">in addition to the review packages for planned periodic committee reviews, procure for regular data transfers after
first two dose escalations and then quarterly thereafter of all clinical and available biomarker data from such Collaboration Studies or Exploratory Studies which are ongoing, such data to include raw data, SDTM and Adam. In addition, Innate shall
enable <FONT STYLE="white-space:nowrap">ad-hoc</FONT> data transfer upon request from MedImmune; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">transfer all data and documents described in this clause (d)&nbsp;through a secure portal which is jointly established by
the Parties (eg: sFTP or BOX); </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left">provide to the OC a quarterly report summarising all adverse drug reaction experiences related to CD39 Option Products as
required to be reported to the appropriate Regulatory Health Authorities in the countries in which such trials are being conducted in accordance with the Applicable Law; and </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">if such Party is MedImmune, provide to Innate monthly clinical summary reports including efficacy and safety data.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party shall provide the other Party with (i)&nbsp;drafts and final versions of all top line data and other
reports obtained in each of the Collaboration Studies assigned </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
to it (as such data may be specified in the Development Plan or the relevant Collaboration Study Protocol) within [***] after its receipt thereof from a CRO or such time when such drafts and
reports otherwise become available to such Party; (ii)&nbsp;a draft of each Collaboration Study Preliminary Report within [***] after its receipt of such draft from a CRO or such time when such draft otherwise becomes available to such Party; and
(iii)&nbsp;the relevant Collaboration Study Preliminary Report within [***] after availability of the Primary End Point Results. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left"><B>INNATE DEVELOPMENT COSTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party acknowledges and agrees that MedImmune shall reimburse Innate any Costs incurred by Innate: (a)&nbsp;in
accordance with the Collaboration Budget (subject to Section&nbsp;6.3) and (b)&nbsp;in the performance of the Development activities (which are assigned to Innate under the Development Plan) in accordance with this Agreement (the &#147;<B>Innate
Development Costs</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Within [***] after the end of each Calendar Quarter, Innate shall provide MedImmune with detailed, itemized accounting
of the Innate Development Costs incurred by Innate during such Calendar Quarter, which report shall be itemized on a CD39 Option <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-CD39</FONT></FONT> Option Product basis, in
such other form as the Parties may mutually agree from time to time. For clarity, for calculation of Costs pursuant to this Section&nbsp;6 with respect to any activity performed by a CRO, the Costs shall be the actual costs charged to Innate by such
Third Party, with no additional <FONT STYLE="white-space:nowrap">mark-up.</FONT> For the avoidance of doubt, subject to Section&nbsp;8, income and withholding taxes imposed on Innate hereunder shall not be included as part of such Costs.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Overruns. Innate shall promptly notify MedImmune upon becoming aware that the anticipated Innate Development Costs to
be incurred by Innate for a given Calendar Year are likely to exceed the Collaboration Budget for such Calendar Year. The aggregate amount of any Innate Development Costs reported by Innate pursuant to this Section&nbsp;6 with respect to a Calendar
Year, which exceed [***] of the aggregate amounts budgeted to be incurred by or on behalf of such Party for its activities under the Development Plan in such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Calendar Year in the Collaboration Budget (&#147;<B>Excess Costs</B>&#148;), will not be included in the calculation of the Innate Development Costs for the purposes of this Section&nbsp;6 and
MedImmune shall have no responsibility for such Excess Costs, provided, that a given Excess Cost will be included: (a)&nbsp;to the extent such Excess Cost is or was attributable to: (i)&nbsp;a change in Applicable Law; (ii)&nbsp;a Force Majeure
event; (ii) variation in actual patient enrolment from projected patient enrolment not caused by the default of Innate; or (b)&nbsp;to the extent such Excess Cost is otherwise not incurred as a result of Innate&#146;s failure to perform its
obligations under the Development Plan in accordance with the Innate Standards. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Reconciliation Discussion. In the event MedImmune has any questions or concerns regarding the Innate Development Costs
reported by Innate pursuant to this Section&nbsp;6, MedImmune shall promptly notify Innate with respect thereto and the Parties shall work together in good faith, to resolve such questions and concerns within [***] after the end of each Calendar
Quarter. In the event that MedImmune disagrees with, or identifies a discrepancy in, the Innate Development Costs submitted by Innate and the disagreement or discrepancy cannot be resolved or rectified between the Parties within a period of [***] of
the matter being first raised by a Party, either Party may appoint an independent, internationally recognised accountant to review the alleged discrepancy. The costs of carrying out such review shall be borne by the Party requesting it unless the
accountant finds a discrepancy which is greater than [***], in which case Innate shall bear the costs. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><FONT STYLE="white-space:nowrap">True-up.</FONT> Within [***] after the end of each Calendar Quarter, Innate shall
deliver to MedImmune an invoice for amounts to be reimbursed by MedImmune, and MedImmune shall pay for amounts set out in such invoice to the extent validly issued, within [***] after its receipt of such invoice. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>AUDIT AND REVIEW RIGHTS, OPTION COMMITTEE </B></P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">During the term of this Agreement, Innate shall ensure that MedImmune or its authorized representatives are entitled,
during regular business hours, with reasonable prior written notice and no more than once in any given year during the term of this Agreement (provided that MedImmune shall be entitled to audit more
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
frequently if any material areas of concern, in MedImmune&#146;s reasonable judgment, are discovered as a result of an annual audit or otherwise) to (a)&nbsp;inspect the premises where any part
of the Collaboration Studies assigned to Innate under the Development Plan is being, will be or has been conducted, (b)&nbsp;review all Study Documentation and any other books, records and data relating to a Collaboration Study (unless to the extent
prohibited by mandatory Applicable Law regarding personal data, biological samples or similar), and (c)&nbsp;interview the Principal Investigator and the Study Site Staff of Innate-sponsored studies in the presence of Innate&#146;s representatives.
Innate shall, and shall cause the Principal Investigator and the Study Site Staff to, cooperate with any such activities. Innate shall (unless to the extent prohibited by mandatory Applicable Law) promptly inform MedImmune of any inspections and the
like by authorities that may affect or relate to a Collaboration Study and shall provide MedImmune with a copy of any reports from such inspections. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Without prejudice to the foregoing, Innate shall, during the term of this Agreement and at MedImmune&#146;s reasonable
request, assist MedImmune as necessary to enable MedImmune to evaluate the outcome of each of the Collaboration Studies. Such assistance shall include providing MedImmune with all reasonable and material information in Innate&#146;s possession or
control (including for the avoidance of doubt any information in its Affiliate&#146;s or a CRO&#146;s possession) relating to each Collaboration Study. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">With effect from the Effective Date the Parties shall establish a committee (the &#147;<B>Option Committee</B>&#148;
or &#147;<B>OC</B>&#148;) to have oversight of the CD39 Program, to provide a forum to facilitate communication between the Parties and to enable Innate to provide to MedImmune certain information in respect of the initiation, conduct and completion
of the Collaboration Studies for the purposes of MedImmune&#146;s Evaluation with respect to the CD39 Program. The OC shall consist of six (6)&nbsp;members with equal numbers appointed by each Party (it being understood that a Party may appoint an
employee of its Affiliate to act as such Party&#146;s representative on the OC). The OC members appointed by each Party shall have the requisite experience. Each Party may replace its members of the OC upon written notice to the other Party,
provided that any such substitute member shall have substantially the equivalent experience as the member that such person replaces. The chairman </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
of the OC shall be one of Innate&#146;s members of the OC. The OC, will have the following responsibilities: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">review and approve proposed actions related to any Material Issues; </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">review and approve the Collaboration Study Protocols and the Development Plan and the Collaboration Budget, and any
amendment thereto. Should MedImmune propose any variation to the Development Plan, that proposed variation and any consequent change to the budget, shall be presented to the OC by MedImmune and discussed by the OC; </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">discussing progress under the Development Plan, including the review of emerging clinical and biomarker data from the
Collaboration Studies, review of progress toward timelines and budget; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">discussing publication plan and draft scientific publications; </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">review and approve any proposal to commence any new clinical study with any CD39 Option Product;
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">review and approve any <FONT STYLE="white-space:nowrap">pre-clinical</FONT> activities to be performed by Innate under
the Development Plan; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">review and approve the appointment or replacement of the Principal Investigator(s); </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">review and make recommendations with respect to the overall performance of the Collaboration Studies, including the
quality and timeliness of data transfers from such Collaboration Studies; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">review and approve the scope and content of Study Documentation with respect to the Collaboration Studies and the
Collaboration Study Preliminary Reports; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">review and make recommendations with respect to the conduct of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Manufacturing activities by MedImmune; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">review and approve whether either Party shall terminate a Collaboration Study; and </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">review and approve any <FONT STYLE="white-space:nowrap">non-clinical</FONT> toxicology activities to be performed by
Innate with respect to CD39 Option Products, </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">provided that, in the case of (b), (c), (e), (h), (i) and (k),
excluding any [***] Study or the Study Documentation, Collaboration Study Preliminary Reports with respect to any CD39 [***] Study (as applicable). </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Any decision within OC&#146;s authority shall be made only by unanimous consent, with the MedImmune voting members
cumulatively having one (1)&nbsp;vote and the Innate voting members cumulatively having one (1)&nbsp;vote, irrespective of the number of members actually in attendance at a meeting. In the event that unanimity cannot be reached by the OC on a matter
before it for decision within [***] after the matter was first considered by it then the matter may be referred by either Party to the Senior Executives, who shall meet (in person, via internet, telephonically or by videoconference) and attempt to
resolve the matter within [***] of such referral. In the event that the Senior Executives are unable to reach consensus within such [***] period: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***] </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding anything to the contrary set forth in this Agreement, the OC will have no authority to (a)&nbsp;amend,
modify or waive compliance with this Agreement or otherwise impose any obligation on the Parties in deviation from this Agreement, or (b)&nbsp;resolve any dispute concerning the validity, compliance with, or breach of, this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Meetings with the OC shall be held once every [***] with at least one (1)&nbsp;meeting a
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
year being <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face</FONT></FONT> and other meetings being held by video or telephone conferences or in person and more
frequently when required at such dates and times as will be mutually agreed upon by the OC. A quorum of the OC shall require the attendance of at least two of each Party&#146;s members of the OC. OC members may be represented at any meeting by
another person designated in writing by the absent OC member. The venue for meetings of the OC shall, when held in person, alternate between the premises of the Parties. Each Party shall bear the costs associated with the activities of its members
of the OC. The OC shall be dissolved upon the termination of this Agreement, unless extended or earlier dissolved by mutual agreement of the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">For the avoidance of doubt, each Party shall have sole decision making for any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">matters relating to the conduct of the activities under the Development Plan assigned
to such Party that do not fall within the approval authority of the OC, including any matters with respect to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of such Party with respect to
such activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provision in this Agreement, in no event shall either Party
be obligated to disclose to the other Party any information with respect to any CD39 [***] Combo or CD39 [***] Bispecific being Developed by or on behalf of such Party, or any CD39 [***] Studies being performed by or on behalf of such Party, save
for such information which is: (a)&nbsp;necessary for the other Party to comply with its regulatory or pharmacovigilance obligations under Applicable Law, or (b)&nbsp;disclosed under any CD39 [***] Plan under Section&nbsp;4.5. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="left"><B>PAYMENTS AND TAXES </B></P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Any amount payable by MedImmune to Innate in accordance with this Agreement (&#147;<B>Payments</B>&#148;) shall,
unless specified otherwise, be made by bank transfer in immediately available funds to Innate&#146;s nominated bank account, within [***] of the receipt of a validly issued invoice from Innate (unless otherwise specified in this Agreement). Innate
shall provide to MedImmune its bank details, i.e. bank number and bank code and SWIFT-address, to which all Payments are to be made. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Payments made by MedImmune to Innate pursuant to this Agreement shall [***] (and that, if applicable, all governmental
authorisations that are required to be received by the appropriate Party have been so received) at least [***] prior to the time that the Payments are due. If MedImmune [***]. This Agreement being entered into between a French resident entity and a
UK resident entity within the meaning of Article 4 of the France &#150; UK Double Tax Treaty, the Parties acknowledge and agree in accordance with the Applicable Laws as of the Effective Date, no withholding tax shall apply to the Payments. If, in
accordance with the foregoing, [***]. In the event that (i)&nbsp;MedImmune assigns or otherwise transfers its rights or obligations under this Agreement to [***], then MedImmune procures that [***], provided that [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding anything contained in Sections 8.1 and 8.2 the following shall
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
apply with respect to Indirect Taxes. All amounts expressed to be payable under this Agreement (including any Payments) by any Party to this Agreement which (in whole or in part) constitute the
consideration for any supply for Indirect Tax purposes are deemed to be exclusive of any Indirect Tax which is chargeable on that supply, and accordingly, if any Indirect Tax is or becomes chargeable on any supply made by any Party to this Agreement
(the &#147;<B>Supplier</B>&#148;) and the Supplier or an Affiliate of the Supplier is required to account to the relevant Governmental Body for the Indirect Tax, the Party receiving such chargeable supply (the &#147;<B>Recipient</B>&#148;) shall pay
to the Supplier (in addition to and at the same time as paying any other consideration for such supply, or [***] after the receipt by the Recipient of an appropriate invoice in respect of such Indirect Tax) an amount equal to the amount of the
Indirect Tax. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties shall issue invoices for any payment due under this Agreement consistent with Indirect Tax requirements.
In this respect, the Parties shall cooperate and provides information or assistance as may be necessary to enable to issuance of such invoices consistent with Indirect Tax requirements. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>REGULATORY </B></P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Clinical Study Regulatory Activities. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall have the sole right to, and shall use Commercially Reasonable Efforts to: (i)&nbsp;prepare, obtain and
maintain any IND/CTA/Regulatory Approvals necessary to conduct any Collaboration Study for which MedImmune is the sponsor or is the Party contracting with a CRO to conduct any Collaboration Study (such Collaboration Studies, the &#147;<B>MedImmune
Collaboration Studies</B>&#148;), each of which shall be a new, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
separate IND/CTA/Regulatory Approval, and (ii)&nbsp;to conduct communications with the Regulatory Health Authorities with respect thereto, including any
<FONT STYLE="white-space:nowrap">pre-IND/CTA</FONT> meeting, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-phase</FONT></FONT> 1 meeting,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-phase</FONT></FONT> 2 meeting or <FONT STYLE="white-space:nowrap">pre-phase</FONT> 3 meeting with the FDA in the United States or any corresponding meetings with Regulatory
Health Authorities outside the United States. MedImmune shall constitute the Lead Regulatory Party with respect to each MedImmune Collaboration Study. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall have the sole right to, and shall use Commercially Reasonable Efforts to, (i)&nbsp;prepare, obtain and
maintain any IND/CTA/Regulatory Approvals necessary to conduct any Collaboration Study for which Innate is the sponsor or is the Party contracting with a CRO to conduct any Collaboration Study (such Collaboration Studies, the &#147;<B>Innate
Collaboration Studies</B>&#148;), each of which shall be a new, separate IND/CTA/Regulatory Approval, and (ii)&nbsp;conduct communications with the Regulatory Health Authorities with respect thereto, including any
<FONT STYLE="white-space:nowrap">pre-IND/CTA</FONT> meeting, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-phase</FONT></FONT> 1 meeting,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-phase</FONT></FONT> 2 meeting, <FONT STYLE="white-space:nowrap">pre-phase</FONT> 3 meeting or any corresponding meetings with Regulatory Health Authorities. Innate shall
constitute the Lead Regulatory Party with respect to each Innate Collaboration Study. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Regulatory Approvals and Submissions. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Lead Regulatory Party with respect to each IND/CTA or any other Regulatory Approval in respect of a Collaboration
Study shall provide for OC&#146;s review and approval copies of all major regulatory filings and documents related to any IND/CTA or any other Regulatory Approval for which such Lead Regulatory Party is responsible. No Lead Regulatory Party shall
file any such regulatory filings or documents with the applicable Regulatory Health Authority unless and until approved by the OC. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall provide to Innate, in a timely manner so as not to delay the filing of any IND/CTA or any other
Regulatory Approval, a complete data package with respect to CMC as is required to enable Innate, as Lead Regulatory Party, to make the relevant submission for each IND/CTA or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
any other Regulatory Approval. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Except to the extent prohibited by Applicable Law, all Regulatory Documentation (including all Regulatory Approvals)
relating to a Collaboration Study developed or granted after the Effective Date shall be owned by, and be the sole property and held in the name of, the applicable Lead Regulatory Party (or its designee with respect thereto). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:7%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Provided that, in each case (a)&nbsp;to (c), provision of such filings, data package or documents (as applicable) by MedImmune may be in
a form or method as enables MedImmune to retain its confidentiality in the MedImmune Manufacturing Information or with respect to any MedImmune Product. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Communications with Regulatory Health Authorities. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Lead Regulatory Party with respect to each IND or any other Regulatory Approval in respect of a Collaboration
Study shall coordinate in good faith with the other Party with respect to scheduling all meetings, conferences or discussions (whether <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face</FONT></FONT> or teleconference and
including any meeting of experts convened by a Regulatory Health Authority) scheduled with a Regulatory Health Authority concerning any IND or any other Regulatory Approval in the Territory for which such Lead Regulatory Party is responsible and
shall promptly (within [***]) notify the other Party of the scheduling of such meeting, conference or discussion and provide the other Party advance copies of all related documents and other relevant information relating to such meetings or other
contacts. Such other Party shall have the right to have reasonable representation present at and to participate in any such meetings, conferences and discussions. The Lead Regulatory Party shall use good faith efforts to provide the other Party with
an opportunity to be present at and participate in, to the extent practical, any unscheduled or <FONT STYLE="white-space:nowrap">ad-hoc</FONT> meetings, conferences or discussions with any Regulatory Health Authority concerning any IND or any other
Regulatory Approval in the countries in the Territory for which such Lead Regulatory Party is responsible. Notwithstanding the foregoing, at any meeting, conference or discussion </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
with, or in any communication to, the Regulatory Health Authorities in the countries in the Territory concerning a Collaboration Study at which MedImmune and Innate are present or in which both
Parties participate, MedImmune shall take the lead on matters relating to the CMC data with respect to any CD39 Option Product and at any such meeting, conference or discussion with, or in any such communication to, such Regulatory Health
Authorities concerning a CD39 Option Product at which MedImmune is not present or does not participate, Innate shall not engage in any substantive discussions pertaining to the CMC data with respect to any CD39 Option Product, including making any
commitments with respect thereto. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Lead Regulatory Party shall promptly provide the other Party with: (i)&nbsp;&nbsp;copies of all regulatory
correspondence to or from the Regulatory Health Authorities relating to any IND, or any other Regulatory Approval for which such Lead Regulatory Party is responsible; provided that in no event shall MedImmune be obligated to disclose any MedImmune
Manufacturing Information to Innate or any of its Affiliates and (ii)&nbsp;notices of any revocations of any IND or any other Regulatory Approval for which such Lead Regulatory Party is responsible. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding the foregoing, clauses (a)&nbsp;and (b) above shall not apply with respect to any IND or Regulatory
Approval in respect of any CD39 [***] Studies (and any meetings, conferences and discussions scheduled with, or other communications with, a Regulatory Health Authority with respect thereto). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Recalls, Suspensions or Withdrawals. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party shall notify the other Party promptly (but in no event later than [***]) following its determination that
any event, incident or circumstance has occurred that may result in the need for a recall, market suspension or market withdrawal (each, a &#147;<B>Recall</B>&#148;) of the applicable product controlled by such Party in the Territory (in the case of
Innate, any CD39 Option Product, and in the case of MedImmune, any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
MedImmune Product), and shall include in such notice the reasoning behind such determination and any supporting facts. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">As between the Parties, each Party shall have the sole responsibility and right to (i)&nbsp;determine if any Recall is
necessary with respect to any such Party&#146;s proprietary product in the Territory (in the case of MedImmune, including any MedImmune Product), and (ii)&nbsp;initiate, undertake, execute and implement such Recall; provided that prior to any final
determination or implementation of such a Recall, MedImmune or Innate, as applicable, shall, to the extent practicable under the circumstances, consult with the other Party and shall consider its comments in good faith. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">As between the Parties, the Party undertaking any Recall pursuant to this Section&nbsp;9.4 shall be solely responsible
for the execution and implementation thereof, shall bear all costs and expenses associated therewith. The other Party shall reasonably cooperate with the Party responsible for any Recall. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Pharmacovigilance </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties will execute a Pharmacovigilance Agreement, as soon as practical following the Effective Date of this
Agreement, which will govern the procedure for the mutual exchange of safety information within appropriate timeframes and in an appropriate format to enable the Parties to comply with the terms of this Agreement, and with any local and
international regulatory reporting obligations and to facilitate appropriate safety reviews. The Parties agree to use any such pharmacovigilance information provided by the other Party pursuant to this Agreement solely to conduct the CD39 Program
and evaluate the safety of the CD39 Option Product. Sponsor shall be responsible for all safety reporting requirements (submission of all SUSARs from the Study to the Regulatory Health Authorities where the Collaboration Study is conducted and to
the investigators in the Collaboration Study) in accordance with Applicable Law. For all other required safety reporting, such as cross reporting where applicable by Applicable Law) Innate shall be responsible for reporting to </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Innate IND/CTAs and MedImmune shall be responsible for reporting to MedImmune IND/CTA/NDA/MAH. Each Party shall promptly report to the other Party safety information which could impact the
Collaboration Study subjects safety or the conduct of the Collaboration Study or would otherwise necessitate amendments to the Collaboration Study protocol that are required to be implemented by Regulatory Health Authorities, or are implemented by
the respective Party, in each case where, in particular because of their severity, frequency or lack of reversibility, and which a Party would reasonably need to know such safety information in order to ensure patient safety and prevent unreasonable
risks in the conduct of the Collaboration Study. All such disclosures under this Section&nbsp;9.5 are Confidential Information of the Party disclosing same. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. AstraZeneca pharmacovigilance standards will be followed for any combination use trials that include a
MedImmune Product. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune may share any of the following materials or information with any of its Affiliates which may include
information containing combination use with a CD39 Option Product: </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">any materials or information provided to MedImmune or any of its Affiliates by or on behalf of Innate or any of its
Affiliates in accordance with this Section&nbsp;9.5 or under the Pharmacovigilance Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">any other materials or information provided to Medimmune or any of its Affiliates by or on behalf of Innate or any of
its Affiliates under this Agreement in respect of any actual or alleged defect in the CD39 Option Product, including (i)&nbsp;any injury alleged to have occurred as a result from the use or application of the CD39 Option Product, (ii)&nbsp;any facts
or circumstances that may give rise to any obligation or liability in respect of the CD39 Option Product, or (iii)&nbsp;a recall or market withdrawal or any regulatory action with respect to the CD39 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">Option</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Product. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The decision to initiate a recall of MedImmune Product will be the sole responsibility of and at the sole cost of
MedImmune. At MedImmune&#146;s request, Innate shall provide any reasonable assistance to MedImmune, at MedImmune&#146;s cost, for the recall of a MedImmune Product. Recalls will proceed in accordance with any clinical quality agreement entered into
between the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If, in the reasonable opinion of Innate, a Safety or Regulatory Issue occurs prior to or during the conduct of the
Innate Collaboration Studies, Innate shall promptly notify MedImmune thereof in writing (&#147;<B>S/R Notice</B>&#148;) and take such appropriate actions as may be required to protect the health, safety or well-being of any Subject. The S/R Notice
shall include a reasonably detailed description of the Safety or Regulatory Issue. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties shall promptly upon MedImmune&#146;s receipt of an S/R Notice meet to discuss an appropriate course of
action in good faith, including whether or not further Collaboration Studies can or should be initiated or, as the case may be, whether any or all of the Collaboration Studies should be discontinued. With respect to any and all matters pertaining to
pharmacovigilance assessments or statements on the MedImmune Product, including combination use statements, Innate shall discuss with MedImmune to agree conclusions. Should the Parties disagree, [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>DATA PROTECTION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">MedImmune and Innate agree that they shall comply with their obligations under applicable Data Protection Law in connection with their
respective activities under this Agreement. Accordingly, the Parties shall, as soon as reasonably practicable after the date of this Agreement, and in any event before any Personal Data is Processed or transferred under or pursuant to this
agreement, agree the terms of a data sharing and transfer agreement between them. Such agreement shall contain usual and customary terms for an agreement of that nature. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>CONFIDENTIALITY </B></P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">At all times during the term of this Agreement and for a period of [***] following termination or expiration thereof,
each Party (the &#147;<B>Receiving Party</B>&#148;) shall (i)&nbsp;keep confidential and not disclose to any Third Party, other than its and its Affiliates&#146; officers, directors, other employees, contractors and advisors on a need to know basis,
any Confidential Information provided to it by the other Party (the &#147;<B>Disclosing Party</B>&#148;) and (ii)&nbsp;not publish or otherwise use, directly or indirectly, for any purpose, such Confidential Information, except to the extent
permitted by the terms of this Agreement or to the extent such use is necessary for the fulfilment of the Receiving Party&#146;s obligations under this Agreement. The Receiving Party shall cause all of its and its Affiliates&#146; officers,
directors, other employees, contractors and advisors to whom the Receiving Party has disclosed Confidential Information to comply with confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations at least as restrictive as those
set out in this Agreement and shall be liable to the Disclosing Party for any breach thereof by such Affiliates, officers, directors, other employees, contractors and advisors. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> in Sections 11.1 and the
obligations set forth in Section&nbsp;11.5 shall not extend to any Confidential Information that: (a)&nbsp;is or comes into the public domain without breach of this Agreement, (b)&nbsp;is received by the Receiving Party from a Third Party (other
than an Affiliate of the Disclosing Party) without any obligation of confidentiality and without breach of this Agreement, or (c)&nbsp;the Receiving Party can prove was already in its possession without any limitation on use or disclosure prior to
the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding Section&nbsp;11.1, the Receiving Party shall be entitled to use and disclose Confidential Information
to the extent reasonably required for the Receiving Party&#146;s exercise of its rights granted to it and the performance of its obligations under this Agreement and the License Agreement. In addition each Party shall be entitled to disclose the
terms of this Agreement and the License Agreement on a confidential basis to actual or potential investors or in connection with any permitted assignment under this Agreement or in connection with any proposed grant of a <FONT
STYLE="white-space:nowrap">sub-license</FONT> by MedImmune as permitted by the License Agreement provided that in each case the Receiving Party shall cause any and all </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
parties to whom such disclosure is made to comply with confidentiality and <FONT STYLE="white-space:nowrap">non-</FONT> use obligations at least as restrictive as those set out in this Agreement
and shall be liable to the Disclosing Party for any breach thereof by such parties. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">This Agreement shall not restrict the Receiving Party from complying with a lawfully issued governmental order or
legal requirement or requirement under applicable stock exchange rules to produce or disclose Confidential Information; provided, however, that, in the event of governmental orders, the Receiving Party shall promptly notify the Disclosing Party to
enable the Disclosing Party to oppose the order or obtain a protective order and the Receiving Party shall cooperate fully with the Disclosing Party in any such proceeding. If the Receiving Party is legally required or required under applicable
stock exchange rules to disclose Confidential Information, the Receiving Party and the Disclosing Party will endeavour to agree to a mutually satisfactory means to disclose such information. Nothing contained herein shall prohibit either of the
Parties from immediately disclosing results of the Collaboration Studies to the extent necessary to prevent or mitigate a serious health hazard; provided, however, that the Party intending to make such disclosure shall notify the other Party prior
to and immediately after such disclosure and, to the extent it is reasonably practicable to do so, the nature and content of such disclosure shall be agreed between the Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Neither Party shall issue any other public announcement, press release or other public disclosure regarding this
Agreement or its terms without the other Party&#146;s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, provided that such consent cannot be withheld for public announcement, press release or other public
disclosure with respect to material development milestones achieved by the CD39 Option Product (such material development milestones being the start of GLP Toxicology studies and the start of any Clinical Trial), to the extent limited to, and
consistent with, publicly available information with respect to such Clinical Trial, if the form of announcement, press release or other publication with respect to such key development milestones is in a form reasonably agreed by MedImmune, and in
any event, except for any such disclosure that is, in the opinion of the disclosing Party&#146;s counsel, required by Applicable Law, the Listing Rules or any other rules of a stock exchange (including Paris Euronext) on which the securities of the
disclosing Party are listed (or to which </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
an application for listing has been submitted). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties acknowledge that scientific publications must be strictly monitored as the timing, nature and content of
publications, in particular premature publication of the Study Results, may materially affect the value of the CD39 Option Product. Accordingly and without prejudice to the confidentiality obligations set forth above in this Section&nbsp;11 (but
subject to Section&nbsp;11.4), if either Party wishes to publish or present (including in any clinical trial registries whether or not required by Applicable Law) or otherwise disclose any Study Results or other material related to the CD39 Option
Products then: </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">if such Party is MedImmune, MedImmune shall provide a draft of such publication, disclosure or presentation to Innate,
which will have [***] to provide comments. MedImmune shall, in good faith, consider the comments made by Innate, including any request to defer the publication or presentation for a period not exceeding [***] if a Patent may be filed using the <FONT
STYLE="white-space:nowrap">Know-How</FONT> covered in the proposed publication or communication; or </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">if such Party is Innate, Innate shall provide a copy of any such proposed publication, disclosure or presentation to
MedImmune at least [***] prior to the intended date of publication or presentation, for MedImmune&#146;s consent, which consent cannot be unreasonably withheld or delayed. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Notwithstanding the foregoing, Innate may publish any publications pursuant to manuscripts submitted prior to the Effective Date (as
contained in the Innate Data Room as of the Effective Date), provided that, Innate shall provide to MedImmune any revised drafts of such manuscripts and shall take into account MedImmune&#146;s comments with respect to such drafts in good faith. If
[***] or other Third Party notifies Innate that it wishes to publish or present any publication or presentation with respect to the CD39 Option Technology, Innate shall promptly notify MedImmune thereof (and shall provide a copy of such draft
publication or presentation to the extent available to Innate). Innate shall exercise any of its rights under the applicable agreement with such Third Party, in order to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">implement MedImmune&#146;s comments (including any requests to delay or withhold such
publication or presentation) to the fullest extent possible. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties acknowledge and agree that Innate&#146;s Background IP, the Innate Collaboration IP and the Innate Study
Results shall be deemed Innate&#146;s Confidential Information (and Innate shall be deemed to be the Disclosing Party and MedImmune the Receiving Party with respect to such Confidential Information). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties acknowledge and agree that the Joint Collaboration IP and the terms of this Agreement shall be deemed each
Party&#146;s Confidential Information (and each Party shall be deemed to be the Disclosing Party and also the Receiving Party with respect to such Confidential Information). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties acknowledge and agree that the MedImmune Manufacturing Information, MedImmune Collaboration IP and the
MedImmune Study Results shall be deemed MedImmune&#146;s Confidential Information (and MedImmune shall be deemed to be the Disclosing Party and Innate the Receiving Party with respect to such Confidential Information). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>INTELLECTUAL PROPERTY RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">During the term of this Agreement, each Party shall promptly disclose to the other Party all Intellectual Property
Rights arising and which is created by or on behalf of such Party as a result of carrying out the activities assigned to it under the Development Plan. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">As between the Parties, each Party shall retain and be the sole owner of all rights, title and interest in and to its
Background IP. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party acknowledges and agrees that: </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall own all right, title and interest in and to any: </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Collaboration IP generated solely by or on behalf of MedImmune; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">other Collaboration IP claiming or otherwise covering any CD39 [Adenosine Pathway] Combo or any CD39 <FONT
STYLE="white-space:nowrap">Bi-Specific</FONT> Molecule which is allocated for Development by MedImmune under the Development Plan, </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:14%; font-size:11pt; font-family:ARIAL" ALIGN="justify">together with the MedImmune Manufacturing IP, the &#147;<B>MedImmune Collaboration IP</B>&#148;; </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall own all right, title and interest in: </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">any Intellectual Property Rights arising from any Exploratory Study; </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Collaboration IP generated solely by or on behalf of Innate; and </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">other Collaboration IP claiming or otherwise covering any CD39 [***] Combo or any CD39
<FONT STYLE="white-space:nowrap">Bi-Specific</FONT> Molecule which is allocated for Development by Innate under the Development Plan, </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:14%; font-size:11pt; font-family:ARIAL" ALIGN="justify">(i) to (iii)&nbsp;together, the &#147;<B>Innate Collaboration IP</B>&#148;; and </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">each of MedImmune and Innate shall jointly own all right, title and interest in and to any Collaboration IP generated
jointly: (i)&nbsp;by or on behalf of MedImmune and (ii)&nbsp;by or on behalf of Innate, excluding any MedImmune Collaboration IP and Innate Collaboration IP (the &#147;<B>Joint Collaboration IP</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall retain and be the sole owner of all rights, title and interest in and to any and all Intellectual
Property Rights relating to MedImmune&#146;s manufacturing capabilities, as applicable (the &#147;<B>MedImmune Manufacturing IP</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune hereby grants to Innate a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> Right of Reference under the
MedImmune Study Results, and Innate hereby grants to MedImmune and its Affiliates a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right of reference under the Innate Study Results, in each case to the extent necessary or useful for the
Development of a CD39 Option Product during the CD39 Option Period. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party acknowledges and agrees that: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall own all right, title and interest in and to all Study Results of the Exploratory Studies and the Innate
Collaboration Studies (the <B>&#147;I</B><B>nnate Study Results</B><B>&#148;</B>); and </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall own all right, title and interest in and to all Study Results of the MedImmune Collaboration Studies
(the &#147;<B>MedImmune Study Results</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall procure that it shall have the right to grant to MedImmune the rights and licenses contemplated by the
License Agreement with respect to the Innate Study Results that are investigator sponsored studies subject in each case to the terms of any Third Party Agreement or other agreement with CROs contracted to carry out the Collaboration Studies, the
terms of which have been disclosed to MedImmune prior to the Effective Date. Innate shall cause the Principal Investigator and Study Site Staff of the Collaboration Studies sponsored by Innate to assign and transfer all their rights, title and
interest in and to the Innate Study Results throughout the world to Innate. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune and its Affiliates shall, for the duration of the CD39 Option Period, have the right to access and use the
Innate Study Results, provided, however, always that the restrictions with regards to Confidential Information in Section&nbsp;11 are observed and adhered to. Moreover, MedImmune shall for the duration of the CD39 Option Period and upon prior
written notice thereof to Innate, be entitled to engage its Affiliates and Third Party experts in respect of such activities, provided, however, always that such Affiliates and Third Party experts (i)&nbsp;need to know the information provided for
purposes of advising MedImmune and its Affiliates on the Evaluation, and (ii)&nbsp;are bound by confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations not less restrictive than those imposed on MedImmune under this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate and its Affiliates shall, for the duration of the CD39 Option Period, have the right to access the MedImmune
Study Results, provided that, MedImmune shall only be required to make available information with respect to any CD39 [***] Study to the extent such information is strictly necessary for Innate&#146;s
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
compliance with any requirements of Regulatory Health Authorities (and MedImmune shall not be required to make available any other information or Study Results with respect to any CD39 [***]
Study), and further provided that, the restrictions with respect to Confidential Information in Section&nbsp;11 are observed and adhered to. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Licences. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">During the CD39 Option Period, the term of the License Agreement, and after the CD39 Option Period if MedImmune has
not exercised the CD39 Option prior to the expiry or termination of the CD39 Option Period, each Party shall grant to the other Party and its Affiliates a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-free, fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> worldwide license under the Intellectual Property Rights Controlled by such Party which claims any CD39/[***] Combination Product, to the extent necessary for the other Party to research, Develop,
commercialise or otherwise Exploit the molecule which binds [***] Controlled by the other Party, but for the avoidance of doubt, without granting that other Party under this license any rights with respect to any molecule that binds CD39.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">During the CD39 Option Period, Innate shall grant to MedImmune a <FONT STYLE="white-space:nowrap">non-</FONT>
exclusive, royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> sublicensable (to MedImmune&#146;s subcontractors only), worldwide sublicense under the [***], for MedImmune to perform its obligations under this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">For clarity, except as expressly provided herein, this Agreement does not grant any license to MedImmune under the
CD39 Option Technology, unless and until the CD39 Option has been validly exercised by MedImmune under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">During the CD39 Option Period, Innate shall be responsible for all costs and payments (including without limitation
upfront fees, annual fees, milestone payments and royalties) associated with all licences of Third Party intellectual property rights entered into by Innate, including under the Third Party Agreements, with respect to the CD39 Option Technology that
is required for the performance of the Collaboration Studies. MedImmune shall be responsible for all costs and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
payments (including without limitation upfront fees, annual fees, milestone payments and royalties) associated with all licences of Third Party intellectual property rights entered into by
MedImmune and associated with its activities pursuant to the Development Plan. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If the Parties determine that any Patent <FONT STYLE="white-space:nowrap">in-licensed</FONT> by Innate under a Third
Party Agreement is or becomes required to Develop, manufacture or commercialize any CD39 Option Product, and shall be an CD39 Option Patent, Innate shall include such Patent into the CD39 Option Patents following the exercise of the CD39 Option, and
when it is or becomes required, provided that, if Third Party consent is required, Innate shall, at its own expense, procure for MedImmune such consents and licences as may be required promptly following the exercise of the CD39 Option, from any
applicable Third Party to a Third Party Agreement and under any other head- license, license or agreement existing at the Effective Date and relating to the CD39 Option Technology and the CD39 Option Products (including the manufacture of the CD39
Option Products). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If MedImmune determines that [***] in accordance with this Agreement, MedImmune may notify Innate thereof, upon which
Innate shall, [***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In the event that additional head-licenses, licenses or other agreements are entered into by Innate or its Affiliates
after the Effective Date which relate to the CD39 Option Technology, CD39 Option Products or the Collaboration Studies, Innate shall use Commercially Reasonable Efforts to procure that the necessary rights or consents are included in such
head-licenses, licenses and agreements in order to give full effect to this Agreement and to enable the License Agreement to come into full effect without the need for further consent from such Third Parties. The foregoing provision shall include
using Commercially Reasonable Efforts to procure any consents necessary for Innate to grant <FONT STYLE="white-space:nowrap">sub-licensable</FONT> licenses to CD39 Option Patents jointly owned by Innate and a Third Party. If MedImmune elects to
include the Patents which are the subject of such head-license, license or agreement in the CD39 Option Patents: (a)&nbsp;Innate shall consult with MedImmune in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
connection with, and shall use reasonable efforts to procure that MedImmune shall be involved in, the negotiations with such Third Party with respect to the terms of such head-license, license or
agreement, provided that MedImmune&#146;s involvement shall not unreasonably delay or otherwise materially adversely impact such process, and shall only enter into such head-license, license or agreement on terms approved by MedImmune (such approval
not to be unreasonably withheld by MedImmune); and (b)&nbsp;upon any exercise of the CD39 Option, Innate shall be responsible for [***] of the payments due to the applicable Third Party in relation to any such head-licenses, licenses and agreements
entered into after the Effective Date, and MedImmune shall bear [***] of any such payments, in accordance with the terms of Section&nbsp;12.12 of the License Agreement. If MedImmune does not elect to include such Patents in the CD39 Option Patents,
such Patents shall be excluded from the CD39 Option Patents, unless otherwise agreed between the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall not, during the term of this Agreement: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">make any material changes or alterations to the Third Party Agreements or any other head-licenses, licenses or
agreements relating to the CD39 Option Technology, CD39 Option Products or the Collaboration Studies that would have a material adverse effect on the rights granted to MedImmune hereunder except with the prior written consent of MedImmune; or
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Patent Prosecution. During the term of this Agreement Innate shall have the right to, and shall use Commercially
Reasonable Efforts to, file, prosecute (including any interferences, reissue proceedings and <FONT STYLE="white-space:nowrap">re-examinations</FONT> and opposition proceedings) and maintain the Listed Patents and any Patents claiming any Innate
Collaboration IP throughout [***]. Innate shall bear all costs and expenses of filing, obtaining and maintaining such Patents, including fees and expenses paid to outside legal counsel and experts, direct costs of
<FONT STYLE="white-space:nowrap">in-house</FONT> counsel and filing, prosecution and maintenance expenses associated therewith. In this regard Innate shall, in each case in [***]: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">use Commercially Reasonable Efforts to file and prosecute Patent
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
applications to secure granted Patent rights for the Listed Patents; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">use Commercially Reasonable Efforts to file and prosecute Patent applications to secure Patent rights for such other
patentable Innate Collaboration IP as the Parties may from time to time separately agree on in writing; </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">use Commercially Reasonable Efforts to apply for and obtain patent protection for the CD39 Lead alone or in
combination, in accordance with best practice in the pharmaceutical industry; and </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">upon issuance, maintain all such Patents in full force in the aforementioned countries. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall have the sole right to file, maintain, prosecute, enforce and defend any Patent claiming or covering
any MedImmune Collaboration IP, and the first right to file, maintain, prosecute, enforce and defend any Patent claiming or covering Joint Collaboration IP, at MedImmune&#146;s sole costs. If MedImmune does not intend to file, maintain, prosecute,
enforce and defend any Collaboration IP, MedImmune shall notify Innate with sufficient advance notice but not less than within [***] before an action need to be taken with respect to such filing, maintain, prosecution, enforcement or defence, and
upon the receipt of such notice, Innate shall have the right to take such actions, at Innate&#146;s sole costs. The Party taking the lead of such actions shall consult with the other Party as set forth in Sections 12.18 to 12.20 which shall apply
<I>mutatis mutandis</I>. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall have the sole right to file, maintain, prosecute, enforce and defend
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
any Patent claiming any Innate Collaboration IP. Prior to [***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall consult with MedImmune as to the strategy and prosecution of Patent applications and the maintenance or
extension of the Patents referred to in Section 12.16. Innate shall cause its patent attorneys and agents to consult with MedImmune (so far as practicable) on all material issues relating to the filing, prosecution (including any interferences,
reissue proceedings and <FONT STYLE="white-space:nowrap">re-examinations</FONT> and opposition proceedings) and maintenance of such Patents. In this regard, Innate shall, through its patent attorneys and agents, cooperate with MedImmune, through its
patent attorneys and agents, as follows: Innate shall provide MedImmune with a reasonable opportunity to review and comment on the nature and text of new or pending applications, amendments, registrations, filings, submissions, pleadings, responses
or correspondence with any patent authorities with respect to the Patents referred to in Section&nbsp;12.16 and shall, in advance of submitting or communicating any of the foregoing to the patent authorities, consider in good faith any reasonable
comments provided by MedImmune. Without prejudice to the foregoing, Innate shall (a)&nbsp;notify MedImmune as early as reasonably practicable in advance of all meetings and significant communications with any patent authorities concerning the
aforementioned Patents and, so far as reasonably practical and provided Innate has the right to allow such participation, shall permit, MedImmune to participate in such meetings, (b)&nbsp;promptly prepare and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
deliver to MedImmune minutes of any such meeting or communications, and (c)&nbsp;promptly forward to MedImmune copies of all office actions and material written communications received from any
patent authorities with respect to the aforementioned Patents upon receipt therefrom. The Parties shall each appoint a single patent coordinator to coordinate the Patent activities under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If Innate elects not (a)&nbsp;to pursue or continue the filing, prosecution (including any interferences, reissue
proceedings and <FONT STYLE="white-space:nowrap">re-examinations)</FONT> or maintenance of the Listed Patents in a particular country, or (b)&nbsp;to take any other action with respect to the aforementioned Patents in a particular country that is
necessary or useful to establish, preserve or extend rights thereto, including by seeking any Patent term extension, restoration or the like that may be available now or in the future, then in each such case Innate shall so notify MedImmune in
writing not less than [***] before any deadlines by which an action must be taken to establish or preserve any such rights in such Patent in such country. Such notice may also, in Innate&#146;s discretion, offer MedImmune the right through counsel
of its choosing, to pursue the filing or registration, or support the continued prosecution in Innate&#146;s name (including any interferences, reissue proceedings and <FONT STYLE="white-space:nowrap">re-examinations)</FONT> or maintenance, of such
Patent at MedImmune&#146;s expense in such country. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate will notify MedImmune as soon as possible following Innate becoming aware of any actual or potential
infringement of or challenge to a CD39 Option Patent by a Third Party (&#147;<B>Patent Action</B>&#148;). Innate will have the sole right to take such steps as it deems appropriate with regard to any such Patent Action provided that Innate will keep
MedImmune informed with regard to any action it does take and before taking any such action will consult with MedImmune and take MedImmune&#146;s reasonable comments into account. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall appoint a mutually agreeable patent attorney to prosecute, maintain and extend the Patents in the
Joint Collaboration IP, and shall consult with Innate as to the strategy and prosecution of Patent applications and the maintenance or extension of the Patents in the Joint Collaboration IP. MedImmune shall cause its patent attorneys and agents to
consult with Innate (so far as practicable) on all material issues relating to the filing, prosecution (including any interferences, reissue proceedings and <FONT STYLE="white-space:nowrap">re-examinations</FONT> and opposition
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
proceedings) and maintenance of such Patents. In this regard, the Parties shall <FONT STYLE="white-space:nowrap">co-</FONT> operate, through such mutually agreed external patent attorney, as
follows: MedImmune shall provide Innate with a reasonable opportunity to review and comment on the nature and text of new or pending applications, amendments, registrations, filings, submissions, pleadings, responses or correspondence with any
patent authorities with respect to the Patents in the Joint Collaboration IP and shall, in advance of submitting or communicating any of the foregoing to the patent authorities, consider in good faith any reasonable comments provided by Innate.
Without prejudice to the foregoing, MedImmune shall (a)&nbsp;notify Innate as early as reasonably practicable in advance of all meetings and significant communications with any patent authorities concerning the aforementioned Patents and, so far as
reasonably practical and provided such external patent attorney has the right to allow such participation, shall permit Innate to participate in such meetings, (b)&nbsp;promptly prepare and deliver to Innate minutes of any such meeting or
communications, and (c)&nbsp;promptly forward to Innate copies of all office actions and material written communications received from any patent authorities with respect to the aforementioned Patents upon receipt therefrom. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Head License. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall not modify or amend any Head License in any way that would adversely affect MedImmune&#146;s rights or
interest under this Agreement or under the License Agreement, and shall not terminate any Head License (whether in whole or in part), without MedImmune&#146;s prior written consent Innate shall provide MedImmune a copy of all modifications or
amendments of any Head License. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall provide MedImmune with reasonable advance, written notice prior to exercising any right (including rights
of consultation or participation) or enforcing or waiving any obligation, or electing to forego such exercise or enforcement, under any Head License that could affect in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
any respect MedImmune&#146;s rights or interests under the this Agreement or the License Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***], or otherwise provide of assistance in relation to any negotiations with the head licensors (as applicable)), as
may be necessary or as MedImmune may reasonably request in order to ensure that MedImmune enjoys the continued benefit of the rights with respect to Intellectual Property Rights licensed under the License Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>EXCLUSIVITY </B></P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><U>&nbsp;</U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Exclusivity</U> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">During the term of this Agreement Innate shall not, and shall ensure that its Affiliates shall not, sell, transfer,
assign, <FONT STYLE="white-space:nowrap">out-license,</FONT> encumber or otherwise grant or offer any rights to (in whole or in part) the CD39 Option Technology and the Study Results in a manner inconsistent with this Agreement and the License
Agreement, to any Person other than MedImmune or MedImmune&#146;s Affiliates, as directed by MedImmune, or initiate or conduct any discussions or negotiations regarding such grant or offer with any such Person; provided, however, that this
Section&nbsp;13.1 shall not prevent Innate from granting licenses to the CD39 Option Technology and Study Results to Third Parties to allow for contract research or development services as necessary or desirable in connection with its performance of
this Agreement or for the purposes of carrying out the Development Plan, including the Collaboration Studies. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">During the CD39 Option Period, neither Party nor any of its Affiliates (each, a
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
&#147;<B>Restricted Party</B>&#148;) shall, either by itself or through a Third Party, conduct any clinical development or commercialisation in respect of any CD39 Competing Product, except for
any activities contemplated under the Development Plan. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding the foregoing, a Restricted Party&#146;s direct or indirect acquisition by/of, or merger with, in
whole or in part, a Person (or group of companies) or the business of a Person (or group of companies) having any activity contravening the covenants set forth above in Sections 13.2 or 13.3, shall not constitute a breach of such covenants, if:
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Other than in publications in accordance with Section&nbsp;11.6, Innate shall not, and shall ensure that its
Affiliates shall not, disclose any <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to CD39 Lead, or contained in the CD39 Option Know&#150;How or Study Results to any Person other than MedImmune, except (a)&nbsp;as necessary
for the conduct of the Development Plan (including the Collaboration Studies) or as necessary or desirable in connection with its performance of this Agreement; (b)&nbsp;in the ordinary course of Innate&#146;s or its Affiliates&#146; business to
their head licensors or contractors; (c)&nbsp;as legally required by Applicable Law or required by applicable stock exchange rules, provided, however, always that any disclosure as per (a)&nbsp;or (b) is, except to the extent prohibited by
Applicable Law, made pursuant to written agreements imposing confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations on the recipients substantially similar to those imposed on Innate hereunder and, further, that Innate shall
be liable to MedImmune for any breach of such obligations by such recipients. Innate will notify MedImmune in writing if Innate wishes to supply or is otherwise requested to supply any CD39 Option Product to a Third Party in order to enable that
Third Party to carry out combination studies using the CD39 Option Product </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
with another product owned or controlled by that Third Party. Innate shall not make any such supply without first obtaining MedImmune&#146;s prior written consent which if given will provide a
limited exception to the exclusivity provisions set out above. If any such consent is given it will be conditional on MedImmune having the right to approve the terms of any such supply and on Innate ensuring that any supply of a CD39 Option Product
to a Third Party will not adversely impact Innate&#146;s ability to carry out the Collaboration Studies in accordance with this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Parties agree that the restrictions contained in this Section&nbsp;13 are reasonable and necessary for the
protection of the Parties&#146; respective Confidential Information and business and investment in the CD39 Option Technology and CD39 Option Products, that such restrictions are reasonable in all the circumstances and that the Parties would not
have entered into this Agreement without the protections afforded to them under this Section&nbsp;13. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>REPRESENTATIONS AND WARRANTIES</B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party represents, warrants and covenants to the other Party that, as of the Effective Date (or as of such other
dates or time periods as may be specified below or as the context requires): </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Corporate Power</B>. It is duly organized, validly existing and in good standing under the laws of its jurisdiction
of incorporation or formation, has full legal power to grant the rights granted to MedImmune under this Agreement and the License Agreement, and has full corporate power and authority to enter into this Agreement and the License Agreement and to
carry out the provisions thereof. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Due Authorisation</B>. The execution, delivery, and performance of the Agreement and the License Agreement by it
does not, and would not, conflict with any agreement, instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any material law or regulation of any court, Governmental Body, or administrative or
other agency having jurisdiction over it. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>Binding Agreement</B>. This Agreement is a legal and valid obligation binding upon such Party and enforceable in
accordance with its terms. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate represents, warrants and covenants the following to MedImmune, as of the Effective Date (or as of such other
dates or time periods as may be specified below or as the context requires). For the avoidance of doubt, Innate shall not be liable for facts and circumstances fairly disclosed to MedImmune prior to the Effective Date. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Intellectual Property</U> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate is: (i)&nbsp;the sole and exclusive owner of the entire right, title and interest in the CD39 Option Patents
listed in <U>Schedule 14.2(a)(i) </U>(the &#147;<B>Owned Patents</B>&#148;), (ii) the sole and exclusive licensee of the CD39 Option
Patents&nbsp;&nbsp;&nbsp;&nbsp;listed&nbsp;&nbsp;&nbsp;&nbsp;in&nbsp;&nbsp;&nbsp;&nbsp;<U>Schedule</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>14.2(a)(ii)</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U>(the&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Exclusively Licensed</B>
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
<B>Patents</B>&#148;), but limited to the extent of the grant of licence in connection with the CD39 Program Antibodies, (iii)&nbsp;the <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
licensee of the CD39 Option Patents listed in <U>Schedule 14.2(a)(iii) </U>(the &#147;<B><FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Patents</B>&#148;), but limited to the extent of the grant of licence in connection with the
CD39 Option Products, and (iv)&nbsp;either itself or through its Affiliates, the sole and exclusive owner or licensee of the entire right, title and interest in the Intellectual Property Rights subsisting in the CD39 Option <FONT
STYLE="white-space:nowrap">Know-How</FONT> listed in <U>Schedule 14.2(a)(iv) </U>and has the right to grant an exclusive license to MedImmune under the Owned Patents and the Exclusively Licensed Patents, and a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to MedImmune under the <FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Patents, under the terms of the License Agreement (or, if applicable, this Agreement). To the
extent any rights, title or interests in the CD39 Option <FONT STYLE="white-space:nowrap">Know-How</FONT> are owned by its Affiliates, Innate shall procure that such rights are transferred to Innate such that MedImmune shall receive from Innate all
rights and licenses granted to it under this Agreement and such that Innate shall be entitled without restriction to grant the rights to MedImmune specified in License Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Other than for the restrictions set forth in the Third Party Agreements, which have been disclosed to MedImmune prior
to the Effective Date, none of the CD39 Option Patents is subject to any encumbrance or lien permitted by Innate and none of the Owned Patents is subject to any encumbrance or lien permitted by Innate or, to Innate&#146;s knowledge, to any claim of
ownership by any Third Party. For the duration of this Agreement, Innate shall not encumber the rights granted to MedImmune hereunder with respect to the CD39 Option Technology in a manner that would have a material adverse effect on
MedImmune&#146;s rights hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The Third Party Agreements and the Head Licenses are in full force and effect and Innate has no knowledge of any
circumstances that may lead to the termination of such agreements. Without limiting the foregoing, Innate has not received any notices from any licensor under the Head Licenses notifying Innate of any intention of such licensor to terminate the
applicable Head License. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">As at the Effective Date, Innate does not own or <FONT STYLE="white-space:nowrap">in-license</FONT> any Product
Trademarks, <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patents, other than the CD39 Option Technology, that are necessary for the Research, Development and Exploitation of the CD39 Option Products as currently contemplated and cannot be
included in the CD39 Option Technology pursuant Section&nbsp;12.12. The Patents specified in Schedules 14.2(a)(i), 14.2(a)(ii) and 14.2(a)(iii) constitute all of the CD39 Option Patents existing at the Effective Date. To Innate&#146;s and its
Affiliates&#146; knowledge, the CD39 Option Patents have as of the Effective Date been diligently and properly filed, prosecuted and maintained in accordance with Applicable Law and where applicable in the course of normal patent prosecution of
patents that are intended to be maintained, all applicable fees have been paid on or before the due date for payment. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">To the knowledge of Innate&#146;s and its Affiliates&#146; personnel responsible for patent matters, in respect of all
US patent applications in the Listed Patents, Innate (or, as appropriate, its licensor) has submitted all material prior art of which it is aware in accordance with the requirements of the United States Patent and Trademark Office.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">To Innate&#146;s and its Affiliates&#146; knowledge, as of the Effective Date, the CD39 Option Patents properly
identify each and every inventor of the claims of the CD39 Option Patents. To Innate&#146;s and its Affiliates&#146; knowledge, each Person who has contributed to the conception of inventions claimed in the CD39 Option Patents existing as of the
Effective Date, has duly assigned and has executed an agreement assigning to Innate, or as appropriate, Innate&#146;s licensor, such Person&#146;s entire right, title and interest in and to such CD39 Option Patents. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Where CD39 Option <FONT STYLE="white-space:nowrap">Know-How</FONT> has been disclosed to a Third Party under terms of
confidentiality, to Innate&#146;s knowledge no breach of such confidentiality obligations has been committed by any such Third Party. MedImmune shall not, before, on or after the Effective Date, have any obligation to contribute to any remuneration
of any inventor employed or previously employed by Innate or any of its Affiliates in respect of the CD39 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Option Patents or CD39 Option <FONT STYLE="white-space:nowrap">Know-How.</FONT> Innate or its Affiliates are solely responsible for paying all such remuneration and neither Innate nor any of its
Affiliates has received notification that such payments are insufficient compensation. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate and its Affiliates have no knowledge of any actual or threatened infringements or misappropriation of the CD39
Option Technology. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate and its Affiliates have not been notified of any threatened or pending proceedings in any court, arbitration,
patent office, administrative or other tribunal which are concerned with (a)&nbsp;the ownership of any of the CD39 Option Technology, or (b)&nbsp;the validity of any of the CD39 Option Patents (other than pending Patent applications), and, in both
cases, to Innate&#146;s and its Affiliates&#146; knowledge, there have been no allegations or assertions by a Third Party which are likely to give rise to a claim by such Third Party for ownership or invalidity of the CD39 Option Patents.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Third Party Rights</U> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The conception, development and reduction to practice of the CD39 Option
<FONT STYLE="white-space:nowrap">Know-How</FONT> and CD39 Option Patents existing as of the Effective Date has not, to Innate&#146;s knowledge, constituted or involved the misappropriation of trade secrets of any Person. Other than the amounts owed
by Innate under the Third Party Agreements, there are no claims, judgments or settlements against or amounts with respect thereto owed by Innate or any of its Affiliates as of the Effective Date relating to the Regulatory Documentation, Listed
Patents or CD39 Option <FONT STYLE="white-space:nowrap">Know-How,</FONT> or amounts owed by Innate or its Affiliates with respect to any such claims, judgments or settlements. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">To Innate&#146;s and its Affiliates&#146; knowledge, as of the Effective Date, the Development and the
commercialization of the CD39 Option Products does not infringe or misappropriate the Patents, of any Third Party, and there is no claim or litigation brought or threatened by written notice to Innate
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
as of the Effective Date by any Person making such allegations. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall not, before, on or after the Effective Date, have any obligation to pay any fees, charges or other
sums due to a Third Party under the Third Party Agreements in relation to CD39 Option Products. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Head License is valid, binding on the parties thereto and in full force and effect. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">None of Innate or its Affiliates is party to any other agreement or arrangements regarding the CD39 Option Products
other than pursuant to the Head Licenses. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">None of Innate, its Affiliates, or, to Innate&#146;s knowledge, the applicable licensor, is in breach of any of its
obligations under any Head License, and Innate has not received any notice relating to any alleged, threated or actual breach by Innate under such Head License, and has no knowledge of any event or circumstance that has occurred that, with a notice
or lapse of time, would constitute a breach of a Head License that may lead to the termination of the Head License. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Regulatory and Compliance</U> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">As of the Effective Date, Innate, its Affiliates and, to their knowledge, their contractors, have at all times
(a)&nbsp;researched and developed the CD39 Option Product in accordance with all Applicable Laws, and (b)&nbsp;undertaken clinical trials and prepared, maintained and retained all Regulatory Documentation in accordance with GLP, GCP, regulations and
other Applicable Laws. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate has made available to MedImmune all Regulatory Documentation,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
CD39 Option <FONT STYLE="white-space:nowrap">Know-How</FONT> and other information in its Control as of the Effective Date regarding or related to any CD39 Program Antibody or CD39 Option Product
that MedImmune has specifically requested, with reasonable clarity, in writing to Innate to make available or that Innate would reasonably consider based on the information available at the Effective Date to be material to MedImmune&#146;s
evaluation of whether to enter this Agreement and all such items are true, complete and correct. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(s)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">All Regulatory Documentation that are the material regulatory filings or approvals held by Innate or its Affiliates in
relation to the Research, Development and Manufacture of the CD39 Option Products have been provided to MedImmune prior to the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(t)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate and its Affiliates have not knowingly withheld from a Regulatory Health Authority or from MedImmune any
material information, including CMC <FONT STYLE="white-space:nowrap">Know-How,</FONT> Serious Adverse Events and results from clinical trials (whether or not completed) relating to the safety, toxicity, quality or efficacy of the CD39 Option
Products. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(u)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate and its Affiliates have the right to refer to and use any data that has been created by the manufacturers of
the CD39 Option Product which is necessary for the use and registration of the CD39 Option Product and MedImmune will have the same rights under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">In the course of the Development of the CD39 Option Product, Innate has not knowingly used, any employee or consultant
that is debarred by any Regulatory Health Authority or, to its knowledge, is the subject of debarment proceedings by any Regulatory Health Authority. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(w)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The information provided by Innate to MedImmune (for the purposes of MedImmune&#146;s assessment as to whether or not
filing is required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to this Agreement or the transactions contemplated herein) regarding Innate&#146;s and its Affiliates&#146; corporate structure and financial
status is correct, complete and not misleading. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Neither Innate nor any Innate Affiliate is engaged in any litigation, opposition or arbitration affecting or relating
to the CD39 Option Products and, as to Innate and its Affiliates&#146; knowledge as at the Effective Date, there are no such litigation, opposition or arbitration pending or threatened by written notice to Innate and no material facts which are
likely to result in a material judgment against Innate or its Affiliates relating to the CD39 Option Products. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(y)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The rights granted to MedImmune under this Agreement are not subject to any right, license or interest under the CD39
Option Patents in favour of any government due to funding obtained with respect to CD39 Option Products or clinical trials carried out in government owned hospitals which would conflict with the rights granted to MedImmune under this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>General</U> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(z)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate has access to sufficient funds, resources and expertise to complete the Collaboration Studies in accordance
with this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><U>Data Protection</U> </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(aa)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate represents, warrants and covenants to MedImmune that: </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">It and its Affiliates shall, and shall cause any of their respective agents or permitted <FONT
STYLE="white-space:nowrap">sub-contractors</FONT> to: </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="21%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Process the Transferred Data in accordance with Data Protection Law; and </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="21%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Process the Transferred Data only for purposes compatible with the purposes for which it was Processed as of the
transfer date, except to the extent Innate has obtained consent from the relevant Data Subject with respect to any new purpose for Processing or it is otherwise compliant with Data Protection Law; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">It has in place and shall maintain appropriate technical and organisational measures (a)&nbsp;to protect Personal Data
against accidental or unlawful destruction, loss, alteration, unauthorised disclosure or access and (b)&nbsp;that provide a level of security appropriate to the risk represented by the Processing and the nature of the Transferred Data.
</P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>MedImmune Warranties</B>. MedImmune provides the following representations, warranties and covenants to Innate as
of the Effective Date (or as of such other dates or time periods as may be specified below). </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(bb)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">The information provided by MedImmune to Innate (for the purposes of Innate&#146;s assessment as to whether or not
filing is required under the Hart- Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to this Agreement or the transactions contemplated herein) regarding MedImmune&#146;s and its Affiliates&#146; corporate structure and
financial status is correct, complete and not misleading. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTION 14
NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR
IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE <FONT STYLE="white-space:nowrap">NON-</FONT> INFRINGEMENT OF ANY INTELLECTUAL PROPERTY
RIGHTS OF THIRD PARTIES. </B></P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>INDEMNIFICATION AND INSURANCE</B> </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall indemnify and hold MedImmune its officers, Affiliates, agents and employees (the &#147;<B>MedImmune
Indemnitees</B>&#148;) harmless from and against all claims and proceedings made or brought by or on behalf of Subjects for personal injury (including death) [***] for, loss, damages, costs and expenses (including reasonable legal costs and
expenses) (whether successfully or otherwise) arising out of the conduct </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">of any activities hereunder, including any activities assigned to Innate pursuant to the Development Plan
(&#147;<B>MedImmune Third Party Claim</B>&#148;), save where such claims and proceedings, loss, damage, costs or expenses arise as a direct consequence of the gross negligence of MedImmune or any of the MedImmune Indemnitees or as a consequence of a
breach of this Agreement by MedImmune. </P></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall indemnify and hold Innate its officers, Affiliates, agents and employees (the &#147;<B>Innate
Indemnitees</B>&#148;) harmless from and against all claims and proceedings made or brought by or on behalf of Subjects for personal injury (including death) or any other Third Party for, loss, damages, costs and expenses (including reasonable legal
costs and expenses) (whether successfully or otherwise) arising out of the conduct of any activities assigned to MedImmune pursuant to the Development Plan hereunder (&#147;<B>Innate Third Party Claim</B>&#148;), save where such claims and
proceedings, loss, damage, costs or expenses arise as a direct consequence of the gross negligence of Innate or any of the Innate Indemnitees or as a consequence of a breach of this Agreement by Innate. [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Mechanism. In the event that a Party (the &#147;<B>Indemnified Party</B>&#148;) is seeking indemnification under
Section&nbsp;15.1 or 15.2 as the case may be, it shall notify the other Party (the &#147;<B>Indemnifying Party</B>&#148;) in writing of the relevant Third Party Claim and the relevant Loss for which indemnification is sought as soon as reasonably
practicable after becoming aware of such claim. Such notices shall contain a description of the Third Party Claim and the nature and amount of the Loss (to the extent known). The Indemnified Party shall furnish promptly to the Indemnifying Party
copies of all papers and official documents received in respect of such Third Party Claim or Losses. For the avoidance of doubt, all indemnification claims in respect of a Party, its Affiliates, and each of its and their respective employees,
officers, directors and agents shall be made solely by such Party to this Agreement. To the extent that the Indemnifying Party irrevocably commits to indemnify any Indemnified Party in respect of the Third Party Claim, the Indemnified Party shall
permit the Indemnifying Party to assume direction and control of the defense of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">the relevant Third Party Claim (including without limitation the right to settle the
claim solely for monetary consideration), and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of the claim. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Notwithstanding Section&nbsp;15.3, the failure to give timely notice to the Indemnifying Party shall not release the
Indemnifying Party from liability to the Indemnified Party to the extent the Indemnifying Party is not prejudiced thereby and, for the avoidance of doubt, the Indemnifying Party shall not be liable to the extent any Loss is caused by any delay by
the Indemnified Party in providing such notice. Notwithstanding the provisions of Section&nbsp;15.3 requiring the Indemnified Party to tender to the Indemnifying Party the exclusive ability to defend such claim, if the Indemnifying Party does not
satisfy the condition set forth in Section&nbsp;15.3, or declines to or fails to timely assume control of the relevant Third Party Claim, the Indemnified Party shall be entitled to assume such control, conduct the defense of, and settle such claim,
all at the sole costs and expense of the Indemnifying Party; provided, however, that neither Party shall settle or dispose of any such claim in any manner that would adversely affect the rights or interests or admit fault, of the other Party without
the prior written consent of such other Party, which shall not be unreasonably withheld, delayed or conditioned. Each Party, at the other Party&#146;s expense and reasonable request, shall cooperate with such other Party and its counsel in the
course of the defense or settlement of any such claim, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information, and witnesses. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">LIMITATION OF LIABILITY. EXCEPT IN CIRCUMSTANCES OF NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS AFFILIATES,
OR WITH RESPECT TO THIRD PARTY CLAIMS UNDER SECTIONS 15.1 and 15.2, IN NO EVENT SHALL EITHER PARTY OR ITS RESPECTIVE AFFILIATES AND SUBLICENSEES BE LIABLE FOR INDIRECT OR CONSEQUENTIAL LOSSES, WHETHER IN CONTRACT, WARRANTY, TORT, STRICT LIABILITY,
OR OTHERWISE. This Section&nbsp;15.5 shall not limit either Party&#146;s liability under Section&nbsp;11. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Each Party shall insure against any potential liabilities it may have in connection with their activities hereunder
and shall, upon the reasonable written request of the other Party provide such evidence of compliance as such other Party reasonably </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
deems sufficient, it being understood that self-insurance by MedImmune or any of its Affiliates shall discharge its obligations under this Section&nbsp;15.6. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>16</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>TERM AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">This Agreement shall enter into effect on the Effective Date and shall, unless earlier terminated pursuant to this
Section&nbsp;16, remain in full force and effect until the earliest of: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the entry into force of the License Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">the end of the CD39 Option Period, provided that a CD39 Option Notice has not been delivered to Innate within the CD39
Option Period; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">termination as set forth in Section&nbsp;16.2 to 16.4 below. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Termination Without Cause. MedImmune may, at its sole discretion and without having to explain the reasons for doing
so, terminate this Agreement in its entirety effective following a [***] prior written notice to Innate. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Termination for Breach. Each of MedImmune and Innate may terminate this Agreement effective immediately at any time
upon written notice to the other Party if the other Party is: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">in material breach of this Agreement and, where such breach is capable of being cured, fails to remedy such breach
within [***] after having been given a written request for such remedy, including notice that the Agreement may otherwise be terminated; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">(i) judicially declared insolvent, or (ii)&nbsp;has an administrator or receiver appointed (or equivalent in the
applicable country) over all or parts of its assets, or (iii)&nbsp;has ceased to cease to carry on its business as a going concern without a successor. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">16.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Termination by Innate for Patent Challenge. Except to the extent the following is
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
not enforceable under the law of a particular jurisdiction, this Agreement may be terminated by Innate in its entirety upon written notice to that effect to MedImmune, if MedImmune or any of its
Affiliates has challenged the validity, enforceability or scope of any CD39 Option Patent (an &#147;<B>IP Challenge</B>&#148;) and failed to withdraw the IP Challenge within [***] after having received Innate&#146;s written notice of the IP
Challenge requiring such IP Challenge to be withdrawn (including notice of Innate&#146;s intention to otherwise terminate this Agreement). This Section&nbsp;16.4 shall not apply in relation to any IP Challenge made by MedImmune as a counterclaim or
defence in response to an action brought by Innate, its Affiliates or any Third Party licensee or licensor of Innate or its Affiliates alleging infringement of a CD39 Option Patent by MedImmune for activities that do not relate to the CD39 Option
Products. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>17</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>CONSEQUENCES OF TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Upon expiration or earlier termination of this Agreement the Receiving Party shall return to the Disclosing Party all
Confidential Information and <FONT STYLE="white-space:nowrap">Know-How</FONT> from the Disclosing Party or any Third Party on behalf of the Disclosing Party, including any Study Documentation, Study Results, CTA Materials, received from that
Disclosing Party, save for one copy thereof, which the Receiving Party may retain for archival purposes and for the purpose of determining its obligations under Section&nbsp;11. Notwithstanding the foregoing, (a)&nbsp;in case of expiry of this
Agreement pursuant to Section&nbsp;16.1(a) the Receiving Party shall retain and be allowed to disclose and use, subject to the terms of the License Agreement, all Confidential Information and <FONT STYLE="white-space:nowrap">Know-How</FONT> received
from the Disclosing Party or any Third Party on behalf of the Disclosing Party, including any Study Documentation, Study Results, CTA Materials, without restriction under this Agreement but in accordance with the terms and conditions of the License
Agreement; and (b)&nbsp;in case of expiry or termination of this Agreement for any other reason Innate shall retain all rights, title and interest in and to and be free to Exploit or otherwise dispose of the CD39 Option Technology and all Study
Documentation, Study Results and CTA Materials (in each case, with respect to Innate Collaboration Studies), without restriction and without any requirement to account to MedImmune (subject to Section&nbsp;4.13). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Termination or expiry of this Agreement shall not affect any rights and obligations
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
of the Parties that accrued prior to termination. The respective rights and obligations of the Parties under [***]: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">MedImmune shall pay to Innate any reasonable and documented Costs incurred by Innate in the performance of the
Development Plan prior to the effective date of termination of this Agreement as well as those reasonably committed that cannot be cancelled, to the extent such Costs do not exceed [***] of the aggregate Innate Development Costs allocated under the
Collaboration Budget with respect to the applicable period. If MedImmune has not exercised the CD39 Option, from the date of expiry or termination of the CD39 Option until the earlier of: (a) [***]; and (b) [***] (the &#147;<B>Tech Transfer
Period</B>&#148;), upon Innate&#146;s request, MedImmune shall ensure that any resulting manufacturing process for the relevant CD39 Option Product (excluding any CD39 <FONT STYLE="white-space:nowrap">Bi-Specific</FONT> Molecule) is transferable to
Innate or its designee for the purposes of manufacturing, testing, validating, releasing or Exploiting that CD39 Option Product, and MedImmune shall make available 1 FTE of its personnel to support such technology transfer activities (the
&#147;<B>Tech Transfer FTE</B>&#148;). In particular, during the Tech Transfer Period and Innate&#146;s request, MedImmune shall (i)&nbsp;promptly provide to Innate all support, documentation and information as is useful for an orderly,
uninterrupted transfer of the Manufacturing activities </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
of such CD39 Option Product to Innate or its designee, including, any and all documentation, quality and testing, working instructions, process and analysis related to <FONT
STYLE="white-space:nowrap">IND-Enabling</FONT> studies, Manufacturing, Quality and Control procedures, including but not limited to, analytical methods, and all regulatory documentation including Regulatory Health Authorities&#146; assessments,
meeting minutes, MedImmune responses and commitments linked to CMC submissions and consultations (ii)&nbsp;grant to Innate the right to observe the Manufacturing at a facility of MedImmune&#146;s manufacturing contractors and send the appropriate
resources at Innate&#146;s or its subcontractor&#146;s manufacturing facility during the technology transfer to support Innate until the end of the Tech Transfer Period, (iii)&nbsp;&nbsp;promptly transfer to Innate any remaining materials related to
the Manufacturing activities of the CD39 Option Product (including MCB, WCB, reference material, raw materials), any drug substance and drug product batches, at (provided that Innate reimburses MedImmune for such remaining materials at Cost), (iv)
grant to Innate a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, royalty free, worldwide license, with the right to grant sublicenses to use any confidential manufacturing or CMC related information owned by or licensed to
MedImmune which are used in relation to the CD39 Option Product at the date of the expiry or termination of the CD39 Option solely to practice the Manufacturing activities of the CD39 Option Product; (v)&nbsp;provide to Innate access to its batch
records at its premises. Innate shall bear the Costs of the manufacturing technology transfer to Innate, save for the Tech Transfer FTE provided by MedImmune at its Cost. Innate shall have the right to disclose under a confidentiality agreement all
such information to Third Parties solely for purposes of allowing Innate to assess the feasibility of such Third Parties Manufacturing the CD39 Option Product and to allow such Manufacturing, provided that, such Third Parties shall be subject to
confidentiality obligations no less stringent than those set out in Section&nbsp;11. During the Tech Transfer Period, the Parties shall cooperate to obtain all necessary assurances and cooperation from any Third Party contract manufacturers of the
CD39 Option Product with respect to the foregoing material transfer activities. MedImmune covenants to Innate that any Third Party agreements under which MedImmune engages such Third Party to Manufacture the CD39 Option Product contain provisions
regarding the allocation of Intellectual Property Rights and to perform its rights. If MedImmune has not exercised the CD39 Option, at Innate&#146;s request, after the expiry or termination of the CD39 Option until the earlier of: (i)&nbsp;the
completion </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
of the technology transfer under this Section&nbsp;17.3; and (ii)&nbsp;the second (2nd) anniversary of the date of the expiry or termination of the CD39 Option Period, MedImmune shall continue
the manufacturing and testing of the requirements of the CD39 Option Product of Innate in the form of drug substance, drug product and finished product, pursuant to a service and supply agreement at reasonable terms and conditions consistent with
the biotechnology industry practices, which will be negotiated in good faith by the Parties. Innate shall use diligent efforts to cease reliance on MedImmune to supply and test such CD39 Option Product, and to procure that such manufacturing and
testing shall be transferred to Innate or its contract manufacturer as soon as reasonably practicable, and shall keep MedImmune reasonably informed and updated of such efforts and plans. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">If MedImmune has not exercised the CD39 Option by the date of expiry or termination of the CD39 Option, and if at the
time of such expiry or termination any MedImmune Collaboration Study has been initiated but not yet completed, then the Parties shall work together in good faith to ensure that MedImmune&#146;s involvement in and responsibilities for such activities
will be discontinued and ceased as efficiently and promptly as possible (by way of transitioning such involvement and responsibilities to Innate or by other means agreed to by the Parties), subject to Applicable Laws, including GCP.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>ASSIGNMENT; SUCCESSOR; SUBCONTRACTING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Neither Party may assign any of its rights or obligations under this Agreement in any country in whole or in part without the prior
written consent of the other Party, except that each Party shall have the right, without such consent, (i)&nbsp;to perform any of its obligations and exercise any of its rights under this Agreement through, and to assign all of its rights and
obligations under this Agreement to, any of its Affiliates; and (ii)&nbsp;on written notice to the other Party, to assign all of its rights and obligations under this Agreement to a <FONT STYLE="white-space:nowrap">non-Affiliate</FONT> successor in
interest, whether by merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar transaction, to all or substantially all of the business to which this Agreement relates. In the event that a Party performs its
obligations or exercises its rights under this Agreement through an Affiliate or assigns its rights and obligations to an Affiliate as permitted under this Section&nbsp;18, doing so shall not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">
relieve the relevant Party of its responsibilities for the performance of its obligations under this Agreement, and the relevant Party shall remain responsible for the performance by its
Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance). This Agreement shall survive any succession of interest permitted pursuant to this Section&nbsp;18, whether by merger,
consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar transaction, provided, that, in the event of such merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar
transaction, no Intellectual Property Rights of the acquiring corporation and its Affiliates (other than a Party and its Affiliates prior to such acquisition) shall be included in the technology licensed hereunder, unless such Intellectual Property
Rights arise as a result of the performance of this Agreement by such corporation after such transaction becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Innate
may not subcontract its obligations with respect to any Development activity assigned to it under the Development Plan to any Third Party apart from a CRO, and any such subcontracting shall not relieve Innate of any of its obligations under this
Agreement, and Innate shall remain responsible for the performance of its obligations under and in accordance with this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>19</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>ANTI-CORRUPTION LAWS </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">19.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Both Parties shall ensure that in connection with this Agreement, they shall conduct their activities in a manner that
is consistent with the Anti-Corruption Laws. Each Party further undertakes that none of its or its Affiliates&#146; employees, directors or officers shall, directly or indirectly, engage in any activities that violate any Anti- Corruption Law
(a)&nbsp;in order to influence official action of any Government Official, or (b)&nbsp;with the intention of or as a condition to inducing any person to carry out a duty or function improperly or to reach a favourable decision on an improper basis,
in each case in connection with the activities contemplated under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">19.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate shall promptly provide MedImmune with written notice of (a)&nbsp;becoming aware of a Material Anti-Corruption
Law Violation by it or any of its or its Affiliates&#146; employees, directors or officers with respect to the subject matter of this Agreement, or (b)&nbsp;upon receiving a formal notification that it or any of its or its
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:11pt">
Affiliates&#146; employees, directors or officers is the target of a formal investigation by any Governmental Body for a Material Anti-Corruption Law Violation. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">19.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Innate acknowledges that its undertakings given in this Section&nbsp;19.3 are material to MedImmune in entering into
this Agreement. Notwithstanding any other provision of this Agreement, if MedImmune becomes aware of what it determines, acting reasonably, to be a breach of these undertakings, then MedImmune shall be entitled to terminate this Agreement in its
entirety and to terminate any other agreement between the Parties, on notice with immediate effect. Subject to the accrued rights of the Parties pursuant to termination, MedImmune shall have no liability to Innate for any fees, reimbursements or
other compensation or for any loss, cost, claim or damage resulting, directly or indirectly, from such termination. At the sole discretion of MedImmune, any breach of an Innate obligation with respect to its obligation in this Section&nbsp;19.3 may
be cured (if capable of being cured) within a reasonable period of time after learning of such material breach or Material Anti-Corruption Law Violation. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>20</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>GOVERNING LAW AND ARBITRATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">20.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Governing Law. The interpretation and construction of this Agreement (including
<FONT STYLE="white-space:nowrap">non-contractual</FONT> disputes and the arbitration clause set out in Section&nbsp;20.2) shall be governed by the laws of England and Wales excluding any conflicts or choice of law rule or principle that might
otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">20.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Arbitration. Any dispute arising out of or in connection with this Agreement, including any question regarding its
existence, validity or termination, shall be referred to and finally resolved by arbitration under the Arbitration Rules of the International Chamber of Commerce (ICC), which Rules are deemed to be incorporated by reference into this clause. One or
more arbitrators shall be appointed in accordance with the said Rules. The seat, or legal place, of arbitration shall be London. The language to be used in the arbitral proceedings shall be English. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>21</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>NOTICES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Any notice, request, or other communication permitted or required under this Agreement shall be in writing, shall refer specifically to
this Agreement, and shall be deemed given only if hand delivered, sent by an internationally recognised overnight delivery service, costs prepaid, or sent by email (providing such email is read receipted and such notice is also despatched by an
internationally recognised overnight delivery service, costs prepaid, on same day) to the Party to whom notice is to be given at the following address (or at such other address such Party may have provided to the other Party in accordance with this
Section&nbsp;21): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">If to MedImmune: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">MedImmune LLC </P> <P STYLE="margin-top:1pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">One
MedImmune Way </P> <P STYLE="margin-top:1pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Gaithersburg </P>
<P STYLE="margin-top:1pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">MD 20878 </P> <P STYLE="margin-top:1pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">USA </P>
<P STYLE="margin-top:1pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">with a copy
(which shall not constitute effective notice) to: </P> <P STYLE="margin-top:1pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***] </P>
<P STYLE="margin-top:1pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">and with a copy (which shall not constitute effective notice) to: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:10%; text-indent:5%; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:11pt; font-family:ARIAL" ALIGN="justify">If to Innate: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:14%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Address: </P> <P STYLE="margin-top:1pt; margin-bottom:0pt; margin-left:14%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Innate
Pharma S.A. </P> <P STYLE="margin-top:1pt; margin-bottom:0pt; margin-left:14%; font-size:11pt; font-family:ARIAL" ALIGN="justify">17, Avenue de Luminy - BP 30191 </P>
<P STYLE="margin-top:1pt; margin-bottom:0pt; margin-left:14%; font-size:11pt; font-family:ARIAL" ALIGN="justify">13276 Marseille Cedex 09 FRANCE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:14%; font-size:11pt; font-family:ARIAL" ALIGN="justify">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Such
notice, shall be deemed to have been given as of the date delivered by hand, or on the second business day (at the place of delivery) after deposit with an internationally recognised overnight delivery service, whichever is the earlier. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>22</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>WAIVER </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:10%; font-size:11pt; font-family:ARIAL" ALIGN="justify">A Party&#146;s failure to enforce, at any time or for any period of time, any provision of this Agreement, or to exercise any right or
remedy shall not constitute a waiver of that provision, right or remedy or prevent such Party from enforcing any or all provisions of this Agreement and exercising any rights or remedies. To be effective any waiver must be in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>23</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>SEVERABILITY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:12%; font-size:11pt; font-family:ARIAL" ALIGN="justify">If any provision of this Agreement is held to be invalid, illegal or unenforceable, in any respect, then such provision will be given
no effect by the Parties and shall not form part of this Agreement. To the fullest extent permitted by Applicable Law and if the rights and obligations of a Party will not be materially and adversely affected all other provisions of this Agreement
shall remain in full force and effect and the Parties will use all reasonable efforts to negotiate a provision in replacement of the provision held invalid, illegal or unenforceable that is consistent with Applicable Law and achieves, as nearly as
possible, the original intention of the Parties. To the fullest extent permitted by Applicable Law, the Parties waive any provision of law that would render any provision in this Agreement invalid, illegal or unenforceable in any respect. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>24</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>FURTHER ASSURANCE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:12%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Each Party shall perform all further acts and things and execute and deliver such further documents as may be necessary or as the other
Party may reasonably require to implement or give effect to this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>25</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>ENTIRE AGREEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:12%; font-size:11pt; font-family:ARIAL" ALIGN="justify">This Agreement, including without limitation all schedules attached hereto, constitutes the entire agreement between the Parties with
respect to the subject matter of the Agreement. This Agreement supersedes all prior agreements, whether written or oral, with respect to the subject matter of the Agreement. Each Party confirms that it is not relying on any representations,
warranties or covenants of the other Party except as specifically set out in this Agreement. Nothing in this Agreement is intended to limit or exclude any liability for fraud. All Schedules referred to in this Agreement are intended to be and are
hereby specifically incorporated into and made a part of this Agreement. In the event of any inconsistency between any such Schedules and this Agreement, the terms of this Agreement shall govern, provided that upon the entry into force of a License
Agreement the terms of the License Agreement shall govern the Parties&#146; relationship with respect to the subject matter of the License Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>26</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>AMENDMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:12%; font-size:11pt; font-family:ARIAL" ALIGN="justify">Any amendment or modification of this Agreement must be in writing and signed by authorised representatives of both Parties. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>27</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>COUNTERPARTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:12%; font-size:11pt; font-family:ARIAL" ALIGN="justify">This Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together
shall be deemed to constitute one and the same instrument. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>28</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify"><B>NO PARTNERSHIP </B></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:12%; font-size:11pt; font-family:ARIAL" ALIGN="justify">It is expressly agreed that the relationship between Innate and MedImmune shall not constitute a partnership, joint venture, or agency.
Neither Innate nor MedImmune shall have the authority to make any statements, representations, or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior consent of such other Party to do so. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">[Signature page overleaf] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">THIS AGREEMENT IS EXECUTED by the authorised representatives of the Parties as of the date first
written above. </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:11pt; font-family:ARIAL">SIGNED for and on behalf of</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">SIGNED for and on behalf of</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:11pt; font-family:ARIAL"><B>Innate Pharma S.A.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>MedImmune Limited</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px dotted #000000; margin-left:1.00em; font-size:11pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px dotted #000000; margin-left:0.05em; font-size:11pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:11pt; font-family:ARIAL">Signature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.05em; font-size:11pt; font-family:ARIAL">Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px dotted #000000; margin-left:1.00em; font-size:11pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px dotted #000000; margin-left:0.05em; font-size:11pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:11pt; font-family:ARIAL">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.05em; font-size:11pt; font-family:ARIAL">Name</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px dotted #000000; margin-left:1.00em; font-size:11pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px dotted #000000; margin-left:0.05em; font-size:11pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:11pt; font-family:ARIAL">Title</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.05em; font-size:11pt; font-family:ARIAL">Title</P></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>CD39 OPTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>SCHEDULES OPTION CD 39 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Schedule 1.12</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>CD39 <FONT STYLE="white-space:nowrap">Back-Ups</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Schedule 1.80</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>License Agreement</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Schedule 1.81</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>CD39 Option Listed Patents</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Schedule 1.135</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Third Party Agreements</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Schedule 4.13</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Total Reimbursement Costs</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Schedule&nbsp;14.2&nbsp;(a)&nbsp;(i)</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Owned Patents</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Schedule14.2&nbsp;(a)&nbsp;(ii)</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Exclusively Licensed Patents</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Schedule 14.2 (a) (iii)</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B><FONT STYLE="white-space:nowrap">Non-Exclusively</FONT> Licensed Patents</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Schedule 14.2 (a) (iv)</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Owned and Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>SCHEDULE 1.12 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>CD39 <FONT STYLE="white-space:nowrap">BACK-UPS</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">[***] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>SCHEDULE 1.80 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>See attachment </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>SCHEDULE 1.81 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>LISTED PATENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>[***] </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>SCHEDULE 1.135 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>THIRD PARTY AGREEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>[***] </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>Schedule 4.13 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>Total Reimbursement Costs </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>[***] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>SCHEDULE 14.2 (a)&nbsp;(i) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>OWNED PATENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>[***] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>SCHEDULE 14.2 (a) (ii) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>EXCLUSIVELY LICENSED PATENTS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>[***]
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>SCHEDULE 14.2 (a) (iii) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-EXCLUSIVELY</FONT> LICENSED PATENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>[***] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>SCHEDULE 14.2(a)(iv) </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>OPTION <FONT STYLE="white-space:nowrap">KNOW-HOW</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>[***] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOINT RESEARCH, DEVELOPMENT, OPTION AND LICENSE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Joint Research,
Development, Option and License Agreement, made and effective as of March&nbsp;28, 2006 is entered into by and between Novo Nordisk A/S <FONT STYLE="white-space:nowrap">(CVR-no.</FONT> 24 25 67 90), a corporation existing under the laws of<I>
</I>Denmark and having its principal place of business at Novo<I> </I>All&eacute;, 2880 Bagsvaerd, Denmark (hereinafter NN), and Innate Pharma SA, a corporation existing under the laws of France and having its principal place of business at Grand
Pr&eacute; &#150; 119/121, ancien chemin de Cassis, 13009 Marseille, France (hereinafter IPH); NN and IPH hereinafter are also referred to individually as &#147;<U>Party</U>&#148; and collectively as &#147;<U>Parties</U>&#148;. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>WITNESSETH </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">WHEREAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NN is a pharmaceutical company with expertise in the discovery and global development of protein drugs;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>WHEREAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">IPH is a biotech company with expertise in the discovery and development of drugs and other types of therapy acting at <FONT STYLE="white-space:nowrap">non-conventional</FONT> lymphocytes such as gamma delta T cells and natural
killer (NK) cells;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>WHEREAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">IPH Controls certain Intellectual Property Rights, and possesses research and development skills, in respect of neutralizing monoclonal antibodies;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>WHEREAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">NN Controls certain Intellectual Property Rights relating to the expression, purification, production, and formulation of proteins;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>WHEREAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">NN has research and development skills which NN believes may enable it to further develop pharmaceutical products for human therapeutic, as well as potential diagnostic or prophylactic, use utilizing Intellectual Property Rights
Controlled by IPH;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>WHEREAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Parties have previously entered into a collaboration governed by an agreement entitled &#147;Research, Development and Licence Agreement&#148; with an effective date of September&nbsp;30, 2003 (the &#147;<U>Kirostim
Agreement</U>&#148;) in respect of receptors KIR 2DL1 and KIR 2DL2/3 and wish to expand that collaboration by entering into a strategic collaboration in the Collaboration Field under which IPH and NN will work, independently, jointly, and/or
together with agreed-upon Third Parties, to (a)&nbsp;discover or identify Drug Candidates, and (b)&nbsp;optimize Drug Candidates for progression to (i)&nbsp;Licensed Products for further development and commercialization by NN, or (ii)&nbsp;Niche
Candidates for further development and commercialization by NN or IPH, for all uses and purposes, including therapeutic, prophylactic and, except as otherwise expressly herein provided, diagnostic uses; and</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WHEREAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Each Party desires to obtain from, and is willing to grant to the other, such licenses and sublicenses to specified Intellectual Property Rights Controlled by it as are necessary or useful to enable NN and IPH to exercise their
rights and perform their obligations hereunder, on the terms set out in this Agreement;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">NOW, THEREFORE,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">in consideration of the foregoing premises, the mutual promises and covenants set forth in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, NN and IPH, each
intending to be legally bound, hereby agree as follows:</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS AND CONSTRUCTION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Definitions</U>. When used in this Agreement, the following capitalized terms shall have the meanings set
forth in this Section<B>&nbsp;1.1</B>, unless the express provisions or context of their use herein clearly otherwise require: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Additional Kirostim Field</U>&#148; shall mean any human therapeutic, prophylactic or diagnostic
indications outside the Kirostim Field. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Affiliates</U>&#148; shall mean (a)&nbsp;any Person which directly or indirectly owns, is owned by or
is under common ownership with a Party to this Agreement to the extent of more than fifty percent (50%) of the equity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) having
the power to vote on or direct the affairs of the entity, and (b)&nbsp;any Person actually controlled by, controlling or under common control with such Party. For purposes of this definition and Section<B>&nbsp;20.4</B>, the terms &#147;controlled
by&#148;, &#147;controlling&#148; and &#147;under common control with&#148;, with respect to any Person, shall mean the possession, directly or indirectly, of the power or ability to direct or cause the direction of the management or policies of
that Person, or otherwise direct the affairs of such Person, whether through the ownership of equity participation, voting securities, beneficial interest, by contract relating to voting rights or corporate governance, or otherwise.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Agreement</U>&#148; shall mean this Joint Research and Development, Option and License Agreement,
including all recitals and schedules hereof, which are hereby incorporated and made part of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U><FONT STYLE="white-space:nowrap">Anti-KIR</FONT></U>&#148; shall mean ***. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Background IPH IPR</U>&#148; shall mean any IPR in the Collaboration Field other than the
Collaboration IPR that is necessary or useful for Commercial Optimization and is as of the date of this Agreement Controlled by IPH or any of its Affiliates with the exception of ***. All Patents within the Background IPH IPR as of the date of this
Agreement are identified and listed in the annexed Schedule <B>1.1.5</B> </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(all currently known Patents within Background IPH IPR other than Background IPH Research Technology IPR) or Schedule <B>1.1.6</B> (all currently known Patents within significant Background IPH
Research Technology IPR). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Background IPH Research Technology IPR</U>&#148; shall mean the IPR identified and listed in the
annexed Schedule <B>1.1.6</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Background NN IPR</U>&#148; shall mean the IPR in the Collaboration Field comprised of the Patents
identified and listed in the annexed Schedule <B>1.1.7</B>. In addition, if NN shall determine or IPH shall notify and demonstrate at any time during the Term that other or additional IPR (other than Collaboration IPR) Controlled by NN or its
Affiliates as of the date of this Agreement and the date of such determination or notification is necessary for IPH&#146;s development or commercialization of a Niche Candidate, Licensed Candidate, or Residual Product authorized for IPH&#146;s
development and commercialization under the terms of this Agreement, then (a)&nbsp;such IPR shall be included in the Background NN IPR (effective as of the date of such determination), and (b)&nbsp;Schedule <B>1.1.7</B> shall be updated accordingly,
and (c)&nbsp;neither Party shall have, with respect to such IPR, any liability or obligation to the other during, arising out of, or relating to the period prior to the date of such determination. Should the Parties fail to agree with respect to
such determination or demonstration, the matter shall be decided in accordance with Section<B>&nbsp;21.14</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Background NN Research Technology IPR</U>&#148; shall mean IPR identified and listed in the annexed
Schedule <B>1.1.8</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Backup Product</U>&#148; shall mean any Drug Candidate comprised of, modulating, interacting with, or
derived from the same Collaboration Target as another Drug Candidate (including any Licensed Product) comprised of, modulating, interacting with, or derived from the same Collaboration Target. The adoption of an alternative to or replacement of any
Drug Candidate may be due to factors that include such alternative&#146;s or replacement&#146;s possession of a better drug profile than the prior Drug Candidate, or toxicity issues, formulation problems, lack of efficacy, safety issues or any other
factor having an adverse effect upon the ability to effectively develop or commercialize such prior Drug Candidate with the exercise of Commercially Reasonable Efforts. For the avoidance of doubt, no Drug Candidate comprised of, modulating,
interacting with or derived from NKG2A shall be a Backup Product for <FONT STYLE="white-space:nowrap">Anti-KIR.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Biological Target</U>&#148; shall mean any molecular structure, including any protein (such as any NK
cell or NK target cell receptor or receptor fragment), any lipid or any glycolipid, or any fragment or derivative of any of the foregoing, such molecular structure being a target for any molecule with pharmaceutical activity. For purposes of
illustration, and not limitation, such molecules with pharmaceutical activity include, but are not limited to, antibodies, soluble receptors and other proteins, and any fragments or derivatives of any thereof, and any small molecule.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Class</U><U></U><U>&nbsp;A Licensed Products</U>&#148; shall mean Licensed Products comprised of,
modulating, interacting with, or derived from the Collaboration Targets identified in the annexed Schedule <B>1.1.11</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Class</U><U></U><U>&nbsp;B Licensed Products</U>&#148; shall mean Licensed Products comprised of,
modulating, interacting with, or derived from any of the Collaboration Targets identified in the annexed Schedule <B>1.1.12</B>, as the same may be amended from time to time by written agreement of the Parties or pursuant to the terms of this
Agreement. Class&nbsp;B Licensed Products shall not include naturally occurring ligands for Collaboration Targets, or any variants of such ligands, or any derivatives of such ligands or variants, or antibodies to such ligands, except in the case
that the Background IPH IPR comprises a Valid Claim that would be infringed by the manufacture, use, sale, offer for sale, importation, or exportation of such ligand, variant, derivative, or antibody. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Class</U><U></U><U>&nbsp;C Licensed Products</U>&#148; shall mean Licensed Products comprised of,
modulating, interacting with, or derived from any of the Collaboration Targets identified in the annexed Schedule <B>1.1.13</B> as the same may be updated or otherwise amended from time to time by written agreement of the Parties, and shall include
any other Licensed Products that are not Class&nbsp;A Licensed Products or Class&nbsp;B Licensed Products pursuant to the terms of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Collaboration</U>&#148; shall mean the Parties&#146; collective enterprise during the Collaboration
Term pursuant to this Agreement to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">research, discover and identify Biological Targets in the Collaboration Field (as hereinafter defined) as
Collaboration Targets and further develop and progress such Collaboration Targets themselves or ligands or other molecules, compositions or formulations that interact with such Collaboration Targets to Drug Candidates in accordance with the Target
Discovery Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">conduct additional and other research and development to optimize such Drug Candidates and further develop and
progress them to M1 status in accordance with the Drug Discovery Plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Collaboration Field</U>&#148; shall mean any projects, activities, biological materials (including
Biological Targets), <FONT STYLE="white-space:nowrap">Know-How</FONT> (including Materials and Research Technology), IPR and other subject matter the use of which can result inthe modulation of the activity of isolated NK cells (for example
resulting in the modulation of the production of cytokine or in the modulation of any biological (including any cell-regulatory) activity of NK cells), as observable in a bioassay comprising only purified NK cells or NK cell lines, with or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
without any target cells, such modulation being triggered by the binding of any ligand or molecule to any of the cell surface receptors expressed on NK cells or to any of their ligands. These
include, but are not limited to: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the NK cell surface receptors and ligands thereof identified as Collaboration Targets, including but not
limited to those listed in Schedule <B>1.1.11; 1.1.12 or 1.1.13</B>, as well as other potential targets discovered during the course of the Collaboration, including new NK cell surface receptors and ligands thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">and the use of any of the foregoing (in each case (a)&nbsp;through (f)), for any purpose, including any
prophylactic, diagnostic or therapeutic use or purpose. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>Subject Matter Not Included in the Collaboration Field</U>.
Notwithstanding any other provision of this Agreement, unless the Parties shall otherwise hereafter expressly agree in writing, the Collaboration Field shall not include any: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Collaboration IPR</U>&#148; shall mean IPR (including Collaboration
<FONT STYLE="white-space:nowrap">Know-How)</FONT> that is: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">generated or acquired (by assignment, license or otherwise) by or on behalf of either or both of the Parties or
their Affiliates during the Collaboration Term and (i)&nbsp;is in the Collaboration Field or (ii)&nbsp;originates from activities undertaken in the Collaboration Field (regardless of whether such IPR is in or outside the Collaboration Field), or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">expressly identified in, or identified or developed pursuant to, any of the Collaboration Plans, and is
generated or acquired (by assignment, license, or otherwise) during the *** period following the expiry or earlier termination of the Collaboration Term; </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:19%; font-size:10pt; font-family:Times New Roman">by or on behalf of either or both of the Parties and includes the IPR listed in Schedule
<B>1.1.16</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT></U>&#148; shall mean <FONT
STYLE="white-space:nowrap">Know-How</FONT> generated or acquired during the Collaboration Term by either or both of the Parties or their Affiliates and shall include such <FONT STYLE="white-space:nowrap">Know-How</FONT> that is recorded in the
records of the Joint Steering Committee or the Development and Commercialization Committee. For the avoidance of doubt Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT> includes but is not limited to that
<FONT STYLE="white-space:nowrap">Know-How</FONT> listed in Schedule <B>1.1.17</B>, which Schedule shall amended or updated from time to time by the Joint Steering Committee. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Collaboration Patent</U>&#148; shall mean any Patent within the Collaboration IPR.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Collaboration Plans</U>&#148; shall mean the Target Discovery Plan or Drug Discovery Plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Collaboration Research Goal</U>&#148; shall mean ***. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Collaboration Research Technology IPR</U>&#148;<B> </B>shall mean any IPR within the Collaboration IPR
that is solely in respect of Research Technology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Collaboration Targets</U>&#148; shall mean the Biological Targets listed in Schedule <B>1.1.22</B> as
may be updated or amended by the joint Steering Committee pursuant to Article 4. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Collaboration Term</U>&#148; shall mean ***. For the avoidance of doubt, unless otherwise expressly
provided, all references in this Agreement to acts, events or occurrences taking place within a specified period after the expiration or earlier termination of the Collaboration Term shall mean the Collaboration Term excluding the aforementioned, or
any other, additional holdover negotiation period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Collaboration Year</U>&#148; shall mean such annual period during the Collaboration Term as commences
upon the date of this Agreement (&#147;<U>Collaboration Year 1</U>&#148;) or upon the anniversary of the date of this Agreement (&#147;<U>Collaboration Year 2</U>&#148;, &#148;<U>Collaboration Year 3</U>&#148;, etc.). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#148;<U>Combination Product</U>&#148; means any Licensed Product, Niche Candidate or Residual Product that
(a)&nbsp;is incorporated in a physical admixture with one or more other pharmacologically active ingredients that do not constitute Licensed Products, Niche Candidates or Residual Products, (b)&nbsp;is contained separately but marketed as a unit
with one or more other pharmacologically active ingredients that do not constitute Licensed Products, Niche Candidates or Residual Products, or (c)&nbsp;is incorporated in a physical admixture with, or contained separately but marketed as a unit
with, </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement
(indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
one or more other Licensed Products, Niche Candidates or Residual Products, the Net Sales of which require the payment of a different royalty rate than the Licensed Product, Niche Candidate or
Residual Product with which they are combined or otherwise sold (by reason of different Product Class&nbsp;categorization under Subsections <B>1.1.11</B>; <B>1.1.12</B> or <B>1.1.13</B>, different applicable Scenarios pursuant to Section [7.8, or
otherwise under the terms of this Agreement). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.26</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Commercial Optimization</U>&#148; shall mean the optimal effectiveness, productivity or success of the
Collaboration, including with respect to </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the execution of any <FONT STYLE="white-space:nowrap">Pre-project,</FONT> Project, Target Discovery Plan or
Drug Discovery Plan<B> </B>(including any project undertaken pursuant to such plans); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the identification, discovery, development or commercialization of any Collaboration Targets, Drug Candidates,
Licensed Products, Niche Candidates or Residual Products (including, in each case, with respect to any assessment, testing, manufacturing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development or use, or FDA, EMEA or other
regulatory authority application, submission, authorization or approval with respect thereto; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the generation or acquisition of IPR by or on behalf of either or both of the Parties or any of their
respective Affiliates (including any rights in respect of any <FONT STYLE="white-space:nowrap">Know-How,</FONT> Research Technology or Patents) with respect to any of the foregoing, or the prosecution, maintenance or enforcement of any such rights
of either or both Parties or any of their respective Affiliates with respect thereto; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exercise of any rights or licenses, performance of any obligations, or conducting of any other activities
authorized or required by this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.27</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Commercially Reasonable Efforts</U>&#148; shall mean such commercially reasonable efforts as are
consistent with the efforts that a comparable Third Party in the pharmaceutical industry would employ for other products or, where applicable, IPR, of a similar strategic importance and commercial value. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.28</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Confidential Information</U>&#148; shall mean the specific terms of this Agreement or the Kirostim
Agreement and any of the following that are, or have been, received or otherwise obtained by a Party or its Affiliate (the &#148;<U>Receiving Party</U>&#148;) directly or indirectly, from the other Party or the other Party&#146;s Affiliate (the
&#148;<U>Disclosing Party</U>&#148;) at any time in connection with the Parties&#146; discussions and negotiations pertaining to this Agreement or upon or after the Effective Date hereof, and that comprise or regard the existing or prospective
Intellectual Property Rights, products, business, assets or objectives of the Disclosing Party, or any item or aspect thereof: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Know-How,</FONT> Materials and unpublished Patents (including any claims or
other contents of such Patents); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other knowledge, concepts, ideas, information or data; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any tangible embodiments of any of the foregoing items referred to in (i)&nbsp;or (ii), including any
biological materials; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other tangible or intangible matter comprising, regarding or reflecting the Disclosing Party&#146;s
existing or prospective Intellectual Property Rights, products, business, assets or objectives, in each case ((i) through (iv)) whether or not the items referred to are patentable. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, Confidential Information shall include, without limitation, any such
<FONT STYLE="white-space:nowrap">Know-How,</FONT> Materials, information or other matter so received or obtained by the Receiving Party as comprises or regards the Disclosing Party&#146;s existing or prospective:
<FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical or other research (including any associated plans, practices, processes, protocols, data or results); discoveries or inventions; scientific, manufacturing, marketing, financing, business
or product research, developments, opportunities, plans, methods, processes or procedures; quality controls; security controls; unpublished cost, price or pricing information; financial or personnel matters; or customer, client or supplier lists or
information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Confidential Information shall not include <FONT STYLE="white-space:nowrap">Know-How,</FONT>
information or other matter that the Receiving Party can prove by ***: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">was known or used by the Receiving Party prior to its date of receipt or procurement by the Receiving Party
directly or indirectly from the Disclosing Party; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">either before or after the date of the receipt or procurement by the Receiving Party is lawfully disclosed to
the Receiving Party by sources other than the Disclosing Party rightfully in possession of such information or other matter and not bound by confidentiality obligations to the Disclosing Party; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">either before or after the date of the receipt or procurement by the Receiving Party is or becomes published or
otherwise is or becomes part of the public domain through no breach hereof on the part of the Receiving Party; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is independently developed by or for the Receiving Party without reference to or reliance upon the Confidential
Information of the Disclosing Party as demonstrated by written records. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.29</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Control</U>&#148;, &#148;<U>Controlled</U>&#148;, &#148;<U>Controls</U>&#148; and
&#148;<U>Controlling</U>&#148; shall mean, with respect to any tangible or intangible subject matter, including, without limitation, any IPR, the possession of the legal right, power and ability (whether by ownership, license or otherwise) to grant
any access to, possession or use of, or assignment, license, sublicense or other authorization or right with respect to or under, such Intellectual Property Rights or other subject matter as provided for in this Agreement (independently and other
than by reason of any license, sublicense, consent or authorization by the other Party or any Affiliate of the other Party), without violating any applicable Law, agreement or arrangement, or other enforceable obligation, existing and in effect at
the time of such grant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.30</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Drug Candidate</U>&#148; shall mean any molecule or precursor to any molecule, or any composition or
formulation of any molecule or of any precursor to any molecule, which is comprised of, modulates, interacts with, or derived from any Collaboration Target or of any ligand thereof, in the Collaboration Field. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.31</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Drug Discovery Plan</U>&#148; shall mean the Parties&#146; joint research plans for individual
projects in the Collaboration Field that involve Drug Candidates, in respect of one or more indications, that are <FONT STYLE="white-space:nowrap">post-M0</FONT> but <FONT STYLE="white-space:nowrap">pre-M1</FONT> and are to be actively pursued by
IPH and NN as set forth in the annexed Schedule <B>1.1.31</B> or in any update or amendment to such Schedule as may hereafter be directed by the Joint Steering Committee pursuant to the terms and conditions of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.32</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Effective Date</U>&#148; shall mean September&nbsp;30, 2003. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.33</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Exploratory Targets&#148; shall mean the Biological Targets identified in Schedule <B>1.1.33</B> and any
other Biological Targets that the Joint Steering Committee finds to be of sufficient potential interest for identification, study or assessment or future identification, study or assessment in the Collaboration and are subsequently added to Schedule
<B>1.1.33</B> after the date of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.34</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U><FONT STYLE="white-space:nowrap">Ex-vivo</FONT> Cellular Therapy Candidate</U>&#148; shall mean any
specific molecule, composition or formulation that is hereafter classified for Independent further development for use in an <FONT STYLE="white-space:nowrap">ex-vivo</FONT> setting pursuant to the terms and conditions of such <FONT
STYLE="white-space:nowrap">Ex-Vivo</FONT> Task Force guidelines as may hereafter be agreed to by the Parties in accordance with Section<B>&nbsp;6.2</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.35</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>First Commercial Sale</U>&#148; shall mean, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the first date that a Licensed Product, Niche Candidate or Residual Product<B> </B>is sold or in any other way made commercially available for marketing in such country by a Party or
any of its Affiliates or <FONT STYLE="white-space:nowrap">Out-licensees</FONT> after having obtained the applicable regulatory marketing authorization approval. First Commercial Sales shall not include any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">not-for-profit</FONT></FONT> disposition for charitable, promotional, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical, regulatory or governmental purposes. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, (a)&nbsp;any reference in this Agreement to the First Commercial Sale of a product
for a specified indication shall mean solely the First Commercial Sale of such product for the specified indication; and (b)&nbsp;any reference herein to a First Commercial Sale as a Development Milestone shall mean a
<FONT STYLE="white-space:nowrap">one-time</FONT> event comprised of the First Commercial Sale in any country in the Territory, such that NN shall be required to pay the specified Development Milestone amount no more than once irrespective of the
number of countries in which such First Commercial Sale is ultimately achieved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.36</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Force Majeure</U>&#148; shall mean any event or circumstance which intervenes after the Effective Date
and is beyond the control of the affected Party or other Person rendering performance hereunder and which could not reasonably have been foreseen and not reasonably prevented by that Party or other Person and which results in or causes the failure
of that Party to perform any or all of its obligations under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.37</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Independent IPH IPR</U>&#148; shall mean such IPR in the Collaboration Field as is generated or
acquired (by assignment, license or otherwise) by IPH or any of its Affiliates (other than such IPR generated or acquired by any Third Party prior to it becoming an Affiliate of IPH): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at any time during the portion of the Collaboration Term commencing upon the date of this Agreement; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">within the period of *** following immediately after the expiration or termination of the Collaboration Term;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that is not within the Collaboration IPR but is Controlled by IPH or any of its Affiliates and is necessary or
useful for Commercial Optimization of Licensed Products, Niche Candidates, or Residual Products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.38</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Independent IPR</U>&#148; shall mean Independent IPH IPR or Independent NN IPR. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.39</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Independent NN IPR</U>&#148; shall mean such IPR in the Collaboration Field as (a)&nbsp;is generated
or acquired (by assignment, license or otherwise) by NN or any of its Affiliates (other than such IPR generated or acquired by any Third Party prior to it becoming an Affiliate of NN) at any time during the portion of the Term commencing upon the
date of this Agreement, and (b)&nbsp;is not within the Collaboration IPR but is Controlled by NN or any of its Affiliates and is necessary or useful for Commercial Optimization of such Niche Candidates, Residual Products or Licensed Products as IPH
may hereafter become authorized to commercialize pursuant to the terms and conditions of this Agreement. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.40</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Intellectual Property Rights</U>&#148; or &#148;<U>IPR</U>&#148; shall mean any legally, equitably or
otherwise enforceable right, title or interest (including all rights of authorship and copyrights, provisional and other Patent rights, Trade Secret rights, registered design rights, and rights in databases and data compilations) arising from,
comprising, comprised in, or with respect to any Patents or <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.41</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Intermediate Discovery Milestone</U>&#148; shall have the meaning ascribed to it in Schedule
<B>1.1.41</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.42</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Joint IPR</U>&#148; shall mean Collaboration IPR that is generated by one or more employees, agents,
consultants or other Persons acting on behalf of IPH or any of its Affiliates (acting independently or with one or more Third Parties), on the one hand, and NN or any of its Affiliates (acting independently or with one or more Third Parties), on the
other hand (so as to establish joint inventorship in the case of Patents), or that is otherwise jointly owned by (a)&nbsp;the Parties, (b)&nbsp;a Party and one or more Affiliates of the other Party, or (c)&nbsp;one or more Affiliates of a Party
together with one or more Affiliates of the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.43</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Joint Steering Committee</U>&#148; shall mean the committee established pursuant to Article <B>3</B>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.44</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Kirostim Agreement</U>&#148; shall mean the Research, Development and License Agreement between IPH
and NN dated September&nbsp;30, 2003. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.45</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Kirostim Field</U>&#148; shall mean<B> </B>any human therapeutic, prophylactic or diagnostic
indications in the following fields: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.46</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U><FONT STYLE="white-space:nowrap">Know-How</FONT></U>&#148; shall mean any ideas, concepts, knowledge,
information, skill, experience, materials (including any Materials), Research Technology, inventions, Trade Secrets or data, whether or not confidential or proprietary, patented or patentable, copyrighted or copyrightable, or in written, electronic
or any other tangible or intangible form, that comprise or relate to, without limitation, discoveries, formulae, algorithms, computer programs, software, specifications, directions, instructions, libraries, biological or other materials including
molecules, manufactures, compounds, </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been
excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
compositions, formulations, reagents or other biological or chemical entities, agents, targets, processes or materials (including, for example, antibodies, specialized tools, data compilations,
data collections or databases, models, designs, drawings, plans, prototypes, practices, methods, processes, procedures, systems, techniques, technologies or means (including high-throughput screening, gene expression, genomics, proteomics,
purification or isolation techniques, antibody generation or characterization techniques or other drug identification, research, discovery or development technologies), identification schemes, test protocols, procedures or results, data generated in
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical studies (including pharmacological, toxicological or clinical information or test data), analytical, quality control or quality assurance data, manufacturing, marketing, pricing,
distribution, cost or sales information, data or descriptions. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.47</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Law</U>&#148; shall mean any law, statute, code, treaty, convention, ordinance, rule, regulation,
judgment, award, order, directive or pronouncement of any domestic, foreign, federal, state, local or other government or governmental organ, agency or subdivision having the binding effect of law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.48</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Licensed Product</U>&#148; shall mean any Drug Candidate that has attained *** and has been discovered
or developed, in whole or in part, pursuant to the Collaboration, and shall include, with respect to any such Drug Candidate any Backup Product or Backup Products for such Drug Candidate, and which shall together constitute but a single
&#148;Licensed Product&#148; for purposes of determining the milestone payments payable under Article <B>7</B> of this Agreement. For the avoidance of doubt, <FONT STYLE="white-space:nowrap">Anti-KIR</FONT> shall be a Licensed Product for the
purpose of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.49</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Material Adverse Effect</U>&#148; shall mean any material adverse effect of any nature or relevance
upon the business, assets, liabilities, rights, privileges, results of operations, business or financial opportunities or prospects, or financial condition of, the affected Party or any of its Affiliates, or the ability of the Party to exercise its
rights, fulfill its warranties or perform its obligations under this Agreement or consummate the transactions contemplated hereby, either directly or through permitted other Persons. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.50</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Materials</U>&#148; shall mean all biological, chemical and other materials in the Collaboration Field
that are (a)&nbsp;contributed by either or both Parties to the other Party or the Parties under the Collaboration; (b)&nbsp;generated or acquired by one or both Parties during the Collaboration Term pursuant to activities conducted pursuant to the
Collaboration, (c)&nbsp;exchanged by the Parties pursuant to the Collaboration, or (d)&nbsp;exchanged between a Party and any Third Party pursuant to activities conducted pursuant to the Collaboration, during the Collaboration Term.
</P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement
(indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.51</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>M0</U>&#148; shall have the meaning ascribed to it in the annexed Schedule <B>1.1.51</B>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.52</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>M1</U>&#148; shall have the meaning ascribed to it in the annexed Schedule <B>1.1.52</B>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.53</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Net Sales</U>&#148; shall mean ***. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.54</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<U>Niche Candidate</U>&#148; shall mean any Drug Candidate or Licensed Product that NN, in the
exercise of its sole discretion, has approved for independent further development by IPH (whether solely or with NN) pursuant to the provisions of Article <B>6</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.55</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U><FONT STYLE="white-space:nowrap">Out-license</FONT></U>&#148; and &#148;<U><FONT
STYLE="white-space:nowrap">Out-licensing</FONT></U>&#148; shall mean such a grant to a Third Party of some or all of the rights and obligations of a Party under this Agreement as includes the grant of a right to sell, have sold or otherwise
commercialize the Licensed Products, Niche Candidates or Residual Products for one or more applications, uses, purposes or indications. &#147;<U><FONT STYLE="white-space:nowrap">Out-licensor</FONT></U>&#148; and &#148;<U><FONT
STYLE="white-space:nowrap">Out-licensee</FONT></U>&#148; shall be construed accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.56</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Patent</U>&#148; shall mean any U.S., <FONT STYLE="white-space:nowrap">non-U.S,</FONT> international
or multinational patent, patent application (petty, provisional, <FONT STYLE="white-space:nowrap">non-provisional</FONT> and other), or other government-issued indicia of invention or industrial design ownership, including but not limited to
continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisionals, continued prosecutions, utility models, extensions (including but not limited to extensions under the U.S Patent Term
Restoration Act, extensions of patents under the Japanese Patent Law, and supplementary protection certificates and any amendments thereof as well as any equivalent or other extensions in other jurisdictions), registrations, renewals, restorations,
confirmations, substitutions and additions thereof and all reissues, validations, revalidations and reexaminations thereof, including any patents issuing therefrom and any foreign counterparts thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.57</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Person</U>&#148; shall mean any person, organization or entity, whether natural, legal or other,
including any individual, corporation, firm, partnership, limited liability company, joint venture, estate, trust, unincorporated association or governmental entity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.58</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U><FONT STYLE="white-space:nowrap">Pre-project</FONT></U>&#148; shall mean any Collaboration research
project agreed upon by the Joint Steering Committee that both (a)&nbsp;deals with research of a specific idea or concept through target validation and identification of at least one lead compound until achievement of M0 status, and (b)&nbsp;is
included in the Target Discovery Plan; and &#147;<U>Project</U>&#148; shall mean any Collaboration research project agreed upon by the Joint Steering Committee that deals with any bona fide and approved research in respect of a Drug Candidate for
one or more indications between M0 and M1 pursuant to the Drug Discovery Plan. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.59</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Product Class</U>&#148; shall mean any class of Licensed Product referred to in Sections <B>1.1.11,
1.1.12 or 1.1.13</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.60</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Project Review</U>&#148;<B> </B>shall mean the *** review of projects in the NN Research and
Development portfolio that take place in the spring and fall of each calendar year. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.61</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Research Technology</U>&#148; shall mean any process, or any molecule, manufacture, compound,
composition, formulation, reagent or other biological or chemical entity, agent, target or material (including, for example, any antibody), used or usable primarily as a research tool (for example, as a target for screening), as distinguished from
any actual or potential use primarily as a therapeutic, prophylactic, or commercializable diagnostic product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.62</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Research Technology IPR</U>&#148; shall mean any IPR in respect of Research Technology. For the
avoidance of doubt, all licenses hereunder with respect to Research Technology IPR authorize use of Research Technology solely as a research tool (as opposed to use as a therapeutic, prophylactic, or commercializable diagnostic product).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.63</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Residual Product</U>&#148; shall mean a Drug Candidate to which: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="28%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(a)&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="33%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="33%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="33%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="28%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="33%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="33%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.64</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U><FONT STYLE="white-space:nowrap">Sub-license</FONT></U>&#148; and&#148;<U><FONT
STYLE="white-space:nowrap">Sub-licensing</FONT></U>&#148; shall mean the grant of a <FONT STYLE="white-space:nowrap">sub-license</FONT> to perform some of the rights and obligations under this Agreement but shall not include the grant of a right to
sell, have sold or otherwise commercialize a Licensed Product, Niche Candidate or Residual Product.&#148;<U><FONT STYLE="white-space:nowrap">Sub-licensor</FONT></U>&#148; and&#148;<U><FONT STYLE="white-space:nowrap">Sub-licensee</FONT></U>&#148;
shall be construed accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.65</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Target Discovery Plan</U>&#148; shall mean the joint research plans for individual projects in the
Collaboration Field that are in the <FONT STYLE="white-space:nowrap">pre-M0</FONT> stage of development and that are to be actively pursued by IPH and NN as set forth in the annexed Schedule <B>1.1.65</B> or in any update or amendment to such
Schedule pursuant to <B>Article 4</B>. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has
been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.66</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Term</U>&#148; shall mean the period commencing upon the Effective Date, and expiring, on a Licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product, Niche <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Candidate-by-Niche</FONT></FONT> Candidate, and Residual
Product-by-Residual Product basis, upon the later to occur of the expiration, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Valid Claim
of all: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Collaboration Patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Patents within the Background IPH IPR; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Patents within the Background NN IPR; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Patents within the Independent IPH IPR listed in Schedule <B>9.5.4(a)</B>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Patents within the Independent NN IPR listed in Schedule <B>9.5.4(b);</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that would be infringed by the unlicensed manufacture, use, importation or sale in or into such country of such
Licensed Product, Niche Candidate or Residual Product, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a period of ten (10)&nbsp;years following immediately after the First Commercial Sale of a Licensed Product,
Niche Candidate or Residual Product in the relevant country. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.67</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Territory</U>&#148; shall mean the entire world, including all countries thereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.68</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Third Party</U>&#148; shall mean a Person other than the Parties or their Affiliates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.69</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Third Party Collaboration</U>&#148; shall mean collaborative work undertaken by independent Third
Parties together with either Party, or both Parties, that (a)&nbsp;exist at the date of this Agreement and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">are listed in either Schedule <B>1.1.69A</B> (NN Collaborations Relevant to this Agreement) or Schedule
<B>1.1.69B</B> (IPH Collaborations Relevant to this Agreement) or (b)&nbsp;that will be established pursuant to the terms and conditions of this Agreement. Third Party Collaborations that are entered into pursuant to the terms and conditions of this
Agreement shall be listed in Schedule <B>1.1.69C</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.70</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Third Party IPR</U>&#148; shall mean IPR Controlled by either or both Parties that is acquired (by
assignment, license, or otherwise) from, or that is generated as part of a collaboration with, any Third Party as a result of agreement of the Parties pursuant to Section<B>&nbsp;3.4</B>. To the extent such IPR is Controlled by a Party, Third Party
IPR in the Collaboration Field shall constitute Collaboration IPR. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.71</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Trade Secret</U>&#148; means any idea, information, data, material or other tangible or intangible
matter, including any formula, pattern, compilation, program, device, method, technique, or process, that derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means
by, other Persons who can obtain economic value from its use or disclosure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.72</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Upside Revenue</U>&#148; shall mean ***. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.73</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Valid Claim</U>&#148; shall mean, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, a claim of an issued and unexpired Patent which (a)&nbsp;has not been held permanently revoked, unenforceable or invalid by a decision of a
court or other governmental agency of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, and (b)&nbsp;has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise. As used
in this Agreement, &#148;expire,&#148; &#147;expiration&#148; and words of similar effect, when referring to a Valid Claim or Patent shall mean any expiration, revocation, invalidation or other termination of such Valid Claim or Patent, and a Valid
Claim or Patent shall be deemed to expire at 00:00 a.m. on the date of such expiration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitions of other terms used in this Agreement: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affected IPH Persons</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arm&#146;s Length Transaction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.1.53</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Buy-In-Option</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.5.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change of Control</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">20.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Claim</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">16.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical Hold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">12.7</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Combination Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.1.25</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defending Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.15</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development and Commercialization Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Developing Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">12.8</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development Milestones</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">7.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosing Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.1.28</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discovery Milestones</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">7.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">13.3.6(a)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FTE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnified Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">16.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnifying Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">16.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">14.2</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Indemnitees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">16.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1.1.53</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Introductory&nbsp;Paragraph</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Introductory Paragraph</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product Marks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.17.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Project</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Project Manager</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receiving Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Residual Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share Purchase Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.1</TD>
<TD NOWRAP VALIGN="bottom">(b)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">***</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Construction</U>. As used in this Agreement, unless the express terms or context herein clearly require
otherwise: (a)&nbsp;words denoting the singular shall include the plural and vice versa; (b)&nbsp;words denoting the masculine shall include the feminine and vice-versa; (c)&nbsp;words denoting persons shall include bodies corporate and vice-versa;
(d)&nbsp;references to Recitals, Articles, Sections, Subsections and Paragraphs are to recitals, articles, sections, subsections and paragraphs of this Agreement; (e)&nbsp;references to Exhibits, Schedules or Appendices are to exhibits, schedules
and appendices to this Agreement; (f)&nbsp;references to Laws are to such Laws as they may be amended from time to time or to any successor Laws, and references to particular provisions of a Law include any corresponding provisions of any succeeding
Law; (g)&nbsp;references to agreements and contracts shall include any amendments and supplements thereto duly executed from time to time; (h)&#148;include,&#148; &#147;including&#148; and words of similar effect are used in the inclusive sense of
&#148;including, without limitation&#148;; (i) &#148;or&#148; is used in the inclusive sense of &#148;and/or&#148;; (j)&#148;any&#148; is used in the sense of &#148;any and/or all&#148;; (k) section captions and headings are used for convenience of
reference only and shall not affect the interpretation of this Agreement; (l)&#148;herein,&#148; &#147;hereof&#148;, &#148;hereunder&#148; and words of similar effect refer to the entirety of this Agreement; and (m)&#148;days&#148; refer to calendar
days. The language of this Agreement shall be construed according to its fair meaning and not strictly against either Party. In the event of any translation of this Agreement from its original written expression in English, the original, English
version of this Agreement shall control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NATURE OF AGREEMENT AND PRIVILEGED COMMUNICATIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Collaboration Exclusivity</U>. Save for only such activities, personnel, resources and facilities of any
Affiliate of a Party that, prior to it&#146;s becoming an Affiliate of such Party, have been made subject to a binding commitment that would conflict with such Affiliate&#146;s performance of the exclusivity requirements set forth in this
Section<B>&nbsp;2.1</B>, below: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exclusivity During Collaboration Term</U>. During the Collaboration Term, the Collaboration shall be
exclusive with respect to all matters in the Collaboration Field and each Party (including each of their respective Affiliates) shall dedicate all its activities, personnel, resources and facilities in the Collaboration Field exclusively to the
Collaboration. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this
agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exclusivity Holdover Period</U>. Except as otherwise expressly herein provided, (a)&nbsp;neither Party, nor
any of such Party&#146;s Affiliates, shall undertake or use in the Collaboration Field any such activities, personnel, resources or facilities independently of the Collaboration for *** following the expiry or earlier termination of the
Collaboration Term, and (b)&nbsp;neither Party, nor any of such Party&#146;s Affiliates, shall enter into collaboration with any Third Party in respect of subject matter of any Target Discovery Plan or Drug Discovery Plan for the two years following
the expiry or earlier termination of the Collaboration Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, after the expiration of such *** post-Collaboration Term period, each Party and its
respective Affiliates shall have the right to undertake any activities in the Collaboration Field independently of the Collaboration, whether individually or with any Third Party, including for purposes of the discovery, development or
commercialization of products in the Collaboration Field, subject only to the obligations of such Party and the rights or licenses of the other Party that, by the express terms of this Agreement, survive the expiration or termination of the
Collaboration Term, including, where applicable, the obligation to obtain and provide to the other Party the Third Party rights and licenses necessary to secure the freedom of operation to exercise its rights and licenses hereunder.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Joint Research Agreement</U>. This Agreement is intended and shall serve, among other things, as a
&#148;joint research agreement&#148; for purposes of Section 103(c) of the U.S. Patent Act, as amended, 35 U.S.C. &#167; 103(c), and the Parties shall render to one another all reasonable assistance and cooperation, including the preparation and
filing of such terminal disclaimers and other documents, required to procure and preserve the protections under said statute. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Kirostim Agreement</U>. This Agreement shall supersede and replace the Kirostim Agreement and all amendments
thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COLLABORATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Collaboration Objective</U>. The undertaking and objective of the Collaboration, as set out in the
Collaboration Plans, is for each Party individually, jointly with the other Party, or pursuant to one or more approved Third Party Collaborations, to<B> </B>research, discover and identify (i)&nbsp;Biological Targets within the Collaboration Field
as Collaboration Targets, and (ii)&nbsp;ligands and other molecules, compositions, formulations and processes modulating or interacting with such Collaboration Targets, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to further develop and progress such targets, ligands and other agents to Drug Candidates possessing M0 status
as set forth in the annexed Schedule <B>1.1.51</B>, in accordance with the Target Discovery Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to conduct additional and other research and development to optimize such Drug Candidates and further develop
and progress them to M1 status as further set forth in the annexed Schedule <B>1.1.52</B>, in accordance with the Drug Discovery Plan, in each case in accordance with the terms and conditions of this Agreement; and </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a result of the foregoing, to enable (i)&nbsp;NN to further develop, and progress Licensed Products for
further development and commercialization exclusively by or on behalf of NN (or its Affiliates or <FONT STYLE="white-space:nowrap">Out-licensees)</FONT> in accordance with its rights and licenses hereunder, and/or (ii)&nbsp;to license or <FONT
STYLE="white-space:nowrap">co-license</FONT> to IPH pursuant to Article <B>6</B>, the exclusive or <FONT STYLE="white-space:nowrap">co-exclusive</FONT> (with NN) right (with the rights to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT
STYLE="white-space:nowrap">Out-license)</FONT> to develop and progress such Drug Candidates as may hereafter be approved by NN as Niche Candidates for further development and commercialization. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Duration of the Collaboration</U>. The initial duration of the Collaboration shall be for a period of three
(3)&nbsp;years commencing upon the date of this Agreement&nbsp;&nbsp;&nbsp;&nbsp;In addition<I>:</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Optional Extensions of the Initial Collaboration Term</U>. Irrespective of whether or not the Parties have
attained the Collaboration Research Goal on or before the third anniversary of the date of this Agreement, NN shall have the right to *** annual extensions of the initial term of the Collaboration, upon notice to be provided to IPH at least ***
prior to the third and fourth anniversaries of the date of this Agreement, respectively, for a maximum extension of two (2)&nbsp;years, subject to the requirement that NN continue to provide to IPH annual research funding during each such annual
extension period of no less than the amount of funding required to be provided by NN during the third year of the Collaboration pursuant to Section<B>&nbsp;3.13</B> (which amount shall be adjusted for inflation pursuant to the French INSEE inflation
index effective upon the commencement date of each such annual extension period) and IPH shall dedicate exclusively to the Collaboration, on a full-time basis, the corresponding number of FTEs required by that Section; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Option to Discuss New Collaboration During Holdover Negotiation Period</U>. In the event that NN shall
exercise the above renewal option for both annual extension periods, upon notice to be provided by either Party to the other at least *** prior to the expiration of the second such period, the Parties will have *** following the expiration of such
extension period to negotiate in good faith the terms of a new agreement, and for the duration of such negotiation period (and any extension of such period as may be agreed to by the Parties) the Collaboration Term shall be extended and this
Agreement shall remain in full force and effect, <I>provided that</I>, for the avoidance of doubt, NN shall have no research funding obligation to IPH with respect to such post-expiration holdover negotiation period. In the event that the Parties
shall fail to agree in writing to the terms of a new agreement prior to the expiry of such negotiation period, the Collaboration Term shall expire upon the close thereof; </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Revised Objectives for Extended Collaboration</U>. If NN shall cause the initial term of the Collaboration
to be extended for any annual period pursuant to Section <B>3.2(a)</B>, prior to, or within *** after, the commencement of such extension period the Joint Steering Committee shall adopt specific objectives for such extension period in substitution
for the Collaboration Research Goal in accordance with the procedures set forth in Section<B>&nbsp;4.5</B>, save that the adoption of such objectives for any such extension period shall be subject to the written approval of the senior management of
both Parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Failure to Attain Collaboration Research Goal</U>. For the avoidance of doubt, and without limitation of the
Parties&#146; obligations to exercise Commercially Reasonable Efforts, or of any other obligations under this Agreement or remedies for the material breach thereof, the failure to attain the Collaboration Research Goal, in and of itself, shall not
constitute a breach of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Third Party Collaborations</U>. It is the intent of the Parties that IPR and
<FONT STYLE="white-space:nowrap">Know-How</FONT> in the Collaboration Field that is useful for Commercial Optimization and is acquired (by license, assignment or otherwise) under or generated within any Third Party Collaboration shall be, to the
extent authorized by contract and permitted by applicable law, made available to the other Party as part of the Collaboration, during the Collaboration Term (and throughout the Term in respect of Collaboration IPR arising therefrom).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Duty to Maintain</U>. Except as otherwise agreed to by the Parties, during the Collaboration Term, and to
the extent authorized by contract and permitted by applicable Law, any Party that is also a party to a Third Party Collaboration listed in the annexed Schedules <B>1.1.69A, 1.1.69B, or 1.1.69C</B> shall use Commercially Reasonable Efforts to
maintain such Third Party Collaboration (including by, at its own expense, renewing any agreement that governs such Third Party Collaboration that may expire) during the Collaboration Term under similar terms to those that exist as of the date of
this Agreement or when such Third Party Collaboration is otherwise added to Schedule <B>1.1.69C</B>). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that any such Third Party Collaboration is terminated either (a)&nbsp;by breach of the Party or
action of the other party thereto (without reasonable possibility for revival or replacement) or (b)&nbsp;otherwise by approval of the Parties, during the Collaboration Term, the original Party to such terminated Third Party Collaboration shall, to
the extent authorized by contract and permitted by applicable law, use Commercially Reasonable Efforts to promptly provide the other Party with, or assist the other Party in acquiring, the opportunity to enter into a similar Third Party
Collaboration with the other party to such terminated Third Party Collaboration. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Reports on Progress in and Status of Third Party Collaborations</U>. During the Collaboration Term and to
the extent authorized by contract and permitted by applicable Law, a Party to a Third Party Collaboration shall keep the other Party reasonably regularly notified regarding the status and progress of such Third Party Collaboration in respect of
projects in the Collaboration Field (including by reporting such progress in the context of the Joint Steering Committee). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPR that is or may be Acquired Under Third Party Collaborations</U>. During the Collaboration Term, and to
the extent authorized by contract and permitted by applicable Law, any Party that is also a party to a Third Party Collaboration listed in the annexed Schedule <B>1.1.69A, 1.1.69B, and 1.1.69C</B> shall </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">promptly notify the other Party of any IPR in the Collaboration Field arising from such Third Party
Collaboration that is acquired (by license, assignment or otherwise) or generated as party of such Third Party Collaboration, and thereby Controlled by the Party (such IPR shall be, to the extent appropriate, be added to Schedule <B>1.1.16</B>), and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event that an opportunity to acquire IPR as part of such Third Party Collaboration arises that the Party
to the Third Party Collaboration does not intend to pursue, promptly notify the other Party of such opportunity and provide the other Party with such opportunity in accordance with the provisions of Section<B>&nbsp;3.4</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Procedure for New Third Party Collaborations</U>. During the Collaboration Term, the Parties shall enter
into Third Party Collaborations only in accordance with the provisions of Section<B>&nbsp;3.4</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Allocation of <FONT STYLE="white-space:nowrap">Pre-project</FONT> or Project Responsibilities to Third Party
Collaborations</U>. The Parties may, to the extent authorized by contract and permitted by applicable Law, by agreement of the Joint Steering Committee, allocate responsibilities for any <FONT STYLE="white-space:nowrap">Pre-project,</FONT> Project
or aspect of any such Project or <FONT STYLE="white-space:nowrap">Pre-project</FONT> to any Third Party Collaboration, in accordance with the terms and conditions of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Non-interference</FONT></U>. Except as provided for herein or otherwise
agreed by the Parties, neither Party shall interfere with any Third Party Collaboration involving the other Party or any prospective renewal or expansion of the same during the Collaboration Term. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Third Party Collaboration Materials and <FONT STYLE="white-space:nowrap">Know-How</FONT></U>. During the
Collaboration Term, any Party to a Third Party Collaboration shall, to the extent authorized by contract and permitted by applicable Law, make available to the other Party reasonable quantities of any samples of Materials or other <FONT
STYLE="white-space:nowrap">Know-How</FONT> arising from such Third Party Collaboration that may be useful for Commercial Optimization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Presentation of <FONT STYLE="white-space:nowrap">In-Licensing</FONT> and New Third Party Collaboration
Opportunities</U>. The Parties shall present to the Joint Steering Committee all opportunities that arise during the Collaboration Term to <FONT STYLE="white-space:nowrap">(a)&nbsp;in-license</FONT> or otherwise acquire Third Party Controlled IPR in
the Collaboration Field or (b)&nbsp;generate or otherwise acquire IPR as part of a collaboration with any Third Party. All such opportunities shall be considered by the Joint Steering Committee on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. The Parties shall have *** days after a Party&#146;s presentation of such opportunity to decide whether or not to: <FONT STYLE="white-space:nowrap">(a)&nbsp;in-license</FONT> or otherwise
acquire such IPR as Third Party IPR; or (b)&nbsp;establish a new Third Party Collaboration (which shall be added to Schedule <B>1.1.69)</B> pursuant to which any IPR licensed or otherwise acquired under or that arises from the Third Party
Collaboration is made accessible to the other Party for the purposes of the Collaboration (any such IPR shall also be considered Third Party IPR and shall be listed in Schedule <B>1.1.16</B>. The Party presenting such opportunity shall make a full
written disclosure to the other Party of all material facts known by such Party with respect to the subject matter of the proposed opportunity, in such timely fashion as to permit the other Party to make an informed decision as to how to proceed in
respect of such matters. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Determination of Responsibility for Acquisition of Approved Third Party IPR</U>. If one Party presents such
an opportunity to the Joint Steering Committee, then if the other Party agrees that the Collaboration should take one of the proposed actions, the Parties shall negotiate in good faith, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, which Party shall be responsible for negotiation of the relevant Third-Party IPR acquisition (including <FONT STYLE="white-space:nowrap">in-licensing)</FONT> or collaboration opportunity
as well as whether and in which proportions the responsibility for payment for access to or acquisition of such third-party IPR shall be borne by the respective Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Impact of Acquired Approved Third Party IPR on Royalty Class. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Acquisition by IPH</U>. If the opportunity was presented by IPH and IPH wishes to negotiate and pay for the <FONT
STYLE="white-space:nowrap">licensing-in</FONT> or other acquisition of such Third-Party IPR, or if it is agreed by the Parties that IPH shall negotiate and pay, in whole or in part for the <FONT STYLE="white-space:nowrap">licensing-in</FONT> or
other acquisition of any such Third-Party IPR, then any product the sale of which for any purpose without a license under such IPR would infringe a Valid Claim of such IPR by virtue of such IPR comprising a Valid Claim covering the product or the
prophylactic, therapeutic, or diagnostic use thereof (as opposed to the production or other use of such product), shall, except where such product already constitutes a Class&nbsp;A Licensed Product, constitute a Class&nbsp;B Licensed Product and
IPH shall be entitled to NN&#146;s payment of the corresponding Class&nbsp;B Licensed Product royalties on Net Sales of such product during the Term in accordance with Section<B>&nbsp;7.6.2</B> and in all other events shall be classified as a
Class&nbsp;C Licensed Product; and </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been
excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Acquisition by NN</U>. If the opportunity was presented by NN and NN wishes to negotiate and pay for the <FONT
STYLE="white-space:nowrap">licensing-in</FONT> or other acquisition of such Third-Party IPR, or if it is agreed by the Parties that NN shall negotiate and pay, in whole or in part, for the <FONT STYLE="white-space:nowrap">licensing-in</FONT> or
other acquisition of any such Third-Party IPR, then any product the sale of which for any purpose without a license under such IPR would infringe a Valid Claim of such IPR by virtue of such IPR comprising a Valid Claim covering the product or the
prophylactic, therapeutic, or diagnostic use thereof (as opposed to the production or other use of such product) shall, except where such product already constitutes a Class&nbsp;A Licensed Product or Class&nbsp;B Licensed Product, constitute a
Class&nbsp;C Licensed Product and IPH shall be entitled to NN&#146;s payment of the corresponding Class&nbsp;C Licensed Product royalties on Net Sales of such product during the Term in accordance with Section<B>&nbsp;7.6.3</B>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Non-Agreed-Upon</FONT> Third-Party IPR. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Right of Acquisition by Presenting Party</U>. If, pursuant to the procedures set forth in Subsection
<B>3.4.2</B>, the Party that is not presenting the <FONT STYLE="white-space:nowrap">in-licensing</FONT> or other acquisition opportunity does not wish the IPR of or collaboration with the Third Party to be included in the Collaboration, then the
Party presenting such opportunity to the Joint Steering Committee shall have the exclusive right to take such action(s) at its own expense and on its own behalf. In the event that such Party does so, any IPR acquired or arising pursuant to such
proposed <FONT STYLE="white-space:nowrap">in-licensing,</FONT> other acquisition or Third Party collaboration shall be deemed (i)&nbsp;Independent IPH IPR if IPH is the Party taking such action or (ii)&nbsp;Independent NN IPR if NN is the Party
taking such action. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exclusive Rights of Acquiring Party</U>. In such event, the Party that acquires (by assignment, license or
otherwise), or enters into a collaboration with a Third Party with respect to, such IPR pursuant to this Subsection <B>3.4.3</B>, that Party shall have the exclusive right throughout the Territory, with the right to
<FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT STYLE="white-space:nowrap">Out-License,</FONT> to develop and commercialize products (in general or for one or more specific indications) encompassed by a Valid Claim in such IPR, without
obligation to pay or provide any royalty or other consideration to the other Party except with respect to the Net Sales of such products the sale of which are covered by a Valid Claim of a Collaboration Patent or (i)&nbsp;if NN or one of its
Affiliates is commercializing such product, a Valid Claim of a Patent within the Background IPH IPR or Independent IPH IPR; and (ii)&nbsp;if IPH or one of its Affiliates is commercializing such product, a Valid Claim of a Patent within the
Background NN IPR or Independent NN IPR. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such products covered by such Valid Claims shall be subject to the payment of either a royalty of *** on the
Net Sales thereof or alternatively *** of all royalties received by either of the Parties or any of their Affiliates in respect of Net Sales during the Term by its <FONT STYLE="white-space:nowrap">Out-licensees</FONT> of such products, as
calculated, <I>mutatis mutandis</I>, pursuant to Subsection <B>1.1.53</B>. Payment obligations in respect of royalties received from <FONT STYLE="white-space:nowrap">Out-licensees</FONT> shall be subject to the
<FONT STYLE="white-space:nowrap">Out-licensing</FONT> Party&#146;s obligation to pay to the other Party a minimum royalty equal to ***, and a maximum royalty equal to ***, of the <FONT STYLE="white-space:nowrap">Out-licensee&#146;s</FONT> Net Sales
of such products. Any of such payments shall be made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the expiration of the last to expire of the aforementioned Valid Claim covering such product in such country. For the avoidance of doubt,
(a)&nbsp;the foregoing payment obligation is in lieu of, and not in addition to, any potential or actual Upside Revenue payment obligation, (b)&nbsp;the foregoing royalty obligation shall not be subject to the alternative <FONT
STYLE="white-space:nowrap">ten-</FONT> <FONT STYLE="white-space:nowrap">(10-)</FONT> year royalty payment period prescribed by Section<B>&nbsp;1.1.66</B>, and (c)&nbsp;the Party commercializing such product shall have no obligation to pay or provide
any milestone fee or other consideration to the other Party in connection with its development or commercialization thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No NN Funding of <FONT STYLE="white-space:nowrap">Non-Collaboration</FONT> Activities</U>. For the avoidance
of doubt, NN shall have no research funding obligation with respect to, and IPH shall not assign any FTEs funded by NN hereunder to, any activities in connection with the research, development or commercialization of or under any IPR (or any <FONT
STYLE="white-space:nowrap">Know-How,</FONT> Biological Target or other subject matter encompassed by such IPR) that is <FONT STYLE="white-space:nowrap">in-licensed</FONT> or otherwise acquired by IPH pursuant to this Subsection <B>3.4.3</B>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Obligation to Diligently Seek <FONT STYLE="white-space:nowrap">Sub-License</FONT> Rights in All
Collaborations with Third Parties</U>. During the Collaboration Term, each Party shall, in negotiating any <FONT STYLE="white-space:nowrap">in-licensing,</FONT> collaboration, partnering or other agreements or arrangements in the Collaboration
Field, exercise diligent efforts to obtain the right to grant to the other Party (by license, sublicense or other transfer) the rights and licenses acquired by such Party (by assignment, license or otherwise) in the Collaboration Field pursuant to
such Third Party agreements or arrangements (including Third Party Collaborations) for purposes of Commercial Optimization, and to avoid, and if such avoidance is not possible, to minimize, any requirement to provide additional consideration to such
third-parties for obtaining or exercising such right. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Collaboration Plans</U>. The Target Discovery Plan and Drug Discovery Plan, including detailed work plans
and performance criteria with respect to the Parties&#146; respective responsibilities and obligations thereunder, as contemplated by the Parties as of the date of this Agreement, are set out, respectively in Schedules <B>1.1.65</B> and
<B>1.1.32</B>. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this
agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Commercially Reasonable Efforts</U>. Each Party shall use Commercially Reasonable Efforts during the
Collaboration Term: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fulfil the responsibilities assigned to such Party in the Collaboration in accordance with the applicable
Target Discovery Plan or Drug Discovery Plan as the same may be amended by the Joint Steering Committee from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to perform its obligations under the Collaboration in good faith in a commercially reasonable and workmanlike
manner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as appropriate and to the extent authorized by contract and permitted by applicable Law, to make available to
the other Party resources that are necessary or useful for Commercial Optimization (without limitation of either Party&#146;s specific performance obligations hereunder, including the affirmative obligation to provide or make accessible to the other
Party any <FONT STYLE="white-space:nowrap">Know-How</FONT> (including reasonable quantities of samples of any relevant Materials) Controlled by the first Party that are necessary or useful for such Commercial Optimization); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to carry out all work done in the course of the Collaboration in material compliance with the Target Discovery
Plan and Drug Discovery Plan and all applicable Laws and professional standards governing the conduct of such work. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Legal Compliance</U>. In the course of carrying out any work under this Agreement, each Party will comply
with all applicable Laws regarding the conducting of tests in animals for laboratory research purposes. IPH shall at NN&#146;s expense comply with any additional requirements requested by NN in accordance with NN&#146;s policy for use of animals for
laboratory research purposes as set forth in the annexed Schedule <B>3.8</B> as the same may be amended by NN from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Research Personnel</U>. During the Collaboration Term, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Party shall continue to contribute to the Collaboration all its research and development activities in the
Collaboration Field that are ongoing as of the date of this Agreement, which shall include the activities listed, in the case of NN, in Schedule <B>1.1.69A</B> and, in the case of IPH, in Schedule <B>1.1.69B</B>, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Party shall further contribute to the Collaboration as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall deploy and dedicate to the Collaboration, on a full-time basis at least *** of its full-time
employees (&#147;<U>FTEs</U>&#148;) during Collaboration Year 1 *** of whom shall be assigned on a full-time basis to the continuation of projects under the former Kirostim Agreement) and at least *** of its FTEs during each of Collaboration Years 2
and 3, with no fewer than *** of such FTEs involved in the Drug Discovery Projects at any given time during the Collaboration, and with the precise allocation and deployment of IPH FTEs to be determined by the Joint Steering Committee twice each
year during the Collaboration Term for the following <FONT STYLE="white-space:nowrap">six-(6)</FONT> month period. In its deployment of FTEs to the Collaboration pursuant to this paragraph, IPH shall </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="32%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
maintain an FTE ratio of at least *** with an academic degree from a higher institution of learning (e.g., a university or an engineering school or engineering institute) to *** at all times
during the Collaboration. IPH shall further dedicate to the Collaboration appropriately ample time and involvement by IPH management, including regular participation in various Collaboration committees (e.g., the Joint Steering Committee), and
provide and ensure the full participation of Project Managers for each project defined by the Joint Steering Committee. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During each of Collaboration Years 1 through 3 and, if the Collaboration is thereafter extended, during each of
the first two (2)&nbsp;annual extensions of the Collaboration Term, NN shall, in addition to its research funding of IPH pursuant to Section<B>&nbsp;3.13</B>, provide sufficient annual research funding to cover its own research costs in relation to
the Target Discovery and Drug Discovery Plans, including, but not limited to, the funding of *** NN FTEs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Project and <FONT STYLE="white-space:nowrap">Pre-Project</FONT> Groups</U>. The Parties shall form one
project group for each project and one ore more <FONT STYLE="white-space:nowrap">Pre-project</FONT> Group(s) (as determined by the Joint Steering Committee) for each or all <FONT STYLE="white-space:nowrap">Pre-Project(s),</FONT> identified in the
Collaboration Plans. Each such Project group or <FONT STYLE="white-space:nowrap">Pre-project</FONT> group shall be composed of at least *** and *** representative appointed by each Party who shall have the appropriate experience, expertise, and
familiarity with the scientific or intellectual property issues confronted by the Project group to which he or she has been assigned. Each Project group or <FONT STYLE="white-space:nowrap">Pre-project</FONT> group shall meet at least once per
calendar quarter in order to manage effectively each aspect of the Target Discovery Plan or Drug Discovery Plan being implemented by the Project or <FONT STYLE="white-space:nowrap">Pre-project</FONT> to which it has been assigned.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Project Managers</U>. For each Project and for one or more
<FONT STYLE="white-space:nowrap">Pre-projects</FONT> (as the Joint Steering Committee shall decide) , each Party shall appoint a head of its research team (a &#148;<U>Project Manager</U>&#148;) who shall act as the primary contact between the
Parties during the Collaboration and shall be responsible for: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the internal management of each Collaboration project pursuant to the Collaboration Plans;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the coordination of each project with the other Party&#146;s Project Manager; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the facilitation of communication between the Parties on a regular<B> </B>basis to discuss the progress of each
Project or <FONT STYLE="white-space:nowrap">Pre-project;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ensuring that all raw data and results generated by or though the Project or
<FONT STYLE="white-space:nowrap">Pre-project</FONT> are freely exchanged between the Parties pursuant to the terms of this Agreement; and </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the provision of regular progress reports and input to the Joint Steering Committee and the Parties&#146;
respective management teams, including the preparation of written project reports, including all summaries and analyses of Project or <FONT STYLE="white-space:nowrap">Pre-project</FONT> data, on a monthly basis throughout the Collaboration Term, and
submission thereof to NN and IPH management. Such project reports shall </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">describe all research, development and other Collaboration activities that have been performed, or caused to be
performed, since the last such report, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluate the work performed in relation to the goals of the Collaboration and the applicable Target Discovery
Plan or Drug Discovery Plan, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide such other information as may be required by this Agreement or the applicable Target Discovery Plan or
Drug Discovery Plan, or that is reasonably requested by the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Research Funding</U>. With the sole exception of the following annual research funding contributions to be
made by NN to IPH to ensure IPH&#146;s compliance with its obligation to deploy, on a full-time basis, the number and quality of full time employees required pursuant to Section<B>&nbsp;3.9</B>, NN and IPH shall each pay all costs and expenses of
the activities it is responsible to perform pursuant to the terms of this Agreement and the relevant Collaboration Plans: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With the exception of the above-noted <FONT STYLE="white-space:nowrap">pre-paid</FONT> research funding for
Collaboration Year 1, NN shall pay to IPH, as NN&#146;s annual research funding contribution for each of the first three years of the Collaboration, *** for each of the above-specified IPH FTEs deployed by IPH on a full-time basis in compliance with
Section<B>&nbsp;3.9</B>. With the exception of the above-noted <FONT STYLE="white-space:nowrap">pr-paid</FONT> research funding for Collaboration Year 1, NN shall pay in full the annual research funding contribution to IPH for Collaboration Year 1
upon the Parties&#146; execution and delivery of this Agreement on the date of this Agreement. Commencing with the first anniversary of the date of this Agreement, with respect to each remaining Collaboration Year of the Collaboration Term, NN shall
pay the annual research funding contribution to IPH for each such Collaboration Year in advance, upon the anniversary of the date of this Agreement. NN shall have no research funding obligation to IPH after the expiration of the Collaboration Term,
irrespective of any continuation of this Agreement thereafter during any holdover period, as set forth in Section <B>3.2(b)</B>. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MANAGEMENT OF THE COLLABORATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Project Group Decisions</U>. Decisions in the project groups will be taken by consensus of the Parties&#146;
respective Project Managers and any dispute that may arise between them as to such decisions shall be referred for resolution to the Joint Steering Committee in accordance with Section<B>&nbsp;4.5</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Joint Steering Committee</U>. The Parties have previously established a Steering Committee pursuant to the
Kirostim Agreement. Within *** days after the date of this Agreement, the Parties shall form a Joint Steering Committee under this Agreement. The Joint Steering Committee will function throughout the Collaboration Term as the key coordination,
supervisory and liaison body in relation to the Collaboration and shall, upon its formation, supersede, replace and undertake the duties of the Steering Committee formed under the Kirostim Agreement, which Steering Committee shall be dissolved,
automatically and without further action by the Parties, effective upon the formation of the Joint Steering Committee. The Joint Steering Committee shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consist of *** members having requisite skills to enable them to make recommendations to the Parties&#146;
management with respect to the Collaboration, *** of whom shall be appointed by and represent NN, and *** of whom shall be appointed by and represent IPH, as notified by each Party to the other from time to time in writing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">accord one vote to each Party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be chaired by *** representative (for administrative purposes), as chosen by ***; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">hold meetings in person as frequently as the members of the Joint Steering Committee may agree shall be
necessary during the period of the Collaboration, or more frequently upon the reasonable request of either Party, but in any event no less frequently than four (4)&nbsp;times in any Collaboration Year, two (2)&nbsp;of which meetings shall take
place, if at all practicable, within one month prior to an NN semi-annual Project Review. Dates of Joint Steering Committee meetings to be held in person shall be agreed upon by the Joint Steering Committee not less than *** days beforehand;
responsibility for arranging the meetings, including providing notice and an agenda shall rest with the chair of the Joint Steering Committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">establish its own procedural rules for the Joint Steering Committee&#146;s operation, except as to the
specifications and procedures expressly set forth in this Section<B>&nbsp;4.2</B>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designate individuals who shall be responsible for sending draft minutes of each meeting to each of the Joint
Steering Committee members without undue delay and ensuring that all such minutes are submitted for written approval by both Parties; and </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be dissolved automatically and without further action by the Parties, upon the expiration of three
(3)&nbsp;months after the effective date of the expiration or earlier termination of the Collaboration Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Duties of Joint Steering Committee</U>. The Joint Steering Committee shall have the following, among other,
duties and responsibilities: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following the first meeting of the Joint Steering Committee preparing a Target Discovery Plan for Projects in
the Collaboration Field that are in the <FONT STYLE="white-space:nowrap">pre-M0</FONT> stage of development and that are to be actively pursued by one or both of the Parties or their respective Affiliates (alone or with one or more Third Parties)
and annexing such Target Discovery Plan hereto as Schedule <B>1.1.65</B>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">monitoring and managing the progress of the Target Discovery Plan and the Drug Discovery Plan, including, but
not limited to, updating all associated work plans, allocating IPH&#146;s FTEs among projects, and providing recommendations respecting the allocation of NN&#146;s FTEs among projects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">managing the deployment, allocation and use of Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT>
or other Materials and <FONT STYLE="white-space:nowrap">Know-How</FONT> contributed by the Parties to, or generated or acquired (by assignment, license or otherwise) by, the Parties pursuant to the Collaboration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">classifying <FONT STYLE="white-space:nowrap">Pre-projects</FONT> or Projects within any of the Collaboration
Plans, or any associated or other project or aspect thereof (including any activities in respect of the discovery or development of any Drug Candidate) as being active, suspended or terminated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">identifying and assessing Exploratory Targets and updating Schedule <B>1.1.33</B> accordingly;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewing, and preparing proposed updates or other amendments (as necessary) to, Schedules <B>1.1.12 and
1.1.13</B> for review and written approval by the Parties&#146; respective management to record the addition and proper classification of Licensed Products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">preparing, within *** days prior to the expiry or effective date of the termination of the Collaboration Term,
the final version of Schedules <B>1.1.12 and 1.1.13</B> for review and written approval by the Parties&#146; respective management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">considering and, if necessary updating, Schedule <B>1.1.22</B> (Collaboration Targets)&nbsp;(a) no less
frequently than once during each *** period in the Collaboration Term, (b)&nbsp;within *** after receipt of the written request of either Party during the Collaboration Term, and (c)&nbsp;in a final version of such Schedule to be fixed and final as
of the date of the expiration or earlier termination of the Collaboration Term; </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewing, and preparing proposed updates or other amendments (as necessary) to Collaboration Plans for review
and written approval<B> </B>by the Parties&#146; respective management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">assessing, evaluating and making recommendations to the management of the Parties regarding Third Party
Collaborations, Third Party IPR <FONT STYLE="white-space:nowrap">in-licensing</FONT> and acquisition opportunities, and other IPR <FONT STYLE="white-space:nowrap">in-licensing</FONT> and acquisition opportunities in the Collaboration Field <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> any Third Party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">receiving IPH&#146;s requests, and initiating and monitoring the process by which a Drug Candidate may be
referred to NN&#146;s management for the determination, in the sole discretion of NN&#146;s management, whether or not to classify and approve such Drug Candidate as a Niche Candidate for independent development by IPH under this Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prioritizing the discovery and research activities of the Collaboration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">identifying which disease states, indications and conditions might best be targeted by the Collaboration;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">establishing such subcommittees as the Joint Steering Committee may deem appropriate without extending the
rights or obligations of the Parties under this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">making proposals to the management of the Parties for the review or amendment of the Target Discovery Plan,
Drug Discovery Plan, or any other work plans or time schedules under the Collaboration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liaising with the <FONT STYLE="white-space:nowrap">Ex-Vivo</FONT> Task Force with respect to development of <FONT
STYLE="white-space:nowrap">ex-vivo</FONT> applications of Drug Candidates pursuant to Section<B>&nbsp;6.2</B>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">developing, agreeing upon and recording procedures for issuing publications and press releases with regard to
the Collaboration, subject to the terms of this Agreement set forth in Article <B>18</B>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">establishing a Joint Patent Committee to oversee, coordinate and monitor Patent and other IPR management,
development, maintenance and enforcement efforts and strategies in accordance with Article <B>9</B>, and to report to the Joint Steering Committee with respect thereto; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(s)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluating and making proposals and recommendations to the management of the Parties with respect to the number
of FTEs required to implement current and planned projects under the Collaboration Plans, including, where applicable, the retention and deployment of additional FTEs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(t)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">performing such other functions and responsibilities as the Parties may hereafter agree to in writing,
<I>provided that</I>, for the avoidance of doubt, it is hereby acknowledged and agreed that the Joint Steering Committee shall have no authority to countermand, modify or amend the terms of this Agreement or of any other written agreement between
the Parties, or to cause the Parties&#146; obligations (including any payment obligation) to be otherwise than as stated herein or therein; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(u)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">updating Schedule 1.1.17 (containing Collaboration <FONT STYLE="white-space:nowrap">Know-How.</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Participation in Committee Meetings</U>. The Joint Steering Committee and each of its members shall have
power to invite persons whose special skills or influence might advance the Collaboration to attend and address meetings of the Joint Steering Committee. Persons invited may, but are not required to be, employed by the inviting Party or its
Affiliates. The inviting Party shall have the obligation to secure that such persons are bound by obligations of confidentiality that are at least as stringent as those set forth in this Agreement. The Joint Steering Committee shall decide on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis who shall be responsible for the expenses incurred by the invitation. For the avoidance of doubt, it is agreed that such invited persons shall not be a
member, and shall not have a right to vote or participate in the decision-making process of, the Joint Steering Committee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Decision-making Procedures</U>. The Joint Steering Committee shall form a quorum when two representatives of
each Party are present. Decisions of the Joint Steering Committee shall be made by unanimous consent of the Parties, with each Party having a single vote, irrespective of the number of representatives actually in attendance at a meeting, or by
written resolution signed by one designated representative of each of the Parties. Draft minutes shall be prepared and circulated to the Parties for approval and signature without undue delay after each Joint Steering Committee meeting. If any issue
remains unresolved after *** following the formal consideration of such issue by the Joint Steering Committee, either Party may by written notice to the other refer that issue to the Chief Scientific Officer of NN and the Chief Executive Officer of
IPH, who shall in good faith negotiate to resolve that issue within *** of such notice. Except with respect to the specific issues expressly identified in Section<B>&nbsp;3.4</B> (which shall be decided in accordance with the terms and conditions of
that Section), in the event that said officers fail to reach agreement within ***, or for such other period as the Joint Steering Committee may agree, such issue shall be determined by ***, in the good faith exercise of its sole discretion and such
determination shall be final and binding upon the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disputes and Continued Performance</U>. For the avoidance of doubt, notwithstanding any failure of the Joint
Steering Committee, or the Chief Science Officer of NN and Chief Executive Officer of IPH, to reach agreement resolving any dispute presented to them, the existence of any disputes between the Parties shall not excuse either Party from rendering
full performance of its obligations under this Agreement. During the pendency of any such dispute and unless and until this Agreement is terminated in accordance with the express terms and conditions of Article <B>12</B>, the provisions of this
Agreement shall remain in full force and effect and the Parties shall be obligated to perform their </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
respective obligations and be entitled to their respective rights under this Agreement. Not withstanding the foregoing, or any other, provision of this Agreement: (a)&nbsp;in the event that this
Agreement is terminated by either Party, the Parties shall be entitled to such rights and licenses, and bear such obligations, as survive such termination pursuant to the express terms hereof, and (b)&nbsp;no such termination shall take effect
during the pendency of any dispute as to the right of the terminating Party to terminate this Agreement, <I>provided that</I> such dispute is submitted to arbitration in accordance with Section<B>&nbsp;21.14</B> within *** days after the effective
date of such termination. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Expenses</U>. ***. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Limited Authority</U>. For the avoidance of doubt, the Joint Steering Committee shall have no competency to
increase or decrease the total number of IPH or NN FTEs required by this Agreement or to make any other change in the Collaboration which would materially affect the scope, costs or other terms thereof as set forth in this Agreement. Any such change
shall require a written agreement between the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Development and Commercialization Committee</U>. The Parties have previously established a Development and
Commercialization Committee pursuant to the Kirostim Agreement. Within *** after the date of this Agreement, the Parties shall form a committee to be designated as the &#147;<U>Development and Commercialization Committee</U>&#148; that shall, upon
its formation, supersede, replace and assume the duties of the Development and Commercialization Committee established under the Kirostim Agreement, which prior Development and Commercialization Committee shall be thereupon be dissolved
automatically without further action of the Parties. The Development and Commercialization Committee shall function throughout the Term as a forum for the Parties&#146; communication and discussion concerning
<FONT STYLE="white-space:nowrap">(a)&nbsp;post-M1</FONT> development and commercialization, both during and after the Collaboration Term, of all Licensed Products, including all products discovered or developed pursuant to the Kirostim Agreement,
and (b)&nbsp;any Niche Candidates. The Parties shall agree on the rules and procedures for such a Development and Commercialization Committee, which shall in any event: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consist of three (3)&nbsp;ordinary representatives of each Party, as may be designated by each Party to the
other Party from time to time in writing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be chaired by an additional *** representative to be chosen by *** and who shall constitute the seventh (7<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) member of the Development and Commercialization Committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">hold meetings in person as frequently as the members of the Development and Commercialization Committee may
agree shall be necessary but in any event no less frequently than once every ***. Dates of meetings to be held in person shall be agreed by the parties not less than *** beforehand with the first meeting to take place before December&nbsp;31, 2006,
with responsibility for arranging the meetings, including providing notice and an agenda, resting with the chairman; </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appoint a representative as secretary who shall be responsible for preparing and circulating to the Parties,
for their required review and approval, draft minutes of each meeting without undue delay after each Development and Commercialization Committee meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GRANT OF RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN Licenses in the Field</U>. IPH hereby grants to NN, and NN hereby accepts: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an exclusive (even as to IPH) right and license during the Term, to practice, exercise and use all Background
IPH IPR other than Background IPH Research Technology IPR; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an exclusive (even as to IPH) right and license during the Collaboration Term, and <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> right and license during the balance of the Term remaining after the expiration or earlier termination of the Collaboration Term, to practice, exercise and use all Background IPH Research Technology
IPR; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an exclusive (even as to IPH) right and license during the Term, to practice, exercise and use all
Collaboration IPR Controlled by IPH (including, for clarity, any Joint IPR or Third-Party IPR); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the Collaboration Field and throughout the Territory, in each case ((a) through (c)), with the right to <FONT
STYLE="white-space:nowrap">Sub-license</FONT> and <FONT STYLE="white-space:nowrap">Out-license,</FONT> for purposes of achieving Commercial Optimization, including the right and license to conduct research with and of, discover, develop, use,
manufacture, have manufactured, register, package, sample, distribute, promote, market, offer for sale, import, export, sell and have sold Licensed Products, Niche Candidates and Residual Products for all uses and purposes, subject to the terms and
conditions of this Agreement, including the rights and licenses granted back, or agreed to be granted back, to IPH pursuant to Sections <B>5.3 and 5.5(a)</B>, below. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN License to Collaboration IPR Outside the Collaboration Field</U>. IPH hereby further grants to NN, and NN
hereby accepts, a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">Sub-licensable</FONT> right and license, without the right to <FONT STYLE="white-space:nowrap">Out-license,</FONT> to practice exercise and use
throughout the Territory during the Term, any Collaboration Research Technology IPR Controlled by IPH, for purposes of NN&#146;s and its Affiliates&#146; use for the discovery, development or commercialization of biologics or other products or
processes outside the Collaboration Field. In the event that NN wishes to <FONT STYLE="white-space:nowrap">Out-license</FONT> such IPR, it shall notify IPH of its desire to do so in a written request setting forth in reasonable detail the
contemplated nature and terms of, and parties to, the proposed <FONT STYLE="white-space:nowrap">Out-license,</FONT> and the Parties shall negotiate in good faith a separate license agreement providing for such
<FONT STYLE="white-space:nowrap">Out-license,</FONT> any such agreement being subject to the final management approval of each Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Grant Backs to IPH</U>. NN hereby grants back to IPH, and IPH hereby accepts for no additional
consideration, a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right and license, with the right to <FONT STYLE="white-space:nowrap">Sub-license</FONT> (but without the right to <FONT STYLE="white-space:nowrap">Out-License),</FONT>
throughout the Territory, to practice, exercise and use (a)&nbsp;during the Collaboration Term, Background IPH </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
IPR licensed to NN pursuant to Section<B>&nbsp;5.1</B>, and (b)&nbsp;during the Term, all Research Technology IPR licensed to NN during the Term pursuant to Section<B>&nbsp;5.1</B>, in each case
((a) and (b)) solely to conduct research and development for purposes of Commercial Optimization. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Licenses to NN Background Research Technology IPR and NN Controlled Collaboration IPR</U>. NN hereby
grants to IPH, and IPH hereby accepts, a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right and license, with the right to <FONT STYLE="white-space:nowrap">Sub-license</FONT> (but without the right to
<FONT STYLE="white-space:nowrap">Out-License),</FONT> throughout the Territory during the Term, to practice, exercise and use any Background NN Research Technology IPR or Collaboration IPR that is Controlled by NN, solely to conduct research and
development for purposes of Commercial Optimization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Future IPH License in the Field for Niche Candidates</U>. NN hereby agrees to grant or grant back to IPH an
exclusive right and license, including the right to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT STYLE="white-space:nowrap">Out-license,</FONT> throughout the Territory during the Term, to develop and commercialize in the
Collaboration Field solely such specific Niche Candidates as IPH may hereafter be authorized to commercialize pursuant to the terms and conditions of Article <B>6</B> hereof: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">under all Intellectual Property Rights licensed exclusively to NN pursuant to Section<B>&nbsp;5.1</B>; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">under all Background NN IPR and Collaboration IPR Controlled by NN, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that such rights and licenses are necessary or useful for purposes of achieving Commercial
Optimization with respect to such specific Niche Candidates in approved indication(s). Notwithstanding the foregoing or any other provision of this Agreement,<I> </I>NN shall not be required to grant or grant back to IPH any such right or license if
to do so is not authorized by contract or permitted by applicable Law or will require NN to pay or provide any consideration (including any royalty, sublicense fee or other payment) to any Person, save that, in the event that NN shall decline to pay
or provide such consideration to procure or grant such license, IPH shall have the right to do so to the extent authorized by contract and permitted by applicable Law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, the exclusivity of any license granted or granted back to IPH pursuant to this
Section<B>&nbsp;5.5 </B>shall be comprised solely of the exclusive rights of commercialization, and development for commercialization, and only as they may hereafter apply to such specific products as IPH is hereafter authorized to develop pursuant
to<B> </B>Article <B>6</B>, and shall not in any way limit or derogate from NN&#146;s rights with respect to any IPR licensed to IPH under this Agreement (including any right of NN to practice, use or exploit such IPR), or any of the rights or
licenses of NN under this Agreement to practice, use or exploit any IPR licensed to NN hereunder for any purpose other than for commercializing such specific Niche Candidates for such specific indications or uses as are hereafter licensed
exclusively to IPH to commercialize pursuant to the terms and conditions of Article <B>6 </B>and this Section<B>&nbsp;5.5</B>. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Sub-licensing</FONT></U>. Except as is otherwise herein expressly provided,
and subject to the terms of this Agreement, each of IPH and NN shall be entitled to <FONT STYLE="white-space:nowrap">Sub-license</FONT> their rights and obligations under this Agreement <I>provided that</I> (a)&nbsp;the <FONT
STYLE="white-space:nowrap">Sub-licensing</FONT> Party shall secure appropriate covenants, obligations and rights from any proposed <FONT STYLE="white-space:nowrap">Sub-licensee</FONT> so as to ensure that such
<FONT STYLE="white-space:nowrap">Sub-licensee</FONT> is able to comply with the <FONT STYLE="white-space:nowrap">Sub-licensing</FONT> Party&#146;s covenants and obligations hereunder, and (b)&nbsp;during the Collaboration Term, all such <FONT
STYLE="white-space:nowrap">Sub-licensing</FONT> by the Parties shall be subject to the prior approval of the Joint Steering Committee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Party that <FONT STYLE="white-space:nowrap">Sub-licenses</FONT> any rights, licenses or obligations hereunder
to any Person shall ensure that, prior to and as a condition of the grant of such <FONT STYLE="white-space:nowrap">Sub-license,</FONT> the proposed <FONT STYLE="white-space:nowrap">Sub-licensee</FONT> enters into binding obligations of
confidentiality, <FONT STYLE="white-space:nowrap">non-use,</FONT> and IPR ownership that shall be enforceable by both Parties and at least as stringent as those set out in the text hereof, and that, with respect to Materials, shall conform to the
Material Transfer Agreement and other requirements set forth in Section<B>&nbsp;10.4</B>. Each Party shall be liable for any such work performed by its <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> hereunder as if the work had been performed
by the Party itself. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, FTEs of the Parties&#146; <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> who
are dedicated on a full-time basis to perform activities for or on behalf of the Collaboration and who otherwise meet the qualification requirements applicable to the respective Parties under Section<B>&nbsp;3.7</B> shall be counted as FTEs of the <FONT
STYLE="white-space:nowrap">Sub-licensing</FONT> Party for purposes of determining the Parties&#146; respective contributions of personnel to the Collaboration pursuant to that Section. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Regulatory Exclusivity</U>. For no additional consideration: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall grant a license or authorization to NN (and do all such reasonable acts related thereto) under any
regulatory exclusivity (such as orphan drug exclusivity, new chemical entity exclusivity, pediatric exclusivity, and the like) and any regulatory reference rights, authorizations, or approvals held by IPH or any of its Affiliates with respect to the
development or commercialization of a Niche Candidate, Residual Product or Licensed Product that are necessary for NN to develop or commercialize any Licensed Product, Niche Candidate or Residual Product that might otherwise be barred from
regulatory approval by such exclusivity; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall grant a license or authorization to IPH (and do all such reasonable acts related thereto) under any
regulatory exclusivity (such as orphan drug exclusivity, new chemical entity exclusivity, pediatric exclusivity, and the like) and any regulatory reference rights, authorizations, or approvals held by NN or any of its Affiliates with respect to any
Licensed Product, Niche Candidate or Residual Product that are necessary for IPH to develop or commercialize any Niche Candidate, Residual Product or Licensed Product authorized for commercialization by IPH hereunder that might otherwise be barred
from regulatory approval by such exclusivity. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Freedom of Operation in Respect of Independent IPR</U>. It is the Parties&#146; intention that each of them
have and retain throughout the Term the freedom to operate necessary to enable them to exercise their respective rights and licenses, and fulfill their respective obligations, under this Agreement for the purposes of achieving Commercial
Optimization of Licensed Products, and Niche Candidates and Residual Products. To this end, the Parties shall be obligated as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH License to NN of Independent IPH IPR. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall, and hereby does, in each case at its own expense, grant, or shall procure for NN or its Affiliates,
or pay for the procurement by or on behalf of NN of, the grant of, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> rights and licenses (including the right to grant <FONT STYLE="white-space:nowrap">Sub-licenses</FONT> and <FONT
STYLE="white-space:nowrap">Out-licenses),</FONT> throughout the Territory during the Term under all such Independent IPH IPR as (i)&nbsp;is generated or acquired (by assignment, license or otherwise) at any time during the Collaboration Term or the
*** period following immediately after the expiration or termination thereof by or on behalf of (A)&nbsp;IPH or any of its Affiliates, either jointly with one another or independently, or (B)&nbsp;IPH, or any of its Affiliates, or any Third Party
(whether independently of or jointly with IPH or any of its Affiliates) in connection with any collaboration by IPH or any of its Affiliates with such Third Party, and (ii)&nbsp;is necessary for the achievement of Commercial Optimization of Licensed
Products, Niche Candidates, or Residual Products, and, in particular, for NN fully to exercise its rights and licenses and fulfill its obligations under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, NN shall not be required to pay or provide any fee, royalty or other consideration
(such as the payment of any premium or performance of any obligation) by reason of or in consideration of IPH&#146;s grant or procurement of the grant to NN of any right or license pursuant to this Subsection <B>5.8.1</B>, other than or in addition
to such royalty obligations as might apply to NN&#146;s use of Independent IPH IPR pursuant to Subsection<B> 5.8.1(a)</B> hereof </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, it is understood that NN may need to pay or provide consideration to Third Parties
by the terms of such agreements or arrangements as NN may need to enter into (or authorize IPH to enter into) with such Third Parties to secure NN&#146;s freedom of operation pursuant to the express, post-purchase/acquisition exclusion to IPH&#146;s
payment obligation set forth in the second paragraph of Subsection <B>5.8.1(a)</B> with respect to IPR that is first generated or acquired by IPH or an IPH Affiliate after the effective date of a purchase or acquisition of IPH.
</P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement
(indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN Assistance, and License of Independent NN IPR, to IPH for Niche Candidates or Abandoned Licensed
Products</U>. To the extent authorized by contract and permitted by applicable Law, NN shall grant to IPH, or provide reasonable cooperation and assistance to IPH to procure the grant to IPH of, <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
rights and licenses (including the right to grant <FONT STYLE="white-space:nowrap">Sub-licenses</FONT> and <FONT STYLE="white-space:nowrap">Out-licenses),</FONT> throughout the Territory during the Term<B> </B>under all such Independent NN IPR as
(a)&nbsp;is generated or acquired (by assignment, license or otherwise) at any time during the Term by or on behalf of (i)&nbsp;NN or any of its Affiliates, either jointly with one another or independently, or (ii)&nbsp;NN, or any of its Affiliates,
or any Third Party (whether independently of or jointly with NN or any of its Affiliates) in connection with any collaboration by NN or any of its Affiliates with such Third Party, and (b)&nbsp;is necessary for (i)&nbsp;the achievement of Commercial
Optimization of such Niche Candidates, Licensed Products or Residual Products as IPH may hereafter be authorized to develop for commercialization (and, in particular, for IPH fully to exercise such rights and licenses in respect of such Niche
Candidates, Licensed Products or Residual Products as may hereafter be granted hereunder, and (ii)&nbsp;IPH to fulfill its obligations under this Agreement. In no case shall NN be required to procure or exercise the right to grant any such rights or
licenses to IPH in the event that to do so would require NN to provide or pay any consideration (including any royalty, license fee or other payment) to any Person, save that IPH may elect to pay for and obtain the right to such procurement or
exercise to the extent authorized by contract and permitted by applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN License to IPH of Independent NN IPR for Residual Products</U>. To the extent authorized by contract and
permitted by applicable Law, NN shall grant to IPH or provide reasonable cooperation and assistance to IPH to procure the grant to IPH of <FONT STYLE="white-space:nowrap">non-exclusive</FONT> rights and licenses (including the right to grant <FONT
STYLE="white-space:nowrap">Sub-licenses</FONT> and <FONT STYLE="white-space:nowrap">Out-licenses),</FONT> throughout the Territory during the Term under all such Independent NN IPR as (a)&nbsp;is generated or acquired (by assignment, license or
otherwise) at any time during the Collaboration Term or the *** period following immediately after the expiration or termination thereof (or in the case of Sections <B>13.4 and 13.5</B> during the Term) by or on behalf of (i)&nbsp;NN independently,
or (ii)&nbsp;NN or any Third Party (whether independently of or jointly with NN) in connection with any collaboration by NN with such Third Party, and (b)&nbsp;is necessary for the achievement of Commercial Optimization of such Residual Products as
IPH may hereafter be authorized to develop for commercialization. In no case shall NN be required to procure or exercise the right to grant any such rights or licenses to IPH in the event that to do so would require NN to provide or pay any
consideration (including any royalty, license fee or other payment) to any Person, save that IPH may elect to pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by applicable Law.
</P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement
(indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Discussion Regarding Other Independent IPR Necessary for Freedom of Operation</U>. Notwithstanding the time
limitations in Subsections <B>5.8.1(a) </B>and<B> 5.8.3</B> in respect of the obligations of the Parties to grant or procure the grant of Independent IPR, the Parties shall negotiate in good faith the terms under which any other Independent IPR
(i.e., Independent IPR arising subsequently during the Term) may be licensed during the remainder of the Term with respect to any Residual Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Terminated Collaboration Properties and <FONT STYLE="white-space:nowrap">Out-licensing</FONT></U>. Upon the
request of either Party (which request shall not, save for extraordinary circumstances, be more frequent than ***), with respect to any: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">terminated Collaboration <FONT STYLE="white-space:nowrap">Pre-projects</FONT> or Projects, or any aspects or
elements of either thereof, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Collaboration IPR that the Parties agree no longer has any value for Commercial Optimization,
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">the Parties shall confer to evaluate and assess: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>first,</I> the possibility and conditions pursuant to which the grant or grant back of a license may be made
to one of the Parties as necessary for such Party independently to conduct further research, development or commercialization of the subject matter described in the above paragraph (a)&nbsp;or to practice, use or exploit any of the IPR described in
the above paragraph (b), in each case on written terms to be mutually agreed and satisfactory to the Parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>&nbsp;&nbsp;</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>second</I>, the possibility of <FONT STYLE="white-space:nowrap">Out-licensing</FONT> to a Third Party or
entering into a arrangement with a Third Party with respect to the IPR or other subject matter described in the above paragraphs (a)&nbsp;or (b) of this Subsection upon Arm&#146;s Length Transaction terms. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to any such terminated <FONT STYLE="white-space:nowrap">Pre-projects,</FONT> Projects, or any
aspect of either thereof as the Parties determine should be <FONT STYLE="white-space:nowrap">Out-licensed</FONT> or made subject to such Third Party arrangement in order to maximize its commercial potential, the Parties shall assess and evaluate the
feasibility and desirability of such <FONT STYLE="white-space:nowrap">Out-licensing</FONT> or arrangement upon Arm&#146;s Length Transaction terms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the Parties shall decide to go forward with such Third Party
<FONT STYLE="white-space:nowrap">Out-licensing</FONT> or arrangement in accordance with this Section<B>&nbsp;5.9</B>, the Parties shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agree upon the allocation of all revenues and profits that result from each such
<FONT STYLE="white-space:nowrap">Out-licensing</FONT> or arrangement prior to the undertaking of any commitment to enter into such <FONT STYLE="white-space:nowrap">Out-licensing</FONT> or other arrangement, which allocation shall take into account
the stage of development of, and contribution of each of the Parties with respect to, the <FONT STYLE="white-space:nowrap">Pre-project,</FONT> project, or aspect thereof to be submitted for <FONT STYLE="white-space:nowrap">Out-licensing</FONT> to or
arrangement with such Third Party; and </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has
been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appoint one of the Parties as the Party responsible for such
<FONT STYLE="white-space:nowrap">Out-licensing</FONT> or arrangement, who shall bear responsibility for entering into and implementing such <FONT STYLE="white-space:nowrap">Out-licensing</FONT> or arrangement on Arm&#146;s Length commercial terms,
and shall keep the other Party regularly and fully informed of all material activities and developments and other relevant facts in respect of such <FONT STYLE="white-space:nowrap">Out-licensing</FONT> or Third Party arrangement, including all Net
Sales and required payments of royalties in connection therewith. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the Parties reach no agreement regarding
<FONT STYLE="white-space:nowrap">Out-Licensing</FONT> or other arrangement regarding such Collaboration IPR, the Party responsible for prosecution or maintenance of such IPR pursuant to Article <B>9</B> may abandon such IPR without any further
obligation to the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Procedure for Terminating Background IPR</U>. Upon the written request of either Party with respect to any
Background IPR which such Party believes no longer has any value for the development or commercial exploitation of any Licensed Products, Niche Candidates or Residual Products, (a)&nbsp;during the Collaboration Term, the Joint Steering Committee (by
unanimous decision), and (b)&nbsp;thereafter, the Parties, shall confer to evaluate and assess jointly and in good faith whether such IPR has value for purposes of such development or commercial exploitation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Decision Not to Terminate IPR</U>. In the event that the Joint Steering Committee determines unanimously, or
the Parties agree, that such Background IPR has value for the development or commercial exploitation of any Licensed Products, Niche Candidates or Residual Products, then such determination or agreement shall be set forth in writing and the Party
Controlling such IPR shall retain such Control in accordance with the terms and conditions of its obligations hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Decision to Terminate IPR</U>. In the event that the Joint Steering Committee determines unanimously, or the
Parties agree, in writing that such IPR does not have value for the development or commercial exploitation of any Licensed Products, Niche Candidates or Residual Products, then such IPR shall no longer constitute or be licensed hereunder as
Background IPH IPR or Background NN IPR, as the case may be, and shall be deleted or otherwise excluded from the applicable IPR Schedule, and the Party in Control of such IPR (a)&nbsp;shall have no further obligation to retain such Control, and
(b)&nbsp;shall have the right to assign, license or otherwise transfer all or any part of its right, title and interest in and to such IPR, including the Control thereof, to a Third Party. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Failure to Reach Decision Whether to Terminate IPR</U>. If the Joint Steering Committee shall fail to reach
a unanimous decision, or the Parties shall fail to agree, within *** of receipt of the Controlling Party&#146;s written request pursuant to this Section<B>&nbsp;5.10</B> (or such longer period as the Parties may hereafter agree in writing), as to
whether or not such IPR has value for the development or commercial exploitation of any Licensed Products, Niche Candidates or Residual Products, then the Joint Steering Committee or the Parties, as applicable, shall consider in good faith the
possibility and conditions pursuant to which the grant of a license or assignment, or other transfer, may be made by the Party in Control of such IPR to the other Party (or such other Party&#146;s Affiliate) as necessary for such other Party (or its
Affiliate) independently to conduct further, research, development or commercialization of such IPR, or to practice, use or exploit such IPR, in each case on written terms to be mutually agreed and satisfactory to the Parties. In the event that the
Parties shall fail to enter into such a written agreement within *** of the Joint Steering Committee&#146;s or other Party&#146;s receipt of the Controlling Party&#146;s written request pursuant to the first paragraph of this
Section<B>&nbsp;5.10</B>, the matter shall be decided by the arbitration procedure set forth in Section<B>&nbsp;21.14</B>, <I>provided that</I>: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Party not in Control of such IPR shall fail to commence an arbitration proceeding seeking the resolution
of such matter within *** after the expiration of the aforementioned *** period, or if such arbitration proceeding is commenced within such *** period and the arbitral body deciding such matter shall determine that the IPR does not have such value,
then, in each case, it shall be conclusively established that such IPR does not have such value, this determination shall be final and binding upon the Parties, and the Party in Control of such IPR shall have all the rights set forth in Subsection
<B>5.10.2</B> with respect to such IPR; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if such arbitration is commenced within such *** period and the arbitral body deciding such matter shall
determine that the IPR does have such value, and the Parties shall fail to agree, in writing, to the terms of a settlement providing for the Party in Control&#146;s transfer of rights in the IPR to the other Party, then the Party in Control of such
IPR shall be required to retain such Control in accordance with the terms and conditions of its obligations hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN <FONT STYLE="white-space:nowrap">Out-licensing</FONT> and Upside Revenue</U>. Pursuant to the terms and
conditions of Section<B>&nbsp;5.1</B>, NN shall be entitled to <FONT STYLE="white-space:nowrap">Out-license</FONT> its rights and licenses under this Agreement with respect to Licensed Products in
<FONT STYLE="white-space:nowrap">Out-licensing,</FONT> partnering and other agreements or arrangements, <I>provided that</I> it may do so only on the following conditions: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If NN or any of its Affiliates <FONT STYLE="white-space:nowrap">Out-licenses</FONT> any Licensed Product to a
Third Party before the first use of same in human clinical trials, NN shall pay to IPH *** of all Upside Revenue received by NN in consideration of its grant of such <FONT STYLE="white-space:nowrap">Out-license.</FONT> NN shall pay all amounts due
to IPH in respect of Upside Revenue described in this Section <B>5.11(a)</B> within *** after the date of actual receipt by it of any such Upside Revenue payment. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If NN or any of its Affiliates <FONT STYLE="white-space:nowrap">Out-licenses</FONT> any Licensed Product to a
Third Party after the first use of same in human clinical trials but prior to the start of the first use of the same in Phase III clinical trials, NN shall pay to IPH *** of all Upside Revenue received by NN in consideration of its grant of such <FONT
STYLE="white-space:nowrap">Out-license.</FONT> The payment obligations under Section <B>5.11(a)</B> and this Section <B>5.11(b)</B> are <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and mutually exclusive. NN shall pay all amounts due to
IPH in respect of Upside Revenue described in this Section <B>5.11(b)</B> within *** days after the date of actual receipt by it of any such Upside Revenue payment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall not be entitled to any percentage of Upside Revenue received by NN in consideration of the <FONT
STYLE="white-space:nowrap">Out-licensing</FONT> of any Licensed Products, Niche Candidates or Residual Products at any time after the start of the first use of same in Phase III clinical trials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Cumulative Payments</U>. All payment obligations set forth in this Article <B>5</B> in respect of <FONT
STYLE="white-space:nowrap">Out-licensing</FONT> shall be in addition to, and not in lieu of, any milestone, royalty, or other payment obligations expressly provided for by this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Future Obligation to Provide Licenses Under Specific Third Party Agreements if Deemed Necessary</U>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN Obligation to Grant Sublicense Under *** License In Respect of an NN Approved Niche Candidate</U>. In the
event that IPH shall hereafter request to become authorized to develop and commercialize any Drug Candidate as a Niche Candidate pursuant to Article <B>6,</B> then, if NN shall grant such request, and IPH shall further request, in good faith and
upon an opinion of intellectual property counsel or such other reasonable basis as shall be reasonably satisfactory to NN, that a license from *** is necessary for IPH&#146;s development of such Niche Candidate, NN shall grant a sublicense to IPH
under the IPR Licensed to NN under the agreement between NN and *** dated October&nbsp;26, 2004, within *** of such request, as necessary for the development or commercialization of such Niche Candidate, throughout the Territory and during the Term
(including the right to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT STYLE="white-space:nowrap">Out-license).</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If NN fails to grant such a sublicense for IPH, upon satisfaction of the requirements of this Subsection
<B>5.13.1</B>, NN shall pay to IPH an increase of *** with respect to the next Discovery Milestone payment to IPH under this Agreement. NN&#146;s failure to grant such sublicense shall not in any event be deemed to constitute a breach of this
Agreement and the payment obligation of NN under this Subsection <B>5.13.1</B> shall be IPH&#146;s sole remedy for NN&#146;s failure to obtain such license. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If NN grants such sublicense to IPH, IPH shall be responsible for complying with all obligations to *** under
such a sublicense including payment of all applicable sublicensing royalties, milestones, or maintenance fees, maintenance of requisite insurance, and compliance with applicable production requirements thereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** <U>IPR</U>. In the event that the Joint Steering Committee acting in good faith recommends the grant of a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> <FONT STYLE="white-space:nowrap">sub-license</FONT> to NN (with right to sublicense with respect to Licensed Products) of any IPR which is the subject of IPH&#146;s agreements with *** (the
&#147;Licensors&#148;) dated June&nbsp;24, 2005, and February&nbsp;19, 2003, respectively, IPH shall, during a period of *** following immediately after such recommendation, seek to negotiate amended
<FONT STYLE="white-space:nowrap">sub-licensing</FONT> terms under such agreements which are acceptable to IPH. IPH shall be obligated to seek such amended sublicensing terms, save that IPH not to be obligated to pay *** more than ***, respectively,
in order to obtain a sublicense including such amended terms. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:28%; font-size:10pt; font-family:Times New Roman">5.13.2.1 In the event that ***, respectively, requires
payment of more than *** for the grant such sublicense including such amended terms (as IPH shall reasonably require), IPH shall promptly notify NN of such fact and NN shall thereafter have the right (without obligation) to pay such additional
amounts to obtain such sublicense(s). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:28%; font-size:10pt; font-family:Times New Roman">5.13.2.2 In the event that IPH is unsuccessful in obtaining such a license within such *** period,
the sum of *** shall be deducted from the next Discovery or Development Milestone payment due to IPH under this Agreement in full and final settlement of its obligations to seek such sublicense. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">***<U> IPR</U>. In the event that the Joint Steering Committee acting in good faith recommends that IPH seek to
negotiate an exclusive license including the right to sublicense to NN to any IPR which is the subject of IPH&#146;s agreements with *** dated April&nbsp;28, 2000 (reference number 97097), IPH shall during a period of *** following immediately after
such recommendation, seek to negotiate the terms of such a license acceptable to IPH. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:28%; font-size:10pt; font-family:Times New Roman">5.13.3.1 In the event that IPH is
unsuccessful in obtaining such a license including such terms within such *** period the sum of *** shall be deducted from the next Discovery Milestone payment due to IPH under this Agreement in full and final settlement of its obligations to seek
such a license from ***. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement
(indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:28%; font-size:10pt; font-family:Times New Roman">5.13.3.2 If *** requires a payment of more than *** in order for IPH to obtain such a license
(including such terms), IPH shall promptly notify NN of such fact and NN shall thereafter have the right (without obligation) to pay such additional amounts to obtain such licenses. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IAP Technology</U>. In the event that the Joint Steering Committee acting in good faith recommends that IPH
seek to negotiate a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to NN (without right to sublicense other than with respect to a Licensed Product) to any IPR which may be the subject of IPH&#146;s future agreement with ***
concerning US provisional patent applications *** (and any related Patents) (the &#147;IAP Technology&#148;), IPH shall during a period of *** following immediately after such recommendation, seek to negotiate the terms of such a license on terms
acceptable to IPH. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:28%; font-size:10pt; font-family:Times New Roman">5.13.4.1 In the event that IPH is unsuccessful in obtaining such a license including such terms
within such *** period the sum of *** shall be deducted from the next Discovery Milestone payment due to IPH under this Agreement in full and final settlement of its obligations to seek such a license from ***. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:28%; font-size:10pt; font-family:Times New Roman">5.13.4.2 If *** requires a payment of more than *** in order for IPH to obtain such a license (including such terms), IPH shall promptly
notify NN of such fact and NN shall therafter have the right (without obligation) to pay such additional amounts to obtain such licenses. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NICHE CANDIDATES AND <FONT STYLE="white-space:nowrap">EX-VIVO</FONT> CELLULAR THERAPY CANDIDATES
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Niche Candidates</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon IPH&#146;s request at any time during the Collaboration Term, the Joint Steering Committee shall consider
and address to the Development and Commercialization Committee whether a Drug Candidate or Licensed Product identified by IPH may be classified as a Niche Candidate for IPH&#146;s further development and commercialization for one or more indications
specified by IPH relative to such proposed Niche Candidate. After due consideration, and in any event within *** of presentation of IPH&#146;s request to the Joint Steering Committee (or such other period as the Parties may hereafter agree to in
writing), the Development and Commercialization Committee shall submit a recommendation or recommendations respecting the matter to NN&#146;s senior management. NN&#146;s senior management shall review the recommendation(s) of the Development and
Commercialization Committee and, after having given due consideration of the matter, decide, in the exercise of NN&#146;s sole discretion, whether such Drug Candidate or Licensed Product shall be classified as a Niche Candidate for any such
indication(s), which decision shall be set forth in writing and be final and binding upon the Parties. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon and subject to NN&#146;s written approval pursuant to Section <B>6.1(a)</B> of the development and
commercialization of such Drug Candidate or Licensed Product as a Niche Candidate for any indication: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall have the exclusive right to conduct the development and commercialization of such Drug Candidate or
Licensed Product as a Niche Candidate solely for the indication(s) specified by such approval, and shall diligently undertake such development and commercialization pursuant to a license that shall be granted by NN to IPH in conformity with
Section<B>&nbsp;5.5</B> and the other terms and conditions of this Agreement. IPH shall not conduct, or cause to be conducted, any such development or commercialization of such Drug Candidate or Licensed Product as a Niche Candidate for any use or
indication without having first obtained NN&#146;s written approval in accordance with this Section<B>&nbsp;6.1</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall provide IPH with all information (regulatory, clinical, CMC and other) in its possession or control
that is necessary or useful for purposes of IPH&#146;s development or commercialization of the such Niche Candidates for all such approved indications, and, to the extent authorized by contract and permitted by applicable Law, IPH shall have the
right to reference all NN regulatory filings (including all Drug Master Files) for IPH to pursue registrations in respect of such indications. NN&#146;s reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs connected with providing IPH such information and arranging for such rights of reference, including the use of NN staff resources shall be paid by
IPH on an hourly basis reflecting the actual cost to NN but in no circumstances shall such costs exceed a total of ***. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Ex-Vivo</FONT> Cellular Therapy Candidates</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon or within *** after the date of this Agreement, the Parties shall form an
<FONT STYLE="white-space:nowrap">Ex-Vivo</FONT> Task Force having the purpose of preparing, for submission to the Joint Steering Committee and Development and Commercialization Committee within *** after the date of this Agreement, a recommendation
or recommendations setting forth proposed substantive and procedural guidelines in respect of the further development and commercialization of <FONT STYLE="white-space:nowrap">ex-vivo</FONT> applications of Drug Candidates, which may include, among
other relevant factors, business, market, manufacturing and regulatory considerations in respect of the development and commercialization of potential <FONT STYLE="white-space:nowrap">Ex-vivo</FONT> Cellular Therapy Candidates. The Joint Steering
Committee and the Development and Commercialization Committee shall, upon receipt of the recommendation(s) of the <FONT STYLE="white-space:nowrap">Ex-Vivo</FONT> Task Force, present the recommendation(s) to the senior management of the respective
Parties. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this
agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to and upon the finalization and written approval by the Parties&#146; respective senior management of
the <FONT STYLE="white-space:nowrap">Ex-Vivo</FONT> Task Force&#146;s recommended guidelines described in Section <B>6.2(a)</B>, such guidelines will be annexed as an amendment to this Agreement. Particulars as to the objectives, mandate and
procedures of the <FONT STYLE="white-space:nowrap">Ex-Vivo</FONT> Task Force shall be set forth in the annexed Schedule <B>6.2</B>. In the event of a dispute with respect to the adoption or implementation of the
<FONT STYLE="white-space:nowrap">Ex-Vivo</FONT> Task Force guidelines, the matter shall be referred to the Joint Steering Committee and the provisions of Sections <B>4.5</B> and<B> 4.6</B> shall control. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Royalty Obligation</U>. For each Niche Candidate under development and commercialization by IPH and for
which NN has not exercised its <FONT STYLE="white-space:nowrap">Buy-In</FONT> Option rights under Section<B>&nbsp;6.5</B>, IPH shall pay to NN royalties on Net Sales of such Niche Candidate in accordance with the schedule set forth in
Section<B>&nbsp;7.8</B> and the other royalty provisions of Article <B>7</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Access to Materials</U>. In the event that IPH undertakes the development and commercialization of a
Niche Candidate in accordance with Section<B>&nbsp;6.1</B>, IPH shall, solely for purposes of the exercise of its license pursuant to Section <B>5.5(b)</B>, have the right to access reasonable quantities of samples of such Materials in NN&#146;s
Control as are (a)&nbsp;claimed or otherwise covered by the Collaboration IPR or Background NN Research Technology IPR licensed to IPH under Section <B>5.5(b)</B>, and (b)&nbsp;comprise or are directed to such Niche Candidate, for purposes of its
Commercial Optimization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN <FONT STYLE="white-space:nowrap">Buy-In</FONT> Option</U>. The Parties shall have the following rights in
respect of such Niche Candidates as may be developed and commercialized by IPH pursuant to Section<B>&nbsp;6.1</B> hereof: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN and its Affiliates shall, with respect to each indication for each such Niche Candidate being developed and
commercialized by IPH, have the exclusive right and option, hereby irrevocably granted by IPH to participate on a <FONT STYLE="white-space:nowrap">co-exclusive</FONT> basis with IPH in the further development and commercialization of such Niche
Candidate for such indication and to share on *** basis all profits derived from the commercial exploitation thereof (after deduction and reimbursement of the marketing and other costs expended by the respective Parties&#146; in developing and
commercializing such Niche Candidate after NN&#146;s exercise of this option), subject to NN&#146;s payment to IPH of *** of all reasonable, documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
costs expended by IPH prior to NN&#146;s exercise of this option for the development and commercialization of the subject Niche Candidate for such indication, and NN&#146;s undertaking to share with IPH, on *** basis, responsibility for all costs
incurred for the purposes of the further development and commercialization of such Niche Candidate for such indication incurred after the exercise of this option (the &#148;<U><FONT STYLE="white-space:nowrap">Buy-In-Option</FONT></U>&#148;).
</P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement
(indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
NN may exercise this exclusive right and option any time prior to notice from IPH of IPH&#146;s good faith intent to enter into the first Phase III clinical trial with respect to such indication
for such Niche Candidate or the expiration of *** after NN&#146;s receipt of such notice. In each case, IPH shall, within *** after its decision to proceed to any Phase III trial, provide NN with notice of its intention to enter into such trial
together with a draft Phase III trial protocol and all preceding Phase I and Phase II trial data in respect of the Niche Candidate IPH proposes to progress to Phase III trial. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Option to Discontinue Participation In Development Upon NN Execution of
<FONT STYLE="white-space:nowrap">Buy-In</FONT> Option</U>. In the event that NN exercises the foregoing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Buy-In-Option</FONT></FONT> pursuant to Subsection <B>6.5.1</B> with respect to
any Niche Candidate, IPH shall have the option to discontinue its participation in the further development and commercialization of such Niche Candidate for the indication(s) with respect to which NN has exercised the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Buy-In-Option,</FONT></FONT> which <FONT STYLE="white-space:nowrap">opt-out</FONT> option may only be exercised by IPH&#146;s delivery to NN of written notice thereof within *** after
IPH&#146;s receipt of notice of NN&#146;s exercise of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Buy-In-Option.</FONT></FONT> In the event that NN exercises the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Buy-In-Option</FONT></FONT> and IPH exercises the foregoing <FONT STYLE="white-space:nowrap">opt-out</FONT> right: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN or its Affiliates shall assume the sole and exclusive right and license (with the rights to <FONT
STYLE="white-space:nowrap">Sub-license</FONT> and <FONT STYLE="white-space:nowrap">Out-license)</FONT> to further develop and commercialize such Niche Candidate for such indication(s) in the Territory during the Term, subject to NN&#146;s payment to
IPH of (i)&nbsp;one hundred percent of all reasonable, documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs expended by IPH for the development and commercialization of such Niche Candidate
for such indication(s) prior to NN&#146;s exercise of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Buy-In-Option</FONT></FONT> (in lieu of and not in addition to the *** of such costs payable under Subsection <B>6.5.1</B>,)
(ii) IPH&#146;s *** share of all reasonably documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred by the Parties during the period between NN&#146;s exercise of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Buy-In-Option</FONT></FONT> and the effective date of IPH&#146;s exercise of its option to discontinue its participation in the development and commercialization of such Niche Candidate for
such indication(s)), and (iii)&nbsp;royalties in accordance with Subsection <B>7.8.3 (Scenario 3(A), 3(B) or 3(C))</B>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN or its Affiliates shall bear the sole and exclusive responsibility for all costs of such further development
and commercialization, and have the exclusive right to all revenues derived from the commercialization, of such Niche Candidate for such indication(s) incurred after the effective date of IPH&#146;s election to opt out of such further development
and commercialization pursuant to this Subsection <B>6.5.2</B>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall have no further right or license to develop or commercialize such Niche Candidate for such
indication(s) and all rights and licenses granted to IPH hereunder in respect of the relevant indication(s) for such Niche Candidate shall be granted or granted back to NN. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH <FONT STYLE="white-space:nowrap">Out-License</FONT> of Niche Candidates; NN Right of First Offer</U>. In
the event that IPH desires to <FONT STYLE="white-space:nowrap">Out-license</FONT> any Niche Candidate before its determination to initiate the first Phase III trials for such Niche Candidate for any indication(s) with respect to which IPH has
acquired exclusive rights under Section<B>&nbsp;6.1</B>, NN and its Affiliates shall have an irrevocable first right of offer, hereby granted, to negotiate an <FONT STYLE="white-space:nowrap">Out-license</FONT> with IPH in respect of such Niche
Candidate pursuant to the procedures set forth in Subsection <B>13.3.6</B>. If such an <FONT STYLE="white-space:nowrap">Out-license</FONT> agreement is signed by NN and IPH, IPH shall have no further right or license to develop or commercialize such
Niche Candidate in the indication(s) covered by such agreement, save that if no such agreement is executed within the period of *** after such First Offer NN shall have no further right and option under Subsection <B>6.5.1</B>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN <FONT STYLE="white-space:nowrap">Co-Marketing</FONT> Option</U>. In addition to the foregoing rights,
save where IPH has previously <FONT STYLE="white-space:nowrap">Out-licensed</FONT> any rights in respect of a Niche Candidate to a Third Party, NN and its Affiliates shall have the exclusive right and option, hereby irrevocably granted by IPH, to <FONT
STYLE="white-space:nowrap">co-market</FONT> any such Niche Candidate for any indication(s) with respect to which IPH has acquired exclusive rights under Section<B>&nbsp;6.1</B> on terms to be negotiated between the Parties in good faith, which
option may be exercised by NN at any time during the first *** following the First Commercial Sale anywhere in the Territory with respect to each such Niche Candidate for such indication(s). In the event that the Parties are unable to agree to the
terms of <FONT STYLE="white-space:nowrap">co-marketing</FONT> in good faith any remaining disputed terms shall be determined in accordance with Section<B>&nbsp;21.14</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Assistance to NN Upon NN Exercise of <FONT STYLE="white-space:nowrap">Buy-In</FONT> or <FONT
STYLE="white-space:nowrap">Co-Marketing</FONT> Option</U>. If NN shall exercise any of its rights or options under Subsections <B>6.5.1</B> or Section<B>&nbsp;6.6</B>, or enter into any <FONT STYLE="white-space:nowrap">Out-license</FONT> with IPH
pursuant to Subsection <B>6.5.3</B> IPH shall provide NN with all information (regulatory, clinical, CMC and other) in its possession or control that is necessary or useful for purposes of NN&#146;s development or commercialization of the affected
Niche Candidates for all indications concerned, and NN shall have the right to reference all IPH regulatory filings (including all Drug Master Files) for NN to pursue registrations in respect of such indications. IPH&#146;s reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs connected with providing NN such information and arranging for such rights of reference, including the use of IPH staff resources shall be paid by NN on an
hourly basis reflecting the actual cost to IPH but in no circumstances shall such costs exceed a total of ***. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Licenses to NN for Niche Candidates</U>. If NN shall exercise its options pursuant to either
Section<B>&nbsp;6.5 or 6.6</B>, IPH shall, for no additional consideration, grant to NN: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the necessary licenses under any IPR under its Control that is necessary for NN to develop and commercialize
the relevant Niche Candidates pursuant to this Article <B>6</B>; and </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a license under any trade mark, trade dress or similar rights held or exercised by IPH or any of its Affiliates
anywhere in the Territory in connection with the marketing of such Niche Candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to <FONT STYLE="white-space:nowrap">co-marketing,</FONT> in the event that such trade marks do not
exist, the Parties shall in good faith agree upon the adoption and use of trade marks and similar trade designations (including trade dress) for the marketing of such Niche Candidates without any obligation of further payment or consideration.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exclusion of Funded FTEs</U>. For the avoidance of doubt, references in this Agreement to IPH&#146;s <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs shall not include any employee compensation or other costs or expenses that have been underwritten by any NN research funding contributions, including any
such funding contributions pursuant to Section<B>&nbsp;3.12</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TECHNOLOGY FEES, MILESTONES AND ROYALTIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Consideration</U>. In consideration of the rights and licenses granted to NN hereunder, NN agrees to pay to
IPH the upfront technology access fee, milestone payments and royalties set forth in this Article <B>7</B> in accordance with the terms and conditions set forth therein. Notwithstanding any other provisions of this Agreement, but subject to each
Party&#146;s obligations to pay royalties to the other Party during the ten (10)&nbsp;year period following First Commercial Sale, IPH and NN shall have no obligation to pay any royalty or other consideration whatsoever for or upon any Net Sales of
any product (including any Licensed Product, Niche Candidate or Residual Product) in any country, ***. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Technology Access Fee</U>. NN shall pay to IPH, upon the Parties&#146; execution and delivery of this
Agreement on the date of this Agreement, a total <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> technology access fee of ***. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Discovery Milestones</U>. NN shall pay to IPH the following milestone payments for the Collaboration
achievements in research set out below (&#147;<U>Discovery Milestones</U>&#148;) within *** of the achievement of each such Discovery Milestone: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** as defined in Schedule <B>1.1.51 </B>after the date of this Agreement<B> </B>during the Collaboration Term
or within the *** period following immediately after the Collaboration Term: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** as defined in Schedule <B>1.1.41</B> after the date of this Agreement<B> </B>during the Collaboration Term
or within the *** period following immediately after the Collaboration Term: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** as defined in Schedule <B>1.1.52 </B>after the date of this Agreement<B> </B>during the Collaboration Term
or within the *** period following immediately after the Collaboration Term: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, the Parties acknowledge and agree that all Discovery Milestones have been paid in
full in respect of <FONT STYLE="white-space:nowrap">Anti-KIR.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Development Milestone Payments</U>. NN shall pay to IPH the following milestone payments for the
achievements in development set out below (&#147;Development Milestones&#148;) within *** of the achievement of each such Development Milestone. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Class&nbsp;B Licensed Products and Class&nbsp;C Licensed Product Development Milestones </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Development Milestones shall be payable for each Class&nbsp;B Licensed Product or Class&nbsp;C Licensed
Product, on a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-duplicative</FONT> Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis,
irrespective of the number of indications or Backup Products per Licensed Product and any <FONT STYLE="white-space:nowrap">Out-licensing</FONT> or <FONT STYLE="white-space:nowrap">Sub-licensing</FONT> by NN: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.4.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Milestone Payment Terms</U>. All the above Development Milestone payments (specified in
Section<B>&nbsp;7.4.1</B>) are: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Class&nbsp;A Licensed Product Development Milestones. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.4.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>First Developed in Kirostim Field</U>. *** for a Class&nbsp;A Licensed Product first occurs in the Kirostim
Field the payment of the Development Milestones for each such Class&nbsp;A Licensed Product shall be, on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis, irrespective of
the number of indications or Backup Products for such Class&nbsp;A Licensed Product, and any <FONT STYLE="white-space:nowrap">Out-licensing</FONT> or <FONT STYLE="white-space:nowrap">Sub-licensing</FONT> by NN as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, each of the foregoing Development Milestone payments (a), (b), (c), (d), (e), (f),
(g) and (h)&nbsp;shall be payable only once regardless of the number of indications in the Kirostim Field for which a Class&nbsp;A Licensed Product is developed. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">If a Class&nbsp;A Licensed Product achieves First Commercial Sale in a cancer indication in the
Kirostim Field, Development Milestone (g)&nbsp;shall be payable. If a Class&nbsp;A Licensed Product achieves First Commercial Sale in a <FONT STYLE="white-space:nowrap">non-cancer</FONT> indication in the Kirostim Field, Development Milestone
(h)&nbsp;shall be payable. If a Class&nbsp;A Licensed Product achieves First Commercial Sale in both a cancer indication and a <FONT STYLE="white-space:nowrap">non-cancer</FONT> indication in the Kirostim Field, Development Milestones (g)&nbsp;and
(h) shall both be payable. For the avoidance of doubt, if any Class&nbsp;A Licensed Product is first developed in the Kirostim Field, the Development Milestones will amount to a maximum of ***. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.4.2.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Milestone Payment Terms</U>. All the above Development Milestone payments (specified in Subsection
<B>7.4.2.1</B>) are: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="35%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="35%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="35%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.4.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Subsequent Development in the Additional Kirostim Field</U>. If a Class&nbsp;A Licensed Product has achieved
Development Milestone (a)&nbsp;in the table of Subsection <B>7.4.2.1 </B>in respect of development in the Kirostim Field, and the development of such Class&nbsp;A Licensed Product in the Additional Kirostim Field commences after the achievement of
Development Milestone (a)&nbsp;in the Kirostim Field, then Development Milestones (c), (d), (e), (f) and (g)&nbsp;in the table of Subsection <B>7.4.2.1</B> shall be payable for each indication for which that Class&nbsp;A Licensed Product is
developed in the Additional Kirostim Field. For the avoidance of doubt, for each Class&nbsp;A Licensed Product developed for any given indication in the Additional Kirostim Field, the maximum Development Milestones payable shall be *** per
indication in the Additional Kirostim Field in addition to the Development Milestone payments in the Kirostim Field. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.4.2.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Milestone Payment Terms</U>. All the above Development Milestone payments (specified in Subsection
<B>7.4.2.2</B>) are: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="35%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="35%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="35%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.4.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>First Developed in Additional Kirostim Field</U>. In the event that the *** for each Class&nbsp;A Licensed
Product first occurs in the Additional Kirostim Field the Development Milestones for each Class&nbsp;A Licensed Product, in every separate indication in the Additional Kirostim Field, on a Licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis, irrespective of the number of Backup Products per Licensed Product and any <FONT STYLE="white-space:nowrap">Out-licensing</FONT> or
<FONT STYLE="white-space:nowrap">Sub-licensing</FONT> by NN shall be as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:23%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt if such a Class&nbsp;A Licensed Product is developed in the Additional Kirostim Field in such circumstances, the
Development Milestons payable to IPH shall amount to a maximum of *** per indication in the Additional Kirostim Field. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.4.2.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Milestone Payment Terms</U>. All the above milestone payments (specified in Subsection <B>7.4.2.2</B>) are:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="30%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="30%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="30%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">7.4.2.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Subsequent Development in the Kirostim Field</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:24%; font-size:10pt; font-family:Times New Roman">If a Class&nbsp;A Licensed Product has achieved Development Milestone (a)&nbsp;in respect of development in the Additional Kirostim Field
(under Subsection <B>7.4.2.3</B>), and the development of such Class&nbsp;A Licensed Product in the Kirostim Field commences after the achievement of such Development Milestone (a)&nbsp;in respect of development in the Additional Kirostim Field,
then Development Milestones (c), (d), (e), (f), (g) and (h)&nbsp;in the following table shall be payable, only once per Class&nbsp;A Licensed Product, regardless of the number of Backup Products to such Licensed Product or the number of indications
for which such Class&nbsp;A Licensed Product is developed in the Kirostim Field. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, the maximum Development Milestones payable under this Subsection <B>7.4.2.3.2</B>
for development in the Kirostim Field shall be *** for each Class&nbsp;A Licensed Product based on the achievement of all of the foregoing Development Milestones (c), (d), (e), (f), (g), and (h)&nbsp;in addition to the Development Milestone payments
payable in the Additional Kirostim Field. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All the above milestone payments (specified in Subsection <B>7.4.2.3.2</B>) are: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Royalty Calculation and Payments</U>. In addition to all fees and other amounts payable by the Parties under
this Agreement, each Party shall pay to the other, on a quarterly basis throughout the Term, commencing with the First Commercial Sale by Selling Parties comprised of such Party, any of its Affiliates, or any of such Party&#146;s or its
Affiliates&#146; respective <FONT STYLE="white-space:nowrap">Out-licensees,</FONT> on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product, Niche <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Candidate-by-Niche</FONT></FONT> Candidate or Residual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Residual</FONT></FONT> </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Product basis (as the case may be), incremental running royalties on the aggregate Net Sales attained by such Selling Parties throughout the Territory during the immediately preceding calendar
quarter, in accordance with the schedules set forth in Sections <B>7.6</B> and <B>7.7</B> and the other terms and conditions of this Agreement. Each Party shall further calculate and pay to the other Party within *** of the end of each calendar year
during the Term all royalty payments remaining due and payable by that Party in respect of that calendar year. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Royalties on Licensed Products</U>. Each Party shall pay to the other the following percentage royalties on
all Net Sales of Licensed Products in the Territory by such Party (or its associated Selling Parties) on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Licensed-Product-by-Licensed-Product</FONT></FONT> basis during the Term for
each such Licensed Product in accordance with Section<B>&nbsp;7.11</B>: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Percentage Royalties on Net Sales of Class</U><U></U><U>&nbsp;A Licensed Products</U>. Percentage royalties
on Net Sales of Class&nbsp;A Licensed Products (notwithstanding any royalties that such Party or its associated Selling Parties may have to pay to Third Parties with respect to the affected Licensed Products): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of illustration, in the event that the annual Net Sales in a calendar year are *** the
royalties payable to IPH will be calculated as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Percentage Royalties on Net Sales of Class</U><U></U><U>&nbsp;B Licensed Products</U>. Percentage royalties
on Net Sales of Class&nbsp;B Licensed Products (notwithstanding any royalty that such Party or its associated Selling Parties may have to pay to Third Parties with respect to the affected Licensed Products): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Percentage Royalties on Net Sales of Class</U><U></U><U>&nbsp;C Licensed Products</U>. Percentage royalties
on Net Sales of Class&nbsp;C Licensed Products (notwithstanding any royalty that such Party or its associated Selling Parties may have to pay to Third Parties with respect to the affected Licensed Products): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Royalties on Residual Products</U>. Drug Candidates that; (a)&nbsp;would have been classified as being
Class&nbsp;A Licensed Products, Class&nbsp;B Licensed Products, or Class&nbsp;C Licensed Products provided they had passed M1; and (b)&nbsp;subsequently are designated as Residual Products pursuant to Subsection <B>1.1.63</B> and Article <B>13</B>;
shall retain that classification and be treated as Licensed Products of the applicable Product Class&nbsp;for the purposes of calculating royalties payable in respect of such products except for products that would have been classified as being
Class&nbsp;C Licensed Products and where M0 approval has occurred less than *** prior to the expiry of the Collaboration Term, which royalty payments shall be according to Subsection <B>13.3.3</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Royalties on Niche Candidates</U>. Each Party identified below shall pay to the other Party the following
royalties on all Net Sales by the first Party (or any of its associated Selling Parties) in the Territory of each Niche Candidate commercialized by the first Party pursuant to Article <B>6</B> on a Niche <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Candidate-by-Niche</FONT></FONT> Candidate basis for each such Niche Candidate (in each case notwithstanding any royalty the first Party or any of its associated Selling Parties may have to pay to Third Parties with
respect to the affected Niche Candidate) during the Term for each such Niche Candidate in accordance with Section&nbsp;7.11: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Scenario 1</U>: IPH&#146;s payment to NN of royalties on Net Sales of any Niche Candidate that IPH develops
independently of NN to M1 status and subsequently commercializes shall be: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Scenario 2</U>: IPH&#146;s payment to NN of royalties on Net Sales of any Niche Candidate that IPH develops
independently of NN commencing after such Niche Candidate attains M1 status and subsequently commercializes shall be: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Scenario 3</U>: NN&#146;s payment to IPH of royalties on Net Sales of any Niche Candidate with respect to
which NN has exercised its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Buy-In-Option</FONT></FONT> and IPH has exercised its opt out option pursuant to Subsection <B>6.5.2</B> shall be as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.8.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Scenario 3(A)</U>: If NN assumes exclusive development and commercialization of such Niche Candidate prior
to the filing of the first IND for such Niche Candidate: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.8.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Scenario 3(B)</U>: If NN assumes exclusive development and commercialization of such Niche Candidate after
the filing of the first IND for such Niche Candidate but before the dosing of the first patient in the first Phase II trial for such Niche Candidate: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.8.3.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Scenario 3(C)</U>: If NN assumes exclusive development and commercialization of such Niche Candidate after
the dosing of the first patient in the first Phase II trial but prior to the expiration of *** after its receipt of notice of IPH&#146;s decision to proceed to Phase III trials for such Niche Candidate in accordance with Subsection <B>6.5.1</B>:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Records of Net Sales</U>. Each Party shall keep complete and correct records of its Net Sales and the Net
Sales of its associated Selling Parties and shall provide to the other Party on a quarterly basis a summary report indicating all Net Sales giving rise to royalties payable to the other Party on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis for the preceding quarter. Quarterly royalty payments under this Agreement shall
be calculated at the royalty rates set out in Sections <B>7.6m 7.7</B> and <B>7.8</B> or Article <B>13 </B>and<B> 3</B>, as applicable, save that the royalty rate(s) applicable to the whole or any portions of any quarterly royalty payment shall be
calculated by adding together on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis all Net Sales made by a Party and its associated Selling Parties so far during that calendar year. Such
quarterly payments shall be due and payable within *** after March&nbsp;31, June&nbsp;30, September&nbsp;30 and December&nbsp;31 of each calendar year. Exchange rates applicable for the calculation of quarterly royalty payments shall be based on
***. For the avoidance of doubt, only one (1)&nbsp;royalty shall be payable on the Net Sales of any item of Licensed Product, Niche Candidate or Residual Product, irrespective of (a)&nbsp;the number of indications for which such Licensed Product,
Niche Candidate or Residual Product, or any combination thereof, is sold or used, or (b)&nbsp;the number of Valid Claims that cover such Licensed Product, Niche Candidate or Residual Product, and shall end all further payment obligations to the
licensor Party in respect of the commercial exploitation of such item, including any obligation of any end user or other Person to whom or which such item is sold. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Annual Recalculation and Report</U>. Each Party shall within *** after the end of each calendar year during
the Term deliver a final report including a calculation of the annual Net Sales in the preceding calendar year and a final calculation of the total annual royalty payments due for that calendar year. Exchange rates for this calculation shall follow
that for the quarterly calculation. Any difference between the sum of the quarterly royalty payments made by a Party for the calendar year in reference and the total annual royalty payments due and payable by such Party for the calendar year shall
be paid by to the other Party within *** after delivery of the final report. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Royalty Term</U>. Except as otherwise herein expressly provided, the Parties&#146; respective obligations to
pay royalties on Net Sales of Licensed Products, Niche Candidates and Residual Products under this Agreement shall commence, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis with the First Commercial Sale of such product in the relevant country and expire, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, with the expiration of the Term with respect to such </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
product in such country, as set forth in Subection <B>1.1.66</B>. After the expiration of the Term with respect to any Licensed Product, Niche Candidate or Residual Product in any country(ies),
no further royalties or other consideration shall be required to be paid or provided for or upon any Net Sales or other commercial exploitation of such Licensed Product, Niche Candidate or Residual Product in such country(ies), and the rights and
licenses granted herein with respect to such Licensed Product, Niche Candidate or Residual Product in such country(ies) shall be deemed fully <FONT STYLE="white-space:nowrap">paid-up</FONT> and without obligation to provide any further
consideration. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Effect of <FONT STYLE="white-space:nowrap">Out-licensing</FONT> on Royalties</U>. Each Party shall pay
the milestones payments and royalty rates it has herein agreed to in this Agreement whether or not such Party enters into any <FONT STYLE="white-space:nowrap">Out-licenses</FONT> with different milestones or royalty rates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FINANCIAL PROVISIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment by Wire Transfer</U>. All amounts due under this Agreement shall be paid by wire transfer to such
bank account as the Party to whom such amounts are due may direct in writing from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Currency</U>. All payments shall be made in Euro. All amounts to be paid are intended to be net of any
deduction imposed by a government authority including any tax, duty, levy, fee or charge that may be applied to such amount. To the extent income is received or expenses are incurred in a currency other than Euro, the applicable income or expenses
shall be converted into Euro using such bona fide publicly quoted commercial rate of exchange contemporaneously in general use by the paying Party at the given time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Withholding Tax</U>. If any payment made by a Party under this Agreement is subject to recoverable
withholding tax, the Parties shall support legal efforts of minimizing such withholding taxes, and provide each other with information about any documentation to reduce the withholding tax to a legal minimum. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Audits</U>. If either Party requests, the other Party shall allow its books and records to be audited by an
independent major certified public accountant selected by the requesting Party, to whom the other Party has no reasonable objection. The objective of such audits shall only be to examine the calculation of the royalties payable under this Agreement.
Such audits shall take place upon reasonable (but not less than ***) notice, only during normal business hours and no more than one time in any calendar year, shall not cover transactions that occurred before for more than the preceding ***, shall
not cover entries in books and records which predate the Effective Date and shall cover only the transactions relating to Net Sales under this Agreement. Such auditor shall not in any way be compensated (in whole or in part) contingent on the
outcome of the audit. Any information gathered or obtained during any such audit shall be deemed the Confidential Information of the audited Party, and the auditor must sign a confidentiality agreement undertaking that he shall not disclose to any
Person, including the Party who has requested the audit, any information obtained in the course of the audit other than information relating solely to the accuracy and validity of the royalty statements provided by the audited Party. Such audits
shall </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement
(indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
be (a)&nbsp;conducted in accordance with generally accepted auditing standards; (b)&nbsp;limited to those books and records described in this Section<B>&nbsp;8.4</B>; and (c)&nbsp;undertaken for
the sole purpose of verifying the accuracy and validity of the royalty information, statements and documentation information provided by the audited Party. A copy of the auditor&#146;s report shall be furnished to each Party promptly after the
completion of such audit. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Cost of Audit</U>. The cost of any audit pursuant to Section<B>&nbsp;8.4</B> shall be the responsibility of
the Party that has requested such audit. In the event that such audit discloses that the royalties have not been calculated accurately and this has resulted in an underpayment of *** or more by either Party in total during a calendar year, the costs
of the audit shall be borne by the audited Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Right to Audit Third Parties</U>. In the event that Net Sales are generated by the Affiliates or <FONT
STYLE="white-space:nowrap">Out-licensees</FONT> of either Party, such Party shall ensure that the books of such Affiliates and <FONT STYLE="white-space:nowrap">Out-licenses</FONT> may also be audited by the other Party in accordance with
Section<B>&nbsp;8.4</B> above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disclosure of <FONT STYLE="white-space:nowrap">Know-How</FONT></U>. During the Collaboration Term, each
Party shall promptly disclose to the other Party the conception, reduction to practice, or other generation or acquisition of potentially patentable, otherwise legally protectable, or commercially useful
<FONT STYLE="white-space:nowrap">Know-How</FONT> in the Collaboration Field (including any relevant invention disclosures), by employees or others acting on behalf of such Party, and shall freely share data and results obtained in the Collaboration.
During the Collaboration Term, each Party shall also provide the other with such technical information and assistance as is sufficient to enable the other Party to assess the progress of the work performed by such Party pursuant to the Collaboration
and to assist the other Party in achieving Commercial Optimization. All disclosures of <FONT STYLE="white-space:nowrap">Know-How</FONT> under this Section<B>&nbsp;9.1</B> shall be made at least *** prior to any public disclosure of such <FONT
STYLE="white-space:nowrap">Know-How</FONT> or any required submission to government agencies in compliance with the requirements of government supported research. Any Patent filed after the date of this Agreement (and any Patents related to any such
Patent), in respect of <FONT STYLE="white-space:nowrap">Know-How</FONT> that is the subject matter of an invention disclosure listed as Background IPR of a Party as of the date of this Agreement in a relevant Schedule hereto shall be treated as
Background IPR of that Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Ownership of Collaboration IPR</U>. All right, title and interest, as between the Parties, in all
Collaboration IPR shall be owned as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall own all Collaboration IPR that is invented or otherwise generated or acquired solely by one or more
employees, agents, or other Persons acting on behalf of IPH, either alone or together with Persons other than NN, NN Affiliates, or any employees, agents or other Persons acting on behalf of NN or any of NN&#146;s Affiliates; </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall own all Collaboration IPR that is invented or otherwise generated or acquired solely by one or more
employees, agents or other Persons acting on behalf of NN, either alone or together with Persons other than IPH, IPH&#146;s Affiliates, or any employees, agents or other Persons acting on behalf of IPH or any of IPH&#146;s Affiliates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of IPH and NN shall jointly own all Joint IPR. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">All questions of inventorship shall be determined in accordance with United States Patent Laws (Title 35, United States Code). All
determinations of inventorship shall be documented to ensure that any divisional or continuation Patent applications reflect appropriate inventorship. The Parties acknowledge and agree that the ownership rights set out in this
Section<B>&nbsp;9.2</B> are subject to the rights and licenses granted pursuant to this Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disputes Regarding Inventorship or Ownership of Collaboration IPR</U>. During the Collaboration Term, if a
dispute shall arise regarding the inventorship, ownership, validity or enforceability of any Collaboration Patent or other Collaboration IPR, the Joint Steering Committee shall establish a procedure to resolve such dispute, which may include
engaging a Third Party neutral patent attorney jointly selected by agreement of the Parties to assist them regarding the resolution of any such dispute. The Joint Steering Committee, however, shall not have the authority to resolve any such dispute.
If (a)&nbsp;the Joint Steering Committee or the executive officers of the Parties cannot agree upon a procedure to resolve such dispute within *** or (b)&nbsp;the dispute arises after the expiration or earlier termination of the Collaboration Term,
such dispute shall be submitted for resolution by arbitration in accordance with Section<B>&nbsp;21.14</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Duty to Require Assignment of Collaboration IPR by Employees, Consultants, and Collaboration Partners</U>.
Each Party shall ensure that all employees acting on behalf of itself or any of its Affiliates in performing such Party&#146;s obligations under the Collaboration shall be obligated to assign to such Party, or as such Party shall direct, all
Collaboration IPR conceived or reduced to practice by such employees as part of the activities conducted under this Agreement. In the case of consultants, Third-Party collaboration partners and other
<FONT STYLE="white-space:nowrap">non-employees</FONT> working with or on behalf of a Party, that Party shall exercise best efforts to obtain, at its own cost (unless hereafter otherwise decided in writing by the Joint Steering Committee or the
Parties), either an assignment or an exclusive license establishing its exclusive Control of all Collaboration IPR conceived or reduced to practice by such <FONT STYLE="white-space:nowrap">non-employees</FONT> and, at a minimum, an exclusive option
or first right of negotiation to secure such exclusive rights. In all events, each Party shall perform its obligations pursuant to Section<B>&nbsp;5.8</B> to preserve the other Party&#146;s freedom of operation to exercise its rights and fulfill its
obligations hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Obligations to Maintain Control of Licensed IPR</U>. Subject to Section<B>&nbsp;5.10</B>, throughout the
Term: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Obligation</U>. IPH shall maintain Control of Background IPH IPR, Collaboration IPR, and Independent IPH
IPR, to the extent such IPR is Controlled by IPH as of the date of this Agreement or acquired by IPH during the Term, throughout the Term, and </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately
with the Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN Obligation</U>. NN shall maintain Control of Background NN IPR, Collaboration IPR, and Independent NN
IPR, to the extent such IPR is Controlled by NN as of the date of this Agreement or acquired by NN during the Term, throughout the Term, except that NN shall have no obligation to retain Control of Independent NN IPR if doing so will require
NN&#146;s provision or payment of any additional consideration to any Person for such retention save that IPH may pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by applicable Law.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exception for Third Party Diligence Obligations</U>. The Parties&#146; obligations under this Agreement to
maintain Control of IPR shall be subject to the limitations set forth in agreements with Third Parties with respect to development and commercialization diligence obligations and neither Party shall be in breach of this Agreement in the event of the
termination of rights to such IPR resulting from its failure to fulfil such diligence obligations, <I>provided that</I> such failure does not result from the failure of the Party to exercise Commercially Reasonable Efforts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Limitation of Obligation regarding Identified Independent IPR</U>. The obligation of either Party to Control
Independent IPR shall only apply to Independent IPR that one Party has specifically identified to the other Party as being necessary for the identifying Party&#146;s freedom of operation to commercialize products in accordance with its rights and
licenses hereunder. Independent NN IPR identified by IPH pursuant to this Section shall be listed in Schedule <B>9.5.4(a)</B> and Independent IPH IPR identified by NN pursuant to this Subsection <B>9.5.4 </B>shall be listed in Schedule
<B>9.5.4(b)</B>. NN shall within *** of any reasonable request by IPH update Schedule <B>9.5.4(a)</B> and IPH shall within *** of request by NN update Schedule <B>9.5.4(b)</B> (e.g. to provide the serial number and publication number of related
patent applications, the patent number of related patents, and to provide the status of listed patents and patent applications to the Patents initially listed therein). At the request of a Party that is obligated to maintain Control of any
Independent IPR pursuant to this Subsection <B>9.5.4</B>, the Parties shall determine in good faith whether continued maintenance of Control over such IPR is required and, in cases where the Parties agree such continued maintenance of Control is no
longer required the Party previously required to maintain such control shall have no further obligation to maintain Control of such IPR. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Prosecution of Patents</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Correspondence Regarding Proposed Patent Submissions</U>. Subject to the terms and conditions of
Section<B>&nbsp;21.2</B> and the Common Interest Agreement annexed as Schedule <B>21.2</B> hereto, the Party responsible for prosecuting any Patent under this Article <B>9</B> shall promptly, and in any event no less than *** prior to any final
deadline for submission of such documents or required filing date, deliver or have delivered to the other Party copies of: </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all proposed amendments, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all proposed Patents (including drafts of new original applications, proposed continuations, proposed
divisional applications, proposed reissue applications, and proposed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part)</FONT></FONT> or, in instances where several proposed Patents are substantially similar, a
representative Patent for such proposed Patents (such as in the case of national phase filing of an International (PCT) patent application), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all substantive documents proposed to be filed in patent authority appeal proceedings, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all substantive documents proposed to be filed in inter partes disputes (including opposition, reexamination,
or interference proceedings) before patent authorities or before any judicial body on appeal of such proceedings, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other substantive proposed patent authority submissions reasonably and specifically requested by the other
Party, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">in respect of such Patents (except for Patents in the Independent IPR of either Party), so as to provide the
other Party with a sufficient opportunity to review and comment on such proposed submissions. However, except as otherwise provided for in this Section<B>&nbsp;9.6</B>, the prosecuting Party shall have no obligation to act in accordance with any
such comments. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Patent Authority Correspondence</U>. The Party responsible for prosecuting any Patent under this Article
<B>9</B> shall with respect to such Patent (other than any Patent included in the Independent IPR of either Party): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify the other Party of receipt of all office actions or other substantive patent authority correspondence
requested by the other Party and filing of responses thereto in the prosecution of (i)&nbsp;any U.S., European, or Japanese patent application, (ii)&nbsp;any other specific patent application specifically requested by the other Party, or
(iii)&nbsp;patent applications of any other country, region, or patent examining authority specifically and reasonably requested by the other Party, in such Patent, and provide all copies of such documents to the other Party that are not readily
publicly available, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify the other Party of the allowance of any such Patent, giving the other Party the expected date of
issuance thereof, allowed claims, and its plans with respect to filing of any continuation, divisional, or similarly related patent application to such allowed Patent, and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify the other Party of the issuance of any such Patent. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Patents Prosecuted by NN</U>. NN shall, during the Term, have the exclusive right and sole discretion to
file, prosecute, and maintain Patents with respect to any discoveries or inventions encompassed by the Joint IPR, NN owned Collaboration IPR, Background NN IPR, or Independent NN IPR, <I>provided that</I> NN has such rights to file, prosecute, and
maintain <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> Third Parties. NN shall bear sole responsibility for the preparation of and all costs of procuring the filing, prosecution, and maintenance of
such Patents, including attorneys&#146; fees and payments due to Patent authorities to maintain such Patents. NN may, at its option, prepare, file, prosecute, and maintain all such Patents, including any Patents within the Joint IPR, by using
NN&#146;s <FONT STYLE="white-space:nowrap">in-house</FONT> patent attorneys/patent agents, and IPH acknowledges and agrees that this does not create an attorney-client relationship between NN and IPH. NN may enter into any arrangement it deems
appropriate with any relevant Third Party(ies) regarding prosecution of Patents that are owned by NN and IPH together with one or more such Third Parties, and IPH shall provide to NN all reasonable assistance with respect to entering into such
arrangements as may be requested by NN. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Prosecution of Patents in Independent IPH IPR</U>. IPH shall, during the Term, have the exclusive right
and sole discretion (to the extent authorized by contract and permitted by applicable Law) to file, prosecute and maintain Patents with respect to any discoveries or inventions encompassed by Independent IPH IPR <I>provided that</I> IPH has such
rights to file, prosecute, and maintain <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> Third Parties. IPH shall bear sole responsibility for the preparation of and all costs of procuring the filing,
prosecution and maintenance of such Patents, including attorneys&#146; fees and payments due to Patent authorities to maintain such Patents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Prosecution of Patents in Background IPH IPR and IPH Owned Collaboration Patents</U>.<I> </I>IPH shall
be responsible for the prosecution of Patents in the Background IPH IPR and Collaboration IPR owned by IPH but not by NN. IPH shall bear sole responsibility for the preparation of and all costs of procuring the filing, prosecution, and maintenance
of such Patents, including attorneys&#146; fees and payments due to Patent authorities to maintain such Patents, provided that IPH has such rights to file, prosecute, and maintain
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> Third Parties. IPH may, at its option, prepare, file, prosecute and maintain such Patents by using IPH&#146;s
<FONT STYLE="white-space:nowrap">in-house</FONT> patent attorneys/patent agents, and NN acknowledges and accepts this and that this does not create an attorney-client relationship between NN and IPH. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.6.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN&#146;s Limited Right to Comment On or Direct Prosecution of Patents Prosecuted by IPH Under Subsection
</U><B><U>9.6.5</U></B>. With respect to Patents prosecuted by IPH under this Section<B>&nbsp;9.6.5</B>, NN may, (i)&nbsp;any time prior to *** before the deadline for filing </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
any response, application, or the like in respect of any proposed filing or submission concerning such Patents provided to NN by IPH under Subsection <B>9.6.1</B> or (ii)&nbsp;at any other time
with respect to prosecution of such Patents, provide comments to IPH regarding such proposed submission or prosecution. IPH shall consider NN&#146;s comments in good faith and shall notify NN within the shorter of either *** of its receipt of such
comments or *** before any deadline for filing or submission as to whether it intends to adopt or reject NN&#146;s suggestions. In the event that IPH notifies NN that it will not adopt NN&#146;s suggestions, NN may at any time thereafter:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">direct IPH to make additions, modifications, or deletions in proposed Patents and patent authority
correspondence to be filed after the date of this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to adopt or modify the prosecution strategy for such Patents and for Patents that have already been filed by
the date of this Agreement (such as by accelerating prosecution or adding additional claims with respect to such Patents). </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">IPH shall comply with any such directions provided by NN <I>provided that</I> such directions do not materially impact IPH&#146;s ability to
prosecute or obtain claims of its choice in at least one related Patent in any applicable patent family in any country or region in such Patents or limit the term of such related Patent. In cases where NN has provided such directions to IPH in
respect of a Patent of a particular patent family and country or region, IPH shall have the right to file one or more continuation applications, divisional applications, or the like with respect to such Patent, wherein NN shall not have such right
to direct prosecution so long as IPH&#146;s prosecution of such other applications does not materially limit the term of any Patent in which NN has the right to provide such directions. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH Right to Pursue Patents in Joint IPR and <FONT STYLE="white-space:nowrap">NN-Owned</FONT> Collaboration IPR
for Licensed Products, Niche Candidates or Residual Products. In the event that IPH shall become licensed hereunder to commercialize a Licensed Product, Niche Candidate or Residual Product, IPH shall, at its own expense and to the extent permitted
by contract and applicable Law, during the Term, have the exclusive right and sole discretion to file, prosecute, maintain, and defend such Joint Patents and Patents in NN solely owned Collaboration IPR that claim solely, specifically, and
exclusively, such products <I>provided that</I> IPH&#146;s prosecution, maintenance, or defense of such Patents does not materially prejudice NN&#146;s ability to obtain patent protection relevant to Licensed Products, Niche Candidates or Residual
Products licensed to NN hereunder. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been
excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.6.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Rights of the Parties to Pursue Continuations of Allowed Patents</U>. Where either Party notifies the other
of the allowance of a Patent prosecuted pursuant to this Article <B>9</B> (except for Patents within the Independent IPR of either Party) and indicates that it does not intend to pursue a continuation application, divisional application, or
similarly related patent application to such allowed Patent, the other Party shall have the right to file such a related patent application at its own expense and the notifying Party shall assign its rights in such Patent to the other Party and
provide any other assistance reasonably requested by the other Party in connection with the filing and prosecution of such related patent application (including providing the other Party with power of attorney to file and prosecute such patent
application). The other Party shall thereafter grant to the notifying Party a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under such Patent for no additional consideration. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.6.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice and Effects of Either Party&#146;s Decision to Abandon; Disclaim; or Discontinue Prosecution,
Maintenance, or Defense of Patents. In the event that either Party decides in respect of any Patent for which it is responsible for prosecution hereunder (except for Patents within the Independent IPR of that Party): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to discontinue the prosecution or maintenance of any Patent, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to discontinue the defense of any Patent (such as by discontinuing efforts to defend a Patent that is the
subject of an opposition, reexamination, nullity, or interference proceeding), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to not file a priority patent application with respect to (i)&nbsp;an invention disclosure in the Collaboration
IPR or (ii)&nbsp;any Patent to which it is the prosecuting Party (including by decision (A)&nbsp;not to enter the national or regional phase in any country or region that is a designated state of a PCT application filed by such Party or (B)&nbsp;not
to pursue an application in a country wherein an application claiming priority to another application filed by such Party may be filed), or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to abandon or disclaim (in whole or in part, other than by terminal disclaimer), without possibility of
restoration, any Patent, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">it shall provide written notice to the other Party at least *** in advance of such abandonment
or deadline for such filing &#150; except in the case of national phase filing, in which case such notice shall be provided at least *** in advance of the date of the first applicable deadline for national phase entry &#150; so as to allow the other
Party the opportunity to file, defend, maintain (including by payment of annuities, issue fees, maintenance fees, or the like), or continue prosecution of such Patent, at its own expense. In such an event, the notifying Party shall provide any
assistance reasonably requested of it by the other Party (including providing the other Party with power of attorney to perform such tasks) and, to the extent authorized by contract and permitted by applicable Law, assign its rights to such Patent
to the other Party. The notified Party shall thereafter grant to the notifying Party a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">
license with respect to such Patent for no additional consideration. The Parties acknowledge that any abandoned Patents listed as Background IPR as of the date of this Agreement in the applicable
Schedules hereto represent <FONT STYLE="white-space:nowrap">Know-How</FONT> of the Party associated with such IPR and that such party shall, during the Term, be entitled to file, prosecute, and maintain Patents in respect of such subject matter and
any Patent arising therefrom shall be deemed Background IPR of such Party. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.6.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Obligation to Provide Assistance With Respect to Other Party&#146;s Patent Prosecution</U>. Except with
respect to Patents in the Independent IPR of either Party, each Party shall support a prosecuting Party&#146;s efforts to obtain Patent protection, including participating in or causing the preparation, execution, and filing of appropriate formal
documents in national and international patent offices and obtaining the cooperation of inventors in supporting Patents prosecuted pursuant to this Article <B>9</B>. The other Party shall make available to such prosecuting Party (or to such
prosecuting Party&#146;s authorized attorneys, agents or representatives) the other Party&#146;s employees, agents, consultants, and, to the extent possible, Third Party collaboration partners to the extent necessary or reasonably useful to enable
the prosecuting Party to file, prosecute, maintain, and defend said Patents for such periods of time as are sufficient for the prosecuting Party to obtain the necessary assistance from such Persons. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.6.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Discovered Information</U>. Each Party shall provide the other Party with timely notification regarding any
information it discovers during the Term that may be reasonably considered to materially impact the validity, enforceability, scope or term of any Patent under this Article <B>9</B>, except with respect to Patents in the Independent IPR of either
Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.6.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Diligence in Patent Prosecution</U>. Each Party shall exercise diligent endeavours in its filing,
prosecution, and maintenance of Patents for which it is the prosecuting Party under this Article <B>9</B>. Such duty shall not apply, however, with respect to Patents in the Independent IPR of either Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Updating of Patent Schedules and Patent Information</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall, (a)&nbsp;within *** of any reasonable request from IPH, update Schedule <B>1.1.7</B> or Schedule
<B>1.1.8</B> to include Background NN IPR and Background NN Research Technology IPR, respectively (including providing the application and publication numbers for any counterparts of patent applications originally listed therein and indicating the
status of such applications and any related patents), (b) provide any information reasonably requested concerning Collaboration Patents prosecuted by NN, and (c)&nbsp;provide any information reasonably requested regarding Patents in Third Party IPR
acquired or licensed by NN or arising from a Third Party collaboration to which NN is a party, and </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall, (a)&nbsp;within *** of any reasonable request from NN, update Schedule <B>1.1.5</B> or Schedule
<B>1.1.6</B> to include Background IPH IPR and Background IPH Research Technology IPR, respectively (including providing the application and publication numbers for any counterparts of patent applications originally listed therein and indicating the
status of such applications and any related patents), (b) provide any information reasonably requested concerning Collaboration Patents prosecuted by IPH, and (c)&nbsp;provide any information reasonably requested regarding Patents in Third Party IPR
acquired or licensed by NN or arising from a Third Party collaboration to which NN is a party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall, within *** of any reasonable request by IPH, update Schedule <B>1.1.16</B> including using
information provided to it by IPH under Subsection <B>9.7.2</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Patent Term Extension</U>. IPH shall advise NN of any communications between IPH and any regulatory agency
(including the FDA or EMEA) or other governmental body that may be reasonably considered pertinent to an extension of the term of a Patent exclusively licensed to NN hereunder (including, without limitation, patent term restoration under the U.S.
Patent Statutes (35 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&#167;1-376)</FONT> and supplementary protection certificates in the member states of the European Union or European Economic Area, or Switzerland). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN, at its sole discretion and cost, may seek, or direct IPH to seek, where appropriate, an extension of the
term of any Patent licensed exclusively to NN hereunder or other patent Controlled by IPH covering a Licensed Product (including, without limitation, filing for patent term restoration under the U.S. Patent Statutes (35 U.S.C. <FONT
STYLE="white-space:nowrap">&#167;&#167;1-376)</FONT> and seeking supplementary protection certificates in the member states of the European Union or European Economic Area, or Switzerland). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall not seek an extension of the term of any patent exclusively licensed to NN hereunder without
NN&#146;s prior written consent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH hereby authorizes NN to act as IPH&#146;s agent before any patent authority (including the United States
Patent and Trademark Office) and agrees that NN is entitled to rely on any activities of IPH as a marketing applicant before any Regulatory Agency in any seeking of an extension of any patent for a Licensed Product. IPH shall cooperate with any
efforts by NN to extend the term of such patent for a Licensed Product, including diligently supplying all information relating to such extension to NN, and executing supporting documents required to comply with all laws pertaining to the extension
of patent term including granting NN or its representatives any power of attorney necessary to seek such extension </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>License Registration</U>. Either Party may, at its own expense and to the extent possible, register
information concerning the rights licensed to it herein, in whole or in part, with appropriate patent or other government authorities, where </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
necessary to fully enjoy the rights and licenses provided to it hereunder, <I>provided that</I> the Party proposing to do so provides the other Party with a copy of any information or documents
it proposes to file in association with such registration at least *** prior to the filing thereof. Each Party shall endeavour to maintain as much confidentiality as possible regarding this Agreement in making such disclosures. Any such disclosures,
not objected to by the other Party, and made in accordance with this Section, shall not constitute a breach of the Confidentiality Provisions of this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Implied Rights</U>. Except as otherwise expressly provided in this Agreement, this Agreement does not
grant, license, or otherwise transfer or convey to either Party any ownership interest or other right, title or interest in or to the Patents, other IPR, or Confidential Information of the other Party, including any Materials or <FONT
STYLE="white-space:nowrap">Know-How</FONT> Controlled by the other Party (whether or not delivered by the other Party to said Party), at any time. For the avoidance of doubt, the combination of a Licensed Product, Niche Candidate or Residual Product
with Other Products as a Combination Product shall not grant or confer any right or license to either Party in respect of such Other Products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notice of Infringement or Misappropriation</U>. <B></B>Within *** of its discovery thereof, IPH or NN notify
the other in writing </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">of any known, alleged or threatened (i)&nbsp;infringement of any Patents described in this Article <B>9</B>
other than Patents in the Independent IPR of either Party (ii)&nbsp;infringement or misappropriation of any other IPR that threatens to have an adverse affect upon Commercial Optimization, or (iii)&nbsp;attempt to invalidate any Collaboration
Patent, or any other Patents described in this Article <B>9</B> other than Patents in the Independent IPR of either Party, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if either Party, or any of their respective Affiliates, is named as a defendant in a legal proceeding by a
Third Party for infringement of a Patent or infringement or misappropriation of any other IPR because of the manufacture, use, importation or sale of any Licensed Product, Niche Candidate, or Residual Product, or use of any <FONT
STYLE="white-space:nowrap">Know-How</FONT> comprised in Collaboration IPR. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Any notice provided under
Section<B>&nbsp;9.11</B> shall set forth all relevant facts (to the extent known by the Party giving notice) in reasonable detail and shall include a reasonable description of available evidence associated therewith or copies of any readily
available documentary evidence associated therewith. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exclusive First Right of Enforcement of Licensed IPR</U>. Each Party shall have the exclusive right, without
obligation, to initiate or defend any suit, opposition, interference, other legal action (including proceedings before the US International Trade Commission), or to take other appropriate action, that it, in its sole discretion, believes is
reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any Patents or other IPR to which it has been granted an exclusive license under this Agreement (in its
own name or, if authorized by contract and </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information
has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
permitted by applicable Law and required by applicable Law, in the name of the other Party or an Affiliate of the other Party), and shall bear its own costs and expenses in respect thereof and be
represented by counsel of its choice. Where any uncertainty exists regarding which Party has the right to bring such legal action, NN shall be presumed to have the first right. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Required Joinder</U>. If the other Party is required under applicable law to join any such legal action
initiated pursuant to this Section<B>&nbsp;9.12</B> or if the failure of such other Party be a party to such suit, action, or proceeding would in the opinion of counsel of the initiating or defending Party risk dismissal thereof, the other Party
shall execute all papers and perform such other acts as may be reasonably required to permit the litigation to be initiated or conducted (including initiating a suit before a court or tribunal at the initiating or defending Party&#146;s request or
permitting the initiating or defending Party to initiate a legal action under this Section<B>&nbsp;9.12</B> in the name of itself and the other Party). In such an event, the initiating or defending Party shall reimburse the other Party for its
expenses relating to its joining thereto and participation therein. If the other Party is required to be joined as a party in any such action, then upon the request of the initiating Party, it shall waive any objection to such joinder on the grounds
of personal jurisdiction, venue, or forum non conveniens. The Party joined in such proceedings shall be represented by counsel for the initiating Party in such litigation or other proceedings at the initiating Party&#146;s cost.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Settlement</U>. A Party initiating or defending a proceeding under Section<B>&nbsp;9.12</B> shall have the
exclusive right, in its sole discretion, to settle any such suit or other dispute, whether by settlement or other voluntary final disposition, without the prior written approval of the other Party or the other Party&#146;s Affiliate, <I>provided
that</I> the terms of such resolution do not: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enjoin any future action by the other Party or any of its Affiliates,
<FONT STYLE="white-space:nowrap">Out-licensees,</FONT> <FONT STYLE="white-space:nowrap">Sub-licensees,</FONT> or Third-Party collaboration partners (&#147;<U>Affected Persons</U>&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">derogate from or diminish any of the other Party&#146;s rights or licenses under this Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">require any of the Affected Persons to make any payment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fail to grant the other Parties and its Affiliates a release of all claims in the dispute;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">require the admission or concession that any claim or aspect of any Patent Controlled by the other Party or its
Affiliates is invalid or unenforceable, or require any waiver or disclaimer of any rights with respect to such claim or Patent; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">otherwise have a Material Adverse Affect upon any of the Affected Persons or any of their assets, or any IPR
licensed under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Second (</U><U>&#147;</U><U><FONT STYLE="white-space:nowrap">March-In</FONT></U><U>&#148;</U><U>)
Enforcement Rights</U>. In the event a Party having an exclusive license to IPR under this Agreement does not exercise its rights to initiate or defend a proceeding under Section<B>&nbsp;9.12</B> within *** of its receipt of notice under
Section<B>&nbsp;9.11</B>, the other Party shall have the exclusive right to initiate or defend such proceeding at its own expense as if it were the Party initiating proceedings in accordance with the provisions of Section<B>&nbsp;9.12</B> and the
other Party shall comply with the terms of that Section accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Share of Recoveries</U>. Any recoveries resulting from the enforcement of Patents or other IPR by the Party
authorized to undertake such enforcement pursuant to Section<B>&nbsp;9.12</B> or Section<B>&nbsp;9.13</B> shall first be used to cover the reasonable prosecution costs of such Party and any remaining sums shall be divided between the Parties as
follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the infringement has taken place before the First Commercial Sale of the Licensed Product, Niche Candidate,
or Residual Product claimed or covered by the IPR or Valid Claim(s) of the Patent enforced by such enforcing Party&#146;s action, such remaining sums shall be (i)&nbsp;retained by or paid to the Party Controlling such IPR or Patent in the event that
it is not jointly owned by the Parties; and (ii)&nbsp;shared in the proportion *** in the event of the Parties&#146; joint ownership of such Patent or other IPR, or if the subject matter of such enforcement has been any Patent(s) or other IPR
Controlled by more than one of the Parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if infringement has taken place after the First Commercial Sale or starts before First Commercial Sale but
continues after the First Commercial Sale of a Licensed Product, Niche Candidate, or Residual Product claimed or covered by the IPR or Valid Claim(s) of the Patent enforced by such enforcing Party&#146;s action, (i)&nbsp;to the extent that such
recovery is expressly for, or attributable to, lost profits on lost sales of such Licensed Product, Niche Candidate, or Residual Product, such remaining sums shall be treated as Net Sales of the Party engaged in the sale (or <FONT
STYLE="white-space:nowrap">Out-licensing</FONT> to a Third Party of such sale) of such Licensed Product, Niche Candidate, or Residual Product and shall be paid to or retained by such Party subject to the payment of royalties to the other Party in
the applicable percentages set forth, respectively, in Article <B>7 or 13</B>, and (ii)&nbsp;to the extent that the recovery is other than expressly for, or attributable to, such lost profits, it shall be allocated in accordance with the above
Section <B>9.14(a)</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Third Party Litigation</U>. If the manufacture, use, or sale of any Licensed Product, Niche Candidate, or
Residual Product, or performance of any other activity conducted pursuant to this Agreement results in any claim, suit, or proceeding by a Third Party alleging IPR infringement or misappropriation by either Party (the &#148;<U>Defending
Party</U>&#148;), or any of the Defending Party&#146;s Affiliates, <FONT STYLE="white-space:nowrap">Sub-licensees,</FONT> or </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<FONT STYLE="white-space:nowrap">Out-licensees,</FONT> such Defending Party will within *** of its discovery notify the other Party thereof in writing. The Defending Party (or its Affiliate, <FONT
STYLE="white-space:nowrap">Sub-licensee,</FONT> or <FONT STYLE="white-space:nowrap">Out-licensee)</FONT> shall have the exclusive right to defend and control the defense of such claim, suit or proceeding at its own expense, using counsel of its own
choice, <I>provided that</I> each Party shall in all events have exclusive control over the defense of any claim, suit, or proceeding, or any part thereof, that challenges any Patent or IPR that is subject to such Party&#146;s exclusive enforcement
rights under Section<B>&nbsp;9.12</B>, and neither the other Party nor any of its Affiliates, <FONT STYLE="white-space:nowrap">Sub-licensees,</FONT> or <FONT STYLE="white-space:nowrap">Out-licensees</FONT> may, without such enforcing Party&#146;s
prior written consent, enter into any settlement or other voluntary final disposition of such claim, suit or proceeding containing terms respecting such IPR or Patent and, in particular, but without limitation, that admits or concedes that any claim
or aspect of such Patent or IPR is invalid or unenforceable or requires any waiver or disclaimer thereof. Each Party will keep the other reasonably informed of all material developments in connection with any such claim, suit, or proceeding. The
Defending Party shall provide the other Party with copies of all pleadings filed in the action and allow the other Party reasonable opportunity to participate in the defense of the claims. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Cooperation in Legal Proceedings</U>. If either Party shall become engaged in or participate in any suit or
proceeding described in this Article <B>9</B>, or any investigation, claim, interference or other proceeding with any Third Party (including any proceeding before a relevant regulatory authority or government body) relating in any way to any Drug
Candidate, Licensed Product, Niche Candidate, or Residual Product, or any <FONT STYLE="white-space:nowrap">Know-How</FONT> affecting either Party&#146;s ability to attain Commercial Optimization, the other Party, at the request of such Party, shall
cooperate and endeavour to cause its and its Affiliates&#146;, <FONT STYLE="white-space:nowrap">Sub-licensees&#146;,</FONT> and <FONT STYLE="white-space:nowrap">Out-licensees&#146;</FONT> employees to cooperate, in all reasonable respects with such
Party (including by providing such documents, information, witnesses, and testimony; attending such conferences, discovery proceedings, hearings, trials and appeals; and negotiating such Third-Party licenses, as may be reasonably be requested by
such Party in connection with, and using diligent efforts to make reasonably available to such Party, free of charge (other than reimbursement of actually incurred, reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses), such employees and agents who may be helpful with respect to, such suit, investigation, claim, interference or other proceeding), and joining,
or authorizing and empowering such Party to act in its name and stead, in such suit, investigation, claim, interference or other proceeding where necessary for the effective prosecution or defense thereof or for securing full and appropriate relief
therein. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Trademarks</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Acquisition and Ownership of Product Marks</U>. NN shall, in its sole discretion, select and own all trade
marks and service marks associated with Licensed Products (collectively, &#148;<U>Product Marks</U>&#148;). NN shall also own any domain names associated with Licensed Products, including any domain names which contain Product Marks.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Obligation to Respect Trade Mark Rights</U>. Except as otherwise specified herein or as the other Party may
otherwise hereafter agree in writing, at no time shall either Party or any of such Party&#146;s Affiliates </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">use or register (i)&nbsp;any trade marks, trade names, logos, or other designations of source, affiliation, or
sponsorship of the other Party or any of the other Party&#146;s Affiliates, or of any of the other Party&#146;s or its Affiliates&#146; respective businesses, products or services, or (ii)&nbsp;any trade marks, trade names, logos, or other
designations confusingly similar to, such trademarks, trade names, or other designations of the other Party or its Affiliates, used to identify any business, products, or services of itself or any of its Affiliates, or for any other commercial
purposes, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take any other action with a view to or that may reasonably be viewed as resulting in damaging the rights or
goodwill in any of such trade marks, trade names, logos, or other designations of the other Party or its Affiliates in any country. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Agreement, each Party and its Affiliates shall have the right to make truthful
references to or identifications of the other Party or its Affiliates, or to the business, services, or products of the other Party or its Affiliates, in compliance with the provisions of Article <B>18</B> hereof. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Implied Grant of Right or License In Respect of Trade Mark Rights</U>. Nothing contained in this
Agreement shall be construed as conferring any rights to use in advertising, publicity, or other promotional materials or activities any name, trade name, trade mark, trade dress, or other designation of a Party hereto, including any contraction,
abbreviation, or simulation of any of the foregoing, unless the express written permission of such Party has been obtained. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Determination of Patent Issues to be Made Under Applicable National Law</U>. Except as provided for under
Section<B>&nbsp;9.2</B> (which shall control issues of inventorship) and Section<B>&nbsp;9.20</B>, any dispute regarding infringement, validity or enforceability (other than based on inventorship) of Patents between the Parties shall be made under
applicable national law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Acknowledgment of Intellectual Property Rights; Termination of License with Respect to Specific Patents</U>.
Each of the Parties hereby acknowledges and agrees that its obligation to pay royalties pursuant to this Agreement is supported by good and valuable consideration comprised, among other things, of its receipt of a license under secret, substantial
and identifiable <FONT STYLE="white-space:nowrap">Know-How,</FONT> including Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT> and under certain specified Patents Controlled by the other Party. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Either Party may terminate its license to the other Party under any Patent or any Collaboration
<FONT STYLE="white-space:nowrap">Know-How</FONT> under this Agreement immediately by notice in writing to the other Party in the event that the other Party shall challenge the validity or enforceability of any such Patent or the secret, substantial
and identified nature of the Collaboration <FONT STYLE="white-space:nowrap">Know-How.</FONT> For the avoidance of doubt, such challenge of the validity or enforceability shall not be a breach of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties further acknowledge and agree that one Party may not avoid the payment of royalties to the other
during the Term on the basis that Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT> has ceased to be secret, substantial and identified as a result of any action or omission by or on behalf of the first Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties acknowledge and agree that royalties payable under this Agreement shall, for the purpose of the
commercial convenience of the Parties, be payable during the Term pursuant to the terms and conditions of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Survival</U>. The Parties&#146; rights and obligations under this Article <B>9</B> shall survive the
expiration or earlier termination of this Agreement for any reason (whether before or after the expiration of the Collaboration Term), <I>provided that</I>, (a)&nbsp;neither Party shall be required to pay any royalty to the other in respect of Net
Sales of any product (including any Licensed Product, Niche Candidate or Residual Product) in any country after the expiration of the Term of this Agreement with respect to such product in such country. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIAL INFORMATION AND MATERIALS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Superseding of Prior Agreements</U>. The confidentiality and use provisions of this Agreement, as set forth
in this Article <B>10</B>, Subsection <B>1.1.28</B> and elsewhere in this Agreement, terminate, supersede and replace in their entirety the provisions of the Confidentiality Agreements between the Parties dated April&nbsp;29, 2003, January&nbsp;28,
2005 and November&nbsp;10, 2005 as well as any other confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> agreements entered into between the Parties prior to the date of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Confidentiality and Use Restrictions</U>. The Receiving Party in respect of any Confidential Information
undertakes from the date of disclosure to treat all received Confidential Information as strictly confidential during the Term of this Agreement and for a minimum term of five (5)&nbsp;years thereafter and, therefore, not to disclose it without the
prior written and express consent of the Disclosing Party and to make no use of it, except as specifically provided for in this Article <B>10</B> without the prior written and express consent of the Disclosing Party in each case; <I>provided
that</I>, (a)&nbsp;in the event that such Confidential Information shall constitute a Trade Secret, the Receiving Party shall be obligated to continue to comply with the foregoing requirements until such time, if ever, as it shall lose its character
as a Trade Secret through no fault of the Receiving Party and (b)&nbsp;in the event that either Party shall enter or have obligations under an agreement with a Third Party which entails a longer period for maintaining Confidential Information the
Receiving Party shall comply with such obligations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disclosures to Authorized Persons</U>. The Receiving Party may disclose Confidential Information only to its
reliable employees, and to such of its agents, consultants, <FONT STYLE="white-space:nowrap">Sub-licensees,</FONT> <FONT STYLE="white-space:nowrap">Out-licensees</FONT> and other Third Parties it may authorize hereunder to receive such Confidential
Information, who, in each case, need to know such Confidential Information in order to carry out, or to consider carrying out, such evaluations, and other discovery, development or </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
commercialization activities with respect to IPR, Licensed Products, Niche Candidates, Residual Products and such other subject matter as is encompassed by the Receiving Party&#146;s rights,
licenses or performance obligations under this Agreement, provided that such Persons are bound by obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> to the Receiving Party that are no less protective of the Disclosing
Party&#146;s rights or interests in respect of Confidential Information than those set forth in this Agreement. The Receiving Party shall ensure that such employees and other Persons are made fully aware of the obligations of this Agreement in
respect of Confidential Information and shall be responsible for all acts and omissions of such employees and other Persons to whom it directly or indirectly makes available, discloses or provides Confidential Information, which, if committed by the
Receiving Party, would constitute a breach of the Receiving Party&#146;s obligations under this Article <B>10</B>, and shall take appropriate action, whether by instruction, agreement or otherwise, to ensure the protection, confidentiality and
security of Confidential Information. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Material Transfer Agreement</U>. No Materials may be transferred, or caused or authorized to be transferred,
directly or indirectly to any Third Party for any research or other purposes except by a Party or its Affiliate, or the <FONT STYLE="white-space:nowrap">Out-licensee</FONT> of a Party or its Affiliate, pursuant to a legally binding, written material
transfer agreement identical in substance to the Material Transfer Agreement annexed as Schedule <B>10.4</B>. Except as provided for in Subsection <B>10.4.1</B>, the Parties shall use the Material Transfer Agreement annexed as Schedule <B>10.4</B>,
which may be modified by the Joint Steering Committee from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Procedure for IPH Obtaining Approved Exceptions to Material Transfer Agreement Requirements</U>. In the
event that IPH shall contemplate entering into a material transfer agreement that deviates in substance from the annexed Material Transfer Agreement, prior to entering into such agreement IPH shall submit a copy thereof to NN for NN&#146;s approval.
IPH shall not enter into such agreement without having received such approval from NN, <I>provided that</I>, if NN shall fail to respond to IPH&#146;s submission to NN of such proposed agreement within *** of its receipt thereof, NN shall be deemed
to have approved of IPH&#146;s entry into such agreement. Each Party shall provide all such Third Party material transfer agreements entered into pursuant to this Section<B>&nbsp;10.4</B> to the other Party for archival purposes. With respect to any
Materials transferred to any Third Party pursuant to any material transfer agreement as described by this Section<B>&nbsp;10.4</B>, in the event of a conflict between the provisions of this Article <B>10</B> or Subsection <B>1.1.28</B> with any term
or condition of such material transfer agreement that conforms to the provisions of the Material Transfer Agreement, such conforming term or condition of the material transfer agreement shall prevail. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional Terms of Confidentiality</U>. Except as expressly set forth herein the following provisions shall
apply: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Receiving Party shall not use Confidential Information for any purpose other than for purposes of
exercising its rights or licenses or performing its obligations under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential Information is the sole property of the Disclosing Party and nothing in this Agreement, other than
the licenses set forth herein, shall be construed as granting to the Receiving Party, by implication or otherwise, any right or license with respect to Confidential Information or any Patents or any claims of Patents now or hereafter filed or issued
with respect to Confidential Information and the Receiving Party shall refrain from filing applications or otherwise seeking proprietary rights and protection in respect of Confidential Information. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Receiving Party shall keep the Disclosing Party informed of all uses made of Confidential Information. With
the exception of such Confidential Information as is required for the Receiving Party&#146;s exercise of such rights or performance of such obligations as survive such expiration or termination, upon the termination or expiration of this Agreement,
the Receiving Party shall return to the Disclosing Party all surviving tangible embodiments of Confidential Information received hereunder and any material, data, and results derived from such Confidential Information. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as expressly set forth herein or in another written agreement relating to Confidential Information in
force between the Parties, neither Party shall incur any obligation or liability to the other Party merely by disclosing or receiving Confidential Information to or from the other Party. It is further agreed that the furnishing of Confidential
Information shall not constitute any grant, option or license under any Patent or other rights now or hereinafter held by either Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the Disclosing Party&#146;s reasonable request, the Receiving Party shall provide to the Disclosing Party a
copy of such written agreements as have been entered into by the Receiving Party with any Persons to whom or which the Receiving Party has disclosed Confidential Information, including the provisions of such agreements that set forth such
Person&#146;s or Persons&#146; agreement to be bound by the confidentiality and use obligations set forth herein. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as reasonably necessary in connection with the exercise of the Receiving Party&#146;s rights or
licenses, or the performance of its obligations, under this Agreement, the Receiving Party shall not copy or authorize the copying, in whole or in part, of any Confidential Information received by it, directly or indirectly, from the Disclosing
Party without first receiving written consent from the Disclosing Party. Any copyright, confidentiality or other proprietary notices appearing on or in connection with such Confidential Information shall be reproduced and included on all copies made
by or under the authorization of the Receiving Party. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.5.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Receiving Party acknowledges that all Confidential Information is provided &#147;<U>as is</U>&#148; and
without any representation or warranty, express or implied, as to the accuracy or completeness of such Confidential Information, including, without limitation, any implied warranty of merchantability or fitness for a particular purpose, or, except
as expressly provided in Article <B>15</B>, any warranty that the use of Confidential Information will not infringe or violate any Patent or other proprietary rights of any Third Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Permitted Disclosures</U>. Notwithstanding any provisions of this Agreement to the contrary, the Receiving
Party may disclose Confidential Information: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">required to be disclosed to comply with applicable Laws, to defend or prosecute litigation or to comply with
governmental regulations, <I>provided that</I> the Receiving Party provides prior written notice of such disclosure to the Disclosing Party with no undue delay so that the Disclosing Party may contest such potential disclosure, and <I>further
provided that</I> the Receiving Party takes reasonable and lawful actions to avoid or minimize the degree of such disclosure, including without limitation by seeking confidential treatment (to the extent available) from the applicable governmental
or regulatory body; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Receiving Party is the Party authorized to prosecute, maintain or enforce any Patent pursuant to Article
<B>9</B>, for purposes of any such action with respect to which such Party is so authorized, including for purposes of compliance with any Laws or regulations requiring any such disclosure relating to such Patent, <I>provided that</I> the Receiving
Party takes any and all reasonable and lawful actions to avoid or minimize the degree of such disclosure, including by seeking confidential treatment (to the extent available) from the applicable governmental or regulatory body;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on a confidential basis to its legal or financial advisors who are bound by professional obligations of
confidentiality; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on a confidential basis to the Receiving Party&#146;s (a)&nbsp;Affiliates; (b) existing or potential acquirers
or merger candidates; (c)&nbsp;investment bankers; (d)&nbsp;existing or potential investors, venture capital firms or related financial service providers, for purposes of obtaining financing, each ((a) through (d)) of whom or which, prior to such
disclosure, shall have first entered into a binding written agreement to be bound by use and disclosure restrictions that are at least as protective as those set forth in this Article <B>10</B>, <I>provided, however, that</I> (i)&nbsp;the Persons
described in clauses (b)&nbsp;through (d) shall only be allowed to view such Confidential Information (including this Agreement or the Share Purchase Agreement (as hereinafter defined)) at the premises of one of the Parties or its legal advisors and
shall not be allowed to make copies (electronically or in hard copy) of such Confidential Information (other than this Agreement or the Share Purchase Agreement) without the prior written approval of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the Disclosing Party and (ii)&nbsp;IPH shall not disclose any Confidential Information of NN (other than this Agreement or its terms) to any Person, including any existing or potential acquirer
or merger partner, who or that is substantially involved in the discovery, development, manufacture, sale or other exploitation of any drug candidates, biologics or other products developed, marketed or used for the same indications as any Drug
Candidates, Licensed Products, Niche Candidates, Residual Products or any other products discovered, developed or commercialized under this Agreement, without first providing NN with reasonable advance written notice of such proposed disclosure and
obtaining NN&#146;s written consent thereto. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Required Notices</U>. The Receiving Party shall promptly notify the Disclosing Party if it becomes aware
that any Confidential Information has been made available to any Third Party, or of any breach of confidence by any Person to whom or which the Receiving Party has disclosed any of the Disclosing Party&#146;s Confidential Information, and shall give
the Disclosing Party all reasonable assistance in connection with any action, demand, claim or proceeding that the Disclosing Party may institute against such Person in respect of such disclosure. Each Party shall keep the other Party informed in
the event that this Agreement or the Share Purchase Agreement has been made available to any Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Relief</U>. Each Party acknowledges that Confidential Information is of a special and unique nature and
agrees that the other Party&#146;s remedies at law for a breach by it of its obligations under this Article <B>10</B> would be inadequate and that the Disclosing Party shall, without need to post any bond or prove actual damages, be entitled to seek
and, if prevailing, obtain, in arbitration pursuant to Section<B>&nbsp;21.14</B> (or where necessary to avoid irreparable harm, in any court of competent jurisdiction), specific performance and provisional, permanent and mandatory injunctive and
other equitable relief, as well as recovery of its court costs, expenses and reasonable attorneys&#146; fees, as remedies for any breach or threatened breach of any of the provisions of this Article <B>10</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DURATION OF THE AGREEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Agreement shall be in full force and effect from the Effective Date and shall expire, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, with the Parties&#146; respective obligations to pay royalties on the Net Sales
of such products in such countries, pursuant to the terms and conditions of this Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MATERIAL BREACH AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Material Breach, Damages and Termination</U>. Except as otherwise expressly provided in this Agreement, each
Party shall have a remedy in compensatory damages for any injuries caused by the other Party&#146;s material breach of this Agreement. Except as otherwise expressly provided in this Article <B>12</B>, (a) neither Party may terminate this Agreement,
in whole or in part, for any reason, and (b)&nbsp;such termination shall not be of the entirety of this Agreement, but shall be on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">project-by-project,</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Breach of Confidentiality Resulting in Loss of Patent Rights</U>. Without limitation of the foregoing, in
the event that either Party shall at any time commit a material breach of its obligations under Articles <B>10</B> or <B>18</B> and such breach shall directly result in a material loss of Patent coverage for any Drug Candidate, Licensed Product,
Niche Candidate or Residual Product being commercialized or developed for commercialization by the other Party, then the royalty rate thereafter required to be paid by such other Party on the Net Sales of such Licensed Product, Niche Candidate or
Residual Product (or such product as results from the development of such Drug Candidate) shall be reduced by *** from the rate otherwise payable pursuant to the terms of this Agreement, and such royalty reduction shall be such commercializing
Party&#146;s sole and exclusive remedy, and the breaching Party&#146;s sole liability, for such breach. In this Section<B>&nbsp;12.2</B> whether a loss of Patent coverage is material shall be determined, in default of agreement between the Parties,
in accordance with Section<B>&nbsp;21.14</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for Convenience</U>. NN may, for any reason or no reason, at any time during the Collaboration
Term terminate this Agreement, in whole or in part, on *** written notice to IPH. Termination pursuant to this Section<B>&nbsp;12.3</B> shall not constitute a breach of this Agreement, and NN&#146;s only liability and obligation, and IPH&#146;s only
rights and remedies in respect of each termination shall be those set forth in Section<B>&nbsp;13.4</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for Material Breach</U>. Either Party may immediately terminate this Agreement with respect to
the affected product(s), project(s), and country(ies) upon the material breach by the other Party of any material term or material condition of this Agreement with respect to such product(s), project(s) and country(ies), if such breach continues for
*** after the receipt by the breaching Party of written notice thereof from the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party, <I>provided that</I>, (other than a payment obligation) if the noticed breach is such that cure can be made,
but cannot reasonably be completed within said *** period, then the Party complaining of such breach shall have the right to terminate this Agreement by reason of such breach only if the defaulting Party shall have failed to commence to cure such
breach within the specified *** notice period and to thereafter promptly and diligently complete such cure. Notwithstanding the foregoing, if the Party in breach disputes the existence, materiality, nature or extent of any default set forth above,
(i)&nbsp;the Parties shall use good faith efforts to resolve the dispute amicably and, (ii)&nbsp;if resolution cannot be thereby reached, then the dispute shall be resolved pursuant to Section<B>&nbsp;21.14</B>. This Agreement shall, however,
continue to remain in full force and effect during the pendency of any such dispute as to the existence, materiality, nature or extent of such breach, as set forth in Section<B>&nbsp;4.6</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Establishing Materiality and Scope of Alleged Breach</U>. For the avoidance of doubt, the Parties must agree
on whether a breach of this Agreement has been committed and, if so, the scope and effect of the alleged breach and whether such breach amounts to a material breach in any particular case. If, after exercising good faith efforts to resolve these
issues amicably, the Parties do not agree that such a breach exists or is material, or agree as to the scope of a breach, the dispute shall be resolved pursuant to the procedures described in Section<B>&nbsp;21.14</B>. In the event that a dispute
shall arise as to whether a material breach has been committed so as to establish the right to terminate all or any </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
aspect of this Agreement, the Parties shall have the continued right to exercise their rights and licenses, and shall continue to perform their obligations, hereunder during the pendency of such
dispute in respect of this Agreement or aspect, and, except as otherwise expressly permitted by this Agreement, neither Party shall commence any work in the Collaboration Field in respect of such matter(s) independently of the Collaboration (whether
individually or with any Third Party), until a final resolution has been reached either by the Parties&#146; written agreement or by arbitration pursuant to Section<B>&nbsp;21.14</B> establishing that the termination of this Agreement has been
properly effected by reason of a material breach. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination Upon Bankruptcy</U>.<B> </B>This Agreement may be terminated, in whole or in part, by either
Party upon written notice to the other: in the event that (a)&nbsp;the other Party (i)&nbsp;adopts a resolution for, or undertakes to effect, a discontinuance of its business or dissolution, or otherwise terminates or suspends its business
operations for a period of more than *** other than by reason of Force Majeure; (ii)&nbsp;becomes insolvent or unable to pay its debts when due; (iii)&nbsp;makes an assignment in bankruptcy or other assignment or general arrangement for the benefit
of its creditors; (iv)&nbsp;commences a proceeding, or files for or seeks relief, under any bankruptcy, insolvency or other Law of any jurisdiction, now or hereafter in effect, regarding the bankruptcy, insolvency or relief of debtors, including any
petition in bankruptcy, petition or application to any tribunal for the appointment of any custodian, receiver, trustee or similar functionary for it or a substantial part of its assets, or for any arrangement, reorganization, composition,
dissolution, liquidation, business rehabilitation, business preservation, readjustment of debt or similar relief; (v)&nbsp;is made subject to any attachment, seizure or other legal process against a substantial part of its assets or against any
right, title or interest in this Agreement or any material product, IPR or other subject matter of this Agreement; (vi)&nbsp;is made subject to any bona fide petition, application or proceeding described in (iv)&nbsp;above that is filed or commenced
against it, in which an order for relief is entered or which remains undismissed for a period of *** or more; or (vii)&nbsp;by any act or omission shall indicate its consent to, approval of or acquiescence in any such petition, application or
proceeding or order for relief, or the appointment of a custodian, receiver, trustee or similar functionary for it or any substantial part of its assets, or shall suffer any such custodianship, receivership or trusteeship to continue undischarged
for a period of *** or more; or (b)&nbsp;anything analogous to any of the foregoing occurs in any applicable jurisdiction. Termination shall be effective upon the date specified in such notice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Development Diligence Requirements</U>. For the purposes of this Section<B>&nbsp;12.7</B>, each Party shall
be obliged to promptly notify the other Party in writing of any decision to abandon the development, marketing or sale of any Licensed Product, Residual Product or Niche Candidate for any indication(s) and with respect to any country(ies) and in the
absence of notification the first Party shall be deemed to have abandoned the development of such Licensed Product, Niche Candidate, or Residual Product for such indication being developed for commercialization exclusively by or on behalf of that
Party if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman"><I>provided that</I> the time periods in (i)-(iii), above: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shall not include any time period during which the relevant Licensed Product, Niche Candidate or Residual
Product shall have been subject to a Clinical Hold (as defined below) and the Party developing same shall have been using Commercially Reasonable Efforts to remove such Clinical Hold; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shall be altered by the Parties to take into consideration unforeseen delays or obstacles in continuing the
development of the relevant Licensed Product, Niche Candidate or Residual Product outside the reasonable control of the developing Party, in which case the Parties shall agree to a reasonable extension having regard to the delay, <I>provided
that</I> the developing Party must make a request for such extension to the other Party at the time of, and not solely after, the delay. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Within *** of any of the occurrence of any of the events specified in (i), (ii), or (iii)&nbsp;above, the developing Party may, by paying to
the other Party the relevant fee provided for below, extend the deadline for achievement of the required step on an annual basis for up to a period of *** the relevant fee being: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman"><I>provided that</I> the developing Party shall only have the right to such extension under two of events (a), (b) or (c)&nbsp;of this
Section<B>&nbsp;12.7</B>, unless the Parties hereafter agree otherwise in writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#147;<U>Clinical Hold</U>&#148;, as used in this
Section<B>&nbsp;12.7</B>, shall mean a bona fide decision of the developing Party or a decision of a regulatory authority or another governmental body to suspend a clinical trial or other study when it does not believe that such clinical trial or
other study can be conducted without unreasonable risk to the subjects in such clinical trial or study, and the existence of such circumstances shall be subject to arbitration in accordance with Section<B>&nbsp;21.14</B>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for Failure to Employ Commercially Reasonable Efforts</U>. Notwithstanding any other provision
of this Agreement, in the event of the abandonment of the development by a Party (the &#147;<U>Developing Party</U>&#148;) (by express notice to the other Party or by operation of this Section<B>&nbsp;12</B>), or a
<FONT STYLE="white-space:nowrap">non-transient</FONT> material failure of the Developing Party to employ Commercially Reasonable Efforts in respect of the marketing or sale of any Licensed Product, Residual Product or Niche Candidate in any country,
all licenses granted to the </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded
from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Developing Party under this Agreement for the purposes of Commercial Optimization of any such Licensed Product, Residual Product or Niche Candidate a Party is authorized to develop but that has
been abandoned in such country(ies) shall terminate immediately and the following provisions shall apply: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Developing Party shall have an obligation to grant to the other Party, at the other Party&#146;s request,
an irrevocable, world-wide, fully paid up, exclusive license under all its right, title and interest to the Collaboration IPR, Background NN IPR or Background IPH IPR (as applicable) and Independent IPR, and grant the right set out in
Section<B>&nbsp;5.7</B>, in the county(ies) and for the specific indication(s) with respect to which such specific Licensed Product, Residual Product or Niche Candidate has been abandoned, solely for the purposes of Commercial Optimization of such
specific Licensed Product, Residual Product, or Niche Candidate for such indication(s) in such country(ies), and all supporting regulatory documentation, to the other Party only for no additional consideration other than as provided for herein; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the other Party shall, in its discretion, assume such license it shall notify the Developing Party to this
effect within *** of the Developing Party&#146;s abandonment or the determination of abandonment, whichever is the later, upon which assumption the other Party shall have the exclusive right to exploit such IPR solely with respect to such abandoned
product(s), for such specific indication(s), in such country(ies) and for such purposes as are specified in clause (a)&nbsp;above, provided that such right shall not include the right or license to develop or commercialize any product comprised of,
interacting with, modulating or is derived from the same Biological Target for the same indications(s) as any (i)&nbsp;Licensed Product or Residual Product encompassed by the Developing Party&#146;s exclusive rights or license hereunder; or
(ii)&nbsp;Niche Candidate marketed by the Developing Party (or its <FONT STYLE="white-space:nowrap">out-licensee)</FONT> pursuant to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Buy-In-Option.</FONT></FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the date of such abandonment is prior to the first dosing of humans in clinical trials with such abandoned
Licensed Product, Residual Product or Niche Candidate, Sections <B>12.8(a) </B>and<B> 12.8(b)</B> shall apply, save that, in consideration of the grant of such rights, if and only if the other Party subsequently
<FONT STYLE="white-space:nowrap">Out-licenses</FONT> such IPR within the period of *** following the date of the other Party&#146;s assumption of rights, the other Party shall pay to the Developing Party a percentage of all revenue actually received
by IPH in respect of such license on the following basis: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the effective date of abandonment is after the first dosing of humans in clinical trials with such abandoned
Licensed Product, Residual Product or Niche Candidate but prior to the first dosing in Phase III, the above Sections <B>12.7(a) and (b)</B>&nbsp;shall apply save that in consideration of the grant of such rights, if and only if the other Party
subsequently <FONT STYLE="white-space:nowrap">Out-licenses</FONT> such IPR within the period of *** following the date of the other Party&#146;s assumption of rights the other Party shall pay to the Developing Party a percentage of all revenue
actually received by the other Party in respect of such license on the following basis: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the date of such abandonment is after the beginning of the first dosing in Phase III then NN and IPH shall
***. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of its abandonment of a Licensed Product, Residual Product or Niche Candidate and irrespective of
the effective date of such abandonment, the Developing Party shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make no further representation regarding its status as a licensee of the other Party in respect of such
abandoned Licensed Product, Residual Product or Niche Candidate for the specific indications and with respect to the specific country(ies) with respect to which it has been abandoned; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cease any activities with respect to the marketing, promotion, sale or distribution of such abandoned Licensed
Product, Residual Product or Niche Candidate for the specific indications and with respect to the specific country(ies) with respect to which it has been abandoned; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event that at the date of such abandonment there are ongoing clinical trials of such abandoned Licensed
Product, Residual Product or Niche Candidate, pay for the completion of such clinical trials in respect of all patients enrolled at the effective date of abandonment except if the Agreement is terminated because of adverse events in the clinical
trial(s) causing the trials(s) to cease due to regulatory requirements or regulatory considerations (including an actual or anticipated regulatory warning); </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the other Party&#146;s option and at the other Party&#146;s expense, and to the extent such transfer is
authorized by contract and permitted by applicable Law, to transfer to the other Party, the benefit of any contracts between the Developing Party and any Third Party in respect of the manufacture of such abandoned Licensed Product, Residual Product
or Niche Candidate, with respect to the supply thereof for marketing for the indication(s) and in the country(ies) with respect to which such product has been abandoned, <I>provided that</I> for the avoidance of doubt the Developing Party shall not
be required to cause or effect any such transfer if to do so will require the Developing Party&#146;s payment or provision of additional consideration to any Person save that the other Party may pay for and obtain the right to such procurement or
exercise to the extent authorized by contract and permitted by applicable Law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the other Party&#146;s option, and at the other Party&#146;s expense, and to the extent authorized by
contract and permitted by applicable Law, assign or cause to be assigned to IPH any regulatory submissions and approvals with respect to such abandoned Licensed Product, Residual Product or Niche Candidate and take such actions and execute such
other instruments, assignments and documents as may be necessary to effect the transfer of all rights thereunder to the other Party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the other Party&#146;s option and at the other Party&#146;s expense, provide to the other Party all <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data in respect of such abandoned Licensed Product, Residual Product or Niche Candidate and all research reagents and materials intended for use in clinical trials of such abandoned
Licensed Product, Residual Product or Niche Candidate, in the Developing Party&#146;s possession or control; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="23%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the other Party shall pay the Developing Party&#146;s reasonable costs in connection with the above activities
at a reasonable hourly rate representing the actual cost of the Developing Party of providing such services up to a maximum of ***. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following the transfer of rights from one Party to another pursuant to this Section<B>&nbsp;12.8</B> the other
Party shall have no further obligations under Sections <B>12.7, 12.8, 12.9 or 12.10</B> in respect of the development, sale or marketing of any such product. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limitation of the Parties&#146; obligations to exercise Commercially Reasonable Efforts, or of any
other obligations under this Agreement or remedies for the material breach thereof, the failure to attain any benchmark or objective set forth in any of Sections (i), (ii) or (iii)&nbsp;of Section<B>&nbsp;12.7</B> shall not constitute a breach of
this Agreement, and the provisions of this Section<B>&nbsp;12</B> prescribe the Developing Party&#146;s sole and exclusive liability, and the other Party&#146;s sole and exclusive remedy for such failure. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Development or Marketing of Other Products</U>. The development, sale or marketing, by a Party its
Affiliates or <FONT STYLE="white-space:nowrap">Out-licensees</FONT> having the obligation to use Commercially Reasonable Efforts, of a product (other than a Licensed Product, Niche Candidate or Residual Product) that is directed to the same
indication as, and that results in substantial material prejudice to the development or commercialization of, a Licensed Product, Niche Candidate or Residual Product, shall constitute a failure to exercise Commercially Reasonable Efforts in respect
of such Licensed Product, Niche Candidate or Residual Product in such indication. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Determination of Abandonment and Opportunity to Remedy</U>. At any time after the end of the Collaboration
Term IPH or NN shall have the right to request a determination as to whether abandonment has occurred in respect of any Licensed Product, Residual Product, or Niche Candidate in accordance with Section<B>&nbsp;21.14 </B>and this Article <B>12</B>,
and for the purposes of Sections <B>12.7,</B> <B>12.8</B> and <B>12.9</B> (except as otherwise specified in Section&nbsp;12.7), a <FONT STYLE="white-space:nowrap">non-transient</FONT> material failure to use Commercially Reasonable Efforts shall
constitute abandonment. Following a request for such determination the other Party shall have *** to seek to cure or remedy such alleged abandonment and any such efforts shall be considered as a part of such arbitration. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for IPH Transfer</U>. In addition to its right to terminate this Agreement and other remedies in
the event of IPH&#146;s material breach of the terms of Section<B>&nbsp;20.1, </B>NN shall have the right to terminate this Agreement, in whole or in part, immediately upon notice to IPH in the event that IPH undertakes any Change of Control or
other Transfer pursuant to Section<B>&nbsp;20.2</B> at any time, and the sole and exclusive rights, remedies and obligations of the respective Parties in the event of such IPH Change of Control or other Transfer shall be those set forth in
Section<B></B><B>&nbsp;13.4</B>. No Change of Control or other Transfer undertaken by either Party or any of its Affiliates in accordance with Section<B></B><B>&nbsp;20.2</B> shall constitute a breach of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Survival of Terms</U>. All provisions of this Agreement (including all terms, representations, rights and
obligations) consisting of or relating to representations, warranties, confidentiality, specified licenses, indemnification, limitations of liability, ownership rights, or defined terms, and all other provisions hereof that by their express terms or
sense and context are intended to survive the expiration or earlier termination of this Agreement, shall each survive any expiration or termination hereof for any reason. In furtherance and not in limitation of the foregoing, this
Section<B>&nbsp;12.9</B> and the following Articles and other Sections shall survive any such expiration or termination of this Agreement: all obligations under Article 10 (Confidential Information and Materials) or Section 20.15 (Further
Assurances) that relate to the preservation or protection of any right, title or interest that itself survives such expiration or termination. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONSEQUENCES OF TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General</U>. Except as otherwise expressly provided in this Agreement, the expiration or earlier termination
of this Agreement for any reason will not release either Party from any obligation or liability arising by reason of any breach that occurred prior to such expiration or termination, or as a result of such termination, or which may thereafter come
into being as the result of any breach of any of the terms or conditions of this Agreement that survive such expiration or termination of this Agreement in accordance with the provisions of Section<B>&nbsp;12.12</B> hereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Costs for Regulatory Documentation</U>. A Party required to provide regulatory documentation under this
Agreement shall bear the reasonable cost for providing such documentation to the other Party, up to a limit of ***. Any additional reasonable costs of obtaining such documentation shall be the responsibility of the other Party.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Expiration of Collaboration Term</U>. Upon and after the expiration of the Collaboration Term:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Limitation of NN Payment Obligation Upon Expiration of Collaboration Term</U>. NN shall have no obligation
to pay to IPH any annual research funding pursuant to Section<B>&nbsp;3.11</B> other than such outstanding amounts as then may be due and unpaid, or any royalties, fees or other amounts other than such royalties, fees and other amounts as are
expressly required to be paid by the terms of this Section<B>&nbsp;13.3</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN Retained Rights to Licensed Products, Niche Candidates and Drug Candidates Upon Expiration of
Collaboration Term</U>. NN shall retain all rights and licenses granted to NN under this Agreement that are necessary or useful for the Commercial Optimization of Licensed Products, Niche Candidates or, subject to IPH&#146;s rights under Subsections
<B>13.3.4 and 13.3.5</B>, Drug Candidates including: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exclusive rights and licenses (with the rights to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT
STYLE="white-space:nowrap">Out-license)</FONT> granted to NN pursuant to the terms and conditions of Section<B>&nbsp;5.1</B>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent authorized by contract and permitted by applicable Law, the right, pursuant to
Section<B>&nbsp;5.8</B>, to IPH&#146;s grant or procurement of the grant to NN of the rights and licenses required for NN&#146;s freedom of operation to exercise the foregoing exclusive rights and licenses, </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in each case without any limitation, restriction or other derogation of such rights or licenses occurring as a
result of such expiration of the Collaboration Term, <I>provided that </I>the exclusivity of NN&#146;s rights and licenses under this Subsection <B>13.3.2</B> shall be subject to such, if any, of IPH&#146;s rights and licenses as have been granted
to IPH under Article <B>6</B> and retained by IPH pursuant to Subsection <B>13.3.4</B>, and <I>further provided that</I>, (A)&nbsp;with respect to Licensed Products,<I> </I>NN shall continue to be bound by the terms and conditions of this Agreement
in respect of the payment to IPH of (i)&nbsp;the applicable amount(s) specified by Section<B>&nbsp;7.3</B> for the achievement of the M0 status Discovery Milestone, the Intermediate Discovery Milestone and the M1 status Discovery Milestone, but only
if such milestones are achieved as of the effective date of such expiration or within the *** following immediately thereafter, (ii)&nbsp;the applicable amount(s) specified by Section<B>&nbsp;7.4</B> for the achievement of Development Milestones
with respect to the Licensed Products, (iii)&nbsp;royalties on Net Sales of such Licensed Products during the Term pursuant to the terms and conditions of Article <B>7</B>, and (iv)&nbsp;the percentage of Upside Revenue realized by NN that is
applicable pursuant to the terms and conditions of Section<B>&nbsp;5.11.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN Residual Rights in the Field Upon Expiration of Collaboration Term</U>. Without limitation of NN&#146;s
rights under Subsection <B>13.3.2</B> and in addition thereto, NN shall have the exclusive right and license throughout the Territory during the Term, pursuant to the terms and conditions of the rights and licenses granted to it under Sections
<B>5.1</B> and <B>5.8</B>, to develop and commercialize Residual Products from Drug Candidates that have attained at least M0 status but not M1 status during the Collaboration Term or prior to the expiration of the *** period following immediately
after the effective date of the expiration of the Collaboration Term. The royalties payable to IPH on Net Sales of such Residual Products shall be governed by the terms and conditions of Article <B>7</B> <I>save that</I> royalties payable to IPH on
Net Sales of such Residual Products that would, upon achievement of M1, be classified as Class&nbsp;C Licensed Products and for which M0 status has been achieved less than *** prior to the expiry of the Collaboration Term shall be reduced by ***
from the applicable royalties set forth in Article <B>7</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH Retained Rights to Niche Candidates Upon Expiration of Collaboration Term. IPH shall retain, throughout the
Territory during the Term: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right pursuant to the terms and conditions of Section<B>&nbsp;5.5</B>, to the grant back by NN to IPH of an
exclusive right and license, with the rights to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT STYLE="white-space:nowrap">Out-license;</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to NN&#146;s reasonable cooperation and assistance, pursuant to the terms and conditions of
Section<B>&nbsp;5.8</B>, in granting to IPH, or procuring the grant to IPH of, the rights and licenses required for IPH&#146;s freedom of operation to exercise said right and license, </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to develop and commercialize only such, if any, Niche Candidates as IPH has, prior to the effective date of
such expiration, received exclusive authorization to develop and commercialize pursuant to the terms and conditions of Article <B>6</B> of this Agreement, without any limitation or other derogation of such rights or licenses occurring as a result of
such expiration, <I>provided that</I> (i)&nbsp;the exclusivity of IPH&#146;s rights and licenses under this Subsection <B>13.3.4</B> shall be subject to NN&#146;s rights and licenses under Subsection <B>13.3.2</B> and apply solely to the
commercialization and development for commercialization of those, if any, specific Niche Candidates with respect to which IPH has received such exclusive authorization to develop and commercialize pursuant to Article <B>6</B>, (ii) NN&#146;s
obligations under this Subsection <B>13.3.4</B> shall not include any requirement that NN grant to IPH or assist IPH in obtaining any grant of any rights or licenses if doing so should fail to be authorized by contract or permitted by applicable
Law, or would require NN&#146;s payment or provision of any additional consideration to any Person save that IPH may elect to pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by
applicable Law, and (iii)&nbsp;IPH shall continue to be bound by the terms and conditions of this Agreement in respect of the payment to NN of royalties on Net Sales during the Term pursuant to the terms and conditions of Article <B>7</B>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Residual Rights in the Field Upon Expiration of Collaboration Term</U>. Without limitation of IPH&#146;s
rights under Subsection <B>13.3.4</B> and in addition thereto, IPH shall have, throughout the Territory during the Term, under all Background NN Research Technology IPR and Collaboration IPR Controlled by NN, the exclusive right and license, with
the rights to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT STYLE="white-space:nowrap">Out-license,</FONT> to develop and commercialize Residual Products from Drug Candidates that have not attained at least M0 status, as of the
effective date of the expiration or earlier termination of the Collaboration Term or prior to the expiration of the *** period following immediately thereafter, and shall retain, throughout the Territory during the Term, the right, pursuant to the
terms and conditions of Section<B>&nbsp;5.8</B>, to NN&#146;s reasonable cooperation and assistance in granting or procuring the grant to IPH of the rights and licenses required for IPH&#146;s freedom of operation to exercise the aforementioned
exclusive right and license, <I>provided that</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall pay royalties to NN on Net Sales during the Term of such Residual Products covered by a Valid Claim
of a Patent forming part of the Background NN IPR, Collaboration IPR invented solely by NN or Independent NN IPR in accordance with Scenario 1 of Section<B>&nbsp;7.8</B>, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall pay to NN (i)&nbsp;royalties of *** of the Net Sales by IPH or any of its Affiliates during the Term
or (ii) *** of all royalties received by IPH or any of its Affiliates in respect of Net Sales during the Term by any of their respective <FONT STYLE="white-space:nowrap">Out-licensees</FONT> of all Residual Products resulting from the development
and commercialization of such Drug Candidates, as calculated, mutatis mutandis, pursuant to Subsection <B>1.1.53</B>, which payment obligation in respect of royalties received from <FONT STYLE="white-space:nowrap">Out-licensees</FONT> shall be
subject to IPH&#146;s obligation to pay to NN a minimum royalty equal to ***, and maximum royalty equal to ***, of the <FONT STYLE="white-space:nowrap">Out-licensee&#146;s</FONT> Net Sales of such Residual Products, </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no grant of any right or license pursuant to this Subsection <B>13.3.5</B> shall include, in respect of such
right and license, the right or license to develop or commercialize any Residual Product comprised of or directed to the same Biological Target as any Licensed Product, Residual Product or Niche Candidate being developed or marketed by NN or its
Affiliates (or <FONT STYLE="white-space:nowrap">Out-licensee</FONT> of either thereof) pursuant to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Buy-In-Option</FONT></FONT> (for the avoidance of doubt, the limitations on the
licenses and rights otherwise granted to IPH, pursuant to this Subsection <B>13.3.5</B>, shall not in any way impose a limitation of any other rights IPH may have to develop or commercialize such Residual Product), </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH hereby covenants and agrees that subject to the terms of this Agreement neither IPH nor any of its
Affiliates will at any time during the Term develop or commercialize, or cause or authorize to be developed or commercialized, any product comprised of or directed to the same Biological Target as any Licensed Product, Residual Product or Niche
Candidate being developed or marketed solely by NN or its Affiliates (or <FONT STYLE="white-space:nowrap">Out-licensees</FONT> thereof). This covenant and agreement shall not apply at any time after the effective date of any purchase or acquisition
of IPH, except in respect of products that would infringe a Valid Claim of a Patent in the Collaboration IPR or Background NN IPR to the extent that NN retains exclusive rights of commercialization under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN&#146;s obligations under this Subsection <B>13.3.5</B> to grant or assist in the procurement of the grant to
IPH of specified rights or licenses shall not include any requirement that NN do so if such undertaking would not be authorized by contract or permitted by applicable Law or would require NN&#146;s payment or provision of any consideration to any
Person, save that, should NN decline to make any payment or provision of consideration required to make or obtain such grant, IPH may elect to do so and obtain the grant of such rights and licenses to the extent authorized by contract and permitted
by applicable Law, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN and its Affiliates shall have the right of first negotiation in the event that IPH proposes to Out-License
any of its rights or licenses under this Subsection <B>13.3.5</B>, to any Third Party pursuant to the provisions of Subsection <B>13.3.6</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN Right of First Negotiation In Respect of IPH <FONT STYLE="white-space:nowrap">Out-License</FONT> of
Retained or Residual Rights Arising Upon Expiration of Collaboration Term</U>. If IPH or any of its Affiliates intends to <FONT STYLE="white-space:nowrap">Out-license</FONT> any of its rights or licenses under Subsections <B>13.3.4 </B>or<B>
13.3.5</B> at any time during the Term for any purpose, then the following provisions shall apply. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>First Offer to NN</U>. IPH and its Affiliates shall, prior to offering such rights or licenses to any Third
Party, offer the same to NN and its Affiliates on such financial and other terms and conditions as IPH shall present in the form of a definitive written agreement proposal (&#147;<U>First Offer</U>&#148;). As part of the First Offer, IPH shall
include: ***. Upon receipt of the First Offer, NN may accept it as such, or request negotiations based thereon. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Negotiation of <FONT STYLE="white-space:nowrap">Out-License.</FONT></U> The Parties agree to negotiate in
good faith and on an exclusive basis with the objective of executing a mutually acceptable definitive written agreement granting the contemplated <FONT STYLE="white-space:nowrap">Out-license</FONT> to NN or its designated Affiliate(s), <I>provided
that</I>, in the event the Parties fail within *** of IPH&#146;s First Offer, or any separately agreed written extension of such period, to execute a mutually acceptable definitive agreement, then IPH or its Affiliates shall be free, subject to
Subsection <B>13.3.6(c)</B>, to enter negotiations regarding an <FONT STYLE="white-space:nowrap">Out-license</FONT> of the subject matter of the contemplated <FONT STYLE="white-space:nowrap">Out-license</FONT> to NN with any Third Party.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Limitations on IPH Entering Into Agreement More Favorable to Third Party During NN Consideration of First
Offer</U>. Neither IPH nor any of its Affiliates shall within *** of a First Offer enter into any definitive agreement or commitment with any Person in respect of such <FONT STYLE="white-space:nowrap">Out-license</FONT> on any terms that when taken
as a whole are, more favorable to such Person when compared to the terms proposed in NN&#146;s or NN&#146;s Affiliate&#146;s last offer without first offering such terms to NN (or its Affiliates), save that after the expiry of such twelve month
period NN shall have no further rights and IPH shall have no further obligations pursuant to this Subsection <B>13.3.6</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Offer of Similar Terms to NN.</U> In the event that IPH or any of its Affiliates is prepared to enter
into a definitive agreement with any Person other than NN or NN&#146;s designated Affiliate(s) on such more favourable terms, IPH shall, prior to entering into such agreement, first offer such terms to NN or NN&#146;s designated Affiliate(s). NN and
its designated Affiliate(s) shall have *** after the receipt of such offer to accept or reject it. If NN or any of its Affiliates accepts such offer, the Parties shall enter into a definitive written agreement incorporating the material substantive
terms of such offer, <I>provided that,</I> in the event the Parties fail within *** of such IPH offer, or any separately agreed written extension of such period, to execute a mutually acceptable definitive agreement, or if NN and its Affiliates
reject such offer, IPH and its Affiliates shall be free to enter into a definitive agreement with such other Person incorporating the material substantive terms of such offer. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Any IPH Breach of Its Obligations to NN Upon Expiration of Collaboration Term is Material</U>. The breach by
IPH of any of its obligations under this Subsection <B>13.3.6</B> shall constitute a material breach of this Agreement. If, after such <FONT STYLE="white-space:nowrap">Out-license</FONT> agreement is </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
entered into by IPH with a Third Party, NN shall have a good faith basis for believing that IPH&#146;s entry into such agreement was in violation of NN&#146;s rights or in breach of IPH&#146;s
obligations under this Subsection <B>13.3.6</B>, NN shall have the right to commence a proceeding pursuant to Section<B>&nbsp;21.14</B> for recovery of its resulting damages. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Rights Outside the Collaboration Field Upon Expiration of Collaboration Term</U>. In addition to, and
without limitation of, NN&#146;s rights and licenses under Subsection <B>13.3.2</B>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall retain the right and license granted to NN pursuant to Section<B>&nbsp;5.2</B> on a perpetual,
irrevocable, <FONT STYLE="white-space:nowrap">fully-paid-up,</FONT> royalty-free basis; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent that any Collaboration IPR other than that governed by Section<B>&nbsp;5.2</B> has application
outside of the Collaboration Field, if either of the Parties wishes to exploit such Collaboration IPR their rights shall be as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if such IPR is owned solely by one of the Parties pursuant to Section <B>9.2(a) or 9.2(b)</B> (i.e., is not
owned jointly with the other Party or with any of the other Party&#146;s Affiliates) that Party shall have the exclusive right to exploit such IPR outside the Collaboration Field; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if such IPR is Joint IPR then the Parties shall negotiate in good faith on a case by case basis the terms on
which a Party shall have exclusive rights to exploit such IPR outside the Collaboration Field, which terms shall be fair and reasonable and have due regard to the relative contribution of the Parties to the discovery and development of such Joint
IPR and comparable agreements entered into by the respective Parties or observable in the industry; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if such IPR is Third-Party IPR then (A)&nbsp;if such IPR was acquired in exchange for consideration provided or
paid solely by one of the Parties, that Party shall have the exclusive right to exploit such IPR outside the Collaboration Field, or (B)&nbsp;if such IPR was acquired in exchange for consideration provided or paid by both Parties then the Parties
shall negotiate in good faith on a case by case basis the terms on which a Party shall have exclusive rights to exploit such IPR outside the Collaboration Field, which terms shall be fair and reasonable and have due regard to the relative
contribution of the Parties to the acquisition and development of such Third Party IPR and comparable agreements entered into by the respective Parties or observable in the industry </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN Termination for Convenience Prior to Expiration of Collaboration Term</U>. In the event that this
Agreement is terminated, prior to the expiration of the Collaboration Term, by NN for convenience pursuant to Section<B>&nbsp;12.3 </B>the following shall apply: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN&#146;s Research Funding Obligation Upon NN Termination for Convenience Prior to Collaboration Term
Expiration</U>. NN shall continue to pay to IPH all remaining unpaid amounts, if any, payable to IPH in respect of the annual research funding contribution prescribed by Section<B>&nbsp;3.11</B> for the Collaboration Year in which such termination
takes effect, such payment to be made pursuant to the terms and conditions of that Section. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Residual <FONT STYLE="white-space:nowrap">Pre-M1</FONT> Rights Upon NN Termination for Convenience Prior
to Expiration of the Collaboration Term</U>. Subject to such rights and licenses of NN as shall survive the termination of this Agreement pursuant to this Section<B>&nbsp;13.4</B>, IPH shall have, throughout the Territory during the Term, under all
Background NN Research Technology IPR and Collaboration IPR Controlled by NN and necessary for such purpose the exclusive right and license, with the rights to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and
<FONT STYLE="white-space:nowrap">Out-license,</FONT> to commercialize, and develop for commercialization, Residual Products from Drug Candidates that have not attained M1 status, as of the effective date of such termination or within the *** period
following immediately thereafter, <I>provided that</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall pay to NN during the Term: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a flat royalty rate of *** of Net Sales of such Residual Products sold by IPH or its Affiliates as are covered
by a Valid Claim of a Patent forming part of the Background NN IPR, Collaboration IPR invented solely by NN or Independent NN IPR and a flat royalty rate of *** of Net Sales of such Residual Products sold by IPH or its Affiliates as are covered by a
Valid Claim of a Patent forming part of the Joint IPR; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** of all royalties received by IPH or any of its Affiliates in respect of Net Sales during the Term by their
respective <FONT STYLE="white-space:nowrap">Out-licensees</FONT> of all such Residual Products, as calculated, <I>mutatis mutandis</I>, pursuant to Subsection <B>1.1.53</B>, which payment obligation in respect of royalties received from <FONT
STYLE="white-space:nowrap">Out-licensees</FONT> shall be subject to IPH&#146;s obligation to pay to NN a minimum royalty equal to ***, and maximum royalty equal to ***, of the <FONT STYLE="white-space:nowrap">Out-licensee&#146;s</FONT> Net Sales of
such Residual Products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Limitations on Licenses to IPH for Such Residual Products.</U> The foregoing rights and licenses granted to
IPH shall not include, in respect of such rights and licenses, a right or license to develop or commercialize any Residual Product comprised of or directed to </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the same Biological Target as any (i)&nbsp;Licensed Product, (ii)&nbsp;Residual Product or (iii)&nbsp;Niche Candidate being developed or marketed by NN (or its
<FONT STYLE="white-space:nowrap">Out-licensee)</FONT> pursuant to the <FONT STYLE="white-space:nowrap">Buy-In-Option.</FONT> For the avoidance of doubt, the limitations on the licenses and rights otherwise granted to IPH, pursuant to this
Subsection, shall not in any way impose a limitation of any other rights IPH may have to develop or commercialize such Residual Product. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH&#146;s Limited Covenant Not to Compete by Marketing or Sale of Other Products.</U> IPH covenants and
agrees that neither IPH nor any of its Affiliates will at any time during the Term develop or commercialize any therapeutic, prophylactic or diagnostic product comprised of or directed to the same Biological Target as any Licensed Product, Residual
Product or Niche Candidate being developed or marketed solely by NN or its Affiliates (or <FONT STYLE="white-space:nowrap">Out-licensees</FONT> thereof). This covenant and agreement shall not apply at any time after the effective date of any
purchase or acquisition of IPH except in respect of products that would infringe a Valid Claim of a Patent in the Collaboration IPR or Background NN IPR to the extent that NN retains exclusive rights of commercialization under this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Limitation on NN&#146;s Obligations to Provide Licenses</U>. NN&#146;s obligations under this Subsection
<B>13.4.2</B> shall not include any requirement that NN grant to IPH or assist IPH in obtaining any grant of any rights or licenses if doing so should fail to be authorized by contract or permitted by applicable Law, or would require NN&#146;s
payment or provision of any consideration to any Person save that, should NN decline to make any payment or provision or consideration required to make or obtain such grant, IPH may elect to pay for and obtain the right to such procurement or
exercise to the extent authorized by contract and permitted by applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN Retained Rights Upon NN Termination for Convenience Prior to Expiration of the Collaboration Term</U>. NN
shall retain, throughout the Territory during the Term, all rights and licenses granted to NN under this Agreement that are necessary or useful for the Commercial Optimization of Licensed Products (including Drug Candidates that have attained M1
status as of the effective date of such termination or within the *** period following immediately thereafter) or any Niche Candidates with respect to which it has been granted or acquired the exclusive right to commercialize hereunder, including:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exclusive rights and licenses (with the rights to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT
STYLE="white-space:nowrap">Out-license)</FONT> granted to NN pursuant to the terms and conditions of Section<B>&nbsp;5.1</B>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent authorized by contract and permitted by applicable Law, the right, pursuant to
Section<B>&nbsp;5.8</B>, to IPH&#146;s grant to NN of the rights and licenses required for NN&#146;s freedom of operation to exercise the foregoing exclusive license throughout the Territory during the Term, </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in each case to develop and commercialize such Licensed Products and Niche Candidates without any limitation,
restriction or other derogation of such rights or licenses occurring as a result of such termination, <I>provided that </I>the exclusivity of NN&#146;s rights and licenses under this Subsection <B>13.4.3</B> shall be subject to such, if any,
IPH&#146;s rights and licenses as have been granted to IPH under Article <B>6</B> and retained by IPH pursuant to Subsection <B>13.4.5</B>, and <I>further provided that </I>NN shall continue to be bound by the terms and conditions of this Agreement
in respect of the payment to IPH of (i)&nbsp;the applicable amount(s) specified by Section<B>&nbsp;7.3</B> for the achievement of the M1 milestone, but only if such milestone is achieved as of the effective date of such expiration or within the ***
following immediately thereafter, (ii)&nbsp;the applicable amount(s) specified by Section<B>&nbsp;7.3</B> for the achievement of Development Milestones with respect to the Licensed Products, in each case ((i) and (ii)) pursuant to the terms and
conditions of Sections <B>7.4</B>, (iii) royalties on Net Sales of Licensed Products and Niche Candidates during the Term pursuant to the terms and conditions of Article <B>7</B>, and (iv)&nbsp;the percentage of Upside Revenue realized by NN that is
applicable pursuant to the terms and conditions of Section<B>&nbsp;5.11</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN Rights Outside the Field Upon NN Termination for Convenience Prior to Expiration of the Collaboration
Term</U>. In addition to, and without limitation of, NN&#146;s rights and licenses under Subsection <B>13.4.3</B>, NN shall retain its nonexclusive right and license under Section<B>&nbsp;5.2</B> to practice, exercise and use throughout the
Territory all Collaboration Research Technology IPR Controlled by IPH, for NN&#146;s internal use outside the Collaboration Field, which right and license shall be on a perpetual, irrevocable, <FONT STYLE="white-space:nowrap">fully-paid-up,</FONT>
royalty-free and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Retained Rights Upon NN Termination for Convenience Prior to Expiration of the Collaboration Term</U>.
IPH shall retain, throughout the Territory during the Term: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right pursuant to the terms and conditions of Section<B>&nbsp;5.5</B>, to the grant back by NN to IPH of an
exclusive right and license, with the rights to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT STYLE="white-space:nowrap">Out-license;</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to NN&#146;s reasonable cooperation and assistance, pursuant to the terms and conditions of
Section<B>&nbsp;5.8</B>, in obtaining for IPH the rights and licenses required for IPH&#146;s freedom of operation to exercise said right and license, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:17%; font-size:10pt; font-family:Times New Roman">to develop and commercialize only such, if any, Niche Candidates as IPH has, prior to the effective date of such termination, received
exclusive authorization to develop and commercialize pursuant to the terms and conditions of Article <B>6</B> of this Agreement, without any limitation or other derogation of such rights or licenses occurring as a result of such termination,
<I>provided that</I> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement
(indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exclusivity of IPH&#146;s rights and licenses under this Subsection <B>13.4.5</B> shall be subject to
NN&#146;s rights and licenses under Subsection <B>13.4.3</B> and apply solely to the commercialization, and development for commercialization, of such, if any, specific Niche Candidates as IPH has received such exclusive authorization to develop and
commercialize pursuant to Article <B>6</B>, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN&#146;s obligations under this Subsection <B>13.4.5</B> shall not include any requirement that NN grant to
IPH or assist IPH in obtaining any grant of any rights or licenses if doing so should fail to be authorized by contract or not permitted under applicable Law, or would require NN&#146;s payment or provision of any consideration to any Person save
that, should NN decline to make any payment or provision or consideration required to make or obtain such grant, IPH may elect to pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by
applicable Law, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall continue to be bound by the terms and conditions of this Agreement in respect of the payment to NN of
royalties on Net Sales during the Term, save that IPH shall only pay to NN either (A)&nbsp;royalties of *** of the Net Sales during the Term by IPH or any of its Affiliates; or alternatively (B) *** of all royalties received by IPH or any of its
Affiliates in respect of Net Sales during the Term by their respective <FONT STYLE="white-space:nowrap">Out-licensees</FONT> of all products resulting from the development and commercialization of such Niche Candidates, as calculated, mutatis
mutandis, pursuant to Subsection <B>1.1.53</B>, which payment obligation in respect of royalties received from <FONT STYLE="white-space:nowrap">Out-licensees</FONT> shall be subject to IPH&#146;s obligation to pay to NN a minimum royalty equal to
***, and maximum royalty equal to ***, of the <FONT STYLE="white-space:nowrap">Out-licensee&#146;s</FONT> Net Sales of such products in lieu of the royalties specified by Section<B>&nbsp;7.8</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Right to Third-Party Collaborations Upon NN Termination for Convenience Prior to Expiration of the
Collaboration Term</U>. Subject to the Parties&#146; respective rights, licenses and obligations hereunder that, by the terms of this Agreement, survive such termination of this Agreement, in the event that this Agreement is terminated in its
entirety pursuant to Section<B>&nbsp;12.4</B>, IPH shall, commencing with the effective date of such termination, have the right to conduct all activities in the Collaboration Field independently of the Collaboration, both individually and with
Third Parties. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this
agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Additional Consideration</U>. NN and IPH shall have and enjoy their respective rights and licenses
pursuant to this Section<B>&nbsp;13.4</B> without requirement that either of them pay or provide any consideration other than or in addition to such consideration as is expressly specified by the applicable Subsection thereunder and, except for the
rights and licenses described in this Section<B>&nbsp;13.4</B> and such other rights and licenses that by their express terms shall survive the termination of this Agreement, all rights and licenses granted under this Agreement by NN to IPH or by
IPH to NN shall terminate automatically and immediately upon the effective date of such termination without requirement of any further action by the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exclusive IPH Remedies</U>. The sole liability and obligations of NN and sole rights and remedies of IPH in
the event of any termination of this Agreement for convenience by NN pursuant to Section<B>&nbsp;12.3 </B>shall be those<B> </B>set forth above in this Section<B>&nbsp;13.4</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for IPH Transfer</U>. In the event that NN shall terminate this Agreement pursuant to
Section<B></B><B>&nbsp;12.11</B> for IPH&#146;s Change of Control or other Transfer, the terms and conditions of Section<B>&nbsp;13.3 </B>(Expiration of Collaboration Term) shall apply and the respective rights and obligations of the Parties shall
be as set forth in that Section, save that (i)&nbsp;the rights set forth in Subection <B>13.4.6</B> shall be enjoyed by both Parties such that both IPH and NN shall, commencing with the effective date of such termination, have the right to conduct
all activities in the Collaboration Field independently of the Collaboration, both individually and with Third Parties, and (ii)&nbsp;(A) NN shall be obligated to pay only the outstanding and unpaid portion of such pro rata share of the research
funding contribution for the Collaboration Year in which such notice of termination is effective as corresponds to the portion of that Collaboration Year consisting of the period commencing with the first day of such Collaboration Year and ending on
the effective date of such termination, (B)&nbsp;IPH shall reimburse NN for any amounts paid by NN in respect of such research funding contribution for that Collaboration Year that exceed NN&#146;s payment obligation under the foregoing clause (A),
and (C)&nbsp;NN shall have no obligation to pay any additional annual research funding contribution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for NN</U><U>&#146;</U><U>s Material Breach</U>. In the event that IPH shall terminate this
Agreement pursuant to Section<B>&nbsp;12.3</B> for NN&#146;s Material Breach, the terms and conditions of Section<B>&nbsp;13.4</B> shall be incorporated, <I>mutatis mutandis</I>, into this Section<B>&nbsp;13.6</B> and the respective rights, remedies
and obligations of the Parties shall be as set forth in Section<B>&nbsp;13.4</B>, subject solely to the following exception, modifications and addition: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of Section<B>&nbsp;13.4.4</B> shall not apply; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The royalty percentage terms set forth in Subsections <B>13.4.2 (a)</B><B></B><B>&nbsp;(i) and (ii)</B> shall
be superseded and replaced by the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;IPH shall pay to NN during the Term a flat royalty rate of *** of Net Sales of such Residual Products
sold by IPH or its Affiliates as are covered by a Valid Claim of a Patent forming part of the IPR solely Controlled by NN or Joint IPR&#148;; and </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;IPH shall pay to NN (i)&nbsp;royalties of *** of Net Sales of such Residual Products during the Term by
IPH or any of its Affiliates; or (ii) *** of all royalties received by IPH or any of its Affiliates in respect of Net Sales during the Term by its <FONT STYLE="white-space:nowrap">Out-licensees</FONT> of all such Residual Products, as calculated,
<I>mutatis mutandis</I>, pursuant to Subsection <B>1.1.53</B>, which payment obligation in respect of royalties received from <FONT STYLE="white-space:nowrap">Out-licensees</FONT> shall be subject to IPH&#146;s obligation to pay to NN a minimum
royalty equal to ***, and maximum royalty equal to ***, of the <FONT STYLE="white-space:nowrap">Out-licensee&#146;s</FONT> Net Sales of such Residual Products;&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The royalty percentage terms set forth in Subsection <B>13.4.5</B> shall be superseded and replaced by the
following: &#147;(iii) IPH shall continue to be bound by the terms and conditions of this Agreement in respect of the payment to NN of royalties on Net Sales during the Term, save that IPH shall only pay to NN either (A)&nbsp;royalties of *** of the
Net Sales during the Term by IPH or any of its Affiliates; or alternatively (B) *** of all royalties received by IPH or any of its Affiliates in respect of Net Sales during the Term by its <FONT STYLE="white-space:nowrap">Out-licensees</FONT> of all
products resulting from the development and commercialization of such Niche Candidates, as calculated, mutatis mutandis, pursuant to Subsection <B>1.1.53</B>, which payment obligation in respect of royalties received from <FONT
STYLE="white-space:nowrap">Out-licensees</FONT> shall be subject to IPH&#146;s obligation to pay to NN a minimum royalty equal to ***, and maximum royalty equal to ***, of the <FONT STYLE="white-space:nowrap">Out-licensee&#146;s</FONT> Net Sales of
such products&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Damages for NN&#146;s Breach</U>. In addition to the other rights and remedies of IPH under this
Section<B>&nbsp;13.6</B>, and subject to the terms and conditions of Section<B>&nbsp;21.8</B>, in the event that IPH shall terminate this Agreement prior to the expiration of the Collaboration Term pursuant to Section<B>&nbsp;12.4</B> for NN&#146;s
material breach, IPH shall have the right to commence an arbitration proceeding against NN pursuant to Section<B>&nbsp;21.14</B> and to recover compensatory damages for such losses it incurs as a direct and proximate result of such breach to the
extent that such losses have not been fully remedied by its rights and remedies under this Section<B>&nbsp;13.6</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for IPH</U><U>&#146;</U><U>s Material Breach</U>. In the event that NN shall terminate this
Agreement prior to the expiration of the Collaboration Term pursuant to Section<B>&nbsp;12.4</B> for IPH&#146;s material breach: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Limitation of NN Payment Obligations Upon IPH&#146;s Material Breach</U>. NN shall have no obligation to pay
to IPH any royalties, fees or other amounts (including any research funding contribution pursuant to Section<B>&nbsp;3.11</B>) in addition to or other than those expressly set forth </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
in this Section<B>&nbsp;13.7</B>. Further to and not by way of limitation of the foregoing, (a)&nbsp;NN shall be obligated to pay only the outstanding and unpaid portion of such pro rata share of
the research funding contribution for the Collaboration Year in which such notice of termination is effective as corresponds to the portion of that Collaboration Year consisting of the period commencing with the first day of such Collaboration Year
and ending on the effective date of such termination, and (b)&nbsp;IPH shall reimburse NN for any amounts paid by NN in respect of such research funding contribution for that Collaboration Year that exceed NN&#146;s payment obligation under the
foregoing clause (a). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Assignment of IPR to NN Upon IPH&#146;s Material Breach</U>. Subject to the rights and licenses retained
by IPH under Subsection <B>13.7.5</B> and such other rights and licenses of IPH as, pursuant to the terms of this Agreement, survive such termination by NN, IPH shall, for no additional consideration, assign to NN its entire right, title and
interest in the Collaboration IPR without any limitation or restriction as to NN&#146;s (or its transferees&#146;) right to exercise, practice or use such Collaboration IPR within the Collaboration Field. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN Retained Rights to Licensed Products, Residual Products and Niche Candidates Upon IPH&#146;s Material
Breach</U>. NN shall retain, throughout the Territory during the Term, all rights and licenses granted to NN under this Agreement that are necessary or useful for the Commercial Optimization of Drug Candidates (or any Residual Products resulting
from the development thereof), Licensed Products or Niche Candidates, including: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exclusive rights and licenses (with the rights to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT
STYLE="white-space:nowrap">Out-license)</FONT> granted to NN pursuant to the terms and conditions of Section<B>&nbsp;5.1</B>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent authorized by contract and permitted by applicable Law, the right, pursuant to
Section<B>&nbsp;5.8</B>, to IPH&#146;s grant or procurement of the grant to NN of the rights and licenses required for NN&#146;s freedom of operation to exercise the foregoing exclusive license, to develop and commercialize such Drug Candidates,
Residual Products, Licensed Products or Niche Candidates, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in each case without any limitation, restriction or other derogation of such rights or licenses occurring as a
result of such termination, <I>provided that </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exclusivity of NN&#146;s rights and licenses under this Subsection <B>13.7.3</B> shall be subject to such,
if any, IPH&#146;s rights and licenses as have been granted to IPH under Article <B>6</B> and retained by IPH pursuant to Subsection <B>13.7.5</B>, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall pay to IPH: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="30%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the applicable amount(s) specified by Section<B>&nbsp;7.3</B> pursuant to the terms and conditions of that
section for the achievement of the M1 milestone, but only if such milestone is achieved as of the effective date of such termination or within the *** period following immediately thereafter, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="30%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the applicable amount(s) specified by Section<B>&nbsp;7.4</B> pursuant to the terms and conditions of that
section for the achievement of Development Milestones with respect to the Licensed Products,; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="30%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the all Licensed Products as of the date of termination, the royalties specified in Article <B>7 </B>on Net
Sales during the Term of all Classes of Licensed Products (Classes A, B and C) on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, in accordance with the terms and conditions of Article <B>7</B>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall also pay to IPH during the Term a flat royalty rate of *** of Net Sales of Residual Products as are
covered by a Valid Claim of a Patent forming part of the Background IPH IPR, Collaboration IPR invented solely by IPH, Joint IPR or Independent IPH IPR. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN Rights Outside the Field</U>. In addition to, and without limitation of, NN&#146;s rights and licenses
under Subsection <B>13.7.3</B>, NN shall retain its nonexclusive right and license under Section<B>&nbsp;5.2</B> to practice, exercise and use throughout the Territory all Collaboration Research Technology IPR Controlled by IPH, for NN&#146;s
internal use outside the Collaboration Field, which right and license shall be on a perpetual, irrevocable, <FONT STYLE="white-space:nowrap">fully-paid-up,</FONT> royalty-free and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis and
without the right to <FONT STYLE="white-space:nowrap">Out-license,</FONT> for purposes of the discovery, development and commercialization of products outside the Collaboration Field. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Retained Rights</U>. IPH shall retain, throughout the Territory during the Term: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right pursuant to the terms and conditions of Section<B>&nbsp;5.5</B>, to the grant back by NN to IPH of an
exclusive right and license, with the rights to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT STYLE="white-space:nowrap">Out-license;</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to NN&#146;s reasonable cooperation and assistance, pursuant to the terms and conditions of
Section<B>&nbsp;5.8</B>, in granting to IPH, or procuring the grant to IPH of, the rights and licenses required for IPH&#146;s freedom of operation to exercise said right and license, </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
to develop and commercialize only such, if any, Niche Candidates as IPH has, prior to the effective date of such termination, received exclusive authorization to develop and commercialize
pursuant to the terms and conditions of Article <B>6</B> of this Agreement, without any limitation or other derogation of such rights or licenses occurring as a result of such termination, <I>provided that</I> (i)&nbsp;IPH&#146;s rights and licenses
under this Subsection <B>13.7.5</B> shall be subject to NN&#146;s rights and licenses under Subsection <B>13.7.3</B> and apply solely to the commercialization, and development for commercialization, of such, if any, specific Niche Candidates with
respect to which IPH has received such exclusive authorization to develop and commercialize pursuant to Article <B>6</B>, (ii) NN&#146;s obligations under this Subsection <B>13.7.5</B> shall not include any requirement that NN grant to IPH or assist
IPH in obtaining any grant of any rights or licenses if doing so would not be authorized by contract or permitted by applicable Law or would require NN&#146;s payment or provision of any additional consideration to any Person save that IPH may pay
for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by applicable Law, and (iii)&nbsp;IPH shall continue to be bound by the terms and conditions of this Agreement in respect of the payment to
NN of royalties on Net Sales during the Term pursuant to the terms and conditions of Article <B>7</B>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NN Damages for IPH&#146;s Breach</U>. In addition to the other rights and remedies of NN under this
Section<B>&nbsp;13.7</B>, and subject to the terms and conditions of Section<B>&nbsp;21.8</B>, in the event that NN shall terminate this Agreement prior to the expiration of the Collaboration Term pursuant to Section<B>&nbsp;12.4</B> for IPH&#146;s
material breach, NN shall have the right to commence an arbitration proceeding against IPH pursuant to Section<B>&nbsp;21.14</B> and to recover compensatory damages for such losses it incurs as a direct and proximate result of such breach to the
extent that such losses have not been fully remedied by its rights and remedies under this Section<B>&nbsp;13.7</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>M1 Grace Period and Audit Rights</U>. In addition to the other consequences of termination set forth in this
Article <B>13</B>, in the event that (i)&nbsp;the Collaboration Term expires or (ii)&nbsp;this Agreement is terminated prior to the expiration of the Collaboration Term by either Party for any permitted reason </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Drug Candidate that shall have achieved M1 status within *** after the effective date of such termination
shall be deemed to have achieved such M1 status prior to such effective termination date for the purposes of this Article <B>13</B>, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Party, upon written request to the other Party, shall have the right to conduct an examination of all
documents, information, materials and facilities generated or maintained by or on behalf of the other Party (or of any Affiliate or <FONT STYLE="white-space:nowrap">Sub-licensee</FONT> of the other Party) in or in connection with the Collaboration,
including all laboratory and other notebooks, records and reports, reference </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
samples of Drug Candidates and Biological Targets, all assay and other test protocols, data and results, and all summaries and analyses of any of the foregoing, that relate to the discovery,
research or development of any Drug Candidate, solely for purposes of the examining Party&#146;s determination of whether such Drug Candidate has attained M1 status prior to the effective date of such termination. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All such examinations under this Section<B>&nbsp;13.8</B> shall be: (i)&nbsp;conducted only once with respect
to any single Drug Candidate, in each case within *** after the expiration of the *** period following immediately after the effective date of such termination; (ii)&nbsp;upon not less than *** prior written notice by the examining Party to the
other Party; (iii)&nbsp;conducted only by qualified personnel or representatives of the examining Party; and (iv)&nbsp;conducted without undue interference with the business or operations of the examined Party&#146;s facility(ies) or operations.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The documents, information, materials and facilities required to be made available for purposes of such
examination shall be limited to only those that are relevant to assessing whether the Drug Candidate(s) in question have attained M1 Status prior to the effective date of such termination or during the
<FONT STYLE="white-space:nowrap">one-hundred-eighty</FONT> day period following immediately thereafter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Party made subject to any examination pursuant to this Section<B>&nbsp;13.8</B>, whether directly or by or
through its Affiliate(s) or <FONT STYLE="white-space:nowrap">Sub-licensee(s),</FONT> shall render, or cause to be rendered, all reasonable cooperation and assistance to the examining Party in connection with such examination. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The examining Party shall, within *** after the completion of such examination, provide to the other Party
notice of its conclusion as to whether the Drug Candidate(s) under examination have or have not attained M1 status prior to the effective date of such termination or within the *** period following immediately thereafter, in which the examining
Party shall specify, in reasonable detail (a)&nbsp;the affected Drug Candidate(s), and (b)&nbsp;the basis for the examining Party&#146;s conclusion as to whether or not such Drug Candidate(s) has or have attained M1 status prior to the effective
date of such termination or the following *** period. If the examined Party disagrees with such conclusion it shall, within *** after its receipt of such notice, respond to the examining Party&#146;s conclusion with a written statement setting forth
in reasonable detail the basis for its disagreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the examined Party shall fail to provide such reasonably detailed written statement of
disagreement within the above-specified *** period with respect to any Drug Candidate, it shall be deemed to have accepted and agreed to the examining Party&#146;s conclusion as to the M1 or <FONT STYLE="white-space:nowrap">non-M1</FONT> status of
such Drug Candidate, and such conclusion shall be final and binding upon the Parties for purposes of determining their respective rights, licenses and obligations with respect to such Drug Candidate under this Article <B>13</B>.
</P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement
(indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.8.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the examined Party shall have provided to the examining party a reasonably detailed written statement of
disagreement within the *** period specified in Subsection <B>13.8.4</B> with respect to any Drug Candidate, the Parties shall submit such disagreement for resolution pursuant to Section<B>&nbsp;21.14</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Cumulative Remedies</U>. Except as otherwise expressly provided in this Agreement, the provisions under
which this Agreement may be terminated shall be in addition to any other remedies which either Party may have hereunder or at law, in equity or otherwise, for the actual or anticipated breach of any terms hereof, and do not in any way limit any such
other remedies such Party may have. Without limitation of the generality of the foregoing, such remedies may include an award of specific performance or provisional, permanent or mandatory injunctive or other equitable remedies in those instances in
which an award of damages does not afford an adequate remedy, or where such remedies are otherwise necessary to avoid irreparable harm. Relief pursuant to the above clause may be sought from any court of competent jurisdiction in the event that the
granting of such relief is not within the authorization, power or policy of any arbitral authority selected by the Parties, or is not expressly denied on the merits by such arbitral authority but nevertheless will not adequately be enforced by the
relevant courts or be obtainable from the arbitral authority in such time and manner as will avoid irreparable harm, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EQUITY FINANCING AND FUTURE IPO </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Equity Investment</U>. Subject to and conditioned upon NN&#146;s satisfactory completion of its due
diligence review and the Parties&#146; execution and delivery of this Agreement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN intends to invest *** to acquire *** newly-issued preferred shares of IPH at a purchase price of *** per
share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that this transaction shall take place, it shall take effect and be governed in all respects
pursuant to the terms and conditions of a separate equity purchase agreement (the &#148;<U>Share Purchase Agreement</U>&#148;) executed by the Parties contemporaneously with this Agreement and containing provisions customary in this type of
investment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the Share Purchase Agreement, in connection with the contemplated equity purchase, NN will also
receive from IPH warrants which will afford NN anti-dilution rights comparable to those provided in the warrants attached to IPH&#146;s Series D Stock. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The above-described equity purchase shall close *** after the date of this Agreement of this Agreement, unless
provided otherwise in the Share Purchase Agreement or the Parties hereafter agree otherwise in writing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REPRESENTATIONS AND WARRANTIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Mutual Representations and Warranties</U>. Each Party hereby covenants, represents and warrants to the other
Party that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Organization and Good Standing</U>. As of the date of this Agreement such Party (a)&nbsp;is a corporation
duly organized, validly existing and in good standing under the Laws of its jurisdiction of incorporation and has all requisite corporate power and authority to own, lease and operate its properties and to carry on its business as now being
conducted, (b)&nbsp;is duly qualified or authorized to do business as a foreign corporation and is in good standing under the Laws of (i)&nbsp;each jurisdiction in which it leases real property and (ii)&nbsp;each other jurisdiction in which the
conduct of its business or the ownership of its properties requires such qualification or authorization, except where the failure to be so qualified or authorized would not have a Material Adverse Effect on such Party, the other Party, the
Collaboration, or the attainment of Commercial Optimization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Authority</U>. Such Party (a)&nbsp;as of the date of this Agreement has, and at all times during the Term
shall have, the full right, power and authority to (i)&nbsp;execute and deliver this Agreement and each other agreement, document, instrument or certificate contemplated by this Agreement or required by this Agreement to be executed by such Party,
(ii)&nbsp;to grant all rights and licenses herein granted by such Party (including all rights to <FONT STYLE="white-space:nowrap">Out-license</FONT> and <FONT STYLE="white-space:nowrap">Sub-license),</FONT> and to fully perform its obligations
hereunder and thereunder; and (b)&nbsp;as of the date of this Agreement has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement
has been duly and validly executed and delivered on behalf of such Party, constitutes a legal, valid and binding obligation of such Party, and is enforceable against such Party in accordance with its terms subject to the effects of bankruptcy,
insolvency or other Laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance, injunctions and other remedies, and binding public policy constraints (including
those pertaining to limitations or exclusions of liability, competition law, penalties and jurisdictional issues, including conflicts of laws). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Conflict</U>. The execution and delivery of this Agreement and the performance of such Party&#146;s
obligations hereunder do not, as of the date of this Agreement (a)&nbsp;conflict with or violate any requirement of applicable Law or any provision of the articles of incorporation, bylaws or any comparable charter or constitutional instrument of
</P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement
(indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
such Party, in any material way, or (b)&nbsp;conflict with, violate, result in a breach or termination of, or constitute a default (or, with notice or the lapse of time, become a default),
require any consent, or give rise to any &#148;<U>take back</U>&#148; right or right of termination or acceleration or right to increase or modify the obligations under, any contractual obligation, permit or court or administrative order to which
such Party is a party or by which such Party or the properties or assets of such Party is or are bound; (c)&nbsp;conflict with any right previously granted by such Party to another Person; (d)&nbsp;constitute a violation of any law applicable to
such Party, <I>provided that</I> any required clearance by any EU Competition Law authority, shall have been received; or (e)&nbsp;result in the creation of any encumbrance upon the properties or assets of such Party, other than, in the case of
clauses (a), (b), (c) or (d), any such conflicts, violations, breaches, terminations, defaults, rights or encumbrances that, individually or in the aggregate, would not (i)&nbsp;have a Material Adverse Effect on such Party, the other Party, the
Collaboration or the attainment of Commercial Optimization, (ii)&nbsp;impair in any material respect the ability of such Party to perform its material obligations under this Agreement, or (iii)&nbsp;prevent or materially delay the consummation of
any of the material transactions contemplated by this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Warranty of No Litigation</U>. As of the date of this Agreement there is no claim, investigation,
litigation, proceeding or dispute (including any opposition, interference or <FONT STYLE="white-space:nowrap">re-examination)</FONT> pending or threatened with respect to, (a)&nbsp;for NN&#146;s covenant, representation and warranty hereunder, the
Background NN IPR, and (b)&nbsp;for IPH&#146;s covenant, representation and warranty hereunder, the Background IPH IPR, and such Party has not received any communication respecting and is not aware of any other claim, investigation, litigation or
proceeding or dispute pending or threatened against it that, individually or in the aggregate, could reasonably be expected to materially impair the ability of such Party to perform any obligation under this Agreement or have a Material Adverse
Effect upon such Party, the other Party, the Collaboration or the attainment of Commercial Optimization other than matters (i)&nbsp;raised in the ordinary course of Patent prosecution that are publicly available or (ii)&nbsp;any matter that was
disclosed to the other Party prior to the date of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Consents and Approvals</U>. As of the date of this Agreement all necessary consents, approvals, orders,
registrations and authorizations of all regulatory authorities and other Persons required to be obtained by such Party in connection with the entry into this Agreement have been obtained, <I>except for</I> (a)&nbsp;the filing with any EU Competition
Law authority, of such, if any, notifications and reports as may be required under EU Competition Law, and (b)&nbsp;such other consents, approvals, orders, authorizations and registrations, the failure of which to be obtained or made would not
(i)&nbsp;have a Material Adverse Effect on either Party, the Collaboration or the attainment of Commercial Optimization, (ii)&nbsp;impair in any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
material respect the ability of such Party to perform its obligations under this Agreement, or (iii)&nbsp;prevent or materially delay the consummation of any of the material transactions
contemplated by this Agreement, and such Party has obtained, or will exercise diligent, commercially reasonable efforts to obtain, all such consents, approvals, orders, authorizations and registrations required for its performance hereunder.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Legal Compliance</U>. Such Party shall carry out, and shall cause all its Affiliates, and its and their
respective officers, employees and agents and require all its contractors, <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> and <FONT STYLE="white-space:nowrap">Out-licensees,</FONT> and all Persons under their control or for whose actions they
are otherwise liable, to carry out all obligations and activities hereunder in material compliance with the terms and conditions of this Agreement and all material applicable Laws. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Necessary Capacity</U>. Such Party will use all reasonable efforts during the Collaboration Term to have the
requisite facilities, personnel, equipment, expertise, experience, knowledge and skill to timely and effectively perform the obligations contemplated to be performed by or on behalf of such Party under this Agreement in all material respects.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disclosure</U>. Such Party has not, in connection with the Parties&#146; entry into this Agreement,
communicated or otherwise provided to the other Party any statement of material fact, which it has failed to correct, or failed to communicate or otherwise provide to the other Party any material fact, the communication or omission of which is, as
of the date of this Agreement, known, or should, upon reasonable inquiry, have been known by such Party to be, false, misleading or deceptive in any material respect, including any information provided or communicated by such Party that is set forth
in this Agreement (including any Schedule hereto). Such Party has, prior to the date of this Agreement, provided, and shall throughout the Term provide, to the other Party all material information, data and documents (including any licenses,
assignments, agreements or other instruments, any documents evidencing or relating to any Patent, and any legal notices or other legal documents) that is in the possession, custody or control of such Party or any of its Affiliates, or such
Party&#146;s <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> or <FONT STYLE="white-space:nowrap">Out-licensees,</FONT> or, in the case of information and data, that is otherwise known to such Party or any of its Affiliates, <FONT
STYLE="white-space:nowrap">Sub-licensees</FONT> or <FONT STYLE="white-space:nowrap">Out-licensees,</FONT> and that has been requested by the other Party with respect to, or that is otherwise material to, the Collaboration or Commercial Optimization,
including the research, development or commercialization of any Licensed Product, Niche Candidate, or Residual Product under development or commercialization by the other Party pursuant to license hereunder (including with respect to any IPR
comprising or relating to any of the foregoing), and, as of the date of this Agreement, neither such Party nor any of its Affiliates is aware, nor after reasonable inquiry should be aware, that any such information, data
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
or document is inauthentic, inaccurate, untrue or misleading in any material respect. Should such Party or any of its Affiliates become aware that any such information, data or document is
inauthentic, inaccurate, untrue or misleading, such Party will promptly notify the other Party of this fact. The provisions of this Subsection <B>15.1.8</B> are subject in all respects to the exception of such binding obligations of confidentiality
and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> to Third Parties as (a)&nbsp;the Parties have incurred prior to, and that remain in effect as of, the date of this Agreement, or (b)&nbsp;the Parties are unable to avoid or negate in their
agreements with their respective <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> or <FONT STYLE="white-space:nowrap">Out-licensees</FONT> after having made diligent good faith efforts to do so, in each case ((a) and (b)) for so long as such
obligations shall remain in effect. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Unauthorized Disclosure</U>. Such Party has not delivered or otherwise made accessible, and will not deliver
or make accessible, to the other Party confidential or proprietary <FONT STYLE="white-space:nowrap">Know-How</FONT> of any Third Party without disclosing to the other Party, in writing in advance of such disclosure, the source thereof and such
Party&#146;s right to make such disclosure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disclaimer of Warranty</U>. <B>EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, n</B><B>o warranty is given
by either Party as to the validity of any Patents, <FONT STYLE="white-space:nowrap">Know-How</FONT> or other IPR licensed by it under this Agreement or that any activity covered by such Patents, <FONT STYLE="white-space:nowrap">Know-How</FONT> or
other IPR licensed hereunder will not infringe the Intellectual Property Rights of any Third Party.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Representations and Warranties In Respect of IPR</U>. IPH hereby covenants, represents and warrants to
NN that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exclusive Ownership and Control</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of the date of this Agreement, IPH possesses exclusive Control, within the Collaboration Field, of all
Background IPH IPR and Collaboration IPR in existence and Controlled by IPH as of the date of this Agreement, free of any security interest, lien or encumbrance other than the restrictions in IPH&#146;s agreements with Third Parties which have
previouslybeen disclosed to NN. Subject to the other provisions of this Agreement in cases in which IPH shall, in the first instance, have or obtain such exclusive Control of Background IPH IPR, it shall retain exclusive Control throughout the Term,
and in such cases in which IPH shall, in the first instance, have or obtain <FONT STYLE="white-space:nowrap">non-exclusive</FONT> Control of Background IPH IPR, it shall retain such <FONT STYLE="white-space:nowrap">non-exclusive</FONT> Control, and
where necessary for Commercial Optimization, exercise diligent efforts to obtain exclusive Control, throughout the Term, and in all cases such Control shall be free of any security interest, lien or encumbrance. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as expressly authorized pursuant Articles <B>5 </B>and<B> 6 </B>or<B> 13</B> of this Agreement, or as NN
may hereafter otherwise expressly agree in writing, IPH shall not at any time during the Term grant, transfer or convey to any Third Party any license or any other right, title or interest in respect of, or otherwise encumber, any Background IPH IPR
or Collaboration IPR, or grant, transfer or convey to any Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall promptly secure and retain throughout the Term any and all licenses, assignments and transfers of all
rights required to maintain the rights of Control described in Subsections <B>15.3.1(a) </B>and<B> 15.3.1(b)</B> or to otherwise fulfill its warranties under those Subsections. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Patent Validity</U>. As of the date of this Agreement, no Patent within the Background IPH IPR has, in whole
or in part, been waived, disclaimed, or held revoked, unenforceable or invalid by decision of any court or other governmental agency of competent jurisdiction, or is or has been subject to any claim, or threat to assert a claim, of invalidity in any
proceeding (other than (i)&nbsp;proceedings in the ordinary course of Patent prosecution as would be reflected in publicly available documents as of the date of this Agreement or (ii)&nbsp;that was disclosed to NN prior to the date of this
Agreement) and IPH is not aware of any reason (other than (i)&nbsp;proceedings in the ordinary course of Patent prosecution as would be reflected in publicly available documents as of the date of this Agreement or (ii)&nbsp;that was disclosed to NN
prior to the date of this Agreement) to believe that any such Patent is, in whole or in part, invalid or unenforceable, or requires any waiver or disclaimer of any rights with respect thereto. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Infringement of Third Party IPR</U>. As far as IPH is aware, as of the date of this Agreement, (a)&nbsp;none
of this Agreement or the exercise of any of the rights or licenses, or performance of any of the obligations under this Agreement, pursuant to the terms and conditions hereof, infringes, misappropriates or otherwise violates any IPR or other rights
of any Person and (b)&nbsp;no Person has alleged any such infringement, misappropriation or violation and there is no basis for any claim thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Patents; Third-Party Infringement</U>. As far as IPH is aware, as of the date of this Agreement:
(a)&nbsp;there is no material unauthorized use, infringement or misappropriation by any Third Party of any of the Patents or other IPR within the Background IPH IPR; (b)&nbsp;none of the Patents within the Background IPH IPR is the subject of any
pending <FONT STYLE="white-space:nowrap">re-examination,</FONT> opposition or interference proceedings, or any litigation or similar proceedings, and no claim has been made asserting the misuse, unregistrability, unenforceability or <FONT
STYLE="white-space:nowrap">non-infringement</FONT> of any of such Patents or challenging IPH&#146;s or any of its Affiliates&#146; right to use or ownership of any of such Patents (other than (i)&nbsp;proceedings in the ordinary course of Patent
prosecution as </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
would be reflected in publicly available documents as of the date of this Agreement or (ii)&nbsp;that was disclosed to the other Party prior to the date of this Agreement), or making any adverse
claim of ownership with respect thereto; and (c)&nbsp;there has been and currently is no threat of such a proceeding, or any facts that likely would be the basis for instituting any such proceeding. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Limitations on IPH Awareness for Purposes of Section</U><U></U><B><U>&nbsp;15.3</U></B>. For the purposes of
this Section<B>&nbsp;15.3</B>, awareness of IPH shall mean the actual knowledge of ***. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEMNIFICATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Mutual Indemnification</U>. Each Party (the &#148;<U>Indemnifying Party</U>&#148;) agrees to indemnify, hold
harmless, and defend the other Party (the &#148;<U>Indemnified Party</U>&#148;) and its Affiliates, and each of such Indemnified Party&#146;s and its Affiliates&#146; respective officers, employees, and agents,
<FONT STYLE="white-space:nowrap">Sub-licensees</FONT> and <FONT STYLE="white-space:nowrap">Out-licensees</FONT> (collectively, the &#148;<U>Other Indemnitees</U>&#148;), against any claims, suits, losses, damages, costs, fees and expenses against
the Indemnified Party or any of the Other Indemnitees by, or incurred by any of them to, any Third Party (collectively, &#148;<U>Claim</U>&#148;), including reasonable legal costs, expenses and attorneys&#146; fees, resulting from or arising out of
or in connection with the willful misconduct of the Indemnifying Party or any of its employees, agents or other Persons for whom such Party may be held legally responsible; (b)&nbsp;any breach by the Indemnifying Party of any of its representations,
warranties, covenants, agreements or obligations under this Agreement, (c)&nbsp;the Indemnifying Party&#146;s activities (including the exercise of its rights or performance of its obligations) under this Agreement, or (d)&nbsp;or the sale or use of
any Licensed Product, Niche Candidate or Residual Product by the Indemnifying Party, its Affiliates, <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> or <FONT STYLE="white-space:nowrap">Out-licensees,</FONT> except in each case ((a) through
(d)) to the extent that such Claim results from or arises out of or in connection with the acts or omissions of the Indemnified Party or any employees, agents or other Persons for whom the Indemnified Party may be held legally responsible.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Indemnification Procedure</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notice of Claim</U>. The Indemnified Party shall promptly notify the Indemnifying Party in writing of any
Claim or the discovery of any fact upon which the Indemnified Party intends to base a request for indemnification under Section<B>&nbsp;16.1</B>, but the failure or delay to provide such notice shall not, however, relieve the Indemnifying Party of
any of its indemnification obligations hereunder except to the extent that the Indemnifying Party is materially prejudiced thereby. Each such notice shall contain a description of the nature and amount of the asserted Claim to the extent then known
by the Indemnified Party. The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of such Claim. All requests or demands for indemnification by or on behalf of the Other
Indemnitees shall be made solely by the Indemnified Party. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Other Indemnification Procedures</U>. The obligations of an Indemnifying Party under this Article <B>16</B>
shall be governed by the following additional terms and conditions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Control of Defense</U>. The Indemnifying Party shall have the obligation to assume and the right to
exclusive control of the defense of all Claims, <I>provided that</I> the Indemnified Party shall have the right and option to assume and control such defense by giving written notice to the Indemnifying Party of such assumption within *** after
providing the Indemnifying Party with notice of the relevant Claim under Section<B>&nbsp;16.2.1</B>. The Party assuming the defense of a Claim shall have the right to appoint legal counsel of its own choice as lead counsel in such defense. In the
event that the Indemnified Party shall assume control of such defense, the Indemnifying Party shall be responsible for all reasonable costs and expenses (including reasonable attorneys&#146; and experts&#146; fees) incurred by the Indemnified Party
in connection therewith. Should the Indemnifying Party assume the defense of a Claim, the Indemnifying Party shall not be liable to the Indemnified Party or any of the Other Indemnitees for any legal costs or expenses subsequently incurred by such
Indemnified Party or Other Indemnitees in connection with such defense. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Right to Participate in Defense</U>. Without limitation of the Parties&#146; rights and obligations under
Subsection <B>16.2.2(a)</B>, in the event that the Indemnifying Party shall assume control of the defense of a Claim, the Indemnified Party and each of the Other Indemnitees shall be entitled to participate in, but not control, the defense of such
Claim and to employ counsel of its choice for such purpose, <I>provided that</I> such employment shall be at its own cost and expense unless specifically requested and authorized by the Indemnifying Party in writing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Settlement of Claims</U>. The Party in control of the defense of a Claim shall have the exclusive right, in
its sole discretion, to settle such Claim, whether by settlement or other voluntary final disposition, without the prior written approval of the other Party (or, if the Indemnified Party controls such defense, the approval of the Other Indemnitees),
<I>provided that</I> the terms of such resolution do not: (a)&nbsp;enjoin any future action by the other Party (or, if the Indemnified Party controls such defense, such action by any of the Other Indemnitees); (b) derogate from or diminish any of
the other Party&#146;s rights under this Agreement; (c)&nbsp;require the payment or provision of consideration by the other Party (or, if the Indemnified Party controls such defense, by any of the Other Indemnitees); (d) fail to grant a release of
such Claim to the other Party (and, if the Indemnified Party controls such defense, to any of the Other Indemnitees); (e) require the admission or concession that any claim or aspect of any Patent Controlled by the other Party or its Affiliates is
invalid or unenforceable, or require any waiver or disclaimer of any rights with respect to such claim or Patent; or (f) otherwise have a Material Adverse Affect upon the other Party (or, if the Indemnified Party controls such defense, on any of the
Other Indemnitees). </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from
this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Cooperation</U>. Regardless of which Party controls the defense of any Claim, the Indemnified Party shall,
and shall diligently endeavor to cause each of the Other Indemnitees to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery
proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the indemnifying Party to, and reasonable retention by the Indemnified
Party of, records and information that are reasonably relevant to such Claim, and making Indemnitees and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided
hereunder, and the indemnifying Party shall reimburse the Indemnified Party for all its reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses in connection therewith. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Expenses</U>. In the event that the Indemnified Party assumes control of the defense of a Claim pursuant to
Subsection <B>16.2.2(a)</B>, the reasonable and verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with such Claim shall be reimbursed by the Indemnifying Party on a calendar
quarter basis, without prejudice to the Indemnifying Party&#146;s right to contest the Indemnified Party&#146;s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify
the Indemnified Party by a legally binding final decision of a court or arbitrator that is unappealable or unappealed within the time allowed for appeal. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Non-Waiver</FONT></U>. The assumption of the defense of a Claim by the
Indemnifying Party shall not be construed as an acknowledgment that the Indemnifying Party is liable to indemnify any Person in respect of the Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against
any claim for indemnification hereunder. In the event that it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold harmless an Indemnitee from and against the Claim, the Indemnified Party shall reimburse
the Indemnifying Party for any and all costs and expenses (including attorneys&#146; fees and costs of suit) and any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys&#146; fees and expenses) incurred by the
Indemnifying Party in its defense of the Claim with respect to such Indemnitee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FORCE MAJEURE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Force Majeure</U>. In the event of Force Majeure, a Party thereby prevented from performing its obligations
or duties shall not be held liable or responsible to the other Party, nor be deemed to be in default under or in breach of any provision of this Agreement, by reason thereof. The Party prevented from performing its obligations because of Force
Majeure shall promptly notify the other Party of the occurrence and particulars of such Force Majeure and shall provide such other Party, from time to time, with its best estimate of the duration of such Force Majeure and with notice of the
cessation thereof. The Party so affected shall use diligent, commercially reasonable efforts to avoid or remove such causes of nonperformance and, upon cessation of Force Majeure, shall resume performance as soon as practicable.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PUBLICATIONS AND DISCLOSURES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Publication</U>. Each Party shall furnish, and shall cause its Affiliates, and to the extent authorized by
contract and permitted by applicable Law, contractually require all its new <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> and Third Party licensors, investigators and collaboration partners, to furnish, to the other Party copies of any
proposed publication or public disclosure (including any oral disclosure made with or without obligation of confidentiality) by or on behalf of such Party or other Person of any Collaboration <FONT STYLE="white-space:nowrap">Know-How,</FONT> in
advance of such publication or disclosure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The receiving Party shall have *** after receipt of such proposed publication or disclosure to object to such
proposed publication or disclosure because there is patentable subject matter or other confidential information contained therein, which may need protection, and shall have the right, upon written request, to </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a delay in publication or presentation for up to *** in order to protect patentable subject matter,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">propose modifications to the publication or presentation for patent or confidentiality reasons, or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">request that the information be maintained in confidence. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the receiving Party objects to such publication or disclosure, the other Party shall refrain
from making such publication or disclosure and shall cause its Affiliates, and to the extent authorized by contract and permitted by applicable Law, contractually require its <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> and Third Party
licensors, investigators and collaboration partners to refrain from making, such publication or disclosure, until approved by the other Party, which approval shall not be unreasonably withheld or delayed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In no event, shall a Party publish or present the other Party&#146;s Confidential Information without prior
written approval of such other Party. The Parties shall obtain and maintain throughout the Term all authorizations, consents and agreements of their respective Affiliates, and employees and agents, and shall exercise diligent, commercially
reasonable efforts to obtain and maintain throughout the Term all authorizations, consents and agreements of their Sub-licensees and Third-Party licensors, investigators and collaboration partners, necessary to perform their obligations under this
Section<B>&nbsp;18.1</B>. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded
from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Communication Guidelines</U>. The Parties have agreed to the communication guidelines set forth in Schedule
<B>18.2</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Press Releases</U>. Following the date of this Agreement, the Parties shall issue one or more press
releases, to be approved by both Parties, regarding this Agreement and the Share Purchase Agreement, the timing and content of which shall be mutually agreed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">18.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless agreed otherwise, no press releases or other public announcements with respect to this Agreement, the
Share Purchase Agreement, or any subject matter or terms of either of them, shall include any information about funding conditions or monetary amounts. Except to the extent required by Law or the rules of a relevant Stock Exchange or as otherwise
permitted in accordance with this Section<B>&nbsp;18.3</B>, neither Party shall make any further press releases or other public announcements concerning this Agreement or the Share Purchase Agreement or the terms or subject matter hereof or thereof,
or that explicitly refers to the other Party or its trade name or trademark(s), without the prior written consent of the other Party, which shall not be unreasonably delayed, conditioned or withheld. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">18.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any copy of this Agreement or the Share Purchase Agreement required to be filed with any governmental or
regulatory authority shall, if permitted by applicable Law, be redacted to the reasonable satisfaction of both Parties; <I>provided that</I>, in the event that such governmental or regulatory authority objects to the redaction of any portion of the
Agreement after the initial submission, the filing Party shall consult with the other Party respecting the objections and shall in good faith respond to the objections in an effort to limit the disclosure required by such authority.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">18.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the foregoing, the Parties agree that each Party may desire or be required to issue press or
other public announcements releases relating to this Agreement, the Share Purchase Agreement or activities hereunder or thereunder, and each of the Parties agrees to consult with the other Party reasonably and in good faith with respect to the text
and timing of such press releases or other public announcements and not to issue any such press releases or public announcements without the prior written consent of the other Party prior to the issuance thereof, <I>provided that</I> (a)&nbsp;a
Party may not unreasonably delay, condition or withhold consent to such press releases or public announcements, (b)&nbsp;either Party may issue such press releases or public announcements as it determines, based on advice of counsel, are reasonably
necessary to comply with Law or for appropriate market disclosure, and (c)&nbsp;the contents of any such press release or public announcement or similar publicity which has been reviewed and approved by the reviewing Party may be <FONT
STYLE="white-space:nowrap">re-released</FONT> by either Party without a requirement for <FONT STYLE="white-space:nowrap">re-approval.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">18.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The principles to be observed by the Parties in any press releases or other public disclosures with respect to
this Agreement or the Share Purchase Agreement shall be: accuracy, compliance with applicable legal requirements, the requirements of confidentiality under Article <B>10</B> and as set forth in this Section<B>&nbsp;18.3</B> and elsewhere in this
Agreement, and normal business practice in the pharmaceutical and biotechnology industries for disclosures by companies comparable to IPH and NN. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">18.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any provision hereof to the contrary, in the event of any such proposed press release or public
announcement by IPH, NN shall be afforded a minimum of *** after its receipt thereof in which to review, comment and approve (or request modifications or conditions of approval of) such press release or public announcement, unless a shorter period
is required by applicable Law or the rules of a relevant Stock Exchange, in which event IPH shall provide NN with a copy of the contemplated press release or public announcement immediately upon the completion thereof, together with written notice
of such shorter period, unless such prior submission to NN is contrary to applicable Law or otherwise impossible due to circumstances beyond IPH&#146;s control. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disclosure of Agreement</U>. Except as permitted by this Agreement, and subject to applicable Law, the terms
and conditions of this Agreement, the activities hereunder and the existence of the Agreement shall be kept confidential by the Parties and shall not be disclosed in any way without the prior written approval of the other Party, <I>provided that</I>
each Party may disclose the contents of this Agreement to Affiliates or professional advisors who agree or are under a professional obligation to maintain the same in confidence. However, such approval shall be unnecessary if the Disclosing Party is
subject to a legal requirement to disclose the existence and terms of this Agreement. In such event, the Disclosing Party shall notify the other Party without delay and provide the other Party with a copy of the contemplated disclosure prior to its
being made, unless notifying is impossible due to circumstances beyond the Party&#146;s control. The other Party may provide comments to the proposed disclosure and the Disclosing Party shall in such case take into consideration all such reasonable
comments. Unless otherwise agreed upon in writing with the other Party the Disclosing Party shall only disclose such information that is needed to comply with applicable Law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise specified herein, all notices, requests, demands, approvals, consents, tenders, offers, acceptances, rejections or other communications
required or permitted hereunder (other than routine communications lacking legal effect), must be written and in English and shall be deemed to have been duly given if (a)&nbsp;delivered personally, (b)&nbsp;mailed, certified or registered mail,
return receipt requested, postage prepaid, (c)&nbsp;sent by internationally recognized overnight courier service or overnight express mail, postage prepaid, or (d)&nbsp;sent by telecopy, followed with an original sent in accordance with (b)&nbsp;or
(c) above, as follows: </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement
(indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">If&nbsp;to&nbsp;Novo&nbsp;Nordisk:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk A/S</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo All&eacute;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">DK-2880</FONT> Bagsvaerd</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denmark</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">***</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">With&nbsp;a&nbsp;copy&nbsp;to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">***</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">If to IPH:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Innate Pharma SA</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">121 ancien chemin de
Cassis.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13009 Marseille</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">France</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">***</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNMENT </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General</U>. Except as set forth in Section<B>&nbsp;20.2</B> below, or as otherwise expressly provided with
respect to any right to <FONT STYLE="white-space:nowrap">Sub-license,</FONT> <FONT STYLE="white-space:nowrap">Out-license</FONT> or subcontract set forth in this Agreement, neither this Agreement nor any rights, licenses or obligations hereunder may
be sold, transferred, assigned, assumed, delegated, mortgaged, pledged, hypothecated or encumbered, in whole or in part (each of the foregoing a &#148;<U>Transfer</U>&#148;), by either Party, without the prior written consent of the other Party,
which consent shall not unreasonably be delayed, conditioned or withheld. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Permitted Transfers</U>. Notwithstanding the provisions of the above Section<B>&nbsp;20.1</B>, either Party
may, without the consent of the other Party, transfer or assign this Agreement and any or all of its rights, licenses and obligations hereunder (a)&nbsp;to any Affiliate or successor in interest, or (b)&nbsp;in connection with a Change of Control or
sale, merger or consolidation of all or substantially all of it&#146;s business or assets related to this Agreement, <I>provided that</I>, (i)&nbsp;such Affiliate or other assignee, transferee or successor shall enter into a binding written
agreement by which it shall assume all of such Party&#146;s agreements, undertakings and obligations hereunder; and (ii)&nbsp;NN shall, pursuant to Section<B>&nbsp;12.11</B>, have the right to terminate this Agreement in the event of any Transfer
(including any Change of Control) by IPH pursuant to this Section<B>&nbsp;20.2</B>. &#147;<U>Change of Control</U>&#148; for purposes of this Section<B>&nbsp;20.2</B> shall mean, with respect to a Party, the occurrence of any one or more of the
following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a merger or consolidation of such Party in which the Party&#146;s shareholders or equity owners immediately
prior to such merger or consolidation do not in the aggregate own directly or indirectly at least a majority equity interest and a majority of the voting capital stock or interests in the surviving entity (if the Party is a constituent corporation
in such merger or consolidation) or in the Party (if the Party is not a constituent corporation in such merger or consolidation), as the case may be, immediately following such merger or consolidation; </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sale, lease, exchange or other disposition (in one transaction or a series of transactions) of all or
substantially all of the assets of such Party; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any transaction, circumstance or event that would result in any Person, or any group of Persons acting in
concert, acquiring direct or indirect beneficial ownership of more than fifty percent (50%) of the equity interests or voting capital stock or interests of such Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Deemed Approval</U>. In the event that either Party shall propose a Transfer required to be approved by the
other Party pursuant to Section<B>&nbsp;20.1</B>, such Transfer shall be deemed approved by the other Party in the event that said other Party shall fail to object to the proposed Transfer by written notice to the Party proposing such Transfer sent
within *** after its receipt of the Transferring Party&#146;s written notice of the proposed Transfer setting forth in reasonable detail particulars as to the identity, financial strength and ability of the Person contemplated to receive such
Transfer to perform the agreements, undertakings and obligations of such Party under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Noncompliant Transfers</U>. Any Transfer not in compliance with this Article <B>20</B> will be void ab
initio and of no force or effect and shall constitute a material breach of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Obligation to Obtain Assignments</U>. Each Party shall cause all principals, officers, employees,
contractors, <FONT STYLE="white-space:nowrap">Sub-licensees,</FONT> <FONT STYLE="white-space:nowrap">Out-licensees</FONT> and other Persons who or that perform any research, services or other activities on its behalf in connection with this
Agreement, including any research, discovery, development, improvement or commercialization of any Collaboration Targets, Drug Candidates, Licensed Products, Niche Candidates or Residual Products, or of any Research Technology, Research Technology
IPR, or other IPR comprising or relating to any of the foregoing, to take all actions and sign all documents and instruments (including any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-made-for-hire</FONT></FONT> agreements
or assignments) required to confer upon such Party exclusive ownership of all rights arising from such research, services or activities, so as to enable such Party fully to: (a)&nbsp;grant the rights and licenses it has herein granted;
(b)&nbsp;maintain said rights and licenses in full force and effect throughout the Territory during the applicable Term of their grants hereunder, (c)&nbsp;exercise its rights and perform its obligations hereunder, and (d)&nbsp;consummate the
transactions contemplated by this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Privileged Communications</U>. In furtherance of this Agreement, it is expected that NN and IPH will, from
time to time, disclose to one another privileged communications with counsel, including opinions, memoranda, letters and other written, electronic and verbal communications. Such disclosures shall be made with the understanding that they shall
remain confidential and that they are made in connection with the shared community of legal interests existing between NN and IPH, including the Parties&#146; common legal interest in avoiding infringement of any valid, enforceable Patents and
protecting the ability of the Parties to enforce any IPR that it licensed under this Agreement. In furtherance of the foregoing, </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the Parties shall enter into a mutually acceptable Common Interest Agreement on or within *** after the date of this Agreement in substantive conformity with the form annexed as Schedule
<B>21.2</B> hereto and the Parties shall retain and have benefit of all applicable joint defense, common interest and other privileges and immunities with respect to such documents and information to the full extent available under applicable Law.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Non</U><U><FONT STYLE="white-space:nowrap">-Solicitation</FONT> of Employees</U>. Until the expiration of at
least *** following expiration or termination of the Agreement, neither of the Parties nor any of their respective Affiliates shall intentionally solicit for employment, employ or hire the employees of the other Party. Notwithstanding the foregoing
or any other provisions of this Agreement, neither Party nor any of its Affiliates shall be prohibited from placing help wanted advertisements in its own internal publications, its Web site or any media of general circulation, from posting position
openings at such Person&#146;s places of business, or from hiring an employee of the other Party<B> </B>who answers any advertisement or who otherwise voluntarily applies for hire without having been initially personally solicited or recruited by
the hiring Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Competition Law Submissions</U>. If it is determined that any transaction under this Agreement needs to be
notified to the European Commission or other European Competition Law authority, the Parties shall cooperate in making such notification and in seeking a conclusion of the notification process satisfactory to both Parties. If at any time the
European Commission or controlling authority determines that any provision of this Agreement is unenforceable or otherwise not permitted under the Laws of the European Union or member states, the Parties agree to initiate good faith negotiations
aimed at modifying such provision in a manner that is acceptable to the European Commission or such member states and the Parties and that is consistent with the intent of the Parties under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Relationship of the Parties</U>. The relationship between NN and IPH is that of independent contractors.
This Agreement does not constitute either Party as being the agent or legal representative of the other for any purpose whatsoever. Neither Party is granted any right or authority to assume or to create any obligation or responsibility, express or
implied, on behalf of, or in the name of the other, with regard to any manner or thing whatsoever, unless otherwise specifically and expressly agreed upon in writing. No joint venture, <FONT STYLE="white-space:nowrap">co-venture,</FONT> franchise,
business opportunity, fiduciary, partnership, employment or principal-agent relationship between the Parties is intended, established or evidenced by this Agreement, and neither Party shall have any authority or responsibility with respect to the
other Party&#146;s employees, including in respect of the hiring, termination, compensation or employee benefits of such employees. In furtherance and not in limitation of the foregoing, no fiduciary or quasi-fiduciary relationship does or shall
exist between the Parties by reason of or in connection with this Agreement, in whole or in part, and each of the Parties hereby irrevocably waives any claims and causes of action against the other for the breach of any fiduciary or quasi-fiduciary
duty arising out of or in connection with this Agreement or any performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> hereunder. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Effect of Rejection in Bankruptcy</U>. The Parties expressly acknowledge and agree that the subject matter
of this Agreement, including the Intellectual Property Rights licensed hereunder, are unique and irreplaceable, and that the loss thereof cannot adequately be remedied by an award of monetary compensation or damages. Accordingly, in the event that
IPH, whether directly, or by or through a trustee or similar functionary in bankruptcy acting on behalf of its estate, terminates or rejects this Agreement or NN&#146;s right to continue the licenses under this Agreement, it is the Parties&#146;
express intention and agreement that NN shall continue to have the benefit of all licenses granted to it under this Agreement, which licenses shall remain in full force and effect for the stated Term regardless of any termination or rejection in
bankruptcy of this Agreement or any other terms hereof, such that NN shall have the right, should it so elect, to retain all its license rights under this Agreement under applicable Law (including any applicable principles under, or correlative to,
or no less favourable than, those set forth in Section&nbsp;365(n) of the U.S. Bankruptcy Code, 11 U.S.C. &#167; 365(n)). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Costs and Expenses</U>. Except as otherwise expressly provided in this Agreement, each Party shall bear its
own costs and expenses (including, without limitation, the fees of any attorneys, accountants, investment bankers, consultants or other representatives) incurred in connection with its entry into this Agreement, the transactions contemplated by this
Agreement (whether or not such transactions are consummated), and the exercise of its rights and licenses, and performance of its activities and obligations, hereunder, without charge or expense to the other Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Limitation of Liability</U></B><B>. EXCEPT FOR CLAIMS FOR INDEMNIFICATION PURSUANT TO ARTICLE 16, IN NO
EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INJURY TO OR LOSS OF DATA, GOODWILL, REPUTATION, BUSINESS (</B><B>IRRESPECTIVE OF WHETHER ANY SUCH INJURY OR LOSS IS </B><B>DEEMED</B><B> TO CONSTITUTE GENERAL, DIRECT OR ANY OTHER
CATEGORY OF DAMAGES</B><B>), OR ANY SPECIAL, INDIRECT, PUNITIVE, EXEMPLARY, ENHANCED, TREBLED, INCIDENTAL OR CONSEQUENTIAL DAMAGES WHATSOEVER, ARISING OUT OF OR IN CONNECTION IN ANY WAY WITH THIS AGREEMENT OR ANY SUBJECT MATTER HEREOF (INCLUDING ANY
EXERCISE OF ANY RIGHTS OR LICENSES, OR PERFORMANCE, OR FAILURE TO PERFORM, ANY OBLIGATIONS OR ACTIVITIES HEREUNDER), EVEN IF THE PARTY AGAINST WHOM SUCH LIABILITY IS CLAIMED HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, DAMAGES OR LIABILITIES,
AND WHETHER OR NOT OR SUCH LOSSES, DAMAGES OR LIABILITIES ARISE IN CONTRACT, WARRANTY, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, PRODUCT LIABILITY OR ANY OTHER THEORY OF LIABILITY, </B><B>AND NOTWITHSTANDING THE FAILURE OF ANY AGREED OR OTHER
REMEDY OF ITS ESSENTIAL PURPOSE</B><B>. IN THE EVENT THAT ANY FOREGOING EXCLUSION OR LIMITATION OF LIABILITY IS NOT ALLOWED PURSUANT TO APPLICABLE LAW IN A JURISDICTION, THE LIABILITY OF EACH PARTY IN SUCH JURISDICTION SHALL BE LIMITED TO THE
MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW.</B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severability</U>. If any provision of this Agreement is adjudged to be illegal, invalid or unenforceable in
its current form or scope under any applicable present or future Law, and if the rights or obligations of either Party under this Agreement shall not be materially and adversely affected thereby, (a)&nbsp;such provision shall be fully severable,
(b)&nbsp;this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c)&nbsp;the remaining provisions of this Agreement shall remain in full force and effect and shall not
be affected by the illegal, invalid or unenforceable provision or by its severance herefrom, and (d)&nbsp;in lieu of such severed provision, there shall be substituted as a part of this Agreement, a legal, valid and enforceable provision as similar
in terms to such severed provision as may be possible so as to effect, as closely as possible, the intent of the Parties in entering into this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IPH Financial Information</U>. IPH agrees to keep NN informed as to its financial condition throughout the
Term of this Agreement. If at any time the financial resources of IPH are not reasonably sufficient to enable it to continue to meet its obligations hereunder for at least the coming ***, the Parties will meet to review and consider steps that might
be taken to preserve the objectives of the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Waiver</U>. Either Party may waive any term, condition, or obligation of this Agreement which is for its
benefit, but only in a signed writing. The failure or delay of either Party to enforce at any time any provision of this Agreement, or any right with respect thereto, or to exercise any election herein provided, shall in no way be considered to be a
waiver of such provision, right or election, or in any way affect the validity of this Agreement. Except as otherwise expressly herein provided, the exercise by either Party of any right or election under the terms or covenants herein shall not
preclude or prejudice such Party from exercising the same or any other right it may have under this Agreement, irrespective of any previous action or proceeding taken by the Parties hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendment</U>. Except as otherwise expressly provided herein or required by Law, this Agreement may be
modified or amended only by a written document signed by both Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Applicable Law</U>. Except as otherwise indicated herein, this Agreement, and the rights and obligations of
the Parties hereunder, shall be construed and governed, including, without limitation, as to validity, interpretation and effect, by the internal laws of England. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Dispute Resolution</U>. Both Parties will use their best efforts to settle all matters in dispute amicably.
In the event that a dispute of any kind related to this Agreement cannot be solved amicably by the Parties, then either Party may submit the dispute for determination by binding arbitration before a panel of three arbitrators (one arbitrator chosen
by each of the parties and the third arbitrator chosen by the first two, unless the parties agree otherwise), the third arbitrator having a minimum of *** of experience in the field of biotechnology or pharmaceuticals and shall be administered under
the WIPO Expedited Arbitration Rules except as to the number of arbitrators which shall be three (3). The venue for the arbitration shall be in London, England, conducted in the English language, and, except to the extent otherwise expressly herein
provided, the governing law shall be that of England and Wales without regard to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">conflicts-of-laws</FONT></FONT> provisions of such laws. The arbitrators shall have the authority
to grant </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this
agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
specific performance and to allocate between the parties the costs of arbitration, including but not limited to reasonable attorney&#146;s fees, in such equitable manner as they determine.
Notwithstanding the foregoing dispute resolution and governing law provisions, each of Licensor and Licensee retains the right to seek judicial injunctive relief. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Further Assurances</U>. Each Party shall provide such full and continuing cooperation and assistance to the
other Party as may be reasonable and necessary to secure, perfect, defend, protect or enforce any of such other Party&#146;s rights or licenses under this Agreement, including any right, title or interest of such other Party in respect of any
Intellectual Property Rights that are subject to the terms hereof, and shall duly execute and deliver, or cause to be duly executed and delivered, such documents and instruments and do and cause to be done such acts and things, including the
execution and filing of such assignments, agreements, powers and other documents and instruments, as may be necessary, or as the other Party may reasonably request, to carry out more effectively the provisions and purposes of, or to better assure
and confirm unto the other Party its rights and remedies under, this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Entire Agreement</U>. This Agreement, including all annexed schedules and exhibits, together with the Share
Purchase Agreement, sets forth the entire agreement between the Parties, fully superseding any and all prior and contemporaneous negotiations, agreements, representations or understandings between them, whether oral or written, pertaining to the
subject matter hereof. The Parties hereby expressly confirm that there are no other oral or written agreements, &#148;<U>side-deals,</U>&#148; arrangements or understandings between them with respect to the subject matter hereof other than as
expressly stated otherwise in this Agreement or the Share Purchase Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts</U>. This Agreement may be executed in two (2)&nbsp;or more counterparts, each of which shall
constitute an original for all purposes, including for purposes of any delivery of this Agreement required by the terms hereof, and all of which together shall constitute one and the same instrument with the same effect as if all Parties hereto had
signed the same document. Once this Agreement has been duly executed, any faithful reproduction by reliable means (such as by photocopying or facsimile) of a duly executed original of this document shall constitute and be effective as an original of
this Agreement for all purposes, including for purposes of any delivery of this Agreement required by the terms hereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed, under seal, by their respective duly
authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Marseille</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Bagsvaerd</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: March <U>28</U>, 2006</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Date: March <U>28</U>, 2006</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Innate Pharma SA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Novo Nordisk A/S</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Herv&eacute; Brailly</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Terje Kalland</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Herv&eacute; Brailly</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Terje Kalland</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Senior Vice President,<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biopharmaceuticals Research Unit</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table of Contents </U></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">1.&#8195;&#8194;&#8201;DEFINITIONS AND CONSTRUCTION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">1.1&#8195;&#8201;Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">1.2&#8195;&#8201;Definitions of other terms used in this Agreement:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">1.3&#8195;&#8201;Construction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">2.&#8195;&#8194;&#8201;NATURE OF AGREEMENT AND PRIVILEGED COMMUNICATIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">2.1&#8195;&#8201;Collaboration Exclusivity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">2.2&#8195;&#8201;Joint Research Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">2.3&#8195;&#8201;Kirostim Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.&#8195;&#8194;&#8201;COLLABORATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.1&#8195;&#8201;Collaboration Objective</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.2&#8195;&#8201;Duration of the Collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.3&#8195;&#8201;Third Party Collaborations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.4&#8195;&#8201;Presentation of In-Licensing and New Third Party Collaboration
Opportunities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.5&#8195;&#8201;Obligation to Diligently Seek Sub-License Rights in All Collaborations with
Third Parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.6&#8195;&#8201;Collaboration Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.7&#8195;&#8201;Commercially Reasonable Efforts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.8&#8195;&#8201;Legal Compliance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.9&#8195;&#8201;Research Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.10&#8194;&#8201;Project Groups</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.11&#8194;&#8201;Project Managers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.12&#8194;&#8201;Research Funding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">4.&#8195;&#8194;&#8201;MANAGEMENT OF THE COLLABORATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">4.1&#8195;&#8201;Project Group Decisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">4.2&#8195;&#8201;Joint Steering Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">4.3&#8195;&#8201;Duties of Joint Steering Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">4.4&#8195;&#8201;Participation in Committee Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">4.5&#8195;&#8201;Decision-making Procedures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">4.6&#8195;&#8201;Disputes and Continued Performance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">4.7&#8195;&#8201;Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">4.8&#8195;&#8201;Limited Authority</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">4.9&#8195;&#8201;Development and Commercialization Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.&#8195;&#8194;&#8201;GRANT OF RIGHTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.1&#8195;&#8201;NN Licenses in the Field</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.2&#8195;&#8201;NN License to Collaboration IPR Outside the Collaboration Field</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.3&#8195;&#8201;Grant Backs to IPH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.4&#8195;&#8201;IPH Licenses to NN Background Research Technology IPR and NN Controlled
Collaboration IPR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.5&#8195;&#8201;Future IPH License in the Field for Niche Candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.6&#8195;&#8201;Sub-licensing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.7&#8195;&#8201;Regulatory Exclusivity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table of Contents </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.8&#8195;&#8201;Freedom of Operation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.9&#8195;&#8201;Terminated Collaboration Properties and Out-licensing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.10&#8194;&#8201;Procedure for Terminating Background IPR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.11&#8194;&#8201;NN Out-licensing and Upside Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.12&#8194;&#8201;Cumulative Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">5.13&#8194;&#8201;Future Obligation to Provide Licensees Under Specific Third Party Agreements
in Deemed Necessary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">6.&#8195;&#8194;&#8201;NICHE CANDIDATES AND EX-VIVO CELLULAR THERAPY CANDIDATES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">6.1&#8195;&#8201;Niche Candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">6.2&#8195;&#8201;Ex-Vivo Cellular Therapy Candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">6.3&#8195;&#8201;IPH Royalty Obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">6.4&#8195;&#8201;IPH Access to Materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">6.5&#8195;&#8201;NN Buy-In Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">6.6&#8195;&#8201;NN Co-Marketing Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">6.7&#8195;&#8201;IPH Assistance to NN Upon NN Exercise of Buy-In or Co-Marketing
Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">6.8&#8195;&#8201;Licenses to NN for Niche Candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">6.9&#8195;&#8201;Exclusion of Funded FTEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">7.&#8195;&#8194;&#8201;TECHNOLOGY FEES, MILESTONES AND ROYALTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">7.1&#8195;&#8201;Consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">7.2&#8195;&#8201;Technology Access Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">7.3&#8195;&#8201;Discovery Milestones</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">7.4&#8195;&#8201;Development Milestone Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">7.5&#8195;&#8201;Royalty Calculation and Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">7.6&#8195;&#8201;Royalties on Licensed Products</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">7.7&#8195;&#8201;Royalties on Residual Products</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">7.8&#8195;&#8201;Royalties on Niche Candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">7.9&#8195;&#8201;Records of Net Sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">7.10&#8194;&#8201;Annual Recalculation and Report</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">7.11&#8194;&#8201;Royalty Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">7.12&#8194;&#8201;No Effect of Out-licensing on Royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">8.&#8195;&#8194;&#8201;FINANCIAL PROVISIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">8.1&#8195;&#8201;Payment by Wire Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">8.2&#8195;&#8201;Currency</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">8.3&#8195;&#8201;Withholding Tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">8.4&#8195;&#8201;Audits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">8.5&#8195;&#8201;Cost of Audit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">8.6&#8195;&#8201;Right to Audit Third Parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.&#8195;&#8194;&#8201;INTELLECTUAL PROPERTY RIGHTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.1&#8195;&#8201;Disclosure of Know-How</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.2&#8195;&#8201;Ownership of Collaboration IPR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.3&#8195;&#8201;Disputes Regarding Inventorship or Ownership of Collaboration IPR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table of Contents </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.4&#8195;&#8201;Duty to Require Assignment of Collaboration IPR by Employees, Consultants, and
Collaboration Partners</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.5&#8195;&#8201;Obligations to Maintain Control of Licensed IPR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.6&#8195;&#8201;Prosecution of Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.7&#8195;&#8201;Updating of Patent Schedules and Patent Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.8&#8195;&#8201;Patent Term Extension</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.9&#8195;&#8201;License Registration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.10&#8194;&#8201;No Implied Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.11&#8194;&#8201;Notice of Infringement or Misappropriation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.12&#8194;&#8201;Exclusive First Right of Enforcement of Licensed IPR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.13&#8194;&#8201;Second (&#147;March-In&#148;) Enforcement Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.14&#8194;&#8201;Share of Recoveries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.15&#8194;&#8201;Third Party Litigation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.16&#8194;&#8201;Cooperation in Legal Proceedings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.17&#8194;&#8201;Trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.18&#8194;&#8201;Determination of Patent Issues to be Made Under Applicable National
Law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.19&#8194;&#8201;Acknowledgment of Intellectual Property Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">9.20&#8194;&#8201;Survival</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">10.&#8195;&#8201;CONFIDENTIAL INFORMATION AND MATERIALS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">10.1&#8194;&#8201;Superseding of Prior Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">10.2&#8194;&#8201;Confidentiality and Use Restrictions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">10.3&#8194;&#8201;Disclosures to Authorized Persons</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">10.4&#8194;&#8201;Material Transfer Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">10.5&#8194;&#8201;Additional Terms of Confidentiality</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">10.6&#8194;&#8201;Permitted Disclosures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">10.7&#8194;&#8201;Required Notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">10.8&#8194;&#8201;Relief</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">11.&#8195;&#8201;DURATION OF THE AGREEMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">12.&#8195;&#8201;MATERIAL BREACH AND TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">12.1&#8194;&#8201;Material Breach, Damages and Termination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">12.2&#8194;&#8201;Breach of Confidentiality Resulting in Loss of Patent Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">12.3&#8194;&#8201;Termination for Convenience</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">12.4&#8194;&#8201;Termination for Material Breach</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">12.5&#8194;&#8201;Establishing Materiality and Scope of Alleged Breach</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">12.6&#8194;&#8201;Termination Upon Bankruptcy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">12.7&#8194;&#8201;Development Diligence Requirements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">12.8&#8194;&#8201;Termination for Failure to Employ Commercially Reasonable Efforts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">12.9&#8194;&#8201;Development or Marketing of Other Products</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">12.10&#8201;Determination of Abandonment and Opportunity to Remedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">12.11&#8201;Termination for IPH Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">12.12&#8201;Survival of Terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table of Contents </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">13.&#8195;&#8201;CONSEQUENCES OF TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">13.1&#8194;&#8201;General</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">13.2&#8194;&#8201;Costs for Regulatory Documentation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">13.3&#8194;&#8201;Expiration of Collaboration Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">13.4&#8194;&#8201;NN Termination for Convenience Prior to Expiration of Collaboration
Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">13.5&#8194;&#8201;Termination for IPH Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">13.6&#8194;&#8201;Termination for NN&#146;s Material Breach</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">13.7&#8194;&#8201;Termination for IPH&#146;s Material Breach</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">13.8&#8194;&#8201;M1 Grace Period and Audit Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">13.9&#8194;&#8201;Cumulative Remedies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">14.&#8195;&#8201;EQUITY FINANCING AND FUTURE IPO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">14.1&#8194;&#8201;Equity Investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">14.2&#8194;&#8201;Underwriting of IPO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">15.&#8195;&#8201;REPRESENTATIONS AND WARRANTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">15.1&#8194;&#8201;Mutual Representations and Warranties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">15.2&#8194;&#8201;Disclaimer of Warranty</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">15.3&#8194;&#8201;IPH Representations and Warranties In Respect of IPR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">16.&#8195;&#8201;INDEMNIFICATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">16.1&#8194;&#8201;Mutual Indemnification</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">16.2&#8194;&#8201;Indemnification Procedure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">17.&#8195;&#8201;FORCE MAJEURE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">18.&#8195;&#8201;PUBLICATIONS AND DISCLOSURES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">18.1&#8194;&#8201;Publication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">18.2&#8194;&#8201;Communication Guidelines</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">18.4&#8194;&#8201;Disclosure of Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">19.&#8195;&#8201;NOTICES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">20.&#8195;&#8201;ASSIGNMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">20.1&#8194;&#8201;General</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">20.2&#8194;&#8201;Permitted Transfers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">20.3&#8194;&#8201;Deemed Approval</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">20.4&#8194;&#8201;Noncompliant Transfers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">21.&#8195;&#8201;MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">21.1&#8194;&#8201;Obligation to Obtain Assignments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">21.2&#8194;&#8201;Privileged Communications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">21.3&#8194;&#8201;Non-Solicitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">21.4&#8194;&#8201;Competition Law Submissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">21.5&#8194;&#8201;Relationship of the Parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">21.6&#8194;&#8201;Effect of Rejection in Bankruptcy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table of Contents </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">21.7&#8195;&#8201;Costs and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">21.8&#8195;&#8201;Limitation of Liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">21.9&#8195;&#8201;Severability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">21.10&#8194;&#8201;IPH Financial Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">21.11&#8194;&#8201;Waiver</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">21.12&#8194;&#8201;Amendment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">21.13&#8194;&#8201;Applicable Law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">21.14&#8194;&#8201;Dispute Resolution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">21.15&#8194;&#8201;Further Assurances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">21.16&#8194;&#8201;Entire Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.50em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">21.17&#8194;&#8201;Counterparts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>GUIDE TO SCHEDULES </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Subject Matter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Content on <BR>date&nbsp;of&nbsp;Agreement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Updating Obligation</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Background IPH IPR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">For inclusion of related Patents (continuations, foreign counterparts, issued patents, etc.) or removal of Patents (due to abandonment, etc.) only (&#167;9.7.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Background IPH Research Technology IPR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">For inclusion of related Patents or removal of Patents only (&#167;9.7.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Background NN IPR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">For either inclusion of related Patents or removal of Patents (&#167;9.7.2) or to include certain other identified Patents (&#167;1.1.7)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Background NN Research Technology IPR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">For either inclusion of related Patents or removal of Patents only (&#167;9.7.2)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;A Licensed Products</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">None (not to be updated)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;B Licensed Products</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by agreement of Parties (&#167;1.1.12; &#167;4.3(f)) or due to acquisition of certain Third Party IPR by IPH (&#167;3.4.2(a))</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class&nbsp;C Licensed Products</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by the Joint Steering Committee (&#167;4.3(f))</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Biological Targets for which IPH has previously licensed diagnostic rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">None</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Collaboration IPR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes (Kirostim Patents)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by NN using NN and IPH information (&#167;9.7.3)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes (Kirostim <FONT STYLE="white-space:nowrap">Know-How)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by Joint Steering Committee (&#167;4.3(u))</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Collaboration Targets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by Joint Steering Committee (&#167;4.3(h))</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.31</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Drug Discovery Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by the Parties pursuant to Joint Steering Committee recommendation (&#167;4.3(o))</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Subject Matter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Content on <BR>date&nbsp;of&nbsp;Agreement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Updating Obligation</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.33</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exploratory Targets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by the Joint Steering Committee (&#167;1.1.33; &#167;4.3(e))</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.41</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Intermediate Discovery Milestone</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">None</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">M0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">None</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">M1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">None</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Target Discovery Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">No</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by the Parties pursuant to Joint Steering Committee recommendation (&#167;4.3 (a) and (o))</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.69&nbsp;A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">NN Third Party Collaborations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">None</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.69&nbsp;B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">IPH Third Party Collaborations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">None</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1.69 C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New Collaborations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">No</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by the Parties upon approval of Joint Steering Committee (&#167;3.4)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">NN policy for use of animals for laboratory research purposes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes (&#167;3.8)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ex vivo Task Force Particulars</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">No</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Ex-vivo</FONT> Task Force (&#167;6.2)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.5.4 A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent NN IPR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">No</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by Parties pursuant to (&#167;9.5.4)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.5.4 B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent IPH IPR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">No</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by Parties pursuant to (&#167;9.5.4)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Material Transfer Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joint Steering Committee may under &#167;10.4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">18.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Communication Guidelines</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">None</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">21.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Community Interest Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">None</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Background IPH IPR </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>***
</B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Background IPH Research Technology IPR</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Background NN IPR </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Background NN Research Technology IPR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.11 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;A Licensed Products </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;B Licensed Products </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.13 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;C Licensed Products </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.15 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Specified antibodies excluded from use in the Collaboration for diagnostics purposes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Collaboration IPR </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.17 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.22 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Collaboration Targets </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">***
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.31 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Drug Discovery Plan </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Part 1
of 2 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.31 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Drug Discovery Plan </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Part 2
of 2 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.33 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exploratory Targets </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>***
</B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.41 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Intermediate Discovery Milestone Criteria for NKG2A and NKG2D Collaboration projects </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.51 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Definition of M0 criteria&nbsp;: NN Biopharmaceutical Research Board </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.52 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Definition of M1 criteria&nbsp;: NN Biopharmaceutical Research Board </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.65 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Target Discovery Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Research Program: <FONT STYLE="white-space:nowrap">Pre-project</FONT> activities </B></P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.69 A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Third-Party Collaborations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NN Collaborations Relevant to this Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.69 B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Third-Party Collaborations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Innate Pharma Collaborations Relevant to this Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.69 C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Third-Party Collaborations </B></P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 3.8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Novo Nordisk Principles for the Use of Animals </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 6.2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Recommendations of the <FONT STYLE="white-space:nowrap">Ex-vivo</FONT> Task Force </B></P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 9.5.4 A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Independent NN IPR </B></P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 9.5.4 B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Independent IPH IPR </B></P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 10.4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MATERIAL TRANSFER AGREEMENT </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Between</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Innate Pharma S.A.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">Gran Pre
119/121 ancien chemin de Casiss</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">13009 Marseille</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">France</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(hereinafter referred to as INNATE PHARMA)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">and&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[XXXX]</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">[Address]</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(hereinafter referred to as RECIPIENT)</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INNATE PHARMA and RECIPIENT are hereinafter also referred to individually as &#147;Party&#148; and collectively as
&#147;Parties&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PREAMBLE </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">INNATE PHARMA has valuable material and information concerning
<FONT STYLE="white-space:nowrap">non-conventional</FONT> lymphocytes such as natural killer (NK) cells ; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%" VALIGN="top" ALIGN="left">WHEREAS</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RECIPIENT desires to obtain such material and/or information solely for evaluation purposes;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, the Parties have agreed on the following terms: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 1 - DEFINITIONS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Definitions to this Agreement: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;</B>Samples&#148; shall mean those biological, chemical or other materials described in Article 2.1
and listed in <B>Appendix A</B>, or such other compounds and/or tangible material as INNATE PHARMA should deliver to RECIPIENT. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;</B>Information&#148; shall mean any and all information disclosed by INNATE PHARMA to RECIPIENT in
oral, visual, written, or electronic form under this Agreement. &#147;Information&#148; shall also mean any and all technical or <FONT STYLE="white-space:nowrap">non-technical</FONT> information obtained in any form by RECIPIENT during observation
or examination of the foregoing or the samples, which may include, but is not limited to, technical processes, specifications, instrumentation, chemical formulae, assays, manufacturing techniques, sales and marketing information, material, or data.
This also includes any other confidential information about INNATE PHARMA obtained through the disclosure of information and samples, as well as the fact that disclosure has taken place. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;Samples&#148; and &#147;Information&#148; are hereinafter referred to as INFORMATION.
</P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 2 - CONFIDENTIALITY </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement will come into force on the date of the last signature hereto. In consideration of any
disclosure at any time by INNATE PHARMA to RECIPIENT of INFORMATION in whatever form on the subject of natural killer cells and natural killer cell inhibitory receptors, as well as their applications in human therapeutics and diagnostics.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">RECIPIENT undertakes from the date of disclosure to treat all received INFORMATION as strictly confidential for a period
of *** from date of disclosure and therefore not to disclose it to any third party without the prior written and express consent of INNATE PHARMA and to make no use of it, except as specifically provided for in Article 4, without the prior written
and express consent of INNATE PHARMA in each case. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RECIPIENT may disclose INFORMATION only to reliable employees who need to know in order to carry out the
evaluations under this Agreement, provided that such persons are bound by obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> to RECIPIENT which are equal to the terms of this Agreement. RECIPIENT shall ensure that
such employee(s) are fully aware of the obligations of this Agreement and shall be responsible for any breach of these provisions by its employee(s). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 3 - NON-DISCLOSURE AND EXCEPTIONS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The obligations set forth in Article 2 above shall not apply to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">INFORMATION which at the time of disclosure is already in the public domain; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">INFORMATION which, after disclosure, becomes part of the public domain through no violation of this Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">INFORMATION which RECIPIENT is able to prove to have been in possession of prior to disclosure by INNATE
PHARMA. In this case, RECIPIENT will, in writing and within *** from the date of disclosure, demonstrate to the satisfaction of INNATE PHARMA that it was in possession of such INFORMATION; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">INFORMATION which is hereafter lawfully disclosed by a third party to RECIPIENT, which INFORMATION such third
party did not acquire under a still effective obligation of confidentiality to INNATE PHARMA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">INFORMATION that can be demonstrated as independently developed or acquired by RECIPIENT without reference to
or reliance upon confidential INFORMATION defined in this Agreement, as evidenced by RECIPIENT&#146;s written records; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">INFORMATION disclosed to the extent required by law or regulation provided that RECIPIENT shall give INNATE
PHARMA prompt written notice and sufficient opportunity to object, time permitting, to such disclosure. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RECIPIENT shall keep INNATE PHARMA fully and effectively indemnified against any and all losses, expenses, and
damages suffered by INNATE PHARMA arising from any unauthorised disclosure or use of any part of INFORMATION by RECIPIENT or RECIPIENT&#146;s employees, including, but not limited to, reasonable attorney&#146;s fees and costs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>RECIPIENT shall not publish or otherwise disseminate such results of the disclosure of INFORMATION, or
any raw data generated thereby without the prior and express written permission of INNATE PHARMA. At least *** prior to making any submission for publication or other public disclosure in which any direct or indirect reference is made to
INFORMATION, RECIPIENT agrees to provide INNATE PHARMA with a copy thereof for review and comment. INNATE PHARMA shall be entitled to postpone the intended publication or other disclosure if in the opinion of INNATE PHARMA, publication or other
disclosure is believed to interfere with INNATE PHARMA patent work or involves <FONT STYLE="white-space:nowrap">know-how,</FONT> results or other confidential information developed by INNATE PHARMA or RECIPIENT and relating to INFORMATION.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 4 - USE OF THE INFORMATION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RECIPIENT hereby agrees to use INFORMATION in compliance with any and all applicable law or regulation.
RECIPIENT shall keep INNATE PHARMA informed of all uses made of INFORMATION. RECIPIENT shall provide INNATE PHARMA with a full copy of its protocol and study design for approval by INNATE PHARMA prior to the furnishing of INFORMATION. Any and all
changes in such protocol and study design shall forthwith be submitted, in writing, to INNATE PHARMA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RECIPIENT shall not use INFORMATION for any purpose other than the evaluation purposes described in this
Agreement. Samples provided under this Agreement shall not be analysed or used except to the extent necessary to carry out such evaluation. RECIPIENT also agrees not to use INFORMATION to make more compound, and not to use INFORMATION in research
subject to consulting, licensing, or other obligations, to any third party. RECIPIENT certifies that it is regularly engaged in conducting tests in vitro or in laboratory research animals. INFORMATION will be used for tests in vitro or in laboratory
research animals only and will not be administered to humans. No animal used in such tests will be used for any food purposes, as domestic pets, or as livestock. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>INFORMATION is the sole property of INNATE PHARMA and nothing in this Agreement shall be construed as
granting to RECIPIENT, by implication or otherwise, any right or license with respect to INFORMATION, or any patent applications, patents or any claims of patent now or hereafter filed or issued with respect to INFORMATION, and RECIPIENT is
obligated to refrain from filing applications or otherwise seeking proprietary rights and protection in respect of INFORMATION. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any and all industrial and/or intellectual property rights including, but not limited to, results, inventions,
improvements, and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to INFORMATION or use by RECIPIENT of INFORMATION shall be the sole property of INNATE PHARMA and shall be included in the secrecy obligation of this Agreement. To safeguard
the interests of INNATE PHARMA in </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been
excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
results, inventions, improvements, and <FONT STYLE="white-space:nowrap">know-how,</FONT> RECIPIENT shall forthwith inform INNATE PHARMA in the event of these in full detail, including all raw
data. RECIPIENT undertakes to assign free of charge to INNATE PHARMA any such result, invention, improvement, and/or <FONT STYLE="white-space:nowrap">know-how.</FONT> RECIPIENT agrees to do any reasonable act or thing or execute any reasonably
required document to give effect to the foregoing. Upon completion of the evaluation by RECIPIENT of INFORMATION, RECIPIENT undertakes to return to INNATE PHARMA all INFORMATION received hereunder and any material, data, and results derived from
such INFORMATION and all copies hereof as well as any remaining sample. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RECIPIENT acknowledges that INFORMATION is provided &#147;as is&#148; and without any representation or
warranty, express or implied, as to the accuracy or completeness of INFORMATION, including, without limitation, any implied warranty of merchantability or fitness for a particular purpose, or any warranty that the use of INFORMATION will not
infringe or violate any patent or other proprietary rights of any third party. Acceptance of INFORMATION will constitute acceptance by RECIPIENT of liability for any damages or injuries resulting from its possession or use of INFORMATION.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 5 - GOVERNING LAW AND DISPUTE RESOLUTION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Both parties will use their best efforts to settle all matters in dispute amicably. All disputes and
differences of any kind related to this Agreement, which cannot be solved amicably by the parties, shall be referred to arbitration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>All disputes arising out of or in connection with the present contract shall be finally settled under
the Rules of Arbitration of the International Chamber of Commerce by one arbitrator appointed in accordance with the said Rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The arbitration shall take place in Copenhagen and shall be conducted in the English language. The award of the
arbitrator shall be final and binding on both parties. The parties bind themselves to carry out the awards of the arbitrator. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This contract shall be construed and interpreted pursuant to the laws of Denmark to the exclusion of any rule
that would refer the subject matter to another forum. The English wording in this Agreement shall prevail. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 6 - SIGNATURE
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each person signing below and each Party on whose behalf such person executes this Agreement warrants that he
or it, as the case may be, has the authority to enter into this Agreement and perform the obligations herein. </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SIGNED BY: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">INNATE PHARMA A/S</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">[XXXX]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: [Insert full name and title in print]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By: [Insert full name and title in print]</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">APPENDIX A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Complete list of samples/quantities provided to RECIPIENT: </P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 18.2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Communication Guidelines </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>*** </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 21.2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Community Interest Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMUNITY OF INTEREST AGREEMENT BETWEEN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVO NORDISK A/S AND INNATE PHARMA SA REGARDING POTENTIAL </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LITIGATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%" VALIGN="top" ALIGN="left">Whereas</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Novo Nordisk A/S (&#147;NN&#148;) and Innate Pharma SA (&#147;IPH&#148;), are considering entering into a
relationship concerning certain technology relating to the Collaboration Field as defined and described in a Joint Research, Development, Option and License Agreement by and between the parties dated March&nbsp;28, 2006 (TECHNOLOGY);
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%" VALIGN="top" ALIGN="left">Whereas</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN and IPH believe that litigation concerning such TECHNOLOGY may occur; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%" VALIGN="top" ALIGN="left">Whereas</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN and IPH share a common interest concerning this potential litigation concerning the TECHNOLOGY;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%" VALIGN="top" ALIGN="left">Whereas</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN and IPH have mutually concluded that their interests will be best served by sharing certain work product and
privileged information concerning this potential litigation in confidence for their common purpose and mutual interest and benefit; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%" VALIGN="top" ALIGN="left">Whereas</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN and IPH wish to avoid any suggestion of waiver of the confidentiality of trade secret, work product and
privileged information and documents, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NN and IPH have agreed to enter into this COMMUNITY OF INTEREST Agreement (the
&#147;Agreement&#148;) regarding potential litigation concerning the TECHNOLOGY. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Definitions</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The term TECHNOLOGY includes without limitation the parties&#146; respective interests in and actions concerning the certain technology
discussed above, and party or <FONT STYLE="white-space:nowrap">non-party</FONT> United States patents concerning such technology. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Solely
for purposes of this Agreement, the term &#147;NN&#148; includes any and all of its corporate affiliates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Solely for purposes of this
Agreement, the term &#147;IPH&#148; includes any and all of its corporate affiliates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The term &#147;NN&#148; includes (i)&nbsp;any
employees or agents of NN; (ii)&nbsp;all outside, <FONT STYLE="white-space:nowrap">in-house</FONT> and other counsel for NN; and (iii)&nbsp;any experts or consultants retained by NN. </P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The term &#147;IPH&#148; includes (i)&nbsp;any employees or agents of IPH; (ii)&nbsp;all outside,
<FONT STYLE="white-space:nowrap">in-house</FONT> and other counsel for IPH; and (iii)&nbsp;any experts or consultants retained by IPH. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The
term &#147;party&#148; refers to NN or IPH. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The term &#147;parties&#148; refers to NN and IPH. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The term <FONT STYLE="white-space:nowrap">&#147;non-party&#148;</FONT> refers to any person or entity other than the parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The term &#147;COMMUNITY OF INTEREST communications&#148; means all ideas, information, data, materials and other tangible or intangible matter
comprising, concerning or relating to TECHNOLOGY in whatever form transmitted by and between the parties that would (if not so transmitted) otherwise be subject to the work product doctrine or the attorney-client, trade secret or any other
applicable protection or privilege. COMMUNITY OF INTEREST communications includes, but is not limited to all communications between NN and IPH including witness interviews and communications among counsel. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Agreement</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In view of the foregoing, the parties agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">COMMUNITY OF INTEREST communications shall be used solely in connection with the preparation, prosecution or defense of potential, agreed upon
litigation concerning the TECHNOLOGY. The parties will not use one another&#146;s COMMUNITY OF INTEREST communications or disclose one another&#146;s COMMUNITY OF INTEREST communications to any third party without prior consent from the party who
originally provided such COMMUNITY OF INTEREST communication (the &#147;disclosing party&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">It is the desire, intention, and mutual
understanding of the parties that </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the parties&#146; disclosure of COMMUNITY OF INTEREST communications to one another is not intended to, and
shall not, waive or diminish in any way the confidentiality of such COMMUNITY OF INTEREST communications or their continued protection under the attorney-client privilege, the work product doctrine or any other applicable privileges or protections,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all COMMUNITY OF INTEREST communications provided by a party pursuant to this Agreement that are entitled to
protection under the attorney-client privilege, the work product doctrine or other applicable privileges or protections, shall remain entitled to such protection under the joint defense doctrine and common interest privilege, and may not be
disclosed to any <FONT STYLE="white-space:nowrap">non-party</FONT> except as provided in Paragraph 3 or 5, as applicable, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all COMMUNITY OF INTEREST communications shall be treated and maintained by the parties as privileged and
confidential communications in pursuit of their common interest. </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Disclosure To Any <FONT STYLE="white-space:nowrap">Non-Party</FONT></U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">COMMUNITY OF INTEREST communications may not be disclosed to any <FONT STYLE="white-space:nowrap">non-party,</FONT> except on the explicit
advance written consent of the disclosing party. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Confidentiality</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">COMMUNITY OF INTEREST communications shall continue to be held confidential by the parties as joint prosecution defence communications fully
subject to the nondisclosure use and other terms and conditions of this Agreement even if adversity of interests should be subsequently be discerned or arise between the parties and regardless of whether the COMMUNITY OF INTEREST relationship
becomes inapplicable thereafter. In the event that a party determines that it no longer has a mutuality of interest with the other party with regard to litigation in respect of the TECHNOLOGY, such party shall terminate this Agreement. Each party
has a duty to terminate the Agreement when, in good faith, it reasonably believes that a commonality of interest no longer exists and to give prompt written notice of such termination to the other party pursuant to Paragraph 7. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U><FONT STYLE="white-space:nowrap">Non-Party&#146;s</FONT> Request Of COMMUNITY OF INTEREST
Communication</U> </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If any <FONT STYLE="white-space:nowrap">non-party</FONT> requests or demands, by subpoena or
otherwise, any COMMUNITY OF INTEREST communication from either party, the party receiving such request or demand will (i)&nbsp;immediately notify the other Party and (ii)&nbsp;decline to produce the requested COMMUNITY OF INTEREST communication,
unless the privilege is waived by the disclosing party. Each party shall take all steps necessary to permit the assertion of all applicable rights, privileges and protections with respect to such COMMUNITY OF INTEREST communications and the parties
shall cooperate fully with one another in any proceedings relating to the disclosure of COMMUNITY OF INTEREST communications. Nothing in this Agreement shall require either party to refuse to obey any court order which has not been stayed. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Violation Of Agreement</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A violation of this Agreement by either party shall not be deemed to destroy the COMMUNITY OF INTEREST privilege, or be deemed a waiver of the
attorney-client privilege, the work product doctrine or any other subject matter whatsoever, including any applicable doctrine or privilege. </P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Termination</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Either party may terminate its participation in this Agreement by providing notice in writing to the other party. Such notice shall become two
(2)&nbsp;business days after receipt of the notice of termination by the <FONT STYLE="white-space:nowrap">non-terminating</FONT> Party and shall operate prospectively only. Such termination shall not affect the privileged nature of COMMUNITY OF
INTEREST communications made between the parties prior to the termination of this Agreement. Upon termination of this Agreement or demand, each party shall return all COMMUNITY OF INTEREST communications to the disclosing party. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Exchange Of Materials</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">All materials that are exchange pursuant to this Agreement shall be marked and identified as being provided with the following language:
&#147;Confidential and privileged communication produced pursuant to joint defence agreement.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Disclosure of COMMUNITY OF INTERST Communications</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Each party shall provide reasonable advance notice to the other party of the identity of any counsel, experts or consultants to whom the party
intends to convey COMMUNITY OF INTEREST communications. Unless prior written consent to such disclosure is received from the disclosing party, the receiving party may not disclose any COMMUNITY OF INTEREST communications received from the disclosing
party to any counsel, experts or consultants of the receiving party except </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(a) attorneys for the receiving party (and their legal
assistants and support staff) who are (1)&nbsp;directly employed by the receiving party or by an affiliate of such party (including such party&#146;s direct or indirect parent or a direct or indirect subsidiary of a direct or indirect parent of such
party); and (2)&nbsp;responsible, on behalf of their employer, for agreed upon litigation concerning the TECHNOLOGY as set forth above; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(b) outside counsel of record in such litigation for the receiving party; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(c) legal assistants and support staff who are directly employed by or retained by such outside counsel in the prosecution or defen<B>c</B>e
of such litigation. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Written Records</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Each party shall maintain written records identifying persons having access to COMMUNITY OF INTEREST communications received from the other
party. Any expert witness, consultant or counsel to whom COMMUNITY OF INTEREST communications are provided shall agree, in writing, to be bound by the terms of this Agreement and to ensure that those of their employees who are permitted access to
any COMMUNITY OF INTEREST communications are specifically advised of, and bound by, the terms hereof. </P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Disclosures Between The Parties</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Agreement does not create any duty requiring disclosure between the parties. Each party retains the right to refuse to produce to the
other Party any COMMUNITY OF INTEREST communication. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Attorney-Client Relationship</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Nothing in this Agreement shall be construed to create a new attorney-client relationship whether express or implied. Each party represents and
acknowledges that it is represented exclusively by its own Attorney and agrees that nothing in this Agreement shall be construed to affect the separate and independent representation of either Party by its own respective counsel. Each Attorney
participating in the joint defence is obligated to maintain the confidentiality of information as specified in this Agreement, but each Attorney does not act on behalf of any person other than his or her own party. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Applicable Law</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Agreement shall be construed according to and governed by the law of England, with giving effect to principles of choice or conflicts of
law. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Effective Date</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The effective date of this Agreement is _March 28, 2006__ </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Entire Agreement</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Agreement memorializes and supersedes any prior or contemporaneous oral understanding or agreement between the parties regarding COMMUNITY
OF INTEREST communications or any of the other subject matter hereof and applies to all communications and other exchanges of information (whether written or oral) between the parties prior to the execution of this Agreement that relate to
litigation in respect of the TECHNOLOGY. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Modifications And Amendments</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The provisions of this Agreement may be modified or amended only by written agreement by the parties. </P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Agreements With Third Parties</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Neither this Agreement, nor any of the provisions hereof, shall limit the freedom of either party to independently negotiate or enter into any
settlement, compromise or other agreement or arrangement with any third party respecting the TECHNOLOGY or any litigation in respect thereof, provided that the parties hereby agree to comply with the terms and conditions of this Agreement and
acknowledge that such terms and conditions do not derogate from their exercise of such freedom. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Disqualification Of Counsel</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The disqualification of counsel for a party shall not require or constitute grounds for the disqualification of counsel for the other Party by
reason of the parties&#146; entry into or exchange of information pursuant to this Agreement, and the party whose counsel has been disqualified hereby waives the right to seek such disqualification of the other party&#146;s counsel by reason of such
entry into this Agreement or the sharing of such other party, or such other party&#146;s counsel, of any COMMUNITY OF INTEREST communications pursuant to the terms hereof. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Counterparts</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in counterparts, each of which shall be deemed an original, and all of which together will constitute one and
the same instrument. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NN </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Bagsvaerd&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March<U></U>&nbsp;28, 2006</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Terje Kalland</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terje Kalland</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Senior Vice President,
Biopharmaceutical Research Unit</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center">IPH</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Marseille &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March 28<U><SUP
STYLE="font-size:85%; vertical-align:top">th</SUP></U> 2006</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Herv&eacute; Brailly</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Herv&eacute; Brailly</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such
information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT AND SUPPLEMENT NO. 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to the </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOINT RESEARCH,
DEVELOPMENT, OPTION AND LICENCE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>dated </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH 28, 2006 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>between
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVO NORDISK A/S </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INNATE PHARMA SA
</B></P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>October 6, 2008 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page&nbsp;No.</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1. DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2. RECLASSIFICATION OF ANTI-KIR AS A NICHE CANDIDATE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3. AMENDMENT OF AGREEMENT TO PROVIDE FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ANTI-KIR AS A
NICHE CANDIDATE BY IPH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4. OTHER AMENDMENT OF AGREEMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5. KNOW-HOW TRANSFER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6. CLINICAL TRIALS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7. TRANSFER OF ANTI-KIR SUPPLIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8. REGULATORY OR SAFETY DELAY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9. FEES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10. POST-DOCTORATE RESEARCH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11. MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">C-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">E-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit F</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit G</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">G-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit H</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">H-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT AND SUPPLEMENT NO. 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOINT RESEARCH,
DEVELOPMENT, OPTION AND LICENCE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amendment and Supplement dated as of October 6, 2008 (the &#147;<U>Amendment No.1</U>&#148;) to the Joint
Research, Development, Option and Licence Agreement (hereinafter the &#147;<U>Agreement</U>&#148;) dated March 28, 2006 between Novo Nordisk A/S (CVR-no. 24 25 67 90), a corporation existing under the laws of Denmark and having its principal place
of business at Novo All&eacute;, 2880 Bagsvaerd, Denmark (hereinafter &#147;NN&#148;), and Innate Pharma SA, a corporation existing under the laws of France and having its principal place of business at Grand Pr&eacute; &#150; 119/121, ancien chemin
de Cassis, 13009 Marseille, France (hereinafter &#147;<U>IPH</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>WITNESSETH </U></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WHEREAS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Pursuant to the Agreement, NN and IPH agreed to work, independently, jointly, and/or together with agreed-upon Third Parties, to (a) discover or identify Drug Candidates, and (b)&nbsp;optimize Drug Candidates for progression to
(i) Licensed Products for further development and commercialization by NN, or (ii) Niche Candidates for further development and commercialization by IPH (either alone or together with NN), in each case for all uses and purposes, including
therapeutic, prophylactic and, except as otherwise expressly therein provided, diagnostic uses;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WHEREAS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NN desires to cease its development of Anti-KIR as a Licensed Product and IPH desires that Anti-KIR be reclassified as a Niche Candidate for IPH&#146;s sole independent further development and commercialization, and NN and IPH
desire to amend and supplement the Agreement to provide for such future development of Anti-KIR;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WHEREAS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NN and IPH have agreed to enter into an Amendment and Supplement No.&nbsp;2 to the Agreement (&#147;<U>Amendment No.&nbsp;2</U>&#148;) dated and effective as of the date hereof that provides that (i) the Agreement shall be
amended to exclude Anti-NKG2D (as defined in Amendment No.&nbsp;2) from the scope of the Agreement, (ii) the Assigned IPR (as defined in Amendment No.&nbsp;2) and certain assets and materials relating to Anti-NKG2D shall be assigned to NN, and (iii)
IPH shall grant NN an exclusive, royalty-free, worldwide licence under the Licensed IPR (as defined in Amendment No.&nbsp;2) and a non-exclusive royalty-free, worldwide licence under the Innate Anti-NKG2D FoO IPR (as defined in Amendment No.&nbsp;2)
for the purposes of research, development and commercialisation of Anti-NKG2D Products (as defined in Amendment No.2).</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:15%; font-size:10pt; font-family:Times New Roman">in consideration of the foregoing premises, the mutual promises and covenants set forth in this Amendment No.1, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, NN and IPH, each intending to be legally bound, hereby agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise specifically defined herein, each term used herein that is defined in the Agreement has the
meaning assigned to such term in the Agreement. Each reference to &#147;hereof&#148;, &#147;hereunder&#148;, &#147;herein&#148; and &#147;hereby&#148; and each other similar reference and each reference to &#147;this Agreement&#148; and each other
similar reference contained in the&nbsp;Agreement shall, after the Amendment No.1 Effective Date, refer to the Agreement as amended hereby. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Amendment No.1 Effective Date&#148; shall mean the date of this Amendment No.1. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RECLASSIFICATION OF ANTI-KIR AS A NICHE CANDIDATE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms and conditions of this Amendment No.1 and with effect from the Amendment No.1 Effective
Date, NN hereby classifies Anti-KIR as a Niche Candidate for independent further development and commercialization by IPH for any human therapeutic, prophylactic or diagnostic indication or application. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH acknowledges and agrees that, with effect from the Amendment No.1 Effective Date, Anti-KIR shall be
classified as a Niche Candidate and IPH further agrees that, notwithstanding any non-compliance by either Party with the procedures set out in Section 6.1 of the Agreement, neither the discontinuation of development of Anti-KIR by NN nor the
subsequent classification by NN in this Amendment No.1 of Anti-KIR as a Niche Candidate constitutes the abandonment of any Licensed Product or Niche Candidate for the purposes of the Agreement or gives rise to any right to terminate the whole or
part of the Agreement or any of the associated remedies under Articles 12 and 13 of the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any provision of the Agreement, IPH acknowledges that, with effect from the Amendment No.1
Effective Date, NN shall have no further obligations under the Agreement, this Amendment No.1 or otherwise to develop or commercialize Anti-KIR and NN acknowledges that IPH shall have the exclusive right to conduct the development and
commercialisation of Anti-KIR as a Niche Candidate for any human therapeutic, prophylactic or diagnostic indication or application. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AMENDMENT OF AGREEMENT TO PROVIDE FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ANTI-KIR AS A NICHE CANDIDATE
BY IPH </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from the Amendment No.1 Effective Date, Article 1 of the Agreement is hereby amended by:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adding the following <I>proviso</I> to the definition of &#147;Background NN IPR&#148; immediately following
the current text of such definition: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Provided</U>, <U>however</U>, that for the purposes of the licences
granted to IPH pursuant to Section 5.5 hereof to develop and commercialize Anti-KIR as a Niche Candidate and otherwise in connection with the interpretation of this Agreement in connection with such development and commercialization by IPH of
Anti-KIR as a Niche Candidate, &#147;Background NN IPR&#148; shall mean only the IPR identified and listed in Schedule 1.1.7A to the Agreement.&nbsp;Such Schedule 1.1.7A shall not be subject to the aforementioned notification, demonstration and
updating process applicable to Schedule 1.1.7 and may not be amended except with the express consent in writing of the Parties hereto.&#148;; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adding the following <I>proviso</I> to the definition of &#147;Collaboration IPR&#148; immediately following
the current text: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Provided</U>, <U>however</U>, that for the purposes of the licences granted to IPH pursuant
to Section 5.5 hereof to develop and commercialize Anti-KIR as a Niche Candidate and otherwise in connection with the interpretation of this Agreement in connection with such development and commercialization by IPH of Anti-KIR as a Niche Candidate,
&#147;Collaboration IPR Controlled by NN&#148; shall mean only the IPR comprised of (x) (i) the Patents identified and listed in Schedule 1.1.16A to the Agreement and (ii) any Patents in which any Anti-KIR Know-How is disclosed but not including any
Patent listed in Schedule 5.8.2A and (y) the Know-How listed in Schedule 1.1.17A to the Agreement.&nbsp;Such Schedules 1.1.16A and 1.1.17A shall not be subject to any updating process that is otherwise applicable to Schedules 1.1.16 and 1.1.17 and
may not be amended except with the express consent in writing of the Parties hereto.&#148;; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deleting the final sentence from the definition of &#147;Licensed Product&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">inserting the words &#147;Anti-KIR as well as&#148; immediately following the words &#147;shall mean&#148; in
the definition of &#147;Niche Candidate&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adding the following definitions: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-KIR Know-How</U>&#148; shall mean Collaboration Know-How listed in Schedule 1.1.17A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-KIR Patent</U>&#148; shall mean (i) a Patent listed in Part A of Schedule 1.1.16A
and (ii) a Patent in which any Anti-KIR Know-How is disclosed but not including any Patent listed in Schedule 5.8.2 A; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-KIR
Product</U>&#148; shall mean ***. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>&#147;Anti-KIR Regulatory Milestones</U>&#148; shall have the meaning ascribed to it in Section 7.4A.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>&#147;Anti-KIR Sales Milestones</U>&#148; shall have the meaning ascribed to it in Section 7.4B. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-NKG2A Product</U>&#148; shall mean any product that contains fully human or humanized monoclonal antibodies, antibody fragments,
or derivatives of either thereof, which are reactive against wild type, variant or mutant human natural killer cell receptor NKG2A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-NKG2D Product</U>&#148; shall mean any product that contains fully human or humanized monoclonal antibodies, antibody fragments,
or derivatives of either thereof, which are reactive against wild type, variant or mutant human natural killer cell receptor NKG2D. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Continuation</U>&#148; shall mean, with respect to any patent or patent application, any continuation, continuation-in-part,
divisional, continued prosecution or other similar application. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Medarex Sublicence</U>&#148; shall mean ***. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>NN Anti-KIR FoO IPR</U>&#148; shall mean (a) such Patents listed in Schedule 5.8.2 A, (b) such Patents that are either (i) Controlled,
through exclusive ownership, by NN or its Affiliates during the Term and claim the benefit of a priority date on or before October 6, 2011 or (ii) Controlled, through licence or otherwise but not exclusive ownership, by NN or its Affiliates at
October 6, 2008, (c) such Know-How that is either (i) Controlled, through exclusive ownership, by NN or its Affiliates during the Term and generated on or before October 6, 2011 or (ii) Controlled, through licence or otherwise but not exclusive
ownership, by NN or its Affiliates at October 6, 2008 and (d) such Patents based in part or in whole on Know-How that is (i) Controlled, through exclusive ownership, by NN or its Affiliates during the Term and (ii) generated on or before October 6,
2011, in each of (a), (b) and (d) that are or is (y) not within the Background NN IPR or Collaboration IPR and (z) necessary for the development and commercialization of an Anti-KIR Product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shared Anti-KIR Patent</U>&#148; shall mean an Anti-KIR Patent listed in Part B of Schedule 1.1.16A.&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Background NN IPR Licensed by NN to IPH for development and commercialization by IPH of Anti-KIR as a Niche
Candidate</U>.&nbsp;With effect from the Amendment No.1 Effective Date, the Agreement is hereby amended by inserting Exhibit A to this Amendment No.1 as Schedule 1.1.7A to the Agreement. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Collaboration IPR Controlled by NN and Licensed by NN to IPH for development and commercialization by IPH of
Anti-KIR as a Niche Candidate &#150; Anti-KIR Patents and Anti-KIR Know-How</U>.&nbsp;With effect from the Amendment No.1 Effective Date, the Agreement is hereby amended by inserting Exhibit B to this Amendment No.1 as Schedule 1.1.16A to the
Agreement and Exhibit C to this Amendment No. 1 as Schedule 1.1.17A to the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Schedule 5.8.2A NN Anti-KIR FoO Patent</U>.&nbsp;With effect from the Amendment No.1 Effective Date, the
Agreement is hereby amended by inserting Exhibit D to this Amendment No.1 as Schedule 5.8.2A to the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Exclusivity Holdover Period</U>.&nbsp;With effect from the Amendment No. 1 Effective Date, Section 2.1.2
of the Agreement shall be deleted and replaced with the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#147;2.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[Reserved]</B>&#148;. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Development and Commercialization Committee Input for Anti-KIR</U>.&nbsp;With effect from the Amendment
No. 1 Effective Date, Section 4.9 is hereby amended by inserting the following text in the first paragraph after the words &#147;(b) any Niche Candidates&#148;: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;(other than Anti-KIR)&#148;. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No JSC Approval of Sub-licensing by IPH of an Anti-KIR Niche Candidate</U>.&nbsp;With effect from the
Amendment No.1 Effective Date, Article 5 of the Agreement is hereby amended by deleting the words &#147;that shall be enforceable by both Parties&#148; from the second paragraph of Section 5.6 and by inserting the following text immediately
following Section 5.6: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;5.6A <U>No JSC Approval of Sub-licensing by IPH of Anti-KIR as a Niche
Candidate</U>.&nbsp;Notwithstanding Section 5.6, the JSC shall not be required to approve any Sub-licensing by IPH of its rights and obligations under this Agreement if such Sub-licensing by IPH is reasonably necessary for the development and
commercialization of Anti-KIR as a Niche Candidate or any Anti-KIR Product.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Licence by NN to IPH of Independent NN IPR for development and commercialization by IPH of Anti-KIR as a
Niche Candidate; FoO for Anti-KIR as a Niche Candidate</U>.&nbsp;With effect from the Amendment No.1 Effective Date, Article 5 is hereby amended by inserting the following text immediately following Section 5.8.2: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;5.8.2A&nbsp;<U>No Licence by NN to IPH of Independent NN IPR for development and commercialization by IPH of Anti-KIR as a Niche
Candidate; FoO for Anti-KIR as a Niche Candidate.</U>&nbsp;Notwithstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Section 5.8.2, NN shall not be obliged to grant to IPH, or to provide reasonable cooperation and assistance to IPH to procure the grant to IPH of, non-exclusive rights and licences under any
Independent NN IPR for the purposes of IPH&#146;s development and commercialization of Anti-KIR as a Niche Candidate or any Anti-KIR Product; <U>provided</U>, <U>however</U>, that NN shall grant to IPH a non-exclusive licence (with the right to
Sub-license and Out-license) under any NN Anti-KIR FoO IPR to develop and commercialize Anti-KIR Products for no additional consideration.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No IPH Access to Materials; No NN Buy-In and Co-Marketing Options</U>.&nbsp;With effect from the Amendment
No.1 Effective Date, Article 6 is hereby amended by inserting the following text immediately following Section 6.1: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;6.1A&nbsp;<U>No IPH Access to Materials.</U>&nbsp;Notwithstanding Section 6.4, IPH shall have no rights to access Materials pursuant to
such Section 6.4 with respect to the development or commercialisation of Anti-KIR as a Niche Candidate pursuant to Section 6.1 hereof.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.1B&nbsp;<U>No NN Buy-In and Co-Marketing Options for Anti-KIR Niche Candidate</U>.&nbsp;Notwithstanding Sections 6.5, 6.6, 6.7 and 6.8, NN
shall have no rights pursuant to such Sections 6.5, 6.6, 6.7 and 6.8 with respect to Anti-KIR as a Niche Candidate being developed and commercialized by IPH pursuant to Section 6.1 hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.1.C&nbsp;<U>IPH Access to Raw Data</U>.&nbsp;If reasonably required by IPH to respond to any request from, or fulfill any requirement of, any
regulatory authority in connection with IPH&#146;s development and commercialization of Anti-KIR as a Niche Candidate or any Anti-KIR Product, NN shall, upon reasonable notice from IPH, provide IPH or any regulatory authority with a reasonable
opportunity to review any original documentation and raw data archived by NN for no additional consideration.&nbsp;NN shall not destroy or otherwise dispose of any original documentation and raw data related to NN&#146;s development of Anti-KIR that
IPH or a regulatory authority may reasonably be expected to require in connection with IPH&#146;s development and commercialization of Anti-KIR as a Niche Candidate or any Anti-KIR Product without the prior written consent of IPH which shall not be
unreasonably delayed or withheld. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.1.D <U>Reporting Obligations</U>.&nbsp;IPH shall prepare written annual reports (each a
&#147;<U>Development Report</U>&#148;) in respect of IPH&#146;s development of Anti-KIR as a Niche Candidate during each calendar year commencing January&nbsp;1, 2009 and deliver such Development Report to NN no later than *** in the calendar year
following that calendar year to which such Development Report relates.&nbsp;Each Development Report shall include a description of preclinical and clinical work carried out during the calendar year, any clinical trial reports received during such
calendar year and projected development time lines.&nbsp;Within *** days of NN receiving a Development Report and upon reasonable written notice by NN to IPH, the Anti-KIR project leader at IPH shall meet with representatives of NN to discuss such
Development Report. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** Portions of this page have been omitted pursuant to a
request for Confidential Treatment and filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.1.E <U>NN Corporate Alliance Management</U>.&nbsp;NN shall, for so long as IPH shall develop
and commercialize Anti-KIR as a Niche Candidate during the Term, assign a member of its Corporate Alliance Management Department to serve as the liaison officer between NN and IPH on all matters relating to the development and commercialization of
Anti-KIR as a Niche Candidate.&nbsp;Such NN Corporate Alliance Management Department liaison officer shall respond in a reasonably timely manner to all reasonable requests for information made by IPH. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Regulatory Milestones</U>.&nbsp;With effect from the Amendment No.1 Effective Date, Article 7 of the
Agreement is hereby amended by inserting the following text immediately following Section 7.4: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;7.4A <U>Anti-KIR
Niche Candidate Regulatory Milestone Payments.</U>&nbsp;Notwithstanding Section 7.4, in respect of Anti-KIR Products IPH shall only pay to NN the following milestone payments for the achievement of the following regulatory milestone events by an
Anti-KIR Product pursuant to IPH&#146;s development of Anti-KIR as a Niche Candidate (&#147;<U>Anti-KIR Regulatory Milestones</U>&#148;) within *** days of the achievement of each such Anti-KIR Regulatory Milestone. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Such milestone payments shall be made for the first Anti-KIR Product that achieves an Anti-KIR Regulatory Milestone and, subsequently, for each
Anti-KIR Product that *** previously achieved such Anti-KIR Regulatory Milestone, but ***, in each case on a one-time, non-duplicative basis, irrespective of the number of indications per Anti-KIR Product and any Out-licensing or Sub-licensing by
IPH. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To the extent that IPH is required to license (or sublicense) Third Party IPR for the development and commercialization of Anti-KIR Products,
IPH shall be responsible for all costs associated with such licences (or sublicences) other than amounts previously paid by NN before the Amendment No. 1 Effective Date and there shall be no reduction in the milestone payments set forth above as a
result of such payments.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Sales Milestones</U>.&nbsp;With effect from the Amendment No.1 Effective Date, Article 7 of the Agreement is
hereby amended by inserting the following text immediately following Section 7.4A: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;7.4B <U>Anti-KIR Niche
Candidate Sales Milestone Payments.</U>&nbsp;Notwithstanding Section 7.4, in respect of Anti-KIR Products IPH shall </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
only pay to NN the following milestone payments for the achievement of the following sales milestone events by an Anti-KIR Product pursuant to IPH&#146;s development of Anti-KIR as a Niche
Candidate (&#147;<U>Anti-KIR Sales Milestones&#148;</U>) within *** days of the achievement of each such Anti-KIR Sales Milestone. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Such
milestone payments shall be made for the first Anti-KIR Product that achieves an Anti-KIR Sales Milestone and, subsequently, for each Anti-KIR Product that *** previously achieved such Anti-KIR Regulatory Milestone, but ***, in each case on a
one-time, non-duplicative basis, irrespective of the number of indications per Anti-KIR Product and any Out-licensing or Sub-licensing by IPH. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To the extent that IPH is required to licence (or sublicence) Third Party IPR for the development and commercialization of Anti-KIR Products,
IPH shall be responsible for all costs associated with such licences (or sublicences) other than amounts previously paid by NN before the Amendment No. 1 Effective Date and there shall be no reduction in the milestone payments set forth above as a
result of such payments.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Royalties</U>.&nbsp;With effect from the Amendment No.1 Effective Date, Article 7 of the Agreement is hereby
amended by inserting the following text immediately following Section 7.8: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;7.8A&nbsp;<U>Royalties on Anti-KIR
Products.</U>&nbsp;Notwithstanding Section 7.8 hereof, in respect of Anti-KIR Products IPH shall only pay to NN the following percentage royalties on all Net Sales of the first Anti-KIR Product and, subsequently, for each Anti-KIR Product *** that
previously achieved such Anti-KIR Regulatory Milestone, but ***, in the Territory by IPH (or its associated Selling Parties) during the Term in accordance with Section 7.11 (notwithstanding any royalties that IPH or its associated Selling Parties
may have to pay to Third Parties with respect to the affected Anti-KIR Product): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To the extent that IPH is required to licence (or sublicence) Third Party IPR for the development and commercialization of Anti-KIR Products,
IPH shall be responsible for all costs associated with such licences (or </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain
information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
sublicences) other than amounts previously paid by NN before the Amendment No. 1 Effective Date and there shall be no reduction in the royalty payments set forth above as a result of such
payments.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Records of Net Sales.</U>&nbsp;With effect from the Amendment No.1 Effective Date, Article 7 of the
Agreement is hereby further amended by inserting &#147;and 7.8A&#148; immediately after &#147;7.8&#148; in Section 7.9. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Anti-KIR Patents.</U>&nbsp;With effect from the Amendment No.1 Effective Date, Article 9 of the Agreement is
hereby amended by inserting the following text immediately following Section 9.1: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;9.1A&nbsp;<U>Anti-KIR
Patents.</U>&nbsp;The provisions of this Section 9.1A shall apply in relation to IPH Controlled Patents (as defined below) (including Shared Anti-KIR Patents) but no other Patents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">9.1A.1&nbsp;<U>Anti-KIR Patents</U>. Notwithstanding anything to the contrary in this Agreement, as between the Parties: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise set forth in Section 9.1A.1(b) hereof, IPH shall have the exclusive right and sole
discretion during the Term to prepare, file, prosecute, and maintain the Anti-KIR Patents and any Patent claiming a therapeutic, prophylactic or diagnostic use of Anti-KIR in which any NN Anti-KIR FoO IPR (but not including any Patent listed in
Schedule 5.8.2 A) is disclosed (&#147;<U>IPH Controlled Patents</U>&#148;) and to conduct any interferences, re-examinations, reissues, limitations, and oppositions with respect to such IPH Controlled Patents; <U>provided</U>, <U>however</U>, that
IPH may neither disclose any Anti-KIR Know How or NN Anti-KIR FoO IPR related to either (x) manufacturing methods, processes or procedures or (y) formulation, assay and delivery methodologies in the preparation, filing, prosecution or maintenance of
any Patent nor prepare, file or prosecute any Patent which would require the disclosure of any Anti-KIR Know How or NN Anti-KIR FoO IPR related to either (x) manufacturing methods, processes or procedures or (y) formulation, assay and delivery
methodologies.&nbsp;IPH shall bear sole responsibility for the preparation, filing, prosecution and maintenance of any Patent contemplated by this Section 9.1A.1 (a) and all costs associated therewith accruing after October 6, 2008, including
attorneys&#146; fees and payments due to patent authorities to maintain such Patents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to the Shared Anti-KIR Patents, NN shall have the exclusive right and sole discretion during the
Term to (A) at NN&#146;s sole cost and expense, direct IPH to take any steps required to ensure that all Anti-NKG2A Products, Anti-NKG2D Products and/or any other Licensed Products and their respective uses are excluded from the scope of any claims
of any Shared Anti-KIR Patents to the extent reasonably possible, and (B) at NN&#146;s sole cost and expense, prepare, file, prosecute and maintain Continuations thereof to the extent the claims of any such Continuations cover any
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Anti-NKG2A Products, Anti-NKG2D Products and/or any other Licensed Products or their respective uses (the &#147;<U>NN Continuations</U>&#148;) and to conduct any interferences, re-examinations,
reissues, limitations, and oppositions with respect to such NN Continuations. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">9.1A.2 <U>Correspondence Regarding Proposed
Patent Submissions</U>. IPH, with respect to the Shared Anti-KIR Patents, and NN, with respect to the NN Continuations, shall promptly, and in any event no less than *** prior to any final deadline for submission of such documents or required filing
date, deliver or have delivered to the other Party copies of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all proposed amendments or other applications in relation to such Shared Anti-KIR Patents or NN Continuations
or, in instances where several such proposed amendments or applications are substantially similar (such as multiple national phase filings of a single international (PCT) application), a representative sample of such proposed amendments or
applications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all substantive documents proposed to be filed in any patent authority appeal proceedings relating to such
Shared Anti-KIR Patents, NN Continuations and any applications in relation to the foregoing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all substantive documents proposed to be filed in any inter partes disputes (including opposition,
reexamination, or interference proceedings) before any patent authority or before any judicial body on appeal of such proceedings which relate to such Shared Anti-KIR Patents, NN Continuations and any applications in relation to the foregoing; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other substantive documents proposed to be submitted to any Patent authority which relate to such Shared
Anti-KIR Patents, NN Continuations or any applications in relation to the foregoing which are reasonably requested by the other Party, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">in each case, in a manner which provides the other Party with a sufficient opportunity to review and comment on such documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">9.1A.3 <U>Patent Authority Correspondence</U>. IPH, with respect to the Shared Anti-KIR Patents, and NN, with respect to the NN Continuations,
shall: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify the other Party of its receipt of all office actions from any Patent authority or any other substantive
correspondence from any Patent authority notification of which has been requested by such other Party (and any planned responses to the foregoing) which relate to any Shared Anti-KIR Patent; NN Continuation or any applications in relation to the
foregoing, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify the other Party of the allowance of any Shared Anti-KIR Patent, NN Continuation or any applications in
relation to the </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this
agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
foregoing (including notifying such other Party of the expected date of issuance, providing copies of all allowed claims and whether or not such Party intends to file any further applications
with respect to such Shared Anti-KIR Patent or NN Continuation), and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify the other Party of the issuance of any Shared Anti-KIR Patent or NN Continuation or any applications in
relation to the foregoing. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">9.1A.4 <U>Limited Right to Comment</U>. With respect to the Shared Anti-KIR Patents, IPH
shall notify NN at least *** before either any applicable deadline of any patent authority for filing, or the date that IPH intends to file, any response, application or the like in respect of any proposed filing or submission concerning any such
Shared Anti-KIR Patent.&nbsp;IPH shall give reasonable consideration to any comments, suggestions, recommendations or other requests (&#147;<U>Requests</U>&#148;) regarding the preparation, filing, prosecution or maintenance of any such Anti-KIR
Patent that NN shall provide to IPH at any time prior to *** before such deadline or intended filing date and IPH shall notify NN in writing within *** of its receipt of any Request (but in no event later than *** before any applicable deadline of
any patent authority for filing any response, application or the like to which such Request applies) whether it intends to adopt or reject such Request.&nbsp;In the event that IPH notifies NN that it will not adopt any Request of NN, and the failure
to adopt such Request would be reasonably expected to materially impair NN&#146;s business or rights in any NN Continuations, NN may direct IPH to implement such Request at any time following the receipt of such notice and IPH shall implement any
such Request, <I>provided that</I> IPH shall have no obligation to implement such Request to the extent that such Request would reasonably be expected to materially impair IPH&#146;s business or ability to prosecute or obtain claims of its choice in
at least one of the Anti-KIR Patents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">9.1A.5 <U>Notice and Effects of IPH&#146;S Decision to Abandon; Disclaim; or Discontinue
Prosecution, Maintenance, or Defense of Shared Anti-KIR Patents</U>. In the event that IPH decides in respect of any Shared Anti-KIR Patent: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to discontinue the prosecution or maintenance of such Shared Anti-KIR Patent, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to discontinue the defense of such Shared Anti-KIR Patent (such as by discontinuing efforts to defend such
Shared Anti-KIR Patent in any opposition, reexamination, nullity, or interference proceeding), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to not file an application for a Continuation (or, as the case may be, further Continuation) with respect to
such Shared Anti-KIR Patent (including by decision (A) not to enter the national or regional phase in any country or region that is a designated state of a PCT application filed by IPH or (B) not to pursue an application in a country wherein an
application claiming priority from a Shared Anti-KIR Patent may be filed), or </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to abandon or disclaim (in whole or in part, other than by terminal disclaimer), without possibility of
restoration, any Shared Anti-KIR Patent, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">in each case, IPH shall provide written notice to NN at least *** in advance of
the deadline relating to any of the events described above (except in the case of national or regional phase filing, in which case such notice shall be provided at least *** in advance of the date of the first applicable deadline for national or
regional phase entry) so as to allow NN the opportunity to file, defend, maintain (including by payment of annuities, issue fees, maintenance fees, or the like), or continue prosecution of such Shared Anti-KIR Patent, at its own expense. In such an
event, IPH shall provide any assistance reasonably requested of it by NN (including providing NN with power of attorney to perform such tasks) and, to the extent authorized by contract and permitted by applicable Law, assign its rights to such
Shared Anti-KIR Patent to NN. NN shall thereafter grant to IPH a worldwide, non-exclusive licence (including the right to sub-license and further sublicense) with respect to such Shared Anti-KIR Patent for no additional consideration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">9.1A.6 <U>Future Limitations on Continuations</U>. Upon the occurrence of an event following which the Laws of the United States or the Laws
now or hereinafter in effect in any jurisdiction (including any regulations of the U.S. Patent and Trademark Office or any similar foreign governmental agency) are likely to be amended in the near future to limit the number of Continuations that a
Person may file in connection with any Patent, either Party may provide written notice to the other Party of such event and the Parties shall meet in a timely manner in advance of the date such Laws are expected to become effective and negotiate in
good faith a revised paradigm addressing the manner in which any Continuations (or, as the case may be, further Continuations) of the Shared Anti-KIR Patents may be filed.&nbsp;From the time such notice is provided until the time the Parties agree
on such a revised paradigm, neither Party shall take any action that could limit the other Party&#146;s right to file or prosecute any Continuations (or, as the case may be, further Continuations) of any Shared Anti-KIR Patents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">9.1A.7 <U>Enforcement of IPH Controlled Patents, Shared Anti-KIR Patents and NN Claims</U>.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise provided in Sections 9.1A.7(b) and 9.1A.7(c) and subject to Sections 9.12.1 and 9.12.2, IPH
shall have the exclusive right (but not the obligation) to initiate or defend any suit, opposition, interference or other legal action (including proceedings before the US International Trade Commission) or to take other appropriate action that IPH,
in its sole discretion, </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded
from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
believes is reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any IPH Controlled Patent (in its own
name or, if authorized by contract and permitted by applicable Law and required by applicable Law, in the name of the NN or an Affiliate of NN), and shall bear its own costs and expenses in respect thereof and be represented by counsel of its choice
and shall further indemnify NN and any of its Affiliates for any costs incurred by NN or any of its Affiliates in connection with such suit, opposition, interference or action. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in this Agreement, except as otherwise provided in Section 9.1A.7(c)
and subject to Sections 9.12.1 and 9.12.2, IPH shall have the exclusive right (but not the obligation) to initiate or defend any suit, opposition, interference, other legal action (including proceedings before the US International Trade Commission)
or to take other appropriate action that IPH, in its sole discretion, believes is reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any Shared Anti-KIR
Patent (in its own name or, if authorized by contract and permitted by applicable Law and required by applicable Law, in the name of the NN or an Affiliate of NN) against any Person for infringement of any claims of such Shared Anti-KIR Patent and
shall bear its own costs and expenses in respect thereof and be represented by counsel of its choice and shall further indemnify NN and any of its Affiliates for any costs incurred by NN or any of its Affiliates in connection with such suit,
opposition, interference or action.&nbsp;To the extent that such infringement relates to any Anti-NKG2A Product or Anti-NKG2D Product or their respective uses, IPH shall give reasonable consideration to any comments or suggestions of NN in
connection with any such suit, opposition, interference or legal action, including with respect to any negative impact such suit, opposition, interference or legal action could reasonably be expected to have on the Shared Anti-KIR Patents.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in this Agreement, subject to the provisions of 9.12.1 and 9.12.2, NN
shall have the exclusive right (but not the obligation) to initiate or defend any suit, opposition, interference, other legal action (including proceedings before the US International Trade Commission) or to take other appropriate action that NN, in
its sole discretion, believes is reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any NN Continuation (in its own name or, if authorized by contract and
permitted by applicable Law and required by applicable Law, in the name of the IPH or an Affiliate of IPH), and shall bear its own costs and expenses in respect thereof and be represented by counsel of its choice and shall further indemnify IPH and
any of its Affiliates for any costs incurred by IPH or any of its Affiliates in connection with such suit, opposition, interference or action. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">9.1A.8 <U>Dispute Resolution</U>.&nbsp;The Parties acknowledge that all disputes arising under
this Section 9.1A shall be subject to the dispute resolution procedures set forth in Section 21.14.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Development Diligence Requirements for Anti-KIR as a Niche Candidate</U>.&nbsp;With effect from the
Amendment No.1 Effective Date, Article 12 of the Agreement is hereby amended by inserting the following text immediately following Section 12.7 and Section 12.7 shall no longer apply to Anti-KIR as a Niche Candidate or the marketing or sale of an
Anti-KIR Product: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;12.7A&nbsp;<U>Development Diligence Requirements for Anti-KIR Niche Candidate</U>.
Notwithstanding Section 12.7 hereof, with respect to either the development of Anti-KIR as a Niche Candidate or the marketing or sale of an Anti-KIR Product, IPH shall be obliged to promptly notify NN in writing of any decision to abandon the
development of Anti-KIR as a Niche Candidate or the marketing or sale of an Anti-KIR Product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the absence of notification, IPH shall be
deemed to have abandoned the development of Anti-KIR as a Niche Candidate if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>provided that</I> the time periods in (i)-(iii), above: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shall not include any time period during which the relevant Anti-KIR Product shall have been subject to a
Clinical Hold (as defined below) and IPH shall have been using Commercially Reasonable Efforts to remove such Clinical Hold; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shall be extended by a reasonably appropriate amount of time to reflect any delays or obstacles to the
development of the relevant Anti-KIR Product that (i) occur following the designation of Anti-KIR as a Niche Candidate, (ii) result from unexpected or unclear clinical trial efficacy or safety data not reasonably forseeable by IPH at the date of the
designation of Anti-KIR as a Niche Candidate and (iii) are not caused by an inability of IPH to secure appropriate financing or a development partner, <U>provided</U>, <U>however</U>, that IPH shall have notified NN of such delays or obstacles
promptly upon such delays or obstacles becoming reasonably forseeable and shall have been using Commercially Reasonable Efforts to overcome such delay or obstacle. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Within *** of any of the occurrence of any of the events specified in (i), (ii), or (iii) above,
IPH may, by paying to NN the relevant fee provided for below, extend the deadline for achievement of the required step on an annual basis for up to a period of ***, the relevant fee being: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Clinical Hold</U>&#148;, as used in this Section <B>12.7A</B>, shall mean a bona fide decision of IPH or a decision of a regulatory
authority or another governmental body to suspend a clinical trial or other study when it does not believe that such clinical trial or other study can be conducted without unreasonable risk to the subjects in such clinical trial or study, and the
existence of such circumstances shall be subject to arbitration in accordance with Section <B>21.14</B>.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination upon Abandonment of Development of Anti-KIR Niche Candidate.</U>&nbsp;With effect from the
Amendment No.1 Effective Date, Article 12 of the Agreement is hereby amended by inserting the following text immediately following Section 12.8 and Section 12.8 shall no longer apply to Anti-KIR Products: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;12.8A Notwithstanding Section 12.8 hereof, in the event of the abandonment by IPH of its development of Anti-KIR as a Niche Candidate (by
express notice to NN or by operation of this Article 12), the following provisions shall apply and supersede Section 12.8 with respect to such abandonment: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all licences granted to IPH under this Agreement for the purposes of Commercial Optimization of Anti-KIR as a
Niche Candidate that IPH is authorized to develop and commercialize shall terminate immediately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall have an obligation to grant to NN, at NN&#146;s request, an irrevocable, world-wide, fully paid up,
exclusive licence under all its right, title and interest to the Collaboration IPR or Background IPH IPR (as applicable) and Independent IPH IPR, and grant the right set out in Section 5.7 (including all supporting regulatory documentation), for the
development and commercialization of Anti-KIR, for no additional consideration other than as provided for herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if NN shall, in its discretion, assume such licence it shall notify IPH to this effect within *** of IPH&#146;s
abandonment or the determination of abandonment, whichever is the later, upon which assumption NN shall have the exclusive right to exploit such IPR for the development and commercialization of Anti-KIR; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the date of such abandonment is prior to the first dosing of humans in Phase II clinical trials of Anti-KIR
as a Niche Candidate, </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from
this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Sections <B>12.8A(a)</B> and <B>12.8A(b)</B> shall apply, save that, in consideration of the grant of such rights, if and only if NN subsequently Out-licences such IPR within the period of ***
following the date of NN&#146;s assumption of rights, NN shall pay to IPH a percentage of all revenue actually received in respect of such licence on the following basis: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the effective date of abandonment is after the first dosing of humans in Phase II clinical trials of
Anti-KIR as a Niche Candidate but prior to the first dosing in Phase III, the above Sections <B>12.8A(a) </B>and<B> 12.8A(b)</B> shall apply save that in consideration of the grant of such rights, if and only if NN subsequently Out-licences such IPR
within the period of *** following the date of NN&#146;s assumption of rights NN shall pay to IPH a percentage of all revenue actually received by NN in respect of such licence on the following basis: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event of its abandonment of the development of Anti-KIR as a Niche Candidate and irrespective of the
effective date of such abandonment, IPH shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make no further representation regarding its status as a licencee of NN in respect of Anti-KIR;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event that at the date of the abandonment by IPH of its development of Anti-KIR as a Niche Candidate
there are ongoing clinical trials with respect to such development, IPH shall pay for the completion of such clinical trials in respect of all patients enrolled at the effective date of abandonment except if the Agreement is terminated because of
adverse events in the clinical trial(s) </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has
been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
causing the trials(s) to cease due to regulatory requirements or regulatory considerations (including an actual or anticipated regulatory warning); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at NN&#146;s option, and at NN&#146;s expense, and to the extent authorized by contract and permitted by
applicable Law, assign or cause to be assigned to NN any regulatory submissions and approvals with respect to Anti-KIR and take such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of
all rights thereunder to NN; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at NN&#146;s option and at NN&#146;s expense, provide to NN all pre-clinical and clinical data in respect of
Anti-KIR and all research reagents and materials intended for use in clinical trials of Anti-KIR in IPH&#146;s possession or control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the transfer of rights from IPH to NN pursuant to this Section <B>12.8A</B> IPH shall have no further obligations under Sections <B>12.7</B>,<B>
12.8, 12.8A</B>,<B> 12.8B, 12.9 </B>or<B> 12.10</B> in respect of the development or commercialization of Anti-KIR.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination upon Abandonment of Marketing or Sale of Anti-KIR Product.</U>&nbsp;With effect from the
Amendment No.1 Effective Date, Article 12 of the Agreement is hereby amended by inserting the following text immediately following Section 12.8A and Section 12.8 shall no longer apply to Anti-KIR Products: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;12.8B Notwithstanding Section 12.8 hereof, in the event of the abandonment by IPH of its marketing or sale of any Anti-KIR Product, the
following provisions shall apply and supersede Section 12.8 with respect to such abandonment: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all licences granted to IPH under this Agreement for the marketing or sale of such Anti-KIR Product, shall
terminate immediately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall have an obligation to grant to NN, at NN&#146;s request, an irrevocable, world-wide, fully paid up,
exclusive licence under all its right, title and interest to the Collaboration IPR or Background IPH IPR (as applicable) and Independent IPH IPR, and grant the right set out in Section 5.7 (including all supporting regulatory documentation) with
respect to which such Anti-KIR Product has been abandoned, solely for the purposes of the commercialization of such specific Anti-KIR Product, for no additional consideration other than as provided for herein; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if NN shall, in its discretion, assume such licence it shall notify IPH to this effect within *** of IPH&#146;s
abandonment, upon which assumption NN shall have the exclusive right to exploit such IPR for solely with respect to such abandoned Anti-KIR Product and for such purposes as are specified in clause (a); </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the above Sections <B>12.8B(a) </B>and<B> 12.8B(b)</B> shall apply save that in consideration of the grant of
such rights, if and only if NN subsequently Out-licences such IPR within the period of *** following the date of NN&#146;s assumption of rights, NN shall pay to IPH a percentage of all revenue actually received by NN in respect of such licence on
the following basis: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event of its abandonment of the marketing or sale of any Anti-KIR Product irrespective of the effective
date of such failure, IPH shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cease any activities with respect to the marketing, promotion, sale or distribution of the Anti-KIR Product
with respect to which such abandonment has occurred; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at NN&#146;s option and at NN&#146;s expense, and to the extent such transfer is authorized by contract and
permitted by applicable Law, to transfer to NN the benefit of any contracts between IPH and any Third Party in respect of the manufacture of such abandoned Anti-KIR Product, with respect to the supply thereof for marketing with respect to which such
abandonment has occurred, <I>provided that</I> for the avoidance of doubt IPH shall not be required to cause or effect any such transfer if to do so will require IPH&#146;s payment or provision of additional consideration to any Person save that NN
may elect to pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by applicable Law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at NN&#146;s option, and at NN&#146;s expense, and to the extent authorized by contract and permitted by
applicable Law, assign or cause to be assigned to NN, any regulatory submissions and approvals related to the Anti-KIR Product with respect to which such abandonment has occurred and take such actions and execute such other instruments, assignments
and documents as may be necessary to effect the transfer of all rights thereunder to NN; </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall pay IPH&#146;s reasonable costs in connection with the above activities at a reasonable hourly rate
representing the actual cost of IPH of providing such services up to a maximum of ***. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following the transfer of rights
from IPH to NN pursuant to this Section <B>12.8B</B> IPH shall have no further obligations under Sections <B>12.7</B>,<B> 12.8, 12.8A, 12.8B</B>,<B> 12.9 </B>or<B> 12.10</B> with respect to the marketing and sale of the Anti-KIR Product with respect
to which the abandonment has occurred.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Publication concerning an Anti-KIR Niche Candidate.</U>&nbsp;With effect from the Amendment No.1 Effective
Date, Article 18 of the Agreement is hereby amended by inserting the following text immediately following Section 18.1: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Section 18.1A&nbsp;<U>Publication concerning Anti-KIR as a Niche Candidate or Anti-KIR Products</U>.&nbsp;Notwithstanding Section 18.1,
NN shall have no rights pursuant to such Section 18.1 with respect to publications or disclosures concerning the development or commercialization of Anti-KIR as a Niche Candidate pursuant to Section 6.1 hereof or any Anti-KIR Product;
<U>provided</U>, <U>however</U> that (a) IPH shall provide to NN a copy of such publication or disclosure as soon as reasonably practicable following such publication or disclosure and (b) in no event shall IPH publish Confidential Information of NN
relating to (i) manufacturing, marketing, financing or business developments, opportunities, plans, methods, processes or procedures, (ii) quality controls, (iii) security controls, (iv) unpublished cost, price or pricing information, (v) financial
or personnel matters, or (vi) customer, client or supplier lists or information, in each case without prior written approval of NN.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OTHER AMENDMENT OF AGREEMENT. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from the Amendment No.1 Effective Date, the Definitions &#147;Out-license&#148; and
&#147;Out-licensing&#148; (set forth in Section 1.1.55) and &#147;Sub-license&#148; and &#147;Sublicensing&#148; (set forth in Section 1.1.64) shall be interpreted by the Parties to mean the grant by a Party of an Out-licence or Sub-licence to any
Out-licensee or Sub-licensee or any further grant of a Sub-licence or Out-licence by such Out-licensee or Sub-licensee or its Out-licensees or Sub-licensees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from the Amendment No.1 Effective Date, Article 12 of the Agreement is hereby amended by:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deleting the text of Section 12.7 in its entirety and replacing it with the following: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;12.7 <U>Development Diligence Requirements</U>. For the purposes of this Section 12.7, each Party shall be obliged to promptly notify the
other Party in writing of any decision to abandon the development, marketing or sale of any Licensed Product, Residual Product or Niche Candidate </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and in the absence of notification the first Party shall be deemed to have abandoned the development of such Licensed Product, Niche Candidate, or Residual Product being developed for
commercialization exclusively by or on behalf of that Party if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>provided that</I> the time periods in (i)-(iii), above: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shall not include any time period during which the relevant Licensed Product, Niche Candidate or Residual
Product shall have been subject to a Clinical Hold (as defined below) and the Party developing same shall have been using Commercially Reasonable Efforts to remove such Clinical Hold; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shall be altered by the Parties to take into consideration unforeseen delays or obstacles in continuing the
development of the relevant Licensed Product, Niche Candidate or Residual Product outside the reasonable control of the developing Party, in which case the Parties shall agree to a reasonable extension having regard to the delay, provided that the
developing Party must make a request for such extension to the other Party at the time of, and not solely after, the delay. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Within *** of any of the occurrence of any of the events specified in (i), (ii), or (iii) above, the developing Party may, by paying to the
other Party the relevant fee provided for below, extend the deadline for achievement of the required step on an annual basis for up to a period of ***, the relevant fee being: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">provided that the developing Party shall only have the right to such extension under two of events (a), (b) or (c) of this Section <B>12.7</B>,
unless the Parties hereafter agree otherwise in writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Clinical Hold</U>&#148;, as used in this Section <B>12.7</B>, shall mean
a bona fide decision of the developing Party or a decision of a regulatory authority or another governmental body to suspend a clinical trial or other study when it does not believe that such clinical trial or other study can be conducted without
unreasonable risk to the subjects in such clinical trial or study, and the existence of such circumstances shall be subject to arbitration in accordance with Section <B>21.14</B>.&#148; </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** Portions of this page have been omitted pursuant to a request for Confidential
Treatment and filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deleting the text of Section 12.8 in its entirety and replacing it with the following: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;12.8 <U>Termination for Failure to Employ Commercially Reasonable Efforts</U>. Notwithstanding any other provision of this Agreement, in
the event of the abandonment of the development by a Party (the &#147;Developing Party&#148;) (by express notice to the other Party or by operation of this Article 12), or a non-transient material failure of the Developing Party to employ
Commercially Reasonable Efforts in respect of the marketing or sale of any Licensed Product, Residual Product or Niche Candidate, all licences granted to the Developing Party under this Agreement for the purposes of Commercial Optimization of any
such Licensed Product, Residual Product or Niche Candidate that a Party is authorized to develop&nbsp;but that has been abandoned shall terminate immediately and the following provisions shall apply: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Developing Party shall have an obligation to grant to the other Party, at the other Party&#146;s request,
an irrevocable, world-wide, fully paid up, exclusive licence under all its right, title and interest to the Collaboration IPR, Background NN IPR or Background IPH IPR (as applicable) and Independent IPR, and grant the right set out in Section
<B>5.7</B>, with respect to which such specific Licensed Product, Residual Product or Niche Candidate has been abandoned, solely for the purposes of Commercial Optimization of such specific Licensed Product, Residual Product, or Niche Candidate, and
all supporting regulatory documentation, to the other Party for no additional consideration other than as provided for herein; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the other Party shall, in its discretion, assume such licence it shall notify the Developing Party to this
effect within *** of the Developing Party&#146;s abandonment or the determination of abandonment, whichever is the later, upon which assumption the other Party shall have the exclusive right to exploit such IPR solely with respect to such abandoned
product(s) and for such purposes as are specified in clause (a) above, provided that such right shall not include the right or licence to develop or commercialize any product comprised of, interacting with, modulating or is derived from the same
Biological Target for the same indication(s) as any (i) Licensed Product or Residual Product encompassed by the Developing Party&#146;s exclusive rights or licences hereunder; or (ii) Niche Candidate marketed by the Developing Party (or its
Out-licencee) pursuant to the Buy-In-Option. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information
has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the date of such abandonment is prior to the first dosing of humans in clinical trials with such abandoned
Licensed Product, Residual Product or Niche Candidate, Sections <B>12.8(a)</B> and <B>12.8(b)</B> shall apply, save that, in consideration of the grant of such rights, if and only if the other Party subsequently Out-licences such IPR within the
period of *** following the date of the other Party&#146;s assumption of rights, the other Party shall pay to the Developing Party a percentage of all revenue actually received in respect of such licence on the following basis:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the effective date of abandonment is after the first dosing of humans in clinical trials with such abandoned
Licensed Product, Residual Product or Niche Candidate but prior to the first dosing in Phase III, the above Sections <B>12.7(a)</B> and <B>(b)</B> shall apply save that in consideration of the grant of such rights, if and only if the other Party
subsequently Out-licences such IPR within the period of ten years following the date of the other Party&#146;s assumption of rights the other Party shall pay to the Developing Party a percentage of all revenue actually received by the other Party in
respect of such licence on the following basis: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the date of such abandonment is after the beginning of the first dosing in Phase III then NN and IPH shall
***. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of its abandonment of a Licensed Product, Residual Product or Niche Candidate and irrespective of
the effective date of such abandonment, the Developing Party shall: </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make no further representation regarding its status as a licensee of the other Party in respect of such
abandoned Licensed Product, Residual Product or Niche Candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cease any activities with respect to the marketing, promotion, sale or distribution of such abandoned Licensed
Product, Residual Product or Niche Candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event that at the date of such abandonment there are ongoing clinical trials of such abandoned Licensed
Product, Residual Product or Niche Candidate, pay for the completion of such clinical trials in respect of all patients enrolled at the effective date of abandonment except if the Agreement is terminated because of adverse events in the clinical
trial(s) causing the trials(s) to cease due to regulatory requirements or regulatory considerations (including an actual or anticipated regulatory warning); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the other Party&#146;s option and at the other Party&#146;s expense, and to the extent such transfer is
authorized by contract and permitted by applicable Law, to transfer to the other Party, the benefit of any contracts between the Developing Party and any Third Party in respect of the manufacture of such abandoned Licensed Product, Residual Product
or Niche Candidate, with respect to the supply thereof for marketing, provided that for the avoidance of doubt the Developing Party shall not be required to cause or effect any such transfer if to do so will require the Developing Party&#146;s
payment or provision of additional consideration to any Person save that the other Party may elect to pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by applicable Law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the other Party&#146;s option, and at the other Party&#146;s expense, and to the extent authorized by
contract and permitted by applicable Law, assign or cause to be assigned to IPH any regulatory submissions and approvals with respect to such abandoned Licensed Product, Residual Product or Niche Candidate and take such actions and execute such
other instruments, assignments and documents as may be necessary to effect the transfer of all rights thereunder to the other Party; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the other Party&#146;s option and at the other Party&#146;s expense, provide to the other Party all
pre-clinical and clinical data in respect of such abandoned Licensed Product, Residual Product or Niche Candidate and all research reagents and materials intended for use in clinical trials of such abandoned Licensed Product, Residual Product or
Niche Candidate, in the Developing Party&#146;s possession or control; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the other Party shall pay the Developing Party&#146;s reasonable costs in connection with the above activities
at a reasonable hourly rate representing the actual cost of the Developing Party of providing such services up to a maximum of ***. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following the transfer of rights from one Party to another pursuant to this Section <B>12.8</B> the other Party shall have no further
obligations under Sections <B>12.7</B>, <B>12.8</B>, <B>12.9</B> or <B>12.10</B> in respect of the development, sale or marketing of any such product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Without limitation of the Parties&#146; obligations to exercise Commercially Reasonable Efforts, or of any other obligations under this
Agreement or remedies for the material breach thereof, the failure to attain any benchmark or objective set forth in any of Subsections (i), (ii) or (iii) of Section 12.7 shall not constitute a breach of this Agreement, and the provisions of this
Article 12 prescribe the Developing Party&#146;s sole and exclusive liability, and the other Party&#146;s sole and exclusive remedy for such failure.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deleting the text of Section 12.9 in its entirety and replacing it with the following: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;12.9<B>&nbsp;[Reserved]</B>&#148;. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>KNOW-HOW TRANSFER </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH has requested that NN transfer to IPH the Know-How comprising the information (regulatory, clinical, CMC
and other) listed in Exhibit C to this Amendment No.1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall transfer, and take such actions as are reasonably required to ensure the effective transfer of, the
Know-How listed in Exhibit C to Innate as soon as possible and in any event no later than December&nbsp;30, 2008 in accordance with the terms of this Amendment No. 1 including the guidelines set out in Exhibit G. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of any dispute between NN and IPH regarding the actions of NN that are reasonably required to
ensure the effective transfer of the Know-How listed in Exhibit C, such dispute shall in the first instance be referred to the CSO of NN and the CEO of IPH who shall seek to resolve </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
such dispute.&nbsp;In the event that the CSO of NN and the CEO of IPH are unable to resolve the dispute, NN or IPH may seek the non-binding opinion of an expert, in accordance with the procedures
set forth in Exhibit H, on whether or not any additional actions of NN are reasonably required to effect such transfer; <U>provided</U>, <U>however</U>, that neither NN nor IPH shall be obliged to take any actions based on such expert&#146;s
opinion.&nbsp;Notwithstanding the above, either Party may at any time refer any such dispute to arbitration in accordance with Section 21.14 of the Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, on or before December 30, 2008, IPH gives notice to NN that IPH has identified Know-How that is (x)
Controlled by NN at that date, (y) not listed in Exhibit C and (z) necessary for the purposes of IPH&#146;s development or commercialization of the <FONT STYLE="white-space:nowrap">Anti-KIR</FONT> Niche Candidate, then NN shall deliver to IPH the
documents, files and materials containing such Know-How as soon as reasonably practicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH acknowledges and agrees that, subject to Section 5.8.2A of the Agreement (as amended by this Amendment No.
1) and Sections 5.2 and 5.4 of this Amendment No. 1, NN shall have no further obligation to transfer Know-How to IPH pursuant to Section 6.1 of the Agreement or otherwise in connection with IPH&#146;s development and commercialization of Anti-KIR as
a Niche Candidate. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CLINICAL TRIALS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Definitions.</U> The following terms, as used in this subsection herein, shall have the following meanings:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Clinical Trial</U>&#148; shall mean any of&nbsp;the ongoing clinical trials of ***, as further described below.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;***<U> Clinical Trial</U>&#148; shall mean ***. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;***<U> Clinical Trial</U>&#148; shall mean ***. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;***<U> Clinical Trial</U>&#148; shall mean ***. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of NN and IPH shall use all reasonable endeavours to cause the sponsorship of the Clinical Trials to be
transferred to IPH no later than December&nbsp;1, 2008. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH or NN, as appropriate based on the regulatory guidelines applicable, shall use reasonable endeavours to
file with the appropriate regulatory authority an application to transfer sponsorship of each Clinical Trial from NN to IPH no later than November&nbsp;1, 2008, and NN or IPH, as the case may be, shall reasonably cooperate with the other Party in
the preparation of such application. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(a) From the date of the approval of the transfer of sponsorship from NN to IPH of a Clinical Trial, IPH shall
assume responsibility for such Clinical Trial, including any reporting obligations to appropriate regulatory authorities. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In no event will NN be liable to IPH for any claims, suits, losses, damages, costs, fees, or expenses resulting
from the conduct of a Clinical Trial after the date of the approval of the transfer of sponsorship from NN to IPH of such Clinical Trial. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH agrees to indemnify, hold harmless, and defend NN and its Affiliates, against any claims, suits, losses,
damages, costs, fees, or expenses resulting from the conduct of a Clinical Trial after the date of the approval of the transfer of sponsorship from NN to IPH of such Clinical Trial. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where not prohibited by its terms or applicable Law, or not requiring any payment by NN, NN shall use all
reasonable endeavours to assign the rights, benefits and obligations of each agreement set forth in Exhibit F to IPH, and IPH shall accept such assignment, as and from the date on which approval of the transfer of sponsorship from NN to IPH of the
Clinical Trial to which such agreement relates is granted by the appropriate regulatory authority. Pending such assignment to IPH or where such assignment is not possible, IPH shall reimburse NN within *** of NN&#146;s presentation of an invoice to
IPH for payments, falling due pursuant to the agreements set forth in Exhibit F from the earlier of (x) 1&nbsp;November 2008 or (y) the date on which approval of the transfer of sponsorship from NN to IPH of the Clinical Trial to which such payment
or cost relates is granted by the appropriate regulatory authority. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall notify NN upon the completion (i.e., last patient, last visit) of each Clinical Trial.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSFER OF ANTI-KIR SUPPLIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall transfer to IPH the materials described further in Exhibit E (the &#147;<U>Anti-KIR
Supplies</U>&#148;) as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Section 7.3, within *** of the Amendment No. 1 Effective Date, NN shall cause those Anti-KIR
Supplies set forth in Part of A of Exhibit E to be shipped to IPH; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall cause those Anti-KIR Supplies set forth in Part B of Exhibit E which are reasonably required to
conduct a Clinical Trial to be shipped to IPH, or to a location directed by IPH, acting reasonably, as soon as practicable following a request by IPH; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Section 7.3, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(i) NN shall update the &#147;Quality Investigational Medicinal Product Dossier&#148; or Q-IMPD documents in e-submission format related to the
implementation of the second drug product batch of </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been
excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
the Anti-KIR Supplies set forth in Part C of Exhibit E for the re-supply of Clinical Trials *** and ***, and NN or IPH, as NN reasonably deems appropriate, shall file such updated Q-IMPD with the
appropriate regulatory authorities; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(ii) NN shall label using NN labels and package the Anti-KIR Supplies set forth in Part C of
Exhibit E which are reasonably required to conduct the re-supply of Clinical Trials ***, and NN shall use all reasonable endeavours to cause such Anti-KIR Supplies to be shipped to IPH no later than 1&nbsp;January 2009; <U>provided</U>,
<U>however</U>, that NN shall not cause any of such Anti-KIR Supplies to be shipped to IPH if such Anti-KIR Supplies shall fail, in NN&#146;s reasonable determination, the stability testing ongoing at the Amendment No. 1 Effective Date. IPH
acknowledges that is it responsible for any re-labeling of such Anti-KIR Supplies as may be required by applicable regulatory guidelines in connection the use of such Anti-KIR Supplies in Clinical Trials for which sponsorship has been transferred to
IPH. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall transfer those Anti-KIR Supplies set forth in Part D of Exhibit E to IPH at such time as the Parties
agree but no later than January 1, 2009. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Title to the Anti-KIR Supplies shall transfer to IPH upon delivery of such Anti-KIR Supplies to IPH or to a
third party for shipment to IPH and IPH shall be responsible for all storage costs for such Anti-KIR Supplies as and from such date; <U>provided</U>, <U>however</U>, that NN shall be responsible for all shipment (but not including insurance) costs
with respect to such shipment of Anti-KIR Supplies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="6%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">7.3. </P></TD>
<TD WIDTH="9%" VALIGN="Top" ALIGN="left">(a)</TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="left">If the 61 gram batch of Anti-KIR active product ingredient (&#147;<U>API</U>&#148;) identified in Part A of Exhibit E as &#147;API &#150;
hybridoma&#148; (the &#147;<U>Current Batch</U>&#148;) does not meet the &#145;30-month appearance&#146; stability specification reasonably required by IPH to conduct clinical trials, NN acknowledges that IPH will reprocess the Current Batch using a
sub-contractor and IPH acknowledges that IPH will be responsible for the cost of any such reprocessing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If such reprocessing by a sub-contractor does not yield a drug product that meets the specifications reasonably
required by IPH for the conduct of clinical trials, then NN will use reasonable efforts to manufacture a new batch of API from the 146 gram batch of API at the K1-eluate step at Novo Nordisk at the Amendment No. 1 Effective Date, identified in Part
A of Exhibit E as &#147;Hybridoma captured intermediate material&#148;, either by using Novo Nordisk&#146;s facilities or by seeking a sub-contractor to do so. IPH will be responsible for any direct costs associated with such manufacture. NN will
use reasonable efforts to manufacture or seek a subcontractor to manufacture such new batch of API as soon as reasonably practicable and in as cost-effective a manner as reasonably practicable. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">AT THE AMENDMENT NO 1. EFFECTIVE DATE, THE ANTI-KIR SUPPLIES ARE BEING SOLD &#147;AS IS&#148; AND WITHOUT ANY
REPRESENTATIONS OR WARRANTIES BY NN.&nbsp;NN MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, OF ANY TYPE WHATSOEVER, REGARDING THE ANTI-KIR SUPPLIES, AND TO THE FULLEST EXTENT PERMITTED BY LAW, NN EXPRESSLY DISCLAIMS ANY IMPLIED
WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, CONSISTENCY OR COMPLIANCE WITH ANY SAMPLES PREVIOUSLY PROVIDED OR NONINFRINGEMENT. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REGULATORY OR SAFETY DELAY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any provision of this Amendment No. 1: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN may delay the transfer of any Anti-KIR Know-How, any Anti-KIR Supplies or the sponsorship of any Clinical
Trial to IPH; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if transfer of any Anti-KIR Know-How, any Anti-KIR Supplies or the sponsorship of any Clinical Trial shall have
occurred, IPH shall permit access by NN to such Anti-KIR Know-How, Anti-KIR Supplies or Clinical Trial documentation; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">in
each case as may be required, in NN&#146;s reasonable determination, to respond to any request from, or fulfill any requirement of, any regulatory authority, or otherwise to ensure Clinical Trial patient safety. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall use all reasonable endeavours to cooperate with NN to permit NN to respond to any request from, or
fulfill any requirement of, any regulatory authority, or otherwise to ensure Clinical Trial patient safety. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FEES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Fees</U>. In consideration of the grant by NN to IPH of the rights under this Amendment No. 1, the grant by
IPH to NN of the rights under Amendment No. 2 and the transfer of the Anti-KIR Supplies IPH shall pay to Novo Nordisk: *** in each case by wire transfer of immediately available funds to such bank account as NN may designate in writing.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>POST-DOCTORATE RESEARCH </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN has disclosed to IPH that an Employee of NN is currently working on a non-competitive Anti-KIR monoclonal
antibody.&nbsp;NN agrees to grant to IPH, or procure the grant to IPH of, an exclusive right and licence, including the right to Sub-license and Out-license, throughout the Territory to develop and commercialize any Anti-KIR Product under all IPR
created by such Employee (as defined below) that relates to Anti-KIR arising from his research during his employment by NN.&nbsp;NN shall promptly disclose to IPH the results of such research, shall not publish or otherwise disclose to a Third Party
any results arising from such research without the prior written consent of IPH and shall not utilize the results of such research that relate to Anti-KIR for any pre-clinical or clinical activity with respect to Anti-KIR. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Employee&#148; means any employee of NN carrying out research in relation to Anti-KIR.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Effectiveness and Integration</U>. This Amendment shall become effective as of the Amendment No.1 Effective
Date and the amendments made to the Agreement pursuant to Article 3 and Article 4 hereof shall thereafter be deemed an integral part of the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Other Changes or Repetition of Warranties</U>. Except as expressly set forth herein, all provisions of
the Agreement shall remain unchanged and in full force and effect.&nbsp;Nothing in this Amendment No.1 shall cause, or shall be deemed to cause, any representation or warranty set out in the Agreement to be repeated. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Conflicts Between Agreement and Amendment No.1</U>. To the extent that the Agreement is explicitly amended
by this Amendment No.1, the terms of the Amendment No.1 will control where the terms of the Agreement are contrary to or conflict with the provisions of this Amendment.&nbsp;Where the Agreement is not explicitly amended by this Amendment No.1, the
terms of the Agreement will remain in force. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Applicable Law</U>. This Amendment No.1 shall be construed and interpreted pursuant to the Laws stipulated
in the Agreement.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Dispute Resolution</U>. All disputes arising out of or in connection with this Amendment No.1 shall be
finally settled as stipulated in the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts</U>. This Amendment No.1 may be executed in two (2) or more counterparts, each of which shall
constitute an original for all purposes, including for purposes of any delivery of this Amendment No.1 required by the terms hereof, and all of which together shall constitute one and the same instrument with the same effect as if all parties hereto
had signed the same document. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this Amendment No.1 to be executed, under seal, by their respective
duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marseille</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Bagsvaerd</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32" COLSPAN="3"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Innate Pharma SA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Novo Nordisk A/S</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32" COLSPAN="3"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Herv&eacute; Brailly</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jesper Brandgaard</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Herv&eacute; Brailly</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jesper Brandgaard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President and Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.7A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Background NN IPR for the development and commercialization of Anti-KIR as a Niche Candidate </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.16A </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part
A &#150; Anti-KIR Patents </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part B &#150; Shared Anti-KIR Patents </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.17A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-KIR Know-How </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>See
attached</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.17A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-KIR Know-How </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">***
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule 5.8.2A </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-KIR Supplies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">***
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Clinical Trial Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit G </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Basic Guidelines for NN&#146;s and IPH&#146;s Collaboration on Transfer of the Anti- </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KIR Project from NN to IPH </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit H </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Non-Binding Opinion Procedure </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such
information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATED</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2008</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVO NORDISK A/S </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INNATE PHARMA SA </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT AND SUPPLEMENT NO. 2
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOINT
RESEARCH, DEVELOPMENT, OPTION AND LICENCE AGREEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TAYLOR WESSING LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Carmelite </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 Victoria Embankment </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Blackfriars
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">London EC4Y 0DX </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">+44 (0)20
7300 7000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">+44 (0)20 7300 7100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DX41 London </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ref: MRB/TAW </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS AMENDMENT AND SUPPLEMENT NO. 2 TO THE JOINT RESEARCH, DEVELOPMENT, OPTION AND LICENCE AGREEMENT (the
&#147;<B>Amendent</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">is made on&nbsp;&nbsp;&nbsp;&nbsp;October
6<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>,&nbsp;&nbsp;&nbsp;&nbsp;2008 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BETWEEN: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOVO NORDISK A/S </B><FONT STYLE="white-space:nowrap">(CVR-no.</FONT> 24 25 67 90), a corporation existing
under the laws of<I> </I>Denmark and having its principal place of business at Novo<I> </I>All&eacute;, 2880 Bagsvaerd, Denmark (&#147;<B>NN</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INNATE PHARMA SA </B>a corporation existing under the laws of France and having its principal place of
business at Grand Pr&eacute;&nbsp;&#150; 119/121, ancien chemin de Cassis, 13009 Marseille, France (&#147;<B>IPH</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BACKGROUND </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN is a pharmaceutical company with expertise in the discovery and global development of protein drugs.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH is a biotech company with expertise in the discovery and development of drugs and other types of therapy
acting at <FONT STYLE="white-space:nowrap">non-conventional</FONT> lymphocytes such as gamma delta T cells and natural killer (NK) cells. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN and IPH have previously entered into a collaboration governed by an agreement entitled &#147;Joint Research,
Development, Option and License Agreement&#148; with an effective date of 28&nbsp;March 2006 (the &#147;<B>Agreement</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the Agreement, NN and IPH agreed to work, independently, jointly, and/or together with agreed-upon
Third Parties, to (i)&nbsp;discover or identify Drug Candidates, and (ii)&nbsp;optimize Drug Candidates for progression to (a)&nbsp;Licensed Products for further development and commercialization by NN, or (b)&nbsp;Niche Candidates for further
development and commercialization by NN or IPH, for all uses and purposes, including therapeutic, prophylactic and, except as otherwise expressly therein provided, diagnostic uses. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN and IPH have agreed that (i)&nbsp;the Agreement shall be amended to remove Anti-NKG2D (as defined below)
from the scope of the Agreement, (ii)&nbsp;the Assigned IPR (as defined below) and certain assets and materials relating to Anti-NKG2D shall be assigned to NN, and (iii)&nbsp;IPH shall grant NN royalty-free, worldwide licences under Licensed IPR (as
defined below) and the IPH Anti-NKG2D FoO IPR (as defined below) for the purposes of research, development and commercialisation of <FONT STYLE="white-space:nowrap">Anti-NKG2D</FONT> Products (as defined below). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AGREED TERMS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Amendment (including its recitals and any Schedules), unless otherwise stated, all defined terms shall
have the meaning given to them in the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without prejudice to clause 1.1, the following words and expressions shall have the following meanings,
provided that where a term is defined both in the Agreement and in this Amendment, the meaning given to that term in this Amendment shall prevail: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Amendment No.</B><B></B><B>&nbsp;1</B>&#148; means the Amendment and Supplement
No.&nbsp;1 to the Agreement, of the same date as this Amendment; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Anti-NKG2D</B>&#148;<B> </B>fully human or humanized monoclonal
antibodies, antibody fragments, or derivatives of either thereof, which are reactive against wild type, variant or mutant human natural killer cell receptor NKG2D; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Anti-NKG2D IPR</B>&#148; means the Intellectual Property Rights Controlled by IPH at the Effective Date that relate exclusively to
Anti-NKG2D; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Anti-NKG2D Product</B>&#148; means any product that contains Anti-NKG2D; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Anti-NKG2D Project</B>&#148; means the research and collaboration project relating solely to Anti-NKG2D as carried out under or
pursuant to the Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Assigned Assets</B>&#148; means those assets listed in Schedule 1; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Assigned IPR</B>&#148;<B> </B>means such of the Anti-NKG2D IPR as IPH is able to assign to NN, including without limitation the
Intellectual Property Rights listed in Schedule 2; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Date</B>&#148; means the date of this Amendment; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>IPH Anti-NKG2D FoO IPR</B>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) such Patents that are either (i)&nbsp;Controlled, through exclusive ownership, by IPH or its Affiliates during the Term and claim the
benefit of a priority date on or before [30&nbsp;September 2011] or (ii)&nbsp;Controlled, through licence or otherwise but not exclusive ownership, by IPH or its Affiliates at [30&nbsp;September 2008], </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) such <FONT STYLE="white-space:nowrap">Know-How</FONT> that is either (i)&nbsp;Controlled, through exclusive ownership, by IPH or its
Affiliates during the Term and generated on or before [30&nbsp;September 2011] or (ii)&nbsp;Controlled, through licence or otherwise but not exclusive ownership, by IPH or its Affiliates at [30&nbsp;September 2008], and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) such Patents based in part or in whole on <FONT STYLE="white-space:nowrap">Know-How</FONT> that is (i)&nbsp;Controlled, through exclusive
ownership, by IPH or its Affiliates during the Term and (ii)&nbsp;generated on or before [30&nbsp;September 2011], </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">in each of (a)&nbsp;and
(c), that are or is: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(y) not within the Background IPH IPR or Collaboration IPR; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(z) necessary to conduct the research, development and commercialization of Anti-NKG2D Products; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">provided that IPH Anti-NKG2D FoO IPR shall not include any IPR that is generated or acquired by a Third Party prior to it becoming an IPH
Affiliate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licensed IPR</B>&#148; means the Anti-NKG2D IPR other than the Assigned IPR. Licensed
IPR comprises the Patents listed in Schedule 3 and such Intellectual Property Rights covered by the licences listed in Schedule 3. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Amendment (except where the context otherwise requires): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any statute or statutory provision includes a reference to that statute or statutory provision as amended,
extended or <FONT STYLE="white-space:nowrap">re-enacted</FONT> and to any regulation, order, instrument or subordinate legislation under the relevant statute or statutory provision; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the singular includes a reference to the plural and vice versa; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any paragraph of the introduction, clause, <FONT STYLE="white-space:nowrap">sub-clause</FONT> or schedule is to
a paragraph of the introduction, clause, <FONT STYLE="white-space:nowrap">sub-clause</FONT> or schedule (as the case may be) of or to this agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the word &#147;include&#148; or &#147;including&#148; is, unless otherwise stated, to be construed without
limitation to the generality of the preceding words; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any person includes any reference to a body corporate, unincorporated association or a partnership and any
reference to any party who is an individual is also deemed to include his respective legal personal representative(s). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RELATIONSHIP WITH AMENDMENT NO 1</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Amendment shall not be effective until Amendment No.&nbsp;1 is in effect. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AMENDMENT OF THE AGREEMENT WITH RESPECT TO ANTI-NKG2D</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN and IPH agree that, with effect from the Effective Date, the Agreement shall be amended to exclude any
application to Anti-NKG2D and the Anti-NKG2D Project. In particular, and without limitation, all licences granted by one Party to another under the Agreement for the purposes of the research, development and commercialization of Anti-NKG2D shall
cease to have effect on the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNMENT OF IPR </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH hereby assigns and transfers absolutely to NN all of its existing rights, title and interest in and to the
Assigned IPR and the Assigned Assets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall execute, sign and do all such further documents, acts and things as NN may reasonably require to vest
fully in it all of IPH&#146;s right, title and interest in the Assigned IPR and the Assigned Assets. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSFER OF ASSETS AND <FONT STYLE="white-space:nowrap">KNOW-HOW</FONT></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within sixty (60)&nbsp;days of the end of the Collaboration Term, IPH shall deliver to NN:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the documents, files, materials and other assets comprised in the Assigned Assets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any further materials that embody the Anti-NKG2D IPR. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, on or before [December 30, 2008], NN gives notice to IPH that NN has identified <FONT
STYLE="white-space:nowrap">Know-How</FONT> that is (x)&nbsp;Controlled by IPH at that date, (y)&nbsp;not set forth in Schedule [3] and (z)&nbsp;necessary for the purposes of NN&#146;s research, development or commercialization of Anti-NKG2D
Products, then IPH shall deliver to NN the documents, files and materials containing such <FONT STYLE="white-space:nowrap">Know-How</FONT> as soon as reasonably practicable. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LICENCE</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH hereby grants to NN an exclusive, worldwide, royalty-free licence under the Licensed IPR to conduct
research, development and commercialisation of Anti-NKG2D Products, save that the licence in respect of the antibody ON72 and US patent application No 10/898,003 is limited solely to such rights as IPH may have in respect of such assets,.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH hereby grants to NN a worldwide, royalty-free <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licence
(with the right to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT STYLE="white-space:nowrap">Out-license)</FONT> under any IPH Anti-NKG2D FoO IPR to conduct the research, development and commercialisation of Anti-NKG2D Products.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NO WARRANTY </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Assigned IPR and the Assigned Assets are assigned and transferred under this Amendment &#147;as is&#148;,
without any representation or warranty by IPH. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Licensed IPR and the IPH Anti-NKG2D FoO IPR are licensed under this Amendment &#147;as is&#148;, without
any representation or warranty by IPH. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH makes no representation or warranty, express or implied (whether by statute, custom, trade practice or
otherwise), regarding any of the Assigned IPR, the Assigned Assets, the Licensed IPR or the IPH Anti-NKG2D FoO IPR , and to the fullest extent permitted by law, IPH expressly disclaims any implied warranties, including without limitation warranties
of merchantability fitness for a particular purpose or <FONT STYLE="white-space:nowrap">non-infringement.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LIMITATION OF LIABILITY</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except for injury or loss arising from wilful misconduct, including fraud, of IPH, in no event will IPH be
liable to NN for any injury to or loss of, data, goodwill, or reputation (irrespective of whether any such injury or loss is deemed to constitute general, direct or any other category of damages), or any special, indirect, punitive, exemplary,
enhanced, trebled, incidental or consequential damages whatsoever, arising out of or in connection in any way with this Amendment or any subject matter hereof (including any exercise of any rights or licenses, or performance, or failure to perform,
any obligations or activities hereunder), even if IPH has been advised of the possibility of such losses, damages or liabilities, and whether or not or such losses, damages or liabilities arise in contract, warranty, tort (including negligence),
strict liability, product liability or any other theory of liability. In the event that any foregoing exclusion or limitation of liability is not allowed pursuant to applicable law in a jurisdiction, the liability of IPH in such jurisdiction shall
be limited to the maximum extent permitted by applicable law. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GENERAL</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Failure by a Party to exercise or enforce any right conferred by this Amendment shall not be deemed to be a
waiver of any such right nor operate so as to bar the exercise or enforcement of such right or of any other right on any other occasion. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any part, term or provision of this Amendment not being of a fundamental nature is held illegal or
unenforceable, the validity or enforceability of the remainder of this Amendment shall not be affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Amendment may only be modified if such modification is in writing and signed by a duly authorised
representative of each Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A person who is not a party to this Amendment has no rights (and the parties hereby exclude any such rights)
under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this Amendment but this does not affect any third party right or remedy which exists or is available apart from that Act. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Amendment may be executed in any number of counterparts, each of which, when executed and delivered, is an
original, but all the counterparts taken together shall constitute one document. This Amendment shall not take effect until it has been executed by all the Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Amendment shall be governed by and construed in accordance with English law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Both Parties will use their best efforts to settle all matters in dispute amicably. In the event that a dispute
of any kind related to this Amendment cannot be solved amicably by the Parties, then either Party may submit the dispute for determination by binding arbitration before a panel of three arbitrators (one arbitrator chosen by each of the parties and
the third arbitrator chosen by the first two, unless the parties agree otherwise), the third arbitrator having a minimum of five (5)&nbsp;years of experience in the field of biotechnology or pharmaceuticals and shall be administered under the WIPO
Expedited Arbitration Rules except as to the number of arbitrators which shall be three (3). The venue for the arbitration shall be in London, England, conducted in the English language, and the governing law shall be that of England and Wales
without regard to the <FONT STYLE="white-space:nowrap">conflicts-of-laws</FONT> provisions of such laws. The arbitrators shall have the authority to grant specific performance and to allocate between the parties the costs of arbitration, including
but not limited to reasonable attorney&#146;s fees, in such equitable manner as they determine. Notwithstanding the foregoing dispute resolution and governing law provisions, each of IPH and NN retains the right to seek judicial injunctive relief.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of any conflict between the terms of this Amendment, the Agreement and Amendment No 1, the terms of
this Amendment shall prevail. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this Amendment No.1 to be executed, under seal, by their respective
duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Marseille</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Bagsvaerd</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Innate Pharma SA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Novo Nordisk A/S</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Herv&eacute; Brailly</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jesper Brandgaard</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Herv&eacute; Brailly</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jesper Brandgaard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive Vice President and Chief</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Financial Offer</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Assigned Assets </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Assigned IPR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:0%; font-size:11pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Licensed IPR </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such
information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT AND SUPPLEMENT NO. 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOINT RESEARCH,
DEVELOPMENT, OPTION AND LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to the Joint Research, Development, Option and License Agreement dated March&nbsp;28, 2006, as
amended by Amendment and Supplement No.&nbsp;1, dated October&nbsp;8, 2008, and Amendment and Supplement No.&nbsp;2, dated October&nbsp;8, 2008 (collectively &#147;the Agreement&#148;) between Innate Pharma SA, a corporation existing under the laws
of France (&#147;IPH&#148;), and Novo Nordisk A/S, a corporation existing under the laws of Denmark (&#147;NN&#148;) (NN and IPH may each individually be referred to as a &#147;Party&#148; and collectively as &#147;Parties&#148;); and </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Whereas</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Parties wish to extend the period in which NN may achieve M0 in respective of the NKp46 and <FONT
STYLE="white-space:nowrap">LLT-1</FONT> Projects; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Whereas</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Parties wish to simplify the management of patent prosecution matters in and arising from the
Collaboration; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Whereas</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Parties can amend the Agreement upon written mutual agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Whereas</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties have agreed to execute this amendment (the &#147;Amendment&#148;); </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now, therefore, intending to be legally bound, the Parties agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties agree that the terms of this Amendment are intended to be supplemental to the terms of the
Agreement. The terms of the Agreement remain in full force and effect and shall apply to the Amendment as well. To the extent the Agreement is explicitly amended by this Amendment, the terms of this Amendment will control. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Amendment the phrase &#147;<B>Amendment and Supplement No.</B><B></B><B>&nbsp;3 Effective
Date</B>&#148; means the date of this Amendment and Supplement No.&nbsp;3. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Agreement is hereby amended as follows (for convenience all modifications are bolded, additions are
underlined, and deletions are identified by strikethroughs). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The beginning portion of Section&nbsp;1.1.63 is amended by substitution with the following amended passage:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1.63</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<U>Residual Product</U>&#148; shall mean a Drug Candidate to which: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">NN is granted the exclusive rights to develop and commercialize under this Agreement by virtue of such Drug Candidate having achieved at least M0 status but less than M1 status as of <B><U>either</U></B>
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><U>(x)</U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U></U></B>the expiration of the *** period following immediately after: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the expiration of the Collaboration Term pursuant to Subsection <B>13.3.3</B>, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN&#146;s termination of the Agreement prior to the expiration of the Collaboration Term for an IPH Change of
Control or other IPH Transfer, pursuant to <B>Section</B><B></B><B>&nbsp;13.5</B>, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN&#146;s termination of the Agreement prior to the expiration of the Collaboration Term for IPH&#146;s
material breach pursuant to Section<B>&nbsp;13.7</B>; or </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain
information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><U>(y)</U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>December</U><U></U><U>&nbsp;31, 2009 in the case of Drug Candidates that modulate action of NKp46 and/or <FONT
STYLE="white-space:nowrap">LLT-1;</FONT> or</U> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section [4.3(h)] is substituted with the following amended Section 4.3(h): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">considering and, if necessary updating, Schedule<B> 1.1.22 </B>(Collaboration Targets)&nbsp;(i) no less frequently than once during each <FONT STYLE="white-space:nowrap">six-</FONT>
<FONT STYLE="white-space:nowrap">(6-)</FONT> month period in the Collaboration Term, (b)&nbsp;within fifteen (15)&nbsp;days after receipt of the written request of either Party during the Collaboration Term, and (c)&nbsp;in a final version of such
Schedule to be fixed and final as of <B><U>September</U></B><B><U></U></B><B><U>&nbsp;28, 2009</U></B> <B><STRIKE>the date of the expiration or earlier termination of the Collaboration Term</STRIKE></B>, <B><U>which final version shall include the
designation of CD147, NKp46 and <FONT STYLE="white-space:nowrap">LLT-1</FONT> as Collaboration Targets</U></B>; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The beginning portion of Section&nbsp;7.3 is substituted with the following amended portion:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>Discovery Milestones</U>. NN shall pay to IPH the following milestone payments for the Collaboration achievements in research set out below (&#147;<U>Discovery Milestones</U>&#148;) within *** of the achievement of
each such Discovery Milestone: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Approval by NN of M0 status as defined in Schedule 1.1.51 <B><STRIKE>after the date of this
Agreement</STRIKE></B> <B><U>(a)</U></B><B><U></U></B>&nbsp;during the Collaboration Term<B><U>, (b)</U></B><B><STRIKE>&nbsp;or</STRIKE></B> within the *** period following immediately after the Collaboration Term<B><U>, or
(c)</U></B><B><U></U></B><B><U>&nbsp;by December</U></B><B><U></U></B><B><U>&nbsp;31, 2009 in the case of achievement of M0 status for a Drug Candidate that modulates action of NKp46 and/or <FONT STYLE="white-space:nowrap">LLT-1</FONT></U></B>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Each of the first three <FONT STYLE="white-space:nowrap">Pre-projects</FONT> passing M0:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Each of the subsequent
<FONT STYLE="white-space:nowrap">Pre-projects</FONT> passing M0: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;13.3.3 is substituted with the following amended Section&nbsp;13.3.3: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3.3</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>NN Residual Rights in the Field Upon Expiration of Collaboration Term</U>. Without limitation of NN&#146;s rights under Subsection <B>13.3.2</B> and in addition thereto, NN shall have the exclusive right and license
throughout the Territory during the Term, pursuant to the terms and conditions of the rights and licenses granted to it under Sections <B>5.1</B> and <B>5.8</B>, to develop and commercialize Residual Products from Drug Candidates that have attained
at least M0 status but not M1 status during <B><U>(a)</U></B><B><U></U></B>&nbsp;the Collaboration Term<B><U>, (b)</U></B><B><STRIKE>&nbsp;or</STRIKE></B> prior to the expiration of the *** period following immediately after the effective date of
the expiration of the Collaboration Term<B><U>, or (c)</U></B><B><U></U></B><B><U>&nbsp;by December</U></B><B><U></U></B><B><U>&nbsp;31, 2009 in the case of Drug Candidates that modulate action of NKp46 and/or
<FONT STYLE="white-space:nowrap">LLT-1</FONT></U></B>. The royalties payable to IPH on Net Sales of such Residual Products shall be governed by the terms and conditions of Article <B>7</B> <I>save that</I> royalties payable to IPH on Net Sales of
such Residual Products that would, upon achievement of M1, be classified as Class&nbsp;C Licensed Products and for which M0 status has been achieved less than *** prior to the expiry of the Collaboration Term shall be reduced by *** from the
applicable royalties set forth in Article <B>7</B>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;13.3.5 is substituted with the following amended Section&nbsp;13.3.5: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3.5</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>IPH Residual Rights in the Field Upon Expiration of Collaboration Term</U>. </TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">
Without limitation of IPH&#146;s rights under Subsection <B>13.3.4</B> and in addition thereto, IPH shall have, throughout the Territory during the Term, under all Background NN Research
Technology IPR and Collaboration IPR Controlled by NN, the exclusive right and license, with the rights to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT STYLE="white-space:nowrap">Out-license,</FONT> to develop and commercialize
Residual Products from Drug Candidates that have not attained at least M0 status, <B><U>either (a)</U></B>&nbsp;as of the effective date of the expiration or earlier termination of the Collaboration Term<B><U>,
(b)</U></B><B><STRIKE></STRIKE></B><B><STRIKE>&nbsp;or</STRIKE></B> prior to the expiration of the *** period following immediately thereafter, <B><U>or (c)</U></B><B><U></U></B><B><U>&nbsp;by December</U></B><B><U></U></B><B><U>&nbsp;31, 2009 in
the case of Drug Candidates that modulate action of NKp46 and/or <FONT STYLE="white-space:nowrap">LLT-1,</FONT></U></B> and shall retain, throughout the Territory during the Term, the right, pursuant to the terms and conditions of
Section<B>&nbsp;5.8</B>, to NN&#146;s reasonable cooperation and assistance in granting or procuring the grant to IPH of the rights and licenses required for IPH&#146;s freedom of operation to exercise the aforementioned exclusive right and license,
<I>provided that</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sections 9.1A.2, 9.1A.3, 9.1A.4, and 9.1A5 are deleted. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;9.6 is amended by the addition of a new Section&nbsp;9.6.0: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><U>9.6.0</U></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><U>Group I Patents</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Group I Patents&#148; means all Patents in Schedule
1.1.5, item 1 (NKG2A Autoimmune/INNA-041228), Schedule 1.1.5 item 7 <FONT STYLE="white-space:nowrap">(Anti-KIR/ADCC/INNA-030724),</FONT> and Schedule 1.1.16, item 2.5 (LDGL CIP/INNA-051014), and any continuations or divisionals thereof or patents
issuing from any such patent applications and all patent applications claiming priority to ***, any patent application directed to an invention made before December</U></B><B><U></U></B><B><U>&nbsp;31, 2009 relating to agents that modulate NKp46
and/or <FONT STYLE="white-space:nowrap">LLT-1</FONT> and that is based on a new original application not listed in the update to the Schedules of May</U></B><B><U></U></B><B><U>&nbsp;22, 2008, and any continuations or divisionals thereof or patents
issuing from any such patent applications).</U></B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;9.6.1 is amended by substitution with the following amended Section: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.6.1</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>Correspondence Regarding Proposed Patent Submissions</U>. Subject to the terms and conditions of Section<B></B><B>&nbsp;21.2</B> (and the Common Interest Agreement annexed as Schedule <B>21.2</B> hereto), the Party
responsible for prosecuting any <B><U>Group&nbsp;I</U></B> Patent under this Article <B>9</B> shall promptly<B><STRIKE>,</STRIKE></B> and in <B>***</B> prior to any final deadline for submission of such documents or required filing date, deliver or
have delivered to the other Party copies of: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all proposed amendments, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all proposed Patents (including drafts of new original applications, proposed continuations, proposed
divisional applications, proposed reissue applications, and proposed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part)</FONT></FONT> or, in instances where several proposed Patents are substantially similar, a
representative Patent for such proposed Patents (such as in the case of national phase filing of an International (PCT) patent application), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all substantive documents proposed to be filed in patent authority appeal proceedings, </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all substantive documents proposed to be filed in inter partes disputes (including opposition, reexamination,
or interference proceedings) before patent authorities or before any judicial body on appeal of such proceedings, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other substantive proposed patent authority submissions reasonably and specifically requested by the other
Party, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">in respect of such <B><U>Group I</U></B> Patents <B><STRIKE>(except for Patents in the Independent IPR of either
Party)</STRIKE></B>, so as to provide the other Party with a sufficient opportunity to review and comment on such proposed submissions. However, except as otherwise provided for in this Section<B>&nbsp;9.6</B>, the prosecuting Party shall have no
obligation to act in accordance with any such comments. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;9.6.8 is amended by substitution with the following amended section: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.6.8</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>Notice and Effects of Either Party&#146;s Decision to Abandon; Disclaim; or Discontinue Prosecution, Maintenance, or Defense of Patents</U>. In the event that either Party decides in respect of any Patent for which
it is responsible for prosecution hereunder (except for Patents within the Independent IPR of that Party): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to discontinue the prosecution or maintenance of any Patent, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to discontinue the defense of any Patent (such as by discontinuing efforts to defend a Patent that is the
subject of an opposition, reexamination, nullity, or interference proceeding), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to not file a priority patent application with respect to (i)&nbsp;an invention disclosure in the Collaboration
IPR or (ii)&nbsp;any Patent to which it is the prosecuting Party (including by decision (A)&nbsp;not to enter the national or regional phase in any country or region that is a designated state of a PCT application filed by such Party or (B)&nbsp;not
to pursue an application in a country wherein an application claiming priority to another application filed by such Party may be filed), or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to abandon or disclaim (in whole or in part, other than by terminal disclaimer), without possibility of
restoration, any Patent, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">it shall <B><U>employ its best efforts to</U></B><B> </B>provide written notice to the other
Party at least *** in advance of such abandonment or deadline for such filing &#150; except in the case of national phase filing, in which case <B><U>the notifying Party shall employ its best efforts to provide</U></B><B> </B>such notice at least
*** in advance of the date of the first applicable deadline for national phase entry &#150; so as to allow the other Party the opportunity to file, defend, maintain (including by payment of annuities, issue fees, maintenance fees, or the like), or
continue prosecution of such Patent, at its own expense. In such an event, the notifying Party shall provide any assistance reasonably requested of it by the other Party (including providing the other Party with power of attorney to perform such
tasks) and, to the extent authorized by contract and permitted by applicable Law, assign its rights to such Patent to the other Party. <B><U>Automatically upon any such assignment, the notified Party hereby automatically grants</U></B>
<B><STRIKE>The notified Party shall thereafter grant to</STRIKE></B> the notifying Party a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license<B><U>, including the right to sublicense through multiple tiers,</U></B> with respect
to such Patent for no additional </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this
agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
consideration. The Parties acknowledge that any abandoned Patents listed as Background IPR as of the date of this Agreement in the applicable Schedules hereto represent <FONT
STYLE="white-space:nowrap">Know-How</FONT> of the Party associated with such IPR and that such Party shall, during the Term, be entitled to file, prosecute, and maintain Patents in respect of such subject matter and any Patents arising therefrom
shall be deemed Background IPR of such Party. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from the Amendment No.&nbsp;3 Effective Date, Schedule 21.2 of the Agreement will be deleted and
replaced with the following Common Interest Agreement: </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 21.2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>COMMON INTEREST AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NN and IPH hereby set forth their agreement regarding the Parties&#146; common legal interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prosecution and maintenance of Patents under the Agreement has required, and prosecution, maintenance, enforcement, and exploitation of
Patents may in the future require, the disclosure by one Party to the other Party of privileged information including, for example, information relevant to a Party&#146;s strategy for prosecuting, maintaining, or exploiting the Patents and/or
information regarding a Party&#146;s proprietary business strategy, technology, products, or methods. The Parties have believed, and on the basis of currently available information continue to believe, that they share common and substantially
identical legal interests relating to the Patents and Agreement (&#147;Joint Interest Matters&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such exchange or disclosure of
materials among the Parties and their counsel has been done and will be done solely to further the Parties&#146; separate but common interests, and will be treated as confidential and protected from disclosure to any third parties by the
attorney-client privilege. It is the Parties&#146; mutual understanding that such exchanges or disclosures are not intended to diminish in any way the confidentiality of privileged materials. It is their additional understanding that any exchange of
privileged materials does not constitute a waiver of any otherwise available privileges and immunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties agree that any
privileged materials they exchange pursuant to this Agreement will be used solely in connection with the Joint Interest Matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Parties also agree that nothing in this Common Interest Agreement requires any Party to make available any specific documents, materials, information, or communications, unless otherwise agreed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties further agree to take all actions necessary to maintain the privilege of such materials unless otherwise agreed by the Parties.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties additionally agree that any Party may withdraw from this Common Interest Agreement upon written notice to the other Party at
their regular place of business and, upon such notice, this Common Interest Agreement will be terminated as to that Party; provided, however, that no such termination will affect or impair the obligations of the confidentiality or the privilege or
immunities with respect to privileged materials previously furnished pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in this Agreement,
each Party is responsible for its own legal expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any person or entity requests or demands, by subpoena or otherwise, any
privileged materials from any Party, such Party will promptly notify the other Party to this Agreement of the request or demand and provide such Party with a copy of said request or demand prior to making the disclosure. The Party in receipt of the
request or demand will assert all applicable rights, privileges and objections with respect to such request or demand, and cooperate fully with the other Party, with the other Party paying the Party&#146;s reasonable expenses, in making every
reasonable effort to prevent the disclosure of the privileged materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing in this Agreement shall be construed to affect the
separate and independent representation of each Party by its respective counsel according to what its counsel believes to be in its Party&#146;s best interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Common Interest Agreement by and between the Parties memorializes the understandings between the Parties as to the sharing of information
relating to the Joint Interest Matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Party understands that this Common Interest Agreement does not, and will not, create an
attorney-client relationship with the other Party&#146;s counsel. </P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By signing below, each person signing this Amendment acknowledges his/her acceptance of the above-described
changes that are to be effective as of the day of the last to sign and that such changes will become an integral part of the Agreement. Further, each person who executes this Amendment represents and warrants that he/she has the authority to cause
the Party he or she is associated with to enter into this Amendment and be obligated to perform the obligations set forth herein. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signed by: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2009-06-26</FONT></FONT></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of Novo Nordisk A/S</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Terje Kalland</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Terje Kalland</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: Senior Vice President,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biopharmaceutical Research Unit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2009-06-26</FONT></FONT></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of the Innate Pharma SA</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Herv&eacute; Brailly</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Herv&eacute; Brailly</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: Chief Executive Officer</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Amendment No. 4 is made and entered into as of December 13<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> 2010 (&#147;Effective Date of this
Amendment&#148;) between Innate Pharma SA, a corporation existing under the laws of France (&#147;IPH&#148;) and Novo Nordisk A/S, a corporation existing under the laws of Denmark (&#147;NN&#148;) with regards to the Joint Research, Development,
Option and License Agreement dated March 28, 2006, as amended by Amendment and Supplement No. 1, dated October 8, 2008, and Amendment and Supplement No. 2, dated October 8, 2008, and Amendment and Supplement No. 3, dated June 26, 2009 (collectively
the &#147;Agreement&#148;). NN and IPH may each individually be referred to as &#147;Party&#148; and collectively as &#147;Parties&#148;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Whereas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">under the Agreement, the Parties have agreed to collaborate and conduct research on the targets LLT-1 (Lectin-like Transcript-1, also known as CLEC2D) and NKp46 (Natural Cytotoxicity triggering receptor-1, also known as NCR1).
Originally these targets were designated as Exploratory Targets according to Schedule 1.1.33 of the Agreement. However, in Amendment and Supplement No. 3 as mentioned above, the Parties agreed to designate these targets as Collaboration Targets in
Schedule 1.1.22 of the Agreement. In addition to these targets the Parties have separately agreed to collaborate and conduct research on MICA/B (MHC class I polypeptide-related sequence A and -B). LLT-1, NKp46 and MICA/B are in this Amendment No. 4
jointly referred to as the Targets.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Whereas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">the Parties now wish to discontinue the collaboration regarding the Targets, including discontinuing designating the Targets as Collaboration Targets and/or Exploratory Targets. Each Party will as of the Effective Date of this
Amendment have the right to freely conduct research with regards to the Targets.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Whereas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NN shall have the right to use IPH&#146;s Know-How (as defined in the Agreement) developed under the Agreement and existing as of the Effective Date of this Amendment, if any, in any future research, use or exploitation relating
to the LLT-1.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Whereas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">IPH shall have the right to use NN&#146;s Know-How (as defined in the Agreement) developed under the Agreement and existing as of the Effective Date of this Amendment, if any, in any future research, use or exploitation relating
to the NKp46 and MICA/B .</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Whereas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">the Parties can amend the Agreement upon written mutual agreement and have agreed to do so in this Amendment No. 4.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now, therefore, the Parties, intending to be legally bound agree as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The terms defined in the Agreement shall have the meaning herein as therein, unless otherwise defined herein or
unless the context otherwise requires. To the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
extent that the Agreement is explicitly amended by this Amendment, the terms of the Amendment will control where the terms of the Agreement are contrary to or conflict with the following
provisions. Where the Agreement is not explicitly amended by this Amendment, the terms of the Agreement will remain in force.</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties agree that the Targets, as defined above, will as of the Effective Date of this Amendment,
discontinue being part of the Parties&#146; collaborative research activities, including discontinuing being in the definition of Collaborative Target or Exploratory Target. As of the Effective Date of this Amendment any rights or obligations of the
Parties pertaining to (i) the Targets and (ii) the Parties collaboration under the Agreement are exclusively stipulated in this Amendment No. 4. Hence, as of the Effective Date of this Amendment, the Parties will have no rights or obligations
(including any payment obligations) under the Agreement in relation to the Targets except for what is specifically stated in this Amendment No. 4. For the sake of clarity, NN will have no obligations to make any payments to IPH relating to the
Targets (including Discovery Milestones as set out in 7.3 of Amendment No. 3). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH hereby grants to NN a world-wide, non-exclusive, perpetual license, with the right to sublicense, to
IPH&#146;s Know-How relating to LLT-1 developed under the Agreement and existing as of the Effective Date of this Amendment, if any, to research, develop, make, have made, use, import, export, distribute, sell, offer for sale, and otherwise transfer
LLT-1 products. The consideration for the license granted herein is the mutual granting of the license and no payments will be made by either Party to the other Party under this Amendment or at any time for this license. For the sake of clarity,
this license does not include any rights to Know-How developed by IPH (i) outside the Agreement, or (ii) after the Effective Date of this Amendment No. 4. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN hereby grants to IPH a world-wide, non-exclusive, perpetual license, with the right to sublicense, to
NN&#146;s Know-How relating to NKp46 and MICA/B developed under the Agreement and existing as of the Effective Date of this Amendment, if any, to research, develop, make, have made, use, import, export, distribute, sell, offer for sale, and
otherwise transfer NKp46 and MICA/B products. The consideration for the license granted herein is the mutual granting of the license and no payments will be made by either Party to the other Party under this Amendment or at any time for this
license.&nbsp;For the sake of clarity, this license does not include any rights to Know-How developed by NN (i) outside the Agreement, or (ii) after the Effective Date of this Amendment No. 4. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limiting the aforementioned, as of the Effective Date of this Amendment, each Party, by itself or in
collaboration with any third party, has the right to (i) freely conduct any research relating to the Targets; (ii) file any patent application without providing notification to the other Party relating to the Targets. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Amendment does not cause any of the Parties to transfer any documents, materials or other Know-How to the
other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Amendment shall be deemed an integral part of the Agreement. Except as expressly set forth herein, all
provisions of the Agreement shall remain unchanged and in full force and effect. The Parties expressly affirm their mutual intention that this Amendment to the Agreement shall constitute a legally binding Amendment to the Agreement.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Amendment shall be construed and interpreted pursuant to the laws stipulated in the Agreement. All
disputes arising out of or in connection with the present Amendment shall be finally settled by arbitration as stipulated in the Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS HEREOF the Parties have executed and delivered this Amendment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">On behalf of Novo Nordisk A/S</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">On behalf of Innate Pharma SA</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Esper Boel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Herv&eacute; Brailly</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Esper Boel</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: Corp. Vice
President</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date: Jan. 5/2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Herv&eacute; Brailly</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: C.E.O.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date: 16&nbsp;December 2010</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such
information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;5 is made and entered into as of 13&nbsp;December 2010 (&#147;Effective Date of this Amendment&#148;) between Innate Pharma SA, a
corporation existing under the laws of France (&#147;IPH&#148;) and Novo Nordisk A/S, a corporation existing under the laws of Denmark (&#147;NN&#148;) with regards to the Joint Research, Development, Option and License Agreement dated
March&nbsp;28, 2006, as amended by Amendment and Supplement No.&nbsp;1, dated October&nbsp;8, 2008, and Amendment and Supplement No.&nbsp;2, dated October&nbsp;8, 2008, Amendment and Supplement No.&nbsp;3, dated June&nbsp;26, 2009, Amendment
No.&nbsp;4, dated [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] (collectively the &#147;Agreement&#148;). NN and IPH may each individually be referred to as
&#147;Party&#148; and collectively as &#147;Parties&#148;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Whereas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">under the Amendment and Supplement No.&nbsp;1, dated October&nbsp;8, 2008, the Parties have agreed to classify <FONT STYLE="white-space:nowrap">Anti-KIR</FONT> as a Niche Candidate for IPH&#146;s sole independent further
development and commercialisation, and the Parties have inserted Exhibit B of the Amendment and Supplement No.&nbsp;1, dated October&nbsp;8, 2008 as Schedule 1.1.16A to the Agreement, listing the <FONT STYLE="white-space:nowrap">Anti-KIR</FONT>
patents licensed by NN to IPH.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Whereas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NN has now been assigned rights in patents filed by the Trustees of Indiana University, the patents arising out of a material transfer agreement between NN and Trustees of Indiana University dated February&nbsp;27,
2007.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Whereas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">the Parties now wish to update Parts A and B of Schedule 1.1.16A to the Agreement to include the patents filed by the Trustees of Indiana and assigned to Novo Nordisk.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Whereas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">the Parties can amend the Agreement upon written mutual agreement and have agreed to do so in this Amendment No.&nbsp;5.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now, therefore, the Parties, intending to be legally bound agree as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The terms defined in the Agreement shall have the meaning herein as therein, unless otherwise defined herein or
unless the context otherwise requires. To the extent that the Agreement is explicitly amended by this Amendment, the terms of the Amendment will control where the terms of the Agreement are contrary to or conflict with the following provisions.
Where the Agreement is not explicitly amended by this Amendment, the terms of the Agreement will remain in force. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN and IPH hereby agree that as from the Effective Date of this the following Patents shall be deemed
incorporated into Part A <U>and</U> Part B of Schedule 1.1.16A. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application&nbsp;No.</B><br><B>Filing&nbsp;date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Status</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Combination&nbsp;therapy&nbsp;to&nbsp;enhance&nbsp;NK cell&nbsp;mediated&nbsp;cytotoxicity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Abandoned</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PCT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Combination therapy to enhance NK cell mediated cytotoxicity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Pending</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Amendment shall be deemed an integral part of the Agreement. Except as expressly set forth herein, all
provisions of the Agreement shall remain unchanged and in full force and effect. The Parties expressly affirm their mutual intention that this Amendment to the Agreement shall constitute a legally binding Amendment to the Agreement.
</P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement
(indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Amendment shall be construed and interpreted pursuant to the laws stipulated in the Agreement. All
disputes arising out of or in connection with the present Amendment shall be finally settled by arbitration as stipulated in the Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS HEREOF the Parties have executed and delivered this Amendment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">On behalf of Novo Nordisk A/S</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">On behalf of Innate Pharma SA</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Esper Boel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Herv&eacute; Brailly</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Esper Boel</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: Corp. Vice
President</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date: Jan. 5/2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Herv&eacute; Brailly</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: CEO</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date: December 16<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2010</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such
information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Amendment No. 6 (the &#147;Amendment&#148;) is made and entered into as of 1&nbsp;July, 2011 (&#147;Amendment No. 6 Effective Date&#148;) between Innate
Pharma SA, a corporation existing under the laws of France (&#147;IPH&#148;) and Novo Nordisk A/S, a corporation existing under the laws of Denmark (&#147;NN&#148;) with regards to the Joint Research, Development, Option and License Agreement dated
March 28, 2006, as amended by Amendment and Supplement No.1, dated October 8, 2008, Amendment and Supplement No. 2, dated October 8, 2008, Amendment and Supplement No. 3, dated June 26, 2009, Amendment No. 4, dated December 13, 2010, and Amendment
No. 5, dated December 13, 2010 (collectively, the &#147;Agreement&#148;). NN and IPH may each individually be referred to as &#147;Party&#148; and collectively as &#147;Parties&#148;. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Whereas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">pursuant to the Agreement, NN and IPH agreed to work, independently, jointly and/or together with agreed-upon Third Parties, to (a) discover or identify Drug Candidates, and (b) optimize Drug Candidates for progression to (i)
Licensed Products for further development and commercialization by NN or (ii) Niche Candidates for further development and commercialization by IPH (either alone or together with NN), in each case for all uses and purposes, including therapeutic,
prophylactic and, except as otherwise expressly therein provided, diagnostic uses;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Whereas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">pursuant to Amendment No.1 and with effect from the Amendment No.1 Effective Date, NN classified Anti-KIR as a Niche Candidate for independent further development and commercialization by IPH for any human therapeutic, prophylactic
or diagnostic indication or application;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Whereas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as a condition precedent to its entry into a license agreement with IPH pursuant to which Bristol-Myers Squibb Company (&#147;BMS&#148;) will become an Out-licensee under the Agreement (the &#147;Outlicense&#148;), BMS has requested
that NN and IPH further amend the Agreement to clarify certain matters with respect to the rights and obligations of the Parties and of BMS thereunder with respect to Anti-KIR; and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Whereas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Parties can amend the Agreement upon written mutual agreement and have agreed to do so in this Amendment No. 6.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now, therefore, the Parties, intending to be legally bound, agree as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The terms defined in the Agreement shall have the meaning herein as therein, unless otherwise defined herein or
unless the context otherwise requires. To the extent that the Agreement is explicitly amended by this Amendment, the terms of the Amendment will control where the terms of the Agreement are contrary to or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
conflict with the following provisions. Where the Agreement is not explicitly amended by this Amendment, the terms of the Agreement will remain in force. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Collaboration Term expired as of March 28, 2009. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from the Amendment No. 1 Effective Date, Section 1.1.4 is hereby amended as follows:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;1.1.4&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Anti-KIR</U>&#148; or &#147;<U>Anti-KIR Antibody</U>&#148; shall mean ***.
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from the Amendment No. 1 Effective Date, the definition of &#147;Anti-KIR Product&#148; is hereby
amended as follows: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<U>Anti-KIR Product</U>&#148; shall mean any pharmaceutical product containing an
Anti-KIR Antibody (alone or with any other pharmaceutically active ingredient), in all forms, presentations, formulations and dosage forms.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything in Section 5.5 of the Agreement to the contrary but subject to amendments made
applicable to Section 5.5 in Sections 3.1.1 and 3.1.2 of Amendment No. 1, IPH obtained a grant (or grant back, as the case may be) from NN of an exclusive right and license, including the right to Sub-license and Out-license, throughout the
Territory during the Term, under (a) all Intellectual Property Rights licensed exclusively to NN pursuant to Section 5.1, and (b) all Background NN IPR and Collaboration IPR Controlled by NN, to the extent that such rights and licenses are necessary
or useful to conduct research with and of, discover, develop, use, manufacture, have manufactured, register, package, sample, distribute, promote, market, offer for sale, import, export, sell and have sold Anti-KIR Antibodies and/or Anti-KIR
Products for all uses and purposes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BMS&#146;s status under the Agreement as a result of the rights granted to it by IPH under the Outlicense is as
an Out-licensee and not as a Sub-licensee or Third Party Collaborator, and those provisions of the Agreement that apply to Sub-licensees or Third Party Collaborators, but not to Out-licensees, including Sections 3.3, 3.4, 3.5 and 5.6, shall not
apply to BMS. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Anti-KIR Antibodies and Anti-KIR Products that are subject of the rights and licenses set forth in
Paragraph 5 above shall not be considered Licensed Products or Residual Products under the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN has provided to IPH copies of all research results developed by the NN Employee referenced in Section 10.1
of Amendment No.1 to the Agreement, and any and all Intellectual Property Rights generated by such Employee relating to Anti-KIR Antibodies are included in the scope of the grant set forth in Paragraph 5 above. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain
information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from the Amendment No. 6 Effective Date, Section 12.7A (as amended in 3.15 of the Amendment No. 1)
is hereby&nbsp;deleted in its entirety and replaced by the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">&#147;12.7A</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Development and Commercialization Diligence Requirements for Anti-KIR Niche
Candidate</U>.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Diligent Efforts</U>.</P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i)<I> Development</I>.&nbsp;Notwithstanding Section 12.7 hereof, with respect to the Development of Anti-KIR as a Niche Candidate, IPH, by
itself or through its Affiliates, Sub-licensees or Out-licensees, shall use Diligent Efforts to Develop an Anti-KIR Antibody or Anti-KIR Product for the treatment, prevention or control of any human disease, disorder or condition for the purpose of
obtaining a Regulatory Approval in each Major Market. For clarity, it is understood and acknowledged that Diligent Efforts in the Development of Anti-KIR Antibodies and Anti-KIR Products may include sequential implementation of clinical trials or
intervals between clinical trials for data interpretation and clinical program planning and approval.&nbsp;IPH, by itself or through its Affiliates, Sub-licensees or Out-licensees, shall initiate at least two Phase 1 Clinical Trials with respect to
an Anti-KIR Antibody or Anti-KIR Product within twelve (12) months following the completion of IPH&#146;s ongoing Phase 1 Clinical Trial [2102-101], provided that such twelve (12) month period shall be extended to the extent of any delay that is
attributable to any of the following factors: (I) any safety reason arising from such Phase 1 Clinical Trial [2102-101], (II) insufficient quantities of the applicable Anti-KIR Product are available to initiate and complete such two Phase 1 Clinical
Trials, (III) approval of regulatory authorities for IPH, its Affiliates, Sub-licensees or Out-licensees to conduct such Phase 1 Clinical Trials, if required by applicable law, is not received or (IV) any required consent of a Third Party
collaborator of IPH, its Affiliates, Sub-licensees or Out-licensees for the use of a compound other than an Anti-KIR Antibody or Anti-KIR Product in such Phase 1 Clinical Trial&nbsp;is not received. For purposes of the preceding sentence, (A) the
initiation of a Clinical Trial shall mean the first administration of the Anti-KIR Product to the first patient and (B) the completion of IPH&#146;s Phase 1 Clinical Trial [2102-101] shall mean the availability of the full data set of such Clinical
Trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;3&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii)<I> Commercialization</I>.&nbsp;Notwithstanding Section 12.7 hereof, with respect to the
Commercialization of an Anti-KIR Product, IPH, by itself or through its Affiliates or Out-licensees, shall use Diligent Efforts to Commercialize an Anti-KIR Product in each Major Market for which IPH, its applicable Affiliate, Sub-licensee or
Out-licensee receives Approval for such Anti-KIR Product. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for Failure to Employ Diligent Efforts</U>.&nbsp;Notwithstanding Section 12.8 hereof, and
subject to Sections 12.7A(b)(i) and 12.7A(b)(ii), NN shall have the right to terminate this Agreement with respect to Anti-KIR on a Major Market-by-Major Market basis with respect to all Anti-KIR Antibodies and Anti-KIR Products if IPH is in
material breach of its obligation to use Diligent Efforts, alone or through its Affiliates, Sub-licensees or Out-licensees, as set forth in Section 12.7A(a) with respect to such Major Market; provided however, such license shall not so terminate
unless (A) IPH is given *** prior written notice by NN of NN&#146;s intent to terminate, stating the reasons and justification for such termination and recommending steps which NN believes IPH, alone or through its Affiliates, Sub-licensees or
Out-licensees, should take to cure such alleged breach, and (B) IPH, or its Affiliates, Out-licensees or Sub-licensees, has not (1) during the *** period following such notice, provided NN with a plan for the diligent Development or
Commercialization of Anti-KIR Products in such Major Market as set forth in Section 12.7A(a) and (2) during the *** period following such notice carried out such plan and cured such alleged breach by diligently pursuing the Development or
Commercialization of Anti-KIR Products in such Major Market as set forth in Section 12.7A(a). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) If IPH disputes in
good faith the existence or materiality of an alleged breach specified in a notice provided by NN pursuant to this Section 12.7A(b), and if IPH provides notice to NN of such dispute within the *** following such notice provided by NN, NN shall not
have the right to terminate this Agreement with respect to Anti-KIR unless and until the existence of such material breach or failure by IPH has been determined in accordance with Section 21.14 and IPH, alone or through its Affiliates, Sub-licensees
or Out-licensees, fails to cure such breach within *** following such determination.&nbsp;It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the
Parties shall continue to perform all of their respective obligations hereunder. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;4&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) Notwithstanding anything herein to the contrary, in the event that: (A) NN terminates, or
has the right to terminate, this Agreement pursuant to this Section 12.7A(b) with respect to an Anti-KIR Product in the U.S., the EU, and Japan, then NN shall have the right to terminate this Agreement with respect to such Anti-KIR Product in the
entire Territory, and (B) NN has the right to terminate this Agreement pursuant to this Section 12.7A(b) with respect to an Anti-KIR Product in one or two Major European Countries, then NN may not terminate this Agreement with respect to such Major
European Country(ies); provided, that if IPH has such right to terminate this Agreement with respect to such Anti-KIR Product with respect to any three Major European Countries, then NN shall have the right to terminate this Agreement with respect
to such Anti-KIR Product in all of the EU. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>Definitions</U>.&nbsp;The following terms, as used in this Section 12.7A or in Sections
12.8A and 12.8B, shall have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Approval</U>&#148; shall mean, with respect to an Anti-KIR Product in any
regulatory jurisdiction, Regulatory Approval and, where applicable, receipt of pricing and reimbursement approvals. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commercialize</U>&#148; or &#147;<U>Commercialization</U>&#148; shall mean the marketing, promotion, sale (and offer for sale or
contract to sell), distribution, importation or other commercial exploitation (including pricing and reimbursement activities) for an Anti-KIR Product.&nbsp;Commercialization shall include commercial activities conducted in preparation for Anti-KIR
Product launch. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Develop</U>&#148; or &#147;<U>Development</U>&#148; shall mean all activities that relate to (a) obtaining,
maintaining or expanding Regulatory Approval of an Anti-KIR Product and to support appropriate usage for such Anti-KIR Product, for one or more indications.&nbsp;This includes: (i) preclinical/nonclinical research and testing, toxicology, and
clinical trials; (ii) preparation, submission, review, and development of data or information and regulatory materials for the purpose of submission to a governmental authority to obtain, maintain or expand Regulatory Approval of an Anti-KIR Product
(including contacts with regulatory authorities), and outside counsel regulatory legal services related thereto; provided, however, that Development shall exclude Commercialization and manufacturing activities (including manufacturing activities
related to Development). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Diligent Efforts</U>&#148; shall mean the carrying out by IPH, BMS, or their Affiliates, Sub-licensees
or Out-licensees of such obligations or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;5&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
tasks with a ***.&nbsp;Such efforts may take into account, without limitation, issues of safety and efficacy, regulatory authority-approved labeling, product profile, the competitiveness of
alternative products in the marketplace, pricing/reimbursement for the product in a country relative to other markets, the likely timing of the product&#146;s entry into the market, the patent and other proprietary position, the likelihood of
regulatory approval and other relevant scientific, technical and commercial factors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Major European Countries</U>&#148; shall
mean ***. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Major Market</U>&#148; shall mean each of the ***. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory Approval</U>&#148; shall mean, with respect to a country, extra-national territory, province, state, or other regulatory
jurisdiction, any and all approvals, licenses, registrations or authorizations of any regulatory authority necessary in order to commercially distribute, sell, manufacture, import, export or market a product in such country, state, province, or some
or all of such extra-national territory or regulatory jurisdiction, but which shall exclude any pricing and reimbursement approvals.&#148;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from the Amendment No. 6 Effective Date, the following&nbsp;passage of Section 12.8A (as amended in
3.16 of Amendment No. 1): </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>12.8A Notwithstanding Section 12.8 hereof, in the event of the abandonment by IPH of its
development of Anti-KIR as a Niche Candidate (by express notice to NN or by operation of this Article 12), the following provisions shall apply and supersede Section 12.8 with respect to such abandonment:</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">is hereby deleted and replaced by the below first paragraph: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;12.8A <U>Effects of Termination of Agreement for Failure to Employ Diligent Efforts in Development</U>.&nbsp;With effect from the
Amendment No. 1 Effective Date, upon any termination pursuant to Section 12.7A(b) due to IPH&#146;s failure, by itself or through its Affiliates, Sub-licensees or Out-licensees, to use Diligent Efforts to Develop an Anti-KIR Antibody or Anti-KIR
Product as set forth in Section 12.7A(a)(i), the following shall apply and supersede Section 12.8 with respect to the terminated Anti-KIR Antibody(ies)/Product(s) and terminated country(ies):&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">and the remainder of Section 12.8A shall remain unchanged. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from the Amendment No. 6 Effective Date, the following passage of Section 12.8B (as amended in 3.17
of Amendment No. 1): </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>12.8B Notwithstanding Section 12.8 hereof, in the event of the abandonment by IPH of its
marketing or sale of any Anti-KIR Product, the following provisions shall apply and supersede Section 12.8 with respect to such abandonment:</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">is hereby deleted and replaced by the below first paragraph: </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;6&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;12.8B <U>Effects of Termination of Agreement for Failure to Employ Diligent&nbsp;Efforts in
Commercialization</U>.&nbsp;With effect from the Amendment No. 1 Effective Date, upon any termination pursuant to Section 12.7A(b) due to IPH&#146;s failure, by itself or through its Affiliates or Out-licensees, to use Diligent Efforts to
Commercialize an Anti-KIR Product as set forth in Section 12.7A(a)(ii), the following shall apply and supersede Section 12.8 with respect to the terminated Anti-KIR Antibody(ies)/Product(s) and terminated country(ies):&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">and the remainder of Section 12.8B shall remain unchanged. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of Sections 12.7A(b), 12.8A and 12.8B shall be NN&#146;s sole and exclusive remedy for any
breach by IPH of Section 12.7A(a). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section 13.3.6 of the Agreement shall not apply to the Outlicense or to any future grant of rights thereunder
by BMS to any other person. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding Section 15.3.1(a) and 15.3.1(b) of the Agreement, IPH may grant to BMS a security interest,
lien or other encumbrance on any Intellectual Property Right owned by IPH and licensed by IPH to BMS under the Outlicense. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding Section 9.8 of the Agreement, BMS shall have the sole right, but not the obligation, to apply
for any patent term adjustment, patent term extension, supplemental patent protection or related extension of rights with respect to the Patents, set out in a list attached to this Amendment No. 6 as <B>Attachment 1</B>, licensed to BMS under the
Outlicense.&nbsp;Without limiting the foregoing, NN covenants that it will not seek patent term extensions, supplemental protection certificates, or similar rights or extensions for such Patents without the prior written consent of BMS.&nbsp;NN will
cooperate fully with and provide all reasonable assistance to BMS and use all Commercially Reasonable Efforts consistent with its obligations under applicable Law (including any applicable consent order or decree) in connection with obtaining any
such adjustments or extensions for such Patents.&nbsp;To the extent reasonably and legally required in order to obtain any such adjustment or extension in a particular country, NN will make available to BMS a copy of the necessary documentation to
enable BMS to use the same for the purpose of obtaining the adjustment or extension in such country. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall not exercise its &#147;March-In&#148; right under Section 9.13 with respect to any IPR licensed to BMS
under the Outlicense without the prior written consent of BMS, which consent shall not be unreasonably withheld. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of the Amendment No. 6 Effective Date, there are no information, materials or Intellectual Property Rights
controlled by UCSF, HSS, Tours and/or INSERM that are necessary or useful for the development, manufacture or commercialization of Anti-KIR Antibodies or Anti-KIR Products, which Intellectual Property Rights could become Controlled by NN and/or IPH
as the result of any action contemplated by the provisions of Section 5.13 of the Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;7&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding Section 21.1 or anything else in the Agreement to the contrary, BMS shall not be required,
during or following the term of the Outlicense, to maintain, grant, assign or otherwise convey to IPH, NN, or any other Third Party, any rights under any IPR that BMS or its Affiliates may own or control (other than such IPR as is licensed to BMS
under the Outlicense). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BMS may exercise any right as an Out-licensee under the Agreement and may exercise IPH&#146;s right to cure
under Sections 12.4 and 12.7A(b) of the Agreement and any right of IPH under Article 9 with respect to the patent rights listed in <B>Attachment 1</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BMS shall have no obligation under the Agreement other than those obligations expressly imposed on
Out-licensees and, for clarity, BMS&#146;s obligations under Section 15.1.6 shall only apply to other terms and conditions of the Agreement that are expressly imposed on Out-Licensees.</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Provided that BMS becomes an Out-licensee and effective as of the Amendment No. 6 Effective Date, NN has
terminated that certain Exclusive Commercial License between NN and Medarex, Inc. (now a wholly owned subsidiary of BMS), effective as of December 7, 2004, relating to the Antibody ***. It is understood and agreed that in the proposed license
between BMS and IPH, BMS will grant to IPH the right to prosecute and maintain the patent rights that are listed in <B>Attachment 1</B>, in the event that BMS would discontinue such prosecution or maintenance.&nbsp;As between IPH and NN, in the
event that BMS discontinues the prosecution or maintenance of such patents rights, IPH shall exercise its right to prosecute and maintain such patent rights pursuant to the agreement between BMS and IPH. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BMS may disclose Confidential Information of NN relating to Anti-KIR Antibodies and IPR licensed to BMS under
the Outlicense that it obtains from IPH without any obligation to obtain consent therefor from NN. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding Section 15.1.8 or anything else in the Agreement to the contrary, BMS shall have no obligation
to provide any information to NN regarding any activity under the Outlicense beyond such information that BMS provides to IPH under the Outlicense. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">24.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN has transferred to IPH ownership of all regulatory filings held by NN relating to Anti-KIR Antibodies,
including INDs and other such filings as may be necessary for the conduct of clinical trials of Anti-KIR Antibodies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">25.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything in the Agreement to the contrary, BMS&#146;s rights under the Outlicense shall survive
any termination of the Agreement (other than a termination directly resulting from a material breach by BMS of its obligations under the Outlicense or as an Out-licensee under the Agreement), subject to (a) the payment by BMS to NN of any milestones
or royalties with respect to Anti-KIR that IPH would have been required to pay NN under the Agreement and (b) the provision by BMS to NN of information consistent with Paragraph 23 above. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;8&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">26.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH&#146;s obligation to make royalty payments to NN under the Agreement on the Net Sales of IPH&#146;s
Out-licensees with respect to any Anti-KIR Antibody or Anti-KIR Product shall be cancelled and replaced by the following obligation: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">IPH shall pay to NN *** of all royalty payments based on Net Sales of Anti-KIR Products, as received by IPH from its Out-licensees. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">27.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of this Amendment confer a benefit on and are intended to be (and shall be) enforceable by BMS
in the event BMS becomes an Out-licensee by virtue of the Contracts (Rights of Third Parties) Act 1999.&nbsp;Otherwise no person who is not a Party shall have the right to enforce any term of this Amendment by virtue of the Contracts (Rights of
Third Parties) Act 1999. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">28.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The rights of the Parties to terminate or rescind, or agree any variation of or waiver or settlement under,
this Amendment is subject to the consent of BMS as long as BMS is an Out-licensee (and the Parties shall not do any such thing unless BMS has given its prior written consent). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">29.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BMS may assign the benefits conferred on it by this Amendment, without the consent of NN or IPH, to any Person
to which BMS also assigns the Outlicense. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">30.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise agreed by the Parties in writing, this Amendment shall be of no further force or effect after
the date, if any, that BMS ceases to be either an Out-licensee under the Agreement or a direct licensee of NN pursuant to Paragraph 25 above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">31.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Amendment shall be deemed an integral part of the Agreement. Except as expressly set forth herein, all
provisions of the Agreement shall remain unchanged and in full force and effect. The Parties expressly affirm their mutual intention that this Amendment to the Agreement shall constitute a legally binding Amendment to the Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">32.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Amendment shall be construed and interpreted pursuant to the laws stipulated in the Agreement. All
disputes arising out of or in connection with the present Amendment shall be finally settled by arbitration as stipulated in the Agreement. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;9&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS HEREOF the Parties have executed and delivered this Amendment. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">On behalf of Novo Nordisk N/S</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">On behalf of Innate Pharma SA</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Lars Fruergaard J&oslash;rgensen</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">/s/ Herv&eacute; Brailly</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Lars Fruergaard J&oslash;rgensen</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name: Herv&eacute; Brailly</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: Senior Vice President</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title: CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 1-July-2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Date: 5&nbsp;July 2011</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;10&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Attachment 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A. KIR-specific patents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. Antibodies, antibody
fragments, and derivatives thereof that cross-react with two or more inhibitory receptors (KIR2DL1 and KIR2DL2,3) which potentiate NK cell cytotoxicity. Applicant/owner: Innate Pharma and University of Genoa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;11&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Cross-reactive (KIR2DL1 and KIR2DL2,3) anti-KIR antibodies.&nbsp;Applicant/owner: Novo Nordisk, Innate Pharma
and University of Genoa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;12&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Human anti-KIR antibodies, including Anti-KIR (1-7F9).&nbsp;Novo Nordisk, Innate Pharma and University of
Genoa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;13&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. Treatment of viral infection, including but not limited to HIV treatment.&nbsp;Applicant/owner: Novo Nordisk
and Innate Pharma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. Anti-KIR
combination treatments, including but not limited to combination with cytokines.&nbsp;Applicant/owner: Novo Nordisk and Innate Pharma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">***
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;14&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. Non-competitive antagonist KIR-binding agents. Applicant/owner: Novo Nordisk and Innate Pharma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. Formulations and dosages of containing
Anti-KIR antibodies.&nbsp;Applicant/Owner: Novo Nordisk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;15&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. Anti-KIR + lenalidomide combination therapies for the treatment of cancer. Applicant/owner: Novo Nordisk </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;16&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B. Multiple target patents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. Use of blocking anti-KIR mAbs (as well as anti-NK receptor mAbs) in combination with depleting mAbs, where the anti-KIR mAb-mediated NK cell activation
enhances ADCC toward a target cell.&nbsp;Applicant/owner: Innate Pharma. (see Patent Assignment agreement of February 2006 between IPH and the University of Perugia). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;17&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Use of depleting anti-KIR (and other NK receptor) mAbs for the treatment of LGL and other suitable and/or
related diseases including T-cell type LDGL, autoimmune disorders, and any other immunoproliferative or malignant disorders involving NK or other KIR-expressing lymphocytes. Applicant/owner: Innate Pharma and University of Genoa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;18&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Use of depleting Anti-KIR (and other NK receptor mAbs) mAbs for eliminating NK cells in inflammatory
indications. Applicant/Owner: Novo Nordisk, Innate Pharma and University of Genoa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;19&nbsp;- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution version </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT AND
SUPPLEMENT NO. 7 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to the </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOINT RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;28,
2006 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Between </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVO NORDISK A/S </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INNATE PHARMA SA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Relating to the Buy Back of Anti-NKG2A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>February&nbsp;5, 2014 </B></P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RECLASSIFICATION OF ANTI-NKG2A AS A NICHE CANDIDATE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">AMENDMENT OF AGREEMENT TO PROVIDE FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ANTI-NKG2A AS A NICHE CANDIDATE BY IPH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">KNOW-HOW</FONT> TRANSFER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CLINICAL TRIALS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TRANSFER OF ANTI-NKG2A SUPPLIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NO WARRANTY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REGULATORY OR SAFETY DELAY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINANCIAL CONSIDERATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PRESS RELEASE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">11.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OTHER ADJUSTMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">12.&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">B-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">C-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">D-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">E-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit F</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit G</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">G-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT AND SUPPLEMENT NO. 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOINT RESEARCH,
DEVELOPMENT, OPTION AND LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amendment and Supplement dated as of February&nbsp;5, 2014 (the &#147;<U>Amendment
No.</U><U></U><U>&nbsp;7</U>&#148;) to the Joint Research, Development, Option and License Agreement dated March&nbsp;28, 2006 as amended (hereinafter the &#147;<U>Agreement</U>&#148;) between Novo Nordisk A/S
<FONT STYLE="white-space:nowrap">(CVR-no.</FONT> 24 25 67 90), a corporation existing under the laws of Denmark and having its principal place of business at Novo All&eacute;, 2880 Bagsvaerd, Denmark (hereinafter &#147;NN&#148;), and Innate Pharma
SA, a corporation existing under the laws of France and having its principal place of business at avenue de Luminy, 13009 Marseille, France (hereinafter &#147;<U>IPH</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>WITNESSETH </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WHEREAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to the Agreement, NN and IPH agreed to work, independently, jointly, and/or together with agreed-upon Third Parties, to (a)&nbsp;discover or identify Drug Candidates, and (b)&nbsp;optimize Drug Candidates for progression to
(i)&nbsp;Licensed Products for further development and commercialization by NN, or (ii)&nbsp;Niche Candidates for further development and commercialization by IPH (either alone or together with NN), in each case for all uses and purposes, including
therapeutic, prophylactic and, except as otherwise expressly therein provided, diagnostic uses;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WHEREAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">NN desires to cease development of Anti-NKG2A as a Licensed Product and IPH desires to buy back the rights to Anti-NKG2A (as defined below). To that effect, the Parties have agreed that Anti-NKG2A be reclassified as a Niche
Candidate for IPH&#146;s sole independent further development and commercialization, and NN and IPH desire to amend and supplement the Agreement to provide for NN&#146;s grant or grant back to IPH of an exclusive right and license, including the
right to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT STYLE="white-space:nowrap">Out-license,</FONT> throughout the Territory during the Term, under (a)&nbsp;all Intellectual Property Rights licensed exclusively to NN pursuant to
Section&nbsp;5.1, and (b)&nbsp;all Background NN IPR and Collaboration IPR Controlled by NN, to the extent that such rights and licenses are necessary or useful to conduct research with and of, discover, develop, use, manufacture, have manufactured,
register, package, sample, distribute, promote, market, offer for sale, import, export, sell and have sold Anti-NKG2A Antibodies and/or Anti-NKG2A Products for all uses and purposes.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NOW, THEREFORE,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">in consideration of the foregoing premises, the mutual promises and covenants set forth in this Amendment No.&nbsp;7, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, NN and
IPH, each intending to be legally bound, hereby agree as follows:</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise specifically defined herein, each term used herein that is defined in the Agreement has the
meaning assigned to such term in the Agreement. Each reference to &#147;hereof&#148;, &#147;hereunder&#148;, &#147;herein&#148; and &#147;hereby&#148; and each other similar reference and each reference to &#147;this Agreement&#146; and each other
similar reference contained in the Agreement shall, after the Amendment No.&nbsp;7 Effective Date, refer to the Agreement as amended hereby. </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Amendment No.&nbsp;7 Effective Date&#148; shall mean the date of this Amendment No.&nbsp;7.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RECLASSIFICATION OF ANTI-NKG2A AS A NICHE CANDIDATE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms and conditions of this Amendment No.&nbsp;7 and with effect from the Amendment No.&nbsp;7
Effective Date, NN hereby classifies Anti-NKG2A as a Niche Candidate for independent further development and commercialization by IPH for any therapeutic, prophylactic or diagnostic indication or application. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH acknowledges and agrees that, with effect from the Amendment No.&nbsp;7 Effective Date, Anti-NKG2A shall be
classified as a Niche Candidate and IPH further agrees that, notwithstanding any <FONT STYLE="white-space:nowrap">non-compliance</FONT> by either Party with the procedures set out in Section&nbsp;6.1 of the Agreement, neither the discontinuation of
development of Anti-NKG2A by NN nor the subsequent classification by NN in this Amendment No.&nbsp;7 of Anti-NKG2A as a Niche Candidate constitutes the abandonment of any Licensed Product or Niche Candidate for the purposes of the Agreement or gives
rise to any right to terminate the whole or part of the Agreement or any of the associated remedies under Articles 12 and 13 of the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any provision of the Agreement, IPH acknowledges that, with effect from the Amendment
No.&nbsp;7 Effective Date, NN shall have no further obligations under the Agreement, this Amendment No.&nbsp;7 or otherwise to develop or commercialize Anti-NKG2A and NN acknowledges that IPH shall have the exclusive right to conduct the development
and commercialization of Anti-NKG2A as a Niche Candidate for any therapeutic, prophylactic or diagnostic indication or application. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Anti-NKG2A Antibodies and Anti-NKG2A Products that are subject of the rights and licenses pursuant to this
Amendment No.&nbsp;7 shall not be considered Licensed Products or Residual Products under the Agreement </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AMENDMENT OF AGREEMENT TO PROVIDE FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ANTI-NKG2A AS A NICHE
CANDIDATE BY IPH </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from the Amendment No.&nbsp;7 Effective Date, Article 1 of the Agreement is hereby amended by:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adding the following proviso to the definition of &#147;Background NN IPR&#148; immediately following the
current text of such definition: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<U>Provided</U>, <U>however</U>, that for the purposes of the licenses granted to IPH
pursuant to Section&nbsp;5.5 hereof to develop and commercialize Anti-NKG2A as a Niche Candidate and otherwise in connection with the interpretation of this Agreement in connection with such development and commercialization by IPH of Anti-NKG2A as
a Niche Candidate, &#147;Background NN IPR&#148; shall mean only the IPR identified and listed in Schedule 1.1.7B to the Agreement. Such Schedule 1.1.7B shall not be subject to the aforementioned notification, demonstration and updating process
applicable to Schedule 1.1.7 and may not be amended except with the express consent in writing of the Parties hereto.&#148;; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adding the following proviso to the definition of &#147;Collaboration IPR&#148; immediately following the
current text: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<U>Provided</U>, <U>however</U>, that for the purposes of the licenses granted to IPH pursuant to
Section&nbsp;5.5 hereof to develop and commercialize Anti-NKG2A as a Niche Candidate and otherwise in connection with the interpretation of this Agreement in connection with such development and commercialization by IPH of Anti-NKG2A as a Niche
Candidate, &#147;Collaboration IPR Controlled by NN&#148; shall mean only the IPR comprised of (x)&nbsp;(i) the Patents identified and listed in Schedule 1.1.16B (Parts A and B) to the Agreement and (ii)&nbsp;any Patents in which any Anti-NKG2A <FONT
STYLE="white-space:nowrap">Know-How</FONT> is disclosed but not including any Patent listed in Schedule 5.8.2B and (y)&nbsp;the <FONT STYLE="white-space:nowrap">Know-How</FONT> listed in Schedule 1.1.17B to the Agreement. Such Schedules 1.1.16B and
1.1.17B shall not be subject to any updating process that is otherwise applicable to Schedules 1.1.16 and 1.1.17 and may not be amended except with the express consent in writing of the Parties hereto.&#148;; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deleting the final sentence from the definition of &#147;Licensed Product&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">inserting the words &#147; Anti-NKG2A as well as&#148; immediately following the words &#147;shall mean&#148;
in the definition of &#147;Niche Candidate&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adding the following definitions: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-NKG2A <FONT STYLE="white-space:nowrap">Know-How</FONT></U>&#148; shall mean <FONT STYLE="white-space:nowrap">Know-How</FONT>
generated or acquired by either or both Parties or their Affiliates in relation to Anti-NKG2A, within the categories listed in Schedule 1.1.17B. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-NKG2A Patent</U>&#148; shall mean (i)&nbsp;a Patent listed in Part A of Schedule 1.1.16B and (ii)&nbsp;a Patent in which any
Anti-NKG2A <FONT STYLE="white-space:nowrap">Know-How</FONT> is disclosed but not including any Patent listed in Schedule 5.8.2B. &#147;<U>Anti-NKG2A</U>&#148; or &#147;<U>Anti-NKG2A Antibody</U>&#148; means any antibody or antigen-binding fragment
or derivative thereof, whether human, humanized, chimeric, murine or from another source (and including bispecific antibodies, single chain antibodies and immunoconjugated antibodies) that has been raised, engineered, or otherwise optimized to bind
Anti-NKG2A (in addition to any other target or receptor such antibody may bind to). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-NKG2A Product</U>&#148; means any pharmaceutical product containing any Anti-NKG2A
Antibody (alone or together with any other pharmaceutical active ingredients), in all forms, presentations, formulations and dosage forms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-NKG2A Regulatory Milestones</U>&#148; shall have the meaning ascribed to it In Section 7.4C. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<U>Continuation</U>&#148; shall mean, with respect to any patent or patent application, any continuation,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuation-in-part,</FONT></FONT> divisional, continued prosecution or other similar application. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<U>Formulation Patent</U>&#148; shall mean the Patents listed in Part B of Schedule 1.1.16B.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<U>*** License</U>&#148; shall mean the license between Novo Nordisk A/S and *** dated as of December&nbsp;8, 2004. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<U>*** License</U>&#148; shall mean the license between Novo Nordisk A/S and *** with respect to inter alia the manufacturing of any
Anti-NKG2A Antibody or Anti-NKG2A Product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<U>NN Anti-NKG2A FoO IPR</U>&#148; shall mean (a)&nbsp;such Patents listed in Schedule
5.8.2B, (b)&nbsp;such Patents that are either (i)&nbsp;Controlled, through exclusive ownership, by NN or its Affiliates during the Term and claim the benefit of a priority date on or before February&nbsp;5, 2017 or (ii)&nbsp;Controlled, through
license or otherwise but not exclusive ownership, by NN or its Affiliates at February&nbsp;5, 2014, (c) such <FONT STYLE="white-space:nowrap">Know-How</FONT> that is either (i)&nbsp;Controlled, through exclusive ownership, by NN or its Affiliates
during the Term and generated on or before February&nbsp;5, 2017 or (ii)&nbsp;Controlled, through license or otherwise but not exclusive ownership, by NN or its Affiliates at February&nbsp;5, 2014 and (d)&nbsp;such Patents based in part or in whole
on <FONT STYLE="white-space:nowrap">Know-How</FONT> that is (i)&nbsp;Controlled, through exclusive ownership, by NN or its Affiliates during the Term and (ii)&nbsp;generated on or before February&nbsp;5, 2017, in each of (a), (b) and (d)&nbsp;that
are or is (y)&nbsp;not within the Background NN IPR or Collaboration IPR and (z)&nbsp;necessary for the development and commercialization of an Anti-NKG2A Product. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Background NN IPR Licensed by NN to IPH for development and commercialization by IPH of Anti-NKG2A as a
Niche Candidate</U>. With effect from the Amendment No.&nbsp;7 Effective Date, the Agreement is hereby amended by inserting Exhibit A to this Amendment No.&nbsp;7 as Schedule 1.1.7B to the Agreement. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Collaboration IPR Controlled by NN and Licensed by NN to IPH for development and commercialization by IPH of
Anti-NKG2A as a Niche Candidate &#151; Anti-NKG2A Patents and Anti-NKG2A <FONT STYLE="white-space:nowrap">Know-How</FONT></U>. With effect from the Amendment No.&nbsp;7 Effective Date, the Agreement is hereby amended by inserting Exhibit B to this
Amendment No.&nbsp;7 as Schedule 1.1.16B (Parts A and B) to the Agreement and Exhibit C to this Amendment No.&nbsp;7 as Schedule 1.1.17B (Parts A and B) to the Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Schedule 5.8.2B NN Anti-NKG2A FoO Patent</U>. With effect from the Amendment No.&nbsp;7 Effective Date, the
Agreement is hereby amended by inserting Exhibit D to this Amendment No.&nbsp;7 as Schedule 5.8.2B to the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Development and Commercialization Committee Input for Anti-NKG2A</U>. With effect from the Amendment
No.&nbsp;7 Effective Date, Section&nbsp;4.9 is hereby amended by inserting the following text in the first paragraph after the words &#147;(b) any Niche Candidates&#148;: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">&#147;(other than <FONT STYLE="white-space:nowrap">Anti-KIR</FONT> and Anti-NKG2A)&#148;. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No JSC Approval of <FONT STYLE="white-space:nowrap">Sub-licensing</FONT> by IPH of an Anti-NKG2A Niche
Candidate</U>. With effect from the Amendment No.&nbsp;7 Effective Date, Article 5 of the Agreement is hereby amended by deleting the words &#147;that shall be enforceable by both Parties&#148; from the second paragraph of Section&nbsp;5.6 and by
inserting the following text immediately following Section 5.6A: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">&#147;5.6B <U>No JSC Approval of <FONT
STYLE="white-space:nowrap">Sub-licensing</FONT> by IPH of Anti-NKG2A as a Niche Candidate</U>. Notwithstanding Section&nbsp;5.6, the JSC shall not be required to approve any Sub-licensing by IPH of its rights and obligations under this Agreement if
such <FONT STYLE="white-space:nowrap">Sub-licensing</FONT> by IPH is reasonably necessary for the development and commercialization of Anti-NKG2A as a Niche Candidate or any Anti-NKG2A Product.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, it is acknowledged and agreed that the provisions of Section&nbsp;5.6 shall not apply to <FONT
STYLE="white-space:nowrap">Out-Licensing</FONT> and further sublicenses by the <FONT STYLE="white-space:nowrap">Out-Licensee.</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No License by NN to IPH of Independent NN IPR for development and commercialization by IPH of Anti-NKG2A as
a Niche Candidate; FoO for Anti-NKG2A as a Niche Candidate</U>. With effect from the Amendment No.&nbsp;7 Effective Date, Article 5 is hereby amended by inserting the following text immediately following Section 5.8.2A: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">&#147;5.8.2B <U>No License by NN to IPH of Independent NN IPR for development and commercialization by IPH of Anti-NKG2A as a Niche Candidate;
FoO for Anti-NKG2A as a Niche Candidate</U>. Notwithstanding Section&nbsp;5.8.2, NN shall not be obliged to grant to IPH, or to provide reasonable cooperation and assistance to IPH to procure the grant to IPH of,
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> rights and licenses under any Independent NN IPR for the purposes of IPH&#146;s development and commercialization of Anti-NKG2A as a Niche Candidate or any Anti-NKG2A Product; <U>provided</U>,
<U>however</U>, that NN shall grant to IPH a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">license (with the right to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT
STYLE="white-space:nowrap">Out-license;</FONT> however, IPH shall not be entitled to <FONT STYLE="white-space:nowrap">Sub-license</FONT> or <FONT STYLE="white-space:nowrap">Out-license</FONT> any Patent
<FONT STYLE="white-space:nowrap">in-licensed</FONT> by NN under the *** Agreement until the earlier of: (i) *** approval of such right to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and <FONT STYLE="white-space:nowrap">Out-license</FONT>
(which approval NN shall use reasonable efforts to obtain by September&nbsp;30, 2014, subject to no additional payments by NN in connection with such right to <FONT STYLE="white-space:nowrap">Sub-license</FONT> and
<FONT STYLE="white-space:nowrap">Out-license,</FONT> without prejudice to NN&#146;s payment obligations in Section 7,8D), or (ii)&nbsp;the expiry of the last Valid Claim of any such Patents) under any NN Anti-NKG2A FoO IPR to develop and
commercialize Anti-NKG2A Products for no additional consideration.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No IPH Access to Materials; No NN <FONT STYLE="white-space:nowrap">Buy-in</FONT> and <FONT
STYLE="white-space:nowrap">Co-Marketing</FONT> Options</U>. With effect from the Amendment No.&nbsp;7 Effective Date, Article 6 is hereby amended by inserting the following text immediately following Section 6.1E: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">&#147;6.1F <U>No IPH Access to Materials</U>. Notwithstanding Section&nbsp;6.4 and except as otherwise set forth in this Amendment, IPH shall
have no rights to access Materials pursuant to such Section&nbsp;6.4 with respect to the development or commercialization of Anti-NKG2A as a Niche Candidate pursuant to Section&nbsp;6.1 hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">6.1G <U>No NN <FONT STYLE="white-space:nowrap">Buy-in</FONT> and <FONT STYLE="white-space:nowrap">Co-Marketing</FONT> Options for Anti-NKG2A
Niche Candidate</U>. Notwithstanding Sections 6.5 (NN <FONT STYLE="white-space:nowrap">Buy-In),</FONT> 6.6 (NN <FONT STYLE="white-space:nowrap">Co-Marketing</FONT> Options), 6.7 (IPH Assistance), 6.8 (Licenses to NN for Niche Candidates), NN shall
have no rights pursuant to such Sections 6.5, 6.6, 6.7 and 6.8 with respect to Anti-NKG2A as a Niche Candidate being developed or commercialized by IPH pursuant to Section&nbsp;6.1 hereof, provided however that if within *** following the Amendment
No.&nbsp;7 Effective Date, IPH intends to <FONT STYLE="white-space:nowrap">Out-License</FONT> any Anti-NKG2A in a field that substantially relates to diabetes or inflammation (the &#147;Restricted Field&#148;), then NN shall have a right of first
offer as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall provide to NN the data package relating to such Anti-NKG2A as prepared by IPH for such <FONT
STYLE="white-space:nowrap">Out-Licensing</FONT> process and NN shall have *** to review such package and indicate to IPH whether it is interested in entering into negotiation for an <FONT STYLE="white-space:nowrap">Out-License;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If NN notifies its interest within such *** timeline, IPH and NN shall engage in exclusive negotiations for an <FONT
STYLE="white-space:nowrap">Out-License</FONT> for *** following NN&#146;s notice of interest (the &#147;Exclusive Negotiation Period&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If NN does not notify its interest within the above *** timeline or the Parties fail to enter into an <FONT
STYLE="white-space:nowrap">Out-License</FONT> within the Exclusive Negotiation Period, IPH shall be free to enter into an agreement for the <FONT STYLE="white-space:nowrap">Out-License</FONT> such Anti-NKG2A in the Restricted Field to a Third Party
without further notice to NN, provided that for *** following the expiry of the Exclusive Negotiation Period, any such Third Party <FONT STYLE="white-space:nowrap">Out-License</FONT> shall not be at terms that are, taken as a whole, less favorable
to IPH than the latest terms offered in writing by NN during the Exclusive Negotiation Period. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If the proposed <FONT STYLE="white-space:nowrap">Out-License</FONT> does not relate
substantially to diabetes and/or inflammation but relates to any broader field including diabetes or inflammation, then the above procedure shall apply provided that the *** and *** timelines set forth above shall be reduced by half to be brought to
respectively *** and the negotiation period shall not be exclusive. For the avoidance of doubt, and by way of example, the Parties agree that if the proposed <FONT STYLE="white-space:nowrap">Out-License</FONT> relates to any oncology indication or
to all indications, it shall not be regarded as substantially related to diabetes or inflammation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">6.IH <U>IPH Access to Raw Data</U>. If
reasonably required by IPH to respond to any request from, or fulfill any requirement of, any regulatory authority in connection with IPH&#146;s development and commercialization of Anti-NKG2A as a Niche Candidate or any Anti-NKG2A Product, NN
shall, upon reasonable notice from IPH, provide IPH or any regulatory authority with a reasonable opportunity to review any original documentation and raw data archived by NN for no additional consideration. NN shall not destroy or otherwise dispose
of any original documentation and raw data related to NN&#146;s development of Anti-NKG2A that IPH or a regulatory authority may reasonably be expected to require in connection with IPH&#146;s development and commercialization of Anti-NKG2A as a
Niche Candidate or any Anti-NKG2A Product without the prior written consent of IPH which shall not be unreasonably delayed or withheld. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">6.1.I <U>Reporting Obligations</U>. IPH shall prepare written annual reports (each a &#147;<U>Development Report</U>&#148;) in respect of
IPH&#146;s development of Anti-NKG2A as a Niche Candidate during each calendar year commencing January&nbsp;1, 2015 and deliver such Development Report to NN no later than January&nbsp;31 in the calendar year following that calendar year to which
such Development Report relates. Each Development Report shall include a high level description of clinical studies carried out during the calendar year. Anti-NKG2A </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">6.1.J <U>NN Corporate Alliance Management</U>. In order to facilitate the transfer of Know How and supplies to IPH pursuant to this Amendment,
NN shall assign a member of its Corporate Alliance Management Department to serve as the liaison officer between NN and IPH on all matters relating to such transfer. Such NN Corporate Alliance Management Department liaison officer shall respond in a
reasonably timely manner to all reasonable requests for information made by IPH. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Regulatory Milestones</U>. With effect from the Amendment No.&nbsp;7 Effective Date, Article 7 of the
Agreement is hereby amended by inserting the following text immediately following Section 7.4B: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">&#147;7.4C <U>Anti-NKG2A
Niche Candidate Regulatory Milestone Payments</U>. Notwithstanding Section&nbsp;7.4, in respect of Anti-NKG2A Products and subject to Section </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">7.8D, IPH shall only pay to NN the following milestone payments for the achievement of the
following regulatory milestone events by an Anti-NKG2A Product pursuant to IPH&#146;s development of Anti-NKG2A as a Niche Candidate (&#147;<U>Anti-NKG2A Regulatory Milestones</U>&#148;) within *** of the achievement of each such Anti-NKG2A
Regulatory Milestone. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Such milestone payments shall be made for the first Anti-NKG2A Product that achieves an Anti-NKG2A Regulatory
Milestone and, subsequently, for each Anti-NKG2A Product that includes an antibody, antibody fragment, or derivative of either thereof that is different in terms of amino acid sequence or chemical derivation from each Anti-NKG2A Product that
previously achieved such Anti-NKG2A Regulatory Milestone, but not different dosages or formulations of the Anti-NKG2A product nor any post-translational modifications arising as a result of different cell culture conditions, in each case on a <FONT
STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-duplicative</FONT> basis, irrespective of the number of indications per Anti-NKG2A Product and any <FONT STYLE="white-space:nowrap">Out-licensing</FONT> or <FONT
STYLE="white-space:nowrap">Sub-licensing</FONT> by IPH. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Sales Milestones</U>. With effect from the Amendment No.&nbsp;7 Effective Date, Article 7 of the Agreement
is hereby amended by inserting the following text immediately following Section 7.4C: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">&#147;7.4D <U>Anti-NKG2A Niche
Candidate Sales Milestone Payments</U>. Notwithstanding Section&nbsp;7.4, in respect of Anti-NKG2A Products IPH shall have no payment obligation with respect to the achievement of sales milestone events by any Anti-NKG2A Product pursuant to
IPH&#146;s development or commercialization of Anti-NKG2A. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Royalties</U>. With effect from the Amendment No.&nbsp;7 Effective Date, Article 7 of the Agreement is
hereby amended by inserting the following text immediately following Section&nbsp;7.8: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">&#147;7.8C <U>Royalties on
Anti-NKG2A Products</U>. Notwithstanding Section&nbsp;7.8 hereof and subject to Section 7.8D, 7.8E, 7.8F and 7.8 G below, in respect of Anti-NKG2A Products IPH shall during the Term pay to NN the following percentage royalties (the &#147;Base
Royalty Rates&#148;) on Net Sales of each Anti-NKG2A Product on an Anti-NKG2A Product by Anti-NKG2A Product basis in the Territory by IPH, its Affiliates, <FONT STYLE="white-space:nowrap">Sub-Licensees</FONT> or
<FONT STYLE="white-space:nowrap">Out-Licensees</FONT> (or its associated Selling Parties) in accordance with Section&nbsp;7.11. For purposes of the foregoing, an Anti-NKG2A Product that includes an antibody, antibody fragment, or derivative of
either thereof and an Anti-NKG2A Product that include that an </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">antibody, antibody fragment, or derivative of either thereof is different in
terms of amino acid sequence or chemical derivation shall be regarded as two different Anti-NKG2A Products, but not Anti-NKG2A Products having solely different dosages or formulations nor any post-translational modifications arising as a result of
different cell culture conditions). </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this
agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">With respect to aggregate Net Sales of any Anti-NKG2A Product that is <FONT
STYLE="white-space:nowrap">Out-Licensed</FONT> by IPH in any given country prior to the first administration in patient of such Anti-NKG2A Product in a Phase III Trial on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">*** </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">With respect to aggregate Net Sales of any Anti-NKG2A Product that is not <FONT STYLE="white-space:nowrap">Out-Licensed</FONT> in any given
country by IPH prior to the first administration in patient of such Anti-NKG2A Product in a Phase III Trial on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">*** </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reductions. With effect from the Amendment No.&nbsp;7 Effective Date, Article 7 of the Agreement is hereby
amended by inserting the following text immediately following Section 7.8C: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;7.8D *** </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Subject to the other provisions of this Section 7.8D, IPH shall bear the following payments that NN represented to IPH would be due by NN to
***, as a result of the sublicense granted by NN pursuant to this Amendment (together the &#147;*** Fee&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">starting as of calendar year 2015, a minimum yearly payment not to exceed &pound;***; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">one or two regulatory milestone payments *** upon initiation of the first phase II for each Anti-NKG2A and ***
upon initiation of the first Phase III in each clinical indication for each Anti-NKG2A). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Except for the *** Fee, NN
shall bear all royalty and other payments if any that would be due by NN to ***, as a result the sublicense granted by NN pursuant to this Amendment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">IPH shall negotiate its own license with *** with respect to the Patent and Know How Controlled by *** and necessary to manufacture Anti-NKG2A
and shall bear all payments related thereto, subject to the other provisions of this Section 7.8D. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Notwithstanding Section&nbsp;7.8
hereof, IPH shall be entitled to deduct: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** of the royalty payments due by IPH to *** in connection with Anti-NKG2A under IPH&#146;s own license with ***
from the royalty payable by IPH to NN pursuant to Section 7.8B, provided that such deduction shall not exceed *** of Net Sales. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each payment of the *** Fee, from any milestone payment that is subsequently payable by IPH to NN pursuant to
Section 7.4B above. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;7.8E Patent Expiry. If there is no Valid Claim covering any Anti-NKG2A in any given country,
the Base Royalty Rates applicable to such Anti-NKG2A in such country shall be reduced by ***. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;7.8F Generic Competition. During the
portion of the applicable Term in a particular country where there are one or more products being sold in such country that are Generic Products with respect to such Anti-NKG2A Product, then the applicable royalty, with respect to such Anti-NKG2A
Product shall be reduced as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> by *** in the event that in any two consecutive calendar quarters such
Generic Product(s), by unit equivalent volume in such country, exceed a *** share of the market; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> by *** in
the event that in any two consecutive calendar quarters such Generic Product(s), by unit equivalent volume in such country, exceed a *** share of the market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section 7.8F, &#147;market&#148; refers to the aggregate of the sales of the Generic Product(s) and the applicable Product
in a country. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;7.8G If IPH enters into an <FONT STYLE="white-space:nowrap">Out-License</FONT> covering at least one Major Market
containing additional royalty adjustments to those set forth in Sections 7.8E and 7.8F (including a broader anti-stacking royalty adjustment) or similar royalty adjustments to those set forth in Sections 7.8E and 7.8F but with less favorable terms
to IPH, then IPH may request to NN that IPH and NN enter into good faith negotiations in order to preserve the economic balance of this Amendment with respect to the Anti-NKG2A Products and countries covered by such
<FONT STYLE="white-space:nowrap">Out-License,</FONT> provided that the royalty mechanism resulting from this renegotiation shall not cause the royalties due by IPH to NN hereunder to be lower than *** of applicable Base Royalty Rate plus the
deductible portion of the Lonza royalty pursuant to Section 7.8D. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Records of Net Sales</U>. With effect from the Amendment No.&nbsp;7 Effective Date, Article 7 of the
Agreement is hereby further amended by inserting &#147;and 7.8C&#148; immediately after &#147;7.8&#148; in Section&nbsp;7.9. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Anti-NKG2A Patents</U>. With effect from the Amendment No.&nbsp;7 Effective Date, Article 9 of the Agreement
is hereby amended by inserting the following text immediately following Section&nbsp;9.1: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">&#147;9.1B1 <U>Anti-NKG2A
Patents</U>. The provisions of this Section 9.1B shall apply to Anti-NKG2A Patents but no other Patents. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">9.1B2 <U>Anti-NKG2A Patents</U>. Notwithstanding anything to the contrary in this Agreement, as
between the Parties, IPH shall have the exclusive right and sole discretion during the Term to prepare, file, prosecute, and maintain the Anti-NKG2A Patents listed in Schedule 1.1.16B Parts A (which for avoidance of doubt excludes the Formulation
Patent) and to conduct any interferences, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> reissues, limitations, and oppositions with respect to such Anti-NKG2A Patents; <U>provided</U>, <U>however</U>, that IPH may neither disclose any
Anti-NKG2A Know How or NN Anti-NKG2A FoO IPR related to either (x)&nbsp;manufacturing methods, processes or procedures or (y)&nbsp;formulation, assay and delivery methodologies in such preparation, filing, prosecution or maintenance of any Patent
nor prepare, file or prosecute any Patent which would require the disclosure of any Anti-NKG2A Know How or NN Anti-NKG2A FoO IPR related to either (x)&nbsp;manufacturing methods, processes or procedures or (y)&nbsp;formulation, assay and delivery
methodologies. IPH shall bear sole responsibility for the preparation, filing, prosecution and maintenance of any Patent contemplated by this Section 9.1B.1 (a) and all costs associated therewith </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">accruing after February&nbsp;5, 2014 including attorneys&#146; fees and payments due to patent authorities to maintain such Patents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">9.1B.3 <U>Notice and Effects of NN&#146;s Decision to Abandon; Disclaim; or Discontinue Prosecution, Maintenance, or Defense of Formulation
Patents</U>. In the event that NN decides in respect of any Formulation Patent: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to discontinue the prosecution or maintenance of such Formulation Patent, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to discontinue the defense of such Formulation Patent (such as by discontinuing efforts to defend such
Formulation Patent in any opposition, reexamination, nullity, or interference proceeding), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to not file an application for a Continuation (or, as the case may be, further Continuation) with respect to
such Formulation Patent (including by decision (A)&nbsp;not to enter the national or regional phase in any country or region that is a designated state of a PCT application filed by NN or (B)&nbsp;not to pursue an application in a country wherein an
application claiming priority from a Formulation Patent may be filed), or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to abandon or disclaim (in whole or in part, other than by terminal disclaimer), without possibility of
restoration, any Formulation Patent, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">in each case, NN shall provide written notice to IPH at least *** in advance of
the deadline relating to any of the events described above so as to allow IPH the opportunity to file, defend, maintain (including by payment of annuities, issue fees, maintenance fees, or the like), or continue prosecution of such Formulation
Patent, at its own expense. In such an event, NN shall provide any assistance reasonably requested of it by NN (including providing IPH with power of attorney to perform such tasks) and, to the extent authorized by </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
contract and permitted by applicable Law, assign its rights to such Formulation Patent to IPH, IPH shall thereafter grant to NN a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
licence (including the right to <FONT STYLE="white-space:nowrap">sub-license</FONT> and further sublicense) with respect to such Formulation Patent for no additional consideration. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.1B.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Enforcement of Anti-NKG2A Patents, Formulation Patents and NN Claims</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise provided in Sections 9.1B.4(b) and 9.1B.4(c) and subject to Sections 9.12.1 and 9.12.2, IPH
shall have the exclusive right (but not the obligation) to initiate or defend any suit, opposition, interference or other legal action (including proceedings before the US International Trade Commission) or to take other appropriate action that IPH,
in its sole discretion, believes is reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any Anti- </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">NKG2A Patent listed in Schedule 1.1.16B Part A (which for avoidance of doubt excludes the Formulation Patent) (in its own name or, if
authorized by contract and permitted by applicable Law and required by applicable Law, in the name of the NN or an Affiliate of NN), and shall bear its own costs and expenses in respect thereof and be represented by counsel of its choice and shall
further indemnify NN and any of its Affiliates for any costs incurred by NN or any of its Affiliates in connection with such suit, opposition, interference or action. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in this Agreement, except as otherwise provided in Section 9.1B.4(c)
and subject to Sections 9.12.1 and 9.12.2, NN shall have the primary right (but not the obligation) to initiate or defend any suit, opposition, interference, other legal action (including proceedings before the US International Trade Commission) or
to take other appropriate action that NN, in its sole discretion, believes is reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any Formulation Patent
(in its own name or, if authorized by contract and permitted by applicable Law and required by applicable Law, in the name of the NN or an Affiliate of NN) against any Per<SUP STYLE="font-size:85%; vertical-align:top">-</SUP>son for infringement of
any claims of such Formulation Patent and shall bear its own costs and expenses in respect thereof and be represented by counsel of its choice and shall further indemnify IPH and any of its Affiliates for any costs incurred by IPH or any of its
Affiliates in connection with such suit, opposition, interference or action. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in this Agreement, except as otherwise provided in Section 9.1B.4(c)
and subject to Sections 9.12.1 and 9.12.2, if within *** following IPH&#146;s notice to NN, NN does not initiate or defend any suit, opposition, interference, other legal action (including proceedings before the US International Trade Commission),
then IPH shall </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this
agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
have the right to initiate or defend any suit, opposition, interference, other legal action (including proceedings before the US International Trade Commission) or to take other appropriate
action that IPH, in its sole discretion, believes is reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any Formulation Patent (in its own name or, if
authorized by contract and permitted by applicable Law and required by applicable Law, in the name of the NN or an Affiliate of NN) against any Per<SUP STYLE="font-size:85%; vertical-align:top">-</SUP>son for infringement of any claims of such
Formulation Patent , to the extent that such infringement relates to an anti-NKG2A antibody and would be materially detrimental to the development/commercialization of any Anti-NKG2A Product, or has resulted in sales by the infringing product of
excess of *** in the aggregate. IPH shall bear its own costs and expenses in </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">respect thereof and be represented by counsel
of its choice and shall further indemnify NN and any of its Affiliates for any costs incurred by NN or any of its Affiliates in connection with such suit, opposition, interference or action. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Monetary Awards</I>. Any damages or other monetary awards recovered in a legal action initiated or conducted
by IPH under Section 9.1B.4(c) will be allocated to the Parties in the following manner: (1)&nbsp;IPH will be reimbursed for its internal and external expenses (including reasonable attorneys&#146; fees and costs) incurred in the legal action; and
(2)&nbsp;the remaining balance from such recovery will be allocated to IPH and will be treated as Net Sales. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">9.1B.5
<U>Dispute Resolution</U>. The Parties acknowledge that all disputes arising under this Section 9.1B shall be subject to the dispute resolution procedures set forth in Section&nbsp;21.14.&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Development Diligence Requirements for Anti-NKG2A as a Niche Candidate</U>. With effect from the Amendment
No.&nbsp;7 Effective Date, Article 12 of the Agreement is hereby amended by inserting the following text immediately following Section&nbsp;12.7 and Section&nbsp;12.7 shall no longer apply to Anti-NKG2A as a Niche Candidate or the marketing or sale
of an Anti-NKG2A Product: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">&#147;12.7B <U>Development and Commercialization Diligence Requirements for Anti-NKG2A Niche
Candidate</U>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Diligent Efforts</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Development</I>. Notwithstanding Section&nbsp;12.7 hereof, with respect to the Development of Anti-NKG2A as
a Niche Candidate, IPH, by itself or through its Affiliates, <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> or <FONT STYLE="white-space:nowrap">Out-licensees,</FONT> shall use Diligent Efforts to Develop an Anti-NKG2A Antibody or Anti-NKG2A
Product for the treatment, prevention or control of any </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain
information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
human disease, disorder or condition for the purpose of obtaining a Regulatory Approval in each Major Market. For clarity, it is understood and acknowledged that Diligent Efforts in the
Development of Anti-NKG2A Antibodies and Anti-NKG2A Products may include sequential implementation of clinical trials or intervals between clinical trials for data interpretation and clinical program planning and approval. IPH, by itself or through
its Affiliates, <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> or <FONT STYLE="white-space:nowrap">Out-licensees,</FONT> shall initiate at least one Clinical Trial with respect to an Anti-NKG2A Antibody or Anti-NKG2A Product within ***
following later of: (i)&nbsp;the completion by NN of the Ongoing Clinical Trial (as defined below) and the (ii)&nbsp;the complete transfer by NN to IPH of all Know How and Anti-NKG2A supplies pursuant to this Amendment, provided that such *** period
shall be extended to the extent of any delay that is attributable to any of the following factors: (I)&nbsp;any safety reason arising from the Ongoing Clinical Trial, (II)&nbsp;insufficient quantities of the applicable Anti-NKG2A Product are
available to initiate and complete such two Phase 1 Clinical Trials, (III)&nbsp;approval of regulatory authorities for IPH, its Affiliates, <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> or
<FONT STYLE="white-space:nowrap">Out-licensees</FONT> to conduct such Phase 1 Clinical Trials, if required by applicable law, is not received or (IV)&nbsp;any required consent of a Third Party collaborator of IPH, its Affiliates, <FONT
STYLE="white-space:nowrap">Sub-licensees</FONT> or <FONT STYLE="white-space:nowrap">Out-licensees</FONT> for the use of a compound other than an Anti-NKG2A Antibody or Anti-NKG2A Product in such Phase 1 Clinical Trial is not received. For purposes
of the preceding sentence, (A)&nbsp;the initiation of a Clinical Trial shall mean the first administration of the Anti-NKG2A Product to the first patient and (B)&nbsp;the completion of the Ongoing Clinical Trial shall mean the availability of the
full data set of such Ongoing Clinical Trial. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:19%; font-size:10pt; font-family:Times New Roman">(ii)<I> Commercialization</I>. Notwithstanding Section&nbsp;12.7 hereof, with
respect to the Commercialization of an Anti-NKG2A Product, IPH, by itself or through its Affiliates or <FONT STYLE="white-space:nowrap">Out-licensees,</FONT> shall use Diligent Efforts to Commercialize an Anti-NKG2A Product in each Major Market for
which IPH, its applicable Affiliate, <FONT STYLE="white-space:nowrap">Sub-licensee</FONT> or <FONT STYLE="white-space:nowrap">Out-licensee</FONT> receives Approval for such Anti-NKG2A Product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination for Failure to Employ Diligent Efforts</U>. Notwithstanding Section&nbsp;12.8 hereof, and subject to Sections 12.7B(b)(i)
and 12.7B(b)(ii), NN shall have the right to terminate this Agreement with respect to Anti-NKG2A on a Major <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Market-by-Major</FONT></FONT> Market basis with respect to all Anti-NKG2A
Antibodies and Anti-NKG2A Products if IPH is in material breach of its obligation to use Diligent Efforts, alone or through its Affiliates, <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> or
<FONT STYLE="white-space:nowrap">Out-licensees,</FONT> as set forth in Section 12.7B(a) with respect to </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
such Major Market; provided however, such license shall not so terminate unless (A)&nbsp;IPH is given *** prior written notice by NN of NN&#146;s intent to terminate, stating the reasons and
justification for such termination and recommending steps which NN believes IPH, alone or through its Affiliates, <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> or <FONT STYLE="white-space:nowrap">Out-licensees,</FONT> should take to cure
such alleged breach, and (B)&nbsp;IPH, or its Affiliates, <FONT STYLE="white-space:nowrap">Out-licensees</FONT> or <FONT STYLE="white-space:nowrap">Sub-licensees,</FONT> has not (1)&nbsp;during the *** period following such notice, provided NN with
a plan for the diligent Development or Commercialization of Anti-NKG2A Products in such Major Market as set forth in Section 12.7B(a) and (2)&nbsp;during the *** following such notice carried out such plan and cured such alleged breach by diligently
pursuing the Development </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">or Commercialization of Anti-NKG2A Products in such Major Market as set forth in Section 12.7B(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:19%; font-size:10pt; font-family:Times New Roman">(i) If IPH disputes in good faith the existence or materiality of an alleged breach specified in a notice provided by NN pursuant to this
Section 12.7B(b), and if IPH provides notice to NN of such dispute within the *** following such notice provided by NN, NN shall not have the right to terminate this Agreement with respect to Anti-NKG2A unless and until the existence of such
material breach or failure by IPH has been determined in accordance with Section&nbsp;21.14 and IPH, alone or through its Affiliates, <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> or <FONT STYLE="white-space:nowrap">Out-licensees,</FONT>
fails to cure such breach within *** following such determination. It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue
to perform all of their respective obligations hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:19%; font-size:10pt; font-family:Times New Roman">(ii) Notwithstanding anything herein to the contrary, in the event that:
(A)&nbsp;NN terminates, or has the right to terminate, this Agreement pursuant to this Section 12.7B(b) with respect to an Anti-NKG2A Product in ***, then NN shall have the right to terminate this Agreement with respect to such Anti-NKG2A Product in
the entire Territory, and (B)&nbsp;NN has the right to terminate this Agreement pursuant to this Section 12.7B(b) with respect to an Anti-NKG2A Product in ***, then NN may not terminate this Agreement with respect to such ***; provided, that if IPH
has such right to terminate this Agreement with respect to such Anti-NKG2A Product with respect to any *** then NN shall have the right to terminate this Agreement with respect to such Anti-NKG2A Product in all of the EU. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:19%; font-size:10pt; font-family:Times New Roman"><U>Definitions</U>. The following terms, as used in this Section 12.7B or in Sections 12.8C and
12.8D, shall have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:19%; font-size:10pt; font-family:Times New Roman">&#147;<U>Approval</U>&#148; shall mean, with respect to an Anti-NKG2A Product in any regulatory
jurisdiction, Regulatory Approval and, where applicable, receipt of pricing and reimbursement approvals. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:19%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commercialize</U>&#148;
or &#147;<U>Commercialization</U>&#148; shall mean the marketing, promotion, sale (and offer for sale or contract to sell), distribution, importation or other commercial exploitation (including pricing and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:19%; font-size:10pt; font-family:Times New Roman">reimbursement activities) for an Anti-NKG2A Product. Commercialization shall include commercial activities conducted in preparation for
Anti-NKG2A Product launch. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:19%; font-size:10pt; font-family:Times New Roman">&#147;<U>Develop</U>&#148; or &#147;<U>Development</U>&#148; shall mean all activities that relate to
(a)&nbsp;obtaining, maintaining or expanding Regulatory Approval of an Anti-NKG2A Product and to support appropriate usage for such Anti-NKG2A Product, for one or more indications. This includes: (i)&nbsp;preclinical/nonclinical research and
testing, toxicology, and clinical trials; (ii)&nbsp;preparation, submission, review, and development of data or information and regulatory materials for the purpose of submission to a governmental authority to obtain, maintain or expand Regulatory
Approval of an Anti-NKG2A Product (including contacts with regulatory authorities), and outside counsel regulatory legal services related thereto; provided, however, that Development shall exclude Commercialization and manufacturing activities
(including manufacturing activities related to Development). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:19%; font-size:10pt; font-family:Times New Roman">&#147;<U>Diligent Efforts</U>&#148; shall mean the carrying out by IPH, or
its Affiliates, <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> or <FONT STYLE="white-space:nowrap">Out-licensees</FONT> of such obligations or tasks with a level of effort and resources consistent with the commercially reasonable practices
devoted by the applicable entity for the research, development, manufacture or commercialization of a pharmaceutical product owned by it (or to which it has rights) at a similar stage of development or commercialization and of similar market
potential, profit potential and strategic value, based on conditions then prevailing. Such efforts may take into account, without limitation, issues of safety and efficacy, regulatory authority-approved labeling, product profile, the competitiveness
of alternative products in the marketplace, pricing/reimbursement for the product in a country relative to other markets, the likely timing of the product&#146;s entry into the market, the patent and other proprietary position, the likelihood of
regulatory approval and other relevant scientific, technical and commercial factors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:19%; font-size:10pt; font-family:Times New Roman">&#147;<U>Major European Countries</U>&#148; shall
mean ***. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<U>Major Market</U>&#148; shall mean each of ***. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory Approval</U>&#148; shall mean, with respect to a country, extra-national territory, province, state, or other regulatory
jurisdiction, any and all approvals, licenses, registrations or authorizations of any regulatory authority necessary in order to commercially distribute, sell, manufacture, import, export or market a product in such country, state, province, or some
or all of such extra-national territory or regulatory jurisdiction, but which shall exclude any pricing and reimbursement approvals.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The provisions of Sections 12.7B(b), 12.8C and 12.8D shall be NN&#146;s sole and exclusive remedy for any breach by IPH of Section 12.7B(a).
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination upon Abandonment of Development of Anti-NKG2A Niche Candidate</U>. With effect from the
Amendment No.&nbsp;7 Effective Date, Article 12 of the Agreement is hereby amended by inserting the following text immediately following Section 12.8B and Section&nbsp;12.8 shall no longer apply to Anti-NKG2A Products: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;12.8C <U>Effects of Termination of Agreement for Failure to Employ Diligent Efforts in Development</U>. With effect from the Amendment
No.&nbsp;1 Effective Date, upon any termination pursuant to Section 12.7B(b) due to IPH&#146;s failure, by itself or through its Affiliates, <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> or
<FONT STYLE="white-space:nowrap">Out-licensees,</FONT> to use Diligent Efforts to Develop an Anti-NKG2A Antibody or Anti-NKG2A Product as set forth in Section 12.7B(a)(i) (such termination may be designated for purposes as this Amendment as the
&#147;abandonment&#148;), the following shall apply and supersede Section&nbsp;12.8 with respect to the terminated Anti-NKG2A Antibody(ies)/Product(s) and terminated country(ies):&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all licenses granted to IPH under this Agreement for the purposes of Commercial Optimization of Anti-NKG2A as a
Niche Candidate that IPH is authorized to develop and commercialize shall terminate immediately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall have an obligation to grant to NN, at NN&#146;s request, an irrevocable, world-wide, fully paid up,
exclusive license under all its right, title and interest to the Collaboration IPR or Background IPH IPR (as applicable) and Independent IPH IPR, and grant the right set out in Section&nbsp;5.7 (including all supporting regulatory documentation),
for the development and commercialization of Anti-NKG2A, for no additional consideration other than as provided for herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if NN shall, in its discretion, assume such license it shall notify IPH to this effect within *** of IPH&#146;s
abandonment or the determination of abandonment, whichever is the later, upon which assumption NN shall have the exclusive right to exploit such IPR for the development and commercialization of Anti-NKG2A; </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the date of such abandonment is prior to the first dosing of humans in Phase II clinical trials of
Anti-NKG2A as a Niche Candidate, Sections 12.8C(a) and 12.8C(b) shall apply, save that, in consideration of the grant of such rights, if and only if NN subsequently <FONT STYLE="white-space:nowrap">Out-licenses</FONT> such IPR within the period of
*** following the date of NN&#146;s assumption of rights, NN shall pay to IPH </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">a percentage of all revenue actually
received in respect of such license on the following basis: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the effective date of abandonment is after the first dosing of humans in Phase II clinical trials of
Anti-NKG2A as a Niche Candidate but prior to the first dosing in Phase Ill, the above Sections 12.8C(a) and 12.8C(b) shall apply save that in consideration of the grant of such rights, if and only if NN subsequently
<FONT STYLE="white-space:nowrap">Out-licenses</FONT> such IPR within the period of *** following the date of NN&#146;s assumption of rights NN shall pay to IPH a percentage of all revenue actually received by NN in respect of such license on the
following basis: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event of its abandonment of the development of Anti-NKG2A as a Niche Candidate and irrespective of the
effective date of such abandonment, IPH shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make no further representation regarding its status as a licensee of NN in respect of Anti-NKG2A;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event that at the date of the abandonment by IPH of its development of Anti-NKG2A as a Niche Candidate
there are ongoing clinical trials with respect to such development, IPH shall pay for the completion of such clinical trials in respect of all patients enrolled at the effective date of abandonment except if the Agreement is terminated because of
adverse events in the clinical trial(s) causing the trials(s) to cease due to regulatory requirements or regulatory considerations (including an actual or anticipated regulatory warning); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at NN&#146;s option, and at NN&#146;s expense, and to the extent authorized by contract and permitted by
applicable Law, assign or cause to be assigned to NN any regulatory submissions and approvals with respect to Anti-NKG2A and take such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer
of all rights thereunder to NN; </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been
excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at NN&#146;s option and at NN&#146;s expense, provide to NN all
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data in respect of Anti-NKG2A and all research reagents and materials intended for use In clinical trials of Anti-NKG2A in IPH&#146;s possession or control. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Following the transfer of rights from IPH to NN pursuant to this Section 12.8C IPH shall have no further obligations under Sections 12.7, 12.8,
12.8C, 12.8D, 12.9 or 12.10 in respect of the development or commercialization of Anti-NKG2A.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination upon Abandonment of Marketing or Sale of Anti-NKG2A Product</U>. With effect from the Amendment
No.&nbsp;7 Effective Date, Article 12 of the Agreement is hereby amended by inserting the following text immediately following Section 12.8C and Section&nbsp;12.8 shall no longer apply to Anti-NKG2A Products: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">&#147;12.8D <U>Effects of Termination of Agreement for Failure to Employ Diligent Efforts in Commercialization</U>. With effect from the
Amendment No.&nbsp;1 Effective Date, upon any termination pursuant to Section 12.7B(b) due to IPH&#146;s failure, by itself or through its Affiliates or <FONT STYLE="white-space:nowrap">Out-licensees,</FONT> to use Diligent Efforts to Commercialize
an Anti-NKG2A Product as set forth in Section 12.7B(a)(ii) (such termination may be designated for purposes as this Amendment as the &#147;abandonment&#148;), the following shall apply and supersede Section&nbsp;12.8 with respect to the terminated
Anti-NKG2A Antibody(ies)/Product(s) and terminated country(ies):&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all licenses granted to IPH under this Agreement for the marketing or sale of such Anti-NKG2A Product, shall
terminate immediately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall have an obligation to grant to NN, at NN&#146;s request, an irrevocable, world-wide, fully paid up,
exclusive license under all its right, title and interest to the Collaboration IPR or Background IPH IPR (as applicable) and Independent IPH IPR, and grant the right set out in Section&nbsp;5.7 (including all supporting regulatory documentation)
with respect to which such Anti-NKG2A Product has been abandoned, solely for the purposes of the commercialization of such specific Anti-NKG2A Product, for no additional consideration other than as provided for herein; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if NN shall, in its discretion, assume such license it shall notify IPH to this effect within *** of IPH&#146;s
abandonment, upon which assumption NN shall have the exclusive right to exploit such IPR for solely with respect to such abandoned Anti-NKG2A Product and for such purposes as are specified in clause (a); </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the above Sections 12.8D(a) and 12.8D(b) shall apply save that in consideration of the grant of such rights, if
and only if NN subsequently <FONT STYLE="white-space:nowrap">Out-licenses</FONT> such IPR within the period of *** following the date of NN&#146;s assumption of rights, NN shall pay to IPH a percentage of all revenue actually received by NN in
respect of such license on the following basis: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*** </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event of its abandonment of the marketing or sale of any Anti-NKG2A Product irrespective of the
effective date of such failure, IPH shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cease any activities with respect to the marketing, promotion, sale or distribution of the Anti-NKG2A Product
with respect to which such abandonment has occurred; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at NN&#146;s option and at NN&#146;s expense, and to the extent such transfer is authorized by contract and
permitted by applicable Law, to transfer to NN the benefit of any contracts between IPH and any Third Party in respect of the manufacture of such abandoned Anti-NKG2A Product, with respect to the supply thereof for marketing with respect to which
such abandonment has occurred, provided that for the avoidance of doubt IPH shall not be required to cause or effect any such transfer if to do so will require IPH&#146;s payment or provision of additional consideration to any Person save that NN
may elect to pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by applicable Law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at NN&#146;s option, and at NN&#146;s expense, and to the extent authorized by contract and permitted by
applicable Law, assign or cause to be assigned to NN, any regulatory submissions and approvals related to the Anti-NKG2A Product with respect to which such abandonment has occurred and take such actions and execute such other instruments,
assignments and documents as may be necessary to effect the transfer of all rights thereunder to NN; </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall pay IPH&#146;s reasonable costs in connection with the above activities at a reasonable hourly rate
representing the actual cost of IPH of providing such services up to a maximum of ***. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Following the transfer of rights
from IPH to NN pursuant to this Section 12.8D, IPH shall have no further obligations under Sections 12.7, 12.8, 12.8C, 12.8D, 12.9 or 12.10 with respect to the marketing and sale of the Anti-NKG2A Product with respect to which the abandonment has
occurred.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Publication concerning an Anti-NKG2A Niche Candidate</U>. With effect from the Amendment No.&nbsp;7
Effective Date, Article 18 of the Agreement is hereby amended by inserting the following text immediately following Section 18.1A: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">&#147;Section 18.1B <U>Publication concerning Anti-NKG2A as a Niche Candidate or Anti-NKG2A Products</U>. Notwithstanding Section&nbsp;18.1, NN
shall have no rights pursuant to such Section&nbsp;18.1 with respect to publications or disclosures concerning the development or commercialization of Anti-NKG2A as a Niche Candidate pursuant to Section&nbsp;6.1 hereof or any Anti-NKG2A Product;
<U>provided</U>, <U>however</U> in no event shall IPH publish Confidential </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Information of NN relating to (1)&nbsp;manufacturing,
marketing, financing or business developments, opportunities, plans, methods, processes or procedures, (ii)&nbsp;quality controls, (iii)&nbsp;security controls, (iv)&nbsp;unpublished cost, price or pricing information, (v)&nbsp;financial or
personnel matters, or (vi)&nbsp;customer, client or supplier lists or information, in each case without prior written approval of NN.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">KNOW-HOW</FONT> TRANSFER </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH has requested that NN transfer to IPH the <FONT STYLE="white-space:nowrap">Know-How</FONT> comprising the
information (regulatory, <FONT STYLE="white-space:nowrap">non-clinical,</FONT> clinical, CMC and other) listed in Exhibit C to this Amendment No.&nbsp;7. The Parties agree to update Exhibit C no later than 30 days after the Amendment No.&nbsp;7
Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall transfer, and take such actions as are reasonably required to ensure the effective transfer of, the <FONT
STYLE="white-space:nowrap">Know-How</FONT> listed in Exhibit C to Innate as soon as possible and in any event no later than June&nbsp;30, 2014 and no later than October&nbsp;31, 2014 with respect to the final report and database of the Ongoing
Clinical Study in accordance with the terms of this Amendment No.&nbsp;7 including the guidelines set out in Exhibit F.In the event of any dispute between NN and IPH regarding the actions of NN that are reasonably required to ensure the effective
transfer of the <FONT STYLE="white-space:nowrap">Know-How</FONT> listed in Exhibit C, such dispute shall in the first instance be referred to the CSO of NN and the CEO of IPH who shall seek to resolve such dispute. In the event that the CSO of NN
and the CEO of IPH are unable to resolve the dispute, NN or IPH may seek the <FONT STYLE="white-space:nowrap">non-binding</FONT> opinion of an expert, in accordance with the procedures set forth in Exhibit H, on whether or not any additional actions
of NN are reasonably required to effect such transfer; <U>provided</U>, <U>however</U>, that neither NN nor IPH shall be obliged to take any actions based on such expert&#146;s opinion. Notwithstanding the above, either Party may at any time refer
any such dispute to arbitration in accordance with Section&nbsp;21.14 of the Agreement. </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, on or before June&nbsp;30, 2014, IPH gives notice to NN that IPH has identified <FONT
STYLE="white-space:nowrap">Know-How</FONT> that is (x)&nbsp;Controlled by NN at that date, (y)&nbsp;not listed in Exhibit C and (z)&nbsp;necessary for the purposes of IPH&#146;s development or commercialization of the Anti-NKG2A Niche Candidate,
then NN shall deliver to IPH the documents, files and materials containing such <FONT STYLE="white-space:nowrap">Know-How</FONT> as soon as reasonably practicable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH acknowledges and agrees that, subject to Section 5.8.2A of the Agreement (as amended by this Amendment
No.&nbsp;7) and Sections 4, 5 and 6 of this Amendment No.&nbsp;7, NN shall have no further obligation to transfer <FONT STYLE="white-space:nowrap">Know-How</FONT> to IPH pursuant to Section&nbsp;6.1 of the Agreement or otherwise in connection with
IPH&#146;s development and commercialization of Anti-NKG2A as a Niche Candidate. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CLINICAL TRIALS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Definitions</U>. The following terms, as used in this subsection herein, shall have the following meanings:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">&#147;<U>Ongoing Clinical Trial</U>&#148; shall mean the ongoing clinical trial conducted by NN on Anti-NKG2A. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall complete the Ongoing Clinical Trial and comply with all sponsorship obligations relating thereto at
its own costs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN agrees to indemnify, hold harmless, and defend IPH and its Affiliates, against any claims, suits, losses,
damages, costs, fees, or expenses resulting from the conduct of the Ongoing Clinical Trial. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall notify IPH upon the completion (i.e., last patient, last visit) of the Ongoing Clinical Trial and
shall provide IPH for prior review and comment drafts of all submissions to be made to the regulatory authorities or ethic committees and copies of all correspondance with the regulatory authorities or ethic committees in connection with the Ongoing
Clinical Trial. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSFER OF ANTI-NKG2A SUPPLIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall transfer to IPH the materials described further in Exhibit E (the &#147;<U> Anti-NKG2A
Supplies</U>&#148;) as follows: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Section&nbsp;6.4, within *** of the Amendment No.&nbsp;7 Effective Date, NN shall cause those
Anti-NKG2A Supplies set forth in Part of A of Exhibit E to be shipped to IPH; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall cause those Anti-NKG2A Supplies set forth in Part B of Exhibit E which are reasonably required to
conduct a Clinical Trial to be shipped to IPH, or to a location directed by IPH, acting reasonably, as soon as practicable following a request by IPH after the Innate shareholder vote as described in 9.3.2; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>NN shall transfer those Anti-NKG2A Supplies set forth in Part D of Exhibit E to IPH at such time as the
Parties agree but no later than June&nbsp;30, 2014 (the &#147;<B><FONT STYLE="white-space:nowrap">In-Process</FONT> Batch</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Title to the Anti-NKG2A Supplies shall transfer to IPH upon delivery of such Anti-NKG2A Supplies to IPH or to a
Third Party for shipment to IPH and IPH shall be responsible for all storage costs for such Anti-NKG2A Supplies as and from such date;<U> </U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>provided</U>,<U> however</U>, that NN shall be responsible for all shipment (but not including insurance) costs with respect to such
shipment of Anti-NKG2A Supplies. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>IPH shall reimburse NN for internal costs related to the transfer of the Anti-NKG2A Supplies to IPH of
*** to be paid within *** from receipt of an invoice from NN to be issued following the satisfactory completion of the transfer of Know How within the timelines set forth in Section&nbsp;4.2, and provided that such transfer occurs within such
timelines. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall analyze all <FONT STYLE="white-space:nowrap">on-going</FONT> stability studies relating to Anti-NKG2A
and make available to IPH all related data. After analyses NN shall transfer to IPH all stability samples. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NO WARRANTY </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">AT THE AMENDMENT NO 7. EFFECTIVE DATE, THE Anti-NKG2A SUPPLIES ARE BEING SOLD AND THE <FONT
STYLE="white-space:nowrap">KNOW-HOW</FONT> LISTED IN EXHIBIT C AND THE Anti-NKG2A PATENTS AND THE NN Anti-NKG2A FoO IPR ARE BEING LICENSED &#147;AS IS&#148; AND WITHOUT ANY REPRESENTATIONS OR WARRANTIES BY NN. NN MAKES NO REPRESENTATIONS OR
WARRANTIES, EXPRESS OR IMPLIED, OF ANY TYPE WHATSOEVER, REGARDING THE Anti-NKG2A SUPPLIES, THE <FONT STYLE="white-space:nowrap">KNOW-HOW</FONT> LISTED IN EXHIBIT C,THE Anti-NKG2A PATENTS AND THE NN Anti-NKG2A FoO IPR, AND TO THE FULLEST EXTENT
PERMITTED BY LAW, NN EXPRESSLY DISCLAIMS ANY IMPLIED WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, CONSISTENCY OR COMPLIANCE WITH ANY SAMPLES PREVIOUSLY PROVIDED OR NONINFRINGEMENT. </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REGULATORY OR SAFETY DELAY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any provision of this Amendment No.&nbsp;7: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN may delay the transfer of any Anti-NKG2A <FONT STYLE="white-space:nowrap">Know-How,</FONT> any Anti-NKG2A
Supplies to IPH; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if transfer of any Anti-NKG2A <FONT STYLE="white-space:nowrap">Know-How,</FONT> any Anti-NKG2A Supplies shall
have occurred, IPH shall permit access by NN to such Anti-NKG2A <FONT STYLE="white-space:nowrap">Know-How,</FONT> Anti-NKG2A Supplies; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">in each case as may be required, in NN&#146;s reasonable determination, to respond to any request from, or fulfill any requirement of, any
regulatory authority. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall use all reasonable endeavours to cooperate with NN to permit NN to respond to any request from, or
fulfill any requirement of, any regulatory authority, or otherwise to ensure Clinical Trial patient safety. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FINANCIAL CONSIDERATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In partial consideration for the buy back of Anti-NKG2A, including the licenses and rights granted hereunder to
IPH pursuant to this Amendment, IPH shall pay to NN *** in cash within thirty (30)&nbsp;days of the Innate shareholder vote as described in 9.3.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPH shall also pay *** of any upfront payment(s) received by IPH in connection with the any <FONT
STYLE="white-space:nowrap">Out-License</FONT> for Anti-NKG2A to be entered into by IPH, minus *** to the extent that such difference is positive. For this avoidance of doubt, &#147;upfront payment(s)&#148; shall mean the payment(s) made immediately
following the execution of the <FONT STYLE="white-space:nowrap">Out-license</FONT> in partial consideration of the grant of rights, and shall exclude any other payments (including any development or regulatory milestone payments).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition, IPH shall for the sale and partial cost reimbursement for the Anti-NKG2A supplies, toxicology, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data and results owe to NN a payment of *** (the &#147;Additional Payment&#148;), which payment will become due and payable as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to the vote by its shareholders, IPH will issue and allocate to NN *** new shares forming the share
capital of IPH (the &#147;Shares&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as soon as possible after this Amendment no. 7, IPH will convene an extraordinary shareholders&#146; meeting to
be set for March&nbsp;27, 2014, for the purpose of voting on a resolution authorizing the issue of shares to NN (the &#147;<B>Resolution</B>&#148;); </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the chairman of the extraordinary shareholders&#146; meeting, which shall be the chairman of the Supervisory
Board of IPH, as per article <FONT STYLE="white-space:nowrap">R225-100</FONT> of the French Commercial Code, shall vote the unnamed proxies in favor of the Resolution, as provided in article <FONT STYLE="white-space:nowrap">L.225-106</FONT> III al.
5 of the French Commercial Code ; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as of the date of this Amendment No.&nbsp;7 and until the expiry of a 180 day period starting on the closing of
the Innate Fundraising (as defined below), NN irrevocable undertakes that neither it nor any of its Affiliates will (i)&nbsp;directly or indirectly, offer, transfer, issue or agree to offer, transfer, issue, the Shares or any financial instruments
giving right, of immediately or in the future to the </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Shares, (ii)&nbsp;enter into any swap or other agreement that
transfers, in whole or in part, any of the economic consequences of the ownership of the Shares, whether any such transaction described in (i)&nbsp;or (ii) above is to be settled by delivery of the Shares or in other securities, or in cash or
otherwise; or (iii)&nbsp;grant options to subscribe for or purchase the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">For the purposes of this Amendment No.&nbsp;7,
&#147;<B>Innate Fundraising</B>&#148; shall mean a capital increase realized by IPH with a closing date occurring on or before December&nbsp;31, 2014. For the purpose of clarity, if the Innate Fundraising does not occur by December&nbsp;31, 2014,
then the restrictions set forth in this 9.3.4 shall not apply to NN with respect to the Shares. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to section 9.4, the Additional Payment shall become due and payable (&#147;<I>liquide et
exigible</I>&#148;) on the date on which IPH issues and allocates the Shares to NN, which date shall be no later than 10 business days following the approval of the resolution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall subscribe the Shares and the subscription price shall be paid by the setoff against the Additional
Payment. IPH shall provide all necessary documents and assistance to facilitate NN&#146;s subscription of the Shares and will take the necessary steps for the Shares to be listed on Euronext Paris. If despite such steps and NN receiving such
assistance, NN fails to subscribe the Shares as allocated to NN by IPH, and such failure is notified in writing by Innate to NN, the Additional payment shall no longer be due and payable by IPH to NN. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Resolution is not approved by the shareholders of IPH on March&nbsp;27, 2014, this Amendment No.
7&nbsp;may be terminated by either Party upon notice to the other Party. In such event of termination, all rights, license sand obligations provided in this Amendment No.&nbsp;7 shall terminate effective upon the date of the termination notice,
provided that IPH shall return to NN all materials and documents provided by NN to IPH pursuant to Section 4, Section&nbsp;5 and Section&nbsp;6 of this Amendment No.&nbsp;7 within thirty (30)&nbsp;days of the termination date, except for those
materials which have been consumed by IPH prior to the termination date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall submit an invoice to IPH corresponding to the payments of Section&nbsp;9.1 and 9.3, at IPH&#146;s
request and no later than fifteen days prior to the due date of such payments, which invoice shall include the term &#147;reverse charge&#148; in consideration of VAT. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If by September&nbsp;30, 2014, NN has delivered less than 500g of the
<FONT STYLE="white-space:nowrap">In-Process</FONT> Batch, then NN shall pay to IPH liquidated damages in the amount of ***. If by September&nbsp;30, 2014, NN has delivered to IPH at least 500g but less than 1000g of the <FONT
STYLE="white-space:nowrap">In-Process</FONT> Batch, then NN shall pay to IPH liquidated damages in the amount following the formula: liquidated damages (in Millions euros) = *** x quantity (in grams). By way of example: if only 750g of the <FONT
STYLE="white-space:nowrap">In-Process</FONT> Batch have been </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">delivered on September&nbsp;30, 2014, the liquidated
damages amount shall be *** x 750 = ***. If by September&nbsp;30, 2014, NN has delivered to IPH more than 1000g of the <FONT STYLE="white-space:nowrap">In-Process</FONT> Batch then no liquidated damages will be due. The amount of liquidated damages,
if any, will invoiced by IPH to NN and paid by NN within *** following the receipt of such invoice. Such payment shall not be subject to any setoff right. The Parties agree that the amounts payable under this Section&nbsp;9.6 are a genuine <FONT
STYLE="white-space:nowrap">pre-estimate</FONT> of the loss that IPH will suffer as a result of the failures to deliver the <FONT STYLE="white-space:nowrap">In-Process</FONT> Batch as required by Section&nbsp;6.1 (c). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PRESS RELEASE. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Simultaneously with the execution of the Amendment No.&nbsp;7, the Parties shall issue a joint press release on the buy back by IPH of the
Anti-NKG2A program in the form attached as Exhibit G. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OTHER ADJUSTMENTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding Section 15.3.1(a) and 15.3.1(b) of the Agreement, IPH may grant to any <FONT
STYLE="white-space:nowrap">Out-Licensee</FONT> a security interest, lien or other encumbrance on any Intellectual Property Right owned by IPH and licensed by IPH to any <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> under the Outlicense.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding Section&nbsp;9.8 of the Agreement, upon execution of an
<FONT STYLE="white-space:nowrap">Out-License,</FONT> IPH may request that its <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> shall have the sole right, but not the obligation, to apply for any patent term adjustment, patent term extension,
supplemental patent protection or related extension of rights with respect to the Patents licensed to any <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> under the Outlicense. Without limiting the foregoing, NN covenants that it will not seek
patent term extensions, supplemental protection certificates, or similar rights or extensions for such Patents without the prior written consent of IPH. NN will cooperate fully with and provide all reasonable assistance to IPH or its designated <FONT
STYLE="white-space:nowrap">Out-Licensee</FONT> and use all Commercially Reasonable Efforts consistent with its obligations under applicable Law </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(including any applicable consent order or decree) in connection with obtaining any such adjustments or extensions for such Patents. To the extent reasonably and legally required in order to
obtain any such adjustment or extension in a particular country, NN will make available to IPH or its designated <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> a copy of the necessary documentation to enable IPH or its designated <FONT
STYLE="white-space:nowrap">Out-Licensee</FONT> to use the same for the purpose of obtaining the adjustment or extension in such country. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NN shall not exercise its <FONT STYLE="white-space:nowrap">&#147;March-In&#148;</FONT> right under
Section&nbsp;9.13 with respect to any IPR licensed to any <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> under the <FONT STYLE="white-space:nowrap">Out-license</FONT> without the prior written consent of any
<FONT STYLE="white-space:nowrap">Out-Licensee,</FONT> which consent shall not be unreasonably withheld. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding Section&nbsp;21.1 or anything else in the Agreement to the contrary, any <FONT
STYLE="white-space:nowrap">Out-Licensee</FONT> shall not be required, during or following the term of the Outlicense, to maintain, grant, assign or otherwise convey to IPH, NN, or any other Third Party, any rights under any IPR that any <FONT
STYLE="white-space:nowrap">Out-Licensee</FONT> or its Affiliates may own or control (other than such IPR as is licensed to any <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> under the Outlicense). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> may exercise any right as an <FONT
STYLE="white-space:nowrap">Out-licensee</FONT> under the Agreement and may exercise IPH&#146;s right to cure under Sections 12.4 and 12.7B(b) of the Agreement and any right of IPH under Article 9 with respect to the patent rights listed in Exhibit B
of this Amendment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> shall have no obligation under the Agreement other
than those obligations expressly imposed on <FONT STYLE="white-space:nowrap">Out-licensees</FONT> and, for clarity, any <FONT STYLE="white-space:nowrap">Out-Licensee&#146;s</FONT> obligations under Section&nbsp;15.1.6 shall only apply to other terms
and conditions of the Agreement that are expressly imposed on <FONT STYLE="white-space:nowrap">Out-Licensees.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> may disclose Confidential Information of NN relating
to Anti-NKG2A Antibodies and IPR licensed to any <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> under the Outlicense that it obtains from IPH without any obligation to obtain consent therefor from NN. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding Section&nbsp;15.1.8 or anything else in the Agreement to the contrary, any <FONT
STYLE="white-space:nowrap">Out-Licensee</FONT> shall have no obligation to provide any information to NN regarding any activity under the Outlicense beyond such information that any <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> provides to
IPH under the Outlicense. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything in the Agreement to the contrary, any
<FONT STYLE="white-space:nowrap">Out-Licensee&#146;s</FONT> rights under the Outlicense shall survive any termination of the Agreement (other than a termination directly resulting from a material breach by any
<FONT STYLE="white-space:nowrap">Out-Licensee</FONT> of its obligations under the Outlicense or as an <FONT STYLE="white-space:nowrap">Out-licensee</FONT> under the Agreement), subject to (a)&nbsp;the payment by any
<FONT STYLE="white-space:nowrap">Out-Licensee</FONT> to NN of any milestones or royalties with respect to Anti-NKG2A that IPH would have been required to pay NN under the Agreement and (b)&nbsp;the provision by any
<FONT STYLE="white-space:nowrap">Out-Licensee</FONT> to NN of information consistent with Section&nbsp;11.6. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of this Amendment confer a benefit on and are intended to be (and shall be) enforceable by any <FONT
STYLE="white-space:nowrap">Out-Licensee</FONT> in the event any <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> becomes and as long as it remains an <FONT STYLE="white-space:nowrap">Out-licensee</FONT> by virtue of the Contracts (Rights of
Third Parties) Act 1999. Otherwise no person who is not a Party shall have the right to enforce any term of this Amendment by virtue of the Contracts (Rights of Third Parties) Act 1999. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Effectiveness and Integration</U>. This Amendment shall become effective as of the Amendment No.&nbsp;7
Effective Date and the amendments made to the Agreement hereunder shall thereafter be deemed an integral part of the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Other Changes or Repetition of Warranties</U>. Except as expressly set forth herein, all provisions of
the Agreement shall remain unchanged and in full force and effect. Nothing in this Amendment No.&nbsp;7 shall cause, or shall be deemed to cause, any representation or warranty set out in the Agreement to be repeated. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Conflicts Between Agreement and Amendment No.</U><U></U><U>&nbsp;7</U>. To the extent that the Agreement is
explicitly amended by this Amendment No.&nbsp;7, the terms of the Amendment No.&nbsp;7 will control where the terms of the Agreement are contrary to or conflict with the provisions of this Amendment. Where the Agreement is not explicitly amended by
this Amendment No.&nbsp;7, the terms of the Agreement will remain in force. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Applicable Law</U>. This Amendment No.&nbsp;7 shall be construed and interpreted pursuant to the Laws
stipulated in the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Dispute Resolution</U>. All disputes arising out of or in connection with this Amendment No.&nbsp;7 shall be
finally settled as stipulated in the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts</U>. This Amendment No. 7&nbsp;may be executed in two (2)&nbsp;or more counterparts, each of
which shall constitute an original for all purposes, including for purposes of any delivery of this Amendment No.&nbsp;7 required by the terms hereof, and all of which together shall constitute one and the same instrument with the same effect as if
all parties hereto had signed the same document. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[SIGNATURE PAGE FOLLOWS] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this Amendment No.&nbsp;7 to be executed by their respective duly
authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marseille</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Innate Pharma SA</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Herve Brailly</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By:
&nbsp;&nbsp;&nbsp;&nbsp;Herve Brailly</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:&nbsp;&nbsp;Chief Executive/Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bagsvaerd</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk A/S</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lars Fruergaard J&oacute;rgensen</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: &nbsp;&nbsp;&nbsp;&nbsp;Lars Fruergaard J&oacute;rgensen</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title:&nbsp;&nbsp;Chief Information Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Novo Nordisk A/S</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page to Amendment No.&nbsp;1 to the joint Research, Development, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Option and License Agreement] </P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.7B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Background NN IPR for the development and commercialization of Anti-NKG2A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as a Niche Candidate </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>To be mutually
agreed upon as needed. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.16B </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part
A &#151; Anti-NKG2A Patents </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit B-1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.16B </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part <FONT
STYLE="white-space:nowrap">B-</FONT> Formulation Patent </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit B-2 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1.1.17B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-NKG2A <FONT STYLE="white-space:nowrap">Know-How</FONT> Categories </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit C-1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 5.8.2B </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit D-1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-NKG2A Supplies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit E-1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Basic Guidelines for NN&#146;s and IPH&#146;s Collaboration on Transfer of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-NKG2A Project from NN to IPH </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>*** </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">End of Document </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by
&#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;F-1 </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit G </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Press Release </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">INMATE PHARMA
ACQUIRES FULL RIGHTS TO ANTI-NKG2A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CHECKPOINT INHIBITOR FROM NOVO NORDISK A/3 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVO NORDISK A/S TO REINFORCE ITS EQUITY STAKE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IN INMATE PHARMA </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anti-NKG2A is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT>
therapeutic mAb that is Phase II ready </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NKG2A is a NK and T cell checkpoint relevant in both inflammatory disorders and immuno-oncology
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Innate Pharma will prioritize development of anti-NKG2A in immuno-oncology and trials are expected to start in
2014 </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Agreement subject to approval by Innate&#146;s shareholders on March&nbsp;27, 2014 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Marseille, France, and Bagvaerd, Denmark, February</U><U></U><U>&nbsp;5, 2014 </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Innate Pharma SA and Novo Nordisk A/S today announce that Innate Pharma has acquired full development and commercialization rights to the anti-NKG2A antibody
(&#147;anti-NKG2A&#148;), a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk conducted a large Phase I safety trial with NKG2A in patients with rheumatoid arthritis, demonstrating a good safety profile for both iv and sc
routes at single and multiple administrations. Novo Nordisk has decided to advance other compounds for further development in inflammation, including anti-NKG2D<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>, currently in Phase II development
and generated within the collaboration between Innate Pharma and Novo Nordisk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk will receive &#128;2&nbsp;million euros in cash and six
hundred thousand (600.000) shares for licencing anti-NKG2A to Innate and be eligible to a total of &#128;20m in potential registration milestones and single-digit tiered royalties on future sales. The acquisition of the Innate shares is subject to
approval by Innate&#146;s shareholders&#146; at an extraordinary general meeting on March&nbsp;27, 2014. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Innate Pharrna has no remaining rights on this candidate </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit <FONT
STYLE="white-space:nowrap">G-1</FONT> </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Herve Brailly, CEO of Innate Pharma noted: <I>&#147;This is a superb opportunity for Innate Pharma. In addition
to lirilumab partnered to Bristol-Myers Squibb and currently in Phase II, we now have a proprietary</I> <I>Phase II ready, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> iminuno-modulating antibody
with favorable Phase I safety data and the promise of broad development potential. Our initial clinical development plan is in oncology and we expect to start the clinical program before the end of this year. This licence consolidates Innate
Pharma&#146;s leadership in immnuno-modulating antibodies targeting the innate immune system&#148;.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nicola&iuml; Wagtmann, CSO of Innate Pharma,
said: <I>&#147;Anti NKG2A is a very exciting immune checkpoint inhibitor targeting both NK and T cells that was selected in the Novo Nordisk - Innate Pharma research alliance for development in cancer and inflammatory disorders. We are very pleased
with the progress in the development of this drug candidate, and we look forward to now taking it forward in cancer indications where there is a great need for better treatments and where drugs of this type have shown tremendous benefit in recent
years.&#148;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per Falk, Senior Vice President Biopharmaceutical Research, Novo Nordisk A/S, added: <I>&#147;The new field of innate immunity
pharmacology opened by IPH has proven highly productive, as exemplified by <FONT STYLE="white-space:nowrap">anti-KIR</FONT> and anti-NKG2D now in Phase II clinical trials. In view of recent successes with this type of drug candidates in cancer
patients, we believe that anti-NKG2A has its greatest potential in oncology and that Innate Pharma is in the best position to pursue its development.&#148;</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Innate Pharma will host a
conference call today at 6:30pm [DETAILS TO BE ADDED]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IPH2201, anti-NKG2A antibody </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IPH2201 (anti-NKG2A) is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> humanized IgG4 antibody. NKG2A is a
checkpoint receptor that inhibits anti-cancer functions of cytotoxic NK and T lymphocytes. NKG2A recognizes <FONT STYLE="white-space:nowrap">HLA-E</FONT> ligands, and by expressing <FONT STYLE="white-space:nowrap">HLA-E,</FONT> cancer cells can
protect themselves from killing by CD94/NKG2A-positive <FONT STYLE="white-space:nowrap">NK-,</FONT> <FONT STYLE="white-space:nowrap">NKT-,</FONT> and <FONT STYLE="white-space:nowrap">T-cells</FONT> (<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>/<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> and <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>/<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>). <FONT STYLE="white-space:nowrap">HLA-E</FONT> is frequently
<FONT STYLE="white-space:nowrap">up-regulated</FONT> on cancer cells and this occurs in patients with different types of solid tumors or haematological malignancies. In some types of cancers, high-levels of
<FONT STYLE="white-space:nowrap">HLA-E</FONT> appear to confer poorer prognosis. IPH2201 blocks the inhibitory function of CD94/NKG2A, thereby unleashing NK and T cells to kill cancer cells, despite expression of
<FONT STYLE="white-space:nowrap">HLA-E.</FONT> IPH2201 enhances NK and T cell killing of a variety of cancer cell types. Hence, IPH2201 may potentially <FONT STYLE="white-space:nowrap">re-establish</FONT> a broad anti-tumor response mediated by NK
and T cells. Anti-NKG2A mAb may also enhance the cytotoxic potential of other therapeutic antibodies. In an <FONT STYLE="white-space:nowrap">on-going</FONT> single- and multiple-dose Phase I dose-escalation safety trial in patients with rheumatoid
arthritis, IPH2201 appears to have a safe and well-tolerated profile at all doses tested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IPH2201 was the third therapeutic antibody generated in the
Novo Nordisk A/S &#150; Innate Pharma partnership to enter clinical trials, and the second targeting a checkpoint receptor (after lirilumab). Under this agreement, Novo Nordisk A/S had licenced anti-NKG2A from Innate Pharma in 2006 as part of a
multi-year research and collaboration agreement. That initial license included total milestones of &#128;25&nbsp;million and single-digit royalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit <FONT
STYLE="white-space:nowrap">G-2</FONT> </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novo Nordisk A/S: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading
positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 37,000 employees in 75 countries, and markets its products in more than 180 countries. For more
information, visit novonordisk.com. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman">Further information </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman">Media: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman">Katrine Sperling </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman">+45 4442 6718 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman">krsp@novonordisk.com
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ken Inchausti (US) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 609 514 8316 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">kiau@novonordisk.com </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman">Investors: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman">Kasper Roseeuw Poulsen </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman">+45
4442 4303 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman">krop@novonordisk.com </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frank Daniel Mersebach </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+45 4442 0604 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">fdni@novonordisk.com
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman">Daniel Bohsen </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman">+45 3079 6376 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:20pt; font-size:10pt; font-family:Times New Roman">dabo@novonordisk.com
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lars Borup Jacobsen </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+45 3075 3479 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">lbpj@novonordisk.com
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Innate Pharma: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Innate Pharma S A. is a biopharmaceutical company conducting research and development of innovative immunotherapy drug candidates for cancer and inflammatory
diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit <FONT
STYLE="white-space:nowrap">G-3</FONT> </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company specializes in the development of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Three product-candidates resulting from
the company&#146;s research platform are currently being tested in clinical trials, two of which by partners Bristol-Myers Squibb and Novo Nordisk A/S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Listed on Euronext-Paris, Innate Pharma is based in Marseilles, France, and had 84 employees as at September&nbsp;30, 2013. Learn more about Innate Pharma at
www.innate.pharma.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Learn more about Innate Pharma at www.innate.pharma.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Practical Information about Innate Pharma shares: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ISIN code</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">FR0010331421</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ticker code</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">IPH</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Disclaimer:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit <FONT
STYLE="white-space:nowrap">G-4</FONT> </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains certain forward-looking statements. Although the company believes its expectations
are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which
could cause the company&#146;s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (&#147;Facteurs de Risque&#148;) section of the
<I>Document de Reference </I>prospectus filed with the AMF, which is available on the AMF website <FONT STYLE="white-space:nowrap">(http://www.amf-france.org)</FONT> or on Innate Pharma&#146;s website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe
to shares in Innate Pharma in any country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>For additional information, please contact</B>: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Innate Pharma</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>ATCG Press</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Laure-H&eacute;l&egrave;ne</FONT> Mercier</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Marielle Bricman</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Director, Investor Relations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phone: +33 (0)4 30 30 30 87</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mob.: +33 (0)6 26 94 18 53</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">investors@innate-pharrna.com</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">mb@atcg-partners.com</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit <FONT
STYLE="white-space:nowrap">G-5</FONT> </P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such
information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>CONFIDENTIAL</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FINAL </P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT AND SUPPLEMENT NO. 8
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to the </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOINT
RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH 28, 2006 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Between
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVO NORDISK A/S </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INNATE PHARMA SA
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Relating to the Buy Back of Anti-NKG2A </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16 September, 2016 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT AND SUPPLEMENT NO. 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOINT RESEARCH,
DEVELOPMENT, OPTION AND LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amendment and Supplement dated as of September 16, 2016 (the &#147;<U>Amendment No. 8</U>&#148;) to the
Joint Research, Development, Option and License Agreement dated March 28, 2006 as amended (hereinafter the &#147;<U>Agreement</U>&#148;) between Novo Nordisk A/S (CVR-no. 24 25 67 90), a corporation existing under the laws of Denmark and having its
principal place of business at Novo All&eacute;, 2880 Bagsvaerd, Denmark (hereinafter &#147;NN&#148;), and Innate Pharma SA, a corporation existing under the laws of France and having its principal place of business at avenue de Luminy, 13009
Marseille, France (hereinafter &#147;<U>IPH</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>WITNESSETH </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WHEREAS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NN and IPH wish to amend the Agreement in order to change the payment obligations regarding the *** License;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">in consideration of the foregoing premises, the mutual promises and covenants set forth in this Amendment No. 8, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, NN and IPH,
each intending to be legally bound, hereby agree as follows:</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise specifically defined herein, each term used herein that is defined in the Agreement has the
meaning assigned to such term in the Agreement. Each reference to &#147;hereof&#148;, &#147;hereunder&#148;, &#147;herein&#148; and &#147;hereby&#148; and each other similar reference and each reference to &#147;this Agreement&#146; and each other
similar reference contained in the Agreement shall, after the Amendment No. 8 Effective Date, refer to the Agreement as amended hereby. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Amendment No. 8 Effective Date&#148; shall mean 16&nbsp;September 2016. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from the Amendment No. 8 Effective Date, Subsection 7.8D (***)&nbsp;is deleted in its entirety and
replaced with the following wording: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.8D ***. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Subject to the other provisions of this Section 7.8D, IPH shall bear the following payments that NN represented to IPH would be due by NN to
***, as a result of the sublicense granted by NN pursuant to this Amendment (together the &#147;*** Fee&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="right">-</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Starting as of calendar year 2015, a minimum yearly payment not to exceed ***, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="right">-</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as of calendar year 2017, a minimum yearly payment equal to the payment that *** is invoicing Novo Nordisk which is *** indexed to the Retail Price Index from 2004 and adjusted periodically to take account of increases
in the Retail Price Index; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="right">-</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">one regulatory milestone payment (*** upon initiation of the first Phase III in each clinical indication for each Anti-NKG2A). </TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Except for the *** Fee, NN shall bear all royalty and other payments if any that would be due by
NN to ***, as a result of the sublicense granted by NN pursuant to Amendment No. 7. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">NN shall notify IPH of the expiration of the ***
License promptly upon expiration or abandonment of the last patent that is issued from the Application (International patent application ***). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">IPH has negotiated its own license with *** with respect to the Patent and Know How Controlled by *** and necessary to manufacture Anti-NKG2A
and shall bear all payments related thereto, subject to the other provisions of this Section 7.8D. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding Section 7.8 hereof, IPH
shall be entitled to deduct: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">-</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">*** of the royalty payments due by IPH to *** in connection with Anti-NKG2A under IPH&#146;s own license with ***, from the royalty payable by IPH to NN pursuant to Section 7.8B, provided that such deduction shall not
exceed *** of Net Sales. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">-</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each payment of the *** Fee, from any milestone payment that is subsequently payable by IPH to NN pursuant to Section 7.4B above.&#148; </TD></TR></TABLE>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this Amendment No. 8 to be executed by their respective duly authorized representatives as of the day and year
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marseille</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Bagsvaerd</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32" COLSPAN="3"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Innate Pharma SA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Novo Nordisk A/S</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32" COLSPAN="3"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Herve Brailly</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Haahr</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Herve Brailly</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Peter Haahr</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive/Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Corporate Vice President</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this
agreement (indicated by &#147;[***]&#148;) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g752656g00p38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g00p38.jpg
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M 0$! 0$! ?_  !$( +\!S ,!$0 "$0$#$0'_Q  >  $  @(# 0$!
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M=EK>,#8C'R\:-=] HIM4YLE#(ZIH)*E5EW#28VTRA_L\## \D8XA:4M<I.
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MY*8QW$7C6VESQZ52N*;1MV1?:%"+9M'HJN3+D7P<4-2;DQ>1SPEYS_U I((
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MQNKMG,0J*VK%/''!)7X:(Z"1E5#()6N+W85/+'5L9(Y\<D<;7$2"\C^^'4M
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M89.D1J+HDR&(+R#5P[<#V9!\FDEG+,:2<>C8N*R2!IOT\I5#0"==!K>W:%U
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M.&3P:X=AR+P8Y7'$$=FS\>LNR60559/F^VR#QKOOL@Y1VV263WTSG7E+V,D
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M@"%;K+;CA+O"K!ENLKLV;I;*;YVEM+2M+2VG@:6/=*PB&,%DC[!\C2&]2]P
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MQ'H]&(P&/EK8<0B4?\X>YDL>,K%DG*^*CK:@PTI?5QQNJZ5TS9I1$R)M0T1
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MPUJ$DQ-X]D096-#W[ FB07*.B!+DW[9N=!OU]9TW+*)=U3HBP(+-8)8L#&V
M/L-L;TFQR6()EY@==R"* H28,:R3T*9,08=1:+QL*BZC>XCU%B #-QB+1,:S
MT1)<C<;+JJOJSKQ+7(*ZZN9(N@ZDMD<YB28[4B,B@.Q]HDYHV434#$2#5DD!
ME'N-%$X&ZQJ/;,FS5W)W#08W)RR4DC9->/[]U;:JVJXE3T&'UU#4'^D7&/9
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M@TS']H."ST-"_P"-U945#3\UQ.BB(_[G$]X^;U:WXS6/L.P.P7/7 XYC</\
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M80HAK&[2B=>7X,+R^)4SK7=G2Z>*MY;$SYRH3,-L.-NK-KT="++D6DM'67K
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MW<N[3OA4L^4-<N_JN30ZZ*AJ!Q%(7:FIUQX!N*P''K$J-6-SW"%6I:4;D6:
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M4;6[QN-.4'E[V^RK'!C,77#LI 9ET-QU)!W@;C8]H@JWKEQ65P>HGY5W>/\
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M6\<N*RN#U$_*N[Q_JGJ%_!DIS+XE^!L [F*?O;5H^S?X[<T+]+97_29E8]S
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M.?JQ:UG=4+%5"OJVS1U#)C'/%$(&21-9$X0B(P\&>#:T/;P),1#P[-%\6Z[
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?V...-H8R-C &M8QK0&M:UH :T   6"Y_*56G"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g752656g01r15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g01r15.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2,64&AO=&]S:&]P(#,N,  X0DE-! 0
M     #X< 5H  QLE1QP"   " (8< E  #D1R;W)Y+"!*87-O;B!,' (% !=0
M;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0      $"0G)&TIW=_/TK*4
MB8+' E$X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q :IJ/8         IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ /      0 " \     !  (X0DE-!"8
M  X             /X   #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M              *A   #K          !                          $
M             ZP   *A                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *A     %)G:'1L;VYG   #K     9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MH0    !29VAT;&]N9P   ZP    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
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M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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MVM< ]VGYUC/YG>__ +=J]5955N/L:P?6"QS)8VL!KM\ -_G-=M3]V_\ -_\
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M *#_ /R"J_\ -S(U_6VZB#-/;_MU(?5O('&8W4R9IF3_ "OTJ?P\O^]+[?\
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M+6%Q:2XBS>QNY[O4]-[&LW_H_P#2_P#:BKTZEN-F]1ZA;?TRHWUM 8'G9L<
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MM<"T@'C1W[RS6]+PWD$UL![1Z@[[O^Y'[RMXN/5AUOV?1@N(UC03^>ZQWO\
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M?HU<T)1D9QV/S(NGXN+CV'[+4*:F\ALP71Z;?I%WT6*Z\L=JYH)\2 55;:
M!$=HX2=< -3"<8L8G0WWU7M%?[K?N"T.E4EE)M=HZV"!_)'T/_)*KB8+\APL
MN!;4-0TZ%WR_T:UTR9&P^K-A@;XSI^[_ !72224;84DDDDI22222E++ZK066
M-R6CVNAMGD?S'?\ ?%J*+V->PL> YKA!!X(*,31M;DAQQ(^QQJ[$5SM];F!V
MTO:6AP$D2-NZ#^ZH9&#=CDFL&VKQ&KA_7'YW]9 %[?%34#J&IQ&!J0IJ8F/G
M8V2PW9KW5U'W4@NA\  >^U]CMFX?ZV*%U&>^MM;,]S6L;#['-WO+I>[=ZKW&
MS\ZO\_\ P:NEXL(8!O<>&@;C]ROX73G!S;L@ %NK*O _O/A(U'4[JB)S/#'Y
M?+9L=.QW4XXWB+'^Y_EX-_S5:224)-FVY&(B !T?_];U5,>#_%?*R22GZ/N]
M+>=_V6?Y'J3_ &O21<+9ZS=GV:/+?ZG]CU5\UI)Y^7]+]C /G_R?T^=^JDE\
MJI)C._522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4J.7_.?]I?\ KWTE
M\QI(CZ_1$MNG^%L_4.%] _S/_6.%97RJD@H;=/H_522^54DDO__9.$))300A
M      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M 0 X0DE-!"(      4I-30 J    "  ( 1(  P    $  0   1H !0    $
M  !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @
M !0   "< 3L  @    \   "PAVD !     $   #     [  @>:P  "<0 "!Y
MK   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C$S
M(# T.C$Q.C(S $1R;W)Y+"!*87-O;B!,     Z !  ,    !__\  * "  0
M   !   #K* #  0    !   "H0         & 0,  P    $ !@   1H !0
M  $   $Z 1L !0    $   %" 2@  P    $  @   @$ !     $   %* @(
M!     $              $@    !    2     $X0DE- _T       @
M     /_A 4Q-30 J    "  ( 1(  P    $      1H !0    $   !N 1L
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M 1L !0    $   %" 2@  P    $  @   @$ !     $   %* @( !     $
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MZ4E_$V_^YQ)\C^']:4I1.1+,\DHYJLZ0%)R^:H*A[*B4WEJKD(;0@4-")1$
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MBE'%*.*4<4HXI1Q2CBE'%*.*4<4HXI1Q2CBE'%*.*4<4HXI1Q2CBE5WRQ_E
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M(9"!2(]!$Y?4B[TZJ4<B/R*9V*@[V5,VAYJO7NVO@?3+9Q5GJB=4N$J4CN+
MI6L*3S&Y92B1U$R)&,BI7IG!.MZBM"2Q[(E7[]R%I3MQGPI4HCGR$X-5KLWB
MEN[M=4E<@8F"1[BFO*'4EGRI3%  VBW%FS2,4NC" JNB;[ (EUS2>N=ONOW*
M%C1+)-@VH_=NW20[=# DNH2I;,;MQ1M));"2H[B0-CZ5V46B'$?M.[2^Z,N>
MS*6EH@F1M*VTJPC:%X3"@0!&:@V9S?F!X*RA[Y)-.HQM),&L:T03$1,($*4C
M4RH%+W !%;?8 '8Z'FJ=0[6^TUY;BF^++Q@J4HAMEAE#:)5[K:4@$(3R .>4
MQFM@VG9YPE; !RQ6]M@$E0))CGXE'GSS^!FFL;-N8(P2K(9 G5CAWZ'/LKI(
M?01ZDET#E'>P[!T_'8^G(F]VH=I]JKO$<<ZS()64J6DH41XHCHDY$#IZ5DE=
MG7"*Q_X!0"A!((! ^((CGT(S'2IZQAXSY./D&D7E!FDZCU%DTORCB$#(&8[$
MH&<R+$!.0Z!?4ZK0Q3$ 1_O8Y1,/-P]GOVG+VUN;>SXS:>N&;FX:8<O;=+7=
MVC;CB4J?="UI6IMM)*U;$J6 DP"<5KKBWL@MV4O7&@.%"6&ENBUN%+4XX4)*
MMC92DC>J#M"E 3BMD4-8(^;:LWL<N1ZR?ID79O6ZB:K=RW43%0BR2A!$IB&
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MRI5T('_'D/\ PHP_VI+BE7!#T_$?YQXI7WBE'%*ZEC 5,PC]GV^H@']/.JB
M),Q(Y23)( B,Y,<J#]352/$9G]+&#-&!KQFSVXRB8J-4'!?-;P[404)]:O4]
MEZC"<"D9M1,07"@"J)O)2/OS[VT]L"> 6!I^F*2_K-VD(2T!N3;-N!07<.*$
MA*VSM+;:H*I) (!K8G G C_%ESW[Z-FE,$EY_< HN#+;:$'Q*W&=Q2%  <I-
M:R7LA,6>4<3ECD7<M+/%#JJ/W:OFJB4YCF!(G5[J")0.($01*FBF4 (F0A0
M \(W.L:KKM[<7^J:E>7-W<J*EW"EJWE!5(:.[]Q,SRB1(%>I--L+/AZS:M+!
MA"$H2$;PE(4K CR/O222?Y4L,FB6A*?S#CZE#OZ]^^M=A[ .]A\_AKF08;3
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M(?<L^-92,%1CRCIY?TQT,5(&[EM0YF1T@_F<>G\J:KML0 $#[$.P%$0V ?B
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MJVXNV1_J%M5,;*'R2YL5B32&,J/Y(QSV05N/M:P>6P4@(X7[SV\#IG;-164
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M13NI>)BT6ZQU&5A\ &QFI<!P^GBB9\.LO!VZ-N*28J8S<.5\E'MZDI 33?\
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M4!M5)@3!Y$Q6*) $C:#(Y$'^GP^?K2C]6E^8_J+RO["CTKKN_P!*?I7 [$A
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ME8J_8 KU@J3E]&34(Z:O6YI&K6RRUV13\PR2\7,NBID1>%0>)*5!T/X%_#K
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M&P[?VZ1Y -.&!\)K8MY[JOK^)I8>EZHL5=ATHNXX3;]=$DF9A$/7L!1ZA]-
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MQN@1SY>M9ZR,K\Q)QGUSY8G]=(YDR^[H2>H]A$ [=_7Y_(/3D'NQ"CCF1_\
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M[@ ]@ ._KOT  #N/V!R/WH&X".:1CYKK(6ZCW9)4?>,F3Z4QY,0.  F'681
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M%#J A$6Z0)ID(41T4"% I #7H'/J%I]FUI]M;6%N@MVVGVEM96R"5':TPV$
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ML^G<J\Q7W_G8\8>OYK[Z(;*7?M$* =1C 0 V+H UU& -^O?L \[?]P/$G_\
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MM!S,V:@HI ,>(GQ8Q_+EUZU@W6%*)4DI B!S!\LB.GZ]':R7V8"#[H@ CU"
M?#U][X]QV'X\RQ6M)VA6!C!_E'Z_.R4TL$CRYG,'KU'Z\YIQI+EU\Q H;[A^
M(C^KF>:4-J3(G8)GX#X_B!5BIA1*LC),]/I /Y#X5E(OP..A]0].CIUH/MWV
MYPA]6X$S[PF!!B1\S5$-E."9!,?V_6/YYP."C\3_ ,@?;\3<R2+A#@4H!02@
M2HD8 F,P37!:2,G:/B3GX?K^5?!=@4!Z1V;N E$0'0!W$1[C\O7[>=3<LD[4
MG>2>0\O,SR'+YQ0- GPJ2#SF3$?E2>NY$Q"F$-E]=AK6]=PV'J(?^W*+RDK2
MH@B&QN)QF>B<#\:JI843&Y.8Q))'QG^U(SMP0Q2" @7[#" ;T(?/Y_V[;YA+
MEQ:RGNPI($Y5@'ER@F8ZU=-L*0%92<CE./CBFR^<E$JH[ 1 F@,&M .^WW#^
MY[!\>8^Y60S"SF29G&1 $X///(=:NF@=P;@DR3,8$Q!].5?:!3 R%9UV[XA3
MU^NE;.Y=!10?+EGJP><RB%BE P*,TB![9()&[*>8R1UY*[LBN4[/^$VN+M;N
MW+HENRT5QCVA"=P&J-NH;?-B\.0827%*4Z"7-TM[=HW5AN*=7_9%J6&BKVJX
M3"5(C:A)$DDDR"<1"3U@R*L)EW"5,S5C.?Q7?(5E)U>P1IV2[4@^4K&N" !F
M4C$.?+ZV<A&N"D=,'*8%,V52(!0,01 ?4%]HNG7^EN:2];-^R%H,--A"80T@
M;6Q @)*$  ;9. 1!J$<&\9\0\$<2:=Q7H-\Y8ZQI]P;H/-K44O!:MSUHZDE/
M>V]UE+R5$;4GPA1 (\3V2XNRX%R9F;#U3R1(/H6/L3ZB6.3J\D_BHZX1D)(
MX293C9LJ@D[]A<E]FD&IO,03DD9!NBH=J=3S?&^J*O\ A/5=1TO3M15W)6MM
M99<5"TS&U0"04J3E)\H(D]/O%P4YH?:[PAP-Q[Q)PLRUJJ+9.KZ>QJ+"''],
MNG6]B_9G%;BXRZ%%;:U)2%H*%EI"L"%P;D*4"%2(  /PZ2@ >H](=(AO?<.W
MKR*+WJ.XK43ZDG/KF?CG^VV4E"4[$GNT;8"$)"0/0 0D \C@CXU;WPB>+W)'
MA/OT9*PTM(2>-7SUNE=\?J.5!B9*-44\IU(Q;8YA286!BV5569NFWLY7BA0:
M/@604#RM@<&<=ZGPU=V[3CSCVF*<BX8G>H)*2 IG>I(2I*BE1'(I!2,D&O/W
M;IV <(=LG#]VA[3[:PXKMK9TZ)K3* PIJXE*]M[W#95<L+0%ME*@M2=P6#*$
MFO9U1[/%VFK5ZRPSD)*$L$*RG(J1(JDJF\BY!JF]9.$E4SG X+-E4Q =[_<F
M[@//7[5VW=LVERB=MVR%H(@CQ("O$1YCXYBOA1<Z9>:-?7&CWB2U>:;>W=E<
M-N@AUIRVN%L$+!3.5))3/-&>=:S9M=>+^D:@U4@Z"2CYBJ8/@=M-8AGPZ/M.
M9:O$ 2]RB9/?5L.;J80E_LMU54$^PKE?62S=, [,3S?ZP(GRKSG=Z@^SVRZ1
M;-':FY;:+DR!LO+.Y6TG$\E6\J,<R(W FML1EBG1*<@& I@'0CV$ (([WK>O
MT1]-_#Y\TQOEM?,%O>%'H>Y7L7!SS@E.,@@F*]! @+0HB>\VJ$9,.)W"?E /
MK'3->5WQ.NI-WXA,QN9M1Q]9!>YIIY:HG+Y;%JM[/#)(@;W11"&18*)#H T<
M1#GO[LX;TY'!G#XMD-J#^GLO+Y$EUP?>J,0 K>DI(F93)Z3\M>U97$SG'7%C
MZKEYJW:UJ\92ONT*2RRTH):;\2@L0SL<2$H*-KB86250_P"D5"!MV&:U O&S
M-E)!D"U6N0GR%3))?D36 Q_%W1LHY'I.JVC8^YI6%%$QO*3+#N%- .Q&%\6:
MKJ.D<97KZ+F^;LDZ7IC+5G;O)[M5WJ2-439RVME;83W^EO&X4D]Z._8*"9V(
ME'#&CVO$?!7#[+C[*[YOB^^U%[5VK9I+Z]*T5.D-:C9EU;C3I"6=>6\AM04S
MLMKA1_="LO(--J=FN$A8%ZX[8/+JYF311:XZ29UFA?DYC&JVIN9^W)&K(OTG
M;V64!P"KN(21BF1WB .')E^8O1^*]=TRQMM.>NK-Y=@CNGG+EN[?N[I1O+AE
MPH=+K064]WN0HMHW*4E!2D S=<0\'Z1JFMWE\U973"-=>U)_O-->M[72M!]G
MT&P>83<V:6%!Q-T^I6\!Q&UJ5RXHFFY(8AIB4@Y0B64ZNTK<\K&3I7UF:",J
MV3QN^O"CPSP(%'ZB8L'D,Y:N2H(S#M>+-YS5 []=) ,J]QYJMC8F\O+C3!WF
MG.:FREK3;A;B6&[]-GW2D^VPNX6'-Z9(;&T%:@DG;U<X-TV\??M[5[5NYL[I
MRVNU.7UHVT7&N&5<3%3*DVBU-6X81[*GPK<+RPV$@(+JGA9L50-;I2[.#C7\
MF9)>0E&T4R=(KR\P6=+X4)$D"VE7U=;2/0"MZE6D:Y^JV;\GM"*JC<NW:+K$
MZ?Q5J5]?:=J%P[:VS2T6R5*5[6IAE0;X];[Y;/>@$GV2U*D%PH(B2DI;"<O?
M\&Z7I>CW5K;V=Q=7EHM]]L)N6G'+E*T]G-P6$N>QE:T :Q<)84EI*]R%0D)>
M>#D;R&/:R[EG$-7(FTHO8NR8NJT\U<R:LZS-*VM_9F5K)'+IPD9YS&+491K-
MI*$;)MBO2OEBB+==OUYQ/'.J,V:;^YN],<MW6-3>MTLZ<\'P;!MM;:7DJO(!
M>&Y:0%JQ[P!F(;=<)6EW<OV>FV&KVU];7>@VMTZ+QMU ]O?NV[Y=JLV36]#2
M2PDN%($H<6C>"T%JY,;8[C(M520C;&^>L8F%GG2B=D:,TGA9?*3G'_U4+48%
MT+4&J M9-!]YC@73\BB9DD4C"Z"H>+.)%L]\FYT78+V_MDDZ;=1&FZ8-2=6F
M+O)4!W2$P 3$P*O;GA+AO3[;O'KOB1VX;M-,NKAIF^L>\#&J\0JX<6W"K4)"
MFSWCRI5E(3XAO\#RIV$ZNVGFP/\ V]20JUXJ)NIW)IN2S,8_S6TI I/H-&!7
MCT8I]%.$W"3IW/!(/GX.0&&-'*% F#U/CC6[IAZPM;FP9>797*W7FM.N$);2
MUH*M:=0T\+_O$7!1OM@0V E<*"@09D.D]G-C;/6MW?76H.HM>)=!9>0]=,7"
M7V/^,;32]WLB+)25,BP2VI3CKJ"E<@-+:5N37[*%:@H1:(E*_%S<$WG).YQY
MH.><).W+0:I-?5J<@15-C&F2;2*3DK=5D5LHFVD(V222<K)D2(2?<#ZOJFHL
M7EO?W#%PNS38?XJW:6RVI-Y:(N0VLN./*<=;2M()\,)4D&>9UIQYI^GZ5<,/
M:5IUP^S=ZCKZ&[6_O5E]@6>LW5NEQI;=FP56URC:M 6F6UI<0A2D1%UOHNG$
MH3.EC8,3'4AW= D5YU-/J]F3<,9B'"#45'IT58I7<L1#TZRG7  T0=:\^T#:
MVKG#NF>T*"WTZE+"L!826OO!S!VREN8]1\=T?9@U"[?XQU%#5D;%C]BK3=LI
M>4\U*'VPPZ5*0@A:I6 DIQ'O'<8]!2( "90 -!LP@ ?#9S#_ $\\I9Z\X'X"
M!^$5[G  P.4G\3)_&NWBN:.*4<4KJ6 XD_8PV;X!V#X#^^T'KK@?3U\JX,P8
MYP8^-5_S_P"'^L^(&BN:9:$UFYBK_64-+-#)>W0LPFF8J#]J901((D%54JB*
MA5$5T3G25(8ANTBX5XHU'@_5F]2TXE8CNGV"? ^P5!2FU D8)2(/[L C,@PW
MCS@G2N/]$_96J)#:VP';6Y ERVNDI4A#B" 9@*(4#X5#!@P:U:./HK<JH.7:
ML9EFNE341<-$U?J:29O5F3I(Z+ANX%K* F8KIL=5F[2V""R#@Y3%$HG+S?"N
MWS3W6[5#W#KKGWB5/(5<-.MM%,*#C>]$[D+2"@PI23[O(5YB?^S#KFYXVO$M
MBUN5#BA;NMKO+7N+EE=HZ4$A*7>^2%C<$G;XB4Q'=_S8.<DS N7-$.+A/ZM<
M(JD1GP42?Q* -&#M,QI7W7+5CYC!LJ'=NQ5.R1,5L<R8V*^VO0RTXG_A/<74
M/,%.^VVI96MVX@@IREQ[9O R5K*R!MW)[-?9HXL;"S_QHRIY1+X?_P 8E:7T
ML7=E;EL\PY;V=X4-J)2 AD(D;\_?^:_SBLH+MQFR&5=JN D5%G"-B5=?6@"!
M/;S+_6IA,_! I6Y7/6)RM"@U!3R2E3"NSVW\/LLIMT\)%+*$!D(#EN$%I"@Z
MA&W9[@= <"?_ 'GB(JFY]F?BQ\H>>XPMG'P\W=EQQ-VIWVIM/=!PK)/C+/@4
ML'*<!63/>K]&3GI9J@P5SJQ69((D;H-C+V@K5J@BBHV111:C)&23*1JNY:I@
MF7]C;KKI%$$U3%&BGMJX90ZMX<%NI=<47'%MNVLK=*VWMZI(W*+K#*U$B5+2
MDFKA7V;^,R&D'C6V<;;4A2&UKO@AL-I=;0A">[4$(#5P^V$)) ;<4G$@5UJ?
M1F^( [%>)-G1%2(= =-Q%&>VKZM7;* !%D%69I;R#)KD#0D%$=$V38 /2/3_
M +Y^&0^E]/!3?>(<;2AU0M.^0RH2ZH+"2H+2<)@D=?.NBOLX]H'<FW1V@V:;
M8E*?9BC45(4V! [S"0Y  !4H!6,(( -=\I]&7GF74)]9YRC9),Z M%BOS6=\
ME[,HJS<KHF3=RQP\EPZCF+APF0O2LNT;JJ%,=,ABUK?MLX=LPV+7@X-*1M5O
M;7;H4%M(6VVI.UL *V..)"C)AQ<G)%='/LU\:W!B_P".F-00XA:7DO)O"E?>
ME*U2%3CO$-K4F"DK;0H1L21U(?1B9V9.#NF.<HIJY6,\57<-"61NNLXD@2"2
M665+*@<ZKWR6_M2AA,986S<QA$S=$Q>[O;;PZ^V&G>#PM#8;0TA:[9:4HMR5
MVR4I4W 2TM2RV"/"5$QFNUK]FOBZS>2^WQA;+=W*6X3[:D.K> %PITA04M3P
M2D/*))<2E 5NVBN;CZ,K/KF/<QBV=V2D>]Z3/F*[BU+LWJHB45EG3524,BNJ
MOY:0.#J%,9<$D04$X)$ M-OMHX;:>:N&>#VVWF@D(=W,%: G?&P]U*3]ZL @
MCF9'*NCWV;^/GF[FW5QW8&UO;ARY?M3;W:FRX^$)=WDJ\0/<LJ(@B4)@2*?.
M(?HP7]3O4);,B72)L<= O6THA"P,:NS(_?LERN&WUBM(N''4V*J!5%$&Z9/.
M%),AC@GU$/C^).W)^^TJ[L='TERS?O&U-.7"[A*U(;=2I#@0"$@*(5A9)*?*
MI)PA]F^[T[6-/ON)^(;'4K'3EH<8LK.S=8W.M*0MI3KBA):3L*5-A,J*@9 !
M-;8G*C:+2Z5C&0TW7,B40ZR^6W(8YAV0#%*!":$>H2_9Z<\^(:.YH>\I3X4K
M_4MY<D?7 Q'R->J5K[M"C 0E+*D( Y!++:E8 Y>!)()\HYFM3/@5 UPSOF7(
MRZ9EQ7;R3Q%8WHDM<+Q/2"8CU&ZC&&&@8<0$H:$BA1-[H$ -P]HC*=.X;T&P
M;;"7UM(6I,I)4 V@1N'AYDJ)F,0,B*T5V6:@->XLXBU!YE3B6$]XU=DP/97G
M'.Z&Q4*$K;=.TIWY22 (G<"BN0J90,;9O>-H"'_1%00#X=_77-1 >$'H(2?^
M8#..?,'TK?"25&.95*P< ;29$\@,1@TP<B9<QKBJ =6?(EWKM+@&1S)N):P2
M2$<T!4A!,+=-1<Q17="'8C5 %'"AO<33,?W>6E[?V>FM=]?7#=JU@[WCL3!Y
M&3T/G_*LUH'#VN<4WJ-.X<TJ]UJ]6K;[/IS"[E:"#!4]W8*6&T_O./%MM/50
MJHT3]*!X'9N60A6>>(=%TX6*W1=24#;HF)454,!2=4S*0#.*0((ZTHN\3)H0
M$3<BS?:'P<ZZ64:VQO"ML%FZ2DF8PM3 0<C!"H(R,5N2Z^R_V[V=A^TGNSW5
M#:[0K[BYTRYN-I ,^R6]Z[=1!Z,YZ35TVEIA)N*1D8>7:2L=),RKQ[^/6*Z8
MOF[E,XH+M7B/6V715* F(JFJ8G1HXF @[Y+''&W;1QUIQ+C:FEPXTH.#*2-Q
M+>[:!/O& .9-:*N;:XL+Q=E?,NV5TPX6WFKIM3"VG$&%MJ#@3]ZV0=[0/>).
M"D&O+OXCO$M7L766UQ[%%&Q7=>Q3ROU/[0)6<8H>2=*^?./$@,9 X 8.EDWZ
MG8FZA,1$ !0/E$C@>XU7B[BV\U!+C-J]KNH.,N**0I:#>WKDMA2@2=KB3XB@
M'DI040#]2^R?L=U[C;0>'[R_2_IVF,:>V6KU8#:74FU/=EI*CN<2L[4E:$F-
MTP=I*9NQ-=D<@4FKW-!@ZC GHPCM6.=]0&:K 8R2R:?4!.I %DU1:K 4I5FW
MEJDZ2J%#F,NM)1I5X_8MW 6AES:5),@*S&4SZ CFF"E0!!J"<3Z(.'M;O-%*
MDW:&%N)]J!$2@P$Q[Q*@><0/,BIF;JG,)"@8Q0*IU=)3"!0'T W1OIV78BF.
MO<,)SD]XYC#E[<AA*"ES?."<XQ(/U^<>8J"7UHIL[TCWC ,I]3'G'SY"":?\
M2\,4OO: NR]]  F 1'UUK8[W^D._7[^26VNW$I2X#]VV0'#,;29V^&9,@*/A
M!CK%8Y;0VGO!M.(_>D8)Y QTCEY1BGXP?!KL($'X:#0;UV$-!K0_9KT#Y[Y,
MK5YMU"'$N-RH @*6E$C&0%E).<3RY^58A]@;5".<\_(?*.?IR^E/9D][E$IM
MAH-CO]?80^(]A^'QWR26:O&G[QG,1]^R)/(_O?'/PCTP"[=84L!,_P#4F1Y1
MD<IZ<C3O:.?-_==)@#?6'K]WV['6O7MKF74ZA*RA2P7)YI4E23U]],HCUD@Q
MSBK)Q 02E7.?CGETF.O7IYTLMW8D W4/8=  ^HCK?J']/I^(CR[#SF!X?J(C
MH9Y'\_2L8I"RI49&Y7D(SU!/Z^H"DW6Z# 8H!H# )A[^FPV'<?E\N95LI+B-
MQ &],Y'*1/(GI5HJW?@GNQ(!(\:>8&/C\*UT?229PS'B:"\-K##$WD2"E\I>
M(M''UB'$M J&3,CR-8+AK+]W,QJE3O/1 .W7UY2X1Q(+K.FJC6&;R*A5  1$
M)7PPU8W)U3VLI+#+>XD[@!+K:)5 )CQ&.68!/2L%JZ[IM5HEA.Y3AA:90/W2
MJ 20,1TG .,XIC_=4^-6K3EVNN2,J14-,X:R)X ,8W#PR?D51W+.ZROB*IF#
MV66&L;8F +6ME:HRQY&L%BAB0DK(1#8851F=)>+.+A.5.:#I2[*Y?MT)2!:O
M.(<*P"=BC "29Y(DX,"9@@"L4BZNVG4)<24_>AM603D"<A1GGCIRG'.[F-/&
M AEKQ@R="J=AE&^'$?#"A=6L1<Z/.X[FSY-:9SL-'F'Z+2\P=>LB\:: :LFC
M,2MC1;U9NJ^8**AUF&&:AI_<:#;W+0[QQ5V\V\6UH6E*$H0I$["1.3G=(,@P
M9K+LW:O;762I0);06QL4-Q,A4R($>9CIY87_  M92S-=;_XP:OFQ_47CS%6?
M8FITF-IK=R$17Z1.84Q;?XF+/(OFS20FY,I[<NM,2;M!,JDPL_)')HQ)&#9'
M&Z^S;6]GH:VR4J?M'EO @Y6EX)Y0" <]#B),G.<T=Q2_:TNR%-.I2D&#(4">
MDB021S/+TDVADI!)/K$#@FD "H?>^@ )LPF-O0= "'O!L.V]Z =A"KY]LH+:
M5#O-BEIW>%)" 2HE:H3X0"529 $D09J2V;+9<*E8[Q*DHY^)20"H>D)."<3[
MI/*K78-KJT9CZ+D%VPIR%E!S8'9CB3S#$DU!4C"'[@8IT(@(YJ8H@&A;B)@*
M8=<]"]E>D*L.$+*^6SW=YJ[:KY844[E,/.N+LU*$^!2K,LJ+:]KC9.QQ"'$J
M2-(\57QO=7O0E6YMIQ+;?,>)II+:X!QAP*@P.D2,U)LD=\DU4%),14Z5@V42
M_ J_3Z#ON84B_</?6MAL\^Z?.$X&,XW9],]?KUC]NF;BU2O"3<2[)!VL[I!P
M8]WH)(Y1SKP 6.1>RUELDI*^:$K(V*:D905NHRGU@^D73MV"AS;ZSBY75$Y@
M$=GV;>QWSP-JBE+U;4%NJWJ5>W<[CN/^>L$DDF#/,'/Y5^D?AA%LSP[H3%F@
M-VK&C:8RPVE!2E*$V=O&P0,%.TR)YP3(-.3'6,[SERR)T_'<.%@M"L7*S#:#
M(\9LWTBT@VQI"42C"OET$GSYM').7I(]%47;I%LL#9)=1,$CU-)TB_UM]=MI
MS0??0VIWNBZTTI81$A!>6V%$%0,3) ,"L;QGQKPWV?Z.-?XKOQIFC"_LK![4
M5L7+]O:+OWDL,.7/LK+SC+!<4E"[AQ 88W!;JVT!2TM6=AYJM2+Z"L,3)04Y
M&+BVD(F98N8V09+D,'4DZ:.TD5T3%WW Y  ?3ORWO;&\TUY3%[;NVSR>;;@A
M7I$$@^A!K-Z7JNF:W:MZCHM]::K8O)*F+FPN&[EATEO>D)=;4I'BD9)@3DC,
M>P'Z,27D)CP3X@>R2BIQ91%@@FIU-B4L9!6>=C8XH"/;H3;$1;$U[OEMBG+^
MQ=)A]D]G;[UWP9H3MQ'>(:6V@E045-I*TH.,"4@8.>0QFOAI]JG3['2/M!\?
M-V*4HM7[S3+QY"4*2AE]VQMW;PA) A)?4M2U ;8DS%17EIZVCO'SBB2 PI(/
M38P JXIG(13S([*E<5%,YBZ4((NDB]11$HE%,0$2F*(^F.''$W/93Q$E(4I;
MYO@TG8L%1#^GK .Y(VJ*4+.U9"@!,00:^<W$2TVG;CP]N)2'+31GDE0@*9::
MU.V<6DQXD%UU"4+3(7N*D%20HC; S$#( D(")B)E X#V]XX',.AUT[$!]2B/
MJ'S#FE]H4VXCEWCS\YR$*=69*>8]Z8(!],5Z/02%)*N;33*<"1O#21 (E)@@
MY!(]:H)XGO 3 9ZGAN]9G5*5<5DDF\HX,S0?Q$V1'94EI%F"S=<CYNB)6Y';
M=;J4;%*DH4_002;9X&[5]3X1:_93MHF_TIHEQK<L(<;4H)"D-KA2PGP!82I!
M *B09) T3VD]A^F\;W2M9L-0=TG67FT-OPGO+)[8I92X^S/B<(7M6M)\24(!
M]V:JJ3Z+'**:(-DLSQ[= B$BD5)O&RJ2()RR*#>40(F293 "22+9 CXG2"3M
M-NBDX\PJ:0EGEQVZ:3<K6M[A+OE*2R-SETVHS;%Q3*I4T#+9?>[HG+94HB-U
M:E:^R]Q.VE"4<<VC*4*4I+=O97+;22Z%-W)VA>/:[=:&GXG?[,@D"$[E%+Z,
M#+:;=ZS+G=$C2912;S30K&:*WE46R)4&J,DB6=\ITFV0(5N@"A5--R%;&_O<
M )RD>V_0UJ;=<X+2MYA2E,.*?MM[:EJ*E%"NY\)W$J*L*63*N9J\7]F;B50N
M$M\=--,7B;07UJ&;W9>FV/\ YD+C:I$-A,I"$I$;J^)?1?Y=162<H9X0:NDE
M"J^UH,IQ-P+D&ZC'VU10L]M5P$:LJP%41$XLE5F@]2*AB&Y>[<-#?:+3W!:7
M6U-]P4KN+8@LJ6EU:([B A3J4N%/\8W"" JNK?V9>(V'W+BWXV9MUNN/.RTS
M>!;;CMLNP2X%AT?>LV2RTVX)(1*8$[3])]&5FCSBJ#GY<JP+@N+TQ)XSDJP"
MR+YI%_RA\X!Z8>&4V!@$1C8XG8&#<24E=MFA]V&4\%I#2D*04A^VVI3N6 @C
MNAB+R\4" <K>!(#GBKG[-O%"TDGCL(>2VG8^EJZ+P>]I94IU*E.$;^XL;)!F
M$PTRH$K9" HJ?1IYO,J9^/B/>*2:K;V%5\8ED!\9B9<CD6IGHV051;IK$*LF
M@4?+35+UI 0XB8>BNV7AM# M&^!;<L!1<">]MPGO5C8MS;W(\902"N-VWPS
M KH?LW\9Y?':5=KN5I[IQ3J'U$M RE.X.2$I5XT(!A*P%$324/T7.4C=0'S8
MP.F9$$E$5(N8.15)-<KQ!$YC3HF.1"0+]8($,!B(O/[Z)I80-RY3V[:4(3_P
M<I*"5.;1=6X2''D=R\K#!4%K9);6>1;.W,&*!^S!K9LG;=?%]LZ\X4[KA=M=
ME7=-/&Z:9"2Y[B+DAUL2-KJ O&"<O_FS<T%12;_W02QD/;$WGD)MYXJ*3HST
M9-5T*061(AE?K,J<DHL!3*J2&W@?LXG.:B>VW0TN=XG@=M2EJ;;=5[1:E2F>
MZ5:*DJ922A%J0V$9^[)2$DB*OA]F_B@R%<?N-I6I"RAIJY*$*4LO/*2E;I"5
M*?2BX*TC<+C[Q,F8QGWT7.4)ET1[,YO9RKE("MBKRL-)2+HK1$QQ321</)YV
MH1$!454(EY@!YBRJQR^<H<PU;7MVL;5MU%IPDBS0X\ZX6V[EM"5*PA#A#* D
MJ4A"2HF"9$A)FJ%Q]F37+AQ#K_'"KQQ">Z2Y<VRW%-LI6I24H*U&$RI2HYRH
MS5]?"]X4Z]X:X630C5UIVRSRB!I^R.DV[95\1F0_LC5NV24.1JR;J+N3((@8
MQA,N=590YQ ":DXVX[U3CB^MW;NV%G:6P4AFW2M*D(2#(<)2I16MR<F$D  %
M(Z[X[->S+3>SFQNF[>Z.H:A>$.7-\X@I6LP(90"!L;;R0-R@5*)W'$6[3 0(
M4#!H>^PV _$?B';TY#$B!!\S]),?A%;,_M_<?+E79SFE'%*.*4<4HXI1Q2CB
ME'%*.*4<4HXI1Q2CBE<3&*7748"[[!L=? 1_F 1'[ WS@D" 2 5':F>I@F!Y
MF <>E.A/0"3Z#SJ%/$!:FE.Q+D&TF<HIN8:DVARR RA"F4=!$./)(GU" "<5
M!)T@'<3" :YE]"MO;-:TRS(DW%XPD)B2=JPLP.>$I)QD"3TJ,<9:DG2N%.(=
M2[Q*/8='U"Y"E+"4IVVKB LDGD"L9Y9%4P^C8K'L..+M:5DA%Q*W,E<*8"B(
M&:4NL5^(\PIM:Z5)3ZU,.AT90QMCU";4^[7+L'6=.L$*!3:Z>PI8!G8;ARX?
M2D_PRTMM8F)0I) @@UK/L+L>[TG6-04(-SJ0L0LCFW::9IW>2<26[QRZ96(E
M#K;B#XDD5?FZ6Z%IE;L%GG7K=A$UB(D)R8<+J F1C&1K19\X<KCZD2(W0.?J
M#0B =A].:AN+MNRM;FZ<(2BV0XMPGW4)!*MRCT&V%9P0<=*]!Z5I5UK>IZ7H
MEBRX_>ZOJ%IIUHTTE2G77;Q_V=A#:4@E2G7 4I@9(5_"8\3/BM\4MX\56392
MY65T^;51J[=HT&FBHH6.K$&=72(^QD\M%6:D$B$<S$D=,RZ[DP)=96Z**)?&
MW''&&H<5ZLM;SZQIULZMJSMD':V&$F$K*9(+BP!N4<]!"8 ^]'87V*\-=C?"
M%CIFF:?;_MJ]M[=[B#5U,I7=WVHK0%/)4Z4J<1;,N*6EAK=M0F205%:U5E$@
M"'<#".M]&Q'11    (/N>G<!*7J#6P,/(7M<_P#+/J #*@)Q)!*IY>D&MX%,
MR#[I!2<P#/,'S'3.(.8JW>$O&;XE</XWL>$<6V%^,3='3%K6V96B\I8*Q).G
M!TW"="*!CBS>3QE442M4D'!4'I4G+!%%T<3FG_#G'7$>F6+N@:<M5R=2"[*V
MW;W7FG+U)MXMD^)16I3D(&3N,@;J\\]HOV>>RCC/B.PX]XKTVS93PY:N76I,
M[K>STO4[:P_Q*7]<=.Q'=63;:EI<>4A*&TE+ZBRDH$^43P172ERD59_$?#R"
M<U86H6:.K4LM[8JY,\5!R=W:7WF+^V2Z:IC*2,09<YT%E2#(F6.H9,=&]K&J
M\1<&W[.EN:?<,/W[9?7>K;<2E;BPI:D-K*0DK@$N $J!D2,@ZMX@^T7H7$%D
MOAKLK?M5Z5IZ4V+VI-%#*O9[=ONVF=-MB OV7P-=U?H2&74)4EM:@03=Z.33
M9I-T6J::"229$4D42 1))-, (4I"% "D*4I0T    &@  #7-*Z;>7+W>NON;
MW7')4)E4$D^[,C^U>?GT7-P[<7MVZIVY=<)VJ.Y9"IGGE6><?$FGTQ<"8J??
M1^P''MO0%[C]GO?'Y=NX[U+V'7"AL$*YX)"LX,1T\_KTQ4?U)*PVE12H)!DD
MCEC\)_$BG8SD-' HAHH#H V!0WW -CZ:WOWOAWW\0Y)+!"WWK>U,H1</M-..
M*D(25JVH222 "J5!,GICE-8BXN$6EC</K3N\(+9B9A*MVT]>:01TQU(K5IB7
MZ2+*5NQU=<A250QN_=MEXRKT"AQ,+F.LO'-YMV::_AJF)VJ_VZN$QZXK@OYQ
M*3G7%1F)611;F$6Z1",GY$O4#O9IPW9+TYI^[+]T; /NH0MHK0A"'7EH[I*R
MX%@)64A1S*)(*L:E/$KMVE]Q22UL=+:0J4R,;520G!*A) /(R)%.*\?2-Y4Q
MXT9U=\^\,LKD!IXCCX1L]FK;_+%JHD$R#%%UR#[1,TFM0\IE&(LB4Y2WM0-'
M&CWZ"X@>=)TQ9R'3RFG]GG#]R+N\4Q?LLIMPMHNMJ:25I*6X;<7M0L*F?#M@
MDI(E))Q=QKRTJ92A:5N+<A:$*E24PI<J"94DGXD9F2*<C#Z2O,#?Q31GAX"O
M8;L[PU\\.]$4JU:89A;9!M4?EO$N.LFWS(]4<R$"I5HVHXV8W&8G'T;;W438
M6M6K;CZT:HR2Z*BEXQP/8'AM_4T7"F]C+ZV2[MP&EN);23))*RWMW# *D] H
MU:7&M/\ [4::2TM;04D*6D$@2$E148VB)F"1@'.16[ML[ Y0*82F$/AL!W]H
M=Q =_,!U\@YK@.*2E*0J=H \/+$#SZGEYYJ5E"%#=X87XLQ$JS(,>O(1\:5D
M'X%+HQ@ZA'OL0_#6QY<)O5;T8R%)CZCR(JU D@$P"0#RB#SYS3?G:Y6+1(5:
M4L$#%34E2)X]IISZ29HNG%:L9X66KAYN%45*<6$D:!GIN(]K0Z%O8)5\WZ@*
MN(<KVVHW+)NF&]Z$W8V*7"@G;N2K).(E _ X/*U7:-OO!2RG:VH[3..HP0>H
M\O,".<QE)>'#P]2664,^2F&<<R&:D%HQ=')[ZLQKNX(N(>)2@XQTC+N4E%DG
MK");(,&;Q,2NVS=(A4E2=!>F]7KNJ(ME6:;ATLK\!2E:B@#G)2"01(F8YQUJ
MS_9C/M*%J1*0J23RZYD?$\C&WPB,"DC*?AM\.V9+/"WK+6&\>Y#N%7CT(NO6
M>UP#.5F(6-:R:TTW8Q[]<HK-VK>5<.)%%(INA-TLHH3IZA#E%GB'5K"S>L65
M..(?G$J($R%&!B2E6T^DS-7YTZU7=J=&P=TT%!1"<A,%62.28$GFF9D4[X)E
M3F$O=9FM,J\WG+;86\E?Y&((R+(3-FCX&*@&CBPK-A%16495N'AHM$'.E48U
MBS2 O04!-B+O4+YY-NB[?#I;;6&TI5N[M*E;E I!\,G/(=3UK)ITTV *W&U,
MBY:3=I+R5("F)V)>25CQ-$F YD$XGH%5HP5M=C@ZFT345/-ODFCXZ(@8S>)'
MJ6EW ZV8GEQ:;D"'UTE<*-" ;J7* XZULG^(]:TO1;=+BBY=L,7G=)*EMV%\
MX/:[E8$D--6MJ^T5GPAQ]"9!5%4M3N#IFFW]VX0TIED"V*B$]X^Y([MN1XG(
M*%$"2$*F(,G9=&(IMV#5!%+R444_*22Z1)Y::9A*0@%$ $H%*  !=  !H [:
MY[DMV46[*&&TA#;0*$I A*0E1 "1CP?P1C;$5YZ6XIY:G5SN<45JGG*C)GU\
MZY*H@J!@,41UY@E]0[B.OAZ[*(Z]?@/PY6K@':H*'-.1^<?.*\6'TA/AML'A
MQ\1UT35BW">/LAS<I=,?2Q4E0CEVTR\7?R]?35$GE$?5N17<MCM"F\PL4>,=
MB4"KB!?'?:1PD_P_KCURVTX=/OG5W#=QW:@REQTE:V.] VA6Z2 524YY9K[E
M_97[6[#M-[-M*M'+NV3Q%PO;6^BZK9JN&C>NIM&6F[>_4P5![N7VTA(<V%OO
M.\0%2"*KK@'*#K"^;<796;BH):-=(.:>I)B8IW$*=P#&Q-.V@$KV >R30V]E
M$%3 (@'<(YPIJJ=)XBTN^+G=LHOK=5S')5N70'DD$Q!;*I,<H-;9[6.#VN/.
MSGC#A1QM#CFKZ'?L696D$,Z@AAQ=B_D^\Q=)0X!CEZU[!,V^&_P]^*2GI+Y&
MHL3.E78).8J[LQ^J9Z%9OR).T'D78VID7!$SI&(9,IUEV*X" '1.FH4!]C7_
M  WH'$UFVJZLF76[ML*:<"!WA\.Y*FUI&\2I(R#U@U\)>#>U7M$[)=6OFN&-
M;U&R<TZ^N5:OIZW'6M/=7:J<8=%Y:/%*#W#/>.2@ H[KO) ;W#@H7''@A\.-
M=I4"H^E8^J,$:U1X1PNDYLEUL<BLL9!D)$$$RK/I24="YD%T6H)H)&<+^4 %
M*0TEX1X0:?.FZ%8!=I:M)V/7+FX,V;+<.%QYP^%L;$J *R HDB<FM9]L':K?
M7VHZ_P =\1K1=ZQJCZ0Q:(4G?J%ZXGN&K-I),J3D!W:#W3(6LC:DUKQK&+,X
M^)+\I\HH3!'\W0TVC*OR26V4?8K#&6!_/RM6J$DT3 S:!JB<FYK<38!,]%Q(
M)D5174:I;YOU7$&A<(-L\.O6P6QJ3QO76% =[;VCEJU;MOW#12(-RIL/ +2D
M*2HR"KWO'%AP]QAVBW&J\3L7FX\/MBPTR\03%Y<BY<N[FPTYX$=[8Z;O]E9?
M0I:%+'O1.RRGA/\ %G),'T?AO-#MRRF4Y$:W6[/8@*TD7$DS.#4U,MXG$I6E
MP9*"1!JNH!6\\W,@X;J*KN$3/(5Q;PBP4+US14[K:Y27UM,)WI:3C:XC:2.Z
M7*B 8*2"D\JVQV?<=WL(T'B7=;7ELINW2]=[F7'%J*D!I8<"3W@5"1T4%#S%
M;5D%4CE_8S%$.H0_2 1WH!'[?B';UYK%)QY$8(Z@^1\C$'YUO",_'/R(!'IG
MGC%9'.U*.*4<4HXI1Q2CBE'%*.*4<4HXI1Q2CBE'%*.*4<4HXI1Q2CBE'%*.
M*4<4HXI1O7<>P<4J.LE9#J&-JN_MMQF6L-"Q '6<.7"Q""H<$E>ALV1 16=N
MES!T-VC8BKA=3I*BDH;0<O+'3[S5+A%G8M%U]XA(@$[ 2 5DQ"8) W' !K':
MKJ=EH]F[J&H.AIBW273)C=M"B$Q()!@X$R1%:D<J^)#)7B&<R^(ZI4C-8:^1
M["*@ZRHS.M=RQ:EDA7<A=;@KYB;2H0/U$WDVS&-D#F?O_;T5R)E3( AMO0N'
M-"X5>L-7U6Z+CVGJN'+A>^6@][&^EEEG]YU:72"XI(V@IB0H[*\U<6\9Z[Q^
MB^X2TFP4NRU]#5FU9-)_Q2K?VNW?N;JX6G-LR;-IU W^\'084GQU+/@$S(C'
M$?>'FQ1*,!9(%W9YEH958?:I>15LLBZM[%\D<A ;RL)(OD2D;D,L5Q%&0>-E
ME6I/.Y9=I^B&X=1Q59N%ZSU"WL5)('^4E-FR&DX*AL+83DD0N00GW1+>QKB#
MN;1?"E\VBWOK+4=9/<G#B0]JMY<AIPD)*G6VWFS$&&B@2H $RU]) YFFO@ZS
MR>L,7TE+R]/95\K.):.9"1=-)2=BXR30:,V1%73A92*>/R&213.<Q1UT#H=^
M=>.FKM[A+6$6*5&X<:&$ DJ"N[21 !/))'Z->ZOLXC1T=M7 3VMO);LK36%W
MBRZM*4(5IEEJ%\RHE1"1#VTB8R(F8KRY8Z\"7BUR@#12N82N4:Q>D353E[:V
M0J48FBKKI5$]@69+"GH1'2+94?@ #KOY@TWLYXLU$)4W8=VE4$+?/=3/4!8D
M^F,_&OKWQ+]IOL6X5:*M0XTT^X="3NM-)(U2\:4.:7F;53I;<!PI*^1!Y'E!
MV3\=3V(;Y8L;6IY!O;/4W:<98 KTA]9QK&4\A)PXB_;P00(LZ8@LFD^*D3H;
MNO,;B85$C@6.:YHMUP_J:["X=;<=0D=YW1*D!1!E!,#Q(,I5SY1,@QLC@'C7
M2^T+A>QXLT9%PWINHJ?5:FZ;+3KK+;A0AY31,I2\@!Q ,':H& ""53"BSU#-
MF&5HPHGDDLIX[.P(41ZCO"V^&%NF !Z^8H)2"'Q*80]!'E7A0N)XDX>+7^:-
M;TLMCS6+]@I!]"J :Z=HB&E]G7'Z7R PK@OBE+TQ'='0M0WDST"9/3E/2O;[
M;\9U/(\*6(M<6E(->E$S0^Q0>LU"I$!)TQ>IZ6:K=&@$R1@!0H FJ!R]N>L^
M,^ .%>T/2AIW$^F)>4I  =1X+AI25H<!;<3"T^)"=Q!&X2DXQ7YY-$US5N&[
MU%WHUVXV1;M^ *)2M);2DI6DP" "3GKD1SJE-O\ !')1ZAEZ7<FZK;S-)1MD
M:]*R:8B(D*$HS /.$O<O6LUZQ 0,<3#W-Y"XC^R'J"'G7>%.)+:TL^\E&GZB
M%+04R<%R%0H8"3(ZS@S6Z]&[;G0V+;6V)&#WS?O%2< 02"9S(3/ISJKF:Z'<
M/#W2)6^W9E'DAH\4T&[B.EFC@DE*/%@;QL:V25,T=*+NUSE*!4D%3)I>8X4T
MBW6,76NL]C?%7!K*W]4L;&U:2H-MZG:OJ*;I6Z5-[5*, )W.@I'[O6MD\*\;
MZ-QCJMII=D'5*6N7@XA1"4<O%[P3XCS5B2 (D"J0>%JQY=NEWMUA=.Y64I!S
MN'%@458O7T>UG7NG$8SC#@@=*/4;-A.*B0JH(FC$FYUR=:B1E+%:-1L[!B]L
M+1YY+&H61<6&U. J;[S:I2DI4-V-RH,#*22D)C:?&;?#VF,LZ4Y[.BX<:<*$
MK<0E?_E@^%2P3.X1(\CSB7_2O!7A2N52U8Z5L^7;!CJV1DC$JX^M&6)V3K$
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M,5N1QY26F)L15>@)R\M86- IT56B3DP9-S-2K. C$6 .WOLK=(B[Q1!MW!)
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M>$ 'X_$>P_,?F//4 YJ\(2"9P(W$\R<02>9/6:\P!,>IP,^G+Y#IY5W 0@;
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MG]GE4&.8D!4'&)Z5Y'$BE-^D4!T/;J !U[B?IO>O4?3YCSR(GW?C/SS7VP>
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MPILI/03NF>1D5GM!XPXAX=;OK*QO'DZ3JK;C.IZ:M0=T^^;>3M7W]J\%M%P
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M4-LE*E?]/(XF?O#=XSW&6L957,&&+^[MM!M(20Q"]@BUCG,O"S4C R;1VPD
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M<GZS=[G'SF!G^=9G(]?JZ<C.L+55L=#X?K+B^FT5@^9MTTCFQY:9>->0A5I
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M(Y!RJT #%4%LHK"% JQ=@=(%0\LXE B@E*<QB[<1]FOA55CWB+G45NHRH%:
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M4Z1 04$/T# (#L>7"'W##>Y*72!W;:@/&GH0OW1C.<U<+LT0I3:DK"$I*U3
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M^_IZAS-=_!*0B=IB8YP8GT^=0LVOF(4/>2004GJGG$R(Z<J1'#'1!V7MKO\
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M*:2;73G5NH=MK2$)#YA0N.9D0  -@.NPF$-";7QT!2B CZB @&A["'-G #!
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M% (IM,6@&(71@*'Q#I].P"(?+[ Y?7+B"$A,2% Q!P((DXDY/3TS6)MV9 Q
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MM*\8\/+T?4FR/$W<V-KJEK<)("5:7>+6Q:(VR3W@6V4+0?$V4>-"4F:S'K-
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MVGQ*%>ARP256?TU)J[20DIY.6:6IK)O'#5Z;H7R/#&L7%PHVUP2XCN;Q:W'
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MLSUM>EZTK2GW/\-J2-C142![2@?=H SE;>]),#W4 &#C9$V.11(#)B EWZ@
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M*\>\?ZM8:IJ*+334J?T_3;-K3K.[*2%/.-/.7-Y=$;4D-O7#SK3"5& PVVN
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MK_,)4DI3M02E1E2C'2 1@#&M>/=6T_2+J_O=R%I>M[=IAM*@I3SIM& I*-L
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M3,WK^=-DI5&>I39N=1U5UVK>>9H3AT!C5WLD]9/&#,HL'+L:*]+U1Q=P@/K
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M]Q=,ZC87K"-0T/6+6?8==T1X!6G:K9J'A/?6^QJ];!*K:_9N&'/&"18-HEV
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M0% '"5 J'B(& H[1@GD*DO!'"=RW=_M;4&U,O(4I;*%[@3N)*=P4E,;9R0D
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MIM'D/H*^"BB/JDF.AWW(4>X>GPX.1!R/(\OI3: 9 $^<":^%;H$$!(BD40V
M"4A0T B(B'8/B(B(_:/.H0@'<$)"OX@!/UYUR229)D^9YU5+Q2"<V/&.S")2
M7"+Z@$1$.CV&4]W7?8=?2.O38 /P#4GX4 _:XP,VY)P.<#-:R[5E*'#("21.
ML,)(!.6RVXI2?^4J@[>4P8Q5'8LH&$"CH $0#?R[!_-\-=]^G?DW1R5/+'PS
M/Z-:*M0%.-I)VA6T%7\(,#=\N<]*=L I:K+.J5BB5Q"5D8QJ@YG'<W+##5Z"
M36_9HYG+21&$U(KSLH@FJZ9Q$9%NC#%Z?RKR.27C32$3U36O9GNZ80A3LPAM
M0E)(,F><D)!5'F)'E6_>#NSIO4M,M^)>('KG1M!?6X-.88:2_JFJ6]JXI+]Q
M;AU)1W-LZ@6]P\XD(<*]HF*EQGCO.*:Q$?J3&8+$*4P$4NMF WN* 8RI0_-Z
M8P!U'!+K ?00#W3#S#N:[>*206[9*I& $@1GJ /AR@<IJ9L<$\',J:?9ON*(
M8<:3WAM+$%+S;A?)"BW'>=R1$G=*<R@12LVJ&;^@0-"8C=H%!(3'-=[(H  (
MIF24,8<="7J6,*:_KL16*J( )B<M5:K>*!26[<@\P4@@GUP9@G/^U9 \(<,)
M*&W[SB51$;=UI9&74K93<*$HG<5-/N%1)*EIW+R5*I83@\ZI@)"5K%JA^H3&
M%"[64O4<ZIB"90?S>%$YA6*HGU"41'H$1$1V/*1O[[ ;1;I'(A..>1@#RS'2
M3ZU<CA[A1">Z>O>)$I2MY:!['9<W'E^..[C<XPFV<6005%7\(23@R=IO]"%D
MOD:I0T?77[Q!DI:*I87D^QKSIVH1NR5M3&5KM>>,(5VZ.BV&;CQDD6"RH*RR
M#",3<2*0:I<-E/?MHA1C<CD)@#G/7F>GH:IKX-T^_9NSP[J-R]=VK ?1IVHL
MM-7-V05=X&.ZA"@$ %"8WJ4EP20 *F1KW0(82'2$VSBFH<YS$$PB82B90QA'
M0CVT/1K70 %T 9MH[D)43,R9^))'GR&*@;B4)=V):<9*4I2ZT\2I:7DH >&<
MA/>A12D^Z(%=^@^0?JY4KHL "0.O\JC*]9,J])2\B8<=<@N4QFT='@11\L3K
M$H"9,!#R2B(  **G3+V-O?PN[.Q?O# 24CENZ>A&?R_E4?UWB73M$:2B\6@O
M*@H:92"\1_JV\HQE9$F?2J]/O$/*KK]3"JMR-P'W2N7QP5.4H &SD:H"D4Q]
M=724ZA0WOK$=E+GO^&2E0)>)4#TR.N(W>O.?EBM=O]I+JW"IC36P@']]9&(C
M(2A('7'+U\LN/SHP=F*C/1!X?J,4#/43>ULRF$N_V0>E)TF =MG%%4NQ$-AZ
M\/:,[;MEY!#A20D)/."=N,D3G&1Z55MN/+>[6&KRV%H%&"ZG8M 5$^+PA:1R
MR$J$F")R'R9VU?( ]:J)KMER]2*R1@42.0>Y1(8!T(; 0^91 0-KE@0ZF0MK
MNQY[-IF9VD]?/Y5GD.,OI#S3J7D+&Y)20I)3G( QZ9S,X$4RY$P%$X^FP-K7
MP_MOES;Q*A,3W?GY&1CSK":C"0F,25\AS]WG\R*CMYW4'?KW[C\/M_#F29'W
MB?B/_J%1M_,S_J_#E5N_"4 A#7,O_P#/V_IZ"(0L9L0^X #O]@!R(<9@"[:@
M ?<-\A'[[GY?RK<?9-C3M2SCVP\N7_AV,?E^%7(2_:R_C_\ 4/(C6V:[.*4<
M4K67XD&QD<MNU!WIU 0[@-]@V55\VV'_ )!@UZ;. _=L?AI85H!3B$7"MH\C
MC,\\S$$G$'UKSCVFM%'%2%<N\LVU#Y%8CUY<_,SF!4?Q!R "91$.K8]N^^X#
MK^77,JZ-R('G^51:SQ!\C^<16=8+:%89CY94W$B[(*+! P^X54-"=PMTE$P(
MH$-UG#0F.(E3(0PG[6[%NM3BBY)0$R.0@S&(C)SS)'T%7M_K"--MX:"3<.CN
MV4DD@':"I:N9*4")Q*C '4B(TFKZ96"3DU573MT8PJ*K=_=  T5)/J,1 @>@
M$2Z2E* %#T#F80\AA(2B$S[PYD[8CG)',\HD'F< 0KN;B^7[1<%3JUE04M1P
M!@PD# 2!   '(CG3F3KQ2IATHEUK8]@[CKU[CL/3TUVY6-WB2I(CT _+Z>OP
MBKY.F0F0CIZ]/^H?@#_*DE]""E^RI$\M<FC)'2$R)TS@("4Y5":,31@ >HNC
M>NAWSA5RAU&U>U2<B(3ZS)YGGYGGT%6KE@ME7>M@A8@I4DE)201M(,X,]1!@
M=*L;A7)KUZN2F6IQY\@FGTPTBL8A5'J29/,.U7$I2^8Z13,!DUQ$1<HET8 <
M(+"K%-<T\,I%W;)VH6"I2$R0,P/>W0#'3D>6"(VCP1Q.Y=*&CZFZ5W2$[;9]
M< NI3XBA6T *<2DX49*TI@D*2K=:0 T  ([T !L/0=?$-=N1Y("DA1&5 $\^
MHFMF$J3B9C$P,QCRK#%8X (B8 #TV/24!$>P!L0 -B/P]?CSL<# D]!T.,#T
MK@D]3]3\/[5@KZ,!>P=AWV-OW?LUV'^VOARF'+@20P)C^(_3F<^G.J2@D@RK
MISQR^4>OSJ/L@UEA<ZE8ZE).';:,LT2[@Y%6/<^R/0822)FKPC9SY#DS=15L
MHJD"Y4#*)]8G3Z3%*<M-Y"[II;%PV&VW $+(6I)VD\@H%)&[E*2#ZUCM0LV+
MVRNK)U9[JY8<MWH6II1:<!2X@+;2IQ!4@J3N0 I,RE23D,2DT2J8LJ<;2J5&
MC&5Z'(LFP8B^=O3I@X65=+&.X>&5<*&4<***&ZEQ(4R@@F0A1Z0O=)T^UTFU
M[BR;VMD[MA<6N"9D[W%+7\B2#)/.(C]IIMCHUE;Z98-!JTM=Z6FR\^^I(6HN
M+WNO#O%[EDJW+<5DX@8K@_<%*579"@( ;]UH1W]PC_('R^SF896H!2>Z3DI_
M?5.)C]X9S^N9LKMQLIA0R <Y,#X&)^N?SCF64*<AQ  *;WRZ 1$1#?Z6OWH[
M'1@#I$H=0"(;'EVV5*(*DA!D" 21 ^/S_ETJ,WFW:HIY0KS\C^$]>7RJ-IHQ
MQ1> F/OEC7!B@  (]0'-T^OS-KUW]VN95C(</\-J['IE9_.HY=Y2I*>?<S'K
MWI(_(?HUN)K+8S6#A6XE$OD0\>AW[]TFB!!#?Q_1'FGW25..*)DE:B3RF5'I
MT^%>P;%.RRM$1&RV83'EM:2"#ZR,^M.#E.KJCBE'%*.*4<4HXI1Q2CBE'%*.
M*4<4HXI1Q2CBE'%*.*4<4HXI58/%*T V*GJZ1!\QE.P3LI@$1Z3'D46(FT.P
M'W7I@T8!#OO0"&PS_#3@3JZ #"BT1\?#/\JUUVFL%WA&Y<@J+-W;/@_PK[P-
M;CY^%9$'PYY=:H-%F,.O+$>KW0#IZ>H#&#0"7J 2]6]=.P$ $ '6M\G>TE*D
MC!(4,>>(_,_&M!V8W.-P%*)4A("8W$DQ"=P*9F(D$>>*;<J3)+BL/(_#2+I3
M+M*R+DJW&^K'# Z[@)KPZWN+QC-JM9LY8Z6C&ME5K]8*@_1>,!E80[1PDFV;
MG5+H[C+]J-Z@HV*EHN$-WBF7@EM7=O"QN0R2AQ"FURX$)2E:%IW05 Q7T<[)
M=0X4/"^F.\5*MD</W?"&G<,-H>0]=L(N]'XPT>ZXFL+=ZW<3=:=</Z:W=WHN
MDOM//L!U*'?&!3Z3I7BP:Y02LJ]GN<D2 GXFMMY!5&CBVM^/'^;JNXFFDPQ2
MCD671'4)_97B3R.8QDN";-(AG:[AHFV<8/V?7%WZU%Y3K8NH""&D#V96KMA2
M3L2D^&P4ML*G<-H5EWQ&;W6L]E#G#26;>PTAJYO],NM2-L%:QOL-8MN$-3"
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M\0H$*(CR'7Z0?H1ZUE4:9 'W8QYY^."J(K!?P9#'$5$RA[ORT.P#9>Y=#V$
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MXI&3C5)ZH5Q'S+9%(SF)=N(Q]&.F[\[ETPF$FJ3=UY*ZS8DHX>U1QVZM[;O
M[;O/G<XL[G$DA'A2M)"=L 8*"05*GF (;Q7P]9V%BUJ&EW+EW9.K<MBZZXAP
M%YO<"4%+:2EO>E390I2EH< &Z#MIA-6!I6<C(LNQ5E)..BNDNA$4'D@@BH(>
MOO%35,H CL-%[@/H.P5+%M;WKI]YEMQ*09C89(\CNSSF,\L36M;=DW>H6-JG
M*[JY884!T;4\D*($'Q *49A2<1$UN*9%Z&C8GIT(D+K>]=)0#6_LUKFGB0HE
M0,@DF?.37L$)"0$CDD ">< 0/+IZ"LKBN:.*4<4HXI1Q2CBE'%*.*4<4HXI1
MQ2CBE'%*.*4<4HXI1Q2CBE0YFV(4F\97%BB7S%RQ+EV@0  3&78 #YN4 Z3=
MS+()!VT.AV'?0A?Z0[[/J3+T\R$YF/$"D\O3/QJ-\7V:;[AG5;:%*AA3@"8W
M;VAWJ.:5 RI(]?*M8<&J4R*"Q1#J.*1Q 1[ &P.'8! 0V AK8[WO[.;80AON
MD.2=Y()'[I,CT."0>O(UY;LW" A0YI4"09$)!!'NE*@=IDY!GEY4Y!K42^=,
MY5%:4A9ADDLW:SE=F9&%F$6[G7GMO;&+A,[ADL<I%58]X#EBHNFFX,U%=,BA
M8QJFE6EV[+J5)5,[D0"//WDJP>1D008(YFMK\&<?:[PG:W-EIBK5>FWRV%W^
MF7UN+RRNG&-P;>4AY?>V[Q"MCCEF[;+<:\#BE(\)>;*N/52D\W).6!T  42W
MF1#H+L!T31-DV(;$0T.Q$0'OS#JX?LFQ*7;L+F#]ZW.1$F6>95G."1RZ5/&^
MU35'G'7U:5P[O=W% &FN%%NI;2VE.6Z?:Y2J7"YXRXD.!)"=L)IQ-J8IV3+D
MG+7083&Z?R\D^QSF,<YPT7L(B80$![ &A  , :MW=&MMHBXNXD_OM>N/\D<I
M_ ?/)L=J.KJ<*W=*X=>6I+2)7IB\):+A0D);N4)$;D@DC<KNF@2845K@XZ2<
M@D"F0\LF I@-H;W(F#J+KI,)3I&(<0+O],I@V(F#WQ$_.J=(: ,7%T=VW.]O
MH(YAD9D29YDDX&*OE]H=[<*;+FC<-K:'>=[;KTL+:>[P* W[GR\G8XLO(++K
M2@Z!N4I [LKD5C2MLY-C,OGMHM,A%+J.HE6X6B9L"$0\4241,_CH]VY"-;2)
M4%3H(RA68R3=$QTF[M(AU"FIHT>V2Z'5.7#I"0$I=6VI @D[@D-#Q2><]!C%
M4[SCW6KNWN;1+.F6EM>I0W=(L-/9M%OH2VVVIMRX: NBEWN4+>2'@%K&0$0@
M2DBX.<Q2G$H[W[W[HP_:.]"(CZCK8_?R_P!H3*1R2,3\L?*< <@*BH=6ZHJ<
M,J/,P 3$ <@ 3'6))R:I7F>8//9'7B^L?9*VT2:(IAL %ZY23</E#=QV<"*-
M42CV'I3$H=NX2_0T):M77U ))!4%9R![L_CD =>M:1XXNU7W$ M$J);L6TMA
M'0.+2%NDCS(*$@^AZ1%17'BPHE>RAD#$+V F3VN@3N"XGI!RR1:VAOFVQ8_K
MP2L"HJ30DH:^1ZXXM#!4YG8M7C([;0/4#&L;S4F%/!!*LSR/4ST\L^4_+EE=
M.X=?7;6KS:0KVBT>N8QX0TI283@P#$QF9P1%2QX;?$A ^)=]9&]'I$VUA:4S
M(UMMLD)6+5B8F\N))Z5M0VZ#1,[J3E6]<;LK--/$?)90Z,S%1"AG,LJX;MK
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MK)',$$@=#CG\^M8J]65-J)Z* @3D0F>L^76MC7AOB1CL4U[S"F*>3]LF]F
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MEP+>P>*3*KJ$1,%,':2(G</#R@$3Z9QG9WIHU/BBT=<\#5@AU]1"0O<H)4$
MR4Q*EI(.9VG'*-H;<!!%,#>H%#?W\U@VDH0A),E*0">4D>E>EC7=SO2CBE'%
M*.*4<4HXI1Q2CBE'%*.*4<4HXI1Q2CBE'%*.*4<4HXI2<\CDWC=VW5, IND3
MI' 2 )0*=(4QV CWV ['[.WISE)*5)4.:3(_I^%47&4NMO-+\2'DE)!& "(^
M?/T_.M/4S!+U*TSU<4,;H@IATP1$Q1**K!)8#1ZI@$1$!58&;JB.S;$_<PZ
M>;<LEBXTUJZ2KQ>%2FQD"(W#=\?](B)^'D75+(Z7KFHV$%"+5];39C_,;!^Y
M7MP!N04JYD&8Y"G+&.$S%*7U^/P'?81_]_Y-\H/(WGO)Y<Q'J!SD1G(Q]*O[
M5WPA,3SS^('QY?H4_&3GI ! ?37N[_I'?R_7RQ>1X>9][XX@\_GS]*D-H^G
M*?CD1&!/6<\Z>C)<@@D8#:,&A$-!ON "(>N^V_A_5RR6@$ %1B>>.<>708_4
M5G&7!X2!T!/7./,#\/I!IV(.-E#0]O3?;M]NNVNPC_\ ?E)8[O:)GGB(\OCU
MG\JRC3NX#$1@YZGY8\Z5D%1 NS'V =M:[?#OL/C_ &^/*4%60/I]>1/ZZ5>H
M6(,J],'X<_/]2:SR.4PT "._W(_#J$>WIOXC\PYU+<Y)SU3B<=?PY1ZS58+
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MJNQ^KG+"&9-Y$9)[$P]5*5NY11(H1=S!PT'!G,F8HFB8B.9F$&K% J=JA3+
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MU -RB!U%.KJ5?Q26A 5S )CKL"='MAR@9L47&BGF.A:^)%K=&"4J0%J\(Y@
M$D#PP,DX'7 FM,<<=GI4X[JFAI#25)4[<VJ 1O5A16TE(]Y6=R$^\2")-5*:
M/E$P,BH"@'0.*9R* )5$U [&34(( )# (Z$IB@(#VT'IR5AI2)*5!2%9&PA0
M&1DP8CIS^M:<;N5@*:6E:'&U;2%#:H=((,$&3R,?"G TD.D!Z!_2]>KN&]?
M!UH?Z/GZ<IK3OC<1(]1(S\,],Q@^57K5R4S$GSGX>O+GCIY9(I<;R("0?,$
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MDRUV"=G;J& OUJZ3,UBT#;Z1,+I4G2N)1$VDV17)Q /?Z-EYC;O7+*V;<#A
M?V'9',*Z$9!^O2LUI7"^OZXI!M+52620DO.!3;2,P25$'ESA&X]<#-7/QEX;
MH6IK-)FT.@L5A(<%4P.D!(N.5!,OO-&IQ,91?8#ITX ZI $02!$IE04@FH\0
MW-R%- PP3D><&0#\XQ@''I6[^&.SBPT@-7E^\FZU%/B3(AI!(@AM.22$D^-1
M*O*,S:EJ0"B4 'L5,2A\0ULFM#\@UH-['7J/SC_-17_%_,Y^6!6R8 "0,!*=
ML>?K^O.LWG-*.*4<4HXI1Q2CBE'%*.*4<4KCTE'U*4?P#BE8;UBV>(+(KHI*
MIJ)])DSD*8IBAU"(&*(" @.Q#O\ ,?GSLE10H*22",@@D'ZBJ;S:7VRTX I!
MF0H!0R(.#(JN=M\-F/+,X<.&S5S79-4!4%Y"&!JD=4?>$SAB**C!;W@WL4BF
MWO8['7,Q:\07UDH0"XV,PJ59Z]9'TCK\(+JW9WPYJVY8:7:WB\%ZVAMLY\)*
M-I:GG("1)YGG4&2?A*L[<3#"V6/D4NH1(21;*LUQ]= 91'VI(-CV$Q4"B'82
M@ !TC)+?C*S7FXM5!PA.XIB)^& ,>OQF<0*[[(+UHJ%IJ2'$I/@#J-ICXI*A
MZ8'TY4SE?#+EDIS 0D <H&$ \N64*(=^W5YD<0X]OB(=_4=#VY<GBC2B9[IT
M$R2/6?60/2/ECGAE=EO%()"7K0I!Q]ZH&.D_=CIS]:4F7A=R8L&I"2KD84PE
MT<5G3XP=PW^PIL4"F$.P_M@&^ "7UYPOC'3]B@AAQ3FTA.($D0,R?WH)].E7
M5MV3\1O* N+RS91C=!4X8)&-I2D'KS(]*E:N^$JOH"DO:;!)32VPVT9!]4LC
M'#7NF,D11Z=,?30.DR]]" ]^8"YXINEC[IL))ZQGX@B #ZP3Z5+]-[)M*8V_
MM*Y>NER)#:NZ;)\B4RJ.>-X$^9DU9NHTBMTY%)E Q+./2(!A-Y+=,%%#&()3
MF57\L%55#  ;,=0QC (@._4< _=OW2MSJU&?W2I48/D3'ETQ6R--T;3-':#%
MA:M,@?OH;2%'$&5QN42,$DR8YF<OGH(.@$A=!Z>Z';[NW+>LF<\\_&OH  >@
M 'W<4K[Q2CBE'%*.*4<4HXI1Q2CBE'%*.*4<4HXI1Q2CBE'%*.*4<4HXI1Q2
MCBE'%*.*4<4HXI7P0 ?4 '[PWQ2O@E*/J4H_> <4BN!T$5"F(=)(Y3@(&*9,
MABF ?@8! 0$/L'@>$RG!\Q@_A7"@%B% *'DK(^AD5$-IPOCVSK*+2=6BA74#
MJ,Y9(DCG)C (^\*S%-NH90>_48QA$0 H?#8WMOK&JV2P+9Z6O>/>**CO/A/O
M3C:E.//G6 U'A3AW59-Y9,)<(VE3326B4R3*E-;%$RI4DR2(](B];PEXY<&,
MHDYLK#J.)@31E3+E*&NGI#VM)?MV[ .];]=AS+GB_5 86VVLQE001/T(Y#GB
M9J).=DW"ZEE3;MZA)R$I>)2/, *2KKZUQ1\(^.DS]2S^SNB=(AY:LB0A1'8>
MOLR"!O3?<#[^SX\ZGBO43GNT)/. DS_]7ZZYFN$]DG#(B7+Q0\B^ #USM0E7
MXT_:[@7&=943<-ZZS>.$^D$W,J R2Q0)L T=\+@0$2^NAT&MZ[=K*[X@U>Z
M2MX(1R 3"($0)VA)P/B?.:D.F<#<,Z5!:LDNJ$>)Y)?,@1S=*^?F/ES$3BBV
M;-R FW;H()E   B*2:1  /0 *0I2@ ?  #MS&%2E94I2CYDD_G4J0VVV-K:$
M(2.00D) ^20!7;T%WOI+L/0=!L/AZZ^7;G6N]?0  ]  /N#BE?>*4<4HXI1Q
(2CBE'%*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g752656g06k36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g06k36.jpg
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & :Y[IXD<<N14[3[+N_5<%LJ:UY)M)R@O+*ZFW(4F?8N"NFEBJ35&40
M9UVQH.$T526&(;M)GO;-.Y\(-&P) BJFQ;=!GMO<<-)[]H\/K;=%"C]F46"?
M0\HPK5OD)R7CC2U?\(8.7D@7E!6FYB*613=L)6:5D)!M( :13<E?G.Y,%[;,
MCB_<R:--M^O;^6H;=YNFJ51.B5[9LA-V:1M\72R)%34JB$L_FG"YZ^^4 S^6
MB5Q593,PJXFY9%[,.G#Y43==E\N&[R%9:Y]'OPBU%N*4W_K/B[IJD[BEW\G+
M.+U 4V.92;.7FDUT9F8@FQ2#%UJ7ET';Q"4E:ZPBY"0;OGZ#QRLB^=D6!7*J
M(BJMDV(;'[&US2]M4JQ:YV)")V:CVZ,>0=IK3IY(M(VQ0<BW59R<'-)QKQD>
M2A)5FLLREHAVHK'2C)99F_;.&RITC""CW?"CB\_K6H:<[U+%+5;C_*1<WHZ"
M&;MA8W4<S!(^K0$MKMN2?*6I2==:=6-=?0GJ;J 8&,PAU63,QD!$W7//;MY^
MGB2=IQ<T3'[/N^ZHZAIQVV]DP 56][%CK%;6%MM%921,W90$K,M)Y%VM#PZ1
M@"OQY5"-:X=-!6!2CE6Z!TQ%URYMB;O(5RQ]'_P[C*9KS74;HNM1U!U'>2;.
MU52V$G:6=7UML=)^]E4+Y1(-M/)QM3N#:5DY24:6.";L99I)2TL_;.TG<I(+
M.1-UVWV[>?IX]99+?B_HMIM>R;T9T8K/<=PJAZ+9MEL[';FERFJ:*)TD*N]G
M&\^F]/!1QS@]AHTJA6L'*I-IB&38RK1L]1$76UKY<-Q 3<"N':FCI;C2MQ_H
M+C0DU.!:'6JG31\ZI[6S>U3SIK'"1KA^J%;GE)M1:76F*ZI%R*\FNX?+.3NG
M"RJ@G65%O=;\;YF7J_"7B52%Y%]3>/NL:K,2U '5C^R5ZN-H>W+Z\4<R3Y[4
MRV]AX%G0B9B0F9:1L*3>624LDE)/9&>5D7KE5<P:RKO7;?;OXF,/P1XD*:]U
MIJ8VDJT&L],6]O?]249-_9$JUK6[LES.HRU4>*2FR-JS.PKM9X]@)&((U<P#
MZ3F7L*=BZFI99Z%UX[=J[UZ5VF/VSZ/CA)O?:41NS<?&'4&R-JPS6-8HW:V5
M-G*S$FRAP2)$M+2*_5K<VT:F@@BQ1M[:<3:H(I((E(BF0@!=42R*MMMK[S<-
M-,B1"))$(FFF0J:::90(1,A  I"$(4 *4A2@!2E*  4     #!!0%)XO:(U@
MO57] UI$1*NN6LRGK*&/*3SNL:[5GF3IC-*:[K4K)2E:UV\GF3Q]&S4M3X2*
MD)".DY1H]5=-9)^@Y$W7OW[Y<$-;.,\#R9WAM6)Y+\R..%+XS7/4]&O6H].Z
MN@=O5_>\H".R;)5YK9^SY2[UVO0<+&M;-&ZYUM7J776J:L[#LF=\7L"Y"6AE
M&L 6R9(M[VONZMYM'=>->DMAV.R6VVT1K(6&Z56-H=XD6<Q8X(U\HD0K+K1U
M&OK> F(MI>*4U/8;!VU*UMY>OG)/3:2L<=*6D". NO?T<.KF,;?^)_&W:5QU
M=?\ 8&E=?VBX:6:N8[5TY(0+8'-/B70,_%@X])MX#5>O@>.8K(5^0;O(5JZ:
M-W;5BBY2(J 77CMS7I385](>CWX12N^3<GI'B[IM[OE26:6)?9#BFQRDP[L\
M>H19A;'K42>QWUO8N4D7;*VNXU:QM7J#=ZA)INT$5B!=;6NML\KK;/;Y=Y9Z
M7&?2+?;-GWNUI!&.X[G5STFT;(C[!:X^VS%.$BH-ZNYEF4Z@N6 C%5C/8.)0
M%)E7Y0B$O!HQ\HV;NTA%]V[;8K0. ?#L-//^/@:'J/Q&2EE+<9+48N)\=>OK
M063+.>VW54&8&'7?&GDT; JHHU,"U@;M9U4IY9JW>)"=9;WNM^-\_*;9QD<V
MB(YE%LQ="TCVJ+-L+Y^_E7G@-TRI)>LR4HY>2+Y;L*'>Y>NG#E8W4ZRQSB)A
M$'.P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@'J<Y$R&44,4B9"F.<YS 4A"% 3&,8QA I2E* B8PB
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MB(@ ![QP##0LV69-*@5JJV+&29X\AU#=Q7B7JC1XB\3#M(9,BR3L@@D<!,4
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MX=*I(@80+WB8Q2FE$OS=/?/J(5;<Z\._I(PXB]H3 "8;#7JFF;S*W:1;JQN
M ?FE575>0:*2I?+Q 2([2[@$I%#EZ*#/B\%7I6WF]9%G+OMT9^GON(P_J.[F
M(&<P.RJS,*E 1)%V"JO8ANL;H/0#S$;,RZK<HCT*(A".1 !$WRN@%%=OXO:I
M%G;G>5/XD39[[EJA.L*KNNK+49_*+^J0MA3<)R-/L#@ $?"BI]$I&X.S%(=4
M(N1)'S)4"BX4CB("4^3JWNK5OS6S3?SC65+(Y.O^'>W;LPV=-WB";EJJ1=!4
MH'343,!BF*8.H" @(AYAE"YR, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , QTO+1T#&/YF6=)LHV-;*NWKI7KV(H(E$QA[2@8ZAS>1$DDRG56
M4,1)(AU#E*($19P"5J4866SL>Y4I1<0L.Z*4Y85JX* IBN0!,F:672[#/U2B
M8$3CZF@H=%$%%1&:[\NKRW[4[H3Q-)-$@)I$(F0H !2D*!2@ >[H   8)/!T
MTE [5")G ?+H<I3=0'R]Q@'\V 4EL'4!I53X5ZXF%:!L>. BT?-1W<6*FBH&
M%0(.WQ!3%:3T$\'N241=IG78F5%Y&+LWA"K@([]^]O.DDU?L,]]B9%.6B%:S
M<ZM)&@+K5UU 6-$S*:"3E-PQ<]"^OP,PS61DH.2 A/6&BPH.$T)!H^:MQ)8$
MB\+'LEW9BB?PB")$RAU,HH/R4TB!])U#B4A0^DQ@#Z<!5L1)ZY1IL#*6:4*5
MY,'1 ZI?$ IG+Q8P)Q\*T5$I_";>LJ)-BG*02]14>JI_. MFHBKXRZK&HKGN
MW-8U+N=:Z76R9)?QELU-J&2"%T\K(F75TCD:F^W/S(U+JO-=54@=0V19)BSQ
M\3)(Q*C.54=)%]2:NFRK 6L8_?E."BKYV#@JIFA$5 4(0>Y3Q$Q(4/"'#!41
MU'*M;$]BQLY1'+(C[IRD;+.3DVV7Q[HJ*EK65%]T;BOPJ.CITF;,YSD<UKD<
MU$1RN7:VRY6LN7C73?D7MF0T9ZF*4Y3$.4IR'*)3D, &*8I@Z&*8H]0,4P"(
M" @(" ]!\L Z^+$V6XG[IK#N! [71NY)=Q$%A2?)C:%L,R*L@,9&D'H1I VA
MB@^DHB.3ZHQCV-F&C<&L<,4S1R)XZ67:B9+QS[=N?-SH8UNQ;IL7O;OUG8&@
MLFY0272,!DUDRJ$,'N$IP 0$/S@.8S(4_=KQL6DS1GOP"1MFOC@AWRE9?.5;
M3"B*9"N596O*-5!>M"KB8R;F'4<>&VZJ/TF2:1EC@6!6;= VZ.0DH5Z1=%<A
M3@D<2D<)B8.O8HF!C )B^X13.H3J ]#CTP+GU?5J+DY!P]D6B#LJS%JR%%9,
MIR&*V6=K%.;J'41ZNS%#J/D >6",UYD2UK;^GF(ZEJVE-YT+$A%>%)B4A5#E
M77%%8B8E$A54#'%,Y2F(0>@AT^07[TO0+<ZDH=H+LG)Y%B4IRJI]CUEW FFX
M,0"@DY(;H()NDTR^#W]H@NEV)+>23<Z$IV[N?F(5;*G!;W[]\DX(:4<IKU)R
MM GZR$0C+&F1:04742J*BA9K#./VT-6X&7'O1*_824Z]CVKQBN0(Y9%4Y7K=
MPB00&N^WER[+]^HL7+Q9X\P7&G4D1K^,.@^FW*RE@N\\@B"!)ZWR*+<DD[02
M I/5XQHFW;Q<,U[">!%L6OB@9T=RJK(-C#& I1,8>A2@(B/[P '4< K2:DA;
ML%K4Y(FNIXQ6M69+AU;IJJ"8I)15+J7Q5C)D6>) !NXC)$!24347,9/G]*L?
M@T7T?Q/'*AJ2-H*=9(X5=J>$5,CFPTM/K9JU)JB2-CG(U58USGZJHTS4M.ZI
MJ(X454UW65?Q6I=7.MLR;>R=&];)!X*OSUO<C(.9)XDV0<")I9=8ZKDKDO0Q
MR1*/>4C=1/N  62*BS:F$I4DEQ34;D^)Z!X;I]IO5TNF&/:3XEAF"^&^&4&&
M8=4O@BK?!YU:L24C'K3PX>CHWTSEJF5%34QI(BI:3PA^ZKI*&B8ZD@IHY)M3
M4DED:BJS6:BZVLJ:RR9HY-54:U;<-4O963C6[MO'N)%BB_=%[FS)9VW2>.2]
M1#N0;'.594.I3!U3(8.I3?O#T_1ASYSL T"WI677'.WL.0NNT3,:3,V"-C=U
MU%D7LBT5)U\E'L=B1K,@ FR7/)NF\?;$6Q02>G?-)XZ2*Z4Z\>W:J+XJ]7\2
MCD5/&3K]&1O- S+2P1#"88J%5;/VR3A(Y1Z@)5"@8.@_[<HN2JG NF:(O$PN
MPY:5@*#=9R":+/IJ'JE@DXEFW*4ZSB28Q3MRR223, @H<SA-/M3[3&4'Y!2F
M,8"B!BM9+1Q:!5%VGRP>P[-VHL804</G3A$BSI\Z6'N4<.7:YSKN'*ICJKJG
M,HH8QS&QZ"/3?OWV;":'=FZAVAVA[PZ=!\OR_G_W8(6_&U]R6OSYKZOK^8.E
M>O[_ -(>X/+_ &^7G]/T>0]?+'/NV%52RWW[?==7!5YKY;K9J?-9\@HFH@\0
M Z*A!(H AW%,4X=! 2^?EY]!]PA[P\\MJ[T6_4OHN%=N5%[]2=/3S%?WK:D)
MK.LNYJ0BYB3:1343$;Q";99=9%N0/(HO'30I#@0ON4/YB =3?*ZY"HJ;4M?O
MV%FNUDZ-O?OS&1U!M.L[LUQ5]H4\DHE7K6U=N&3>:9>SY5JK'23V&D6;YJ"J
MZ9%V<G'/6IE&[ART< B#EFY<-545U(+$SF'BS5L";0I3OWBA6K(ANO;XRO4/
M$4Z=1!% @'76$ $023.( (@&"%[]_P"/0I[Q44A%H&(F)EG"Y@5>O5?-P\<"
M'0RJINHB!0\RHH@/AH)]$TP  $1+_#F");IWKQ*DGDMR#MB"4A%6@:U!-I[3
M(88WL\+H;VF5T18/:IGYC 'J!FG5N0/ [A*'K@#LHEP[P&5)4=X9XVI;7O?\
M#55/YO4_'1V>VV>J9TY'DEO?E,[;>KFMQW]A=V:TPD;M]0K=]KDI4[=$-9R
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M^^LW<ZH]EBIB/:+NM-CB!NP P0NSL3IW&S1#I@7L()1!, +[^@ !0Z>_\G3
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M)!*IT+6V\_?)%R_@;-0\:M'HMU$6IF9#)%!>,5627,W,(=1*BX14.DIV#U
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M?*M_0IX7[D.R%BCZNS:H>[P6Z2?_ *! +_\ 3,9D.5@# & , 8 P!@# & ,
M8 P!@'5S5 [_ $GNQQZ=>RFM1ZA]'_>XHQ.OO_SNG^WW9^/<%\;^5[I7_P!.
M P]FBNCB>DW#_P"AXO[1;?GI/0=HV?L(TYI3R,_P]<5?]+);_M.IYT6$_P!%
MXW_8Q_Z9CYEIE]]N@7]_J/\ S4!NMG.GTT8 P!@# & , 8!7]UK+F0>UVU1"
M(.)VIN'O8Q$R"03<#,)(H3L%XS@2(HK. :L)&/55412"4BF22Z[=JNX73$*E
MT[]^_$RD!)(2B N8AP5=NDL=LZ;KE.W>L'2?:*S"29+ 5RP?MP,7Q6SE--4
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M.[D$8^%",:*&BD7?<A&R];ESE=JCX"4B4T@@[04,+)46@D[,L \" & 0'W"
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MS$</4OKO?G\IB)OEIR[K32!:3VHJ_&SULL"E:JJ:VJMH":?G&^I^5MX-"1,
M2Z'E)&0<2VB]<JB9L]$D=7]FJ^MIJ&CT)A6;)QRX]:)P39=>%R+KPWVMY5VW
MMP[3(TW<_->ON;7'2^G9299R%TN4TQD)VJW"8<T>&>;0M;)G"MG$=*LT[_"M
M*ZG6D:NV@$HIZTBGQK X7EH=FN5 B):]\^&6?7N"JJ+LNEN"[3$MMI\T9V3K
M<3+:KN-$:R&\M:6&?>1T+<;(X;UH-MZ2;WVDM9I%ZM#15+AM?RVPEI.7=L7<
M+;F+.04JI8UW$O3F63C?+T*O3MRMT<;#/M3SV7U][KL%L7<_):%L=UC*=JF.
M<1T+L>(J$(YEZ3LJ<:KTN<I<#*Q^USSE,-((6.&1N[J8I]BJE:B%+55&R2-B
MDVZL6P=+/(RW]BIS]_XY3GVV\V?G[I9=?*;L3F?5+]8GKJB7FXU]W9+A&EAK
M+!6IVT8UI?DGR:+!R5-6]7AHY]+QFKT=,*L26.<KL9)48&H+2J$VXC4G$V2R
M9HG\&]>V_>Y&=[V5?+Q7=LV6X>53M>RI88 P!@# & , 8 P#K5UI;^25;^&,
MA,UC8MDEW.\;W UE&S0^QY&*A=*RG)IU#EN4K#.2QT?,*5;3[FI2.N8NM2!+
M/*0PVJ1F4W[=@[%"5MNX9\-G\>O(JFMGPO9.CCT=N^]D(S);_P"<#Z*K4Z\X
M[O(*PQ4)(VWX.04)>IJ%=3*O&;=TRA3K8NUEXMQ*+MMX0%+JIHAI'KPP(V2K
M2<;;'\PY#V,LG>R7S3R9*3=>'U9+PV[-R[_+)9GDMR_@(NS2+[0\2#&LC<UQ
ML#NKW&&B96(@GUV4+.*MG]C.I7&%>K$/59]V,E(.R7]29=Q-5<1#Y$Q6:R7M
M?AGPOZN_ BZVO;J7;]7;Z2'U[?7,:S7*@7UMK9XK1Y",BHAVSCJ!?BU2TUBY
M[*XK-W5Z;Q"TXO*UZQTJJW3>SB(D'KR193\#KM].)PZD5.QJC9;=?C?ISR[.
MVVT:U]R[MR[[9[+?P,KQWV3R_8RU5;WS7%Q?P=L-IEE:R6N&N*TM13.]4ZI;
MW"1@EYI9FP<1K&[/KL6Z*S5B6F6;Y%28B(RRFC9:+6+:Z].7;WOZPBKP7KZ$
MW]*KV\+':-D%C6?E0GMCXOHM_I-U/);"K]H;VV*BX=%VJPMZ5/A)VT+:]LQT
MFKEDT@-B+1+6DK/I$6R;)[/,G39XW>)('R4Y]G?9SD+S;>^WF-7/C>Y84"U;
M96)K&^7HEAWC #5XV6IENFX&LZU-K72#FP1-;E*XJW8-VD7:IG:[!C/ TEFT
MS,P"KA<RC3U)%U-D[..^Z^C=ETYD75.*Y\.A=N5DOT]A-0W;S$DHJ"?PNHH%
M":>T'<MNFJ;-ZZV&Q6B+IKI'7?P0TZ-S?6^*KJ\CL5])["9P&RVC=[57[2)A
M9:/AG"2+]F]BR<=Z>1;YV\F1-UX;KKT\._U+7]BY/<JW%L6UM'ZGCPEW\,I)
M(-XZGWEE:)"F.]FRE&>W]F![$O\  $L)5DE+/&L+,RD7<]+096$6?Q+9!MF2
MR6O?OZ>^0^OCLR[<]G:?.D\B^8-;JVNX6Y:8EIB0925 A+=;9;7&PV*;FI.H
M'C.6V6Z<DVDC*$A[#7I#96XEYMPK%+Q4H35,T^;LXD[)>+>RMMR\>?>ODV=.
M9"*NQ4Z]F[MSX=AYUMRTY4;+B$9" U=1U_&J$[,"Z?T'?<(V96ME0M>S\;39
MV-"#FIZ#<2$M9I^6@95:/=P]WIK&*1@'[:U*NXLI4\O2FRZ[]G#MRL-;;S<$
MYDW;4W[4MSG85JZPVFUT*NV"[5IS3[3)-G*DS67;;U5:(<I2#ML1N"?M"3,H
MB9!%%9J[4<IK/FRJ+U:/B5G!XIE4LE]Y/\ 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8!U>:I^5Z2;=X^0]M*=?S1^N"#T_* CT_P!^?C_0OQOY5_LAKPT?
MF[*;11OF-Q/_ $33_P!HGGE.T//V :<TIY&?X>N*O^EDM_VG4\Z+"?Z+QO\
ML8_],Q\RTR^^W0+^_P!1_P":@-ULYT^FC & , 8 P!@# & , 8 P!@# .O!#
MF22OUNU; NS>'KKR/N'*IH74[6GV5Q=)FN\7XVWKJD=W-!T>NPEOF*_5XJZ
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M@QDQ%DU%=;:[51,\LKWY^"77IN71R0UGRDU/J'E1MQIS'V4O5]7ZJY(;6U+
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M:2.26.5%LYS6+,EG621MD<J72ZHY$1R[5UE=>^2K!9+6%T<\7=?ZK-7@=6F
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M2FT;<J>$5%')4<IK)JLGNCX*5R;GRP,FFS7="U$594M<F:\Z08 P!@# & ,
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ML5(@@8WA _C6:X@(I  P+YVXI?/IV6Z.^1>V"PP!@# & , 8 P!@# & , 8
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M:5FCY1FJG?FW)PZCK'UWHRY4*ZO+9-RSAI'"Y\=9205(BS;(E.)A,=5QVIE
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M & , 8 P!@# & , THM7[N?6O^JI_P#\._9T<'WM5G]];YZ0^95_]:>"_P"
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M *JG_P#P[]G1P?>U6?WUOGI#YE7_ -:>"_X!+YL6-U\YP^FC & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M!$+QL&AZR@OA1LBZU2@5KVI"P?PAN=AB:Q">VK)*-8.O1'M6:=LF/M.>FW[&
M'AF/C^M2DJ]:1S))=VY11.%K[,S[5&\TF_QSB8HEPJ]UB6<BZAWDG4Y^*L3!
MI+L@2,]BG3R(=O&[>29@LB+M@LH1TV\5/QDB=Y>H$IP!@# & , 8 P!@# &
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M_P"JI_\ \._9T<'WM5G]];YZ0^95_P#6G@O^ 2^;%C=?.</IHP!@# & , 8
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M\?=1:K\^R-W8MTZC_<W&'DPZ^:'4>GJ^HU>O3K]'7S\O?Y8( \H=9=1 (#D
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MJJ!'-,=KPTY>HV3LB<FL9=VT8N;C<9&!9Q$C9)-VN]H,6^"?IZ;Z8?;&T/\
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MHM-+S7)V=_B?*$G88"T, 8 P!@# & , 8!P5XR-=*"LYCV+A40 !57:-UE!
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , TWY)\C'^F;9K]1E(UM"F5NP525WRE*.F:4TUU[L:6D==5F1@47"H+J(P
M-G5<WFTN&**CEC7*6JBIT;RX@?H,(PEN(05:.9,M1+%.S#%8BK&M52,;5S,E
M5,KRPHVF@1RHCIJA%3.,X?2G2>3 ZS#59+2MH:6IHYM(6RO8E0S#<3FEPRDE
MIVN<CE;3U:NQ"K?&USF4M"YJV;-GD;I9M@/>6=)U)#[$L%3I=AX^;)V(^:04
M/07;L+-4=@:PK,6X0D+13;&Y(U4C;I*"\9F.=)5PBQ52\ J2Z;FE/#2MP.HK
MI*2*>HBQ6DI6NDDJFMY&>EJYGM5L-1"VZ/IV:KK71%<BWNELM=5XE)IE08+!
MB=11T%3HWBF)R,IX,.>]*NBQ+"J6%S9*NAJG(Q8JZ;78JJCG)&K=6SD=Q]?<
M@)Z/C.2,'M((B2M'&RYMZRK.PB18*.V#&VBF5F[ZZ4(S>.W36%MLRWMD95IB
M/2=J18V0@/8\K-C)H1C":O"XG/PB6BUV0XO3K,D<EY'4CX:B:FJT5S6M=)!&
MZ!\\;U:C^175=K.8KWUPW22HCBTHI\6Y&2KT6KF4CJF%$IXL2BJZ"DQ##'(Q
M[WM@K)VUD5)/&CUB\*3E(D9'*V*.O(;D'?YGB5R6GG]H@6V_..<#N2)L<]46
MT.^@75EH]8D+M0[;$1<HUE(]:NW2HN*M-"V=,SD*9]+Q29T7D>HJAZY,*I8\
M=P>)D,JX7BTN'OABJ%>V5(:F9E-502/8YCDEIZA)X[M<F38WK=KT1=;!I)B,
M^ANE-1)5T[=(M&*?&X:JHHF024[ZK#Z26OP^LABF9-&M+7T3J.?5>Q419)H6
MJCXU<WSK"X;YV;=JC"0>Q+DIJR0U!5K]>=F/];U6&EXK8KI1%(NN:/*RNOX^
MG3L98&;Q::G#EJUCDJHC!IM1L#1:S1R356P891T\\DE)3^&MKYZ6FHVUD\C)
M*1M_]KJ6,JG5$3XG-2./^>B9.LE^2<D+U<PFMTBQ6OHH(,3KEPB3!:3$<0Q6
M7"Z2">'$W*UOM702S8;'15$-3&]T]0J4E3+1I3M;X2Q:N)K8)7]E[Z><--I\
MCE=T3CFRU#7W+=TSBG50U>$4C8-1W^]Q6O9MJFRH;-<1;1%!%A8F$@Y?,9CV
MRZ=-D(QRW:*(^J6CPQND-%A"8?&D-15X$USVSUNNL5?2TKZN-5=4N3.2IUHG
M-:UT?)HU5>BJBZ^GQ72%^@V+Z3KCD[JNBPS3)[(746$\BE3@N(XA%AL[49A[
M'>+!AW)U,<CGQS<NY[&Q.:Q4N#XS-AT':W')W>;T\E=0;PUTO4W)Y*(IT8W@
M-[M(!K=8-Y)3,978MRE&7NKL+@S8QX.T&;2Q0;-%$@IRJ+5+7>!TM50XLVFI
MFLK\.JTG:C)*A[I<,=*ZGE:R-\KT5]-,ZG<Y^JKG12.55\17+NO;7$L.Q?1A
M^(8A)-@N/X8ZC=RL%%$VFT@93,KZ=\L\5+$](L0I(ZUD<>NUC*J!C6HJ3-8V
M'[$VKM.LU_C+9@V+<V$;O/D4_AI!M$T2I3\\TU%:*-M2\T2'80337<Y+%GF,
M14ZBK)*$C9&40=/K$W?*.$DVJK#T4E%132XQ#X)3N?AN$M>Q9*F>*):^"HHJ
M:JD?(ZKC9R3I)YT8BO9&K6PN:C5UD?XL3QC%Z2FT4JDQ.NCBT@TGDIY&PX?1
MU%0S!:R@Q>OP^&.G9AD\R5$<-'1+*J12RM=)4MD5Z(QT>UVHI=Y8X*T/SVR\
M6)HI<)N-AW-\I4=1;1!MHAI'0SJ/-"IU6IJK,_;C&6FXB0FZRU>NV$LV Y7L
M<DQ<+Z2OC2&6%O(4T3DIXWO2EJ75,,JO<^1K^4Y>=$=R;F1R,BF<UKHU]R]7
M(G8X-,^IIZJ1:ROJ6+6SQ0/Q&ACP^K@9"R*!\:TZ4=&KF>$1S5$$L]*Q\D<S
M<GQ)&YW7^[WWR-C^,]+W7!6QY<[/"<C-U,+O5W%8I1"W736FKANU.?K$2E%5
MJ.<1UI4HFJTW4/)QZQ'3NQ"NBJFLW?H-V?4-PS"7XQ48=+ VGAEPG#G4TR35
M"^#8AB%/AJQ3R*^5Z/@2JK521CDU6PV5%16*KOF[M(])V:*T6/4]6^NJZ?2?
M'HJ^C=24/^WX'@==CS:BD@2&EB='6+A^$(^"6-R/?4ZS51S9&L9>%[W_ &BP
M;YXJ5S5-L:I:BV-8G[2YSD=&0\HK;QE]&7;<=5AXJ0EV#X89*,A:U69N859M
MR/).*V!#D:/F*K1QW:ZFPN&+"\;FKH'+7TD3'4\3WR,\'U,2IL/FD>QCF\IK
MR331QHY=5CZ636:Y'(;_ !#2.KJ=(M#Z;!ZQB8+BE5(RNJ(HH975O+Z/XACE
M'##)/')R#8H*2DGG<QJ/EAQ*%&21N8XQ>I>1M]A;7R)UUMIV6V6*JSUIN.AE
MTV$3!O\ 8&N%-DSVH8&F&+#L&46M:X+9D SJ\A(^JH"Y3O%1>ND$BNC&R]=A
M-++!A-70-Y"*>*&GQ1%<^1E+5I215\M3_./<]():.5TS&:RV6FG:U55$0Q8/
MI/B-/6:2X9C+_#*FCJ*NNT>>D<-/)B6%KBE1@U/0KR,;(5K*?%*>.DEEU&ZR
M5]%(YJ(^Y6^NMV[YE*+Q1EK1LU5[8MF<OMQ:9V&M%5.D1\1)U2A/>03..9PS
M):LNW<005-2P1O6P?+RIT7\L1=^JJLT59>NKPW#&5..,AHT;%1X#08A2(^>I
M?(R>J;A3GND<DS6R?\=+XNJC+M99B(CD=JL+Q_2&;#]#YJO%5?4XMIKCF!XD
MZ&CH(X9:/#7Z2LB9!&ZE>^'/!:==?E'2JV2='2*KHUCV4W+,;3:O-VLZ)LV0
MJTA%:OU1+T4'%<I<S#UNUVVY[$@7\DZ;R%:7E)B-=(5B&*ZC7LH<4TC20QKA
MBX<MEF6GP^.B<W#G5-&R9KZRNCJ;2U$<DT$%/22M8BMF1D;T6:35>UB9ZFNC
MD14=U6.38NU^.LP_%9*26+"L'FP_6I:&>"EK*RNQ*GDE>V2E=+/"]M+ CXGR
MJJ)RO)/8Y['1QG6N\K=M"<HU1L$D]UAMFE6R?H?(#6$8VK[YI[81H4_8("SP
M#ZPP4G*KT6V#%MK11)V.<MT9&*7<1,F+B2C)-!OGK,-@HHZF>)C:VAJ((ZK"
MZQ[I6NY-:J**6&5L4K&)4P:[H*J)Z*K)$1[+,>Q5\N%Z05N+3X?15,C\)QFA
MK:C#M(\)B;32,Y9,-JJFFJZ>2IIY9G8?6K"RKP^HB>U)(5=!*KI89FMH]IM/
M?[[@Y>N21]TS3>UTK7G(:<8-&U.U<+*6L6O[S?(BMK32#BAKIA%1\-4HQN9C
M$^S7,@[?2KIZ^, ,4FVQ6BPMND=+A'M=&L%1585&]RU%;K,BJJ:FDE2-4J47
M7?).]VL_71B-C:UONU=H&XQI&_0#$=*5QR=M9089I-41L;183R<U3AE?B,-*
MZ=KL/<G(QP4435CAY)\CY)GOD7^;1E][.C^2=8U>?8FM]IV"]2];7J6P7E"E
M:OK!&2O-.8-$'.Q-<Q<K'T:-0C9:6C$EG]'F"-1>HSJBD/)JNF#MFZC-91NP
MB:M\$JZ**ECF2>E;5,FK%935#G*E)5O8^I>KXV/5&5,:NU5B_G&(US7-?T6+
M1Z44F$KB6%XM48A-2NH\1?ATU)A39<0HHV(_$\,BFCP^)L4TT2+)03(S7;4*
MZ&5SHWL?#;.EKM([>;K;EB;!+#J:[PL$KJVKOXB)8&<PY6PN7E^?*'B$;*V<
M69VX,UB(5W+N6"$#&,YSPP=6$6,/X<1IV4"IA\D3/#J:25*V9LCW6DOJMI6H
MDBPJD+4UI)&QHY97NCOJQ:TFXP*OEQIJXY#4S>TU?!3KA%))##'KP:NN_$9%
M6!M4QU6]VK! ^=\;:>)E1;7J5CAOC-8=", 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@%'3
M6AJK9Z]N"O6MVYLZ.YCSJ<Z]F8RNKO8>+FZJPIH0D"9.'211C8N$C6Y(TKU%
MZY*],YD'CAX[=KJ'V4>)SPRT$L"-A7#^26)L;Y49(^*=U1RDJ+(JJ]\CUUU:
MK4U4:QJ-:U$303Z/4=738W35CW5;<<6H2H?/%3.?#%/1QT/(4]H&M;%%3Q-2
M))&R.217R/<][W*L+A^,7L6RZYN+3<>SE+-K73DAI&*FWC?7D@^EJM*2M6EW
MLM/"_HKIN^M2SFFP'=*$;(-#^K.%%HU59ZY44]$F,\I#5P.P^B2&KQ!N(OC:
MM6QD<S&31MCBU*IJM@1*B7Q+JY+HB/1&HB>&'13D*O#*YF-XJM7A6"28##.]
MN&R234DLU)-)-4<IA[VR5;G4-/>5&M8NJY5B5SW*LFB^.U2AF<>R8S-B7!;9
MAMM; =S!H68?;<N(L09H.K^J[AA;J,XX[:$>PL;6FM<CX)Q5JLUAFK&'AD8L
M^%^+3R.<YT<26HTH:5(^4C;04^MK*VE1LET<]%D;*^99GRI/.Z1SI)%>GJAT
M9HH&1LCGJ7:V*KC.)/G6">3&:[DTC:_$5?!JJR)64\E/%2LI8J9U'1M@9'#
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MP0,2.))5@BAC<YK&HBN;&W6VJERSL\9MA@# & , 8 P!@# & , 8 P!@# &
=, 8 P!@# & , 8 P!@# & , 8 P!@# & , __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g752656g07h45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g07h45.jpg
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M Q$!_\0 %@ ! 0$                 " <)_\0 '1   @,! 0$! 0
M    !08$!P@# @$)%O_$ !<!  ,!                   ! @/_Q  F$0 !
M P($!@,            ! !$A05$B,6%Q A*!D:&QT>'P_]H # ,!  (1 Q$
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&?.GE?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g752656g10m39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g10m39.jpg
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M 1$  A$! Q$!_\0 'P !  (" @,! 0            8'!0@$"0(#"@$+_\0
M1Q   @(" @$ !@@!"@0$!04 ! 4#!@('  $($1(3%!58"187&!F8UMB7(2(W
M.%56=Y6VUR0E=K@*(S&W)T%1<7@R,S1"@?_$ !T! 0 !!0$! 0
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MU:^K-5"UULXW7E7@,<S;?LMOLYIUJI&F%KB%?7ZO:S(:/T2:SGQ('Q0.>\T
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M:@R?)$2FDBS*525M1T%K+M"UDRJ4CH)9:BBJTZ:#SJTZ163CZ7Z^&OV*9FZ
MT6QJQ=&8:;U<?2SUPB@^IF4*KE5PU2 ^+M(*LM-.KS7DK0K,P.L0@,P^8H[P
MTIM#%@>1+/D35^^Z]S/16E77=D^,:EUPUZN,<\-LQ94NO'1V2,O-#(;T[C)7
MRQL^V$E6J^;'(O&7)AE6:[V;E/\  U?NI0JUK6F_$7:\4MWK^G--6G)3?KZ#
M,]GUA7\&(.QZAM^<_8.<N;5 ,QBLBS=M'F=MV.>'1,]W1_6#$H@[K$^0IXMZ
M.K3AZ%Z[WJSQ ULE1%7;4VF$RXAG5Z;3UOV95]DR;/ +<9L>FU*E5E2@/=O7
M:Z[0,]A5VOUE6<Q L K.XKPX3!#641./OT\.*Y5*UCXH[&/GOE4U%JQD_JK4
MFI%.S]3K4EMK+M0O=C%I28K%6EED2,PE>P+&--#- *3@%;7(^7?L6QN$I'U;
MG]_?1NI9_+QE\9'"6-9GH?2;2ND+$2Z)?EKBEFI9D]=IS;7M;!C%[42@R+$F
MO[ ]I*47&/L5=4'36N!80IF)8<Q1J_/KQ]W7'ZT5XTT,FO2AZ2UDC*/L4R])
M,AU<JSDQ>6 1!(=F3,D03>X#M(M=5*=JR:Y#*IS:=4R&17;%.CDA*=7[_I]^
M^_I5NO*53[,VJ;ZQU>OO7=#;E6"D-VZ@!BSI[TY,QKIKJLG%P2DHVIE><-T)
M3!9(,7.E:LU<LN8+ N"8H58,:EX]J;FJI#*ET >X[),DV$J43T\*66Q,M2W=
M5LK&R8$?"Y (V-+V39E^PP)92!RP[R[)N*_#M^<Q92$]^M9AJ-I31B5_<&8%
M'UND>L$"2P.^ER]-"U/L=GG5UI(1*-!A(5DTN%V.C4J8\<XY;#;&I(P_Q!ZQ
MF*)[^_D9:^6"M^#@"NTTT93I[7I5*J&2R!W6J/4TI]%6Z*6XU9,3KYF552T$
M[;Q^DV6*FKRM$.[QUH[MT%=[3 %/)E)A3QZ>/V^U<WQ>\:_'N@U-A-0!:Y;H
M9@;1K)L3]2*Q41%8(YX:2\TN6C)*]7P*V6T/JJ4:_K2E QKPRM(HV<&*Y(A
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MP"\1(KY3%SV><U?>G: FG>Z?+IW>CQ=#]#*O_&_SEN=KSU #M4=6[?[K\6?
MR_T=%3$D"*=IN?R,H_E)>-E+\CG=AR6 5<"N>/#&S*L#3(B5H0+!2+)87)RL
M0N&?@W2I=N?3N._/WFTT]?\ HK+$^DDT9F=5!F]?V'4@;6SUNJP=VP2F*52,
MG8[?<5.C[=RX74J;&.H;/TE:-57'-3 VZ!N;BF2J_C%3M %HY*C=?U^73CZ6
MXMWU>3+RHUHM+H2+/WXJ\W.W46C.-<@L*F3=]86+855<VM$)LQ/A9?0@QP@1
ME+3,PB&V7Q'.+(*,U?U.?"4:/[]2I*J?2$:]O>.N)TVLMR+*ULVN^,+J&]L
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M1-[CMNIMN(!=>,K^B>E804)]G/8:+XV5;RU^"*@:[>69IA#S2=L :B&R0C*
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MY_% 1S9G;/-TN",'76'WGU7PC+&$?&(HUU4ZATGJ<9Z@L@E"KP+2KB5P%!V
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M:D2,)DA-H$#(@BB)O2:)='COQ:<'VOU<L>IM<4=7:%Z]390:NF'L"Q49\06
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M=!)Y%?LY4'?6(KL!@&4L99R2>XM!!IA35G63=P=3&X+L^9'MV+QJ<:4FC(4
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M26NZ,<)3F^ZSR?2,6>3Z19W?1N#,[OP92T7D^D6>3OS,S.[\&U?@W'@W'Q*
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MN1%*&KU(C3GV%TX5J$*M<6W9.V9XH*E>I &D-.9FL298A!5X8<4I11DTV \
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MU)J6P>)@MOTU&OPU>LH'BMLYS>0'M]74L(YLDJ?E76>VU5]6  !S6F8)-OC
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M"Z>^G#/F"DU^*AC-;A1]O"9MY;=HU51A@B+PX12Y!J_7UY#HAE\/C5]]-V6
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M(WE2AM%J?6>_/L-I!!,1K!<?EVO@B*(UT=6YDK8J=;.;UGXJC$37\+;VWJ0
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M@A8="XY>]LEY/M9V1</9.#C]I)?)BW<?(BOY>F3:*V.MRE>=FU6Q.8O!#7<
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M<B^"[+3/7JV<A4Q=B_F]J<%0^-Q6\=6L7-EL96R93$MV!L*M4R4;@*E&V;0
M[4YO?G3J#G::X*Q:0+7&R+5=CDJQ2P8E[8,R T%X&RKZ6QA-0)A_3AD$0 \$
MQCSRR[[SDCF[P]8?V$\W48_(!R,;!*VY.N(@8@LB+ H;8CTJEX5@$H:LXIAM
MB:+N_&49/'6&Y.7#9?#V<-*H"XQ!7# LSLTC@+7L8X]3)Y#%6*5D9=)1L"LX
MX\IQ9M(QG!I.Q>4&.4<V"U"_.^NN_P#UZZ[_ /OQHS\[:HOWT==?^G7H]/\
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M[$ZQ@2')V>WBMN,IB,*+9\-3&V<4UC.GMU;@K989.&T%/#4[E6_ =T(YA!+
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M8,7Y,<R3830'N#AI,YM#E-HR8\^7-&S9QV+K8@=IX-&Q8JU"'G7G<(W&S:A
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M_2Z[[[]A_+VW[_E:=]_RG]__ ,OVO,CL"C]3J<]A_P#AP\]O_BG_ +'/9_\
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D6<9(E;!XFO-X&M/!YAH5QR>#RI1D\7E%WB[QB[MIJS/P7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g752656g13m51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g13m51.jpg
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M86=E<R!H879E(&$@<F5S;VQU=&EO;B!B96QO=R R-C4N)B-X03LF(WA!.^*
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M5W%+!N$J-4@3#Y$*OFA]N),J8H< =<44@5, J)MVP&!(D_J%QT?_ $W9_O\
MC>UZVNTSQBZV7) T$DC(N=$E^XL#/\N[MO\ ^KM=:K__ )18?+UE>8;:#/.]
MDW![FK,H/=10<II4CQ!^?Z'%%=QZU1Y_Y+9! H<_"!> X?UT,PH7-<- ;O\
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MB:(FB)HB_!,!0$3"  'F(CP :(N"I*1J13&._9E O4 _XRCR(D#DQ0 #\B8
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M:P,Y&6//R7RCMZ%+8NHK<8]=[$S2SYR^%TU4.V>(@GPV1*55,Q#](>"8XE[
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M)T@DH(=P+P&BN,21'MS6*OU!J64:O*T^WQ3>4AY9JJW71<)$.9,5"&("Z!C
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M6[9J@0 (DB0.VILZF=)QC[>G#)7;,0W#EIB,LO%2P^VXXF?L/4%:G$@CT]/
M,T../+R\/C_9K7!9VCKUU\YJ)C[+L?PTJ-DH*\C0;2D40;6&H/%H*2*'/7X+
M@[$R23YF8X *K%^DZ9K\=*R"A1XU( RP\.N/4!7:.^#GGNG3K=A"Y5DS/E'
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M6\7#LC**"V:(&'DH*J*N5U#*N'2R[E91022KPE3<"Y555 OQ&,("3]40'L4
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M.)PC$P=^0A:Q!PC',#WW1GE/GBJPY!<Q1HQ:N56,,QCEU"*/WBQ"IKO_  3
M=)$"%$13;%4 J@B<PF4,4H=)  0-('AE$Y'.3P]=,5L3&/IU\*L[^K"8Q@,D
M;OSS\(\?/^WG_P!>>I!WA39(Q!B?MAX>G 0N(RIA3K%_1"/?MP7@ [^7<.?_
M %^W3'K/R_@H02<\/68(GU5HL4X^4*_8G4:J)IF52$#*)&(0P=0" %$Q0 W4
M(=N.0'Y=M![\^766:IP!SP'@3Y^6*_H1^C-QV[QMLPP_%R")F[^=8RMP<(G(
M)#D2LDL[>QHG >_4I$>SU0Y ! IRE$.2CKN,N?OY+B[.#N 'HKZ:JB:(H:N6
M!,97BWPV0)6!]4O$$F*#&UPKQY"S1V8B)O9\BZCG#<)B-(<141CI<CYDW4,H
ML@@FL?Q (I)90ZK)$C8L@NX0(0I *Z3(JH;@>!$YP$A1Y+V#A,.!^(>0^'1%
MPG"9HQ1-0YD$2KKF2*8G7X1Q$ICE Y!#A)0Y0,'(F%,#%#XA,<":(N09L66:
MK,WJ!116)TJ%'R.'F4Y#<@(" @!BG*/)3  AP(=R==;EB7B;N$9*>*1Q(,T0
M$4SH@*SU(A2@'2H@7J4<_+](@ G$ $3) /)C$45/[[57?6DG.,F#U$WQ-9%3
MU13D!$! R:OQ)F#@0X.4//C]FK)RP\Q..&/7NJ"1I'%H/O/LN.6Z,I0@QT9.
M-#.!3Z#K,A%^Y$3]N&[=N!E3'#_E"4I"_KG,4@<Z$RIO_@1UUPS<)%(Q38BA
MUG"AD$E@0,\5(=<AW0^(\?N# (E%XZ, %-TCX3=N0K9'MXAE77'J?PLSG&?+
M+=X^@E0?F"]5V!A)!!F\;NI9=%5,$6JI'3\YS%-\":29NH#\_P"<J*12^9CE
M*7D*W^X=;E1U/7SA"KOZ.%)M[T=QKATJW6G'3;';DZ("FX=1$6 VQNS9*.BE
MY+ZTJFX?+IE,!%'1E%  P%()=/R\QIH?/P\^"J[<=<T31$T1-$5=\VYF;4F5
MI^-(!\W#)&2'"Z<6F($7/7*RRX+-W!VW,!R"5H)TV$,BX+X3Z8<)B*:[1C($
M*)CKK\G!::V=V ]>"ERIP,9 0[-C&D,#=!+K4<+G,LY=N%1%1P\=N%!,HX<N
M5S*+N%E#&.HJ<QCB(B.BSF9Z\N'PO;8+3#5R.>2TQ(M(N*CT3+O9!XL5!N@D
M40#DQS"'ZQA*1,I>5%5#%33*8YBE'6R8G+Q6@TGAP/77F%$KC.K-JS]L%QYE
M5Q7#* 4D\C4O"340'G_'0K[R1;7(&GS*HI62&4+PHDF=,0/ILG\P8^</!4LC
M#:;.DGE,1/A\3)-:R!6[8P0DH*2;R#-<I# 8G6BX1,<H'\%VS<$1=LG)2F*)
MVSMNBNGU!UIAV#39T(/"?E9(C _RMJ4%E((*MG*2+ENX3.BL@N0BR*R2I1(H
MDJF<!*<BA!$AR'*)3%$2F 0$0UE14D@Z@_VM9IA8^HN#_P"#WFB:<1SVH*G,
MHWQADZ2$RT5+UT3B)FE;MSH@Q$E&$'U9O+.H]XD5$WK1W,]CZ?S[^.&O[@3_
M *AZC\>RO3JK*:(HYS!1QR7BG(^/2+%;J76DV:L(KF$ (DO-1#M@@HIR!@\,
MBRQ!4[#\ &_MT0+^:ODG:7?L!9VG6<E!.X.RU:PR$?(,713IE'P7!VSAL?N*
M;ELX1 W0ND=1%9,R;A%0P"173KKKTP5W_'V&'JI=M[F'K5-?W"?,9K&QS,'#
MHI@ RHJ#TE(S3#@H*+JK&!),.0#D?$'X"&U"0,RH.CHJ6U;<91K;-'8#7'K%
M$5O#3<'>$.<P"/ZPD(D4G[0 HB/?CD>!T!!,8<^77\JGCOX1GOZ_"MW%U2,>
M,4):/#UAJL!?/GK2$>>GJZNPE'R 0X[@("'EJJ9+<XZO@3I*5/@.0X* >8=A
M^KR^OSX^L-$6^,(Q%L4%%1 . YZ>.W;O_P!0=N_EHBGG!+R@R^5L=U6\.W3>
MKSEQ@8ZQFCA+ZZE".I%NE(*(G-U D<Z G235$@BF8PG(!C% -%=_/\+[JH&)
MB(*#AX6 :-F$'$QC&.AV3,A4VK6,9MDT&2#<A0 "HI-TTRD /\T $>1'G119
M;1$T1-$31$T1-$31$T1-$72UZ2V*DVN<-O5KFVKI/'3:-LT*$T=-4T5'VZ5D
M(A46KUP0#(MUY.+9-@CRKB0SCU!X5'J%,P%VUP&?'UV?A%<+#-2,:M1<O!NT
MG;([9,P>"<%"@ % >0,41Y "F ._</+^S)S*==;E9^,, @DFY[#V 1'S >>!
M'R'GO_\ <=3KKD@XYX[^/GNCF,@MQ30 OPE* CQSY@/;S^OCRXT1:%&-11R#
M;'*X_&YCZ^1F!@[%:MF[H! H^0%%XJZZN [F[B(ZRX$Q WYX2/#K<G7KUY+9
M7YBB4I>?/GZ_J'^>CA/(CSP(]D,QAQCQ6#(H(F$@B(?/D/\ 9Y>0?^/]NO,&
M5,MG?P./',;_ $U6,L&YC=C'Y.(WY1O 7F*?48!$?(0_ZOV?MX^7]WU^BB"Q
MK@1!=Q\=.!62PDL,8@R<>,Z^>]8278$"2K;LB@BLE+]8% #< !8]X)C\B =@
M*7D1[!V$-;755SRCE.V1=F1BH$R9DQ< 585$?$*5,#<'XXX[\ (@/(\>7'EJ
M@$X#KQ3/K[*JFYS=] 42M/&#R<:%D3L#$.S:>$==144A+T=)>3$$QBB7DW _
MV!KHT0/J^VD;L<!R" =$_E:!Z-W:-8+;<$=Y.9F4C%R#EQ).,04]\F=NY9L9
M!N[CU+E,HK$*LDL\9KKH0#$Z9 *S5-+&,<';($LN,^?MN]-#KJ47>KK")HBI
MO@1=6/-DV,?=17:F6LG)O%!*!?$6&[33I!<2A^J5RV<(K)AV#PE"<!QQK(S/
M7^IW76&G;LL@-TY#SZYV;;LA.4!Z@$ ^0#]8=OV_^N?JU3PZ]XY+((!&_AUD
MJLY:K2\A+6J!'QBN)=-C8XT1!0R;ED6+90CU%N<0Z?%8NXSQW:*?5X24BT65
MZ?6 YZV6KW3X) (,SXC'3=_. 6JK.]:#'TF1&0D>9SP,P=ZZN)[9NN]N?TK<
MH*^(V6,L10!'I3(!^3&,8!X+P =Q,   !R/UZ_34[R;W1:3,CUX[]^6[T/@>
MQX^D")..1$>?@-^)P789MTKGK2C%@Q'UN @'35S+S =9V*CV+6*[81,<X /!
M>O"2*+=R_40,JBQ1;F16,5RX1*3X5LM#:KCE)G?YCYCVE=Z5-S03YG3'A.&/
M@KF*^(N=8B!.OOP02' 1$?KX[#P'8?GVUXEUU_CU428[@S/MP&2K*[.9PK4J
M76*6U< /)"O;.\7M%D:G'_.42;1%/.'<!*501$.%"Z@\9\]^_#AN6LA$1\ 8
M?=68!! %C. 12!P8@)F7!,@+&3*/)2&5XZQ( ]P*)ND!\@T@3,"<IW\U%[=5
M$T1-$5=]T.'&V:\33M9!),TPR3/+02B@E('KK9(X*-A4-P!$WC<5$AY$I05!
M YA ":CA(XC$=>BTTP?' KXL<P046TM$RP8+IN"LGSELHLD(&1.JBJ8AP1,'
M(*$*<!*"A?@-W$HF*(".,29&<<YW9@@B8$G&-T+3@#)X[YP\(D&3PPDSBJU2
MT.(]93$YYZNPASS_ ##S\NX=OEK)'IF>6[<>!.)E0.C#B-_WY<(\5%$S32.!
M,)"  B(]O[?[>//R[_MY'ZH1&6(\( ^/XP6@9.AX8SGSB,QCN"T-?'ZICCPE
MQW'R\A_LX ?V_P"O4GQ\OM)'OJM2>'J,?6/GQ6]4_'3*/0D)Y^T37-'%3*S1
M4*!T_6E0.8%E"#V-X1$_@*8! 3' W BF4=:!W[MV.OE!XX:;L%DDX >>!&/C
MAF<![JAF>[U?CRJH1TI(,DTE3>&1FJHAT=!N2] I"42CQY"'!AX\^>=9/AUZ
M+0TZ^_NOM._W-1O2S#N#P#D'".:9J2M<EA!Q!+4&S3*YW<R:B3*:S(E;?O5.
M5GR%=D&/$2NY46<I,) L>"GJ;!FDCU82<#ZY\9_/V7-P&8ZTZ\%]-.MK":(F
MB)HBT2_%F_9C12$BQF#HO.MRR2.F1WX/@J$!=IXYTT5%$C&Z3I&.0QTE#BF8
MQB>"J1:=#+Y0[<0*;-MT%,4LF_: J'(C\!4VRCDQ# 7XC%4\, Y H<G#IT3)
M<]_=)>!42):HI9@V6,DB$B02NHP%7'!2$.Y2  0$5!*F'K )?$<H!SSHBURP
M.JG(BDX?M8E^HCU> J\9M'2J76'!O"47(<R8'+P4>C@#!QR(@'&GEU[*8S_'
M\]'@M.=V^ A43)LP8LD0*)C%;IMD"CP CW!(I2C]?S^OG1($\?$Y>$K3$9&\
MY12>MZ&P!>/;J&:NYJ0> SC07(7E1LW6$JBCI8O)1/ZLBJ5,!*"AR&$I1Z_2
M&@PWK/(%7#<.NI775NY<;CL3QZT36<)WBZ6"=!5",G*;792W0:(G_1G<.WL,
MT<J-3%,<@D;/4FJZGZP)^&50R8;.8Q\!U$;LIXE%:GT5.WC).'<37:[YKB)"
M%RMEZW$GI6.ECI^U(^N1;+U2NLI!%%54C1QUNI5\+ PE59D>)(N$TUTS))8=
M'COG/A&HB-2B[4-91-$4';DMP^,MJ.$;]N S!(OXV@8[C6;R5]D1YY:<E9"8
MEXZN5JM5Z+(HC[1L5JL\Q#UN!9J.&C9>6E69'CUDT%=VB5 DP%7'<EOQ+M0Q
MI8LHYAVZ9F:5RM-\3+O75:=XUGF#EWF')L!BB$KC"5/>HYDK:ZM:+1 FO,6Y
M,TCV46_"3J4U=&:#A9,@&T8''T$KJ0/Z0[""V]G.-ZRNO)U:<HN<J-M/B*[:
MI&M0$%3U9&GWNT4Z;GL@/9LU*B*3D)WCZ_JP$^,LLX>V9VQKJ\8U>KJ>KY@D
MXY9>7KF?# >1ZQ#,-XF?/$CP&GCO7=Q6MU&,I_#>.<T6*3-A>DY&J=4L\2RS
M6XBL;V"%-;:^E86-<M;.;DR-(FV,61ETY.%3D'8MW#!\"*SE!N9P/1D?W$@<
M#G[Y\^:P&1G@/?EY\5#=?W&86ON<YJK26<,1O9V"DF,#C'#Y,BTY6WSTL%3<
MW.1NB%/"6^D$RX=0;69>5U1%@Z;)5:NR=DC!!HM(O-:#PYX Q'A_JQRWF.6_
MBI6>6,EH..)($ 3@,8P]-#."C";WN0=KN.X6I4.@9#RY_@P#&Q^4F]")6RNW
M5LEJT6V%H%"8ST]#C<[C#U]Q&R-DCRK13-F$Q'PT._L-K]>KC/C6G:V2<-^)
MS\O33S7C-9S7,ES6BI.R73D#LR2&_2TG '@28$$P-"^DBQ9 WRU_2"F9"I]'
MQ;NS:[);ID239TU2LPU^L;*OO:V_E A+8]GPHLM-6ZJ,(VTN( YH25EUT9EG
M7H9:0D"^<ATX$9!P&,X&()\9)S\5ZP"Y@,SM-#P,?#'PQG'=OP5ZZ=N\H]MW
M)92VQ0:$ZZMV(L?4G(5FLAF:*=0<H7:TWJHMX*$DA<^L2TQ S&/YMI9%&S,8
MN,D2*09I!2=C)N.C.X=@"<^&_P!@,]^&\;EH,) (.<Y\.:HMN1](<6Y61]AF
M(P%FBN9(QW7L!YBLJ4T;'0DKE<RG=9*-JKY\WB;W)282$.^J;QW;(INR6?UY
MB=-91-=5O)(,='*??#SQ&'QY*M$8R#,@9[HG=!&/6*[DI?-6'Z[.C5+-E3&]
M;MI*^ZM3BJ3UYK$19&M;81$A/R,\XA)"4;R2,+'PD1+R[V54:E8M8N*DI!=<
MC1@Z62JYP=%2+<GZ4G;]MP<6,7$99\M0M<VV9'W.*VC#\GCZTUV0J>)\NX\P
MW>:M'R;BZQB*EUBK)DB)<^SE12C?5HR<9NI9I,LDHUR.&*ULF)RQ#<=3)^R[
M*P[]]%E5YS+M2V_9_6;O,K8S@+/)M2$20F3$7CYHJ*9NHC<\I&K-':[<H\@"
M+A55,H"(%* #HG64^ZZ$O3E[%<8T[9!$(8,QA%5UO'9+C%[5)L$',C,>H+04
MT@Q!S*/E'CU"//(^$*Q"K),U7H1X*D,LFQ\/F\$Q )\-W706VG/GIAF<N(&'
MIFOBUHN$92,FB@+5;Q"+E .4C$#X3  ^8!S]8ASQ_M'48#)D<P=>HWB)E4XQ
MB-)GCC@#E!\8&*[@<(8YGY6"5C8Z&E)@Z#%,5$HV/=R"J1@5(/6)&R*PE*4P
M](F$/\_@3<B ZZK $_ TZU67R<I[G%X9G<H.3KSB9;&>,R34<_CG+MJ*AT2+
M,VSE%%9RD<Y#E*LDDJF8Z2A"GZR& "O@.>_[<A.6]1E=9FQ+I,RU5@H*$HS3
M<)/WI%$R($6$Z9BD0^!150AB")1,5,O @)@$.0T4PG0=<.O56UV [7;_ )IS
M73(IDQ?OTR3C"9LTVN"@-F$<R62</'*[@"^&@F1(JA$$B@!3*"1)-,3&(42#
M7*/?</YXZ+[M6C8C-HU9I<BFU;HMDQ-YB1!,J1.?V])0Y_;HHN1HB:(FB)HB
M:(FB)HB:(FB+5;M1ZED:LRM.O$!&V:LS;8S62B)5N5PU<)F[E, #P=%=$X%6
M;.FYTG+5<B:[=9)9,ARD56L4[;[O@FS/V=!O0SN)WG"D;4;D9R[L%6. \"RC
M[.4RIIJ(!/A-JE,LQEVY2\.9F0YY(16G.Q.Y3ZG,>=LX2#D%&ZB:@&'PNH3$
M*0QA-\0^&)1*!CF*/!1(("8A /4+S;/#MPZ%O$$"E^$XI&(H4H<\ JF<"G((
M@';DH%'N #\M$7 E8T[Y9K*QIRDD&G4F8RG().F:I@.HV6[]A P>*BH(<IJ=
M0#\"A@ B];AZW43#QQ!JX('"R"P@FHF(<_%P80 2&["!TS&((<B4XZ)NX]3]
MEJS]Z9HNDH0IE$5/@ R0"H0WSX,).0Y[\AW*/'/'UZU]/_++AR^ZT-C>'3J-
MF/GV7 F)]Z#55&$;$6?"3@%W*A46303<<JN%3#P!2 // <F$0X HCK)X9+/7
M77A*\F82"B1'3Q8%5D6@-& " D*?J*4'D@=/CDAW2@ #=(PF.BT*43@5598A
M'7CE\J$Y?.0Q,^A56<^.XZHU>8D$UT"2RS90H/%3=FOB%Z3&(80$15X$"ID(
M!E#'X*0IC<!K;,_)51-L$VWXFO%9<[@<ATEI:\HN[G9V;!W:U#S3*K1L5)BE
M!(0<"\ZXF,?$BBL':LH#565%XY<&(\23 B9*YQ&6!Q,C.)@>!P]B$7;2FDDB
M4"))II$#@ *F0I"@ !P  4H '8   [=@#C7-%[-$31%7M]#H4K)DL]=%1;5;
M)QV+AN^-\"47D%DW]27:NE!X3;I6:-09*L3"/2M*-)%,X@NZ:D7F_P ??^/9
M7, [VX>1^"I2:KK-3 11,W;X3EX'GM\R\=A\N0'N''E\^:IUT%RI&*C9E%$S
MUFFX% _CMCJ%$J[5;I,05FJY>E=JOT&,3Q6ZB:@E,8G5TF, P@'&,>7LH'O:
M2W_2<-1PG,;^9G1:%*4"HR(BE*1BLDW$>5&4A+33V-<!R ]#R+<OU8]ZGU
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M*N#N#*= )D3*U$PF,;@  0'D1#CSUB/MB</GYX+<G#"<YC[3NPY$+ZU?0R[
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MR/4YVCW:%96&K66/7C)F(D$@5;.VBY>#!\C)+)&Z5F[A(Q%VRZ::Z*A%4R&
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MN"&0]7OZVQ5=O5=Q56C"?KN<B[:57ZT5>BMD_P!(ZEL/SP/Q1346^ABBI@2
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MXW]<5V/M6K9DV09LT$6K1JBFW;-FZ9$4&Z") 321123 I$TTR%*0A"% I2@
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M*\CP>,B,6(,']=\!&<E_6GQ@6;K,BTTP1@#EFL+L,VWW+;K@O'4)>LNYRO\
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M"/B$\42)>#XAP3YZQ*GZPAUFZ>">.CU"'B$ZB+VZ(FB)HB:(M%R1_P 4'O\
MTE6O^T\/JC/R/L5#EYCW"WK4531$T1-$58-Z%1LE[VO9BJ=0AWE@LDQ6FZ45
M#1R8*OGZS>;BGJJ+5(1**JP-FRRA$BB)U!)T)E,<Q2B15RQCB/)$+NDV\VN4
MJ4HTK=5V8U^D6":4(D+"+MK%-DU=5]PN10P!)IJCSZN7J$Z13K$$R29SE@P
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M[A;UJ*IHB:(FB)HB:(J2[J\\9ZP)-5>UTS$\=D3#+>,66R"];&D366+?@[6
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M5G/''#'['GOTC' K96NVG.3/+ZMM/43O8H/2$5K<2$DI>(5R[<XWB/1B5W:
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MO7XNG_S#2!H.023J>93WH9,^\2]?BZ?_ ##2!H.023J>93WH9,^\2]?BZ?\
MS#2!H.023J>93WH9,^\2]?BZ?_,-(&@Y!).IYE/>ADS[Q+U^+I_\PT@:#D$D
MZGF4]Z&3/O$O7XNG_P PT@:#D$DZGF4]Z&3/O$O7XNG_ ,PT@:#D$DZGF4]Z
M&3/O$O7XNG_S#2!H.023J>93WH9,^\2]?BZ?_,-(&@Y!).IYE/>ADS[Q+U^+
MI_\ ,-(&@Y!).IYE/>ADS[Q+U^+I_P#,-(&@Y!).IYE/>ADS[Q+U^+I_\PT@
M:#D$DZGF4]Z&3/O$O7XNG_S#2!H.023J>93WH9,^\2]?BZ?_ ##2!H.023J>
M93WH9,^\2]?BZ?\ S#2!H.023J>93WH9,^\2]?BZ?_,-(&@Y!).IYE/>ADS[
MQ+U^+I_\PT@:#D$DZGF4]Z&3/O$O7XNG_P PT@:#D$DZGF4]Z&3/O$O7XNG_
M ,PT@:#D$DZGF4]Z&3/O$O7XNG_S#2!H.023J>93WH9,^\2]?BZ?_,-(&@Y!
M).IYE/>ADS[Q+U^+I_\ ,-(&@Y!).IYE<J,R'?Y*=JK"1O-P?L7=SI2#ID]L
MTTZ:.43VN& Z+ALN]4162.'8R:A#$,'80'4($' 9'=P5!,C$YC?Q7<9KBNR:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
;HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g752656g13o50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g13o50.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1K:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #X< 5H  QLE1QP"   " (8< E  #D1R;W)Y+"!*87-O;B!,' (% !=0
M;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0      $"0G)&TIW=_/TK*4
MB8+' E$X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q 9T#5          IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ /      0 " \     !  (X0DE-!"8
M  X             /X   #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M              )O   $E0         !                          $
M            !)4   )O                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   )O     %)G:'1L;VYG   $E0    9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M;P    !29VAT;&]N9P  !)4    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M    3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N
M9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L
M;VYG       X0DE-!"@       P    "/_         X0DE-!!$       $!
M #A"24T$%       !     8X0DE-! P     $&H    !    H    %4   '@
M  "?8   $$X &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_
MVP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4
M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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ML8YSZV^I^Z_]%ZFS_1?I/H>IZ9J^OBS*Q<=N#EM&6W<++*BQK!-K8LW?1?\
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MV3A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !#
M %, -@    $ .$))300B      %*34T *@    @ " $2  ,    !  $   $:
M  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M?@$R  (    4    G $[  (    /    L(=I  0    !    P    .P '&*D
M   G$  <8J0  "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.3HP-SHQ,R P-#HS.3HU-0!$<F]R>2P@2F%S;VX@3     .@ 0 #     ?__
M  "@ @ $     0  !)6@ P $     0   F\         !@$#  ,    !  8
M  $:  4    !   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !
M   !2@("  0    !              !(     0   $@    !.$))30/]
M   (          #_X0%,34T *@    @ " $2  ,    !      $:  4    !
M    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (
M   4    G $[  (    /    L(=I  0    !    P    .P   /      0
M \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHQ
M,R P-#HS.3HU-0!$<F]R>2P@2F%S;VX@3     .@ 0 #     ?__  "@ @ $
M     0  !)6@ P $     0   F\         !@$#  ,    !  8   $:  4
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M)ZI;6&+ERO$151E!=)K*CJ'YA (@+@$FPN;W-^6OG:V_+16)S5!F.^5C1?\
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M3/RN7O7(/?5[EH4&X%H2X,@L";8BZMMK<&<99,W(6&M[BW,E6!O)*X\\-;0
M[#)"XN9;J;N(YWUL!>Z^9NSGX/C?GA#?XXSD\QHSK4/==SFY>^9TO]H/MINE
M$G,(Y/L=EL=4AL,V6.0DMW+.\/W+ROHRR%W/7:VS:1WH"AG$4V9L"ZTS@(69
M@6N+96D. :;F6]R-/6MF!.X[WTKFM2+ROR]YH,):1F.T-G"^VE\IM?70ZK[(
M;A=@T-G;<YBO<TEE"[4*5IN*[I@K(%,A8:MS-<R_AJ^R;6:L-%GCSD<]DZV1
MV]:B16<KR[:7]#<JH-7#-< =EYWQ1NAKJ5[26XE RF+F[1.CFCJ&O) (#;Q%
MM[M%W#4FU]3(2V$V[U-(9H][YBPQD"_,M.FFPZ'32VUWX*6%V[Y.P5?+-N%R
MYG&$VHT*ZXRVJ46[P5&A8O#M-OS>-B9Y-[+5."CY>^SY:Y$15:8S4^X2(UA6
M1$PCSN0!T38SR!M7(6!U141TU.Z2SLW84\D=FMMH+VS'0D-OMJL!&"6M=ZKI
MS4Z7 #^RF99XS6U[3P[UK6V,1<G?!)9=W2[T?A K#E;*.3\.;4=PLQM2%:J4
M)SC>48[D*OBJHE-:8&?,[;35WQZI 6F)CV"$ND6 <2T?*RB2#678JIN6>=(
MRG<'@A\6+U-9&T@CZ!;'(!IFS=HX W(L#IS6D[BZHA>&@M;A]/"YXWS![BYA
ML;=T!I/=OKJ5-NW?!6XFM.&M[V%5;SD5A7=\N8&N9+J^8(U\LE1IAFTQXT1A
MJ:!X=5H$3X6.(TP^NFTBZXD7:8. ,DV\+,PB5E'')_Z#6FNB=:Q[5SS(3YYB
M-K6L+[+7.6,F<RQ<^&2.U]P]A:=+"]R=!S(N0!OK#)?P.U*R3?<I**9URU ;
M><^Y;Q[GC/>VF.@Z,K6,CY-QV-55:/$KN^@%[K5("S/*=!/KE7X9\8)APS_L
M.0BTE3)&V!R"G#1<T]:ZLB);?(Z7,UPN,M[9W$WN<M]B5B&?G2X6:7TL4;G7
MM<M>PD&Y(O8; "W/HIW;7=J=8VK_ (?BU.=LUB#<)N5RCN:L?QB28!ZDM.40
M@2RT%##&LF90@(\8- 8XKWTJ1,5145W3@0*">>9[A""T@1PU8U!W=4]HT'GF
M<'$@<P"05H"&BV[M#>UQ>QOMMTWW/10RR'\$!BV\1^3WT1E[+N/\G7#>@_WT
MX]RS5B5?XS8=S-(5R.K*S6M,9"#=1,W3'$4Q.UE*_9F\AZV0=G1>.B^CI&"8
MW/C93EH==CSFT-\I#MQR&VXY\]E$GYUCHGD92/9<:C6_4:'>]MEOO:+L-2VY
MY.RGG_)F;LC[G-R68XBI5.W9@R-$U2MA&46D&?+U^C4BF4J(BJY4:TC(2+R6
MD$&A7+F6EE"OGKHZJ*8*:@VS6^EZWCY_'UJA[^7-?\UZEQ[+#W[]/-?1#12F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HBMZR=_G%[>?S@[=N>_?MV[_5HB=9.1#K+R'F'4'(?6'.B()B
MAYF*'M[B'E[]$777>MFZC=)9P@DHZ6!NV344*0[A<2*+"DB!C *J@((+JB0@
M&,!$5#B'20P@\>751< @$@$["^I\NJ[/47WA]H:BXZCWA2G47WA]H:7'4>\(
MG44/,P?:&EQU'O16^(GW#Q"<AQS\XO;GRY[]N?9[]6L=-#KMIOY*+C74:;ZC
M2^U^ET\1/O\ /)V$0'YQ>PAW$![^8!W$-1MOYJ1K<C4#<C6WGT5^B)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HBH)BE_&$ ^L0#R\_/2_+FBIU%_*+]H:(J]1?+
MD.>W;D/;Y?;P/'U:(J=9?RB]PY#N'< YY'S\@X'[!]VB*O47\H/M#W\?M[?7
MVT14ZB_E%^T/H#]H@'YP]X:(J\AY\AQ[]$3J#WA[O,-$5 .0?(Y1Y[AP8!Y
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MYHD:WUBPN:'6MF&I7N</5^$T.(EV-X,[&:%T1:Z".I-%,YMVN<(JL1S&FD<
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M=2-2#^.AOLMT?(ZOH]_EO[N@Y[\?&+%P<<^SC\%6O5_*NE('_D5PH1N+TN+
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M"JB*H$$03-QZ-)6TF(0!U)6-EVS%A!D9>Q&;N@$[@:_J^1X@X?X@P&NJ1C6
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M1C+Q,O6%@94-NZ:1]"]=I3"K=LRO[]Q8CN'U;GHR.0IZ5C6,_B7Y'Y(]! 7
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M!RH80* @(EX)[.H1]@PWY(^'GO>UN,\#Y0+L;\YX@^9AD9V3G'MH',(/T;L
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MLP]D2SX/89.A+!)3+C*:D'CM["OY*."'E#PLG>I@ZIX^4B5$$)6$HKF"*_:
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MTL+<M4#]721ETK"W+D=#V;6NVN'$=XWYC<<SK;LLY BKM1N+@RIRF#YH%.)
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M'E8UG(Q<NV=,Y2/>HE79R#-\B=N\:NT%"G370=(*'1714*9-1,YB&*(#QJ'
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M)HB:(FB)HB:(O)FH&'L<>XBIV.:RL:Z*0KEB]3!9LN5-0BQ"JI&^:<I52$.
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M=??P!\#[B%ZVK(FB((<]AT(OH431$T11?W##Q>MI \\<;D%!Y[=O]83.G?N
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M;GO\C[5/^C)I^4%!_4SAC]/Q1_XA3LYOY[)^A@_PD^3UD_\ IL;GO\C[5/\
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M^T0+\NO*_BI-A')(;VC8YUA_9:7'D=P/POLI$HK"J4#=@ 1#CL/D/!N/,?G
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MY1Y !U9IN 2J\[> ^_\ !5U*E-$7&J8Q2@)> Y, "(ASP' CY=N?+57&PO\
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M8$[6-OJ4N[K@-[WU\ES:E%:81 .2AU#R7M] F !'V^0"(_FT_6H)L-KZCZR
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M<Z.E9F;G>ZHFUOE(8 S*+6<>M]0"1L-U]^$E.L #IXX*'^G'';53O;EU6PU
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M>UQ]XC*TV8U:/]72Z54+'H^D2,0^?]3E2[V>CLF=?M<C,+?8=W_S@Z<;W?\
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MIV$QB#+9.T((;ZVI;KN,KN>MEE >U930O_-R21B=TE\V][MR]T&PL;W'0 W
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MYZ%L) Z>KY6)T7NTO:[A3'N1?PMT^C1T)D;\$U1P8-H0?SB[D<4T1RX>U&H
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M.-F?O,9!&YUK9V09\K=+'9Y N3;QNJR 22.D<-ZA]1E&@SO#0?#Z/Q8*&X?
MXX!O6\K<UNTW!PU=R\YR_D3"5^QG65SW"%;T57$>.*[4C,+C'QEF:5G(S-Y9
M*VPM47'V*$?QT8NB4H-S*+.C+12Q>BT\4+2"Z/$*^MS!H +*S)EC -R'1EKB
M7 V-Q8"RN]Q?.9CZO81PAG,%I>7.S"VA#FV%M+>5I*5_X,O9I5\TDW!PF'F+
M3*C;)$_ER+F M>0#PL!D6W1SZ+M]LKM*5MBE*@Y6U,Y)V%C-&U]NC,K&1<OD
ME7+1BLUU;=K'-N27->T':P>YSO,VS;75'"XB L!$;VUU.:^GQ[U3'/P96S'%
M+V!?4?#K**/4\RRV?Z@U5M5[D(RHY4FXF9A)&P5J(D+.YB(9FO'V&=(-;9,$
M:R5:4<O2Q /_  W:=;/#8FYM8XYHKG6[9Q9PL;VY>[JK D/F<#;MNR-AR=$[
M,">O/ROS7E4_X+39;1 OS2L8I=1E<R16;S3K#0T\D97/C5"MY,3.2_1E;QRK
M>#TJGEM'BKB^<52"AG: K*>KEV1#"0<WQ/-/) UX;VF7O9=LIB/*W.(65BYI
ME=+EU>Z5SO\ WF7[+'?KUU6Q+%L"VI6IE*1T[B"O23*8VV16T%^@Z?V90BVW
M&#?FE(?&(%]>@4D;&2*BCUI+E*%F2<]"@374F02S)$9!4 NMV]3!4[;24[&M
M8X]7 YS<6T=;Q5 ;,:W^*7ZWW#]QRZ-]UEK>,^"OV61C_$\A^"Z4E1PJG6PH
M4;8<H9;L5=0=TV;D['4):Q5:;O+^N7*:JLS-2CZNRULC)E_$G<D1:."-6C1!
M'9Q>Z9\I=;.UH<!I=P)[QZW%M[[*SLK@ &V N;$WU(L3[?CHOH<DF)/,0'L
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M9W67,I9GCA,BL?;!A)*NM[-#.WD2Z;H-';P'-6C*V6.Y,4K^U<PG9]K7OY>
M4&_YAVG:P,=&U]@+M<[,1S.YYEQ\=5@N,?@5]NV,IRMJ$REGZYX^Q?7\QUG;
M]B&[72 E:#MZC<[1<G"7Y3&Z36GL)]=Z$++/(:L+W2=MA*W&JJ(MDES' Y(+
M21);+F?3FESEMW" O$CF7\7M!/6PN-%-[%CFW!$PF?KH]P:6BUK6T/EX++;?
M\$5A*=QAM)QS4<N;A<1RNR^O2-(P]EO%][AJWEHM!L5<:U.XU.?L 5%S#O&E
ML@V+%*0>1U>BGK5XQ:O(U5J4JK99(#)*^<D"62C;22.%^^V(6A)&W<!?M8DN
MO=0SN0F( 6-:*LDZ[9CD!TMJ[?72W2QQ&"^!&VG5NB16.8JT9J+7(;;'G#:8
MQ%U<J^]E"8NS]DEYE&YNE)%S3%%'-N83[P6E=FG)%6K6(220E(N8? >24B=L
MDMPUS6-<,/:\6O=M Z8MVL+O;+;;0BZNPM:&79<QU,]0TWYSL#'-/E8$'PU!
M6G]^WP/S;*F';:.WR9DW>79G"FV/;8I%WNZHURM2>$MN67:_DQLUBIJ)I$LM
M 9/F@BCLD[1*1\U4?&,GZ94DFXJJD/);.91>TU7%.]HY&-A: +W]8G77QW*A
M@'HS8'D$Q4\\+'$'4S/SW(!Y 6TMR MSDG\%IM;W$[7\<Y7I&;+$C\2I3(WK
M? ^,G%QA\E6#$]!]2,4)*$L&1J_CC%458'4[9!D)YNR8U4$8)JNDT-*R+I9T
M=+9[8W4T4)%W7E,AY/;))G:-MVD',>=]+ +-O=J'2AI%Q&1<WN8V9.A%CT\-
M0L)3^!<PE%UV4@JGG?<Q3UXK<5*[G<'3$)>*N9]MMR+8W=O?6YIB9.1HS]@%
M3NJ]VFBVZO7%G:D9EN2.1,L@=D5=3(@ML8CE/9& WN?S)<USF"UB+EC>9VU2
M1HD;,UP'YUS77L26EKFNN-1T(TMRZ+;"GP?4#A[8ENCVQ8,EIZTW7/M'W"2$
M]?LJV%%_:LDYNS?5;"REKWD*QLXIDQ([EYF18$>+QD$U9QT<U;I-(X"-@ZLJ
MV%U52MIF.;&&NB=<MS ]E/#-:UQZPB()OZSK@"UEO"]L56^JRGONC<6@ZV9$
M^,B^@^E<:#:QW4.=O'P%V*([ [JK;B,JYZR'D?(VS^G;6;2>7R9%V:-PK2T0
M@;%;J9@1\^IB9(>!4NL6+B,=6%A8UT(INUCT 2:BX(OVS2"26:1K<I?64]9&
M227,DIPW)F-SF-P3IEY7N1=48[(Z%VI[+MQ;;,)[WVVM?>VOEHIWY@^#/V[Y
MUL[RS9)^-\WZQVBVC9=(P!)IFS@'F)[58Z]:W<H<C>'++)7EE,U:(6C)UO+(
ML&A4CF&$66$BQ>7(2^ME)!FKI::>9^MC-2/?)"\#6UG/-_#S(-'"YIR"0('5
M1&OK>DLR$'39HN;<S[+1T/\  E;?K)1,O5#+N:MRF;)W,&+Z#@U_D_(5VI[K
M(=/PQC.WQ=XJN.Z2\BL?1E>CX[XPP[%_/2DK7)F;L#A/TAZ_!<J2B6AN[M'.
M#3+/)'),_7\XZ-P<#;EMOOS5VNREA%^XV1N^_:,<SPM;-?G?P7T5W([;Z5NC
MV]91VUY$?V!A1,MT]]2K,^JKUE&V1M$R!TCK*P[^0C9=@U?$%(G@K.XJ01#O
MXS9;DP#2H89B7 Y27P/U%_WJ=DIT_M!F4=";\@D#W0 9#9P9,R^NTT4D1VML
M'WMX>^"66/@@,47_ "!-9+Q]N%W3;:[/?,=4W%>8U=OV2XJH,\S5*B09:U7%
M;PSE*E/HDL[&!+ZH3LU=+"/BL5%TRD*JL98+/:7NF)-VS5';93>S>[8MM?6Y
M-[^\$JHT;3BW?IX#"'[%VM[G[+&_A8:'Z(X&P5C;;7B+'V#,05Y"JXUQC765
M7J,$@LNY%I&,@,/B.GCDQW#Z2?N5'$A*R+DYG,C)NW;]R<[ARJ<UW$N#1L&V
MM[/C3W*K6Y<W,NYVMSO\>5UN'4*R:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*
MTQ2FXZ@YZ1Y#GW\<?LT4$7MX:H!"E$1 .!'^//[=%*NT14$ 'L( (?3WT1.
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MGD;7T;U.G@I=X4W!U+-S:&>5E-TDVL&+L:Y=AEW"[59*0K&22SJ#5$BC90Q
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MP%U6O@22**QU&QQ<(JH<*% ?%3,0>!#C58*F*IDEBA=G="+OM8CGMK>XMJ"
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MHP,^[<FR3.,9M0:J0TZY71%% J?AJN5,?=;A4J@?/4.H)CFY'J$1Y'BFP;A
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M%]/%("'LUY$;M-[W'CT\>6J].GQC%:2GJZ2DQ&IIJ6M%JVECD>(:\6M:H:'
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M!,E134TKJ<. ,S\K-'EP$X#1C5PLWDA:M5'J22A4G HH&5\-0H@!/2?#ZB
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M"#HX_45LR/F8Z59-)&/<%=,G[=%VS<I?.2<-G! 5072-S\])9,P'3. =)RB
ME$0YXW:YKFAP(L0"#?<&UOM"\.>">FFEIYXGQ3P2/BFC>+.BDC<6/:\7T+7
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M-55'EAE453(2#1VQ4 4B%\1 PI*] E.?\F#^)<-QC#,/Q,4TT-;3/D,\%--
M&]G ZI[6H<7OCAC?$6&,N< XNM9=[JW&L/QG#*3$*W#:JFQ(5@::>EDI3":6
M(2#,Y]5.)"\W%LK2W4W*F0S>H/@.LW,8Q1Z.3B =)N!.7YI@$P&XZ?G<#[2C
MR/.OIXY!,S,P.#'%P8XVLX,>YI+<I<"V[;M-QF:YI7V!:&..5P=F:'9FW+2"
M7-TN.H=?V>"T5D2R[GXJRBTQ7B3#=TJAF+50DS=,ZVO'T[ZQ,*OIK0]>B<$W
MYD#1#^1]&>EL2BSGK4!5FV\,HJ^Q1TV"2Q?NZOKJ>5IL&4U!'4M(UU+W8A3&
M]@WZ&Y<-@":O-LH;:YO<DY;=/HO^K58.E=-\:JR9%=N^W1-,#E\0Q=U%].)2
M"/ F\/Y+*8GX\RDZR@<2\"8 '74ZBX9R/R8OBY?;N@X1"UKCT+AC!+?,-=OT
M5;RM-@(W'GWR2/+\T/?=9ONC>9,C,'69?% RR>0EW](80QH $#RB82E[J\9,
M"S<NZ_9FS$H0KR3!>8=5R41B&OC2AV)Q:AT?/F.Q9EU#7;N/>(ZG?W7]^ZT%
M^>^O[?C]2A-,9+WO8FCY&)GZZUR,M5%&<DS<1,//V^8EFMO:9WEF$=-V2!J5
M-BK(QH,/4* SGOB[3(66FIB:;MB+,EUF"LQH[O2QD:1E_P">Y]S*=@;W.;+I
M>QU-[([6.1H%W.: WD+YFG6W@%GU.RUN#LN*]P4JWH[:G.*?BZXRN-GD!C:U
M5V<O=Z7F,H>K[G$5BTE=+-4;$A7Z[9T*J^C96:]:6M0LJZ<$5;.)/,YR'Z:]
ML.S.:WYBSK@Z>M?+SY;F^ESE/9Z^I'E=SNZ[?/06/OM86UY<4W[-\CEBOQ]@
ME\INY5U;<M,LIT>P8Y]2XOI./H=&Q_@SGJA=@I46F_E955M2?#,A=K$M.$L-
ME6<P[#U(*$3!NUX_B'NV'\8[?9J?UJKK&V4G?6_3V=?;]ZTEB3+F[1:8Q,_F
MG=UR#CK+$SMGC#3[:DQRBM,<36*ZM?,B3,F_BH-DD[QY>7,[88A2<\--*CV*
MK1L4D^,2RJC%=-A&X-<>\YCB.;;-OH3O<VTOO< [JLS<Q;EV%BX;'?7]AMRO
MJI\TJUS=@R1DZ$_!/\1!:-O ;9/482ZOQU/&*#'P[ARN]I-=82:+)LN+AFBW
MM4[X;4ZS=%1))0RH<T#@YDAU]>VMAMMYV'V^ *$=X.Y#->WCL!KX<QITTL8\
M5MYG>298)G+)DO(=>E8''&0KSF-VO2XEG0)X]-<N8>)8SE2/5U)YC-V.4GV5
MD)&P=JC7OQ8I#Z/:(BO($E U)L+GETWZ=?9Y*K0<KP=R06Z@V[P-[^0\=?>=
M0[KLL;PJU>,IQ.% N,I7[5M^H:6,)JN8Y+.QM,RLBOD6W6RU,W#B#D@<J3>/
MJXXC&T3/.9)@SLZ%-B_12/K(07F$/=<<UM=M=SOIKX<]^?):.L0RWT;DCV6^
MW70K%[+N\WA/(;(T9%X8E<?N6;FW,J_9!Q#?K._1GH]W8&D-1V$=!N)9A)2<
MRR:Q5BCLGR!8^KE!VO&RU2:%",?R=Y-K\A>_D>GQ]EE'Q\;K+JONJW72MNBJ
M"UQ-,-59'U#$_&J[8HO7H,#(O;ECJ-D9F2D8^3C&TS&&K5PL\HT0684LS<:@
MN473U(LFLUTC[S;[6;?4V.GASV3X^/8I?169LGA!8 <R&&Y.1E<HU>K2E_68
M-K:Q0QS,R[:&]<-WC!"EV,$"1Z[]Z<4K#,P"B"<>=-R[$2J+)D6F]PV0LR46
M<S"9"Q9*&H*-L#EQVCCC&[:3E(^5L4E>8^W1REC4KMR23BE%HF!E+?9UJ]-K
MU>$6!K&PZ\D_8F=+V]FOQU0[%8O-Y1W%CF/;/ PLO:IRL*5O'T?EF188XLD5
M7[?99,SUO>I-J62QB=-%E&L@BY]Z68L^,B5>/?).(LMPEE'U8BX9HY[GC2W=
M UV!]US;;SY*3;LPWGSMT\_*_+7;3E=?-Q6[VKV*X.H;#T/:ZO$R%K0@(AA1
M+\-BDVL?/Y0KT*N:80D7;%WXJ-+K=E<&CX;^SX^R(,(XI0<1TBYQ8=^TWY<^
M7W[_  %#M[LL-O#E;S/Q=;:VV96R7D/)-M;WI1VTCFN-JY(0\8-:EJ=$R9F^
M4LP59*^Q-7M+0+C74[G U^!7/#6&3>@W(R0=1IA9NDWS_;Z%S^^:#0:>_P _
ML1_[YW!^;\=_C\5-AW!0DBXBWDA#QCYW"NE'\,Y>,6SIQ$OEFCABJ\C%EDCJ
M,7:K)V[:*.6IDEE&SE= QQ264*:47K:(M5YNAG<[B7(,;&0+RSS#BLR1X6OL
M)R3K;F8G&J)G,*P+.P\I"R<:DO)I-2.'+.49JE;F6 %>#"4U'YLAR>MR]_BB
M^8[#:CEZ'MECJ4;:<XJUE?'D:TD+G)7:5?MA5K<-2)9K%X]=GRP,TL^N-TC+
M,TGV$[#Q"C*-?N 0L*; C )'1ELAS^O86'+<7^J_/\"^/C]GN4T]LYLZL8ZY
MUO+\ =@^B9DRT);'LX6>/:74LYDUWITR$?G,E$1;9&&&.33;1'@M7QHA9JM)
M1,A+OX18^S9Y-;;R\6#?9^E3*!]N&X,8DE4JDU75VY2Y-VT>EA)*RUQLR;SK
M*+8$!:HL.@Q%S'(8#D(4BFSHB:(FB)HB:(FB)HB:(FB+#9JF5^PE5;3U=B9U
MDHX%YZ/,,F4FV])ZC\*E:OTET2J%(<Y0."8& #G* _/,(Y3Q1S%G:0LERV N
M!8 ;'4W.N_G<<UU4-=78=*^6@K:VAE>QS34TM7/#-9V\0,3VD0[=V]MA:P6$
MVS$L789NG6Q*.8DM.-RV!Q07BAE$V$*]GH)> <IKLVBK<[R-.S42 [ JR"?\
MBF=,Z:R*)BX3444\U/-=S'4K'B(#7O.%@':^J!R!(!V7J8;Q#B%#38EAY?')
M08^[#X\::YF>IDAI*GTATM//("8YW$N&:^9U[.)"U^K,YPH%#:+7*.JU_MKN
M^U&"62H$'/PD4UK-HML'"RDF+&0E[3)'7K\=(R$X\7,[39&;M# L5(I%#:I+
M)4BFO)%&^=TC0&"P:6=IE!]8CU021O?2UEW1T?"U?BDL6%R8MA.&1T-3,R3$
M)J:HF%?%$^2*,%C8P8YGAG>URYR+@@KK94-BW.$!DW;B2UT^7M,S3YB+G*XH
M^C9.:K:R[5!2+FI"OF<F=)EB91[&RS90Z*()NR,3)+$4,B(UJFQ8C25E%VK&
M5 8UHC):XQYX@Z]M1H7,+"+D9@1J-._AF;B7@O$^&>//F_$AA='B@J*>MB@-
M/35LE+*(:JD;4D-C<VII?389R7%MFOC>._E=&2H[T4L+-+-BW<&7INV,QLD9
M'R%0IUU0AK; 52!JSB"?MDW3:=$JTV68=MS.22BS1%S%+>,*0J$)KQ*+&!AS
M#1XBZ9TD(>TO]$J27,8&%I $;KZ&P.;+W>6B_0,4^2>LXL=2\3<#Q2U&$XLV
M&L>ROK\-CJ*>LJWSNK(".VB#F0SM(C:UN8L<T .(-MZL]]6WEQ8'<(-CG2I,
MXF)E2/PH]\,54\DYEFYV@-TZT9P0S0D6FL995,$%BO2E1$PI* 7TF<08:]^0
M.G+M"1Z)4[.N&FYB&]B0.=MCJOE:CY&^.8J05;\,80ZHFB#174&\0C)T%5S,
MEM-=-2 MJT+<?AW*5D<52E6A:4L:,2I-JQ#V L,([-$(.T&*S] DY$QH.4$7
MCUJW5,V%04U'*)3@43EYZX,3I*BI=312.-0V)LQC?')$>S+BT.O(UH(S @VN
M;\E\YC7 ?%?#V&-QC%,(E@PR2LCPXU;)8*B%E5+#-4Q0/,$DA9))#!-(P$"X
MC-C>U]P*1[>1;J$% BJ?B<=*Q1*03IB7\8H"7K+V* "(" ](<@(!P'>0'>LW
M)?5UMS>QOS\/'3V+Y( LRG.YXCOV;1*^/+9SF$!S+$6(=:^X-P2'77(I#(+H
M^CK-4#(^$0H%Z2& IB<\ !#!T]//M$>1ZC<\<B(U?&U[.SN0+Z'7WDWO?PM9
M!)*V0RM>]KW-U<R5[9!_8S_2;SNX\_!:RK>-+-"3MGE9+)=WM49/K%4BZQ-H
MTQ&(IZ8.'"@(5]:"KL/*J$(DLFV(,U(RP@BW2$>M85%#X0T[H \-E<X$Z!Q!
MMI?0%@L+\B3KJ"-"O8K<5I:^APVC&"8?12T+B^HKV.JWU>(FXNRJ/I3H^\!Z
MS(V$7W!)*ZE3QI>8"O6&%E,MWZUOIP77H-FLC>A!.58JB'@-R02<%5(R(4*W
M.(NT@F(Z5ZG!0!<3H\(Z@02-;*UL[P7$%KM#8V-P.ZVUKV'=/C<6*UQ#&J.N
MK:*L@X<PG#::E#6S873NK3!692TYYGRUM0^[K.OEECT>1;:W*RQA=6^/7M-<
M9EO[^?='5.ADETUH1;@P(JX36!NV;-*:A4A0123%NGZ16W"PIK*&47.J"2J>
M;::H;&6>E/))N']W.-OI9-O]6_B5>3&J)V+1XDSA["FTK6@/P<FL]!E/>UD(
MJ>WTS&V287Z BZZTUB^[2%*@:HVS-D"$F8HQ#/<@1;6B'M4UX0*]2;]M(4]Y
M5R$="L7Q_0*\P,0&R7@&3ZE2J6]'E[(,=,YSFFX=<!QWW.6W,7LT7M[X@QFA
MBQ2HQ!W#N#OIIH\L>&2.KS14;K#\Y3VJ1.YYM_#2R,%SW==.Q7IW(;>^V:I3
M5?=.J77:33Y"N7HZT8=_;[$X7L#6U1CUHV6:IMG[!)C7WZ9T(UA'KA+N/"$"
MH@1)":L&1LD0R-R]F\.8;WS9LP#B0?5(N+&YVMK6JIL,EH*&N@JV08A58A6,
MJ\/:R814M*V.!U*^*5[7-<U[G5#'-,KGL[-O=(O96<FS=AKUBGWF*,E5=S ^
MD@UK-A;5(EAL8(-2KD/7B15NE8M0')A%LB,K*19O2>LAP22*576X=*0?S=B-
MKVU^L#ZQ]BYJC#889Z>)F)4TC9R&N>QSLD0/-YR7&O,-=[-+\37)\VKCQ:\C
MB;)R$HBNL@7';EM3PO;H$UTT05;()VX]:!-4.7!#*V9'^QBJ'4!-<H(Z@OD:
MTET?>OR+=1OI8V!_ ['0W?A,#*P48Q2E?'V7;&I:^0Q!P('9YG1A^:Q)MDMZ
MMKW5\YE&<AZ3"7!+$V3)F1EU&R;BAQ#:G'N,(#@BZBBDJF^N$? $*T\(I%_0
M9YZ('62!+QBB82U,SQ_!GV6/V'\?)5BPR&2JDIOG*G8QL3GMF>7!CW-RV:TA
MA=F.8@7!&AU7:M>1IJM)5,[+&.1+>>RK(D>EK#6J*FJ(+%:"8]D"6M<,!"("
MZ.4_J@9@P^AOOFG*1 5X](<=1&3<:VMIIS!-@3X>?)12X7%.9V/Q&GC;%G<Q
M\CRT2F,G*&96/)S6)%]-6@D<K[)>IV+M<%3V>/;S*H3J(BK>HAM6EZA6U3@N
MF 3_ *PL\9.B=,R95E21L*](*:J/A*=9U/#-E?)=C1D)&C[ V(OMOKITZ<EE
M!1P/@DK)ZN+]SR1M]%+Y&RU#'.;F$98QP!RD@N-K;FUBO*JE5S.SJEBCK)D2
MKS-P?*NOBY9H^AFAXN&*9J0K8SRNFM<F:7\!V"RQRFEX\5DSD0$$^@534;'6
M^C3,?4-,S@>Q>(PW)M:X#B+CO"]]>8YKU*^NX8FQ##I\-X?KJ&@IPT8C1U.-
M/JI,0/>$CH:@4H]%NTC*TQO#2+W*Q&^X5R9D7#CK'MCR%"JVMW(P,DM;F-.!
MK%'/7;9'6>.;A5%+&L)")J1;-!90; ?T@ 5,*9>L"!GZ-5FA[!U9^ZM;S]DV
MUKWME#^G=WTWU7338GPE!Q(*^3AG$)^&&,=V?#QX@+:KMG0.C#Y,4^;AG:R4
MB8-$ O8,N-UI=38N6*Q;D7'=-M$?#J9AR.ED[)BTC#2K^ ?V!6%KT7(H4R#C
MKA"2%%@U7=6AY-I"LK#(,V1_6+5N1-N^!-M$E-4FDHX6U#C)#*U\Q+01(WO9
MFM&=EKD@ZG2V@-UCAM?PS3XUB5;BF!UF(87512LHL-@Q;T=](7$=EV\YH?W4
M&-[I;:/,;.S M%]HW/95A+(>+*EB2VU=VXKE*9J-JVYCK+8X^<A3O%V[F3-'
MSH2Z\L9-^JU1!9%^\?$.W_D5!.)2&#T&@ Q/-\\3@X&_,'?3R%OQU7SLL@/;
MQPM8RDD>3'!,T2OA8"<F63;,T.T=IJ-K:+.L5[<:3B&S6"S5A>Q.'$ZDLQ;L
MYR8+)QU7AGEOLU\D8&K(>C(*L(I_;+;,S#L'J\B_4/ZM8@]+%Q,:R:27',2!
M?-?,? _MO^U8EH+6C8M(.GAM[.5E(?12FH.Q\BBT3N/BK!,XDMC"IDMRMI7:
M-4*T2E6>PU"7+/NI!LRB7+B<J\A%3#:#8.W1)&P@V?)B:%:/A, ](:RRNZ?6
M/Q3K]2^>S/&.YN+L^3ZU Y-S=+1U=B4)6(M-D+?4W#V3J#.N0%1J4 \ELC/*
M=;CWSQY*YR]GKT) %CYR"]59)934;/O8=QLBF_MZLV7I_']C:WRHO*]>*W.3
M$*S=V9\\]$M[@K<CX+$0WJINM'PJ\N\<LV[:,;2<:V8M"EB9"10 @D(L+Q,I
MD17=SF(<BLZ:SD0V^8+]!)2Y*:DF1V@Y!SP)C.U9N*B%TW +>(4A$4%$O##D
MRG4( )%-31$T1-$31$T1-$31$T1-$31$$ $! >X#V$/H'1%&3.NTS".X>>HL
M_E.BQ5J=4.0?/6 O4Q [IN^A)J&4BG3A-5)R6-!27)*F2;JIG.]BV '$[<%4
M5/:PCB3'<!%7'A.(/I(JR)K9V-M9TD4C)(W@%CQF&7)<CNM)MNL9*>"4M=+"
MV1S#W20+@:W%][:[ [V-M% 3<+L(VRXLIN/)2GXBKC.SK[C<;D9S@@N>2197
MC**!I&";N#.3))Q_H,J>% IB JZ8(I@\4<*=9Q^A@XEXAXFI.(,-QJJ&)4U3
MPGQ!%Z#)$TPNF;A,T<$G;-C;)&_,&YG1D$9G.:1LO&QC"</K*;LYZ<!K7V:\
M#,X"31[+ N):[1I%K$;CFMU82W 67'E*K6,K1A;*)YNK-(&E-C1T=#/0E)9O
M75I9=(BZMA3!PL=LRDGJ'A!U*1S,ZQBE$@Z_!>'L0KZ.C=02<-XK3R85%#1N
MCCC?/ [L&'/-#*2<S9'O/>+N\,AY@#YGAWB"LH<,IL*K,)Q*:HPVGIJ5SX8(
MYRY_8AS@7LF( #LV0NL2VQ/>N%MJL[G[/,MWRJ^ ,P&,UFIF,3%G 12A/#C9
M-TR(5<5K$3H=E30(#M,/Y(CCQ"IF$G''?#Q/4/N78!BL<9>Y@<ZE>W1MAJ'
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MXYX$.P]A$-$7-Z.B B8$PZA'GGOW,   "/?@>. XY[!Y^>B+B(V)\X3IASP
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MY\>_ZM$\%U3-0'@?"Y$/(>H.0]O8>H!X$?,.1 >1Y >1Y9B-KF^^WUW5<M[
MDD--VC46/70[VT5/11$0$4QYXZ?QP[!Y\\@?GGGV@//(\CW$1U.8]+6UY;^R
M_P"%@H+&ZD@DN&7UCW1O<7.GLUNJ>A]BEZ#?-[@;K !#Z.0, \<"/ >0=_>/
M(ZWN!Y:V]@VZ[]2H$;18=XV-\Q=J-]+W!U\!R5PM1$W/A]^/Q@, "';CCGK
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MCTT4Z,%+12EP?^CD)Z4-U)/"L=%-P!UO1CP7(E.#?Q.D@+'T#:LS$NG8V -
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M?=C!T^+W6GSO$+7?2"^UZV ?_P"R#N;W&?T><+?IB5S[K-6[+@'^O(_X$/\
M-T^=X?Y2C_WZG_YU4NYK<:)@ -O&%S"80*!0WA5TPB(]@ "EQ8)A'GW!^KG3
ML> G$-''&8N<UK0, S$N<0 +#%[ZD^0W*EN*QN<&M?1ESB  *ZFU)V'KKI7?
M/F]!"A6&<J^U.A"\2@Y)[$2D3N+:6H_CM43B1=E"M\3(A-J)JE^8P1=)G=@!
MB)'Y\N^CPG@J>2$_E=,Z*0NLX<-RL:X-.0G.,4=E:':$@'8C3==+:FI> Z.F
M;('-<YKA*',(!RDYFAP%CH+D7-@-[K/4<J[T#I%,;:%01$0'G_OH6/(#R("
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M)SF,)CF'N8>YN1U<!HV]]^1_8N,O>\YB2X:- W((&QN="-K?@NRL=(A.L3@
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MZ@TV#4EV3"-EU(FKP4<I*QT2DDA%,9(S1@EZ<TC$44T8]NY\1%FDFFF@0A2
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M(=$(]6.M,Q4YJ067(*(KF=)N:=&)MCD7(FFBJ\ R9SJD.F19GHB:(FB+P;-
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M(J&*!@X'R_ZA#1%A5(HL;1&LXTBW3UTC/6^VW-SZ>9$YT)*XSSZP2+=J9!%
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MT15T1-$5! ![" "'T]]$5.DO//27GW\!S]OYQT17:(FB)HBH)2B/(E 1\N1
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MTC;39;CA^YN5JXO$0*YH>3=31[-"0N1Y3(9619>>7A!CVE#F%2UV9;%D'[=
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9FB)HB:(FB)HB:(K2_P#)+^_1%=HB:(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g752656g14p44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g14p44.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1N@4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&Y8
M8D         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  @/
M     0 ".$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         ".$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             !C0   DH          0
M               !              )*   !C0                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   !C0    !29VAT;&]N9P   DH
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   8T     4F=H=&QO;F<   )*     W5R;%1%6%0    !
M        ;G5L;%1%6%0    !        37-G951%6%0    !       &86QT
M5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q4
M97AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!
M;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R
M=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC
M94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *
M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    #.$))300,     !(?
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
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MJ39Z;TWIU50MLL,SBVY/46]18[[+]'-R_LV+5C^E;=;5_@UHX-77:L=N)TW
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M ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "
M0P!3 #8    ! #A"24T$(@     !+DU- "H    (  <!$@ #     0 !   !
M&@ %     0   &(!&P %     0   &H!*  #     0 "   !,0 "    '@
M '(!,@ "    %    )"':0 $     0   *0   #0 "4*Y   )Q  )0KD   G
M$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#8Z,#0@,#8Z
M-3DZ,C4   .@ 0 #     ?__  "@ @ $     0   DJ@ P $     0   8T
M        !@$#  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H
M  ,    !  (   (!  0    !   !+@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0$P34T *@    @ !P$2
M  ,    !      $:  4    !    8@$;  4    !    :@$H  ,    !  (
M  $Q  (    >    <@$R  (    4    D(=I  0    !    I    -    /
M     0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.3HP-CHP-" P-CHU.3HR-0   Z !  ,    !__\  * "  0    !   "2J #
M  0    !   !C0         & 0,  P    $ !@   1H !0    $   $> 1L
M!0    $   $F 2@  P    $  @   @$ !     $   $N @( !     $
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M=GFVN?_$ !0! 0                    #_Q  4$0$
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MZ4-+-<<DB3HGD]R3Y(1\"AX7!?$I+0\[6HD#^Y,AA32B"UJN/%;XU*F82(W
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MXW6.3L=I<B^/-,8!(_WJU-Y@76 W=V*M*&I*=&U[2FI'^-5<B/&V;0J$_O\
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M];U^V];U^^MZ_MP,%7UT_P Z<MP];/>C+OJ^E(BA3F*#'FR)FQQ8M2$O6]_
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MD_[&-P^-HS3(XPJI5)E9/VK.QMX#7I]5E[*2)E9^MZP) 8# 8# 8# 8# 8#
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M;.\*-96FQUT@^U?XRHFRDF?O)-<P.O3Y"FCFPM*^=.A)VPJ0H B]V[X][?\
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@MN_*?-[_ ,*W?'[3 M"P& P& P& P& P& P& P&!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g752656g14z14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g14z14.jpg
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M 0$! 0'_P  1"  B  \# 1$  A$! Q$!_\0 &0   @,!
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g752656g21p77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g21p77.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1EB4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #X< 5H  QLE1QP"   " (8< E  #D1R;W)Y+"!*87-O;B!,' (% !=0
M;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0      $"0G)&TIW=_/TK*4
MB8+' E$X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q :].V0         IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ /      0 " \     !  (X0DE-!"8
M  X             /X   #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M              (J   $>          !                          $
M            !'@   (J                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   (J     %)G:'1L;VYG   $>     9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M*@    !29VAT;&]N9P  !'@    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
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M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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MJ2'KL$Y)PJ#EZ9!K;ZO;WQ[^$=,G04I!S-WV2[;]+TW1'P1DDE(H'H[*Q[0
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M)$9776W96T,:.&M$#\%6_:G3_P#3#[C_ ')?M3I_^F'X_P!R2FVDJG[4Z?\
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M0>CZD'Z$;HD;_H_RMJ-KO;,=^$#*]*.XZ>*J?__9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M     4I-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L
M @    \   "PAVD !     $   #     [  A]_   "<0 "'W\   )Q!!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C$S(# T.C0V.C$U
M $1R;W)Y+"!*87-O;B!,     Z !  ,    !__\  * "  0    !   $>* #
M  0    !   "*@         & 0,  P    $ !@   1H !0    $   $Z 1L
M!0    $   %" 2@  P    $  @   @$ !     $   %* @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 4Q-
M30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    \
M  "PAVD !     $   #     [    \     !   #P     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C$S(# T.C0V.C$U $1R;W)Y
M+"!*87-O;B!,     Z !  ,    !__\  * "  0    !   $>* #  0    !
M   "*@         & 0,  P    $ !@   1H !0    $   $Z 1L !0    $
M  %" 2@  P    $  @   @$ !     $   %* @( !     $
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MN..7V_U5R,7=GI_3CYKYYL.U1ZP=M@Z%  %"\@ &#@3"7GOP;CCCY!\-7&W
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M8BR*\DNFJ B)E#@8P_$.1#L >0<]^!^//GSVJU/,<K>XN===--5=.9RTR[]
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MY%2@+''E0<+QSD$>"G$4C)K=( 'O=0(**<"7D.0[\!YB''.KQ(+;=@X'7O\
M8L9UKG[._P"P=]^&8%HJRY.HW2$W)!*4I1$WXW/?CD!\A*'F4>?AJ+97[!EE
MW>W4<SVA4NR%^S3NR]I7T1>BWW:I.(R'VW6ML1)1F,LO19\72:22J2AS2*U;
M<MCE PN2K*O7$>LDHH*Y5#-SD Y$C'L/81=U_P!:UL^5_?3E8*EKKY:+O #N
M #\]6U4FB)HB:(FB)HB:(O @ ^?VZ@@'47MFB\&*!N.>>W]O+4%C20>7 9 ]
M]D&7'Z/J 7'45(B<O6H0O/EU]A'ZB]P P\? /+M]6K;Y(8W-;))&QTGJQB1[
M07D9D-#G N(OH!EXJ0USK[H<;9G=%^?80O0=RF(=C!R)NX=1/F/ <";D>>P\
M>??5/7P7N)H;BX($\6@-LQO>.EQH;<&Z[_0><O\ 0=YY!5$LETNDI=6\0K"2
MC=^U63>4VO,G::;.1,1T= )>X+HN3JD8MRD!R5F8K1$Z)D^LYNR@_G)MMTJ]
M*&/]+-)L]5;(;1TV-83-38AT7;!X76Q"@QN8ULT#=J>DRHI:Z6HI,+PV2F;7
M0T;OS;3R4Q#*HR1%[IO4:#!<&I\(?5MJXY:9PW<9Q69FZ^"4L#FX;AD!:TNG
MGN(FSN$X#R#NV;NJ/=Q$_NPIDCC]#&:$G9J^M4;N_P IR59JK&5L;*00L5$2
MJQ*4U<-'S1:5;(R,X*T2\:OCR=2:69TQ;.)YC%B3]#NC;"Z^AV<B@V[QN''M
MIQ*R6IQ!D+*"E<Z?TF62CCI82US</H[QP0S&1TKYV0N=+U;Y&+1X9'LU52U9
MJ/[W8R>,439WG<?&YP$CJHM#7#]'<M,;F 3=7>[26FK]3R#Z0QO0[M+WUM>4
M;).UB3D,<,82@QS]W&W"%R"A$,H"<8QV.9$]<:3]84)(MQERSS&69K+RCBUT
M=HS<G+Z'50;-"IIXJ7<=&V5@J9'R/:QT+H@7OC<Z8!Y9*=VPW'- ($<N1.UK
M:38[TN&"BDAEC961QU,G6O ]%,#7.D8[K&M);*=V]L@/@O)6T5;+>\>."G3<
M_!Y@FF2=X>DSE#R>&T#A681'*S**@66*&%>KB$U;(]]0#2<C8)*.4NR;9%-B
M^9335P<45K%138+*VIBC-/&YD;#0R,G>>N/4[TGI1DD,;'"0 1@-BN Z[2""
M+%70;.2NK8(7X=#NP@X9*VM,;JB3JMY_I?7/?'8/L&AGHQN"#?>%M\D-]=0V
MZ5'-N8MRUHO]+QI'W-K$XJ@<J8[>4J]SW5'+N7[>IQRE9JOMV$<K@4(=LHVD
MIB#8,5'MHF?&E6[%CJ,0IX(64[8'0.>8&NF]'EZR)KG&S6GUY")=W.2Q#+FS
M&@"YYC%J6GI8L-BB-')5RQ.=4F@G](@#B;,87=9(1(T-/6"^[ZS=WDOFP]*=
MOXI7I3L9UNGXAB9B!B,9STK8UV[N2!=_/I2C=NP9/%V"+5%-#V;ZNJ3W5G0!
MZ^8!$A@$3X+6"PS-K:G+AR["#X6\-$W/6P-C[WSM>U^WN*ZL\,XB<PV)K;77
M;54KDLY[0$RB?X15)9BU;@'<@&Y(=L<_ ^0JCV#@>+^XT-UU%[<3?Q\_%70Z
MUAEG8<;WYZ\>)S!SX&RK=:,4J(2*YO /W4$0 2!W 3<]^W8>!#Z^.VJ#?VCR
MO_4^'%NEW6_,]NNF5N6>7*Q7(KU .DL4!1.!0-S^( !U=NWXOD///'U:7 ]S
M<Y::7X@ZWN3VHX[HR SX',]W YY$9Y>85M,=U!1,Z!03,//0/XO =C<\!S]?
MF/E\O@.KC,M[2YL!KS-N>E\\NQ67.).HO?*USQN+:B]\SY#B%?2H1GJR#5OQ
MP9,I.?GU=N?+M]?V  :D<!VC+L&=\Q<<QWG)8[]>X7]MNS*_DM1N$Z5*\':$
M.4WAL&9%"\C[AA.Y.'/ A^.0Y3!]O80X'0YN/(FW;<>_D5<8+  Z&U^8)N1]
MBW>,5*JFB"@=0#Y\]^_;CR_MW#4'G?/3*_#+/MT^O-4[@S\[7L.[3W[UV&[
M83'SW<ECX;NJHU24=":"\,J8-'5I0 %X5C(&.')&[M8BA2*%$QC.2((=@5,<
MB0?HR0!HV_F/KLJ&_"UXGNL ;>]E]3,S"Q5FA)2OSC-"3A9R-?1$M'N2%5:R
M$9)-5F3YFX3, E4;NVBZJ*I..#)J" < .L575\QESA:_M]W 4&U9)SIZ,_;@
MZVLU@,)8?NFX',]\W!;@D\<UL\ZRI<U-8QAKS@FFL+U&UVR/XB'>SD;9+' 0
MLV_C6TVY!\\5<D7=/L<S_3<]4.R254W"R6Y=6"M!V\MD,^)'^):N5:18(N6T
M11F2T!&,9VNL4DU#)236:MKDBZZ[>0G5EDB)$(KQZ(FB)HB:(FB)HB:(FB)H
MB_)C%* F,8"@'(B(B     B/<?D "(_4 CHBJ[5+B&:L@R3IBN@OC:C2@MZ\
MLV$%"6:R,_%;2$NN8_412-C%Q5:1!"%(DNH4TF!UNIN*1%:,  H<!Y:(@F O
M<1X^']OT:(M#F<E5*%D48E:0</))18R"C2&BI2<49J$+UB61&):.R1O(>7KQ
MD1,80* "(AJG?:#;>%_<?2JQ&\BX;]'*_P!"Q,YF"GUMLB_G LD?'*K> >16
MI=M]09CP ^/(NDH=9*/9AR "]=F2:]7)15#I,(0'M.0.?)06/%R6FP6\5^R5
M^UQ;::K4U%3\0\*8S62AG[:28K@0XIJ DZ:*JHF,D<HIJD _6F<HD4(0X"4*
MU2LNHF"A1*/D)1*(=A 0'Y@(" ^7RT\;=O\ 6X1=76YC %\Q?/FW+8<RI>*U
M+PQE#9"K4'%406-CHJKP'4JU!DZJ;I%5Y$M_'=0SIV5<[1VF50YE2K.05P7T
MU06EL5;,P$EY)ZHD'(6;O1N;:V@W3G=:VII*V6.2.GQNJH0X[X8(:.5@<3\)
MIFI92+ !H:;MX@7.>D[MMK&>LT0&$G-"RY9LE,F>2*W:W1K"G08#[GH=V@DL
MVNT>>'A*Z5ZK#)#XR3-8KYP<SCEHV4,*A0Y3:#9_%:W\V.IL1GE$-:Q\W7=1
M'8 AV]:&./?+0-#<<[Y+RO;S8O:G&8< AP_'*S%'4V.0U54RH-#2.IZ3)IJ6
M/I:>E:]L.Z3U>ZYYWKLN<ER]J&U_.6*I#="O?6;R3&^91CY:JN?NL1BU[2Q:
MK2J[FSK.84ZB; KMO),VRC)1JT5%1B9(&Z3=)N(^5=(NPFU.,;%;2X=A>$RX
MQB>(8Q1S4U#3;33[+/?!',722NQ>D:#U;F.!?!N@.&\!=Y75]#V 8MLCM#M;
M6;0536T^)U@DHI9&,K=]C9)G&9D!)$;I&R-N+:@LW=T*TXXHN"W[K38<3&\S
MR>0+3(<B'Q$J1TDS#QV+P(&#OY\]_EMOY-_254O#Y^C#9D/(^'BO2]MKB$@<
M>)92U])%(+Y[I %KFY&2^D/[48.W(8O7@6TIL"H8#EG8/W7[HN,[_"%[]N.*
M=+$TNUDYBL43UA-1L5RUB9&5=6B/;/CJ(IO&2$H[<$5*84SE4!)$#F+U )O>
M[ZXR0_DY8_@V/[3;!=%/YT;/%'483L]M1C^,=(&#4E8Z6V*8-2XUB%7')'/#
M!-)4,IZ9KRUH8YY#B\76"+:N":DHL3QECW-<Z)]92T\&'RR- /532Q0L<US_
M -7>=NW;V+B[@Y#=];!Q5+[,K!@YM77#F=5R0IE:-GI$56JK),( (E.#716*
M*+LKM.49^(U=E7.Q5!86Z+ANM^F71]M=L'MO@%-M/A];/BV$8K305&'55 YD
M9:3O^E4]3%,"^"M@?N1STTL<;X7AP>"XMMR>&T6!X;/B%'M;3XI3U4+XVP14
M+&..[>02/<Y]VELEHG0.!W2 \W(("B3#$5Z5Y*U1BF8K+M)/4PI)2R*</7;T
MZ>EN822O!>EI-0YE "/Z#.'Z"R<><AD6Z$2FNDJY/V56_95L)]$CQ1LW697F
M@,?5[H&5XB;$[V1&\,L[6!OXD[85]*1AS,<;/UEV];U$9MNLNZ[HG?H]=T9.
MWKWRS57/2X;4]U^Y?;<V(=/$-M<X[GSV0*[486XQ4F\CGB";67<IK3,[8$7
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MC3;>YB^O>+]G#G?O%U+@"!W_ (:6M_73BN6P@Q*)1,7R\NWG]8\?#\P?9\I
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M)<^]SP "/?GL/<.!^/\ -K+6&M+R29,U-F 6*0Y%8MZ"H&("B9DS-S 8HD,
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M0 1#K4'E0WE[Q^D?+D8=I]'9;(CP-\M!E94:G[?K/8ML1CC.6Y4Q+R/3R)N
M$"E'@1Y ?/\ 3Y^7D.JPWU0#_0ZJHG4Y:Z9YV%O?37/(A;Y@+;7<\P9(1KE/
M@W+HTA()JOI$4!!FT:I&236>/7!B^&DT03+U'.)^.>2AR8Y &DV;<N-AI?B>
M(&M^%CGIYJ 2<@/;[CCRU[,E]A>.J>VQ_1JG26:@K-:M 1<(BL(<"J6/:D;B
MJ(<%XZS$$P%X#@!#YZPSV:*XT$#/W]_PX+<NHH#P(\#V'N \=_+OY?RZ*KL^
MHK]:(FB)HB:(FB)HB:(FB)SY!\_+1%53=-!K+QN,K:DW.X)2\F1#MX*8)@9H
MPG63^NK/15.(&(@DXD&9'!2<G4(KV#@HCHBEZ!64(@@BL7E,0(9+D>0Z3% 2
MB4?(!X$![<AWXY[!H@OF/?PR\/I4@-#(B =!AZ^G@2B//;S#X!\OY]$6JV:&
M<N'C*79I%64:E69OF_;K<QCGI%041XZC.&BJ9%T$N0\4IG"13%.<G%$D8D;N
MNT.OC[]_)7HI3$;CLT[/J6HO:HG(>\F0J@"'5P3J Q0'L'B$.4%"&[" E.4#
M=A[B(:TD^%EY]5M\\NZ_?X\^/?TU%C@B'K2;IL-;VTURXC2VG8L$%;;QJQ$T
MDCNW1C%Z&;5,SET(&Y'K.0@#X*8=(@958Q$R\<B(<B.K#<,.\+M.HMG?CG?G
M;6_+BKM1C\CVD!V5C<BP'(<?+AXK;H&EK#+M+/8>LJ\:T72A(<%NMI$*N2&(
M^D7 )\).I9P@!&J2YP4(P:>L(LS\O')U-[3P-A8 !G]N>F?TGPS7,550:A^\
M?/GR\,SV:++.5DE' GZN@.H0+W[''RY#G@1Y'OVX\^._EK(6*HNSDC*-L93S
M>" R\_8_4JW$^ @1RJ@M..TF0+ID5X+R@1;QE.>P%(/(@ @.B*>H=DVAHF+B
M&X\-XN/91R " \@BR;)MT@'GD1'PT@Y$1$1\^_.B+*Z(OR)B@/ CP/Y_L_M_
MZZ(L=,3,37XF2GIV19Q$)#,'DI+2LBX3:,(V-CVZCM\^>NES$2;-&C9%5PX7
M5,5-)%,ZAS 4HCHBT;$F9,59^H43D_"N0JID_'M@]<)"W*E3#2<@) [!TLP>
MD:R#)11$ZK-ZW6;.$^04162,0Y0$-$54=B^UW<)MG0SLGGW=C<]U"V3\RSV0
MJ*XM\>X8CC*I2:1$VM*B2.):6*BQ1,4IS,(P8^"9"D4(R.0!58RA%?K1%\,7
M]TL;DLHV/<)$X B)!\SQUCF!B7JT2S<+$:R=FGX].5<2[U$@%37709.T(]J!
MQ.#=-%;HX\93JNM%A<#/C^&G#Z=>!D=FM_?VGB.XKH*P/(65@_:CZRX*(*DY
M_"&$0Z3 ("(B/'^5]OS^.JA\(#F>VW=R[[7[;G,9!T(N-,QE;+/,Z<]/*Y7<
MI#1);W14O:**8R+5J9TU<B0/$ Z0!XA>KS\-5,IP.3L F-U '4!1"[:Q)!MJ
M?(VSU[^WD%CZ<>_Z\_KS"B]:@&*8W"73R(\#P7S^7( (B'SY#ZP^H7$#>=N[
MH+03<7N[(6%]3F,A[%-\KDY:$DZ7.5KFU^7MYKFL:(J!R?@>0 0ZA$OZ>_EY
M?'CMQ]@Z'>T-@;9YC,9G+=N; =OV(^[#NN+0<L@1QT^#K;O-O-21$51NTZ3&
M( \#SP)0XY ?GYB'_P"T?L^K5/8!GSRR[N'<=3?MNJ=]MCIWG6V7#Z_HX;^R
M8#P4I"!Q\@#CCGR_]O/XZF]LM3]9X=_;GRT5DYDVTYY^W7ED/8MVBF1$3%%0
M/(0'IY .0[<]^_GSQ]7UZJ:TC,ZH;9 #+GS[?IX'ZEV[[!\80^2YTBJ"A/ @
MC-W<X@82^,W:<B)."]7)@='(*"1P  ZA,(@' ZHF^!_]PX:Y$V\.?AJI;\*U
MM+\=#H3]2^@=N@DV1200(5-)),B2:9  "D33*!2%* =N"E "A]0!K%5U>[1$
MT1-$31$T1-$31$T1-$31$T1-$31$T1:_;+$RJ%7L5KDQ,$=6H23G7XD*)C^I
MQ+-9\YZ2@ B)O!0/T@ "//&I N0.9MYHOYSN8?2!Y3W,[W;M-Y-EGPUR?>25
M<H\$HLN$15(^-D5SP<5&MS&\) CAOZP1PKT%.[>J&<*]2JO2%QH+'7/=EG[Z
M$=]E6&.UMED<_HT[/?-2O9:F28;@[2('6HF!C@40'CL'(\<>7;O\   #GG5^
M]B;=]M+\K>' ^7 03J.'(^0]G/Q5?IBCJ)*G**0B'4(]7RY$?@7Y<?(>?Y=#
M9P.F>0OD>Z_V:*IIOV]N0=W?7KX\%@2U(Q1*(IF$.> Y#@!'ZN>._8?Y=0&6
M/ZI/F?'C;SX9*L.%[:GN.7:;V]M[\BMIC*JH42E\'SX$."\AP ]Q[AS\A[<@
M/<?MJ!W1F<AI;/.VAL![?%4N(-C>UN5KCO XY:WU]DKUZIG$Y#>$8I@ ..DO
M !WYZA$ #CGR'Y@ !]6J22>QO=SR\>?GRNJ+\.'+V&Q-^_LOXJ<XB+*U3(GW
M$2CW-W'@>P\%Y\@Y[CQYB'/V3H,CERR.6>O#CF!V#4A6'?"T[N=\L\LSV7[N
M"D*&CS&,7W>1Y+SS\1Y[?V'Z]!F=[]5M[#V_C[%&@(XG6W <M/.Q[U9S#>-9
M7)%YJ-$A41/)VF9:QJ9RDZ@:M3&\21?J=AZ4(]@1RZ6,;@H$2[B!1ZM4O?ZI
MM<'*Q\>_DH%S8>2^KO'^-:1C6"9P5,K<1 M&[9NW5-',4&RSTS<@$\=ZL0H+
M.5CF 3G.N<X]9C<<>6L8N<[4DJXUMCV6\5OP=NP>0:A5K@/C*)IBHBB*Z@"F
M()E5(D)_? !#K/P4. Y$0YY-QP <CK#KI9XH'R4M(ZMG:Z,"!D[:<EKGM#W]
M8\AMHV;SRW5P!:,RJF-#G!KG[C<R3N[W#EKP7/UF*E-$31$T1-$31$T1-$7C
MXC\O_3[/^/\ RU''CEY%%@;17F5KK\M79$@&9R[%RQ6'I QDP72.0BZ8&[>*
M@H)%DA[=*A"F 0$ $)11[3"R!(<M?FU"*6:KD(R>J 44RRC5,G#66:E'GJ;N
MTP\0>!,*:WBH',)TC !%N"+E5!0%" /'2 '+W'CX"(\]_/Y?/YZ(MC:N/6.X
M\_B\](]@Y#C[/T"'G\-$7(,"1.XD#D>1[!YB'S^?G\=$7I!1L41$"<";CJ$"
M\"/'ER(#R/'PYT49\AY_@N.Y6(H44P.)2"4>LH" &'D>1Y\Q[\Z*5J+E(IUB
MJ%*!BI&$$"!YB;N "/YQ^/!?F/''!%5O*NY/%6-;[1"YGR91\48T"VL:M"3U
MYM#"N)7[,TR!TJ[2X(KU1%.01CV:BTHX4\0$4W@L3K&(EX8B18O>SM%RUNGD
M]N4GBS=AE#;&WPQF*)R3<6&.3K^KY=KC$S,ZE-LOJLO$&49B5JLBV3?'E(;H
ME'YG\,^,5IX)%*>[3>=MTV-8XALJ;F+\7']*G;A!4&)DPA9NP.'MFGQ6]19I
M1M>CY%^*1$&KMZ^>"V*T8LFR[ARHF0H )%$6Y3:%/[H\V;/MP-.W29<Q#6=O
M%H?7B3QYCQZNWI^<XBP(P[QG&7!$DFP(+8J4>5J59ZPFD5(69EFB;%LNX*[*
M1>O&>\[;GO%SKN^V+LJQ=Y:>P!&H4_-+.YTU6*H-IA[PS>1,E&0$L9ZHM,-%
M6ZKED[];9Q?KJ"XO(DSYB/K0$4PXNQ/MC]'KMPD*U0H>NX/V]8BA;5>)Q15X
M]/#5N(1]<LELL<O)2+A\_5 I0=/GCA99=3PTP32+P1-/1%)^#\YXFW)8OJV:
M,'7B%R/C"ZMG+NLV^ 46/&RB3)ZYC7I2%<HMW2"[.09NF;ILZ;H.$'""B:B9
M1#N12QHB^2?TX.S*P6/-RN9D8Q1[7[M&Q"24BDUZD&LG#Q+:*<1CE0@FZ' I
M,B/4A4Z 53=& G/@''58=8 ?TSYYYYVY=ZD&W]<O?1=(E)VZNHA\F=9F5$A#
MEY$2D$> . B !V$>P>?/\G?5YHL1<CCQ'T9]X[>S)7#(-WMSN;6][:^7++L<
MQSC*95@ES,(YT+-%H9L"XMU/ $QB=!_P@!TB8Q3B8$^0'S'@ +SJMK;W/.]N
M[GS-_,^*QRX.! UUX<,SG?,Y<+W4&9L6G\?-8-K#MXHUBGIM*/C8Z75(GZ\D
M44R.@;)'<LQ7.59PU2.)%R&2!7K*"A@ ANIV5P:EQ6JGEK ^2EIJ6:8MB N7
M!I+2X.+1^J2TW))&B[?8?9RDQVJK!BD<S</AHI)7S,:W]$X!Q:7$N;:X:XML
M<R+$9&TD-*=8 C"OUX:1(0B*8/7"+!T+!%P %*X2]9$@I%*FOU)EZU>KRZAY
MYURH  ZQEW1R/E<S>R>UK))(V[X!(:;-OJ01F"N)>V,OD;3.<^FCFF93ODRD
M?"R1S6N>!< V&@)L.-ES&E==+& $VZI@^71QY\#S_G<?H[:D;YST[;G/PT]B
MM6 U/E[V_%<IRDA%%$5O=.7J P#V*!B\<@(\#STCSS]@?7I8,SU/ 9<.7+LS
M4@W]70>XY\?K/A%MCR<QB5"I%5ZW!O=0;)<"NL/?@2E+R($ 1#J4$.D.>W(]
MM+N/9[+=OX7TSMQ5?5FVOLOV^'$VY<2%WP>ALH%PF)6]9?G6\_%5T(1A UXW
MA*-X"P/G2[D\N4C@X<21H1-%KU"B()INGA1,<3)"0+,C[C=S)!!OX'CQU[\L
M]0@:0>''LY<+=G-=_P '8 #Y?FU95:ZT\H;N=QJ&[B_[8,#84P?<4L9X@P_E
MFTW',>X6S8C.LCE^S94KL=#5V%KV#\HEDU8C[UL@[>.7<I%\C)LT4T1)XBI"
M*J^3/3-56 S'DK#>.FVVNR35;W"T':;1QNVZN+HS^S9JL-<BK7=9RT0['']K
M=U'#=':/)FFDMC12PVFRY3KCND,J:V</$GJ)%VP5#<A@JYV>[X_K>9\167(>
M+6JKK*=*K.2:K/6''9&H@E(*V^(9R)I:NM&#KJ;NG4VQCRME2BFZ!!<#(@10
M_->D:V(0%2B;](;O-N?W$3F0#8LCK<SS!1I*M'OZ<>I+N*RYG(V9=QD>_9Q!
M E'QI!RU;,H]=H[<KIMWS-5<BFLFXW 2N26F&4\UXD/F"0C49ECBDN2*<.27
ML2Y8%E&\DSHX3 V9RQ6C#DD4G2,6=!2/-ZZF<S;\()%^J1N)P1DJXR6/<?YD
MQ7=KW#1;F;F*;4L@U6Q6F*AV4X]K#R4D8")DW4HS8L[)'/H!VZ<-4T6TNT78
M+'(Y*"9B*9]$4=V'+F+ZDZ!E:,ATFO/!,!/59FT0\<YZQ$0 @H.G2:H&Y#\4
M2@// ?/@BP;3<#@Y^Z!BRR]C1T\,!!!JC=:^HX$%/Q!\(KX3\&[=(\=_S#HB
ME5D^92+9%XP=M7K5P7K0<M'"3ENL3D0 Z2R)CIJ%$0_&*80Y[:(N7HB:(FB)
MHBT7*%;<7+&]]J30Y$W5GI]C@&RBG/01>7B7;!(Q^._2"BY1-QWXU(-B#K8W
MMW(OYR&=-I]BI64YU%>,=Q<M$SKD#AX)R.FKYH]./O<%Y*HBJF(E. "41*4Q
M3" @(WP-ZS\@3?496/(\>-N6>2OMD&1MF-3[^-M3V9*V=)757J/KUB)Z@XBF
M1U)91</"1!-JD8ZSXIA\DCD(94_;@IO<\^D!NQ125$\5/"TOFFD9%&S0;SW-
M8W,W.I )MSY*B)AFJ(Z9ES/++'$R,#>SD<&,N1IJ+W&F=U7G(VXO#=6:QBYW
MSN47E$SK$;,VADG#1,JW@_W^#L$@14,;GI3*"@F+P<.2B CE8AA]3ADHAJVM
M;(38@.N01VVSXC0C3,+:8K@=?@M9^;\0C;'6"!M6Z)K@X-I'D-9-OV&;GN8W
M<#;C>URL<ECV_8YR.8OLM1TS75$.@CH4C )A[<#T!T!]@@'(<C\-8 L<K&_'
MSMR/&W/EJM4YI:,SIPSMQ%_/VJ>T::W:"0PE*<# !B'+QTG#GS#MSV'S#D./
M+50MP'G<V\A;S"MEP;J+WT][_:MH9QA40 $R<=@YX#R[\<<_+R^//\NITU.8
M]G</*W#P+2J2_/(7]BVIE'>1C^Z';DPASQ]?';_EH&[W8/I]_*^@U5!(N3Q/
M#ED./?[+Z&RV)J_9,U"D%0 'D._)0#W1Y[]_(?JY\]5W%K#D>[3GI[4M]F=A
M8D<O;X+O2]%!4J'/%O.2O6DY"[0ZZ-:8LCIE\.$A':1EG$BVYY,HYEG" ME%
M@ H-VK5-,HB+Q36-(;'=]OBI9\+AH?J*[J=6E=31%^#$ P\_9_)SQ\0U26AV
MI/#*YMEW$7\2B_>JD31$T1-$31$T1-$31$T1-$6"F8-&5!%=)91A)LP4,PDV
MQ0]9;','XI@Y KAJ<P!X[18#(K%#@0*?I.4BU5:U-H$R2%U13ASG.5)*<)U?
M<\].;GPQ%V8G_P -<*?%H_Z#=?45!9R4O7HBWAHJR6 JK1=%=,Y.HJB*R:J9
M@'R$IB#P8! .Q@Y#1%CY5^DTY,94A?+@3' "E[!SS\/C\1#R^.B+5W%F9H]E
M7K=,> 'CQ"]0!R/ ]C<<"("'ES_)HEQ;@>WW-EI5CRO3JXV,ZE['&MB])CE*
MHY3\0Y2%'N5,HB<_E^*4#''R(4PB "11C'364,SO/5J8T?XYQ\8B7M'(LTP,
ME8Y=%3I4.RH4$\*D9NJ=+@CFQS;4[-L"BGLUJ^<I$41(L]GC9)MAW.5O'52S
MSB:OY,@L4W6.R)1F=A/(F&(N$:)A)+J+-'K5:1,^$Y_;#614=,)<#"61:.2<
M$ BC7?)*;^X6+PB7835\/V607S!76>;D<LO5V2,;B Q1]L/*YTR,<0[U(>?6
M#H'=RJ*7@>RXYV<RH)$5L<CXEQGF2NM*MEJ@4[(U=:RD;/(05TKT998EO-Q*
MI7,;*(,I9LY03?,' >(U=%("I.3%YZ3F 2+?VZ";9$B")$TT4BE3222(":22
M1"@1---,OND(0A2E*4O!0 ."@ < !%PVL/%,GS^39QL>TD)4432;ULR;H/)$
M[9,$6QWSE,A5G1FZ >"B*YCBFGP0G24.-$6+N5.K&0JK8:/=H&*M-/MT+)UR
MT5N<9(R,//0,RT582L1*,7!3(.V$@R76;.FZI3$514,40[\Z(M<Q%A[&&!,=
MUO$V&J-7<;XVI[59E6:;5(]*,@X9LX=+OG";1HEV SAZZ<NW"IS'57<+JK*G
M.<YA$BDG1%JMSI%5R% /:O<H..L,!($Z'<;)-RKH*" \D4+W*=%9,WO)+HG(
MLF;N0X<CR14<5]&%M34E%)1.NV)OXBQE@8HSYO42@8_6*0$4:*+BEWZ  S@Q
MP)_E\]]%!%P0K7PF#L3U:GIT6'HE=1JA#D4/$K,4W)'"Y0X!VY7<^*X<.^D.
MGQU51/T"8.H"B(#.\1Q(OEJ<[\/%0&VY6XD\!]=M>!.68LJ>9;VU8/S?NLPA
M'SN-JZ\6V^5=]E@[]B@>-,RDI"QLX[&<2Y+&*LTG<:I)UJTS[F->)KH++0C$
M%DU6[E8@[JAQ"LP_"Z]U/*875SQ1@&Q=U;&E\SFY9;PD8W)P^$>("ZS#<4Q'
M"\ Q$PS-CAQ61M"T6N\L@!DD=&[(M!;*&W;<7X@A7_&LUYQ$O(-:#B31+Y%P
MV>1AH]KZBNB\*8'*2K7P@2.5?Q#^, E]\3&$>X\ZT@)L#IQRRUS-O-<H&AH
M L,[#O))\R2>&J^?CT@.Q?(N.:X25VP46T9$"QV1!HG5ZZW0=S4,@NB_=JMS
M"HHW13B$3MTR(O7"J92%.@@LH)^!/=$I#=VU^V_OWZ^'!06W-[V\/Q74# 8Q
MW%6*-N%3MF++E4K75T2N92/DH)^K+PC5%=%NY=/$P;E31;'%PDD5R(J-CG42
M,DJH!BF-=#@0,]<]3>]LQJ+Y#/AP'!-W0WT[+<;Y6]_',[CM^]'QFW,LTE+5
M:ES,Q'^W6L/*V^8(FQA(===5,JSAXX=J$7<I1B2@+NT(MN]503 I3(E,<@'A
MSQ;7ZKGB-3[Z\U7?*W#W]_+DOK^VSX><X&PC0<4O9=I.NZC%N&3B58L#1K5V
MJYDGL@)TFJBJRA 3!V"(G4/XBPI^,<J8G%,N.3<W4*>-0BZ3=T&QC+EYWQ7O
M<M";3]D&ZZF7'!6$<:0D?NCO,W6+)CFR8ON&8;#-RE9:M]N.:X\[.R-LAP*9
MUD9.&<BO72 Y143*W.F1;FVV#9/#+HY%=#C)&/4])@EO)6:MG4BJ^2QC_P!$
MIOA!2OIF4JZ1%+:G>TUY=-@8Z<0:&,63&83E%#QY"*H]3]$=F<E#R'@^R*X\
M;Q3?$6Z'$^+]R37/^?K/<I2+W 2#J3,2V;:I.#BL75HMC>>RG.7%(F]V!O/O
MHEU*UEC#2$H@O$$5L,B;<-XN3<?8+GG>#MF]'RUMMW%X_P LUG'E3R?>%L6Y
M,J];Q?><7S4=*VU3 ,9-8_=(L[J20JD.E3+RT9M*^QAWDJ8JJ;EL11:T]'MN
M;<S1\?RT+MI:8\G=[<%O:G-Q4=.W%WN+A9-#+,3FF2QC"5UQCMC%R+Y@_CE,
M,P&3G.2HM$,)G2CG6/$GA#1ZA%=_9YM_C]FN EX>Y0].-?AR3N NDI+TID1T
M[L".7,XW3(T*Q))O(N(E7DDI7Y>K1\J@X*FT1D(<B15W#"-9O!(LU-PV9\XE
MYFI.0QO4'*WX"MUF179RKAJ \]<].(%3=+J+$$O4S8J-612&,FH1P/2J0BST
M'L_QM'H-BN81H[<IF(NL\=D([>.''B H=5PZ<@HNX5, <>*J<QPY$W5U:(L9
M;=FN.IXRJOL-B;Q2"D<O@H@?I/QR)>2=(=N2@(=(AR/?L&B+3J]@#).#17<X
M:LZL?'&-ZVXIDL0\G3Y-;D"* =@*I'$<LL@FDB=U$N&JI133.;Q )TB1315-
MR\",PTIV58P^*[@Y4(W9#-+@I4+"N <'"O6DWA-/%,8.$XZ7+'2)^HH((N>D
MX@16<(<JA2G(8#$, &*8H\@8HAR @(>8" @(#\0'G1%^M$31%X$.0$!^.B*C
M6Y;81AO<?(&L<HW=U6Z"0I%K)")M3>TP('!!E6"P DZ4(7@OK)%&[I0I2E56
M.4H=-8D<!;(\KZCN((1=0>YGT4W2C5<0X;S*\+D^Z.GD\\-)P)6D1"8^K277
M-S-A?1[YX\CVB\BYBX:*018N5)N6=D9>&1@E)NVG2;-XA3X7/48C5P&2!K0R
MG>VQE;5$GJPTNLU]B-YP :6- -R2 >TV.JJ3!JFJQW$J=DU)2Q"(![=Z5U;)
M_BWHHWFMM&[=?+</(8"0X6"^.+<QB6<B<LV>**JJ=E%2CN-0X2*DF=./<BW(
MH1%+A-#QA2%44DR] "<>GW>-:K$JY^*U]15ROD-W$QM=NBX)MD+99&_+F+:Z
MC%L5EQK$ZW$99Y)G3-#&OFW=YL#7M+*=A#6 0M< 6 BX('K&RE7;]6I6.>L^
MDBQ0\1+S*?I_&'S#D!'G[ _-QK%9J1P /"W(6O:U[G*W!:I_P+>6O: ;Y:D\
MLQDNY*MQ:TA"H <G4LW%$>3!_DG3Y.'V=0!V#CCCY\\W +@V-K.U&F5N'XWO
MG=8DAL1X^^1^OS62?(1L FFK*N4VR:QNE/D  3G+QU<<B #P E#@.1#SU-FC
M,Y]^?9W6TU&7/147)T[K <.7UZG7O6FW&UM("/2D/6$?47*2@M%"FY*L<@ (
MI$*'O&4Y$ Z"]1C";MT]M'9\[6R&ESY:]^EN^P>5M3RU[;^7DH(BK)9KM,%3
M;)+Q\(FIU++FY*NZ( ]P$?>\),3 '!.KK'@>OW>0TRM^.0%[ZY6R'#/C8ZJ[
MNM: 1>^I'T=F8Y>SC],7H;:Q+L6N4K"JW63B'+>%C45C ((J/"JN' D*(_C'
M!(@F,)>>""3D2@<@'QI/AGMS_HK;/A=W]/?W*[S=6U=31$T1-$31$T1-$31$
MT1-$31$T1-$31%QW+5!XDJW=))N&ZQ!350633514(/F4Z:A3%. _$# (?5HB
MB>6PC3GXB>,<V*IF-QUA5)MQ%MQZ1Y#I8'*ZCD>!$?\ Z=HESS[W/ <$[5K3
MW;M!O0*"U^R@8 (H3O9&@CP<@D$0,6& Q1 !Z@$!#W@*/?C@2+6%-I5+<)BB
MXN^5UR',4QQ/;R=1ND>>D3&C $ '\4>DGXH^Z(&[@1;M3MMV)*4_+,,J^M,3
MA2&($U:9)Y8GQ>L2B)D22*JK%H?W" !V;-N?I(4.H>.Y%.A2@0."^0>0=N X
M^0    ?4';1%^M$31$T1-$31$T1-$31$'R'1%B7LJUC4A<2#INT;%,D4RRX@
MFF!EC@F0@F,H  <QQ A>0'J,/ %Y[:U.)XQ0X-3&LQ2LIZ&C9(QCZRH<V.GW
MY)-QD-W2 MD<?5#C=F\-#\$78H9)G;L3'/>0=U@S<;"_+/)>J:E&<;#R$H[5
M(5DQ9N7RZO8"%0:('<JF,8YB$  (3GJ.<J?P,8 Y'6TB_OAL?5EKQ,UIC<P7
M:\26+'-UN"""-53%$^>:.G:PNDEE9"&6)NY[@T AIO:YX9\-5U(^B1O&2<Y1
MFYK<Q?;+9Y.$RUF=['8V@[C7FL1,5RBTY)<D.R;O6?+)[$)DG!8MT(Y5TQ;O
MH^2< [6=O7?'7[5P4]"_"\.@B;&^EH&/J2TYNJ9C:3?%];Q[X):'$/ )+6MM
MZ%T@TE'A4V$8-30LAFH\/9)6"+>$?7S -=9CBYV\3$7ESB20\ 9!=Q !QS]8
M\_#_ (!_/R/UZY)>=+SHBX9H]F8ZJIFZ)E%D_"54%),3JH]^$5#"03'2#D>$
MSB) \^.1$1(O+)@RCD?5V#1LR;]9E/ :H)-TNL_'4?PT2$)U&X#J-QU&XY,(
MCWT1<O1$T143F-SF9[#NKM>WS"&%J==*IAEOB1_N"R-?<NNL=O:TAEY26>QL
M9BZG1>,;ZID.<KU/BE;?,EL=@QW".?68VMQ<TO).)!U%$76ODKTIMYSGA/=K
M&47"&0Z5CJ4VW[YR8AS[729A)-5RQX&Q_D1HTL]_D'.%:AC+'J-S?UJ4D,7R
MN/\ .N2I=K*QL;%V!K7K'($9,2*X/H\+I<;5E_>6PL]KLEC8UYQLT" 9SLY)
MR[6$"Q;(<(62?+$(2#IPE'%F[%)2,]+E9E1"1F7[V4> L]=+KG(NU/1%C9>6
M804:]EI-<K9BP;J.7"Q@$W21,O/!2% 3J*''@B:9"F.H<Q2% 3& !(M,@V4A
M9TPGI]L+/UE0YHR*7$BBC"/ 3 W!<$Q,B#QP02KNC%,8Z9S>K]BI  $6^HMD
M42%(1,A   #@@=(" ?4' ?:'' _'1%R-$31%^3$(<.#% 0'GM]OGHBBO*6':
M1EFKR%8MD,T?,GJ1^#J)\K-W $$$'2"W/6BL@81.0Q!#N(\Z(J:8MR%;=J]T
MBL&9FF74SC*=>(1F+,B/@66/!/7:@E9U2R/U@.<T4]5,"$%)N5U3L7/5&NU2
ML_5%$B+L@*(& #!Y"'(?9HB\Z(FB*!]Q>>*?MOQ%>,PWV3")K=-BS.EG:C"0
MD$1?NC@QAFBK>):/9 4W\JNT:'.@W.*15@./2'O:R\/HY<1K(J2$7?(\-X#+
M5Q&\0/5;<\R<NP[+",,FQC$:;#X!9TK@^1]P R!I_2.SR-F@G+DH7V9P&49Z
MB/\ -VX6 @XW-F92,9&7CH"1&7@ZQ0&)5!H-/@G/BJ^''M6#]U-R*8*G4=6*
M;EWS@W*B*+?)Q?T:*I-%1/=)1TUP'.!!?4 M$KS=K=Z[FV:; ;K!8 :[+::3
M#XZMF%X/-)+AE '-:9F-!?4$N;.\O#&F6[@!&YY<6MR;NC)=!7I&_1AS56R5
M8,BU*M.)K']DD7,NT>QC,SLT$L^4,LM%2B21!.CZNJ90&SCH%)= 4@\05Q.F
M7#8>LOO6)&F0&60-P-V^O$^:YYKW-%AIW#EGPST&N668*H+C/;/-)RS6.@JS
M*R,HNL1)!!O'+G.*IS@4I03(F<QA X]N"_C=N!'MJ20P7M?.UN1YG,\N)S)[
MB:)'NW==3]N??[]J^A[;1Z+Z">8\1D\UN;)"V6270=LX>#D&K)6.C@* ^%)^
M.S>AZTZY$ 3+P=LF3WA*JH/30Z4V:&7;:]]#?EP\<N=E;;ZWPL[>&O=W**-]
MOH@Y6]5.I+;8IF4;3D,^=A88B<GFA7<PT="06KIA(/RM6#8S(2'37;B=OXR1
MRJ%.HJ7HT;+E9X+L]?P]];:*L!HX>T^_O?@H8QUZ%_,3O$K1"X62MQ=T:2KD
M4*W.OCRH%8B42B\=3L9[2:D<+J_N+1N1PFDU*GXJQ%A,@6>M%K;OE;Z[^>?+
MM2S=;6/82/K4B8^]#ADIK+LRVNV46,@4W!!=C#+RCYYX//)P0;*QC-$Q^
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M:X$I64.,8_+4XUB?4T=XXW%]4X4_6M8S=8V%ALZ1VZ&WRT(LK?-5%%$Q%0!
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ML+$3L),R!$_$<,%09RR")B+J1X-S KJMIW@#S5MPW21K;L(^E2UV[\^7Q_\
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MZ#?U<\A=?/?2+@NUF.;4T]!2^C8[@L8AQ&3"WB&CDPYD!%.:.2L&[+N5]WR
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M:@GX0(@D4H$*F4GNE*0  @ 7IXXU(:  T !K= !D.[E[A2&M:T,: UC<FL:
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M0QN4T$H<I'<T<I!#DJBM@>O"J@)C%$K1$Q!*)C@)%>=-5)$2HI]R%*'XOS[
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M^JG,_P"V31$]E;_?IWL__53F?]LFB)[*W^_3O9_^JG,_[9-$3V5O]^G>S_\
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MK;TKC)O:[A-[I(O$5MFGV2<:P>3F\56\?6'#DY%GDF,9,^S$23>1H-DZDD2
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MAQ\<Q3",2P:I-)B=)+23"]A( 62-'Z\,K2Z*5G_:C>X<"0<EL>NT6M7#=_\
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M6$>5F&PYBN)K<A$U^!?U^,Q[4F$(^@ZG(/9:K0KR*:Q"3!U$UJ5DY&2@(Y=
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K@ZJ*R>D--3TU(9W,9+/4%\[6,<3,(VEH#'.%AU=P38FYN!E?>]>C+6K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g752656g23f14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g23f14.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1?L4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(Q-3$Q.#$< @4
M0$UI8W)O<V]F="!0;W=E<E!O:6YT("T@26YS97)T7V9O<B!46#%?1BTQ(%)E
M<&QA8V5M96YT($EM86=E<RYP<'1D.$))300E       0.(PS[L^N=B/P6&WK
M<,YFZCA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              *>   '9          !
M                          $             !V0   *>
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   *>     %)G:'1L
M;VYG   '9     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   "G@    !29VAT;&]N9P  !V0    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     8X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU- "H
M   (  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!*  #
M     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"'
M:0 $     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,3<@,3DZ-30Z-#, <G(Q-3$Q.#$
M      .@ 0 #     ?__  "@ @ $     0  !V2@ P $     0   IX
M    !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,
M   !  (   (!  0    !   !1@("  0    !              !(     0
M $@    !.$))30/]       (          #_X0%(34T *@    @ " $2  ,
M   !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q
M  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
MO    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD ,C Q.3HP-SHQ-R Q.3HU-#HT,P!R<C$U,3$X,0       Z !  ,
M   !__\  * "  0    !   '9* #  0    !   "G@         & 0,  P
M  $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$
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M,E25EO$S0E8(%R08)312<G:RM-,U-F)F<W23LT-&U?_:  P# 0 "$0,1 #\
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M31$T1-$31$T1-$31$T1-$31%X**$2(=14Y$TTRF.HHH8"$(0H<F,<YA I2E
M!$QA$   Y$>-$4!6K=#A&I.UHYS<TIN2;'%-RPJ$;*6]9JH7R,DZ5K[-^S:K
M /NBBX<I+ ;R$GD/!%'H[X,*(KE3?M<BQB!A$ ?O*!-F:>O "8&9';L@&#DP
M"=J7@H>_TCP D4TXZSIB;+"CAO0KK%3;]H43N8@Y7<5.(I!P KGA)ALPE!;
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M9'#U??[%C^45L+;8*=#.I*JR%EL-IF6M4QYCFF1:,A<<@6YTDHJUK]<C^I!
MO0W05>R<F^<-8N(8(JNWSHGXE-;672ZTUIAC?*R6HFJ)&T]'1P-Z2JK*AP+A
M# S(&< NDD>YD448+Y'-  /;MCMC+IMG7U--23T=NM]LI'W*^7RY2^;VFR6R
M)S6OK:Z?=>_5[FQ04\+)*BJF<V.&,X>YL-2</O/E(X;,MM7V^DA^Z!T&-?KL
MF?K0!MT ;P'TA&D#CD)GI]T4?'>R_$!W8RHI#XC6J\\VLQT_R):>B_>\R^5I
MA78Q^Z9A1^9=+PTW^CWN$F!E=T^0O(GTGR=\_-L_.M[H_E_YHT?S>W\XZ;S#
MY5^7O-1QST7G&[KT&]Z"R3$-/PSN*KTE/UJ%G*3=:58'%;NE+L#0U>R)B^[,
M"$67BI3P*XB@OW*J3V)F8EZO&RK!9%W'NU %9)':6JZ4]U@D?&V:">GE-/6T
M=2T,J:2H: 3#,S)&K2'1R,+HY8W!['N'#I>V.QMSV-KZ:FJYJ.XV^YTC+E8K
M[;)O.+5>[9*]S(ZRBF(:\;KV/BJ*>9D5133L=%-&WT'/G,]JRWA]J8;'&/LJ
MU%BGU*/(_N"7UBT3'I$Y"J"VCK.") Y%-RI'2J@ <YGK]?I34VGOZ\>/4NH@
MY[.6/'N4ST#*-&RA6SVNC3S><BFZBS9\5--=K(1;]LF55Q&2T6]3;OXN10(8
MACM'K=%02'35(!T5$U#03@$G@!GV*[6E[FM'%S@T9ZW' SZRH9KN\/#5H@<;
M6:(>3:L/E&(83$$Y6CF[<(Q)Y?JMC9=I8P5?E"+?1-HMT>A+) 9RBV:-9%VF
MNN1!$'.DAVAMM1%13Q/D,=?&V6%Q8&[@-53T1;-EW[-\<]0QL@U#0U[LD ;W
MH==Y+MJ[=6W^WU4-(RJV<J9J6LC;.]YJ'166XW]DE!NP$U,53;K9,^F=B-TD
MDD$18QSW='['N[3';5G&R36NY(FHQ_&N;4X?P5/6DT(7&B4L[AV66)M-!YXI
ME1)Y9@^>UQ0C=Q9IR&8OIN/K*T4R>.T)??J1K6/;#6RL>TSN?#3%XBHND=&V
MOEP[>%+*6.=#NAT\L;7RQP.C8YPK!Y-+Y+)40R5^S])/!/';F0UMU;3OK-H'
M4T55-LS1ET)CEO5$R>&*O#GQVZDJI8J2:XMJ9HHG\ZXW*T2.G+O#3</>*ZUI
M57NEQ+9)ZLK1M;M\%CEQ'L;RZICY5P+J4"O2$M&,CB]8Q:<P9\@]K:DU%":0
M+E-XI62U4<L=5 VEAJ*CIYH#'!414CFLJG4SB[>DZ!\C&N+F1B3?:^ RQY>.
M''L#>:BCL]51U5GKY;O<;3:G6^BN J+A:JV^LFFLT=VA;$(Z;S^"FJ)F=#-4
MNIA#)%7MI*D" RW1KE"Y#IM8O-=,Y-"6R$CIZ-!Z@+1\BVDFR;DC:0:&,<S.
M0:"<S9^S.85&CQ%9NH/6F;7/I:B.KIX:J'>Z*>)DK-X;K@U[0X!S<G=>W.Z]
MIU:X$<EUJ\6JKL=UN%GKA&*NV5E115!A?TD+I*>1T9D@E  E@EW1)#* !)$Y
MCP,."P^8S13H-A(R+TDP+>+N<O1'((,D5%1FX6OOK(\.F079 ,P&.CW!47 F
M*<[GNT3(D PG+G6M7)VS*E1I59KELGW#QM$VF3KT5%]VU[YUW]B)XE)=R@53
M\2SBHQ-[-3CGK.6.AXR1>F!0C82F(O7D#)C:@N:]'A4KE<Y:S*2@1T32V,.]
M?%1AF[=P_=NO;4[ M4FR)7;<@"1RJJ=14 *ET@8P$5,.T_SS;L*; <T9)HX2
MM7O4S4HVMUH[D$F\W6I.[.&L6Y74%DX>-VTQ"QCJ14(HU=N$F\BV3.W<J@0B
MAJNT:?'-2!D@%?S,X2C/Y^P+RMJM;.!1%XJHHLZ,K(2SPQE!,=5)FF<O '$3
M"99XY0,8W)B%5 >H<&1IV]VN>[3[^2SJ_>*OH=7 1)&6E](*=WTCXU-!%)0?
M='\A+J$GP  $YA  $!'5VNQGGGB.[/N]G!4<">KLU/9IU=GW+Z[=BYV\N1[O
M3#-RIOT45I6*2.9)15^D;A5\T,'X@QG*)4152,9(YEBG5 QSJB @W48U!(R=
M<:<>?OP,\,* [&ASGW^/O'JWH]CEE^UT'<;5*IXIT6$R DI6[#%'%0$E%%43
MG9.3HC[H.&4@FBL102@<J??)@/2N?F[23CE@<.OMZQ[3E4=@'0Z<?'#Q[%V_
M968B()FI(S<I'0\>C_G7TH];1[-+_P#$<NU442?^D<-74+Y(*T5FT('<UJQ0
M=A;)F$BCB#EF$LBF</4IU6#A<A3!\C& =$5?-U^Z> VC8Y#*-JQ/GC*E:;+R
M(SZ>!L<'R/*4^%B(20GI2V6YH$O#IPE4CV,:N5W-+N3(H.%$$SD J@J%(H[V
MN]H#A/=+3I>\1<)DC"D3&4J-RBT:[CJ_"8GE[%B*5CTY%KF*N1SRSR:LCBGN
MU2-U;X<S:OIO>IL+P3E-P16#_"&P%[9BZY]>&(?I#.*0R4+!?633?;,NK8X0
MEEKZ<9&>V?&OSSM<43GX<C5!4TE"J$E&8+,3E7$B\W&X/ K2@%RPZS;B1MBT
M\@>))DE?(]/1H1I1-ZI&J1I;>I,%KYGY)!)5B=F$@+@KQ,[84P6*8@$7OLV>
M,'TL\*G<<R8KJBEDC&4U7263(-3@SST-)2+*(CI:%+)RS4TI&OY62CXQD^8@
MNU=2#YFS05.X<HIG(LLNM\H^-:Z]M^1;E5:#4XTR!9"SW2PQ-7KS SI8C=L5
MY,S;MC'-C.'"B:"!5G)!56.1-,#', "18Q.9QPK68:FV*R9>QA7Z_D5=DVQ_
M.3=^JL7#WES)))KQ[>GR;Z509659\@JDLS2AEGIW*2B:B)3D.41(JJ9A[23;
MO@^YYOHET;9#4F\ 2.V2,OAX2M1[]BHYW96H:=BL8)PM/LSR*24N FM!UT60
MQ#3\<V+)G'NM$5_=$31$T1-$31$T1-$31$T1-$31$T1-$48Y$RC%4%)%H1@^
ML=GD$Q/%5J) GBER]0D!V_=*_P!&BHTJ@"4[MR)E%!*<C-L[6(9("*MJU;W#
MY87.I9+P\HT YZC$K5#ZX0$FX\F*B[L?2-B>*=(@195!\P;+](B#%$IA3U&O
M=[\_;\-??!([^[V8[^SBJ&VX,9N9ZV1%(Q[N7W"(T.2>05[O6,(A]:ZO6YZ-
M.8)>N-YNQ6R&=6F<A>!-*Q]0;S7@U#$;F4,[,*!>MS;2P":HBHK==+JRDD,-
M74VZECEIX9FG$D37S3P.J9(L'I64S)MTD-_>RU>LT'DDN4E!;JR_;4;&[&U%
MYIXJRS6G:F[ST=TKJ*H;FEKI*>DH:YEMHZO(%--<I:7I0'/W6Q 2.G#$%!LU
MEK$%E#;WG6[OJK)]^I&G&<F).*(X9+'92$/.U.U@Y392$:[07824/)Q;60CG
M22B?=H* 0^MU0UU+<J:*LHY1-!,#NN#7-.\UQ:YCHWAKXY&/#F/C>UKVN&'
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M5&+.R"L=-<[Q(SA$QQ(")B"(MTVP=0J!ST^GEYU+7%V>6I'KZL=>!QU]I0.
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M:IB7#^-4F-MF4YR?D;C,TB277<,V(LV:1W#:Y-"MFC1+O!2301(8RRZAEE%
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MP<6NWD@VAH=I*S9ZDKMGJEU/,8H:FNVDV=L?2M$ GWIH+I=J=]([<SZ,Y&2
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MYG48'O(]FONZLJJ;5=TANZB2I%$6SK&%N8.>!#W>F7K4@FH8O(#[IVI$^>#
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M48D0$@1:HDZ0^8$ "A^O@.!]/3^]KP/@\U (.N.[KQZ^7CCHLU[P#EY*(?I
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M1P9BRXD,]R1BS%5MFG)A4=.9"A5V2!,3!_FDG<I'.7ZX%Y'E==4#J&$3@FB
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MSGACM![#UZ_:K'5YH=:?AD2&()H:+E7[TPI"(IIR@M&3!$5O=*D=R9L[7Z!
M3'(Q$1  $AA[W1LW8@3Q/N_OGQS\<NTHDG(&HU)'7KH".OV#L4@*'#S HAR
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MFB)HB:(FB)HB:(FB)HBJGN)A5FMOPSD$A>&,'8):IS3@!X!JTN2#'V:Y5$1
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M@<"3Q[>X=H(/(JA.#G7D".S)Q]O7ZN*E"!P05@^*?NP.4% $ 3((B(<_#W0
M/\?G\M6$>N> ]6OL]W8HW].WW>,*S+-DVJ4.= 1(60=MQ;-6Y>!.@DH7I474
M /,H '/2(_E' "ASP;BV &Z$'7.OP[\>!RIDD]I7(5)F95^V*!1\C$]  ?B'
ME^H1$.?(>/7R\Q*.NZ!P+L\\Z$N/#NXY]O-U^!U9\:>K1=M+LP<HSTQB=GBJ
M9CS*M:4Q<.X*:(< [J*=OBK#$/$1 >I1!X^7.S<)'X%MU(*$ R!5%;#GV?W]
MVBC&/7K]GV+:1J431$T1-$31$T1-$31$T1-$31%A]SI[6W,6A/$FC)B'?)2U
M>FT4BK.(B31 2=Z5(YB X:.VYU64BS,HF5TS75(51%<$'")%P,5:.^EDJO;6
MZ->N!TCF9I@H92&M+=  [R0KCTX$[\2\@+R*7!.7CQ\UFZC4R#Q=G3'KQVX5
M<:YY\/=[#[AZPI ;M3HB BH/'/F4/R1_5SZ?[>/71,:\",X.N,#'8.OCZ\\5
M53>E*2$?B2*9C(OH6FV3)%$JV4YV-<F8.H?&\W+"VGE@E"%.>):R+GV9!2,F
M4AO!QLL\4'I+R<NCV@>YE UID=#3S5=)!6S,<6.CHY90V8B0:QA_HQ/D&"QD
MCG9&,CS[RF3S1;/4\732TMLK;W:*"_U<$AADIK)55!CJW].-8(YI/-Z2:8 ]
M'#4R..F2*;72,@TZ9G5G9L04S$4!AIO$R.+[K4)>MMK%CRT)8^@Y^J-:]*PD
M"PEK0\LEF>(=:QGR@.?:IXQV5R*76.EJHHA2W(36^EMT-M8V2AJJ9\(EI*AM
M+$^G\W,<+7R/EF>!C.'](87L>UQ!\ZN=/2-M>UL==L[:]G:39AM/+8+I;9Z.
M*MLU>+-25EOCHZFEI(:BODK:^2,E_3DR&H,$F^]H)V8T.5G9.B4N2MC8K&T2
M%3KCVR,BE[HK2>=PS-Q,-NYZC=SW$BHY2[KDP)]'1U#QKN%*9I*:G?,S<G?!
M$Z9@T#)71M,C.H;KR1Q/>O=;1-5S6JV3W&/H;A-;J*:MBW=PQU<E+$^JCW?\
MNY.Y[<9.,$<ES+^39-4CJNEDDTB>8BJ<I2  <<B(FX_7Z<<!S\-<@ C.3C3U
MG7E_=<\G>Q@9[-??XZ^'%5 F:%DK/\[;FE5SQ;:_B!^51A)BTI='7C'[DI$D
MEZW4Y1Y#^VY:,;G(JI.32[Y1B*RPPS,SM=-][-U511U\LKWPW>HIHG$%L+*6
MB>UF  0'20O><G)RYQ.N <8 ZQ6V2_U-5-/2;85UN@D<'1T<-JLU0R!NZT%C
M9JFDDG?EP+LR/><N_>P,*5$,*YP;(HMF^ZZX(MVZ2:""*6+<2$2112(":229
M"UH"D33(4I2%*  4I0    XUQ_DVZ?Z@J_J5M_#+B?-W:C_7MRQU?(FS_P"!
M^Q:[K+L)W72V;MP=S;9L.:.R#C*8@(JXKGBF<I<EY-A%-4*?.P3!B1I6HU(T
M>=%S*1#9(6J"3-2,$5'#PJ/4)=D[])=+Q5"ZG<K;>^"*I.XV6=SVQAM/-$R,
M,@C;N',D(#F@@QX<YZ\KJ_)CMO/M%M/7MV@S%<[144L5R>Z"*>YF:*!C+=54
ML,(CHX1T1:^:!C0QC8S#K)*&WQV*86R%@+;O6\>9-D$7=G:R\_*'8M7P236!
M8RC\R[6';OB"*3@"""KY441,BFY?K))'.5,#F[1LM;*NT6:GHJU[73QOE<6L
M<7LB;(\N;$UV@(;DG0;H+B!P7IODVV?NFS.RM):KQ(QU8RHJYNACE$T=)%/+
MO,IF2-]!V/2F<&98U\SFM) R?OWB5R\9#Q%8L5T;%9[_ "]]8A$LIY[-5J'K
MM%>F<I'1M$HM)RC><*XAA($C'>P(M^Z5>(I)]: "81S;00U-7;IZ&EHO.I*M
MG1MD?+%%#3.R"V>1SGB7]D1OLZ%CWEX &[Q&3;^DN-UL-59;;8_E6>YQB%E3
M+4T=-1VR0/:6UL[YYV50?3X$L'FD$SS(T E@R3\E;V_YSBZ[ Q;_ '=Y)4?1
MT-&,7BC>F8N<H'=-&2""YD7,E4G,BX2%5,_=KR#A=ZL3A1TLHN8YQI#:KFR*
M)CMH*XN9&QCBVFMY!<UH!(,E*]YR1Q>YSCQ<2<E8:397:>"EIH9-O[QOPT\,
M3]RV6*1N^R-K7;LE1;I)Y&Y!W7S/?*X8=(YSR2O@O./LGX]I=LOECW?Y0;P%
M,K<U:)E<*)B(QDXR"CG$F],0H4ODRGAVQP3*'Y1^D/CK)\F7'Z?K_JUL_!KD
M?-K:3_7][_E6SGV6O/LX<5T,;MO\REO+W#W1_EZ:5E%6S$T70BO(^$CW;.JP
MD@^,A$/3047$LY"1(A(&D'+PS8#JJ&>=T5-HF@@CL*>.5D;8Y*B2H>T'>FD$
M0>\@\Q"R.,=S6#3K.">W4%)-14<5/4UU1<ZA@/25M4R".69Q.23'2PT\#&C(
M:UK(VX'$N=DG$[;2P7ZET"<E/R82]//'D/J/Q#U\_P"\-9RX:APTX8 ZCWKF
MCL.#Q//77 ^WK[^4+/:@<IS?BN! ?,!+SS^KGX_J#CY#QJF&<@1W:=W4?45;
M)XZ>ONUSR&OLZN2]+>L"!@]S^X  !'](^7K\A$ ]?74D,!X9P,=Y[\Y[/O4Y
M/+&O/7X8'+M'WY['14BH@FS.Y>F:$XZ&IG*RC8O'Q*@90R91 0 0$I?+60G'
M,\.75D<,Z>OCJ%49ZL9SDD:GGZN?9[E.-8<V1DB1$DP_*@0H%(F943]!0X "
MD%0#J%  #@"E, %#T#6,Y<,#@#DD\].T^W'VZ0< =1QH/OTP>\_$96?M4G+I
M7OG"JKA4PAU*+',H<PAZ!R81-QS^HH>?'KK("#KPX^#RX8[EC4N5J)%,"F,3
MS-P(AQ\/4 $/@//Z.. #^PT[V3RSZ/VD=A4\L>WMUT_NNQ-V;NQW&MGQFRS9
MENH)6"5F9QRK2(Z2.K[+1@(P"- E%V!!(#M60E"/P3*Y,= 6K1NH"1BK<C.!
MG/,J/L6\%LV;LVZ#1H@BU:MDDT&[9NF1%!!%(H$32123 I$TTR !2$(4"E*
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M")SQ$7]"V9T(;"Z5L8D=& TNQG,S'("A#D$3 !RF((D,8AP P" B4Y!*<A@
M?=,40,4>!*(" #K8KL!&01KKU'!]1&H[Q@CD05 M/VWXXJ&2Y;, FLUKR+)L
M%(=M9;O9)"S/*_"*',H>%K9'I@0B(\PG.4Q4$A<'3.HF=P8BJQ5-7!:*."MD
MN/[:>L>PQB>IF?,Z&$G)A@#CNQ1DZD-&3S)76;?LC:;?>)[]FMKKM-&8&5ER
MK):V2EIG')IJ,2'=IX3G&&@O()!>=Y^]/FMG@=0]@79UZ'3ELR;.'CQ=%JS:
M(+.73EPH1%NW;()F577754$J:2**1#**J',!"$*8QA  $=,#J'L1?S]^TSWV
M;7LG[MLG*88&8L]7?2Q2/[7X9NPAY>QMD4V,Y(5PIQ4=.X5X];'>-)!XDT.^
M.X67(V!NH@H?$]VFF=#ZCJ._/C&JR-:1@YQU>.Y4M;U2$OL>>1K+T3N3$[T&
M#LI2F/U%ZN@BQ! "G$!]P3%[LQ@Z1,3D>+-+2",<,DXSR^WU^XJ=003PT&>'
MCK]7(%18\IZJ*RB:J(IJ$.8BA5" !BG(;I.4P"'4 E-R AZ@///IJ,,TX\.L
M:8UZ^SGU\E.>WJY'&I]61U?'5>3:L\&_(^7D4  /^SY>O/PU +>0/(#(^\Z]
M_O4^,#W\LYXK-(NN'Y(4I/0?0 '@.//D!'SY >!\N/GR&K%P&F,_ =8QKPZE
M7!/'(' CK[<_;SQGNGBN+6!HW(@68D2HE*!2IBY4-TAP ])!,)CE*'EZ&*'P
M#C4-WBX\F@Z#'7D:^S(QPYCDH=@#ADD#7[?'Z+.V3=150%%3'54,;WC*&$YS
M#QY<F,/4(\_$1'Y>7GJVAR!UY["?7]WMYX_[>/8K)8DIKB7EF29$S'$ZQ.1
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M6.D *F]/4PAU"!AY$1$?CSJP#",$:\,<\]GK]G-4WCSU]A]NASPZ^2PU.HI
M(#Y=(\<<>@AZ\@ ^0@//_N]/.<$-YY]6>/8.SE\%.]KSQKIG[/ X=2R!G7D4
M>.E,QAYY#W0 .?GY^OSX#X?+G3#0 2.SB3[NOX=:C><>&G/QXUX=BRUG&#R
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MJIW[KG0%JG?:'MJE<(1$_=;OD3(>0,K9=;P=@R(>X6->4A8&:!LL]<P-5C!
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MMG7R3U]+:Y+ULM%;]G;G<*9L](9*=]<ZZ62&:6KHX:&OKI)Z&JCGDEP^.'<
M>YH:W@FE;D,H6W;YBIID%.7R'3<?V9MEF\8X91T8[QUC*Q8R2K"%"FYM":M4
M9,6!]<E63IB)70KB9DYFD(]@5,KU7'3E\M?98!/%4UE!#*^X30,W6PT4E&8F
MTD\C9IP^26KZ&5K2_+^@=)NM&'.X]H=-5;1; T+*ZENEYV?M]5+?ZN@ACBBM
M=FGLK*.*SW"IAK*R&KJI;KT4L;6S!SC"^I%/$P%[KJV?:QA6:QV\H$;1JY66
MIF*";"7@8:/C9EB^8($38R82+1ND[6=)F1347546%1<X"J8X+]"I>W+W'Q]_
MCDOOVZ6:SRM)=56]NQD;OCB8<4V<ECF Q[ V9)(KP-D.8!Y45EH==J+Y;@O>
MRK>1'H(("0I%/^B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+%[A:XZFP:\S(#UCWJ+./9E.4B\G
M*.S]TRCVW5SRJNJ/)C !@10(LX.'=HG$"+ZZ^@N6/2>/C%4DI I73Y0H"!05
M.7R01 PB)&S8OXI G(B! ZC"8YCF,4#77V>OJSV8SCFN=T4KTN'#=HBHX=+H
MMFZ11.JNX5(BBD4/4RBJABD(4/B)C  ?$=% (/#[54'/^57<M*8\Q!CB^Q]3
M>9+7LDA;\D,7S 5J+C>E,6SVTR40\<'%BSGY19]'0D1)..]1C#.W,AT LW05
M3TUUGG,E);J:4TTE<9WS53<!]-14K6.J)(B[+1,]TL,,;G!S8^D,A!W %T+;
M.Y5YJK+LS:Z[Y*GOIKZBXWAI8);58K3"R:Y5-.^3]G%53&6&EAJ'AS*;I))B
M&N8QS:Q,<?[1GF:[!B<C:GQC&'Q= 7J.SHPRM*-\CN[C*6!_&NC_ $X&R"1Q
M*()MDY<X"=43.%S'69"U,1(-(VEL3KE-;Q' SHZ&&K;<V5T@K3-)/+&[-493
M(Z1NX)"XR'5V',PO/8K1Y.Y-IZS9YK+;!%36&DNL&U46T$[;U)<YZR:"0_*I
MKL/J(VL;4XR[]H_>=%T9#5)N,L9L<MY'M5+W#/V69'NWYA'PM,-/14:[B+14
MLAD;V*KY*EP3*=)Y<UHZ'5K$FL0"L3A&*R#=+O91=13>6J>?>JZ"JD$\U ^(
M,J= ZII*AG24TLH;Z(FPU\<I:&M>Z,O:T!R]&V-N5P=+>MG+M5_*5;L]/2""
MZ^B'W2SW*G\XM594;G[,U>XR:"J?'ADLD/3 ?M"XY_D+'26 K)$YIQ-&H0E9
MCA9Q>4:)"-464-+TH5C)KR+2,:IIMTI&K^)6FHPZ"9%0%-ZR PMY%=/6X7>E
M=!!=%R@BY;J$60<))KH+)F Z:J*I 4343.41*8AR&*8I@$0,40$!X'1%[=$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:K8D76;
M]X]WM '*O"T1P&.JZ8G"B:36MJ+EF%TQZA+U.;$O+F,8O "D1$H@ D'EV=?C
M7QV*,Z<,]BV8@_:QY$X]N8IC(%!,Y@'R*8 \P#YF#CS^!0X ?D%@TD9]7L'/
M'#[53>#=.)YGUY[<\>M5HW3U:BW[';6M6['M.R1*6"?CZ_2HZYP3.:9QE@E@
M6[V<1%P4'3 T3#MI*0.LP<-%E@:ILQ6*5QP/#KK;07&$07"DIZR(.+VQU$3)
M UV,!["<N8X<G-+78SJ.![#L]M3M%LI6.K]FKW<K)5N9T<LMNJY:<S1@Y,-0
MR-W1U,63DQ3,DC+M=W."N#Q3MUP1MHC@<XUQI4*_:E(TC&6MK2+04LTGU$3\
M2BI.O._DTF*JB13GCT'*+$QDRF\, @'''MUAL]K<Z6W6VDI)'-W7R0Q#I2S0
MX,CMZ3=)U+=\,SJ1G*YFT_E(VWVM@BI-I-J;Q>:2%XE92554_P S;*W.)?,X
M!%2F=H<0)G0F1H.Z'X6?G=%L'?*/WG=@)1Z2B'64#"4.."#[H^?'/5Y>OPUS
MWG)XXP.!.AZL#AR[/:ND,JP7$:'LUSV:\3D=8X=RP2P1$7)JQ$?<Z_7[577#
MZ-KKF)EXAE)L'40^>)-FQ'K-^DX:N_9KY1O(M%5DSJLA*J5J)"JKE7XTS(JE
MAAJ(HYHB '121MD8X#AO,>T@GL((&!PT4UE#076E?2W"CI:^EE(=)35D$55
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M \BU"22=&'J*4J"*P^I0U5Y)+2TG0Y(["<]>#CGIKVZ!2T$!W61PXD:'CU>
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MM9BH0D>YM+>"M+Y2X2;2*4;HI.43H5 SH-2= !S6(!SB&M!<YQ :UHRYSB<
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MW.JU<JD*LBJD8P'3.4)1:2K7_P PF]G_ /58C_\ Z=#7U90?^]GDN_[@R?\
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M$!#X\_IT\>/N0ZCGKZC[^M8"ZS%0T!,*EDC0X$W/])2_[3 /(AZA_C\!G+>
MSIQY>SV'"CTSU =_KY'/8?=S4?2FYK'*#PD5%2:UAFEA C6%KS5Q,2CE01,
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MR/N3EKM!X<@205@DD[3)X[K(7"W-U9:,C'D/ A&5\0?$6L+^+1?#_1F"CET
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M/ZM$4&4C<EAS(N:\U[>:A:E9/+>WAMCYWENLG@;"P2K*&4H-Q8Z0=*<D(MK
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M9_\ :%_Q=D__ *=[_P#%:E=7!O\ WAO/_33FC_K(L.O"%],+,,G_ /-KD/\
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M[%PK-6SV52JM,(XIKU[=HM(V13;H5T*_,2R2AED%6D89P639>%DTF[Q)D]O
M#!ZN/Q]7,+(Y\V U[Y,=&UH:XNQT9+7M !/[F0US0/1R X:@%9-N$OESB\H=
MII^!_=\F&VVL*7V1C29M&%[)<[#<:MLPE:<Z)D:U8GE$G<K:Q?*U,(M27GHP
M7D\K7'$W*/UE1(Z=$9+M<D\>.>LYXZ\<Y[=55SWO.7N<\ZZN<7'TG%[M22=7
MN<X];G%QU)*^#.-KH$5C+M2XOLX,BY)M?9[Q/9YUN9GY=.YY/M.,ZCN^<95@
M46C'$MIR ]=RJ5@E<6 K)9!8UJ279MY,S<)@&T@5JT19)QKPTUZM=!U:G/\
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MY)/,\2?O*$OD>7.+GO>XESB2Y[WN.223DN<XG))R23UK24VQGE#:1OM[)[:
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M%SCIR:T%Q/  $G0+C^TSVZ53!<+A'8K!;;8:S+8<[.F:@<59SNN,]RF;@O\
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MD8Z0$F0![Y>C>YVZ\DEQ^&&C&^2<=]E[LK[.JB3.>J'CBWY WK9KE=TT1D;
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+;3]_>W_\N[Z7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g752656g34u16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g34u16.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ": +\# 1$
M A$! Q$!_\0 'P   @(!!0$!              <&" 4" P0)"@$+_\0 .A
M 04  0,$ 0($ P<#!0  ! $" P4&!P 1$@@3%"$5(C$)%B-!)#)1%S-"4F%Q
M@0HFD31B<I+P_\0 ' $!  (# 0$!              $% @,$!@@'_\0 1!$
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MI67J[VGNFO6LL!RUCD+8^-CG,F1 K$VIFF2"5L<SA''UYD(IK8U#.; LX4Y
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M>KXU >3J[=>HK/MTS*2UPDW'URT*#*MGE)$M!#[#XZV/O)%#(VY@5!DF[-?
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MZS1#S8FSJ:XH@^GM*VZK9)9+BCOHQ20+2H!+ N*J&NT-:K2H:VX#'L+"(I4
MXI+D^A+B8N8LN;2\AML#UNY3[$8W&B$FFW?%B<4ML3(Q\1&$4;GJ]D6IQLDX
MDC<ALT(LZ!@-=96M.>J<GIM_?/KX#-6BX_P]?QUEQ,G565Y; !&W1HY6B.99
M6:+>75A>$#/,8.-[@HI5C/ !&Z-5%"8.*UZQPL[*BIITI1TI6%TEV-FL[?Z,
MU40//TMI=EJJ^*(-5 SGSJKO[)[4#^Z_V_?JONMP9M%KN5UD?]/;+?,N#^^/
MX,*.Y)=WZ>XVK?I62$E:DH'-2@D?%1 _6D]Z7J0JBX#XRC/1?R5SGTV%HYR*
MDC[+<&E[ UTW?]7NI/>/8]'*JL5OM_LQ$3PWL?M[UN]FO"*9/_5S[6+Y,)&%
MJE\0OO7V07.NL.7%25!1*DZ=)/NUT3%!4I[')*NS'AAL!L8__FGWU^DURU!.
M3,-#R/B;K).LR*(PQU99T.A$@C*+S.MS-Q7Z?&ZD4.=S!CR,SK*:FOH*\Q5!
M/EKFAG,D$GF8Y2J2V_".LLO43@_4A;\'[2P]0?'N9U^3J+[->I(JL]*]^+LZ
M6HH3+728N_MC]7G2F5U*/)[.:X0O"PCY8VV=OOIJ2@OP%3G8CH?+?(\_Z\L[
M9Q5S.*\/887,D#7]N/H=AH[^]V6VOQ I*X&RTVC.>61!5 3$FDAY[/5[:W)Y
M40TZPLALM04H]I96=E&78$JBI52?TBM&(GZ81[UT@\2_\$=C5UEH2]O?[<R:
MT,L9O+[3W'RQM5$C\6U5M]Q^\1QLVS<RME'^E$N%"G/*'4I<G29CF=QK4M V
M1@6$[WFK:\3J6Y "75>*HTJ5$:2>@*(C$9&.>D()^]DY_JUJOI!<G[RPJ=WQ
MSE*JE.N?FW"&V$<*O&%D(48J&G%F/</- UHD_NWIL:(^6(>O'F\$1R.3XF_Q
M$^VJ^\+^VCV!^S/AOA"]<5?;7%'VO>V8G;6ZUR9J[==(?"MLEWQ<.7#::MLS
MO?&EWCAMV5&A</09?9!IS6/:</65B59K]<I,MF+V,7LF"K2XZE <:7*=2P%I
M62XC1#95LE2Y"TYR*>9+PWHP$QPKOR#9AV!DNB<AK?8>\F!D$O\ ]2WXZ2.F
MC1CT]E'N>WP1W7VQD#2"0%*Y#/,@9(3G<X )^&]>.2VM25K2A:D- %Q:4DI;
M"E!"2M0!" I1"05$ J(2,DBNMJR_A*^C"QY&GY%;B;FND+LEM2\C5WGP\?.4
M^9Q$K6@-#=9"B2S.5WP@K886)G]$:."!$B1I'ASK"KF;CC+@S>9<+@G>Y7!7
MV9.JH2:GC2X@K%CEJ,M('!"?3TJOC,C'H)2 84L:YC%K7E#QJ1$I+4DP*V]:
M6E+0'%I4M+94D.*0@@*6E&=12DJ2%* PDJ )&174B%,7$>GMQ)2X$=YF-(FH
M8=5$8D2$N+CL/20@LMO/H8>6RTM:5NI9<4A*@VHA,:GB+T:<::/C:IM^%>)Z
M^X+9(#FI4QF7C914F?8&-^;N23(X&MJQ[JTS.7%+)4X\S3ZK.U@L)!%@KX],
MB9'C.,-.JPM\JTCW0$H;TA3JRH@);#CC+(.ZE//LH2DE>UQ9N%KQ?H5VGVZ.
M78]H1'+Q"75+D29)=6U!B(:;<4]+,*)<KHX@Z&VK9:KC+>=0B/A5R&,9$QD<
M;&QQQM:R.-C48QC&(C6L8UJ(UK6M1&M:U$1$1$1$1.NJO.UJZ4HZ4I=[7BO&
M\@Z#C/3Z<:ZGM^(]@1N\1)5ZS5YT,71E9>_Q\T]W5YZZJZS6UZT6FMX&TFK$
MNJ:,F:&P8 TX48B)3.,^>U9/?$[\3+&S\85&1O=HTRC;75FZT%QE\S/7RWU9
M%I)3;NASFLM!2PLP^X.I88*$N*PO!JZM-FK@2R;,-2HQCN7:K=;O68_/YG8$
MT68S>3T8'+;0*DKB#=/U%AJJPO/8+8UMV<Z_TN**RDK-S6OK 8J+\S0-86;*
M=-&(IC'[=:;'2E'2E'2E'2E'2E5V]5E@2-P3M:BOD5MIMOP?'56QO^>8K?:"
MLRDL;$[IY*@-H9,YO?NZ.)Z)W541?RWVSR7FO9S?X,96F9Q#]G<+0TCFX]Q+
M<X=F6A(_FQ&F/K4D;E"% 5U0@#);41E+>IU7D&TE>?Q ^?ASK:Y2X6VFM(Q!
MO'?*9?%Y?&]>4%DF#T;+VGF?>9ZYQ][-K:=]C62:.*NH3ZT_#ABVE'!1:ZK9
M=7'\RAN@J!?TJ)&9A18T..G0Q$CLQF$#^1EAM+3:?_BA"1\JYB2HE1W)))/F
M3D_C4=IN ^3J_86>IGYRMU'/N\M:Q4D(>B,%AK*S-5>=TF2E-O-I:V\N?N')
MH;VH8-8@2T6EL*R_E2U/KSW7'14?+UXU!*7TS^H4**4BU]5-E97Q0^]@FNHL
MC:1R"1:X;&BT(=-%9;FWEJ ,/+E%O X "QW::Y*8S4R6-=^3%M53GR'3U\^M
M69XEQ>QPM ?5;3?F\B'D60!@=L>.3 0&/#D\Q468JN,LK2>5EIJ:K0ZUD?OQ
MCUB:7\&%"T&J&DD5%-+I2H^-]:BZ:GTBT6;E5$_N]QVHC<]4_P"9S(8V=_W5
ML;47Z:G54S_XW<4]/LNSKQ_N5*O:2KPR4MH3GGA !V JP=_\*A'KW^Y)!_VA
MBU* ^ 4M1QXJ)ZU(.K6J^E/JMYQ3GMUFJ_9\C\?YS4(&4S,YG1:_/TU]8%7D
MT ?S*ZHLK$8\Q[XQG5X;A1Y5E<67"WNY43KR5QX3AW7C#AOBN<EMYWA.VWV/
M9&5)U=WN/$7<(\ZYC.R)#-L@.6Z,XG*A'NMS0<!P9ZVY2VH<F*WD"4XPI]0_
MF;C]HI#7CI+B^T4.6IIL[XVK9ZOZ?E:DN./N8, 8,52<<F1:2^JK.P6-0+/-
M2ES5T&4KT:BE7'+N=O\ 8\(6D:2/1)]GDKI1IG9IB+UWMN8VY%G1E)4W%4'7
M$+5C0MHDH#"<;N36G)%O7OSD,.8_@U^R^R.7PM-B<0<(WYEYJ;Q&RJVP)46.
M%A^-<TLHD.76020U#X1N4"S<;Q5%*<HLMVA=J@7(FMXCU5:;9<R4_%W&>"T:
M4D%B&;<[,G.)I':*@ V=UD[^6B#!O:VDQF:C+S%VQ-WR/HJ0RY%B;+QKA>09
M)V3#R;R[(G(B1(SW9A:5+?+0=[9I+[C#JFTI=0W'9"FG!WF4ZVIU(S#CRB01
MBCV6VVS\&S.)^);];C.<C/,PK,U<OL[[.GOV6%=H"9SS\&5-O-R4S=(*OL+A
MRW3F83BRGB6^\/I06W)US5P*%ZA",];@[_5XFSQ.OK8R&51"SP.ARVG:::ZC
MF;.+<8#76=8IU5%N\);T%_)1W4U3?KH:9@U8/4P)\#C5J;(@RWHSMAXDN_#\
MYA*TK4S-X?NCL5[!24NPWI3"6Y++\=QI[N4YI+P=04H%#P5QX]P W<HKU@M5
M[C7JTRM!EMZ%I<N=M+# FI*'H=^M$:3V$M=AOL.X0!.A(EP/LZ:793B X&PM
M;RIS7;Z[EV:TU/)7$(= %46M@0P4<V7%[7ESBPCYU0% -5$BIIN.X>5Q@QA!
M@A]9J*71?&4BIS4E=V6Z.B9<7'IQ<>EPD,AM:SI"BP_-AJU-I"6RGMX@FI2$
MA*7GVW<:D,Z/?<=7R1POP7#M/"2(MKX;XM>N#TR+';4ZXTF\67A'BALLRWUN
MRVGOLSB)7";KKCSKSEIMDRW]KV<RY)DV.VVNW^LT/(M)B+J_R.1XBBKZ_6V^
M%S.?UG+&QY M,S5;87$X&OV8-OC*0*LS&BQQ=E>Z'-Z,?0%Z]U4*3BF9*VO3
MO5U\X^OAZ]>%0;AGF6\N,[PAR,-L]5R5PMZ@VBAT-MR9C<]A^6N/M/:4EQ<T
ML&G&QU'D\G9Y:X(H2LDT<;*AW5-K3J(@>^VF;T+CLPJ?'QS\L>77^E75Z5%'
M2E'2E(M<'><2Y[B? ^F'CSA3&<=5'(<,>\R9 Y^%I,SQ7;QZJ\U]AQ;08;.E
M5$_(!>U/J; >KN8:7/6,=GIK"RMH;)1OD*GXY]<JT\U4=I6QT_,?'_$$/,O-
M7'(AN<X_S1'(;>-XG9_DO3X8#DESKVR8=F6*#GL^-IV-N*2Q,,?EVT5(16%7
MDT\B@\,X']\4]NE16B1KG1O:QZQO<QS62(UKEC<J*C7HUR*URL7LY&N16KV[
M*BITI2-X\UV[J@EH.6&0VUY7&E@S:[.T[Q*TMD+U>'+:5<$Y3PB2PW#D(2#$
MT"?WT5P59V2-ZF1XU.P.0\U>S% 9TR6TM!I'CO$2OLA%AF1DBH^=YX@K$&8K
M/ZDL;I$[.8C$>Z1B.4K*5$"V].$S10@6IU>>]TKI@QWL995%A*@-@P=['QB'
MQ^R.9%)"V-P\[DE&6-OMJFEZ/'DA"9##,A+3S4AM+S2'0W(86'&'T!:5!#S+
MB4N-.IPMM8"D*"@#4@D<B1D$'!QD'F/@>HI0>I+U&9/TV\>V>TO0+#26T8L[
MZ+(4C7/M+@B)J>4Y4S8B(Z6@#>Z-;;0G1*'7LDCB8PH\D( K=45->%>1B>7>
M)\#R:7F+#&S[?-@:!<U9SM*+K&',5\+?E-@%^4,3#[9@)3A19" 2!II!1Y'N
MA8I_7Z;4T.E*.E*PNC)NP\_>%YJL&NM$+4V)%%4&&MK1+2WA$EDKJ\FP<R1H
M4!A;8AY2G-5L#)%D=V:U52MO#USCVFYR+-"9N5W8@2W;7;Y$D0V)UP;8<7#B
M/2RE8C-R) ;:6^I)2VE96K !([;:U!?N,!FYRG85M=F1FY\QE@R7HD-;R$R9
M#4<%)?<99*W$- @N*2$C<XJ-8PO06$K3]55"T>D(QN+=H*<$]MF'4WCY=(38
MUH]@QK6%L$D)8ULS/)CV.8YDLS%;*^GX=?NLMQ,J^0&+9>'N'>'#=K?&E";'
M@7-2[P],AM2TI2F0F.MY(2XG*5)*2E2TD+59WIFWQTF/:9;L^VMWJ]BW37XY
MB/3(*4VUN-)<CJ*E,J=2V24*(4E04%)0<H'&YCO=+EN(>5--C!I#-AG>-]Q>
MY,2*ODMI2M+49BTL*(:.JB19;.2>T'%B97QHLAKG(,Q%=(B=>JKS]5&L[+/\
M6\G^D?ACC6MPNEXC]2B<ME<K:"ZJ8M?IN3&47$D^JSVUOMLZQ4/3E[*U=!)?
M7>@K+LC3_+&A#L!!W*,0J=^?A\=O"H9M*K6P47)/$?%=+:6^"XYYS!-R(8$,
MY]3D2,_QCQ[R#C.,JWP4@F+-4WJ$U&3N Q(UDHLABP]%B01Z;-8<2K!IKT)*
MV&FX[:W"'.W44I*AVD<:XB#IR?>G&*M1QI#+3Q5[HK]1]E3ECB7>X3KU/C1$
MFWFU,H>>2RX8=Y68O$TELKP@]AP>CB&,R-:7E7.?;&V$J<<3783A<C78/&Y7
M&5:N>#E<[39T8B7[(*AIP(0F$E2?;I225B>21*]SGR$32RO<Y[W.6RC,)BQV
M(Z-TL,MLI)YD-H"05'JHXR3U)).YKP-[NTB^WBZWF4 E^ZW&;<74)SV;;DR0
MM]3;0_E;;UAMM(P$MH0@ )2 %/G\UJJ#FVXM33'.RNJ%T15171DR/B&.A9D_
ME&3C]O8A(.2&1D:HY95B$>Y_BCT1?A[@?V>^TO@C_&)Q9Q+>+NXY[,O:5:_:
M!<^%K Q<)#T6W7J*S[*$W"Z3H(0F%&GWD1)+4/2MZ28MIDN.=B'BAST<VX6V
M;PA$C-,@7.VO06Y4A3:0IUA9NG9M(<SK4VSJ2I60$A3H SC(FF>XES&9W-WO
MZV6T;<WK]$I(SRHDJHXM/)DB[*&,.(>-ST9:Y/\ +A2$332BG:/3N8]8K1L0
M_P!N-0669+DI!7VCA>R"H:!VQ84L!( _G8"TY)(4Z]T7@5UPXLN=RL<*P24Q
M3#@IMX;<#2^]*5;$W=J,M3RG% $Q;MW1Y+:$(=8MUL!2%Q2IQ5<K\2<A&S<D
M3\860BT_,U'%4\D9B;:7/&5^'=CT4&59R-QSR9193='9W6%XVOJ,E;51>8E&
M-AS^3N\]I,/;TMU-K^RO,CU_;^M8CB7A/>5(?%-%MI *3!\(N(/Q.7AY T'+
M&KTVAEJ;NBJ[K?;K09/#CP5>5I])<#T6(I\]9A#VC,_<#:<,7,5E$JI..GKZ
MFK=]*BCI2CI2CI2CI2D5H,SRYGKXO2X?8R:BE+)F+/X_UD82J,V1?-T.6NX1
MQIHXFK^D:LM)XVL[JGYA(T8.BE,3(; ?5B.D00@ X9[X+$&=$20(R![HB!I6
MKXR1RPS,=&^.2-KFN147O^ZNF?E^?[4SOCQ_2I3$+!"\B1C&^94OO3N5$59)
M$CCA:J_7WXQ11L3_ .UB)_;I48Y^?ET\//K^-#!A8I72QP01S/;^I[(V-D<W
MNG?NK41RIW[?:]*G%1^['(#B-L*TAPA$\/>?P8R1LSX6>+)%9(U[&SM8B,;,
MB(Y6HUDGFR.-&3Z'KUX>%8DX/D2.?(;],_ETY[50'9X9OJ"Y3R'&.A>49D$(
M)WG(3'RR.2WS6.*KF@9<F95\FQ:'3V](TF)',66DK[R(=8WM1S,1O^7X5E4I
MYI]8Q7%-CS7FZ/'ALAX]X<N]OQ;?6%??RYG>:3C&PK N7,@/((+45,J8^'88
M2MK \]H;"W(N!>11+"OK&8B1ADU.-@<C?IU'GZ\JE/$7.?-?(VSY!QNIRN$X
MLM^)]1D*RYI=0^P*NN0,;L]=H(\SR%G65VCD'Q0&MX^K:\S.TMDNU*AY+_FO
MCFY."(QY=H:H1RZY_/J/E^6#UJZG2HHZ4J/4?]0W3E)^J*>^2,>7]T>P&FIZ
M\AC%_P"6"R%L('-^D;/'-]=U55J;9[TF]/CWFW;II:<Z*3%MUOB/)2?]+4UB
M6TH='4.XYY-C.]UFUM'9;=OU.(ZI4_-F2&U$>+D5V.X#S+:F_*I#U;574@W>
MG/$BR%PYG0\GX//V))!5EC<)R;K\QDWR%S/(*;15@-DDF A)(EG*(AXT+Q<<
MYI)5A*UYY,Y4BE9$';<!<.5@>$%V?'F)"I5(:RBGU%4.7 4<81861UJIA\ED
M3;6]H69;7=S<2SVES;FFVUL878FDE2J4T:#29[55T=QF+VGT=3,Y[(K.BLPK
M8"1\:]I&,, FG'<^-?I[$D\F+].1%Z4K*201220S/8UTHRR/@>J*KHW21NB?
MX]NRJCF.5JM_9?I?W1%3F>AQGWXDEYE"Y$%;KD1TCWV%OL+CO%"AOAQEQ2%I
M.4G8D:DI(R"E)"D@D)6 %#HH!04,CR(!']35 \WZFO45"#FRM+Z==3IG7'$>
M$V1Z9W <AX2:LY)T5IBJO8<7$5^J@TA@A&'%T16E_/GJ-4WX/SZ:&>N.P.M.
MFZ:C;Y_WZ^O+/*G-C.>-IL;^GJY>%MEE:L^\?46%UH:7?!K6B2\>WFXK[]@5
MEQY3"$U1)8-7E9T)NJTT#3F'4-B*%:0TPU\J/70U$<[ZF=S+C<*3<\+;*TWM
MGQ+A=YM\U4Y[3Y:SH;^R?F:_?TT6,U53+IX(,S8ZNM(I(VS7,^D$J]Y65Y)%
M[Q];AF*G'F.>V_Q_;ZCI4AK_ % [U^),T!O ')<E\!#2HVBBH[4":ZFL,'::
MHF< ,BN-L:^&+1U,W'<89L,QPFG/IC+Q*G(V8NID5'S]>M_Z[5S[/FCD@>EX
M9OH.&=2V+;W%=+R14#5&BO+GCO*W]@+EJB<@7\10'/T%9H=/F-#L*U:LA:'$
M9_D(Y(R1ZD6\Z4I*X/U >J72,SL-[PXVE?9<35^VDM"^+.3J0:RY,?F^-;:S
MX3?2W-VVQPIHUCHM57P\B:DLO-3/$8+#7%'8W6PS*D@=#UQ^>^W/USSM;7B'
M1:S5XJMO]DD$%Q9C59DE;%@]?QY/2O)S],18TY])MK*RN"# ;R:V8I[5#'09
M1JQX:6%:>44J*9_2E8#2ZK-XVH)OM7>U>=I@V^1%E;FP BL7LOC&DD[V))-(
MJ>,,$7G/,]4CBC>]R-52E!PX>3K;[D#DB-"A,WK;.N9DJ\L=XA$]+2U@U8W0
M3"31QDC/OYX93X8R8XB4 >#&3#'/%(Q'G6)(SOT_7Z9._P M]J<%W9D!"PH%
M&Q3#3@JX5TZ.6&*0N=K)2)6-5%>T49)R4C\V>\Z%L/FQ9/)%,G)V^FWX[<^7
M+SI=ZBGJ7-_)#MA@LZ@AY8=F^-TEF\M6^),TMFV2(]B/B7P2*.=L"1I'#[7Q
MV-C;&H:BC!"@,DGE@_MD?6H!))\!CP&V>?7/ZCP.*DF9T46@Q6=M;*2!2K:A
MKCR?U-C9*\H2.1\[&(K?&,CR6=C?%J-8]$1$[=DR'/\ '?Y;_2A._+E^//;Y
M$^'EGPJF[.;<MPAK]UH=+2WMP%8L$!&7-" F6 40)EB0L?L''UT:BD_+C1[H
MR45LHT*.CD:Y'PP/W_.L@<],<ORIH<>^H/TI\W6%/DZ6PQYFJLEN3@L-JLO!
M77\9Q[9[#1-A!M:[X15@:D1)UL^J+._),CF-?.5$UTW2IJT$]!1%6E==DTM2
M1=5$) ]3;SUH<UI5CEM1A<%<?)"XL*$EB(PB(:6)DS41LC7(B)TI66Z4K;FF
MB'AE(GD9#!!')--+(Y&QQ11-5\DCW+]-8QC5<YR_2(BJO6#CC;+;CKJTMM-(
M4XXXLA*4-H25+6HG8)2D$DG8 $UDA"W%H;;25N.*2A"$C*E+60E*4@<RHD #
MJ32MAR&FL+3C_2#;:[S-?40Z:RT^+%  D T]AKX7EQQV,Y<;R0_Y:LBYYPF,
M9-[CFMCD]IR2/D\0WP_>9<[A2\,\27.RQ(#=ZF7OAMB+$7%O4OB!M4A")CKZ
M%/1_L:;(==C)2ES64I2O0=:E^K7>+7&B<0VQVQP;I)F+M<6UWMV1(3(M<>S+
M#*E1FV5):>^TXS3;;ZE%&D$J3K&E*6MU[JO)4N[<)>0QIZX>S- RT94PE@35
MDR"%:"09[H2P8#(%9/#413M>,5*--&^QFBG&5R L?\Y4;^O7[?/E6NLXIXZJ
M*UM4#CJ&$)(UC6+\<,ODUWVY7*L?=7.7[<O[JOVO=>E36!7AC+U,Y%I@EFX^
MOYF.1;//-C9 2[LOMI:U$[9*NX@C<JJV&P&F]OR<X=T$JI(BHQCK^/K/YUOX
M7;WA-R=@>0 @JS>50DEF,55LGCS^TSC"(Q4T>>:3+/.,\::<4:_I)R"9Z4TH
M5$**#-$(>J:;'2E'2E*OD/F7BKB6:>3D/5UN4G3";7D)\IXE@]Y6+XQ=2/V!
MPTH8)*V$]"[7T[XZ$1Q%Z=^5<^GJS?;,6%2I%_M%X_2QGIW;C(LMQ9 82JF7
M15$5F+/9E6 ->.37R%M+'(-.J;0(4>:%DTQ=:<-&QTPD[(U*X'^UCC%T@,,'
M(&/-GLFLDKQZW0U=F28.ZSIJ=Y@XU>23/( -9:&C&/L&QJ%7?E YCR!H)FR]
M*5(JG5Y:_*,!HM+071M?&/,>'4W%=9% Q%M5PLI@X9,THT9+6N<.^9C&S-:J
MQJY$7I2L\JHB*JJB(B=U5?I$1/W55_LB="<;G8#<D]*5 >4M!J\UQQLM!@<X
M_8[2NSQY&2S<79S;F_?"L=2-*J30=PU,DAE,5L\*_#CG5DL;NST@$$ @@@C(
M(W!!Y$'J#2NO_B+T<<J[6[@Y5]6FZ*TNS<Y2Z[,M,@LP<S[KO><(-!#_ .VJ
M6"%WZ?@T Y([VM1\IKY?-5FE.K!<R9VNY"N,;6VS;BN%+GK ["!G8:=P;_:\
M&*Q?:5K7,DA9)#_1F]KSA7PD9W?'EM\OKO4'?]O';EZSXU;$@QEU4D?BR(8;
M!L:RA2D#N(C#L(E\Q9YQ_.%\T,<S6.EB9-"^:%7QLFB<_P VOR\:CIC \Q\L
M[;CK@9I-A3[4WY]?J ::G25SXRR:\[\H,5'/![1#ZE9H0RX6]E?\=M@)!(/(
MYCY/EMA6(C+?)S@9YGJ0/Q^1ZD;'QQVVQDX\NN^,_#;._+EL:67*LGX5!K2E
M1H@E15J'&-&Y81&0QQ>S$Z5J*C6Q01(R(6%J+)(]K4:U6HG6*L9&.6P\^6-O
M7+)K)((&_/<^M_7QJN'HNL;O=\H<J5/)/%M[H<R=#)<8O?:2EG/R(<%98_C#
M<Z.ZT$=7O-MU-2R")&E(E?!7&#/2*.*)7JRKLXJ\#A:,YMG2XO)U%DQ'-985
MF=J #F->US'HPL4.*=J/:YS7(V1$<URHO=%5.E*EG2E'2E1[1_XD86E;]NO2
MXZ^=O]OQ;6O*N?<5O]2..>L') CG8G>,TX-OG&Z1LC:B\?QF6+:-S=)"8KHZ
M=Q2E3]RUX]]"'833T1#J1[DF5&&I!6%IL;;_  G'9QY0&52$'KWI1#,+3GW5
M*;E.-2%-J/O,,/G2L)*3(>K>JZE#SI?V]%QO<1YXAXFCTA51CJ(N)528$[5V
M8M-+9CN3_*33UQ1UP.J]V^\ Q%147LJE3C,58.7SU-FPU:R"CJPJZ)/OLC18
M&1=D_=57]/WW^U55[KW[]*QSX#X],?'X[[C/SI&\@<I#TA:$$$$20))V!B&*
M*%%2)R>$<CV"S0J7+,B^XKB%>R/S1D+&^*O?YVYWQ,)10,;'&2,DGR'@:]]P
M[P<J[MA9*B2G44A70C.Q^1\,;_"LKQYJC3+ &81YTM/;-*B+#/L"K#X1[!WG
M!EU\QTA!<(Q(XQ\!@3B'BQS,KW PBI\WY'9;)RIR-9&-LG?8@]<$X!!QL,#!
M\MZ?B&SHL[O9)5JRK V&0<^\/$C'S'.I!R1:0 6O%MS$.V4V/D2LHHY$:BS0
MC:<4JC.:KD_5[#XC&3R,7NQ9!H)53W(8G-M\8Y\]OPW_ *5YD'./GG'+(Q^]
M2;?Z?69>N"*R''5MR0>2;\:>KJ;W-T$@(WL2R_/G+TUA7B/A]UD8_M022D><
MS7^W[;7N3S7$UWO5GBQWK'PM-XKDO2.R<APKC:K8N.UV:U]Y<?N\J*PIO6E+
M6AM:G=3@5IT!1&]I"%DAQU+0 SJ4E:LGP 0"<]:5/^U+U!2?[GTMGQ?Z?D>9
M..1__P!O@/M>W_7MY?\ GKQ?_&/M.7_R_8[(1GEWKCSA9H_/NQF8^6:W]C%_
M_='RCNG\]/KPI.<MX3D7GH:O"Y+])^8N1:JOU-;5QV'J,)KFU\>SSYF5T!0[
M<QE8)&6)-!8&UX]@D[RJQ"'D5DHIK8R6O^)_:VY_R_979F,]97M%BJ(^*8W#
MKP_!9IV40?\ Y:SCPC'_ .S@^H%01?3%M2[VQTJ<$<?"7EOR%G.4K&QMO4KS
M%82D[?(QWD6:M9FAT_MK#41Z2YC@JHV-J)F&*PH$AD,#8WVM[:'?^7P;P)$_
M]UQC=7\?'NW#8S\J@IA_^O(4/)E ^I=_3]ZQL_HPVE@PR(GC7@M@UCC<WQ\8
M*?S)ZB[B.7&Y2WS]_24*QM:"R(06WRU&4YXLL!,S0D%DG4*20=[MO;DOE;_9
M3&'37=N+92A\0BSQ4_@NI_R/^J63Y(93OU/WSS\-OI32PG G.W'>CT&LR4/I
MXHK[56.DN= =*WF?1?D+G83YXO46KQK'6B!QF71N7IS2W#C#PM*A(E%A'^<:
MV=V?MR7SF>RB/YBW\72R/@#<H8/QV^%,P/"6?_DRG_Z&F[_+WJR(_P!]R9PI
M7=_W_'\9:HOQ_P#Q^?O$[]O[>7[]D[_NO3[,]M+O_,XM]G\7_P!MPC>7\?#O
M/$@S\ZC5"'_DR#\7D#\FZ2?!O%OJ>I.3M#?6'(@%+Q'->3$198O,20C:1%\/
MG$Y?%EW=D1QS4''(60*YEX$3(DC"WY>,<E@H_P"?>SO@[VO6_BZZ7*3Q3'M_
M!"[BMU%FD6=;;5V'N]Y=L]@?N,MWA2#)D!]UA2;C'=7J3(59TM.I9;Z9#T)3
M*$AHJ?TXUA?W/ +<"0'E)& ?=(YC7G<RKU;<N7E=+DO3[QS$21R;S0YP490K
MT9_+.10N,:XMR%1%D8IH[3Q(9&>'L"BVA22L('%9-],U5^O7KZ4],3Q#G>,,
M-#G<51T4]R+7,:MG>P*KKFW;$GN&6YT(Y!J133^3_"!CVCQJV(>)K&M1%*R)
M6T'Q-%8&;F&M!L*P*KFDAS45A816Y=T08#65- (\5EI8VIE@%($+70#2D3R3
M#>#/ZW@Q6./AG\!GX?A^&:IUM><]1G;F<+:XVTPII==^=J@KLNIE^51ODDB:
M4TBJ.L!(IAY(G1V $T[+ !_M*6/"P@=\HDGK4@ # I3\:["?U7S[>ER>F#_)
M9 $:Q'IIV3,#LF$$SB2^X:QSOASQO9 T=2()(YG3.^QF1RR]*FKF^EF]Y$(R
M=YC.0<-?923CRTASM!:W($E?%HZCV9)(T!;(U(SV4BQH$MQ7O)J;(64&08P@
MIA_@I5H>E*.E*.E*C=8OY.VL+E?L43WJ*I7^SF0$-6\,9_E<B%68\5=[<K%3
MQH8RQI'0']W4\+_.SY5Q.[,?M+7 /^I+3H-SD)^Z0'YK+<30M)&FUHD,K+4K
M>SE?Y6)'A<G7BB?,'@7&R(#)Y@EJ*ZN3J0H;W!3+J0Y'VDG5Q592?YNJR#L@
M#:#-5ZY+5YO5DL1KG=JNM/2"Z(<UO=SFU],:?9JQJ.<[X7BQJR*WI2F%6OCE
M8WY/A\AZ(YSFO1T<JJU%\XU_9S7M5'L5.Z*UW=/WZR.<#PVQCS'X^._CFL$X
MR?')_#\OTY4G[[B6&T<YAT#"(1I'(%+ L")($UZJ)%+$1+"L1D$?C#-X^8TW
MMM(9(QTSAAZ.;9F9B]9(YY(.>?7<?W\S7K[1Q9+M3?9)"CL4A2<9Q@\\D#EG
MQZ9VJ29?)QYH=99&Q*Z!DC0AX7JYL+I6.B<3.]S&M<0V%\D4;6,6*%DL[6R$
M+*U[.^#"1$1I0<\LG& ,>&-_U-4MXNSUT=[1W;<XWR3YGPZC'GX5I,!%NM=A
M8%_K3U)%IJS89>RH.,%6$4H'NL9W:V:>UNX# _-&^2U13HU\A96]=JCD_#H?
M/?U\*JD#KX^1Z?'Z[?"FYUC6=0G":F[UE;:FWN*N\*37Z2ZI!:Z]G"G)M*ZL
M(;"'H17 R21M M6*KQV/7S18I%C>0*X<LCS7"]\N5^ASI-TX;N7"[T2\7&VL
M0[H[&=>FPX3H;CW9E45:T)BSTDJ92HZ@4+*5.LEI]V\O]J@VB3$8@7R#?FY%
ML@SG9,!M]MN+)E-E;UN=$A"%&1$4 EQ21I(4D*#;H<9;FW7I:HZXIIHE:&78
MGD1" @"SFF%3N1D(P@L3YR")GK],BAA8^21R_36-55_;I2J&ZSF#6CTW$&]Y
M"Y1W'"]-SYN<3B>)L9QEQOD-033'<EDBC8 'F>]W66W<Y=Y<2'5C] +B0,;7
M8UQEQ7R6.AH<G;<EN5/KGZ]<C5FN,]CK#+S8\;\BMHYMWA!\W<OO,N";59[8
M8K:+?09;5"4A]G>EY@Z2WR>PS=OFR=!>2CFYAUV.?^*T%8,.J*<72E'2E*>3
MAK'S\Q0<WDL-)V8>2?CJY9IVNKZ^LE)4B>04=(T<TF572QH]\CTB:29[36J5
M+W4IL=*4L;7 &W?*.?V]E;CSYO+4$T5+EEKW++'LBISAWZF>R<4L4C1*$XBL
M !0%'PSF$FJ5YLA8BE*_U0<&VO,N>R1.4-"KMGA]77W59,>YT8MA1E$#0:BB
MGG9'*^%# 8H+$1W@L;[2H @G="/--/$I3NF)P^:TM=!(W/TVMY EFKP5C$#%
MN]2_.UQUQ+ ^>&%I=A%3UZG%(I,CX0T(>UCF2F,9-63+S:X$ZTVR9.CQ[A?7
MI4>T0W%@/SW8,-V?+3';W4L1HC+CSR]D(&A)5K<;2KNC6RX3(EQGQ8CST*TM
M1WKE*0C+,-N7);AQE/KV"2_)=0TTG=:SJ(3H;6I,PZLZX:.E*P.I?I69N]?C
M8J>?6,J3G9R'0O+CHY;I!Y%KF6SP.QC:]Q7MH5\96S>UY(Q\:KYMJKXJ\ILU
MT5PZW;G;\F!*-G;NRGT6Q=R#*S$3/5%_S(B%_0'^Q*7-&=*DGWA86D6M5S@"
M]JFHM!EQQ<UVX,JGI@EQ/>50Q(RP9 :U%KM04:\:DJ&QPPYNFDH,[4W2U@FZ
MMZ</^8'4#B)*>I+C$&326-3(>CBE!%+ED&H5-9+-*617(7$^!ILL5>W)O*[5
M9X%Q[DQQ/<+?&^UC:E/+M\!]## O4RWKE OF*Q(<6S:N\(<=<?>A]X;4T)*V
M^QQBUIN%REP>]/6&'-?^SA<0VF;,94\[]EQIB8Y#0?=90EVX=@I"$,MR>Q6E
MPL(7,!18 A1PQ8VPBB00C#0M[JV*""-L44;5<JN5&1M:U%<JJJ)]JJ_?7H&&
M&HS#,9A :8CM-L,MISI;::0$-H&23A*$@#))VW)-4[KKC[KCSJBMUYQ;KBSC
M*W'%%:U'  RI1). !OL*W^MM:ZTN:U[7,>UKF.:K7-<B.:YKD[.:YJ]T5JHJ
MHJ*G94^EZ4J!RUEOF&HM%7-T=)$UK8<^I0X=O5Q-^FP41QTL%>8%&B-0>KMB
M@5#9YL&ME&:-70LGQJ,#;;EZ_K\:C-[RJ@421MX_Y2G):_M)"+@[FP2-R(O=
M&E5D1H,R=^Z>X.3-$[MW;(J*U5 XWQ_?S^%0<\AMT\O6!S\\==H]7Z_D/6N^
M/G.-[VCA?].ON0&QYNN&3R1'JE,LI&G,G:WN^&)E.,),Y$CELA4=[K<RL]-O
MB2?VJ-'B?P %-_-9MM##/*26ZUN[!8WVUS-!$/(4L*RJ,(/!%W:'55Z33,K@
M4DE6))9R22"[$PXXK"LP,<JDW2E'2E871Z&FR5!<ZC1',K:'/UAMQ<6$D4\S
M ZZO@>262Z$6*<F;VH(WO]H>&:>141D43Y'-:M;>+O;K!:KC>[O)3#M=IA2;
MC<):T.N)CPXC2GY#Q;90X\YH:0I0;:;<=60$MH4LA)[K;;IMXN$*U6UA4JX7
M&4Q"A1TJ;07I,EQ+3+86ZMMI&MQ21K<6AM .I:TI!(VZJTH-OF:^XK91[O,:
MRD&/"F?!)\6UH[L)D\#Y!2XHI4@-!);[@Y4$<B,D=%/$QWDQ,K5=(%\M=NO-
MJDIF6R[08MRM\M"7$)DPIK")$5]*'D-NH#K+B%A#K:'$ZM*T)4"D8W&WS+3/
MFVNX,*C3[=*D09L=2D+4Q*BNJ9?:*VE+;66W4*3J;6M"L90I22":/ZS@3DDV
MNXWX_P!1F N:...([7+V/'\+N0*;+1WQ_'FMQFUXFO>8J;1\=:*V$U?&-OAJ
M%@N[XRVKBM;*[1G6^' KM%+EQ["N3/XG.?GYYWSUS5H.-,5J*NVU_('(9E*5
MR#O&T(!M?F)32,QC\CDTMWY7#4=E8AU=CHXJFQTFKO++6VE-2V%_=Z>SDCI:
M&D&I,_4*BF]TI7&-@E*#+&@*F!G(&G@A.';$^<.66)\<94#)XY8'3#O<DT;9
MHI(G/8U)(WL56KIDM+>COLM/N17'676FY+0;4['6XA24/MI=2MI3C2B'$!Q"
MVRI("TJ3D':PXAI]EUQE$A#;K;BV'"L-O(0L*4RX6U(<"' "A10I*PE1*5 X
M(C6$SMOD\C1YV]U=IN+:K%? ;J[J$>"SN)'$33-G*B&[Q,=#%*P6/]<LKH8(
MW$3SD.EFDIN%K1<+#8+9:+I?IW$]P@LJ:DWVY-M-3;BM3SKB7'VV,MI+:%H8
M1[RUEMI"G7772MQ5G?[E#N]XGW*WVB+88<MU+C%H@K<<BPDAM""VTMW"R%K2
MIU7NH0%N*#;;;80A/%S=+M:[2[BQT>RAT.<NCZN?%9Z.@"JI,:", Z&S#FM!
MGN)O761KF%-F-1'B^TK8E1DZPPZ+-;>)(EYXFF7CB-N[V>XRH+O#=H1:8T%?
M#L9F*IN;'<G,K4]=#,DE+X<D@*8[,A!TN]FUMN<VQR;98HUMLCEMN<*/+;OE
MQ5<7Y:;T^[("XKZ(CJ0U;^[,!310P=+NL%8U-ZW)QUZ:J*CI2HFX82XU413Q
M1R&904@>$F:".9\5U<-#FE05\C?<&(KZJ&))98E5LT5[[*/:\<AG5"IEBXWQ
M#ZF67DV%AUIMYQI#BF[E<1'<<#"UIUL/1(#37:+;R'6[H&]04RZFK8.O0K4M
MI+KC:KLZVXMM"U("X,(O(074I.EUN1+<7H0O!0N!K*2'&U5Q^0J78:'(VM3@
MMBS ZHI0EK-7)1 Z5M8D%@*08U::Q?&&5\T&(D!'2N_PZD_)C19(F)UIXMMW
M$-VL$Z!PMQ"GA6^O]V[E?5VN->4P@U+8=D@VZ8I,=_O,5#T4%9RR7@\@%;:1
M6WAR;9K=>(DSB"RJXAM+7;]ZM";@_:S**X[K;!$V,E3S/82%-2"$#^(&NR5A
M*R:F,;7MCC;(_P!V1K&MDD1J,]QZ-1'/\$549YN[N\454;W[(J]NO1("DH0%
MJUK"4A:](3K4  I6D$A.HY.D$@9QFJ9125**4Z4E1*4Y*M*2=DZCN<#;)W/.
MN!:6<-6.V1[)""")4&KP!_%2[$U[7OB$&:]S6>2LCDEFFE?&,&)$0<;,.$,1
M/'RS9K<)I*U)6\\ZL,Q8K.DORY"DJ4AAE*BE.K2E;CCBU(9CL(=DR'&H[+KJ
M-\6*N4X4A26VVTEV1(<R&HS"2 IYT@$X!4E"$("G7W5ML,(<?=;;5L5%=,(A
M!I\D<]O8K&\^>+R6&)D/G\6M"=(UDB5]>DLK1T<R-9YYB["6*,DXA%U6^&XP
M'9,M2';A,T*E.(U%MM+85V$.,5@*$2(%K#0*4=JZY(EK;0]*>%;)DE#O9L1T
MJ;AQM0CMKP%J4O3VTIX))3WB24(+A"E:&T,QDK4U':-9GJQKBHZ4HZ4J(&\@
MX*MM;2BL=OD +NC9E)+JF-TM,+:T[-Y:F46'?:5\YL9=>S9W==84^4<7#"FB
MM03*^H4PL6>%BE&6Y!P.YC9+B=OD-C%+3U6ACDRVEI=#')07SC64=XQ]2:6U
M]/<OK;%E59M50K%P!K0YYE%G2-2LI?:7.94.*QT]_2YROG-%KH3KZT!J YK
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:J*.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g752656g41a29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g41a29.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1L<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #X< 5H  QLE1QP"   "&PD< E  #D1R;W)Y+"!*87-O;B!,' (% !=0
M;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0      $%O0-ETA+K[ME,RB
MV=9_L=<X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q ;ST&(         IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ /      0 " \     !  (X0DE-!"8
M  X             /X   #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M              $"   "50         !                          $
M             E4   $"                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $"     %)G:'1L;VYG   "50    9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
M @    !29VAT;&]N9P   E4    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
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M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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MX+T?TW\[4DIK#-M;T464.=C95]]GHUO:PVR;['V5>C=;56ZQM7J;_P!+[/\
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MKWY#,>PBX-%MUCZ<6UNQEMCKF55_I-E=E6]-=CY^1T*VK*J8<JU[ #DM%C;
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M  ))<[T/HJCEMM]1S^J7>H]P-;L6@2P,V/M>)>=C&VU-=8_U:OM'Z&S[+O\
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %*34T
M*@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    /
ML(=I  0    !    P    .P )B'^   G$  F(?X  "<0061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHQ,R P-3HQ-#HQ,P!$<F]R>2P@
M2F%S;VX@3     .@ 0 #     ?__  "@ @ $     0   E6@ P $     0
M 0(         !@$#  ,    !  8   $:  4    !   !.@$;  4    !   !
M0@$H  ,    !  (   (!  0    !   !2@("  0    !              !(
M     0   $@    !.$))30/]       (          #_X0%,34T *@    @
M" $2  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    /    L(=I  0
M   !    P    .P   /      0   \     !061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q.3HP-SHQ,R P-3HQ-#HQ,P!$<F]R>2P@2F%S;VX@
M3     .@ 0 #     ?__  "@ @ $     0   E6@ P $     0   0(
M    !@$#  ,    !  8   $:  4    !   !.@$;  4    !   !0@$H  ,
M   !  (   (!  0    !   !2@("  0    !              /      0
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M%R$B(S$E)S5!=[:W)#(W.%98879XEI>XU-?_Q  = 0$  04! 0$
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M1ND?NZW#O+1TA!-ZR;4U)0G@=<W=]^5I9;'TO6F++<LZ!K9;%BVUD:.S)J\
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M>Y&=-KI-8\]F.E[VOLX^GF\+<=R-)*PB,D<</I>#6&)8",HQ=>Q_H%PO9WN
M;#E_%_HS']2.8T^:UM7I;?)3QG;\(M>5;7-9T-SC5V>INWO)2MW=DM\V(M/$
MJ12/96U72O+J.@V#W1)=US&9POW4KM@&Y!632&@>P<.16,YN<8R7,=!G0F4K
M.,9(WEVE^&/G^'FP82AAB,<AE0QH4E9O,R)XCQD+_P"HN.F+?ZB>_P!<Y$V(
MG787EM54I65N6A8I10BO'4G$[B:K'7'Q E>3RB2$?$2H$_TY&5=?9"=*NEGF
MTBPJ=U'GR<"3677:;<VNM.A%,]9(<?VXX](;&LS%)M_9FVWEUU_K#MY4RSR>
M>,9&JG_HLK_S+<_]\'OC&27QC#QC,M?U%O?CIWIO5E3.C\#=67\C;@D&;_<=
M@=>:203)OR^\"[%8LA%IW:DR?46CZOEM;%UG 92B[M-(H-9M?<WYCL.+UXY*
MFFEL>I92'WEGQ]@5,7JE4]O.;'JL>XU$R0+VDA4R=#OKW^R__9PXG]=-Q<J<
M@^I&OU/M=+8V0XWHQ8/+%D2_[%9+/XOJH],M.)?"U*==:VLQCLU$E6HSR&.Y
MGKAV6R=RYG5[U9N27;DI[VJ5.P;K;;L@W$.GL2G# G%=W6/&#F1<!)\N,26=
M+6&F\!86VZO2;)<(N4:/:3[:A7N6-;:UKS5JTQCL^B5<SQ!V] QRO*40_K/%
M!(59#Z??D%T3]4>#:KZ?<LV_'M3S30<TK:[<[G6+;THV2S5X]7=-6([-;>OK
M45LV%[/CJ;^WJ+)#.%N-&(7FK\V[?[G"-;E*H]=5#BN)KQU"LH<$ZLD[5LCK
M='MM@H-I VUL;69R!97R92C:[DHJJ-J4U4+JR58#'ILU0F<UQC'Y1UKNMFZ
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MQ>-==8J+^&=&P'DLT[ 26/W^K::E96J]._#%L*DLM2S,B2J3\TS]0_TT>O\
M./8%D[L;WE-F1<-L"NG%L=9&.AUV;.@$G6,69ZM84QGNUN='6W]2/7+;JSK+
M24E6J59*B3*I-"]7\:X'LZ&Z>6>;76(=3-'5>3N0-;DE2+9>XECDJRF2U4CN
MQK!8]2"0M'''YB*+\W='UL_M7<)Y3]-:FOU>OYEJ=C]0M;<WL-8K5:MH*="S
ML.&'4:^U6WU1:>BY#:XW<EVFE-3:TTBMW+GHR7KBM#IG[H&>GKMIR7G?L;V-
M7Q?HC!]/;./W5;:5]"Z'7]ZS*&QL6Z/HIBPV.B(;((#H@?SFL$0]H%VD1@FS
M,XX-8-J[5=;,U:"]/[>9G,E:5&].6/T^F8B?P80(W0!9V0.P 5BZCK\A.;/P
MR>73Z[DNZBTFRDL-;TUZ*W'K]E6-4I+9,&S:)_P^O:2/V]AGEKK;3RKQR-*
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MUSX5C/Q==$SC^N,W$'.,X_U_YOZ+Y3H_]ZW/_F47_P /JL^5_P#M;W_BD_\
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M&-=<8QC&/+A$6-51%5$10B(H"JJJ %55'0"J   !T .AE4 * J@*J@!5
M'0  ^  /@ ? &?7SUGW#QC#QC#QC#QC,ZO4STX[-ZO7!D7%VCA-@YW:%=>&O
ME7JWJ[<.>W2[66M"V_37J#J^2>TMQ1&=8N9MD5S]2N[/F[0J\"U92)H(CGUA
M/$8RJ/OM89*I[S<+*%>4]2?8ZGQ5(.CM+KU[(FO@XO;KK$S7JHNN"&V'DI%2
M66 I[^^D:QWKTN4T>EU\4"T5&&<IC-M6@&C58Q5R$G!QL@2P)"UADR]D+H9!
M(/L0O/'VT(!.AUDS((9!OK,-/K'-%MK)IKG#&)9;ZW\G7Y08F0[MH*\IC20
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M!@CU+N2=T&5 RFF*W8R" T.DT[O/,Y*K5T26?;A/5D<K(!>-JU.3H;5Z^BI
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:,8>,8>,8>,8>,8>,8>,8>,8>,8>,8>,9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g752656g41w75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g41w75.jpg
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M+M[8]T+[0!(:HU :Z7LK[6X>W18J'@1K)M%4)3TFOA[5/-JS%LF^VU@N0VQ
M><;7:&I.4Y@P24F(60>TFP.GS[=MCN6F6BR6ZG"[_P"8;LD/_([V]_\ U!N!
MK18NTL_UC_Y'+2O19+9G9SA]%[L;7;U;CN[AHK+^R@>N'#(!VKNDL$H%ROU%
MVRJSC!G)P;&B=N6R[MX*=9&>[D! \\GGMQ]V$.D%BYQ! M>^W5G/R'BI9?[&
MKQ>1# D!-HE6@F#Y<Z$ #9^Z^UD(@>FUG;>I;N6!0,=*N#) Q%$[?WBL'IDH
M;%E-(22Q!0I9&/)BLECUC=NXZ[6[[K MR>"C??9_;BT;F[E"ZS6!%6([-CWQ
M*KC7C5@)HWXJ5GOFW103"KDXO&E!BU,J[MCP2<G,,.CR@S$',V0V88$E0]KC
M87UZ/KW:%J5HLUNIMU_Z/GBS_P"59P,?]F/'GHL#^-G<_P#^E:5Z+--$6U7#
MYPF7KB3IFYY_;N? ?LVWIS;$ /ITYP<,[ZI>Y4FV-LJ;LIDP)"@VPT6GD9<A
M9->6I678[#;K2U*5@L7.R;7T'M\O'L_?L6,[%-Q-KJMG*V 3!#6X05P/KFWH
MXM4K,<NT%T'Q*RHM@#3!EN2.8#R;1PNW^JQ52W4SRN5Q35>@'(&$H?+'K1<
M9QFSYQJ[+;5$X3L?/$69!6VVY@T2+3:/!LDBR6QG<FEV ) )5S;7<S=-=86_
M5#!YU%JFU_9_<*'W#?99E@#@!8VY)K2IPUR85ZQNV_8+&^FPWW4AG>Q3<9D"
M^W*D!MM6"F:I<#E21/)W/;BMNS9 _>*G;'!,R(DV[2(H^?;;WN)18%?&)*S^
MZ;-B02%S"00>2+1BG6ML"<U[9K$VS7^7;],X7F_HMB:(FB+=7LB'Y<'=C]";
M9_\ 9'0]%A'^!O<L7X4.&)GB=-[FCINZ53VA#;64*L;AV2XWG##-6'U^Q[[[
M,;#OSS!626$QPX^OE-Z0]J,3'5R7.]T";;'0YYI0L9/*N=DVS7N;>-B?LL=X
M@-@6^'HYBCV.^"SVX3-7V8N<L/7PY%VLOUK>W:4/O( G@K=*<8R46$K-JJ$$
M\S-!A<.&C;Z*ZZ>$BI!=T@-^RPSC/IS&VCOON6NFBR6ZG9%?R['$+^K1C_\
M#P718L_"/'ZE2)LAV/F1O5LU4=UFM]]N*.3O [?6=5Z'<$XA&['(V'%0S5C%
MUYQ!93Y&4^)(-&Y,^2,'5X #&G99<VU/C@Q5B+%TEB1DDV+;D;?#]Y4&USA1
MO,K<GB/VEN\N/0[UPRT/>BV7@2ZW$L;3QO8\AD3::E#)!BBA;SCI-F;#BG8$
MTF*<5%ZZ.J5'=0]HJ7BS2,^40!V:=:U9T6:W6[(]^7QXL_\ #E?/^MWM%BS\
M(\?J5.U,[%Q=-RJ91B.WN\NVI[=#<;:?;?=&H;)$)L"O74VSNA>*EMW7AT>2
M2/X$C!Z;9;(81ZRVF16Q\PI(%Q K)7MDR[72PZVQ-VFP<6WOJN3V:=0[]6>"
MN#S@P-<7=@F5P9>8%$G,;J<.&U+"RH&478=*<1^[(W:0"4?S&)078X^NE2L4
ML52VU*?E#,/8A(5(2VV\6;G9.>V:Q.W,+Z+=RTQFLMQIDN.RXMYIB2^RT\XT
MEAQUMIU:$..,I=D)96M*<*4TE]Y+:LY1AUS&.GDLEN7V2+_TA''!_P K+B"_
M[4[1HL6?@;_JM^@4];G=BUN]/K&Y1BB[Q[:[IV;:8;#L%VVY$S1X.Y ZOC:;
M<?>XR?)QIY^2.A8@;<[8V8Z+KJR"[E8&A194.MLL- Y%B+$29Q=I%^WL[!L[
M3;1HSJ$.'[@K*;\[6']SH]_AU=H!/W[AOA)5<D$I#R-@N%;<;BL.NIEH+P4M
MNG*SMJ7JPN.N-G#)^</?F/MC\R78Y4NL0+7O;MUFRA7B!V7D\/F\IC:>98&+
M1) 0*$66:C#W!;$EN[T>KWR*RF$[+G.-+@Q+-'@2%9DK2Y)C/.-\FE(T633<
M VM?L4L=D<_](9QX_P#+-XH?^V^\Z*,_ W_5;] NVD\!VZ<W<5&R-'E1KWO9
M'IVP5[+TX8S#%U^( XBJMMV>I*H%[-F80F?+B'=XMI]O2R)<03#?N5UCYK\X
MY5ATZS(*9>:Y%FY['2;@G-:VH$]HL#>R[%WL:/&"P$BV)_;ZMLB)5=S:\RG=
MU-K6\PJ^WMA9-Y7R)6.JX8DBFXNV]5)V.4V09C/L=9 $K:P<FM#=$ZQNW3;0
M==OKO[-!M^YKL8O&A73ZJV:VO#CR>;)+I["I&YVUJ!DVU#+>5H1FO0#F;CW&
MF%PEM"DQ1> S/5)A-0IAEQO-?@SBL4IUC+7O\CO[NWD+K078\N(8_$,-0A]2
ME66#/HK(VOB]Q]L"_=01?Z5:=QZ[9NWH-X6XU7[)1*VFS4,M"@%!FX,0BW"K
M$Z68CNC5%2]H(SZ;C0=(L+:-O@H,XAM@[/PXW<1M]<I4=^QS=OZ%=RL..A*<
M@9ETKD,Y)K,IQJ3,BRYM>DR'A4J?!DNP9SL7,J(KJ748P5:[*!.TC<?NI>X5
M?_,KV1W_ )%=2_\ U .!71':6?ZQ_P#(Y:5Z+)-$7HF5['-N)+J6W!;;2_4/
M<B\WO:FK;RR]HV# 6N7\#0[54ZE88I](TH?=P1&12MNA55UU_N1-F$6Y!02.
M(UX992M=+7U@SW!'M%M](N.;]P[K\0=V,/BO,/"Q0D-MR2M92ZV"BYJ$/=_;
M9XN++UIC;-XBH[/Q9,5D1C*]W:*Q''3#R#V<EDR) B-"ZB5()UC=MK7O;-;/
MP\>Q1%?."SB%VPH]CW#W JU?JE=JD3:B4=08W#V^BG8KV]]?MUMVQ$L5E5F[
MX"!ZSU6B6NQM APZ65@!Q#LPG%AH>C8>*A[2;"Y\-1M?N6JFBS31%NKQ-_E>
M>QS?\EK=#_\ /5Q>Z+!OXI.]O_E"TJT6::(FB)HBJGESQTLYPGGCI93C"LXQ
MS\><)RI.%9QCR8RI.,Y\72QY=$7H'8NQU;R+W6W0V@VKDC]TK1M/<"M5L6,2
M:]1V):8I':BM!9H7%IM3+A699KMNY7:H+!Q$ND.VGHTUWE$D2U#"U]8,Q(M?
MQU[ >PW/8N@$=CAXO3TDE"%;;B94T)/L@D_$QN-MNU(KAFE63;^GW8)9$/6M
MOO>-5"S[L;7BCPHUF#.81N!5C4=B5726##97K&[;6O>U@;WT7[CN*RY78N^+
M*/",)G5(#%/CIX[M0:G<+:^0%FU[N#Q36"R6"1:F[U@<-Q787"+NN_W-=9>D
M$(HO+O60I,RN0K*4ZUN;GW;?76L$5P*[L4[<G:RB[\SZQL<&W.MURJ&;L:L%
M<MPVH2: &!G;B5LHNGGB1-@%71UH 2295A#L;E(*CQZR%AK5A!#B"0$$M!-K
M9K:;FV93W'[%%O#'#CG+/:!U;MB!FYDBXU-T-VV]1#>VY;=@,_6#,O)R'*GE
M2D[:<DQA0(02C"GBD1D@ZAUB0G18F8=@U:3;3O[%%3?8RN+QM^Z1RU"%A'*$
M6O-5L.)%K %.U]P*  4>+;;\ZW--ICW>;A*QH4205";*36)CT:4H9"E$&BRZ
MQN;3GV<;;]&U6K[&'QJ('*+(VFC2H.)QF&A4&][?SY,EJML;92+&4@#H=F>)
M$@P%&\.W:"A0=#E16)-@S#0MR6*,L#R=8WG;HT:;V[%C6> 3B$01&#' 0MQR
M99*912$X8="'P@._;F*>QME62!T 2)BLMWIMT-) V!B6X )1"4^2)GE&JI;,
MAR=8WY7&T 9]WS[+K2C1;$T1-$31$T1-$7V2?4DW_P!H!_\ =4__ '(Z+CS_
M -#_ +7V7T+A>R*<3UD<>:KVVVWAUR-U.9" ]-OI)4?$ASJ8^7\0[L]EG#SO
MXVUESHX<7S2G.<XSC7YZX?\ PH_2_BSY&87T4Z,8D^+J^M;0X#TCJS%UK^KB
M,@@Q^3JQ(_V6%]@YUP+D+S+L*HVVRII6WT94D0OW7C72>$YW\_\ 93:/X@N'
MT\UX_P#.Z])7^9NA/ZLQS_\ T:R_)%-[\_Q1_P#"7I_PF[RVC?;:5J^6^"!'
MF'+&:$9CUR+/AC<1AW:G4+PR2)EY/7JZ]?6JS,RA7)/0;1RSS^O_ $*=/,8]
M(W0EG23'*?#::N=BM?0F+"X:F"EZJEZGJW".JJZV7K#UCLL]?DFPR6-SW\/6
MT[*:?JF%Q;DM==Y!-S>^@-'R7R%<1_U*/Q';W<0^_6\XGBJV2""MW=Y]T=SQ
M@8C5+V^0$#[]>#MKA#)[T9G,9Z9 C%FXLIV/G+#C[2UM9RWE.O;:P;,  ,DY
M@!N"CJK?4E'&71B_=^D\<NU%/.X'&0^#=6%[J5\O@38A$T!8!?=(2J),[G'0
M)(B$,PNN[6)B)\T;-:?ARGV7"&9ITMOWV63"/J5OCY ,C8H3LAE'%PP]6ET4
M7!A9WB8'P*.1/$[41I4: B3B&U3R5F-FK"1JZ6.X4\V8*E)<!Z:1F//$,K#I
M9?<I7OWU.-V3W<6Z(W ,=DEH@FT-OG9C1"GQMVZ@XV2M0<M7;274X ?@R))J
MRUHZ5JALQ-?DDIU,DM4AR5BG#Q@*$4$D8%LB_?;@L"LOU,!V1ZYBC &X=DP$
M6L'867HY\-93N^QT4<CR"%7+2&# XH4E0R;+Y6CTHF\U-9?0Z0J%7FK2J37Q
M+D0J)6#1';N 4._B/CB>]U[L-]R&X/\ $:*]>/=.\*>-H_J53B+VXVZXI*5.
MXIME",O?[9"M;5!9L2JWIN. (@N)7A]WR>*E$/,X<D0GQ&SA0&VU$YOI)&![
MZL=JLR,X*&8$M]DYC?3L(^Z@?\1\<3WNO=AON0W!_B-%>O'NG>%E=>^I-.-:
MHP#PJI\=^V-8%VIL0U9QM>@[LA8%C:KY>-8 +1Z&-=C1S#80]"AFQ""#<A(T
MO$C$H>&9C#3R"AF:=++]]BIO _4X/9/PET%W^5V3"K6RS!L6WN=-O<O>VY9B
M/7JI(HMLFQ%'B,Q^"3.5)B&!GEA[\0F^+'CX+DM42&PR@H9&'^A;1HL-&A1]
M<OJ6_L@NX$<R/N'9#J :"'U"NZ=8?B[K,T]<8!,)3ZT+B4Z(J/5QH.JR3!15
M2 #1,0+56ITF/7X V.ZIK)42L']#QS7T6ON43?B/CB>]U[L-]R&X/\1HKUX]
MT[PIXK'U*IQ%@>&K>78U[BFV4?+[G;Q</FY8\XU5;TD:,@;-U/B*KI0;,86S
MVT[,,/[TBI ]UC&666@I!,C.%OQN98F8%S38Y@?G;@H'_$?'$][KW8;[D-P?
MXC19=>/=.\)^(^.)[W7NPWW(;@_Q&B=>/=.\+/J7]2G<=^V[!2+MYV06B4**
M;D#)9J-2\[QU9@O*"=N]QI)1D'*@MSY CND1[F/2TNN0.WYO:JFNVG^L*&9I
MTLOWV*S23]3+=DSF0WQTSLH;$L?)Q*3)@R;5O^_#D8G-65B=A^,Z84P[B8Q<
M[@S*PXA6)#5KLK;W30=*8E$ZUGZ/Y!?K*^IGNR=38LR%,[*2F7#(SBQ,A$E6
M_B"?BSB1X?:1)PA,8=-+:E3C0J\W486EOH6^1'W"TPYCCT:P%FY9.M9^C^0Y
M[!N7YH^IF.R:-D7##?91&6R[TZ<3>*(M?$ @BZ2)W +N$2(.3DF<25SB%^K=
M=O$Z6IW,B7< (6S/N.&A<&:P3K6>Y\ASVG>H-S]1\\3^<YSGB]V'SG.>><YJ
M&X6<YSGRYSGJ/'G.BO7CW3\E3\1\<3WNO=AON0W!_B-$Z\>Z=X3\1\<3WNO=
MAON0W!_B-$Z\>Z=X4L<4GU+WOOO5OK=]RAO%3LV!AV!NJ1VQ1"GWN3+BKKM*
MKE8?RZ_%:RPO$B0&=E-=#^Q9>;2OZ]*M%@VH8P!I!N HA!_4J_%C68-F&5OC
MHVPKPVZ@TUBY#P8/=83!MM;26%GTUZS1(#D>.>!I.A II(DJW+@8+"!9'$?M
MR!$>:*^LQZCFS\YER3?U+)Q?642& V/CSVYL .NQ(8^OAC8K=HJ*!0!S#L4?
M"#CISS\09$@1GWH\*-"989BL/.LL(;;<6G)3UF,:&_+R6*?B2?B%]V!L=]Q&
MX?\ $Z*^M,U'GP4\<3OU,)OEOQOUN9N\'XJMG 0R]'FR\,03IU\D3X+2!D"#
MEF2]%:S'<<RN(ISFUGH]%:<>7&=%!4L  L>?!8*,^I?>-8+"K(T-V0FF"1U*
M3;44V ,9WE@0JDB_05"[VBLQ8LMI@"FZC5K'6U(IN+BQP5JB&,3(ZLMY)ZS'
M[NG3FTVT=B[@M]3/<>IXL4/G.R2A#1TW6K'3#1HM-WR(EB]/N-A,6ZW5,H1F
M$GID^M6FUV*P6>Q@I;SHLY83I@T3BRB1.;)?)ZQ%[NW0."BG\23\0ONP-CON
M(W#_ (G17UIFH\^"GGBB^IA-\M_.(G>;>D-Q4[. !6YVX-BN0\*3IU\D$!D4
MU-7*:AS'XK68SLAE*\)<6QG+>58^M\6BC:E@ %CSX+&P_P!3.\>E=+A#]?[)
M(#!'JS6@=,KAL/,WQ&%Z_3JP<@6>M5,(2A$F)@JM5ZRBAEA!@H#S L2<&P"T
M"+'GPX\ALGK$7N]M]':>W1I7[A_J:;C]KQJ98P'9+!0.PD7Z/)('@Y'?48:G
M2=L4P$;:R)A2$38G27]O4"AB:.Z^^MRII'0$@%#\0X^&R>L1:,G-GS6UZ>SM
M[5%$CZDOXC);[TJ5QC[)R9,EYR1(D2*;N,\_(?>6IQYYYYQM3CKSKBE....*
M4M:U*4I659SG17UEFH\^"G3BE^IA-\M_N);?_?,+Q5;.@!&\.\NY.YPL(4IU
M\?)!X%XMY>R0QD]^(UF*],@L$6XTAV/G+*WFUJ:ST,XT4%0P- L38 ;A;4NC
M8^IJ./Z*7LM@C=DM%QSUS:BL7 VP2WV9+VMB#6#-)A,V4DV43,.M0Z98K!48
MK91Z4B/6#ID UA HG-B/D]8B]W1HS:/DOS@_4T?'R,P?P-[)2''XM9NV66T8
M@S]\XF+)8[Z")5>\GS^&";?=@W=*R9,5VV%2/;,ZQ BI(08?F#YTJ.Z3UB+W
M=F@=FCL[%AMF^I6N+&\6)VUWGCHVQNEDEI'-3K!:@>ZUB.S8XF%%&#6)1<PY
M,GR&AXN##&P&WI"T1($2-#CX;CL--H*^LLU'GP4F\4/U,!OGOYQ,<1.^@;BJ
MV< A]Z=]-V]V10,G3KY()!1NXU_L%P@B2#\5K,5Z<.BF6H<MV-G,=R0RXMG.
M6U)T4;4L  L<P W#N6.#_J9CCO$J"+%=D@KXQ=:'P!%=6/D[WPE@!(K#"18P
M*J,0:4+'C4QHR1\*#EB-"Q'8Q&:;PTWT2>L1>[MT=NO0N\Q]3?\ 9%,0LCL=
ME!;P/R-4&S P?W^Q"R(779%14*S%[L=1D:JIRY=85!RCM7-=DR N6LC7G(RB
M>L1>[MT#@OVE?4X_9&YLMR?-[*.J7.>*M'G9LJR<04B6Z<9*6(VR9<D.FEO+
M*M&K?;"[1%2\S&REHL4]+V)9LD[)*=?%[@W#@N'7_J;?LAE3C0(55[)U%K4,
M4%:K8N)7S6_8:,-KK$&P#& $!@<7C-0PK(VVVH>T*CI;@MP;-8(B&,,&2+<D
MKU\7N;= TZ]"P2Z?4LG%]N0;79=P^/3;J^V-R+%@KL%T%[MVDVN%!1EJ%#65
M./3IZHL1O.6XL?+^68Z,Y0TA"?%H@J8QH%N[]REO8[ZERW[I-)XI*2[Q4;,D
MYV_6P0?:@/+CU&]QXP$@)XE.'?>UTN32^UUDB"Z*V=)A$,1,9D8(F8#ZL=JL
M2<X)ZPUQ%@<QOX6(U;5$'XCXXGO=>[#?<AN#_$:+/KQ[IWA/Q'QQ/>Z]V&^Y
M#<'^(T3KQ[IWA2V'^I=^R*UXBV8 =DH @R[5*$;;-% YC?,81;VZK\X<4 T%
MN="),244H(2$"2(BJI=P"&SA8Z7"@,R(49QHIUK+6R,VFV:U]:YP_P"IB>R3
MB9DTB*[)P/&$"9K%E(SA]CWZA3"%CQ'"Q<'YLJ,6;?EFL1:W78V"KZW)W:X$
M*SU_5BX*6"=:SW.RV@:-7<L>LWU*YQ^740Y7[EV1&G6T"]WJ=<$LTG>@\(=[
MPQ9@'1NL&E9LN&YWF!;"?#U3I,Y[W19PP/#]IQ"<UE\G7,&AEMW;I4;_ (CX
MXGO=>[#?<AN#_$:*]>/=.\)^(^.)[W7NPWW(;@_Q&B=>/=.\*8=Z?J7'?RW[
M<\+NWR.*C9D;/V(V=MNWA><_4;V_%/3+)Q#[W;QQR0U#+/6QXL<9N? #/-2L
M8>5/%S'T?UL\QG)8=>UKG$@^U8[A;[+7;\23\0ONP-CON(W#_B=%?6F:CSX)
M^))^(7W8&QWW$;A_Q.B>M,U'GP3\23\0ONP-CON(W#_B=$]:9J//@GXDGXA?
M=@;'?<1N'_$Z)ZTS4>?!/Q)/Q"^[ V.^XC</^)T3UIFH\^"V#KOU.EV0FKQ+
MY'&=D:I*Y>XU'%;<6$[/@[Q3[*S3 UBJ5FA@@=@DS%E0,/,ZC5B'(;%R8^)(
M(8FOO86&D283Q8F>(V]G1?-86-]-\V=="W]3:=D)9DN36>R;PVICS,*.[+;,
M[]-R78XV,*A#F''TEL.K9@0P(.)":4O*(L8,*882VT.AH9*^L1>[\AP7.7]3
MC]D<<2ZASLI"EH?:?8>2NR<02DO,R8UTA2674J-9PXU(A[D;B1'VUXRAV-?;
MHPYA35I.)G$Z^+W/D."['<OZG/X_MWHM+9W [()M4>G4,:8% K$_4MR$VM4.
MP!(%</-DK0E'=PBDV$',0C;3\[,<TZ^5)EF)ID\=(DB@GC%\QSY]QN.S7G70
M1OJ;3LA,.#D9$[)O#BC5*-*4/C&=^F(*E6288(6)68C19+&5'I]BL$XUG+?,
MI,.F),[KWB<U;Y7UB+W?D."2OJ;/LA$Z45G3>R;0YDT[B3@Y+E&-^I$HSB:+
M) YF"LATLMTCB6%,EQ$GMM;W7BRI(>[THDZ4TZ3UB+W?D."Y[7U.1V1QAW#[
M/92%LO))8,I>:LG$$VZDPEVH2$EL.(-87@DE_;V@O8G8SVUAVCU!S#O3K054
M(IU\7N#<."Z%KZF<XZ6<1DH[(=1.C$9D--)6)W4=PIR1(=F=O2<.Y7B87BS%
MM2QAN9UY@1*@")(J=#>""%P2=?$?Z/R\E%/XDGXA?=@;'?<1N'_$Z++UIFH\
M^"?B2?B%]V!L=]Q&X?\ $Z)ZTS4>?!/Q)/Q"^[ V.^XC</\ B=$]:9J//@GX
MDGXA?=@;'?<1N'_$Z)ZTS4>?!/Q)/Q"^[ V.^XC</^)T3UIFH\^"?B2?B%]V
M!L=]Q&X?\3HGK3-1Y\%[M=A1[#AN3V-7^J7[]]ZJ#N=[-/L-=S.]$#91/</V
M.?95[=[H=VT)[8[I=_<3M3M7GU7<^3UW+K&M%@^5LEK?T;W\;<%U/##VBBW'
MURIL%M3E7E,XA$'Z_#8<;[KA'<OX?M@*P 7WU91VA&'J@X)RW9O1&/(DX2V]
M^3/HA]6;C>).GJ*=I=@\S.HJ9,+@C<WUW#W]:),:P[%,-EE):::*E-,*N=]0
M!1R":S']JJ[Y#;!V9X/LAY.AWZ-S7 =I-[ #."H,#5F0:B29:"0B!AE2VHK)
M*2\R\3E-H;<7$A]3%D--.)0\UG,@FZ/@?CF$]N=)+B4>NZ#"):^&:=M514PC
M)9$RJED9)5S-:USH(.KAE8QP:]A,M6^EIO; Z^X<&\@NL0+.-])%K-&LW(S=
MUSL7NUV.3'+APCXSYKQ:L>G\[O/CQ:_1G^"M_-5'_P!8<9_V5=;Q7_&S_P!&
MS[K?+7TBO&IHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(N+-E(@PY<UQJ2^W#B
MORELPHSTV8\B.TMY342'&0Y(ER7$HRAB,PVMY]W*&FD*6M*<D6J-9XT-I[@#
M)V2OC[61!5FC@MR[V3BXI\N)0*%8+)<:Q%L=F=A7&2ES Z=MQN0NR@J[D_:J
MCF@V47: (BPLP I K:W/;FX]N;:ESXR*!MTR.?OE-W#J6#>UUOW;K[9I&W\=
MVP5JDO[=1C X4EO<%W#UJ4_N:!1#K3RHY)WM0NIYN.AB&J>2W.K3POFNI&VN
MX@:1NV<L-;K<.Q0CE1)6H+:AE@@01DZOEJJ<B"%PR$))23+4U8!Y(3;:F6AL
M2P1^I%H!.*4P^X[!9*6MXYU.6B)HB:(OGIXY;)8A_$WN'$@'C4&*VW5\MQH9
M2=&CMY75 KB\H99?0VCIN*4M713CI+4I6>><YSK\R?X1V-8Q2>E[I+3TF+8E
M2P,I\!R(*>OJH869> X:]V3''*UC<I[G.=9HNYQ<<Y)79\-8PT<1+&DWDSEH
M)_PCNTA:D=^-N_\ :FQ_'9/^5:]'?W1](?\ /N,_K2N_XZYW5Q_HV?"W@G?C
M;O\ VIL?QV3_ )5I_='TA_S[C/ZTKO\ CIU<?Z-GPMX*8JIM_O'<ZTQ:0ELD
MJ'2<GL--2[86B2UKKJQ2"#+;;OXS(E*R:'JC0XTAZ6_'7*F883#&DI$3O6"]
M'_2!C^$Q8SA^/U1I93B08V?'<0AF+L*-$VJ8UKCD22DXA2F&"*22>2-TTXC$
M%)5RP:'R4\;RQT8N,G1&TCV\JQS:![)N2+ V&D@'%) ;>V(B6[*8W$CMP53T
M37'I)QM$18PDH/-1)4M[&&5,EDK&82YE.7B"%PV,.2$*;QX:6F](T#9WS'I9
M$RF=4MJ'25.)L; ZDJS05#92Z4",QUP-& ZV75-=!'ERM<T9@TYL!U1O:U@T
MWN,H6U^SG[LZ[RL4S>6T&B5=9.'A!H5(J\:4./G3HZ3AVX'Q%;"82WR?ST7B
M1P;UBG.KPW&?S(QE:&U]'R.$8-Z0L8Q"KPN/%<6H<0HI,'BFI<2Q3$Z67+QS
M$Z'"</R6_P IFDJ\1I,MSLD-AD,HRFM=;%[Z=C0_(:YIR[%K6D>PQSW:OZ+'
M>(LN97J!O/8FUJ18R@E]!4.)[2-V(["F+=/%ZD%%3&VFVY&%C9DRZ@E1YV%]
M3(BNR)4?+S,=:L[\+Z/^D/%&N+<9Q"BD%904748AB^)T\[GXE78)A]%.UC1*
M'4E1/TAPUT50'=7)"^6:++9$28Z2G;_0:[V7.NUC"/9:]SA?-G C=<=AL"HJ
MG66Y#YLR ]:SZW84J1$=6T<*Y:4Y&=6RM3>5OMKRVI2,Y1E:$*RG.,J0G//&
M.F5&.=(Z:HGIWX]B[GP32PO+,4KRPNB>YCBTNF:XM):2TEK3:UP#F6X1QD ]
M6S/G_"W@N+WXV[_VIL?QV3_E6M/]T?2'_/N,_K2N_P".KU<?Z-GPMX+D1+W=
MH$J-.AV^S1Y<-]J3&?;.$L+9?8<2ZTZCG)SCI(6E*L<\9QSQX\9QXM;J?I7T
MGI*B"JIND6-PU%-+'/!*S%*T.CEB>'QO;>8B[7M#A<$9LX(4,41!!C8018@L
M;G!TC0O8OA>XEXF\PO-:L?50MQ0L'KYS;3>&H=B'L*:86:@)3CJX\A#CK*28
M_'12TZZF1"QF*ZIB'^CGH,]-M-Z2J$X+C/5TO3+#*7K:IC&".FQFDB+(G8G1
MM:,B&9KWQBNHA9L<D@GI0:=[HJ7J^(X>:5W61YX'FPSW,;C_ $3VD:<DZ;9C
MGSG;K7T*O%IHB:(FB)HB:(FB)HB:(FB)HBR^E?DJ]^@'?W>-HLV:?#[A2CHM
MJ:(FB)HB:(FB)HBTYXSZEOW>-I[16.&/=D!L?O82@U_-.W-L]*';A!J[B):H
M,T\B352S<@;.67KD<L%CO2H<U,"00;GMQE/1VEME@2T/&4"1;0#;7VK+ELSV
MJ^IB8](*E&P^693X=# F41GHA90^\+;E3NUADB9(PI<%$DEU$)QQI+T[JVU/
MZ+7V^/:M" .W7$ZW:A!"*1W$$4CNIL;.E5J[;ALV*RCF!N_>^5LW.$*.#-U3
M4*6)&;:V;;BK+ED$6<IN#5P(&&1;@F1T^#"+.[+'7G[.ZW9WGLM?N69&*1Q
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MK$"86V[DLDB#93;.)MX;/395A;GRD*'#]QB15MN<+D*C&F8TQIXM'&O1RO\
M)\WY_<-&=23;1/$NQN=:;!2)"WZG+Q!2*$F"H)P:R(@5VI*EC@PI<]IF$?)F
MWKLXT7+Q967"\8#%EE8-37)PLH,BP!T]QUZUQJ=(XQ,;AA._2%5'-OLV!4<Q
M@:BN-2.]=%%"]J$%= J\20<?O! ^HU&A]=":;""V!"5#5299PAR,]O#3N^WB
ML9M-IXQ*W3#=J<K\,E/&U7<J9,KH"N "9%BU0ZHQ*H+50@C+18"=UK$BV"K'
M!RW,CUNX3Q=JVVQ+!CY06_/.D&1].TY\^?LL"=V8ZPK5$^.E!=,)%>JKPB#8
M*YU1E:Z8ETY58E:L\\JHC&38D.#3Q6P.4D(?8'0LP(CT:WR*K,;%R01".5_D
M]O;KTW^EOM==J.>XSNZ##TT%3V$2 H*,0E8+PI*7;! OEA1)E("K,+%A*R3V
MYS&G%(@I)&SB+81KXED_>A(,J464]C7F\<V8=NDY]!T; N:)$\3!RN[02-T(
MTM^2./7#V6:[MS9Q]--%HQ*OS&Z81'&!-G#1UA:Z6DR(D\)'LH^=-2H*9>43
ME!GV2!/9SV[0+7N;9\_9JV:]"PZPC>."-;(I2GHJ[HFO5FT Z^)L)Z-)#'"I
M'>RGP1,^]9:),D20Z+L.&R?BFX<9%S&[@2KW!1F0%,B \TGL;SJ.;,?OFU6M
MI4CUC'%3)W K4JT+A0-NXUJQ@H,BLTC)B?49U>WEY+LDAB20RDL%/,[,(>34
MGX;4OMPU)8Q)BIG1()#D6-M.V^S1WY].C<IMVQ'VT8#.1[F[,>).;B;GSQCD
MTDV4<[TBNX-C)TIIJ0B3*RS$BU28'B1![BFG!;#"!^8["8R6\%B;9K:A?O4B
MZ*+.*9_;+_$_\JT6R/M\/NOGPX7XLQNX%RR4CFQV $H+,ED++7:[AE!.7 <E
MLLY/5:YJF*GB8I(=U,(&S)4J8AN,;$S7(BW?R9]$,4S,<KJVU*VE_)DU!/-4
MXMA>%AC:N:F=/&PXE@V/F<U-##5TICI\.9,34-;#B%%4/@<_N-6?Y,-]HNR@
MX!K'/T7L?9?':SB'7+B,V=KA>W<[<Q;,1V[N$RF63<"I4J ;MTB75!I8Q.9L
MT656@[:A)4B**5VOORH<%MI!8B4K(Z*[$E)?;BF6F\5Z+Y'HK%B]5T7QVHP#
M%>DV"='Z;$,:EGP2DK:^ICQ>&7":!AHJZIHZW"L+EEAIVM%=55F$TL+X)0]D
M-<Q@PR&2%@FCZQD3Y,F.SW-:"PY;L[ YKWYSH >;$9RW\9]2^QQ_E;X_ZM[3
M_P#+M?8G\%;^:F+_ *PXS_LJ\+BO^-G_ *-GW6^2E83C*E9PE*<94I2LXQA.
M,8YYSG.?%C&,>/.<^+&-?2*\:OP1+BN98PW)CN9E,YDQ<(>;7F3'3AO*I#&$
MJSEYG&'F<Y=;Z3>,.MYRKZ]/,B_5QQMIM;KJT-M-H4XXXXK"&VVT8RI:UK5G
M"4(0G&5*4K.,)QC.<YQC&B*C3K3R>FRZVZCIN-]-I:7$]8RXMEY'21G..FTZ
MA;3B>?20XA:%8PI.<8(OTT16(<;=3TFUH<3A2T94A25IPMI:FG4<TYSCI-N(
M6VM/E0M*D*QA2<XP17Z(FB+A/DAT7#BI1"%&2T[AAU3\IAG#3ZF.VDLN9<<3
MA#JHO]<X;5R7EC\>QCJ_KM$7Y=V!'00YW5&]6[)Q":7V]&Z#DQ3/;"8B%=;R
M7)5'QE_#"<Y=RSCK<(Z'UVB+EM28SZ<J8D,/)P\]&RIIUMQ.)$9QQJ0QG*%9
MQUT=UEUMYK^S:<:<0M*5(5C!%^^B)HB:(FB+B3X,4I FC)S>7H1&))@S&<..
MLY=BRV5QY#>'F%M/M96TXM.'&7&W4<^DVM"\85@BB8;P_P"T(@H4-CZ<TP6L
M,>1#MD]1BPOR;S#DD")3,/<)<@N[[(,.+-,F7!L6ZX/1Q#1HS$%MPXA8@Q))
M<\\[%Q)?#GL]/%Q Q&K3"(Z!1[)MI!8(V^[$%0Z#;GJD_8:E%D3+&_*CA"#M
M$J6>TVGD(B)#,(@]K-O2TR"+-P&VU%JYM^S ZV/A664$;K4VQ9Z^6>G@&#QN
MT1 Y S->DDB ^"?LE@*#HTR2^T.DFB>8*8Z)KZ%D6<:(FB)HB\->,+A[WCOG
M$)>K14J1,,@2&*^B&19(A([;RX5;$PI.,-32<:0GJI3#S6>FRG"LHRI'21E*
ML_ 'IT]$'I'Z5^DW'L=Z/]&*G$L*JX<';35D=;A<+)74V#4%-.!'4UT,S>KG
MADC.5&VY;=MVD$^?H:VEAIHXY9FL>TONTAYM=[B-#2,X(.E:R?U)?$/[6A'X
MWK7\]:]1?F_>F'_0FL_6."?_ '-<O\I4/_*&_#)_N)_4E\0_M:$?C>M?SUI^
M;]Z8?]":S]8X)_\ <T_*5#_RAOPR?[BR\?L/Q9"HH&% I)&/&K+UAD!&^V:.
MYVD]:X3 ZP+Z;TYQR3W1A1F&%XF+D)82TA47#"\=+7G*7T0^GNC@PZGINBU9
M%#A,F*2X>SUCHR_U>3&J>.EQ-V4^L<^7UJGBBC<)G2",,:81&X92P-=AQ+B9
MFW?D91M+GZLDL_HYK$DYM/;=9@]1>.%]#R,@R[.9"C"WG8>=NX$EQRP/$'S+
MBI<%V/*ZP@LI.2^YA["^I>Q'0I,=EAIKSK^@_P#"7D;(W\BU\9E=7.D? _HC
M33.=B<E5)7N,]/-%-E5+JRI$C@_*ZN01-+8HXF,UBIPL?_$:;9.GKB/9 #<Q
M!&;)%MN?23?I8NTG&/"/&K-$J9",<L,X43+SV<[?-KE3PAN'8QDE+*9&(T5R
M,;'PR.>U&6$R'V$]LI>;RM"N!#Z,_P"$/3XE7XO!T;JXL1Q2HHJNNJ8Y.B;7
M35.'XA3XK22B,5'50NBQ"EIZH]1'&)9(F]<)&W:<C68:6M89FEK 0T'KLP<U
MS"-%S=KG#/?,<RY$?:[C/BRVIS-8)IDL0:V-8<6K;YW#$"H&8U@K41AIV0MI
ME@.5A0GXB&T)PEF%#@KZ<"*Q&;V1>CG^$9#,RHCZ/UHFCI\*I8W&3HF\1TV!
MU\.)X3#&Q]0YC(Z&MIZ>2%K6@".G@IW95-#%"T:O#"+=:VUWG,)1G>TM><P_
MI F^TDZ<ZCF5PJ\1LV5)F2=MR#DF7(>E2%X*59K"WWW%.NKPVT80TWA3BU9P
MAM"&T8ST4)2G&,8ZK-Z _3+432SR]"ZMTL\CYI'"OP)@=)(XO>X,9B36-!<X
MG)8UK6Z&@  +:,2H1F]8;F_JR?[J_#^I+XA_:T(_&]:_GK6O\W[TP_Z$UGZQ
MP3_[FGY2H?\ E#?AD_W%R(G")Q"RI4:,K;V3#3(?995+EF:\B+%2ZXE"I$E3
M)9][##.%9<>RRR\[U:5=6TXOHH5NI_X/'I@GGA@=T/FIVS2QQ.J*C$L';! '
MO#3-,8\0ED$40.7(8XY),AIR(WNLTPXG0@$]>#8$V#7W-NP>R,Y[,Z]9]A]A
MZSL=6<#A^&R5F)-LN6:S.,X1((R$8Z6(D3"NDN('B+4I,.'A7-6>E)DY<DNK
M5C] ?11Z*,$]%V""DI RMQRM9&_&\;?&&S5DS1<4].#=U/AU.XD4].#=QO/.
M7S/)'6JRLDK),HW;&VXCCOF:-9UN/:? 9@IVU[57#31$T1-$31$T1-$31$T1
M-$31%E]*_)5[] ._N\;19LT^'W"E'1;4T1-$31$T10-O;O;$VL@)A"XHTU<9
M8^85AB"1:.''Q!D%B2^[/*3GE8Z"IRXCPX",8PH@?+_UE 1E+$MZ/Z0],GID
MI?1E0MI,-IL.QCI;5T-7B=+A6(XK3X10TN&T4-1-)78E6SN!8ZL?2RX?@>'0
MAU=CF*D4=$PB&JFI_8?0/H'-TNJ#/5RU5#@D-3!1S5M+12UM3-5U$D4;:>DI
MXQ[0IVS,JL1JI"*;#:+^^*EP,D$<LS!2;)H0+,1^74%!\,@UA*TN82B9';D)
M1TT_6JRC#G1SG'+QXSXL>37M[",1AQC"L-Q:GL(,3H*2OB >) UE7!'.UN6W
M,XM$F22+7(.8:%T:NI'T%;5T4M^LI*F>F>2TMNZ"1T9=DG. [)N >PK4OC/V
MTW5W@VGM&WFR>^Q;AKW*/P:_WO;RA*>(OA&II&VJ"6+-LU<Y.&0""3P:"0KK
MRU$8;\%DJN?&=4]&0TYY%<(D!X+FY0MHO;7VK+U19C8!4%^1),D&P^8KTM#Z
M0DPK,3"ZER0F2.Q'0(DSG\9<2_ PPF Z[AR+AK#2.B6KMY/[UH!C8CB#0*?;
MP2+.PIN##F:H_O9=%OC0Y^3N X[18EGCJ@DUC:W8[77+G73*9[!9VM4L7ME*
MGPQ;;3R2V93;_>W;FS[A;1I-U-FR>VN\M*LQ:5>KB4L5?(0G(J(LVT(L#SDC
M%^WEL8^:4>) FY,V1 H5QVMH;Y 8NO29\V@.9DQ7J^/#)GEB2#H^G=<"V;3<
M]NG7=1*S2.*2DUC9:IU$\^S=(E9IFV]PMQ-_%XK9N9MQ4KV0G7VW2#@TD1B5
MV]V*57T%'HTH!N*=PZ^)R4&SHP@NR65V&]\^D@9Q:_8.RXW;-*_ 52>.R"YA
M+5KJ<9DM9*A9CCT^T0CSK;J;;6R%X$#V7-O(.1P5^N@S 4;"'2VXLH=9&T1X
M-:,PWS#A+QZMF@ZOKWJ8V1/%<JF[?-/6>HM7!."#^X<E+(F2C,UZ[5 G"AC5
M=[<,?* 0J(QN%6FG8\$6=DF9M%)2WD(:L<IHI[%]GCFTZ/EIV[%U# 'B[5M[
MMO EW4,B^P;E)?W)-PHU-RDQ2U'V9+4(<U)IZQ#4]L"Y('QU0Q M[K([*Y4Q
MV0IR<^3V+GPMIS'MVK&& /'8H;2US+M14%X;@)R\-0HE<R/,8AU0PN8T*S)J
M:Y ^,1M3@6+96\/*E36&))&HSJA%7D0X5_D]6O7OX?/4>E'4WC405E6LL4K$
MBQ9$UN+#&LVF)) )?"5;B05A,B-FKB!7;"[9N'M1!*EAE;#RK#7ZO.=DIARA
M8=#A+L\/GGR?D+:+Z=&WOYE=XWLYEQ8%ZKN(<5^M8$E9+-(P>*1HM3W1?.K.
MP6Z&L)!?)6TCM'"FMB%*;;A@+8Z%7 9D17RQ/8S>-_Q;+??5PZ3%'XWS1VO3
M#%YK@9BKS*3('2AA$+(:,3F*!= M]?MP-BDC8).L6"SD*@0<"QUMF8':9R14
MBU9=R)7&("P#7?2,_?F.OY:+W69VZI<5[]@W"E5RWCI07OEKA?;8+,GU8<-7
M!8L%>EEQYN?F@%#HIF( ADH@M3.#>%&'G)I**8CNH9R4&1F[#VZ3V6U\C4I(
MV,KN\8B7N&5WB)0R!"P6%I\ D<3S+A1@(Y1 <*2D>VQ%'AYSP1D,\9CC([<.
M295/EIR\MQ;[I1Q&8#LO]EL%HL4T1-$31$T1-$6<4S^V7^)_Y5HMD?;X?=?/
MKPMU8R=MM@F1AAI\-!K3C9$B/IJ;G!CSE&0LX/$F09,*;"2^[-@(G0G'&7WH
M3H_);$*;%'2HZ_R=]#V#U^)8WB<\-)B$M!3X2YE54TF MQZGCJ'5]!44,,]-
M-3U%.)7U%,VHIWNCEDIWTOKHIZB&DFB=W&L>UK&@N:'%WL@R=6;9+@X@W!L
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MYX.*>&1"LT33B=:IM7(,R!KP3%>,O-MO-W%S  EQ?1X7V<E=6<X8N).5BXN
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MJJMN/LW=JS5K?7MQH,H#=(-;GUN0_?# F401;Q,,Y7(:AA(S!*0RY060ARV
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MM1.=2W-PE^_<>")L$!7DCG/^=6;(GR_\(3C_ $>?R9U;=V\'Z)?OW$?5%6&
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M3''KJ)$LRU#:'.8B26#XV\UEP>[/FD)+$F/+#V&"RF!#FOCYV<(BX\/T.QK
M<%PC'A75CV8EBD$]%%3.P2JK8V0,I'B"6/$J3I'A#Z9]145,L<T4]!BE,P4T
M%1)2U)R81G,R1[V6'LL(<3EAMSE9P6F)][  BSF$W(RFZ5[$=CC_ "M\?]6]
MI_\ EVONG^"M_-3%_P!8<9_V5>!Q7_&S_P!&S[K?/7TBO&J*I.^&THXI= YJ
M_P!9K<W;XF'$VK-J*1ZO$@2K !>L8=<<@?6.@$X4X;",):(#),R%@C6[2(6^
M@I6#L0>1<,AOWM0.I]\OJKB'F5';:#,(VTZ-(0)\ 7&'R2<*>[)?CRE(A1H,
MT.2CSB!-4 7#3!F3)4YD;#ES6"+@D.(G:0/6#5J-VP:#C XA66\)+3AL2S3E
M!:2'W!)0!%=5.R4)E8]6/B221D6.N9(C3X,R,T\.(C9LPBSF%N3MX1)1PL*]
M4^2;E%)@-@(U90KAE9P<.:+D@>!:)JIV3(T6^R1("\,=O0H+K<N2PVPM+F2+
MK:/NS1MQ"MG"U4LJ>2J,A;1B,N+(CY3'1:;G2$D8RGD)1('O6[;J] &'T*PI
MV95R+B6^TUPI4LBDC1$T10NSQ ;7O6RU4Y5A8BDJ38DU2T2B#L,:+"GLT[%^
M4/(39\N/VI(Q4E(.M-26V7IP?*S(UN:%C2R,<BYHK??: S,+PX>XE1Q@02R*
MS.D6$/'%E9;5<B6N;BODG9R89UL4%F)D%W1KLA(M4>:W-ZG,1_HD7Z'M[MLJ
M[.HT&=:8+^-Q6X\BID!2NZXDE#G6ZB4 =/;)#LR8BX1&[;G4"LPGV7'DNS[1
M"?SA V.2GP2*5]$31$T1-$31%$ [?/;DD^3<P76/KPLQ=JX[>#3*0M'?LNV]
ME73KS76+&3=C14EZ_9HY(.N/+3%05D@K*L Z6CULZ\/(NXB[Q;1SL-J@[I[<
M3$ND)0II46\5F1API!%MG)HUO+)1>%D(85UHO*AIYR(XMQL@ZVB(M+V2+OZM
M=Z7>(LF=2K?5[A"AO(C2YE6/B;!%BR'6&Y+3$F0)ERVF'G(SK4A#3JTK6PXV
MZE.6UI5DBRC1$T1-$7SV\<=JLXSB:W"A#;&>'PVD5C+42"8(1(S>7*H%<<RV
MPQ(;:1E;BU.+Z*,=):E*5S5G.<_F;_",Q_':'TN=)::BQK%J.FCI\",=/2XC
M64\#"_ <->\LBBF9&W*>YSW6:,ISBXW))79L.CC=1Q%S&.-Y,Y:TG_".[2%%
M(FD;X&ZN-N ZU%G09$82-]>Y<"L=R$'#=^:BY&6V^\WTVAK%!LLJ5'@*FSDQ
MHL=QN(YF;%2YT>BP;TE8A@]+CE+C^)/P^JHZO$.L=TAKXG04- ,?=754S)96
M93:2/HUBTLT5,:BH$4,3VPN%1%E<@NI6O+#&S*:0VW5M-W.ZO) L.TRL )L+
MG3F-HY3?=P*X8B2QVX)U^7 6/)0Y\"Q%9<7#KC$>>SC*)3B4K6QEU,>;#EQN
M3<AN1#E,JZ#B,]79TNZ7817T]12=+L7?44CZ6LIZJFQBOGA$A9%51W;/)DN=
M&7".HIYX2&R-EIYXS9[3L,,+VD&%EC=I!8T9LX/9V]A!T6(7L3PT<2 S>X*L
M442R,W"!PT/&QK6,HBE(:%M1\GA.,YST8RWG66YT/*LN#Y+[:,9<CO1W5?HW
MZ$O3/1>D_#'4%>V.BZ8853-DQ.BC!;3U].US(?RMAX)-H7R21LJJ8DOHYY&M
M!?#+#([J^(4#J1V6R[H'FS2=+#G.0[P!R3V@9\X6TNO>Z\:FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HBR^E?DJ]^@'?W>-HLV:?#[A9/>+M5MMJ?9
M+[=S# "I5$1-.V Q(:DR&X R RIZ0ZF+!8E3YKZL)PW%@#XLHA/E+9AP8LF6
M^RRO)C'2/:Q@RG.(:T#M)[\PVDD #.2 N?0T55B5934%#"ZHJZN9D%/"TM:9
M)9#DM!?(YD;&]KY)'LCC:"^1S6-+ABAS?39BM3( X]NKM^,(DRM:"0A\FV!<
M3W2ERC+F52(J&F8J2PJPPT+F"'9#33$V(G,IAU;&.LUDV&5P);&\@!SB0TV
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M8)/R)0MJZ42N-#B,M*75>*4SZAC*]P;3TE(.KHJB7%*D4T4W[*;EL[DU9U[
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MX@Q+O7@JY#B%!^<NE0QIG:!5<NY7"Y-'8C'$63=R9F_@8T]B*U38=<'BX;9
M393-<'E<VKAIY[>W8N>(V6XDL7&OV4_?J4_#0;J96T"H,TDZ/FJ$BN&J&<F-
MC9E)3'-&Y<K;7=[((^:?39@$"YU\? L3$)I^&&)FU<Y_+OLMXM%$T1-$4([R
M[=6"_3-JI@=T&1&43<1^UVNBVJ3+AUC< ))V_O-0C"BS\02?3EVNV"TA;X'8
M(@BXM\S5(.%1QY1(FQ B:UJI'X1KT+[Z4C!6U+H>?/W4[6IDNQ6+O>N==O\
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M2LU]5I 1@:QA,1W0#5X=%PU#T5RFY\VG1F&;-;BJ,\.?$<B+%BD^(.3:76U
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MMN_RYUHJ88/\_KB8?./4#FXS]O-A5\VF;;O\D3+!_P"Q)A\>^#FY^:PI]?\
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M,#QA8C*=*9>@6S#LUVM]=&S3G7[$.'K?>(./32O%F8%#W!L1))?:ME'@A82
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MN19;3+  05>RHV(3CM%W'-1*%CQ]?&\7C>QX_%I8ZCN6;-/A]PI0[X:_CRG
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M+'4=RP)O;Q^I/W4IY/ \9Y9,BL9]&2,/&?W;2QU'<HF#H3/CP8%9QZB$3/\
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M/$J+A?&ELL9F 88]%D<S9W:U! S%BQJ1I$[=+W:-NJ>":FMEW4=M6.Q5 YF
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M-/=!015U2UMM/K#+48Y/A=T#(*:P?EQD95S')4,N6?RAS9/4%LMV-:+DL_E
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MCEDIGUC=YHJ/9?%T2P/'IZ5>GJ]'DY6=/+S^GRX]'C)GUC=YHF/9/LBP//\
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M$31$T1-$31$T1-$31$T19Q3/[9?XG_E6BV1]OA]U\:_]3)Q)>Y[WP_8GOO\
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M?,WIBPO#L(Z9/H\+H:7#Z4890RBGHX8Z>$2/Z[+?U<0:W*=893K7-AG7V+Z
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M431%\U?9'?RU%N_2.J_]4MZ^U?0E_D#1?_/XG_ZER_.W^$;_ #H8A_9>#_\
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-KE[^=%1FT ;AP7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g752656g47j52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g47j52.jpg
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M._\ 8O\ KB(^._\ ZSO_ &+_ *XB/CO_ .L[_P!B_P"N(CX[_P#K._\ 8O\
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MK&3C!U2U[RG?MG[I-+V#?=0^P9=B"N_AAY\K].W@_L]!CMV2K5\3R@]EN/\
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MX?\ .L;[%J,U(YODZ[QB(Q$8B,1&(C$1B)DY+2)]'Z_$T6J21,?7-&\G!4D
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M,)H80=IA*)&\S8YNPHB43<B])J@XD2"C'RTM.&,0\<CX4;&N';;T86)%BZ;
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MVT?#;6I+#T[4-1:U-/P<S.:BOO7+AXM^4U-7-:^[:*$<UU]QT3FX"\W5=^3
M$2!ZD#Z/)V_]Y1'^G\U%_%_YGH=&'_&SU_%7X]M@&?QF]'M#[_%_XD@GZ9]"
M-Z8W]'?,_P#FWIK_ ._?NY>)T]K]GOO;T/6'^]OYQX:;FM][_@[G^^\:3[K\
M'Q_A^W\'Q>GF0Y+X^)?B_%\CS_I\_P#M*E!7:F6@Z6C*U;JQ8I* >T-.Q\%/
MQ4L="D*6XWIB6$ +((C7MN,NHTT8VRO:VG$Z3[R%:U;YFDZKI].-D9^F:A@X
M^:G<P[\S"R<:G+K 5B^-;=6B7H RGE4SC9E.^Q$B&4D@$$CU ()'^ORESYCY
M&,1&(C$1B(Q$S]]FY]8@G[/++_$(#.R?W*WZS[?Z8U;[5ILQVI_DZ_O5_M>2
MO[?K]%;Y%?MCB?WY<ZST=F GSH\1&(C$1B(Q$8B,1,B^'^)W??)!V.&XQ1Q[
M@;,V<BF0,:NYT*M2UCM 5?>M<E#5J)MUH@9*R%Q-;8<G)KZ#%D&H6-4R5*N!
MM$#J=1*6[XS]LUT;F7)0*:U9+_V46(,YC"4JTTV]LV\:<L,S5 '8Z<IEAG:^
MWI-@KTY'2*3I45<,N*-?F$@"L+?TB4SBOC_USR(MDG1N/U1%LM</79NV24.[
M8JM671:Y6V-EV"641;9N!#6-#":47(Z:)6Z*(VZ2ZVEAIQQ*)<S_ (D^2#5Z
MYOS4?D5JF+CV&L W7EL;6FP;6'?J=(-F/-6NKSU:-EJ]+5P9F/D'I6:%E5QL
M(S'GO3)(#81*FD2DS'CAU:$C(Z:("I,A#2O00^6!R];ZYR*W1?X]GBOG"P9<
MA5;S,B1R7!!W2=R\@\+!ML_#<=DD)>9VXB2'9_!?R@IUMME L'/X82^T6:H]
M>MU%&ZER*6NL#+](L%;JU+%.J</?#[ E,U8+A6(S13<<X''OS8*I4@%EW;B4
M3CLO@[Y,5&DA]&G:36F:5*5WH-L@Y^/Z]QB<&LU<Y3+,P71I:I,P709(RVBU
M"8?:CYG=:&E7&"=[0E"_<7M*)B9B(Q$8B,1&(C$1B)[ROX+U]3+NW[SLO]U7
M+L1-P/GI^9^N_:1#_P LV_-DZ7_.%W\'9_FQYQ?[6OT;P_YUC?8M1FI'-\G7
M>,1&(C$1B(Q$8B7"74;7'A_2)]8L(4?\!HKYXN%DA@_EGU:0P1\R\,ACX#RM
MZ2T][_PW%;UI"M[WZ917(H=N"74L^Y'%;$9MQZCB&)W'TC;<?3+RS3M0IJ[U
MN!F54\%L[MF+>E7;<[(_<9 G!B0%;?9CZ$SG&I%T,9"(#J%H*'DFU.QSXT!+
M/LGM(UI2G G6A%(*;2G>E*6PIQ.M;UO>]:W@Y..I8-?2I3PX-J IOZ<@6^'?
M]NTG32M4L6IZ]-S[$O!:ETP\AEN4#<M4RUD6 #R2A(VE.57YY,3J?5"2Z8)3
MOP$S2HTS43M_W]M_!U([9^3V[\36T?#T][_OZVGT][\F3=VHOVA;7W=M^WS7
MGMZ[\-^6VWG?:43AY@Q_>SB9(Q>7#WDT6C'Y[[<>]Q[?+<$<>6^_C:?MNMV)
MV/'EFH":<BBRD B2;<4<N/*-<<^$V(.:EC8SQ3CNMMH';<4ZMS7N)1M7Y,&Z
MD.4-M8=5+,AL4.%'DL5WW"@>22-I$8.:U*9"X>4<>QQ77>,>TTO8QXK6EH3@
MSEOA"JQ8GP!O.\32+H$E]1E0M B1G!6B5$P$LPD=TYUM@)M_;HB--.&/O,LB
MH<]U1#KK;;.EK6G6Y!DXS;<<BAM^1&UM9WX@EMMF\\0"6V] "3XE5]*U.H,;
M=.SZPAK5R^'D($:UE2I6+5CB;'95K!V+LRJNY($ZKU5M \@]$D5N>8E1Q%R#
M\8]#R#4@P TWMUTUX)8Z26Q&VM;<62MM+*&];6I>DZWO)A?04%@NJ*%N <6(
M4+'P%#;[%B?&V^_[)(VGYZ7-C/@YB9"5FYZ&QKEN6E1R:UJB@=:POQ%RH4#R
M3M.UJCW1333Z:A:%,/BK.8>U7Y;;3P+:/BN&-.:$]QP5#?\ Y%D(WME*/[ZE
MZ3^7)?><;<CWBC<-Q([M>X8G8*1R\,3XV]=Y/]ZM4*JXTW/*/6;4?W/(XM4H
MY-8K=O9JPODN"5 \D[2U\KRPC$1B(Q$8B,1&(C$3%_/GOGH1&(C$1B(Q$8B1
MKV:S35*Y!U.X5N.+EK%5N=W2PP,6 .LLR0F8>N2,A%B##-(<=?>?-'8;0TTV
MXXYM7NMMN+WI"L]TKI^)JW4_3NEY]]6-@ZCKFDX.;D7.*ZJ,3*SZ*,BVRQB%
M14I=V+,RJ-MV91NPE<E4=AY(5B!Z[D D#ZYAEXGA4&-\;/&7FL!::U8@8"O0
MO8>KFQ\Q'R ,&0.V7T5]ZPR;3[J(F09ZQ)PQ8;,LL4LL&LSSB4):A9#0_*GM
M)NUF_KWV@:]FZ;J&#=FYV9TQTY5D8E]-V76YKT)$P<=T4Y-#]-8^75:V*+:J
M[M0PE)+9E!LHT\174@8'8!VV(V'_ #>2/39R"-_^G]AD43T-:(KI?.^\\RT1
M8:GYS0<OR/J#T07HM$ 5:79J;XQT5[;3BVG#*%0W3:=,[TXRP&' H$::<DS$
MH<V3#RM/R- USHS7^&#J7L@S,;J?IY,FKM'-KTY,3#ZKT% Z[K5K6LK3JN+N
MKV6VYC6LRX]1*TR&Y+8GE<@%'^D+OOP;U]47P?4#B1L2?-U5WIG*G?-[O'3+
M9=Z75*'XS<:IG%*R_*3D3'QFI2R$E76Z$PH[A"7'CH70 E0(:!:6^IU'T4,R
MZ]K;>\=G=/\ 4:^R/HW0-,TC5M2UCK_JK5>K<],;$R;\@XV!77I.DUY;JA5*
M<SOVZI6]S*@4C)L=4^*3!D-]CEE"U5BL;D;;D\F(_:/Q?_;U.\?&]8B;MY:]
MU[4%U;G_ #:N<0YIRCC\7,7_ $*M[Z+N,XS?^ODUP!Z> V'>H*.0_6A5/QM@
M]^>9'A%1!6_B(UFJNF\G2?9IT?TG;TWK>OY_5^O]2=49&)HQL5#D:7B-HG2]
M6?<N'=W='S+RFH6!+\+CA.^7[S6"IDO/>^QPZH*U1 6^1/)]AO\ C#T]#YV&
MTK_FS9V;/XR],$Y,D2%HW$F*?*.J!G0890?2H&RU"ZLU20A]/_,E:K4+O8YT
M/M3^B[A-Z8VEF8I3S;EG[)=/;3_:!T_9U*;<O5^K7U3'478=V5W=!S<#5-)?
M4J<HIVZSGY8[E&7LIJTO$-@+XNK(1&]MZGXC94X^AV^,%3Q(_8/4;^6/_4LO
M+RBO0-C IWD'Q7J=:ANK^.O/".L1M2LCX9U3Z1SWJT5Z2].6R@E!CE@EV*>T
M%"'0OJ8-*%@Q?O,$389L=BO9YH]V#=JG1/5O3N?E=-]<ZW7TUD:G@);3J6@Z
MYTWD[XVJJYK-2X.*^J-;F4Y?X*S&JNR-FKQ+:KYK6WXV(ZAZE+\3Y#*X\CY[
MGCX(^GQZ^18\Q9HF[>6'$P8HVH<IK?BGXRRW7)>%M02I>+I-RZ8)&P#U2E(8
M2R5,C<K4ZBE9JB7#T;C"'DK6+\P6C,OBX&3I'LUZMNR*=4ZDU#VC]?XO3.-E
MZ;<,7(U;2NG[+\Y=2QLJW!U)/=M3U/:D5K21D5H0+>W2TE)Y75^5055%R#YV
M9]AQ]5\@>=__ *F3=[.,8F<X98NTS+HK]I\A^M](ZU/*'TE.PD2,^]!PD/\
M"^:.6$,##P8I <8Z82Y'LR&V7'G'?B+5J?MU>O#ZPP>D\5;$T[H?IG0>F<+F
M2>\:,),S+R^1KJ%MEV7F6I;D+56+VI#A0O$"?&W-9<^MCLY]/&YVV\>/0?\
MF9_9PM+B,1&(C$1B(Q$S]]FY]8@G[/++_$(#.R?W*WZS[?Z8U;[5ILQVI_DZ
M_O5_M>2O[?K]%;Y%?MCB?WY<ZST=F GSH\1&(C$1B(Q$8B,1-L'LPK56.-">
M6?DC/]$Y]6KGROQ>ZS7/'BJV?I=)J]MF^Y]:B0:4'.4JJV&PQLU-*KM2>FRI
M=^'CG%%(V%'M$NEMMB;1.W[.F^4GQI[;XF=9N-[@4V>Z=@JL>&<)TWFC<=Q?
MB$/=QD]!3T!Z8LFU\V>Z$[+S;[XLM^*TFU2XFP-M)E@>G%MCHF4O Y;QX\3+
ME[6/M$C?.)]'B")*7\>^)4*L]TY\Y8.O<0[3VD=SJMAYVFJWEBS*3'<5%C=A
M3M8<3(!GRQL:"^B0C)=@1$F*]]^YY7K][1[C]![QQV=67XB4SA?LX;#6+]S\
M.@UWQP-GFIWH'#H6ZBS*8^'Z834I7Z%D-WV:$Z!=;-6#$G''R!\(R6B8O^+/
M$O$2O7SV:T9?NN<QJU\/Z5;.Z^7+EI\@:8/ROFE4Y!9?F^5U*9'/L::P-T7J
M@<<@>;@D3!T_'A'BCMPT0*])J%1,:?,N\S'=) _N3>^"<\N?1_(/I!A0=![Q
M4+3T3H+?0)YFT1MEZ'L+J5Q;H%/YL+4*7 0VIP^FT[Z6D-RE3@F%AV.5VB5K
MVI5\J@5[\;^"\?Z'3+QS'QE\2N6\C MG++Y6[I4;7<IF,*M'89]B8ITS*@:(
MGK3/$1,X ^\RMU4-KWQ5"NM//HFJG$1B(Q$8B,1&(C$3WE?P7KZF7=OWG9?[
MJN78B;@?/3\S]=^TB'_EFWYLG2_YPN_@[/\ -CSB_P!K7Z-X?\ZQOL6HS4CF
M^3KO&(C$1B(Q$8B5&(BCYV4CH:+'<*D90P< (=I*EK=)*=2RTC24:4KT]Y>M
MJWK6_=3K:M_DUO)++%JK>QR%2M6=B3L %&Y\RMC8]N7D4XM"-9=D6I34B@DL
M]C!5&PW/J?/R&YFPOK*UPD%T?^S\,V1F*7!53QVF RF7"F@>=2,&.6J;AHP=
MEIQ!DO9&S(APPQR03IMMHP'33CRE(U+ VMMP_>V1:\BV_5JV4@%LM+2O:L=B
M?AKI*V!5"^=U8D#SS)U QQ,36_O/59;DZ7BZ?T;DUVHU@JT:W%2SWK&H15(M
MR,T68[66FX<56ROB6\6'U>#DX$.L4V*KEF3+<=Y?!20]H&>=%K==LI10MQN$
MH]OZ/2VHU]M*00%[E5I=/=0"B.)/6PXS=8-J6M=DV7T]O4,VU&I(#6VTHK8^
M/6/CWX@_$WX/P@Y%U0'?%:_BWXM>#IF/A9HR.F]!Q+Z\]&:O"P\VQZ]1U+(8
M]D*;6 [5).00US"I:'M*E;8O=&MS7-.'<QA*_+/F%0\QTNSN(!*0&*59RUMQ
MSLP4IK0T;]!P,>X@]9CC6Q&5J61IO6]:W7Q<G'.9J>;;;6%%E>'3\2\F6E1S
M%8WW?N6L./'?D? F/U;2M170^E=!Q</(:U\?)UO/(JL%5=F=812V385X4^ZX
ME3"TV,.VI);;<2\!:$>7_P#2QQAV.+;;D=D]3NC:QGD(6/,RGS2FS-*1I(Y,
M97(M<<ZAWT6P\<PV\G3CS:%6[92+]_-1#J>''"QR"/6M.(*D>2'N</X\$*2#
ML/&332+;/]@>F7I<+;W->U-36X!3)O[G&W<#@].'0:&#;%6M56 +*)$W:Y"4
MG3+/?1Z_9Z\+:K=,Q4Q)3KSK8]C 22 ;5XV)%=CXY7R4,+6VBBT)0:L,MP-)
M4DKXX0S=_IJ5U"G%-M-S48Z/6E0&]3$,MSV$._Q6-<57RH90W%/#,=>ZHNR,
MNS/U9,/.PDS]1R<?)NRV8+FU!Z;<"C&1J:?P6-7A+98 +378:^=YYUUK</=Y
M%F:NP,E6GOI:W]5I7/'3& /?=*C1I.K0S+D;OW-;5]*6)30NB4HVEUB&;4P[
MMX>>?;:HZ6AKQF2X=O'P<G+XEM@'9+["'_\ V4C?;Z&L(8>:AO>=67IDZG5=
M@O[QJ74&EZ,;5JW:RBN_ QE-!VW/?S=J^8&Q7&!5N2Y;!;F[M&&1\C(1$% 6
M1G7':73J8)<]O.B546&:AR/QC?;]Z/8TJ=FYJ8%A!5[D2MR#9)FD"-[;02U1
MTQU=$LMMI/WQR,C);'VY7-8;!V0?C/X*NNMK". XD*>1\B7_ %9193;=CXF'
MG(>F]+TW3*]3Y-7I]>,,=_?F&]*;Y>3DY->*A[]G>5[-JU*AQA1FR3BV,1&(
MC$1B(Q$8B,1,7\^>^>A$8B<!!(PB$NE$,#-*>''2X0ZVRA1!;[8HK"5N*2G;
MQ)+S0X[6M^^\^ZVTVE3BTIW,B/82M:,[!7<JBEB$K1K+'(4$\:ZT:QV]$169
MB%!(0.2,6UI\0A@IG:WFM/#NMO-;<'>6.^WIQM2D>^P^TZP\CU]YMYM;:])6
MA2=1>MZVX6(];;*W%U*-Q=0Z-LP!V=&5U.VS*P8;@@Q.?)(C$1B)T]ZCXL8H
MC>@XX1O3YQK^],"#-Z2G;I)A3N_AM(TE"-N/D.JUZ)3M;B_36]ZJ?ALAZT'<
MNL;A34GQ6.Q)"UU5K\3'<D*B*/)("C<Q_P#S_P#?_:6MOHW.E@QTHJ]4O<;*
M08-KB9!=FA-!R%:DBP8^-LD>2HW3)4&>=*Q@0,P.M8!14D",.0XZ8.AS(_>+
M7.]?CC1]5[^/F7:=DT#3\ONT9^/7==?@75BGG7F4U8V1;=BN!=771=8Z!:G*
MR\E]>2[$ [[CT/H?]#]!])=)\C'Q;*"9,\..'<+! ;(/*8$9<.DS&(Z-"0Z0
MMMM1<A(%#  CI5MXLPA@4=#C[S:%8^FB[(<UT4VWNM=US)36]CBG'J>_(M*H
M&(KHHKLNN<CC556]CE45B)IW,I1&(G7<$%>4A;PP[JVGM$-+<9;6IM]*--I>
M0I2=[0\E&M(TXG>EZ1K2=*]/R9.MEBA@KNH92C!6(#(3N48 [%2?)4^"?.V\
M3L9)$8B4@>P01DU)UP29BBK!"!QDA,P8\@(_+Q ,THY$.9)QS;JBP!9949))
MC7RF6FSMQYORJG?E7_<N7P\RK%Q\ZW%R:\++LR*<7,>BU,7)NQ!2<JK'R&45
M768PR,<Y"5NS4B^GN!>XF\-QN1N-QL2/I&^^VX_;L=O]#.ANZT[1$4+NUUOY
MF==FF(4?4Y&;>EWJWHK=B:C6M$[6<N!T"9],I&TYN+V(1HW3&V7-)K?>K5.&
M19][<_MX:XCY;^YY'#&7/[8P6R&[>U(S>]5[H;"OO/<0T\^0W;CP-QN=P//K
MMZ[?/;Z?E.:&ME6L3,61 66!FV)R*<G85Z(EX^1:F(-IX<=R9BUB$/)D(E#Y
M8C*I(3;P>G"AD?&]XAK2Y<K3=1P6R$S<#-Q'Q,D8>6N3BWT-BY;*[KBY"VHA
MIR2E5CBBP+:5KL;ALC; 0=MB#N-QL?4?,?LEP992,8B,1,_?9N?6()^SRR_Q
M" SLG]RM^L^W^F-6^U:;,=J?Y.O[U?[7DK^WZ_16^17[8XG]^7.L]'9@)\Z/
M$1B(Q$8B,1&(C$3]J;<1IM2VUH2ZCXC2E)4G3K>EK:VXWO>M:6CXC;C?O)]4
M^^VM'K[R5:TB?C$1B(Q$8B=Z+C3)F3CH>.:2_(2IPD: RM\<5#QAQ#8HK2R2
MW6!1TN/NH0I\EYD=K6]N/.MMI4O2)*M[X%U/FD9;YBY0$?&1]$Z[.\)LSP]K
MJ$RL+J-9'.*GJ\,-"3LB3*BQK,>^IZR1+)U6=VX&@::?4<'I]$AS$1B(Q$8B
M,1&(C$3WE?P7KZF7=OWG9?[JN78B;@?/3\S]=^TB'_EFWYLG2_YPN_@[/\V/
M.+_:U^C>'_.L;[%J,U(YODZ[QB(Q$_;33CSC;++:WGGEH::::0IQQUQQ6D(;
M;0C6U+6M6])0A.MJ4K>M:UO>]:P2 "2=@/))\  >I)D55F8*H+,Q"JJ@EF8G
M8  >22?  \D^!/+K3K#KC#[;C+S+BVGF74*;=:=;5M#C;C:]:6AQ"];2M"M:
M4E6MI5K6];UD 00""""-P1Y!!]"#](,,K(S*RE64E65@0RL#L58'8@@C8@^0
M?!G'D9",1&(C$1B(Q$8B>=[VK?JK>][]-:]=[WO?HG6DIU^7_P"$IUI.M?X:
MUK6M?DUB-]_7SZ#ZO ^H>!/&(C$3G<%):9')='?;'+^+L5]QIQ#)/P%_#>^7
M=4G2'O@N?^-WX:E?#7_=7Z*_)D RDE0067;D 02N_D;CU&X\C?UDYK=51V1U
M2SEVW*D*_ \6X,1LW$^&XD['P=C.#(R2,1&(C$1B(Q$Q?SY[YZ$1B);MAJL)
M:%0*YE@EY=9L4?:H98LG)QBQIJ,:*8%?=5&&!J-&V.<6.3&G;)C#F'UM&B/M
M^B=7V%J.7IXS!BO6@U#!NT[*%F/CY LQ,AJWL11D56]FSG56]>13V\BET#4V
MHWF0(!VW_P"4AAZ^H_\ ?U/@^#](F$?7;'=>3#6RC<<L1]-I7)/'V&$BEGMQ
MME;%Z1T2WO5'CPJ9V[QU@/6Q!N012K,F4D9*.$J\H"EV/%)?BY4'EGIG TGJ
M6S3=7ZIP:M5U;J;K;*MR12U^GM9H.B:8NI]4V>YZ1?@TA\Q<RL:><>G'OLU'
M'N*WV)7D8UU!RR;K6>*I6-M]F^-FXUC=^1\;>=SMQV\>=Q52^]V2P7&*@(:U
MK@B"O(V&XZ+!#0T.\;JNT^$-N=WGKN/,1ADE!F=$!K5DA:2 'N,?^B2829C$
MEE/'$ 6U?1F!AZ7DYF7IWOE=?0F5U39F/EY:4^_:IF5:3I.%I#XF131FU:'=
MGX&7JMUOO*>])F8N1VJEI2^/=)( .V]O;X[ G8 L2VX)4L 0NVWC8^3OM'$+
MY 62I0<)?"+G/6L"V0WE'Y G09P\,2W*4.C$@P_,Z;$.#0#!D>D.OS=7GIE<
M$M.@2*S:79-&]K.&=SV7T7@:GF9FC)I6%IM^F97L[Z)JS*'RJSCZUK%=V3K^
MJY2V9KUY!MSL/4,/$7,#=Y-0TU,<^*;%E%G'9N1(876$';\5=N(!XCZ"/_\
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M3;FR][B%D.AM-.I=2A#'Q"G7'FE-+2\XEEQ?JL=A39JE:VNTEN50<* 1Q_"
M!B1MY.R@ [C8;[>ID*LRVK$R<-%K[66]#W,0W<_W<NU:JP8 )RL9F7B0S!2?
M*)M1,JRUC$1B(Q$8B,1&(C$1B(Q$Q?SY[YZ$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$S]]FY]8@G[/++_$(#.R?W*WZS[?Z8U;[5ILQVI_D
MZ_O5_M>2O[?K]%;Y%?MCB?WY<ZST=F GSH\1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$3WE?P7KZF7=OWG9?[JN78B;@?/3\S]=^TB'_EFWYL
MG2_YPN_@[/\ -CSB_P!K7Z-X?\ZQOL6HS4CF^3KO&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B)B_GSWST(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B)G[[-SZQ!/V>67^(0&=D_N5OUGV_P!,:M]JTV8[4_R=
M?WJ_VO)7]OU^BM\BOVQQ/[\N=9Z.S 3YT>(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B)[ROX+U]3+NW[SLO\ =5R[$3<#YZ?F?KOVD0_\LV_-
MDZ7_ #A=_!V?YL><7^UK]&\/^=8WV+49J1S?)UWC$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$Q?SY[YZ$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$S]]FY]8@G[/++_$(#.R?W*WZS[?Z8U;[5ILQVI_DZ_O
M5_M>2O[?K]%;Y%?MCB?WY<ZST=F GSH\1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$3WE?P7KZF7=OWG9?[JN78B;@?/3\S]=^TB'_ )9M^;)T
MO^<+OX.S_-CSB_VM?HWA_P ZQOL6HS4CF^3KO&(C$1B(Q$8B,1&(GGTW^K?Z
M\AN/F/E(['Y'ZC/'IO\ 5D=Q\XV/R/U1Z;_5_A_CC<?/U](V/R/U3S[JOR?W
M=_EUM6OR;_*G7KZJU^O6O=5Z[_PU[N_7_#>(V/R/IOZ?0/4_Z>#Y_9/&)",1
M&(C$1B(Q$8B,1&(C$3%_/GOGH1&(C$1B(Q$8B,1.-+S2U.(0ZVM;6]:=0E:5
M*;WOU]-.)UO>T;WZ;]/>UKU]-_JR)4@ D$!MRI((!V]=OGMN-]OG$-NM/)]]
MEQMU'KO7OMK2M/KK_'7O)WO7KK_YUZ_DP5*G9@5/R((/U&)R9")PJ('2K:%/
MLI6E;;>T*=1I6EO?_@HVG:O72W?_ -M.]>J__P!.MY,$<C<*Q!#,"%.Q5/QC
MZ>B_\Q]!],3FR6(Q$_*UH;2I:U)0A.O52UJTE*=:_P =J5O>M:UK]>]^F1 )
M( !)/@ >2?\ 01/.MZ5K2D[UO6]:WK>M^NMZW^76];U^3>MZ_+K>O\<A$\XB
M,1&(C$1B(Q$S]]FY]8@G[/++_$(#.R?W*WZS[?Z8U;[5ILQVI_DZ_O5_M>2O
M[?K]%;Y%?MCB?WY<ZST=F GSH\1&(C$1B(Q$8B,1&(F;G:_'V@TCQ0\&>PT]
MBX$]!\E@^\O7820EPY:!')Y3U57/()FHPD?6PI4+Z5#UH^3;.EIYUP[>FP-#
ML_\ B4B2\=[*;O4;.3,$;T;AC+L#9.K5>1.^G.E. -F\>\;JWY3VDEOX7*UF
MN@D\OLX2(5: OF2[**=$EB@,(%D"T3CL7LJ^\P3$V<)?..62*JFCC[E)PDM?
MFF*K6!O&1'EN':Y%F>YW"%F1LMQW:C @H,>6G6;%\*O244"6^E6D2Q;O[._K
M7.:5T;H-GO7)/H'DD]S:*OX,9-7@VP0L5VBCP/0>,6MV/%YT5MNK]7A)\<*K
M2F]N/QL^))Q-PCJV^"O2T3*Z\^R_KE.Z4_"*L(Q.I3HOM"*1'<M_M#F$24"+
MX<\5C^C@R2>OZX.Y&6LC9<K\_)"$\RIC4_'C0\($5"FS$U*U9$TJXB,1&(C$
M1B(Q$8B,1/>5_!>OJ9=V_>=E_NJY=B)N!\]/S/UW[2(?^6;?FR=+_G"[^#L_
MS8\XO]K7Z-X?\ZQOL6HS4CF^3KO&(C$1B(Q$8B,1&(F<$7>81B/@TOV\#6AO
M%6RU%]AJS!C$HMY$M(OAPZ'%//Z'EG1'0?EWEL.):]UM.][V,MM&M/C6E[2,
M=_BURB\$T,P["UJ&L(V&]88-OY&_T>HWY4Q]6Q$IQ VHT_@^@,[3G5<ZJMQJ
M-F1:]6*&+-PR2C5<6*,$V'J4*CJQW6HBT5J.DILF.A))WO=%G%0H-B%BWQ8"
M"JS$,_8))9;;SL@A9 S1$P_MD5V0D'7#$;8;1[J)GP'IN9*P]JC3,FKNO2;
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M;3:$ZVI:W%J2E"4ZWM2MZUK7KO$3LRD9(PDG(PTN$3&RT0<7&2D<8TM@P"1
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M85%8M+HIAK,C-9C$1B(Q$8B,1&(C$1B)B_GSWST(C$1B(Q$8B,1&(D==4O\
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M+>:X>!\HAD>/(I;T&.XL8M)3ZSFRW)9Q6G%L![0EE"?@JWO:]WM&7W\BZH(
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MZEGZY?JCJ:'?7\W5$U1-6%.&<7%(Q[J,0>X96+F57''\WUXQKPZ9.R VX8@
M!0OJ. &Q7SN?()\@@^?I))DD,>(W#QJ]:*DS SC=7N4'582Q0#=RM;,6>NDP
ML)7JO/\ RP\NUH>U1$36JZR/8QMM2:B82.E'GG)5CYY6#?VE]769VGZF^;B-
MJ.E9FHYF#FMI6FOD4#5LO+SM1PNX^*Q?3<K)U#/=\"SECBO,R,=$7&?LB;LU
M[$;'BP (Y-L>.P!]?4<1Y]? /KYDPR-!A)FGKHLR58):OE"N 2Z3K%,.2<\
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JU(YODZ[QB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g752656g48k25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g48k25.jpg
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M 1$  A$! Q$!_\0 'P !   & P$!              0%!@<("0$" PH+_\0
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M,XQ$C.$#;2E>D5O0A+[.E;V*;-2X#OVMN)S'/-\Y8X2TZ=HED<!&'@%8=R$
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M[G/9L]H/C7J=PZC,"R]H;+DQX>/Y+RSHWT$6:Z4^RY>I)L2;]\Z,AWCR8^#
M'-*:4U&H7\Z2$HUYL!DA#L%Y.TQCA[8S(]Z]4]55T"*J=T7TO(%5I7*J=N?I
M5NT%B-32]*<4B6+P>=:T/3O \U\I)*TCJ>5G].UN6"NTKPU8HY74K #ZCQ&4
MB)7!F-*X?R^RO4@73MM*8NU\Z/40I51K$2\Q%UV(=EH&7?AR85YU,BIK;#9H
M:WV6%J^(K24:VE&I+/)W819;5=36JU+#(%,@+S2".6,2"0 J#OM8 G*W&=+<
M#>;BT!Y"1.4Y?FN.BL&9:[)!2KM9J6'K/6+"8KVK+$75-[( 'C+3W^#@8[B_
M#96+@]"2EA9OA\Y*H=6ZLM^/LB(1'S.U-?\ E6T&+L1O3K;(>D/-M-..%/OK
MOZDLK\CR<;R]R1&LD49 ':&B,GT^?Q9NXZ);QL@*!FO\S3J0=,]*V(*G9/<7
MEI;5@,6,CPW5JCU-K[%8X_37N"Q:8*I,CL;"YE,U#&,9B_GSWYZ$8QC&,93U
MGJ-4NT4N"N=8KUN@W7F2'(:SPL;/Q3A ^]J8?7'2HQ8BWF5;VIEU3.UM[WO:
M%)WO+[C^3Y+B;*W.*Y"]QEQ59%M\?;GI651]!T6>M)'*%< !E#:;0V#D" PT
MP##\" 1_D<I8CC/'B]%I+Y1S4E)\.'7CDD46KO:,K\<\,1'P9>G(M6B(< @,
M1\.,>]\(5X49UAA"V&E)R"=5=41&(Q=2<]&8;4MZ$IS'(H8KLZ21SW(NVP/3
MM3)+*DMA=32))(KN0[ P[$\_0OD:/TCR![ ^/8?A[9 R'*^&+?,&E><<G63,
M/0I1[$A4*>I^4?@F5A5T@QHF.VX:]##J6)"NO)=7'L[6."IE&]HRM#U)U>J1
M/7Y[J01U5MQPO#RG)A*Z7&$UZ.)DGU"MMPLMM4*B=@'F#'1R!2/V*IYT=%5\
MD> ?;SKV'X?;)DODO)&R%R;G,^<ME(L&[FY(+IE920BU-ZVK=L66J-TXFP(3
M[V]SJG-22=>N_FM:]<MQU+U*T8KKS_.&(T?R4L Y6^8SQK'^31$)^TT2=?\
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M,I23<E+$E:66]+ C/+'7D>=XD=B2\B1,2BLS,2[JH)+$D[.=56&UFN -JF[
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M1V:+E3&,8QC&,9G_ .S:^\,9^'5E_N==SLI_!5_I.G_PORO[WQ>8[D_XNO\
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M6*-6#JH!5/30  "--@E4  "AB%+:]^U0?"J!3DN6)8GA>1F66?YF<LS,]BP
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MF5.0JV^K$JQQT5L+!9BCO=/1<AR%7D"M>5:LJO+/!&A]'(%_46!2%5I7[W_
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MR6^?>8.VM.D,$Q=>B=1CB'?=6PZ>RT\GXK[;:K9K*J.<Y%7!([:5;R/'IIV
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M37/RLW3O0_&1<O>@Y&G)-\NG(<[$[RA(:4;1O658(XZ]B))X%V[6^H'\V#L
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+C&,8QC&,8QC/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g752656g59d92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g59d92.jpg
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M1U)3@9&4U.'_Q  = 0$  04! 0$             !0$" P0&!P@)_\0 8Q$
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M-^_>*_&#3LRXB3#4?'#0VK);;E]K 5:4ZXU!KV$2.PM_&=@=W#>_<9CPPGW
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MT4ZK'"=W?Z7_ )07/TBG%8WQ=C[)OR:>-C;_ )YMT>U_9/O13JL<)W=_I?\
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MT4ZK'"=W?Z7_ )07/TBG%8WQ=C[)OR:>-C;_ )YMT>U_9/O13JL<)W=_I?\
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MYA_?#B)],W4OZ,[$KH+![6^_@_._6Q:AKQ[:T_3,3]7(K35R^^<YNG^=R?\
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MJ G23E-9PYS$\#\V''1+M]FM(7"BRILFU3[\[/8=C<)C-H>BQ69=TG-K<?T
M+]T=;,=QU]PIF-*;4A#8?RD$X*E;R %! 2<QRH$D)!W/=;G.[D((Y9$<22>[
MBD-D:VZE90L\P/#\([G-0@\))<6V47!*R%!? ?&X<F^&(RI0OWL=JQ=AVOLW
M0]B^.!6(LNZX3A/CZ(1KM 1HBFVH:,)\SDVB8_,MY6+E-3!6DOS[JIF2NVB+
MQEI-Q?SAMYYF'+>DQ&LK!<*3M,YR,:P /(,\B4[M;..M'R$C!J5]>:5GI2E*
M4I2E*4I2E*4I2E*4I2E*4KYS_O,O^CE_V7JHY1\X_32O6'K[_ *$?S0C7]3,
MJ_;^N'J[Z4K4YL_IG>&.H]CSO5DN7VG:4ZZEI^%R*PR")/1UC4:)N1!*S%Y<
MZA=TUL[:*V07NBE=5/L<^UX]EU6V4Q'5I2H:N% $9)S@_BKZ)L/\&#A0TCLE
MHT@MJ-'S;[U;8=TA%^[EIXQ9T=N2P76N**V;FR<3KHUE:JLC)Q5B^7AX(?A&
MX?9VC[Q5=Q)[G1WQ_94M[$;A=^#T:\=*]#K73TBW2Z:PW#%-)%.),JV5%=JZ
MIW$VV B:,1I( W1&)Q*3 G+7.^1,BW+-2&9A)B4"/FJH\F*</&KY)9LHHBIG
M8BJ05[0)*5)U< Y[(/,*]KX%/X-]_P!&KCI5'X1[=8[AH]I#HRY9E18TY4Q:
MI"KE EMN###*XSC(C*>CRVG$O,2$-.-*2L!0W']'9TBNO^<D!NV<6'Q#>L1'
M-\MA:\Q<7LFY2QNDVRF<,LY4S<D(D_=9X8KH9J+D(P_73$EU%TEQ!<UJ/L*9
M5SH/M5?Z'F(_.-_/CYEX:N!2\\$]XUT;:Y:)7)Y8LMZ*,J;5URQ:[IJ)"&;D
MRV"4K"4,3V4*D1@A2),:+LDK!7A]0SX\_.6Y^?EDTQ_95TI7077^J-%_H^X?
MYW<:A;=_6>D'^,A?Y5"J9E<_4U2E*\WO2Q<FN0.H.0_*>-ZPV].H*!B70H[9
MWG&A,<..1S()N 1RDA,3%[&'(HWMBWE;"-/W@1L5P_NZ0]RJAC?L<[U3LGYA
M_K5Z0#JY'*L#\7-4(=B;9Z0[5/%SFSNN#3OI#81QXC_!6%G@TYYN&]>(;8'\
MM2&X(%@D:T 0ARRTK::S7U:^DJ15P94Q16*/&>.>-\^]_85J\!.L!N)UCR<F
MKCL_+GL8W;^>IES/I1-P:>YJY; Y/Z?WSQ@T)JCHT-Q;B.:>FLYU1-$MK34/
MN?4D:B<M!L]2SV=@FTA(/9)X!B'4H?!G#1<]DL^LU#]T/DE6A(*=Q!)4!D9'
M8.[>!5D<!.:G+?E?I#I+4H7RZT;(>1D=VT.G<:--E7FTM<Z'TI+-+1.0%A&D
MX\))C6DG1U_)<)7 H2<-/T(U)IQ&"DKDZ1'M[\8^44 DIRDXP=W(203R\V=Q
M/R'=5AF>2O*7:O&GHW(8GR?W%JDG+.BPY)\SM@;8AIX6TGNS]Q:7UI!'<%:2
MR3'@QI4E&11:0$Y1,H\E9NE+$5T&YA;N9LAE@H0!KG .%XQOY.NYOQ8/^M9'
MG>[^6&XQ? *>ZKY;[>7YG<J-'\)ML:\X@ZNC<7 :1UE W2$3DO+C?_*Y-9J;
M4DFJ):*,' T,4*>!KX5(4PL3U^/E)6Y-<8I@#6!&X%0*NR3_ &0.8[N<_+\O
MJ!I6.E*5B+D#_ +NW\D6R?T--5O6S^LK?_CHGWANM2?_ $&;_A)/ZE=>-ROH
M*O&J]6_1U_,#X3_12X__ *K(M7A^EGNHTC^G+K]^?KU;1OW/V/Z)M_W5JIDU
MS]35*4I2E*4J&7,/[X<1/IFZE_1G8E=!8/:WW\'YWZV+4->/;6GZ9B?JY%::
MN7WSG-T_SN3_ *A"U^2'\)#_ )S:8?-H_P#_ *Q9J]$MW]#8^9?ZQ=1QKPZM
MVE*4I2J+)"606.G3&+H2QR%!R1'%Z><J,P;3)DS6<V<F':6.:K46C=/MC]RE
MAFH@UQ55PPSRQMC?;M\<2YT**6Y3PDRH[!9A-I=F.AYU#9;B-*(2Y)6%:K#:
MB$K<*4D@$D4)P"=VX$[S@;AV3V!SGFK%<:V2>F>N)?(W07+5!$,T,HM)',VS
MQ6&7[C$V>XS4=B<;PF2$86PS4R45=2,!"5G^+!XHV3[U9M2[CI+AH_"M-_M<
M!N6-)F);L1;L"T.-)NW\;)V1M#YAKN\!B[OA(2EN!-O"&"^TEQ7&DNQ6[ LJ
M0HXU" =ZLZNX9UAG544CG4$YP<;L&K8#;*E\:U).]B'VQ*6C@YA=SKM>2MQT
M'DDMAJC2/M6).3-V8=H/ */I*YD.8E7*.C%\H>G'GQ04V)N'UKR,O1^UW#2>
MRV*$Y'MDB5%0W?46]Q^\6^V75+LYQZ/;W'93K\U+-O;@B2D3Y"!=%3F8\IR.
MVSBW74EM2CE0!ZW6PE2D[AE6  .NSCK1UN,C.:M"3<CY8RRFX!*"#6!J Q^=
ME9H48SKNQD)\%AT6?C_ Y5]KY1.5NRB4U =N3-"XVT#KH'VKK)ZY%-FQ64M^
M@5L>%GFF]2'HE[G66-:8[]FV3LGHD_<F'^BJ6;X#;6HRK1-U%1),]V6A<)UL
M--R7'(U%.D:PU1E(45==N& DC5ZWKO;IY0,;^7&_N/\ DV9;(CU6>N1[S*8N
M<D=;I*3K-KF630W=KS2#U6;VM#G.4)R1+[+ G4FXO&;KJ#6IADYQ9%V23)UB
M8X/8CBGTNWY]KH4WKW]0LR7!&4O1"^Z7M(LY-U;%X"XNCTV&I<DV= D.Q'6R
M[%=4ZV+Q&.LSK'".NY<.(;Z[K>MWK!W:QP".7<;_ )]N4E 97"(X^B+==E)+
M TSTC[\',@\:>GI"PC;5I=R*A)I!+#-X[64:%)LXU\&*W03'"B+PVNH+;0ED
MT4CWNVWB>S='$/6_CBH4#BL(2I[,*"_/==U)-XB+44M-(#L>T-WR7&"U2)+#
M4- DN7+<U%(!3[; )R<)R0!O"3V>37U >0$G<,8$.6+O$&H9"ZT=$["%F829
MIJ&C2V,/FS(&>,SR(D&\4@TPD#K."YL8^Q)'FT>[PX927!Z;>QP>-5<N>B8X
M,VC,$27I W'XTEV7:5)B1$FZVAZ9"B66Z,+N5YM4)M-Y#TYV/"<G<=(MY9B,
MSWY"6VK2_N)"<XW*WG"5 **TG"5'K,#*L:O79R #5&=\L9 "5/INX(A++(%]
MJ&@^<2=RLBDKK;7"T/0P=9+!(%(FMI05\*VRC; N["0O#L,U"DY#H+L>W;;7
M!G!FIA%N]+MA7%T:B2A<VK;'4G2"_HNBRT$S+U <-NC=#7$N*BMR[N<A,>S2
MUH>**;8@GK=;>X1JY/6(U=^Y)ZXZW9(2.RH;JN$OR<DXU8NZ1U>*<QP6WW67
MQ)+;"<M"KB.:$V((U[-G>02T"<I-S+]T=8$8L&N75:D$D23<P;C^;=FJ1T8O
M!Y;I"8K2M(Y+<^2YHC$,=%C;=C-S]-;#*OMH;$LWIM3D1EN&^Q<I8BI=84N.
MY%AS@XZB/4O*!/6# VF_7WX:6$*W:O*2<I&=^#DC=FYH/O$Q)BZPA"/,%Q@8
MW@,D\@/S <")M5)!L>>0F-H1X)A&T1TAQQ5B:."N#@P">JXO4!XK"3GF[I%:
M.O&AT2WQ4RESGD2)<,R+=!A6J1,CNI@V&RW>X+G3#/6_!)3<U%)1%FLI+2WY
M)MT);2TU2X5'&J, ]<2K&,K4E(2-7!]KOR4G>,:QJS)/N_;0?9$L!BHW#RX6
M+SN4A6@]S)7P-8H !:"@&T%<B1.T//*,"*)23+W9=P-'23V[U,6\R9-A5S!*
M7M^A^C$JP6R;)N%TBR[C9;;+=?;M[,Q$:;-TVOFCJ1'C]%(27F%QK<C;;9UM
M3.R5(:#SDD18]I<<"U)"4D!1 ZXC(#25[SJG&]6[&<Y[&,GK..8B>2!\J*UD
M>( 1@^07&/EE9 ,5(&X]#$IBN/?O74)O"AX]VG9T+:/1TWD!GNS!DX<QEN/>
M*NV5Z."LA<*-)TBA,39#\+C#*$P9"&(<Z[*M2'V66[OT7>?:5LY+K,BSPHFR
M+J&[BM]I+3KC ZXA"BD X.\9(3K8.4ZH'* 0HG_T@5WI?RK)01^?'R#7HUTI
M'0DU5?+QR624F-RE<&U"5VV6CR,B)ZO Q+)IDT"OPEG-Y%C*6;G)D0)P9DP<
M+Y,\-JX-6+TQ"?@WR0VF?,M"643[9;H\@6R\Z4QM%XTY4"/I'-N8=#LMF7LQ
M!-M=;#S#%X=>0@.E/E!(*!UH5DA2L:R6RYC6* GD!'+K#<2G%?,GY/E8A('X
M:00K/ Z!3?AG8&-'G<I DSQJ2<:PT/62*LH%:5J88^/EC8FB+C2[]BDT+W9Q
MV6JNHTLHMW!W&ND%B7!NZ3#FJ8EM3;A":MLV/"B6_3^7=4*C/7KH8">DMXQE
MR+@AAY3L7:S[6ENX(24\4D@IWC(P"5 DED)WZFM_\49PG(W]:KK:K ODX^>F
M(@.(ZZ=@F9TRUCALN4>2UNT#&R&P"^O!;-O@MKA)5IB6)#4'(A39?BJ4-9$V
MP$$@4E38D#9:TG@\9:B760Q?FIKT*(Y/AQ8S5L<=EQ&+)%ODEUQ2;\I+IBQY
M"VY2='NF41!&<F35QK:Y'F/5#Q)2-3&2 <E6XE90,=9V2-VOLR<X *L@<4SV
MWMH=N-E!HN#AY 6IL.*1H>V)R!^%4,CS&C-QSXLF;))Q*0J NY#T-$+L70ED
M87<H,;,ED&R9%VJC=:=&-&)&BCUXN,RZL24V.YSWW(\%F6F(_%TRT4LD8PV%
M72"F;M85VE(>;E.Q$-K>VR%N*8:2LI;@<U4A)&N$C)(R"TXLY.J<;TC&,\G)
MO-668YC.W ,40BT':Y^%,(S+!7Y$M(UD0LM>\>RF_P 8$D*@Z"KQ'%-$.R;L
M'K#">(S#.SMN72B>(%RW**2T7@J:1,D,7*\.#H=>!%ELQXL!"Y=K:TZC:$2)
MD!+]Y1="I<MYQ]IXV5=J3LG(J[F9K:XPM,@XRE'*G(R3N462\ K"2D;@ >OU
MM^=7!!.6-B;QD>N8G&#&4*%R0L\U=,]F29JG+EPK$<PUY'X^<D;40\SBA%8N
M\>6-9MPB;I@$0<+HH]WK#$%U5V?,V'0^!?KG<(HN\F!&:TBM.C]O=5:T2GGW
M[[.FPX#DID7-A,5IHQ Y,+;\Q:$+7L42%H2AV];I0$]:"2VI9ZX@ ("2H ZI
MS[;=D#DWXJUL^0:$%;;,%D=9A8\3UO$=SS\V+C4E06"D76N8IIR>Y-VA'*)@
ME,W<J'[I%X$"+@/AD+,BB*=DSK=PV(9R0T'7>7-'I+&D,N=&O]TT2LD.3<+>
MM$MAN_7+2NRA;C N<U(:MK^B4DL1VY1$F))85F$XAQ@4VNKK@H *$N+4 K=E
M"6UG?JC>K:#)QN(/+RU29COLR4($8NGKF,)D@NUH$' X3-\;<('0F>^(OJLS
M*1%UX#X/*N$,) P<L7L1DDP6B;DTU2E-@LA9XQQ_M6K0J)'CL7)5^N"H\O1J
M]RIAM+,-"X<Q.A=RTEB6V5J7OCR$+,%YMYFZ6^UIN;<-Q5MXW!=,]BBG"<C4
M3E*T8UB=XVR6RH91C^T,:JE:N>N((U3D*;;DDD:V=EK^.1=I*2A1M%L!C<W*
M,(J"9*/XUM^5/W:Y!C$),7MFHTUMW!9*[4BDHZ>,,DDQJ*1!PX@K1HI;[AHZ
M+Y/N+MMC1G+B9#D2W&Y3'DLW#1>VL-(8>NEOBD)=O^VUMHPI+;3P4J0M3"$7
M*<(7J)&2<8R=49U7%'>$J/(C W8R>P,FL?DN3)Z00 G,XA&Q8,)DG&F(LR:E
M+'*2VD1R%Q'8F;+"$N0V+4@/1 211G=VSD3HMDNS<%<8YC'\+F4YMC@]A0+W
M&M-TGR9DP*GO28D2VO"WF!#N]SL(=-W;EEUA]<Z EW9.P&XH0ZB,9YG$1%6[
M8J1K)  ZT E77:RDI7C5Q@@ XSG.03JXWU=:_)3)5>'"@\,0>'YTDO@$:$)3
MWL%MWR,\<0NR1DJA'BCA@R428OR6#U 2^75=HH!&X]=RZQ<IQJ.#\)1=9,J[
M+:A692#,=8MO&)*V565N[%42,N=&0\\E3S,=32Y+*$M*7,<?0VV4&XO>U 3D
MKS@%6 "%:O7'!QV>P3D:H!-65".4DA=O8_&ST)=ERBI@.PEID-8^Y'A,YQMN
M8Z\C20MV)@[N*$& /&/HK&2DCE$)4?L,%5P#,\8Q6$U+WC@X@M,SKA"N[46,
MF)*?MD27Q%M^6+/HO:K[<%26I5Y:N;#TPSEIB1H%NNZ6'BE$UV%%*956I>5D
M)4G)R-8C.!K.*0G!"=4@8WDJ3GL G=63ICNN5@]@YP:.:_"GD\#41CG?@O/'
M4<ZS,S R4Z-ZA[2$23+O6R2C2Z15[W9W6E9VV4'BR6>*R"?.VK1&V3+&F\S[
MY+A*5$ND_BL6RMS_ .26F;;X4C^/<O$ <9>5<$*C,[+9*+3B7Y,<%"U7*=4%
MZB4!6](R5ZN]041NU5;@$[SG/,#5AM^7"6<6PG[J *HPEDWC320K-I-9[+64
MEDFHA6WTAP2+XQ])K( S42<%"%3=Y"*?J$<B*^$=L/&*N5)IS@P4FY*LC=[2
MJ\.KN#L%#EOV-L=M]OTIDZ+*D3+B9RG(,MV5"E2DQ!!DL)8#"#/V\A+::;?=
MK%.$C 5ORH*+8< "<84,$ G6!Y3C S7(>Y0R&-I&V)/7<>4E(5-D0N'"3V22
MED\".8:I,%R"#J+:G,R##(>EFP8OE5XDF 9Y/D7SZ1,V+@:J2I"X.8-P5$>C
M7Z<+;+4\P)<NRV^VO-3&[JFU(86U<M)HD$A]>V>92BZ*FNAE3+,!UY#Z8]"\
M1K H&LG!P%%0(*=;.4H)W<AZW&\'.\5TW?*R2*-21<%JL6_ -!<K*,W138JX
M<F[3AD!C.Q2^+@8U@1INSQ7#R.P\7FF5>J.#3+)!XB.&KXE4\K7!K 2Y'BS=
M))#$UV3;([K<:PHE1VC=KW<;#%*)#EZAN/%$NW[>2#&:2W#>"VEOR$&,H7SC
M6" 1JJ5DKQ[5 6<@)/8) QG>.P#FJM-^2#IO&LU(Z([VEGY6?C1[QT\;/>Y<
M->2Z, 7;I4?FR[!?ORV/V4LEVWJ&97PQNL\NHFI;5L^@+:[@$SY/&(K,6R2'
MVFFG&MHJ^VJXSFFTOAW*.*.02DJU?Y1A1U6@E2:N4[@;A@Y6-_\ Z%!)W?+G
MGW?+7!CR.D[,1B08PD;+60R"SC84I=>&ZC ]&P,5M*;,E30MIKWO$WO)BL?[
MPQ9ND:L3*6P+%<1RC*-G'25_2%;G96P>O$BUNR;S9[';6^@Z7H5PFW(VW:IA
MR';[QQP6^-.X[<EJB&/&)BQC(#UPAMJIMCC(3K )4M77=< G6QD!&.N(PD9R
M=Y (237?GG)M[%",Q&A8$UD*D(#R>1%U'<R[R8*!HEK2$;,*7:=IBYO+,FX8
M3-(8,8K60;N';1)PZ(L6;W)5EALO!XU<F+4_+O3D!-XEVZ!%2U:N.$2[II!>
M-'HVTU[C# C(?M"I$AY&NXVTZI#;#SK02Z6\4E8",Z@43E6-R4)6<=:=^%8
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M/+#,U+6M?&UG@YVCU97ZTKY=C>V:.ZAEYMUR.S+0A6LJ-(5(2R\/>.*BOQI
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M>EQRZY!,ZY*LMR%K>#5K9N#TM#2Y>O'5,:3*A-R4*C)D/+*2:Q;?&K\F"9#
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M6GZ9B?JY%>1/I$OGO\F?RIG/]!M7MNA'N6M/]R5]^DU\1<+_ /S'TF_ZUO\
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MLATQRM3#CAKBC4=DC#8<<0("5'[X447?G)KFC(L5G0R^N,@R0NY!X#;@B Q
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MKF!/N7! (/N8?=DDR(#=1=LDQ6V%NQF'6D*AHD0V3+E-3W6(UP;=FRTM0GG
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M_B3S_-7'_=9U<CVZ?[R?TBK5^T5_=5^@U_(QK[NKY!K^H?T=?S ^$_T4N/\
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M(;'@*<G=["E))3O2'A2Q5N]9-54U#OWC=CGWZPR,8!['XJJ6Q>FTXN01O+Y
M'UIR/VEK?7>I^.V^=A[:UO!88_@,*TUR<8Y/]<STSG)-D1B5*-T$NUXR".#8
ML^F+3_=BXZ.E608\Z%J:AY-P.L4X)[(QD?GK.?$3FQ-N2G)GG;I _I:20"+\
M4-O!M:1";/D0N0^8M5HB#-.G91TTF9AY8N?5*VEL59M8X.8)ZY)QQR8?(RIR
M6 BE"  DYWJ!)'-@XK88^_XD\_S5Q_W6=7(]NG^\G](K&OVBO[JOT&OY&-?=
MU?(-?U#^CK^8'PG^BEQ__59%J^+]+/=1I'].77[\_7U-HW[G[']$V_[JU4R:
MY^IJM//3$\@CVNM9:/X[P7AWKOFYLOF-M=;54)T[N-0(AJFZT:CCZ:E#TG6D
M-D1EWPIL/2=A<5BT=R8]I(R)(^U5 )M'ZKT $DE6KJC.0"3R@=CY^6HN]%[I
M?G7Q_P![L@TRZ*+@KPSTC,A<@3V;M;0$QCAC9:F8\(0(Q$*JHVV!)CY<*[E:
M(QJJ.53=C1N#IP_11:J8YN<55601N6I1YCR?IKT44K'4,N8?WPXB?3-U+^C.
MQ*Z"P>UOOX/SOUL6H:\>VM/TS$_5R*PKQ=_P<W/]+_F;_:>VG7!3OZ2OYD?]
M@KIF_:)^:I+UJ5?2E*4I2E*A:+YF1V3<C9GQ9B$90.[<@D]P&241G+6 ] %J
M5EKC3\^.[B.9*#5WC1MB0V^*@D4AH]D7+RJ3M.ZU'H*+82&0Q?,6B$!PG"2G
M(W<JB5 (&_\ ].2>P"-U/W-1I*]*0-9#V!5"":M;J.-&:JW:AKV4<B6T:WA/
MK;/:S%ZVU]H?5N.K"U]OSALG#EQPD9A)8I>1R$L)#)=[NZ,GF%P8R<95[92=
M8(RD:N-ZCK=:-_RT_<UF_:?-4WJR6[&A9748I<_&H$>V##!5]KCKEC0(+M'7
MNJAK_8K(-$3Z6L!L^)[#9R77JC%YL$P3B0*0KR<##Y&/\&5*)9"@"%;B0"=7
M<,I4LXR1K%.KA7(,D8)&^AW?OSG%7.)Y7R$=N*': V?JL=$MIR:<14"Y3B6P
MU9U"4(;.]/\ )C:$0G@22DH-!39BSLMQ9V)!"T:+0Z+/Q)+! RBZ)B%&69&A
M;&H5I42D \J<'6"FTZI&L0-S@(()YL9Y%9 D^])1$]VP361762*,1V++W<$B
MLQ\.6*LL-%QNKRVT#$I':U9A'F5]7@$1.<+.RTK+Q!\?-5V[:T(7CCX1)2EH
M0"A2M;>D:Q3C=C6U<:V?;'E P01V<Y%*[DEY3Z1B4OD$&-24[C(8QD5:ETQ>
MN]DR 78Z%UVOMHE#!LAC\1)Q\[L-'6C9>;):Z!$R,Y> $\G;*/N/N87!I9 4
M ,*Y,J2#C6U<X)&$ZQQDX&:5:.?.7B_=)B]8[&>'0A!K)RB$KBT V5*X1A'8
M4?%1:7S)W.8W#RD08P*,R(RS#G)X]-H0\<]2*X.3:>($[F-KL7.RG'R$@$DC
M( &<Y(W@8SBG[_O]5'G.'C8/S,6=R^5I-H^8V,(-%/$_N7(&-1U#(TX?M*4.
M3V$ R#8:]@$J4RCTJV79]E !!5L_;.I)A<:_NV;%SF&\)(&LG)UMZ1C.<D;P
M.7Y*54G?,KCXRPE*BDHDZR,1G"FM7R['56V2+4Q/6\S(Z\>Q.%.V$(<-=@&A
MLS$$@19G"%C^8A5IF])]R#,T7RE-BYNW#)&<:R=PQG)W[L@Y&>7L;Z50"O.#
M0\;R-JR8X>:-&&*A <@"UGNJ5R;*.#]4ZXV[(34KB ?5N1J%Y1V,;+!/S#,@
MD\Q'#UD;E'@Z08&XR!KL5G&,<V]20,ZRD@ ZV%9*2,\_)D;Z9K(T;Y-:8E^P
MF^L8W)BI63OUY0T$ND8-/L(6=>PA%DK,F$>V4O&$M=2 A%<G[=F?8AY2]=#"
MN+P.Z23*C23)G:6UA.L0,;LC(UAGDRG.L,XW;N3?2L]U92E*4I2E*5'+=?\
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M">Z;@LUEKC;*^.U!GC>U/H7:5Y(WU8WUFZB! %"FV_@+*1XMMTY%G3*-R0J
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MK@=I6VN#.N6:)A^))K"B%F4J(*EA#P@ TZ1TF*:'V@KP?(D(\YB!%9,\-'&
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M[?4W'""[,C*RKJ!Q2*I/UW))^+BQEP-?H-DF,;$.URSE5M+I"GC/G;]_W_\
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ML6J:W;9ML5T38N6S@S7[?<VDQI&PXE<&'(2Q-A.O,*+:'%)56Q>EY .TFSU
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MMK9?5$AW@](0L/%8K%($/'PE$$L+2A,FC4CC9B:$!\HL2EQEHE%!@!PX /8
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M?E]GS)=\YDXZ'.V *U+H+U$<ENQESDQ(D>=E]V0'DJCHL4EQI\$O( 6FZ!H
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M\$<8CWQUI+3W'3(6U':VFW:3$$15N#<Q,A*'$DS53-LI#R4%U*EQ5-.)93(
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M_D>=I[&'1;NBO_>6[T6GDT.9GXT<8_6/:GP[IU:[EVG@]_(\[3V,.BW=%?\
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MQ2E*TY=+U,RXY'@_JJ2;*E6F.-7(#E['-7\G=F0^8DM<$TX2M!ID>BNMR.R
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MS@$2F;]L5E\8AF0P6UO&(_*2;-H1D(<+=D/,O6K=T1;N%T4\\6#S'ZC36_\
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M4 +U5!6L3C.2G5&.Q@;_ )\]C&*IC?G]^SCF/9Y_VU?YG5'):>;?U;,-CO\
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MS=GG['XJ[L0Z4J$3=13O%HK<+UDF<A<2S*,W&OR(Y*:3QY+HH B3ATPF#A%
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..67S6?.LU5*G_ $I7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g752656g72h73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g72h73.jpg
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M 0$!  (# 0               0(% P0&!__$ $H1  $$ 0(# PH% @('! L
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M:,M;%AH> 7'!)."?ZCDX  Z7T1DN<T>FMT]@DMBEI5:^P5VJ4D8V6S+C%(A
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MUXC0?[:<RMOW-7>#Z?/I)\ZVP5\U<Y5D?'3&OW*\X:?Y,[Q_4^3??7)1<_\
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MKF&-TD,36.,9<UQ82!G:7,:2/%H7R&UJNI7HQ#<O6K,37B1L<TSY&!X:YH>
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MQC_<[R";Z?'X9V@VQ\=///=KI Z4=0)[MVJ5]I\,M;I(./$!X/@[O7?VVO\
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M#Q]6,+K Q*F!7G&CKS&Q @914"I=L#HP9S#P;RQ+P=VAJU9H8;OIJ,+LQ8@
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M:0#!R!AYR,'D3@:Z>35VRO%6IITL V['SZC9@E=Z(+M\4>EV&,P_<&XF?N:
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MQFDE,9QZSCZ?S_=7I\*)X1/")X182S $-*W8%@@:EB4Q2-@!E[[)&$9Q!8!
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M:D7/.O\ N?TUSGG!FM0J$T3RN>E.U@1_0?+SW=B]M%UMC.:5=GADVPEIU(<
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M@%I_RD$>..7AW\E;[GWM1P3JM^<\QY[T$:U72OB_?MEBY#:L!B@;RFQ#'ZV
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M#CAK0, [&QAY:'N8'*RS1HM2+&+IR>&J4* 2VC5HQ)A#7K5H \A9QYQ9&\<
MH88L4I!),\FD,$,>\LF^NFNV<>86Q7,57^GAR;L_MW6?U)>@,>V5_MZ?*R'D
M]:&Z)8$**F\Q4@0+DR%Y5IHOO0I+V+NZLM\I,<Z9+!^V[.JOD)KH)R]<EEN.
M-O=^_P!_?1=2/"Q3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PBXK>Q<?
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MS Q\$VCU_$_]%@^?<=K_ #FO0UA58+\U5B2R;@:OKL\*F BEV^?<064$A;C
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M::YVSCP@Y$'P5-UWI<7E_5)GMA2,JQ"^X#=[HIE#(.(.LW#.2O.8QHD^2Q]
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M_G!<$_NW\A_RE4S_ %UX1/YP7!/[M_(?\I5,_P!=>$3^<%P3^[?R'_*53/\
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A)QL\YA<LQ,TLNY%L7A$\(GA$\(GA$\(GA$\(GA$\(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g752656g75o68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g75o68.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1J 4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #X< 5H  QLE1QP"   "&PD< E  #D1R;W)Y+"!*87-O;B!,' (% !=0
M;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0      $%O0-ETA+K[ME,RB
MV=9_L=<X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q :W,S0         IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ /      0 " \     !  (X0DE-!"8
M  X             /X   #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M              (#   "W          !                          $
M             MP   (#                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   (#     %)G:'1L;VYG   "W     9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M P    !29VAT;&]N9P   MP    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
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M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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MV3A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !#
M %, -@    $ .$))300B      %*34T *@    @ " $2  ,    !  $   $:
M  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M?@$R  (    4    G $[  (    /    L(=I  0    !    P    .P (8(@
M   G$  A@B   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.3HP-SHQ,R P-CHR,CHP-@!$<F]R>2P@2F%S;VX@3     .@ 0 #     ?__
M  "@ @ $     0   MR@ P $     0   @,         !@$#  ,    !  8
M  $:  4    !   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !
M   !2@("  0    !              !(     0   $@    !.$))30/]
M   (          #_X0%,34T *@    @ " $2  ,    !      $:  4    !
M    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (
M   4    G $[  (    /    L(=I  0    !    P    .P   /      0
M \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHQ
M,R P-CHR,CHP-@!$<F]R>2P@2F%S;VX@3     .@ 0 #     ?__  "@ @ $
M     0   MR@ P $     0   @,         !@$#  ,    !  8   $:  4
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MX20S0E*4\0H7-$-B<G,8)36"LL+2)F1TDK/_Q  > 0 " @,! 0$!
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M77/:0OR=9DFT9%I(@].+@OUVH"Y)E30E=#ZU7?TF53UM.1HNQ#S-J_M=3WB
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MC2_(JQ[PU:FF;'@<&\B1%7\11,)[R6 ')#5U9@U*9&D.K%^SU;_L<_9-4O\
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M2&G$)6<C"3G4%+ 4$N&.9 Q9JU(QX9Q:FSSUBDLC&N(%'K0##SI6.O\ $02
M#NR-PV\Y&<9X\NW/;D<Z96G7K6O"*E.DW2/B!8C08/XP%U( )R 2 "1P22
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MFU6&:9LRUV'8%CE)FI?NUHGV@6A"B7-Z8)<Q*5JO 7KU!'UGL:T=A[;)[/\
M:G8MJV?9[#VE[;;1VE;=D3!+%JL%IE;-F6+;5JEE;7+-:MH6>U3;&%!24RYL
M@7ELIY3>SU2JM;G46[*+U(0*AU/F4>F5AF[VFY#5,K-HRVFD1:)2@Z/!BMT"
M0M34F$PXM;BSXSAVJV:['LD;79K?M&P[1$Y=NG24+D+4";/W)^)*5 _$%@$
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M\>>/33<C D 5+'CO\,J-A"(&)#\GC2UFM4>@07:G7*G"I,!E&]Z5.?;CM-C
MR=RU GGOM'?YZB23B6IG\V3XD#G"[HJKKSK33&KY9X:,'4_:WZ 4EQ;2^H-.
MFN,+(4U3(LN:K()&06VMBCQDA))'<CL=4JG)<@@&I&#NQXGWB]-GGL"$4R^$
M5&.N>IS.=8TX]M;V>?$0EV[9<=*SM+[]'DI:;SQEQ:4*V  Y_ \9[G?L'+!^
MAC]",]8O58)Z4DE#) )+-0"I-'PW^,.);?M$]$KN6PU0.HENSY$AQ+3+/O*H
M[KBR1A*42&FCN.0 ./B(!QWU),Y*B$D@O]'U\:>48QD&6'(J/=O#'2L/0DI4
MD+24E*@%!0((((R""."#WR#C5H*<F'!L!UUC$,,:149\QC\<YTP^=.L/3G!%
M='0WXG3PQ]7(-##$=?MOP@@T9MC3K+JND$&@P0:'J#E5^7M3TIH0:5*;QC@6
M]?#/2"#]?K\= TI3=7=NWCP8-!UUSBTLD'@GM_7Z:>HI33R_;"*UDO1V;W_:
M%I^Z/Q_GHS\FWXZ/$TU >+14<GD\$CS_ %C1CB/W_?.*B5.:EKVM,<(OZ/O]
MOMSBZ#0?'(MCU]7<00:?*"#2_=NM^D$&C/#G[>Y@@TC0<&8>3>P\\X(-2ZZZ
M$$:.X;DH=IT6I7%<E5A42ATB(Y-J54J#Z&(D*(TG<M]YU?PA(3R -REG"4!2
ME :K4ONTJ4?T@FNXOGC3B*1)$M4U29:02I1"0U:G#K*/&SK%]N+[)]C5.;0K
M J3W46I0GG([TQEE^!1UR&G"VH1YN Z^VI25 +#2-P''?)U$S:02IP*#EB^_
M)ZC7-ZQN+/L><LM-^%!!-X?,*4J]*X[M8X_I_P#;;=/[IJ#+5<L04^FNK;#D
MNEU*1)DH0I6%*#+B1OV8)V;@%# 4#YB=K223WE$Y<<3AN<NWC6+YNPU!([A2
MEK>KD$ ,:TKBW&M=7+ZS?;2^S5TVB0#;L:N7+4IS+1;$R"[2J>T\I)4IA4P%
MP%2#PI" D'.,=M)>UI _ILK5P_!L:.[GARK1L.>7OTT !+XXL.'VAJK%^V^L
M2YZA';JG3]J/3G7 AV73ZG(E2&&E$#*67$ .*PI2AE7EMQA0.A&TTJ4"U*AA
M@[?Y7.YVJ8M5L,A! 6\ROPL6*6#4-1GC0QZT=$/:6Z1=?J9^T.GMQIESFV4N
M3J+*:,:I0_A"E[XZU'<A*BI(4T<':KX1C6PE6E*ENP;3E4]<]VGM%BFV8M,<
M*&(K=-'&7C3&)  @@$=CSQVYYUE C+#W)X^31B^'+#E%=2Z^_E!!I5Z]3O?]
ML8(-#^K=>G301;<\OQ_P\M+4< *9MHYIAI[Q6O+2OM%O*O(X^A/Y_KT^?#KN
M?+=K^V[PA\63UXQD:5=6&C4 IK]MPHT7P:9Z;QXG!J010J2D940!VR2!SZ?7
MCMI.!GNQ?#=7IGA.!5XUU5J5-I$%^I5:?%IU/BM*<D3);J66&T8&"5J(!)[)
M2#N5V0">#%2D?Y@*:XY5\&UQB0EF9@"6Q8.S\CI$->H/7ZZ[K<E6QT<IKK42
M0"P[?TEIUO80/WAHT![W=U12 0W->*FBM0V))P!CSIA2H71>!2_P_$ 22X<
M\>>E(OER2%?%\+ZAN=<<RU>,-E1?9XNB\'D5#J!=%R7,^ZOQ%IJ\QZ2PE1/W
M4QO&]W0D (^$)'8#(2 !BJ*EDJNFNHT8 9$4&F>ZNQ3<2+M\,-",ZT8'4Z9_
MYH>2E^RG; "-E)A)&T?$8$<DX(P#G)& ,GG"O4CG40E9R.YACXOPZ$,6D"@P
M% Q!<#3K#C!7O9+H+K"TMTEAQ)0?@$&.< I/.0!P///'S![1(-:O0T;T;HPP
MSIH0015]XR+:Y&&*KGL<T\J\2-31&4A64.Q&4LN-GR4%-'>"#CE"DKX(24JU
M20IJ OP;KK&,FZ[WBP;]084'$-7 &F=8VMJP>O'11Q:Z/5IUZ6ZC"%6Q<CLF
M0RVP.Z:?-\;QH2@CX$%S<@! "PHI!&9+64)2P).# 5 9WW,?I&#,DHO*-X,U
M"X-3IZT'.)=V%URM"\Q&@S7E6M=+H")-MUQQ4>0E\';L@RWFV8E0"E$;1%>=
M<((RV.YV G I#D!FQ(!J:TW>N&4:Y4D@DH!4#BU6W'?7B=YAZ00>001Z@\9'
M!_G^>-2!"@X+URI^^3]"*R"GY@4\01ZQ7(/GH) ^8@5?KF,>0QA"N%>%825I
M'!4D$G &1W)(Q^8/Y'T.E?2Y2"'"0HAZW:$'%V.1--8E=4X%U1)(2 $DDJ.
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M=.7%8(-/KZ?2"#1S_?''V]J01BS9$>)&=E2W$,QXK:I#SKAPEMM"5$K..?\
MR@ E1X2#G4%ATAM>;5H-*T;2D,)*B .->M8CI<U'G]6Y3!D)6U:,1Y#L"$M1
M95/6GGWZ:TE.5%?_ '3*SP GQ&P2<8RQ\N@>GA]_&,V4$R@02:A\"32@#_\
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M5M.6H*42"+(4W4E1(/=SP!1VH27 9PWF/;?_  *_A;MV5-F=G9UM[.[0,O\
MV<WIEML9F"B4S)"K1(8*^3O HF5>"[JVNGVPZ4>T/:/5[H^OJQ8$>36DPX<Q
MRI6PE]2:K3ZO C"54:*^N2PRAN5&:4AUMT)#,MA2'HQ6E6-?3FP>UUB[0[ E
M[=V>!:!W1-I1?(,B<&)LY^!R7*JE(8)^5C3\R.V/X-=H?P__ !#3^'^WYJ]G
MS9]I_P!BMLQ!79;;95+5+EVJR$K2)R""D%E)(*BG$4:^@^VG:TF2TBM6I4:'
M&>6/$G>^)J?@IW%"MS#$1#Q* =V$A2OB QP,X-F[>25*4+18^Y^()2T^^XJ[
M_P E)H1D:YZ1Z7M3_"MMZ3(7/V;MN1;YQE":F0;&)"IOPE12E7YN8'JSL<1@
MQ!EO:M[VK>M,%7M2M1*W3\H2X]%=27([CG"6)4=93(C/<$EIYM)QR,]M=O8;
M?9MH2!.LLP3020H.RDD)25!M!>%1Y1\W=H^S.V.RMM78-M6*T6.<@L.\E*2E
M0O*0E25%G2HI4 1B08ZK/K@?CK,"GI3S?PJ//#A&A(8Z_</"L^?EJ1U?#WUT
MRK"@/((]=&?WS_9WU&L!J"-80$8.<_P]>/72)8.WG]MWWB(2Q=X4?U^1U$*)
MH *#TX>D2ZZQ@/8GSQ^O3_#4BH4<L6PQ;ES@KUU7RBUXA4/N+ .?C!2/+.4J
M!(&!R,X)QVQC(2Z20Q;(EO+,>M83F\ $J(/Z@*<';&CQ\;?_ $B/VK.J$[JC
M0_9ZLZKU.C]/K9I3-2N&/2)\J,BX*]44!]'[1$=:3(CP&R$,-$EM"P5'/;7.
M;1M,PJ6AP DC.GRN<&ZH^<=9LJS2A)E3@AIBG<D#&\0"W #DT>%/LT0ZK/BW
ML]/>E***?'::2\XZL@/NA3BSXBB>< 9P#M'ESK5@)+$I^*A)).-"Y ZXQN[J
M_P#/C7Y7IXTPT;A#>=0K46FH2#L'^L<.=F.25<=_4#&,]L8[:8I6+"QP%,=&
M/GHXYC@U+5MNH7@MJ4G/?@)X]1R>>?QTBY#8>>&?'TR@NAG<M2K:MES\GJXC
MNJ-1R@H2EH YSD'..PP<_P \^0XU%*6)+N6KCQQSZ>'E3?\ 1B#K3,Y4?%\K
M6I:T;,-D'C/?YY/S/IGOY:G"=JC'FWB]<Q7$&D2KL&*M"VPE)QM3S@C&-I//
MEV[9[\XY.C/@-V9\?:*5XBGA7=AQ\<(E%;3*B^V3D *"CYXP<=N/0Z=&WG.C
M8^6!Z,2& .@.OAPY%V#1J>HDMN+5J6< &1'7DYQG8L@<>O;S'<9]=!Z\O1FQ
MRR,,?;S-6ICP]HU]/?0[@$X21G'^.?D/SQY:0Z;ZQ4&=/$=>^[#AOOV!3:L!
M'EM-OM+4DI"VTY0LXPI"OB*2"!]?EWU(G(CZ\^JC2C6&@?3+RI6GG3>[S1]B
MOHS6+KZRVK @1WY,:%5($IV0TP"EB(P^AUQ;F]24-I0C(W%203MP><:R;)+[
MV:!>:ZEZ@'!6%2/7PQ&#;I@%G630>KC!Z;_I'UFQXX9889!X98:93P/NM("
M>#YXS^.-=3+3=2 [Y<A2.'F +5>?$FC8#ZUQPW1D)&T8[ZGUX^NZ$ P:-/<-
M8BV]0ZS7IRDHAT>E3ZE)6HI"?"A1W)"TDJ^$;@WM /!)P<ZH6LW58?*0 U,#
MAX=4AAW!%3D,7+TZSCS0]G%%:ZH]0[BZL7&MZ54+AJKI@F2"H0Z0R\XW!@L
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MH&4U<>](4E3?Y0D$N^ (C@>J74JW.D73^\.I5YS&J=;5ET&H5^I2%.MI+D>
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M D >0RTXXN=([S9^SRH %+@) >N%&T\Z\<(Y%^Z D@%X))QN!"D\YP>^WO\
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M*K=7945L";%95XL>E-*"79$APM;V\H;"PK&MILS9EIM=KL_^RE(ES M2C?\
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MK99T]!0NS6.T&RRD)*@HM^7$J@*0 * @@U(CZCV5^&G8K9=E19I?9_9MIEI
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MAG\JT/EEKY0^S-#73FB_&4IZ"K!W*(*F2>4I41R<G(!SH RX >T8X9^!!>N
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MZ#G#L6LMPI2I:%DJ4G@\#&.Q!/.<=^.?SUF6=R Y<:FKX_;A&CVF  I@!7(
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MSIJ;L],V\ZYTN7*O31>J$JO!LG2<"8_._MYV<E]D-MVS9R[;+M*94TIE+E$
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MG"TW*9 +3R&N4A13N2I0PI0[DG6SV8I1FJ25*NA+W7)2^K8:5W<(TNUY"5R
MNZ+X5=O71>8,6=G8.:$L'.KCT=]HU"F/:"Z1R7"I4>1;]3C(W)*0EY$YA:PI
M9P"5Y23CN3@:V4]PH'=Y UW#JNFKL!#*KH.8RB<MK2FVJ:A@K&U3+>T ^81W
M^?8?B.?E6GYAS]#!:1\2@,\@V3-P;'A&0EE25J !VJ43GG@9/F,XQ]2>VLE&
M/+W$8A*0 "0#0^KAN.5!"RRH*'('/F>X!&3W [8/8<X[>5L4S""U<'PWU;7'
M><^=J0V%QWVTH +C#Z //+C90<#(\CQ_$8X-4\$RE !W? /]Z>\3DS2E:*4"
MTDG)G#/OW_:.8MI+55LR$Y# <]V6_$=!R5-/1WW&W&EH2"IM2%(*%H<"5A>0
M$[=BCQUL0L%3H4""'<'(#K?32OIFRK8@IEE,Q!#"H4% U;'5W&;,W'AJQ0WG
M%J"T8R3GA7G\([CGMCR]#YC7/6F05.6-7)#:DGWJ!ISCMK!;U))O43K@,6<'
M AL^APJK4*G%J4G'.3A!'IV^(D>?/X_/6N-E?])?0/\ OI3TSWTNWA,M940G
MX30D8,>'-Z#2.LHU%+!2$(!' '?).?GS\R,]AGCG6=9K.S!O(U^'2A/&FM1&
MIM6T$K2I(4EB,7'^9\>5<^</#2O=:-$74)JU&/%"GEH3O"G"E.Y#;924E2UJ
M 0C&<$A1'&NALMG ()QR#YZ=88[AQ.T;6 )@OIH]7#"AKG3/CSA5H1)+L*;6
M:FT$U.Y)S]6F-$%*XS#V!3X3F>ZH<),="\# <2H'G<-=9)E]W+3J1GN_?[1Y
MY:YJ9LTE)! )8@BKMI33#5HVDE3+>Y*4'' Y'PDG.>?ICOSS^&K:8-UXM%(!
MP<@'7EES Z:-4YRM(2D8&<$?//GVQS_#ZZN1@.LSUS@()) <LV_VYG7$UB(/
MM?UB';M@1/V]+,&F5*J0FJBX,E35(1)2Y/<*>"I/N;;B2G*?]8D9Y&M/;[2)
M")MLFD2T6:\%+4;J4RT$B\5%F"AGAK%=OMMFV-LZU;1M8!EV5/>3U$LF1+4Z
MDKFJ51"6P)8&C90WL/[1WH%3&H5(B4^Z%0(C#$1J0S";]W##"0PW^[4L.8#;
M:<9'*<8&N8'XC=G2 H39RDDABH#NR-YP8Y[N,>0#\8NQYF!%^V*3> )$L,03
M6G>7O_&G(P^MA^V'T ZAOLQZ9?5+IE26D(:IE=D-TN2ZM6$I"?>"A*@5%* $
MJRI6< I!(V]@[7[$VLH!%ILR9TM*E29"I\H39B@E3!*"0I6& &KQU&S>W79;
M:BDHL>V+/(7,^2SVF?+DJ*L@4S% N2X J2IHB[[0LGJ%5[B<J5Q0)\*TPXIJ
MWB5)=I;S (#,IN1'RRI4D)+@WDD9&TG)U\C_ (R3>V=KVO/M>T)5ILNQ)8*+
M,9LF9+D]Y_NRE:D)224!;$$N,"V&UMR)UY*YCF4I(7+-"DI(#3'P+XO4,:;X
MZ$AP-DA04!R?-6<=L]\<D9/8C/S\/E *0DSD+4L.I#)+S 6*BFGQ ,FHC7.2
M 0S;V8,6^W+4QI:WTYL3JNQ#LCJ1:%)O:SZW4X$6J6S7(ZWH%0W2D)25!"FG
M67D[@IM^.XT\@I)0L:ZGL=M6V[+[2;(VC8$+ES;-;$(DH8A4R8I20M* *J4E
M)2H@ D4.5<FQSIDBT2U2U-WI2A0)&!+;SG0^XCUJZ8^S+T!Z.V6;"Z7=*;3Z
M?VJZEEV31Z#2DQ4/.I;V)FNS%[YDR4CQG/!ER)+[R$J"4+PD8_0#M5V=V-^(
MFPYNS>UUFE;6L4^3*$V1:2.ZES)DE!6D$@,25' /HQCN=F;8VCL+:,NU;+MD
MZS6PW5K6DDI+I!!#D@@)^%5 '<%V+ZF?[/%#E2''*?<4VF1PE2DPO=VWMJ?N
MMI0MU8=4G<H)"E\CN23KXH[1?X#NQ^T;=;K3V?[2[0V-89K_ /VR7*5,E2%*
M*UBSR57A?DR@TN4<TI3QCV[9W^(+;=ELR;-;-D6&U39<M"#.5,"5SRE*4_F"
ME.)G%IK@-\5#'06OT2M:WGFI\M;]?FM.MKBNRTH+*)""%I<1$:<+"U(P%Y<#
MNPC*0",Z]#_#/_"+^'?8.VR=I6Y<SM#M&SSK/;;+.M"'$J:B8F99YI!)9'>(
M2I)-,2""'CFNU'XP]J-NRIUGLLA&R+-.0NSST60E;HF@H6E2@U2E1<5)=B^,
M.M5J/1JS"-,JL")4HSJ@I<65%9E1BVA0"E)CNH6E VD K0$N(5M2D# 6GZ>V
MOL/8>TK$C9>U]E[*M]E0D2Y-EM4H6J4E")DM'\V0Q+H64!*F9$TRU4:/-MF[
M2VCLJTHMNR=I[2V=:9J56B;:Y*%HF$ *O3)9!'\M9)0H@L0I6!AH:C[.'1Z=
M)<D*M1$+Q,K4(E3JC31)V@!+#,P(:R!GLE/&"->-;4_PY_@[;K:9LWLQ+E3Y
MJA>%EVA.LLF\05%$NSV=5]!(^( I"6!J[ ^DV/\ &_\ $N0@)D]H%S42T%/>
M6J0;2M2 7-Y-U1%1\YP^5W5&PI'L_=(Z+(0Y'L^')D-)#C2ZFJ;/">^5%N3*
M?:7CC:%MX'!Y[#:;)_P^_A-LB:%V/LM)F6B]+FH5:K7:+5W=QV4DVDFXDE3D
MH "F!. C!VO^,WXB[70++:NTDX2%H6A<JQ68V=PIOG"4(*R&-U[UVK,##L+I
ML?\ 9$JEQ([,:,JGR8S++326HR-[*VTI2PUL:2!NQA*4\>N3KV*SV618[)+L
MMDLTFRR)* B7)LY!0$)2P4Z<RP!>M \>:6F=,GVD3IT^T6B8L@KFVE)2LJ)<
MAE$_""7=\2>?PT^T9;+T&]K[ICJ/](IMU7%"6"DA25QJI+:<2I.-P(6@C& H
MX^+G.M):/ZRV+UQ=^6YH[*S*!D2RX^75M?7[1YZW;;Q6IW<VD'GC!XY\_3Z_
MQYU1&4ECB<6WCUZU:A9.J4 I*L(RH'COY?R/\]$,@5;%W=V..%:OGOY1HOV0
MOL4$GT(RGU]/3^.AH56Q. IEN^V^FCY<>E/MD%!<;)!V^&5(YQCL%)Y\N.3H
MA9<</MGB&WYM2'=KG1P=1*#;MP4H*?=@PT0)[+0<<>8?CJ3N]X0E14@+2HX*
MAC"3CST==="'FVA._K!JOPB0G0;I+5:!,CE4=UK9A"4%MY"E92D I"ARE. H
M^6/3R8&N'K7"G'+*M8B:X=:'["FYHZ?JKTK_ &Y?<ZJ18:%I4F(AU]#)*7'F
MVBE9)2KD@G"CQR .1H;K7#U@!ZT\-/:.FLKIJ*:IA2H_B.\80EHC8>0DI)5W
M'EG/GI??KZ081(YQM%NT)YDE(F3FO ;;R-XWC!5@_$ @?%V^+L._,LO3#0<:
MUUTS 98G]\7KNRZ>O-4UE2U,IQC:4\#[W?.>?7OV^?IH;QHV;Y8OY!]-8!^^
M3=:T?&'*]V\6/L )^$#MGY>0[_7RSG29\!D_GE"H"[Z#U/OT(:>OVPMZYX3W
MAE;J(9:;V(4I8\1TD#:GG(R!@^HSCOH=RS@D,&!!QP!K2'@';&NC^/3XQ[E_
M9:=$ZJBX)5^U&"]%I]-C*#3ST=YM#\AT? AM:L(41\6[;N/ XUM-FH6)BE75
M76(O,;KYAV9ZBG/"-'MB8@RP@+25XW'%ZZ[88AZU/"/1'VMJ.['J/2B^6PL,
M4.Z/V75%I!/AQ*NE*&U.8!2E"7FN5[ASD 9(UL[0A3@Y9^&&_P ^;1H[$M*2
M;U*BK$\,!RUJ\28MTN&E4V6A0*'8C*B1P"2D*QW/."//!/F,'-":$$[_ ';G
M&4L7UN ]2[TQ&AW^=,Q'819!6-K@VE()R2.<$9'URKU^0UEH!QRPR_?(Y>L:
MZ:A1705IUSZICEJVG!//?'H<_/YX^FKD@%W+8-7.L4W%:<J=4BWLSM/H2<@X
M\ACMG^ Y[=M)0^%J$L<-X 'I D@/KIO#ON\<\B8;%OWSIS<55JZ6)50L"XWT
MR:O2H#2WZA0*])2TE^N1HZ05/4Z6I(-2::^)M]SQPG 64ZRT65,QS^HXC%F#
M"II4-PC>[.MPLR4I)("7 (<T4HG]/$Y<:O#J?L&!6V$3:1,B5*.ZE*DNQ7@[
MM40%;7D(4I;"P3@H<VE)RE7QI(UH;18%*4;J'Q%"*,6S9\V;TCJ[/M=9 (7\
M+!G+4:E'+,'QJ^3B,;^P[J@LJ90W@9*E;MN"/O?$4CCS!/\ #6*G9X<,]""S
M9/7!4;1>VP4J%X $$?JS!&AIT]8YR:U$ISZ8<!A=4E%6Q8@I+K*'!SND.A(0
MRD<I()(SSN_V=9"-GI*Q<!)R! &6II@[81AKVJGNU?S*TXTRKA7QIG0W&8,U
MY]#]8=:68ZDJBPXZBN.PM*B07"G"7%CX59PK:H9!SK=62Q72>]#!(^$ C$%-
M?AW/C]HY+:&T^],Q$LN2"[@I<84);..@1-+&03NX&TDG@#/D>23W/J<GY':+
MP2,@X'"D:>6DJ"2!4$WMQ+ :X^@UBIE,R L/)SG@<#!_'O@<<?EZFHJ Q]_O
M&0I)-UF+#W).6',QO*71HZPF00,$<8 *2",DX[Y _P 1]:S/*20,!ACH#R<T
M]8LE(4#>--U.&6D>1'VIEWKCLV]:K#I:;D?"\G@MEDN)"DKPE02'&D< D*"5
MJ)'<ZX;MW;%6/8-O2" JTR0F4' O*4'+U9/S'YFRCS+\:-J"P]CC)[Q,I>V;
M0;"P)>9*DFZ2J[\E *K(!\0?%D #:LMI(4K.$*P4H4=V HA/;)Q@:^=Y3FRA
M-T@@$J!24@,[U4 D-QTCXL"")H4 DB\X"5 MH!@YY&+B\#PR0XL''AJ=5D-A
M1Y5S@\9SG(2G&201J<M20D)_GW@04_EPHS M!O)"5)!'SA(4,"EWC+DS)HF"
MZE2E&\$)2L!8600E:0"%? JZLW< "V4>Y_LMINB\?9"N-/4]4F9!I#E<19\J
MKM.HGM4:EPVW:>ZEUT)6Y%;FAQ%/<!(>82"V5(43KU>?9K5MK\-MJ_\ J*0D
M"199J[&F>PG!<M($I2BH_,4%8#!_B>A#'["_#*=M2T]B52]M3ES+EI4;(J<A
M??F4F6H2G4H/=#J9R'NHI$7T*2HHWK)4H[4G:HJ4>PX&2221MP,GRSY?%* N
M;/E&6B8M)*Y4E"$*4M920X1+2"LL6!9.8:-H'JBJE/H7+JUY;GTI$M_9WZ+U
M.M5F%>EPP78]%I;BGX,>2A33E0E(&YA]IMX)4&65#<I:QM5Y'&,^^_A!^&5O
MVAM>S=H-LV:=9=GV2T35RI,T!*UK2B4I*^Y5_-2%7K@44,2DC%*FW%BL=4KG
M? U4."22'JS8)(+9X# F/0.ISVJ93IE2EK++%,CR*A(>4I*DHA1(RWWEJ<SM
M *6S@*4.<'D8!^M-K[8LVR=B[6VI/1W,K9.S[5:0E?PIFKD(6J4E(9U$B6@$
M!-%*":70W2;,V=/VQM39FSI#KM%LMDB5=0'/Y=2DI6HD%@4U 25.0 R3G#JP
M>M=PL-WM4+AERJJ[,MBHWM;\";'<@-T],-Y\NVTS)D-,B3M@N4^3F/N2' XZ
ME2L Z^,.P_XV]H[+([:;;VY:/SR-H[(VCVSV#L^?9K38I=G38)ZQ9]DHM%H3
M+DS$39"D'O4JN*"7"FQ^G.U7X:[&M\_8%CV'*E[-_*;1L79S:]K*I=H7-MBK
M/+3*F&0D]Z#.*5J50IE%DS+BW3'4U_JG?'N[\)B'2:548=>L-3TEIQ4IAVD7
M2I#R(X. 6W0D$2U_ V48V '*==+M[\5^WDS9Z[(4]G[%.DVSL>"N2BV)FVC9
MVT>YVD;DY8$F2I6ST+4DSEI3)4>[FW%.B-'L/\/NRJ-HJ6I5JGV8V';8DWDJ
M)5M?9%EFSYLHRP"JZZ 4K:Y-)"99)+#94[J;6#495#@PFY%8E7?>L9,VO32F
M!#@6W[DY*B15H V^.[(;3"C]F&_%?6I0PD;#9OXL=I['_$MG6"39K;M<]J^V
M5D_,VN;+%GLU@V+8Y&T)A1-6M$N<)BUR)4M,I:KQG!200A1&#:OPWV1,DV*W
M6^<J79%[-V,G\M9E!4\IVQ:Q.L1[M%Z8C^0)DV8%)'=7>[F!"BQTS7M#5"5'
MM]<:U5RA)H-,K-::CI<7XB:G.7";BTYQL;&EI0A3Y=D+*72E3*$(64DZZ=_B
M,VA,F;%*MCHM$VTV.S3]H]TE:/S,BW6R7LVY(6P")J5353Q>(^&04L+T;&3^
M"UGD2MIE&U!W/YA<BP6=8NK2A%FG6M<V9,7\*0)<A20#BHI =1%[L:7U6JK]
MS0J<NAQ6*#+O*I68'O>''*FB7!BHDIDN(*-O@A(VEI.%C[^<@I/4;)_&3;=K
M[0[*L$O8WY;8]H[4(['6$+F)F6DS),N4M<^T,3=3:4S1=4L)0GN57B+PCG=J
M_AELVR;'M]H1;B=H;-V&GM%-EL$R_P"&39DQ"9J)@5=F3 I"KTF6\T AY;$&
M.RZN=8;)Z&=.;IZH=1ZTQ0K4M2$JHU*6\IKQ%(#;;C$*&AUYE,F?+W^"Q'2L
M*<>!&X#XM?2G>H1W\TJ:2M2NZ<$43_+4 G%(3.ES  4U8%KI<^)=TI4\6<.J
M9+6G BJ)B$34%S2J%I./PX' @?%1U*]HKI[[2_5/JGU!Z=4:90;9KE[UJ3'I
M55=CNU!D2I3KX>?3'):;,I3CCVQ).W< 2>"KFIA>8HC J/7UTCM)$E<N3+2L
M,I*0"F\#R<$BH?.F&H$;;NMD[WG4MJ4E63D#R)S_ "Q@>G/E@0<9[^CN]/(Y
M%X!LO-N>Z&1J5!3O7^Z&/_+Y'YC^7RT1,'#=X^K];XY-V@)"]P:QDGR\L?+]
M?CH@)%3@_ C=PKX#SN(HJ4[0&]V"#C'G_3/XZ( H'_IKAGY-X$G/"G=VI4J]
M:TAQ^A2U0E.']^VI >9D#_=<:4=I[#S\L_4@-:8^GA1O#[NNCJC?TACP&ZBS
M3@I("WJ;%$>0L9X&\%6WGOC QD8R=.I^PR^WE"Z_:')MGJ'5PA+=8ALU,C"?
M&VEMU9/WE+V\.*.>5*2".V#H?K]W]LM("*DD\J$<J^9=N<.A$O60IO=!I;$-
MPI&'7,.*!/W<)[ CGGDXT.Y=\,#PRI].,1<5\Z:4)P\8L^+*GOJE3'EOOJ!.
M\E12GS&U)X ^@&.V,:?/7+!QB6+UH*OSAY_4YY8T\#I';T*$5%#JDYQ@)/8\
MIXX^0^?GWT:?L,N&57H:C2"NC'VY/O;'UATZ93O'+;92=RR@82"<[NR1M\R3
MP.23P,G&I?$&" ]2^K:U9SRIAC%:B,26+4H]0"<0:#$UH6&(CU<Z$_9G2+D1
M;U]W_4X$.FUBG0*JBF15R%5,19*&Y,5MT%MM$9:V5I*\K<4"".1@IV5FV>5N
MI26J/U!\Q5R_M0QH+9M2XM4I!JAPI_BKDW@_N"&/L[9=BVWT\H$&V;3IB*=2
MH*4A#:596ZL)"5//*R/$<5CDJ /IVR=LB4)("$AAGUZ,=VI&@GSESUA:RZF
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M#BH0@;?#\,(0G8 @;=F  4)V[<) P"A0(X'&NQLLL2RNZ$!/RE*4A(2L .E
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M>&6D.'3*$E@(!2D'(X .1C/!R,?K@\:(5\:<Z>0^SX81V<:$$@#:2!W '';
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M J/F4!C&/M;M[*LNR9EHLLB:-JG\XB?LZ:)859I5B5+[R:M:R!4K0E("'!4
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M'#%^+OTW1CE7GAN)*D#*CGD?=/GC/H1VYYYU._B^&[SST>&D!P-Z1C7$ ^S
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MR%J2A+#*F@2ZZ@:S]F;-1M*T@VB9^7L5E!M%IG*<)F"6+Z988 S+R@ D)UP
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MLK0I4B<^IM#;:5J2E9*$JS[#LI6TDKF6DBS;+EW5VNV3;TM,DU,M.%Y16RV
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M!M>;P72,CX1LAW'U'\]4QGQ?T018/<_4_P ]$$4T00:((-$$&B"+J.WX_P"
MT015?W3^'\QH@BSH@@T00:((O(^Z/Q_F=$$+3]]/T5_AJE?S'EZ"",)7;_\
MM_\ 6-:M?R*_Y5>AC(C+9[_B?Y:G9_D' >\4H^8<_0P/?_>G_P"A>IS,N?M!
M^O\ ZO>+4S_41_Q_D-9%D_WG_1_^T3FX2N*_2,G_ &E?^1/_ /FC4S_[I/\
M^(>LR*S_ $E?\ZO_ ()BVK_5)^G^(U!7]&?SA)_J2O\ F^D5E?>3_P"5S^3F
ML='RV/\ _,OUBV=_45Q/_P C&&Q]Q/\ Z8_DK5L_YT<$^T62_P"E,_Y#ZF,I
M?_9'/_3<_P#NTT?,.?H8@O\ ]NK_ *?5,+/<_4_SU6?ZB^?M$5?(GEZ0M/\
MWG_IHU&;_35R_P#D()>?+WA([H_#_P"HZLM7R2?^GTB*?U?\IA2ON_\ S'^9
MU=+_ *RNOTIA'$\3ZQB'N?J?YZRH47$=OQ_P&B"%Z1PYCU$$&HC$?\@]8(L'
<N?J?YZG!%-$$&B"#1!!H@@T00:((-$$&B"/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g752656g78x43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g78x43.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  /  \# 1$  A$! Q$!_\0
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%69F\_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g752656g85j93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g752656g85j93.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1P,4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $8< 5H  QLE1QP!6@ #&R5'' (   (;"1P"4  .1')O<GDL($IA<V]N
M($P< @4 %U!O=V5R4&]I;G0@4')E<V5N=&%T:6]N.$))300E       0*H(B
MS@B:*L,[EX3)AU[!4SA"24T$.@      Y0   !     !       +<')I;G1/
M=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E
M $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;654
M15A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\
M9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M
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M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!C,!B@
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN
M9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,
M969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!2
M96-T5&]P;&]N9P      .$))30/M       0 \     !  (#P     $  CA"
M24T$)@      #@             _@   .$))30/R       *  #_______\
M #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          (X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300(       0     0   D    )      #A"
M24T$'@      !      X0DE-!!H      S4    &              '(   #
M2          !                          $              T@   '(
M                      $                         $     $
M  !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   '(
M     %)G:'1L;VYG   #2     9S;&EC97-6;$QS     4]B:F,    !
M   %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N
M9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E
M;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   !R     !29VAT;&]N9P
M T@    #=7)L5$585     $       !N=6QL5$585     $       !-<V=E
M5$585     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(
M5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N
M=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N
M96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R
M5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/
M=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M
M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M      P    "/_         X0DE-!!$       $! #A"24T$%       !
M  0X0DE-! P     $7T    !    H    %<   '@  "C(   $6$ &  !_]C_
M[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1
M"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( %< H ,!(@ "$0$#
M$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $%
M 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "
M$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:B
MLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9V
MAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q
M$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"
MTD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&
MUN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /0&_:,G,SL3UWUOK]-S;6<!
MKSOV,K^BU[6LV>IZGO\ 4_FU*JG*Q,VBM^79D,OWAS; V/:W<W;M;N0XQ;.J
M=0JR-C*Q71O<7.:227;=TO\ 3VM<UGIJ./B].Q\_%^Q/WSZ@=%ILB&>W3>Y)
M3L$AH+G& -23PJ+.H/<Z(]I>U@T@DD,<?I?\<Q'S+&U4[W?1:=Q_L^__ +ZL
MS" LS*G/((J;N)[;WC7_ *AK$E.VDDDDIS^LW648[+6O<&"QC'L9HYV]S:V_
MI 'O;Z>[?[&?I/\ BTUW3\OU'WC/N:)+Q6T-V@3N:P;VO3=?.WI^[:UY%M4;
MRYK1-C&[W.K+7-V3_GI9/3,*RY]_JV"TZEC;7-!/]5KOWDE-O"L?;A8]MAE]
ME;'./$DM!<JK\ZQM&9;('I/>VG3LP,:[^M^FWHN'9Z?2:+(DLQV$#Q(8-%1L
M]-E+:WG>"]Q<_B0QYR<JS^I^CJK3X '<=1_:MF2-G0Q<BRZVP.'L;]$_VK&_
M]0UJM*ATUS:\8V/T-CFF>_N;7L'_ $E?39"B:3$Z!2222"6GF^G=07-S#BBM
MT/M8YH /T-C]\M^D[_/4.FFVVNUKLAUHJL-;+/89:&L=](,]WTE4Q?2&#F[Z
M'YVW(++J36-SG-<S\Q[W5.KJ;LV;/]&K71]OIY&VKT!Z[HJ(#2WVU_FL]J25
MKLG+P[W-=MR*G-+V-T8\00WT_P#1V.]WL_FU:HRJ[R6B6O;J6.!!B8W#\US'
M?O,4<^HV8MFT V-:2PQ)D>[31W[J!Z)?MOI+VQ[',8Z9;.CF.>AJ/$?BD4=#
MH>[H)*CC9CVLV7A[]H&VUC7/W#7^<]-FVNUD?I&H[,RA]HJ]S;' EK7L<R0/
MI;?4:W=M1\1KY((+_]#T!C,=W5NH>L6V-%-1?4X.<0!O=]!S"S9_Q+_I_P"#
M^@@XM_2+>H8AZ:*Q'J;]E988+!^\QBMXE=G[5S;BUPJ<VM@WM(U8'3Z3_HOI
M]_\ VXAYV6:NH8Y-&0YE)?+ZZG6-)<SV[?2W_P#4I*8]7RJI90]T-W0X'0$$
M.:\$Z[=S=[6_]<_X-1P2ZRY^26[]Q K:WAT>YSO^+]8_SG_ _P#"K-K8;KSD
M9XR0^PN?]GKQKB!/#?5V?F;MOL_SUJT]3Q*B6MQ\K< -!BVM ;^:&-%>UK=$
ME.HW=M&Z-T:QQ*=9XZUCF0*,J6F#^K7<\_Z/S2'6L<B11EGD?T:[D:?Z-)2W
M7F,?T\M>_P!,>I5[O='TVZ/](.=M_L>G_I?T:!G5_5YF2_[2*6Y9&\[])W3[
MC^9^9[_^FB]6#LWIU0HK>\W65/8"P@#:?7G(KLV/97^CV_O^HK6:_'IJ-MK-
MSB0QI:PO=),,^@'/^DDIJ"XU]*P0V"7LJ@=O:T6#^SO8W<LVW)KO#<6I_P#.
M-]$O((BH'W6?]=:RZ]_[_P"KL4<S)RW8^"W&HMC'QP;++*+=K7%K6_0V;K+*
MVM?^:GQL<8K6DTN<^0/5=5D.(<8;ZCF_9OTW_!4M].FK_P %4\.&,021Q;@7
M_P!)AGQ&1 !KO7Y.PTAUK&4<-U!=J9/T[7?]:VLK_P"/5]9V/E8>,T-C(>]Y
M]SW8]\N.KO\ 0HW[4Q@0-E\F8_5[^W_65"3KHR@-M) HS*;WEC!8'-&X^I59
M6(XT=<RMKD=!+C=+>^[%SSA7-98[+L-=SP;&P?3/T#Z+_H?H_IO]_P#P?Z)6
M^E-M:,D6N#[!>[<X#:"=M?YLN5C+IQ[L:RO(;OI(E[1.H;[_ ,SW?FK.Z7E8
MN/7<VNJYE3K2ZH"BXC:6UZ[O3<DIUU4P75M#\=LS6Y\20?;O=M'.[V_RTF]3
MQG"0V^-1_1[^QC_0JK=G5>JW)J9?&P2?0N B=_Z1OH[_ */[B2FZ[=3<ZP,!
MKL+0=L[A$^[8UKMR(VZMS@!ND^+7 ?>YJK-ZI3L!LKO:[0$"B\B2=O\ H41F
M?0^QM8;:'/,-W4VM$P7:OLK:QOT?SDVB#H=.R;!Z/__1]50K,>NRZJYT[Z=V
MR"0/<-KMS?SE,O8)EP$1,GB=&I->QWT7 QS!E)2)^)2_*9E'=ZM8VB'$-CW<
ML^A^>Y9^5<WI_47Y/V:^\6U@OLKW.#>&_P U#:6M9Z376/\ 5]7W_0_T>NDD
MIH],KI<+<NNJZE^0XE]=\@^USM6URYK&.W;O8B4=/QL>FRBO>:[IW[WN>=1M
M/NL+G*TDDI#B8E6)2**=VP$D;G%QU_E/E$>T/:6&8<"#!@Z^83ES6B7$ <2?
M-1]6N8WMF8B1SPDI&<.DXC<0[C4UK6CW'=#8V_I =^[VJMU+$K_9HJ#'VMH#
M=E;7.#G0/2]SZVV7.VM=O]C%H))*<BNX=2R*:\C"RL<T$N#W':T.;M+0Y];]
MS]ZOVX5-V35DO+_4I^@ ]P;K^]6'>F[_ #58224U_L-'VS[;[O6V[?I';'_%
M_05A)))2D.G'JH]0U@CU7FQ\DF7&)^E]'Z*(DDIK5=/Q:<>S&J:6573O <XG
MW#TSM<XES?8U93'9GV4=/LZ4\XY,>RV!MW[G^YSW6M]/_C/TW^#6\DDIJW=.
MQ+\5F)8TFFJ-C0YP(VC:WW-<'._M*61@8N2:C<PN-!W5^XB#I^Z1N^BK"22G
M_]+N0,'[?U*G+V?9P*7NW'W$O.Y^YW\ZYGJ^C[-_I?X/TTL0=&'4<4],-<N]
M3U/3,DC9IR?HHPRC7U3J'JN?=575010R'ANXO#CZ;?<U[O\ SW[U&G+QLG/Q
M/L]+Z0#9NW5FL'V::QM24ZY('*JNL>ZY[)AHLK8/B!ZSU/*;Z@95,;G;I\-@
M-C7?V;&L0Z ?T+G&76/?:XQ&A:6MT_J.8HY$D@#2CO\ L_YZ^(%7_+^7I9W6
M/_3,:0(: #_*?(_\@I8ONK]63%FK0>S8BO\ Z/O5-^0+FEM9)]>R) [3Z3?_
M #WZJT@ T!H$ : (0/%*P; _;_Z"J0X15:G]CF=?+&8]%SMLMOK:-_T=KW!M
MLM?NJ_FMWO?7[$#*9]6A=;ZII^U2XNWN,[SNW3N.U6NNVV58;'5VFDF^D%S2
M X@O;N8S=]-S_P!Q0R^HX;;7U.Q[3<):'BDNU[.:]H_S5*L;?3M>GXI.OZ&O
M7^RU2?8[[574TPW8][Q\"QK/^K4>G?\ )^+_ ,37_P!2U*D[\N^P:M8&5 ^8
MW6/_ //K$0GNV57M).7CL!@ /L/GM J_]'*PJM9#\JZUQT9MI;\?YQ_^<Y[&
M?];2"@VDD#$>ZQCKB218]Q8.P:#L9M_KM9ZG]M'00I O?EBFXT,8ZT,<: 7&
M'/C]&+/:S:USOI>]'5+)&(^C*9;>X,=78+MKY+&D18YK?=M<Q+3NIKT7_6(O
ML;=C40&V>FX.+6N<(]#<[==8RNS\[]"IVY/7&V6-JQ*[6R[TW%X8('\W^=8Z
MS?\ ]8_]&V4,;%Z%2ZU]74'UAS;&NK-NQU8L=72YONVY%%E-KJF>YWJLL]-2
MS6='M-OVGJ=];+'.+J76EK3#M?2K>SW4[F;&^E[$DMFS*^L7IEU>#3O!:-IM
M!D%K_4<'>SZ-GH_^#?\ !K487%C2]NUY +F@S![MW?G+G+L?ZO"'?M%[6/)K
M;^DWMAL7^E6][;-C*VV5O]KOZ_YZWL/%KQ:?2K<YS22Z7F3)Y20__]/T*ES1
MU?/+&%UK:JCR-ITLVM^AN8_^V]09DY5^?B')Q78NWU(W/:^?9_(5K&Q+J\_)
MRK"T-N#&L:PG4,F'VM</YWW;?9^8J^<<X=1QS5]G</?Z%=CW5O/L_2<,MW[7
M?NI*1]0ZG378Z0XMDTB--Q!'K^F?W6_0MM_X/97^D4;^H-M!;2YILL:65B=H
M CZ3OSV5?GVV?\'Z:H,Z2^K);1D5T9&38TN ?E/:8DN]E+<?^38I5]/S&9;Z
M,0X]5U8WOJ]9S]'>+78^YOTF>_\ E^Q43'FR23&/#+]&,OUD?M]#<OE@ !*5
MQ_2D/1+_ +MTL2O8X6;BZG&;L:"-2X#T_P!"P?N-_0L_KV_X17S>&5M-G\X[
MAC=23W:W]Y8N,WJ%UEE6W$NLQW!KF,M+ S]UOIMQ[',V_P"C>[_A/ST;%S,Q
M]=E^-5@N97+;+&7N<(;_ "J\?]WWJ;%QQ%<)'XL.3AD;X@6SUPUC"9ZK2YIO
MI$-(#I+VQMW-M:[^JI9N5F5O?37ANNJ+-;@]K0)#MWM?M^BAVA_5\#'=0ZJ#
M8Q]KFO+MI9[_ -!:UON?Z@_/9_-JWF^O]G=Z)K:?SS;.T,_/^@K#"@JRJ\7H
MU%SW-;MIKV[W!K9+6[=SW?1;^\J6+]8.FNH-&#:+[JP=SG U@N=[G7?IO3WM
M>\O?[/\ SW[UF]3Z/G=0Q,2_+LI;A8M# REMY#"\@-]?UW8_Y_LKKW?0_P"N
M*EE_59U6/7DU74T4N+2US[/4:=WNW->^FM_T1OV.<I(C'7JD;\M&2(A6IU>@
MNZC<XMK:[U7@>H0#LK@G>;KK/YS[%CU[/3_[FO\ ^N*=0.2ZFICG $%Y>?:X
M.?[LB_;^:_\ 2?9Z?]%ZM_\ W'6!^PNLX'I5V96$:[K);7<7ECGQ]/8YNQUB
MO[/K)BWLQ69'3<>V\$A@W^HZ#]/]+ZCW<[?H>FB1#I()/#T(>F8QM;&L8-K6
M@-:!P . I+(Z1;F8^19@]1MH?DN_2M]-[G.(/.]ES0[\W\S]'^9Z=2UU&=][
M8SOW4JUK\IS+V#':Z&.],.<"UYCVL<W\UKU9200Y&(<ZMY+>E55/:S:VX/96
M'#=6-NVL765;J]]OI?I-GH^EZG^$4+VYYL>VGI&.'6/(]>QS"TM<[W66L:UM
MFYS?TCVK:224X+QU8@M=TG&,PZ!L>TNC=:YSG.J^D]K/3]G_ !EG^$6SC.R'
M4@Y+&LMETM:9$!QV0?Y3-J*DDI__U/55!WI>HS?M]37TYC=Q[MB^6$DE/U.[
MT?5;NV^K!V3&Z.^W\Y9V7]O;FN?TW[,]P9^EK>0'%TC?NV-]3?Z?H>GOL]/]
M_P#P:^:4DE/T_P!/+S6XWBAN5N/JC',CZ3MF^??O_>_EHU7V78[T=FR3OV1$
MQ[MVW^2OEI))3]34^CZ8]#;Z>L;(VSW^BINV[3NC;&L\0OE9))3]3#T?1$;?
M1VB.-FWM_)VJKU(,.#%)J:XQZ!LV;>/\'ZC7U[O0]39[%\QI)*?I:EW4SDUM
MZFS$%8G8YI.\ND>F:?4_Z:T'_9_59OV>K_@]T;O[$^Y?+*22GZF_5_7_ #/7
MCRWQ_P!5M1%\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?__9 #A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $
M.$))300B      %*34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    /    L(=I  0    !    P    .P %VPV   G$  7;#8
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHQ,R P
M-3HP-SHS-P!$<F]R>2P@2F%S;VX@3     .@ 0 #     ?__  "@ @ $
M 0   TB@ P $     0   <@         !@$#  ,    !  8   $:  4    !
M   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !   !2@("  0
M   !              !(     0   $@    !.$))30/]       (
M  #_X0%,34T *@    @ " $2  ,    !      $:  4    !    ;@$;  4
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M  4    !   !0@$H  ,    !  (   (!  0    !   !2@("  0    !
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M&%GK-5[S=%*[$4Z\UNMVPE,FYFNR*=A=.6[5I85V;4@3[6&7=(2#!VU271<
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M#F0G6,F4$P3XDDRORU&L@Z?HB3,82)B8/(E#?SOYX[_KOO\ GN/\=4&<P U
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M7Q NC-=2.?<NO3%(V@G&1W;94R1C(%:UL6%79OTC\1,4ZYHZ825VXF.5H %
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M4I6ZPXK=>+5DVKE)5]5[-(R%O=/4"V*(142%N,;9:>4E 2,XS>([ZN**3&T
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MZQ)E%-L>TK;'52_Q@40VK#_9+G0:P1XE)V/1(!2J).AVTVW%+H/I*M_P=M?
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MC-E7!FR!U1 R;8J2"0$133(7PO$V(IN,4NE(+CEK:OBVLFDDZ("DLH&5/K2
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MC%8MK4];9U^907#<U^OAW\Z]CHI .#9D6NUI9O&>D:)[#+N%A,7D $-A2MQ
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M\1S>T:?T[^W7816%NF9/M=7'Q$4]]P+D;I\ O[W@O^#E2A OU&-L!0'B ;[
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M"VRXH>@>FKNRPA"%2L/7)#S@<4A3IGU,^00( DLDLDJ J$.42& O$?)=]A,
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MKQ;2$*) S%W[L@!(KTEQ;>@V-PEMSF8IB 0T^\J5&W>>4EL<M)T0E*UI0D;
M$ @D@CZ^AF%C<5+ 5:*4:I3&48;)CA,^R"43&((##5 YB\2N)&:431=R;4X"
M"$4F)E2\WB/.-O>I;<N.,KTH]+Q5=S:\/L$DYBI:T7MV6R28MEEQI"CH%]#D
M-9<MU72+7 67#FL^6YBJ@G5UM0*D(48B7?6Z&.ND&8+9N1L"::6Q40V A
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M$L&X&+: W8L:^1TLQ0BD63HIS+IB0;['6Q1J8ESIH9@'I/D?X=_.H7T>FN
M;-^XP=/U\SKKM7Z%R?Y,GW^@OG^0>?OK!K(V'L%>0T:P$'!19,S \\/.3=+_
M !H/R<;$_;?_ +0#!^FE/HS]=Z^@P: HBJ#1H51J0R350K=,%&Z1@\IHFX;I
M%$=A$$]B^ #B.E9Z?7Y_K4&^FH +U>?$3 /_ )1^GL=@WV 1Z<J4/W$1W'[_
M *^0\; "L)F->Y^M:FM.O4HYFH^7532;M4'+A8QQVV*DF!N7(=BE*7SS,)@V
MW ?;EM2ZTM]=HRTVIQUR]MTH2D3N5 GOH2F(!)F!4'G RT\\M80TVRXI:B8
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M 1,[C74Q_B?!<'"<*:N6U8@R%9<.MN<I:BOQ!*PRB"^M9A(4Z,N=3A!(1-6
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M!F4#A 0S!>&BW3@0$2^OD!>JR+U @F+^S(9FFX$H%63,FH=(T,ZN_P"7\JP
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MDI(4I:W"I;BC_$LJ,]C!JZ@2( B( /U>!^HVP_RWV^WOMOJOH!T&W^>];64
MD]3OJ8^&P]PKLTK--*4TI32E-*4$0#W';^.E*:4II2FE*:4II2FE*:4KX/$/
MJ'8-ON([!Y\?P^^L0)GK]"E<=R%']X ]Q\G^V_D=A';W$//VW#6=]OE6-!U^
M)[:]_.H/_#6$!Z$^E[80';%4. [" [#ZE[X';V']!\Z5G3I]:?RBIQZ4II2F
ME*:4II2OG@-Q]ON(C^@?V  ?R^^E*BO79:#C^I3.Q)>6C(XB]*PWVO7OVK3O
M=I&[@;M^H5(*G 1$#"7D)1]]A -4W/*4V@7"PEMM8*02E.I,G7>)B1/EVK(
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M/R2^@=LN)*U*" D%*0$SL0 )!CJ1,1UBJ,A*4@JU!))C<$D@$3T$ U+, V
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MVB/C7!U@7XDR_J#?B?'*)G*<BF M>IG.B1T/F&14<B"+7_L"X(F9J-PI;#B
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M7<!-_"[^(\&V[;HQ_P#2,T>1_P#,CM_;K2$=21[I_45>")WGX?7QK'V1K_\
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MQ)">M+.4=1T&XDS(L&BJ;A\IW54&R2FLO_:\+S_[/Z<DW9\7AM@R[G40GQ*
M<+0*4@J.8$),$B]E.<+\4$1 C>9WG_"?;\*L3 G47E"Z=3R53D[@C,PT_8\^
MP]AQ4>"CXR2Q! XSD(MMCFP/1!NE9$%KZQ>(N'8V$XH/7+P@0[9LBR6+K-DP
MYRPX^CEENT>USA17<N8DG(V4I40(LR5@@0,I!5G5EK54Y#J$;SF!B=(3(GH=
MM-=/A6T[5]6UK$ZZ\Q9:QA;,>N*#EF#H\'"5Z=NEEH!GD,TON7CL)VMQC.HT
M1>RT>X1#V0[#QZ 1;0[>9?N':0(F;MT3N2TPX;A/1D>L9^64'-[?E6492@YO
M6V DD?'^O;I7'I&ZALI9/RT$/;+<E8$;%5<J6*XX^+%Q3%W@6>I67"TNGU5X
MK'HIR15K16!=R#UM8UW[QT]CE92-<)1;IN@&X_RN:KDG,W",I@IDY$YM% $>
M/-T]FD5%,QXM#)^$Z?*MGNJ:S32E-*4TI32E-*5\$-P$-@-^@[;#_7XTI4>.
MJJ5N]=Z?LH3&-2R*-QCZR<\0XA&?KI9DD=ZQ;RSZ+8$36%W(1L(9Z^9(%;N#
M&6:)E22,H"9#17FR^ 2=.WZUE.7,,VWO^.@/E'7W36-^BNS6:SU+(RTC9+?=
M:1&91GHK$UTO17ZEELE%0C(-4'3J0E&+"2EFC6?7FF$?)/T?5+HMC)''@V3U
M*H]?;\=(J:&E9J'O5VZRI%M\&R^-K9/P;1+/N,HFZP5?B47JELK$_8V4=(,9
M>1,FLZB8%DU.Y=R9VI$RN4MDG;A%L4_/7N"N6,@)^^.?41EY+N4F8_Z4MB!)
MD@@:$U- 3*BI66 (&7-.IGH8TC7X:U'/H[ON8;#F^;B;E9LAS:H5K):^7ZU:
MTWY:QCJ^1F4"QV.82GI.V#9K&M9&B&D71&L2[>MY6/;L9EP<5%$UE-BV3%BT
M74Y+A-MA"5I$'[U.&-IQ"2"H9DWP4E9!*7%>-HJ;(552RK.G*,R-2I4P!H8A
M),]I/7?6MIVE2K5%UG97L$%FG&U$Q]ES(5+R7+1\#,1$09628X>:125K4!TM
M9&[:%72OEIN@H%IT-45Y@I6:+E2:4&*(B@LO6RAU^]+:!F2TD+<U2 E$;^)2
M0?<3O4W4%(TU.VX&HC32#[]/?N;IZ"K[DZWSEU;6:UY"N$"WQ_BJ4LCK("4F
M12L9TDE;4GE*F0'S2/9*LXN/;M:\Y/"-%'<3%+NR!&K FLH4-AQ33BBXP0ID
MJ*4* *02V>6OPJ 5HM*@24@$ZC0BJ$+*A!&50]9)DQKW\]QO6S/<!W#\O?5,
MYO55$;Z?SJRM1W6%D?,57SE",\$V[)$U?2M99N\P^+2:"K/XIQCVVK5VPUYF
M:"2I4LR96PC*1MTQ.SBLI&'B&$5'F(1X9HI2V'/24E:3RO$%JSC3[M67PA4Z
MJ@>KI[-1>HLE@)$<SFVI/A,E NFE/>*(\+(6K<E40D9H!R?T-V>_VI+(2CNU
MY O]%:*X^-!VG(_S,)L+6ZJ;%WDR!16F&<:^6BH2<43!%L9H*46_<R,0W6$&
M8H(= EN(21LKH9)C0;=_=WK3>YGI-N&TI5;HL+4.+\(4+H8KBCCP@A*I%DNR
M4% *04E+847$.)3L>4[G .!=S[AN7F)?'G?Z@,4?X>1\B B'C6JO,$G*,Q[3
M$^^1%6UIOZF,N]:45U$6:-I^/\EU_'#'#6:F='=5\:7.0%BE(6 IDFEDR1*Q
ML#Z=3L44[=2\?3ZT_@FZHG1]0FQDUW2A6M=NHS<!Y(0I67(F<Q@('XDE6^O4
M1,1WD2,H$R1N=NI\MNOP/E4L^B"SV>RP&4Q=VF[7O'D9?633%5TR ,FK8YR"
M6J$ ]L1%'DRQCI2091EQ<SC!FZ=MQ.4$U&J2IV[9$"[2DH0TRE,2$JS1_BTG
M373MI[-JK&ZM(U^/GV^M:FXX$Y45!3 PG OT\=N6^X>0 P@4=O?81V';R ^P
MUU*M%^8<B=0U9S/G)S1,HY-OBLB]M[*9H\9!7^"_P=<=1:])32N-=CG,D_I=
MP4=PRLTI!2L;#%DW,M(#(,3.$F;Q@W6&CZC=^%HJ)!/C'E*4YB?9 'E.HA=2
M&QZ/XEP)$A)F((E<#S\S6QGH^L-GLF.K0[E;':[=5VN3KI&XOMUR/(+6.RXX
M:.T/DDF_>22#*0DB \/)LV4H]0*N_8M&R^YT114.J7\AUGZ]O6I>Z5FFE*:4
MII2FE*HC"#A8UV^D(^,8M'\PHDO*/6S)HW>2*R! 216D'*")%G:B28 FF=P=
M02%^DHE#QK"1E2$R8'3SZZ5'17BW/0^S3].O6JR7;B&WMY#^H1#\@_W:!.41
M[_CK^M9!D37%5)-=,Z2Q"*)*$,F=-0I3D.0X<3%,4P"!@$HB @(" @(@(#K-
M9JB_AFO [C9$8:+%_#M5&44^&.9"\CFBH%*HV8N?3]]F@<I"E,BV.DF8H !B
MCL7;!.43[OCI\YBE5LI2\=@]OY (?8/L'L ; (^=@\B.HZ+$3'6E4:=KU>LC
M1./L4'$3S(%B.$V<S&LI1J1<@&!-<&[Y!=(%" H<I% 3Y% Y@ 0 Q@&0 5"H
MV^73\_YUC-E&4$P>@)UGWU'&<SWTG8^RE'8RF<F8=J&6&"</ QE.>2=<B+4S
M9V'TKB(B6K0Q$GC-O*=YNJPCTA30<D40,FF!E4SAELYU+(UG30[Y1'S(C0GW
M['#J<J4:==!VDSMKY';RV&DI4U.YN(;;;%$H_F [_5_ =M@$/ ["(&$!\8_$
MH=H'Y^?\JD-@>_E%4R6K\+/-P:3<6PEV@*D7!I)LVS]J"Z9A,FN#9XDLB"Z9
MA$4U@)W";B!3  B YI'^73VUQ1KT(WD#2R,7'IRYF:4>:738LDY,6" B*+,7
MR;<K@6J1A,9-L)Q13,83$(4=ME*K6E*\[EHW>)*(.D4G""H "B*R::R)P 0,
M'--0IR&\@4?(#^Z7;V#2E4UI785C(/I9I&LD)63322D))%HU2?O2([]H'3Q-
M$CA<$]S=L%%# 3D/  V#96(]OUK^GT*K(!L !^0 'G]/&E9JD24!#3#ABZE8
MQA(KQBP.8Y1\R:/#,7( 8/4,Q=(+&:N/)1%9N*:O[-,.>Q=A4^H[UR8P</&/
M'[]A&,&C^7436E'S9DT;NY%5%,J22C]R@BFN\432(5-,[DZIB$ "%$"@ !$J
M@A,;_0I56]M2 C04II2FE*:4KB<H'#B.^VX#XV_T1 P>X#]P#2F]4=G7H6/?
M/)-C&L6DC(BB,D_;LVB+V2,W+Q1-(.TT"N7IDR^"&<JJ&('[@ETK$;>7L_E^
M7OJM:5FNM5)-=(Z*I2G34*)#D, &*8I@V$IBF 2F*(>!*8!*8-P$! 1#6" H
M0=OY&:R"001N*HIZO7U'+!Z:'C?6Q27IXQX$>R]7'-N(D%JQ<^G[S-N8HB H
MMSIDV$0  W'4D$H]732/J*@M(7ZTGWU7M8J56[8*U7;,T.RL<'$V%DFH5T5A
M-1L?*M 723,5-8K60071*L4IC%*KQ Y0$0 X%$0U I$E?7?X#;Z[#II6,TG*
M?A[M:AU;>KGI#Q5DYYC:TV*/JUTIH5^MR;EOC.X$@Z<6W,V;JNP;Z^Q=3<U*
MO-Y)H_;'*U6FVS8"+I$6X&V*&$.9R1_#'0Z23]1O[16<F7Q1&;]/\ZG$@<JB
M**A#<B'23.4W(IN13% 2FY$$2FY (#N41*.^X>-64JG2\%#3[?T<Y%Q\PRYI
M*^BE&3609]Y PG16],[262[R1A$2* 7F4?(" @ @BE<$*]"MI-6:1C&"<NJT
M(P/*$8LR2!F*8@9-F9Z1 KD[5,P 9-NHJ=),0^@H!XUC,#^+YU'*.FGF(G\O
MK;:JP   ;!X]_;8/(^1'QXW$1$?;WUF9\ZE'3I7B>QS211].]2*X;#X4;K$3
M415+[E*JFH0Q3@F<"*IB/U$53(H4P&+OJ)2%$$])CWUD& 8Z]>H\Q[M-9TKQ
MMJ]#,Y1S-MHYFA+/4TDGTDBS9HOGR2!3E03?/$FY'3M-#N'%$CA90J1C") +
MN.]F=64HGPGI\].U0R)S!743MUGJ>]5K4:E5%?UV#E#M%9.+822L>L+F.5D&
M35ZI'.>9C@Y8&<HJ^D<%$P%!9#@?B1,!,/ H@K$?7U[>GOKL90,+&NW\A'14
M<P?RBJ2TH^9,6K9W)*HD!--20<HHD6>*$2*"95')U#E3^DI@#2D1\9JK:5FF
ME*:4II2FE*:4II2NLR8&,(B)O)0#;Z=O'(=_W=]_J]]_&WT[;GY*5\(D5,=R
MB;R4"CN(;#L   CL ;B !L _EI6 (^OH_&NW2LUP.0#@ ")@ !W\;>0^X#N
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M0I.4M%M=SS4T,VK$GZIY( 6-<.3)L^3$CA8Q>''MK87>$8O9YDYW<>Q=8&8
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M[2,0R[8?888I7_[P'RGV3R3J=_96PEKT7@+#W#_X]BF(1((_V1NW22#U$O\
M34&9VFI'B!03$?\ 5(0-OY@.WD0W'[>??]-?1G"#G'\*DE6VP4">_0'\J\DW
MX0GV&/@3]?G5K/[+7HEQ#,9%V5JYL[X8B'1.'UNWW8=K@W( >>0H,W"@"(;
M4FYN/WY%]<V5K=IL;AV',9'+9!_$H(RD:F8A8VZGWULL,OWC"[I#<IM@5.JT
M$00.@/4C]-HJY7"Z1$P$1V'<H%\!Y'MF,4?(@&Q1#<1#R''QO[:ZBXR/-IW9
M:S'R"1I[=AIL>]:H5E+9.SJDHW'XM-ST_0[3I4=\8G+*7G,%T*D0A)6YQ-::
M+";Z5&-/@&,8H=( Y 8H3:LL100'_*"8-@_=#Y[PG;KO<5XLQQQ.N(8[AJ+
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M_P!8'ZG\Z5L'UFE-*4TI32E8MR'.C6*%;K"Z7! L)"33WNG "@D#:/7,GOX
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M:M895<7%LRW^\>N&6D[$D.+"2(,B"<LF)'3>MBR;+MY;-'5"U^,:P8*8)(U
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M+)LE&Q4=%UR:CY&EP<FQFY<WHD@2*LGKIVW_ +2>8ZABZ<*BE"",I;R+(0E
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MC2T95! ;NK=J]42IPKYA;"4D%P^LP2^5AG"_&_$RD@7F/7%WP[ACV?(JV:Q
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M16W+J2S#D;%I<-N:1 59] V[*])I%[>69^_+(1<!:Y-&+3"N1K!,47\LHLL
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M?J WT_<>0#X]]P]]-DN*(/CC14 I &7SWWW&AUI^)"AH4F=IG6?Z=:HZK,B
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M&^4QZ9;NW2SIJ\Y>70=)$YI.5.XVB"0*]-QPI"N)<02UJU;J9M4'8?<V[((
MZ:JDQ(.:>]9KE'B4=&O7RQP32:-E7"AS )BD(D43&,8  1XE -S#MX#<?MOK
MZ \XAIIUUQ00VTVIQQ:C 2VA)4M1/9*03YQ%>32A;JT--I*W'5I;:0!)4ZXH
M(:2.GB<4D28 F20 2,#X&2[^-&=B!(_K[O-6.ZF44V[AT[%+NG[#<PCN!0B3
M,"IE.8#$(0J?$HEXE^=_9RTXCA]K$KY!1>8UC&+8HXHC.IRU:Q%YFW=4I&:)
MLVF"E#AYD$)"<P*1ZGC5YMS&KBTMU%36%X?88:RDR BX:LF3<M)S: "\7<:I
M\!5XP3,GP9E71E9#$54\J&F,HP\G)(%!4IQC*E&2UA77/L3<R"4BRC"']RG,
MN0"B("8Q8\<7)](X2L4!+C%_QE9.W+8 7&%?LW%WG'W4"5(8%VBR0LK "5N(
M4H94J*;^$&D-VO%5^\KEN6/"UTS:.=3BSV(88PRT@IU*C:.7KB7$RW#93GS+
M0E5N8/:#;KKF/+A4_5)V2U-Z367)S%$J=9H")H)\+5-;BNT*XLIIHZB9@ %C
M,R+$ $S(*#R/L_9.(X[QIQ:I'.-WQ(]AF"+41XL,P/)@]Z6@LRTV,0L;ML!?
M+YZ6@^RE;#K3B^AQ>XU981POPPDE"K7 &<1Q5(2I/^LL;0K%[3.0 EQ?[/O+
M(YD9N3S.2ZI+K;J$RO9IG21*10NQBE -Q$#"/OY$0$?/G7U\2I2UJ3E4I4 :
M>HD#+L2-RK3>OG3:2E"4GH._4S/Z=_;7JU*ITTI32E4^163:LWKM1-10K5JN
MX,1$@&7.1! ZAR(AXW5,4O$A=PW,)0WU2]ZI_NZGRVUCV3M[*(]< ;J4 //;
M3_.M5_3S\11[FG-[/%[W']6B8^Q62P0T"O#7].?M\3%Q534M,3)7*K_+T#QK
MDY&;Z+L2*#Q8L!**QC%=5918YC7L_>,(=3)3L#M)&68!U'2#U)GO$7/NGW6U
MZ+A)*8G<$[B4Z^W\IK:#-UN"L39HWFX2)F$V;^/E&B<I',GY&DE&KD<L)%L1
MTDH1!\R7*"S1TB!%VZH<T3D-YT3"7$N_C0%A*OQ#.A2%08)\25%)[@FHN N-
M\O\  HH*D_A\*TK$B1,%(.W0$:BL=FP!A(X6T%,.XO4"^*&7NQ3T6KG+;U1=
M$? I92'C!+,J>N(5Z!Y$'(@[*#KPO]>JV\S;2T@$%2B<H(&IZR">FD35BO$X
MA1V0D"3K$:Z _6^NM<&&$\714Q6+%%XCQS&3U2C2P]:F(^GU=G)UJ*(FJFG%
MP3Y!B1U%1Y"+K)IM8]9!$B:RQ"D*190#4E+J4W9;2,R5)]#'A$ISRK+XH;\/
M\67M59&=RV4[LH*%R29\64Y01NOQ=1FVU.]1EZ2>Y_A+?$6!0H$,&?L7B) V
MXE$>G'%OD.(B7<2@7D(>X^^MGHCORV\WDO(GF">L+S"1(.X)&M$24ZC9;F7_
M  !Q62.TH"=.FQ&D5L TJRFE*:4K&^2+4A4J3:+0Y4%-M78&8F':FPCVV\?&
M.W1S;;#S#FD0IB!N.P[B78!'5=JT_<WUA:M)E;EZTS<ZI!2T\EQ+9)D!0*PD
M )*B#!T%;5FWS;NV;;\2G%I4V#H"$D$G,8 @2=2#I UTK'725 .:_P!.N*&\
M@D4LG)5=O99-42I]YQ(VU9Q9GKAP8FYCN5EY=0[@ZIC+'6,H*IA4$PCV,<=2
M]B^(%'[INX<MV^V2V/HX '\(#<)$1EVTBMS''T7.*7+C9E'W+8T(@M6[32A!
MC92%#MIII%2-VURZY--*4TI32E=8JD*)@$=A* B;P;P %Y#[!Y^GSXW_ "]_
M&HI6E2EH!\2"D*$$05 *&I !T/0D#8P:'02=M?/;?0:_*H=]2CLUQOW3YAYD
M(KM[#>'.1;:B !Q3J6*DF,^D+A-4"@9-U:W=9;E('(Z@=TH)B'(Q.[A2D6UE
MC&*+D"VM!:LJU!](OBMK2/$8MT7"B .@]_I,#_LUIB>(J!3DMN1;N0?WCP6"
M- 2- )E,:^1B4;$CHBS W 004%8R@@8NWUIN52B)>8F\B8GON(> 'R&^O,(4
ML\@I$H6ZI4SIRUM.+&DR(5&AUUVKSB8#* ?WG-65"-DJ!UG8B8TDD'6KD$=O
M^H=;94!N:Q6"J1E):ZY"RK3F\3V8;&#FM0RT[WQ4!_9)>+),R4:DD! XEB&#
MJ)%58IS HN^43,4AD#%+9>8?Z/A6&O-+*[B^:>N&VBDH*;=EX-)<45Y(4XH.
M$)5E)"92-IZ-Y9IM6&7W%:7!E&LE2=1.1,K&H$R !,=#6<DA 2 (#N&Y@W\_
M8P@/OY\"&V_W]P\:K&H![@'XB:YT9=-OZZUV:S2FE*:4II2FE*:4KX(@ ;C[
M?U^_C[:PI02"3L/(GRV$FF]65=K(^JL.K+,*U.6I8JJ*015>0:.)$Y5CB45B
MI/7C% 4TP#=03+ 8"_N (^-6V-JU</?>O-LIRR%NYLHCR2%&?=-:UTZ^TWF8
M94\J?52IM)Z;%Q24_/V=:PH;.=I\;X+RYL'N/RNN;[?Z6W_9'_J[[ (AY_7;
M7>_T;8_\Z,-'_LKKX?["=_97*./7?_9%P(WA3?34_P#2QMK^L;YWJLZXL%88
M33V&DZZX>I+'5AYA-!&28B5PJF5-R1JX=H%.<A"K$,DX4**:A#<@,(@'!OV$
MV3CK'I3=XEL@"Y92L-KS)"O"%(;6,LY#*4G,#76M7UW+#;ZVE,+<S2TLC,F%
M*2)(4H:@!0UV/2M [+'O4EF#,/4+8,4M,O-;#4>L6381N:Y#J?G(K&55HU4D
MZB]L%.# BDZX93C$\!\WBB1I:ZT:2#J3(X)*LB(&54I(DVQ4C.R$OJ5! )4&
MBEH0HB<RE0DZ9#*B0*V@)2Z 0E196&R=BZ5M%(TU]5*SF/A$0=5 '!_3)D3*
M]-G^G&_V.P9DH,5E.P=1U7M.6+GGI_F&J9 >,8[)CZHMT\.N[18'5&1KR\ 6
M::R[6OLDVC2 )$*&[4H1,-?#V5M8=AK3HB[9X.X>M7@()1CC3&&_M5@J!4A:
MVG6[P*N4K5;OY9:><"TE5MT@*OG74J!MC=XRIM0$!+#N)+78> @*/-M2E:?#
M+23D<2VL9:F#T4V.UT#-F*Z]D2[Y&M,YF3&]QE8B]P^>U,U86SPO#HQ<ZM=%
M*A85"6K#MA;1PF=Q<?%QL773(.'5>54,X;H(DW64^&'-%:"3!ZQ.F:9@"3YF
M#6L[,_=C-KWRQ,'N/UUBICV//_4M&=:U)PU$X*F)3#<MC6QS<G<"6JDMF:[I
MG9:I'I6PHN'2DDT0A&TE(M%JN<R$M+F<)/6+=PDQ4,%5FDEDBY/+<Z;KG4_P
M%0$CVQ-6.Y=VSFD:#5.L;:@?4UB7J[ZO.HC$.4\C5G%L=BM:IXMQ=B/(LX6[
M,K2[G9Q]DK)DS10A(]_!SD>SBFK=I%&?^M7829TU$Q1.W.5P3A4RN;A0)^[7
M?6N&-[P;ZZ:96RS$>$+2\V>:0&49O&XDA0%8/K)(A2+=RZ4-X8:*@M<Z@D9%
M> $N&/"DZ39:G6QU-O;9/X9C/Z!X[)E"E,[O;1?+/&W"+QW8ZYAR&H$TTB:S
M"!:?F3"?F$\@M49A\]L<DV@(V&>SPQKOO$9(PM'DW#]Y!ENVN56BR092^RG,
M\B" HA*7&CG2.6H*\*C"HDJ D Z+6TV\V 9*FW"L)43JE,E!&51"YUC45"+(
MV><I9\M+24C!RX_B<J99Z,9-+#U)S)/XQ=EB[]T[VVV3E4A;@UF((D!&O9AL
MC*OG!7$>C.?+VZSHJJYTSANVC2G<3MY@,!-P5J(!"8MGU))3() 7EV&DSL-+
M+@<C![IU0(?'(Y>4@J)5>6J" 4DIDI6K<CYF9#5XO5QT\9!Z?HM>KY%MS:]9
MQSG)T' ,MU -[;.P>,D,*QAF4/<,IVR4-&V0L39X^9LL=&2,A,_*_6IIL7:Z
MY2@2,I%VMO-H#&Q ZR0#H)Z FM=?BM4N 2KPDC0&3'4]1KKY=JP[.SW41FA[
M=UIMQ(0#2B=0_4M;KEAJ>ZLIK%UB1@Z10,;DAZY7[;CN2.M-UR!/,2LAZ"/7
M0K,5+RC):3!/FHL&G;,)4/&J!F4=S.L0($CO'LB-JW+S(A#000E8NL/4HP?W
M"<(Q9NZ,C0A-\[9)*9"E%0<0%(;4I.79&\*Y.NF&[ITX9$S?*9/7K.)LOV6I
M3V1I@M$P5@AC2H\[F@W&MJ/AAKA<\OF0=A&#,HS%QDI!\K9B2L?%1R8N\7"%
M-.WH0TIT?LS&1;)2I _U@[@UPSADA:DA(]/5;E2S"4"5K( )K3"RFPLU04+R
M#/)*CG2#F$@',0H9 1ON#E(-7#TR2^1Y:9QK'4[-UW>VOJ.Z1+)EC*$M:+ [
MR4RQ_EIK9JRU93<%5YJ1/&5(J(V:V5Y*M,@C(%52N,4E6;IW$KF4N>26[3%[
MAJ(2K#2RKJ7'$.IN $D@B%MHW$'2)$FIYLUQAK<Z/,7Y6-84ILV2D[@Z@%R-
MATT"A4Y_AXS=HG.EC$+NXVF>N]F+%SS2;MMF?'?ST^[:66<:!)RCDYA [ET1
MH!C)) 5!N4I4$$T4$TDPVK@%#6&JZOM-E?M]$SF>QS;]SW(D:UNX7+W& 9*4
M8AB*FC_Z%W$G%-1.H!;@A)@IG*0""*G9JNMJFE*H;_\ Y.J?<P"FU<J )4Q4
M, E(?803W*"@AN(@01#D.P )3"4P<M6Q_P#LQW_O)J[K_O#K'01\^VOY5H;^
M'G4(Z6S#&YK<TZT*WF[N[V6VY-6ZAL?NDK3Z:;F&#=29PO7FZ$S& 8C1 "P:
MYUQA%$4Q>JN5D!5-UL+/]B5*AK;6IU0520PV?6&B#.LJ!UVJBZU5W$@'4#W>
M?NUK?VA_D4]_]4 _J\:K1M["16:[=2I32E:]^DO_ #JOB1?[<L0_\WG'^_\
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M"S2(=J)#Q   0*) VV$-Q* [Z^B\48D[A'"G$V)Y.6]AG#V*/G-.KEO;OO\
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M[J8 )]]4N_NW_P# ?^X9^591^^9Z^,2/>-*T+_#WI49(9IC\R&I%D3N]Z<9
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MG(@^)>X&ND]=3('LZ5$WK"DE7.(S8]BE%49_,L[7\2QO8,F59%M:)04+ Y3
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M8A!VBR<]W4_';V":R+$3$78HAK8(62:3$8Y275:R#)9-5JY*F8Z)A15()B&
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M?\1\ZS_7Z_G6:V#Z4JD3#CTS<BFZVX'\E0(110Q1V 0 JA#AL B7<0+N [
MAOY@I()2N0G(=5*.@0J,P[22$ZG;742:',$K6!F2A!4I !)7L D1"IU*M"#
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M_P#>%/ZP_P#9K,K_ (!_QC^53@?QH_\ ZA[?P]*["N3" F%(2E !'R;SX ?
MAQ\;_;S[#O\ IIGRI<4Y"$HZYI"A D["-3'6?*L0<R4B%3U$Z>Z/Y5!*]]?-
M4IU@R&C$XARWD#'N')3Y+F#+=+BX9]3:+)-D$'<Z@*#R796"RA4F;E%S;#UN
M)D0A"@NFX RJ!R:BAT++9("4.H=4A68&>4IM)$$#<N#4D 0=ZP?WQ90"LA2
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MV_4BIM^NGS( ]IVK\_'1@UI$%U0T8U5A\;&LEJE<O_CO$%.J&3ZY9NFL\?\
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MDOO$LU"E]$W.<.^IT+' L6QE]G%N+')Y96NSPEL!#5@AQ*V\C\E1>5E7E&<
M!0!W 2-:^Q7"L+9>PWAIN4.I0F[Q5X O7RD+2Z%6X 2;5!4@**4RX0"%&)J1
MC9FV8)%(W(!$R% I2@   %*   % I0   I0 -@]@_,=]>[:9M[1H(:0E"$Q
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M-+J3M%.;35^S%BS&UK<REE;OZHWP=.RH-&+&<DX:%?!)-\_,P5)/5YG&S@H
MF!6BLD=$!,JF8XX8^P+[-;5M;3'#:6V7"2MHXICBVEGK+:\3*-(VRP-?;53O
MVT<;OKSO8K:O?W7<"X?<1J9U:7A2FSKW29T!K)W_ +EKF[??_"@Q[Y.4X@/3
M[9Q#D1H+$H\1ZB1*&S;8FP  "(=P0%7Z]97]A? :]%X7?K&VO$W%$ ;Z?Z[G
MZT@5JI^UWC1'J7]DF-?_  #PZ?\ _4?RVUKP+_"QS(FF94>I;&BRZ!"*$*;I
MXL?-15LW%)N43#U#>1,38@<AV$1 3;F\A7_S _9W.;]B7!6?QJQ_B-2U>UQ6
M+%9@ #51@")  %7?\\W'/JJQ.S(Z@X#PX0 ?(X28U.VQZ58.(_AL=3EJQ[5K
M)D/-F-\:W21CT'$]2$\)6*91KKMHX>D:L@DR=0:!7IBM"D744%,GA3MJ) =$
MYC6C[!^ !H,)O?\ ^9.* (VTRXR 9TDD:^=0_P">'C(S-]AP_P /#G#39[D'
M)@Z9CIJ0G6(UK(Y/A89F1[9B=36-P[1F_ W^#Q9!, ME.XB83?X0XB82J#N/
M+EW/90#%$0U)/V&<!(5G1A5V%"8/^D?%!W!!,*QDCU=-1ITB-,+^U_C I(-_
M8^P8#P\#TV/[*!&P]W?:J?.?#(S[#PLB^ANH['<S+12#:=A853!-L9IR4]5G
MOXCK+,SDO4<F"*2E@:-!6[A5&RJ8=MXDX;E[.N_P]]E?"/#=PJYP:RN[6Y4?
M$M>.X]=IZ"2W>XG<M)[>IM7%QK[0^(<=8Y&+W%I<,)]5+>#X-:'R',L["W<Z
M?Q3K.DZ[;\'R>2IC$>-I#,3"/B<K.Z;7W61HN+(DE'L+>M&-E)UHR11<ODDF
MR#\ZY$2)O710(4O%8X#X^C@@@$=:\*G-'BWZ[?II]>X6=U/X):=26'I_$$G*
M+1,;8YFFO91X@,@@L>+K=P@;)(1[=W%/6#]HYDF4.X8(/V;M)PP7<I.4]U$B
M#J"D(7!(G;\1B1UTCVQM-22I:3(WU&P)^>G;4#K&FM6ABSHCZ>L/7./R!1*Y
M;V%FC$GJ+)W+Y7RM9FR2<BW].[(K#V>Y3$0Y[I1.8IG#-4R)S<DA(<I3%M"U
M!.4'PQ$:;'YU%2<Z@5:P2??(F?A[_P Y< &P  ?;Q^?]H^=1J5-*5"*X](*-
MOS \R&O>Y%E2[+=,?9$NV.2P+94)^YXNB5H2HO4+8,DTD8>,]*9FI*0[2.=F
M>.XUJHA(LD5'/J8,IY7BCQ2?/3ZUZQW-2=5S$Y=8 ('3Y[CIUU[;FM>E0^&%
ME&"SIU/RF.+E3\-XGLF4JK8,;1EEI-SRH\EFAL84AI.2R4V.<:Q(H(A:&4FQ
M/'RZ+Q0BK!15J=)@X1;:L<RN+SD283WT(2!MMN.U5(3E0E&V68&\2HD?/7?R
MUK*5F^&)EJZ))H6_/>#[.@B("BWGNE^RRS=$2J&5#LH/NHY=%+ZS;&[9"\B$
M23-NFBD4G2LL9Q3#LWH-Z]:YHS%DI03&WB"9^?G75LL7Q'#PM-G<<D.90O[E
MAPD)G+JZVLB,QV[^0J@*?"@NR;%!F3+G3HW9,BD!LV0Z2I9NW2X',8@BDCU#
M$(?ZSB)Q.!C*%V(<3 4@%RYCF+N*6MS$[Y2G(SJ5<NR8,C7.(U[1.QD:52K$
M+Y;RGS=/!Y>ZVU%M7G'+RA,C0Y0-)!T-63COX;^?Y&5R :<OF L<(U:ZNZ[0
MY&-Z<9D7EPHK.&B9!C<53Q?4/'O(DKN7E9R,"*75<'3^3@Y.X4*X(FC!>+8D
MXCEN7KSJ)T#BN:)@ 'QA4F ->N^\T.*8E$*Q"^R[Y3>7 ]HCFC7;\M*S>;X=
M.?CM09#U.8L]*4R2A40Z=[N!0.B@9NF8!+U,%,!NR<Q3"!MCB/<.!E  P<U(
M"/5 3_A&4_*/95"WG'%!:@UF'5##+9GO*$)GWZU1Y[X9F7[)#JP5CZ@,)3L0
MMN*L9,=,EGD&JQC(%;!W$WG4@L!S"DF4@"81'ER/OS,8P[=M>WEFX';6ZN&'
M$P4K;=6%)@R(.;2".E7MXC?,+SLW3S9   0HA, ;!L'ER8G1.IDF22:C7CGX
M364+I79XF07/3'C-Y'7FYP<''1G3,]DUYFGQ$RHRK5O^9M.H!LNP6LT<BC)*
MQ0;C&F4].8YS"8==^WXSXD8)G&+Y>@@*=S1$[A8(5((!D']*Z]MQ7C+,_P!L
M41H!]Q;2,L[YF9._6=HJY'/P2Y%T4$U,N85(4IA,46_3=:FQ@'V_RB/4>F(E
M^P ;Q]P !VUNHX_XC0?_  F^1U"@PKH8T4T8[UMCC7&@K2X"2-E)M;0*V[\C
MJ-#KM(JD+_ W<J" &S9BE'@4OTHX%N:(;"80 QMNI4##R-]/D=A$ #;?5H^T
M3B(3_K!SMJS:*C?^)DQO\:?Z:8S)/I6IU)]&LP3/<AGVQL?A6+L3_!7R);J3
M&361KYBG'%P7D;.VDJBCAZYV$D<TC+1+Q5>>A))]2#8BAK!6VD38S) 4!:*2
MQF@^$ '4C]H^/_\ EJCT_<6OY<CX?YU=_ISC(,BZVVBVM!VTCD@;'X'O%9.+
M\#!V)0$,ZXQY@ [&+@.\ .X#X\AU+COMM]S?;SMY ,?\XO$/2^4!VY%F?S8[
M[?*JU<:8TI97Z6<QB3Z-9SH(&O)TT[>RNI;X'$LS;.5$,[X\57*@JHW23PE?
M&IU7!""9%'N!U,*<2*J<4CJ#_D@/N0IS"&S_ )Q,>,!5VD]IM+"-"/\ U;76
M/.JO],<<!E-\[KO+;"AY0%-D#SRQ.DS5D8L^#'DRTT&ISF1,I8_QW>I:-3<V
M&DIXPOU@)79(W<$\:240ZD&Z;X"MR$<=\A$_J4.&P%(4@8/'^/@R;IM2-]++
M#X[;^C::QY';VX1QOC68#TYR=8AE@*VU('*$Z>S7W"LF#\$FTF+P-U(4X2 !
M2@F.',F"F!2[B!0(/4_Q H"([  ;:B./L8!S)<82H_B38X<E1'FI-J"1[3%6
M*XUQM7[R]>=TV>:9> '097&UB.L1H>E5-M\(K*>,V$Q9:#U T&;L\7$RS^#@
MGF&<@>DF9=",<BPCEE'74XHW;%?+]MEZI4AB-BK=X"B*92ZYN)\7W^*VZK:\
M6P\PK='H=BB0#,9FF$*$>1&^IU(//=XGQM]I;+MYSFG!"D/6MH[H3T+EN<NW
MX8,5N?P*-Y+A7%9<HQL;"9(_ E9_',/$!PBXVUC%M_G;*.*+Z2,+-"1]0DU,
M+]X91(I3BX5$PF'RXRQX$A*9,!(@#4[ : $Z^^N$59B3H#V2E* /8E("1[@.
M]9<UFL4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M-*4TI32E-*4TI32E-*4'V'2E:N>DW*>6+9G.3B;59KA-BXJ>8)++%2FX\C>O
M8ON=>S-'P&*X*MF)#L0CR3N-UI&0,V*\>C.I,RV Y^1A$T;!27;(E:<CB2('
M69(/;0CQ=@1'G4;N6[H(1*D'<[: :::D_G^5;0T_W0W_ #-_](=O[-$IRB)G
M4Z^TD^>TQY[U,_H/RU^=8HSH-T+B3(1\>6,]2N;>GV!] 6%.#;V-:-?L(Y9V
MFHUAG:A&SQZJ"1D&8+@LDDX5(J=JZ GIU,+64Q"9F>L;1Y'>:DA 5NJ(CI.\
MCN(BM5K?-'4(-OPFD^NM\3N4C3^D1:N4@D"BA"9*C;VQ1+U$VBU-$X%-(\E7
M$1>O5S"XCOPTXC6YDD ))]H;K,I>?2VX E!0ZHDF=4L.+2-ANI(2#(U.DD15
M=PDLLJ6GQ$*2,H\,RXE)_BZ&3I[8&M;H&ZXKIB($X\0 0^^_@!  \!MMX#^/
MV_.I1APMCI^/Y_TW'>*@VHK2"00?/V#Z]LU$KK<R;%8JPXWL4I=KS2P7N$)%
M,PQV,>SLEGD7[65)'U<+'+L7\73XEV\(C)3=J?)IH1D9%.2'5 '/$\JF8.GO
M\Q'7Z(J$&(<M9[<9;Q3"V7*LY<K.XMF*X(U>@(M)3'=UPQ-8H=3M\R<JZ1A@
M1>R47? 0BE+,@^8%1D8XT6#%LC(^E34 C;3Z_6MT&FO3\I_45FH2]<ENE*EB
MKUL!DNPXRLZJDT%4D(A-ZUAINR,H%\\AH:TV&/J=N<0S [I,'#!J#-J2QR[=
MK7%729)'S!:E(25>M'0:;F-]8^!TW[B2$A:@DR)ZZ&(!,])VVD$=B8F'W3OF
MWJ M^:\9)7"<R$A/6">DV%]Q'8*NA$0M9Q03#,!8JU>7;9"(!O%S$C?GCQHK
M)A)B1X_<.*^"10BA;(W,RZDE1Y>DP0"3&W8^S?RD3%+L-& G/TF8'ZCYZ'<B
MMS>H596N'XB.8NH'&%"C4L&TN_O.^Z:S5HO]"AJY9'L!&1$S!E&KA#S4FS<(
MK6Y%VZ;*3C5J_P#E+)LL)4?4.D54=916JZ:8#J6@]<87;I64Z)_:&(MV+BSJ
M)]&0LW*AH%I'+S-ZN58$ HS@DGJG:-=Y._NZS5BX!ROERR]32$'+V&Z."/['
MGIKD?&,W"^FK>,Z767<>E@Z2CS)QA&T8^LT>N9<[M&6>)V0S]^0JZP0YSA:R
M%\IEQ;@4;AE+N4".42XZ@H*I.;]V%!4)W BM<*"RM.4I*3&IF9D3L(,".NFF
MQUVJ"0#D -_]0=_X"!OL(>^VVX?]&K08,^WYB*D4@B-M021U@S]3-:N^OZYY
M/J%KQT_HN5;)5F\/ 3,\GBJMP%H(^SE8R6.N,(VF,KK!MEVD-(%9+/U4(Y=)
M^LX(LH[4C18H+ND:+9:VKDJ40M)3ZBAYG<F1IJ-O,U->5;):RP20<\_*(!]^
M;V5T]'&4LOW3,CB/NE@N\D\>4;*LQF"E6-@BA!XHO$-F&/A<75VOJI1+-)G\
MYQTXEW:[5%Z_";28-["=7=8I0OMX]#!5JO, -P>L_P!9^4U%<E><>$#\.\B-
MIT^0[=:VEI[\0W_,W]7(=O[-5-3D$]U_#.J.W2I']!^5<]65BFE*:4KI6 >W
MMOY_CQW\#XW\\?X_I["/@1UT[UC;SU\_ZGX=-MJUA]*63\M6K-[B'L]ON%C(
MYKV6'N6ZE8(L&4'BJY0&6SP6,X2OF&(8FCTI_'XE?H1X/'P2K5HE81,'S I@
MPD0 )GY=>TFLDR3 (V]GG]1^1(VA:S2L29Y1NBV',D?T>6@],N;>HS3V LB4
M"A97$8^8LE7B:C2&<KMV[MXH"!D&G=,<B+A1-<4'':["E%R2FW>6G4H;4X /
MQ<L9\O6,V7+,&)F#$58UEYB<VTZ_I\XK5%%9MZB'-ZPDWEK??6UGD:[TLG@*
M.$((P61H:XLG YXL]L10KYB'EH-7U2BPBY8!6S1\>N5N0D@01W+$!Q+O- 2$
M/WUNB3)<]#L,.O4N#8I2^J_6QEURFWSRYS"VW1=!2)R$@R,H D&=>HW'R\HF
MMW&JJG4*^N/)D;B[$[:<D[Q>:01W:HF(8_T> U:V*U2[U%T$56E+$]8O6=-@
M7#P$GE@M+L$4(V.8K JH!5P36KSGF%&700<Q.^DF-.GMI'69\NWZ:[S[JA7B
M'+&>%<K8OA;%E>;N5J=7#&D"O PD3RQU<\,S.*E9>[92,8D.BF[>1UZ3/'FM
M97S4Q7\=Z)-JR1<]K6PI 0$F2K-)VRQ$#;7N"-A[=:P"DD@C;LJ-3KV.O7O\
M:W2E#8A0#R %* ;[F\  >XB.YOX^_P!QWU76:A#UUVR:J6+VSJO9*G\:6%RK
M+$K4E& _8P<M8VT'(/(>(MEBC:C<7D-&K.T2+LFZ3%N%@DF[>".L8'O$NI</
M<D:-9^WBR_,)5[IZ^^MAAA+Q.9>2-)@'>.Y ]NHVZU%;IYS9G:X9PHK:Z3F0
M&MBFY^48W;$E@@$(J!K>(D<.P-DKU^<LT8CA'3DM?'796DPF52KN7[BO>E2^
M7@9/KK0W!A,2(29GQ3TV)G8"/>=JYX<!TR;22"KWG<:Z:Z_I6X1,1[7(P!N'
M,1W#;V,.WO[> #S[?EN&VM,@ G6?,$_SJY)D3MO^9^NW;2M<_P 1++74#CF@
MU]+!-+R ]!X^:RMLO]!AX"Q/Z]&1=BK!2UA*&EI:.=@M<$'CMJM+LVKX\9&M
M'@D0*NX161U+B0MJ 3JN3_P^_KTC?36KVDMJ"RK4@#+K&I)GIT@?459& LL9
M?LG5*I S,[>G*<A8L\MLEXXL,,FTK^-*C6I1B7!\A$]F-328O;)%K;.GB,L^
M)8C*N5]S^@*<N\G*;=0(A1"8/O2?Z?YZ:1D7"8F/$3VU28Z=QOU/G6U/@'Z_
MUZHY?G\OZUL5K#ZZKCDRH6_&;RC94GJJTA8>5G4,6P,):$WV>;22RUAI'4%E
M=(5%5E$22S-9PFT8.@=++%?KO31ZS%L\5::Z$E+Z6C)"OQS&Y'2(.A_B%/KZ
M/]!7CZ/\IY?N67187"S7":7?U3*,CEZEV2.3:1.(;M"9<2A,;5VOBG"QY6*$
MWC\[EV5F1V]++H1R%@^DL@!R=%]M++JFTJSI 20H" <R$JV!(TS$;])]C;\A
M]><>5;2M54II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2NE-N@D)A3013$X[F,1,A1-MOQYB  )A#<=A
M'?;<=OUPD! A(@>4#??M6%>+4R3T/7RUG]:[0WV\AL/Y?SUF@F-=_KM7PQ"G
M\&*4P?\ E  _[P'2)WK,D;?*NHS9N/$1;HF$A1(3=)/<A#; 8A1$OTE$"EW*
M&P"!0 0\!K'JZI$'I&GSTK!$@@Z@[^==A"$(  0A2!L <2% H!L'ML4 #Q[:
MQ'XH\4?/^OUUK( &PCV5Q5314+Q7334)_JJ$*H7V_P!4P"'M^FI3I/3>E14N
MO6KTJXXR/)XLNN4(VN7FON:\PG&CRK7(8FONK6W:O*ZUFKBVK*]/A5)9L\:.
M&I)&?:_LW"1U. & =1:4E\PT<QYR;?4%(+RPDI;!6$@DA:=02G6"9!@ZGDB7
M! Y*KG3QD,H*@IPA&8B"A6A 48D R)E(F_9K%(=)<IRGVX& #;'W#D E^GR4
M2_4!@^D2^=]O.LYA*AKX%EM4@B%#<:C4"?6'AZ3-.B3T4@+&HU2= 8W'L,*\
MJZU%HY;PJ5)0.)3[JMQ,7CS Q1$QTQ*&Q]C  CN!@Y>!#?60,T@"8,$><$Q[
MH,]CH=:P5!.I,:!74:$P//<[;CK7H*BV/]8(I#X NXHE >(<3@7ZB@.P"!3
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M-*4TI32E-*4TI32E-*4TI7!0-RCN.VP;[C[?\-1_!_N_I0;BM*F<D,@M;O\
M$$QBPP!EB_/>I..H\#C*?C*DW=8Q44>X4BZ0XE;%<GK]"-@F56GDUGTJ=V4%
MD$60J,D'"Y@!36;"GF;9MCP.M8U;EU6WAEE84=M$I ,B3TJQ:D,W#[CQS-*P
M=[(B)&8(>2I&^A))[ ZU'%AASJ8D,X,X*>B\J4&M"QS'C"]Y#3E;J:)"I-\*
MNX;&]X6O;Z\-:BI%O;5$Q5@A(.HT]-[59!,C>QSHN53&5V5J0Y;X@R#E?:ML
M7?YBR!F<;>PA39 /XN5Z03/34'0U6L$.6+AU;N7<(M$(3.9*7?3RZ.QU2W/:
M1I)2!92T3U0Y@Q9C3J%5C<H6B]W^3L[V/HM<D+=,8Z.G3&=6HM,6.^I=WK,U
M1Y2SJUF>M=;OYRSM;:HV5Z-@C5 6; 2QAQ+EVR&Q##V#OXJR2K4C%,69N;5.
M^O+L+A* =#EF=!4;KPHO!/B9X@OL-"8,AJU%R,QT_C82#.F8B!J*_2A5#R*E
M>AU)9G\ODSQL>=^Q]5Z\S-Z=BV,[:G?^ ?';N151,\ "@Y$G>XASU)P@K)'S
M]I ]FD:5%KU?KL.O7VU<.JZLII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4JFO/WQ\[!V%]]]]O\D.WGV_/_CJL_O[?_P"L_(3[*PY^Y<]BO^X:T:9<
MALE2<GU]80A\#95M<SU#Y)KO]'EL;U- N,$6$KBVA5D;;,7A](L8^,0J4M%O
MI1P0O*5!6,32C45W)DRDT\,2LVMGRW V1Q%B;RHF0RVW;*6I0T.5681 42I)
M@:2>C?OL)N[,J2'$IP+!4J.A2DAW&0H$Z^)"E(*A!(E&P)K%:N).I:T]2,E'
MRD-E6@4QV\S_ $6^Y"1?75O$A1_Z*I9AB>YN[G(74E2-"KVV"A)^ @*M36CJ
MJ.5?1S$LJ83@ON(N+9QJ^N4A(979*]#08^ZN;3%+:Y6L1L5-V[HV'A43)G7G
M\IT-X8@F<S&$V[@2/$5)PA-A>$@$ ERZ65SIF7J=P!8$A7>J7+N(\?=1"D?E
MJV9 R),6F3946J2-NF,:)%J;"JT6DB+VF7FL3E'E;&-6FK57KZ#><K+4UED
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CE-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
